

[illegible]

[illegible]

[illegible]

[illegible]

310000913144rnr:A3.700SeniorNotesDueApril12025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:RenaissanceReFinanceInc.Memberus-
gaap:SeniorNotesMember2023-12-310000913144rnr:A4.750SeniorNotesDueMay12025Memberbrrn:DavinciReThirdPartyInvestorsMember2024-12-
310000913144rnr:A4.750SeniorNotesDueMay12025Memberus-gaap:EstimateOffFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-
gaap:SeniorNotesMember2024-12-310000913144rnr:A4.750SeniorNotesDueMay12025Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2024-12-
310000913144rnr:A4.750SeniorNotesDueMay12025Memberus-gaap:EstimateOffFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-
gaap:SeniorNotesMember2023-12-310000913144rnr:A4.750SeniorNotesDueMay12025Memberus-
gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2023-12-310000913144us-
gaap:EstimateOffFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2024-12-310000913144us-
gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2024-12-310000913144us-
gaap:EstimateOffFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2023-12-310000913144us-
gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:SeniorNotesMember2023-12-310000913144us-
gaap:EstimateOffFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-
310000913144us-gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:RevolvingCreditFacilityMemberus-
gaap:LineOfCreditMember2024-12-310000913144us-gaap:EstimateOffFairValueFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-
gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000913144us-
gaap:CarryingReportedAmountFairValueDisclosureMemberbrrn:DavinciReThirdPartyInvestorsMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-
310000913144us-gaap:EstimateOffFairValueFairValueDisclosureMember2024-12-310000913144us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310000913144us-
gaap:EstimateOffFairValueFairValueDisclosureMember2023-12-310000913144us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-
310000913144rnr:A5750SeniorNotesDue2033Memberus-gaap:SeniorNotesMember2023-06-050000913144rnr:A5750SeniorNotesDue2033Memberus-gaap:SeniorNotesMember2023-06-
052033-06-050000913144rnr:A3.600SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2019-04-020000913144rnr:A3.600SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2019-04-
020000913144rnr:A3.600SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2019-04-022019-04-020000913144rnr:A3.450SeniorNotesDueJuly12027Member2017-06-
290000913144rnr:A3.450SeniorNotesDueJuly12027Memberbrrn:RenaissanceReFinanceInc.Memberus-gaap:SeniorNotesMember2017-06-
290000913144rnr:A3.700SeniorNotesDueApril12025Member2015-03-240000913144rnr:A3.700SeniorNotesDueApril12025Memberbrrn:RenaissanceReFinanceInc.Member2015-03-
240000913144rnr:PlatinumMember-us-gaap:BridgeloanMember2015-02-250000913144rnr:A4.750SeniorNotesDueMay12025Memberbrrn:DavinciReThirdPartyInvestorsMember2015-05-
040000913144rnr:DavinciReThirdPartyInvestorsMember2015-05-040000913144us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-
310000913144rnr:RenaissanceReMediciFundLtd.Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310000913144rnr:SecuredBilateralFacilityMemberus-
gaap:LeterOfCreditMemberus-gaap:LineOfCreditMember2024-12-310000913144rnr:UnsecuredBilateralFacilityMemberus-gaap:LeterOfCreditMemberus-gaap:LineOfCreditMember2024-12-
310000913144us-gaap:RevolvingCreditFacilityMember2022-11-180000913144us-gaap:RevolvingCreditFacilityMemberus-gaap:BridgeloanMember2022-11-180000913144us-
gaap:RevolvingCreditFacilityMember2024-12-310000913144us-gaap:RevolvingCreditFacilityMember2024-12-310000913144rnr:WellsFargoMemberbrrn:SecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:WellsFargoMemberbrrn:UnsecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:CitibankEuropePcMemberbrrn:SecuredBilateralFacilityMemberbrrn:BilateralFacilityParticipantsMemberus-gaap:LeterOfCreditMember2023-10-
310000913144rnr:CitibankEuropePcMemberbrrn:SecuredBilateralFacilityMemberbrrn:BilateralFacilityParticipantsMemberus-gaap:LeterOfCreditMember2023-11-
010000913144rnr:CitibankEuropePcMemberbrrn:SecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:CitibankEuropePcMemberbrrn:SecuredBilateralFacilityMemberbrrn:BilateralFacilityParticipantsMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:CitibankEuropePcMemberbrrn:UnsecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:CreditSuisseSwitzerlandLtd.Memberbrrn:UnsecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2021-12-
160000913144rnr:CreditSuisseSwitzerlandLtd.Memberbrrn:UnsecuredBilateralFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:NordeaBankAbpNewYorkBranchMemberbrrn:StandbyLeterOfCreditAgreementMemberus-gaap:LeterOfCreditMember2024-10-
030000913144rnr:NordeaBankAbpNewYorkBranchMemberbrrn:StandbyLeterOfCreditAgreementMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:SocieteGeneraleNewYorkBranchSocGenMemberbrrn:UncommittedLeterOfCreditFacilityMemberus-gaap:LeterOfCreditMember2022-09-
080000913144rnr:SocieteGeneraleNewYorkBranchSocGenMemberbrrn:UncommittedLeterOfCreditFacilityMemberus-gaap:LeterOfCreditMember2024-12-
310000913144rnr:CitibankEuropeMemberbrrn:SecuredLeterOfCreditFacilityMemberus-gaap:LeterOfCreditMember2024-12-310000913144rnr:RenaissanceReMediciFundLtd.Memberus-
gaap:RevolvingCreditFacilityMember2024-12-310000913144rnr:TopLayerReMemberus-gaap:LeterOfCreditMember2024-12-310000913144us-
gaap:CapitalSupportAgreementMemberbrrn:TopLayerReMemberus-gaap:LeterOfCreditMember2024-12-310000913144rnr:DavinciReThirdPartyInvestorsMember2024-12-
310000913144rnr:DavinciReThirdPartyInvestorsMember2023-12-310000913144rnr:RenaissanceReMediciFundLtd.Member2024-12-
310000913144rnr:RenaissanceReMediciFundLtd.Member2023-12-310000913144rnr:VermeerReinsuranceLtd.Member2024-12-310000913144rnr:VermeerReinsuranceLtd.Member2023-12-
310000913144rnr:FontanaHoldingsLPMember2024-12-310000913144rnr:FontanaHoldingsLPMember2023-12-310000913144rnr:DavinciReThirdPartyInvestorsMember2024-01-012024-12-
310000913144rnr:DavinciReThirdPartyInvestorsMember2023-01-012023-12-310000913144rnr:DavinciReThirdPartyInvestorsMember2022-01-012022-12-
310000913144rnr:RenaissanceReMediciFundLtd.Member2024-01-012024-12-310000913144rnr:RenaissanceReMediciFundLtd.Member2023-01-012023-12-
310000913144rnr:RenaissanceReMediciFundLtd.Member2022-01-012022-12-310000913144rnr:VermeerReinsuranceLtd.Member2024-01-012024-12-
310000913144rnr:VermeerReinsuranceLtd.Member2023-01-012023-12-310000913144rnr:VermeerReinsuranceLtd.Member2022-01-012022-12-
310000913144rnr:FontanaHoldingsLPMember2024-01-012024-12-310000913144rnr:FontanaHoldingsLPMember2023-01-012023-12-310000913144rnr:FontanaHoldingsLPMember2022-01-
012022-12-310000913144rnr:DaVinciReInsuranceLtd.Member2024-12-310000913144rnr:DaVinciReInsuranceLtd.Member2023-12-
310000913144rnr:DavinciReThirdPartyInvestorsMembersrt:MaximumMember2024-12-310000913144rnr:DaVinciReInsuranceLtd.Member2024-01-012024-12-
310000913144rnr:ThirdPartyInvestorsMember2024-01-012024-12-310000913144rnr:DavinciReThirdPartyInvestorsMemberbrrn:ThirdPartyInvestorsMember2024-01-012024-12-
310000913144rnr:DavinciReThirdPartyInvestorsMemberbrrn:RenaissanceReHoldingsLtd.Member2024-01-012024-12-310000913144rnr:DavinciReThirdPartyInvestorsMember2024-01-012024-12-
310000913144rnr:DavinciReThirdPartyInvestorsMemberbrrn:ThirdPartyInvestorsMember2023-01-012023-12-
310000913144rnr:DavinciReThirdPartyInvestorsMemberbrrn:RenaissanceReHoldingsLtd.Member2023-01-012023-

00000913144rnr:ThreeHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMemberbrrn:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-030000913144rnr:OneHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMemberbrrn:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-06-130000913144rnr:EightyFiveThousandandPrincipalAtRiskVariableRateNoteMemberbrrn:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-200000913144rnr:OneHundredMillionPrincipalAtRiskVariableRateNoteMemberbrrn:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-200000913144rnr:TwoHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMemberbrrn:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-06-290000913144rnr:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-310000913144rnr:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:MonalLisaReMemberbus-gaap:OtherInvestmentsMember2024-12-310000913144rnr:MonalLisaReMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:MonalLisaReMemberbus-gaap:OtherInvestmentsMember2023-12-310000913144rnr:TailwindReLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberbrrn:RenaissanceReHoldingsLtd.Member2024-01-012023-12-310000913144rnr:TailwindReLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberbrrn:RenaissanceReHoldingsLtd.Member2023-01-012023-12-310000913144rnr:TailwindReLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-310000913144rnr:TailwindReLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:TailwindReLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:AlphaCatManagersLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-12-310000913144rnr:AlphaCatManagersLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:AlphaCatManagersLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:AlphaCatManagersLtdMemberbus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310000913144rnr:PublicOfferingMember2023-05-262023-05-260000913144rnr:PublicOfferingMember2023-05-260000913144us-gaap:SeriesFPreferredStockMember2018-06-012018-06-300000913144us-gaap:SeriesFPreferredStockMember2018-06-300000913144rnr:DepositoryShareseachrepresenting1000thinterestinSeriesF5.Member2018-06-012018-06-300000913144us-gaap:DebtInstrumentRedemptionPeriodOneMemberbrrn:DepositorySharesMember2018-06-300000913144us-gaap:SeriesGPreferredStockMember2021-07-012021-07-310000913144us-gaap:SeriesGPreferredStockMember2021-07-310000913144rnr:DepositorySharesEachRepresentingAll1000thInterestInASeriesG4Member2021-07-012021-07-310000913144us-gaap:DebtInstrumentRedemptionPeriodOneMemberbrrn:DepositorySharesMember2021-07-310000913144us-gaap:SeriesCPreferredStockMember2024-12-3100009131442024-07-012024-09-3000009131442024-04-012024-06-3000009131442024-01-012024-03-310000913144us-gaap:SeriesFPreferredStockMember2024-01-012024-12-310000913144us-gaap:SeriesFPreferredStockMember2024-12-310000913144rnr:SeriesFPreferredSharesDepositorySharesMember2024-01-012024-12-310000913144us-gaap:SeriesGPreferredStockMember2024-01-012024-12-310000913144us-gaap:SeriesGPreferredSharesDepositorySharesMember2024-12-310000913144us-gaap:CommonStockMember2024-11-060000913144us-gaap:CommonStockMember2024-12-310000913144rnr:DepositorySharesMember2018-06-300000913144rnr:DepositorySharesMember2021-07-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2024-01-012024-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2023-01-012023-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2022-01-012022-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2024-01-012024-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2023-01-012023-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2022-01-012022-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2023-01-012023-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2022-01-012022-12-310000913144us-gaap:FinancialServiceMember2023-01-012023-12-310000913144us-gaap:RelatedPartyMemberbrrn:TowerHillMember2023-01-012023-12-310000913144us-gaap:FinancialServiceMember2022-01-012022-12-310000913144rnr:ThreeBrokersMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2023-01-012023-12-310000913144rnr:ThreeBrokersMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2022-01-012022-12-310000913144rnr:AonPlcMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2024-01-012024-12-310000913144rnr:MarshMcLennanCompaniesIncMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2024-01-012024-12-310000913144rnr:ArthurJGallagherMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2024-01-012024-12-310000913144rnr:AonPlcMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2023-01-012023-12-310000913144rnr:MarshMcLennanCompaniesIncMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2023-01-012023-12-310000913144rnr:ArthurJGallagherMemberbus-gaap:CustomerConcentrationRiskMemberbrrn:GrossPremiumsWrittenMember2023-01-012023-12-310000913144us-gaap:InternalRevenueServiceIRSMember2024-01-012024-12-310000913144us-gaap:InternalRevenueServiceIRSMember2023-01-012023-12-310000913144country:SG2022-01-012022-12-310000913144country:SG2023-01-012023-12-310000913144country:SG2022-01-012022-12-310000913144country:IE2024-01-012024-12-310000913144country:IE2023-01-012023-12-310000913144country:IE2022-01-012022-12-310000913144country:IE2022-01-012022-12-310000913144us-gaap:InternalRevenueServiceIRSMember2023-01-012023-12-310000913144us-gaap:InternalRevenueServiceIRSMember2022-01-012022-12-310000913144country:AU2023-01-012023-12-310000913144country:AU2022-01-012022-12-310000913144country:CH2023-01-012023-12-310000913144country:CH2022-01-012022-12-310000913144country:LU2024-01-012024-12-310000913144country:LU2023-01-012023-12-310000913144country:CA2024-01-012024-12-310000913144country:CA2023-01-012023-12-310000913144country:GB2024-01-012024-12-310000913144country:GB2023-01-012023-12-310000913144country:GB2022-01-012022-12-310000913144rnr:A2037Memberbus-gaap:InternalRevenueServiceIRSMember2024-12-310000913144rnr:A2024Membercountry:CH2024-12-310000913144country:GB2024-12-310000913144country:IE2024-12-310000913144country:LU2024-12-310000913144rnr:A2027Memberbus-gaap:InternalRevenueServiceIRSMember2024-12-310000913144us-gaap:CorporateNonSegmentMember2024-01-012024-12-310000913144us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000913144us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2024-01-012024-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2023-01-012023-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2022-01-012022-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2023-01-012023-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2022-01-012022-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2023-01-012023-12-310000913144rnr:U.S.andCaribbeanMemberbrrn:PropertySegmentMember2022-01-012022-12-3

gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2022-01-012022-12-310000913144nrn:AustraliaandNewZealandMembernrn:CasualtyandSpecialtySegmentMember2024-01-012024-12-310000913144nrn:AustraliaandNewZealandMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2024-01-012024-12-310000913144nrn:AustraliaandNewZealandMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2023-01-012023-12-310000913144nrn:AustraliaandNewZealandMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2023-01-012023-12-310000913144nrn:AustraliaandNewZealandMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2022-01-012022-12-310000913144nrn:AustraliaandNewZealandMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2022-01-012022-12-310000913144nrn:OtherGeographicalLocationsMembernrn:CasualtyandSpecialtySegmentMember2024-01-012024-12-310000913144nrn:OtherGeographicalLocationsMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2024-01-012024-12-310000913144nrn:OtherGeographicalLocationsMembernrn:CasualtyandSpecialtySegmentMember2023-01-012023-12-310000913144nrn:OtherGeographicalLocationsMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2023-01-012023-12-310000913144nrn:OtherGeographicalLocationsMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2022-01-012022-12-310000913144nrn:OtherGeographicalLocationsMemberus-gaap:GeographicConcentrationRiskMembernrn:GrossPremiumsWrittenBenchmarkMembernrn:CasualtyandSpecialtySegmentMember2022-01-012022-12-310000913144nrn:A2016LongTermIncentivePlanMember2022-05-160000913144us-gaap:RestrictedStockMembernrn:A2016LongTermIncentivePlanMember2024-01-012024-12-310000913144us-gaap:RestrictedStockMembernrn:NonEmployeeDirectorStockIncentivePlanMember2024-01-012024-12-310000913144us-gaap:PerformanceSharesMembernrn:A2016LongTermIncentivePlanGrantedMay2018Member2024-12-310000913144us-gaap:PerformanceSharesMember2024-01-012024-12-310000913144us-gaap:PerformanceSharesMembersrt:ChiefExecutiveOfficerMember2023-11-072023-11-070000913144us-gaap:PerformanceSharesMember2021-12-310000913144us-gaap:PerformanceSharesMember2022-01-012022-12-310000913144us-gaap:PerformanceSharesMember2022-12-310000913144us-gaap:PerformanceSharesMember2023-01-012023-12-310000913144us-gaap:PerformanceSharesMember2023-12-310000913144us-gaap:PerformanceSharesMember2024-12-310000913144nrn:EmployeeRestrictedStockMember2021-12-310000913144nrn:NonEmployeeDirectorRestrictedStockMember2021-12-310000913144us-gaap:RestrictedStockMember2021-12-310000913144nrn:EmployeeRestrictedStockMember2022-01-012022-12-310000913144us-gaap:RestrictedStockMember2022-01-012022-12-310000913144nrn:EmployeeRestrictedStockMember2022-12-310000913144nrn:NonEmployeeDirectorRestrictedStockMember2022-12-310000913144us-gaap:RestrictedStockMember2022-12-310000913144nrn:EmployeeRestrictedStockMember2023-01-012023-12-310000913144nrn:NonEmployeeDirectorRestrictedStockMember2023-01-012023-12-310000913144us-gaap:RestrictedStockMember2023-01-012023-12-310000913144nrn:EmployeeRestrictedStockMember2023-12-310000913144nrn:NonEmployeeDirectorRestrictedStockMember2024-01-012024-12-310000913144us-gaap:RestrictedStockMember2024-01-012024-12-310000913144nrn:EmployeeRestrictedStockMember2024-12-310000913144us-gaap:RestrictedStockMember2024-12-310000913144nrn:EmployeeRestrictedStockMember2024-12-310000913144us-gaap:RestrictedStockMember2024-12-310000913144nrn:EmployeeRestrictedStockMember2024-12-310000913144country:CH2023-12-310000913144country:GB2024-12-310000913144country:GB2023-12-310000913144country:US2024-12-310000913144country:US2023-12-310000913144country:BM2024-01-012024-12-310000913144country:BM2023-12-310000913144country:CH2024-01-012024-12-310000913144country:GB2024-01-012024-12-310000913144country:US2024-01-012024-12-310000913144country:BM2023-01-012023-12-310000913144country:CH2023-01-012023-12-310000913144country:GB2023-01-012023-12-310000913144country:US2023-01-012023-12-310000913144country:BM2022-01-012022-12-310000913144country:CH2022-01-012022-12-310000913144country:GB2022-01-012022-12-310000913144country:US2022-01-012022-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReinsuranceLtd.Member2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReinsuranceLtd.Membersrt:MinimumMember2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReinsuranceLtd.Member2023-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReinsuranceLtd.Membersrt:MinimumMember2023-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Member2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Membersrt:MinimumMember2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Member2023-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Membersrt:MinimumMember2023-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReEuropeAGMember2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReEuropeAGMembersrt:MinimumMember2024-12-310000913144nrn:MultiBeneficiaryReinsuranceTrustMembernrn:RenaissanceReEuropeAGMember2023-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:RenaissanceReinsuranceLtd.Member2024-01-012024-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:RenaissanceReEuropeAGMember2024-01-012024-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Member2024-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Membersrt:MinimumMember2024-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Member2023-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:DaVinciReinsuranceLtd.Membersrt:MinimumMember2023-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:RenaissanceReEuropeAGMember2024-12-310000913144nrn:MultiBeneficiaryReducedCollateralReinsuranceTrustMembernrn:RenaissanceReEuropeAGMembersrt:MinimumMember2023-12-310000913144us-gaap:InterestRateContractMemberus-gaap:NondesignatedMember2024-12-310000913144nrn:ForeignCurrencyForwardContractsInvestmentOperationsMemberus-gaap:NondesignatedMember2024-12-310000913144nrn:CommodityFuturesMemberus-gaap:NondesignatedMember2024-12-310000913144us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2024-12-310000913144us-gaap:NondesignatedMember2024-12-310000913144nrn:ForeignCurrencyForwardContractsInvestmentOperationsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000913144us-gaap:CreditDefaultSwapMemberus-gaap:NondesignatedMember2024-12-310000913144us-gaap:EquityContractMemberus-gaap:NondesignatedMember2024-12-310000913144us-gaap:InterestRateContractMemberus-gaap:NondesignatedMember2023-12-310000913144nrn:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMemberus-gaap:NondesignatedMember2023-12-310000913144nrn:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMemberus-gaap:NondesignatedMember2023-12-310000913144nrn:ForeignCurrencyForwardContractsInvestmentOperationsMemberus-gaap:NondesignatedMember2023-12-310000913144us-gaap:CreditDefaultSwapMemberus-gaap:NondesignatedMember2023-12-310000913144us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2023-12-310000913144us-gaap:NondesignatedMember2023-12-310000913144nrn:ForeignCurrencyForwardContractsInvestmentOperationsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000913144us-gaap:InterestRateContractMemberus-gaap:NondesignatedMember2024-01-012024-12-310000913144us-gaap:InterestRateContractMemberus-gaap:NondesignatedMember2022-01-012022-12-310000913144nrn:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMemberus-gaap:NondesignatedMember2024-01-012024-12-310000913144nrn:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMemberus-gaap:N

012025-01-010000913144us-gaap:SubsequentEventMemberBemrrnr:ThirdPartyInvestorsMember2025-01-012025-01-010000913144rnr:DaVinciReinsuranceLtd.Memberus-gaap:SubsequentEventMember2025-01-010000913144us-gaap:SubsequentEventMemberBemrrnr:FontanaHoldingsLPMember2025-01-012025-01-010000913144rnr:FontanaHoldingsLPMemberus-gaap:SubsequentEventMemberBemrrnr:ThirdPartyInvestorsMember2025-01-012025-01-010000913144rnr:FontanaHoldingsLPMemberus-gaap:SubsequentEventMemberBemrrnr:RenaissanceReHoldingsLtd.Member2025-01-012025-01-010000913144us-gaap:SubsequentEventMemberBemrrnr:FontanaThirdPartyInvestorsMember2025-01-012025-01-010000913144rnr:FontanaHoldingsLPMemberus-gaap:SubsequentEventMember2025-01-012025-01-010000913144rnr:RenaissanceReMediciFundLtd.Memberus-gaap:SubsequentEventMemberBemrrnr:ThirdPartyInvestorsMember2025-01-012025-01-010000913144rnr:RenaissanceReMediciFundLtd.Memberus-gaap:SubsequentEventMemberBemrrnr:RenaissanceReHoldingsLtd.Member2025-01-012025-01-010000913144rnr:MediciThirdPartyInvestorsMember2024-01-012024-12-310000913144rnr:RenaissanceReMediciFundLtd.Memberus-gaap:SubsequentEventMember2025-01-010000913144rnr:CaliforniaWildfiresMemberus-gaap:SubsequentEventMember2025-01-012025-01-310000913144rnr:CaliforniaWildfiresMembersrt:ScenarioForecastMember2025-03-310000913144us-gaap:ForeignGovernmentDebtMember2024-12-310000913144us-gaap:FixedMaturitiesMember2024-12-310000913144us-gaap:EquitySecuritiesMember2024-12-310000913144rnr:FundInvestmentsMember2024-12-310000913144us-gaap:OtherInvestmentsMember2024-12-310000913144us-gaap:EquityMethodInvestmentsMember2024-12-310000913144sr:ParentCompanyMember2024-12-310000913144sr:ParentCompanyMember2024-12-310000913144sr:ParentCompanyMember2023-12-310000913144sr:ParentCompanyMember2024-01-012024-12-310000913144sr:ParentCompanyMember2023-01-012023-12-310000913144sr:ParentCompanyMember2022-01-012022-12-310000913144rnr:ValidusSpecialtyMembersrt:ParentCompanyMember2023-01-012023-12-310000913144rnr:ValidusSpecialtyMembersrt:ParentCompanyMember2023-01-012023-12-310000913144rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMembersrt:ParentCompanyMember2024-01-012024-12-310000913144rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMembersrt:ParentCompanyMember2023-01-012023-12-310000913144rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMembersrt:ParentCompanyMember2022-01-012022-12-310000913144sr:ParentCompanyMember2022-12-310000913144sr:ParentCompanyMember2021-12-310000913144us-gaap:CorporateNonSegmentMember2024-12-310000913144us-gaap:CorporateNonSegmentMember2023-12-310000913144us-gaap:OperatingSegmentsMembersrt:PropertySegmentMember2022-12-310000913144us-gaap:OperatingSegmentsMembersrt:CasualtyandSpecialtySegmentMember2022-12-310000913144us-gaap:CorporateNonSegmentMember2022-12-310000913144sr:ConsolidatedPropertyAndCasualtyInsuranceEntityMember2024-12-310000913144sr:ConsolidatedPropertyAndCasualtyInsuranceEntityMember2023-12-310000913144sr:ConsolidatedPropertyAndCasualtyInsuranceEntityMember2023-01-012023-12-310000913144sr:ConsolidatedPropertyAndCasualtyInsuranceEntityMember2022-01-012022-12-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 10-K ÂÂ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2024 ORÂÂ A TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Commission File No.ÂÂ 001-14428 RENAISSANCE HOLDINGS LTD. (Exact Name Of Registrant As Specified In Its Charter)Bermuda98-0141974(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification Number)Renaissance House, 12 Crow Lane, Pembroke HM 19 Bermuda (Address of Principal Executive Offices) (Zip Code)(441) 295-4513 (Registrant's telephone number, including area code)Securities registered pursuant to SectionÂÂ 12(b) of the Act:Title of each classTrading symbol(s)Name of each exchange on which registeredCommon Shares, Par Value \$1.00 per shareRNRNew York Stock ExchangeDepository Shares, each representing a 1/1,000th interest in a Series G 4.20% Preference Share, Par Value \$1.00 per shareÂÂ RNR PRGÂÂ A New York Stock ExchangeSecurities registered pursuant to SectionÂÂ 12(g) of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Act. Yes xÂÂ No Indicate by check mark if the registrant is not required to file reports pursuant to SectionÂÂ 13 or SectionÂÂ 15(d) of the Act. Yes oÂÂ No Indicate by check mark whether the registrant (1)ÂÂ has filed all reports required to be filed by SectionÂÂ 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)ÂÂ has been subject to such filing requirements for the past 90 days. Yes xÂÂ A No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ÂÂ232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes xÂÂ A No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Act. Large accelerated filer x, Accelerated filer o, Non-accelerated filer o, Smaller reporting company â, Emerging growth company â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. â If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to Â240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes â A No xThe aggregate market value of Common Shares held by nonaffiliates of the registrant at JuneÂÂ 30, 2024 was \$11.5 billion based on the closing sale price of the Common Shares on the New York Stock Exchange on that date.The number of Common Shares, par value US \$1.00 per share, outstanding at FebruaryÂÂ 7, 2025 was 49,251,139.DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrant's definitive proxy statement for the 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this report.RENAISSANCE HOLDINGS LTD.TABLE OF CONTENTSÂÂ A PageNOTE ON FORWARD-LOOKING STATEMENTSÂÂ I3ITEM 1.BUSINESS3ITEM 1A.RISK FACTORS34ITEM 1B.UNRESOLVED STAFF COMMENTS47ITEM 1C.CYBERSECURITY47ITEM 2.PROPERTIES48ITEM 3.LEGAL PROCEEDINGS48ITEM 4.MINE SAFETY DISCLOSURES48PART II49ITEM 5.MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES49ITEM 6.RESERVED50ITEM 7.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS51ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK99ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA105ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE105ITEM 9A.CONTROLS AND PROCEDURES105ITEM 9B.OTHER INFORMATION106ITEM 9C.DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS106PART III107ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE107ITEM 11.EXECUTIVE COMPENSATION107ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS107ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE107ITEM 14.PRINCIPAL ACCOUNTANT FEES AND SERVICES107PART IV107ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES107ITEM 16.10-K SUMMARY11SIGNATURES11INDEX TO CONSOLIDATED FINANCIAL STATEMENTSF-1INDEX TO SCHEDULES TO CONSOLIDATED FINANCIAL STATEMENTSS-1NOTE ON FORWARD-LOOKING STATEMENTSThis Annual Report on Form 10-K for the year ended December 31, 2024, of RenaissanceRe Holdings Ltd. contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, us. In particular, statements using words such as "may," "should," "estimate," "expect," "anticipate," "intend," "believe," "predict," "potential," or words of similar import generally involve forward-looking statements. For example, we may include certain forward-looking statements in "Management's Discussion and Analysis of Financial Condition and Results of Operations" with regard to trends in results, prices, volumes, operations, investment results, margins, combined ratios, fees, reserves, market conditions, risk management and exchange rates; the consequences of our strategic decisions; the performance of our underwriting portfolio, Capital Partners unit, and investment portfolio; and the impact of general economic conditions such as changes in inflation and interest rates on our results of operations. This Form 10-K also contains forward-looking statements with respect to our business and industry, such as those relating to our strategy and management objectives, plans and expectations regarding our response and ability to adapt to changing economic conditions, market standing and product volumes, estimates of net negative impact and insured losses from loss events, competition in our industry, industry capital, and government initiatives and regulatory matters affecting the (re)insurance industries. The inclusion of forward-looking statements in this report should not be considered as a representation by us or any other person that our current objectives or plans will be achieved. Numerous factors could cause our actual results to differ materially from those addressed by the forward-looking statements, including the following: our exposure to natural and non-natural catastrophic events and circumstances and the variance they may cause in our financial results; the effect of climate change on our business, including the trend towards increasingly frequent and severe climate events; the effectiveness of our claims and claim expense reserving process; the effect of emerging claims and coverage issues; the performance of our investment portfolio and financial market volatility; the effects of inflation; our exposure to ceding companies and delegated authority counterparties and the risks they underwrite; our ability to maintain our financial strength ratings; our reliance on a small number of brokers; the highly competitive nature of our industry; the historically cyclical nature of the (re)insurance industries; collection on claimed retrocessional coverage and new retrocessional reinsurance being available; our ability to attract and retain key executives and employees; our ability to successfully implement our business, strategies and initiatives; our exposure to credit loss from counterparties; our need to make many estimates and judgments in the preparation of our financial statements; our exposure to risks associated with our management of capital on behalf of investors; changes to the accounting rules and regulatory systems applicable to our business, including changes in Bermuda and U.S. laws or regulations; the effect of current or future macroeconomic or geopolitical events or trends, including the ongoing conflicts between Russia and Ukraine, and in the Middle East; other political, regulatory or industry initiatives adversely impacting us; the impact of cybersecurity risks, including technology breaches or failure; our ability to comply with covenants in our debt

risk submission we receive utilizing a combination of proprietary data sets, sophisticated risk modelling capabilities, market leading risk selection tools, such as our REMSÂ© exposure management system, and the expertise and judgment of our experienced underwriters. We manage our portfolio of risks dynamically, both within sub-portfolios and across the Company.Superior Capital Management. We aim to match the portfolio of risk that we build with the most appropriate form(s) of capital. As a result of our strategy and the diversified nature of our business, we believe that we are uniquely positioned to utilize various forms of capital depending on the situation. We access capital through joint ventures, managed funds, ceded retrocession, debt and equity markets, and other structures to support underwriting opportunities, and we prudently manage our capital position, which may include returning capital when we believe it would be beneficial. When possible, our preference is to deploy any excess capital into profitable business opportunities before returning excess capital to shareholders. In our Capital Partners unit, we aim to leverage our access to business and our underwriting capabilities on an efficient capital base, develop fee income, generate performance fees, diversify our portfolio, and provide attractive risk-adjusted returns to our capital providers. We believe we are well positioned to fulfill our objectives by virtue of the experience and skill of our management team, our integrated and flexible underwriting and operating platform, our significant financial strength, our strong relationships with brokers, customers and capital partners, our commitment to superior service and our proprietary modeling technology. By consistently applying each of our three competitive advantages we can offer specialized services and products at times and in markets where capacity and alternatives may be limited.UnderwritingUnderwriting IncomeOur first driver of profit is underwriting income, which we earn on our core underwriting business. Our underwriting results are reflected in our reportable segments: (1) Property, which is comprised of catastrophe and other property (re)insurance written on behalf of our consolidated operating subsidiaries, joint ventures and managed funds; and (2) Casualty and Specialty, which is comprised of general casualty, professional liability, credit and other specialty (re)insurance written on behalf of our consolidated operating subsidiaries, joint ventures and managed funds. Our underwriting results reflect the full value of the business written on behalf of our consolidated operating subsidiaries, joint ventures and managed funds, before we reflect the interests of third-party investors in our consolidated joint ventures and managed funds that are not retained by us. 4The following table shows gross premiums written allocated to each of our segments. Operating results relating to our segments are included in â€œPart II, Item 7. Management” Discussion and Analysis of Financial Condition and Results of Operations.â€Year ended December 31, 202420232022(in thousands, except percentages)GrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenProperty\$4,823,731Â 41.1% \$3,562,414Â 40.2Â % \$3,734,241Â 40.5Â %Casualty and Specialty6,909,335Â 58.9Â %5,299,952Â 59.8Â %5,479,299Â 59.5Â %Total gross premiums written\$11,733,066Â 100.0Â %\$8,862,366Â 100.0Â %\$9,213,540Â 100.0Â %Across our segments, we write proportional business, excess of loss business, and business through delegated authority arrangements. The business we write through delegated authority arrangements is primarily insurance business. We view our insurance business through a reinsurance lens, with a focus on approaching it as a portfolio of risks. Our relative mix of business between proportional business and excess of loss business has fluctuated in the past and has the potential to change in the future. Proportional and delegated authority business typically have relatively higher premiums per unit of expected underwriting income as well as a higher acquisition expense ratio and combined ratio than traditional excess of loss reinsurance, as these coverages tend to be exposed to relatively more attritional, and frequent, losses while being subject to less expected severity. The following table shows gross premiums written by type of risk in each of our segments:Year ended December 31, 2024PropertyCasualty and SpecialtyTotal(in thousands)Excess of loss\$3,364,490Â \$1,134,177Â \$4,498,667Â Proportional\$821,955Â 5,308,224Â 6,130,179Â Delegated authority637,286Â 466,934Â 1,104,220Â Total gross premiums written\$4,823,731Â \$6,909,335Â \$11,733,066Â Year ended December 31, 2023(in thousands)Excess of loss\$2,468,566Â \$857,957Â \$3,326,523Â Proportional667,074Â 4,102,088Â 4,769,162Â Delegated authority426,774Â 339,907Â 766,681Â Total gross premiums written\$3,562,414Â \$5,299,952Â \$8,862,366Â Year ended December 31, 2022(in thousands)Excess of loss\$2,354,919Â \$914,607Â \$3,269,526Â Proportional785,394Â 4,092,210Â 4,877,604Â Delegated authority593,928Â 472,482Â 1,066,410Â Total gross premiums written\$3,734,241Â \$5,479,299Â \$9,213,540Â Property SegmentOur Property segment includes our catastrophe class of business, principally comprised of excess of loss reinsurance and excess of loss retrocessional reinsurance, which insures insurance and reinsurance companies against natural and man-made catastrophes. It also includes our other property class of business, primarily comprised of proportional reinsurance, property per risk, property (re)insurance, binding facilities and regional U.S. multi-line reinsurance, which have exposure to natural and man-made catastrophes. 5The following table shows gross premiums written in our Property segment allocated by class of business:Year ended December 31, 202420232022(in thousands, except percentages)GrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenCatastrophe\$2,996,890Â 62.1Â % \$2,146,323Â 60.2Â % \$2,076,752Â 55.6Â %Other property1,826,841Â 37.9Â % 1,416,091Â 39.8Â % 1,657,489Â 44.4Â %Total Property segment gross premiums written\$4,823,731Â 100.0Â % \$3,562,414Â 100.0Â % \$3,734,241Â 100.0Â %We write catastrophe reinsurance and insurance coverage protecting against natural and man-made catastrophes such as earthquakes, hurricanes, typhoons and tsunamis, winter storms, freezes, floods, fires, windstorms, tornadoes, explosions and acts of terrorism. We offer this coverage to insurance companies and other reinsurers primarily on an excess of loss basis. This means we begin paying when our customersâ€™ claims from a catastrophe exceed a certain retained amount. We also offer proportional coverages and other structures on a catastrophe-exposed basis. Our excess of loss property contracts generally cover natural perils, and our predominant exposure under such coverage is to property damage. However, other risks, including business interruption and other non-property losses, may also be covered under our property reinsurance contracts when arising from a covered peril. We offer our coverages on a worldwide basis. Because of the wide range of possible catastrophic events to which we are exposed, including the size of such events and the potential for multiple events to occur in the same time period, our property business is volatile and our financial condition and results of operations reflect this volatility. To moderate the volatility of our risk portfolio, we may increase or decrease our presence in the property business based on market conditions and our assessment of risk-adjusted pricing adequacy. We frequently purchase reinsurance or other protection for our own account for a number of reasons, including to optimize the expected outcome of our underwriting portfolio, to manage capital requirements for regulated entities and to reduce the financial impact that a large catastrophe or a series of catastrophes could have on our results.Casualty and Specialty SegmentWe write casualty and specialty reinsurance and insurance across a broad range of classes of business, including general casualty, professional liability, credit and other specialty lines. This business is predominantly reinsurance, although we also write insurance business, primarily through delegated authority arrangements. As a result of our financial strength and stable, long-term relationships with leading underwriters of casualty and specialty insurance globally, we offer significant capacity in this segment. 6The following table shows gross premiums written in our Casualty and Specialty segment aggregated by class of business:Year ended December 31, 202420232022(in thousands, except percentages)GrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGeneral casualty (1)\$2,280,818Â 33.0Â % \$1,730,102Â 32.6Â % \$1,560,594Â 28.5Â %Professional liability (2)1,212,134Â 17.5Â % 1,212,393Â 22.9Â % \$1,728,570Â 31.5Â %Credit (3)901,716Â 13.1Â % 769,321Â 14.5Â % 1,062,183Â 19.4Â %Other specialty (4)2,514,667Â 36.4Â % 1,588,136Â 30.0Â % 1,127,952Â 20.6Â %Total Casualty and Specialty segment gross premiums written\$6,909,335Â 100.0Â % \$5,299,952Â 100.0Â % \$5,479,299Â 100.0Â % (1)Includes automobile liability, casualty clash, employersâ€™ liability, umbrella or excess casualty, workersâ€™ compensation and general liability. (2)Includes directors and officers, medical malpractice, professional indemnity and transactional liability. (3)Includes financial guaranty, mortgage guaranty, political risk, surety and trade credit. (4)Includes accident and health, agriculture, aviation, construction, cyber, energy, marine, satellite and terrorism.Â Lines of business such as regional multi-line and whole account may have characteristics of various other lines of business, and are allocated accordingly.We offer our casualty and specialty reinsurance products principally on a proportional basis, and we also provide excess of loss coverage. These products frequently include tailored features such as limits or sub-limits which we believe help us manage our exposures. Any liability exceeding, or otherwise not subject to, such limits reverts to the cedant. Certain casualty and specialty lines of business such as marine, energy and terrorism are also exposed to catastrophe risk, and we seek to appropriately estimate and manage correlations between these lines and our property reinsurance portfolio.Our Casualty and Specialty segment also offers certain insurance products, including excess and surplus, general liability and professional liability lines of business, primarily through delegated authority arrangements. We write this business in a similar manner to our reinsurance business, and view it through a reinsurance lens, with a focus on approaching it as a portfolio of risks.OtherIn addition to our two reportable segments, we have an Other category. Our Other category primarily includes the results of: (1)Â our investment unit which manages and invests the funds generated by our consolidated operations; (2) our share of strategic investments in certain markets we believe offer attractive risk-adjusted returns or where we believe our investment adds value, and where, rather than assuming exclusive management responsibilities ourselves, we partner with other market participants; and (3)Â our corporate expenses, certain expenses related to acquisitions and dispositions, capital servicing costs and noncontrolling interests. GEOGRAPHIC BREAKDOWNOur exposures are generally diversified across geographic zones, but are also a function of market conditions and opportunities. Our largest exposure has historically been to the U.S. and Caribbean. 7The following table sets forth the amounts and percentages of our gross premiums written by territory of coverage exposure:Year ended December 31, 202420232022(in thousands, except percentages)GrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenU.S. and Caribbean\$2,996,891Â 25.5Â % \$2,303,013Â 26.0Â % \$2,343,830Â 25.5Â %Worldwide1,063,292Â 9.1Â % 798,623Â 9.0Â % 1,053,369Â 11.4Â % Europe244,523Â 2.1Â % 163,500Â 1.9Â % 62,998Â 0.7Â % (excluding U.S.) (1)180,688Â 1.5Â % 70,464Â 0.8Â % 37,436Â 0.4Â % Japan106,533Â 0.9Â % 85,823Â 1.0Â % 104,767Â 1.1Â % Australia and New Zealand101,976Â 0.9Â % 70,107Â 0.8Â % 86,080Â 0.9Â % Other129,738Â 1.1Â % 70,702Â 0.8Â % 45,761Â 0.5Â % Total Property Segment4,823,731Â 41.1Â % 3,562,414Â 40.3Â % 3,734,241Â 40.5Â % Casualty and Specialty SegmentWorldwide3,217,662Â 27.3Â % 2,280,687Â 25.7Â % 2,328,030Â 25.3Â % U.S. and Caribbean2,986,956Â 25.5Â % 2,333,096Â 26.3Â % 2,556,466Â 27.7Â % Europe353,863Â 3.0Â % 197,228Â 2.2Â % 327,831Â 3.6Â % Worldwide (excluding U.S.) (1)195,489Â 1.7Â % 130,334Â 1.5Â % 177,746Â 1.9Â % Australia and New Zealand43,183Â 0.4Â % 27,397Â 0.3Â % 35,973Â 0.4Â % Other112,182Â 1.0Â % 63,210Â 3.7Â % 53,253Â 0.6Â % Total Casualty and Specialty Segment6,909,335Â 58.9Â % 5,299,952Â 59.7Â % 5,479,299Â 59.5Â % Total gross premiums written\$11,733,066Â 100.0Â % \$8,862,366Â 100.0Â % \$9,213,540Â 100.0Â % (1)The category â€œWorldwide (excluding U.S.)â€ consists of contracts that cover more than one geographic region (other than the U.S.).Principal Wholly-Owned Operating SubsidiariesOur principal wholly-owned operating subsidiaries are Renaissance Reinsurance, RREAG, Renaissance Reinsurance U.S., RenaissanceRe Specialty U.S. and Syndicate 1458. Through these subsidiaries we write the property and casualty and specialty (re)insurance that drives our underwriting income. Renaissance Reinsurance is our primary flagship balance sheet, through which we have broad exposure to a range of risks. Our other balance sheets allow us to optimize where and how we write specific risks, considering geographic location, regulatory flexibility, and the ability to access different markets of risk. For example, RenaissanceRe Specialty U.S. writes excess and surplus U.S. risk which can be supported on a quota share reinsurance or delegated authority basis through managing general agents, and RREAG focuses on writing specialty risks across the European market and in other jurisdictions utilizing its branches and our reinsurance intermediaries. We utilize our integrated and flexible underwriting platform to ensure that risks are matched with the optimal principal wholly-owned operating subsidiary balance sheet. Over the course of 2024, we merged Validus Re and Validus Switzerland, the primary Validus operating entities we acquired in the Validus Acquisition, into our existing operating structure. CAPITAL PARTNERSFee Income We pursue a number of other opportunities, including creating and managing our joint ventures and managed funds, executing structured reinsurance transactions to assume or cede risk and managing certain strategic investments. These opportunities aid us in generating our second driver of profit, the fee income that we earn on our capital management business. We earn two types of fee income by managing third-party capital in our Capital Partners unit: management fee income and performance fee income. Compared to underwriting income, we view fee income, especially management fee income, as being a relatively less volatile and diversifying source of income.Our capital management business is one of the oldest, largest and most respected in the industry and provides us with a larger capital base, through which we are able to write more business and reach a broader customer base. In addition to the business that we write for our own account, we also write risk with capital provided by third parties. Because we often co-invest alongside our third-party capital providers, we view them as partners in achieving our mission of matching desirable risk with efficient capital. Our third-party capital partners are typically institutional investors seeking investment returns that are less correlated with the broader capital markets. We believe that we benefit from our ability to optimize our portfolio construction across our vehicles and business through superior risk selection. Our third-party capital partners benefit from our ability to access the best risk and construct high-quality portfolios in tailored geographies to suit their investment needs. At the same time, this business benefits our customers, as it allows us to write more risk in various forms across balance sheets with diversified counterparties. We are also able to offer additional investment opportunities to institutional and other investors to serve as our capital partners and make targeted investments in certain of the products that we offer. Managed Joint Ventures and Managed FundsWe manage a number of joint ventures and managed funds which provide us with an additional presence in the market, enhance our client relationships and generate management fee income and performance fee income. Currently, our principal joint ventures and managed funds include DaVinci, Fontana, Medici, Vermeer, Top Layer and Upsilon.December 31, 2024EntityConsolidated (1)RenaissanceRe”s Economic Ownership (2)Generates Management Fee Income (3)Generates Performance Fee Income (4)DaVinciX25.4%XXFontanaX26.5%XXMediciX15.8%X”VermeerX”X”Top Layer”A ”A ” (5)”X”Upsilon”A ”A ”X (6)”XX(1)As a result of our controlling voting interest, we consolidate these entities in our financial statements, such that the third partiesâ€™ economic interest in the entitiesâ€™ net assets and net income (loss) are reflected in our consolidated balance sheets and consolidated statements of operations in redeemable noncontrolling interests and net (income) loss attributable to redeemable noncontrolling interests, respectively. (2)Represents the Companyâ€™s noncontrolling economic ownership in each of the entities.(3)Management fees are fees that we receive for the day-to-day management and oversight of our joint venture vehicles and managed funds.(4)Performance fees may be negative in a particular period if, for example, large losses occur, which can potentially result in no performance fees or the reversal of previously accrued performance fees.(5)Top Layer is not consolidated. It is owned 50% by State Farm and 50% by Renaissance Reinsurance.(6)Upsilon includes Upsilon RFO and Upsilon Fund. We consolidate the financial results of certain segregated accounts of Upsilon RFO and account for the portion of its premium that we do not own as a ceded retrocession. We do not consolidate the financial results of Upsilon Fund. DaVinciWe formed DaVinci in 2001 to expand our capacity to provide property catastrophe reinsurance and certain lines of casualty and specialty reinsurance on a global basis. Third-party investors own a majority of the economic interest in DaVinci, which provides them with access to attractive risk while generating a management fee and a performance fee stream of income for us. In addition, we maintain a significant economic investment in DaVinci. We control a majority of the outstanding voting rights in DaVinci, DaVinci Reinsurance”s holding company, and as a result, consolidate DaVinci in our financial results. RUM, a wholly owned subsidiary of RenaissanceRe, acts as the exclusive underwriting manager for DaVinci. Through our operating subsidiaries, principally Renaissance Reinsurance, we participate on every risk that DaVinci Reinsurance assumes, ensuring alignment. From time to time, Renaissance Reinsurance or certain other operating subsidiaries write business for both themselves and DaVinci Reinsurance, and then cede a portion to DaVinci Reinsurance.9FontanaFontana assumes casualty and specialty risks, including long-tail lines. Third-party investors own a majority of the economic interest in Fontana, which provides them with access to attractive casualty and specialty risk while generating a management fee and a performance fee stream of income for us. Fontana also allows us to increase casualty and specialty capacity for our customers. We control a majority of the outstanding voting rights in Fontana, and as a result, consolidate it in our financial results. Fontana assumes a whole account quota share of our global casualty and specialty book of business, including the credit portfolio, ensuring alignment. Fontana comprises a group of reinsurance operating companies and their holding companies, in which we maintain a significant economic investment.MediciMedici principally invests in property catastrophe bonds, although it may also invest in various other insurance-based investment instruments that have returns primarily correlated to property catastrophe risk. Third-party investors own a majority of the participating, non-voting common shares of Medici, pursuant to which they own a majority of Medici”s economic benefits, which provides them with access to attractive catastrophe bond risks while generating a management fee stream of income for us. Medici allows us to increase our participation in our customersâ€™ catastrophe bond offerings and broaden our relationships with them. We control all of Medici”s

outstanding voting rights, and as a result consolidate it in our financial results. RFM, a wholly owned subsidiary of RenaissanceRe, acts as the exclusive investment fund manager of Medici. We maintain a significant investment in Medici. VermeerVermeer expands our ability to provide capacity focused on risk remore layers in the U.S. property catastrophe market. We maintain majority voting control of Vermeer, and as a result consolidate it in our financial results. Stichting Pensioenfonds Zorg en Welzijn, a pension fund represented by PGGM, retains 100% of Vermeer’s economic benefits. Vermeer is managed by RUM in return for a management fee. We separately participate in the risks written by Vermeer through our wholly-owned balance sheets.Top LayerWe established Top Layer in 1999 to expand our ability to write high excess non-U.S. property catastrophe reinsurance. Top Layer is owned 50% by State Farm and 50% by Renaissance Reinsurance, although State Farm provides the majority of Top Layer’s underwriting capacity through a \$3.9 billion stop-loss reinsurance agreement, and therefore, State Farm retains most of Top Layer’s underwriting results. Since we do not control Top Layer, we do not consolidate it in our financial results. Top Layer is managed by RUM in return for a management fee. We maintain a significant investment in Top Layer.Upsilon Upsilon is composed of Upsilon RFO and Upsilon Fund. Upsilon RFO is the risk bearing entity. As a segregated accounts company, Upsilon RFO holds identified pools of assets and liabilities in accounts that are each ring-fenced or segregated from any claims from the creditors of Upsilon RFO’s general account and from the creditors of other segregated accounts within Upsilon RFO. Upsilon RFO’s segregated accounts enter into collateralized reinsurance arrangements, and each account’s capital is sourced either directly from third-party investors, or from Upsilon Fund. We consolidate the financial results of certain accounts of Upsilon RFO and account for the portion of its premium that we do not own as a ceded retrocession. Upsilon gives us the ability to provide additional capacity to the worldwide aggregate and per-occurrence primary and retrocessional markets on a collateralized basis, either directly, or through business written by Renaissance Reinsurance and then ceded to Upsilon RFO. Upsilon Fund is also a segregated accounts company, and each account acts as either a pool of assets from multiple investors, such as Upsilon Diversified, or as a separately-managed account for an individual institutional investor, such as NOC1. Upsilon Fund’s segregated accounts invest in either Upsilon RFO, or in other reinsurance risks that are managed by us. Upsilon Fund is managed by RFM in return for a management fee and a performance fee. We do not consolidate Upsilon Fund. We maintain a significant investment in Upsilon RFO. 10AlphaCatIn connection with the Validus Acquisition, we acquired AlphaCat Managers, which manages third-party capital in various forms, including through closed-end and open-end Bermuda mutual funds and one managed account, collectively, the AlphaCat Funds, which currently generate fee income. Prior to the Validus Acquisition, substantially all of the AlphaCat Funds had received full redemption requests from their investors and capital was being released accordingly, subject to certain constraints. We expect to run off this business over a period of time. Noncontrolling InterestWe manage DaVinci, Fontana, Medici, and Vermeer, and own all or a majority of the voting interests, but own no, or a minority, economic interest of each. As a result of our controlling voting interests, we fully consolidate these entities in our financial statements, even though we do not retain the full value of economic outcomes generated by these entities. The portions of the economic outcomes that are not retained by us are ultimately allocated to the third-party investors who hold the noncontrolling interests in these entities. The economic outcomes may include underwriting results, investments results, and foreign exchange impacts, among other items. For example, if one of these entities were to generate underwriting losses due to a natural catastrophe, the full amount would be reflected in net income (loss) on our consolidated statements of operations, but ultimately we would only retain the portion of that amount corresponding to our economic interest in the vehicle in the net income (loss) attributable to RenaissanceRe. In our consolidated balance sheets and consolidated statements of operations, the aggregated portion of these various economic outcomes attributable to third parties is reflected in net (income) loss attributable to redeemable noncontrolling interests. Refer to Note 10. Noncontrolling Interests in our Notes to the Consolidated Financial Statements for additional information regarding our redeemable noncontrolling interests and how this accounting treatment impacts our financial results.Other TransactionsFrom time to time, we pursue other customized reinsurance and financing transactions. For example, we have participated in, and continuously analyze, other attractive opportunities in the market for insurance-linked securities and derivatives. We believe our products contain a number of customized features designed to fit the needs of our capital partners, as well as our risk management objectives.INVESTMENTSInvestment IncomeOur investment portfolio generates our third driver of profit, investment income. We structure our investment portfolio to emphasize the preservation of capital and the availability of liquidity to meet our claims obligations, to be well diversified across market sectors, and to generate relatively attractive returns on a risk-adjusted basis over time. Our investment portfolio also serves as a stable capital base against which we can underwrite risk, and also allows us to generate relatively attractive investment income and returns over time. Our investment portfolio includes both investments that we make on behalf of the Company and whose investment results are fully retained by the Company, as well as investments that we manage on behalf of our joint ventures and managed funds, in which we retain no, or only a partial, economic interest.The majority of our investments are highly-rated fixed income securities. We also hold a significant amount of short term investments which have a maturity of one year or less when purchased. In addition, we hold other investments, including catastrophe bonds, fund investments, term loans and direct private equity investments, which offer the potential for higher returns but with relatively higher levels of risk. Our investment portfolio takes into account the duration of our liabilities and the level of strategic asset risk we wish to assume over the medium- to long-term. We may from time to time re-evaluate our investment guidelines and explore investment allocations to other asset classes that either increase or decrease our overall asset risk. To further the sustainability of our investment portfolio, we consider certain environmental, social and governance factors within our investment strategy. Our investments are subject to market-wide risks and fluctuations, as well as to risks inherent in particular securities. For additional information regarding our investment portfolio, refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.Financial Condition, Liquidity and Capital ResourcesInvestmentsInvestments 5. Investments in our Notes to the Consolidated Financial Statements.Strategic InvestmentsWe also pursue strategic investments where, rather than assuming exclusive management responsibilities ourselves, we partner with other market participants. These investments may be directed at classes of risk other than catastrophe reinsurance, and at times may also be directed at non-insurance risks. We find these investments attractive because of their target risk-adjusted returns, and because of their ability to help advance our business objectives and capabilities. We believe that our strategic investments provide us with enhanced risk access and information on markets that are core to our business, as well as potential new markets for future growth consideration. For example, we have strategic investments in the Tower Hill Companies which grant us access to participants in the Florida homeowners insurance market. Additionally, we have a strategic investment in TWFG, which distributes personal and commercial insurance across the United States.COMPETITIONThe markets in which we operate are highly competitive. Our competitors include independent reinsurance and insurance companies, subsidiaries, divisions and/or affiliates of globally recognized insurance companies, domestic and international underwriting operations, such as managing general agents, as well as a range of other entities offering risk transfer protection on a collateralized or other non-traditional basis. As our business and the (re)insurance industry continue to evolve, we expect our competitors to evolve as well, and we may face competition from other non-traditional participants, such as technology or Insurtech companies, among others.We believe that our principal competitors are traditional insurance and reinsurance companies, but also include third-party capital managers. We also compete with certain Lloyd’s syndicates active in the London market. Hedge funds, pension funds and endowments, investment banks, insurance exchanges and other capital market participants may also be active in the reinsurance market and the market for related risk, either through the formation of reinsurance companies or through the use of financial products, such as catastrophe bonds and other insurance-linked securities.RISK MANAGEMENTUnderwriting Risk ManagementOur primary underwriting goal is to construct a portfolio of reinsurance and insurance contracts and other financial risks that maximizes our return on shareholders’ equity, subject to prudent risk constraints, and to generate long-term growth in tangible book value per common share plus the change in accumulated dividends. We assess each new (re)insurance contract on the basis of the expected incremental return relative to the incremental contribution to portfolio risk.We have developed a proprietary pricing and exposure management system, REMSA, which has analytic and modeling capabilities that help us to assess the risk and return of each incremental (re)insurance contract in relation to our overall portfolio of (re)insurance contracts. We believe that REMSA is a robust underwriting and risk management system that has been successfully integrated into our business processes and culture. In conjunction with pricing models that we run outside of REMSA, the REMSA framework encompasses and facilitates risk capture, analysis, correlation, portfolio aggregation and capital allocation within a single system for all of our natural and non-natural hazards (re)insurance contracts. We continue to invest in and improve REMSA, incorporating our underwriting and modeling experience and adding proprietary software and industry data. We believe that the expertise and tools are state of the art and have been fully embedded in our underwriting processes.We generally utilize a multiple model/method approach when evaluating a proposed transaction, combining both probabilistic and deterministic techniques. We combine the analyses generated by REMSA with other information and other model inputs available to us, including our own knowledge of the client submitting the proposed program, to assess the premium offered against the risk of loss and the cost of utilized capital which the program presents. The underlying risk models integrated into our underwriting and REMSA framework are a combination of internally constructed and commercially available models. We use commercially available models to assist with validating and stress testing our base model and REMSA results. Before we bind a (re)insurance risk, exposure data, historical loss information and other risk data is gathered from customers. Using a combination of proprietary software, underwriting experience, actuarial techniques and engineering expertise, the exposure data is reviewed and augmented, as we deem appropriate. We use this data as primary inputs into the REMSA modeling system as a base to create risk distributions to represent the risk being evaluated. We believe that the REMSA modeling system helps us to analyze each contract on a consistent basis, assisting our determination of what we believe to be an appropriate price to charge for each policy based upon the risk to be assumed. In part, through the process described above and the utilization of REMSA, we seek to compare our estimate of the expected returns in respect of a contract with the amount of capital we notionally allocate to the contract based on our estimate of its marginal impact on our portfolio of risks. A key advantage of our REMSA framework is our ability to include additional perils, risks and geographic areas that may not be captured in commercially available natural hazards risk models. We periodically review the estimates and assumptions that are reflected in REMSA and our other tools, driven either by new hazard science and understanding or by experience of loss events. We continually monitor frequency and severity trends for our casualty lines of business, in particular emerging trends toward higher levels of social inflation. Where appropriate, we are able to shift our business mix away from classes and industry sectors that are particularly sensitive to higher social inflation trends. More generally, our team of scientists at RenaissanceRe Risk Sciences Inc. have been tracking the influence of climate change to better understand the impact of natural catastrophes on our business. Our underwriters use the combination of our risk assessment and underwriting process, REMSA and other tools in their pricing decisions, which we believe provides them with several competitive advantages. These include the ability to: (i) simulate a range of potential outcomes that adequately represents the risk to an individual contract; (ii) analyze the incremental impact of an individual reinsurance contract on our overall portfolio; (iii) better assess the underlying exposures associated with assumed retrocessional business; (iv) price contracts within a short time frame; (v) capture various classes of risk, including catastrophe and other insurance risks; (vi) assess risk across multiple entities (including our various joint ventures and managed funds) and across different components of our capital structure; and (vii) provide consistent pricing information. As part of our risk management process, we also use REMSA to assist us, as a retrocedant, with the purchase of reinsurance coverage for our own account.Our underwriting and risk management process, in conjunction with REMSA, quantifies and manages our exposure to claims from single events and the exposure to losses from a series of events. As part of our pricing and underwriting process, we also assess a variety of other factors, including: (i) the reputation of the proposed cedant and the likelihood of establishing a long-term relationship with the cedant; (ii) the geographic area in which the cedant does business and its market share; (iii) historical loss data for the cedant and, where available, for the industry as a whole in the relevant regions and lines of business, in order to compare the cedant’s historical catastrophe loss experience to industry averages; (iv) the cedant’s pricing strategies; and (v) the perceived financial strength of the cedant and factors such as the cedant’s historical record of making premium payments in full and on a timely basis.In order to estimate the risk profile of each line of non-natural hazard reinsurance (i.e., our casualty and specialty lines of business), we establish probability distributions and assess the correlations with the rest of our portfolio. In casualty and specialty lines with catastrophe risk, such as marine, energy and terrorism, we seek to directly leverage our skill in modeling property reinsurance risks, and aim to appropriately estimate and manage the correlations between these casualty and specialty lines and our property reinsurance portfolio. For other classes of business, in which we believe we have little or no natural catastrophe exposure, and therefore less correlation with our property reinsurance coverages, we derive probability distributions from a variety of underlying information sources, including recent historical experience, and the application of judgment as appropriate. The nature of some of these businesses lends itself less to the analysis we use for our property reinsurance coverages, reflecting both the nature of available exposure information, and the impact of human factors such as tort exposure. We produce probability distributions to represent our estimates of the related underlying risks which our products cover, which we believe helps us to make consistent underwriting decisions and to manage our total risk portfolio.13In addition, we also produce, utilize, and report on models which measure our utilization of capital in light of regulatory capital considerations and constraints.À Our position in respect of these regulatory capital models is reviewed by our risk management professional staff and periodically reported to and reviewed by senior underwriting personnel and executive management with responsibility for our regulated operating entities. Enterprise Risk Management We believe that high-quality and effective ERM is best achieved when it is a shared cultural value throughout the organization and consider ERM to be a key process which is the responsibility of every individual at RenaissanceRe. We have developed and utilize tools and processes we believe support a culture of risk management and create a robust framework of ERM within our organization. We believe that our ERM processes and practices help us to identify potential events that may affect us, quantify, evaluate and manage the risks to which we are exposed, and provide reasonable assurance regarding the achievement of our objectives. We also believe that effective ERM assists our efforts to minimize the likelihood of suffering financial outcomes in excess of the ranges which we have estimated in respect of specific investments, underwriting decisions, or other operating or business activities, including cybersecurity risks, although we do not believe this risk can be eliminated. In particular, we utilize our risk management tools to support our efforts to monitor our capital and liquidity positions on a consolidated basis and for each of our major operating subsidiaries, and to allocate an appropriate amount of capital to support the risks we have assumed in the aggregate and for each of our major operating subsidiaries. Our Board and its committees are responsible for overseeing enterprise-wide risk management and are actively involved in the monitoring of risks that could affect us. The members of the Board have regular, direct access to the senior executives and other officers responsible for identifying and monitoring our risks and coordinating our ERM, including our Group Chief Risk Officer, Chief Portfolio Officer, Group Chief Underwriting Officer, Chief Financial Officer, and Group General Counsel, each of whom reports directly to our Chief Executive Officer, as well as other senior personnel such as our Chief Investment Officer, Chief Compliance Officer, Chief Accounting Officer, Global Corporate Controller and Head of Internal Audit. The Board also receives regular reports from the Operational Risk and Resilience Committee, which includes members of senior management, compliance professionals and others and oversees policies and procedures relating to accounting, financial reporting, internal controls, legal and regulatory matters, and complex transactions, among other matters.Our ERM framework operates via a three lines model. The first line consists of individual functions that deliberately assume risks on our behalf and own and manage risk within the Company on a day-to-day and business operational basis. The second line is responsible for risk oversight and also supports the first line to understand and manage risk, and is comprised of a dedicated risk team led by the Group Chief Risk Officer who reports to the Board’s Investment and Risk Management Committee and the Chief Executive Officer, and a dedicated compliance team led by the Group General Counsel who reports to the Board’s Audit Committee and the Chief Executive Officer. The third line, our Internal Audit team, reports to the Audit Committee of the Board and provides independent, objective assurance as to the assessment of the adequacy and effectiveness of our internal control systems and also coordinates risk-based audits and compliance reviews and other specific initiatives to evaluate and address risk within targeted areas of our business. The principal risk areas that make up our ERM framework are assumed risk (including reserve risk), business environment risk and operational risk.À Assumed Risk. We define assumed risk as activities where we deliberately take risk against our capital base, including underwriting risks and other quantifiable risks such as credit risk and market risk as they relate to investments, ceded reinsurance credit risk and strategic investment risk, each of which can be analyzed in substantial part through quantitative tools and techniques. Of these, we believe underwriting risk to be the most material to us. In order to understand, monitor, quantify and proactively assess underwriting risk, we seek to develop and deploy appropriate tools to estimate the comparable expected returns on potential business opportunities and the impact that such incremental business could have on our overall risk profile. We use the tools and methods described above in Underwriting to seek to achieve these objectives. Embedded within our consideration of assumed risk is our management of our aggregate, consolidated risk profile. In part through the utilization of REMSA and our other systems and procedures, we analyze our in-force

aggregate assumed risk portfolio on a daily basis. We believe this capability helps us to manage 140our aggregate exposures and to rigorously analyze and evaluate individual proposed transactions in the context of our in-force portfolio. This aggregation process captures line of business, segment and corporate risk profiles, calculates internal and external capital tests and explicitly models ceded reinsurance. Generally, additional data is added quarterly to our aggregate risk framework to reflect updated or new information or estimates relating to matters such as interest rate risk, credit risk, capital adequacy and liquidity. This information is used in day-to-day decision making for underwriting, investments and operations and is also reviewed quarterly from both a unit level and consolidated financial position perspective. We also regularly assess, monitor and review our regulatory risk capital and related constraints. Reserve Risk. Reserve risk is a subcomponent of assumed risk. We define reserve risk as the risks related to our reserve for net claims and claim expenses, including the amount, both absolute and relative, of our reserve for net claims and claim expenses, and the impact of economic, social, legal and regulatory matters. Our reserve for net claims and claim expenses is subject to significant uncertainty and has the potential to develop adversely in future periods. While reserve risk may increase in both absolute terms and relative to its overall consideration in our ERM framework, we employ robust resources, procedures and technology to identify, understand, quantify and manage this risk. Our reserving methodologies and sensitivities for each respective line of business described in Part II, Item 7. Management Discussion and Analysis of Financial Condition and Results of Operations Summary of Critical Accounting Estimates Claims and Claim Expense Reserves Business Environment Risk. We define business environment risk as the risk of changes in the business, political or regulatory environment that could negatively impact our short term or long-term financial results or the markets in which we operate. This risk area also typically includes emerging risks. These risks are predominately extrinsic to us and our ability to alter or eliminate these risks is limited, so we focus our efforts on monitoring developments, assessing potential impacts of any changes, and investing in cost effective means to attempt to mitigate the consequences of, and ensure compliance with, any new requirements applicable to us. Operational Risk. We are subject to a number of additional risks arising out of operational, regulatory, and other matters. We define operational risk to include the risk that we fail to create, manage, control or mitigate the people, processes, structures or functions required to execute our strategic and tactical plans and assemble an optimized portfolio of assumed risk, and to adjust to and comply with the evolving requirements of business environment risk applicable to us. In light of the rapid evolution of our markets, business environment, and business initiatives, we seek to continually invest in the tools, processes and procedures we use to mitigate our exposure to operational risk on a cost-effective basis. As with assumed risk and business environment risk, operational risk presents intrinsic uncertainties, and we may fail to appropriately identify or mitigate applicable operational risk. We address other areas of operational risk through our business continuity and incident response program, human resource practices such as motivating and retaining top talent, our strict tax protocols and our legal and regulatory policies and procedures. ENVIRONMENTAL AND CLIMATE CHANGE MATTERSOur principal economic exposures arise from our coverages for natural disasters and catastrophes. We believe, and believe the consensus view of current scientific studies substantiates, that changes in climate conditions, primarily global temperatures and expected sea levels, have increased, and are likely to continue to increase, the severity and frequency of weather related natural disasters and catastrophes relative to the historical experience over the past 100 years. While it is difficult to distinguish between permanent climate change and transient climate variability, an ever expanding body of research suggests that these trends are in fact man-made, and, if correct, we believe that this trend will not revert to the mean but continue to worsen. We believe that this increase in severe weather, coupled with currently projected demographic trends in catastrophe-exposed regions, contributes to factors that will increase the average economic value of expected losses, increase the number of people exposed per year to natural disasters and in general exacerbate disaster risk, including risks to infrastructure, global supply chains and 15agricultural production. Accordingly, we expect an increase in both the frequency and magnitude of claims, especially from properties located in coastal areas. The consideration of the impacts of climate change is integral to our ERM process. We have taken measures to mitigate losses related to climate change through our underwriting process and by continuously monitoring and adjusting our risk management models to reflect the higher level of risk that we think will persist. We have been progressively integrating the consideration of the financial risk of climate change into our governance frameworks, risk management processes, and business strategies over the past several years, and many of our regulators are increasingly focused on these and other climate change disclosures. Additionally, as a (re)insurance company, we believe that we play a role in helping to facilitate the transition to a lower-carbon economy through three primary means: (i) by assuming risk, to promote the liquidity and capital necessary to enable the orderly transition of industries, businesses and society towards a lower carbon future; (ii) as an asset owner, by using our investment portfolio to promote a low-carbon future; and (iii) through our business operations, by striving to reduce our operational carbon footprint. Our Board and its committees are actively engaged in the oversight of sustainability initiatives and receive regular reports from management on progress and developments. In addition to the impacts that environmental incidents have on our business, there has been a proliferation of governmental and regulatory initiatives and scrutiny related to climate change and greenhouse gases, which may also affect our business. For example, the EU adopted the Corporate Sustainability Reporting Directive that requires disclosure of the risks and opportunities arising from social and environmental issues, and on the impact of companies activities on people and the environment. Other regulators, such as the State of California, have adopted requirements on climate change disclosures that could significantly increase compliance burdens and associated regulatory costs and complexity, and other regulators may propose similar rules in the future. RATINGSFinancial strength ratings are important to the competitive position of reinsurance and insurance companies. We have received high financial strength ratings from A.M. Best, S&P, Moody's and Fitch. These ratings represent independent opinions of an insurer's financial strength, operating performance and ability to meet policyholder obligations, and are not an evaluation directed toward the protection of investors or a recommendation to buy, sell or hold any of our securities. Certain of our entities and the senior notes and preference shares issued by them also have issuer credit ratings. Rating organizations continually review the financial positions of our principal operating subsidiaries and joint ventures and ratings may be revised or revoked by the agencies which issue them. Additionally, rating organizations may change their capital models and rating methodologies, which could have a material impact on our ratings and business. In addition, S&P and A.M. Best assess companies ERM practices, which is an opinion on the many critical dimensions of risk that determine overall creditworthiness. RenaissanceRe has been assigned an ERM score of Very Strong from each of these agencies, which is the highest ERM score assigned. See Part II, Item 7. Management Discussion and Analysis of Financial Condition and Results of Operations, Financial Condition, Liquidity and Capital Resources Ratings for the ratings of our principal operating subsidiaries and joint ventures by segment, and details of recent ratings actions. RESERVE FOR CLAIMS AND CLAIM EXPENSESWe believe for the most significant accounting judgment made by management is our estimate of claims and claim expense reserves. Claims and claim expense reserves represent estimates, including actuarial and statistical projections at a given point in time, of the ultimate settlement and administration costs for unpaid claims and claim expenses arising from the insurance and reinsurance contracts we sell. Our claims and claim expense reserves are a combination of case reserves, ACR and incurred but not reported losses and incurred but not enough reported losses, collectively referred to as IBNR. Case reserves are losses reported to us by insureds and ceding companies, but which have not yet been paid. If deemed necessary and in certain situations, either we establish, or our clients report, ACR. Client reported ACR represents their estimate of additional contract specific claims in excess of the case reserves they have reported to us. ACR established by us represents our estimates for claims related to specific contracts which we believe may not be adequately estimated by the client as of that date or is not within the IBNR. We establish IBNR using actuarial techniques and expert judgment to represent the anticipated cost of claims which have not been reported to us yet or where we anticipate increased reporting. Our reserving committee, which includes members of our senior management, reviews, discusses, and assesses the reasonableness and adequacy of the reserving estimates included in our audited consolidated financial statements. Because of the nature of the coverages that we provide, the amount and timing of the cash flows associated with our policy liabilities will fluctuate, perhaps significantly, and, therefore, are highly uncertain. Our reserving techniques, assumptions and processes differ among our Property and Casualty and Specialty segments. Refer to Note 8. Reserve for Claims and Claim Expenses in our Notes to the Consolidated Financial Statements for more information on the risks we insure and reinsure, the reserving techniques, assumptions and processes we follow to estimate our claims and claim expense reserves, prior year development of the reserve for claims and claim expenses, analysis of our incurred and paid claims development and claims duration information for each of our Property and Casualty and Specialty segments. In addition, refer to Part II, Item 7. Management Discussion and Analysis of Financial Condition and Results of Operations Summary of Critical Accounting Estimates Claims and Claim Expense Reserves for more information on our actual results versus our initial estimates of our claims reserves, and sensitivity analysis for each of our Property and Casualty and Specialty segments. MARKETINGWe believe that our modeling and technical expertise, our broad risk appetite, and our reputation for paying valid claims promptly has enabled us to become a provider of first choice in many lines of business to our customers worldwide. We market our products primarily through reinsurance brokers and we focus our marketing efforts on targeted brokers and partners. We believe that our existing portfolio of business is a valuable asset and, therefore, we attempt to continually strengthen relationships with our existing brokers and customers. We believe that by maintaining close relationships with brokers, we are able to obtain access to a broad range of potential reinsureds. We believe that primary insurers and brokers willingness to use a particular reinsurer is based not just on pricing, but also on the financial security of the reinsurer, its claim paying ability ratings and demonstrated willingness to promptly pay valid claims, the quality of a reinsurers service, the reinsurers willingness and ability to design customized programs, its long-term stability and its commitment to provide stable reinsurance capacity across market cycles. Our portfolio of business continues to be characterized by relatively large transactions with ceding companies with whom we do business, although no current relationship exceeds 10% of our gross premiums written. Our brokers assess client needs and also perform data collection, contract preparation and other administrative tasks, enabling us to market our products cost effectively. Our distribution is reliant on a small number of broker relationships, which has continued to decrease in recent years as a result of consolidation in the broker sector. We expect this concentration to continue. In 2024, three brokerage firms accounted for 82.1% of our gross premiums written. The following table shows the percentage of our Property and Casualty and Specialty segments gross premiums written generated through subsidiaries and affiliates of our largest brokers: Year ended December 31, 2024 Property Casualty and Specialty Total Aon plc 43.9% 23.7% 32.0% Marsh & McLennan Companies, Inc. 30.6% 40.6% 36.5% Arthur J. Gallagher 5.6% 19.2% 13.6% Total of largest brokers 80.1% 83.5% 82.1% All others 19.9% 16.5% 17.9% Total 100.0% 100.0% 100.0% HUMAN CAPITAL RESOURCESHuman Capital Resources OversightAt RenaissanceRe, our people are our most valuable resource and are core to our success. We believe in fostering an open and collaborative culture that encourages employees to take ownership of their performance and development. Our executive management team is committed to creating an environment where every person on our team can succeed. The Corporate Governance and Human Capital Management Committee of our Board is actively engaged in the oversight of our employees, work environment, DEI initiatives and compensation practices, and receives regular updates from management on progress and developments, and our executive management team and Corporate Governance and Human Capital Management Committee receive regular reports on progress against our annual human resources tactical plans. EmployeesAt February 7, 2025, we employed 945 people worldwide (February 14, 2024 - 925, February 3, 2023 - 731). Of these employees, 242 were located in Bermuda, 262 in the U.S. and Canada, 416 in Europe and 25 in the Asia-Pacific region. Talent Acquisition, Development, and RetentionWe strive to hire talented people and invest heavily in their development to aid them in their professional and personal growth. As employees grow at RenaissanceRe, we support them in mastering specific competencies at each career level. We also invest in the professional growth of our leaders through customized leadership development programs to build advanced skills and capabilities across a diverse set of participants within the organization. Our bespoke approach to development encourages continuous learning through skills-based training, technical development and stretch assignments. We aim to attract, motivate, reward and retain the best people by aligning our performance management practices with our compensation and benefits programs. Work EnvironmentWe endeavor to provide a safe, healthy and supportive work environment that promotes the well-being of our employees and the value that they contribute to our global organization. We actively encourage open dialogue with our employees, and conduct regular surveys to measure employee satisfaction and engagement, allowing us to ensure that lower-scoring areas are addressed and clear guidance and support is provided. Diversity, Equity and Inclusion InitiativesWe believe that by seeking diversity, creating equity and practicing inclusion we will build an even stronger culture and company. Our cross-functional DEI Executive Council, chaired by our Chief Portfolio Officer, sets our DEI strategy, identifying focus areas such as raising awareness of DEI throughout our organization. Our DEI governance structure also includes local advisory committees responsible for implementation at a country level. Compensation PracticesWe design our compensation programs to incorporate a range of components that we believe help to attract and retain talented individuals and mitigate potential risks, while rewarding employees for pursuing our strategic and financial objectives through appropriate risk taking, risk management and prudent tactical and strategic decision making. We strive to provide fair and living employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location. We do this by performing regular market checks of our competitive pay programs in each of our locations, as well as an annual pay cycle review where we assess each employees pay levels. REGULATIONMost countries and all U.S. states regulate (re)insurance business to varying degrees. We currently have (re)insurance operations in Australia, Bermuda, Ireland, Singapore, Switzerland, the U.K. and the U.S. Our operating subsidiaries and branches are principally regulated by the regulatory authorities of their respective jurisdictions, and may also be subject to regulation in the jurisdictions of their ceding companies. 18Expansion into additional (re)insurance markets could expose us or our subsidiaries to increasing regulatory oversight. However, we intend to continue to conduct our operations so as to minimize the likelihood that our Bermuda subsidiaries will become subject to direct U.S. regulation. Bermuda Regulation OverviewGenerally, Bermuda companies must comply with the provisions of the Bermuda Companies Act 1981. Bermuda-registered insurance companies and insurance management companies are also regulated under the Insurance Act and related regulations, which impose various requirements depending on a company's classification under the Insurance Act. The Insurance Act imposes solvency and liquidity standards as well as auditing and reporting requirements, and confers on the BMA powers to supervise, investigate and intervene in the affairs of insurance companies. As a holding company, RenaissanceRe is not directly regulated as an insurer under the Insurance Act. Our entities registered under the Insurance Act include: Class 4 general business insurers: Renaissance Reinsurance, and DaVinci Reinsurance; Class 3B general business insurers: RenaissanceRe Specialty U.S., Vermeer and RREAG, Bermuda Branch; Class 3A general business insurers: Top Layer, Fontana Reinsurance Ltd. and Fontana Reinsurance U.S. Ltd.; Class 3 general business insurer: AlphaCat Re, Mont Fort Re Ltd. and Shima Reinsurance Ltd.; Collateralized insurer: Upsilon RFO; Insurance managers: RUM and RenaissanceRe Underwriting Management Ltd. The European Commission recognizes Bermuda's regulatory regime as achieving Solvency II equivalence for its commercial (re)insurers and insurance groups. From time to time, RenaissanceRe's Bermuda-registered entities may apply for, and be granted, certain modifications to, or exemptions from, regulatory requirements which may otherwise apply to them. Group SupervisionThe BMA is the group supervisor of the RenaissanceRe Group and it has designated Renaissance Reinsurance to be the designated insurer in respect of the RenaissanceRe Group. The designated insurer is required to ensure that the RenaissanceRe Group complies with the provisions of the Insurance Act pertaining to groups and all related group solvency and group supervision rules. The BMA has certain powers of investigation and intervention, relating to Bermuda-registered entities and their holding companies, subsidiaries and other affiliates, including the power to cancel a Bermuda-registered entity's registration, which it may exercise in the interest of such an insurer's policyholders or if there is any risk of insolvency or a breach of the Insurance Act or the license conditions of a Bermuda-registered entity. The International Association of Insurance Supervisors, or IAIS, has adopted a Common Framework for the supervision of Internationally Active Insurance Groups, or IAIGs, which is focused on the group-wide supervision of IAIGs. The BMA has issued a consultation paper about proposed enhancements to its insurance group supervision framework. The development and adoption of these capital standards could increase our prescribed capital requirement, the level at which regulatory scrutiny intensifies, limit intercompany capital transactions, suspend debt repayments, and significantly increase our cost of regulatory compliance. Disclosure and Reporting RequirementsAt the group level, the RenaissanceRe Group is required to submit to the BMA a quarterly financial return, as well as the following annual filings: group statutory financial statements, group capital and solvency return, audited group financial statements, and a group solvency self-assessment. At the entity level, our Bermuda registered insurers are required to submit to the BMA both general and statutory audited annual financial statements, which are available free of charge on the BMA's website. Certain insurers and 19insurance groups are also required to prepare and publish a Financial Condition Report, or FCR. We file a consolidated group FCR, inclusive of Renaissance Reinsurance, RenaissanceRe Specialty U.S., DaVinci Reinsurance, Top Layer, Fontana Re, Fontana US and Vermeer. RREAG files a separate FCR in lieu of a standalone FCR for its Bermuda Branch. Our FCRs are available on our website. In addition, general business insurers are generally required to file an annual capital and solvency return, or BSCR, with the BMA. The BSCR is a risk-based capital model designed to give the

BMA robust methods for determining an insurer’s capital adequacy. Our 2023 group BSCR exceeded the target capital level. We are currently completing our 2024 group BSCR, and at this time, we believe we will exceed the target capital, and that each entity that is required to file will exceed the minimum amount of regulatory capital required to be maintained under Bermuda law. The Insurance Act requires that the BMA be notified in writing when any person becomes, or ceases to be, a controlled entity (as defined by applicable regulations to include significant shareholders, managing directors, and chief executives of the registered insurer or its parent company) of any Bermuda registered insurer or an officer (as defined by applicable regulations) of any Bermuda registered insurer or its parent company. We must also file with the BMA any changes to an officer or controller (as such are defined by applicable regulations) of our insurance managers. All registered insurers are required to give notice to the BMA of their intention to effect a material change within the meaning of the Insurance Act. Capital, Solvency, and Liquidity Requirements Certain solvency requirements apply to all Bermuda companies under the Bermuda Companies Act 1981. Additional requirements apply to insurance companies and insurance groups. At the group level, the value of the insurance group’s statutory assets must exceed the amount of the insurance group’s statutory liabilities by the group minimum solvency margin. At the entity level, where applicable, a general business insurer’s statutory assets must exceed its statutory liabilities by an amount equal to or greater than the prescribed minimum solvency margin. The minimum solvency margin is determined on the basis of registration category and the net premiums written and loss reserves posted. Additional regulations apply to the determination of the types of capital instruments that may be used to satisfy the solvency requirements. RenaissanceRe and certain of our Bermuda-registered insurers are also generally required to maintain available statutory economic capital and surplus at a level at least equal to their enhanced capital requirement, which level may be adjusted by the BMA. The BMA has established a target capital level applicable to certain registration categories, and to insurance groups, equal to 120% of the applicable ECR. Failure to maintain statutory capital at least equal to the target capital level would likely result in increased BMA regulatory oversight. An insurer engaged in general business is generally required to maintain a minimum liquidity ratio equal to the value of its relevant assets at not less than 75% of the amount of its relevant liabilities. Restrictions on Dividends, Distributions and Reductions of Capital Our Bermuda-registered insurers are generally prohibited from declaring or paying any dividends if in breach of the required minimum solvency margin or minimum liquidity ratio, if declaring or paying such dividend would cause them to fail to meet the required minimum solvency margin or minimum liquidity ratio, or if certain solvency requirements are not met. Additional restrictions apply to any dividend and any reduction in statutory capital over applicable thresholds. Income Taxes Through December 31, 2024, neither we nor our shareholders were required to pay Bermuda income or profits tax, withholding tax, capital gains tax, capital transfer tax, estate duty or inheritance tax in respect of our shares. However, on December 27, 2023, the Corporate Income Tax Act 2023 was enacted. As a result, certain Bermuda businesses which are part of large multinational groups will be subject to a 15% corporate income tax in Bermuda for fiscal years beginning on or after January 1, 2025, regardless of any assurance given pursuant to the Exempted Undertakings Tax Protection Act 1966. We expect our profits generated on or after January 1, 2025 in Bermuda, except for profits earned by our joint ventures and managed funds, will be subject to the 15% corporate income tax. 20 Additional Rules and Regulations Certain of our Bermuda-registered entities are subject to additional regulatory requirements, including the following: Insurance Code of Conduct. Bermuda registered insurers are required to comply with the BMA’s Insurance Code of Conduct, which establishes duties, requirements and standards regarding sound corporate governance, risk management and internal controls. Special Purpose Insurer and Collateralized Insurer Reporting Requirements. Unlike other (re)insurers, SPLs and collateralized insurers are fully funded to meet their (re)insurance obligations; therefore, the application and supervision processes are less burdensome than traditional registered general business insurers. However, these entities remain subject to annual financial statements and solvency reporting and disclosure requirements. Insurance Manager Reporting Requirements. Insurance managers are required to report to the BMA information regarding their management and operations, as well as certain events, for example, a failure to comply with a condition imposed upon it by the BMA. Economic Substance Act. Every Bermuda registered entity, other than an entity which is resident for tax purposes in certain jurisdictions outside Bermuda, engaged in a relevant activity (which includes, but is not limited to insurance, fund management, financing and leasing, and holding entity activities) and from which it earns gross revenue in a relevant financial period must satisfy economic substance requirements by maintaining a substantial economic presence in Bermuda, and certain of our entities incorporated in Bermuda are subject to annual reporting obligations regarding this requirement. Policyholder Priority. The Insurance Amendment (No. 2) Act 2018 provides that, subject to the prior payment of preferential debts under the Employment Act 2000 and the Bermuda Companies Act 1981, the insurance debts of an insurer must be paid in priority to all other unsecured debts of the insurer. Investment Fund Regulation. The Bermuda Investment Funds Act 2006 sets standards applicable to the establishment and operation of investment funds in Bermuda with a view to protecting investors. Each of our managed funds, including Medici and Upsilon Fund is registered or authorized under the Investment Funds Act and supervised funds regulated by the BMA. Under the Investment Funds Act, registered funds and authorized funds are subject to offering disclosure requirements and obligations with respect to service providers, depositary functions, safekeeping obligations, valuations, and reporting to investors and the public, among other requirements. Investment Business Regulation. In 2024, RFM and AlphaCat Managers, which were both previously exempt from requiring a license from the BMA to carry on investment business activities in or from Bermuda, received a Standard License and Class B Registration, respectively, under the Bermuda Investment Business Act 2003. As a result, RFM and AlphaCat Managers are now subject to supervision by the BMA, including disclosure and reporting requirements and, in the case of RFM, minimum net asset and liquidity requirements. U.S. Regulation Overview Renaissance Reinsurance U.S. is a Maryland-domiciled insurer licensed or accredited as a reinsurer in all 50 states and the District of Columbia. It is also a certified reinsurer with the U.S. Treasury. Renaissance Reinsurance U.S. is subject to considerable regulation and supervision by state insurance regulators. State insurance departments regulate insurer solvency, authorized investments, loss and loss adjustment expense and unearned premium reserves, cybersecurity, and deposits of securities for the benefit of policyholders. They also conduct periodic examinations and require the filing of annual and other reports relating to the financial condition of companies and other matters. The MIA, as Renaissance Reinsurance U.S.’s domestic regulator, is the primary financial regulator of Renaissance Reinsurance U.S. RREAG, US Branch is in runoff, but is still subject to supervision by the NYDFS and remains subject to many of the regulations described below. 21 Holding Company Regulation We are subject to the insurance holding company laws of Maryland, which require Renaissance Reinsurance U.S. to file certain reports concerning its capital structure, ownership, financial condition, general business operations, and material risks with the MIA. Generally, all affiliate transactions involving Renaissance Reinsurance U.S. must be fair and reasonable and, if material or of specified types, require prior notice to and approval or non-disapproval by the MIA. Disclosure and Reporting Requirements Renaissance Reinsurance U.S. is required to file various detailed reports, including annual and quarterly financial statements in accordance with prescribed statutory accounting rules, with regulatory officials in the jurisdictions in which it conducts business. In addition, the Risk Management and Own Risk Solvency and Assessment Act requires Renaissance Reinsurance U.S. and RREAG, US Branch to: (i) maintain a risk management framework for identifying, assessing, monitoring, managing, and reporting its material and relevant risks; (ii) complete an ORSA at least once each year and at any time there is a significant change to the risk profile of the entity or its holding company system; and (iii) submit an ORSA summary report to the MIA at not more than each year. Capital and Surplus Requirements Renaissance Reinsurance U.S. is required to meet certain minimum statutory capital and surplus requirements under Maryland law, including risk-based capital requirements, and to submit an annual report regarding its risk-based capital levels to the MIA. As of December 31, 2024, we believe Renaissance Reinsurance U.S. exceeded all applicable Maryland minimum capital and surplus requirements. Restrictions on Dividends and Distributions Maryland law places limitations on the amounts of dividends or distributions payable by Renaissance Reinsurance U.S., including the requirement that any extraordinary dividends require certain regulatory notices and approvals (or non-disapprovals) and must be paid out of earned surplus. Renaissance Reinsurance U.S. must also provide notice to the MIA of payment of ordinary dividends. Acquisition of Control Any person seeking to acquire a controlled entity (which presumptively includes holders of 10% or more of the outstanding voting securities) of a Maryland-domestic insurer or of an entity that directly or indirectly controls a Maryland-domestic insurer, must provide advance notice to and obtain approval of, the MIA. Therefore, any investor who intends to acquire 10% or more of Renaissance Reinsurance U.S.’s outstanding voting securities may need to comply with these laws and would be required to file statements and reports with the MIA before such acquisition. In addition, any existing controlling person of a Maryland-domestic insurer seeking to divest its controlling interest in the insurer must file with the MIA a confidential notice of the proposed divestiture at least 30 days prior to the cessation of control (unless a person acquiring control from the divesting party has filed notice of the proposed acquisition of control with the Commissioner). RREAG, US Branch The U.S. casualty portfolio of RREAG, US Branch was transferred to Renaissance Reinsurance U.S. in 2019. The remaining property and specialty business portfolio of RREAG, US Branch will be runoff until all liabilities are extinguished, a process that we expect to take several years. RREAG, US Branch is licensed in New York and Kansas and it is an accredited reinsurer in 48 states, and the District of Columbia. The NYDFS is RREAG, US Branch’s insurance regulator in the U.S. RREAG, US Branch is subject to New York’s holding company laws as well as laws and regulations pertaining to solvency, capital and surplus, authorized investments, deposits of securities for the benefit of policyholders, cybersecurity, corporate governance and the financial risks related to climate change. As of December 31, 2024, we believe RREAG, US Branch exceeded all applicable minimum capital and surplus requirements. The NYDFS may conduct periodic examinations of RREAG, US Branch and requires the filing of annual and other reports relating to RREAG, US Branch’s financial condition and risk-based capital levels. RREAG, US Branch does not pay ordinary dividends and would need approval from the NYDFS for any return of capital to RREAG. 22 Reinsurance Regulation The insurance laws of each U.S. state indirectly regulate the sale of reinsurance to licensed ceding insurers by non-admitted alien reinsurers acting from locations outside the state through the state’s credit for reinsurance laws. With some exceptions, the sale of insurance within a jurisdiction where the insurer is not admitted to do business is prohibited. Although reinsurance contract terms and rates are generally not subject to regulation by state insurance authorities, a U.S. insurance company ordinarily will enter into a reinsurance agreement only if it can obtain credit on its statutory financial statements for the reinsurance ceded. State insurance regulators permit U.S. ceding insurers to take credit for reinsurance ceded to non-admitted, non-U.S. reinsurers, or alien reinsurers, if the reinsurance contract contains certain minimum provisions and the alien reinsurer provides appropriate security for its outstanding obligations. The amount of security that an alien reinsurer may be required to provide and the form of that security varies significantly and depends on an alien reinsurer’s financial strength and its status in a given U.S. state. As alien reinsurers, Renaissance Reinsurance, DaVinci Reinsurance, RREAG, Renaissance Re Specialty U.S., and Vermeer have each been approved by one or more U.S. states as a Certified Reinsurer or a Reciprocal Jurisdiction Reinsurer, which permits it to post reduced or zero security, respectively, while still allowing its cedants to take financial statement credit for the reinsurance. Federal Oversight and Other Government Intervention Although generally the insurance industry is not directly regulated by the federal government, federal legislation and initiatives can affect the industry and our business. The Dodd-Frank Act created the Federal Insurance Office, which performs various functions with respect to insurance, including the submission of reports to Congress that could ultimately lead to changes in the regulation of insurers and reinsurers in the U.S., and has preemption authority over state insurance laws that conflict with certain international agreements. The Dodd-Frank Act also authorizes the U.S. Treasury and the Office of the U.S. Trade Representative to enter into international agreements of mutual recognition regarding the prudential regulation of insurance or reinsurance, or recovered agreements that address insurance prudential measures and credit for reinsurance. U.K. Regulation Overview Renaissance Reinsurance U.S.’s principle risk taking balance sheets in the U.K. are Syndicate 1458 at Lloyd’s, which is managed by RSM and RREAG, UK Branch. The PRA and the FCA regulate all financial services firms in the U.K. including the Lloyd’s market, RSM and RREAG, UK Branch, and have substantial powers of intervention in relation to regulated firms. Under the Lloyd’s Acts, the Council of Lloyd’s is responsible for regulating and directing underwriting at Lloyd’s. Co-operation agreements between Lloyd’s and the FCA and the PRA set out, amongst other things, the co-operation and information sharing between Lloyd’s. If it appears to either the PRA or the FCA that either Lloyd’s is not fulfilling its delegated regulatory responsibilities or that managing agents are not complying with the applicable law and regulation, the PRA or the FCA may intervene in the regulation of individuals and entities operating at Lloyd’s and impose penalties or sanctions for non-compliance or misconduct. Lloyd’s Regulation The operations of RSM are subject to oversight by Lloyd’s, substantially effected through the Council of Lloyd’s. RSM’s business plan for Syndicate 1458, including maximum underwriting capacity, requires annual approval by Lloyd’s. Lloyd’s may require changes to any business plan presented to it or additional capital to be provided to support the underwriting plan. We have deposited certain assets with Lloyd’s to support the underwriting business at Lloyd’s of Renaissance Re CCL, the sole corporate member of Syndicate 1458. Renaissance Re CCL’s obligations as a member of Lloyd’s include the following: Capital Requirements. The underwriting capacity of a member of Lloyd’s must be supported by providing a deposit, referred to as Funds at Lloyd’s, or FAL, in an amount determined on the basis of such entity’s solvency and capital requirements. The amount of such deposit is calculated 23 for each member through the completion of an annual capital adequacy exercise. In addition, if the FAL are not sufficient to cover all losses, the Lloyd’s Central Fund provides an additional level of security for policyholders. Dividends from a Lloyd’s managing agent and a Lloyd’s corporate member can be declared and paid provided the relevant company has sufficient profits available for distribution. Ratings. The financial security of the Lloyd’s market as a whole is regularly assessed by three independent rating agencies (A.M. Best, S&P and Fitch). Syndicates at Lloyd’s take their financial security rating from the rating of the Lloyd’s market. Intervention Powers. The Lloyd’s Council has wide discretionary powers to regulate members’ underwriting at Lloyd’s, including, the power to withdraw a member’s permission to underwrite business or to underwrite a particular class of business and to change the basis on which syndicate expenses are allocated. Assessments. If Lloyd’s determines that the Central Fund needs to be increased, it has the power to assess premium levies on current Lloyd’s members up to 5% of a member’s underwriting capacity in any one year. Disclosure and Reporting Requirements RSM is required to provide Lloyd’s with annual financial statements for Syndicate 1458. These financial statements are then published and made publicly available by Lloyd’s on the Lloyd’s website. Capital and Surplus Requirements Following Brexit, with effect from December 31, 2024, the capital adequacy of insurers and reinsurers in the U.K., including Syndicates at Lloyd’s is determined under the PRA’s prudential regime for insurers known as Solvency UK. Solvency UK has replaced the PRA’s previous prudential regulation framework, Solvency II, which was established by EU law and transposed into U.K. law. Under Solvency UK, an insurer’s or reinsurer’s capital adequacy in relation to various insurance and business risks may be measured with an internal model developed by the insurer or reinsurer and approved for use by the PRA. RREAG, UK Branch is not required to hold capital at the branch level. In light of this and related matters, the PRA granted various modifications and waivers to RREAG, UK Branch from its Solvency UK regulatory reporting requirements. Lloyd’s is subject to an annual PRA solvency test which measures whether Lloyd’s has sufficient assets in the aggregate to meet all outstanding liabilities of its members, both current and run-off. If Lloyd’s fails this test, the PRA may require the entire Lloyd’s market to cease underwriting or individual Lloyd’s members may be required to cease or reduce their underwriting. Change of Control Prior approval from the PRA, the FCA, and Lloyd’s is required before any person or entity, together with its associates, acquires a controlled entity of a regulated insurer, reinsurer, Lloyd’s managing agent, or corporate member. Any company or individual that, together with its or his associates, acquires or controls 10% or more of the voting power in a regulated entity or its parent company, would be considered to have acquired control for these purposes, as would a person who had significant influence over the management of such entity or its parent company by virtue of their shareholding or voting power in either. A purchaser of 10% or more of Renaissance Re’s common shares or voting power would therefore be considered to have acquired control of RSM or Renaissance Re CCL. Swiss Regulation Overview RREAG is a reinsurance company licensed and supervised by the Swiss Financial Market Supervisory Authority FINMA, or FINMA. As such, RREAG must comply with Swiss insurance supervisory law and regulations applicable to reinsurers. RREAG maintains branch operations in Australia, Bermuda, the U.K. and the U.S., each in accordance with applicable local regulations. In addition, the group affiliate Renaissance Re Services of Switzerland AG must comply with applicable provisions of the Swiss Financial Services Act to continue its distribution activities for insurance-linked securities. 24 Adequacy of Financial Resources RREAG must comply with capital, solvency, and reserve requirements, such as the Swiss Solvency Test, or SST, under applicable Swiss regulations, including the Insurance Supervision Act and the Insurance Supervision Ordinance. Certain of these requirements may be determined by FINMA. The solvency requirement of the SST is met if the available risk-bearing capital exceeds the required target capital. The SST has been recognized by the EU and the U.K. as an equivalent standard to European and U.K. standards, respectively. At December 31, 2024, we believe RREAG exceeded the minimum solvency and capital requirements required to be maintained under Swiss law. These and other regulations limit the amount of capital that RREAG may distribute to its holding company parent. Additional Regulatory Requirements RREAG is subject to additional regulatory requirements under Swiss law, including the following: Reporting and Disclosure Requirements. RREAG has to submit an annual report (including audited financial statements and a management report), FCR, an annual

supervisory report, and a forward-looking self-assessment of its risk situation and capital requirements, or ORSA, to FINMA each year. RREAG is also required to maintain and update with FINMA a regulatory business plan, including details on their organization, financials, qualified participants, management, oversight, control persons, and responsible actuary. RREAG must notify FINMA of any changes to its business plan, and FINMA is required to approve certain changes.â€¢Dividends and Distributions. RREAG may only distribute dividends out of its retained earnings or distributable reserves based on the audited annual accounts. Any distribution of dividends may be subject to the approval of FINMA (as a change of the regulatory business plan) if they have a bearing on the solvency of the reinsurer and/or the interests of the insured. Change of ControlAny person who intends to directly or indirectly participate in RREAG with a participation reaching or exceeding the thresholds of 10% of the capital or voting rights in RREAG must notify FINMA. Moreover, any participant of RREAG must notify FINMA if it changes its participation to cross below certain thresholds of the capital or voting rights in RREAG. Additional RegulationCertain of our other branches and affiliated entities are subject to regulation in other jurisdictions, including those described below. We do not regard the effect of these regulations to be material to us at this time.â€¢Singapore: Branches of Renaissance Reinsurance and DaVinci Reinsurance based in the Republic of Singapore have each received a license to carry on insurance business as a general reinsurer and are regulated by ACRA as a foreign company pursuant to Singaporeâ€™s Companies Act. Renaissance Services of Asia Pte. Ltd., our Singapore-based service company, is registered with ACRA and subject to Singaporeâ€™s Companies Act.â€¢Ireland: Renaissance Reinsurance of Europe DAC is regulated and supervised by the Central Bank of Ireland and is subject to the requirements of Solvency II. Renaissance Reinsurance of Europe DAC and Renaissance Services of Europe Ltd., our Dublin-based Irish service company, are both registered with the Companies Registration Office in Ireland and subject to the Companies Act 2014. â€¢Australia: RREAG, Australia Branch, based in Sydney, Australia, provides coverage to insurers and reinsurers from Australia and New Zealand. The activities of RREAG, Australia Branch are licensed and regulated by APRA and the Australian Securities and Investments Commission. Pursuant to these regulations, RREAG, Australia Branch is subject to certain reporting and capital requirements in Australia.25GLOSSARY OF DEFINED TERMSâ€¢2020 Weather-Related Large Loss Eventsâ€¢Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contractsâ€¢2021 Weather-Related Large Lossesâ€¢Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contractsâ€¢2022 Weather-Related Large Lossesâ€¢Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contractsâ€¢2023 Large Loss Eventsâ€¢earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Ciaran, and certain aggregate loss contracts triggered during 2023â€¢2024 Large Loss Eventsâ€¢Hurricane Milton, Hurricane Helene and the Other 2024 Large Loss Eventsâ€¢ACRAâ€™s additional case reservesâ€¢AIGâ€™s American International Group, Inc., a Delaware corporation and NYSE-listed company (together with its affiliates and subsidiaries)â€¢AlphaCat Fundsâ€¢collectively, certain third-party closed-end and open-end Bermuda mutual funds and one managed account that are managed by AlphaCat Managers.â€¢AlphaCat Managersâ€¢AlphaCat Managers Ltd.â€¢AlphaCat Reâ€¢AlphaCat Reinsurance Ltd.â€¢A.M. Bestâ€¢A.M. Best Company, Inc.â€¢ACRAâ€™s Accounting and Corporate Regulatory Authorityâ€¢APRAâ€™s Australian Prudential Regulation Authorityâ€¢ASCâ€™s Accounting Standards Codificationâ€¢Baltimore Bridge Collapseâ€¢the collapse of the Francis Scott Key Bridge in Baltimore following a collision with a cargo ship in March 2024â€¢BEPsâ€™s Base Erosion Profit Shiftingâ€¢BMAâ€™s Bermuda Monetary Authorityâ€¢Boardâ€™s the Board of Directors of Renaissance Re Holdings Ltd.â€¢BSCRâ€™s Bermuda solvency and capital requirementâ€¢CITâ€™s Corporate Income Tax Act 2023 â€¢Code of Ethicsâ€¢Renaissance Reâ€™s Code of Ethics and Conductâ€¢DaVinciâ€™s DaVinci Re Holdings Ltd. and its subsidiariesâ€¢DaVinci Reinsuranceâ€™s DaVinci Reinsurance Ltd.â€¢DEIâ€™s Diversity, Equity and Inclusionâ€¢ECRâ€™s Enhanced Capital Requirementâ€¢ERMâ€™s Enterprise risk managementâ€¢EUâ€™s European Unionâ€™s Exchange Actâ€™s the Securities Exchange Act of 1934, as amendedâ€¢EFAâ€™s deposit that must be submitted to support the underwriting capacity of a member of Lloydâ€™sâ€¢FASBâ€™s Financial Accounting Standards Boardâ€™s FCAâ€™s E.U. Financial Conduct Authorityâ€™s FRCâ€™s financial condition reportâ€¢FINMAâ€™s Swiss Financial Market Supervisory Authorityâ€™s Fitch Ratings Ltd.26â€¢Fontanaâ€™s Fontana Holdings L.P. and its subsidiariesâ€¢Fontana Reâ€™s Fontana Reinsurance Ltd.â€¢Fontana U.S.â€™s Fontana Reinsurance U.S. Ltd.â€¢Form 10-Kâ€™s This Annual Report on Form 10-K for the year ended December 31, 2024â€¢GAAPâ€™s Generally accepted accounting principles in the U.S.â€¢GLOBE Rulesâ€™s global anti-basis erosion model rules, approved by the OECD/G20 Inclusive Framework on BEPS â€¢GLOBIACâ€™s Internationally Active Insurance Groupsâ€™s IASBâ€™s International Association of Insurance Supervisorsâ€¢IBNRâ€™s incurred but not reportedâ€¢Insurance Actâ€™s Bermuda Insurance Act 1978â€¢IIRAâ€™s Inflation Reduction Actâ€™s IRSâ€™s United States Internal Revenue Serviceâ€¢MIAâ€™s Maryland Insurance Administrationâ€™s Medicareâ€™s Renaissance Re Medici Fund Ltd.â€¢Moodyâ€™s Moodyâ€™s Investors Serviceâ€™s NAICâ€™s National Association of Insurance Commissionersâ€™s NOC1â€™s NOC1, a segregated account of Upsilon Fundâ€™s NYDFSâ€™s New York State Department of Financial Servicesâ€™s NYSEâ€™s New York Stock Exchangeâ€™s OECDâ€™s Organisation for Economic Co-operation and Developmentâ€™s OFACâ€™s U.S. Treasuryâ€™s U.S. Office of Foreign Assets Controlâ€™s OmegaCat Reâ€™s OmegaCat Reinsurance Ltd.â€™s ORSAâ€™s Own Risk and Solvency Assessmentâ€™s Other 2024 Large Loss Eventsâ€¢the Baltimore Bridge Collapse, a series of severe convective storms impacting the Southern and Midwest United States, the Hualien earthquake which impacted Taiwan in April 2024, a severe hailstorm which impacted Calgary in August 2024, Hurricane Debby, Hurricane Beryl, and certain aggregate loss contracts triggered during 2024â€¢PFIâ€™s passive foreign investment companyâ€™s PGGMâ€™s PGGM Vermogensbeheer B.V.â€™s Platinum Underwriters Holdings, Ltd.â€™s PRAâ€™s U.K. Prudential Regulatory Authorityâ€™s Proxy Statementâ€™s Proxy Statement for the Annual General Meeting of Shareholders to be held on May 6, 2025â€™s REMSâ€™s Renaissance Exposure Management Systemâ€™s Renaissance Reinsuranceâ€™s Renaissance Reinsurance Ltd.â€™s Renaissance Reinsurance of Europe DACâ€™s Renaissance Reinsurance of Europe Designated Activity Companyâ€™s Renaissance Reinsurance U.S.â€™s Renaissance Reinsurance U.S. Inc.â€™s Renaissance Reâ€™s Renaissance Re Holdings Ltd.â€™s Renaissance Re CCLâ€™s Renaissance Re Corporate Capital (UK) Limitedâ€™s Renaissance Re Financeâ€™s Renaissance Re Finance Inc.â€™s Renaissance Re Groupâ€™s Renaissance Re Group of companiesâ€™s Renaissance Re Specialty U.S.â€™s Renaissance Re Specialty U.S. Ltd.â€™s RFMâ€™s Renaissance Re Fund Management Ltd.â€™s RREAâ€™s Renaissance Re Europe AGâ€™s RREAAG, Australia Branchâ€™s Renaissance Re Europe AG, Australia Branch27â€™s RREAAG, Bermuda Branchâ€™s Renaissance Re Europe AG, Bermuda Branch, an overseas company that has been granted a permit from the Minister of Finance to engage in or carry on any trade or business pursuant to the Companies Act and which is also registered to carry on insurance business as a Class 4 insurer pursuant to the Insurance Act in Bermudaâ€™s RREAAG, UK Branchâ€™s Renaissance Re Europe AG, UK Branchâ€™s RREAAG, US Branchâ€™s Renaissance Re Europe AG, US Branchâ€™s RREAAGâ€™s Renaissance Re Europe AGâ€™s RSMâ€™s Renaissance Re Syndicate Management Ltd.â€™s RUMâ€™s Renaissance Underwriting Managers, Ltd.â€™s S&Pâ€™s Standard and Poorâ€™sâ€™s Rating Servicesâ€™s SECâ€™s U.S. Securities and Exchange Commissionâ€™s Securities Actâ€™s Securities Act of 1933, as amendedâ€™s SPIâ€™s special purpose insurerâ€™s SSTâ€™s Swiss Solvency Testâ€™s State Farmâ€™s State Farm Mutual Automobile Insurance Companyâ€™s Stock Purchase Agreementâ€™s Stock Purchase Agreement, dated May 22, 2023, among Renaissance Re Holdings Ltd. and AIG, as amendedâ€™s Syndicate 1458â€™s Renaissance Re Syndicate 1458â€™s Talbotâ€™s A A A Talbot Underwriting Ltd., an affiliate of AIGâ€™s TMRâ€™s collectively, Tokio Millennium Re AG and certain associated entities and subsidiariesâ€™s Top Layerâ€™s Top Layer Reinsurance Ltd.â€™s Tower Hill Companiesâ€™s collectively, our investments in a group of Tower Hill affiliated companies including Bluegrass Insurance Management, LLC, Tower Hill Claims Service, LLC, Tower Hill Holdings, Inc., Tower Hill Insurance Group, LLC, Tower Hill Insurance Managers, LLC, Tower Hill Re Holdings, Inc., Tower Hill Risk Management LLC and Tomoka Re Holdings, Inc.â€™s U.K.â€™s United Kingdomâ€™s U.S. personsâ€™s a citizen or resident of the United States, a U.S. partnership or corporation, or an estate or trust that is not a foreign estate or trustâ€™s U.S. Treasuryâ€™s U.S. Department of the Treasuryâ€™s U.S.â€™s United States of Americaâ€™s Upsilonâ€™s collectively, Upsilon Fund and Upsilon RFOâ€™s Upsilon Diversifiedâ€™s A A A Renaissance Re Upsilon Diversified Fund, a segregated account of Upsilon Fundâ€™s Upsilon Fundâ€™s Renaissance Re Upsilon Fund Ltd.â€™s Upsilon RFOâ€™s Upsilon RFO Re Ltd.â€™s Validusâ€™s Validus Holdings, Validus Specialty, and their respective subsidiaries that were acquired in the Validus Acquisition (including Validus Re and Validus Holdings (UK) Ltd), collectively â€™s Validus Acquisitionâ€™s The acquisitions under the Stock Purchase Agreement, together with the other transactions contemplated in the Stock Purchase Agreement.â€™s Validus Holdingsâ€™s Validus Holdings, Ltd.â€™s Validus Reâ€™s Validus Reinsurance, Ltd.â€™s Validus Specialtyâ€™s Validus Specialty, LLCâ€™s Validus Switzerlandâ€™s Validus Reinsurance (Switzerland) Ltdâ€™s Vermeerâ€™s Vermeer Reinsurance Ltd.28GLOSSARY OF SELECTED (RE)INSURANCE TERMSâ€¢Accident year year of occurrence of a loss. Claim payments and reserves for claims and claim expenses are allocated to the year in which the loss occurred for losses occurring contracts and in the year the loss was reported for claims made contracts.â€¢Acquisition expensesThe aggregate expenses incurred by a company for acquiring new business, including commissions, underwriting expenses, premium taxes and administrative expenses.â€¢Additional case reserves; ACRAAdditional case reserves represent managementâ€™s estimate of reserves for claims and claim expenses that are allocated to specific contracts, less paid and reported losses by the client.â€¢Attachment pointThe dollar amount of loss (per occurrence or in the aggregate, as the case may be) above which excess of loss reinsurance becomes operative.â€¢BordereauxA report providing premium or loss data with respect to identified specific risks. This report is periodically furnished to a reinsurer by the ceding insurers or reinsurers.â€¢BoundA (re)insurance contract is considered bound, and the (re)insurer responsible for the risks of the contract, when both parties agree to the terms and conditions set forth in the contract.â€¢BrokerAn intermediary who negotiates contracts of insurance or reinsurance, receiving a commission for placement and other services rendered, between (1)A policy holder and a primary insurer, on behalf of the insured party, (2)A primary insurer and reinsurer, on behalf of the primary insurer, or (3)A reinsurer and a retrocessionaire, on behalf of the reinsurer.â€¢CapacityThe percentage of surplus, or the dollar amount of exposure, that an insurer or reinsurer is willing or able to place at risk. Capacity may apply to a single risk, a program, a line of business or an entire book of business. Capacity may be constrained by legal restrictions, corporate restrictions or indirect restrictions.â€¢Case reservesLoss reserves, established with respect to specific, individual reported claims.â€¢Casualty insurance or reinsuranceInsurance or reinsurance that is primarily concerned with the losses caused by injuries to third persons and their property (in other words, persons other than the policyholder) and the legal liability imposed on the insured resulting therefrom. Also referred to as liability insurance.â€¢CatastropheA severe loss, typically involving multiple claimants. Common perils include earthquakes, hurricanes, hailstorms, severe winter weather, floods, fires, tornadoes, typhoons, explosions and other natural or man-made disasters. Catastrophe losses may also arise from acts of war, acts of terrorism and political instability.â€¢Catastrophe excess of loss reinsuranceA form of excess of loss reinsurance that, subject to a specified limit, indemnifies the ceding company for the amount of loss in excess of a specified retention with respect to an accumulation of losses resulting from a â€¢catastrophe.â€™s Catastrophe-linked securities; cat-linked securitiesCat-linked securities are generally privately placed fixed income securities where all or a portion of the repayment of the principal is linked to catastrophic events. This includes securities where the repayment is linked to the occurrence and/or size of, for example, one or more hurricanes or earthquakes, or insured industry losses associated with these catastrophic events.â€¢Cede; cedant; ceding companyWhen a party reinsures its liability with another, it â€™s cedesâ€™s business and is referred to as the â€™s cedantâ€™s or â€™s ceding company.â€™s29â€¢ClaimRequest by an insured or reinsured for indemnification by an insurance company or a reinsurance company for losses incurred from an insured peril or event.â€¢Claims made contractsContracts that cover claims for losses occurring during a specified period that are reported during the term of the contract.â€¢Claims and claim expense ratio, netThe ratio of net claims and claim expenses to net premiums earned determined in accordance with either statutory accounting principles or GAAP.â€¢Claim reservesLiabilities established by insurers and reinsurers to reflect the estimated costs of claim payments and the related expenses that the insurer or reinsurer will ultimately be required to pay in respect of insurance or reinsurance policies it has issued. Claims reserves consist of case reserves, established with respect to individual reported claims, additional case reserves and â€™s IBNRâ€™s reserves. For reinsurers, loss expense reserves are generally not significant because substantially all of the loss expenses associated with particular claims are incurred by the primary insurer and reported to reinsurers as losses.â€¢Combined ratioThe combined ratio is the sum of the net claims and claim expense ratio and the underwriting expense ratio. A combined ratio below 100% generally indicates profitable underwriting prior to the consideration of investment income. A combined ratio over 100% generally indicates unprofitable underwriting prior to the consideration of investment income.â€¢Delegated authorityA contractual arrangement between an insurer or reinsurer and an agent whereby the agent is authorized to bind insurance or reinsurance on behalf of the insurer or reinsurer. The authority is normally limited to a particular class or classes of business and a particular territory. The exercise of the authority to bind insurance or reinsurance is normally subject to underwriting guidelines and other restrictions such as maximum premium income. Under the delegated authority, the agent is responsible for issuing policy documentation, the collection of premium and may also be responsible for the settlement of claims.â€¢Excess of loss reinsurance or insuranceReinsurance or insurance that indemnifies the reinsured or insured against all or a specified portion of losses on underlying insurance policies in excess of a specified amount, which is called a â€™s levelâ€™s or â€™s retention.â€™s Also known as non-proportional reinsurance. Excess of loss reinsurance is written in layers. A reinsurer or group of reinsurers accepts a layer of coverage up to a specified amount. The total coverage purchased by the cedant is referred to as a â€™s programâ€™s and will typically be placed with predetermined reinsurers in pre-negotiated layers. Any liability exceeding the outer limit of the program reverts to the ceding company, which also bears the credit risk of a reinsurerâ€™s insolvency.â€¢ExclusionsThose risks, perils, or classes of insurance with respect to which the reinsurer will not pay loss or provide reinsurance, notwithstanding the other terms and conditions of reinsurance.â€¢Expense overrideAn amount paid to a ceding company in addition to the acquisition cost to compensate for overhead expenses.â€¢FrequencyThe number of claims occurring during a given coverage period.â€¢Funds at Lloydâ€™sâ€™s Funds of an approved form that are lodged and held in trust at Lloydâ€™sâ€™s as security for a memberâ€™sâ€™s underwriting activities. They comprise the memberâ€™sâ€™s deposit, personal reserve fund and special reserve fund and may be drawn down in the event that the memberâ€™sâ€™s syndicate level premium trust funds are insufficient to cover its liabilities. The amount of the deposit is related to the memberâ€™sâ€™s premium income limit and also the nature of the underwriting account.30Generally Accepted Accounting Principles in the United StatesAccounting principles as set forth in the statements of the Financial Accounting Standards Board and related guidance, which are applicable in the circumstances as of the date in question.â€¢Gross premiums writtenTotal premiums for insurance written and assumed reinsurance during a given period.â€¢Incurred but not reported; IBNRReserves for estimated losses that have been incurred by insureds and reinsureds but not yet reported to the insurer or reinsurer, including unknown future developments on losses that are known to the insurer or reinsurer.â€¢Insurance-linked securitiesFinancial instruments whose values are driven by (re)insurance loss events. Our investments in insurance-linked securities are generally linked to property losses due to natural catastrophes.â€¢International Financial Reporting StandardsAccounting principles, standards and interpretations as set forth in opinions of the International Accounting Standards Board which are applicable in the circumstances as of the date in question.â€¢LayerThe interval between the retention or attachment point and the maximum limit of indemnity for which a reinsurer is responsible.â€¢LineThe amount of excess of loss reinsurance protection provided to an insurer or another reinsurer, often referred to as limit.â€¢Line of businessThe general classification of insurance written by insurers and reinsurers, e.g., fire, allied lines, homeowners and surety, among others.â€¢Lloydâ€™sâ€™s Depending on the context, this term may refer to (a)A the society of individual and corporate underwriting members that insure and reinsure risks as members of one or more syndicates (i.e., Lloydâ€™sâ€™s is not an insurance company); (b)A the underwriting room in the Lloydâ€™sâ€™s building in which managing agents underwrite insurance and reinsurance on behalf of their syndicate members (in this sense Lloydâ€™sâ€™s should be understood as a market place); or (c)A the Corporation of Lloydâ€™sâ€™s which regulates and provides support services to the Lloydâ€™sâ€™s market.â€¢Loss; lossesAn occurrence that is the basis for submission and/or payment of a claim. Whether losses are covered, limited or excluded from coverage is dependent on the terms of the policy.â€¢Loss reserveFor an individual loss, an estimate of the amount the insurer expects to pay for the reported claim. For total losses, estimates of expected payments for reported and unreported claims. These may include amounts for claims expenses.â€¢Managing agentAn underwriting agent which has permission from Lloydâ€™sâ€™s to manage a syndicate and carry on underwriting and other functions for a member.â€¢Net claims and claim expensesThe expenses of settling claims, net of recoveries, including legal and other fees and the portion of general expenses allocated to claim settlement costs (also known as claim adjustment expenses or loss adjustment expenses) plus losses incurred with respect to net claims.â€¢Net claims and claim expense ratioNet claims and claim expenses incurred expressed as a percentage of net premiums earned.â€¢Net premiums earnedThe portion of net premiums written during or prior to a given period that was actually recognized as income during such period.â€¢Net premiums writtenGross premiums written for a given period less premiums ceded to reinsurers and retrocessionaires during such period.â€¢PerilsThis term refers to the causes of possible loss in the property field, such as fire, windstorm, collision, hail, etc. In the casualty field, the term â€™s hazardâ€™s is more frequently used.31â€¢Profit commissionA provision found in some reinsurance agreements that provides for profit sharing. Parties agree to a formula for calculating profit, an allowance for the reinsurerâ€™s expenses, and the cedantâ€™sâ€™s share of such profit after expenses.â€¢Property insurance or

reinsuranceInsurance or reinsurance that provides coverage to a person with an insurable interest in tangible property for that person's property loss, damage or loss of use. Property per riskReinsurance on a treaty basis of individual property risks insured by a ceding company. Proportional reinsuranceA generic term describing all forms of reinsurance in which the reinsurer shares a proportional part of the original premiums and losses of the reinsured. (Also known as pro rata reinsurance, quota share reinsurance or participating reinsurance.) In proportional reinsurance, the reinsurer generally pays the ceding company a ceding commission. The ceding commission generally is based on the ceding company's cost of acquiring the business being reinsured (including commissions, premium taxes, assessments and miscellaneous administrative expense) and also may include a profit factor. See also Quota Share Reinsurance. Quota share reinsuranceA form of proportional reinsurance in which the reinsurer assumes an agreed percentage of each insurance policy being reinsured and shares all premiums and losses accordingly with the reinsured. See also Proportional Reinsurance. Reinstatement premiumThe premium charged for the restoration of the reinsurance limit of a contract to its full amount after payment by the reinsurer of losses as a result of an occurrence. ReinsuranceAn arrangement in which an insurance company, the reinsurer, agrees to indemnify another insurance or reinsurance company, the ceding company, against all or a portion of the insurance or reinsurance risks underwritten by the ceding company under one or more policies. Reinsurance can provide a ceding company with several benefits, including a reduction in net liability on insurances and catastrophe protection from large or multiple losses. Reinsurance also provides a ceding company with additional underwriting capacity by permitting it to accept larger risks and write more business than would be possible without an equivalent increase in capital and surplus, and facilitates the maintenance of acceptable financial ratios by the ceding company. Reinsurance does not legally discharge the primary insurer from its liability with respect to its obligations to the insured. Reinsurance to CloseAlso referred to as a RITC, it is a contract to transfer the responsibility for discharging all the liabilities that attach to one year of account of a syndicate into a later year of account of the same or different syndicate in return for a premium. RetentionThe amount or portion of risk that an insurer retains for its own account. Losses in excess of the retention level are paid by the reinsurer. In proportional treaties, the retention may be a percentage of the original policy's limit. In excess of loss business, the retention is a dollar amount of loss, a loss ratio or a percentage. RetrocedantA reinsurer who cedes all or a portion of its assumed insurance to another reinsurer. Retrocessional reinsurance; RetrocessionaireA transaction whereby a reinsurer cedes to another reinsurer, the retrocessionaire, all or part of the reinsurance that the first reinsurer has assumed. Retrocessional reinsurance does not legally discharge the ceding reinsurer from its liability with respect to its obligations to the reinsured. Reinsurance companies cede risks to retrocessionaires for reasons similar to those that cause primary insurers to purchase reinsurance: to reduce net liability on insurances, to protect against catastrophic losses, to stabilize financial ratios and to obtain additional underwriting capacity. RisksA term used to denote the physical units of property at risk or the object of insurance protection that are not perils or hazards. Also defined as chance of loss or uncertainty of loss. Solvency IIA set of regulatory requirements that codify and harmonize the EU insurance and reinsurance regulation. Among other things, these requirements impact the amount of capital that EU insurance and reinsurance companies are required to hold. Solvency II came into effect on January 1, 2016. Solvency UKA set of regulatory requirements that codify insurance and reinsurance regulation in the U.K. Among other things, these requirements determine the amount of capital that insurance and reinsurance companies in the U.K. are required to hold. Solvency UK came into effect on December 31, 2024. Specialty linesLines of insurance and reinsurance that provide coverage for risks that are often unusual or difficult to place and do not fit the underwriting criteria of standard commercial products carriers. Statutory accounting principlesRecording transactions and preparing financial statements in accordance with the rules and procedures prescribed or permitted by Bermuda, U.S. state insurance regulatory authorities including the NAIC and/or in accordance with Lloyd's specific principles, all of which generally reflect a liquidating, rather than going concern, concept of accounting. Stop lossA form of reinsurance under which the reinsurer pays some or all of a cedant's aggregate retained losses in excess of a predetermined dollar amount or in excess of a percentage of premium. SubmissionAn unprocessed application for (i) an insurance coverage forwarded to a primary insurer by a prospective policyholder or by a broker on behalf of such prospective policyholder, (ii) an insurance coverage forwarded to a reinsurer by a prospective ceding insurer or by a broker or intermediary on behalf of such prospective ceding insurer or (iii) a retrocessional coverage forwarded to a retrocessionaire by a prospective ceding reinsurer or by a broker or intermediary on behalf of such prospective ceding reinsurer. Surplus lines insuranceAny type of coverage that cannot be placed with an insurer admitted to do business in a certain jurisdiction. Risks placed in excess and surplus lines markets are often substandard in respect to adverse loss experience, unusual, or unable to be placed in conventional markets due to a shortage of capacity. SyndicateA member or group of members underwriting (re)insurance business at Lloyd's through the agency of a managing agent or substitute agent to which a syndicate number is assigned. TreatyA reinsurance agreement covering a book or class of business that is automatically accepted on a bulk basis by a reinsurer. A treaty contains common contract terms along with a specific risk definition, data on limit and retention, and provisions for premium and duration. UnderwritingThe insurer's or reinsurer's process of reviewing applications submitted for insurance coverage, deciding whether to accept all or part of the coverage requested and determining the applicable premiums. Underwriting capacityThe maximum amount that an insurance company can underwrite. The limit is generally determined by a company's retained earnings and investment capital. Reinsurance serves to increase a company's underwriting capacity by reducing its exposure from particular risks. Underwriting expense ratioThe ratio of the sum of the acquisition expenses and operational expenses to net premiums earned. Underwriting expensesThe aggregate of policy acquisition costs, including commissions, and the portion of administrative, general and other expenses attributable to underwriting operations. Unearned premiumThe portion of premiums written representing the unexpired portions of the policies or contracts that the insurer or reinsurer has on its books as of a certain date. AVAILABLE INFORMATIONWe maintain a website at www.renre.com. The information on our website is not incorporated by reference in this Form 10-K. We make available, free of charge through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. We also make available, free of charge from our website, our Audit Committee Charter, Corporate Governance and Human Capital Management Committee Charter, Corporate Governance Guidelines, and Code of Ethics. Such information is also available in print for any shareholder who sends a request to Renaissance Re Holdings Ltd., Attn: Office of the Corporate Secretary, P.O. Box HM 2527, Hamilton, HMGX, Bermuda. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC. The address of the SEC's website is www.sec.gov. ITEM 1A. RISK FACTORSFactors that could have a material impact on our results of operations or financial condition are outlined below. Additional risks not presently known to us or that we currently deem insignificant may also impair our business or results of operations as they become known or as facts and circumstances change. Any of the risks described below could cause our actual results to differ materially from those in the forward-looking statements contained in this Form 10-K and other documents we file with the SEC: Risks Related to our (Re)insurance BusinessOur exposure to natural and non-natural catastrophic events and circumstances could cause significant variance in, or adversely impact, our financial results. We have substantial exposure to natural and non-natural catastrophic events and circumstances, such as earthquakes, hurricanes, tsunamis, winter storms, freezes, floods, fires, tornadoes, hailstorms, drought, pandemics, cyber-risks, political unrest, geopolitical uncertainty and instability, war, riots and acts of terrorism. Historically, a relatively large percentage of our coverage exposures has been concentrated in natural disasters in the U.S. Southeast or West Coast, but we have significant exposure to large catastrophic events globally. We cannot predict or eliminate our exposure to these loss events, and as a result, our operating results have historically been, and we expect will continue to be, significantly affected by the frequency and severity of such events. The occurrence, or nonoccurrence, of catastrophic events, the frequency and severity of which are inherently unpredictable, may cause significant volatility in our quarterly and annual financial results and may materially adversely affect our financial condition, results of operations and cash flows. In addition, we believe that certain factors may continue to increase the number and severity of claims from catastrophic events in the future, including increases in the value and geographic concentration of insured property, increasing risks associated with extreme weather events because of changes in climate conditions and sea-level rise, and the effects of higher-than-expected inflation. The trend towards increasingly frequent and severe climate events could exacerbate our potential exposure to losses from natural perils. Our largest estimated economic exposures arise from natural disasters and other catastrophes. We believe the trend towards increased severity and frequency of weather-related natural disasters and catastrophes arises in part from climate change. In addition, we believe that climate change and shifting economic and demographic trends in catastrophe exposed regions each contributes to increases in the average economic value of expected losses. Further, we believe that the recent increase in catastrophic events is indicative of both permanent climate change impacts and transient climate variability. A substantial portion of our property coverages may be adversely impacted by climate change. While we have invested heavily to understand the influence of climate change on the weather and its impact on the risks that we take, we cannot predict with certainty the frequency or severity of tropical cyclones, wildfires or other natural catastrophes, and our risk assessments may not accurately reflect shifting environmental and climate related risks. Unanticipated factors could lead to additional insured losses that exceed our current estimates, resulting in disruptions to or adverse impacts on our business, the market, or our clients. Further, some of our investments, such as catastrophe-linked securities and property catastrophe joint ventures or managed funds, could also be adversely impacted by climate change. Our claims and claim expense reserves are subject to inherent uncertainties, and if actual claims exceed our reserves, our financial results could be adversely affected. Our results of operations and financial condition depend upon our ability to accurately assess the potential losses associated with the risks that we insure and reinsure. Our claims and claim expense reserves reflect our estimates of these potential losses. We use actuarial and computer models, historical reinsurance and insurance industry loss statistics, and management's experience and judgment to assist in the establishment of appropriate claims and claim expense reserves. See Part I, Item 1. Business "Underwriting and Enterprise Risk Management." We revise our estimates and judgments as additional experience and other data become available, as new or improved methodologies are developed, as loss trends and claims inflation impact future payments, or as rules and regulations change. Due to the assumptions and estimates involved in establishing reserves, they are inherently uncertain. As information emerges and losses are paid, we expect that some of our assumptions or estimates will change, perhaps materially, and that our actual net claims and claim expenses paid and reported will differ, perhaps materially, from the reserve estimates reflected in our financial statements. For example, our significant gross and net reserves associated with the large catastrophe events of the past several years remain subject to significant uncertainty. To the extent we determine that our claims and claim expense reserves are inadequate, we may be required to increase or decrease these reserves at the time of the determination and take charges in our consolidated statements of operations, reducing our net income and available capital. Conversely, if our reserving estimates are too conservative, it could impede our ability to grow our business. Our claims reserves are large, and a small percentage increase to those liabilities could materially adversely affect our financial condition and results of operations. Emerging claim and coverage issues, or other litigation, could adversely affect us. Unanticipated developments in the law as well as changes in social conditions could result in unexpected claims for coverage under our insurance and reinsurance contracts. These developments and changes may adversely affect us, perhaps materially, by, for example, imposing additional coverage obligations beyond our underwriting intent or increasing the number or size of claims to which we are subject. We believe that our property results have been adversely impacted over recent periods by increasing fraud and abuses at the primary claims level, as well as other forms of social inflation, and that these trends may continue. These legal and social changes and their impact may not become apparent until some time after their occurrence. Our exposure to these uncertainties could be exacerbated by social inflation trends, including increased litigation, expanded theories of liability and higher jury awards. The full effects of these and other unforeseen emerging claims and coverage issues are extremely difficult to predict. As a result, the full extent of our liability under our coverages may not be known for many years after a contract is issued. Furthermore, we expect that our exposure to this uncertainty is more pronounced in our casualty business, because in these "long-tail" lines claims can typically be made for many years, making them more susceptible to these trends than our property and specialty businesses, which are generally more "short-tail." We depend on a few insurance and reinsurance brokers for a preponderance of our business, and any loss of business provided by them could adversely affect us. We market our insurance and reinsurance products worldwide through a limited number of insurance and reinsurance brokers, with three brokerage firms (Aon plc, Marsh & McLennan Companies, Inc. and Arthur J. Gallagher) accounting for 82.1% of our gross premiums written. As a result, the loss of a broker, through a merger, acquisition or otherwise, could result in the loss of a substantial portion of our business, which would reduce our premium volume and could have a material adverse effect on us. Further, due to the concentration of our brokers, they may have increased power to dictate the terms and conditions of our arrangements with them, which could have a negative impact on our business. The (re)insurance business is historically cyclical and the pricing and terms for our products may decline, which would affect our profitability and ability to maintain or grow premiums. The (re)insurance industry has historically been cyclical by product and market. After experiencing a prolonged soft market cycle years ago, we believe that the (re)insurance underwriting market has been in a hard market phase for many lines of business for the past several years, characterized by increased prices and improved terms and conditions. While we are at a relatively attractive point in the cycle, rates recently have, and may in the future, decrease in certain lines of business, and we cannot assure you that the higher premium rates will continue. If demand for our products falls or the supply of competing capacity continues to rise, our prospects for potential growth may be adversely affected. In particular, we might lose existing customers or suffer a decline in business during shifting market cycles, which we might not regain when industry conditions improve. We believe the hard/soft market cycle dynamic is likely to persist, and that we may return to soft market conditions in the future. Additionally, it is possible that increased access to capital, new technologies, including artificial intelligence, and other factors may reduce the duration or eliminate or significantly lessen the impact of any current or future hard reinsurance underwriting market. The cumulative impact of these risks could negatively impact our profitability and ability to maintain or grow premiums. Retrocessional reinsurance may not be available to us on acceptable terms or provide the coverage we intended to obtain, or we may not be able to collect on claimed retrocessional coverage. The retrocessional reinsurance that we purchase for our own account is generally subject to annual renewal. Even when reinsurance market conditions in general are strong, retrocessional market conditions may limit or prevent us from obtaining desired amounts of retrocessional reinsurance. For example, large catastrophe events have limited, and may in the future limit or prevent, us from obtaining desired amounts of new or replacement coverage on favorable terms or from entities with satisfactory creditworthiness. This could limit the amount of business we are willing to write or decrease the protection available to us following large loss events. When we purchase reinsurance or retrocessional reinsurance for our own account, complex coverage issues or coverage disputes may impede our ability to collect amounts we believe we are owed. We have significant reinsurance recoverables, and the insolvency of any of our reinsurers, or the inability or reluctance of any of our reinsurers to make timely payments to us under the terms of our reinsurance agreements, could have a material adverse effect on us. In addition, a large portion of our reinsurance protection is concentrated with a relatively small number of reinsurers, which could increase credit risk and may make it difficult to negotiate favorable terms and conditions. The risk of such concentration of retrocessional coverage may be increased by recent and future consolidation within the industry. We are exposed to the procedures and expertise of ceding companies and delegated authority counterparties, who may fail to accurately assess the risks they underwrite, which exposes us to operational and financial risks. We do not separately underwrite each primary risk assumed under our reinsurance contracts or pursuant to our delegated authority business. Accordingly, we are heavily dependent on the original underwriting decisions made by our ceding companies and delegated authority counterparties, who may not have adequately evaluated the risks to be reinsured. As a result, the premiums they cede to us may not properly compensate us for the risks we assume, which could materially adversely affect our financial condition. In addition, it is possible that our delegated authority counterparties or other counterparties authorized to bind and manage policies on our behalf have failed, or may in the future fail, to comply with regulatory requirements, such as those relating to sanctions, or our own standards regarding underwriting and reputational risk tolerance, which could lead to increased regulatory and operational burden, among other risks. Delegated authority counterparties may also fail to handle claims properly and in accordance with accepted claims handling practices, including regulatory standards, which may expose us to financial or reputational risks. To the extent we continue to increase the proportional coverages we offer, we will increase our aggregate exposure to risks of this nature. A decline in our financial strength ratings may adversely impact our business, perhaps materially. Financial strength ratings are used by ceding companies and reinsurance intermediaries to assess the financial strength and quality of reinsurers and insurers. Rating agencies evaluate us periodically and may downgrade or withdraw their financial strength ratings if we do not continue to meet their criteria. In addition, rating agencies may make changes in their capital models and rating methodologies, which could increase the amount of capital required to support our ratings. A financial strength ratings downgrade or other negative ratings action could adversely affect our ability to compete with other reinsurers and insurers, the marketability of our product offerings, access to and cost of borrowing, and ability to write new business. We could also breach covenants under, or incur higher borrowing costs

on, our credit facilities. In addition, if we are downgraded below a certain rating level, nearly all of our reinsurance contracts contain provisions permitting cedants to cancel coverage and/or requiring us to post collateral for our obligations. For the current financial strength ratings of certain of our subsidiaries and joint ventures and additional ratings information, refer to “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” “Financial Condition, Liquidity and Capital Resources” “Ratings.” We operate in a highly competitive environment. Competition and consolidation in the (re)insurance industry could adversely impact us. We face competition from a number of different sources, including insurers and reinsurers, nontraditional competitors such as Insurtech companies and other entities funding reinsurance companies or using other financial products intended to compete with traditional reinsurance. Competition for customers has also increased and become more intense. We expect competition to continue to increase over time. Increased capital from competitors in the market has, and may in the future, cause reductions in prices of our products or the duration or amplitude of attractive portions of the historical market cycles. Competitors may attempt to replicate all or part of our business model and provide further competition in the markets in which we participate. We could incur greater expenses relating to customer acquisition and retention, further reducing our operating margins. Government sponsored (re)insurance funds or other initiatives may also adversely affect demand for insurance and reinsurance. Along with increased competition, there has also been significant consolidation in the (re)insurance industry over the last several years, including among our competitors, customers and brokers. If competitive pressures decrease the prices for our products, we would generally expect to reduce our future underwriting activities, resulting in lower premium volume and profitability. Any of the foregoing could adversely affect our business or results of operations. Large non-recurring contracts and reinstatement premiums may increase the volatility of our financial results. Our premiums are prone to significant volatility due to factors including the timing of contract inception, as well as our differentiated strategy and capabilities which position us to pursue potentially non-recurring bespoke or large solutions for clients. In addition, after a large catastrophic event or circumstance, we may record significant amounts of reinstatement premium, which can cause quarterly, non-recurring fluctuations in both our written and earned premiums in our Property segment. These and other factors have in the past, and may in the future, increase the volatility of our financial results. 37 Risks Related to our Strategy and Operations The loss of key senior members of management and the inability to attract and retain qualified personnel could adversely affect us. Our success depends upon our ability to attract and retain our senior officers and to attract and retain additional qualified personnel in the future. The loss of services of members of our senior management team and the uncertain transition of new members of our senior management team may strain our ability to execute our strategic initiatives, or make it more difficult to retain customers, attract or maintain our capital support, or meet other needs of our business. This risk may be particularly acute for us relative to some of our competitors because some of our senior executives work in countries where they are not citizens (such as Bermuda) and work permit and immigration issues could adversely affect the ability to retain or hire key persons. The preparation of our consolidated financial statements requires us to make many estimates and judgments. The preparation of consolidated financial statements requires us to make many estimates and judgments that affect the reported amounts of assets, liabilities (including claims and claim expense reserves), shareholders’ equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates, including those related to premiums written and earned, our net claims and claim expenses, reinsurance recoverable, fair value measurements and impairments and income taxes. We base our estimates on historical experience, where possible, and on various other assumptions we believe to be reasonable under the circumstances, which form the basis for our judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our judgments and estimates may not reflect, and may deviate materially from, our actual results. For more details on our estimates and judgments, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” “Summary of Critical Accounting Estimates.” We are exposed to risks in connection with our management of capital on behalf of investors in joint ventures or other entities we manage. Certain of our subsidiaries owe legal duties and obligations (including reporting, governance and allocation obligations) to third-party investors in our joint ventures and managed funds. In addition, certain of our operating subsidiaries are registered or authorized investments funds or licensed investment managers subject to laws and regulations relating to the management of third-party capital. Complying with these obligations, laws and regulations requires significant management time and attention. Faulty judgments, simple errors or mistakes, or the failure of our personnel to adhere to established policies and procedures could result in our failure to comply with applicable obligations, laws or regulations, which could result in significant liabilities, penalties or other losses to us and seriously harm our business and results of operations. We are also subject to risks stemming from our relationship to the entities through which we manage capital on behalf of, or transform risk for, investors, and the support that we are required to, or may, provide to them. In addition, we are exposed to the risk that we may be unable to raise new capital for our joint ventures, managed funds and other private alternative investment vehicles, which would reduce our future fee income and market capacity, and thus negatively affect our results of operations and financial condition. Our third-party capital providers may, subject to restrictions, redeem their interests in our joint ventures and managed funds or we may be unable to attract and raise additional third-party capital for our existing or potential new joint ventures and managed funds. The loss, or alteration in a negative manner, of any of this capital support could cause us to forego fee income and other income-generating opportunities. Moreover, we can provide no assurance that we will be able to attract and raise additional third-party capital for existing joint ventures or for potential new joint ventures and managed funds and therefore we may forego existing and/or potentially attractive fee income and other income generating opportunities. Any of the foregoing could adversely affect our reputation, business or financial condition and results of operations. We are subject to cybersecurity risks, which may harm our business or reputation, and which could have an adverse effect on our business strategy, results of operations, or financial condition. Cybersecurity threats and incidents have increased in recent years, and we continue to be subject to heightened cyber-related risks. Our business depends on the proper functioning and availability of our information technology platforms, including communications and data processing systems and our proprietary systems. We are also required to effect electronic transmissions with third parties including brokers, clients, vendors and others with whom we do business, as well as with our Board. We cannot guarantee that the controls and procedures we or third parties have in place to protect or recover our systems and information will be effective, successful or sufficiently rapid to avoid harm to our business or reputation. Security incidents and breaches involving the systems of third parties that have our information, or our system, have in the past and may in the future occur, exposing us to a risk of loss or misuse of our information, litigation, and potential liability. In addition, cyber incidents, such as ransomware attacks, that impact the availability, reliability, speed, accuracy or other proper functioning of our systems could have a significant impact on our operations and financial results. We may not have the resources or technical sophistication to prevent, detect or stop a cyberattack. A significant cyber incident, including system failure, security breach, disruption by malware or other damage could interrupt or delay our operations, result in a violation of applicable cybersecurity and privacy and other laws, damage our reputation, cause a loss of customers or expose sensitive customer data, or give rise to monetary fines and other penalties, which could be significant. While management is not aware of any cybersecurity or information security incident or breach that has had a material effect on our operations, there can be no assurances that a cybersecurity incident that could have a material impact on us has not occurred or will not occur in the future. In addition, artificial intelligence technologies are quickly evolving and being adopted, which may increase or intensify potential cybersecurity risks. The cybersecurity regulatory environment is evolving, in particular with respect to emerging technologies, such as artificial intelligence, and it is likely that the costs of complying with new or developing regulatory requirements will increase. In addition, we operate in a number of jurisdictions with strict data privacy and other related laws, which could be violated in the event of a significant cybersecurity incident or in the event of noncompliance by our personnel. Failure to comply with these obligations can give rise to fines and other penalties, which could be significant. We also have exposure to cybersecurity risks through coverage that we write in our cyber line of business. See “Part I, Item 1C. Cybersecurity” for additional information related to information technology and cybersecurity. We may from time to time modify our business and strategic plan, and these changes could adversely affect us and our financial condition. We frequently monitor and analyze opportunities to acquire or make strategic investments in new or other businesses. The negotiation of potential acquisitions or strategic investments as well as the integration of an acquired business, such as the Validus Acquisition, could be unsuccessful, result in a substantial diversion of management resources, or lead to other unanticipated risks or challenges. In addition, while our current business strategy focuses predominantly on writing reinsurance, we also write insurance business, such as excess and surplus lines insurance through delegated authority arrangements. Risks associated with implementing or changing our business strategies and initiatives, including risks related to developing or enhancing our operations, controls and other infrastructure, may not have an impact on our publicly reported results until many years after implementation. Our failure to carry out our business plans may have an adverse effect on our long-term results of operations and financial condition. The covenants in our debt agreements limit our financial and operational flexibility, which could have an adverse effect on our financial condition. We have incurred indebtedness and may incur additional indebtedness in the future. Our indebtedness primarily consists of publicly traded notes, letters of credit and a revolving credit facility. For more details on our indebtedness, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” “Financial Condition, Liquidity and Capital Resources” “Capital Resources.” The agreements governing our indebtedness contain covenants that limit our ability and the ability of some of our subsidiaries to make particular types of investments or other restricted payments, sell or place a lien on our or their respective assets, merge or consolidate. Some of these agreements also require us or our subsidiaries to maintain specific financial ratios or contain cross-defaults to our other indebtedness. Under certain circumstances, if we or our subsidiaries fail to comply with these covenants or meet these financial ratios, the noteholders or the lenders could declare a default and demand immediate repayment of all 39 amounts owed to them or, where applicable, trigger a cross-default, cancel their commitments to lend or issue letters of credit or, where the reimbursement obligations are unsecured, require us to pledge collateral or, where the reimbursement obligations are secured, require us to pledge additional or a different type of collateral. The determination of impairments taken is highly subjective and could materially impact our financial condition or results of operations. The determination of impairments taken on our investments, investments in other ventures, goodwill and other intangible assets and loans varies by type of asset and is based upon our periodic evaluation and assessment of known and inherent risks associated with the respective asset class. Such evaluations and assessments are revised as conditions change and new information becomes available. Management updates its evaluations regularly and reflects impairments in operations as such evaluations are revised. We cannot assure you that we have accurately assessed the level of impairments taken in our financial statements. Furthermore, management may determine that impairments are needed in future periods and any such impairment will be recorded in the period in which it occurs, which could materially impact our financial condition or results of operations. Historical trends may not be indicative of future impairments. Risks Related to the Economic Environment A decline in our investment performance could reduce our profitability and capital resources. We have historically derived a meaningful portion of our income from our invested assets, which are principally comprised of fixed maturity securities. Accordingly, our financial results are subject to a variety of investment risks, including risks relating to general economic conditions, inflation, market volatility, interest rate fluctuations, foreign currency risk, commodity risk, liquidity risk and credit and default risk. Volatility in global financial markets has impacted, and may continue to impact, the value of our investment portfolio and our strategic investments. Additionally, some of our investments are subject to prepayment or reinvestment risk. Our investment portfolio also includes securities with longer durations, which may be more susceptible to risks such as inflation. Changes in various factors, including prevailing interest rates and credit spreads may cause fluctuations in the market value of our fixed maturity investments. The Federal Reserve increased its benchmark interest rate to the highest level in 20 years in 2023. While the Federal Reserve reduced the federal funds target rate in 2024, it still remains at a relatively high level. Further increases in interest rates could cause the market value of our investment portfolio to decrease, which could reduce our capital resources. Conversely, any decline in interest rates could reduce our investment yield and net investment income, which would reduce our overall profitability over the medium- to long-term. Interest rates are highly sensitive to many factors, including governmental and monetary policies, inflation levels, domestic and international economic and political conditions, and other factors beyond our control. A portion of our investment portfolio is allocated to other classes of investments including equity securities, catastrophe bonds, commodity securities, term loans and interests in alternative investment vehicles such as private equity investments, private credit investments and hedge funds. For certain investments, the valuation on our consolidated balance sheets may differ significantly from the values that would be used if ready markets existed for the securities representing interests in the relevant investment vehicles. If we were to sell these assets (which may be necessary if we need liquidity to pay claims), it may be at significantly lower prices than we have recorded them. Furthermore, our interests in some of the investment classes described above are subject to restrictions on redemptions and sales that limit our ability to liquidate these investments in the short term. The performance of these classes of investments is also dependent on individual investment managers and investment strategies. It is possible that these investment managers managing these investments will leave, the investment strategies will become ineffective or that the managers will fail to follow our investment guidelines. Our investment portfolio may become concentrated in a limited number of issuers or have significant exposure to certain geographic areas or economic sectors. Concentration of investments can increase investment risk and portfolio volatility. Any of the foregoing could result in a decline in our investment performance and capital resources, and accordingly, adversely affect our financial results. We may be adversely impacted by inflation. The principal markets in which we operate are susceptible to monetary inflation, which could cause loss costs to increase, impact the performance of our investment portfolio, and borrowing costs to increase. We believe the risks of inflation across our key markets have increased following significant increases in inflation in the United States and elsewhere in recent years as compared to the last decade. In particular, widespread economic factors such as government deficit spending, wage increases and supply chain disruptions have contributed to, and may continue to contribute to, significant inflation. The impact of inflation on loss costs could be more pronounced for those lines of business that are long tail in nature, as they require a relatively long period of time to finalize and settle claims. Changes in the level of inflation may also result in an increased level of uncertainty in our estimation of loss reserves, particularly for long tail lines of business, and may require us to strengthen reserves, with a corresponding reduction in our net income in the period in which the deficiency is identified. Unanticipated higher inflation could also lead to higher interest rates, which would decrease or create volatility in the value of our fixed income securities and potentially other investments. Higher inflation may lead to currency fluctuation, and we have in the past, and may in the future, experience increased volatility on foreign exchange gains and losses in our consolidated financial statements as a result. If inflation remains elevated for a prolonged period or increases further, any of the risks described above could be exacerbated, and the impact on the global economy generally and on our customers could negatively affect our business, financial condition and results of operations. We are exposed to counterparty credit risk, which could increase our liabilities and reduce liquidity. Counterparty credit risk typically increases during periods of economic uncertainty, and we believe our exposure has increased in recent years. In connection with the settlement of reinsurance balances, we assume a substantial degree of credit risk associated with our brokers. In accordance with industry practice, we pay virtually all amounts owed on claims under our policies to reinsurance brokers, who then forward these payments to the ceding insurers that have purchased reinsurance from us. Likewise, premiums due to us by ceding insurers are virtually all paid to brokers, who then pass the amounts to us. Many of our contracts provide that if a broker fails to make a payment to a ceding insurer, we remain liable to the ceding insurer for the deficiency. Conversely, when the ceding insurer pays premiums to brokers for payment to us, these premiums are considered to have been received by us upon receipt by the broker and the ceding insurer is no longer liable to us for those amounts, even if we have not received the premiums. We are also exposed to the credit risk of our customers, who, pursuant to their contracts with us, frequently pay us over time. We may not collect all our premiums receivable from our ceding insurers and reinsurers, and we may not collect all our reinsurance recoverable from our own retrocessionaires. We have significant premiums receivable and reinsurance recoverable, and our failure to collect even a small portion of these amounts, or a meaningful delay in the collection of recoverables as to which our own underlying obligations are due, could negatively affect our results of operations and financial condition, perhaps materially. We may be affected by adverse economic factors outside of our control, including recession or the belief that a recession may occur, and international socio-political and geopolitical events. An economic recession or slowdown in economic activity may result from international events involving war or civil, political, or social unrest, or from other factors outside of our control. For example, the ongoing conflicts between Russia and Ukraine, and in the Middle East, may expand, which could increase our potential exposures or have far-reaching impacts on the global economy. Additionally, governmental, business and societal responses to such events, such as sanctions, trade restrictions, increased unemployment, and supply chain disruptions could worsen the impact of such events and could have an impact on our business and on our customers’ businesses. Any such events could increase our probability of losses, which may be exacerbated by our exposure to certain lines of business that we write. These events could also reduce the demand for insurance and reinsurance, which would reduce our premium volume and could have a material adverse effect on our business and results of operations. We may be adversely affected by foreign currency fluctuations. We routinely transact business in currencies other than the U.S. dollar, our financial reporting

currency. Moreover, we maintain a portion of our cash and investments in currencies other than the U.S. dollar, and certain of our subsidiaries use or have used non-U.S. dollar functional currencies. Although we generally seek to hedge significant non-U.S. dollar positions, we have experienced, and may in the future experience, losses resulting from fluctuations in the values of these foreign currencies, which could cause our consolidated earnings to decrease. In addition, failure to manage our foreign currency exposures could 41cause our results of operations to be more volatile. Our significant third-party capital management operations further complicates these foreign currency operational needs and risk.We may require additional capital in the future, which may not be available or may only be available on unfavorable terms.Our exposure to significant catastrophic events may cause significant volatility in our operating and capital needs. To the extent that our existing capital is insufficient to support our future operating requirements, we may need to raise additional funds through financings or limit our growth. Any further equity, debt or hybrid financings, or capacity needed for letters of credit, if available at all, may be on terms that are unfavorable to us. For example, in a relatively higher interest rate environment, such as the one prevailing throughout 2023 and 2024, our borrowing costs have and may continue to increase, relative to our existing debt which was issued in a relatively lower interest rate environment. Additionally, any indebtedness we incur at higher interest rates may require higher ongoing debt service payments than our existing debt arrangements, which could leave us with less cash available for our operations. We are also exposed to the risk that the contingent capital facilities we have in place may not be available as expected. Changes to our issuer credit ratings, or the capital models and rating methodologies used by ratings agencies, may also impact our ability to access capital.Our contracts generally require us to post such security via a letter of credit, a trust account, or where applicable, utilize a multi-beneficiary reinsurance trust, with the release of such security being controlled by the ceding insurance company and/or a regulator. If we are unable to obtain adequate capital when needed, we may not be able to grow and take advantage of favorable market conditions, or we may be required to reduce the amount of business that we write, impacting our results of operations and financial condition.In addition, we are exposed to the risk that we may be unable to raise new capital for our joint ventures, managed funds and other private alternative investment vehicles, which would reduce our future fee income and market capacity, and thus negatively affect our results of operations and financial condition. For example, it is possible that substantial losses ceded to the alternative capital sector over a period of years, and restraints on capital return and maintenance of collateral for prior loss periods by a number of market participants, may contribute to a reduction in investor appetite to this product class in the near term.Risks Related to Legal and Regulatory MattersThe regulatory systems under which we operate could restrict our ability to operate, increase our costs, or otherwise adversely impact us.Our operating subsidiaries conduct business globally and are subject to varying degrees of regulation and supervision in multiple jurisdictions. See ¶¶Part I, Item 1. Business¶¶“Regulation.”¶¶These statutes, regulations and policies may, among other things, restrict the ability of our subsidiaries, joint ventures or managed funds to write certain business, make certain investments and distribute funds. We may not be able to comply fully with, or obtain appropriate exemptions from, these statutes and regulations, which could result in restrictions on our ability to do business or undertake activities that are regulated in these jurisdictions, which could subject us to fines and/or penalties. Our current or future business strategy could cause one or more of our currently unregulated subsidiaries to become subject to some form of regulation in the future. Any failure to comply with current or future applicable laws or regulations could result in restrictions on our ability to do business or undertake activities that are regulated in these jurisdictions, which could subject us to fines and other penalties. In addition, changes in the laws or regulations to which our operating subsidiaries are subject or in their interpretation could have an adverse effect on our business. Several of our operating subsidiaries are not licensed or admitted in any jurisdiction except Bermuda, conduct business only from their offices in Bermuda and do not maintain offices in the U.S. The insurance and reinsurance regulatory framework continues to be subject to increased scrutiny in many jurisdictions, including the U.S. and Europe. If our Bermuda insurance or reinsurance operations become subject to the insurance laws of any state in the U.S., jurisdictions in the EU, or elsewhere, we could face challenges to the future operations of these companies. We could also be required to allocate considerable time and resources to comply with any new or additional regulatory requirements in any of the jurisdictions in which we operate, and any such requirements could impact the operations of our insurance and/or non-insurance subsidiaries, result in increased costs for us and impact our financial condition.42The International Association of Insurance Supervisors has adopted a Common Framework for the supervision of Internationally Active Insurance Groups, which is focused on the group-wide supervision of IIGs. The BMA has issued a consultation paper about proposed enhancements to its insurance group supervision framework. The development and adoption of these capital standards could increase our prescribed capital requirement, the level at which regulatory scrutiny intensifies, limit intercompany capital transactions, suspend debt repayments, and significantly increase our cost of regulatory compliance.It is possible that individual jurisdiction or cross border regulatory developments could adversely differentiate Bermuda, the jurisdiction in which we are subject to group supervision, or could exclude Bermuda-based companies from benefits such as market access, mutual recognition or reciprocal rights made available to other jurisdictions, which could adversely impact us. Any such development could significantly and negatively affect our operations.We face risks related to changes in Bermuda law and regulations, and the political environment in Bermuda.We are incorporated in Bermuda and many of our operating companies are domiciled in Bermuda. Therefore, changes in Bermuda law and regulation may have an adverse impact on our operations, such as increased regulatory supervision or the imposition of corporate income tax. The recently enacted Corporate Income Tax Act 2023, discussed below, is an example of a material change in Bermuda law.In addition, we are subject to changes in the political environment in Bermuda, which could make it difficult to operate in, or attract talent to, Bermuda. In addition, Bermuda, which is currently an overseas territory of the U.K., may consider changes to its relationship with the U.K. in the future. These changes could adversely affect Bermuda or the international reinsurance market focused there, either of which could adversely impact us commercially.Political, regulatory and industry initiatives by state and international authorities could adversely affect our business.The insurance and reinsurance regulatory framework is subject to heavy scrutiny by the U.S. and individual state governments, as well as a number of international authorities, and we believe it is likely there will be increased regulatory intervention in our industry in the future, including potential additional group-wide supervision. We could also be adversely affected by proposals or enacted legislation that provide for reinsurance capacity in markets and to consumers that we target, expand the scope of coverage under existing policies for perils such as hurricanes or earthquakes or for a pandemic disease outbreak, mandate the terms of insurance and reinsurance policies, expand the scope of the Federal Insurance Office or establish a new federal insurance regulator or otherwise revise laws, regulations, or contracts under which we operate, which may disproportionately benefit the companies of one country over those of another. Moreover, government-backed entities may represent competition for the coverages we provide, either directly or by competing for the business of our customers, thereby reducing the potential amount of third-party private protection our clients may need or desire.Bermuda is also subject to increasing scrutiny by political bodies outside of Bermuda, including the EU Code of Conduct Group. Due to this increased legislative and regulatory scrutiny of the reinsurance industry and Bermuda, our cost of compliance with applicable laws may increase, which could result in a decrease to our profitability. Further, as we continue to expand our business operations outside of Bermuda, we are increasingly subject to new and additional regulations, including, for example, laws relating to anti-corruption and anti-bribery.Our business is subject to certain laws and regulations relating to sanctions and foreign corrupt practices, the violation of which could adversely affect our operations.We must comply with all applicable economic sanctions and anti-bribery laws and regulations of the U.S. and other jurisdictions. U.S. laws and regulations that may be applicable to us include economic trade sanctions laws and regulations administered by OFAC as well as certain laws administered by the U.S. Department of State. The sanctions laws and regulations of non-U.S. jurisdictions in which we operate may differ from those of the U.S. and these differences may also expose us to sanctions violations. 43In addition, we are subject to the Foreign Corrupt Practices Act and other anti-bribery laws that generally prohibit corrupt payments or improper gifts to non-U.S. governments or officials. It is possible that an employee or intermediary could fail to comply with applicable laws and regulations. In such event, we could be exposed to civil penalties, criminal penalties and other sanctions, including fines or other punitive actions, which could damage our business and reputation, and could adversely affect our financial condition and results of operations.Our business may be subject to governmental and societal responses to climate change which could affect our profitability. In addition to the impacts that environmental incidents have on our business, there are also risks to our business arising from the transition to a lower carbon economy, including from proliferation of governmental and regulatory scrutiny related to climate change and greenhouse gases. Our investment assets could be affected by a market shift away from carbon-intensive industries or businesses, increased costs or fees associated with the production of greenhouse gases, and decreased profitability in sectors that produce or use carbon-based fuels. Additionally, demand for insurance coverage could be negatively impacted to the extent that carbon-intensive businesses are impacted by this transition, and claims and losses related to those industries could increase, either of which could have a material negative effect on our business and results of operations.Concerns over the negative impacts of climate change have led and will continue to lead to new regulatory responses. New laws and regulations relating to sustainability and climate change have been adopted and continue to be considered. These laws and regulations include specific disclosure requirements or obligations, that may result in additional investments and implementation of new practices and reporting processes, all entailing additional compliance costs and risk. For example, the EU adopted the CSRD that will impose disclosure of the risks and opportunities arising from social and environmental issues, and on the impact of companies’ activities on people and the environment. This directive, along with other current or proposed regulations, could significantly increase compliance burdens and associated regulatory costs and complexity.Risks Related to TaxationOur Bermuda subsidiaries may be subject to U.S. corporate income tax.We conduct a significant amount of business through Bermuda subsidiaries that we believe are not subject to U.S. corporate income tax as they are not engaged in a trade or business in the U.S. Since there is considerable uncertainty, however, as to the activities that constitute being engaged in a trade or business within the U.S., we cannot be certain that the U.S. Internal Revenue Service will not contend successfully that any of our non-U.S. companies is engaged in a trade or business in the U.S. Were this to occur, such company could be subject to U.S. corporate income tax and additional branch profits taxes on the portion of its earnings effectively connected to such U.S. trade or business. If we or one or more of our Bermuda subsidiaries were ultimately held to be subject to U.S. taxation, our earnings would correspondingly decline.Certain U.S. tax provisions could reduce our access to capital, decrease demand for our products, impact our shareholders or investors in our joint ventures or other entities we manage or otherwise adversely affect us.U.S. persons may be subject to adverse U.S. federal income tax treatment with respect to an investment in our shares under the controlled foreign corporation, “CFC,” related person insurance income, “RPII” or PFIC provisions of the U.S. Internal Revenue Code of 1986, as amended. Such provisions may apply to a U.S. person who owns (or is considered to own under applicable tax rules) 10% or more of our shares if RenaissanceRe or any of our non-U.S. subsidiaries is considered a controlled foreign corporation in any year, and to a U.S. person who owns any of our shares if RenaissanceRe is considered a PFIC or any of our non-U.S. subsidiaries generates gross related person insurance income that constitutes 20% or more of its gross insurance income in any year. RenaissanceRe may be, and certain of our non-U.S. subsidiaries are, controlled foreign corporations for these purposes. Further, we believe that RenaissanceRe should not be characterized as a PFIC and currently anticipate that the gross related person insurance income of each of our non-U.S. insurance subsidiaries will constitute less than 20% of its gross insurance income for any taxable year in the foreseeable future. However, the application of these provisions is complex, subject to legal uncertainties and dependent on facts that may change from time to time and of which we may have 44limited knowledge. Accordingly, we can provide no assurances that any of these provisions will not apply for any taxable year. In addition, on January 25, 2022, proposed regulations were published that could, if finalized in their current form, substantially expand the definition of related person insurance income to include all insurance income of our non-U.S. subsidiaries related to affiliate reinsurance transactions if U.S. persons own (or are considered to own under applicable tax rules) more than 50% of our shares. These regulations are proposed to apply to taxable years beginning after the date the regulations are finalized. Although we cannot predict whether, when or in what form the proposed regulations might be finalized, if they are finalized in their current form, we may decide not to undertake affiliate reinsurance transactions that would otherwise be undertaken for non-tax business reasons in the future and there may be an increased risk that gross related person insurance income constitutes 20% or more of the gross insurance income of one or more of our non-U.S. insurance subsidiaries in any year.These tax provisions could adversely impact our shareholders and reduce the attractiveness of an investment in our shares and thus our access to capital. Joint venture entities or other entities managed by us may be subject to similar tax risks, which could make these entities less attractive to investors and reduce our fee income.Further, we or our shareholders may be the subject of future changes in tax laws, which could reduce our access to capital, decrease demand for our products, impact our shareholders or investors in our joint ventures or other entities we manage or otherwise adversely affect us.The OECD and the jurisdictions in which we operate may pursue measures that might increase our taxes and reduce our net income and increase our reporting requirements.The OECD has published reports and launched a global dialog among member and non-member countries on measures to limit harmful tax competition. These measures are largely directed at counteracting the effects of jurisdictions perceived by the OECD to be tax havens or offering preferential tax regimes. In the past, Bermuda has been temporarily added to the EU “blacklist” of non-cooperative jurisdictions for tax purposes, as well as the “greylist” of jurisdictions that have made sufficient commitments to reform their tax policies but remain subject to close monitoring while they are executing on their commitments.In addition, in December 2021, the OECD/G20 Inclusive Framework on BEPS approved global anti-base erosion model rules (the “GloBE Rules”) that generally would require large multinational groups to calculate the effective tax rate in each of the jurisdictions in which they operate and pay an additional top-up tax where the group’s effective tax rate in a jurisdiction is below 15%. Certain jurisdictions where we operate have brought into effect laws implementing the GloBE Rules or other changes in response to the GloBE Rules, or are in the process of doing so, and other jurisdictions may do so in the future.Further, in response to the GloBE Rules, Bermuda adopted the Corporate Income Tax Act 2023, the “CIT” on December 27, 2023. Effective January 1, 2025, the CIT generally will impose a 15% income tax on our profits generated in Bermuda (except for profits earned by our joint ventures and managed funds), notwithstanding any assurances that may have been provided pursuant to the Exempted Undertakings Tax Protection Act 1966. We generally expect that the profits generated in Bermuda on or after January 1, 2025 by our joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the GloBE Rules by many of the jurisdictions in which we operate.On January 15, 2025, the OECD issued administrative guidance on Article 9.1 of the GloBE Rules. This guidance, if incorporated into the laws of the jurisdictions in which we operate, could cause additional top-up taxes pursuant to the GloBE Rules to the extent the net deferred tax asset we established upon enactment of the CIT in 2023 pursuant to the economic transition adjustment (approximately \$670A million as of December 31, 2024) reverses after 2026. It is uncertain whether the jurisdictions in which we operate will incorporate this guidance. Further, the amount of such deferred tax asset that reverses in any given year, if any, is uncertain. To the extent the jurisdictions in which we operate incorporate this guidance into their own laws, our overall cash tax savings from the reversal of the deferred tax asset could be limited to the lesser of 20% of the gross deferred tax asset or the portion of the deferred tax asset that reverses in 2025 and 2026.45We expect to incur increased tax liabilities and reporting obligations as a result of the implementation of the CIT in Bermuda and the GloBE Rules in other jurisdictions where we operate. These and any other changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by taxation authorities in the jurisdictions in which we operate may materially adversely affect our results of operations.Risks Related to the Ownership of our SecuritiesBecause we are a holding company, we are dependent on capital distributions from our subsidiaries.As a holding company with no direct operations, we rely on our investment income, cash dividends and other permitted payments from our subsidiaries to make principal and interest payments on our debt and to pay dividends to our shareholders. From time to time, we may not have sufficient liquid assets to meet these obligations. Regulatory restrictions on capital distributions under Bermuda law, Swiss law and various U.S. laws regulate the ability of our subsidiaries to pay dividends or otherwise distribute capital. If our subsidiaries are restricted from distributing capital to us, we may be unable to pay dividends to our shareholders or to repay our indebtedness. Some aspects of our corporate structure may discourage third-party takeovers and other transactions or prevent the removal of our current board of directors and management.Some provisions of our bye-laws may discourage third parties from making unsolicited takeover bids or prevent the removal of our current board of directors and management. In particular, our bye-laws prohibit transfers of our capital shares if the transfer would result in a person owning or controlling shares that constitute 9.9% or more of any class or series of our shares, unless otherwise waived at the discretion of the Board. In addition, our bye-laws reduce the total voting power of any shareholder owning, directly or indirectly, beneficially or otherwise, more than 9.9% of our common shares to not more than 9.9% of the total voting power of our shares unless otherwise waived at the discretion of the Board. These provisions may have the effect of deterring purchases of large blocks of our common shares or proposals to acquire us, even if our shareholders might deem these purchases or acquisition proposals to be in their best interests.In addition, our bye-laws provide for, among other things:¶¶a classified Board, whose size is generally fixed and whose members may be removed by the shareholders only for cause upon a 66 2/3% vote;¶¶restrictions on the ability of shareholders to nominate persons to serve as directors, submit resolutions to a shareholder vote and requisition special general

The Validus Acquisition was immediately accretive to our shareholders upon completion. At the same time, we have deepened, and intend to continue to deepen, our relationship with a core trading partner, AIG, who is one of our five largest clients by premium volume, as the Validus Acquisition provides options for increased future strategic engagement. Revenues and ExpensesOur revenues are principally derived from three sources: (1) net premiums earned from the reinsurance and insurance policies we sell; (2) net investment income and net realized and unrealized gains from the investment of our capital funds and the investment of the cash we receive on the policies which we sell; and (3) fees received from our joint ventures, managed funds and structured reinsurance products, which are primarily reflected in redeemable noncontrolling interest or as an offset to acquisition or operational expenses.Our expenses primarily consist of: (1) net claims and claim expenses incurred on the policies of reinsurance and insurance we sell; (2) acquisition costs, which typically represent a percentage of the premiums we write; (3) operational expenses, which primarily consist of personnel expenses, rent and other expenses; (4) corporate expenses, which include certain executive, legal and consulting expenses, costs for research and development, transaction and integration-related expenses, and other miscellaneous costs, including those associated with operating as a publicly traded company; and (5) interest and dividends related to our debt, preference shares and common shares. We are also subject to taxes in certain jurisdictions in which we operate. Historically, the majority of our income has been earned in Bermuda, which has not had a corporate income tax, so the tax impact to our operations has been minimal. However, on December 27, 2023, the Government of Bermuda announced the implementation of a 15% corporate income tax effective January 1, 2025. As a result, we expect our profits generated on or after January 1, 2025 in Bermuda, except for profits earned by our joint ventures and managed funds, will be subject to the 15% corporate income tax. Furthermore, we generally expect that the profits generated in Bermuda on or after January 1, 2025 by our joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the GloBE Rules by many of the jurisdictions in which we operate. We expect that these developments will increase our income taxes in the future. We believe that the flexible global operating model that we have utilized will continue to prove resilient.The underwriting results of an insurance or reinsurance company are discussed frequently by reference to its net claims and claim expense ratio, underwriting expense ratio, and combined ratio. The net claims and claim expense ratio is calculated by dividing net claims and claim expenses incurred by net premiums earned. The underwriting expense ratio is calculated by dividing underwriting expenses (acquisition expenses and operational expenses) by net premiums earned. The combined ratio is the sum of the net claims and claim expense ratio and the underwriting expense ratio. A combined ratio below 100% indicates profitable underwriting prior to the consideration of investment income. A combined ratio over 100% indicates unprofitable underwriting prior to the consideration of investment income. We also discuss our net claims and claim expense ratio on a current accident year basis and a prior accident years basis. The current accident year net claims and claim expense ratio is calculated by taking current accident year net claims and claim expenses incurred, divided by net premiums earned. The prior accident years net claims and claim expense ratio is calculated by taking prior accident years net claims and claim expenses incurred, divided by net premiums earned.54We manage DaVinci, Fontana, Medici, and Vermeer, and own all, or a majority, of the voting interests, but own no, or a minority, economic interest of each. As a result of our controlling voting interests, we fully consolidate these entities in our financial statements, even though we do not retain the full value of the economic outcomes generated by these entities. The portions of the economic outcomes that are not retained by us are ultimately allocated to the third-party investors who hold the noncontrolling interests in these entities. The economic outcomes may include underwriting results, investments results, and foreign exchange impacts, among other items. For example, if one of these entities were to generate underwriting losses due to a natural catastrophe, the full amount would be reflected in net income (loss) on our consolidated statements of operations, but ultimately we would only retain a portion of that amount in our net income (loss) attributable to RenaissanceRe. In our consolidated balance sheets and consolidated statements of operations, the portion of these items attributable to third parties is reflected in net (income) loss attributable to redeemable noncontrolling interests. Refer to “Note 10. Noncontrolling Interests” in our “Notes to the Consolidated Financial Statements” for additional information regarding our redeemable noncontrolling interests and how this accounting treatment impacts our financial results.Effects of InflationGeneral economic inflation has increased over the past few years compared to recent historical norms, and there is a risk of inflation remaining elevated for an extended period, which could cause claims and claims related expenses to increase, impact the performance of our investment portfolio, or have other adverse effects. This risk may be exacerbated by geopolitical factors and global supply chain issues, among other factors, from time to time. Some central banks have begun to cut interest rates, which could act as a potential supporting force for some of these inflationary pressures, if they have cut rates too soon. The actual effects of the current and potential future increase in inflation on our results cannot be accurately known until, among other items, claims are ultimately settled. The duration and severity of an inflationary period cannot be estimated with precision. We consider the anticipated effects of inflation on us in our catastrophe loss models and on our investment portfolio. Our estimates of the potential effects of inflation are also considered in pricing and in estimating reserves for unpaid claims and claim expenses. The potential exists, after a catastrophe loss, for the development of inflationary pressures in a local economy.55SELECTED CONSOLIDATED FINANCIAL DATAThe following tables set forth our selected consolidated financial data and other financial information at the end of and for each of the years in the five-year period ended December 31, 2024. The results of Validus are included in our consolidated financial data from November 1, 2023. The selected consolidated financial data should be read in conjunction with our consolidated financial statements and related notes thereto and the other information in this “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-K.Year ended December 31, 20242023202220212020(in thousands, except share and per share data and percentages)Statements of Operations Data:Gross premiums written\$11,733,066\$8,862,366\$9,213,540\$7,833,798\$5,806,165Net premiums written9,952,216\$7,467,813\$7,196,160\$5,939,375\$4,096,333Net premiums earned10,095,760\$7,471,133\$6,333,989\$5,194,181\$3,952,462Net investment income1,654,289\$1,253,110\$559,932\$319,479\$354,038Net realized and unrealized gains (losses) on investments(27,840)\$414,522\$(1,800,485)(218,134)\$820,636Net claims and claim expenses incurred5,332,981\$3,573,509\$4,338,840\$3,876,087\$2,924,609Acquisition expenses2,643,867\$1,875,034\$1,568,606\$1,214,858\$897,677Operational expenses496,588\$375,182\$276,691\$212,184\$206,687Underwriting income (loss)\$1,622,324\$1,647,408\$1,494,852\$(108,948)\$(76,511)Net income (loss)\$2,960,532\$(3,620,127)\$(1,159,816)\$(103,440)\$993,058Net income (loss) available (attributable) to RenaissanceRe common shareholders1,834,985\$2,525,757\$(1,096,578)\$(73,421)\$731,482Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share “diluted”\$51.39\$52.27(25.50)(1.57)15.31Dividends per common share1.56\$1.52\$1.48\$1.44\$1.40Weighted average common shares outstanding “diluted”51,339\$47,607\$43,040\$47,171\$47,178Return on average common equity19.34%\$40.54%\$(22.0)%\$(1.1)%11.74%Combined ratio83.94%\$97.74%\$102.14%\$101.94%At December 31, 20242023202220212020Balance Sheet Data:Total investments\$32,639,456\$29,216,143\$22,220,436\$21,442,659\$20,558,176Total assets50,707,550\$49,007,105\$36,552,878\$33,959,502\$30,820,580Reserve for claims and claim expenses21,303,491\$20,486,869\$15,892,573\$13,294,630\$10,381,138Unearned premiums5,950,415\$6,136,135\$4,559,107\$3,531,213\$2,763,599Debt1,886,689\$1,958,655\$1,170,442\$1,168,353\$1,136,265Capital leases21,010\$21,540\$22,020\$22,459\$22,853Preference shares750,000\$750,000\$750,000\$750,000\$525,000Total shareholders’ equity attributable to RenaissanceRe10,574,012\$9,454,958\$5,325,274\$6,624,281\$7,560,248Common shares outstanding50,181\$52,694\$43,718\$44,445\$50,811Book value per common share\$195.77\$165.20\$104.65\$132.17\$138.46Accumulated dividends28.08\$26.52\$25.00\$23.52\$22.08Book value per common share plus accumulated dividends\$223.85\$191.72\$129.65\$155.69\$160.54Change in book value per common share plus change in accumulated dividends19.44%\$59.34%\$(19.7)%\$(3.5)%16.04%\$65SUMMARY OF CRITICAL ACCOUNTING ESTIMATESClaims and Claim Expense ReservesWe believe the most significant accounting judgment made by management is our estimate of claims and claim expense reserves. Claims and claim expense reserves represent estimates, including actuarial and statistical projections at a given point in time, of the ultimate settlement and administration costs for unpaid claims and claim expenses arising from the insurance and reinsurance contracts we sell. Our reserve for claims and claim expense is a combination of case reserves, ACR, and incurred but not reported losses and incurred but not enough reported losses, collectively referred to as IBNR. Case reserves are losses reported to us by insureds and ceding companies, but which have not yet been paid. If deemed necessary and in certain situations, either we establish, or our clients report, ACR. Client reported ACR represents their estimate of additional contract specific claims in excess of the case reserves they have reported to us. ACR established by us represents our estimates for claims related to specific contracts which we believe may not be adequately estimated by the client as of that date or is not within the IBNR. We establish IBNR using actuarial techniques and expert judgment to represent the anticipated cost of claims which have not been reported to us yet or where we anticipate increased reporting. Our reserving committee, which includes members of our senior management, reviews, discusses, and assesses the reasonableness and adequacy of the reserving estimates included in our audited consolidated financial statements.The following table summarizes our reserve for claims and claim expenses by segment, allocated between case reserves, ACR and IBNR:At December 31, 2024CaseReservesAdditionalCase ReservesIBNRTotal(in thousands)\$A A Property\$1,845,228\$1,905,553\$2,821,958\$6,572,739Casualty and Specialty3,081,081\$295,074\$11,354,597\$14,730,752Total\$4,926,309\$2,300,627\$14,176,555\$21,303,491At December 31, 2023(in thousands)Property (1)\$2,461,580\$2,401,911\$2,970,129\$7,833,620Casualty and Specialty (1)\$2,801,016\$331,345\$9,520,888\$12,653,249Total (1)\$5,262,596\$2,733,256\$12,491,017\$20,486,869(1)The previously reported amount has been adjusted to reclassify certain reserves from IBNR to ACR.57Activity in the reserve for claims and claim expenses is summarized as follows:Year ended December 31, 20242023(in thousands)Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period\$15,142,583\$11,181,648Net incurred related to:Current year6,184,315\$4,024,116Prior years(851,334)\$(450,607)Total net incurred\$5,332,981\$3,573,509Net paid related to:Current year488,450\$364,793Prior years3,109,360\$2,630,885Total net paid\$3,597,810\$2,995,678Foreign exchange and other (1)\$(55,653)\$62,902Amounts acquired (2)\$63,320\$2,420Reserve for claims and claim expenses, net of reinsurance recoverable, end of period\$16,822,101\$15,142,583Reinsurance recoverable, end of period\$4,481,390\$5,344,286Reserve for claims and claim expenses, end of period\$21,303,491\$20,486,869(1)Reflects the impact of the foreign exchange revaluation of the reserve for claims and claim expenses, net of reinsurance recoverable, denominated in non-U.S. dollars as at the balance sheet date, as well as reinsurance transactions accounted for under retroactive reinsurance accounting.(2)Represents the fair value of Validus’ reserve for claims and claim expenses, net of reinsurance recoverable, acquired on November 1, 2023.The following table details our prior year net development by segment of our liability for unpaid claims and claim expenses:(Favorable) Adverse DevelopmentYear ended December 31, 20242023(in thousands)Property\$(818,852)\$(408,905)Casualty and Specialty\$(32,482)\$(41,702)Total net favorable development of prior accident years net claims and claim expenses\$(851,334)\$(450,607)Our reserving methodology for each line of business uses a loss reserving process that calculates a point estimate for our ultimate settlement and administration costs for claims and claim expenses. We do not calculate a range of estimates and do not discount any of our reserves for claims and claim expenses. We use this point estimate, along with paid claims and case reserves, to record our best estimate of ACR and IBNR in our consolidated financial statements. Under GAAP, we are not permitted to establish estimates for catastrophe claims and claim expense reserves until an event occurs that gives rise to a loss. Reserving for our claims involves other uncertainties, such as the dependence on information from ceding companies, the time lag inherent in reporting information from the primary insurer to us or to our ceding companies, and different reserving practices among ceding companies. The information received from ceding companies is typically in the form of bordereaux, broker notifications of loss and/or discussions with ceding companies or their brokers. This information may be received on a monthly, quarterly or transactional basis and normally includes paid claims and estimates of case reserves. We may also receive an estimate or provision for IBNR from certain ceding companies. This information is often updated and adjusted from time to time during the loss settlement period as new data or facts in respect of initial claims, client accounts, industry or event trends may be reported or emerge in addition to changes in applicable statutory and case laws. 58Our estimates of large losses are based on factors including currently available information derived from claims information from certain customers and brokers, industry assessments of losses, proprietary models, historical reinsurance and insurance loss experience and statistics, management’s experience and judgment to assist the establishment of appropriate claims and claim expense reserves, and the terms and conditions of our contracts. The uncertainty of our estimates for large losses is also impacted by the preliminary nature of the information available, the magnitude and relative infrequency of the loss, the expected duration of the respective claims development period, inadequacies in the data provided to the relevant date by industry participants, the potential for further reporting lags or insufficiencies and, in certain cases, the form of the claims and legal issues under the relevant terms of insurance and reinsurance contracts. In addition, a significant portion of the net claims and claim expenses associated with certain large losses can be concentrated with a few large clients and therefore the loss estimates for these losses may vary significantly based on the claims experience of those clients. The contingent nature of business interruption and other exposures will also impact losses in a meaningful way, which we believe may give rise to significant complexity in respect of claims handling, claims adjustment and other coverage issues, over time. Given the magnitude of certain losses, there can be meaningful uncertainty regarding total covered losses for the insurance industry and, accordingly, several of the key assumptions underlying our loss estimates. Loss reserve estimation in respect of our retrocessional contracts poses further challenges compared to directly assumed reinsurance. In addition, our actual net losses may increase if our reinsurers or other obligors fail to meet their obligations.Because of the inherent uncertainties discussed above, we have developed a reserving philosophy which attempts to incorporate prudent assumptions and estimates, and we have generally experienced favorable development on prior accident years net claims and claim expenses in the last several years. However, there is no assurance that this favorable development on prior accident years net claims and claim expenses will occur in future periods.Our reserving techniques, assumptions and processes differ among our Property and Casualty and Specialty segments. Refer to “Note 8. Reserve for Claims and Claim Expenses” in our “Notes to the Consolidated Financial Statements” for more information on the risks we insure and reinsure, the reserving techniques, assumptions and processes we follow to estimate our claims and claim expense reserves, prior year development of the reserve for claims and claim expenses, analysis of our incurred and paid claims development and claims duration information for each of our Property and Casualty and Specialty segments.Property SegmentActual Results vs. Initial EstimatesAs discussed above, the key assumption in estimating reserves for our Property segment is our estimate of incurred claims and claim expenses. The table below shows our initial estimates of incurred claims and claim expenses for each accident year and how these initial estimates have developed over time. The initial estimate of accident year incurred claims and claim expenses represents our estimate of the ultimate settlement and administration costs for claims incurred in our Property segment occurring during a particular accident year, and as reported as of December 31 of that year. The re-estimated incurred claims and claim expenses as of December 31 of subsequent years, represent our revised estimates as reported as of those dates. Our most recent estimates as reported at December 31, 2024 differ from our initial accident year estimates and demonstrate that our most recent estimate of incurred claims and claim expenses are reasonably likely to vary from our initial estimate, perhaps significantly. Changes in this estimate will be recorded in the period in which they occur. In accident years where our current estimates are lower than our initial estimates, we have experienced favorable development, in comparison, for accident years where our current estimates are higher than our original estimates we have experienced adverse development. The table is presented on a net basis and, therefore, includes the benefit of reinsurance recoveries. In addition, we have included historical incurred claims and claim expenses development information related to Platinum, TMR and Validus in the table below. For incurred accident year claims and claim expenses denominated in currencies other than USD, we have used the current year-end balance sheet foreign exchange rate for all periods provided, thereby eliminating the effects of changes in foreign currency translation rates from the incurred accident year claims development information included in the table below.59The following table details our Property segment incurred claims and claim expenses, net of reinsurance, as of December 31, 2024.Incurred Claims and Claim Expenses, Net of Reinsurance(in thousands)For the year ended December 31, Accident Year20152016201720182019202020212022202320242015\$506,243\$456,920\$414,379\$397,750\$388,076\$383,214\$374,258\$376,457\$375,420\$373,8952016\$572,814\$521,010\$500,000\$480,000\$460,000\$440,000\$420,000\$400,000\$380,000\$360,0002017\$500,000\$480,000\$460,000\$440,000\$420,000\$400,000\$380,000\$360,000\$340,000\$320,0002018\$400,000\$380,000\$360,000\$340,000\$320,000\$300,000\$280,000\$260,000\$240,000\$220,0002019\$300,000\$280,000\$260,000\$240,000\$220,000\$200,000\$180,000\$160,000\$140,000\$120,0002020\$200,000\$180,000\$160,000\$140,000\$120,000\$100,000\$80,000\$60,000\$40,000\$20,0002021\$100,000\$80,000\$60,000\$40,000\$20,000\$10,000\$5,000\$2,500\$1,250\$6252022\$50,000\$40,000\$30,000\$20,000\$10,000\$5,000\$2,500\$1,250\$625\$312.52023\$25,000\$20,000\$15,000\$10,000\$5,000\$2,500\$1,250\$625\$312.5\$156.252024\$12,500\$10,000\$7,500\$5,000\$2,500\$1,250\$625\$312.5\$156.25\$78.125Initial and subsequent estimates of incurred claims and claim expenses, net of reinsurance, are impacted by available information derived from claims information from customers and brokers, industry assessments of losses, proprietary models, historical reinsurance and insurance loss experience and statistics, management’s experience and judgment to assist the establishment of appropriate claims and claim expense reserves, and the terms and conditions of our contracts. As described above, given the complexity in reserving for claims and claims expenses associated with property losses, and catastrophe excess of loss reinsurance contracts in particular, which make up a significant proportion of our Property segment, we have experienced

development, both favorable and unfavorable, in any given accident year. For example, net claims and claim expenses associated with the 2022 accident year have experienced favorable development. This is largely driven by reductions in estimated net ultimate claims and claim expenses associated with Hurricane Ian. In comparison, net claims and claim expenses associated with the 2020 accident year have experienced adverse development. The adverse development was driven by an increase in expected net claims and claim expenses as new and additional claims information was received associated with the 2020 Weather-Related Large Loss Events and COVID-19. The COVID-19 adverse development was driven by the legacy Validus portfolio prior to the Validus Acquisition and therefore did not impact our financial results. In accident years with a low level of insured catastrophe losses, our other property lines of business contribute a greater proportion of our overall incurred claims and claim expenses within our Property segment, compared to years with a high level of insured catastrophe losses. We expect that certain of our other property lines of business will tend to generate less volatility in future calendar years and, as such, we would expect to see a slower more stable increase or decrease in estimated incurred net claims and claim expenses over time in such business. Certain of our other property contracts are also exposed to catastrophe events, resulting in increased volatility of incurred claims and claim expenses driven by the occurrence of catastrophe events. In addition, volatility in the initial estimate associated with large catastrophe losses and the speed at which we settle claims can vary significantly based on the type of event. Sensitivity Analysis The table below shows the impact on our reserve for claims and claim expenses, net income (loss) and shareholders' equity as of and for the year ended December 31, 2024 of a reasonable range of possible outcomes associated with our estimates of gross ultimate losses for claims and claim expenses incurred within our Property segment. The reasonable range of possible outcomes is based on a distribution of outcomes of our ultimate incurred claims and claim expenses from large losses. In addition, we adjust the loss ratios and development curves in our other property lines of business in a similar fashion to the sensitivity analysis performed for our Casualty and Specialty segment, discussed in greater detail below. In general, our reserve for claims and claim expenses for more recent losses are subject to greater uncertainty and, therefore, greater variability and are likely to experience material changes from one period to the next. 60 This is due to uncertainty with respect to the size of the industry losses, which contracts have been exposed to the loss and the magnitude of claims incurred by our clients. As our claims age, more information becomes available and we believe our estimates become more certain, although there is no assurance this trend will continue in the future. As a result, the sensitivity analysis below is based on the age of each accident year, our current estimated incurred claims and claim expenses for the losses occurring in each accident year, and a reasonable range of possible outcomes of our current estimates of claims and claim expenses by accident year. The impact on net income (loss) and shareholders' equity assumes no increase or decrease in reinsurance recoveries, loss related premium or profit commission, income tax benefit (expense), or redeemable noncontrolling interest. (in thousands, except percentages) Reserve for Claims and Claim Expenses at December 31, 2024 \$ Impact of a Change on Reserve for Claims and Claim Expenses at December 31, 2024 \$ Impact of a Change on Shareholders' Equity at December 31, 2024 \$ Higher \$7,114,722 \$541,983 \$2.5% (18.3%) (5.1)% Recorded \$6,572,739 \$6,227,849 \$ (344,890) (1.6)% 11.6% \$53.3% We believe the changes we made to our estimated incurred claims and claim expenses represent a reasonable range of possible outcomes based on our experience to date and our future expectations. While we believe these are a reasonable range of possible outcomes, we do not believe the above sensitivity analysis should be considered an actuarial reserve range. In addition, the sensitivity analysis only reflects a reasonable range of possible outcomes in our underlying assumptions. It is possible that our estimated incurred claims and claim expenses could be significantly higher or lower than the sensitivity analysis described above. For example, we could be liable for exposures we do not currently believe are covered under our policies. These changes could result in significantly larger changes to our estimated incurred claims and claim expenses, net income (loss) and shareholders' equity than those noted above, and could be recorded across multiple periods. The inflationary outlook is also highly uncertain and could result in larger changes than those depicted above. We continue to monitor the inflationary environment and reflect our view within our best estimate reserves. We also caution that the above sensitivity analysis is not used by management in developing our reserve estimates and is also not used by management in managing the business. Casualty and Specialty Segment Actual Results vs. Initial Estimates As discussed above, the key assumption in estimating reserves for our Casualty and Specialty segment is our estimate of incurred claims and claim expenses. Standard actuarial techniques are used to calculate the ultimate claims and claim expenses. The key assumptions in the determination of ultimate claims and claim expenses include the estimated incurred claims and claim expenses ratio and the estimated loss reporting patterns. The table below shows our initial estimates of incurred claims and claim expenses for each accident year and how these initial estimates have developed over time. The initial estimate of accident year incurred claims and claim expenses represents our estimate of the ultimate settlement and administration costs for claims incurred in our Casualty and Specialty segment occurring during a particular accident year, and as reported as of December 31 of that year. The re-estimated incurred claims and claim expenses as of December 31 of subsequent years, represent our revised estimates as reported as of those dates. Our most recent estimates as reported at December 31, 2024 differ from our initial accident year estimates and demonstrates that our initial estimate of incurred claims and claim expenses are reasonably likely to vary from our most recent estimate, perhaps significantly. Changes in this estimate will be recorded in the period in which they occur. In accident years where our current estimates are lower than our initial estimates, we have experienced favorable development while accident years where our current estimates are higher than our original estimates indicate adverse development. The table is presented on a net basis and, therefore, includes the benefit of reinsurance recoverable. In addition, we have included historical incurred claims and claim expenses development information related to Platinum, TMR and Validus in the table below. For incurred accident year claims denominated in currencies other than USD, we have used the current year-end balance sheet foreign exchange rate for all periods provided, thereby eliminating the effects of changes in foreign currency translation rates from the incurred accident year claims development information included in the table below. The following table details our Casualty and Specialty segment incurred claims and claim expenses, net of reinsurance, as of December 31, 2024. Incurred Claims and Claim Expenses, Net of Reinsurance (in thousands) For the year ended December 31, Accident Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1,163,947 \$ 1,146,693 \$ 1,157,686 \$ 1,129,261 \$ 1,117,185 \$ 1,111,192 \$ 1,123,053 \$ 1,113,440 \$ 1,111,633 \$ 1,111,791 \$ each accident year has developed, our estimated expected incurred claims and claim expenses, net of reinsurance, have changed. For example, our re-estimated incurred claims and claim expenses decreased for the 2021 accident year from the initial estimates. This decrease was principally driven by actual reported and paid net claims and claim expenses associated with the 2021 accident year being lower than expected, which has resulted in a reduction in our expected ultimate claims and claim expense ratio for this accident year. In comparison, the 2019 accident year has developed adversely compared to our initial estimates of incurred claims and claim expenses and our current estimates are higher than our initial estimates. The increase in incurred claims and claim expenses for the 2019 accident year is due to reported losses generally coming in higher than expected on attritional net claims and claim expenses. The reserving methodology for our Casualty and Specialty segment is weighted more heavily to our initial estimate in the early periods immediately following the contracts' inception through the use of the expected loss ratio method. The expected loss ratio method estimates the incurred losses by multiplying the initial expected loss ratio by the earned premium. Under the expected loss ratio method, no reliance is placed on the development of claims and claim expenses. The determination of when reported losses are sufficient and credible to warrant selection of an ultimate loss ratio different from the initial expected loss ratio also requires judgment. We generally make adjustments for reported loss experience indicating unfavorable variances from the initial expected loss ratio sooner than reported loss experience indicating favorable variances as reporting of losses in excess of expectations tends to have greater credibility than an absence of, or lower than expected level of, reported losses. Over time, as a greater number of claims are reported and the credibility of reported losses improves, actuarial estimates of IBNR are typically based on the Bornhuetter-Ferguson actuarial method. The Bornhuetter-Ferguson actuarial method places weight on claims and claim expenses development experience. If there is adverse development of prior accident years claims and claim expenses, we generally select the Bornhuetter-Ferguson actuarial method to ensure the claim experience is considered in the determination of our estimated claims and claim expenses with the associated business. If we believe we lack the claims experience in the early stages of development of a line of business, we may not select the Bornhuetter-Ferguson actuarial method until such time as we believe there is greater credibility in the level of reported losses. As development experience for claims and claim expenses on prior accident years becomes credible, the Bornhuetter-Ferguson actuarial method is generally selected which places greater weight on this reported experience as it develops. The Bornhuetter-Ferguson actuarial method estimates our expected ultimate claims and claim expenses by applying our initial estimated loss ratio to our undeveloped premium, and adding the reported losses to the estimate. 62 Sensitivity Analysis The table below shows the impact on our Casualty and Specialty segment reserve for claims and claim expenses, net income (loss) and shareholders' equity as of and for the year ended December 31, 2024, of a reasonable range of possible outcomes associated with a variety of reasonable actuarial assumptions for our estimates of gross ultimate claims and claim expense ratios and loss reporting patterns. The impact on net income (loss) and shareholders' equity assumes no increase or decrease in reinsurance recoveries, loss related premium or profit commission, income tax benefit (expense), or redeemable noncontrolling interest. (in thousands, except percentages) Estimated Loss Reporting Pattern \$ Impact of a Change on Reserve for Claims and Claim Expenses at December 31, 2024 \$ Impact of a Change on Shareholders' Equity at December 31, 2024 \$ Increase expected claims and claim expense ratio by 10% Slower reporting \$2,448,898 11.5% (82.7)% (23.2)% Increase expected claims and claim expense ratio by 10% Expected reporting \$1,473,464 6.9% (49.8)% (13.9)% Increase expected claims and claim expense ratio by 10% Faster reporting \$595,173 2.8% (20.1)% (5.6)% Expected claims and claim expense ratio Slower reporting \$890,165 4.2% (30.1)% (8.4)% Expected claims and claim expense ratio Expected reporting \$6,572,739 6.6% (49.8)% (13.9)% Expected claims and claim expense ratio Faster reporting \$800,881 (3.8)% 27.1% 6.6% Decrease expected claims and claim expense ratio by 10% Slower reporting \$(636,378) (3.0)% 21.5% 6.0% Decrease expected claims and claim expense ratio by 10% Expected reporting \$(1,441,272) (6.8)% 48.7% 13.6% Decrease expected claims and claim expense ratio by 10% Faster reporting \$(2,164,743) (10.2)% 73.1% 20.5% We believe that ultimate claims and claim expense ratios 10.0 percentage points above or below our estimated assumptions constitute a reasonable range of possible outcomes based on our experience to date and our future expectations. In addition, we believe that the adjustments we made to speed up or slow down our estimated loss reporting patterns represent a reasonable range of possible outcomes. While we believe these are a reasonable range of possible outcomes, we do not believe the above sensitivity analysis should be considered an actuarial reserve range. In addition, the sensitivity analysis only reflects a reasonable range of possible outcomes in our underlying assumptions. It is possible that our initial estimated claims and claim expense ratios and loss reporting patterns could be significantly different from the sensitivity analysis described above. For example, we could be liable for exposures we do not currently believe are covered under our contracts. These changes could result in significantly larger changes to our reserves for claims and claim expenses, net income (loss) and shareholders' equity than those noted above, and could be recorded across multiple periods. The inflationary outlook is also highly uncertain and could result in larger changes than those depicted above. We continue to monitor the inflationary environment and reflect our view within our best estimate reserves. We also caution that the above sensitivity analysis is not used by management in developing our reserve estimates and is also not used by management in managing the business. Premiums and Related Expenses Premiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are determined. Unearned premiums represents the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written. Due to the nature of reinsurance, ceding companies routinely report and remit premiums to us subsequent to the contract coverage period. Consequently, premiums written and receivable include amounts reported by the ceding companies, supplemented by our estimates of premiums that are written but not reported. The estimation of written premiums may be affected by early cancellation, election of contract provisions for cut-off and return of unearned premiums or other contract disruptions. The time lag involved in the process of reporting premiums is typically shorter than the lag in reporting losses. In addition to estimating premiums written, we estimate the earned portion of premiums written which is subject to judgment and uncertainty. Any adjustments to written and earned premiums, and the related losses and acquisition expenses, are accounted for as changes in estimates and are reflected in the results of operations in the period in which they are made. Lines of business that are similar in both the nature of their business and estimation process may be grouped for purposes of estimating premiums. Premiums are estimated based on ceding company estimates and our own judgment after considering factors such as: (1) the ceding company's historical premium versus projected premium, (2) the ceding company's history of providing accurate estimates, (3) anticipated changes in the marketplace and the ceding company's competitive position therein, (4) reported premiums to date and (5) the anticipated impact of proposed underwriting changes. Estimates of premiums written and earned are based on the selected ultimate premium estimate, the terms and conditions of the reinsurance contracts and the remaining exposure from the underlying policies. We evaluate the appropriateness of these estimates in light of the actual premium reported by the ceding companies, information obtained during audits and other information received from ceding companies. We estimate our provision for current expected credit losses by applying specific percentages against each premium receivable based on the counterparty's credit ratings. The percentages applied are based on information received from both insureds and ceding companies and are then adjusted by us based on industry knowledge and our judgment and estimates. We then evaluate the overall adequacy of the provision for current expected credit losses based on other qualitative and judgmental factors. At December 31, 2024, our premiums receivable balance was \$7.3 billion (2023 - \$7.3 billion). Of this amount, the majority are receivables from highly rated counterparties. At December 31, 2024, the provision for current expected credit losses on premiums receivable was \$4.6 million (2023 - \$3.5 million). Reinsurance Recoverable We enter into retrocessional reinsurance agreements in order to help reduce our exposure to large losses and to help manage our risk portfolio. Amounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, we accrue amounts (either assets or liabilities) that are due to or from our retrocessionaires based on estimated contract experience. If we determine that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. The estimate of reinsurance recoverable can be more subjective than estimating the underlying claims and claim expense reserves as discussed under the heading "Claims and Claim Expense Reserves" above. In particular, reinsurance recoverable may be affected by deemed inuring reinsurance, frequency and timing of industry losses reported by various statistical reporting services, loss development, loss buffer tables and various other factors. Reinsurance recoverable on dual trigger reinsurance contracts require us to estimate our ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. In addition, the level of our ACR and IBNR reserves has a significant impact on reinsurance recoverable. These factors can impact the amount and timing of the reinsurance recoverable to be recorded. 64 The majority of the balance we have accrued as recoverable will not be due for collection until some point in the future. The amounts recoverable that will ultimately be collected are subject to uncertainty due to the ultimate ability and willingness of reinsurers to pay our claims at a future point in time, for reasons including insolvency or elective run-off, contractual dispute and various other reasons. In addition, because the majority of the balances recoverable will not be collected

The reinsurers with the three largest balances accounted for 12.6%, 11.0% and 8.3%, respectively, of our reinsurance recoverable balance at December 31, 2024 (2023 - 17.6%, 14.3% and 8.7%, respectively). The provision for current expected credit losses recorded against reinsurance recoverable was \$11.7 million at December 31, 2024 (2023 - \$13.3 million). The three largest company-specific components of the provision for current expected credit losses represented 23.9%, 7.2% and 5.9%, respectively, of our total provision for current expected credit losses at December 31, 2024 (2023A - 10.9%, 10.7% and 8.1%, respectively). Fair Value Measurements and Impairments Fair Value The use of fair value to measure certain assets and liabilities with resulting unrealized gains or losses is pervasive within our consolidated financial statements. Fair value is defined under accounting guidance currently applicable to us as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between open market participants at the measurement date. We recognize the change in unrealized gains and losses arising from changes in fair value in our consolidated statements of operations. FASB ASC Topic 820, Fair Value Measurement prescribes a fair value hierarchy that prioritizes the inputs to the respective valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to valuation techniques that use at least one significant input that is unobservable (Level 3). In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement of the asset or liability. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and we consider factors specific to the asset or liability. In order to determine if a market is active or inactive for a security, we consider a number of factors, including, but not limited to, the spread between what a seller is asking for a security and what a buyer is bidding for the same security, the volume of trading activity for the security in question, the price of the security compared to its par value (for fixed maturity investments), and other factors that may be indicative of market activity. At December 31, 2024, we classified \$45.8 million and \$2.4 million of our assets and liabilities, respectively, at fair value on a recurring basis using Level 3 inputs (2023 - \$159.8 million and \$2.7 million, respectively). This represented 0.1% and 0.0% of our total assets and liabilities, respectively (2023 - 0.3% and 0.0%, respectively). Level 3 fair value measurements are based on valuation techniques that use at least one significant input that is unobservable. These measurements are made under circumstances in which there 65is little, if any, market activity for the asset or liability. We use valuation models or other pricing techniques that require a variety of inputs including contractual terms, market prices and rates, yield curves, credit curves, measures of volatility including credit spreads and projected cash flows, prepayment rates and correlations of such inputs, some of which may be unobservable, to value these Level 3 assets and liabilities. Refer to Note 6. Fair Value Measurements in the Notes to the Consolidated Financial Statements for additional information about fair value measurements. Impairments The amount and timing of asset impairment is subject to significant estimation techniques and is a critical accounting estimate for us. The significant impairment reviews we complete are for our goodwill and other intangible assets and equity method investments, as described in more detail below. Goodwill and Other Intangible Assets Goodwill and other intangible assets acquired are initially recorded at fair value, the assessment of which requires significant judgments, assumptions and estimates which are inherently subjective. As discussed above, the measurement of fair values is a critical accounting estimate, and involves numerous inputs into the assessment, including a range of reasonable judgments that impact the determination of fair value. Subsequent to initial recognition, finite lived other intangible assets are amortized over their estimated useful life, subject to impairment, and goodwill and indefinite lived other intangible assets are carried at the lower of cost or fair value, subject to impairment. If goodwill or other intangible assets are impaired, they are written down to their estimated fair values with a corresponding expense reflected in our consolidated statements of operations. We assess goodwill and other intangible assets for impairment in the second half of each year, or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, we assess qualitative factors to determine if events or circumstances exist that would lead us to conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then we do not perform a quantitative evaluation. Should we determine that a quantitative analysis is required, we will first determine the fair value of the reporting unit and compare that with the carrying value, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, then goodwill is not considered impaired and no further analysis is required. If the carrying amount of a reporting unit exceeds its fair value, we then proceed to determine the amount of the impairment charge, if any. There are many assumptions and estimates underlying the fair value calculation. Principally, we identify the reporting unit or business entity that the goodwill or other intangible asset is attributed to, and review historical and forecasted operating and financial performance and other underlying factors affecting such analysis, including market conditions. Other assumptions used could produce significantly different results which may result in a change in the value of goodwill or our other intangible assets and a related charge in our consolidated statements of operations. An impairment charge could be recognized in the event of a significant decline in the implied fair value of those operations where the goodwill or other intangible assets are applicable. In the event we determine that the value of goodwill has become impaired, an accounting charge will be taken in the fiscal quarter in which such determination is made, which could have a material adverse effect on our results of operations in the period in which the impairment charge is recorded. As a result of our impairment assessment performed during the second and third quarters of 2024, it was determined that certain licenses associated with certain Validus entities that had been amalgamated or merged into the Company, had been cancelled. Accordingly, we determined that these indefinite lived intangible assets of \$13.8 million, recognized in relation to the acquisition of Validus, should be written down to \$Nil. During the year ended December 31, 2024, we recorded an intangible asset impairment charge of \$13.8 million. Refer to Note 4. Goodwill and Other Intangible Assets in our Notes to the Consolidated Financial Statements for additional information with respect to the impairment. As at December 31, 2024, excluding the amounts recorded in investments in other ventures, under the equity method, as noted below, our consolidated balance sheets include \$300.5 million of goodwill (2023 - \$300.5 million) and \$403.6 million of other intangible assets (2023 - \$474.8 million). Impairment charges related to these balances were \$13.8 million during the year ended December 31, 2024 (2023 - \$Nil). Refer to Note 3. Acquisition of Validus in the Notes to the Consolidated Financial Statements for additional information with respect to goodwill and intangible assets acquired in connection with the Validus Acquisition. In the future, it is possible we will hold more goodwill and intangible assets, which would increase the degree of judgment and uncertainty embedded in our financial statements, and potentially increase the volatility of our reported results. Investments in Other Ventures, Under Equity Method Investments in which we have significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, we record our proportionate share of income or loss from such investments in our results for the period. Any decline in the value of investments in other ventures, under equity method, including goodwill and other intangible assets arising upon acquisition of the investee, considered by management to be other-than-temporary, is reflected in our consolidated statements of operations in the period in which it is determined. As of December 31, 2024, we had \$102.8 million (2023 - \$112.6 million) in investments in other ventures, under equity method on our consolidated balance sheets, including \$8.7 million of goodwill and \$0.2 million of other intangible assets (2023 - \$10.8 million and \$7.3 million). The carrying value of our investments in other ventures, under equity method, individually or in the aggregate, may, and likely will, differ from the realized value we may ultimately attain, perhaps significantly so. In determining whether an equity method investment is impaired, we take into consideration a variety of factors including the operating and financial performance of the investee, the investee's future business plans and projections, recent transactions and market valuations of publicly traded companies where available, discussions with the investee's management, and our intent and ability to hold the investment until it recovers in value. Accordingly, we make assumptions and estimates in assessing whether an impairment has occurred and if, in the future, our assumptions and estimates made in assessing the fair value of these investments change, this could result in a material decrease in the carrying value of these investments. This would cause us to write-down the carrying value of these investments and could have a material adverse effect on our results of operations in the period the impairment charge is taken. We do not have any current plans to dispose of these investments, and cannot assure you we will consummate future transactions in which we realize the value at which these holdings are reflected in our financial statements. During the year ended December 31, 2024, we recorded a \$9.1 million impairment charge associated with our investments in other ventures, under equity method (2023 - \$Nil). Income Taxes Income taxes have been determined in accordance with the provisions of FASB ASC Topic 740, Income Taxes. Deferred tax assets and liabilities result from temporary differences between the amounts recorded in our consolidated financial statements and the tax basis of our assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, value of in-force business, VOBA, deferred acquisition expenses, intangible assets, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax laws or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates which are inherently subjective are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances. At December 31, 2024, our net deferred tax asset before valuation allowance and valuation allowance were \$822.6 million and \$147.1 million, respectively (2023 - \$864.7 million and \$213.3 million, respectively). See Note 15. Taxation in the Notes to the Consolidated Financial Statements for additional information. At each balance sheet date, we assess the need to establish a valuation allowance that reduces the net deferred tax asset when it is more likely than not that all, or some portion, of the net deferred tax assets will not be realized. The valuation allowance assessment is performed separately in each taxable jurisdiction based on all available information including projections of future GAAP taxable income from each tax-paying component in each tax jurisdiction. We have unrecognized tax benefits of \$Nil as of December 31, 2024 (2023 - \$Nil). Interest and penalties related to unrecognized tax benefits, would be recognized in income tax expense. At December 31, 2024, interest and penalties accrued on unrecognized tax benefits were \$Nil (2023 - \$Nil). The following filed income tax returns are open for examination with the applicable tax authorities: tax years 2018 through 2023 with the U.S.; 2020 through 2023 with Ireland; 2022 through 2023 with the U.K.; 2020 through 2023 with Singapore; 2021 through 2023 with Switzerland; 2020 through 2023 with Australia; 2020 through 2023 with Canada; and 2019 through 2023 with Luxembourg. We do not expect the resolution of these open years to have a significant impact on our consolidated statements of operations and financial condition. SUMMARY OF RESULTS OF OPERATIONS (in thousands, except per share amounts and percentages) A Statements of Operations Highlights Year ended December 31, 2024 2023 Change Gross premiums written \$1,733,066A \$8,862,366A \$2,870,700A Net premiums written \$9,952,216A \$7,467,813A \$2,484,403A Net premiums earned \$10,095,760A \$7,471,133A \$2,624,627A Net claims and claim expenses incurred \$5,332,981A \$3,573,509A \$1,759,472A Acquisition expenses \$2,643,867A \$1,875,034A \$768,833A Operational expenses \$496,588A \$375,182A \$121,406A Underwriting income (loss) \$1,622,324A \$1,647,408A \$(25,084) Net investment income \$1,654,289A \$1,253,110A \$401,179A Net realized and unrealized gains (losses) on investments (27,840)A \$14,522A \$(42,362) Total investment result \$1,626,449A \$1,667,632A \$(41,183) Net income (loss) \$2,960,532A \$3,620,127A \$(659,595) Net income (loss) available (attributable) to Renaissance Re common shareholders \$1,834,985A \$2,525,757A \$(690,772) Net income (loss) available (attributable) to Renaissance Re common shareholders per common share \$1.35A \$2.27A \$(0.92) Dividends per common share \$1.56A \$1.52A \$0.04A Key Ratios Year ended December 31, 2024 2023 Change Net claims and claim expense ratio \$1.00A \$1.00A \$0.00A Current accident year 61.3A \$53.9A \$7.4A pts Net claims and claim expense ratio \$1.00A \$1.00A \$0.00A Prior accident years (8.5) (6.1) (2.4) pts Net claims and claim expense ratio \$1.00A \$1.00A \$0.00A Calendar year 52.8A \$47.8A \$5.0A pts Underwriting expense ratio 31.1A \$30.1A \$1.0A pts Combined ratio 83.9A \$77.9A \$6.0A pts Return on average common equity 19.3A \$40.5A % (21.2) pts Book value At December 31, 2024 2023 Change Book value per common share \$195.77A \$165.20A \$30.57A Accumulated dividends per common share 28.08A 26.52A 1.56A Book value per common share plus accumulated dividends \$223.85A \$191.72A \$32.13A Change in book value per common share plus change in accumulated dividends 19.4A \$59.3A % (39.9) pts 69 Results of Operations for 2024 Compared to 2023 Net income available to Renaissance Re common shareholders was \$1.8 billion in 2024, compared to \$2.5 billion in 2023. As a result of our net income available to Renaissance Re common shareholders in 2024, we generated an annualized return on average common equity of 19.3% and our book value per common share increased from \$165.20 at December 31, 2023 to \$195.77 at December 31, 2024, a 19.4% increase, after considering the change in accumulated dividends paid to our common shareholders. The most significant items affecting our financial performance during 2024, on a comparative basis to 2023, include: Underwriting Results - we generated underwriting income of \$1.6 billion and had a combined ratio of 83.9% in the year ended December 31, 2024, compared to underwriting income of \$1.6 billion and a combined ratio of 77.9% in the year ended December 31, 2023. Our underwriting income in the year ended December 31, 2024 was comprised of our Property segment, which generated underwriting income of \$1.6 billion and had a combined ratio of 57.2%, and our Casualty and Specialty segment, which incurred an underwriting loss of \$25.4 million and had a combined ratio of 100.4%. In comparison, our underwriting income in the year ended December 31, 2023 was comprised of our Property segment, which generated underwriting income of \$1.4 billion and had a combined ratio of 53.4%, and our Casualty and Specialty segment, which generated underwriting income of \$208.1 million and had a combined ratio of 95.2%. Included in our underwriting results in the year ended December 31, 2024 was the impact of the 2024 Large Loss Events, which resulted in a net negative impact on the underwriting result of \$847.4 million and added 8.8 percentage points to the consolidated combined ratio. In comparison, our underwriting results in the year ended December 31, 2023 were impacted by the 2023 Large Loss Events, which resulted in a net negative impact on the underwriting result of \$298.6 million and added 4.1 percentage points to the combined ratio, primarily within in our Property segment. Gross Premiums Written - our gross premiums written increased by \$2.9 billion, or 32.4%, to \$11.7 billion, in the year ended December 31, 2024, compared to the year ended December 31, 2023. This was comprised of an increase of \$1.6 billion in our Casualty and Specialty segment and an increase of \$1.3 billion in our Property segment, both primarily driven by the renewal of business acquired in the Validus Acquisition, in conjunction with organic growth on legacy lines. Investment Results - our total investment result, which includes the sum of net investment income and net realized and unrealized gains (losses) on investments, was income of \$1.6 billion in the year ended December 31, 2024, compared to \$1.7 billion in the year ended December 31, 2023, a decrease of \$41.2 million. The primary drivers of the lower total investment result include an increase of \$442.4 million in net realized and unrealized losses on investments, which was partially offset by an increase in net investment income of \$401.2 million. The change in net realized and unrealized gains (losses) on investments was a result of net realized and unrealized losses on fixed maturity investments of \$246.4 million in the year ended December 31, 2024, compared to net realized and unrealized gains of \$292.1 million in the year ended December 31, 2023, primarily due to increases in yields on longer duration assets during 2024, compared to decreases in 2023. Offsetting the increase in net unrealized losses on fixed maturity investments was an increase in net realized and unrealized gains on other investments of \$159.4A million, driven by an increase in the value of our investment in TWFG as a result of TWFG, Inc.'s initial public offering in 2024. The increase in net investment income was due to a combination of higher average invested assets, primarily resulting from the Validus Acquisition, and higher yielding assets in the fixed maturity investments portfolio. Net Income Attributable to Redeemable Noncontrolling Interests - our net income attributable to redeemable noncontrolling interests was \$1.1 billion in the year ended December 31, 2024, compared to \$1.1 billion in the year ended December 31, 2023, an increase of \$31.2 million. The higher net income attributable to redeemable noncontrolling interests in the year ended December 31, 2024 was primarily driven by strong underwriting income generated by DaVinci and Vermeer, partially offset by a decrease in net realized and unrealized gains on investments. The decrease in net realized and unrealized gains on investments was primarily due to the increases in interest rates during 2024 discussed above driving net realized and unrealized losses on the investment portfolios of our joint ventures and managed funds. Impact of Large Loss Events - we had a net negative impact on net income (loss) available (attributable) to Renaissance Re common shareholders of \$660.5 million resulting from the 2024 Large Loss Events. This compares to a net negative impact on net income (loss) available (attributable) to Renaissance Re common shareholders of \$213.4 million resulting from the 2023 Large Loss Events. Net Negative Impact Net negative impact on underwriting result includes the sum of (1) net claims and claim expenses incurred, (2) assumed and ceded reinstatement premiums earned and (3) earned and lost profit commissions. Net negative impact on net income (loss) available (attributable) to Renaissance Re common shareholders is the sum of (1) net negative impact on underwriting result and (2) redeemable noncontrolling interest, both before consideration of any related income tax benefit (expense). Our estimates of net negative impact are based on a review of our potential exposures, preliminary discussions with certain counterparties and actuarial modeling techniques. Our actual net negative impact, both individually and in the aggregate, may vary from these estimates, perhaps materially. Changes in these estimates will be recorded in the period in which they occur. Meaningful uncertainty remains regarding the estimates and the nature and extent of the losses from these catastrophe events, driven by the magnitude and recent nature of the events,

the geographic areas impacted by the events, relatively limited claims data received to date, the contingent nature of business interruption and other exposures, potential uncertainties relating to reinsurance recoveries and other factors inherent in loss estimation, among other things

2024 Net Negative ImpactThe financial data below provides additional information detailing the net negative impact of the 2024 Large Loss Events on our segment underwriting results and consolidated financial statements for the year ended December 31, 2024.

Year ended December 31, 2024Hurricane MiltonHurricane HeleneOther 2024 Large Loss Events (1)2024 Large Loss Events (2)(in thousands)Net claims and claim expenses incurred\$(406,878)\$(217,767)\$(381,330)\$(1,005,975)Assumed reinstatement premiums earned\$86,128\$40,655\$53,159\$179,942Ceded reinstatement premiums earned\$(2,158)\$(931)\$(9,971)\$(13,060)Earned (lost) profit commissions\$(9,802)\$(2,180)\$(3,722)\$(8,260)Net negative impact on underwriting result\$(332,710)\$(180,223)\$(334,420)\$(847,353)Redeemable noncontrolling interest\$62,229\$36,969\$87,625\$186,823A Net negative impact on net income (loss) available (attributable) to RenaissanceRe common shareholders\$(270,481)\$(143,254)\$(246,795)\$(660,530) (1)â€œOther 2024 Large Loss Eventsâ€ includes: the Baltimore Bridge Collapse; a series of severe convective storms that impacted the Southern and Midwest United States; the Hualien earthquake which impacted Taiwan in April 2024; a severe hailstorm which impacted Calgary in August 2024, Hurricane Debby, Hurricane Beryl, and certain aggregate loss contracts triggered during 2024.(2)â€œ2024 Large Loss Eventsâ€ includes: Hurricane Milton, Hurricane Helene and the â€œOther 2024 Large Loss Events.â€712023 Net Negative ImpactThe financial data below provides additional information detailing the net negative impact of the 2023 Large Loss Events on our segment underwriting results and consolidated financial statements for the year ended December 31, 2023.

Year ended December 31, 20232023 Large Loss Events (1)(in thousands, except percentages)Net negative impact on Property segment underwriting results\$(298,119)Net negative impact on Casualty and Specialty segment underwriting result\$(507)Net negative impact on underwriting result\$(298,626)Percentage point impact on consolidated combined ratio4.1Â The financial data below provides additional information detailing the net negative impact of the 2023 Large Loss Events on our consolidated financial statements for the year ended December 31, 2023.

Year ended December 31, 20232023 Large Loss Events (1)(in thousands)Net claims and claim expenses incurred\$(354,228)Assumed reinstatement premiums earned\$46,534Ceded reinstatement premiums earned\$(62)Earned (lost) profit commissions\$9,130A Net negative impact on underwriting result\$(298,626)Redeemable noncontrolling interest\$85,276A Net negative impact on net income (loss) available (attributable) to RenaissanceRe common shareholders\$(213,350)(1)â€œ2023 Large Loss Eventsâ€ includes: Hurricane Otis and Storm Ciaran in October and November 2023, the wildfires in Hawaii in August 2023 and Hurricane Idalia, a series of large, severe weather events in Texas and other southern and central U.S. states in June 2023, the earthquakes in southern and central Turkey in February 2023, Cyclone Gabrielle, the flooding in northern New Zealand in January and February 2023, and various wind and thunderstorm events in both the Southern and Midwest U.S. during March 2023, and certain aggregate loss contracts triggered during 2023.

72Underwriting Results by SegmentProperty SegmentBelow is a summary of the underwriting results and ratios for our Property segment:Year ended December 31,20242023Change(in thousands, except percentages)A A Gross premiums written\$8,223,731\$3,562,414\$1,261,317Net premiums written\$3,833,636\$2,967,309\$866,327Net premiums earned\$3,850,352\$3,090,792\$759,560Net claims and claim expenses incurred\$1,141,726\$799,905\$341,821Acquisition expenses\$758,554\$600,127\$158,427Operational expenses\$302,360\$251,435\$50,927Underwriting income (loss)\$1,647,712\$1,439,327\$208,385Net claims and claim expenses incurred â€ current accident year\$1,960,578\$1,208,810\$751,768Net claims and claim expenses incurred â€ prior accidentÂ years\$(818,852)\$(408,905)\$(409,947)Net claims and claim expenses incurred â€ total\$1,141,726\$799,905\$341,821Net claims and claim expense ratio â€ current accidentÂ year50.9Â %39.1Â %11.8Â A ptsNet claims and claim expense ratio â€ prior accident years(21.2)%(13.2)%(8.0)A ptsNet claims and claim expense ratio â€ calendar year29.7Â %25.9Â %3.8Â A ptsUnderwriting expense ratio27.5Â %27.5Â %â€ A A ptsCombined ratio57.2Â %53.4Â %3.8Â A ptsProperty Gross Premiums WrittenIn 2024, our Property segment gross premiums written increased by \$1.3 billion, or 35.4%, to \$4.8 billion, compared to \$3.6 billion in 2023. Gross premiums written in the catastrophe class of business were \$3.0 billion in 2024, an increase of \$850.6 million, or 39.6%, compared to 2023. This increase was principally driven by the renewal of business acquired in the Validus Acquisition, in conjunction with the retention of legacy lines, during 2024.Gross premiums written in the other property class of business were \$1.8 billion in 2024, an increase of \$410.8 million, or 29.0%, compared to 2023. The increase in gross premiums written in the other property class of business was principally due to the renewal of business acquired in the Validus Acquisition and organic growth in both our catastrophe and non-catastrophe exposed business.

Property Ceded Premiums Written Year ended December 31,20242023Change(in thousands)Ceded premiums written\$990,095\$595,105\$394,990A Due to the potential volatility of the reinsurance contracts which we sell, we purchase reinsurance to reduce our exposure to large losses and to help manage our risk portfolio. To the extent that appropriately priced coverage is available, we anticipate continued use of retrocessional reinsurance to reduce the impact of large losses on our financial results and to manage our portfolio of risk; however, the buying of ceded reinsurance in our Property segment is based on market opportunities and is not based on placing a specific reinsurance program each year. In addition, in future periods, we may utilize the growing market for insurance-linked securities to expand our purchases of retrocessional reinsurance if we find the pricing and terms of such coverages attractive.

73Ceded premiums written in our Property segment increased 66.4%, to \$990.1 million, in 2024, compared to \$595.1Â million in 2023. The increase in ceded purchases reflects our larger portfolio resulting from the Validus Acquisition and organic growth, as well as increased utilization of Upsilon, as part of our gross-to-net strategy.

Property Net Premiums WrittenYear ended December 31,20242023Change(in thousands)Net premiums written\$3,833,636\$2,967,309\$866,327A Net premiums written in our Property segment were \$3.8 billion in 2024, an increase of \$866.3 million, or 29.2%, compared to 2023, consistent with the changes in gross premiums written discussed above, partially offset by an increase in ceded premiums written as part of our gross-to-net strategy.

Property Underwriting ResultsOur Property segment generated underwriting income of \$1.6 billion in 2024, compared to \$1.4 billion in 2023, an increase in underwriting income of \$208.4 million. In 2024, our Property segment generated a net claims and claim expense ratio of 29.7%, an underwriting expense ratio of 27.5% and a combined ratio of 57.2%, compared to 25.9%, 27.5% and 53.4%, respectively, in 2023.Impacting the Property segment underwriting result and combined ratio in 2024 were the 2024 Large Loss Events, which resulted in a net negative impact on the Property segment underwriting result of \$779.8 million and added 23.0 percentage points to its combined ratio. In comparison, 2023 was impacted by the 2023 Large Loss Events, which resulted in a net negative impact on the Property segment underwriting result of \$298.1 million and added 10.5 percentage points to its combined ratio.

The net claims and claim expense ratio of 29.7% was comprised of a current accident year net claims and claim expense ratio of 50.9% and 21.2 percentage points of net favorable development on prior accident years. The net favorable development on prior accident years is primarily driven by net favorable development of \$622.2 million from the large loss events across the 2017 to 2023 accident years, including \$464.4 million from 2021 and 2022 Weather-Related Large Losses, driven by better than expected loss emergence and net favorable development on net attritional losses within the other property class of business. In comparison, 2023 had a net claims and claim expense ratio of 25.9%, comprised of a current accident year net claims and claim expense ratio of 39.1% and 13.2 percentage points of net favorable development on prior accident years.

The underwriting expense ratio of 27.5% was comprised of an acquisition expense ratio of 19.6% and an operational expense ratio of 7.9%. In comparison, 2023 had an underwriting expense ratio of 27.5%, comprised of an acquisition expense ratio of 19.4% and an operational expense ratio of 8.1%. The acquisition ratio of 19.6% in 2024 includes 1.9 percentage points of purchase accounting adjustments relating to the Validus Acquisition, which was offset by lower acquisition expenses due to changes in the mix of business as a result of continued relative growth in the catastrophe class of business, which has a lower acquisition expense ratio than the other property class of business.

In 2024, Property segment underwriting income was reduced by total purchase accounting adjustments of \$89.3Â million, which added 2.3 percentage points to the Property segment combined ratio.

Refer to â€œPart II, Item 7. Managementâ€’s Discussion and Analysis of Financial Condition and Results of Operationsâ€’Summary of Critical Accounting Estimatesâ€’Claims and Claim Expense Reservesâ€ and â€œNote 8. Reserve for Claims and Claim Expensesâ€ in our â€œNotes to the Consolidated Financial Statementsâ€ for additional discussion of our reserving techniques and prior year development of net claims and claim expenses.

74Casualty and Specialty SegmentBelow is a summary of the underwriting results and ratios for our Casualty and Specialty segment:Year ended December 31,20242023Change(in thousands, except percentages)A A Gross premiums written\$6,909,335\$5,299,952\$1,609,383A Net premiums written\$6,118,580\$4,500,504\$1,618,076A Net premiums earned\$6,245,408\$4,380,341\$1,865,067A Net claims and claim expenses incurred\$4,191,255\$2,773,604\$1,417,651A Acquisition expenses\$1,885,313\$1,274,907\$610,406A Operational expenses\$194,228\$123,749\$70,479A Underwriting income (loss)\$(25,388)\$208,081A \$(233,469)Net claims and claim expenses incurred â€ current accident year\$4,223,737\$2,815,306\$1,408,431A Net claims and claim expenses incurred â€ prior accident years\$(32,482)\$(41,702)9,220A Net claims and claim expenses incurred â€ total\$4,191,255\$2,773,604\$1,417,651A Net claims and claim expense ratio â€ current accident year67.6Â %64.3Â %3.3Â A ptsNet claims and claim expense ratio â€ prior accident years(0.5)%(1.0)60.5Â A ptsNet claims and claim expense ratio â€ calendar year67.1Â %63.3Â %3.8Â A ptsUnderwriting expense ratio33.3Â %31.9Â %1.4Â A ptsCombined ratio100.4Â %95.2Â %5.2Â A ptsCasualty and Specialty Gross Premiums WrittenIn 2024, our Casualty and Specialty segment gross premiums written increased by \$1.6 billion, or 30.4%, to \$6.9 billion, compared to \$5.3Â billion in 2023. This increase is principally due to the renewal of business acquired in the Validus Acquisition, in conjunction with the retention and organic growth of legacy lines. This growth is primarily reflected in the other specialty, general casualty and credit classes of business, which increased \$926.5 million, \$550.7 million and \$132.4 million, respectively, compared to 2023.

Our relative mix of business between proportional business and excess of loss business has fluctuated in the past and has the potential to change in the future.

4Proportional business, which represents the majority of our Casualty and Specialty segment business, typically has a higher expense ratio and tends to be exposed to more attritional and frequent losses, while being subject to less expected severity as compared to traditional excess of loss business. Casualty and Specialty Ceded Premiums Written Year ended December 31,20242023Change(in thousands)Ceded premiums written\$790,755\$799,448A \$(8,693)We purchase reinsurance to reduce our exposure to large losses and to help manage our risk portfolio. To the extent that appropriately priced coverage is available, we anticipate continued use of retrocessional reinsurance to reduce the impact of large losses on our financial results and to manage our portfolio of risk. As in our Property segment, the buying of ceded reinsurance in our Casualty and Specialty segment is based on market opportunities and is not based on placing a specific reinsurance program each year.

Ceded premiums written in our Casualty and Specialty segment decreased by 1.1%, to \$790.8 million, in 2024, compared to \$799.4Â million in 2023, principally due to a decrease in amount of quota share 75retrocessional coverage purchased, partially offset by the increase in gross premiums written subject to our retrocessional reinsurance programs.

Casualty and Specialty Net Premiums WrittenYear ended December 31,20242023Change(in thousands)Net premiums written\$6,118,580\$4,500,504\$1,618,076A Net premiums written in our Casualty and Specialty segment increased by \$1.6 billion, or 36.0%, consistent with the changes in gross premiums written and quota share retrocessional coverage purchased as discussed above.

Casualty and Specialty Underwriting ResultsOur Casualty and Specialty segment incurred an underwriting loss of \$25.4 million in 2024, compared to underwriting income of \$208.1 million in 2023. In 2024, our Casualty and Specialty segment generated a net claims and claim expense ratio of 67.1%, an underwriting expense ratio of 33.3% and a combined ratio of 100.4%, compared to 63.3%, 31.9% and 95.2%, respectively, in 2023. The increase in the Casualty and Specialty segment combined ratio in 2024 to 100.4% was principally driven by an increase of 3.8 percentage points in the net claims and claim expense ratio and an increase of 1.4 percentage points in the underwriting expense ratio. The increase in the net claims and claim expense ratio was driven by higher current accident year losses, mainly as a result of higher attritional losses within certain casualty lines of business, and the impact of event losses on catastrophe exposed lines within the other specialty class of business. The other specialty class of business included losses related to the Baltimore Bridge Collapse, which added approximately 1.0 percentage point of loss in 2024. During 2024 our Casualty and Specialty segment also experienced net favorable development on prior accident years net claims and claim expenses of \$32.5 million, or 0.5 percentage points, compared to \$41.7 million, or 1.0 percentage point during 2023. The net favorable development during both 2024 and 2023 was primarily driven by reported losses generally coming in lower than expected on attritional net claims and claim expenses from our professional liability, other specialty and credit classes of business, partially offset by higher attritional losses in the general liability line of business.

The increase in the underwriting expense ratio of 1.4 percentage point was primarily driven by a 1.1 percentage point increase in the acquisition expense ratio from the impact of purchase accounting adjustments related to the Validus Acquisition. In 2024, our Casualty and Specialty segment underwriting loss included expenses related to purchase accounting adjustments of \$153.7Â million, which added 2.4 percentage points to the Casualty and Specialty segment combined ratio.

Refer to â€œPart II, Item 7. Managementâ€’s Discussion and Analysis of Financial Condition and Results of Operationsâ€’Summary of Critical Accounting Estimatesâ€’Claims and Claim Expense Reservesâ€ and â€œNote 8. Reserve for Claims and Claim Expensesâ€ in our â€œNotes to the Consolidated Financial Statementsâ€ for additional discussion of our reserving techniques and prior year development of net claims and claim expenses.

76Fee Income Year ended December 31,20242023Change(in thousands)Management Fee IncomeJoint ventures \$157,427A \$122,474A \$34,953A Structured reinsurance products and other29,205A 27,754A 1,451A Managed funds 33,228A 26,371A 6,857A Total management fee income219,860A 176,599A 43,261A Performance Fee IncomeJoint ventures 74,903A 50,656A 24,247A Structured reinsurance products and other21,248A 8,582A 12,666A Managed funds 10,785A 957A 9,828A Total performance fee income106,936A 60,195A 46,741A Total fee income\$326,796\$236,794\$90,002A The table above shows total fee income earned through third-party capital management activities, including various joint ventures, managed funds and certain structured retrocession agreements to which we are a party. Performance fees are based on the performance of the individual vehicles or products, and may be zero or negative in a particular period if, for example, large losses occur, which can potentially result in no performance fees or the reversal of previously accrued performance fees. Joint ventures include DaVinci, Top Layer, Vermeer, and Fontana. Managed funds include Upsilon Fund and Medici. In addition, we manage certain third party capital vehicles through AlphaCat Managers, which were acquired in connection with the Validus Acquisition. Structured reinsurance products and other includes certain reinsurance contracts and certain other vehicles through which we transfer risk to third-party capital.

In 2024, total fee income earned through our third-party capital management activities increased by \$90.0Â million, to \$326.8Â million, compared to \$236.8Â million in 2023, driven by both higher management fee income and performance fee income. Management fee income increased \$43.3Â million compared to 2023, driven by increased capital managed at DaVinci and Fontana, as well as the addition of fees earned by AlphaCat Managers.

Performance fee income increased \$46.7Â million compared to 2023, driven by improved current year underwriting results, primarily in DaVinci, Upsilon Fund, RFO and in our structured reinsurance products. The fees earned through third-party capital management activities are principally recorded through redeemable noncontrolling interest, or as an increase to underwriting income through a decrease in operational expenses or acquisition expenses. Below is a summary of the impact of fee income on the applicable financial statement line items.

Year ended December 3120242023Change(in thousands)Underwriting income (loss) (\$1)\$(42,923A \$34,432A \$8,491A Equity in earnings (losses) of other ventures\$2A (1,423)1,423A Net income (loss) attributable to redeemable noncontrolling interest283,873A 203,785A 80,088A Total fee income\$326,796\$236,794\$90,002A (1)Reflects total fee income earned through third-party capital management as well as various joint ventures, managed funds and certain structured retrocession agreements to which we are a party, recorded through underwriting income (loss) as a decrease to operational expenses or acquisition expenses. The \$42.9 million includes \$51.0 million of management fee income, recorded as a reduction to operational expenses and \$(8.1) million of performance fee income recorded as an increase to acquisition expenses (2023 - \$34.4 million, \$46.4 million and \$(12.0) million, respectively).

77In addition to the \$42.9 million of fee income earned through our third-party capital management activities that was recorded through underwriting income (loss), as detailed above, we also earn additional fee income on certain other underwriting-related activities. These fees, in the aggregate, are recorded as a reduction to operational expenses or acquisition expenses, as applicable. The total fees recorded through underwriting income (loss) are detailed in the table below.

Year ended December 3120242023Change(in thousands)Underwriting income (loss) - fee income on third-party capital management activities\$42,923A \$34,432A \$8,491A Underwriting income (loss) - additional fee income on other underwriting-related activities69,201A 94,577A (25,376)Total fee income recorded through underwriting income (loss) (\$1)112,124A \$129,009A (16,885)Impact of Total fees recorded through underwriting income (loss) on the combined ratio1.1Â %1.7Â % (0.6)A pts(1)The \$112.1 million includes \$114.3 million of management fee income, recorded as a reduction to operational expenses and \$(2.2) million of performance fee income recorded as an increase to acquisition

expenses (2023 - \$129.0 million, \$125.1 million and reduction of \$3.9 million, respectively).Investment ResultsNet Investment IncomeThe components of net investment income are as follows:Year ended December 31,20242023Change(in thousands)Â Â Fixed maturity investments trading\$1,116,649Â \$744,457Â \$372,192Â Short term investments183,153Â 213,303Â (30,150)Equity investments2,460Â 7,261Â (4,801)Other investmentsCatastrophe bonds238,844Â 200,572Â 38,272Â Other82,457Â 87,296Â (4,839)Cash and cash equivalents54,241Â 23,123Â 31,118Â A 1,677,804Â 1,276,012Â 401,792Â Investment expenses(23,515)(22,902)(613)Net investment income\$1,654,289Â \$1,253,110Â \$401,179Â Net investment income was \$1.7 billion in 2024, compared to \$1.3 billion in 2023, an increase of \$401.2 million. This increase was driven by a combination of higher average invested assets, primarily resulting from the Validus Acquisition, and higher yielding assets in the fixed maturity investments portfolio.78Net Realized and Unrealized Gains (Losses) on InvestmentsNet realized and unrealized gains (losses) on investments are as follows:Year ended December 31,20242023Change(in thousands)Â Â Â Gross realized gains on fixed maturity investments trading\$142,243Â 80,905Â \$61,338Â Gross realized losses on fixed maturity investments trading(206,172)(473,946)267,774Â Net realized gains (losses) on fixed maturity investments trading(63,929)(393,041)329,112Â Net unrealized gains (losses) on fixed maturity investments trading(182,494)685,095Â (867,589)Net realized and unrealized gains (losses) on investment-related derivatives (1)(57,279)(68,272)10,993Â Net realized gains (losses) on equity investments355Â (27,492)27,847Â Net unrealized gains (losses) on equity investments10,621Â 73,243Â (62,622)Net realized and unrealized gains (losses) on equity investments10,976Â 45,751Â (34,775)Net realized and unrealized gains (losses) on other investments - catastrophe bonds62,353Â 101,897Â (39,544)Net realized and unrealized gains (losses) on other investments - other202,533Â 43,092Â 159,441Â Net realized and unrealized gains (losses) on investments\$(27,840)\$414,522Â \$(442,362)(1)Net realized and unrealized gains (losses) on investment-related derivatives includes fixed maturity investments related derivatives, equity investments related derivatives and commodity related derivatives. See "Note 19. Derivative Instruments" in our "Notes to Consolidated Financial Statements" for additional information.We structure our investment portfolio to emphasize the preservation of capital and the availability of liquidity to meet our claims obligations, to be well diversified across market sectors, and to generate relatively attractive returns on a risk-adjusted basis over time. A large majority of our investments are invested in the fixed income markets and, therefore, our realized and unrealized holding gains and losses on investments are highly correlated to fluctuations in interest rates. As interest rates decline, we will tend to have realized and unrealized gains from our investment portfolio, and as interest rates rise, we will tend to have realized and unrealized losses from our investment portfolio.Net realized and unrealized losses on investments were \$27.8 million in 2024, compared to gains of \$414.5 million in 2023. Principally impacting the increase in our net realized and unrealized losses on investments in 2024 were:â€¢net realized and unrealized losses on our fixed maturity investments trading portfolio of \$246.4 million in 2024 compared to net realized and unrealized gains of \$292.1 million in 2023, primarily as a result of increases in yields on longer duration assets in 2024 compared to decreases in 2023;â€¢net realized and unrealized gains on other investments of \$202.5 million in 2024 compared to net realized and unrealized gains of \$43.1 million in 2023, driven by an increase in the value of our investment in TWFG as a result of TWFG, Inc.'s initial public offering in 2024; andâ€¢net realized and unrealized gains on catastrophe bonds of \$62.4 million in 2024, compared to \$101.9 million in 2023, a decrease of \$39.5 million. The decrease in net realized and unrealized gains were driven by narrowing risk spreads in the catastrophe bond market, which were generally greater in 2023 compared to 2024. The net realized and unrealized gains are primarily reflected in the Medici portfolio, and are predominantly attributable to third-party investors and allocated through net (income) loss attributable to redeemable noncontrolling interest. 79Net Foreign Exchange Gains (Losses)Year ended December 31,20242023Change(in thousands)Â Â Net foreign exchange gains (losses)\$(76,076)\$(41,479)\$(34,597)In 2024, net foreign exchange losses were \$76.1 million compared to \$41.5 million in 2023. The increase in net foreign exchange losses for 2024 compared to 2023 is primarily driven by lower losses attributable to third-party investors in Medici in the current period, which are allocated through net (income) loss attributable to redeemable noncontrolling interest, slightly offset by a higher impact of certain foreign exchange exposures related to our underwriting activities in the current period compared to the prior period.Our functional currency is the U.S. dollar. We routinely write a portion of our business in currencies other than U.S. dollars and invest a portion of our cash and investment portfolio in those currencies. We are primarily impacted by foreign currency exposures associated with our underwriting operations and our investment portfolio, and may, from time to time, enter into foreign currency forward and option contracts to minimize the effect of fluctuating foreign currencies on the value of non-U.S. dollar denominated assets and liabilities. Refer to "Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk" for additional information related to our exposure to foreign currency risk and "Note 19. Derivative Instruments" in our "Notes to the Consolidated Financial Statements" for additional information related to foreign currency forward and option contracts we have entered into.Equity in Earnings (Losses) of Other VenturesYear ended December 31,20242023Change(in thousands)Â Â Equity in earnings (losses) of other ventures\$47,087Â \$43,474Â \$3,613Â Equity in earnings (losses) of other ventures represents our pro-rata share of the net income from our investments in a select group of insurance and insurance-related companies, including the Tower Hill Companies and Top Layer. Except for Top Layer, which is recorded on a current quarter basis, equity in earnings (losses) of other ventures is recorded one quarter in arrears. The carrying value of these investments on our consolidated balance sheets, individually or in the aggregate, may differ from the realized value we may ultimately attain, perhaps significantly so.Earnings from our investments in other ventures was \$47.1 million in 2024, compared to \$43.5 million in 2023, an increase of \$3.6 million.Corporate ExpensesYear ended December 31,20242023Change(in thousands)Â Â Corporate expenses\$134,784Â \$127,642Â \$7,142Â Corporate expenses include certain executive, director, legal and consulting expenses, costs for research and development, and other miscellaneous costs, including those associated with operating as a publicly traded company, as well as costs incurred in connection with the acquisition of Validus. From time to time, we may revise the allocation of certain expenses between corporate and operational expenses to better reflect the characteristic of the underlying expense.Corporate expenses increased \$7.1 million to \$134.8 million, in 2024, compared to \$127.6 million in 2023. The increase was primarily driven by expenses associated with the Validus Acquisition. 80Interest Expense and Preference Share DividendsYear ended December 31,20242023Change(in thousands)Â Â Â Interest Expense\$750.0 million 5.750% Senior Notes due 2033\$43,125Â \$24,557Â \$18,568Â \$400.0 million 3.600% Senior Notes due 202914,400Â \$4,400Â \$300.0 million 3.450% Senior Notes due 202710,350Â \$300.0 million 3.700% Senior Notes due 202511,100Â \$1,100Â \$150.0 million 4.750% Senior Notes due 2025 (DaVinci)7,125Â 7,125Â \$0Â Â Medici Revolving Credit Facility2,502Â \$2,502Â \$0Other5,166Â 5,649Â (483)Total interest expense\$93,768Â \$73,181Â \$20,587Â Preference Share Dividends\$250.0 million 5.750% Series F Preference Shares14,375Â \$4,375Â \$500.0 million 4.20% Series G Preference Shares21,000Â 21,000Â \$0Â Total preference share dividends\$35,375Â 35,375Â \$0Â Total interest expense and preference share dividends\$129,143Â \$108,556Â \$20,587Â Interest expense increased \$20.6 million to \$93.8 million in 2024, compared to \$73.2 million in 2023, primarily driven by additional interest expense resulting from the issuance of \$750.0 million principal amount in June 2023 of 5.750% Senior Notes due 2033.Income Tax Benefit (Expense)Year ended December 31,20242023Change(in thousands)Â Â Â Income tax benefit (expense) \$(32,628)\$510,067Â \$(542,695)We are subject to income taxes in certain jurisdictions in which we operate; however, since the majority of our income is generally earned in Bermuda, which has not had a corporate income tax, the tax impact to our operations has historically been minimal. On December 27, 2023, the Bermuda CIT was enacted. As a result, we expect our profits generated on or after January 1, 2025 in Bermuda (except for profits earned by our joint ventures and managed funds) will be subject to the 15% CIT. Furthermore, we generally expect that the profits generated in Bermuda on or after January 1, 2025 by our joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the GloBE Rules by many of the jurisdictions in which we operate. As a result, we expect our income taxes to increase beginning in 2025.In 2024, we recognized an income tax expense of \$32.6 million, compared to an income tax benefit of \$510.1 million in 2023. The income tax expense was primarily driven by income in our taxable jurisdictions, offset by a \$33.7 million deferred tax benefit resulting from the merger of RenaissanceRe Europe AG and Validus Switzerland completed in the second quarter of 2024. The 2023 income tax benefit of \$510.1 million was primarily driven by a net deferred tax benefit of \$593.8 million in connection with the enactment of the Bermuda CIT.At December 31, 2024, our net deferred tax asset before and after valuation allowance totaled \$822.6 million and \$675.5 million, respectively. Our operations in Ireland, the U.K. (except RREAG, UK Branch), Switzerland, the RREAG, US Branch, and Luxembourg have historically produced GAAP taxable losses, and we currently do not believe it is more likely than not that we will be able to recover the predominant amount of our net deferred tax assets in these jurisdictions. Accordingly, we have recorded a valuation allowance on the majority of the net deferred tax asset in these jurisdictions.81Our effective income tax rate, which we calculate as income tax benefit (expense) divided by income (loss) before taxes, may fluctuate significantly from period to period depending on the geographic distribution of pre-tax income or loss in any given period between different jurisdictions with comparatively higher tax rates and those with comparatively lower tax rates. Generally, the preponderance of our revenue and pre-tax income or loss is generated by our domestic (i.e., Bermuda) operations, in the form of underwriting income or loss and net investment income or loss, rather than our foreign operations. However, the geographic distribution of pre-tax income or loss can vary significantly between periods for a variety of reasons, including the business mix and geographic location of the balance sheet on which net premiums are written and earned, the size and nature of net claims and claim expenses incurred, the amount and geographic location of operational expenses, net investment income and net realized and unrealized gains (losses) on investments and the amount of specific adjustments to determine the income tax basis in each of our operating jurisdictions. We expect our consolidated effective tax rate will increase in 2025 as a result of the enactment of the CIT in Bermuda and the implementation of the GloBE Rules in certain jurisdictions where we operate. In addition, it is possible we could be adversely affected by other future changes in tax laws, regulation, or enforcement, any of which could increase our effective tax rate more rapidly or steeply than we currently anticipate. In particular, jurisdictions in which we operate may incorporate the OECD's administrative guidance on Article 9.1 of the GloBE Rules. If they were to do so, starting in 2027, a reduction in cash taxes we pay to Bermuda as a result of reversal of the Bermuda CIT deferred tax asset could be offset by an additional top-up tax in such jurisdictions. Such additional top-up taxes could increase our income tax expense and our consolidated effective tax rate in such years.Net Income (Loss) Attributable to Redeemable Noncontrolling InterestsYear ended December 31,20242023Change(in thousands)Â Â Redeemable noncontrolling interest - DaVinci\$627,055Â \$545,812Â \$81,243Â Redeemable noncontrolling interest - Medici202,941Â 239,250Â (36,309)Redeemable noncontrolling interest - Vermeer244,560Â 239,457Â 5,103Â Redeemable noncontrolling interest - Fontana15,616Â 34,476Â (18,860)Net income (loss) attributable to redeemable noncontrolling interests\$1,090,172Â \$1,058,995Â \$31,177Â Our net income attributable to redeemable noncontrolling interests was \$1.1 billion compared to \$1.1 billion in 2023, an increase of \$31.2 million. The increase was primarily driven by the following: â€¢DaVinci, which had higher net income in 2024 compared to 2023, primarily resulting from improved underwriting results;â€¢Vermeer, which had higher net income in 2024 compared to 2023, primarily resulting from improved underwriting results; partially offset by decreases inâ€¢Medici, which had lower net income in 2024 compared to 2023, due to higher foreign exchange losses in the current period and lower net realized and unrealized gains on investments, compared to 2023; andâ€¢Fontana, which had lower net income in 2024, compared to 2023, primarily resulting from an increase in net realized and unrealized losses on investments in 2024.Refer to "Note 10. Noncontrolling Interests" in our "Notes to Consolidated Financial Statements" for additional information regarding our redeemable noncontrolling interests.FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCESFinancial ConditionAs a Bermuda-domiciled holding company, RenaissanceRe has limited operations of its own. Its assets consist primarily of investments in subsidiaries and cash and securities in amounts which fluctuate over time. We therefore rely on dividends and distributions (and other statutorily permissible payments) from our subsidiaries, investment income and fee income to meet our liquidity requirements, which primarily include 82making principal and interest payments on our debt and dividend payments to our preference and common shareholders. The payment of dividends by our subsidiaries is, under certain circumstances, limited by the applicable laws and regulations in the various jurisdictions in which our subsidiaries operate. In addition, insurance laws require our insurance subsidiaries to maintain certain measures of solvency and liquidity. We believe that each of our insurance subsidiaries and branches exceeded the minimum solvency, capital and surplus requirements in their applicable jurisdictions at December 31, 2024. Certain of our subsidiaries and branches are required to file FCRs with their regulators, which provide details on solvency and financial performance. Where required, these FCRs will be posted on our website. The regulations governing our and our principal operating subsidiaries' ability to pay dividends and to maintain certain measures of solvency and liquidity, and requirements to file FCRs are discussed in detail in "Part I, Item 1. Business, Regulation" and "Note 18. Statutory Requirements" in our "Notes to the Consolidated Financial Statements."Liquidity and Cash FlowsHolding Company Liquidity RenaissanceRe's principal uses of liquidity are: (1) common share related transactions including dividend payments to our common shareholders and common share repurchases, (2) preference share related transactions including dividend payments to our preference shareholders and preference share redemptions, (3) interest and principal payments on debt, (4) capital investments in our subsidiaries, (5) acquisition of, or investments in, new or existing companies or books of business of other companies, such as the Validus Acquisition, and (6) certain corporate and operational expenses.We attempt to structure our organization in a way that facilitates efficient capital movements between RenaissanceRe and our operating subsidiaries and to ensure that adequate liquidity is available when required, giving consideration to applicable laws and regulations, and the domiciliary location of sources of liquidity and related obligations. For example, our internal investment structures and cash pooling arrangements among RenaissanceRe and certain of our subsidiaries help to efficiently facilitate capital and liquidity movements. In the aggregate, our principal operating subsidiaries have historically produced sufficient cash flows to meet their expected claims payments and operational expenses and to provide dividend payments to us. In addition, our subsidiaries maintain a concentration of investments in high quality liquid securities, which management believes will provide additional liquidity for extraordinary claims payments should the need arise. In 2024, we received significant distributions of capital from many of our principal operating subsidiaries, both in the ordinary course and in connection with the integration of Validus and streamlining of our corporate structure following the Validus Acquisition. For example, we received dividends from Validus Re, Renaissance Reinsurance and RREAG, following the merger of Validus Switzerland and RREAG in June 2024 and in connection with the amalgamation of Validus Re and Renaissance Reinsurance in October 2024. However, in some circumstances, RenaissanceRe may determine it is necessary or advisable to contribute capital to our subsidiaries, or may be contractually required to contribute capital to our subsidiaries, joint ventures or managed funds. For example, in 2024, RenaissanceRe contributed capital to RenaissanceRe Specialty U.S. to support growth in premiums. In addition, from time to time we invest in new managed joint ventures or managed funds, increase our investments in certain of our managed joint ventures or managed funds and contribute cash to investment subsidiaries, such as the launch of Fontana in 2022. Examples of our contractual requirements to make capital contributions to our subsidiaries or joint ventures or managed funds include our net worth maintenance agreements with certain operating subsidiaries, and Renaissance Reinsurance's obligation to make a mandatory capital contribution of up to \$50.0 million in the event that a loss reduces Top Layer's capital below a specified level.Sources of LiquidityHistorically, cash receipts from operations, consisting primarily of premiums, investment income and fee income, have provided sufficient funds to pay the losses and operational expenses incurred by our subsidiaries and to fund dividends and distributions to RenaissanceRe. Other potential sources of liquidity include borrowings under our credit facilities and issuances of securities.83The premiums received by our operating subsidiaries are generally received months or even years before losses are paid under the policies related to such premiums. Premiums and acquisition expenses generally are received within the first two years of inception of a contract, while operational expenses are generally paid within a year of being incurred. It generally takes much longer for net claims and claim expenses incurred to be reported and ultimately settled, requiring the establishment of reserves for claims and claim expenses and reinsurance recoverable. Therefore, the amount of net claims paid in any one year is not necessarily related to the amount of net claims and claim expenses incurred in that year, as reported in the consolidated statements of operations. We expect that our liquidity needs for the next 12 months will be met by our cash receipts from operations. However, as a result of a combination of market conditions, turnover of our investment portfolios and changes in investment yields, and the nature of our business where a large portion of the coverages we provide can produce losses of high severity and low frequency, future cash flows from operating activities cannot be accurately predicted and may fluctuate significantly between individual quarters and years. In addition, due to the magnitude and complexity of certain large loss events, meaningful uncertainty remains regarding losses from these events and our actual ultimate net losses from these events may vary materially from preliminary estimates, which would impact our cash flows from operations. Our shelf registration statement on Form S-3 under the Securities Act allows for the public offering of various types of securities, including common shares, preference shares and debt securities, which provides a source of liquidity. Because we are a well-known seasoned issuer as defined by the rules promulgated under the Securities Act, we are also eligible to file additional automatically effective registration statements on Form S-3 in the future for the potential offering and sale of additional debt and equity securities. From time to time, we raise capital through public offerings pursuant to our registration statements. For example, in 2023, we

Completed an offering of common shares and an assurance of senior notes for total net proceeds of approximately \$2.1 billion to fund a portion of the cash consideration for the Validus Acquisition, to pay related costs and expenses, and for general corporate purposes. Credit Facilities, Trusts and Other Collateral Arrangements We also maintain various other arrangements that allow us to access liquidity and satisfy collateral requirements, including revolving credit facilities, letter of credit facilities, and regulatory trusts, as well as other types of trust and collateral arrangements. Regulatory and other requirements to post collateral to support our reinsurance obligations could impact our liquidity. For example, many jurisdictions in the U.S. do not permit insurance companies to take credit for reinsurance obtained from unlicensed or non-admitted insurers on their statutory financial statements unless security is posted, so our contracts generally require us to post a letter of credit or provide other security (such as through a multi-beneficiary reinsurance trust). However, certain of our subsidiaries qualify as certified reinsurers or reciprocal reinsurers in one or more U.S. states, which has, and may continue to, reduce the amount of collateral that we are required to post. In addition, if we were to fail to comply with certain covenants in our debt agreements, we may have to pledge additional collateral. 84 Letter of Credit and Revolving Credit Facilities We and certain of our subsidiaries, joint ventures, and managed funds maintain secured and unsecured revolving credit facilities and letter of credit facilities that provide liquidity and allow us to satisfy certain collateral requirements. The outstanding amounts drawn under each of our significant credit facilities are set forth below: At December 31, 2024 Issued or Drawn (in thousands) Revolving Credit Facility (1) \$ 46.1 Medici Revolving Credit Facility (2) \$ 46.1 Bilateral Letter of Credit Facilities Secured 262,168 A Unsecured 357,443 A \$ 619,611 A (1) At December 31, 2024, no amounts were issued or drawn under this facility. (2) RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici's issued voting shares, the financial statements of Medici are included in RenaissanceRe's consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions. Refer to Note 9. Debt and Credit Facilities in our Consolidated Financial Statements for additional information related to our significant debt and credit facilities. Funds at Lloyd's as a member of Lloyd's, the underwriting capacity, or stamp capacity, of Syndicate 1458 is required to be supported by providing a deposit, the FAL, in the form of cash, securities or letters of credit. At December 31, 2024, the FAL required to support the underwriting activities at Lloyd's through Syndicate 1458 was \$ 714.8 million (2023 - \$ 730.9 million). Actual FAL posted for Syndicate 1458 at December 31, 2024 by RenaissanceRe Corporate Capital (UK) Limited was \$ 952.3 million (2023 - \$ 935.8 million), supported by a \$ 952.3 million deposit of cash and fixed maturity securities (2023 - \$ 710.8 million deposit of cash and fixed maturity securities and \$ 225.0 million letter of credit). Multi-Beneficiary Reinsurance Trusts, Multi-Beneficiary Reduced Collateral Reinsurance Trusts Renaissance Reinsurance, DaVinci Reinsurance, and RREAG use multi-beneficiary reinsurance trusts and/or multi-beneficiary reduced collateral reinsurance trusts to collateralize reinsurance liabilities. As of December 31, 2024, all of these trusts were funded in accordance with the relevant regulatory thresholds. However, assets held in these trusts have in the past, and may in the future, exceed the amount required under U.S. state regulations. Refer to Note 18. Statutory Requirements in our Consolidated Financial Statements for additional information on our multi-beneficiary reinsurance trusts and multi-beneficiary reduced collateral reinsurance trusts. Contractual Obligations In assessing our liquidity requirements and cash needs, we also consider contractual obligations to which we are a party. In certain circumstances, our contractual obligations may be accelerated due to defaults under the agreements governing those obligations (including pursuant to cross-default provisions in such agreements) or in connection with certain changes in control of the Company, for example. In addition, in certain circumstances, in the event of a default these obligations may bear an increased interest rate or be subject to penalties. 85 The table below shows certain of our current and long-term contractual obligations: At December 31, 2024 Total Less Than 1 Year 1 Year-3 Years 3 Years-5 Years More Than 5 Years (in thousands) A A A A A Long term debt obligations (1) \$ 750 Senior Notes due 2033 \$ 1,113,568 A \$ 43,125 A \$ 86,250 A \$ 86,250 A \$ 897,943 A 3.600% Senior Notes due 2029 A 1,800 A 14,400 A 28,800 A 418,600 A A 3.450% Senior Notes due 2027 325,875 A 10,350 A 315,525 A A 3.700% Senior Notes due 2025 302,775 A 302,775 A A 4.750% Senior Notes due 2025 (DaVinci) 152,375 A 152,375 A A A A Total long term debt obligations 2,356,393 A 523,025 A 30,575 A 504,850 A 897,943 A Investment commitments (2) 1,953,175 A 1,953,175 A A A A Operating lease obligations 150,740 A 15,657 A 32,900 A 31,527 A 70,656 A Capital lease obligations 10,129 A 2,661 A 5,322 A 2,146 A A Payable for investments purchased 150,721 A 150,721 A A A A A Reserve for claims and claim expenses (3) 21,303,491 A 5,062,987 A 7,135,688 A 4,036,162 A 5,068,654 A Total contractual obligations \$ 25,924,649 A \$ 7,708,226 A \$ 7,604,485 A \$ 4,574,685 A \$ 6,037,253 A (1) Includes contractual interest payments. (2) The investment commitments do not have a defined contractual commitment date and we have therefore included them in the less than one year category. (3) The amount and timing of the cash flows associated with our policy liabilities are highly uncertain. Refer to Note 8. Reserve for Claims and Claim Expenses in our Consolidated Financial Statements for more information on our estimate of claims and claim expense reserves. Cash Flows Year ended December 31, 2024 2023 (in thousands) A A Net cash provided by (used in) operating activities \$ 4,164,822 A \$ 1,911,634 A Net cash provided by (used in) investing activities (3,060,856) A (3,822,636) A Net cash provided by (used in) financing activities (1,287,515) A (588,639) A Effect of exchange rate changes on foreign currency cash (17,365) A (5,542) A Net increase (decrease) in cash and cash equivalents (200,914) A (683,179) A Cash and cash equivalents, beginning of period 1,877,518 A 1,194,339 A Cash and cash equivalents, end of period \$ 1,676,604 A \$ 1,877,518 A During 2024, our cash and cash equivalents decreased by \$ 200.9 million, to \$ 1.7 billion at December 31, 2024, compared to \$ 1.9 billion at December 31, 2023. Cash flows provided by operating activities. Cash flows provided by operating activities during 2024 were \$ 4.2 billion, compared to \$ 1.9 billion during 2023. Cash flows provided by operating activities during 2024 were primarily the result of certain adjustments to reconcile our net income of \$ 3.0 billion to net cash provided by operating activities, including: a decrease in reinsurance recoverable of \$ 862.9 million due to prior year favorable development across the 2017 through 2022 accident years, in addition to paid recoveries; an increase in reserve for claims and claim expenses of \$ 816.6 million, primarily resulting from an increase in reserves in our Casualty and Specialty segment, largely driven by an increase in earned 86 premiums due to the renewal of business acquired in the Validus Acquisition and organic growth, resulting in additional attritional reserves, partially offset by a decrease in reserves in our Property segment primarily due to paid losses and prior year favorable development; partially offset by a decrease in reinsurance balances payable of \$ 381.8 million, principally driven by the redemption of capital from Upsilon RFO and the timing of payments related to underwriting activity. Cash flows used in investing activities. During 2024, our cash flows used in investing activities were \$ 3.1 billion, principally reflecting net purchases of fixed maturity investments trading of \$ 2.8 billion and other investments of \$ 438.2 million, partially offset by cash flows from net sales of short term investments of \$ 174.5 million. The net purchases of fixed maturity investments trading and other investments was primarily funded by cash flows provided by operating activities, as described above. Cash flows used in financing activities. Our cash flows used in financing activities in 2024 were \$ 1.3 billion, and were principally the result of: net outflows of \$ 405.8 million, primarily related to net third-party redeemable noncontrolling interest share transactions in DaVinci, Medici and Vermeer; common share repurchases of \$ 666.9 million; and repayment of debt of \$ 150.0 million related to the Medici Revolving Credit Facility. 2023 During 2023, our cash and cash equivalents increased by \$ 683.2 million, to \$ 1.9 billion at December 31, 2023, compared to \$ 1.2 billion at December 31, 2022. Cash flows provided by operating activities. Cash flows provided by operating activities during 2023 were \$ 1.9 billion, compared to \$ 1.6 billion during 2022. Cash flows provided by operating activities during 2023 were primarily the result of certain adjustments to reconcile our net income of \$ 3.6 billion to net cash provided by operating activities, which exclude the acquired net assets of Validus, including: a decrease in reinsurance balances payable of \$ 1.0 billion, principally driven by the redemption of capital from Upsilon RFO and the timing of payments related to underwriting activity; net realized and unrealized gains on investments of \$ 482.8 million, primarily driven by unrealized gains in our fixed maturity investments due to movements in interest rates; a decrease in unearned premiums of \$ 227.0 million due to a decrease in gross premiums written across both our Property and Casualty and Specialty segments; an increase in premiums receivable of \$ 126.9 million due to the timing of receipts and an increase in our gross premiums written; partially offset by a decrease in reinsurance recoverable of \$ 663.9 million due to the decrease in current year large losses as compared to prior year, as well as an increase in collected recoveries and higher level of prior year favorable development; and an increase in prepaid reinsurance premiums of \$ 223.4 million due to the timing of payments. Cash flows used in investing activities. During 2023, our cash flows used in investing activities were \$ 3.8 billion, principally reflecting net purchases of fixed maturity investments trading of \$ 3.0 billion and other investments of \$ 801.8 million, partially offset by cash flows from net sales of short term investments of \$ 1.8 billion and equity investments of \$ 564.3 million. The net purchases of fixed maturity investments trading was primarily funded by cash flows provided by operating activities, as described above, and cash flows provided by the capital raised as part of our financing plan for the Validus Acquisition, as described below. The net purchase of other investments during 2023 was primarily driven by net purchases of catastrophe bonds in Medici, which were funded by new capital contributions. In addition, we completed our acquisition of Validus on November 1, 2023, resulting in a net cash outflow of \$ 2.4 billion. Refer to Note 3. Acquisition of Validus in our Consolidated Financial Statements for additional information related to the acquisition of Validus. 87 Cash flows provided by financing activities. Our cash flows provided by financing activities in 2023 were \$ 2.6 billion, and were principally the result of: the issuance of 7,245,000 of our common shares in an underwritten public offering at a public offering price of \$ 192.00 per share. The total net proceeds from the offering were \$ 1,351.6 million; the issuance of \$ 750.0 million of 5.750% Senior Notes due June 5, 2033, with net proceeds from the offering of \$ 740.6 million; net inflows of \$ 582.5 million primarily related to net third-party redeemable noncontrolling interest share transactions in Medici and DaVinci; net inflows of \$ 75.0 million from the drawdown of the Medici Revolving Credit Facility; partially offset by dividends paid on our common and preference shares of \$ 75.1 million and \$ 35.4 million, respectively; and repayment of debt of \$ 30.0 million related to the Medici Revolving Credit Facility. Capital Resources We monitor our capital adequacy on a regular basis and seek to adjust our capital according to the needs of our business. In particular, we require capital sufficient to meet or exceed the capital adequacy ratios established by rating agencies for maintenance of appropriate financial strength ratings, the capital adequacy tests performed by regulatory authorities and the capital requirements under our credit facilities. From time to time, rating agencies may make changes in their capital models and rating methodologies, which could increase the amount of capital required to support our ratings. We may seek to raise additional capital or return capital to our shareholders through common share repurchases and cash dividends (or a combination of such methods). In the normal course of our operations, we may from time to time evaluate additional share or debt issuances given prevailing market conditions and capital management strategies, including for our operating subsidiaries, joint ventures and managed funds. In addition, as noted above, we enter into agreements with financial institutions to obtain letter of credit facilities for the benefit of our operating subsidiaries and certain of our joint ventures and managed funds in their reinsurance and insurance business. 88 Our total shareholders' equity attributable to RenaissanceRe and total debt was as follows: At December 31, 2024 2023 Change (in thousands) A A Common shareholders' equity \$ 9,824,012 A \$ 8,704,958 A 1,119,054 A Preference shares 750,000 A 750,000 A A Total shareholders' equity attributable to RenaissanceRe 10,574,012 A \$ 9,454,958 A 1,119,054 A 5.750% Senior Notes due 2033 \$ 742,068 A \$ 741,124 A \$ 944 A 3.600% Senior Notes due 2029 396,051 A 195,137 A 914 A 3.450% Senior Notes due 2027 298,765 A 298,270 A 495 A 3.700% Senior Notes due 2025 299,530 A 299,530 A 71 A 4.750% Senior Notes due 2025 (DaVinci) 149,897 A 149,874 A 310 A Total senior notes 1,886,689 A 1,883,655 A 3,034 A Medici Revolving Credit Facility (2) \$ 75,000 A (75,000) A Total debt \$ 1,958,655 A \$ (71,966) A (1) RenaissanceRe owns a noncontrolling economic interest in its joint venture DaVinci. Because RenaissanceRe controls a majority of DaVinci's issued voting shares, the consolidated financial statements of DaVinci are included in the consolidated financial statements of RenaissanceRe. However, RenaissanceRe does not guarantee or provide credit support for DaVinci and RenaissanceRe's financial exposure to DaVinci is limited

[illegible]

solutions.General Economic Conditions We think that the stresses in the global economy will continue and that this may result in increased market volatility. Global events and geopolitical instability have contributed to widespread economic inflation over the past few years compared to recent historical norms. We consider the anticipated effects of inflation, including social, economic, and event-driven, in our loss models, on our investment portfolio, and generally in the running of our business, and actively monitor trends in these areas. Some central banks have begun to cut interest rates, which could act as a potential supporting force for some of these inflationary pressures, if they have cut rates too soon. The effects of interest rate trends on our reinsurance and insurance business could be magnified for longer-tail business lines that are more inflation-sensitive, particularly in our Casualty and Specialty segment, and in our other property class of business within our Property segment. The risk of a global recession is a continuing concern. However, we think that our business model is well positioned to be less sensitive to an inflationary or recessionary environment. Notwithstanding the many uncertainties and challenges that lie ahead, we believe that our track record of responding to industry events, differentiated risk management and client service capabilities, coupled with access to diverse sources of both capital and risk position us favorably in the current environment. Tax UpdatesOn December 27, 2023, the Government of Bermuda enacted the Corporate Income Tax Act 2023, which will apply a 15% corporate income tax to certain Bermuda businesses in fiscal years beginning on or after January 1, 2025. The act includes a provision referred to as the economic transition adjustment, which is intended to provide a fair and equitable transition into the tax regime, and results in a deferred tax benefit for the Company. Pursuant to this legislation, the Company recorded a net deferred tax asset in the fourth quarter of 2023, expected to be utilized predominantly over a 10-year period. The Company expects to incur and pay increased taxes in Bermuda beginning in 2025. On January 15, 2025, the OECD issued administrative guidance, which, if incorporated into the laws of the jurisdictions in which we operate, could cause additional top-up taxes to the extent the net deferred tax asset that we established upon enactment of the CIT in 2023 pursuant to the economic transition adjustment is utilized after 2026. We continue to monitor potential impacts from changes to global tax regimes, but believe that the flexible global operating model that we have utilized will continue to prove resilient.Three Drivers of ProfitWe had strong overall performance in 2024, with solid contributions from each of our three drivers of profit. This performance reflected our strategy of generating diversified and sustainable earnings streams for our business across underwriting income, fee income and investment income. Having three distinct sources of income makes us more resilient to catastrophe activity and we believe this resilience will reward our shareholders with superior returns. We believe that the momentum across our three drivers of profit will continue. 97Underwriting IncomeThrough disciplined underwriting, we aim to manage the cycle and allocate our capital to the business that will generate the best returns. Portfolio construction is a continuous process, and we believe that we have constructed a large and profitable underwriting portfolio that has been bolstered by our ability to participate broadly across our clientsâ€™ portfolios. We aim to be a provider of first choice and a trusted partner to our customers to help them manage their risk across portfolios and market cycles. We believe that each of our reportable segments have different risk and volatility profiles that contribute in distinct and important ways to our three drivers of profit, and in particular our underwriting income. The Property segment is inherently more volatile, but also provides meaningful underwriting income in lower catastrophe quarters as well as strong fee income from third-party capital. The Casualty and Specialty segment generally provides a more stable underwriting result over-time, along with significant investment income stemming from capital invested on longer tail risk in certain lines of business. These segments also provide us with diversification across our loss reserves and the tail of our risks, which allows us to better manage changes in loss trends, whether favorable or adverse, across our underwriting portfolio.In 2024, we delivered the combined RenaissanceRe and Validus portfolio at attractive rates and terms and conditions. We achieved our goal of creating a larger, well-diversified combined portfolio while also deepening our partnerships with brokers and clients. Even at our increased scale, we continue to remain focused on staying nimble to be able to capture attractive opportunities as they arise and exercising discipline to effectively manage our portfolio.Looking forward to the remainder of 2025, we believe that demand in the market will continue to grow due to several factors, including the impact of recent catastrophe events, the inflation of insured values and cedants adjusting their reinsurance budgets. We believe that we are well positioned to meet this expected demand due to our flexible underwriting platform, our risk expertise, and the strength and durability of our partnerships with clients and brokers. PropertyWith the global impact of climate change, we expect the frequency and severity of perils such as drought, flood, rain, hail and wildfire to continue at the elevated levels we have seen in recent years. We believe that the increase in severe weather, coupled with currently projected demographic trends in catastrophe-exposed regions, contributes to factors that will increase the average economic value of expected losses, increase the number of people exposed per year to natural disasters and, in general, exacerbate disaster risk. The impact from these factors was apparent in the recent California wildfires. However, we think that the underwriting changes that we have made, including requiring higher rates and attachment points, has optimized the portfolio and positioned us so that this catastrophe activity will have a smaller impact on our financial results than it otherwise may have.As expected, at the January 1, 2025 renewals, demand increased at the top end of programs, as did competition for attractive placements. Overall, we deployed property catastrophe capacity with key clients and had a favorable renewal with terms and conditions remaining attractive. Growth was greatest in the property catastrophe class of business where risk-adjusted returns have been strongest and where we were able to capture incremental opportunities. In our Property segment, we have focused on constructing a portfolio that has appropriate attachment points for each of our customers, and we expect this dynamic to persist through 2025, supporting a healthy reinsurance market and the consistent protection our customers need. Looking forward, we expect that the property catastrophe reinsurance market will be impacted by the past several quarters of elevated catastrophe events. These have affected, and we expect will continue to affect, the supply-demand balance, placing upward pressure on rates, and providing new opportunities to deploy capacity to support our customers. A significant portion of our portfolio renews over the next six months, and our strong capital position provides us with the flexibility so that we can move quickly to offer capacity to our partners at attractive rates. Casualty and SpecialtyPart of fulfilling our vision of being the best underwriter is knowing when to grow our portfolio and when to exercise discipline. Each line of business in the Casualty and Specialty segment is at a different point in the cycle and we continually manage our participation to achieve the best portfolio mix and balance of risk and 98reward. Our prior work building strong relationships with key customers has allowed us to gain superior access to desirable business. We have focused our growth in attractive areas while reducing on deals that do not meet our return hurdles. We continue to grow organically in certain credit and specialty lines of business where we are seeing the most attractive risk-adjusted returns. At the January 1, 2025 renewals, we saw favorable underlying conditions in the specialty class of business where we achieved desirable results and maintained our strong leadership in specialty and credit lines. In the casualty class of business, we retained the majority of our portfolio and had discussions with clients on casualty trends, while continuing to reduce lines on some treaties where exposure to loss inflation or loss trends was greatest.Our portfolio management and robust reserving process has provided us with overall stability in the Casualty and Specialty segment, allowing the segment to remain a substantial contributor to our financial results. This diversification has also been beneficial when certain classes of business or underwriting years have experienced increasing loss trends and required more reserves.In our casualty class of business, we have been closely monitoring trends in general liability where inflation and claims severity have been increasing. We typically manage our casualty business over a 10-year cycle. At this point, we believe that the industry requires continued evolution to stay ahead of social inflation trends, and we have been actively working with customers to share our insights and improve data capture throughout the renewal process. This customer-by-customer approach enables us to differentiate between accounts, appropriately price each program, and reduce if needed. We have been encouraged to see progress across the industry and believe that many insurance companies are improving their underwriting and claims management as well as accelerating rate increases.We believe that we have a prudent reserving process for our Casualty and Specialty segment and remain confident in our reserves. We have been closely monitoring casualty loss trends, and our longstanding approach is to recognize increasing trends early. We are reflecting our insights into our prudent reserving process to proactively stay ahead of trend and inform portfolio shaping decisions. Fee IncomeWe take a differentiated approach to our Capital Partners unit, with a focus on first sourcing the risks that we intend to write, and then matching them with the appropriate third-party capital. This business improves our offerings to customers, enhances our ability to optimize our portfolios, and generates attractive fees for doing so. Our Capital Partners unit continues to grow into an attractive market and benefits from increased access to desirable risk. We view this as a growing and sustainable driver of profit that we expect will continue to generate low-volatility management fee income. However, performance fees may be impacted by large losses, which can potentially result in no performance fees or the reversal of previously accrued performance fees.Investment IncomeIn 2024, we benefited from high interest rates and growth in this driver of profit as a result of our proactive rotation of the portfolio into higher yielding securities when we saw increases in interest rates. This was enhanced by the increased size of our investment portfolio, including as a result of the Validus Acquisition. We continue to maintain a relatively conservative position for our investment portfolio. See the â€œRisk Factorsâ€ section in our Form 10-K for additional information on factors that could cause our actual results to differ materially from those in the forward-looking statements contained in this Form 10-K and other documents we file with the SEC.ITEM 7A. A A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK The following risk management discussion and the estimated amounts generated from sensitivities presented are forward-looking statements of market risk assuming certain market conditions occur. Actual results in the future may differ materially from these estimated results due to, among other things, actual developments in the global financial markets and changes in the composition of our investment portfolio, derivatives and product offerings. The results of analysis used by us to assess and mitigate risk should not be considered projections of future events or losses. Refer to â€œNote On Forward-Looking Statementsâ€ for additional discussion regarding forward-looking statements included herein.99We are principally exposed to five types of market risk: interest rate risk; foreign currency risk; credit risk; equity price risk and commodity price risk. Our policies to address these risks in 2024 were not materially different than those used in 2023. Our investment guidelines permit, subject to approval, investments in derivative instruments such as futures, options, foreign currency forward contracts and swap agreements, which may be used to assume risks or for hedging purposes. Refer to â€œNote 19. Derivative Instrumentsâ€ in our â€œNotes to the Consolidated Financial Statementsâ€ for additional information related to derivatives we have entered into.Interest Rate RiskInterest rate risk is the price sensitivity of a security to changes in interest rates. Our investment portfolio includes fixed maturity investments and short term investments, as well as private credit funds and term loans which primarily invest in debt instruments. The fair values of these investments will fluctuate with changes in interest rates. As a result, we are exposed to interest rate risk with respect to our overall net economic asset position, and also from an accounting standpoint since the assets are carried at fair value. We may utilize derivative instruments, for example via interest rate overlay strategies, to manage or optimize our duration and treasury curve exposures. In addition, we attempt to maintain adequate liquidity in our fixed maturity investments portfolio to fund operations, pay reinsurance and insurance liabilities and claims and provide funding for unexpected events.The following tables summarize the aggregate hypothetical increase (decrease) in fair value of our fixed maturity investment and short term investments, private credit funds and term loans from an immediate parallel shift in the treasury yield curve. Assuming credit spreads remain constant and an immediate time horizon, this presents the worst-case scenario:Interest Rate Shift in Basis PointsAt December 31, 2024-100-50Base50100(in thousands, except percentages)Fair value of fixed maturity and short term investments, private credit funds and term loans\$30,409,296\$ 29,662,274\$ 29,275,315\$ 28,888,629\$ 28,502,051\$ Net increase (decrease) in fair value\$773,981\$ 386,960\$ â€”\$ (386,686)\$ (773,264)Percentage change in fair value2.6% 1.3% %â€”% (1.3)% (2.6)%Interest Rate Shift in Basis PointsAt December 31, 2023-100-50Base50100(in thousands, except percentages)Fair value of fixed maturity and short term investments, private credit funds and term loans\$27,259,888\$ 26,865,707\$ 26,560,861\$ 26,246,627\$ 25,904,022\$ Net increase (decrease) in fair values\$699,027\$ 304,845\$ â€”\$ (314,235)\$ (656,839)Percentage change in fair value2.6% 1.1% %â€”% (1.2)% (2.5)%As noted above, we use derivative instruments, primarily interest rate futures, within our portfolio of fixed maturity investments to manage our exposure to interest rate risk, which can include increasing or decreasing our exposure to this risk. At December 31, 2024, we had \$7.1 billion of notional long positions and \$3.1 billion of notional short positions of primarily U.S. treasury and non-US government bond futures contracts (2023 - \$5.9 billion and \$2.7 billion, respectively). Refer to â€œNote 19. Derivative Instrumentsâ€ in our 100â€œNotes to the Consolidated Financial Statementsâ€ for additional information related to interest rate futures entered into by us. At December 31, 2024, the aggregate hypothetical impact of an immediate upward parallel shift in the treasury yield curve of 100 basis points would be a decrease in the market value of our net position in interest rate futures of approximately \$105.0Â million (2023 - \$38.1 million). Conversely, at December 31, 2024, the aggregate hypothetical impact of an immediate downward parallel shift in the treasury yield curve of 100 basis points would be an increase in the market value of our net position in interest rate futures of approximately \$105.0Â million (2023 - \$37.9Â million). The foregoing reflects the use of an immediate time horizon, since this presents the worst-case scenario. Credit spreads are assumed to remain constant in these hypothetical examples.Foreign Currency RiskOur functional currency for consolidated reporting purposes is the U.S. dollar. We routinely write a portion of our business in currencies other than U.S. dollars and invest a portion of our cash and investment portfolio in those currencies. In addition, certain of our entities have, or have had, non-U.S. dollar functional currencies. As a result, we may experience foreign exchange gains and losses in our consolidated financial statements. We are primarily impacted by the foreign currency risk exposures noted below, and may, from time to time, enter into foreign currency forward and option contracts to minimize the effect of fluctuating foreign currencies on the value of non-U.S. dollar denominated assets and liabilities. Refer to â€œNote 19. Derivative Instrumentsâ€ in our â€œNotes to the Consolidated Financial Statementsâ€ for additional information related to foreign currency forward and option contracts we have entered into. Underwriting OperationsOur foreign currency policy with regard to our underwriting operations is generally to enter into foreign currency forward and option contracts for notional values that approximate the foreign currency liabilities, including claims and claim expense reserves and reinsurance balances payable, net of any cash, investments and receivables held in the respective foreign currency. Our use of foreign currency forward and option contracts is intended to minimize the effect of fluctuating foreign currencies on the value of non-U.S. dollar denominated assets and liabilities associated with our underwriting operations. We may determine not to match a portion of our projected underwriting related assets or liabilities with underlying foreign currency exposure with investments in the same currencies, which would increase our exposure to foreign currency fluctuations and potentially increase the impact and volatility of foreign exchange gains and losses on our results of operations.Investment PortfolioOur investment portfolio is exposed to currency fluctuations through our investments in non-U.S. dollar fixed maturity investments, short term investments and other investments. To economically hedge our exposure to currency fluctuations from these investments, we may enter into foreign currency forward contracts. In certain instances, we may assume foreign exchange risk as part of our investment strategy. Realized and unrealized foreign exchange gains or losses from the sale of our non-U.S. dollar fixed maturity investments trading and other investments, and foreign exchange gains or losses associated with our hedging of these non-U.S. dollar investments are recorded in net foreign exchange gains (losses) in our consolidated statements of operations. In the future, we may choose to increase our exposure to non-U.S. dollar investments.101The following tables summarize the principal currencies creating foreign exchange risk for us and our net foreign currency exposures and the impact of a hypothetical 10% change in our net foreign currency exposure, keeping all other variables constant, as of the dates indicated:At December 31, 2024AUDCADEURGBPJPYNZDOtherTotal(in thousands, except for percentages)A Net assets (liabilities) denominated in foreign currencies\$1,053\$ 126,520\$ (541,557)\$ (233,774)\$ (63,163)\$ 9,210\$ (129,188)\$ (760,899)Net foreign currency derivatives notional amounts(26,097) (76,318) 506,972\$ 266,215\$ 25,834\$ 596\$ 64,714\$ 761,916\$ Total net foreign currency exposure\$44,956\$ 50,202\$ (34,585)\$ 32,441\$ (37,329)\$ 9,806\$ (64,474)\$ 1,017\$ Net foreign currency exposure as a percentage of total shareholdersâ€™ equity attributable to RenaissanceRe0.4% %0.5% (0.3)% 0.3% % (0.4)% 0.1% (0.6)%â€”% %Impact of a hypothetical 10% change in total net foreign currency exposure\$(4,496)\$ (5,020)\$ 3,459\$ (3,244)\$ 3,733\$ (981)\$ 6,447\$ (102)At December 31, 2023AUDCADEURGBPJPYNZDOtherTotal(in thousands, except for percentages)A Net (liabilities) assets denominated in foreign currencies\$83,427\$ 133,228\$ (146,480)\$ (161,522)\$ 37,381\$ (50,771)\$ (68,593)\$ (173,330)Net foreign currency derivatives notional amounts(46,640) (95,820) 214,172\$ 74,226\$ 14,617\$ 6,648\$ 20,027\$ 18,230\$ Total net foreign currency exposure\$36,787\$ 37,408\$ â€”\$ 67,692\$ (87,296)\$ 51,998\$ (44,123)\$ (48,566)\$ 13,900\$ Net foreign currency exposure as a percentage of total shareholdersâ€™ equity attributable to RenaissanceRe0.4% %0.4% %0.7% % (0.9)% 0.5% % (0.5)% (0.5)% %Impact of a hypothetical 10% change in total net foreign currency exposure\$(3,679)\$ (3,741)\$ (6,769)\$ 8,730\$ (5,200)\$ 4,412\$ 4,857\$ (1,390)Credit RiskCredit risk relates to the uncertainty of a counterpartyâ€™s ability to make timely payments in accordance with contractual terms of the instrument or contract and market risk associated with changes in credit spreads. We are primarily exposed to direct credit risk within our portfolios of fixed maturity and short term investments, and through customers and reinsurers in the form of premiums receivable and reinsurance recoverable, respectively, as discussed below.Fixed Maturity Investments, Short Term Investments, Private Credit Funds and Term LoansCredit risk related to our fixed maturity investments and short term investments, as well as our private credit funds and term loans which primarily invest in debt instruments, is the exposure to adverse changes in the creditworthiness of individual investment holdings, issuers,

groups of issuers, industries and countries. We manage credit risk in our fixed maturity and short term investments through credit research performed by our investment management service providers, our evaluation of these investment managersâ€™ adherence to investment mandates provided to them, independent credit research and active monitoring of our credit exposure relative to broader economic fundamentals, valuations and technical measurements. The management of credit risk in the investment portfolio is integrated in our credit risk governance framework 102and the management of credit exposures and concentrations within the investment portfolio are carried out in accordance with our risk policies, limits and risk concentrations as overseen by the Investment and Risk Management Committee of our Board. In the investment portfolio, we review on a regular basis our asset concentration, credit quality and adherence to credit limit guidelines. In addition, we limit the amount of credit exposure to any one financial institution and, except for the securities of the U.S. Government and U.S. Government related entities, and money market securities, none of our fixed maturity and short term investments exceeded 10% of shareholdersâ€™ equity at December 31, 2024 and 2023.At December 31, 2024, our fixed maturity investments and short term investment portfolio had a dollar-weighted average credit quality rating of AA (2023 - AA). The following table summarizes the ratings of our fixed maturity investments and short term investments and term loans (using ratings assigned by S&P and/or other rating agencies when S&P ratings were not available) as a percentage of the total of those investments as of the dates indicated:At December 31,20242023AAA17.7% 25.2% AA56.0% 49.3% A10.6% 10.4% BBB10.4% 10.2% BNon-investment grade5.1A %4.6A %Not rated0.2A %0.3A %Total100.0A %100.0A %Private credit funds are not included in the table above. Our investments in private credit funds include limited partnership or similar interests that invest in certain private credit asset classes, including senior secured bank loan funds, U.S. direct lending, secondaries, mezzanine investments and distressed securities. We consider the impact of credit spread movements on the fair value of our fixed maturity and short term investments portfolio, private credit funds and term loans. As credit spreads widen, the fair value of our fixed maturity, short term investments, private credit funds and term loans decreases, and vice versa. The following tables summarize the aggregate hypothetical increase (decrease) in fair value in our fixed maturity investments and short term investments, private credit funds and term loans, from an immediate parallel shift in credit spreads. Assuming treasury yields remain constant, credit spreads cannot be negative and an immediate time horizon, this presents the worst-case scenario:Credit Spread Shift in Basis PointsAt December 31, 2024-100-50Base50100(in thousands, except percentages)Fair value of fixed maturity and short term investments, private credit funds and term loans\$29,567,525A \$29,469,996A \$29,275,315A \$29,049,045A \$28,822,654A Net increase (decrease) in fair value\$292,210A \$194,681A \$â€”A \$(226,270)\$(452,661)Percentage change in fair value1.0A %0.7A %â€”A %0.8(1.5)%103Credit Spread Shift in Basis PointsAt December 31, 2023-100-50Base50100(in thousands, except percentages)Fair value of fixed maturity and short term investments, private credit funds and term loans\$26,854,484A \$26,716,705A \$26,560,861A \$26,345,584A \$26,130,307A Net increase (decrease) in fair values\$293,623A \$155,843A \$â€”A \$(215,277)\$(430,554)Percentage change in fair value1.1A %0.6A %â€”A %0.8(1.6)%We also employ credit derivatives in our investment portfolio to either assume credit risk or hedge our credit exposure. At December 31, 2024, we had outstanding credit derivatives of \$1.0 billion in notional positions to hedge credit risk and \$Nil in notional positions to assume credit risk, denominated in U.S. dollars (2023 - \$1.1 billion and \$22.1 million, respectively). Refer to Note 19. Derivative Instrumentsâ€”to the Consolidated Financial Statementsâ€”for additional information related to credit derivatives entered into by us. The aggregate hypothetical market value impact from an immediate tightening in credit spreads of 100 basis points would cause a decrease in the market value of our net position in these derivatives of approximately \$34.0A million at December 31, 2024 (2023 - \$46.7A million). Conversely, the aggregate hypothetical market value impact from an immediate widening in credit spreads of 100 basis points would cause an increase in the market value of our net position in these derivatives of approximately \$42.3A million at December 31, 2024 (2023 - \$46.7A million). For an immediate downward shift in credit spreads, we do not allow credit spreads to go negative in calculating the impact. The foregoing reflects the use of an immediate time horizon, since this presents the worst-case scenario.Premiums Receivable and Reinsurance RecoverablePremiums receivable from ceding companies and reinsurance recoverable from our reinsurers are subject to credit risk. To mitigate credit risk related to reinsurance premiums receivable, we have established standards for ceding companies and, in most cases, have a contractual right of offset allowing us to settle claims net of any reinsurance premiums receivable. To mitigate credit risk related to our reinsurance recoverable amounts, we consider the financial strength of our reinsurers when determining whether to purchase coverage from them. We generally obtain reinsurance coverage from companies rated â€œAâ€”or better by major rating agencies unless the obligations are collateralized. We routinely monitor the financial performance and rating status of all material reinsurers. Refer to Part II, Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, Summary of Critical Accounting Estimates, Reinsurance Recoverableâ€”for additional information with respect to reinsurance recoverable.Equity Price RiskEquity price risk is the potential loss arising from changes in the market value of equity investments. As detailed in the table below, we are directly exposed to this risk through our investment in equity investments, including certain positions in our strategic investment portfolio, which are traded on nationally recognized stock exchanges; and indirectly exposed to this risk through other investments such as our direct private equity investments, private equity funds and hedge funds, whose exit strategies and market values often depend on the wider equity markets. We may, from time to time, use equity derivatives in our investment portfolio to either assume equity risk or hedge our equity exposure. The following table summarizes a hypothetical 10% increase or decline in the market value of our private equity funds, hedge 104funds, direct private equity investments, and equity investments, holding all other factors constant, at the dates indicated:At December 31,20242023(in thousands, except for percentages)A Private equity funds\$609,105A \$433,788A Hedge funds338,248A â€”A Direct private equity investments 211,866A 59,905A Equity investments117,756A 106,766A Total carrying value of investments exposed to equity price risks\$1,276,975A \$600,459A Impact of a hypothetical 10% increase in the carrying value of investments exposed to equity price risk\$127,698A \$60,046A Impact of a hypothetical 10% decrease in the carrying value of investments exposed to equity price risks\$(127,698)\$(60,046)Commodity Price RiskCommodity price risk is the potential loss arising from changes in the market value of commodities. We are directly exposed to this risk through our investments in commodity derivative instruments, which are exchange traded, but may include over-the-counter derivative instruments when deemed appropriate. At December 31, 2024 the total notional amount of commodity contracts was \$684.8A million (2023 - \$255.7A million), and the aggregate fair value of these contracts was a net asset position of \$6.4A million (2023 - net liability position of \$1.1A million). If the underlying exposure of each commodity derivative held at December 31, 2024 depreciated by 10%, it would have resulted in a reduction in net income of approximately \$68.7A million. If the underlying exposure of each commodity derivative held at December 31, 2024 appreciated by 10%, it would have resulted in an increase in net income of approximately \$68.9A million.ITEM 8.Â A Â A FINANCIAL STATEMENTS AND SUPPLEMENTARY DATAReference is made to Item 15 of this Report for the Consolidated Financial Statements of RenaissanceRe and the Notes thereto, as well as the Schedules to the Consolidated Financial Statements.ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURENone.ITEM 9A.Â A Â A CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(b) and 15d-15(b) of the Exchange Act, as of the end of the period covered by this report. Based upon that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that, at December 31, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in Company reports filed or submitted under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Managementâ€™s Annual Report on Internal Control Over Financial ReportingOur management is responsible for establishing and maintaining effective internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended. Our internal control over financial reporting was designed to provide reasonable assurance regarding the reliability of 105financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and to reflect managementâ€™s judgments and estimates concerning effects of events and transactions that are accounted for or disclosed. Our internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and the dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.There are inherent limitations to the effectiveness of any controls. Our Board and management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. Controls, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Further, we believe that the design of controls must reflect appropriate resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in controls, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within RenaissanceRe have been detected.Management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed our internal control over financial reporting as of December 31, 2024 using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that RenaissanceReâ€™s internal control over financial reporting was effective as of December 31, 2024.PricewaterhouseCoopers Ltd., the independent registered public accountants who audited our consolidated financial statements included in this Form 10-K, audited our internal control over financial reporting as of December 31, 2024 and their attestation report on our internal control over financial reporting is included herein.Changes in Internal Control Over Financial ReportingThere were no changes in our internal control over financial reporting during the quarter ended December 31, 2024, which were identified in connection with our evaluation required pursuant to Rules 13a-15 or 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.ITEM 9B.Â A Â A OTHER INFORMATIONNone.ITEM 9C.Â A Â A DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONSNone.106PART IIITEM 10.Â A Â A DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCEThe information required by this Item relating to our directors, executive officers and corporate governance is incorporated herein by reference to information found in our Proxy Statement for the Annual General Meeting of Shareholders to be held on May 6, 2025. We intend to file our Proxy Statement no later than 120 days after the close of the fiscal year. We have adopted a Code of Ethics within the meaning of Item 406 of Regulation S-K of the Exchange Act that applies to all of our directors and employees, including our principal executive officer, principal financial officer, principal accounting officer, controller and other persons performing similar functions. The Code of Ethics is available free of charge on our website www.renre.com. We will also provide a printed version of the Code of Ethics to any shareholder who requests it. We intend to disclose any amendments to our Code of Ethics by posting such information on our website. Any waivers of our Code of Ethics applicable to our directors, principal executive officer, principal financial officer, principal accounting officer or controller and other persons who perform similar functions will be disclosed on our website or by filing a Form 8-K, as required.We have adopted an insider trading policy that outlines the procedures which employees, officers, directors, independent contractors and consultants of the Company must follow to ensure compliance with U.S. rules related to disclosure and insider trading. In addition, our insider trading policy provides that the Company will not trade in RenaissanceRe securities in violation of applicable securities laws or stock exchange listing standards. A copy of the Companyâ€™s insider trading policy has been filed as Exhibit 19.1 to this Annual Report on Form 10-K.ITEM 11.Â A Â A EXECUTIVE COMPENSATIONThe information required by this Item is incorporated herein by reference to information included in our Proxy Statement.ITEM 12.Â A Â A SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERSThe information required by this Item is incorporated herein by reference to information included in our Proxy Statement.ITEM 13.Â A Â A CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCEThe information required by this Item is incorporated herein by reference to information included in our Proxy Statement.ITEM 14.Â A Â A PRINCIPAL ACCOUNTANT FEES AND SERVICESThe information required by this Item is incorporated herein by reference to information included in our Proxy Statement.PART IVITEM 15.Â A Â A EXHIBITS AND FINANCIAL STATEMENT SCHEDULESFinancial StatementsÂ A Â A The Consolidated Financial Statements of RenaissanceRe Holdings Ltd. and related Notes thereto are listed in the accompanying Index to Consolidated Financial Statements and are filed as part of this Form 10-K.Â A Â A Â A 107Financial Statement SchedulesÂ A Â A The Schedules to the Consolidated Financial Statements of RenaissanceRe Holdings Ltd. are listed in the accompanying Index to Schedules to Consolidated Financial Statements and are filed as a part of this Form 10-K.108Exhibit IndexExhibit NumberDescription2.1Stock Purchase Agreement, dated May 22, 2023, among RenaissanceRe Holdings Ltd. and AIG International Group Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on May 23, 2023.2.1(a)Amendment No. 1 to the Stock Purchase Agreement, dated as of June 15, 2023, by and between American International Group, Inc. and RenaissanceRe Holdings Ltd., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Form 10-Q for the period ended June 30, 2023, filed with the SEC on July 26, 2023.2.1(b)Letter Agreement, dated August 7, 2023, among RenaissanceRe Holdings Ltd. and AIG International Group Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 2, 2023.2.1(c)Letter Agreement, dated October 27, 2023, among RenaissanceRe Holdings Ltd. and AIG International Group Inc.2.1(d)-Letter Agreement, dated November 1, 2023, among RenaissanceRe Holdings Ltd. and AIG International Group Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 2, 2023.2.1(e)Amendment No. 2 to the Stock Purchase Agreement, dated as of January 8, 2025, by and between American International Group, Inc. and RenaissanceRe Holdings Ltd.3.1Memorandum of Association, incorporated by reference to the Registration Statement on Form S-1 of RenaissanceRe Holdings Ltd. (Registration No. 33-70008) which was declared effective by the SEC on July 26, 1995. (P)3.2Amended and Restated Bye-Laws, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2002, filed with the SEC on August 14, 2002.3.3Memorandum of Increase in Share Capital of RenaissanceRe Holdings Ltd., incorporated by reference to Exhibit 3.1 to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended March 31, 1998, filed with the SEC on May 14, 1998.3.4Specimen Common Share certificate, incorporated by reference to the Registration Statement on Form S-1 of RenaissanceRe Holdings Ltd. (Registration No. 33-70008) which was declared effective by the SEC on July 26, 1995. (P)4.1Certificate of Designation, Preferences and Rights of 5.750% Series F Preference Shares, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 19, 2018.4.1(a)Form of Stock Certificate Evidencing the 5.750% Series F Preference Shares, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 19, 2018.4.1(b)Deposit Agreement, dated June 18, 2018, among RenaissanceRe Holdings Ltd., Computershare, Inc. and Computershare Trust Company, N.A., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 19, 2018.4.1(c)Form of Depositary Receipt, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 19, 2018.1094.2Form of Share Certificate Evidencing the 4.20% Series G Preference Shares, incorporated by reference to the Registration Statement on Form 8-A of RenaissanceRe Holdings Ltd. dated July 12, 2021.4.2(a)Certificate of Designation, Preferences and Rights of 4.20% Series G Preference Shares, incorporated by reference to the Registration Statement on Form 8-A of RenaissanceRe Holdings Ltd. dated July 12, 2021.4.2(b)Deposit Agreement, dated July 12, 2021, among RenaissanceRe Holdings Ltd., Computershare, Inc. and Computershare Trust Company, N.A., incorporated by reference to the Registration Statement on Form 8-A of RenaissanceRe Holdings Ltd. dated July 12, 2021.4.2(c)Form of Depositary Receipt, incorporated by reference to the Registration Statement on Form 8-A of RenaissanceRe Holdings Ltd. dated July 12, 2021.4.3Senior Indenture, dated as of March 24, 2015, among RenaissanceRe Finance Inc., as issuer, RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 25, 2015.4.3(a)First Supplemental Indenture, dated as of March 24, 2015, among RenaissanceRe Finance Inc., as issuer, RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 25, 2015.4.3(b)Senior Debt Securities Guarantee Agreement, dated as of March 24, 2015, between RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as guarantee trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 25, 2015.4.4Senior Indenture, dated as of June 29, 2017, among RenaissanceRe

Finance Inc., as issuer, RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 29, 2017.4.4(a)First Supplemental Indenture, dated as of June 29, 2017, among RenaissanceRe Finance Inc., as issuer, RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 29, 2017.4.4(b)Second Supplemental Indenture, March 25, 2019, by and among RenaissanceRe Finance Inc., as issuer, RenaissanceRe Holdings Ltd., as guarantor and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 26, 2019.4.4(c)Senior Debt Securities Guarantee Agreement, dated as of June 29, 2017, between RenaissanceRe Holdings Ltd., as guarantor, and Deutsche Bank Trust Company Americas, as guarantee trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 29, 2017.4.5Senior Indenture, dated as of April 2, 2019, by and between RenaissanceRe Holdings Ltd., as issuer, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on April 2, 2019.1104.5(a)First Supplemental Indenture, dated as of April 2, 2019, by and between RenaissanceRe Holdings Ltd., as issuer, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on April 2, 2019.4.5(b)Second Supplemental Indenture, dated as of June 5, 2023, by and between RenaissanceRe Holdings Ltd., as issuer, and Deutsche Bank Trust Company Americas, as trustee, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 5, 2023.4.6Description of Securities, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K, filed with the Commission on February 4, 2022.10.1*Further Amended and Restated Employment Agreement, dated as of July 22, 2016, by and between RenaissanceRe Holdings Ltd. and Kevin J. Oâ€™Donnell, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the SEC on July 27, 2016.10.2*Legacy Form of Further Amended and Restated Employment Agreement for Named Executive Officers (other than our Chief Executive Officer), incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the SEC on July 27, 2016.10.3*Form of Employment Agreement for Named Executive Officers (other than our Chief Executive Officer), incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the SEC on July 27, 2016.10.4*Employment Agreement, dated as of January 1, 2023, by and between RenaissanceRe Holdings Ltd. and David Edward Marra, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 21, 2024.10.5*Employment Agreement, dated as of November 8, 2023, by and between RenaissanceRe Holdings Ltd. and Shannon Lowry Bender, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 21, 2024.10.6*RenaissanceRe Holdings Ltd. First Amended and Restated 2016 Long-Term Incentive Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 28, 2022.10.6(a)*Amendment Number One to the RenaissanceRe Holdings Ltd. First Amended and Restated 2016 Long-Term Incentive Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the period ended December 31, 2022, filed with the SEC on February 8, 2023.10.6(b)*Form of Director Restricted Stock Agreement under the RenaissanceRe Holdings Ltd. 2016 Long-Term Incentive Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the SEC on July 27, 2016.10.6(c)*Form of Restricted Stock Agreement under the RenaissanceRe Holdings Ltd. 2016 Long-Term Incentive Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2016, filed with the SEC on July 27, 2016.10.6(d)*Form of Performance Share Agreement under the RenaissanceRe Holdings Ltd. 2016 Long-Term Incentive Plan (for awards made in March 2020 and later), incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 7, 2020.1110.6(e)*Performance Share Agreement with Kevin Oâ€™Donnell, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 9, 2023.10.6(f)*Restricted Stock Agreement with Kevin Oâ€™Donnell, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 9, 2023.10.7*RenaissanceRe Holdings Ltd. Deferred Cash Award Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 13, 2017.10.7(a)*Form of Deferred Cash Award Agreement pursuant to which Deferred Cash Awards are granted under the RenaissanceRe Holdings Ltd. Deferred Cash Award Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 13, 2017.10.8*RenaissanceRe Holdings Ltd. 2016 Restricted Stock Unit Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on May 16, 2018.10.8(a)*Form of Restricted Stock Unit Agreement pursuant to which restricted stock unit grants are made under the RenaissanceRe Holdings Ltd. 2016 Restricted Stock Unit Plan, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 10, 2016.10.9*Form of Agreement Regarding Use of Aircraft Interest by and between RenaissanceRe Holdings Ltd. and Certain Executive Officers of RenaissanceRe Holdings Ltd., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on February 22, 2013.10.10*Form of Director Retention Agreement, dated as of November 8, 2002, entered into by each of the non-employee directors of RenaissanceRe Holdings Ltd., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the year ended December 31, 2002, filed with the SEC on March 31, 2003 (SEC File Number 001-14428).10.11Amended and Restated Standby Letter of Credit Agreement, dated as of June 21, 2019, by and among Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Inc., DaVinci Reinsurance Ltd., RenaissanceRe Europe AG, RenaissanceRe Holdings Ltd., as Guarantor, and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on June 24, 2019.10.11(a)First Amendment to Amended and Restated Standby Letter of Credit Agreement, dated as of June 11, 2020, by and among Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Inc., DaVinci Reinsurance Ltd., RenaissanceRe Europe AG, RenaissanceRe Holdings Ltd., as Guarantor, and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the SEC on July 29, 2020.10.11(b)Second Amendment to Amended and Restated Standby Letter of Credit Agreement, dated as of May 5, 2022, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG, RenaissanceRe Specialty U.S. Ltd., RenaissanceRe Holdings Ltd., as Guarantor, and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Quarterly Report on Form 10-Q for the period ended September 30, 2022, filed with the SEC on November 2, 2022.11210.11(c)Third Amendment to Amended and Restated Standby Letter of Credit Agreement, dated February 22, 2023, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG, RenaissanceRe Specialty U.S. Ltd., RenaissanceRe Holdings Ltd. and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on February 22, 2023.10.11(d)Fourth Amendment to Amended and Restated Standby Letter of Credit Agreement, dated December 12, 2023, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG, RenaissanceRe Specialty U.S. Ltd., RenaissanceRe Holdings Ltd. and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on December 13, 2023.10.12Standby Letter of Credit Agreement, dated as of October 3, 2024, by and among Renaissance Reinsurance Ltd., RenaissanceRe Europe AG, RenaissanceRe Holdings Ltd., as Guarantor, and Nordea Bank Abp, New York Branch, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on October 3, 2024.10.13Third Amended and Restated Credit Agreement, dated November 18, 2022, among RenaissanceRe Holdings Ltd. Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG, the various lending financial institutions, Wells Fargo Bank, National Association, Barclays Bank PLC and Wells Fargo Securities, LLC, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 22, 2022.10.13(a)Guaranty Agreement, dated November 18, 2022, among RenaissanceRe Finance Inc., the various lending financial institutions and Wells Fargo Bank, National Association, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 22, 2022.10.14Facility Letter for Issuance of Payment Instruments, dated March 22, 2019, by and among Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG and Citibank Europe plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 25, 2019.10.14(a)Master Agreement for Issuance of Payment Instruments, dated March 22, 2019, between Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance U.S. Inc., RenaissanceRe Europe AG and Citibank Europe plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 25, 2019.10.14(b)Amendment to Master Agreement for Issuance of Payment Instruments, dated November 1, 2023, by and among Renaissance Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance U.S. Inc., and RenaissanceRe Europe AG, and Citibank Europe plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 2, 2023.10.14(c)Accession Undertaking, dated November 1, 2023, by and among Validus Reinsurance, Ltd., Validus Reinsurance (Switzerland) Ltd, and Citibank Europe Plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 2, 2023.11310.15Secured Facility Letter, dated December 19, 2022, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance of Europe Designated Activity Company, and Citibank Europe Plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 2, 2023.10.15(a)Deed of Amendment to Facility Letter (Committed), dated November 1, 2023, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance of Europe Designated Activity Company, and Citibank Europe Plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 2, 2023.10.15(b)Deed of Amendment to Facility Letter (Committed), dated December 23, 2024, by and among Renaissance Reinsurance Ltd., DaVinci Reinsurance Ltd., RenaissanceRe Specialty U.S. Ltd., Renaissance Reinsurance of Europe Designated Activity Company, and Citibank Europe Plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on December 23, 2024.10.15(c)Accession Letter, dated November 1, 2023, by and between Validus Reinsurance, Ltd. and Citibank Europe Plc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 2, 2023.10.16Waiver, dated as of November 15, 2016, by and between RenaissanceRe Holdings Ltd. and BlackRock, Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 18, 2016.10.17Waiver, dated as of May 11, 2018, by and between RenaissanceRe Holdings Ltd. and The Vanguard Group, Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on May 16, 2018.10.18Waiver, dated as of February 6, 2023, by and between RenaissanceRe Holdings Ltd. and T. Rowe Price Associates, Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the period ended December 31, 2022, filed with the SEC on February 8, 2023.10.19Reserve Development Agreement, dated as of March 22, 2019, by and between Tokio Millennium Re AG, and Tokio Millennium Re (UK) Limited and Tokio Marine & Nichido Fire Insurance Co., Ltd., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 22, 2019.10.20Retrocession Agreement, dated as of March 22, 2019, by and between Tokio Millennium Re AG and Tokio Marine & Nichido Fire Insurance Co., Ltd., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on March 22, 2019.10.21Registration Rights Agreement, dated as of November 1, 2023, between RenaissanceRe Holdings Ltd. and American International Group, Inc., incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Current Report on Form 8-K, filed with the SEC on November 1, 2023.19.1RenaissanceRe Holdings Ltd. Insider Trading Policy21.1List of Subsidiaries of the Registrant22.1Issuers of Registered Guaranteed Debt Securities23.1Consent of PricewaterhouseCoopers Ltd.31.1Certification of Kevin J. Oâ€™Donnell, Chief Executive Officer of RenaissanceRe Holdings Ltd., pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.11431.2Certification of Robert Qutub, Chief Financial Officer of RenaissanceRe Holdings Ltd., pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1Certification of Kevin J. Oâ€™Donnell, Chief Executive Officer of RenaissanceRe Holdings Ltd., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2Certification of Robert Qutub, Chief Financial Officer of RenaissanceRe Holdings Ltd., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.97.1RenaissanceRe Holdings Ltd. Policy on Recoupment of Incentive Compensation, incorporated by reference to RenaissanceRe Holdings Ltd.â€™s Annual Report on Form 10-K for the period ended December 31, 2023, filed with the SEC on February 21, 2024.101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema Document101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101)*Â Â Â Represents management contract or compensatory plan or arrangement.*Â Â Â Applicable to Ross A. Curtis and Robert Qutub.Â Â Â A Certain information in this exhibit has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.ITEMÂ 16. FORM 10-K SUMMARYNot applicable.115SIGNATURESPursuant to the requirements of SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Date:February 12, 2025RENAISSANCECERE HOLDINGS LTD./s/ Kevin J. Oâ€™DonnellKevin J. Oâ€™DonnellChief Executive Officer and PresidentPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.SignatureTitleDate/s/ Kevin J. Oâ€™DonnellChief Executive Officer, President and Director (Principal Executive Officer)February 12, 2025Kevin J. Oâ€™Donnell/s/ Robert QutubExecutive Vice President and Chief Financial Officer (Principal Financial Officer)February 12, 2025Robert Qutub/s/ James C. FraserSenior Vice President and Chief Accounting Officer (Principal Accounting Officer)February 12, 2025James C. Fraser/s/ James L. GibbonsNon-Executive Chair of the Board of DirectorsFebruary 12, 2025James L. Gibbons/s/ David C. BushnellDirectorFebruary 12, 2025David C. Bushnell/s/ Shyam GidumalDirectorFebruary 12, 2025Shyam Gidumal/s/ Duncan P. HennesDirectorFebruary 12, 2025Duncan P. Hennes/s/ Torsten JeworrekDirectorFebruary 12, 2025Torsten Jeworrek/s/ Henry Klehm, IIIDirectorFebruary 12, 2025Henry Klehm, III/s/ Loretta J. MesterDirectorFebruary 12, 2025Loretta J. Mester/s/ Valerie RahmaniDirectorFebruary 12, 2025Valerie Rahmani/s/ Carol P. SandersDirectorFebruary 12, 2025Carol P. Sanders/s/ Cynthia TrudellDirectorFebruary 12, 2025Cynthia TrudellÂ 116INDEX TO CONSOLIDATED FINANCIAL STATEMENTSPageReport of Independent Registered Public Accounting Firm (PCAOB ID: 1403)F-2Consolidated Balance Sheets at DecemberÂ 31, 2024 and 2023F-5Consolidated Statements of Operations for the Years Ended DecemberÂ 31, 2024, 2023 and 2022F-6Consolidated Statements of Comprehensive Income (Loss) for the Years Ended DecemberÂ 31, 2024, 2023 and 2022F-7Consolidated Statements of Changes in Shareholdersâ€™ Equity for the Years Ended DecemberÂ 31, 2024, 2023 and 2022F-8Consolidated Statements of Cash Flows for the Years Ended DecemberÂ 31, 2024, 2023 and 2022F-9Notes to the Consolidated Financial StatementsF-10Note 1. OrganizationF-10Note 2. Significant Accounting PoliciesF-10Note 3. Acquisition of ValidusF-16Note 4. Goodwill and Other Intangible AssetsF-21Note 5. InvestmentsF-24Note 6. Fair Value MeasurementsF-27Note 7. ReinsuranceF-38Note 8. Reserve for Claims and Claim ExpensesF-39Note 9. Debt and Credit FacilitiesF-53Note 10. Noncontrolling InterestsF-58Note 11. Variable Interest EntitiesF-61Note 12. Shareholdersâ€™ EquityF-66Note 13. Earnings per ShareF-68Note 14. Related Party TransactionsF-68Note 15. TaxationF-69Note 16. Segment ReportingF-72Note 17. Stock Incentive Compensation and Employee Benefit PlansF-76Note 18. Statutory RequirementsF-79Note 19. Derivative InstrumentsF-83Note 20. Commitments, Contingencies and Other ItemsF-89Note 21. Subsequent EventsF-91F-1Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of RenaissanceRe Holdings Ltd.Opinions on the Financial Statements and Internal Control over Financial ReportingWe have audited the accompanying consolidated balance sheets of RenaissanceRe Holdings Ltd. and its subsidiaries (the â€œCompanyâ€) as of DecemberÂ 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive income (loss), changes in shareholdersâ€™ equity, and cash flows for each of the three years in the period ended DecemberÂ 31, 2024, including the related notes and financial statement schedules listed in the index appearing on page S-1 (collectively referred to as the â€œconsolidated financial statementsâ€). We also have audited the Companyâ€™s internal control over financial reporting as of DecemberÂ 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of DecemberÂ 31, 2024 and 2023, and the results of its operations and its

flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO. Basis for Opinions The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. Definition and Limitations of Internal Control over Financial Reporting A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Critical Audit Matters The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Valuation of Reserve for Claims and Claim Expenses As described in Notes 2 and 8 to the consolidated financial statements, the Company's reserve for claims and claim expenses represents management's estimates, including actuarial and statistical projections at a given point in time, of the ultimate settlement and administration costs for unpaid claims and claim expenses arising from the insurance and reinsurance contracts the Company sells. The Company's reserve for claims and claim expenses was \$21.3 billion at December 31, 2024. In determining management's estimate of the reserve for claims and claim expenses, management's analysis includes consideration of loss development patterns, historical ultimate loss ratios, and the presence of individual large losses. Management's analysis incorporates available information derived from claims information from certain customers and brokers, industry assessments of losses, proprietary models, and the terms and conditions of the Company's contracts. The estimate for the casualty and specialty segment is sensitive to the selection of actuarial methods, expected trends in claim severity and frequency, the time lag inherent in reporting information, and industry or event trends. The estimate for the property segment is sensitive to the preliminary nature of the information available, the magnitude and relative infrequency of the events, the expected duration of the respective claims development period, inadequacies in the data provided to the relevant date by industry participants and the potential for further reporting lags or insufficiencies, and, in certain instances, significant uncertainty as to the form of the claims and legal issues under the relevant terms of insurance and reinsurance contracts. The principal considerations for our determination that performing procedures relating to the valuation of the reserve for claims and claim expenses is a critical audit matter are (i) the significant judgment by management when developing their estimate; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to loss development patterns, historical ultimate loss ratios, and the selection of significant actuarial methods; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the Company's valuation of the reserve for claims and claim expenses, including controls over the development of significant actuarial methods and assumptions. These procedures also included, among others, the involvement of professionals with specialized skill and knowledge to assist in (i) developing an independent estimate for certain reserve segments of the reserve for claims and claim expenses and comparing this independent estimate to management's determined F-3 reserve; and (ii) for certain reserve segments, testing management's process for estimating the reserve for claims and claim expenses by evaluating the appropriateness of management's aforementioned significant actuarial methods and assumptions. Performing these procedures involved testing the completeness and accuracy of data provided by management on a sample basis. /s/ PricewaterhouseCoopers Ltd. Hamilton, Bermuda February 12, 2025 We have served as the Company's auditor since 2022. F-4 RenaissanceRe Holdings Ltd. and Subsidiaries Consolidated Balance Sheets At December 31, 2024 and 2023 (in thousands of United States Dollars, except share and per share amounts) December 31, 2024 December 31, 2023 Assets Fixed maturity investments trading, at fair value - amortized cost \$23,750,540 at December 31, 2024 (2023 - \$20,872,450) (Notes 5 and 6) \$23,562,514 \$20,877,108 Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6) \$4,531,655 \$4,604,079 Equity investments, at fair value (Notes 5 and 6) \$117,756 \$106,766 Other investments, at fair value (Notes 5 and 6) \$324,761 \$315,566 Investments in other ventures, under equity method (Note 5) \$102,770 \$112,624 Total investments \$32,639,456 \$29,216,143 Cash and cash equivalents \$1,676,604 \$1,877,518 Premiums receivable (Note 7) \$29,228 \$28,682 Prepaid reinsurance premiums (Note 7) \$88,332 \$94,774 Reinsurance recoverable (Notes 7 and 8) \$44,481 \$39,054 \$34,286 Accrued investment income \$238,290 \$205,713 Deferred acquisition costs and value of business acquired \$1,552,359 \$1,751,437 Deferred tax asset (Note 15) \$701,053 \$685,040 Receivable for investments sold \$91,669 \$62,197 Other assets \$44,037 \$323,960 Goodwill and other intangible assets (Note 4) \$704,132 \$775,352 Total assets \$50,707,550 \$49,007,105 Liabilities, Noncontrolling Interests and Shareholders' Equity Liabilities Reserve for claims and claim expenses (Note 8) \$21,303,491 \$20,486,869 Unearned premiums \$950,415 \$613,135 Debt (Note 9) \$1,886,689 \$1,958,655 Reinsurance balances payable \$2,804,344 \$3,186,174 Payable for investments purchased \$150,721 \$661,611 Other liabilities \$1,060,129 \$1,021,872 Total liabilities \$33,155,789 \$33,451,316 Commitments and contingencies (Note 20) Redeemable noncontrolling interests (Note 10) \$6,977,749 \$6,100,831 Shareholders' Equity Preference shares: \$1.00 par value \$30,000 shares issued and outstanding at December 31, 2024 (2023 \$30,000) (Note 12) \$750,000 \$750,000 Common shares: \$1.00 par value \$50,180,987 shares issued and outstanding at December 31, 2024 (2023 \$52,693,887) (Note 12) \$125,018 \$125,694 Additional paid-in capital (Note 12) \$1,512,435 \$1,444,459 Accumulated other comprehensive income (loss) \$(14,756) \$(14,211) Retained earnings (Note 12) \$276,152 \$6,222,016 Total shareholders' equity attributable to RenaissanceRe \$10,574,012 \$9,454,958 Total liabilities, noncontrolling interests and shareholders' equity \$50,707,550 \$49,007,105 See accompanying notes to the consolidated financial statements F-5 RenaissanceRe Holdings Ltd. and Subsidiaries Consolidated Statements of Operations For the years ended December 31, 2024, 2023, and 2022 (in thousands of United States Dollars, except per share amounts) 2024 2023 2022 Revenues Gross premiums written (Note 7) \$1,733,066 \$8,862,366 \$9,213,540 Net premiums written (Note 7) \$9,952,216 \$7,467,813 \$7,196,160 Decrease (increase) in unearned premiums \$143,544 \$3,320 \$862,171 Net premiums earned (Note 7) \$10,095,760 \$7,471,133 \$6,333,989 Net investment income (Note 5) \$1,654,289 \$1,253,110 \$559,932 Net foreign exchange gains (losses) \$(76,076) \$(41,479) (\$6,909) Equity in earnings (losses) of other ventures (Note 5) \$47,087 \$43,474 \$11,249 Other income (loss) \$(1,928) \$(6,152) \$12,636 Net realized and unrealized gains (losses) on investments \$(32,981) \$3,573,509 \$4,338,840 Acquisition expenses \$2,643,867 \$1,875,034 \$1,568,606 Operational expenses \$496,588 \$375,182 \$276,691 Corporate expenses \$134,784 \$127,642 \$46,775 Interest expense (Note 9) \$93,768 \$73,181 \$48,335 Total expenses \$7,701,988 \$6,024,548 \$6,279,247 Income (loss) before taxes \$2,993,160 \$3,110,060 \$(1,218,835) Income tax benefit (expense) (Note 15) \$(32,628) \$(510,067) \$50,019 Net income (loss) \$2,960,532 \$3,620,127 \$(1,159,816) Net (income) loss attributable to redeemable noncontrolling interests (Note 10) \$(1,090,172) \$(1,058,995) \$98,613 Net income (loss) attributable to RenaissanceRe \$1,870,360 \$2,561,132 \$(1,061,203) Dividends on preference shares (Note 12) \$(35,375) \$(35,375) \$(35,375) Net income (loss) available (attributable) to RenaissanceRe common shareholders \$1,834,985 \$2,525,757 \$(1,096,578) Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share \$ basic (Note 13) \$35.314 \$52.404 \$(25.50) Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share \$ diluted (Note 13) \$35.214 \$52.274 \$(25.50) See accompanying notes to the consolidated financial statements F-6 RenaissanceRe Holdings Ltd. and Subsidiaries Consolidated Statements of Comprehensive Income (Loss) For the years ended December 31, 2024, 2023 and 2022 (in thousands of United States Dollars) 2024 2023 2022 Comprehensive income (loss) Net income (loss) \$2,960,532 \$3,620,127 \$(1,159,816) Change in net unrealized gains (losses) on investments, net of tax \$1,045,108 \$(4,923) Foreign currency translation adjustments, net of tax \$(1,590,169) \$370 Comprehensive income (loss) \$2,959,987 \$3,621,378 \$(1,164,369) Comprehensive (income) loss attributable to redeemable noncontrolling interests \$(1,090,172) \$(1,058,995) \$98,613 Comprehensive income (loss) attributable to RenaissanceRe \$1,869,815 \$2,562,383 \$(1,065,756) See accompanying notes to the consolidated financial statements F-7 RenaissanceRe Holdings Ltd. and Subsidiaries Consolidated Statements of Changes in Shareholders' Equity For the years ended December 31, 2024, 2023 and 2022 (in thousands of United States Dollars) 2024 2023 2022 Preference shares Balance \$1,750,000 \$750,000 \$750,000 Balance \$1,750,000 \$750,000 \$750,000 Common shares Balance \$1,750,000 \$750,000 \$750,000 Balance \$1,750,000 \$750,000 \$750,000 Issuance of shares (Note 12) \$1,628,209 \$1,628,209 \$1,628,209 Repurchase of shares (Note 12) \$(675,453) \$(161,788) Change in redeemable noncontrolling interest \$(5,029) \$(1,404) \$(5,549) Issuance of performance share and restricted stock awards (Notes 12 and 17) \$4

reinsurance recoverable and premiums receivable, including provisions for reinsurance recoverable and premiums receivable to reflect expected credit losses; estimates of written and earned premiums; fair value, including the fair value of investments, financial instruments and derivatives; impairment charges; deferred acquisition costs, the value of business acquired (â€œVOBAâ€) and the fair value of other assets acquired and liabilities assumed in acquisitions; and the Companyâ€™s deferred tax valuation allowance.Premiums and Related ExpensesPremiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are determined. Unearned premiums represent the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written.Acquisition costs are incurred when a contract or policy is issued and only the costs directly related to the successful acquisition of new and renewal contract or policies are deferred and amortized over the same period in which the related premiums are earned. Acquisition costs consist principally of commissions, brokerage and premium tax expenses and are shown net of commissions earned on ceded reinsurance. Certain of the Companyâ€™s assumed contracts contain profit sharing provisions or adjustable commissions that are estimated based on the expected loss and loss adjustment expense on those contracts. Acquisition costs include accruals for such estimates of commissions. Certain of the Companyâ€™s ceded contracts contain profit sharing provisions which accrue to the benefit of the Company. Acquisition costs are shown net of such commissions and profit commissions earned on ceded reinsurance. In addition, certain of the F-10Companyâ€™s ceded contracts contain override and management fees which are recorded as an offset against operational expenses. Deferred policy acquisition costs are limited to their estimated realizable value based on the related unearned premiums. Anticipated claims and claim expenses, based on historical and current experience, and anticipated investment income related to those premiums are considered in determining the recoverability of deferred acquisition costs.Claims and Claim ExpensesThe reserve for claims and claim expenses includes estimates for unpaid claims and claim expenses on reported losses as well as an estimate of losses incurred but not reported. The reserve is based on individual claims, case reserves and other reserve estimates reported by insureds and ceding companies as well as management estimates of ultimate losses. Inherent in the estimates of ultimate losses are expected trends in claim severity and frequency and other factors which could vary significantly as claims are settled. In addition, the Company does not have the benefit of a significant amount of its own historical experience in certain casualty and specialty and insurance lines of business. Accordingly, the reserving for incurred losses in these lines of business could be subject to greater variability.Ultimate losses may vary materially from the amounts provided in the consolidated financial statements. These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, are reflected in the consolidated statements of operations in the period in which they become known and are accounted for as changes in estimates.ReinsuranceAmounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, the Company accrues amounts (either assets or liabilities) that are due to or from retrocessionaires based on estimated contract experience. If the Company determines that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. Reinsurance recoverable on dual trigger reinsurance contracts require the Company to estimate its ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. Amounts recoverable from reinsurers are recorded net of a provision for current expected credit losses to reflect expected credit losses.Assumed and ceded reinsurance contracts that lack significant transfer of risk are treated as deposits.Certain assumed and ceded reinsurance contracts that do not meet all of the criteria to be accounted for as reinsurance in accordance with Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 944, Financial Services - Insurance have been accounted for at fair value under the fair value option in accordance with FASB ASC Topic 825, Financial Instruments.InvestmentsFixed Maturity InvestmentsInvestments in fixed maturities are classified as trading and are reported at fair value. Investment transactions are recorded on the trade date with balances pending settlement reflected in the balance sheet as a receivable for investments sold or a payable for investments purchased. Net investment income includes interest and dividend income together with amortization of market premiums and discounts and is net of investment management and custody fees. The amortization of premium and accretion of discount for fixed maturity securities is computed using the effective yield method. For mortgage-backed securities and other holdings for which there is prepayment risk, prepayment assumptions are evaluated quarterly and revised as necessary. Any adjustments required due to the change in effective yields and maturities are recognized on a prospective basis through yield adjustments. Fair values of investments are based on quoted market prices, or when such prices are not available, by reference to broker or underwriter bid indications and/or internal pricing valuation techniques. The net unrealized appreciation or depreciation on fixed maturity investments trading is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations. Realized gains or losses on the sale of investments are determined on the basis of the first in first out cost method.F-11Short Term InvestmentsShort term investments, which are managed as part of the Companyâ€™s investment portfolio and have a maturity of one year or less when purchased, are carried at fair value. The net unrealized appreciation or depreciation on short term investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.Equity InvestmentsEquity investments are accounted for at fair value in accordance with FASB ASC Topic 825, Financial Instruments. Fair values are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. Dividend income is included in net investment income and net realized and unrealized appreciation or depreciation on equity investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.Other InvestmentsThe Company accounts for its other investments at fair value in accordance with FASB ASC Topic 825, Financial Instruments with interest and dividend income included in net investment income. Realized and unrealized gains and losses on other investments are included in net realized and unrealized gains (losses) on investments. The fair value of the Companyâ€™s fund investments, which include private equity funds, private credit funds and hedge funds, is generally established on the basis of the net asset value (â€œNAVâ€) per share (or its equivalent) established by each respective fund investments manager, if applicable. The net asset value established by the respective fund investments manager is determined in accordance with the governing documents of such fund investments. The Company applies the practical expedient provided by the FASB ASC Topic 825, Financial Instruments relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of the fund investments based on that NAV per share, or its equivalent. Fund investments are recorded on the consolidated balance sheets in other investments. Fund investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy. Certain of the Companyâ€™s fund investment managers, or their fund administrators, are unable to provide final fund valuations as of the Companyâ€™s current reporting date. The Company typically experiences a reporting lag to receive a final net asset value report of one month for hedge funds and three months for both private equity funds and private credit funds, although the Company has occasionally experienced delays of up to six months, particularly at year end.In circumstances where there is a reporting lag between the current period end reporting date and the reporting date of the latest fund valuation, the Company estimates the fair value of these funds by starting with the prior month or quarter-end fund valuations, adjusting these valuations for actual capital calls, redemptions or distributions, as well as the impact of changes in foreign currency exchange rates, and then estimating the return for the current period. In circumstances in which the Company estimates the return for the current period, all information available to the Company is utilized. This principally includes using preliminary estimates reported to the Company by its fund managers, where available, and estimating returns based on the performance of broad market indices or other valuation methods. Actual final fund valuations may differ, perhaps materially so, from the Companyâ€™s estimates and these differences are recorded in the Companyâ€™s statement of operations in the period in which they are reported to the Company as a change in estimate. The Companyâ€™s other investments also include investments in catastrophe bonds, direct private equity investments and term loans which are recorded at fair value. The fair value of catastrophe bonds is based on broker or underwriter bid indications. The fair value of direct private equity investments is based on quoted prices for similar assets, where available, or on the use of internal valuation models.Investments in Other Ventures, Under Equity MethodInvestments in which the Company has significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, the Company records its proportionate share of income or loss from such investments in its statements of operations for the period. Additionally, the Company records its portion of any changes to the accumulated other comprehensive income or loss of the investee in the Companyâ€™s statements of comprehensive income (loss). If the Companyâ€™s proportionate F-12share of loss from such investment is in excess of the carrying value of such investment, the Company suspends the application of the equity method when the carrying value of the investment is reduced to zero, unless the Company has committed to provide further financial support to the investee. If the investee subsequently reports net income, the Company resumes applying the equity method only after its proportionate share of net income equals the proportionate share of net losses not recognized during the period the equity method was suspended. Any decline in value of investments in other ventures, under equity method considered by management to be other-than-temporary is charged to income in the period in which it is determined. Cash and Cash EquivalentsCash equivalents include money market instruments with a maturity of ninety days or less when purchased.Stock Incentive CompensationThe Company is authorized to issue restricted stock awards and units, performance shares, stock options and other equity-based awards to its employees and directors. The fair value of the compensation cost is measured at the grant date and expensed over the period for which the employee or director is required to provide services in exchange for the award.The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.DerivativesFrom time to time, the Company enters into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company accounts for its derivatives in accordance with FASB ASC Topic 815, Derivatives and Hedging, which requires all derivatives to be recorded at fair value on the Companyâ€™s balance sheet as either assets or liabilities, depending on their rights or obligations, with changes in fair value reflected in current earnings. The Company has adopted hedge accounting for certain of its derivative instruments used as hedges of a net investment in a foreign operation, as discussed below. The fair value of the Companyâ€™s derivatives is estimated by reference to quoted prices or broker quotes, where available, or in the absence of quoted prices or broker quotes, the use of industry or internal valuation models.Hedges of a Net Investment in a Foreign OperationChanges in the fair value of derivative instruments used to hedge the net investment in a foreign operation, to the extent effective as a hedge, are recorded as a component of accumulated other comprehensive income (loss) in foreign currency translation adjustments, net of tax. Cumulative changes in fair value recorded in accumulated other comprehensive income (loss) are reclassified into earnings upon the sale, or complete or substantially complete liquidation, of the foreign operation. Any hedge ineffectiveness is recorded immediately in current period earnings as net foreign exchange gains (losses). Hedge Documentation and Effectiveness TestingTo qualify for hedge accounting treatment, a derivative must be highly effective in mitigating the designated changes in value or cash flow of the hedged item. At the inception of a hedge, the Company formally documents relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking each hedge transaction. The documentation process includes linking derivatives that are designated as net investment hedges to specific assets or liabilities on the consolidated balance sheets. The Company also formally assesses, both at the hedgeâ€™s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the net investment in a foreign operation. The Company will discontinue hedge accounting prospectively if it determines that the derivative is no longer highly effective in offsetting changes in the net investment in a foreign operation, the derivative is no longer designated as a hedging instrument, or the derivative expires or is sold, terminated or exercised. If hedge accounting is discontinued, the derivative continues to be carried at fair value on the consolidated balance sheets with changes in its fair value recognized in current period earnings through net realized and unrealized gains (losses) on investments.F-13Fair Value OptionThe Company has elected to account for certain of its assets and liabilities at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement.Â The Company recognizes the change in unrealized gains and losses arising from changes in fair value in its statements of operations.Business Combinations, Goodwill and Other Intangible AssetsThe Company accounts for business combinations in accordance with FASB ASC Topic 805, Business Combinations, and goodwill and other intangible assets that arise from business combinations in accordance with FASB ASC Topic 350, Intangibles â€“ Goodwill and Other. A purchase price that is in excess of the fair value of the net assets acquired arising from a business combination is recorded as goodwill, and is not amortized. Other intangible assets with a finite life are amortized over the estimated useful life of the asset. Other intangible assets with an indefinite useful life are not amortized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining the fair value of net assets acquired. The significant assumptions include the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges.Goodwill and other intangible assets are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, goodwill is assigned to the applicable reporting unit of the acquired entities giving rise to the goodwill. Goodwill and other intangible assets recorded in connection with investments accounted for under the equity method, are recorded as investments in other ventures, under equity method on the Companyâ€™s consolidated balance sheets.The Company has established the second half of the year as the period for performing its annual impairment tests. The Company may determine to perform additional impairment testing at other times in the year if it is deemed necessary. The Company has elected to use the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. Under this option, the Company is not required to calculate the fair value of a reporting unit unless the Company determines, based on its qualitative assessment, that it is more likely than not that a reporting unitâ€™s fair value is less than its carrying amount. If goodwill or other intangible assets are impaired, they are written down to their estimated fair value with a corresponding expense reflected in the Companyâ€™s consolidated statements of operations.Noncontrolling InterestsThe Company accounts for redeemable noncontrolling interests in the mezzanine section of the Companyâ€™s consolidated balance sheets in accordance with United States Securities and Exchange Commission (â€œSECâ€) guidance which is applicable to SEC registrants. The share classes related to the redeemable noncontrolling interest portion of the issuer are accounted for in accordance with SEC guidance, which requires that shares not required to be accounted for in accordance with FASB ASC Topic 480, Distinguishing Liabilities from Equity, and having redemption features that are not solely within the control of the issuer, to be classified outside of permanent equity in the mezzanine section of the balance sheet. The SEC guidance does not impact the accounting for redeemable noncontrolling interest on the consolidated statements of operations; therefore, the provisions of FASB ASC Topic 810, Consolidation with respect to the consolidated statements of operations still apply, and net (income) loss attributable to redeemable noncontrolling interests is presented separately in the Companyâ€™s consolidated statements of operations.Variable Interest EntitiesThe Company accounts for variable interest entities (â€œVIEsâ€) in accordance with FASB ASC Topic 810, Consolidation, which requires the consolidation of all VIEs by the primary beneficiary, that being the investor that has the power to direct the activities of the VIE and that will absorb a portion of the VIEâ€™s expected losses or residual returns that could potentially be significant to the VIE. When the Company determines it has a variable interest in a VIE, it determines whether it is the primary beneficiary of that VIE by performing an analysis that principally considers: (i)Â the VIEâ€™s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders; (ii)Â the VIEâ€™s capital structure; (iii)Â the terms between the VIE and its variable interest holders and other parties involved with the VIE; (iv)Â which variable interest holders have the power to direct the activities of the VIE that most significantly impact the VIEâ€™s economic performance; (v)Â which variable interest holders have the obligation to absorb losses or the F-14right to receive benefits from the VIE that could potentially be significant to the VIE; and (vi)Â related party relationships. The Company reassesses its determination of whether the Company is the primary beneficiary of a VIE upon changes in facts and circumstances that could potentially alter the Companyâ€™s assessment.Earnings Per ShareThe Company calculates earnings per share in accordance with FASB ASC Topic 260, Earnings per Share. Basic earnings per share are based on weighted average common shares and exclude any dilutive effects of options and restricted stock. Diluted earnings per share assumes the exercise of all dilutive stock options and restricted stock grants.The two-class method is used to determine earnings per share based on dividends declared on common shares and participating securities (i.e., distributed earnings) and participation rights of participating securities in any undistributed earnings. Each unvested restricted share granted by the Company is considered a participating security and the Company uses the two-class method to calculate its net income (loss) available (attributable) to RenaissanceRe common shareholders per common share â€“ basic and diluted.Foreign ExchangeMonetary

assets and liabilities denominated in a currency other than the functional currency of the Company's subsidiaries in which those monetary assets and liabilities reside are revalued into such subsidiary's functional currency at the prevailing exchange rate on the balance sheet date. Revenues and expenses denominated in a currency other than the functional currency of the Company's subsidiaries, are valued at the exchange rate on the date on which the underlying revenue or expense transaction occurred. The net effect of these revaluation adjustments are recognized in the Company's consolidated statements of operations as part of net foreign exchange gains (losses). The Company's functional currency is the U.S. dollar. One of the Company's subsidiaries has a functional currency other than the U.S. dollar. Assets and liabilities of the foreign operation whose functional currency is not the U.S. dollar are translated into the Company's U.S. dollar reporting currency at prevailing balance sheet-date exchange rates, while revenue and expenses of such foreign operation are translated into the Company's U.S. dollar functional currency at monthly average exchange rates during the year. The net effect of these translation adjustments, as well as any gains or losses on intercompany balances for which settlement is not planned or anticipated in the foreseeable future, net of applicable deferred income taxes, is included in the Company's consolidated balance sheets as currency translation adjustments and reflected within accumulated other comprehensive income (loss). Taxation Income taxes have been provided for in accordance with the provisions of FASB ASC Topic 740, Income Taxes. Deferred tax assets and liabilities result from temporary differences between the amounts recorded in the consolidated financial statements and the tax basis of the Company's assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, deferred acquisition expenses, VOBA, intangible assets, value of in-force business, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances. Uncertain tax positions are also accounted for in accordance with FASB ASC Topic 740, Income Taxes. Uncertain tax positions must meet a more likely than not recognition threshold to be recognized. F-15 Recently Adopted Accounting Pronouncements Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (ASU 2023-07). Among other things, ASU 2023-07 improves the disclosures about a public entity's reportable segments and addresses investor requests for additional, more detailed information about a reportable segment's expenses. The amendments in ASU 2023-07 are effective for public business entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the annual reporting period beginning January 1, 2024. The adoption of ASU 2023-07 did not have a material impact on the Company's reportable segment disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). Among other things, ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in ASU 2023-09 are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this guidance. Disaggregation of Income Statement Expenses In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (ASU 2024-03). Among other things, ASU 2024-03 addresses investor requests for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly presented expense captions (such as cost of sales; selling, general and administrative expenses and research and development). The amendments in ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance. NOTE 3. ACQUISITION OF VALIDUS On November 1, 2023, the Company completed its acquisition in accordance with the Stock Purchase Agreement, dated May 22, 2023 (as amended, the "Stock Purchase Agreement"), between RenaissanceRe and American International Group, Inc., (AIG), pursuant to which, upon the terms and subject to the conditions thereof, RenaissanceRe, or one of its subsidiaries, purchased, acquired and accepted from certain subsidiaries of AIG, all of their right, title and interest in the shares of Validus Holdings, Ltd. (Validus Holdings), and Validus Specialty, LLC (Validus Specialty). Substantially all of the assets of Validus Holdings was comprised of its equity interest in its wholly-owned subsidiary, Validus Reinsurance, Ltd. (Validus Re). The Company also acquired the renewal rights, records and customer relationships of the assumed treaty reinsurance business of Talbot Underwriting Limited, an affiliate of AIG (Talbot), a specialty (re)insurance group operating within the Lloyd's market. The acquisitions under the Stock Purchase Agreement, together with the other transactions contemplated in the Stock Purchase Agreement, are referred to herein as the "Validus Acquisition." Validus Holdings, Validus Specialty, and their respective subsidiaries that were acquired in the Validus Acquisition (including Validus Re and Validus Holdings (UK) Ltd) collectively are referred to herein as "Validus." Pursuant to the Validus Acquisition, the Company acquired 100% voting equity interest in each of Validus Holdings and Validus Specialty. In connection with the Validus Acquisition, on November 1, 2023, the Company paid to AIG aggregate consideration of \$2.9854 billion, consisting of the following: (i) cash consideration of \$2.7354 billion; and (ii) 1,322,541 common shares, which were valued at approximately \$250.0A million based on a value of \$189.03 per share at signing, pursuant to the Stock Purchase Agreement. The value of the acquisition consideration was \$3,020 billion as of the closing date. The parties determined that no post-closing adjustment was required to the value of the acquisition consideration as of the closing date. F-16 In connection with the closing of the Validus Acquisition, the Company entered into a reserve development cover whereby the Validus risk-bearing entities agreed to cede to AIG substantially all of their adverse or favorable development on stated reserves at the time of the closing, subject to certain terms and conditions. Under the reserve development agreement AIG assumes substantially all of any favorable or adverse development on the stated reserves, on a whole-account basis, and takes into consideration adverse or favorable performance across the Company's reportable segments. To the extent the combined performance of the acquired reserve for claims and claim expenses is worse than expected on an aggregate basis across reportable segments, the Company is indemnified under the terms of the reserve development agreement and would expect to collect substantially all of the adverse development under the reserve development agreement. To the extent the combined performance of the acquired reserve for claims and claim expenses is better than expected on an aggregate basis across reportable segments, the Company would expect to pay substantially all of the favorable development to AIG under the reserve development agreement. The Company recorded \$61.9A million of corporate expenses associated with the acquisition of Validus during 2024 (2023 - \$76.4A million). Included in these expenses are compensation, transaction and integration-related costs. Acquisition Consideration The Company's total consideration for Validus was calculated as follows: RenaissanceRe Common Shares Common shares issued by RenaissanceRe to AIG 1,323A Common share price of RenaissanceRe (1)\$215.62A Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG \$285.168A Cash Consideration Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market \$1,351,608A Cash consideration funded by net proceeds from the issuance of Senior Notes 740,581A Cash consideration funded by available cash resources 642,811A Total cash consideration paid by RenaissanceRe as acquisition consideration 2,735,000A Total purchase price \$3,020,168A (1) A A A The common share price of RenaissanceRe is based on the closing price of \$226.97 per RenaissanceRe common share on the closing date of the Validus Acquisition, November 1, 2023 with a 5% discount to reflect restrictions on the transfer of those shares. F-17 Fair Value of Net Assets Acquired and Liabilities Assumed The purchase price was allocated to the acquired assets and liabilities of the Company based on estimated fair values on November 1, 2023, the date the transaction closed, as detailed in the table below: Assets: Cash and cash equivalents \$301,253A Investments trading 3,248,242A Short term investments 1,659,902A Investments in other ventures, under equity method 3,997A Reinsurance premiums receivable 2,014,359A Prepaid reinsurance premiums 126,750A Losses recoverable (1),297,270A Accrued investment income 21,441A Deferred acquisition costs and value of business acquired 617,000A Other assets 70,557A Identifiable intangible assets 460,884A Total assets 9,821,655A Liabilities: Reserve for claims and claim expenses (1),628,952A Reserve for unearned premiums 1,804,029A Reinsurance balances payable 298,003A Accounts payable and accrued liabilities 120,994A Deferred tax liability 39,157A Total liabilities 6,891,135A Total identifiable net assets acquired 2,930,520A Total purchase price 3,020,168A Goodwill \$89,648A (1) Includes the net fair value adjustment of \$192.0A million to net claims and claim expenses on November 1, 2023, which was made up of a \$76.8A million decrease to losses recoverable and a \$268.9A million decrease to reserve for claims and claim expenses. The goodwill represents the excess of the purchase price over the fair value of the underlying net assets acquired and liabilities assumed. The significant fair value adjustments and related future amortization are as follows: Deferred acquisition costs and VOBA - to reflect the elimination of Validus' net deferred acquisition costs, and the establishment of the value of business acquired asset, which represents the present value of the expected underwriting profit within the unearned premiums liability, net of reinsurance, less costs to service the related policies and a risk premium. The fair value of VOBA was determined after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio and related expenses. The adjustment for VOBA will be amortized to acquisition expenses over approximately two years, as the contracts for business in-force as of the acquisition date expire; Net reserve for claims and claim expenses - to reflect a decrease related to the present value of the net unpaid claims and claim expenses based on the estimated payout pattern, partially offset by an increase in net claims and claim expenses related to the estimated market-based risk margin. The risk margin represents the estimated cost of capital required by a market participant to assume the net claims and claim expenses. The fair value of net reserve for claims and claim expenses was F-18 determined using certain key assumptions, including the estimated cost of capital and investment yield. This will be amortized using the projected discount and risk margin patterns of the net claims and claim expenses as of the acquisition date; Identifiable indefinite lived and finite lived intangible assets - to establish the fair value of identifiable intangible assets related to the acquisition of Validus described in detail below; and Deferred tax liability - to reflect the net deferred tax liability on the intangible assets and the other fair value adjustments. Identifiable indefinite lived and finite lived intangible assets consisted of the following and are included in goodwill and other intangible assets on the Company's consolidated balance sheet: Amount Economic Useful Life Agent relationships - top four \$195,000A 15 years Agent relationships - other 9,000A 5 years Managing General Agent (MGA) relationships 3,000A 15 years Trade name 5,000A 0.5 years Renewal rights 215,000A 15 years Asset management contracts 20,000A 4 years Insurance licenses 13,884A Indefinite Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023 460,884A Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange 60,489A Impairment loss on insurance licenses 13,767A Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024 \$386,628A Amortization from the acquisition date, November 1, 2023, through December 31, 2023 was included in the Company's consolidated statements of operations for the year ended December 31, 2023. An explanation of the identifiable indefinite and finite intangible assets is as follows: Agent relationships - top four - the value of Validus' relationships with their top four brokers (Marsh & McLennan Companies, Inc., Aon Benfield Group Ltd., Willis Towers Watson PLC and Arthur J. Gallagher & Co.) after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years; Renewal rights - the value of policy renewal rights was determined after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges that would impact the expected cash flows from these renewals over the expected life of these policies. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years; and Insurance licenses - the value of acquired insurance licenses. Financial Results The following table summarizes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. Operating activities of Validus from the acquisition date, November 1, 2023, through December 31, 2023 are included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. F-19 The unaudited net contribution of the acquisition and integration of Validus is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that may be achieved in the future. These results are not used as a part of management's analysis of the financial performance of the Company's business. These results primarily reflect items recorded directly by Validus from November 1, 2023 through December 31, 2023, including: 1) net premiums earned and net underwriting income on the in-force portfolio acquired with the acquisition of Validus and previously retained on Validus entities' balance sheets; 2) net premiums earned and net underwriting income for those contracts which renewed post-acquisition on one of the acquired Validus entities' balance sheets; 3) net investment income and net realized and unrealized gains recorded directly by Validus; and 4) certain direct costs incurred directly by Validus. In addition, these results, where possible, were adjusted for transaction and integration related costs incurred by the Company. However, these results do not reflect on-going operating costs incurred by the Company in supporting Validus unless such costs were incurred directly by Validus. These results also do not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may be achieved in the future. These results involve significant estimates and are not indicative of the future results of the acquired Validus entities which have been, and will continue to be impacted by potential changes in targeted business mix, investment management strategies, and synergies recognized from changes in the combined entity's operating structure, as well as the impact of changes in other business and capital management strategies. Year ended December 31, 2023 (1) Total revenues \$696,888A Net income (loss) available (attributable) to RenaissanceRe common shareholders (2) \$307,802A (1) A A A Includes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) through December 31, 2023. (2) A A A Includes \$76.4 million of corporate expenses associated with the acquisition and integration of Validus for the year ended December 31, 2023. Taxation At the date of the acquisition the Company established a net deferred tax asset of \$73.0A million and recorded a valuation allowance against Validus' deferred tax assets of \$66.0A million resulting in a net acquired deferred tax asset of \$7.0A million. A net deferred tax liability of \$46.2A million was also recorded related to the estimated fair value of intangible assets recorded, VOBA and other adjustments to the fair values of the assets acquired and liabilities assumed. This resulted in a net deferred tax liability of \$39.2A million recorded in conjunction with the acquisition of Validus. The Company estimated that goodwill related to the acquisition of Validus Specialty of approximately \$24A million will be deductible for U.S. tax purposes resulting in an estimated future tax benefit of approximately \$5A million. Supplemental Pro Forma Information The following table presents unaudited pro forma consolidated financial information for the years ended December 31, 2023 and 2022, respectively, and assumes the acquisition of Validus occurred on January 1, 2022. The unaudited pro forma consolidated financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the transaction been completed as of January 1, 2022 or that may be achieved in the future. The unaudited pro forma consolidated financial information does not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may result from the acquisition of Validus. In addition, unaudited pro forma consolidated financial information does not include the effects of costs associated with any restructuring or integration activities resulting from the acquisition of Validus, as they are nonrecurring. Year ended December 31, 2023 2022 Total revenues \$1,611,682A \$7,169,338A Net income (loss) available (attributable) to RenaissanceRe common shareholders \$2,926,518A \$(1,552,425) F-20 Among other adjustments, and in addition to the fair value adjustments and recognition of goodwill, VOBA and identifiable intangible assets noted above, other material nonrecurring pro forma adjustments directly attributable to the acquisition of Validus principally included certain adjustments to recognize transaction related costs, align accounting policies, and amortize fair value adjustments, VOBA, and identifiable definite lived intangible assets, net of related tax impacts. Defined Benefit Pension Plan The Validus group entities have a contributory defined benefit pension plan for employees, which was not material to RenaissanceRe's results of operations, financial condition or cash flows for the year ended December 31, 2024. The plan offers mandatory benefits as prescribed by the applicable law, as well as voluntary benefits. These mandatory benefits include guarantees regarding the level of interest paid annually on accrued pension savings. The Validus group entities and the members of the plan contribute a defined percentage of salary to the pension arrangement and credit accumulation is granted on these contributions. At retirement, the accumulated contributions are converted into a pension. A full independent actuarial valuation is prepared annually. At December 31, 2024, the net balance sheet liability was \$1.6 million, comprising \$10.5 million of projected benefit obligation and \$8.8 million of plan assets at

fair value (2023 - \$1.1 million, \$9.8 million, and \$8.7 million, respectively).NOTE 4. GOODWILL AND OTHER INTANGIBLE ASSETSThe following tables show an analysis of goodwill and other intangible assets, net of foreign currency translation adjustments, included in goodwill and other intangible assets on the Company's consolidated balance sheets:Goodwill and Other Intangible AssetsAt December 31, 20242023Goodwill, net\$300,507A \$300,542A Other intangible assets, net\$403,625A 474,810A Total goodwill and other intangible assets\$704,132A \$775,352A Included in goodwill and other intangible assets on the Company's consolidated balance sheet at December 31, 2024 was gross goodwill of \$302.8 million (2023 - \$302.8 million, 2022 - \$213.2 million). Included in goodwill, net at December 31, 2024 was accumulated impairment losses of \$2.3 million (2023 - \$2.3 million). In addition, the Company has also recorded goodwill and other intangible assets included in investments in other ventures, under equity method on the Company's consolidated balance sheets:Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity MethodAt December 31, 20242023Goodwill, net\$8,724A \$10,808A Other intangible assets, net\$207A 7,260A Total goodwill and other intangible assets\$8,931A \$18,068A Included in investments in other ventures, under equity method on the Company's consolidated balance sheet at December 31, 2024 was gross goodwill of \$13.2 million (2023 - \$15.3 million, 2022 - \$14.4 million). Included in gross goodwill and gross other intangible assets was a reduction of \$2.1 million and \$6.9 million, respectively, related to a change in the classification of the Company's investment in TWFG, from investment in other ventures, under equity method to fair value, as a result of TWFG, Inc.'s initial public F-21 offering in 2024. Included in goodwill, net at December 31, 2024, was accumulated impairment losses of \$4.5 million (2023 - \$4.5 million). GoodwillThe following table shows a roll forward of goodwill included in goodwill and other intangible assets and goodwill included in investments in other ventures, under equity method on the Company's consolidated balance sheets:GoodwillGoodwill and Other Intangible AssetsGoodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity MethodBalance at December 31, 2022, net\$210,894A \$9,903A Acquired\$89,648A 905A Balance at December 31, 2023, net\$300,542A 10,808A Adjustments: - (2,084)Foreign currency translation(35) - A Balance at December 31, 2024, net\$300,507A \$8,724A Other Intangible AssetsThe gross carrying value, accumulated amortization and accumulated impairment losses by major category of other intangible assets included in goodwill and other intangible assets and investments in other ventures, under equity method on the Company's consolidated balance sheets are shown below:Other Intangible AssetsAt December 31, 2024GrossA CarryingA ValueAccumulatedAmortizationAccumulated Impairment LossesNetCustomer relationships and customer lists\$530,528A \$(150,051)\$(1,403)\$379,074A Licenses (1)30,951A - A (20,567)10,384A Value of business acquired20,000A (20,200) - A - A Asset management contracts20,000A (5,833) - A 14,167A Software12,230A (12,230) - A - A Patents and intellectual property4,500A (1,875)(2,625) - A Covenants not-to-compete4,030A (4,030) - A - A Trademarks and trade names6,710A (6,503) - A - A 207A \$629,149A (200,722)\$(24,595)\$403,832A (1)Licenses is comprised of \$10.4 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2024F-22Other Intangible AssetsAt December 31, 2023GrossA CarryingA ValueAccumulatedAmortizationAccumulated Impairment LossesNetCustomer relationships and customer lists\$530,704A \$(101,659)\$(1,550)\$427,495A Licenses (1)37,663A - A (6,653)31,010A Value of business acquired20,000A (20,200) - A - A Asset management contracts20,000A (833) - A 19,167A Software12,230A (12,230) - A - A Patents and intellectual property4,500A (1,875)(2,625) - A Covenants not-to-compete4,030A (4,030) - A - A Trademarks and trade names6,710A (2,312) - A 4,398A \$636,037A \$(143,139)\$(10,828)\$482,070A (1)Licenses is comprised of \$31.0 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2023During 2023, the Company recorded \$460.9 million of gross identifiable intangible assets identified in connection with the Validus Acquisition. See Note 3. Acquisition of Validus for additional information regarding the Validus Acquisition.The Company recorded amortization expense of \$57.6 million and an impairment loss of \$13.8 million related to other intangible assets during 2024 (2023 - \$13.6 million and \$Nil, respectively).In accordance with the Company's established accounting policy, the Company reviewed its finite lived intangible assets for indicators of impairment throughout 2024, testing for impairment as appropriate. During 2024, the Company amalgamated and merged certain Validus Re entities into the Company. As a result of management's review and analysis, it was determined that certain licenses associated with these entities were either cancelled upon amalgamation or merger, or that there was no new business written using these licenses in 2024, and no new business would be incepting using these licenses on a go forward basis. Accordingly, and in connection with the Company's impairment testing performed, it was determined that the licenses associated with these acquired Validus entities, which was initially reflected as an indefinite lived intangible asset of \$13.9 million at the time of the acquisition of Validus, should be written down to \$Nil. The Company recorded an intangible asset impairment charge of \$13.8 million during the year ended December 31, 2024.In performing the impairment assessment, the Company first assessed qualitative factors to determine whether it was necessary to perform a quantitative impairment test. Based on its qualitative assessment, the Company determined it was not more likely than not that the fair value of the goodwill and other intangible assets in question were less than their respective carrying amounts. The qualitative assessment included the following factors which the Company determined had not significantly deteriorated given specific facts and circumstances: macroeconomic conditions; industry and market conditions; costs factors; and overall financial performance. Other than the intangible assets impaired as noted above, and normal course amortization of intangible assets, in accordance with the Company's established accounting policy, there were no adjustments to carried goodwill and other intangible assets during the year ended December 31, 2024.F-23The remaining useful life of intangible assets with finite lives ranges from 0.2 to 13.8 years, with a weighted-average amortization period of 12.7 years. Expected amortization of the other intangible assets, including other intangible assets recorded in investments in other ventures, under equity method, is shown below:OtherIntangibles AssetsOther Intangible Assets Included in Investments in Other Ventures, Under Equity MethodTotal2025\$70,210A \$24A \$70,234A 202661,622A 24A 61,646A 202753,737A 24A 53,761A 202842,661A 24A 42,685A 202934,495A 24A 34,519A 2030 and thereafter130,516A 87A 130,603A Total remaining amortization expense\$393,241A 207A 393,448A Indefinite lived10,384A - A 10,384A Total\$403,625A 207A \$403,832A NOTE 5. INVESTMENTS Fixed Maturity Investments TradingThe following table summarizes the fair value of fixed maturity investments trading:At December 31, 20242023U.S. treasuries\$1,001,893A 10,060,203A Corporate (1)7,862,423A 6,499,075A Residential mortgage-backed1,707,056A 1,420,362A Asset-backed1,422,393A 1,491,695A Agencies623,489A 489,117A Non-U.S. government618,809A 483,576A Commercial mortgage-backed326,451A 433,080A Total fixed maturity investments trading\$23,562,514A \$20,877,108A (1)Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.Contractual maturities of fixed maturity investments trading are described in the following table. Expected maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.At December 31, 2024At December 31, 2023Amortized CostFair ValueAmortized CostFair ValueDue in less than one year\$1,374,089A \$1,373,838A \$587,720A \$582,519A Due after one through five years12,139,153A 12,131,114A 11,439,510A 11,468,263A Due after five through ten years6,339,563A 6,246,506A 5,182,667A 5,188,716A Due after ten years387,413A 355,156A 307,392A 292,473A Mortgage-backed2,094,190A 2,033,507A 1,864,520A 1,853,442A Asset-backed1,416,132A 1,422,393A 1,490,641A 1,491,695A Totals\$23,750,540A \$23,562,514A \$20,872,450A \$20,877,108A F-24Equity InvestmentsThe following table summarizes the fair value of equity investments:At December 31, 20242023Financials\$116,400A \$106,542A Basic materials\$95A - A Industrial, utilities and energy\$312A - A Communications and technology263A 12A Consumer154A 212A Healthcare232A - A Total\$117,756A \$106,766A Pledged InvestmentsAt December 31, 2024, \$10.3 billion (2023 - \$10.5 billion) of cash and investments at fair value were on deposit with, or in trust accounts for the benefit of, various counterparties, including with respect to the Company's letter of credit facilities. Of this amount, \$3.1 billion (2023 - \$2.9A billion) is on deposit with, or in trust accounts for the benefit of, U.S. state regulatory authorities.Reverse Repurchase AgreementsAt December 31, 2024, the Company held \$169.4 million (2023 - \$159.7 million) of reverse repurchase agreements. These loans are fully collateralized, are generally outstanding for a short period of time and are presented on a gross basis as part of short term investments on the Company's consolidated balance sheets. The required collateral for these loans typically includes high-quality, readily marketable instruments. Upon maturity, the Company receives principal and interest income.Net Investment IncomeThe components of net investment income are as follows:Year ended December 31, 202420232022Fixed maturity investments trading\$1,116,649A \$744,457A \$382,165A Short term investments\$183,153A 213,303A 41,042A Equity investments2,460A 7,261A 20,864A Other investmentsCatastrophe bonds\$238,844A 200,572A 94,784A Other\$2,457A 87,296A 37,497A Cash and cash equivalents\$54,214A 23,123A 5,197A 1,677,804A 1,276,012A 581,549A Investment expenses(23,515)(22,902)(21,617)Net investment income\$1,654,289A \$1,253,110A \$559,932A F-25Net Realized and Unrealized Gains (Losses) on InvestmentsNet realized and unrealized gains (losses) on investments are as follows:Year ended December 31, 202420232022Gross realized gains on fixed maturity investments trading\$142,243A \$80,905A \$38,781A Gross realized losses on fixed maturity investments trading(206,172)(473,946)(771,342)Net realized gains (losses) on fixed maturity investments trading(63,929)(393,041)(732,561)Net unrealized gains (losses) on fixed maturity investments trading(182,494)685,095A (636,762)Net realized and unrealized gains (losses) on fixed maturity investments trading(246,423)292,054A (1,369,323)Net realized and unrealized gains (losses) on investment-related derivatives (1)(57,279)(68,272)(165,293)Net realized gains (losses) on equity investments355A (27,492)43,035A Net unrealized gains (losses) on equity investments10,621A 73,243A (166,823)Net realized and unrealized gains (losses) on equity investments10,976A 45,751A (123,788)Net realized and unrealized gains (losses) on other investments - catastrophe bonds62,353A 101,897A (130,335)Net realized and unrealized gains (losses) on other investments - total(202,533A 43,092A (11,746)Net realized and unrealized gains (losses) on investments(27,840)(414,522A \$(1,800,485)(1)Net realized and unrealized gains (losses) on investment-related derivatives includes fixed maturity investments related derivatives, equity investments related derivatives and commodity related derivatives. See Note 19. Derivative Instruments for additional information.Other InvestmentsThe table below shows the fair value of the Company's portfolio of other investments:At December 31, 20242023Fund investments\$2,128,499A \$1,415,804A Catastrophe bonds1,984,396A 1,942,199A Direct private equity investments211,866A 59,905A Term loans - A 97,658A Total other investments\$4,324,761A \$3,515,566A During 2024, the Company recorded a net loss of \$9.7 million (2023 - loss of \$3.0 million, 2022 - income of \$19.8 million), representing the change between the Company's fair value estimate for funds as at the prior year end, and the final reported net asset values provided by the Company's fund investment managers, as discussed in Note 2. Significant Accounting Policies. - A This net loss was included between net investment income and net realized and unrealized gains (losses) on investments for the year ended December 31, 2024.The Company has committed capital to direct private equity investments, fund investments, term loans and investments in other ventures of \$4.5 billion, of which \$2.5 billion has been contributed at December 31, 2024 (2023 - \$3.6A billion and \$2.0A billion, respectively).The Company's remaining commitments to these investments at December 31, 2024 totaled \$2.0 billion (2023 - \$1.6A billion). In the future, the Company may enter into additional commitments for such investments.Fund InvestmentsFund investments are limited partnership or similar interests in private equity funds, private credit funds and hedge funds managed by unrelated third parties.F-26Catastrophe BondsCatastrophe bonds are non-investment grade bonds generally issued by unrelated third parties that generally mature within 1 to 5 years.Direct Private Equity InvestmentsDirect private equity investments are the Company's direct equity investments in companies that are not traded on any nationally recognized equity markets.Term LoansTerm loans represent the Company's participation interest in a senior secured term loan facility, which the Company disposed of during 2024. The Company had committed to a loan participation interest of \$100.0A million which was fully funded as at December 31, 2023. This facility paid interest, had a 5-year maturity and was fully secured by a diversified pool of primarily private equity assets.Investments in Other Ventures, under Equity MethodThe table below shows the Company's portfolio of investments in other ventures, under equity method:20242023At December 31, Ownership % CarryingA ValueOwnership % CarryingA ValueOwnership % CarryingA ValueInvestments in other ventures, under equity method0.1% - 50.0%\$102,770A 0.1% - 50.0%\$112,624A The table below shows the Company's equity in earnings (losses) of other ventures:Year ended December 31, 202420232022Equity in earnings (losses) of other ventures\$47,087A \$43,474A \$11,249A During 2024, the Company received \$109.8A million of distributions from its investments in other ventures, under equity method (2023 - \$41.4 million, 2022 - \$24.2 million). The equity in earnings (losses) of Top Layer Reinsurance Ltd. (a Top Layer Layer), a managed joint venture formed by the Company to write high excess non-U.S. property catastrophe reinsurance, is recorded on a current quarter basis. The equity in earnings (losses) of the Company's investments in other ventures are reported one quarter in arrears.NOTE 6. FAIR VALUE MEASUREMENTS The use of fair value to measure certain assets and liabilities with resulting unrealized gains or losses is pervasive within the Company's consolidated financial statements. Fair value is defined under accounting guidance currently applicable to the Company as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between open market participants at the measurement date. The Company recognizes the change in unrealized gains or losses arising from changes in fair value in its consolidated statements of operations. FASB ASC Topic 820, Fair Value Measurement prescribes a fair value hierarchy that prioritizes the inputs to the respective valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to valuation techniques that use at least one significant input that is unobservable (Level 3). The three levels of the fair value hierarchy are described below: - A Fair values determined by Level 1 inputs utilize unadjusted quoted prices obtained from active markets for identical assets or liabilities for which the Company has access at the measurement date. The fair value is determined by multiplying the quoted price by the quantity held by the Company; - A Fair values determined by Level 2 inputs utilize inputs (other than quoted prices included in Level 1) that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, such as interest rates and yield curves that are observable at commonly quoted intervals, broker quotes and certain pricing indices; and F-27 - A Level 3 inputs are based all or in part on significant unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. In these cases, significant management assumptions can be used to establish management's best estimate of the assumptions used by other market participants in determining the fair value of the asset or liability. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement of the asset or liability. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and the Company considers factors specific to the asset or liability. In order to determine if a market is active or inactive for a security, the Company considers a number of factors, including, but not limited to, the spread between what a seller is asking for a security and what a buyer is bidding for the same security, the volume of trading activity for the security in question, the price of the security compared to its par value (for fixed maturity investments), and other factors that may be indicative of market activity. There have been no material changes in the Company's valuation techniques, nor have there been any transfers between Level 1 and Level 2, or Level 2 and Level 3 during the period represented by these consolidated financial statements.F-28Below is a summary of the assets and liabilities that are measured at fair value on a recurring basis and also represents the carrying amount on the Company's consolidated balance sheets:At December 31, 2024TotalQuotedPrices in ActiveMarkets forIdentical Assets(Level 1)SignificantOtherObservableInputs(Level 2)SignificantUnobservableInputs(Level 3)Fixed maturity investments tradingU.S. treasuries\$11,001,893A \$11,001,893A - A - A Corporate (1)7,862,423A - A 7,862,423A - A Residential mortgage-backed1,707,056A - A 1,707,056A - A Asset-backed1,422,393A - A 1,422,393A - A Agencies623,489A - A 623,489A - A Non-U.S. government618,809A 618,809A - A Commercial mortgage-backed326,451A - A 326,451A - A Total fixed maturity investments trading\$23,562,514A 11,001,893A 12,560,621A - A Short term investments\$4,531,655A 99,343A 4,432,312A - A Equity investments\$117,756A 117,756A - A - A Other investmentsCatastrophe bonds1,984,396A - A 1,984,396A - A Direct private equity investments211,866A - A 168,089A 43,777A 2,152,485A 43,777A Fund investments (2)2,128,499A - A - A Total other investments\$4,324,761A - A 2,152,485A 43,777A Other assets and (liabilities)Assumed and ceded (re)insurance contracts (3)(405) - A - A (405)Derivative assets (4)34,538A 10,614A 23,924A - A Derivative liabilities (4)(75,878)(7,872)(68,006) - A Total other assets and (liabilities)(41,745)2,742A (44,082)(405A \$32,494,941A \$11,221,734A \$19,101,336A \$43,372A (1)Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.(2)Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.(3)Included in assumed and ceded (re)insurance contracts at December 31, 2024 was \$2.0

million of other assets and \$2.4 million of other liabilities.(4)Refer to Note 19. Derivative Instruments for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.F-29At December 31, 2023, Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fixed maturity investments trading U.S. treasuries \$10,060,203A \$10,060,203A \$ Corporate (1)6,499,075A \$ 6,499,075A \$ Asset-backed1,491,695A \$ 1,491,695A \$ A Residential mortgage-backed1,420,362A \$ 1,420,362A \$ A Agencies489,117A \$ 489,117A \$ A Non-U.S. government483,576A \$ 483,576A \$ A Commercial mortgage-backed433,080A \$ 433,080A \$ A Total fixed maturity investments trading20,877,108A \$ 20,060,203A \$ 10,186,905A \$ A Short term investments4,604,079A \$ 130,232A \$ 4,473,847A \$ A Equity investments106,766A \$ 106,766A \$ A Other investmentsCatastrophe bonds1,942,199A \$ 1,942,199A \$ A Term loans97,658A \$ 97,658A \$ Direct private equity investments59,905A \$ 59,905A \$ 2,099,762A \$ A 1,942,199A \$ 157,563A Fund investments (2)1,415,804A \$ 1,415,804A \$ A Total other investments3,515,566A \$ 1,942,199A \$ 157,563A Other assets and (liabilities)Assumed and ceded (re)insurance contracts (3)515,136A \$ 515,136A \$ (515)Derivative assets (4)44,724A \$ 16,701A \$ 28,023A \$ A Derivative liabilities (4)29,992(10,372)(19,620)\$ A Total other assets and (liabilities)14,217A \$ 6,329A \$ 4,034(515)A \$ 29,117,736A \$ 10,303,530A \$ 17,241,354A \$ 157,048A (1)Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.(2)Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.(3)Included in assumed and ceded (re)insurance contracts at December 31, 2023 was \$2.2 million of other assets and \$2.7 million of other liabilities.(4)Refer to Note 19. Derivative Instruments for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.Level 1 and Level 2 Assets and Liabilities Measured at Fair ValueFixed Maturity InvestmentsFixed maturity investments included in Level 1 consist of the Company's investments in U.S. treasuries. Fixed maturity investments included in Level 2 are agencies, corporate (including non-U.S. government-backed corporate), non-U.S. government, residential mortgage-backed, commercial mortgage-backed and asset-backed. The Company's fixed maturity investments are primarily priced using pricing services, such as index providers and pricing vendors, as well as broker quotations. In general, the pricing vendors provide pricing for a high volume of liquid securities that are actively traded. For securities that do not trade on an exchange, the pricing services generally utilize market data and other observable inputs in matrix pricing F-30models to determine month end prices. Observable inputs include benchmark yields, reported trades, broker-dealer quotes, issuer spreads, bids, offers, reference data and industry and economic events. Index pricing generally relies on market traders as the primary source for pricing; however, models are also utilized to provide prices for all index eligible securities. The models use a variety of observable inputs such as benchmark yields, transactional data, dealer runs, broker-dealer quotes and corporate actions. Prices are generally verified using third-party data. Securities which are priced by an index provider are generally included in the index. In general, broker-dealers value securities through their trading desks based on observable inputs. The methodologies include mapping securities based on trade data, bids or offers, observed spreads, and performance on newly issued securities. Broker-dealers also determine valuations by observing secondary trading of similar securities. Prices obtained from broker quotations are considered non-binding, however they are based on observable inputs and by observing secondary trading of similar securities obtained from active and non-distressed markets. The Company considers these broker quotations to be Level 2 inputs as they are corroborated with other market observable inputs. The techniques generally used to determine the fair value of the Company's fixed maturity investments are detailed below by asset class.U.S. TreasuriesLevel 1 - At December 31, 2024, the Company's U.S. treasuries fixed maturity investments were primarily priced by pricing services and had a weighted average yield to maturity of 4.4% and a weighted average credit quality of AA (2023 - 4.1% and AA, respectively). When pricing these securities, the pricing services utilize daily data from many real time market sources, including active broker-dealers. Certain data sources are regularly reviewed for accuracy to attempt to ensure the most reliable price source is used for each issue and maturity date.Level 2 - At December 31, 2024, the Company's corporate fixed maturity investments principally consisted of U.S. and international corporations and non-U.S. government-backed corporations and had a weighted average yield to maturity of 5.5% and a weighted average credit quality of BBB (2023 - 5.7% and BBB, respectively). The Company's corporate fixed maturity investments, other than non-U.S. government-backed corporations, are primarily priced by pricing services. When evaluating these securities, the pricing services gather information from market sources regarding the issuer of the security and obtain credit data, as well as other observations, from markets and sector news. Evaluations are updated by obtaining broker-dealer quotes and other market information including actual trade volumes, when available. The pricing services also consider the specific terms and conditions of the securities, including any specific features which may influence risk. In certain instances, securities are individually evaluated using a spread which is added to the U.S. treasury curve or a security specific swap curve as appropriate.Non-U.S. government-backed corporate fixed maturity investments are primarily priced by pricing services that employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high quality credits. The pricing services then apply a credit spread to the respective curve for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets.AgencyLevel 2 - At December 31, 2024, the Company's agency fixed maturity investments had a weighted average yield to maturity of 4.7% and a weighted average credit quality of AA (2023 - 4.6% and AA, respectively). The issuers of the Company's agency fixed maturity investments primarily consist of the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and other agencies. Fixed maturity investments included in agencies are primarily priced by pricing services. When evaluating these securities, the pricing services gather information from market sources and integrate other observations from markets and sector news. Evaluations are updated by obtaining broker-dealer quotes and other market information F-31including actual trade volumes, when available. The fair value of each security is individually computed using analytical models which incorporate option adjusted spreads and other daily interest rate data.Non-U.S. GovernmentLevel 2 - At December 31, 2024, the Company's non-U.S. government fixed maturity investments had a weighted average yield to maturity of 4.5% and a weighted average credit quality of AA (2023 - 4.4% and AA, respectively). The issuers of securities in this sector are non-U.S. governments and their respective agencies as well as supranational organizations. Securities held in these sectors are primarily priced by pricing services that employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high issuance credits. The pricing services then apply a credit spread for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets.Residential Mortgage-backedLevel 2 - At December 31, 2024, the Company's residential mortgage-backed fixed maturity investments had a weighted average yield to maturity of 5.4%, a weighted average credit quality of AA, and a weighted average life of 7.7 years (2023 - 5.1%, AA and 7.7 years, respectively). Residential mortgage-backed securities include both agency and non-agency mortgage-backed securities. The Company's agency mortgage-backed fixed maturity investments are primarily priced by pricing services using a mortgage pool specific model which utilizes daily inputs from the active to-be-announced market which is very liquid, as well as the U.S. treasury market. The model also utilizes additional information, such as the weighted average maturity, weighted average coupon and other available pool level data which is provided by the sponsoring agency. Valuations are also corroborated with active market quotes. Non-agency mortgage-based securities are primarily priced by pricing services using an option adjusted spread model or other relevant models, which principally utilize inputs including benchmark yields, available trade information or broker quotes, and issuer spreads. The pricing services also review collateral prepayment speeds, loss severity and delinquencies among other collateral performance indicators for the securities valuation, when applicable.Commercial Mortgage-backedLevel 2 - At December 31, 2024, the Company's commercial mortgage-backed fixed maturity investments had a weighted average yield to maturity of 5.7%, a weighted average credit quality of AAA, and a weighted average life of 3.8 years (2023 - 8.8%, AAA and 2.2 years, respectively). Securities held in these sectors are primarily priced by pricing services. The pricing services apply dealer quotes and other available trade information such as bids and offers, prepayment speeds which may be adjusted for the underlying collateral or current price data, the U.S. treasury curve and swap curve as well as cash settlement. The pricing services discount the expected cash flows for each security held in this sector using a spread adjusted benchmark yield based on the characteristics of the security.Asset-backedLevel 2 - At December 31, 2024, the Company's asset-backed fixed maturity investments had a weighted average yield to maturity of 5.9%, a weighted average credit quality of AAA and a weighted average life of 4.7 years (2023 - 7.0%, AA and 3.9 years, respectively). The underlying collateral for the Company's asset-backed fixed maturity investments primarily consists of collateralized loan obligations and other receivables. Securities held in these sectors are primarily priced by pricing services. The pricing services apply dealer quotes and other available trade information such as bids and offers, prepayment speeds which may be adjusted for the underlying collateral or current price data, the U.S. treasury curve and swap curve as well as cash settlement. The pricing services determine the expected cash flows for each security held in this sector using historical prepayment and default projections for the underlying collateral and current market data. In addition, a spread is applied to the relevant benchmark and used to discount the cash flows noted above to determine the fair value of the securities held in this sector.F-32Short Term InvestmentsLevel 1 - At December 31, 2024, the Company's short term investments in U.S. treasuries were primarily priced by pricing services and had a weighted average yield to maturity of 4.2% and a weighted average credit quality of AA (2023 - 5.3% and AAA, respectively). When pricing these securities, the pricing services utilize daily data from many real time market sources, including active broker-dealers. Certain data sources are regularly reviewed for accuracy to attempt to ensure the most reliable price source is used for each issue and maturity date.Level 2 - At December 31, 2024, the Company's other short term investments had a weighted average yield to maturity of 4.4% and a weighted average credit quality of AAA (2023 - 5.3% and AAA, respectively). Amortized cost approximates fair value for the majority of the remainder of the Company's short term investments portfolio and, in certain cases, fair value is determined in a manner similar to the Company's fixed maturity investments noted above.Equity InvestmentsLevel 1 - The fair value of the Company's portfolio of equity investments are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. When pricing these securities, the pricing services utilize daily data from many real time market sources, including applicable securities exchanges. All data sources are regularly reviewed for accuracy to attempt to ensure the most reliable price source was used for each security.Other InvestmentsCatastrophe BondsLevel 2 - The Company's other investments include investments in catastrophe bonds which are recorded at fair value based on broker or underwriter bid indications.Direct Private Equity InvestmentsLevel 2 - At December 31, 2024, the Company's other investments included \$168.1 million (2023 - \$Nil) of direct private equity investments which are recorded at fair value based on quoted prices for similar assets.Other Assets and LiabilitiesDerivativesLevel 1 and Level 2 - Other assets and liabilities include certain derivatives entered into by the Company. The fair value of these transactions includes certain exchange traded futures and options contracts which are considered Level 1, and foreign currency contracts and certain credit derivatives, determined using standard industry valuation models and considered Level 2, as the inputs to the valuation model are based on observable market inputs. For credit derivatives, these inputs include credit spreads, credit ratings of the underlying referenced security, the risk-free rate and the contract term. For foreign currency contracts, these inputs include spot rates and interest rate curves.F-33Level 3 Assets and Liabilities Measured at Fair ValueBelow is a summary of quantitative information regarding the significant unobservable inputs (Level 3) used in determining the fair value of assets and liabilities measured at fair value on a recurring basis:At December 31, 2024Fair Value (Level 3)Valuation TechniqueUnobservable InputsWeighted Average or ActualOther investmentsDirect private equity investments\$43,777A Internal valuation modelDiscount rate10.0A %Liquidity discount15.0A %Total other investments43,777A Other assets and (liabilities)Assumed and ceded (re)insurance contracts(405)Internal valuation modelNet undiscounted cash flows\$12,657A Expected loss ratio1.2A %Discount rate4.4A %Total other assets and (liabilities)(405)Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs\$43,372A At December 31, 2023Fair Value (Level 3)Valuation TechniqueUnobservable InputsWeighted Average or ActualOther investmentsDirect private equity investments\$59,905A Internal valuation modelDiscount rate10.0A %Liquidity discount15.0A %Term loans97,658A Discounted cash flowCredit spread adjustment0.2A %Risk premium2.6A %Total other investments157,563A Other assets and (liabilities)Assumed and ceded (re)insurance contracts(515)Internal valuation modelNet undiscounted cash flows\$12,478A Expected loss ratio2.3A %Discount rate3.8A %Total other assets and (liabilities)(515)Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs\$157,048A F-34Below is a reconciliation of the beginning and ending balances, for the periods shown, of assets and liabilities measured at fair value on a recurring basis using Level 3 inputs.A At Other InvestmentsDirect Private Equity InvestmentsTerm LoansOther Assets and LiabilitiesTotalBalance - January 1, 2024\$59,905A \$97,658A \$(515)\$157,048A Net investment income258A \$ A \$ 258A Net realized and unrealized gains (losses) on investments(16,686)\$ A \$ (16,686)Other income (loss)\$ A \$ 252A 252A Net foreign exchange gains (losses)(7)\$ A \$ (7)Purchases577A \$ A 3,640A 4,217A Sales(270)(94,321)(3,626)(98,217)Settlements\$ A (3,337)(156)(3,493)Balance - December 31, 2024\$43,777A \$ A \$(405)\$43,372A At Other InvestmentsDirect Private Equity InvestmentsTerm LoansOther Assets and LiabilitiesTotalBalance - January 1, 2023\$66,780A \$100,000A \$(1,832)\$164,948A Net investment income250A \$ A \$ 250A Net realized and unrealized gains (losses) on investments(7,120)\$ A \$ (7,120)Other income (loss)\$ A \$ (492)(492)Net foreign exchange gains (losses)(5)\$ A \$ (5)Purchases\$ A \$ 1,809A 1,809A Settlements\$ A (2,342)\$ A (2,342)Balance - December 31, 2023\$59,905A \$97,658A \$(515)\$157,048A Other InvestmentsDirect Private Equity InvestmentsLevel 3 - At December 31, 2024, the Company's other investments included \$43.8 million (2023 - \$59.9 million) of direct private equity investments which are recorded at fair value, with the fair value obtained through the use of internal valuation models. The Company measured the fair value of these investments using multiples of net tangible book value of the underlying entities. The significant unobservable inputs used in the fair value measurement of these investments are liquidity discount rates applied to each of the net tangible book value multiples used in the internal valuation models, and discount rates applied to the expected cash flows of the underlying entities in various scenarios. These unobservable inputs in isolation can cause significant increases or decreases in fair value. Generally, an increase in the liquidity discount rate or discount rates would result in a decrease in the fair value of these private equity investments.Term LoansLevel 3 - During 2024, the Company disposed of its investment in a term loan. At December 31, 2023, the Company's other investments included a \$97.7 million investment which was recorded at fair value, with the fair value obtained through the use of a discounted cash flow model. The significant unobservable inputs used in the discounted cash flow model were the cash flow projection of the associated term loan, and the discount rate. The discount rate used was based on the Secured Overnight Financing Rate (SOFR), which was then adjusted for credit risk and a risk premium. These adjustments may be impacted by market movements implied by transactions of similar or related assets, loan-to-value, tenor, liquidity, credit risk F-35adjustment or other risk factors. Assumptions used in the valuation process may significantly impact the resulting fair value.Other Assets and LiabilitiesAssumed and Ceded (Re)Insurance ContractsLevel 3 - At December 31, 2024, the Company had a \$0.4 million net liability (2023 - \$0.5 million net liability) related to assumed and ceded (re)insurance contracts accounted for at fair value, with the fair value obtained through the use of an internal valuation model. The inputs to the internal valuation model are principally based on proprietary data as observable market inputs are generally not available. The most significant unobservable inputs include the assumed and ceded expected net cash flows related to the contracts, including the expected premium, acquisition expenses and losses; the expected loss ratio and the relevant discount rate used to present value the net cash flows. The contract period and acquisition expense ratio are considered an observable input as each is defined in the contract. Generally, an increase in the net expected cash flows and expected term of the contract and a decrease in the discount rate, expected loss ratio or acquisition expense ratio, would result in an increase in the expected profit and ultimate fair value of these assumed and ceded (re)insurance contracts.Financial Instruments Disclosed, But Not Carried, at Fair ValueThe Company uses various financial instruments in the normal course of its business. The Company's (re)insurance contracts are excluded from the fair value of financial instruments accounting guidance, unless the Company elects the fair value option, and therefore, are not included in the amounts discussed herein. The carrying values of cash and cash equivalents, accrued investment income, receivables for investments sold, certain other assets, payables for investments purchased, certain other liabilities, and other financial instruments not included herein approximated their fair values. DebtIncluded on the Company's consolidated balance sheet at December 31, 2024 were debt obligations of \$1.9 billion (2023 - \$2.0 billion). At December 31, 2024, the fair value of the Company's debt obligations was \$1.9 billion (2023 - \$1.9 billion). The fair value of the Company's debt obligations is determined using indicative market pricing obtained from third-party service providers, which the

Company considers Level 2 in the fair value hierarchy. There have been no changes during the period in the Company’s valuation technique used to determine the fair value of the Company’s debt obligations. Refer to Note 9. Debt and Credit Facilities for additional information related to the Company’s debt obligations. The Fair Value Option for Financial Assets and Financial Liabilities The Company has elected to account for certain financial assets and financial liabilities at fair value using the guidance under FASB ASC Topic 825, Financial Instruments as the Company believes it represents the most meaningful measurement basis for these assets and liabilities. Below is a summary of the balances the Company has elected to account for at fair value: At December 31, 2024 2023 Other investments \$4,324,761A \$3,515,566A Other assets \$2,029A \$2,227A Other liabilities \$2,434A \$2,742A The change in fair value of other investments resulted in net unrealized gains on investments in 2024 of \$243.8 million (2023) gains of \$137.3 million, 2022) losses of \$181.2 million). F-36 Measuring the Fair Value of Other Investments Using Net Asset Valuations The table below shows the Company’s portfolio of other investments measured using net asset valuations as a practical expedient: At December 31, 2024 Fair Value Unfunded Commitments Redemption Frequency Redemption Notice Period (Minimum Days) Redemption Notice Period (Maximum Days) Private credit funds \$1,181,146A \$1,284,699A See below See below Private equity funds \$609,105A \$646,234A See below See below Hedge funds \$38,248A) See below See below See below Total other investments measured using net asset valuations \$2,128,499A \$1,948,933A At December 31, 2023 Fair Value Unfunded Commitments Redemption Frequency Redemption Notice Period (Minimum Days) Redemption Notice Period (Maximum Days) Private credit funds \$982,016A \$949,135A See below See below Private equity funds \$433,788A \$673,778A See below See below Total other investments measured using net asset valuations \$1,415,804A \$1,622,913A Private Credit Funds The Company’s investments in private credit funds include limited partnership or similar interests that invest in certain private credit asset classes, including U.S. direct lending funds, secondaries, mezzanine investments, distressed securities and senior secured bank loan funds. The Company generally has no right to redeem its interest in any of these private credit funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the liquidation or maturity of the underlying private credit assets of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership. Private Equity Funds The Company’s investments in private equity funds include limited partnership or similar interests that invest in certain private equity asset classes including U.S. and global leveraged buyouts. The Company generally has no right to redeem its interest in any of these private equity funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the exit from the underlying private equity investments of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership. Hedge Funds The Company’s investments in hedge funds are primarily focused on global multi-strategy opportunities. These investments are generally redeemable at the option of the Company, at less than a month’s notice. Certain restrictions on redemptions, including initial lock-up periods or redemption gates, may also apply to the Company, as defined by each fund’s governing documents. Redemption gates allow the investment manager of a fund to defer part or all of a redemption request so as to not negatively impact the value of the redemption or the value of any interests that remain in the fund. Limited Partnerships Entities The Company’s fund investments, included within other investments, are primarily variable interests in limited partnerships entities with unaffiliated fund managers in the normal course of business. The Company determined that certain of these interests represent investments in the VIEs and that it is not required to F-37 consolidate these investments because it is not the primary beneficiary of these VIEs. The Company’s maximum exposure to loss with respect to these VIEs is limited to the carrying amounts reported in the Company’s consolidated balance sheets and any unfunded commitment. The following table summarizes the aggregate carrying amount of the unconsolidated fund investments in VIEs, as well as the Company’s maximum exposure to loss associated with these VIEs: Maximum Exposure to Loss Other Investments Carrying Amount Unfunded Commitments Total At December 31, 2024 \$1,993,362A \$1,863,142A \$3,856,504A At December 31, 2023 \$1,251,799A \$1,550,452A \$2,802,251A NOTE 7. REINSURANCE The Company purchases reinsurance and other protection to manage its risk portfolio and to reduce its exposure to large losses. The Company currently has in place contracts that provide for recovery of a portion of certain claims and claim expenses, generally in excess of various retentions or on a proportional basis. In addition to loss recoveries, certain of the Company’s ceded reinsurance contracts provide for payments of additional premiums, for reinstatement premiums and for lost no-claims bonuses, which are incurred when losses are ceded to the respective reinsurance contracts. The Company remains liable to the extent that any reinsurer fails to meet its obligations. The following table sets forth the effect of reinsurance and retrocessional action on premiums written and earned and on net claims and claim expenses incurred: Year ended December 31, 2024 2023 2022 Premiums Written Direct \$1,197,360A \$865,771A \$1,264,410A Assumed \$10,535,706A 7,996,595A 7,949,130A Ceded (1,780,850) (1,394,553) (2,017,380) Net premiums written \$9,952,216A \$7,467,813A \$7,196,160A Premiums Earned Direct \$1,097,726A \$1,013,372A \$1,105,164A Assumed \$10,815,336A 8,072,193A 7,079,632A Ceded (1,817,302) (1,614,432) (1,850,807) Net premiums earned \$10,955,760A \$7,471,133A \$6,333,989A Claims and Claim Expenses Gross claims and claim expenses incurred \$5,629,756A \$3,950,362A \$5,851,140A Claims and claim expenses recovered (296,775) (376,853) (1,512,300) Net claims and claim expenses incurred \$5,332,981A \$3,573,509A \$4,338,840A In assessing an allowance for reinsurance assets, which includes premiums receivable and reinsurance recoverable, the Company considers historical information, financial strength of reinsurers, collateralization amounts, and counterparty credit ratings to determine the appropriateness of the allowance. In assessing future default for reinsurance assets, the Company evaluates the provision for current expected credit losses under the probability of default and loss given default method. The Company utilizes its internal capital and risk models, which use counterparty ratings from major rating agencies, and assesses the current market conditions for the likelihood of default. The Company updates its internal capital and risk models for counterparty credit ratings and current market conditions on a periodic basis. Historically, the Company has not experienced material credit losses from reinsurance assets. Premiums receivable reflect premiums written based on contract and policy terms and include estimates based on information received from both insureds and ceding companies, supplemented by the Company’s estimates of premiums that are written but not reported. Due to the nature of reinsurance, ceding F-38 companies routinely report and remit premiums subsequent to the contract coverage period, although the time lag involved in the process of reporting and collecting premiums is typically shorter than the lag in reporting losses. At December 31, 2024, the Company’s premiums receivable balance was \$7.3 billion (2023 - \$7.3 billion). Of the Company’s premiums receivable balance as of December 31, 2024, the majority are receivable from highly rated counterparties. The provision for current expected credit losses on the Company’s premiums receivable was \$4.6 million at December 31, 2024 (2023 - \$3.5 million). The following table provides a roll forward of the provision for current expected credit losses of the Company’s premiums receivable: Year ended December 31, 2024 2023 Beginning balance \$3,514A \$4,606A Provision for (release of) allowance (1,117A) (2,788) Amounts acquired (1)) Ending balance \$4,631A \$3,514A (1) Represents Validus’s provision for current expected credit losses on premiums receivable, acquired November 1, 2023. Reinsurance recoverable reflects amounts due from reinsurers based on the claim liabilities associated with the reinsurance policy. The Company accrues amounts that are due from reinsurers based on estimated ultimate losses applicable to the contracts. At December 31, 2024, the Company’s reinsurance recoverable balance was \$4.5 billion (2023 - \$5.3 billion). Of the Company’s reinsurance recoverable balance at December 31, 2024, 55.7% is fully collateralized by the Company’s reinsurers, 43.2% is recoverable from reinsurers rated A- or higher by major rating agencies and 1.0% is recoverable from reinsurers rated lower than A- by major rating agencies (2023 - 60.6%, 38.5% and 0.9%, respectively). The reinsurers with the three largest balances accounted for 12.6%, 11.0% and 8.3%, respectively, of the Company’s reinsurance recoverable balance at December 31, 2024 (2023 - 17.6%, 14.3% and 8.7%, respectively). The provision for current expected credit losses was \$11.7 million at December 31, 2024 (2023 - \$13.3 million). The three largest company-specific components of the provision for current expected credit losses represented 23.9%, 7.2% and 5.9%, respectively, of the Company’s total provision for current expected credit losses at December 31, 2024 (2023A - 10.9%, 10.7% and 8.1%, respectively). The following table provides a roll forward of the provision for current expected credit losses of the Company’s reinsurance recoverable: Year ended December 31, 2024 2023 Beginning balance \$13,279A \$12,169A Provision for (release of) allowance (1,549) (3,644) Amounts acquired (1)) Ending balance \$11,730A \$13,279A (1) Represents Validus’s provision for current expected credit losses on reinsurance recoverable, acquired November 1, 2023. NOTE 8. RESERVE FOR CLAIMS AND CLAIM EXPENSES The Company believes the most significant accounting judgment made by management is its estimate of claims and claim expense reserves. Claims and claim expense reserves represent estimates, including actuarial and statistical projections at a given point in time, of the ultimate settlement and administration costs for unpaid claims and claim expenses arising from the insurance and reinsurance contracts the Company sells. The Company’s reserve for claims and claim expenses are a combination of case reserves, additional case reserves () and incurred but not reported losses and incurred but not enough reported losses (collectively referred to as). Case reserves are losses reported to the Company by insureds and ceding companies, but which have not yet been paid. If deemed necessary and in certain situations, either the Company establishes, or the Company’s clients report, ACR. Client reported ACR represents the client’s estimate of additional contract specific claims in excess of the case reserves they have reported to the Company. ACR established by the Company represents the Company’s estimates for claims related to specific contracts which the Company believes may not be adequately estimated by the client as of that F-39 date or is not within the IBNR. The Company establishes IBNR using actuarial techniques and expert judgment to represent the anticipated cost of claims which have not been reported to the Company yet, or where the Company anticipates increased reporting. The Company’s reserving committee, which includes members of the Company’s senior management, reviews, discusses, and assesses the reasonableness and adequacy of the reserving estimates included in the audited consolidated financial statements. The following table summarizes the Company’s reserve for claims and claim expenses by segment, allocated between case reserves, ACR and IBNR: At December 31, 2024 Case Reserves Additional Case Reserves IBNR Total Property \$1,845,228A \$1,905,553A \$2,821,958A \$6,572,739A Casualty and Specialty 3,081,081A 295,074A 11,354,597A 14,730,752A Total \$4,926,309A \$2,200,627A \$14,176,555A \$21,303,491A At December 31, 2023 Property (\$2,461,580A \$2,401,911A \$2,970,129A \$7,833,620A Casualty and Specialty (12,801,016A 331,345A 9,520,888A 12,653,249A Total \$5,262,596A \$2,733,256A \$12,491,017A \$20,486,869A (1) The previously reported amount has been adjusted to reclassify certain reserves from IBNR to ACR. Activity in the reserve for claims and claim expenses is summarized as follows: Year ended December 31, 2024 2023 2022 Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period \$15,142,583A \$11,181,648A \$9,025,961A Net incurred related to: Current year 6,184,315A 4,024,116A 4,586,422A Prior years (851,334) (450,607) (247,582) Total net incurred \$5,332,981A 3,573,509A 4,338,840A Net paid related to: Current year 488,450A 364,793A 105,885A Prior years 3,109,360A 2,630,885A 1,924,271A Total net paid \$3,597,810A 2,995,678A 2,030,156A Foreign exchange and other (1) (55,653) 62,902A (152,997) Amounts acquired (2)) Reserve for claims and claim expenses, net of reinsurance recoverable, end of period \$16,822,101A 15,142,583A 11,181,648A Reinsurance recoverable, end of period 4,481,390A 5,344,286A 4,710,925A Reserve for claims and claim expenses, end of period \$21,303,491A \$20,486,869A \$15,892,573A (1) Reflects the impact of the foreign exchange revaluation of the reserve for claims and claim expenses, net of reinsurance recoverable, denominated in non-U.S. dollars as at the balance sheet date, as well as reinsurance transactions accounted for under retroactive reinsurance accounting. (2) Represents the fair value of Validus’s reserve for claims and claim expenses, net of reinsurance recoverable, acquired on November 1, 2023. During 2024, the Company incurred losses related to Hurricane Milton, Hurricane Helene, the Baltimore Bridge Collapse, a series of severe convective storms that impacted the Southern and Midwest United States, the Hualien earthquake which impacted Taiwan in April 2024, a severe hailstorm which impacted Calgary in August 2024, Hurricane Debby, Hurricane Beryl, and certain aggregate loss contracts triggered during 2024 (collectively, the 2024 Large Loss Events). F-40 The Company’s reserving methodology for each line of business uses a loss reserving process that calculates a point estimate for its ultimate settlement and administration costs for claims and claim expenses. The Company does not calculate a range of estimates and does not discount any of its reserves for claims and claim expenses. The Company uses this point estimate, along with paid claims and case reserves, to record its best estimate of ACR and IBNR in its consolidated financial statements. Under GAAP, the Company is not permitted to establish estimates for catastrophe claims and claim expense reserves until an event occurs that gives rise to a loss. Reserving involves other uncertainties, such as the dependence on information from ceding companies, the time lag inherent in reporting information from the primary insurer to the Company or to the Company’s ceding companies, and differing reserving practices among ceding companies. The information received from ceding companies is typically in the form of bordereaux, broker notifications of loss and/or discussions with ceding companies or their brokers. This information may be received on a monthly, quarterly or transactional basis and normally includes paid claims and estimates of case reserves. The Company sometimes also receives an estimate or provision for IBNR. This information is updated and adjusted periodically during the loss settlement period as new data or facts in respect of initial claims, client accounts, industry or event trends may be reported or emerge in addition to changes in applicable statutory and case laws. The Company’s estimates of large losses are based on factors including currently available information derived from claims information from certain customers and brokers, industry assessments of losses, proprietary models, and the terms and conditions of the Company’s contracts. The uncertainty of the Company’s estimates for large losses is also impacted by the preliminary nature of the information available, the magnitude and relative infrequency of the events, the expected duration of the respective claims development period, inadequacies in the data provided to the relevant data by industry participants and the potential for further reporting lags or insufficiencies; and in certain large losses, significant uncertainty as to the form of the claims and legal issues, under the relevant terms of insurance and reinsurance contracts. In addition, a significant portion of the net claims and claim expenses associated with certain large losses can be concentrated with a few large clients and therefore the loss estimates for these large losses may vary significantly based on the claims experience of those clients. The contingent nature of business interruption and other exposures will also impact losses in a meaningful way, which may give rise to significant complexity in respect of claims handling, claims adjustment and other coverage issues, over time. Given the magnitude of certain events, there can be meaningful uncertainty regarding total covered losses for the insurance industry and, accordingly, several of the key assumptions underlying the Company’s loss estimates. Loss reserve estimation in respect of the Company’s retrocessional contracts poses further challenges compared to directly assumed reinsurance. In addition, the Company’s actual net losses from these events may increase if the Company’s reinsurers or other obligors fail to meet their obligations. The Company reevaluates its actuarial reserving assumptions on a periodic basis. Typically, the quarterly review procedures include reviewing paid and reported claims in the most recent reporting period, reviewing the development of paid and reported claims from prior periods, and reviewing the Company’s overall experience by underwriting year and in the aggregate. The Company monitors its expected ultimate claims and claim expense ratios and expected claims reporting assumptions on a quarterly basis and compares them to its actual experience. These actuarial assumptions are generally reviewed annually, based on input from the Company’s actuaries, underwriters, claims personnel and finance professionals, although adjustments may be made more frequently if needed. Assumption changes are made to adjust for changes in the terms of coverage the Company provides, changes in industry results for similar business, as well as its actual experience to the extent the Company has enough data to rely on its own experience. If the Company determines that adjustments to an earlier estimate are appropriate, such adjustments are recorded in the period in which they are identified. Because of the inherent uncertainties discussed above, the Company has developed a reserving philosophy that attempts to incorporate prudent assumptions and estimates, and the Company has generally experienced favorable development on prior accident years net claims and claim expenses in the last several years. However, there is no assurance that this favorable development on prior accident years net claims and claim expenses will occur in future periods. F-41 The Company establishes a provision for unallocated loss adjustment expenses () when the related reserve for claims and claim expenses is established. ULAE are expenses that cannot be associated with a specific claim but are related to claims paid or in the process of settlement, such as internal costs of the claims function, and are included in the reserve for claims and claim expenses. The determination of the ULAE provision is subject to judgment. Incurred and Paid Claims Development and Reserving Methodology The information provided herein about incurred and paid accident year claims development for the years ended prior to December 31, 2024 on a consolidated basis and by segment is presented as supplementary information. The Company has applied a retrospective approach with respect to its acquisitions, presenting all relevant historical information for all periods presented. In addition, included in the incurred claims and claim expenses and cumulated paid claims and claim expenses tables below are reconciling items that represent the unamortized balance of fair value adjustments recorded in connection with the acquisition of TMR and Validus to reflect an increase in net claims and claim expenses due to the addition of a market based risk margin that represented the cost of capital required by a market participant to assume the net claims and claim expenses of TMR and Validus, partially offset by a decrease from discounting in connection with the acquisition of TMR and Validus, to reflect the time value of money. For incurred and

paid accident year claims denominated in currencies other than USD, the Company used the current year-end balance sheet foreign exchange rate for all periods provided, thereby eliminating the effects of changes in foreign currency translation rates from the incurred and paid accident year claims development information included in the tables below.F.42The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of DecemberÂ 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:Incurred Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,At December 31, 2024Accident Year2015201620172018201920202021202220232024IBNRÂ and ACRÂ (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$1,670,190Â \$1,603,613Â \$1,572,065Â \$1,527,011Â \$1,505,26

Paid Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,Accident Year2015201620172018201920202021202220232024Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$456,673Â \$ liabilities from accident year 2014 and prior, net of reinsurance386,060Â Adjustment for unallocated loss adjustment expenses114,425Â Unamortized fair value and other adjustments recorded in connection with acquisitions(156,488)Liability for claims and claim expenses, net of reinsurance\$16,822,101Â Property SegmentWithin the Property segment, the Company writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes. Under these contracts, the Company indemnifies an insurer or reinsurer when its aggregate paid claims and claim expenses from a single occurrence of a covered peril exceeds the attachment point specified in the contract, up to an amount per loss specified in the contract. Generally, the Company's most significant exposure is to losses from hurricanes, earthquakes and other windstorms, although the Company is also exposed to claims arising from other man-made and natural catastrophes, such as tsunamis, winter storms, freezes, floods, fires, tornadoes, explosions and acts of terrorism. The Company's predominant exposure under such coverage is to property damage. However, other risks, including business interruption and other non-property losses, may also be covered under the Company's catastrophe contracts when arising from a covered peril. The Company's coverages are offered on either a worldwide basis or are limited to selected geographic areas.Coverage can also vary from all property perils to limited coverage on selected perils, such as earthquake only coverage. The Company also enters into retrocessional contracts that provide property catastrophe coverage to other reinsurers or retrocedants. This coverage is generally in the form of excess of loss F-43retrocessional contracts and may cover all perils and exposures on a worldwide basis or be limited in scope to selected geographic areas, perils and/or exposures. The exposures the Company assumes from retrocessional business can change within a contract term as the underwriters of a retrocedant may alter their book of business after the retrocessional coverage has been bound. The Company also offers dual trigger reinsurance contracts which require the Company to pay claims based on claims incurred by insurers and reinsurers in addition to the estimate of insured industry losses as reported by referenced statistical reporting agencies.Also included in the Property segment is property per risk, property (re)insurance, delegated authority arrangements and regional U.S. multi-line reinsurance. The Company's predominant exposure under such coverage is to property damage. However, other risks, including business interruption and other non-property losses, may also be covered when arising from a covered peril. The Company's coverages are offered on either a worldwide basis or are limited to selected geographic areas. Principally all of the business is reinsurance, although the Company also writes insurance business primarily through delegated authority arrangements. The Company offers these products principally through proportional reinsurance coverage or in the form of delegated authority arrangements. In a proportional reinsurance arrangement (also referred to as quota share reinsurance or pro rata reinsurance), the reinsurer shares a proportional part of the original premiums and losses of the reinsured.Claims and claim expenses in the Company's Property segment are generally characterized by losses of low frequency and high severity. Initial reporting of paid and incurred claims in general, tends to be relatively prompt, particularly for less complex losses. The Company considers this business short-tail as compared to the reporting of claims for long-tail products, which tends to be slower. However, the timing of claims payment and reporting also varies depending on various factors, including: whether the claims arise under reinsurance of primary insurance companies or reinsurance of other reinsurance companies; the nature of the events (e.g., hurricanes, earthquakes or terrorism); the geographic area involved; post-event inflation which may cause the cost to repair damaged property to increase significantly from current estimates, or for property claims to remain open for a longer period of time, due to limitations on the supply of building materials, labor and other resources; complex policy coverage and other legal issues; and the quality of each client's claims management and reserving practices. Management's judgments regarding these factors are reflected in the Company's reserve for claims and claim expenses.Reserving for most of the Company's Property segment, in particular catastrophe exposure, generally does not involve the use of traditional actuarial techniques, although for certain classes, such as proportional Property classes, traditional actuarial techniques are applied. Rather, claims and claim expense reserves are estimated by management by completing an in-depth analysis of the individual contracts which may potentially be impacted by the loss. The in-depth analysis generally involves: 1) estimating the size of insured industry losses; 2) reviewing reinsurance contract portfolios to identify contracts which are exposed; 3) reviewing information reported or otherwise provided by customers and brokers; 4) discussing the loss with customers and brokers; and 5) estimating the ultimate expected cost to settle all claims and administrative costs arising from the loss on a contract-by-contract basis and in aggregate for the event. Once a loss has occurred, during the then current reporting period, the Company records its best estimate of the ultimate expected cost to settle all claims arising from the loss. The Company's estimate of claims and claim expense reserves is then determined by deducting cumulative paid losses from its estimate of the ultimate expected loss. The Company's estimate of IBNR is determined by deducting cumulative paid losses, case reserves and ACR from its estimate of the ultimate expected loss. Once the Company receives a valid notice of loss or payment request under a catastrophe reinsurance contract, it is generally able to process and pay such claims promptly.Because losses from which claims arise under policies written within the Property segment are typically prominent, public events such as hurricanes and earthquakes, the Company is often able to use independent reports as part of its loss reserve estimation process. The Company also reviews catastrophe bulletins published by various statistical reporting agencies to assist in determining the size of the industry loss, although these reports may not be available for some time after an event. For smaller events including localized severe weather events such as windstorms, hail, ice, snow, flooding, freezing and tornadoes, which are not necessarily prominent, public occurrences, the Company uses standard actuarial techniques to set reserves as it does in other property. The assumptions used are monitored and reviewed through the year to ensure they reflect the level of small cat activity experienced through the year and the exposure to the geographic regions involved. For these small events, the IBNR is run-off over time using Bornhuetter-F-44Ferguson actuarial method, a standard actuarial technique. The loss development factors for the reported Bornhuetter-Ferguson actuarial method are selected based on a review of the Company's historical experience. The reported loss development factors are typically reviewed annually.In general, reserves for the Company's more recent large losses are subject to greater uncertainty and, therefore, greater potential variability, and are likely to experience material changes from one period to the next. This is due to the uncertainty as to the size of the industry losses, uncertainty as to which contracts have been exposed, uncertainty due to complex legal and coverage issues that can arise out of large or complex losses, and uncertainty as to the magnitude of claims incurred by the Company's customers. As the Company's claims age, more information becomes available and the Company believes its estimates become more certain.The following table details the Company's Property segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of DecemberÂ 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:Incurred Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,At December 31, 2024Accident Year2015201620172018201920202021202220232024IBNRÂ and ACRÂ (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$506,243Â \$456,920Â \$414,379Â \$397,750Â \$388,076Â \$383, Paid Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,Accident Year2015201620172018201920202021202220232024Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$141,410Â \$ liabilities from accident year 2014 and prior, net of reinsurance49,601Â Adjustment for unallocated loss adjustment expenses15,115Â Unamortized fair value and other adjustments recorded in connection with acquisitions(34,183)Liability for claims and claim expenses, net of reinsurance\$4,906,841Â Casualty and Specialty SegmentThe Company offers its casualty and specialty reinsurance products principally on a proportional basis, and it also provides excess of loss coverage. The Company offers casualty and specialty reinsurance products to insurance and reinsurance companies and provides coverage for specific geographic regions or on a F-45worldwide basis. Principally all of the business is reinsurance, although the Company also writes insurance business.As with the Company's Property segment, its Casualty and Specialty segment reinsurance contracts can include coverage for relatively large limits or exposures. As a result, the Company's casualty and specialty reinsurance business can be subject to significant claims volatility. In periods of low claims frequency or severity, the Company's results will generally be favorably impacted while in periods of high claims frequency or severity the Company's results will generally be negatively impacted.The Company's processes and methodologies in respect of loss estimation for the coverages offered through its Casualty and Specialty segment differ from those used for its Property segment. For example, the Company's casualty and specialty coverages are more likely to be impacted by factors such as long-term inflation and changes in the social and legal environment, which the Company believes gives rise to greater uncertainty in its reserves for claims and claim expenses. The Company believes this makes its Casualty and Specialty segment reserving subject to greater uncertainty than its Property segment.The Company calculates multiple point estimates for claims and claim expense reserves using a variety of actuarial reserving techniques for many, but not all, of its classes of business for each underwriting year within the Casualty and Specialty segment. The Company does not believe that these multiple point estimates are, or should be considered, a range. Rather, the Company considers each class of business and determines the most appropriate point estimate for each underwriting year based on the characteristics of the particular class including: (1) loss development patterns derived from historical data; (2) the credibility of the selected loss development pattern; (3) the stability of the loss development patterns; (4) how developed the underwriting year is; and (5) the observed loss development of other underwriting years for the same class. The Company also considers other relevant factors, including: (1) historical ultimate loss ratios; (2) the presence of individual large losses; and (3) known occurrences that have not yet resulted in reported losses. The Company makes determinations of the most appropriate point estimate of loss for each class based on an evaluation of relevant information and does not ascribe any particular portion of the estimate to a particular factor or consideration. In addition, the Company believes that a review of individual contract information improves the loss estimates for some classes of business.When developing claims and claims expense reserves for its Casualty and Specialty segment, the Company considers several actuarial techniques such as the expected loss ratio method, the Bornhuetter-Ferguson actuarial method and the paid and reported chain ladder actuarial method. For classes of business and underwriting years where the Company has limited historical claims experience, estimates of ultimate losses are generally initially determined based on the loss ratio method applied to each underwriting year and to each class of business. Unless the Company has credible claims experience or unfavorable development, it generally selects an ultimate loss based on its initial expected loss ratio. The selected ultimate losses are determined by multiplying the initial expected loss ratio by the earned premium. The initial expected loss ratios are key inputs that involve management judgment and are based on a variety of factors, including: (1) contract by contract expected loss ratios developed during the Company's pricing process; (2) historical loss ratios and combined ratios adjusted for rate change and trend; and (3) industry benchmarks for similar business. These judgments take into account management's view of past, current and future factors that may influence ultimate losses, including: (1) market conditions; (2) changes in the business underwritten; (3) changes in timing of the emergence of claims; and (4) other factors that may influence ultimate loss ratios and losses. The determination of when reported losses are sufficient and credible to warrant selection of an ultimate loss ratio different from the initial expected loss ratio also requires judgment. The Company generally makes adjustments for reported loss experience indicating unfavorable variances from initial expected loss ratios sooner than reported loss experience indicating favorable variances. This is because the reporting of losses in excess of expectations tends to have greater credibility than an absence or lower than expected level of reported losses. Over time, as a greater number of claims are reported and the credibility of reported losses improves, actuarial estimates of IBNR are typically based on the Bornhuetter-Ferguson actuarial method or the reported chain ladder actuarial method. The Bornhuetter-Ferguson actuarial method allows for greater weight to be applied to expected results in periods where little or no actual experience is available, and, hence, is less susceptible to the potential pitfall of being excessively swayed by experience of actual paid and/or reported loss data, compared to the F-46chain ladder actuarial method. The Bornhuetter-Ferguson actuarial method uses the initial expected loss ratio to estimate IBNR, and it assumes that past experience is not fully representative of the future. As the Company's reserves for claims and claim expenses age, and actual claims experience becomes available, this method places less weight on expected experience and places more weight on actual experience. This experience, which represents the difference between expected reported claims and actual reported claims, is reflected in the respective reporting period as a change in estimate. The utilization of the Bornhuetter-Ferguson actuarial method requires the Company to estimate an expected ultimate claims and claim expense ratio and select an expected loss reporting pattern. The Company selects its estimates of the expected ultimate claims and claim expense ratios as described above and selects its expected loss reporting patterns by utilizing actuarial analysis, including management's judgment, and historical patterns of paid losses and reporting of case reserves to the Company, as well as industry loss development patterns. The estimated expected claims and claim expense ratio may be modified to the extent that reported losses at a given point in time differ from what would be expected based on the selected loss reporting pattern.The reported chain ladder actuarial method utilizes actual reported losses and a loss development pattern to determine an estimate of ultimate losses that is independent of the initial expected ultimate loss ratio and earned premium. The Company believes this technique is most appropriate when there are a large number of reported losses with significant statistical credibility and a relatively stable loss development pattern. Information that may cause future loss development patterns to differ from historical loss development patterns is considered and reflected in the Company's selected loss development patterns as appropriate. For certain reinsurance contracts, historical loss development patterns may be developed from ceding company data or other sources.In addition, certain specialty coverages may be impacted by natural and man-made catastrophes. The Company estimates reserves for claim and claim expenses for these losses, following a process that is similar to its Property segment described above.F.47The following table details the Company's Casualty and Specialty segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of DecemberÂ 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:Incurred Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,At December 31, 2024Accident Year2015201620172018201920202021202220232024IBNRÂ and ACRÂ (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$1,163,947Â \$1,146,693Â \$1,157,686Â \$1,129,261Â \$1,117,18

Paid Claims and Claim Expenses, Net of ReinsuranceFor the year ended December 31,Accident Year2015201620172018201920202021202220232024Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)Â (unaudited)2015\$315,263Â \$ liabilities from accident year 2014 and prior, net of reinsurance336,459Â Adjustment for unallocated loss adjustment expenses99,310Â Unamortized fair value and other adjustments recorded in connection with acquisitions(122,305)Liability for claims and claim expenses, net of reinsurance\$11,915,260Â Prior Year Development of the Reserve for Net Claims and Claim ExpensesThe Company's estimates of claims and claim expense reserves are not precise in that, among other things, they are based on predictions of future developments and estimates of future trends and other variable factors. Some, but not all, of the Company's reserves are further subject to the uncertainty inherent in actuarial methodologies and estimates. Because a reserve estimate is simply an insurer's estimate at a point in time of its ultimate liability, and because there are numerous factors that affect reserves and claims payments that cannot be determined with certainty in advance, the Company's ultimate payments will vary, perhaps materially, from its estimates of reserves. If the Company determines in a subsequent period that adjustments to its previously established reserves are appropriate, such adjustments are recorded in the period in which they are identified. On a net basis, the Company's cumulative favorable or unfavorable development is generally reduced by offsetting changes in its reinsurance recoverable, as well as changes to loss related premiums such as reinstatement premiums and redeemable noncontrolling interest, all of which generally move in the opposite direction to changes in the Company's ultimate claims and claim expenses.F.48The following table details the Company's prior year net development by segment of its net claims and claim expenses:(Favorable) Adverse DevelopmentYear ended DecemberÂ 31, 202420232022Property\$(818,852)\$(408,905)\$(205,741)Casualty and Specialty(32,482)(41,702)(41,841)Total net (favorable) adverse development of prior accident years net

claims and claim expenses\$(851,334)\$(450,607)\$(247,582)Changes to prior year estimated net claims and claim expenses increased net income by \$851.3 million during the year ended December 31, 2024 (2023 - increased net income by \$450.6 million, 2022 - increased net income by \$247.6 million), excluding the consideration of changes in reinstatement, adjustment or other premium changes, profit commissions, redeemable noncontrolling interests - DaVinci, Fontana and Vermeer and income tax. Property Segment The following tables detail the prior year net development of the Company's liability for net unpaid claims and claim expenses for its Property segment, allocated between large catastrophe events and other small catastrophe events and attritional loss movements: Year ended December 31, 2024 (Favorable) adverse development Catastrophe net claims and claim expenses Large catastrophe events 2023 Large Loss Events (1)\$(31,899)2022 Weather-Related Large Losses (2)\$(284,327)2021 Weather-Related Large Losses (3)\$(180,028)2020 Weather-Related Large Loss Events (4)\$(47,512)2019 Large Loss Events (5) (14,445)2018 Large Loss Events (6)\$(38,295)2017 Large Loss Events (7)\$(25,692)Total large catastrophe events (622,198)Small catastrophe events and attritional loss movements Other small catastrophe events and attritional loss movements (206,616)Total small catastrophe events and attritional loss movements (206,616)Total catastrophe and attritional net claims and claim expenses (828,814)Actuarial assumption changes 9,962 Total net (favorable) adverse development of prior accident years net claims and claim expenses \$(818,852) (1) 2023 Large Loss Events includes earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other F-49 Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Ciaran, and certain aggregate loss contracts triggered during 2023. (2) 2022 Weather-Related Large Losses includes Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contracts. (3) 2021 Weather-Related Large Losses includes Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contracts. (4) 2020 Weather-Related Large Loss Events includes Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contracts. (5) 2019 Large Loss Events includes Hurricane Dorian and Typhoons Faxai and Hagibis and certain losses associated with aggregate loss contracts. (6) 2018 Large Loss Events includes Typhoons Jebi, Mangkhut and Trami, Hurricane Florence, wildfires in California, Hurricane Michael and certain losses associated with aggregate loss contracts. (7) 2017 Large Loss Events includes Hurricanes Harvey, Irma and Maria, the Mexico City Earthquake, wildfires in California and certain losses associated with aggregate loss contracts. The net favorable development of prior accident years net claims and claim expenses on the large catastrophe events was driven by better than expected loss emergence across the 2017 to 2023 accident years. The net favorable development on other small catastrophe events and attritional loss movements was primarily related to lines of business where the Company principally estimates net claims and claim expenses using traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes. Year ended December 31, 2023 (Favorable) adverse development Catastrophe net claims and claim expenses Large catastrophe events 2022 Weather-Related Large Losses \$(85,653)2021 Weather-Related Large Losses (36,949)2020 Weather-Related Large Loss Events (42,577)2019 Large Loss Events (43,850)2018 Large Loss Events (40,050)2017 Large Loss Events (46,404)Other (14,337)Total large catastrophe events (309,820)Small catastrophe events and attritional loss movements Other small catastrophe events and attritional loss movements (99,925)Total small catastrophe events and attritional loss movements (99,925)Total catastrophe and attritional net claims and claim expenses (409,745)Actuarial assumption changes 840 Total net (favorable) adverse development of prior accident years net claims and claim expenses \$(408,905)The net favorable development of prior accident years net claims and claim expenses was driven by better than expected loss emergence. The net favorable development on other small catastrophe events and attritional loss movements was related to lines of business where the Company principally estimates net claims and claim expenses using traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes. Casualty and Specialty Segment The following table details the net development of the Company's prior accident years net claims and claim expenses for its Casualty and Specialty segment: (Favorable) Adverse Development Year ended December 31, 2024 2023 2022 Actuarial methods - actual reported claims less than expected claims \$(67,595) \$(44,612) \$(63,353) Actuarial assumption changes \$5,113 \$2,910 \$21,512 Total net (favorable) adverse development of prior accident years net claims and claim expenses \$(32,482) \$(41,702) \$(41,841) The Company principally estimates net claims and claim expenses for the Casualty and Specialty segment using traditional actuarial methods. The net favorable development of prior accident years net claims and claim expenses during the three-year period ended December 31, 2024 was primarily due to reported losses generally coming in lower than expected on attritional net claims and claim expenses and was driven by favorable experience within the Company's other specialty, credit and professional liability classes of business, partially offset by adverse experience in general liability. F-51 Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses The reconciliation of the net incurred and paid claims development tables to the reserve for claims and claim expenses in the consolidated balance sheet is as follows: At December 31, 2024 Net Reserve for Claims and Claim Expenses Property \$4,906,841 A Casualty and Specialty 11,915,260 A Total net reserve for claims and claim expenses 16,822,101 A Reinsurance Recoverable Property \$1,665,898 A Casualty and Specialty 2,815,492 A Total reinsurance recoverable 4,481,390 A Total reserve for claims and claim expenses \$21,303,491 A Historical Claims Duration The following is unaudited supplementary information about average historical claims duration by segment: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (Number of Years) At December 31, 2024 21.23 41.56 78.91 10.70 20.74 28.84 16.44 6.94 5.54 0.94 0.94 0.44 0.74 0.24 Casualty and Specialty 12.34 16.34 12.44 12.94 10.64 8.44 6.34 4.54 2.54 1.14 1.14 Claims Frequency Both of the Company's reportable segments are broadly considered to be reinsurance, where multiple claims are often aggregated, perhaps multiple times through retrocessional reinsurance, before ultimately being ceded to the Company. The nature, size, terms and conditions of contracts entered into by the Company changes from one accident year to the next, as do the quantum of contractual or policy limits, and accordingly the potential amount of claims and claim expenses associated with a reported claim, can range from nominal, to significant. These factors can impact the amount and timing of the claims and claim expenses to be recorded and accordingly, developing claim frequency information is highly subjective and is not prepared or utilized for internal purposes. In recent years, the Company has grown its Casualty and Specialty segment where a significant amount of the premium and net reserves come from proportional contracts. The Company does not have direct access to claim frequency information underlying certain of its proportional contracts given the nature of that business. In addition, the Company completed the acquisition of Validus on November 1, 2023. Historically, Validus has not kept nor had access to claim count and frequency information. As providing any claim count and frequency information would exclude the entirety of the legacy Validus portfolio as well as all proportional contracts for the Company, the Company has determined that it is impracticable to provide this information. Assumed Reinsurance Contracts Classified As Deposit Contracts Included in other income (loss) during 2024 was \$0.2 million related to income earned on assumed reinsurance contracts that were classified as deposit contracts with underwriting risk only (2023 - \$0.2 million, 2022 - \$0.2 million). A Deposit liabilities of \$3.5 million are included in reinsurance balances payable at December 31, 2024 (2023 - \$3.7 million). F-52 NOTE 9. DEBT AND CREDIT FACILITIES The agreements governing the Company's debt obligations and credit facilities contain certain customary representations, warranties and covenants. At December 31, 2024, the Company believes that it was in compliance with its debt covenants. Debt Obligations A summary of the Company's debt obligations on its consolidated balance sheets is set forth below: December 31, 2024 December 31, 2023 Fair Value Carrying Value Fair Value Carrying Value 5.750% Senior Notes due 2033 \$755,693 A \$742,068 A \$758,783 A \$741,124 A 3.600% Senior Notes due 2029 \$376,816 A \$396,051 A \$371,276 A \$395,137 A 3.450% Senior Notes due 2027 \$290,070 A \$298,765 A \$283,350 A \$298,270 A 3.700% Senior Notes due 2025 \$299,550 A \$299,908 A \$293,154 A \$299,537 A 4.750% Senior Notes due 2025 (DaVinci) (1) 149,363 A 149,897 A 147,489 A 149,587 A Total senior notes 1,871,492 A 1,886,689 A 1,854,052 A 1,883,655 A Medici Revolving Credit Facility (2) 28 A 28 A 75,000 A 75,000 A Total debt \$1,871,492 A \$1,886,689 A \$1,929,052 A \$1,958,655 A (1) A A A Renaissance Re owns a noncontrolling economic interest in its joint venture DaVinci. Because Renaissance Re controls a majority of DaVinci's issued voting shares, the consolidated financial statements of DaVinci are included in the consolidated financial statements of Renaissance Re. However, Renaissance Re does not guarantee or provide credit support for DaVinci and Renaissance Re's financial exposure to DaVinci is limited to its investment in DaVinci's shares and counterparty credit risk arising from reinsurance transactions. (2) A A A A Renaissance Re owns a noncontrolling economic interest in Medici. Because Renaissance Re controls all of Medici's issued voting shares, the financial statements of Medici are included in Renaissance Re's consolidated financial statements. However, Renaissance Re does not guarantee or provide credit support for Medici, and Renaissance Re's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions. 5.750% Senior Notes due 2033 On June 5, 2023, the Company issued \$750.0 million of its 5.750% Senior Notes due June 5, 2033, with interest on the notes payable on June 5 and December 5 of each year, commencing on December 5, 2023. The notes are redeemable at the applicable redemption price, subject to the terms described in the indenture for the notes. However, the notes (i) may not be redeemed at any time prior to June 5, 2026 without approval of the Bermuda Monetary Authority (the BMA) and (ii) may not be redeemed or repaid at any time if enhanced capital requirements, as established by the BMA, would be breached immediately before or after giving effect to the redemption or repayment of such notes, unless, in each case, Renaissance Re replaces the capital represented by the notes to be redeemed or repaid with capital having equal or better capital treatment as the notes under applicable BMA rules. The notes contain various covenants including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries. The Company received net proceeds of approximately \$741.0A million from the offering of senior notes after deducting the underwriting discounts and estimated offering expenses payable by the Company. The Company used the net proceeds from this offering to fund a portion of the cash consideration for the Validus Acquisition, which closed on November 1, 2023, to pay related costs and expenses, and for general corporate purposes. See Note 3. Acquisition of Validus for additional information regarding the Validus Acquisition. 3.600% Senior Notes Due 2029 On April 2, 2019, Renaissance Re issued \$400.0 million principal amount of its 3.600% Senior Notes due April 15, 2029, with interest on the notes payable on April 15 and October 15 of each year, commencing on October 15, 2019. The notes are redeemable at the applicable redemption price, subject to the terms described in the indenture for the notes. However, the notes may not be redeemed at any time prior to their maturity if enhanced capital requirements, as established by the BMA, would be breached immediately before or after giving effect to the redemption of such notes, unless, in each case, Renaissance Re replaces the capital represented by the notes to be redeemed with capital having equal or better capital treatment as the notes under applicable BMA rules. The notes contain various covenants including limitations on mergers F-53 and consolidations, and restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries. The net proceeds from this offering were used to repay, in full, the \$200.0 million outstanding under the Company's revolving credit facility at March 31, 2019, which the Company used to partially fund the purchase price for the TMR Stock Purchase, and the remainder of the net proceeds was used for general corporate purposes. 3.450% Senior Notes due 2027 of Renaissance Re Finance On June 29, 2017, Renaissance Re Finance Inc. (Renaissance Re Finance) issued \$300.0 million principal amount of its 3.450% Senior Notes due July 1, 2027, with interest on the notes payable on July 1 and January 1 of each year. The notes are fully and unconditionally guaranteed by Renaissance Re and may be redeemed by Renaissance Re Finance prior to maturity, subject to the payment of a make-whole premium if the notes are redeemed prior to April 1, 2027. The notes contain various covenants, including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, stock of designated subsidiaries. 3.700% Senior Notes due 2025 of Renaissance Re Finance On March 24, 2015, Renaissance Re Finance issued \$300.0 million principal amount of its 3.700% Senior Notes due April 1, 2025, with interest on the notes payable on April 1 and October 1 of each year. The notes are fully and unconditionally guaranteed by Renaissance Re and may be redeemed by Renaissance Re Finance prior to maturity, subject to the payment of a make-whole premium if the notes are redeemed prior to January 1, 2025. The notes contain various covenants, including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, stock of designated subsidiaries. The net proceeds from the offering of the notes (together with cash on hand) were applied by Renaissance Re to repay in full a \$300.0 million bridge loan that Barclays Bank PLC provided to Renaissance Re on February 25, 2015 in order to finance a portion of the cash consideration paid by Renaissance Re in connection with the acquisition of Platinum. DaVinci Senior Notes On May 4, 2015, DaVinci Re Holdings Ltd. (DaVinci Re) issued \$150.0 million principal amount of its 4.750% Senior Notes due May 1, 2025, with interest on the notes payable on May 1 and November 1, commencing with November 1, 2015 (the DaVinci Senior Notes). The DaVinci Senior Notes, which are senior obligations, may be redeemed prior to maturity, subject to the payment of a make-whole premium if the notes are redeemed before February 1, 2025. The DaVinci Senior Notes contain various covenants including restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries, limitations on mergers, amalgamations and consolidations, limitations on third-party investor redemptions, a leverage covenant and a covenant to maintain certain ratings. The net proceeds from this offering were used to repay, in full, \$100.0 million outstanding under the loan agreement, dated as of March 30, 2011, between DaVinci and Renaissance Re, and the remainder of the net proceeds were used for general corporate purposes. Scheduled Debt Maturity The following table sets forth the scheduled maturity of the Company's aggregate amount of its debt obligation reflected on its consolidated balance sheet at December 31, 2024: 2024 \$450,000 A 2026 \$207,300,000 A 2028 \$209,400,000 A 2029 \$297,500,000 A Unamortized discount and debt issuance expenses (13,311) A \$1,886,689 A A F-54 Credit Facilities The outstanding amounts issued or drawn under each of the Company's significant credit facilities is set forth below: At December 31, 2024 Issued or Drawn Revolving Credit Facility (1) \$18 A Medici Revolving Credit Facility (2) \$2 A Bilateral Letter of Credit Facilities Secured 262,168 A Unsecured 357,443 A \$619,611 A (1) At December 31, 2024, no amounts were issued or drawn under this facility. (2) Renaissance Re owns a noncontrolling economic interest in Medici. Because Renaissance Re controls all of Medici's voting shares, the financial statements of Medici are included in Renaissance Re's consolidated financial statements. However, Renaissance Re does not guarantee or provide credit support for Medici, and Renaissance Re's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions. The drawn amount of the Medici revolving credit facility is included on the Company's consolidated balance sheets under debt. Renaissance Re Revolving Credit Facility Renaissance Re, Renaissance Reinsurance Ltd. (Renaissance Reinsurance), Renaissance Re Specialty U.S. Ltd. (Renaissance Re Specialty U.S.), Renaissance Reinsurance U.S. Inc. (Renaissance Reinsurance U.S.) and Renaissance Re Europe AG (Renaissance Re Europe) are parties to a third amended and restated credit agreement dated November 18, 2022 (the Revolving Credit Agreement) with various banks, financial institutions and Wells Fargo Bank, National Association (the Wells Fargo) as administrative agent, which amended and restated a previous credit agreement. The Revolving Credit Agreement provides for a revolving commitment to Renaissance Re of \$500.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$700.0 million. Amounts borrowed under the Revolving Credit Agreement bear interest at a rate selected by Renaissance Re equal to the Base Rate or Term SOFR (each as defined in the Revolving Credit Agreement) plus a margin. In addition to revolving loans, the Revolving Credit Agreement provides that the entire facility will also be available for the issuance of standby letters of credit, subject to the terms and conditions set forth therein, and swingline loans, which are capped at \$50.0 million for each of the swingline lenders. At December 31, 2024, Renaissance Re had \$Nil outstanding under the Revolving Credit Agreement. The Revolving Credit Agreement contains representations, warranties and covenants customary for bank loan facilities of this type, including limits on the ability of Renaissance Re and its subsidiaries to merge, consolidate, sell a substantial amount of assets, incur liens and declare or pay dividends under certain circumstances. The Revolving Credit Agreement also contains certain financial covenants which generally provide that the ratio of consolidated debt to capital shall not exceed 0.35:1 and that the consolidated net worth of Renaissance Re shall equal or exceed approximately \$4.0 billion, subject to an annual adjustment. If certain events of default occur, in some circumstances the lenders' obligations to

make loans may be terminated and the outstanding obligations of RenaissanceRe under the Revolving Credit Agreement may be accelerated. The scheduled commitment maturity date of the Revolving Credit Agreement is November 18, 2027. RenaissanceRe Finance guarantees RenaissanceRe's obligations under the Revolving Credit Agreement. Subject to certain exceptions, additional subsidiaries of RenaissanceRe are required to become guarantors if such subsidiaries issue or incur certain types of indebtedness. Bilateral Letter of Credit Facilities Uncommitted, Secured Standby Letter of Credit Facility with Wells Fargo RenaissanceRe and certain of its subsidiaries and affiliates, including Renaissance Reinsurance, DaVinci Reinsurance Ltd. (a Renaissance Reinsurance), Renaissance Reinsurance U.S., RREAG and Renaissance Specialty U.S. are parties to an Amended and Restated Standby Letter of Credit Agreement dated June 21, F-552019, as amended, with Wells Fargo, which provides for a secured, uncommitted facility under which letters of credit may be issued from time to time for the respective accounts of the subsidiaries. Pursuant to the agreement, the applicants may request secured letter of credit issuances up to an aggregate amount of \$200.0 million. RenaissanceRe has unconditionally guaranteed the payment obligations of the applicants other than DaVinci Reinsurance. The agreement contains representations, warranties and covenants that are customary for facilities of this type. Under the agreement, each applicant is required to pledge eligible collateral having a value sufficient to cover all of its obligations under the agreement with respect to secured letters of credit issued for its account. In the case of an event of default under the agreement, Wells Fargo may exercise certain remedies, including conversion of collateral of a defaulting applicant into cash. At December 31, 2024, there were \$20.1 million of secured letters of credit outstanding and \$Nil of unsecured letters of credit outstanding under this agreement. Secured Letter of Credit Facility with Citibank Europe Certain subsidiaries and affiliates of RenaissanceRe, including Renaissance Reinsurance, DaVinci Reinsurance, Renaissance Reinsurance of Europe Designated Activity Company (a Renaissance Reinsurance of Europe DAC) and Renaissance Specialty U.S., are parties to a facility letter, dated December 19, 2022, as amended, with Citibank Europe plc (a Citibank Europe), pursuant to which Citibank Europe has established a letter of credit facility under which Citibank Europe provides a commitment to issue letters of credit for the accounts of the participants in multiple currencies. On November 1, 2023, the aggregate committed amount of the facility was increased from \$180.0 million to \$320.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$350.0 million. The letter of credit facility is scheduled to expire on December 31, 2026. At all times during which it is a party to the facility, each participant is obligated to pledge to Citibank Europe securities with a value that equals or exceeds the aggregate face amount of its then-outstanding letters of credit. In the case of an event of default under the facility with respect to a participant, Citibank Europe may exercise certain remedies, including terminating its commitment to such participant and taking certain actions with respect to the collateral pledged by such participant (including the sale thereof). In the facility letter, each participant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other undertakings. At December 31, 2024, \$232.6 million aggregate face amount of letters of credit was outstanding and \$87.4 million remained unused and available to the participants under this facility. Uncommitted, Unsecured Letter of Credit Facility with Citibank Europe Renaissance Reinsurance, Renaissance Specialty U.S., Renaissance Reinsurance U.S. and RREAG are parties to a Master Agreement for Issuance of Payment Instruments and a Facility Letter for Issuance of Payment Instruments with Citibank Europe dated March 22, 2019, as amended, which established an uncommitted, unsecured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of one or more of the applicants. The obligations of the applicants under this facility are guaranteed by RenaissanceRe. Pursuant to the master agreement, each applicant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other customary undertakings. The master agreement contains events of default customary for facilities of this type. In the case of an event of default under the facility, Citibank Europe may exercise certain remedies, including requiring that the relevant applicant pledge cash collateral in an amount equal to the maximum actual and contingent liability of the issuing bank under the letters of credit and similar instruments issued for such applicant under the facility, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof). In addition, Citibank Europe may require that the relevant applicant pledge cash collateral if certain minimum ratings are not satisfied. At December 31, 2024, the aggregate face amount of the payment instruments issued and outstanding under this facility was \$293.0 million. F-56 Unsecured Letter of Credit Facility with Credit Suisse RREAG, Renaissance Reinsurance and RenaissanceRe were parties to a letter of credit facility agreement with Credit Suisse (Switzerland) Ltd. (a Credit Suisse) dated December 16, 2021, as amended, and which provided for a \$200.0 million committed, unsecured letter of credit facility pursuant to which Credit Suisse (or any other fronting bank acting on behalf of Credit Suisse) may issue letters of credit or similar instruments in multiple currencies for the account of RREAG or Renaissance Reinsurance. The obligations of RREAG and Renaissance Reinsurance under the agreement were guaranteed by RenaissanceRe. The facility was allowed to expire in accordance with its terms on December 31, 2024. At December 31, 2024, letters of credit issued by Credit Suisse under the agreement were outstanding in the face amount of \$19.1 million. Uncommitted, Unsecured Standby Letter of Credit Facility with Nordea RREAG, Renaissance Reinsurance and RenaissanceRe are parties to a standby letter of credit agreement with Nordea Bank Abp, New York Branch (a Nordea) dated October 3, 2024 which provides for an uncommitted, unsecured facility pursuant to which Nordea may issue standby letters of credit in multiple currencies for the accounts of RREAG and Renaissance Reinsurance. Pursuant to the agreement, RREAG and Renaissance Reinsurance may request letters of credit up to an aggregate amount of \$250.0 million. The obligations of RREAG and Renaissance Reinsurance under the agreement are guaranteed by RenaissanceRe. At December 31, 2024, letters of credit issued by Nordea under the agreement were outstanding in the face amount of \$45.3 million. Uncommitted Letter of Credit Facility with Soci@t@ G@n@r@ale Renaissance Reinsurance is party to a letter of credit reimbursement agreement with Soci@t@ G@n@r@ale, New York Branch (a SocGen), dated September 8, 2022, which provides for a \$250.0 million uncommitted letter of credit facility under which Renaissance Reinsurance may request either secured or unsecured letters of credit in multiple currencies for the account of Renaissance Reinsurance, subject to secured letters of credit comprising at least 40% of the maximum aggregate amount. In the agreement, Renaissance Reinsurance makes representations, warranties and covenants that are customary for facilities of this type, and agrees to comply with certain informational and other customary undertakings. The agreement also contains certain financial covenants applicable to the Renaissance Reinsurance customary for facilities of this type. The agreement contains events of default customary for facilities of this type. At any time on or after the occurrence of an event of default, SocGen may exercise remedies, including requiring that Renaissance Reinsurance pledge cash collateral in an amount equal to the maximum liability of the issuing bank under the unsecured letters of credit and similar instruments issued under the agreement, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof). At December 31, 2024, letters of credit issued by SocGen under the agreement were outstanding in the face amount of \$Nil. Vermeer Letter of Credit Facility with Citibank Europe Vermeer Reinsurance Ltd. (a Vermeer) is party to an uncommitted, secured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of the applicant. The obligations of Vermeer under this facility are not guaranteed by RenaissanceRe. At December 31, 2024, the aggregate face amount of letters of credit outstanding under this facility was \$9.4 million. Medici RenaissanceRe Medici Fund Ltd. (a Medici) and RenaissanceRe Fund Management Ltd. (a RFM) are parties to a revolving credit facility, as amended, pursuant to which National Australia Bank Limited provides for a revolving commitment to Medici of \$75.0 million. The obligations of Medici and RFM under this facility are not guaranteed by RenaissanceRe. F-57 At December 31, 2024, the face amount of the outstanding revolving credit facility was \$Nil. Top Layer Renaissance Reinsurance is party to a collateralized letter of credit and reimbursement agreement in the amount of \$37.5 million that supports the Company's Top Layer joint venture. Renaissance Reinsurance is obligated to make a mandatory capital contribution of up to \$50.0 million in the event that a loss reduces Top Layer's capital below a specified level. NOTE 10. NONCONTROLLING INTERESTS A summary of the Company's redeemable noncontrolling interests on its consolidated balance sheets is set forth below: At December 31, 2024 2023 Redeemable noncontrolling interest - DaVinci \$3,061,708A \$2,541,482A Redeemable noncontrolling interest - Medici 1,646,745A 1,650,229A Redeemable noncontrolling interest - Vermeer 1,799,857A 1,555,297A Redeemable noncontrolling interest - Fontana 469,439A 353,823A Redeemable noncontrolling interest \$6,977,749A \$6,100,831A A summary of the Company's redeemable noncontrolling interests on its consolidated statements of operations is set forth below: Year ended December 31, 2024 2023 2022 Redeemable noncontrolling interest - DaVinci \$627,055A \$545,812A \$(65,514) Redeemable noncontrolling interest - Medici 202,941A 239,250A (70,504) Redeemable noncontrolling interest - Vermeer 244,560A 239,457A 43,058A Redeemable noncontrolling interest - Fontana 15,616A 34,476A (5,653) Net income (loss) attributable to redeemable noncontrolling interests \$1,090,172A \$1,058,995A \$(98,613) Redeemable Noncontrolling Interest a DaVinci DaVinci is a managed joint venture formed by RenaissanceRe principally to write property catastrophe reinsurance and certain casualty and specialty reinsurance lines of business on a global basis through its wholly-owned subsidiary, DaVinci Reinsurance. RenaissanceRe owns a noncontrolling economic interest in DaVinci; however, because RenaissanceRe controls a majority of DaVinci's outstanding voting rights, the Company consolidates DaVinci and all significant intercompany transactions have been eliminated. The portion of DaVinci's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company's noncontrolling economic ownership in DaVinci was 25.4% at December 31, 2024 (2023 - 27.8%). DaVinci shareholders are party to a shareholders' agreement which provides DaVinci shareholders, excluding RenaissanceRe, with certain redemption rights that enable each shareholder to notify DaVinci of such shareholder's desire for DaVinci to repurchase up to half of such shareholder's initial aggregate number of shares held, subject to certain limitations, such as limiting the aggregate of all share repurchase requests to 25% of DaVinci's capital in any given year and satisfying all applicable regulatory requirements. If total shareholder requests exceed 25% of DaVinci's capital, the number of shares repurchased will be reduced among the requesting shareholders pro-rata, based on the amounts desired to be repurchased. Shareholders desiring to have DaVinci repurchase their shares must notify DaVinci before March 1 of each year. The repurchase price will be based on GAAP book value as of the end of the year in which the shareholder notice is given, and the repurchase will be effective as of December 31 of that year. The repurchase price can be subject to a holdback and true-up for potential development on outstanding loss reserves. Similarly, when shares are issued by DaVinci and sold to DaVinci shareholders, the sale price is based on GAAP book value and can be subject to a true-up for potential development on outstanding loss reserves. F-58 2024 During 2024, RenaissanceRe sold an aggregate of \$300.0 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$225.9 million of shares from other third-party investors. In addition, DaVinci distributed \$180.6 million to third-party investors and \$69.4 million to the Company. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 25.4%. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received cash inflows of \$69.7 million from subscriptions of shares in DaVinci by third-party investors, and paid \$225.9 million as a result of redemptions of shares from and distributions to third-party investors. Refer to Note 21. Subsequent Events for additional information related to the Company's noncontrolling economic ownership in DaVinci subsequent to December 31, 2024. 2023 During 2023, DaVinci completed an equity capital raise of \$250.0 million, comprised of \$102.2 million from third-party investors and \$147.8 million from RenaissanceRe. In addition, RenaissanceRe sold an aggregate of \$275.0 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$123.3 million of shares from other third-party investors. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 27.8%. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$300.0 million subscriptions of shares in DaVinci by third-party investors, and paid \$123.3 million as a result of redemptions of shares from third-party investors. The Company expects its noncontrolling economic ownership in DaVinci to fluctuate over time. The activity in redeemable noncontrolling interest a DaVinci is detailed in the table below: Year ended December 31, 2024 2023 Beginning balance \$2,541,482A \$1,740,300A Redemption of shares from redeemable noncontrolling interests (406,849) (123,272) Sale of shares to redeemable noncontrolling interests, net of adjustments 300,020A 378,642A Net income (loss) attributable to redeemable noncontrolling interest 627,055A 545,812A Ending balance \$3,061,708A \$2,541,482A Redeemable Noncontrolling Interest - Medici Medici is an exempted company, incorporated in Bermuda and registered as an institutional fund. Medici invests, primarily on behalf of third-party investors, in various instruments that have returns primarily tied to property catastrophe risk. RenaissanceRe owns a noncontrolling economic interest in Medici; however, because RenaissanceRe controls all of Medici's issued voting shares, the Company consolidates Medici and all significant intercompany transactions have been eliminated. The portion of Medici's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. Any shareholder may redeem all or any portion of its shares as of the last day of any calendar month, upon at least 30 calendar days' prior irrevocable written notice to Medici. 2024 During 2024, investors subscribed for \$250.2 million, including \$50.6 million from the Company. In addition, investors redeemed \$382.0 million, of the participating, non-voting common shares of Medici, including \$0.3 million from the Company. Third party investors also received \$24.6 million in dividends. As a result of these transactions, the Company's noncontrolling economic ownership in Medici was 15.8% at December 31, 2024. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received cash inflows of \$163.6 million from subscriptions of shares in Medici by third-party investors and paid \$361.8 million as a result of redemptions of shares from and dividends to third-party investors. F-59 Refer to Note 21. Subsequent Events for additional information related to the Company's noncontrolling economic ownership in Medici subsequent to December 31, 2024. 2023 During 2023, investors subscribed for \$527.3 million, including \$45.2 million from the Company, and redeemed \$117.5 million, including \$10.0 million from the Company, of the participating, non-voting common shares of Medici. As a result of these net subscriptions, the Company's noncontrolling economic ownership in Medici was 11.7% at December 31, 2023. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$531.4 million from subscriptions of shares in Medici by third-party investors, and paid \$102.2 million as a result of redemptions of shares from third-party investors. The Company expects its noncontrolling economic ownership in Medici to fluctuate over time. The activity in redeemable noncontrolling interest a Medici is detailed in the table below: Year ended December 31, 2024 2023 Beginning balance \$1,650,229A \$1,036,218A Redemption of shares from redeemable noncontrolling interests (406,644) (107,549) Sale of shares to redeemable noncontrolling interests 200,219A 482,310A Net income (loss) attributable to redeemable noncontrolling interest 202,941A 239,250A Ending balance \$1,646,745A \$1,650,229A Redeemable Noncontrolling Interest a Vermeer Vermeer is a managed joint venture formed by RenaissanceRe to provide capacity focused on risk remote layers in the U.S. property catastrophe market. RenaissanceRe owns 100% of the voting non-participating shares of Vermeer, while the sole third-party investor, Stichting Pensioenfonds Zorg en Welzijn (a PFZW), a pension fund represented by PGGM Vermogensbeheer B.V., a Dutch pension fund manager, owns 100% of the non-voting participating shares of Vermeer and retains all of the economic benefits. The Company has concluded that Vermeer is a VIE as it has voting rights that are not proportional to its participating rights, and the Company is the primary beneficiary of Vermeer, as it has power over the activities that most significantly impact the economic performance of Vermeer. As a result, the Company consolidates Vermeer and all significant inter-company transactions have been eliminated. As PFZW owns all of the economics of Vermeer, all of Vermeer's earnings are allocated to PFZW in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company has not provided any financial or other support to Vermeer that it was not contractually required to provide. 2024 During 2024, Vermeer declared and paid \$175.0 million of dividends to PFZW. In addition, PFZW subscribed for \$175.0 million of participating, non-voting common shares of Vermeer. 2023 During 2023, Vermeer declared and paid \$175.0 million of dividends to PFZW. The Company does not expect its noncontrolling economic ownership in Vermeer to fluctuate over time. The activity in redeemable noncontrolling interest a Vermeer is detailed in the table below: Year ended December 31, 2024 2023 Beginning balance \$1,555,297A \$1,490,840A Dividends on common shares (175,000) (175,000) Sale of shares to redeemable noncontrolling interest 175,000A a Net income (loss) attributable to redeemable noncontrolling interest 244,560A 239,457A Ending balance \$1,799,857A \$1,555,297A F-60 Redeemable Noncontrolling Interest a Fontana Fontana Holdings L.P. and its subsidiaries (collectively, a Fontana) are a managed joint venture formed by the Company to assume casualty and specialty risks in line with the Company's book of business. RenaissanceRe owns a noncontrolling economic interest in Fontana and controls a majority of Fontana's outstanding voting rights. The Company concluded that Fontana meets the definition of a VIE as the voting rights are not proportional to the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with Fontana and concluded it is the primary beneficiary of Fontana, as it has power over the activities that most significantly impact the economic performance of Fontana. As a result, the Company consolidates Fontana and all significant inter-company transactions have been eliminated. The portion of Fontana's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company may be obligated to repurchase all or a portion of the limited partner interest held by shareholders of Fontana upon request, subject to certain restrictions. The Company has not provided any financial or other support to Fontana

that it was not contractually required to provide.2024During 2024, investors subscribed for \$100.0 million of the limited partner interest of Fontana, including \$50.0 million from the Company. In addition, RenaissanceRe sold an aggregate of \$50.0 million of its limited partner interest in Fontana to other third-party investors. As a result of these transactions, the Companyâ€™s noncontrolling economic ownership in Fontana was 26.5% at December 31, 2024. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received \$129.2 million subscriptions of shares in Fontana by third-party investors. Refer to â€œNote 21. Subsequent Eventsâ€ for additional information related to the Companyâ€™s noncontrolling economic ownership in Fontana subsequent to December 31, 2024.2023During 2023, investors subscribed for \$75.0 million of the limited partner interest of Fontana, including \$23.7 million from the Company. As a result of these subscriptions, the Companyâ€™s noncontrolling economic ownership in Fontana remained at 31.6% at December 31, 2023. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$151.3 million from subscriptions of shares in Fontana by third-party investors. The Companyâ€™s investment in Fontana may fluctuate, perhaps materially, in future quarters. The activity in redeemable noncontrolling interest â€ Fontana is detailed in the table below:Year ended December 31, 20242023Beginning balance\$353,823A \$268,031A Sale of limited partner interest to redeemable noncontrolling interest100,000A 51,316A Net income (loss) attributable to redeemable noncontrolling interest15,616A 34,476A Ending balance\$469,439A \$353,823A NOTE 11. VARIABLE INTEREST ENTITIES Upsilon RFOUpsilon RFO Re Ltd. (â€œUpsilon RFOâ€) is an exempted company incorporated in Bermuda. It is registered as a segregated accounts company and as a collateralized insurer. Upsilon RFO currently has four segregated accounts (Upsilon RFO Diversified I, II, III and IV). RenaissanceRe indirectly owns a portion of the participating non-voting preference shares of three of the existing segregated accounts of Upsilon RFO (Upsilon RFO Diversified I, II and III) and all of Upsilon RFOâ€™s voting Class A shares. The shareholders (other than the voting Class A shareholder) participate in all of the profits or losses of Upsilon RFO while their shares remain outstanding. The shareholders (other than the voting Class A shareholder) indemnify F-61Upsilon RFO against losses relating to insurance risk, and therefore these shares have been accounted for as prospective reinsurance under FASB ASC Topic 944, Financial Services - Insurance. Upsilon RFO is considered a VIE as it has insufficient equity capital to finance its activities without additional financial support. The Company is the primary beneficiary of Upsilon RFO Diversified I, II and III as it has the power over the activities that most significantly impact the economic performance of those segregated accounts and has the obligation to absorb expected losses and the right to receive expected benefits that could be significant to those segregated accounts, in accordance with the accounting guidance. As a result, the Company consolidates Upsilon RFO Diversified I, II and III and all significant inter-company transactions have been eliminated. The Company has determined that it is not the primary beneficiary of Upsilon RFO Diversified IV, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to that segregated account, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of Upsilon RFO Diversified IV. The Company does not have, and does not expect to have, a material investment in Upsilon RFO Diversified IV. In addition, the Company expects its absolute and relative ownership in Upsilon RFO Diversified IV to remain minimal. Other than its equity investments in Upsilon RFO, the Company has not provided financial or other support to Upsilon RFO that it was not contractually required to provide.2024During 2024, and following the release of collateral that was previously held by cedants associated with prior underwriting yearsâ€™ contracts, Upsilon RFO returned \$397.6 million of capital to investors of Upsilon RFO Diversified I, II and III, including \$59.8 million to the Company. At December 31, 2024, the Companyâ€™s participation in the risks assumed by Upsilon RFO Diversified I, II and III was 12.7%. At December 31, 2024, the Companyâ€™s consolidated balance sheet included total assets and total liabilities of Upsilon RFO Diversified I, II and III of \$1.9 billion and \$1.9 billion, respectively (December 31, 2023 - \$2.4 billion and \$2.4 billion, respectively). Of the total assets and liabilities of Upsilon RFO Diversified I, II and III, a net amount of \$60.5 million (December 31, 2023 - \$74.2 million) is attributable to the Company, and \$282.2 million (December 31, 2023 - \$500.0 million) is attributable to third-party investors. Of the total assets and liabilities of Upsilon RFO Diversified IV, a net amount of \$115.9 million (December 31, 2023 - \$88.3 million) is attributable to third-party investors. 2023During 2023, and following the release of collateral that was previously held by cedants associated with prior underwriting yearsâ€™ contracts, Upsilon RFO returned \$988.5 million of capital to investors of Upsilon RFO Diversified I, II and III, including \$125.5 million to the Company. In addition, Upsilon RFO issued \$39.8 million of non-voting preference shares to existing investors, including \$10.2 million to the Company, and 81.4A million of non-voting preference shares to external investors of Upsilon RFO Diversified IV. At December 31, 2023, the Companyâ€™s participation in the risks assumed by Upsilon RFO Diversified I, II and III was 14.3%. Upsilon DiversifiedRenaissanceRe Upsilon Diversified Fund (â€œUpsilon Diversifiedâ€) is a segregated account of RenaissanceRe Upsilon Fund Ltd., (â€œUpsilon Fundâ€), an exempted company incorporated in Bermuda which is registered as a segregated accounts company and a Class A Professional Fund. Upsilon Diversified provides a fund structure through which investors can invest in reinsurance risk managed by the Company, which includes investments in Upsilon RFO and Medici. The Company concluded that Upsilon Diversified meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with Upsilon Diversified and concluded it is not the primary beneficiary of Upsilon Diversified, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to Upsilon Diversified, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of Upsilon Diversified. Upsilon Diversified meets the definition of an investment company in accordance with accounting guidance, and accordingly, is required to account for all of its investments, including its investments in Upsilon RFO and Medici, at fair value. The Company does F-62not have, has not previously had, and does not expect to have, a material investment in Upsilon Diversified. In addition, the Company expects its absolute and relative ownership in Upsilon Diversified to remain minimal. Other than its current equity investment in Upsilon Diversified, the Company has not provided financial or other support to Upsilon Diversified that it was not contractually required to provide. The total assets of Upsilon Diversified principally reflect its investment in Upsilon RFO.2024During 2024, and following the release of collateral from Upsilon RFO, Upsilon Diversified returned \$333.4 million of capital to investors, including \$0.5 million to the Company. In addition, third-party investors subscribed for \$16.9 million of non-voting preference shares. The fair value of the Companyâ€™s indirect equity ownership in Upsilon Diversified is included in investments in other ventures and was \$0.5 million at December 31, 2024 (December 31, 2023 - \$0.8 million). At December 31, 2024, the total assets and total liabilities of Upsilon Diversified were \$440.6 million and \$140.9 million, respectively (December 31, 2023 - \$600.8 million and \$108.0 million, respectively). Upsilon Diversifiedâ€™s investment in Upsilon RFO was valued at \$304.0 million at December 31, 2024 (December 31, 2023 - \$503.1 million).2023During 2023, and following the release of collateral from Upsilon RFO, Upsilon Diversified returned \$844.1 million of capital to investors, including \$1.2 million to the Company. In addition, Upsilon Diversified issued \$30.0 million of non-voting preference shares to existing investors, including \$0.1 million to the Company.NOC1NOC1 is a segregated account of Upsilon Fund formed in 2023, that provides a fund structure through which investors can invest in a portfolio of insurance-linked securities, principally catastrophe bonds. The Company concluded that NOC1 meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with NOC1 and concluded it is not the primary beneficiary of NOC1, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to NOC1, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of NOC1. The Company does not have, and does not expect to have, a material investment in NOC 1 and expects its absolute and relative ownership in NOC1 to remain minimal. Other than its current equity investment in NOC1, the Company has not provided financial or other support to NOC1 that it was not contractually required to provide.2024During 2024, NOC1 issued \$20.0 million of non-voting preference shares to existing investors, including \$0.2 million to the Company. During the year ended December 31, 2024, NOC1 redeemed \$48.8 million of non-voting preference shares to existing investors, including \$0.5 million to the Company. The fair value of the Companyâ€™s indirect equity ownership in NOC1 is included in investments in other ventures and was \$1.7 million at December 31, 2024 (December 31, 2023 - \$1.7 million). At December 31, 2024, the total assets and total liabilities of NOC1 were \$173.4 million and \$2.2 million, respectively (December 31, 2023 - \$196.5 million and \$22.8 million, respectively).2023During 2023, NOC1 issued \$161.5 million of non-voting preference shares to existing investors, including \$1.6 million to the Company.VermeerVermeer provides capacity focused on risk retentive layers in the U.S. property catastrophe market. Refer to â€œNote 10. Noncontrolling Interestâ€ for additional information regarding Vermeer. At December 31, 2024, the Companyâ€™s consolidated balance sheet included total assets and total liabilities of Vermeer of \$1.9 billion and \$93.0 million, respectively (2023 - \$1.7 billion and \$102.7 million, respectively). In addition, the Companyâ€™s consolidated balance sheet included redeemable noncontrolling interests associated with Vermeer of \$1.8 billion at December 31, 2024 (2023 - \$1.6 billion).F-63FontanaFontana provides reinsurance capacity focused on business written within the Companyâ€™s Casualty and Specialty segment. Refer to â€œNote 10. Noncontrolling Interestâ€ for additional information regarding Fontana. At December 31, 2024, the Companyâ€™s consolidated balance sheet included total assets and total liabilities of Fontana of \$2.2 billion and \$1.6 billion, respectively (2023 - \$1.5 billion and \$96.5 million, respectively). In addition, the Companyâ€™s consolidated balance sheet included redeemable noncontrolling interests associated with Fontana of \$469.4 million at December 31, 2024 (2023 - \$353.8 million).Mona Lisa Re Ltd.Mona Lisa Re Ltd. (â€œMona Lisa Reâ€), a Bermuda domiciled special purpose insurer (â€œSPâ€), provides reinsurance capacity to subsidiaries of RenaissanceRe through reinsurance agreements which are collateralized and funded by Mona Lisa Re through the issuance of one or more series of principal-at-risk variable rate notes to third-party investors. Upon issuance of a series of notes by Mona Lisa Re, all of the proceeds from the issuance are deposited into collateral accounts, separated by series, to fund any potential obligation under the reinsurance agreements entered into with Renaissance Reinsurance and/or DaVinci Reinsurance underlying such series of notes. The outstanding principal amount of each series of notes generally will be returned to holders of such notes upon the expiration of the risk period underlying such notes, unless an event occurs which causes a loss under the applicable series of notes, in which case the amount returned will be reduced by such noteholderâ€™s pro rata share of such loss, as specified in the applicable governing documents of such notes. In addition, holders of such notes are generally entitled to interest payments, payable quarterly, as determined by the applicable governing documents of each series of notes. The Company concluded that Mona Lisa Re meets the definition of a VIE as it does not have sufficient equity capital to finance its activities. The Company evaluated its relationship with Mona Lisa Re and concluded it is not the primary beneficiary of Mona Lisa Re as it does not have the power over the activities that most significantly impact the economic performance of Mona Lisa Re, in accordance with the accounting guidance. As a result, the financial position and results of operations of Mona Lisa Re are not consolidated by the Company. The only transactions related to Mona Lisa Re that are recorded in the Companyâ€™s consolidated financial statements are the ceded reinsurance agreements entered into by Renaissance Reinsurance and DaVinci Reinsurance which are accounted for as prospective reinsurance under FASB ASC Topic 944, Financial Services - Insurance, and the fair value of the principal-at-risk variable rate notes owned by the Company. Other than its investment in the principal-at-risk variable rate notes of Mona Lisa Re, the Company has not provided financial or other support to Mona Lisa Re that it was not contractually required to provide. Renaissance Reinsurance and DaVinci Reinsurance have together entered into ceded reinsurance contracts with Mona Lisa Re with ceded premiums written of \$45.2 million and \$11.7 million, respectively, during 2024 (2023 - \$32.8 million and \$8.2 million, respectively, 2022 - \$39.6 million and \$9.9 million, respectively). In addition, Renaissance Reinsurance and DaVinci Reinsurance recognized ceded premiums earned related to the ceded reinsurance contracts with Mona Lisa Re of \$39.5 million and \$10.3 million, respectively, during 2024 (2023 - \$32.8 million and \$8.2 million, respectively, 2022 - \$39.4 million and \$9.8 million, respectively). The following table is a summary of the principal-at-risk variable notes, outstanding at December 31, 2024, Mona Lisa Re issued to investors:Effective DateTotal Principal AmountDecember 3, 2024\$350,000A June 13, 2024\$150,000A December 20, 2022\$85,000A December 20, 2022\$100,000A June 29, 2021\$250,000A F-64At December 31, 2024, the total assets and total liabilities of Mona Lisa Re were \$936.1 million and \$936.1 million, respectively (2023 - \$436.9 million and \$436.9 million, respectively). The fair value of the Companyâ€™s investment in the principal-at-risk variable rate notes of Mona Lisa Re is included in other investments. Net of third-party investors, the fair value of the Companyâ€™s investment in Mona Lisa Re was \$7.0 million at December 31, 2024 (2023 - \$2.2 million).Tailwind Re Ltd.Tailwind Re Ltd. (â€œTailwind Reâ€), a Bermuda domiciled SPI provides reinsurance capacity to subsidiaries of RenaissanceRe through reinsurance agreements which are collateralized and funded by Tailwind Re through the issuance of one or more series of principal-at-risk variable rate notes to third-party investors and the Company. Upon issuance of a series of notes by Tailwind Re, all of the proceeds from the issuance were deposited into collateral accounts, separated by series, to fund any potential obligation under the reinsurance agreements entered into with Validus underlying such series of notes. The outstanding principal amount of each series of notes generally will be returned to holders of such notes upon the expiration of the risk period underlying such notes, unless an event occurs which causes a loss under the applicable series of notes, in which case the amount returned will be reduced by such noteholderâ€™s pro rata share of such loss, as specified in the applicable governing documents of such notes. In addition, holders of such notes are generally entitled to interest payments, payable quarterly, as determined by the applicable governing documents of each series of notes. The Company concluded that Tailwind Re meets the definition of a VIE as it does not have sufficient equity capital to finance its activities. The Company evaluated its relationship with Tailwind Re and concluded it is not the primary beneficiary of Tailwind Re as it does not have the power over the activities that most significantly impact the economic performance of Tailwind Re, in accordance with the accounting guidance. As a result, the financial position and results of operations of Tailwind Re are not consolidated by the Company. The only transactions related to Tailwind Re that are recorded in the Companyâ€™s consolidated financial statements are the ceded reinsurance agreements entered into by certain former Validus entities, which are accounted for as prospective reinsurance under FASB ASC Topic 944, Financial Services - Insurance, and, as at December 31, 2023, the fair value of the principal-at-risk variable rate notes owned by the Company. Other than its investment in the principal-at-risk variable rate notes of Tailwind Re, which were held as at December 31, 2023 but were fully redeemed in the first quarter of 2024, the Company has not provided financial or other support to Tailwind Re that it was not contractually required to provide. The Company recognized ceded premiums written related to the ceded reinsurance contracts with Tailwind Re of \$42.7A million during 2024 (2023 - \$Nil). In addition, the Company recognized ceded premiums earned related to the ceded reinsurance contracts with Tailwind Re of \$42.7A million during 2024 (2023 - \$6.5A million). At December 31, 2024, the total assets and total liabilities of Tailwind Re were \$416.8A million and \$416.8A million, respectively (2023 - \$417.1A million and \$417.1A million, respectively). The fair value of the Companyâ€™s investment in the principal-at-risk variable rate notes of Tailwind Re is included in other investments. Net of third-party investors, the fair value of the Companyâ€™s investment in Tailwind Re was \$Nil at December 31, 2024 (2023 - \$0.8 million).AlphaCatIn connection with the Validus Acquisition, the Company acquired AlphaCat Managers Ltd. (â€œAlphaCat Managersâ€), which manages third-party capital in various forms, including through closed-end and open-end Bermuda mutual funds and one managed account (collectively, the â€œAlphaCat Fundsâ€), which currently generates fee income. The AlphaCat Funds are primarily funded by third-party capital investors. The AlphaCat Funds are invested in various risk-linked instruments through variable funding notes issued by AlphaCat Reinsurance Ltd. (â€œAlphaCat Reâ€), AlphaCat Master Fund Ltd. and OmegaCat Reinsurance Ltd. (â€œOmegaCat Reâ€), which give investors access to a range of property catastrophe risks. Prior to the Validus Acquisition, substantially all of the AlphaCat Funds had received full redemption requests from their investors and capital was being released accordingly, subject to certain constraints. The Company expects to run off the business over a period of time. F-65The Company concluded that the AlphaCat Funds, AlphaCat Re and OmegaCat Re meet the definition of VIEs as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with the AlphaCat Funds, AlphaCat Re and OmegaCat Re and concluded it is not the primary beneficiary as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to the AlphaCat Funds, AlphaCat Re and OmegaCat Re, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of the AlphaCat Funds, AlphaCat Re and OmegaCat Re. The Company has not provided financial or other support to the AlphaCat Funds, AlphaCat Re and OmegaCat Re that it was not contractually required to provide. The total assets of the AlphaCat Funds, AlphaCat Re and OmegaCat Re principally reflect their investments in OmegaCat Re and AlphaCat Re. The fair value of the Companyâ€™s direct equity ownership in the AlphaCat Funds and AlphaCat Re is included in other investments and was \$3.6A million at December 31, 2024 (2023 - \$4.4A million). At December 31, 2024, the total assets and total liabilities of the AlphaCat Funds, AlphaCat Re and OmegaCat Re were \$3.0 billion and \$1.3 billion, respectively (2023 - \$5.0 billion and \$2.4 billion, respectively).Fund InvestmentsThe Companyâ€™s fund investments represent variable interests in limited partnerships entities with unaffiliated fund managers in the normal course of business. Refer to â€œNote 6. Fair Value Measurementsâ€ for additional information. NOTE 12. SHAREHOLDERSâ€™ EQUITY Authorized CapitalThe aggregate authorized capital of RenaissanceRe is 325 million shares consisting of 225 million common shares and 100 million preference shares. The following table is a summary of changes in common shares issued and outstanding:Year ended December 31, 202420232022(thousands of shares)A A Beginning

balance\$2,694.43,718.44,44.54 Issuance of shares\$2.8,568.46"Å Repurchase of shares(2,711)j6c"Å (1,051)Issuance of performance share and restricted stock awards198.408.324.44 Ending balance50,181.52,694.43,718.44 Common SharesOn May 26, 2023, the Company completed an offering of 7,245,000 of its common shares at the public offering price of \$192.00 per share. The Company received net proceeds of approximately \$1,352 million from the equity offering after deducting the underwriting discounts and estimated offering expenses payable by the Company. The Company used the net proceeds from this offering to fund a portion of the cash consideration for the Validus Acquisition, which closed on November 1, 2023, to pay related costs and expenses, and for general corporate purposes. On November 1, 2023, the Company issued 1,322,541 of its common shares to AIG pursuant to the Stock Purchase Agreement, as a part of the total consideration for the Validus Acquisition.See 6cNote 3. Acquisition of Validus6c for additional information regarding the Validus Acquisition.Preference SharesSeries F Preference SharesIn June 2018, RenaissanceRe raised \$250.0A million through the issuance of 10,000 shares of its 5.75% Series F Preference Shares, \$1.00 par value and liquidation preference \$25,000 per share (equivalent to 10,000,000 Depositary Shares, each of which represents a 1/1,000th interest in a 5.75% Series F F-66Preference Share). The 5.75% Series F Preference Shares may be redeemed at a redemption price of \$25,000 per share (equivalent to \$25.00 per Depositary Share), plus declared and unpaid dividends, at RenaissanceRe6c's option on or after June 30, 2023, provided that no redemption may occur prior to June 30, 2028 unless certain redemption requirements are met.Series G Preference SharesIn July 2021, RenaissanceRe raised \$500.0A million through the issuance of 20,000 shares of its 4.20% Series G Preference Shares, \$1.00 par value and liquidation preference \$25,000 per share (equivalent to 20,000,000 Depositary Shares, each of which represents a 1/1,000th interest in a 4.20% Series G Preference Share). The 4.20% Series G Preference Shares have no stated maturity date and may be redeemed at a redemption price of \$25,000 per share (equivalent to \$25.00 per Depositary Share), plus declared and unpaid dividends, at RenaissanceRe6c's option on or after July 15, 2026, provided that no redemption may occur prior to July 15, 2026 unless certain redemption requirements are met. The preference shares have no stated maturity and are not convertible into any other securities of RenaissanceRe. Generally, the preference shares have no voting rights. Whenever dividends payable on the preference shares are in arrears (whether or not such dividends have been earned or declared) in an amount equivalent to dividends for six full dividend periods (whether or not consecutive), the holders of the preference shares, voting as a single class regardless of class or series, will have the right to elect two directors to the Board of Directors of RenaissanceRe.DividendsThe Board of RenaissanceRe declared quarterly dividends of \$0.39 per common share, payable to common shareholders of record on March 15, 2024, June 14, 2024, September 13, 2024 and December 13, 2024, and the Company paid the dividends on March 29, 2024, June 28, 2024, September 30, 2024 and December 31, 2024.The Board of Directors approved the payment of quarterly dividends on each of the series of RenaissanceRe6c's preference shares to preference shareholders of record in the amounts and on the quarterly record dates and dividend payment dates set forth in the prospectus supplement and Certificate of Designation for the applicable series of preference shares, unless and until further action is taken by the Board of Directors. The dividend payment dates for the preference shares will be the first day of March, June, September and December of each year (or if this date is not a business day, on the business day immediately following this date). The record dates for the preference share dividends are one day prior to the dividend payment dates. The amount of the dividend on the 5.750% Series F Preference Shares is an amount per share equal to 5.750% of the liquidation preference per annum (the equivalent to \$1,437.50 per 5.750% Series F Preference Share per annum, or \$359.375 per 5.750% Series F Preference Share per quarter, or \$1.4375 per Depositary Share per annum, or \$0.359375 per Depositary Share per quarter). The amount of the dividend on the 4.20% Series G Preference Shares is an amount per share equal to 4.20% of the liquidation preference per annum (the equivalent to \$1,050 per 4.20% Series G Preference Share per annum, or \$262.50 per 4.20% Series G Preference Share per quarter, or \$1.05 per Depositary Share per annum, or \$0.2625 per quarter).During 2024, the Company paid \$35.4 million in preference share dividends (2023 - \$35.4 million, 2022 - \$35.4 million) and \$80.8 million in common share dividends (2023 - \$75.1 million, 2022 - \$64.7 million).Share RepurchasesThe Company6c's share repurchase program may be effected from time to time, depending on market conditions and other factors, through open market purchases and privately negotiated transactions. On November 6, 2024, RenaissanceRe6c's Board approved an increase in its authorized share repurchase program to an aggregate amount of up to \$750.0 million. Unless terminated earlier by RenaissanceRe6c's Board, the program will expire when the Company has repurchased the full value of the common shares authorized. During 2024, the Company repurchased 2,711,234 common shares at an aggregate cost of \$677.6 million and an average price of \$249.93 per common share. At December 31, 2024, \$287.7 million remained available for repurchase under the share repurchase program. In the future, the Company may authorize additional purchase activities under the currently authorized share repurchase program, increase the amount authorized under the share repurchase program, or adopt additional trading plans. The F-67Company6c's decision to repurchase common shares will depend on, among other matters, the market price of the common shares and the capital requirements of the Company.Refer to Note 21. 6cSubsequent Events6c for additional information related to the share repurchase program subsequent to December 31, 2024.NOTE 13. EARNINGS PER SHARE The following table sets forth the computation of basic and diluted earnings per common share:Year ended December 31,202420232022(common shares in thousands)A Numerator:Net income (loss) available (attributable) to RenaissanceRe common shareholders\$1,834,985A \$2,525,757A \$(1,096,578)Amount allocated to participating common shareholders (1)(27,472)(37,308) (1,079)Net income (loss) allocated to RenaissanceRe common shareholders\$1,807,513A \$2,488,449A \$(1,097,657)Denominator:Denominator for basic income (loss) per RenaissanceRe common share - weighted average common shares (2)51,186A 47,493A 43,040A Per common share equivalents of non-vested shares (2)153A 114A 6c"Å Denominator for diluted income (loss) per RenaissanceRe common share - adjusted weighted average common shares and assumed conversions (2)51,339A 47,607A 43,040A Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share 6c" basic\$35.31A \$52.40A \$(25.50)Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share 6c" diluted\$35.21A \$52.27A \$(25.50)(1)Represents earnings and dividends attributable to holders of unvested shares issued pursuant to the Company6c's stock compensation plans.(2)In periods for which the Company has net loss allocated to RenaissanceRe common shareholders, the denominator used in calculating net loss attributable to RenaissanceRe common shareholders per common share - basic is also used in calculating net loss attributable to RenaissanceRe common shareholders per common share - diluted. For the year ended December 31, 2022, per common share equivalents of non-vested shares of 90 thousand could potentially be dilutive in future periods if the Company reports net income allocated to RenaissanceRe common shareholders.NOTE 14. RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS Tower HillThe Company has entered into reinsurance and other arrangements with certain subsidiaries and affiliates of Tower Hill and has also entered into reinsurance arrangements with respect to business produced by the Tower Hill Companies.During 2024, the Company recorded \$115.1 million (2023 - \$96.8 million, 2022 - \$82.0 million) of gross premiums written assumed from the Tower Hill Companies and its subsidiaries and affiliates. Gross premiums earned totaled \$119.0 million (2023 - \$83.3 million, 2022 - \$80.0 million) and expenses incurred were \$14.2 million (2023 - \$12.7 million, 2022 - \$15.8 million) for 2024. The Company had a net related outstanding receivable balance of \$31.9 million as of December 31, 2024 (2023 - receivable of \$37.0 million). During 2024, the Company assumed net claims and claim expenses of \$94.5 million (2023 - recovered net claims and claim expenses of \$9.8 million, 2022 - assumed net claims and claim expenses of \$68.6 million) and, as of December 31, 2024, had a net reserve for claims and claim expenses of \$95.2 million (2023 - \$50.2 million).In addition, the Company received distributions of \$34.4 million from the Tower Hill Companies during 2024 (2023 - \$22.6 million, 2022 - \$10.5 million).F-68Top LayerDuring 2024, the Company received distributions from Top Layer of \$16.8 million (2023 - \$7.8 million, 2022 - \$8.7 million), and recorded a management fee of \$3.0 million (2023 - \$3.4 million, 2022 - \$2.4 million). The management fee reimburses the Company for services it provides to Top Layer.Broker ConcentrationDuring 2024, the Company received 82.1% of its gross premiums written (2023 - 84.3%, 2022 - 82.2%) from three brokers. Subsidiaries and affiliates of Aon plc, Marsh & McLennan Companies, Inc. and Arthur J. Gallagher accounted for 32.0%, 36.5% and 13.6%, respectively, of the Company6c's gross premiums written in 2024 (2023 - 36.1%, 33.2% and 15.0%, respectively).NOTE 15. TAXATIONThrough December 31, 2024 RenaissanceRe and its Bermuda subsidiaries were not subject to any income or capital gains taxes in Bermuda. A 15% corporate income tax applies to the Company6c's Bermuda operations, except for the Bermuda operations of the Company6c's joint ventures and managed funds, starting in 2025 as a result of the enactment of the Bermuda Corporate Income Tax Act 2023 (6c6cCIT6c) on December 27, 2023. Furthermore, the Company generally expects that the profits generated in Bermuda on or after January 1, 2025 by the Company6c's joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the global anti-base erosion model rules (6c6cGloBE Rules6c) by many of the jurisdictions in which the Company operates. As a result, the Company expects its income taxes to increase beginning in 2025.RenaissanceRe Finance and its subsidiaries are subject to income taxes imposed by U.S. federal and state authorities and file a consolidated U.S. federal income tax return. Should the U.S. subsidiaries pay a dividend to RenaissanceRe, withholding taxes would apply to the extent of current year or accumulated earnings and profits at an expected tax rate of 5.0%. The Company has not accrued withholding taxes on the unremitted earnings of RenaissanceRe Finance to date as there is no intention to remit such earnings. The cumulative amount that would be subject to withholding tax, if distributed, is not practicable to compute. The Company also has operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, Canada and Australia which are subject to income taxes imposed by the respective jurisdictions in which they operate. Withholding taxes would not be expected to apply to dividends paid to RenaissanceRe from its operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, and Australia.The following is a summary of the Company6c's income (loss) before taxes allocated between domestic and foreign operations:Year ended December 31,202420232022DomesticBermuda\$2,704,721A \$2,622,066A \$(672,950)ForeignSingapore61,570A 64,003A 112A Ireland2,650A 1,730A 6A U.S.93,606A 308,768A (367,799)Australi(72,773)Luxembourg(50)(16)6c"Å Canada(3,501)2,040 6c"Å U.K.62,092A 125,915A (76,217)Income (loss) before taxes\$2,993,160A \$3,110,060A \$(1,218,835)F-69Income tax benefit (expense) is comprised as follows:Income tax benefit (expense)CurrentDeferredTotalYear ended December 31,2024\$(56,718)\$24,090A \$(32,628)Year ended December 31, 2023\$(57,422)\$567,489A \$510,067A Year ended December 31, 2022\$(3,078)\$62,097A \$59,019A The Company6c's expected income tax provision computed on pre-tax income (loss) at the weighted average tax rate has been calculated as the sum of the pre-tax income (loss) in each jurisdiction multiplied by that jurisdiction6c's applicable statutory tax rate. Statutory tax rates of 0.0% in Bermuda, 21.0% in the U.S., 12.5% in Ireland, 25.0% in the U.K., 17.0% in Singapore, 19.7% in Switzerland, 24.9% in Luxembourg, 26.5% in Canada and 30.0% in Australia have been used. The Company6c's effective income tax rate, which it calculates as income tax benefit (expense) divided by income (loss) before taxes, may fluctuate significantly from period to period depending on the geographic distribution of pre-tax income (loss) in any given period between different jurisdictions with comparatively higher tax rates and those with comparatively lower tax rates. The geographic distribution of pre-tax income (loss) can vary significantly between periods due to, but not limited to, the following factors: the business mix of net premiums written and earned; the geographic location, the size and the nature of net claims and claim expenses incurred; the amount and geographic location of operational expenses, net investment income, net realized and unrealized gains (losses) on investments; outstanding debt and related interest expense; and the amount of specific adjustments to determine the income tax basis in each of the Company6c's operating jurisdictions.A In addition, a significant portion of the Company6c's gross and net premiums are currently written and earned in Bermuda, which does not currently have a corporate income tax, including the majority of the Company6c's catastrophe business, which can result in significant volatility to its pre-tax net income (loss) in any given period. The Company expects its consolidated effective tax rate will increase in 2025 as a result of the enactment of the CIT in Bermuda and the implementation of the GloBE Rules in certain jurisdictions where it operates. In addition, it is possible the Company could be adversely affected by other future changes in tax laws, regulation, or enforcement, any of which could increase the effective tax rate more rapidly or steeply than currently anticipated.A reconciliation of the difference between the provision for income taxes and the expected tax provision at the weighted average tax rate is as follows:Year ended December 31,202420232022Expected income tax benefit (expense)\$(60,684)\$103,963\$114,721A Nondeductible expenses(1,671)(535)(508)Reinsurance adjustment4,384A 4,746A (1,265)Effect of change in tax rate(160)(729)7,461A OECD Pillar Two global minimum tax(16,603)6c"Å 6c"Å GAAP to statutory accounting difference(1,113)(1,781) (6,019)Withholding tax(1,614)(1,078)(2,154)Recognition of Bermuda net deferred tax asset8,339A 593,765 6c"Å A Change in valuation allowance66,198A 45,192A (62,133)Foreign branch adjustments(30,998)(25,908)11,656A Other1,294A 358A (2,740)Income tax benefit (expense)\$(62,628)\$510,067A \$59,019A F-70The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below:At December 31,20242023Deferred tax assetsIntangible assets\$420,143A \$408,654A Value of in-force business167,599A 167,599A Tax loss carryforwards152,864A 197,498A Reserve for claims and claim expenses131,121A 95,685A Unearned premiums59,441A 68,408A Amortization and depreciation23,877A 16,386A Deferred finance charges17,832A 19,442A Accrued expenses4,336A 2,849A Investments2,687A 37,044A Deferred underwriting results1,548A 9,773A 981,448A 1,022,938A Deferred tax liabilitiesDeferred acquisition expenses(125,347)(112,157)VOBA(17,540)(46,109)Deferred revenue(8,685)6c"Å U.S. tax accounting method change(7,312)6c"Å A (158,884)(158,266)Net deferred tax asset (liability) before valuation allowance822,564A 864,672A Valuation allowance(147,079)(213,277)Net deferred tax asset (liability)\$675,485A \$651,395A A substantial amount of the Company6c's net deferred tax asset is separately reflected as an asset in the consolidated balance sheets with the remaining net deferred tax liability recorded in other liabilities.The Company6c's net deferred tax asset primarily relates to net operating loss and capital loss carryforwards, unrealized losses in the U.S. investment portfolio, and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, value of in-force business, intangible assets, VOBA, deferred acquisition expenses and amortization and depreciation. The Company6c's valuation allowance assessment is based on all available information including projections of future GAAP taxable income from each tax-paying component in each tax jurisdiction. During 2024, the Company recorded a net decrease to the valuation allowance of \$66.2 million (2023 - increase of \$19.6 million, 2022 - increase of \$62.1 million).A valuation allowance has been provided against certain deferred tax assets in the U.S., Canada, Ireland, the U.K., Luxembourg and Switzerland. These deferred tax assets relate primarily to net operating loss carryforwards, deferred finance charges, capital loss carryforwards and unrealized losses in the U.S. investment portfolio. In the U.S. and Switzerland, the Company has net operating loss carryforwards of \$97.3 million and \$350.0 million respectively. Under applicable law, the U.S. and Swiss net operating loss carryforwards will begin to expire in 2037 and 2025 respectively. The Company has net operating loss carryforwards of \$141.2 million in the U.K., \$8.3 million in Ireland, and \$155.7 million in Luxembourg. Under applicable law, the U.K., Ireland and Luxembourg net operating losses can be carried forward for an indefinite period. The Company has capital loss carryforwards of \$131.6 million in the U.S. that begin to expire in 2027. The Company has unrealized losses in the U.S. investment portfolio of \$60.6 million. These unrealized investment losses do not expire. However, if realized, these losses may only offset realized capital gains and would expire, if unused, at the end of the fifth taxable year following their realization.F-71The Company made net payments for U.S. federal and state, Canada, Ireland, U.K., Singapore, Switzerland and Australia income taxes of \$99.5 million for the year ended 2024 (2023 - net payments of \$26.8 million, 2022 - net payments of \$3.1 million).The Company had no unrecognized tax benefits at December 31, 2024 and December 31, 2023. Interest and penalties related to unrecognized tax benefits would be recognized in income tax expense.A At December 31, 2024 and December 31, 2023, there were no interest or penalties accrued on unrecognized tax benefits.The following filed income tax returns are open for examination with the applicable tax authorities: tax years 2018 through 2023 with the U.S.; 2020 through 2023 with Ireland; 2022 through 2023 with the U.K.; 2020 through 2023 with Singapore; 2021 through 2023 with Switzerland; 2020 through 2023 with Australia; 2020 through 2023 with Canada; and 2019 through 2023 with Luxembourg. The Company does not expect the resolution of these open years to have a significant impact on its consolidated statements of operations and financial condition.NOTE 16. SEGMENT REPORTING The Company6c's reportable segments are defined as follows: (1) Property, which is comprised of catastrophe and other property (re)insurance written on behalf of the Company6c's consolidated operating subsidiaries, joint ventures and managed funds, and (2) Casualty and Specialty, which is comprised of casualty and specialty (re)insurance written on behalf of the Company6c's consolidated operating subsidiaries, joint ventures and managed funds. In addition to its reportable segments, the Company has an Other category, which primarily includes its investments unit, strategic investments, corporate expenses, capital servicing costs, noncontrolling interests and certain expenses related to acquisitions and dispositions.The Company6c's reportable segments each have executive leadership who are responsible for the overall performance of their respective segments and who are directly accountable to the Company6c's chief operating decision maker (6c6cCODM6c), the Chief Executive Officer of RenaissanceRe, who is ultimately responsible for reviewing the business to assess performance, make operating decisions and allocate resources. The Company reports the results of its operations consistent with the manner in which the CODM reviews the business.The Company does not manage its assets by segment; accordingly, net investment income and total assets are not allocated to the segments.F-72A summary of the significant components of the Company6c's revenues and expenses by segment is as follows:Year ended December 31, 2024PropertyCasualty and

SpecialtyOtherTotalGross premiums written\$4,823,731Â \$6,909,335Â \$â€”Â \$11,733,066Â Net premiums written\$3,833,636Â \$6,118,580Â \$â€”Â \$9,952,216Â Net premiums earned\$3,850,352Â \$6,245,408Â \$â€”Â \$10,095,760Â Net claims and claim expenses incurred\$1,411,726Â \$4,191,255Â \$â€”Â \$5,332,981Â Acquisition expenses\$75,554Â \$1,885,313Â \$â€”Â \$2,643,867Â Operational expenses\$302,360Â \$94,228Â \$â€”Â \$496,588Â Underwriting income (loss)\$1,647,712Â \$(25,388)\$â€”Â \$1,622,324Â Net investment income1,654,289Â \$1,654,289Â Net foreign exchange gains (losses)(76,076)(76,076)Equity in earnings (losses) of other ventures47,087Â \$47,087Â Other income (loss)\$1,928Â \$1,928Â Net realized and unrealized gains (losses) on investments(27,840)(27,840)Corporate expenses(134,784)(134,784)Interest expense(93,768)(93,768)Income (loss) before taxes2,993,160Â Income tax benefit (expense)(32,628)(32,628)Net (income) loss attributable to redeemable noncontrolling interests(1,090,172)(1,090,172)Dividends on preference shares(35,375)(35,375)Net income (loss) available (attributable) to RenaissanceRe common shareholders\$1,834,985Â Net claims and claim expenses incurred â€” current accident year\$1,960,578Â \$4,223,737Â \$â€”Â \$6,184,315Â Net claims and claim expenses incurred â€” prior accident years(818,852)(32,482)\$â€”Â \$(851,334)Net claims and claim expenses incurred â€” total\$1,141,726Â \$4,191,255Â \$â€”Â \$5,332,981Â Net claims and claim expense ratio â€” current accident year50.9Â %67.6Â %61.3Â %Net claims and claim expense ratio â€” prior accident years(21.2)(0.5)(8.5)%Net claims and claim expense ratio â€” calendar year29.7Â %67.1Â %52.8Â %Underwriting expense ratio27.5Â %63.3Â %31.1Â %Combined ratio57.2Â %100.4Â %83.9Â %F-73Year ended December 31, 2023PropertyCasualty and SpecialtyOtherTotalGross premiums written\$3,562,414Â \$5,299,952Â \$â€”Â \$8,862,366Â Net premiums written\$2,967,309Â \$4,500,504Â \$â€”Â \$7,467,813Â Net premiums earned\$3,090,792Â \$4,380,341Â \$â€”Â \$7,471,133Â Net claims and claim expenses incurred\$799,905Â \$2,773,604Â \$â€”Â \$3,573,509Â Acquisition expenses\$600,127Â \$1,274,907Â \$â€”Â \$1,875,034Â Operational expenses\$25,433Â \$123,749Â \$â€”Â \$375,182Â Underwriting income (loss)\$1,439,327Â \$208,081Â \$â€”Â \$1,647,408Â Net investment income1,253,110Â \$1,253,110Â Net foreign exchange gains (losses)(41,479)(41,479)Equity in earnings (losses) of other ventures43,474Â \$43,474Â Other income (loss)(6,152)(6,152)Net realized and unrealized gains (losses) on investments414,522Â \$414,522Â Corporate expenses(127,642)(127,642)Interest expense(73,181)(73,181)Income (loss) before taxes3,110,060Â Income tax benefit (expense)\$510,067Â \$510,067Â Net (income) loss attributable to redeemable noncontrolling interests(1,058,995)(1,058,995)Dividends on preference shares(35,375)(35,375)Net income (loss) available (attributable) to RenaissanceRe common shareholders\$2,525,757Â Net claims and claim expenses incurred â€” current accident year\$1,208,810Â \$2,815,306Â \$â€”Â \$4,024,116Â Net claims and claim expenses incurred â€” prior accident years(408,905)(41,702)\$â€”Â \$(450,607)Net claims and claim expenses incurred â€” total\$799,905Â \$2,773,604Â \$â€”Â \$3,573,509Â Net claims and claim expense ratio â€” current accident year39.1Â %64.3Â %53.9Â %Net claims and claim expense ratio â€” prior accident years(13.2)(1.0)(6.1)%Net claims and claim expense ratio â€” calendar year25.9Â %63.3Â %47.8Â %Underwriting expense ratio27.5Â %63.1Â %47.8Â %Combined ratio53.4Â %95.2Â %77.9Â %F-74Year ended December 31, 2022PropertyCasualty and SpecialtyOtherTotalGross premiums written\$3,734,241Â \$5,479,299Â \$â€”Â \$9,213,540Â Net premiums written\$2,847,659Â \$4,348,501Â \$â€”Â \$7,196,160Â Net premiums earned\$2,770,227Â \$3,563,762Â \$â€”Â \$6,333,989Â Net claims and claim expenses incurred\$2,044,771Â \$2,294,069Â \$â€”Â \$4,338,840Â Acquisition expenses\$47,210Â \$1,021,396Â \$â€”Â \$1,568,606Â Operational expenses\$194,355Â \$82,336Â \$â€”Â \$276,691Â Underwriting income (loss)\$1(16,109)\$165,961Â \$â€”Â \$149,852Â Net investment income\$559,932Â \$559,932Â Net foreign exchange gains (losses)(56,909)(56,909)Equity in earnings (losses) of other ventures11,249Â \$11,249Â Other income (loss)(12,636)\$12,636Â Net realized and unrealized gains (losses) on investments(1,800,485)(1,800,485)Corporate expenses(46,775)(46,775)Interest expense(48,335)(48,335)Income (loss) before taxes(1,218,835)Income tax benefit (expense)\$59,019Â \$59,019Â Net (income) loss attributable to redeemable noncontrolling interests\$98,613Â \$98,613Â Dividends on preference shares(35,375)(35,375)Net income (loss) available (attributable) to RenaissanceRe common shareholders\$(1,096,578)Net claims and claim expenses incurred â€” current accident year\$2,250,512Â \$2,335,910Â \$â€”Â \$4,586,422Â Net claims and claim expenses incurred â€” prior accident years(205,741)(41,841)\$â€”Â \$(247,582)Net claims and claim expenses incurred â€” total\$2,044,771Â \$2,294,069Â \$â€”Â \$4,338,840Â Net claims and claim expense ratio â€” current accident year81.2Â %65.5Â %72.4Â %Net claims and claim expense ratio â€” prior accident years(7.4)(1.1)(3.9)%Net claims and claim expense ratio â€” calendar year73.8Â %64.4Â %68.5Â %Underwriting expense ratio26.8Â %30.9Â %29.2Â %Combined ratio100.6Â %95.3Â %97.7Â %F-75The following is a summary of the Companyâ€™s gross premiums written allocated to the territory of coverage exposure:202420232022Year ended December 31, GrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenGrossPremiumsWrittenPercentageof GrossPremiumsWrittenWorldwide3,217,662Â 27.3Â %2,280,687Â 25.7Â %2,328,030Â 25.3Â %U.S. and Caribbean2,996,981Â 25.5Â %2,303,013Â 26.0Â %2,343,830Â 25.5Â %Worldwide1,063,292Â 9.1Â %798,623Â 9.0Â %1,053,369Â 11.4Â %Europe244,523Â 2.1Â %163,500Â 1.9Â %62,998Â 0.7Â % (excluding U.S.) (1)180,688Â 1.5Â %70,646Â 0.8Â %37,436Â 0.4Â %Japan106,533Â 0.9Â %85,823Â 1.0Â %104,767Â 1.1Â %Australia and New Zealand101,976Â 0.9Â %70,107Â 0.8Â %86,080Â 0.9Â %Other129,738Â 1.1Â %70,702Â 0.8Â %45,761Â 0.5Â %Total Property4,823,731Â 41.1Â %3,562,414Â 40.3Â %3,734,241Â 40.5Â %Casualty and SpecialtyWorldwide3,217,662Â 27.3Â %2,280,687Â 25.7Â %2,328,030Â 25.3Â %U.S. and Caribbean2,986,956Â 25.5Â %2,333,096Â 26.3Â %2,556,466Â 27.7Â %Europe353,863Â 3.0Â %197,228Â 2.2Â %327,831Â 3.6Â %Worldwide (excluding U.S.) (1)195,489Â 1.7Â %130,334Â 1.5Â %177,746Â 1.9Â %Australia and New Zealand43,183Â 0.4Â %27,397Â 0.3Â %35,973Â 0.4Â %Other112,182Â 1.0Â %331,210Â 3.7Â %53,253Â 0.6Â %Total Casualty and Specialty6,909,335Â 58.9Â %5,299,952Â 59.7Â %5,479,299Â 59.5Â %Total gross premiums written\$11,733,066Â 100.0Â %\$8,862,366Â 100.0Â %\$9,213,540Â 100.0Â % (1)The category â€œWorldwide (excluding U.S.)â€”consists of contracts that cover more than one geographic region (other than the U.S.).NOTE 17. STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANSStock Incentive Compensation Plans and AwardsThe Company is authorized to issue restricted stock awards, restricted stock units, performance share awards, stock options and other share-based awards to its employees and directors pursuant to various stock incentive compensation plans. On May 16, 2022, the Companyâ€™s shareholders approved the Companyâ€™s First Amended and Restated 2016 Long-Term Incentive Plan, which amended and restated the plan initially approved by the shareholders in May 2016 (as amended from time to time, the â€œ2016 Long-Term Incentive Planâ€”). The Company is authorized to issue up to 3,060,092 common shares pursuant to the 2016 Long-Term Incentive Plan. The 2016 Long-Term Incentive Plan permits the grant of restricted stock awards, restricted stock units, performance share awards (including cash-based performance awards), stock options and other share-based awards to employees, officers, non-employee directors and consultants or advisors of the Company and its affiliates.In November 2016, the Company instituted a cash settled restricted stock unit (â€œCSRSUâ€”) plan, the 2016 Restricted Stock Unit Plan, which allows for the issuance of equity awards in the form of CSRSUs. There are currently no outstanding awards under this plan.Restricted Stock AwardsRestricted stock awards granted to employees under the 2016 Long-Term Incentive Plan generally vest ratably over a four-year period. Restricted stock awards granted to non-employee directors generally vest ratably over a three-year period.Performance Share AwardsPerformance share awards granted to certain of the Companyâ€™s executive officers pursuant to the 2016 Long-Term Incentive Plan are subject to vesting conditions based on both continued service and the attainment of pre-established performance goals. If performance goals are achieved, the performance F-76share awards will vest up to a maximum of 200% of target. Performance share awards generally cliff vest at the end of a three-year vesting period based on the attainment of performance goals over the three-year performance period. Performance Share Awards Granted in March 2019Performance share awards granted in March 2019 had a performance condition, which was the percentage change in the Companyâ€™s tangible book value per common share plus change in accumulated dividends, or, in the event of a change in control, a market condition, which was the Companyâ€™s total shareholder return relative to its peer group.Performance Share Awards Granted Beginning in March 2020Beginning with awards granted in March 2020, performance share awards have performance conditions, which are the average percentage change in the Companyâ€™s book value per common share plus change in accumulated dividends over three years and the three-year average underwriting expense ratio rank compared to peers, or, in the event of a change in control, a market condition, which is the Companyâ€™s total shareholder return relative to its peer group. The performance conditions are calculated in accordance with the terms of the applicable award agreement.Valuation AssumptionsPerformance Share Awards Granted in March 2019For performance share awards granted in March 2019, the performance metric related to the percentage change in tangible book value per share plus change in accumulated dividends which is classified as a performance condition under FASB ASC Topic 718, Compensation - Stock Compensation. As a result, the fair value of the performance share awards was determined based on the fair market value of RenaissanceReâ€™s common shares on the grant date. The estimated fair value of performance share awards was amortized as an expense over the requisite service period. Performance Share Awards Granted Beginning in March 2020For performance share awards granted beginning in March 2020, the performance metrics relate to (i) the percentage change in book value per share plus change in accumulated dividends and (ii) average underwriting expense ratio rank compared to peers, both of which are classified as performance conditions under FASB ASC Topic 718, Compensation - Stock Compensation. As a result, the fair value of the performance share awards is determined based on the fair market value of RenaissanceReâ€™s common shares on the grant date. The estimated fair value of performance share awards is amortized as an expense over the requisite service period.Restricted Stock AwardsThe fair value of restricted stock awards is determined based on the fair market value of RenaissanceReâ€™s common shares on the grant date. The estimated fair value of restricted stock awards is amortized as an expense over the requisite service period. The Company has elected to recognize forfeitures as they occurred rather than estimating service-based forfeitures over the requisite service period.F-77Summary of Stock Compensation ActivityPerformance Share AwardsThe following table provides a roll forward of the Companyâ€™s unvested performance share awards:Number ofShares (1)WeightedAverage Grant Date Fair ValueNonvested at December 31, 2021141,068Â \$163.98Â Awards granted69,548Â \$145.49Â Awards forfeited(19,352)\$â€”Â \$Nonvested at December 31, 2022191,264Â \$159.07Â Awards granted160,796Â \$211.18Â Awards vested(38,461)\$170.40Â Awards forfeited(26,994)\$â€”Â \$Nonvested at December 31, 2023286,220Â \$185.73Â Awards granted50,654Â \$223.35Â Awards vested(53,083)\$162.61Â Awards forfeited(2,793)\$â€”Â \$Nonvested at December 31, 2024280,998Â \$197.11Â (1) Â Â Â For performance share awards, the number of shares is stated at the maximum number that can be attained if the performance conditions are fully met. Forfeitures represent shares forfeited due to vesting below the maximum attainable as a result of the Company not fully meeting the performance conditions.Restricted Stock AwardsThe following table provides a roll forward of the Companyâ€™s unvested restricted stock awards:EmployeeRestricted Stock AwardsNon-Employee DirectorRestricted Stock AwardsTotalRestricted Stock AwardsNumber ofSharesWeightedAverage Grant Date Fair ValueNumber ofSharesWeightedAverage Grant Date Fair ValueNumber ofSharesWeightedAverage Grant Date Fair ValueNonvested at December 31, 2021623,332Â \$153.02Â \$162.60Â \$643,933Â \$153.32Â Awards granted354,887Â \$143.86Â \$12,721Â \$145.77Â \$367,608Â \$143.92Â Awards vested(242,628)\$148.30Â \$(2,307)\$159.20Â \$(254,935)\$148.83Â Awards forfeited(22,795)\$â€”Â \$â€”Â \$â€”Â \$(22,795)\$â€”Â \$Nonvested at December 31, 2022712,796Â \$150.19Â \$21,015Â \$154.40Â \$733,811Â \$150.31Â Awards granted378,994Â \$199.24Â \$9,064Â \$215.79Â \$388,058Â \$199.65Â Awards vested(279,363)\$151.15Â \$(11,861)\$161.56Â \$(291,224)\$151.57Â Awards forfeited(15,278)\$â€”Â \$â€”Â \$â€”Â \$(15,278)\$â€”Â \$Nonvested at December 31, 2023797,149Â \$172.74Â \$18,218Â \$180.70Â \$815,367Â \$172.91Â Awards granted260,293Â \$234.94Â \$8,645Â \$223.66Â \$268,854Â \$234.69Â Awards vested(293,175)\$164.67Â \$(10,749)\$177.16Â \$(303,924)\$165.11Â Awards forfeited(17,694)\$â€”Â \$â€”Â \$â€”Â \$(17,694)\$â€”Â \$Nonvested at December 31, 2024746,489Â \$197.26Â \$16,114Â \$207.95Â \$762,603Â \$197.49Â There were 0.8 million shares available for issuance under the 2016 Long-Term Incentive Plan at December 31, 2024. F-78The aggregate fair value of restricted stock awards and performance share awards vested during 2024 was \$82.8 million (2023 - \$70.0 million, 2022 - \$38.8 million). In connection with share vestings, there was a \$2.0 million excess windfall tax benefit realized by the Company in 2024 (2023 - \$1.7 million, 2022 - \$0.1 million). The total stock compensation expense recognized in the Companyâ€™s consolidated statements of operations during 2024 was \$71.4 million (2023 - \$60.3 million, 2022 - \$45.2 million). As of December 31, 2024, there was \$107.6 million of total unrecognized compensation cost related to restricted stock awards and \$17.8 million related to performance share awards, which will be recognized on a weighted average basis during the next 1.8 years and 1.8 years, respectively.All of the Companyâ€™s employees are eligible for defined contribution pension plans. Contributions are primarily based upon a percentage of eligible compensation. The Company contributed \$12.0 million to its defined contribution pension plans in 2024 (2023 - \$9.5 million, 2022 - \$6.7 million).NOTE 18. STATUTORY REQUIREMENTSThe Companyâ€™s (re)insurance operations are subject to insurance laws and regulations in the jurisdictions in which they operate, the most significant of which currently include Bermuda, Switzerland, the U.K. and the U.S. These regulations include certain restrictions on the amount of dividends or other distributions, such as loans or cash advances, available to shareholders without prior approval of the respective regulatory authorities. The following table summarizes the statutory capital and surplus and required minimum statutory capital and surplus of the Companyâ€™s primary regulated insurance operations in its most significant regulatory jurisdictions:Bermuda (1)Switzerland (2)U.K. (3)U.S. (4)At December 31, 202420232024202320242023Statutory capital and surplus\$11,793,261Â \$12,141,907Â \$1,908,106Â \$2,644,998Â \$952,309Â \$935,776Â \$1,255,304Â \$1,044,010Â Required statutory capital and surplus\$2,686,108Â \$2,284,208Â \$1,049,922Â \$987,707Â \$952,309Â \$935,776Â \$967,735Â \$794,061Â (1)Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). The Companyâ€™s primary Bermuda-domiciled insurance subsidiariesâ€”required statutory capital and surplus is based on the minimum solvency margin. On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated. The previously reported statutory capital and surplus and required statutory capital and surplus at December 31, 2023 have been updated to actual amounts filed and reflect guidance received by the BMA on February 23, 2024 related to the impact of the CIT in the statutory financial statements.(2)Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland (which was acquired on November 1, 2023) and its Bermuda branch. On June 21, 2024, Validus Switzerland merged into RREAG.(3)Includes Syndicate 1458. With respect to statutory capital and surplus and required statutory capital and surplus, underwriting capacity of a member of Lloydâ€™s must be supported by providing a deposit in the form of cash, securities or letters of credit, which are referred to as FAL. Syndicate 1458 is capitalized by its FAL, with the related assets not held on its balance sheet.(4)Includes Renaissance Reinsurance U.S.F-79The following table summarizes the statutory net income (loss) of the Companyâ€™s primary regulated insurance operations in its most significant regulatory jurisdictions:Statutory Net Income (Loss)Bermuda (1)Switzerland (2)U.K. (3)U.S. (4)Year ended December 31, 2024\$2,056,265Â \$312,000Â \$89,169Â \$(87,897)Year ended December 31, 2023\$2,699,083Â \$225,751Â \$158,258Â \$(17,618)Year ended December 31, 2022\$706,676(244,035)(24,573)35,344Â (1)Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated.(2)Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland and its Bermuda branch (which was acquired on November 1, 2023). On June 21, 2024 Validus Switzerland merged into RREAG.(3)Includes Syndicate 1458.(4)Includes Renaissance Reinsurance U.S.The difference between statutory financial statements and statements prepared in accordance with GAAP varies by jurisdiction; however, the primary difference is that for the Companyâ€™s regulated entities the statutory financial statements generally do not reflect goodwill and intangible assets. Also, in the U.S., fixed maturity investments are generally recorded at amortized cost and deferred income tax is charged directly to equity. In the U.S. and Bermuda, deferred acquisition costs are generally not reflected in the statutory financial statements. In Switzerland, currency translation adjustment losses are directly charged to net income (loss), while translation gains are not admissible and reflected as translation reserve on the statutory balance sheet. In addition, fixed maturity investments are carried at the lower of amortized cost and market value and recognition of equalization reserves is allowed. The prudence principle standard also allows for valuating certain assets below their nominal value. None of the Companyâ€™s insurance subsidiaries used permitted practices that prevented the trigger of a regulatory event during the years ended December 31, 2024, 2023 and 2022.Dividend Restrictions of RenaissanceReAs a Bermuda-domiciled holding company, RenaissanceRe has limited operations of its own. Its assets consist primarily of investments in subsidiaries and cash and securities. As a result, the Company relies primarily on dividends and distributions (and other statutorily permissible payments) from its subsidiaries, investment income and fee income to meet its liquidity requirements, which primarily include making principal and interest

payments on its debt, and dividend payments to its shareholders, the payment of dividends by the Company and its subsidiaries, limited by the applicable laws and regulations in the various jurisdictions in which the subsidiaries operate, including Bermuda, the U.S., the U.K., Switzerland, Australia, Singapore and Ireland. In addition, insurance laws require the Company's insurance subsidiaries to maintain certain measures of solvency and liquidity. Bermuda-registered insurance companies are regulated under the Bermuda Insurance Act 1978, as amended, and related regulations (collectively, the "Insurance Act"), which impose various requirements depending on a company's classification under the Insurance Act. The Company and certain of its Bermuda-registered insurers are generally required to maintain available statutory economic capital and surplus at a level at least equal to their enhanced capital requirement (the "ECR"), which is established by reference to the Bermuda Capital and Solvency Ratio (the "BSCR") model. The ECR may be adjusted by the BMA if it concludes that the insurer's risk profile deviates significantly from the assumptions underlying its ECR or the insurer's assessment of its risk management policies and practices used to calculate the ECR. The BMA has established a target capital level applicable to certain registration categories, and to insurance groups, equal to 120% of the applicable ECR. Failure to maintain statutory capital at least equal to the target capital level would likely result in increased BMA regulatory oversight. The Company and F-80 certain of its Bermuda-registered insurers are generally required to file an annual BSCR with the BMA. The Company's 2023 group BSCR was filed with the BMA on May 31, 2024 with a BSCR ratio of 263%. Renaissance Reinsurance and DaVinci Reinsurance are registered as Class 4 general business insurers, Renaissance Specialty U.S. and Vermeer are registered as Class 3B general business insurers, and Fontana Reinsurance Ltd. and Fontana Reinsurance U.S. Ltd. are registered as Class 3A general business insurers under the Insurance Act. Class 4, Class 3B and Class 3A insurers are required to maintain available statutory economic capital and surplus at a target capital level equal to 120% of the ECR. Unlike other (re)insurers, special purpose insurers and collateralized insurers are fully funded to meet their (re)insurance obligations. Renaissance Europe AG, Bermuda Branch, a Class 3B general business insurer, has modified requirements, which are addressed under Switzerland, below. Class 4, Class 3B and Class 3A insurers are prohibited from declaring or paying any dividends if in breach of the required minimum solvency margin or minimum liquidity ratio, or if the declaration or payment of such dividend would cause the insurer to fail to meet the required minimum solvency margin or minimum liquidity ratio. Further, certain categories of insurers are prohibited to declare or pay dividends over certain thresholds without the BMA's approval. These restrictions on declaring or paying dividends and distributions under the Insurance Act are in addition to the solvency requirements under the Bermuda Companies Act 1981. Switzerland RREAG is a reinsurance company licensed and supervised by the Swiss Financial Market Supervisory Authority FINMA (the "FINMA"). The minimum capital requirement for a Swiss reinsurance company under the Insurance Supervisory Act for reinsurance license class C1 is CHF 10 million. RREAG must further maintain adequate solvency and provide for sufficient free and unencumbered capital in relation to its activities in accordance with the Swiss Solvency Test (the "SST"). The solvency requirement is met if the available risk-bearing capital exceeds the required target capital. It is then assessed whether the identified available capital can meet the SST requirements and is sufficient to cover the company's obligations in less favorable scenarios. RREAG maintains branch operations in Australia, Bermuda, the U.K. and the U.S., each in accordance with applicable local regulations, which may include statutory capital requirements. RREAG may only distribute dividends out of its retained earnings or distributable reserves based on the audited annual accounts of the company. Any distribution of dividends remains subject to the approval of FINMA (as a change of the regulatory business plan) if they have a bearing on the solvency of the reinsurer and/or the interests of the insured. The solvency and capital requirements must still be met following any distribution. U.K. The underwriting capacity of a member of Lloyd's must be supported by providing a deposit, referred to as "Funds at Lloyd's" or the "FAL", in the form of cash, securities or letters of credit in an amount determined under the capital adequacy regime of the U.K. Prudential Regulatory Authority (the "PRA"). The amount of such deposit is calculated for each member through the completion of a quarterly capital adequacy exercise. Under these requirements, Lloyd's must demonstrate that each member has sufficient assets to meet its underwriting liabilities plus a required solvency margin. The amount of FAL for Syndicate 1458 is determined by Lloyd's and is based on Syndicate 1458's solvency and capital requirement as calculated through its internal model. Dividends from a Lloyd's managing agent and a Lloyd's corporate member can be declared and paid provided the relevant company has sufficient profits available for distribution. U.S. Renaissance Reinsurance U.S. is required to meet certain minimum statutory capital and surplus requirements under Maryland law. Renaissance Reinsurance U.S. is also subject to risk-based capital (the "RBC") requirements under Maryland law, and must file an annual report of its RBC levels. If the report shows Renaissance Reinsurance U.S.'s statutory capital and surplus or total adjusted capital is below certain levels, Renaissance Reinsurance U.S. may be required to take certain corrective action or the Maryland Insurance Administration (the "MIA") may be permitted or required to take certain regulatory action. F-81 Maryland law places limitations on the amounts of dividends or distributions payable by Renaissance Reinsurance U.S. At December 31, 2024, Renaissance Reinsurance U.S. had an ordinary dividend capacity of \$125.5 million which can be paid in 2025. Payment of ordinary dividends by Renaissance Reinsurance U.S. requires notice to the MIA. Declaration of an extraordinary dividend, which must be paid out of earned surplus, generally requires thirty days' prior notice to and approval or non-disapproval of the MIA. An extraordinary dividend includes any dividend whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the lesser of (1) ten percent of the insurer's surplus as regards policyholders as of December 31 of the preceding year or (2) the insurer's net investment income, excluding realized capital gains (as determined under statutory accounting principles), for the twelve month period ending December 31 of the preceding year and pro rata distributions of any class of the insurer's own securities, plus any amounts of net investment income (subject to the foregoing exclusions), in the three calendar years prior to the preceding year which have not been distributed. Multi-Beneficiary Reinsurance Trusts Each of Renaissance Reinsurance, DaVinci Reinsurance, and RREAG was approved as a Trustee Reinsurer and established a multi-beneficiary reinsurance trust (the "MBRT") to collateralize its (re)insurance liabilities. The MBRTs are subject to rules and regulations including but not limited to certain minimum capital funding requirements, investment guidelines, capital distribution restrictions and regulatory reporting requirements. The following table summarizes the assets held under trust and minimum amount required with respect to the MBRTs: At December 31, 2024 2023 Assets Held Under Trust Minimum Amount Required Renaissance Reinsurance (1) \$954,114 \$554,119 \$1,209,808 \$910,646 DaVinci Reinsurance 179,849 \$47,179 \$174,352 \$114,203 RREAG (2) 1,463,275 \$1,312,796 \$1,342,339 \$1,298,712 (1) Renaissance Reinsurance and Validus Re amalgamated on October 1, 2024. Comparative information for 2023 has been reclassified to include Validus Re. (2) RREAG and Validus Switzerland merged on June 21, 2024, with RREAG being the successor to the MBRTs held by Validus Switzerland. Multi-Beneficiary Reduced Collateral Reinsurance Trusts Each of Renaissance Reinsurance, RREAG and DaVinci Reinsurance has been approved as a "certified reinsurer" eligible for collateral reduction in certain states, and are authorized to provide reduced collateral equal to 20%, 20% and 50%, respectively, of their net outstanding insurance liabilities to insurers domiciled in each of those states. Each of Renaissance Reinsurance, RREAG and DaVinci Reinsurance has established a multi-beneficiary reduced collateral reinsurance trust to collateralize its (re)insurance liabilities associated with cedants domiciled in those states. The reduced collateral reinsurance trusts are subject to rules and regulations including but not limited to certain minimum capital funding requirements, investment guidelines, capital distribution restrictions and regulatory reporting requirements. The following table summarizes the assets held under trust and minimum amount required with respect to the reduced collateral reinsurance trusts: At December 31, 2024 2023 Assets Held Under Trust Minimum Amount Required Renaissance Reinsurance 187,742 \$83,622 \$193,922 \$129,380 DaVinci Reinsurance 220,542 \$73,210 \$215,560 \$125,184 RREAG 101,252 \$67,671 \$103,632 \$75,380 F-82 NOTE 19. DERIVATIVE INSTRUMENTS From time to time, the Company may enter into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company's derivative instruments can be exchange traded or over-the-counter, with over-the-counter derivatives generally traded under International Swaps and Derivatives Association master agreements, which establish the terms of the transactions entered into with the Company's derivative counterparties. In the event a party becomes insolvent or otherwise defaults on its obligations, a master agreement generally permits the non-defaulting party to accelerate and terminate all outstanding transactions and net the transactions' marked-to-market values so that a single sum in a single currency will be owed by, or owed to, the non-defaulting party. Effectively, this contractual "close-out netting" reduces credit exposure from gross to net exposure. Where the Company has entered into master netting agreements with counterparties, or the Company has the legal and contractual right to offset positions, the derivative positions are generally netted by counterparty and are reported accordingly in other assets and other liabilities. The Company is not aware of the existence of any credit-risk related contingent features that it believes would be triggered in its derivative instruments that are in a net liability position at December 31, 2024. F-83 The tables below show the gross and net amounts of recognized derivative assets and liabilities at fair value, including the location on the consolidated balance sheets of the Company's principal derivative instruments: Derivative Assets At December 31, 2024 Gross Amounts of Recognized Assets Gross Amounts Offset in the Balance Sheet Net Amounts of Assets Presented in the Balance Sheet Balance Sheet Location Collateral Received Net Amount Derivative instruments not designated as hedges Interest rate futures \$4,198 \$4,198 \$4,198 Foreign currency forward contracts (1) 16,275 \$16,275 Other assets \$16,275 \$16,275 Foreign currency forward contracts (2) 4,085 \$4,085 Other assets \$4,085 \$4,085 Commodity futures \$933 \$933 Other assets \$933 \$933 Commodity options \$483 \$483 Other assets \$483 \$483 Total derivative instruments not designated as hedges 30,974 \$30,974 \$30,974 Derivative instruments designated as hedges Foreign currency forward contracts (3) 3,564 \$3,564 Other assets \$3,564 \$3,564 Total \$34,538 \$34,538 \$34,538 Derivative Liabilities At December 31, 2024 Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Liabilities Presented in the Balance Sheet Balance Sheet Location Collateral Pledged Net Amount Derivative instruments not designated as hedges Interest rate futures \$6,178 \$6,178 Other liabilities \$5,408 \$5,408 Foreign currency forward contracts (1) 53,160 \$53,160 Other liabilities \$5,632 \$5,632 Foreign currency forward contracts (2) 13,171 \$13,171 Other liabilities \$13,171 \$13,171 Credit default swaps 1,675 \$1,675 Other liabilities 1,675 \$1,675 Equity futures 1,694 \$1,694 Other liabilities \$1,694 \$1,694 Total derivative instruments not designated as hedges 75,878 \$75,878 \$75,878 Total \$75,878 \$12,715 \$63,163 (1) Contracts used to manage foreign currency risks in underwriting and non-investment operations. (2) Contracts used to manage foreign currency risks in investment operations. (3) Contracts designated as hedges of net investments in a foreign operation. F-84 Derivative Assets At December 31, 2023 Gross Amounts of Recognized Assets Gross Amounts Offset in the Balance Sheet Net Amounts of Assets Presented in the Balance Sheet Balance Sheet Location Collateral Received Net Amount Derivative instruments not designated as hedges Interest rate futures \$13,162 \$13,162 Other assets \$13,162 \$13,162 Foreign currency forward contracts (1) 16,827 \$16,827 Other assets \$16,827 \$16,827 Foreign currency forward contracts (2) 10,448 \$10,448 Other assets \$10,448 \$10,448 Credit default swaps 749 \$749 Other assets \$749 \$749 Commodity options 3,538 \$3,538 Other assets \$3,538 \$3,538 Total derivative instruments not designated as hedges 44,724 \$44,724 \$44,724 Total \$44,724 \$44,724 Derivative Liabilities At December 31, 2023 Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Balance Sheet Net Amounts of Liabilities Presented in the Balance Sheet Balance Sheet Location Collateral Pledged Net Amount Derivative instruments not designated as hedges Interest rate futures \$5,768 \$5,768 Other liabilities \$5,720 \$5,720 Foreign currency forward contracts (1) 11,890 \$11,890 Other liabilities \$11,890 \$11,890 Foreign currency forward contracts (2) 2,603 \$2,603 Other liabilities \$2,603 \$2,603 Credit default swaps 1,248 \$1,248 Other liabilities 1,248 \$1,248 Commodity options 3,162 \$3,162 Other liabilities \$3,162 \$3,162 Commodity futures 1,441 \$1,441 Other liabilities \$1,441 \$1,441 Total derivative instruments not designated as hedges 26,112 \$26,112 \$26,112 Derivative instruments designated as hedges Foreign currency forward contracts (3) 3,879 \$3,879 Other liabilities \$3,879 \$3,879 Total \$29,991 \$29,991 \$29,991 (1) Contracts used to manage foreign currency risks in underwriting and non-investment operations. (2) Contracts used to manage foreign currency risks in investment operations. (3) Contracts designated as hedges of net investments in a foreign operation. F-85 The location and amount of the gain (loss) recognized in the Company's consolidated statements of operations related to its principal derivative instruments are shown in the following table: Location of Gain (Loss) Recognized on Derivatives Amount of Gain (loss) Recognized on Derivatives Year ended December 31, 2024 2023 2022 Derivative instruments not designated as hedges Interest rate futures (1) Net realized and unrealized gains (losses) on investments \$81,400 \$83,877 \$86,863 Foreign currency forward contracts (2) Net foreign exchange gains (losses) (27,918) (877) (51,401) Foreign currency forward contracts (3) Net foreign exchange gains (losses) (32,687) (11,761) 21,689 Credit default swaps (1) Net realized and unrealized gains (losses) on investments (54,757) (9,924) (9,084) Total return swaps (1) Net realized and unrealized gains (losses) on investments \$1,046 \$632 \$632 Commodity options Net realized and unrealized gains (losses) on investments (4,517) (4,553) \$0 Commodity futures Net realized and unrealized gains (losses) on investments 81,062 \$5,256 \$0 Total derivative instruments not designated as hedges (11,690) (80,705) (188,539) (1) Fixed income related derivatives included in net realized and unreal

portfolio to either assume credit risk or manage its credit exposure.Credit Default SwapsThe fair value of the Company's credit default swaps is determined using industry valuation models, broker bid indications or internal pricing valuation techniques.Â The fair value of these credit default swaps can change based on a variety of factors including changes in credit spreads, default rates and recovery rates, the correlation of credit risk between the referenced credit and the counterparty, and market rate inputs such as interest rates. At December 31, 2024, the Company had outstanding credit default swaps of \$1.4 billion in notional positions to protect the investment portfolio against increasing credit risk and \$Nil in notional positions to assume credit risk, denominated in U.S. dollars (2023 - \$1.5 billion and \$22.1 million, respectively).Equity DerivativesEquity FuturesFrom time to time, the Company uses equity derivatives in its investment portfolio to either assume equity risk or hedge its equity exposure. The fair value of the Company's equity futures is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had \$437.2 million of notional long positions of equity futures (2023 - \$Nil notional long positions).F-87Commodity DerivativesThe Company uses commodity derivatives within its investments portfolio to assume risk and manage its exposures in the insurance industry. Commodity derivatives expose the Company to potentially unfavorable price changes to the underlying commodities.Commodity FuturesThe fair value of the Company's commodity futures is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had a \$684.3 million of notional long positions of commodity futures, denominated in U.S. dollars (2023 - \$255.2 million of notional long positions).Commodity OptionsThe fair value of these derivatives is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had \$0.5 million of notional long positions of exchange traded commodity option contracts (2023 - \$0.4 million of notional long positions). The notional amounts for options are based on the fair value of the underlying commodities as if the options were exercised at the reporting date.Derivative Instruments Designated as Hedges of Net Investments in Foreign OperationsForeign Currency DerivativesHedges of Net Investments in Foreign OperationsOne of the Company's subsidiaries currently uses a non-U.S. dollar functional currency. The Company, from time to time, enters into foreign exchange forwards to hedge non-U.S. dollar functional currencies, on an after-tax basis, from changes in the exchange rate between the U.S. dollar and these currencies.As of December 31, 2024 and 2023, this included the Australian dollar net investment in a foreign operation. These foreign exchange forward contracts were formally designated as hedges of its investment in subsidiaries with non-U.S. dollar functional currencies and there was no ineffectiveness in these transactions.The table below provides a summary of derivative instruments designated as hedges of net investments in a foreign operation, including the weighted average U.S. dollar equivalent of foreign denominated net assets (liabilities) that were hedged and the resulting derivative gains (losses) that are recorded in foreign currency translation adjustments, net of tax, within accumulated other comprehensive income (loss) on the Company's consolidated statements of changes in shareholders' equity:Year ended December 31, 20242023Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities)\$61,120Â \$59,664Â Derivative gains (losses)\$6,194Â \$205Â F-88NOTE 20. COMMITMENTS, CONTINGENCIES AND OTHER ITEMS Concentration of Credit RiskInstruments which potentially subject the Company to concentration of credit risk consist principally of investments, including the Company's equity method investments, cash, premiums receivable and reinsurance balances. The Company limits the amount of credit exposure to any one financial institution and, except for the securities of the U.S. Government and U.S. Government related entities, and money market securities, none of the Company's fixed maturity and short term investments exceeded 10% of shareholders' equity at December 31, 2024. Refer to Note 7. Reinsurance, for information with respect to reinsurance recoverable.Employment AgreementsThe Board has authorized the execution of employment agreements between the Company and certain officers. These agreements provide for, among other things, severance payments under certain circumstances, as well as accelerated vesting of options and certain restricted stock grants, upon a change in control, as defined in the employment agreements and the Company's stock incentive plan.Letters of Credit and Other CommitmentsAt December 31, 2024, the Company's banks have issued secured and unsecured letters of credit totaling \$619.6 million in favor of certain ceding companies. In connection with the Company's Top Layer joint venture, Renaissance Reinsurance has committed \$37.5 million of collateral to support a letter of credit and is obligated to make a mandatory capital contribution of up to \$50.0 million in the event that a loss reduces Top Layer's capital and surplus below a specified level.Refer to Note 9. Debt and Credit Facilities for additional information related to the Company's debt and credit facilities.Investment CommitmentsThe Company has committed capital to direct private equity investments, fund investments and investments in other ventures of \$4.5 billion, of which \$2.5 billion has been contributed at December 31, 2024. The Company's remaining commitments to these investments at December 31, 2024 totaled \$2.0 billion. These commitments do not have a defined contractual commitment date. In the future, we may enter into additional commitments in respect of these investments or individual portfolio company investment opportunities.Indemnifications and WarrantiesIn the ordinary course of its business, the Company may enter into contracts or agreements that contain indemnifications or warranties. Future events could occur that lead to the execution of these provisions against the Company. Based on past experience, management currently believes that the likelihood of such an event is remote.LeasesThe Company's operating leases primarily relate to office space for its global underwriting platforms principally in Bermuda, Australia, Ireland, Singapore, Switzerland, the U.K. and the U.S. These leases expire at various dates through 2039 with a weighted average lease term of 5.9 years. Included in other assets and other liabilities at December 31, 2024 is a right-of-use asset of \$83.8 million and a lease liability of \$114.3 million, respectively, associated with the Company's operating leases (2023 - \$72.9 million and \$103.9 million, respectively). During 2024, the Company recorded an operating lease expense of \$14.8 million included in operational expenses (2023 - \$12.8 million).The Company's financing leases primarily relate to office space in Bermuda with an initial lease term of 20 years, ending in 2028, and a bargain renewal option for an additional 30 years. Included in other assets and other liabilities at December 31, 2024 is a right-of-use asset of \$16.1 million and a lease liability of \$21.0 million, respectively, associated with the Company's finance leases (2023 - \$16.6 million and \$21.5 million, respectively). During 2024, the Company recorded interest expense of \$2.1 million associated with its finance leases (2023 - \$2.2 million) included in interest expense and amortization of its finance leases right-to-use asset of \$0.5 million included in operational expenses (2023 - \$0.5 million).F-89Future minimum lease payments under existing operating and finance leases are detailed below, excluding the bargain renewal option on the finance lease related to office space in Bermuda:Future Minimum Lease PaymentsOperating LeasesFinance Leases2025\$15,657Â \$2,661Â 2026\$16,461Â 2,661Â 2027\$16,439Â 2,661Â 2028\$16,328Â 2,146Â 2029\$15,199Â 2,146Â After 2029\$70,656Â 66,566Â Future minimum lease payments under existing leases\$150,740Â \$10,129Â A Legal ProceedingsThe Company and its subsidiaries are subject to lawsuits and regulatory actions in the normal course of business that do not arise from or directly relate to claims on reinsurance treaties or contracts or direct surplus lines insurance policies. In the Company's industry, business litigation may involve allegations of underwriting or claims-handling errors or misconduct, disputes relating to the scope of, or compliance with, the terms of delegated underwriting agreements, employment claims, regulatory actions or disputes arising from the Company's business ventures.Â The Company's operating subsidiaries are subject to claims litigation involving, among other things, disputed interpretations of policy coverages. Generally, the Company's direct surplus lines insurance operations are subject to greater frequency and diversity of claims and claims-related litigation than its reinsurance operations and, in some jurisdictions, may be subject to direct actions by allegedly injured persons or entities seeking damages from policyholders.Â These lawsuits, involving or arising out of claims on policies issued by the Company's subsidiaries which are typical to the insurance industry in general and in the normal course of business, are considered in its loss and loss expense reserves. In addition, the Company may from time to time engage in litigation or arbitration related to its claims for payment in respect of ceded reinsurance, including disputes that challenge the Company's ability to enforce its underwriting intent. Such matters could result, directly or indirectly, in providers of protection not meeting their obligations to the Company or not doing so on a timely basis. The Company may also be subject to other disputes from time to time, relating to operational or other matters distinct from insurance or reinsurance claims. Any litigation or arbitration, or regulatory process, contains an element of uncertainty, and the value of an exposure or a gain contingency related to a dispute is difficult to estimate. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its financial condition, business or operations.F-90NOTE 21. SUBSEQUENT EVENTSShare Repurchase ProgramSubsequent to December 31, 2024 and through the period ended February 7, 2025, the Company repurchased 928,880 common shares at an aggregate cost of \$227.7 million and an average price of \$245.10 per common share.On February 5, 2025, the Board approved a renewal of the authorized share repurchase program for an aggregate amount of up to \$750.0 million.DaVinciEffective January 1, 2025, RenaissanceRe sold an aggregate of \$69.7 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$26.9 million of shares from third-party investors. At December 31, 2024, \$69.7 million, representing the net amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 24.3%.FontanaEffective January 1, 2025, Fontana completed an equity capital raise of \$100.0 million, comprised of \$29.2 million from third-party investors and \$70.8 million from RenaissanceRe. In addition, RenaissanceRe sold an aggregate of \$100.0 million of its limited partner interest in Fontana to third-party investors and purchased an aggregate of \$72.0 million of limited partner interest in Fontana from third-party investors. At December 31, 2024, \$129.2 million, representing the net amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in Fontana subsequent to these transactions was 28.7%.MediciEffective in January and February 2025, Medici issued an aggregate of \$107.9 million of non-voting preference shares to investors, including \$50.1 million to the Company, and redeemed an aggregate of \$16.5 million of non-voting preference shares to investors, including \$Nil to the Company. In January 2025, Medici declared a dividend of \$15.2 million, all of which is payable to third-party investors. At December 31, 2024, \$39.0 million, representing the amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in Medici subsequent to these transactions was 17.7% effective February 1, 2025.California WildfiresThe California wildfires, commencing in January 2025, have led to a range of publicly available industry insured loss estimates. The Company expects its pre-tax net negative impact to be approximately 1.5% of the California wildfires' aggregate industry insured loss. Based on a \$50.4 billion aggregate industry insured loss, the Company estimates a pre-tax net negative impact on net income (loss) available (attributable) to common shareholders of approximately \$750.0 million in the first quarter of 2025. The Company expects the wildfires will primarily impact its Property segment and, to a lesser extent, the Casualty and Specialty segment.Net negative impact on underwriting result includes the sum of (1) net claims and claim expenses incurred, (2) assumed and ceded reinstatement premiums earned and (3) earned and lost profit commissions. Net negative impact on net income (loss) available (attributable) to RenaissanceRe common shareholders is the sum of (1) net negative impact on underwriting result and (2) redeemable noncontrolling interest, both before consideration of any related income tax benefit (expense).The Company's assessment of the impact from the California wildfires is preliminary, and is based on, among other things, initial industry insured loss estimates, market share analysis, the application of F-91 modeling techniques, a review of in-force contracts and potential uncertainties relating to reinsurance recoveries. It is difficult at this time to provide an accurate estimate of the financial impact of the California wildfires, including as a result of the preliminary nature of the information provided thus far by industry participants, the magnitude and recency of the California wildfires, and other factors. The Company's actual net negative impact from this event will be reflected in the first quarter 2025 results of operations, when reported.Crash of American Airlines Flight 5342On January 29, 2025, a helicopter collided with a commercial airline flight near Ronald Reagan Washington National Airport. The Company is in the preliminary stage of assessing the impact of this event on the Company's financial results for the first quarter of 2025, and expects any impact would primarily be in the Casualty and Specialty segment. It is difficult at this time to provide an accurate estimate of the financial impact of this event given the preliminary nature of the information available, and other factors.F-92RENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIESINDEX TO SCHEDULES TO CONSOLIDATED FINANCIAL STATEMENTSÂ A Page1Summary of Investments other than Investments in Related Parties at December 31, 2024S-211Condensed Financial Information of Registrant at December 31, 2024 and 2023, and for the years ended December 31, 2024, 2023 and 2022S-3111Supplementary Insurance Information at and for the years ended December 31, 2024, 2023 and 2022S-61VSUPPLEMENTAL Schedule of Reinsurance Premiums for the years ended December 31, 2024, 2023 and 2022S-7V1Supplementary Insurance Information Concerning Property-Casualty Insurance Operations for the years ended December 31, 2024, 2023 and 2022S-7Schedules other than those listed above are omitted for the reason that they are not applicable.S-1SCHEDULE IRENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIESSUMMARY OF INVESTMENTSOTHER THAN INVESTMENTS IN RELATED PARTIES(THOUSANDS OF UNITED STATES DOLLARS)Â A December 31, 2024Â Amortized Cost or CostFair ValueAmount atWhich Shown in theBalance SheetType of investment:Fixed maturity investments tradingU.S. treasuries\$11,062,641Â \$11,001,893Â \$11,001,893Â Corporate7,919,470Â 7,862,423Â Residential mortgage-backed1,761,607Â 1,707,056Â 1,707,056Â Asset-backed1,416,132Â 1,422,393Â 1,422,393Â Agencies633,726Â 623,489Â 623,489Â Non-U.S. government624,381Â 618,809Â 618,809Â Commercial mortgage-backed332,583Â 326,451Â 326,451Â Total fixed maturity investments trading23,750,540Â 23,562,514Â 23,562,514Â Short term investments\$4,532,166Â 4,531,655Â 4,531,655Â Equity investments117,756Â 117,756Â Other investmentsFund investments2,128,499Â 2,128,499Â Catastrophe bonds1,984,396Â 1,984,396Â Direct private equity investments211,866Â 211,866Â Total investments4,324,761Â 4,324,761Â Investments in other ventures, under equity method102,770Â 102,770Â Total investments\$32,639,456Â \$32,639,456Â S-2SCHEDULE IIRENAISSANCERE HOLDINGS LTD.CONDENSED FINANCIAL INFORMATION OF REGISTRANTRENAISSANCERE HOLDINGS LTD.BALANCE SHEETSAT DECEMBER 31, 2024 AND 2023 (PARENT COMPANY)(THOUSANDS OF UNITED STATES DOLLARS)Â A At December 31, 20242023AssetsFixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil)\$153,504Â \$66Â A Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917)\$131,236Â 277,917Â Total investments284,740Â 277,917Â Cash and cash equivalents20,054Â 45,080Â Investments in subsidiaries10,732,129Â 9,632,226Â Due from subsidiaries7,919Â 52,816Â Accrued investment income1,052Â 161Â A Deferred tax asset10,334Â 33,646Â Receivable for investments sold1,329Â 2,849Â Other assets681,322Â 660,818Â Goodwill and other intangible assets98,662Â 101,509Â Total assets\$11,837,541Â \$10,806,861Â Liabilities and Shareholders' EquityLiabilitiesDebt\$1,138,119Â \$1,136,260Â Due to subsidiaries17,051Â 136,729Â Other liabilities108,359Â 78,915Â Total liabilities1,263,529Â 1,351,904Â Shareholders' equityPreference shares: \$1.00 par value - 30,000 shares issued and outstanding at December 31, 2024 (2023 - 30,000)750,000Â 750,000Â Common shares: \$1.00 par value - 50,180,987 shares issued and outstanding at December 31, 2024 (2023 - 52,693,887)50,181Â 52,694Â Additional paid-in capital1,512,435Â 2,144,459Â Accumulated other comprehensive income (loss)(14,756) (14,211)Retained earnings8,276,152Â 6,522,015Â Total shareholders' equity attributable to RenaissanceRe10,574,012Â 9,454,957Â Total liabilities and shareholders' equity\$11,837,541Â \$10,806,861Â S-3SCHEDULE IIRENAISSANCERE HOLDINGS LTD.CONDENSED FINANCIAL INFORMATION OF REGISTRANTÂ A CONTINUEDÂ RENAISSANCERE HOLDINGS LTD.STATEMENTS OF OPERATIONSFOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022 (PARENT COMPANY)(THOUSANDS OF UNITED STATES DOLLARS)Â A Year ended December 31, 202420232022RevenuesNet investment income\$58,166Â \$97,395Â Net foreign exchange gains (losses)(23,916)Â 1,129Â (46,796)Other income (loss)(95) (907)Net realized and unrealized gains (losses) on investments(4,840) (73,572) (3,017)Total revenues29,315Â 24,045Â (2,847)ExpensesOperational expenses15,866Â 32,066Â 14,818Â Corporate expenses86,314Â 98,493Â 99,614Â Interest expense59,384Â 40,416Â 15,315Â Total expenses161,564Â 170,975Â 69,747Â Income (loss) before equity in net income (loss) of subsidiaries(132,249) (146,930) (72,594)Equity in net income (loss) of subsidiaries(2,017,805) 2,708,061Â (988,610)Income (loss) before taxes1,885,556Â 2,561,131Â (1,061,204)Income tax benefit (expense)(15,196) 66,566Â Net income (loss)\$1,870,360Â 2,561,131Â (1,061,204)Dividends on preference shares(35,375) (35,375) Net income (loss) available (attributable) to RenaissanceRe common shareholders\$1,834,985Â \$2,525,756Â \$(1,096,579)RENAISSANCERE HOLDINGS LTD.STATEMENTS OF COMPREHENSIVE INCOME (LOSS)FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022 (PARENT COMPANY)(THOUSANDS OF UNITED STATES DOLLARS)Â A Year ended December 31, 202420232022Comprehensive income (loss)Net income (loss)\$1,870,360Â \$2,561,131Â \$(1,061,204)Change in net unrealized gains (losses) on investments, net of tax1,045Â 1,082Â (4,923)Foreign currency translation adjustments, net of tax(1,590)169Â 370Â Comprehensive income (loss) attributable to RenaissanceRe\$1,869,815Â \$2,562,382Â \$(1,065,757)S-4SCHEDULE IIRENAISSANCERE HOLDINGS LTD.CONDENSED FINANCIAL INFORMATION OF REGISTRANTÂ A

RENAISSANCE HOLDINGS L.P. STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022 (PARENT COMPANY) (THOUSANDS OF UNITED STATES DOLLARS) Year ended December 31, 2024 2023 2022 Cash flows provided by (used in) operating activities: Net income (loss) \$1,870,360 \$2,561,131 \$1,061,204 Less: equity in net income (loss) of subsidiaries (2,017,805) (2,708,061) 988,610 (147,445) (146,930) (72,594) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Net realized and unrealized (gains) losses on investments 334 67,868 2,051 014 142,051 72,691 36,601 Net cash provided by (used in) operating activities (5,060) (6,371) (33,942) Cash flows provided by (used in) investing activities: Proceeds from sales and maturities of fixed maturity investments trading 309,490 1,613,740 198,341 Purchases of fixed maturity investments trading (387,276) (1,505,160) (375,804) Net sales (purchases) of short term investments 147,296 (211,370) (21,037) Dividends and return of capital from subsidiaries 1,079,438 1,097,301 1,009,108 Contributions to subsidiaries (247,147) (169,204) (349,336) Due to (from) subsidiary (115,041) (7,088) (178,470) Due to (from) subsidiary for the purchase of Validus Specialty (45,467) (2,689,533) (2,689,533) Net cash provided by (used in) investing activities 786,760 (1,916,781) 282,802 Cash flows provided by (used in) financing activities: Dividends paid (80,850) (75,112) (64,675) Dividends paid (80,850) (75,112) (64,675) Preference shares (35,375) (35,375) (35,396) Renaissance common share repurchases (666,921) (166,664) Renaissance common share issuance, net of expenses (1,351,608) (277,646) Effect of exchange rate changes on foreign currency cash (740,581) (23,580) (20,518) (10,911) Net cash provided by (used in) financing activities (806,726) (1,961,184) (2,776,646) Effect of exchange rate changes on foreign currency cash (740,581) (23,580) (20,518) (10,911) Net cash provided by (used in) financing activities (806,726) (1,961,184) (2,776,646) Cash and cash equivalents, beginning of year 45,080 7,048 35,834 Cash and cash equivalents, end of year 2024 \$45,080 2023 \$7,048 2022 \$35,834 SCHEDULE I IIRENAISSANCE HOLDINGS LTD. AND SUBSIDIARIES SUPPLEMENTARY INSURANCE INFORMATION (THOUSANDS OF UNITED STATES DOLLARS) A December 31, 2024 Year ended December 31, 2024 A Deferred Policy Acquisition Costs Future Policy Benefits, Losses, Claims and Loss Expenses Unearned Premiums Premium Revenue Net Investment Income Benefits, Claims, Losses and Settlement Expenses Amortization of Deferred Policy Acquisition Costs Other Operating Expenses Net Written Premiums Property \$234,652 \$6,572,739 \$1,193,695 \$3,850,352 \$1,141,726 \$758,554 \$302,360 \$3,833,636 Casualty and Specialty 1,317,707 14,730,752 4,756,720 6,245,408 4,191,255 1,885,313 149,228 6,118,580 Other (1,654,289) (1,654,289) (1,654,289) Total \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289 Year ended December 31, 2023 \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289 Year ended December 31, 2022 \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289 6SCHEDULE IV IRENAISSANCE HOLDINGS LTD. AND SUBSIDIARIES SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS (THOUSANDS OF UNITED STATES DOLLARS) A Property and Liability Premiums Earned Gross Amounts Ceded to Other Companies Assumed From Other Companies Net Amount Percentage of Amount Assumed Net Year ended December 31, 2024 \$1,097,764 \$1,817,302 \$10,815,336 \$10,095,760 107 % Year ended December 31, 2023 \$1,013,372 \$1,614,432 \$8,072,193 \$7,471,133 108 % Year ended December 31, 2022 \$1,105,164 \$1,850,870 \$7,079,632 \$6,333,989 112 % SCHEDULE V IRENAISSANCE HOLDINGS LTD. AND SUBSIDIARIES SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS (THOUSANDS OF UNITED STATES DOLLARS) A Affiliation with Registrant Deferred Policy Acquisition Costs Reserves for Unpaid Claims and Claim Adjustment Expenses Discount, if any, Deducted Unearned Premiums Earned Premiums Net Investment Income Consolidated Subsidiaries Year ended December 31, 2024 \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289 Year ended December 31, 2023 \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289 Year ended December 31, 2022 \$1,552,359 \$21,303,491 \$5,950,415 \$10,095,760 \$1,654,289

amended or modified by (i) that certain Amendment No. 1 to the Stock Purchase Agreement, dated as of June 15, 2023, by and between the Parent and Acquiror (the Amendment No. 1a), (ii) that certain Side Letter, dated as of August 7, 2023, by and between Parent and Acquiror (the Side Letter No. 1a), (iii) that certain Side Letter, dated as of October 27, 2023, by and between Parent and Acquiror (the Side Letter No. 2a), and (iv) that certain Side Letter, dated as of November 1, 2023, by and between Parent and Acquiror (the Side Letter No. 3a), and together with the Original Agreement, the Purchase Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement. WHEREAS, Parent agreed to provide a certain reserve development cover to the Acquiror in respect of the Subject Business in accordance with Section 2.09 (Reserve Developments) of the Purchase Agreement, WHEREAS, under the Purchase Agreement, the Subject Business included certain business that was assumed on a fronted basis by Validus Reinsurance, Ltd. (the Validus Bermuda) and/or Validus Reinsurance (Switzerland), Ltd. (the Validus Switzerland) and together with Validus Bermuda, the Validus and reinsured by OmegaCat Reinsurance Ltd. (the OmegaCat) in respect of OmegaCat's 2019-2020 underwriting year (the 2019-2020 Fronted Business); WHEREAS, Validus and OmegaCat entered into certain other transactions on or about July 25, 2024, pursuant to which the 2019-2020 Fronted Business was commuted between Validus and OmegaCat and simultaneously ceded to, and reinsured by a third party; WHEREAS, Parent and the Acquiror wish to remove the 2019-2020 Fronted Business from the Subject Business solely with respect to Section 2.09 (Reserve Developments) of the Purchase Agreement by amending the Purchase Agreement on the terms set forth in this Amendment; and NOW, THEREFORE, Parent and the Acquiror hereto agree as follows, effective as of the date hereof: 1. Amendments to the Purchase Agreement. Pursuant to Section 11.07 of the Purchase Agreement: (a) the definition of the Subject Business set forth in Exhibit A of the Purchase Agreement shall be deleted and replaced in its entirety with the following defined terms: the Subject Business (except as used in Section 2.09, and except with respect to any defined term used in Section 2.09 that includes the term the Subject Business in its definition) means the business comprised of all insurance and reinsurance contracts that were issued or assumed by a Reinsurance Entity (including the entire term of multi-year policies or contracts) prior to the Closing Date on the terms as in effect at Closing; provided that such contracts may be transferred to an insurance or reinsurance company of Acquiror and still qualify as Subject Business. (b) the definition of the Subject Business (solely as used in Section 2.09, including with respect to any defined term used in Section 2.09 that includes the term the Subject Business in its definition) means, excluding the contracts listed on Schedule V, the business comprised of all insurance and reinsurance contracts that were issued or assumed by a Reinsurance Entity (including the entire term of multi-year policies or contracts) prior to the Closing Date on the terms as in effect at Closing; provided that such contracts may be transferred to an insurance or reinsurance company of Acquiror and still qualify as Subject Business. (b) a New Schedule V attached hereto as Exhibit A shall be added to the Purchase Agreement. For the avoidance of doubt, this Schedule V shall not alter any other schedules to the Purchase Agreement. 2. No Other Changes. Except as expressly set forth herein, the terms, provisions and conditions of the Purchase Agreement remain in full force and effect and nothing in this Amendment will (a) constitute a waiver of compliance with respect to the Purchase Agreement, (b) prejudice any right or remedy that the parties hereto may now or in the future have under or in connection with the Purchase Agreement or (c) change, amend, supplement or modify, or be construed as a change, amendment, supplement or modification to, any other term, provision or condition of the Purchase Agreement. Each reference in the Agreement to the Agreement, the Agreement, the Agreement, or words of like import referring to the Purchase Agreement shall mean the Purchase Agreement, as modified and amended by this Amendment other than references to the Agreement, the Agreement, or similar references which shall continue to refer to May 22, 2023. 3. Miscellaneous. The provisions of Section 11.01 (Notices), Section 11.03 (Severability), Section 11.04 (Entire Agreement), Section 11.05 (Assignment), Section 11.06 (No Third-Party Beneficiaries), Section 11.07 (Amendment; Waiver), Section 11.09 (Governing Law; Venue; Waiver of Jury Trial), and Section 11.10 (Rules of Construction) of the Purchase Agreement are hereby incorporated into and will apply to this Amendment mutatis mutandis. 4. Counterparts. This Amendment may be executed in two or more counterparts, and by the different parties to each such agreement in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by facsimile or other means of electronic transmission (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall be as effective as delivery of a manually executed counterpart of this Amendment. [Signature Page follows] IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written. AMERICAN INTERNATIONAL GROUP, INC. By: Adam BurkName: Adam BurkTitle: Vice President, Global Treasurer and Head of Corporate Development [Signature Page to Amendment No. 2 to the Stock Purchase Agreement] IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written. RENAISSANCE HOLDINGS LTD. By: Shannon Lowry BenderName: Shannon Lowry BenderTitle: EVP, Group General Counsel [Signature Page to Amendment No. 2 to the Stock Purchase Agreement] EX-19.1.4 insidertradingpolicy.htm EX-19.1 Document Exhibit 19.1 Insider Trading Policy RenaissanceRe Holdings Ltd. NOTICE: No part of this document should be relied upon in any manner by anyone other than the employees of RenaissanceRe. Any external use, exploitation, commercialization or modification of this document, or any part thereof is strictly prohibited. Table of Contents 1. Introduction 2. Application 3. Roles and Responsibilities 4. Insider Trading Policy 5. Persons Subject to the Policy 6. Material, Non-public Information 7. Reporting 8. Permitted Transactions 9. Investments in the (Re)Insurance Sector 10. Insurance Sector Trading Policy 11. Application 12. Permitted Transactions 13. Short-Swing Trading/Control Stock/Section 16 Reports 14. Administration of Policies 15. Confidentiality of Policy Decisions 16. Amendment of the Policy 17. Duration of Policy 18. Applicability 19. Responsible Party 20. Review and Approval 21. Introduction This purpose of this Insider Trading Policy (the Policy) is to outline the procedures which employees (including officers), directors, independent contractors and consultants of RenaissanceRe Holdings Ltd. and its subsidiaries (collectively, the RenaissanceRe, the Company or the we) must follow to ensure compliance with U.S. rules and regulations relating to insider trading. The legal regimes of other jurisdictions may also apply to transactions in or relating to securities. 2. Application This Policy applies to RenaissanceRe and its employees, directors, independent contractors and consultants. 3. Roles and Responsibilities Unlawful insider trading occurs when a person purchases, sells or otherwise engages in transactions in a company's securities while in possession of material, non-public information about that company or its securities, or provides such material, non-public information to others outside the company. This Policy outlines procedures for transacting in securities of RenaissanceRe and other companies with which we deal, and related matters. Violations of the insider trading rules can give rise to significant civil and criminal penalties and could lead to disciplinary action, including termination of employment. The application of these insider trading rules can be complex and at times counterintuitive. This Policy is intended to protect against adverse outcomes to protect the Company and its people. 3.1 Insider Trading Policy Except for the Permitted Transactions described in Section 3.5 below, no employee, director, independent contractor or consultant of RenaissanceRe may purchase, sell, gift or otherwise transact in the securities of RenaissanceRe or of any other company with whom RenaissanceRe deals while aware of material, non-public information concerning or affecting RenaissanceRe or the other company. There are no exceptions to this policy except as specifically noted herein. In addition, it is the policy of the Company that the Company will not trade in RenaissanceRe securities in violation of applicable securities laws or stock exchange listing standards. 3.1.1 Persons Subject to the Policy This Policy applies to all employees, directors, independent contractors and consultants of RenaissanceRe and its subsidiaries. When we refer to you or the directors or employees in this Policy, in addition to you, we also mean members of your immediate family or other persons with whom you share a household, persons that are your economic dependents, and any person or entity you control. For purposes of this Policy, the members of your immediate family include your spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law, and anyone (other than domestic employees) who shares your home. Regulatory authorities regard trades made at your direction or at the direction of those named in the preceding sentence as trades made by you. Certain aspects of this Policy apply only to Designated Officers, as defined in Section 3.6. 3.3.1.2 Material, Non-public Information Information is considered material if a reasonable investor would consider it important in making a decision on whether to buy, sell, or hold the security, or a reasonable investor would view the information as significantly altering the total mix of information in the marketplace about the issuer of the security. Examples of material information might include, but are not limited to, the following: information about upcoming earnings or losses; the impact of a pending or recent catastrophic event; proposed or negotiation of a potential merger, acquisition or disposition; news of a ratings upgrade or downgrade; results of reinsurance renewals; the gain or loss of a substantial contract, customer or vendor relationship or program; a significant purchase or sale of assets; changes in dividend amounts or policy sales or purchases by the Company of its own securities; initiation of or significant developments in litigation; a major regulatory development; development or marketing of new products; a major cybersecurity incident, or changes in top management. Information is considered non-public if the information has not been broadly disseminated to the public for a sufficient period to be reflected in the price of the security. Examples of public disclosure include disclosure within a report filed by the Company with the U.S. Securities and Exchange Commission, such as a Form 8-K and issuance of a press release by the Company. Even after the Company has initially disclosed material, non-public information to the press or the information has been reported, at least one Trading Day must elapse before the information is considered to be broadly disseminated. For purposes of this Policy, a Trading Day shall mean any day on which the New York Stock Exchange (the NYSE) is open for trading. For example, if the Company discloses material, non-public information during an earnings call, it is impermissible to trade on such information until the opening of the NYSE on the following Trading Day. 3.1.3 Insider Trading in Other Companies Additionally, if during the course of performing your duties for RenaissanceRe, you learn material non-public information about another company, you are prohibited from trading in securities of such company for as long as the information remains material and non-public. For example, you may be involved in a transaction in which RenaissanceRe expects to substantially reinsure another company, or enter into a new venture or other relationship with the company. Even if the monetary amount of the transaction is immaterial to RenaissanceRe, it may be material to the other company. In order to protect our senior managers from risks in this area, Designated Officers are also required to comply with our policy strictly restricting investment activities in the insurance sector. See Section 3.6, Investments in the (Re)Insurance Sector, for details. Other employees, directors, independent contractors and consultants should be mindful of how the legal requirements described above could apply to information in their possession. 3.1.4 Tipping In addition to the prohibition on insider trading, this Policy also prohibits tipping (i.e., communicating material non-public information about the Company to persons who might be expected to trade while in possession of that information). Under this Policy, you can be held responsible for the trading by anyone to whom you disclose, directly or indirectly, material, non-public information about the Company, even if you, the tipper, do not receive any monetary benefit from the trade. Furthermore, you are also prohibited from tipping information about other companies that you have gained through your relationship with the Company. For example, if you learn material non-public information about another company with which RenaissanceRe does business or is negotiating a potential transaction, not only must you refrain from trading in the securities of the other company until such information has been made public for at least one Trading Day, you must also refrain from tipping others about that information. 3.1.5 Purchases and Sales Purchases and sales of securities encompass not only traditional purchases and sales, but any arrangement which changes a person's economic exposure to changes in the price of the securities. For example, a purchase or sale would include a purchase of standardized put or call options, the writing of put or call options, the purchase of straddles, equity swaps or other derivative securities that are directly linked to equity securities, selling stock short, buying or selling securities convertible into other securities, participating in a dividend reinvestment plan (sometimes referred to as a DRIP), or merely engaging in a private agreement where the value of the agreement varies in relation to the price of the underlying security. Purchases or sales of securities can result in liability whether executed in the public markets or in a private transaction. 3.1.6 Margin Loans and Pledging of RenaissanceRe Securities Employees, directors, and their respective designees are not permitted to have margin loans on RenaissanceRe securities and are not permitted to pledge or otherwise use RenaissanceRe securities as collateral for a loan. Sales forced because you have borrowed money and pledged securities as security for the loan (a margin loan) are not exempt from the insider trading rules. Under margin arrangements, the broker may be entitled to sell your shares without your permission if the value of your securities falls below the broker's margin requirements. The sale, even though not initiated at your request, is still a sale for your benefit and may subject you to liability under the insider trading rules if made at a time when you are aware of material, non-public information. Similar cautions apply to a bank or other loans for which you may have previously pledged stock as collateral. Any questions should be referred to the Group General Counsel. 3.1.7 Hedging and/or Short Selling of RenaissanceRe Securities Employees, directors, and their respective designees are not permitted to directly hedge or short sell the market value of any RenaissanceRe securities. However, hedging transactions which could be deemed to provide some degree of economic protection but do not directly involve RenaissanceRe securities (e.g., a basket of property and casualty (re)insurance companies) will be evaluated on a case-by-case basis. This prohibition does not prohibit receipt or exercise of Company-issued option awards. 5.2 Trading Window Periods Directors and employees, and their family members, may only effect transactions in RenaissanceRe securities (other than certain Permitted Transactions as described below) during open Trading Window Periods, as defined below. This includes purchasing, selling, or gifting of securities, or transactions which are in economic substance substantially the same as such transactions. Our Trading Window Periods are generally the four-week period beginning on the Trading Day following the earnings call regarding quarterly or annual financial results. The Chief Corporate Counsel, Deputy Chief Compliance Officer or Group General Counsel will notify employees of the opening and closing of each Trading Window Period. Nonetheless, as discussed above, no trade or gift of RenaissanceRe securities may be made during these Trading Window Periods if the person covered by this Policy possesses material non-public information which has not been disseminated in the public market for at least one Trading Day. The Group General Counsel or the Group General Counsel's designee may suspend a Trading Window Period at any time that the Group General Counsel determines that a Blackout Period (as defined below) is in the best interest of the Company and/or its employees. A Blackout Period is a period of time when individuals subject to this Policy must refrain from trading in the Company's securities. Blackout Periods must be strictly observed by employees and directors, and their family members. The Group General Counsel may also extend a Trading Window Period at any time that they determine it is in the best interest of the Company and/or its employees to do so. The trading restrictions set forth in this Section 3.2 do not apply to any trades or gifts made pursuant to a properly qualified, adopted and submitted Trading Plan, as defined below. Whether or not a proposed transaction is of a type that is required to be subject to our window period policy can be a complex question. Please discuss any questions you may have with the Group General Counsel, the Chief Corporate Counsel or the Deputy Chief Compliance Officer. 3.3 Pre-Approval In addition to complying with the provisions of this Policy regarding Trading Window Periods and Blackout Periods set forth in Section 3.2 above, the Company's employees and directors must first obtain pre-clearance from the Company's Group General Counsel (or their designee) before engaging in any transaction in RenaissanceRe securities, including gifts, and before adopting, modifying, and terminating any Trading Plan, as defined below. A request for pre-clearance should be submitted to the Group General Counsel (or their designee) in advance of the proposed transaction, and the Group General Counsel (or their designee) will respond within two business days. If a proposed transaction receives pre-clearance, the pre-cleared action must be effected within two business days of receipt of pre-clearance. If the person becomes aware of material nonpublic information before the action is executed, the pre-clearance is void and the trade must not be completed. Transactions not effected within the time limit become subject to pre-clearance again. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in RenaissanceRe securities, and should not inform any other person of the restriction. The pre-approval requirements set forth in this Section 3.3 do not apply to any trades or gifts made pursuant to a properly qualified, adopted and submitted Trading Plan, as defined below. 6.3.4 Reporting Trades We require that all executive officers and directors submit to the Company's Group General Counsel (or their designee) a copy of any trade order or confirmation relating to the purchase, sale or gift of RenaissanceRe securities on the date of any such transaction. This information is necessary to enable the Company to monitor trading by executive officers and directors and ensure that all such trades are properly reported. Your adherence to this Policy is vital to your protection as well as the Company's. The reporting requirements set forth in this Section 3.4 also apply to any trades or gifts made pursuant to a Trading Plan, as defined below. 6.3.5 Permitted Transactions The restrictions on trading set forth in this Policy do not apply to certain Permitted Transactions

defined below) because they are not expected to pose securities law risks to you or the Company. This means you may effect these transactions without regard to trading window periods. Permitted Transactions are: acceptance of a grant of restricted stock or stock options issued or offered under Renaissance's employee stock incentive plan, or the cancellation or forfeiture of stock or options pursuant to the plan; vesting of shares of restricted stock or stock options and any related stock withholding (but not market sales in connection with such vesting events); transfer of shares that does not involve a change in the beneficial ownership of the shares, for example, to an inter vivos trust of which you are the sole beneficiary during your lifetime, bona fide gifts to members of your immediate household, or changing the form of ownership to include a member of your immediate household as a joint owner (since members of your household are considered the same as you for purposes of this Policy); acquisition or disposition of stock in a stock split, stock dividend, or other transaction affecting all stockholders equally; execution of a transaction pursuant to a contract, instruction, or plan described in Exchange Act Rule 10b5-1(c)(1)(i)(A) (a Renaissance 10b5-1 Trading Plan) or another pre-established trading arrangement, including an arrangement which qualifies as a non-Rule 10b5-1 trading arrangement under Item 408(c) of Regulation S-K under the Exchange Act (together with Rule 10b5-1 Trading Plans, a Trading Plan), which has been approved in writing in advance by our Group General Counsel (or their designee) in accordance with Section 3.3 and not modified, and which requires the holder of the securities, broker or other counterparty to notify the Group General Counsel (or their designee) immediately upon execution of a transaction pursuant to the Plan; the exercise of an employee stock option at the time of such option's expiration (whether arising as a result of the end of the option's term, or as a result of the departure of an employee or director from the Company), provided that such exercise shall be an exercise and hold transaction and it shall occur via net exercise or shall be otherwise settled not involving the sale of Renaissance securities in the market. To mitigate the risks that a transaction might be misconstrued, to assist with SEC filings if necessary, and to maintain our corporate records, Permitted Transactions should be previewed with the Group General Counsel, the Chief Corporate Counsel or the Deputy Chief Compliance Officer, before being completed. Investments in the (Re)Insurance Sector. 3.6.1 (Re)Insurance Sector Trading Policy. As discussed above, the U.S. federal securities laws also prohibit trading in securities of any company about whom you learn material, non-public information through the course of performing your duties for Renaissance. In order to protect our senior managers from risks in this area and to avoid even the appearance of impropriety, Designated Officers (as defined below) may not trade, including taking long or short positions, in securities of (Re)Insurance Sector (as defined below) companies, including stocks or related derivatives of such companies, subject to the exceptions listed in Section 3.6.3.6.2 Application. For purpose of this Section 3.6, a Designated Officer is a senior officer of Renaissance who could be deemed to have access to a broad range of information, including employees who are at or above career level 3, as well as members of the immediate family of Designated Officers. Employees who are not Designated Officers should also be mindful of how they may come into possession of material, non-public information. (Re)Insurance Sector for purposes of this Policy includes reinsurance or insurance companies who are engaged in property or casualty business, including: property, liability and casualty lines (surety, accident and health, and financial guarantee coverages, and Certain diversified companies whose operations include significant insurance, reinsurance or financial guaranty units (e.g., Fairfax Financial). 3.6.3 Permitted Transactions. This prohibition on trading in securities of (Re)Insurance Sector companies does not apply to the following: Positions held by Designated Officers at the original date of adoption of this Policy (August 2004) or at the time of the person's hiring or promotion, but these positions should be disclosed to the Company's Deputy Chief Compliance Officer, as should any proposals to transact in the relevant security. Securities held in accounts, funds, partnerships or other vehicles which are managed by unaffiliated third parties and not subject to the Designated Officer's investment discretion. Positions in broad-based, readily available indices (e.g., the S&P 500) is permitted, but not the Bermuda insurance index. Equity grants to spouses or other immediate family members of Designated Officers who are employed at companies whose operations include insurance, reinsurance or financial guaranty. When in doubt, ask. Designated Officers should seek interpretative assistance from the Group General Counsel, Chief Corporate Counsel or Deputy Chief Compliance Officer before effecting transactions. For example, if a Designated Officer wishes to trade securities of a diversified company whose operations do include insurance, reinsurance or financial guaranty units, but those units are immaterial to the company, the officer should submit the proposed investment to the Deputy Chief Compliance Officer for prior review with substantial lead-time, as various corporate priorities may prevent an immediate response. Proposed transactions will be reviewed on a case-by-case basis, taking into account all of the facts and circumstances surrounding such transaction. Short-Swing Trading/Control Stock/Section 16 Reports. Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care not to violate the prohibition on short-swing trading (Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule 144 under the Securities Act of 1933, as amended), and should file or cause to be filed all appropriate Section 16(a) reports (Forms 3, 4 and 5) and any notices of sale required by Rule 144.3.8 Administration of Policies. 3.8.1 Administration by Group General Counsel. The Group General Counsel shall administer this Policy. If you have any questions concerning the interpretation of this Policy, you should contact them or their express designee. 3.8.2 Requests for Waivers or Interpretations of the Application of our Policy. This Policy is intended to mitigate the risks that our employees, directors, independent contractors or consultants may violate, even inadvertently, relevant aspects of the securities laws, and in some instances to reduce the risks that can arise out of the appearance of impropriety. In many cases, application of our Policy requires judgment and may not be subject to clear, bright-line rules. Requests for waivers or interpretations of this Policy should be directed to the Group General Counsel or their express designee. 3.8.3 Confidentiality of Policy Decisions. You should keep certain information concerning the operation of this Policy in strict confidence, since knowledge of certain decisions made pursuant to this Policy could itself constitute material, non-public information. For example, if you are made subject to a special blackout pursuant to Section 3.2, you should keep that fact confidential. 3.8.4 Amendment of the Policy. Renaissance reserves the right to amend and interpret this Policy from time to time. 3.8.5 Duration of Policy's Applicability. If you are in possession of material, non-public information regarding Renaissance or other companies with whom Renaissance deals when your relationship with the Company concludes, you may not trade in Renaissance securities or the securities of such other company until such information has been publicly disseminated or is no longer material. 3.8.6 Responsible Party. Remember, the ultimate responsibility for complying with this Policy and applicable laws and regulations rests with you. You should use your best judgment and consult with your own legal and financial advisors, as needed. Review and Approval. This Policy shall be reviewed at least annually by the Chief Corporate Counsel. Any changes to this Policy must be approved by the Group General Counsel. EX-21.1 5 ex2112024.htm EX-21.1 Document Exhibit 21.1 SUBSIDIARIES OF RENAISSANCE HOLDINGS LTD. Name Jurisdiction Ownership Interest Held Directly or Indirectly by Renaissance Holdings Ltd. AlphaCat Reinsurance Ltd. Bermuda 100% DaVinci Reinsurance Ltd. Bermuda (1) DaVinci Re Holdings Ltd. Bermuda (1) Fontana Holdings L.P. Bermuda (2) Fontana Reinsurance Ltd. Bermuda (2) Fontana Reinsurance U.S. Ltd. Bermuda (2) Fontana Holdings U.S., Inc. Delaware (2) Fontana UK Holdings Limited U.K. 100% Mont Fort Re Ltd. Bermuda 100% Renaissance Investment Holdings Ltd. Bermuda 100% Renaissance Investment Management Company Limited Bermuda 100% Renaissance Other Investments Holdings Ltd. Bermuda 100% Renaissance Other Investments Holdings II Ltd. Bermuda 100% Renaissance Other Investments Holdings III Ltd. Bermuda 100% Renaissance Reinsurance Ltd. Bermuda 100% Renaissance Reinsurance of Europe DAC Ireland 100% Renaissance Reinsurance U.S. Inc. Maryland 100% Renaissance Underwriting Managers, Ltd. Bermuda 100% Renaissance Re Corporate Capital (UK) Limited (3) U.K. 100% Renaissance Re Europe AG Switzerland 100% Renaissance Re Finance Inc. Delaware 100% Renaissance Re Fund Holdings Ltd. Bermuda 100% Renaissance Re Medici Fund Ltd. Bermuda (4) Renaissance Re Specialty Holdings (UK) Limited Bermuda 100% Renaissance Re Specialty U.S. Ltd. Bermuda 100% Renaissance Re Syndicate 1458 U.K. 100% Renaissance Re Upsilon Co-Invest Fund Ltd. Bermuda 100% Renaissance Re Ventures Ltd. Bermuda 100% RenRe Insurance Holdings Ltd. Bermuda 100% RenRe North America Holdings Inc. Delaware 100% Shima Reinsurance Ltd. Bermuda 100% Top Layer Reinsurance Ltd. Bermuda 50% Upsilon RFO Re Ltd. Bermuda (5) Vermeer Reinsurance Ltd. Bermuda (6) (1) As of December 31, 2024, the Company owned 25.4% of the outstanding equity of DaVinci Re Holdings Ltd. (the "DaVinci") but controlled a majority of DaVinci's outstanding voting power, and accordingly, DaVinci's financial results are consolidated in the Company's financial statements. DaVinci Reinsurance Ltd. is a wholly owned subsidiary of DaVinci. (2) As of December 31, 2024, the Company owned 26.5% of the outstanding equity of Fontana Holdings L.P. ("Fontana") but controlled a majority of Fontana's outstanding voting power, and accordingly, Fontana's financial results are consolidated in the Company's financial statements. Fontana Holdings U.S. Inc., Fontana Reinsurance U.S. Inc., and Fontana Reinsurance Ltd. are all wholly owned subsidiaries of Fontana. (3) Renaissance Re Corporate Capital (UK) Limited is the Lloyd's sponsor of Renaissance Re Syndicate 1458. (4) As of December 31, 2024, the Company owned 15.8% of the outstanding equity of Renaissance Re Medici Fund Ltd. ("Renaissance Re Medici Fund") but controlled a majority of Renaissance Re Medici Fund's outstanding voting power, and accordingly, Renaissance Re Medici Fund's financial results are consolidated in the Company's financial statements. (5) Upsilon RFO Re Ltd. is considered a variable interest entity and the Company is considered the primary beneficiary of Upsilon RFO Re Ltd., as a result its financial results are consolidated in the Company's financial statements. As of December 31, 2024, the Company's participation in the risks assumed by Upsilon RFO Ltd. was 12.7%. (6) Vermeer Reinsurance Ltd. (the "Vermeer") is considered a variable interest entity and the Company is considered the primary beneficiary of Vermeer, as a result its financial results are consolidated in the Company's financial statements. The Company maintains a majority voting control of Vermeer, while the sole third-party investor retains all of the economic benefits. The names of a number of the Company's subsidiaries and equity entities have been omitted because considered in the aggregate they would not constitute a single significant subsidiary. EX-22.1 6 exhibit22.1-listofregistre.htm EX-22.1 Document Exhibit 22.1 Issuers of Registered Guaranteed Debt Securities Renaissance Re Finance Inc. (the "Renaissance Re Finance") is an indirect wholly owned subsidiary of Renaissance Re Holdings Ltd. (the "Renaissance Re Holdings"). As of December 31, 2022, (i) Renaissance Re Finance was the issuer of \$300.0 million principal amount of its 3.450% Senior Notes due July 1, 2027 (the "2027 Notes") and (ii) Renaissance Re Finance was the issuer of \$300.0 million principal amount of its 3.700% Senior Notes due April 1, 2025 (the "2025 Notes"). Each of the 2027 Notes and the 2025 Notes are fully and unconditionally guaranteed by Renaissance Re. EX-23.1 7 ex231202410-kpwc.htm EX-23.1 Document Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-272124 and No. 333-265020) and Form S-8 (No. 333-265021 and No. 333-211398) of Renaissance Re Holdings Ltd. of our report dated February 12, 2025 relating to the financial statements, financial statement schedules and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. /s/ PricewaterhouseCoopers Ltd. Hamilton, Bermuda February 12, 2025 EX-31.1 8 ex3112024.htm EX-31.1 Document Exhibit 31.1 CERTIFICATION, Kevin J. O'Donnell, certify that: 1. I have reviewed this Form 10-K of Renaissance Re Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: February 12, 2025 /s/ Kevin J. O'Donnell Kevin J. O'Donnell Chief Executive Officer EX-31.2 9 ex3122024.htm EX-31.2 Document Exhibit 31.2 CERTIFICATION, Robert Qutub, certify that: 1. I have reviewed this Form 10-K of Renaissance Re Holdings Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant

link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - ACQUISITION OF VALIDUS link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - REINSURANCE link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - DEBT AND CREDIT FACILITIES link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - NONCONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - VARIABLE INTEREST ENTITIES link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - SHAREHOLDERSâ€™ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - TAXATION link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - STATUTORY REQUIREMENTS link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9952178 - Disclosure - SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 9952179 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT link:presentationLink link:calculationLink link:definitionLink 9952180 - Disclosure - SCHEDULE III. SUPPLEMENTARY INSURANCE INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952181 - Disclosure - SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS link:presentationLink link:calculationLink link:definitionLink 9952182 - Disclosure - SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - ACQUISITION OF VALIDUS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - REINSURANCE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - DEBT AND CREDIT FACILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - NONCONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - VARIABLE INTEREST ENTITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - SHAREHOLDERSâ€™ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - TAXATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - STATUTORY REQUIREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - ACQUISITION OF VALIDUS - Overview (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Financial Results (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - ACQUISITION OF VALIDUS - Taxation (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Supplemental Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - ACQUISITION OF VALIDUS - Defined Benefit Pension Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill and Other Intangible Assets Included in Equity Method Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Expected Impairment Charges and Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - INVESTMENTS - Schedule of Fair Value of Fixed Maturity Investments Trading (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - INVESTMENTS - Schedule of Contractual Maturities of Fixed Maturity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - INVESTMENTS - Schedule of Fair Value of Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - INVESTMENTS - Pledged Investments and Reverse Repurchase Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - INVESTMENTS - Reverse Purchase Agreements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - INVESTMENTS - Schedule of Net Investment Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - INVESTMENTS - Schedule of Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - INVESTMENTS - Term Loans (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - INVESTMENTS - Schedule of Investments in Other Ventures, under Equity Method (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - INVESTMENTS - Schedule of Equity in (Losses) Earnings of Other Ventures, Under Equity Method (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information Used as Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Balances Elected to Account for at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Other Investments Measured Using Net Asset Valuations (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - REINSURANCE - Schedule of Effect of Reinsurance and Retrocessional Activity on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - REINSURANCE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - REINSURANCE - Schedule of Provision for Current Expected Credit Losses of Premiums Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - REINSURANCE - Schedule of Provision for Current Expected Credit Losses of Reinsurance Recoverable (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Schedule of Reserve for Claims and Claim Expenses by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Schedule of Liability for Unpaid Claims and Claim Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Schedule of Incurred and Paid Claims Development (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Prior Year Development of the Reserve for Net Claims and Claim Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Historical Claims Duration (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - DEBT AND CREDIT FACILITIES - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - DEBT AND CREDIT FACILITIES - Debt Obligations Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - DEBT AND CREDIT FACILITIES - Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - DEBT AND CREDIT FACILITIES - Schedule of Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - DEBT AND CREDIT FACILITIES - Credit Facilities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - NONCONTROLLING INTERESTS - Summary of Redeemable Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - NONCONTROLLING INTERESTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - NONCONTROLLING INTERESTS - Schedule of Redeemable Noncontrolling Interest Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - VARIABLE INTEREST ENTITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - VARIABLE INTEREST ENTITIES - Summary of the Principal-at-risk Variable Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - SHAREHOLDERSâ€™ EQUITY - Rollforward of Shares Issued and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted Earnings Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - TAXATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - TAXATION - Income (Loss) Before Income Taxes, Foreign and Domestic (Details) link:presentationLink link:calculationLink link:definitionLink 9955587 - Disclosure - TAXATION - Components of Income Tax Benefit (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 9955588 - Disclosure - TAXATION - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955589 - Disclosure - TAXATION - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955590 - Disclosure - SEGMENT REPORTING - Schedule of Significant Components of the Company's Revenues and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9955591 - Disclosure - SEGMENT REPORTING - Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details) link:presentationLink link:calculationLink link:definitionLink 9955592 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955593 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Equity Compensation Other than Options (Details) link:presentationLink link:calculationLink link:definitionLink 9955594 - Disclosure - STATUTORY REQUIREMENTS - Statutory Capital and Surplus (Details) link:presentationLink link:calculationLink link:definitionLink 9955595 - Disclosure - STATUTORY REQUIREMENTS - Statutory Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955596 - Disclosure - STATUTORY REQUIREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955597 - Disclosure - STATUTORY REQUIREMENTS - Schedule of Assets Held Under Trust And Minimum (Details) link:presentationLink link:calculationLink link:definitionLink 9955598 - Disclosure - STATUTORY REQUIREMENTS - Schedule of Multi-Beneficiary Reduced Collateral Reinsurance Trusts (Details) link:presentationLink link:calculationLink link:definitionLink 9955599 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955600 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955601 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955602 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation (Details) link:presentationLink link:calculationLink link:definitionLink 9955603 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955604 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS - Schedule of Future Minimum Payments, Operating and Finance Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9955605 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955606 - Disclosure - SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 9955607 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Balance sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9955608 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Balance Sheets Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955609 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955610 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955611 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 9955612 - Disclosure - SCHEDULE III. SUPPLEMENTARY INSURANCE INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 9955613 - Disclosure - SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS (Details) link:presentationLink link:calculationLink link:definitionLink 9955614 - Disclosure - SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 rnr-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 14 rnr-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 15 rnr-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 2020 Large Loss Events 2020 Large Loss Events [Member] 2020 Large Loss Events Non-Employee Director Restricted Stock Awards Non-employee Director Restricted Stock [Member] Non-employee Director Restricted Stock [Member] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Redemptions of third-party

redeemable noncontrolling interest shares Payments for Repurchase of Redeemable Noncontrolling Interest Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net Investment Income SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Net Investment Income Credit spread adjustment Measurement Input, Credit Spread [Member] Remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Expected income tax benefit (expense) Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Cover [Abstract] Cover [Abstract] After 2029 Lessee, Operating Lease, Liability, to be Paid, after Year Five Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Gross realized losses on fixed maturity investments trading Debt Securities, Trading, Realized Loss Accident Year 2016 Short-Duration Insurance Contracts, Accident Year 2016 [Member] Discount rate Measurement Input, Discount Rate [Member] Schedule of Future Minimum Payments, Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Ownership% A Equity Method Investment, Ownership Percentage Series F Preferred Stock Series F Preferred Stock [Member] Net realized gains (losses) on equity investments Equity Securities, FV-NI, Realized Gain (Loss) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Gross Amounts of Recognized Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Dividends declared per common share (in usd per share) Common Stock, Dividends, Per Share, Declared Position [Axis] Position [Axis] Dividends on common shares Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Line of Credit Facility [Table] Line of Credit Facility [Table] Short term investments Short-Term Investments [Member] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Reinsurance Reinsurance Accounting Policy [Policy Text Block] Net realized and unrealized gains (losses) on equity investments Equity Securities, FV-NI, Gain (Loss) Earnings Per Share Earnings Per Share, Policy [Policy Text Block] ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Change in net unrealized gains (losses) on investments, net of tax Change in net unrealized gains (loss) on investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Net Investment Hedging Net Investment Hedging [Member] Third-Party Investors And RenaissanceRe Third-Party Investors And RenaissanceRe [Member] Third-Party Investors And RenaissanceRe Short-duration Insurance Contracts, Accident Year [Domain] Short-Duration Insurance Contracts, Accident Year [Domain] Amount of Gain (loss) Recognized on Derivatives Derivative, Gain (Loss) on Derivative, Net Redeemable Noncontrolling Interest [Table] Redeemable Noncontrolling Interest [Table] Investment, Name [Domain] Investment, Name [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Net income (loss) allocated to RenaissanceRe common shareholders Undistributed Earnings, Basic Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed Lessee, finance lease, renewal term Lessee, Finance Lease, Renewal Term 2016 Long-Term Incentive Plan 2016 Long-Term Incentive Plan [Member] 2016 Long-Term Incentive Plan [Member] Plan Name [Domain] Plan Name [Domain] Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share 3.450% Senior Notes due 2027 3.450% Senior Notes Due July 1 2027 [Member] 3.450% Senior Notes Due July 1 2027 [Member] Finance Lease, Liability, Statement of Financial Position [Extensible List] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] U.S. UNITED STATES Deferred acquisition expenses Deferred Tax Liabilities, Deferred Expense, Deferred Acquisition Costs Deferred Tax Liabilities, Deferred Expense, Deferred Acquisition Costs Participating, Non-voting Common Shares Participating, Non-voting Common Shares [Member] Participating, Non-voting Common Shares [Member] U.S. and Caribbean U.S. and Caribbean [Member] U.S. and Caribbean [Member] Short-duration Insurance Contracts, Claims Development [Table] Short-Duration Insurance Contracts, Claims Development [Table] VARIABLE INTEREST ENTITIES Variable Interest Entity Disclosure [Text Block] Validus Specialty Validus Specialty [Member] Validus Specialty Total Expected Amortization of Other Intangible Assets Expected amortization of other intangible assets. Operating Segments Operating Segments [Member] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items] Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Affiliation with Registrant [Domain] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Affiliation with Registrant [Domain] Credit Suisse (Switzerland) Ltd. Credit Suisse (Switzerland) Ltd. [Member] Credit Suisse (Switzerland) Ltd. [Member] Additional CaseA Reserves Liability for Unpaid Claims and Claims Adjustment Expense, Additional Case Reserves, Amount Liability for Unpaid Claims and Claims Adjustment Expense, Additional Case Reserves, Amount Award Timing Method Award Timing Method [Text Block] Marsh & McLennan Companies, Inc. Marsh & McLennan Companies, Inc. [Member] Marsh & McLennan Companies, Inc. [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Liability for claims and claim expenses, net of reinsurance Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net STATUTORY REQUIREMENTS Dividend Restrictions and Statutory Requirements Disclosure [Text Block] Dividend Restrictions and Statutory Requirements Disclosure [Text Block] 3.600% Senior Notes due 2029 3.600% Senior Notes Due 2029 [Member] 3.600% Senior Notes Due 2029 [Member] Tailwind Re Ltd Tailwind Re Ltd [Member] Tailwind Re Ltd 2022 Weather-Related Large Loss Events 2022 Large Loss Events [Member] 2022 Large Loss Events Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use Of Estimates In Financial Statements Use of Estimates, Policy [Policy Text Block] Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Amounts acquired Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Premiums receivable (Note 7) Premiums receivable Premiums Receivable, Net Tabular List, Table Tabular List [Table Text Block] DaVinci Reinsurance DaVinci Reinsurance Ltd. [Member] DaVinci Reinsurance Ltd. [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Schedule of Short-duration Insurance Contracts, Claims Development Short-Duration Insurance Contracts, Claims Development [Table Text Block] Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Reserve for claims and claim expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Claims and Claim Expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Claims and Claim Expenses Credit Facility [Domain] Credit Facility [Domain] Total return swaps Total Return Swap [Member] Reserve for claims and claim expenses (Note 8) Total Reserve for claims and claim expenses, end of period Total reserve for claims and claim expenses Liability for Claims and Claims Adjustment Expense Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Casualty and Specialty Casualty and Specialty Segment [Member] Casualty and Specialty Segment [Member] AmortizedA Cost Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract] Cash consideration funded by available cash resources Business Combination, Consideration Transferred, Available Cash Resources Business Combination, Consideration Transferred, Available Cash Resources Goodwill Goodwill, net Goodwill beginning balance Goodwill ending balance Goodwill Schedule of Provision for Current Expected Credit Losses of Reinsurance Recoverable Reinsurance Recoverable, Allowance for Credit Loss [Table Text Block] Proceeds from sales of other investments Proceeds from Sale of Other Investments Taxes paid on withholding shares Payment, Tax Withholding, Share-Based Payment Arrangement Share repurchase program, authorized aggregate amount Share Repurchase Program, Authorized, Amount Redemption price per share (in usd per share) Preferred Stock, Redemption Price Per Share Entity Information [Line Items] Entity Information [Line Items] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Foreign Exchange Forward Foreign Exchange Forward [Member] Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table] Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Noncontrolling interest, increase from sale of parent equity interest Noncontrolling Interest, Increase from Sale of Parent Equity Interest Comprehensive income (loss) attributable to RenaissanceRe Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plan Pension Plan [Member] Net claims and claim expense ratio      current accident year Net Claims and Claims Expense Ratio Current Year Net claims and claim expense ratio - current accident year is derived by dividing net claims and claim expense - current accident year by net premiums earned. Repayment of Medici Revolving Credit Facility Repayments of Lines of Credit Tower Hill Companies Tower Hill [Member] Tower Hill [Member] 2025 Finance Lease, Liability, to be Paid, Year One Medici RenaissanceRe Medici Fund Ltd. [Member] RenaissanceRe Medici Fund Ltd. [Member] Schedule of Contractual Maturities of Fixed Maturity Investments Investments Classified by Contractual Maturity Date [Table Text Block] Award Type [Axis] Award Type [Axis] Liability for Unpaid Claim and Claim Adjustment Expense, Change [Table] Liability for Unpaid Claim and Claim Adjustment Expense, Change [Table] Corporate Corporate Debt Securities [Member] Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Proceeds from sales and maturities of fixed maturity investments trading Proceeds from sales and maturities of fixed maturity investments trading Proceeds from Sale and Maturity, Debt Security, Trading, and Equity Security, FV-NI, Held-for-Investment Ceded Credit Risk [Line Items] Ceded Credit Risk [Line Items] Amortization of Deferred Policy Acquisition Costs SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Amortization of Deferred Policy Acquisition Cost ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Depository Shares [Member] Depository Shares [Member] Total liabilities Liabilities Liabilities Investments trading Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Trading Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Trading Other Investments Other Investments [Policy Text Block] Disclosure of accounting policy for other investments in financial assets, including private equity partnerships, senior secured bank loan funds, catastrophe bonds, non-U.S. fixed income funds, hedge funds and miscellaneous other investments. May describe its policy for assessing, recognizing and measuring impairment of the investment. Expected loss ratio Measurement Input, Expected Loss Ratio [Member] Measurement Input, Expected Loss Ratio [Member] Common shares, par value (in dollars per share) Common Stock, Par or Stated Value Per Share U.S. tax accounting method change Deferred Tax Liabilities, U.S. Tax Accounting Method Change Deferred Tax Liabilities, U.S. Tax Accounting Method Change Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Economic Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Foreign Exchange Foreign Currency Transactions and Translations Policy [Policy Text Block] \$150 Million Principal-At-Risk Note One Hundred And Fifty Million Principal At Risk Variable Rate Note [Member] One Hundred And Fifty Million Principal At Risk Variable Rate Note Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Cash flows provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net Cash Provided by (Used in) Investing Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount RenaissanceRe Upsilon Diversified Fund RenaissanceRe Upsilon Diversified Fund [Member] RenaissanceRe Upsilon Diversified Fund Top Layer Reinsurance Ltd. Top Layer Re [Member] Top Layer Re [Member] Voting, Non-participating Shares Voting, Non-participating Shares [Member] Voting, Non-participating Shares [Member] Accident Year 2020 Short-Duration Insurance Contract, Accident Year 2020 [Member] Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6) Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917) Other Short-Term Investments Amount allocated to participating common shareholders Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Unfunded Commitments Other Investments, Unfunded Commitments [Member] Other Investments, Unfunded Commitments Tax loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Internal valuation model Internal Valuation Model Valuation Technique [Member] Internal Valuation Model Valuation Technique [Member] Other assets Other assets Other Assets, Fair Value Disclosure Insurance Loss Reserves [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Reserve for claims and claim expenses Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve Segment Reporting, Measurement Disclosures [Abstract] Segment Reporting, Measurement Disclosures [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Other assets Other Assets Basis Of Presentation Basis of Accounting, Policy [Policy Text Block] Denominator for diluted income (loss) per RenaissanceRe common share - adjusted weighted average common shares and assumed conversions (in shares) Weighted Average Number of Shares Outstanding, Diluted Statutory Accounting Practice, Jurisdiction [Axis] Statutory Accounting Practice, Jurisdiction [Axis] Loan agreement with related party Loans and Leases Receivable, Related Parties Statutory Accounting Practices [Line Items] Statutory Accounting Practices [Line Items] Condensed Financial Statements, Captions [Line Items] Condensed Financial Statements, Captions [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total shareholders     equity attributable to RenaissanceRe Beginning balance Ending balance Equity, Attributable to Parent Deferred tax assets Deferred Tax Assets, Gross RenaissanceRe Holdings Ltd. RenaissanceRe Holdings Ltd. [Member] RenaissanceRe Holdings Ltd. [Member] Issuance of debt, net of expenses Proceeds from Issuance of Debt Weighted average yield to maturity Debt Securities Weighted Average Yield To Maturity Debt Securities Weighted Average Yield To Maturity Underwriting expense ratio Underwriting Expense Ratio Concentration Risk Type [Domain] Concentration Risk Type [Domain] Letters of credit outstanding Letters of Credit Outstanding, Amount Impairment loss on insurance licenses Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Impairment Loss Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Impairment Loss Due to subsidiaries Accounts Payable Contributions to defined contribution pension plans Defined Contribution Plan, Cost Net unrealized gains (losses) on fixed maturity investments trading Debt Securities, Trading, Unrealized Gain (Loss) Aggregate authorized shares (in shares) Stock, Shares Authorized The maximum number of common shares and nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items] SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items] Shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Foreign currency translation adjustments, net of tax Foreign currency translation adjustments, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Document Fiscal Period Focus Document Fiscal Period Focus Series G Preferred Stock Series G Preferred Stock [Member] 2028 Long-Term Debt, Maturity, Year Four Average annual percentage payout, year six Short-Duration Insurance Contracts, Historical Claims Duration, Year Six All Executive Categories All Executive Categories [Member] Per common share equivalents of non-vested shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Schedule of Short-duration Insurance Contracts, Schedule of Historical Claims Duration Short-Duration Insurance Contracts, Schedule of Historical Claims Duration [Table Text Block] Equity investments Equity Securities [Member] Business acquisition, share price (in dollars per share) Business Acquisition, Share Price 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Expected tax deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Change in redeemable noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Document Type Document Type Derivative Contract Type [Domain] Derivative Contract [Domain] Schedule of Significant Components of the Company's Revenues and Expenses Schedule of Segment Reporting Information, by Segment [Table Text

[Block] Net realized and unrealized gains (losses) Investments Gain (Loss) on Investments [Member] Software Computer Software, Intangible Asset [Member] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Net fair value adjustment Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period Reserve for claims and claim expenses, net of reinsurance recoverable, end of period Net Reserve for Claims and Claim Expenses Liability for Unpaid Claims and Claims Adjustment Expense, Net Amortization, accretion and depreciation Depreciation, Amortization and Accretion, Net Schedule of Expected Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Average annual percentage payout, year four Short-Duration Insurance Contracts, Historical Claims Duration, Year Four Subsequent Event [Table] Subsequent Event [Table] Parent Company Parent Company [Member] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Reinsurance recoverable, allowance for credit loss Beginning balance Ending balance Reinsurance Recoverable, Allowance for Credit Loss Goodwill, accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Total remaining amortization expense Finite-Lived Intangible Assets, Net Schedule of Claims and Claim Expenses Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Investment Type [Axis] Investment Type [Axis] REINSURANCE Reinsurance [Text Block] Accrued investment income Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Investment Income Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Investment Income Performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period Accrued investment income Accrued Investment Income Receivable Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Payments to noncontrolling interests Payments to Noncontrolling Interests Income (loss) before Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Premium receivable, allowance for credit loss Beginning balance Ending balance Premium Receivable, Allowance for Credit Loss Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Name Outstanding Recovery, Individual Name Schedule of Actual and Required Statutory Capital and Surplus Schedule of Statutory Capital, Surplus and Unrestricted Net Assets [Table Text Block] Schedule of Statutory Capital, Surplus and Unrestricted Net Assets [Table Text Block] Acquired Reinsurance Recoverable, Allowance for Credit Loss, Period Increase (Decrease) Title and Position [Axis] Title and Position [Axis] Net paid related to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Public Offering Public Offering [Member] Public Offering Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Assumed Gross premiums earned Assumed Premiums Earned Dividends paid â€” RenaissanceRe common shares Payments of Ordinary Dividends, Common Stock Due to (from) subsidiary Payments for (Proceeds from) Businesses and Interest in Affiliates Investment, Name [Axis] Investment, Name [Axis] Reinsurance balances payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Balances Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Balances Payable Beginning Expiration Year [Domain] Beginning Expiration Year [Domain] Beginning Expiration Year [Domain] Customer relationships and customer lists Customer Relationships [Member] Forecast Forecast [Member] Investors of Upsilon RFO Diversified IV Investors of Upsilon RFO Diversified IV [Member] Investors of Upsilon RFO Diversified IV Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share â€” diluted (in dollars per share) Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share â€” diluted (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Amounts acquired Premium Receivable, Allowance for Credit Loss, Period Increase (Decrease) Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Industrial, utilities and energy Commercial and Industrial Sector [Member] RESERVE FOR CLAIMS AND CLAIM EXPENSES Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Current Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Hedge funds Hedge Funds [Member] Ownership [Axis] Ownership [Axis] Schedule of Other Investments Securities Owned and Other Investments Not Readily Marketable Disclosure [Table Text Block] Deferred tax liabilities Deferred Tax Liabilities, Gross [Abstract] Net foreign exchange gains (losses) Net foreign exchange gains (losses) Gain (Loss), Foreign Currency Transaction, before Tax Preference shares, shares issued (in shares) Preferred Stock, Shares Issued Major Customers [Axis] Customer [Axis] External Credit Rating, Standard & Poor's [Domain] External Credit Rating, Standard & Poor's [Domain] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset-backed Asset-Backed Securities [Member] Total fair value of shares and share units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Investment owned, fair value Investment Owned, Fair Value Investments in other ventures, under equity method Equity Method Investments [Member] Income tax benefit (expense) (Note 15) Income tax benefit (expense) Income tax benefit (expense) Income Tax Expense (Benefit) Derivative, notional amount Derivative, Notional Amount Derivative assets Net Amounts of Assets Presented in the Balance Sheet Derivative Asset Reinsurance Recoverable, Allowance for Credit Loss [Roll Forward] Reinsurance Recoverable, Allowance for Credit Loss [Roll Forward] Periods for recognition of compensation costs not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Revenue recorded Revenue from Contract with Customer, Excluding Assessed Tax Significant observable and unobservable inputs Alternative Investment, Measurement Input Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Premiums Written Premiums Written, Net [Abstract] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Risk premium Measurement Input, Risk Premium [Member] Measurement Input, Risk Premium Investments in Other Ventures, Under Equity Method Equity Method Investments [Policy Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Additional paid-in capital (Note 12) Additional paid in Capital Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Loss contingency incurred percentage Loss Contingency, Industry Amount Incurred, Percentage Loss Contingency, Industry Amount Incurred, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Net investment income Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract] Percentage interest in underlying shares Preferred Stock, Percentage Interest In Underlying Shares Preferred Stock, Percentage Interest In Underlying Shares Unearned premiums Increase (Decrease) in Unearned Premiums Scenario [Domain] Scenario [Domain] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Table] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Table] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Amortized Cost or Cost SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost Financial Instruments [Domain] Financial Instruments [Domain] Soci  t   G  n  rale, New York Branch (  cSocGen  ) Soci  t   G  n  rale, New York Branch (  cSocGen  ) [Member] Soci  t   G  n  rale, New York Branch (  cSocGen  ) [Member] Nonvested, beginning balance (in usd per share) Nonvested, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities, Noncontrolling Interests and Shareholders  ” Equity Liabilities and Shareholders  ” Equity Liabilities and Equity [Abstract] Fair Value Alternative Investment Subscriptions of third-party redeemable noncontrolling interest shares Proceeds From Repurchase Of Redeemable Noncontrolling Interest Proceeds From Repurchase Of Redeemable Noncontrolling Interest Other liabilities Other liabilities Other liabilities Other Liabilities, Fair Value Disclosure Restatement Determination Date Restatement Determination Date Investments-related derivatives Derivative [Member] Fair Value Estimate of Fair Value Measurement [Member] Reinsurance premiums receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Premiums Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Premiums Receivable Net investment income (Note 5) Net investment income Net investment income Net Investment Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Other   Assets and (Liabilities) Other Assets (Liabilities) Member The fair value of other assets and liabilities included in the Company's total other assets and liabilities. Other Operating Expenses SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense Interest rate futures Interest Rate Contract [Member] CONDENSED FINANCIAL INFORMATION OF REGISTRANT Condensed Financial Information of Parent Company Only Disclosure [Text Block] Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Erroneously awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Loss before equity in net income of subsidiaries Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net Condensed Financial Information Disclosure [Abstract] Condensed Financial Information Disclosure [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Purchases of investments in other ventures Payments to Acquire Equity Method Investments EARNINGS PER SHARE Earnings Per Share [Text Block] Subsequent Event Subsequent Event [Member] Redeemable Noncontrolling Interest [Line Items] Redeemable Noncontrolling Interest [Line Items] Schedule of Equity In Earnings of Equity Method Investments Schedule of Equity In Earnings (Losses) of Equity Method Investments [Table Text Block] Tabular disclosure of the equity in earnings (losses) of other ventures, under equity method. Dividends on preference shares (Note 12) Dividends on preference shares Dividends on preference shares Dividends, Preferred Stock Discount, if any, Deducted SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Discount Deducted from Reserve Awards granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Net realized and unrealized (gains) losses on investments Gain (Loss) on Investments Liability for Catastrophe Claims [Table] Liability for Catastrophe Claims [Table] Taxation Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Schedule of Future Minimum Payments, Finance Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Customer Two Customer Two [Member] Customer Two Drawdown of Medici Revolving Credit Facility Proceeds from Lines of Credit PEO PEO [Member] Other Other Large Catastrophe Events [Member] Other Large Catastrophe Events [Member] Initial commitments Private Equity Investments and Other Entities, Initial Commitments Private Equity Investments and Other Entities, Initial Commitments Premiums receivable Increase (Decrease) in Premiums Receivable Name Trading Arrangement, Individual Name Net balance sheet liability Defined Benefit Plan, Funded (Unfunded) Status of Plan Agent relationships - other Agent Relationships - Other [Member] Agent Relationships - Other Share repurchase requests, limit Minority Interest, Aggregate Share Repurchase Request, Limit As Percent Of Capital This item limits the aggregate of all share repurchase requests to 25% of DaVinciRe's capital in any given year and satisfying all applicable regulatory requirements. If total shareholder requests exceed 25% of DaVinciRe's capital, the number of shares repurchased will be reduced among the requesting shareholders pro-rata, based on the amounts desired to be repurchased. Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Entity Public Float Entity Public Float Equity in earnings (losses) of other ventures (Note 5) Equity in earnings (losses) of other ventures Income (Loss) from Equity Method Investments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Accident Year 2023 Short-Duration Insurance Contract, Accident Year 2023 [Member] Projected benefit obligation Defined Benefit Plan, Benefit Obligation Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Premiums and Related Expenses Revenue Recognition, Premiums Earned, Policy [Policy Text Block] RenaissanceRe Finance, Inc. RenaissanceRe Finance Inc. [Member] RenaissanceRe Finance Inc. [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Case Reserves Liability for Unpaid Claims and Claims Adjustment Expense, Reported Claims, Amount Reinsurance recoverable Reinsurance Recoverables, Including Reinsurance Premium Paid Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount SUMMARY OF INVESTMENTS, OTHER THAN INVESTMENTS IN RELATED PARTIES SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Text Block] Local Phone Number Local Phone Number Net realized gains (losses) on fixed maturity investments trading Debt Securities, Trading, Realized Gain (Loss) Gross   Carrying   Value Intangible Assets, Gross (Excluding Goodwill) Liabilities: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Deferred tax asset, valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Investment in variable interest entity Contributions to subsidiaries Payments to Acquire Interest in Subsidiaries and Affiliates Equity Method Investment [Table] Equity Method Investment [Table] Intangible assets Deferred Tax Assets, Intangible Assets Deferred Tax Assets, Intangible Assets Change in: Increase (Decrease) in Operating Capital [Abstract] Goodwill and Other Intangible Assets Goodwill And Other Intangible Assets [Member] Goodwill And Other Intangible Assets Accident Year 2021 Short-Duration Insurance Contract, Accident Year 2021 [Member] PEO Total Compensation Amount PEO Total Compensation Amount Receivable for investments sold Receivable from Broker-Dealer and Clearing Organization Gross Amounts of Recognized Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Shares issued (in shares) Common shares issued by RenaissanceRe to AIG (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Supplementary Insurance Information SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Disclosure [Text Block] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Amount at Which Shown in the Balance   Sheet SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable and Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable and Accrued Liabilities Common Shares, Par Value \$1.00 per share Common shares Common Stock [Member] Prepaid reinsurance premiums Increase (Decrease) in Prepaid Reinsurance Premiums Other Other Geographical Locations [Member] Other Geographical Locations [Member] Schedule of Condensed Financial Statements [Table] Condensed Financial Statements [Table] Collateral Pledged Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Average annual percentage payout, year eight Short-Duration Insurance Contracts, Historical Claims Duration, Year Eight Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Effect of Reinsurance and Retrocessional Activity on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred Effects of Reinsurance [Table Text Block] Redemption period one Debt Instrument, Redemption, Period One [Member] Line of Credit Line of Credit [Member] Due in less than one year Trading Securities, Debt Maturities, within One Year, Fair Value This item represents the fair value of debt securities which are expected to mature within one year of the balance sheet date and are categorized as trading securities. Renewal rights Renewal Rights [Member] Renewal Rights [Member] Entity Central Index Key Reverse repurchase agreements Securities for Reverse Repurchase Agreements Scenario [Axis] Scenario [Axis] Schedule of Finite and Indefinite-lived Intangible Assets [Line Items] Schedule of Finite and Indefinite-lived Intangible Assets [Line Items] Schedule of Finite and Indef

3 Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Purchases of fixed maturity investments trading Payment for Acquisition, Trading Security, Held-for-Investment Ceded Credit Risk, Unsecured Ceded Credit Risk, Unsecured [Member] Right to elect directors, number of directors Preferred Stock, Right To Elect Directors, Number Of Directors Preferred Stock, Right To Elect Directors, Number Of Directors Arthur J Gallagher Arthur J Gallagher [Member] Arthur J Gallagher Restricted stock awards Total Restricted Stock Awards Restricted Stock [Member] [Member] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Measurement Basis [Axis] Measurement Basis [Axis] Series F Preferred Shares, Depository Shares Series F Preferred Shares, Depository Shares [Member] Series F Preferred Shares, Depository Shares Average annual percentage payout, year three Short-Duration Insurance Contracts, Historical Claims Duration, Year Three Title Trading Arrangement, Individual Title Consolidated Entities [Axis] Consolidated Entities [Axis] 2018 Large Loss Events 2018 Large Loss Events [Member] 2018 Large Loss Events [Member] Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Other investments, at fair value (Notes 5 and 6) Other investments Other Long-Term Investments Geographic Concentration Risk Geographic Concentration Risk [Member] Unrecognized tax benefits Unrecognized Tax Benefits Comprehensive (income) loss attributable to redeemable noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Position [Domain] Position [Domain] U.S. Internal Revenue Service (IRS) [Member] Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] City Area Code City Area Code Equity in net income (loss) of subsidiaries Less: equity in net income (loss) of subsidiaries Income (Loss) from Subsidiaries, Net of Tax Auditor Location Auditor Location Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Property Property Segment [Member] Property Segment [Member] Fund investments Fund Investments [Member] Fund Investments Schedule of the Balances the Company has Elected to Account for at Fair Value Fair Value Option, Disclosures [Table Text Block] Medici Third-Party Investors Medici Third-Party Investors [Member] Medici Third-Party Investors RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS Related Party Transactions and Major Customers Disclosure [Text Block] Related Party Transactions and Major Customers Disclosure [Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Purchases of short term investments Payments to Acquire Short-Term Investments Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Equity futures Equity futures Equity Contract [Member] Noncatastrophic Event [Axis] Noncatastrophic Event [Axis] Net claims and claim expense ratio â€” prior accident years Net Claims And Claim Expense Ratio Prior Years Net claims and claim expense ratio - prior accident years is derived by dividing net claims and claim expenses - prior accident years by net premiums earned. Reinsurance adjustment Effective Income Tax Rate Reconciliation, Reinsurance Adjustment, Amount Effective Income Tax Rate Reconciliation, Reinsurance Adjustment, Amount Preference shares Preferred Stock [Member] Loan agreement, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity RenaissanceRe common share repurchases Payments for Repurchase of Common Stock Summary of Derivative Instruments [Abstract] Summary of Derivative Instruments [Abstract] Schedule of Net Investment Income Investment Income [Table Text Block] Premiums Earned Premiums Written and Earned [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Effect of change in tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Written notice period for redemption Noncontrolling Interest, Redemption Provision, Notice Period Noncontrolling Interest, Redemption Provision, Notice Period Weighted AverageÂ Grant Date FairÂ Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Series G Preferred Shares, Depository Shares Series G Preferred Shares, Depository Shares [Member] Series G Preferred Shares, Depository Shares Deferred acquisition costs and value of business acquired Increase (Decrease) in Deferred Policy Acquisition Costs Expenses Benefits, Losses and Expenses [Abstract] Retained earnings (Note 12) Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Long Long [Member] Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market Business Combination, Consideration Transferred, Proceeds from Issuance of Common Stock Business Combination, Consideration Transferred, Proceeds from Issuance of Common Stock Renaissance Reinsurance Renaissance Reinsurance Ltd. [Member] Renaissance Reinsurance Ltd. [Member] Unamortized fair value and other adjustments recorded in connection with acquisitions Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Unamortized Fair Value Adjustments Associated With Acquisition Class of Stock [Domain] Class of Stock [Domain] Right to elect directors, required number of dividend periods in arrears Preferred Stock, Right To Elect Directors, Required Number Of Dividend Periods In Arrears Preferred Stock, Right To Elect Directors, Required Number Of Dividend Periods In Arrears Related Party Transaction [Line Items] Related Party Transaction [Line Items] Worldwide Worldwide [Member] Worldwide [Member] Unfunded commitments Private Equity Investments and Other Entities, Unfunded Commitments Private Equity Investments and Other Entities, Unfunded Commitments Corporate expenses Corporate expenses Corporate expenses General and Administrative Expense Net unrealized gains (losses) on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) 2026 Long-Term Debt, Maturity, Year Two Non-U.S. government Debt Security, Government, Non-US [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Operating lease, liability Operating Lease, Liability Nordea Bank Abp, New York Branch Nordea Bank Abp, New York Branch [Member] Nordea Bank Abp, New York Branch OECD Pillar Two global minimum tax Effective Income Tax Rate Reconciliation, BEAT, Amount Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Net in earnings (loss) Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings 2029 Finance Lease, Liability, to be Paid, Year Five Amendment Flag Amendment Flag Carrying Value Reported Value Measurement [Member] Short-duration Insurance Contracts, Historical Claims Duration [Table] Short-Duration Insurance Contracts, Historical Claims Duration [Table] Target percentage of ECR Target Percentage Of Enhanced Capital Requirement Target Percentage Of Enhanced Capital Requirement Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Activity in redeemable noncontrolling interest Increase (Decrease) in Temporary Equity [Roll Forward] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Aggregate deposit liabilities Deposit Contracts, Liabilities Claims and Claim Expenses Policyholder Benefits and Claims Incurred, Net [Abstract] Finance lease, right-of-use asset, amortization Finance Lease, Right-of-Use Asset, Amortization Validus Holdings, Ltd [Member] Validus Holdings, Ltd Subsequent Events [Abstract] Subsequent Events [Abstract] SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract] SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract] Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction NOC1 NOC1 [Member] NOC1 DEBT AND CREDIT FACILITIES Debt Disclosure [Text Block] Minimum net worth requirements Banking Regulation, Mortgage Banking, Net Worth, Minimum Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount Face amount Debt Instrument, Face Amount Gross premiums written Gross Premiums Written [Member] Gross Premiums Written [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code SUPPLEMENTAL INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Text Block] Reinsurance balances payable Increase (Decrease) in Reinsurance Payables Earned Premiums SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Earned Premium Unrealized losses in the US investment portfolio Operating Loss Carryforwards, Unrealized Gain (Loss) Operating Loss Carryforwards, Unrealized Gain (Loss) Actuarial assumption changes Change in Actuarial Assumption [Member] Change in Actuarial Assumption [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investment [Table] Schedule of Investments [Table] Foreign currency forward contracts Foreign Currency Forward Contracts, Underwriting and Non-investment Operations [Member] Foreign Currency Forward Contracts, Underwriting Operations Related Foreign Currency Contracts [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Amortization of Deferred Policy Acquisition Costs SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost Awards forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Upsilon RFO Re Ltd, Upsilon RFO Re Ltd, [Member] Upsilon RFO Re Ltd, [Member] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Finite and Indefinite-lived Intangible Assets [Domain] Finite and Indefinite-lived Intangible Assets [Domain] Finite and Indefinite-lived Intangible Assets [Domain] Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] NONCONTROLLING INTERESTS Noncontrolling Interest Disclosure [Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Future Policy Benefits, Losses, Claims and Loss Expenses SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Deferred underwriting results Deferred Tax Assets, Deferred Income Other small catastrophe events and attritional loss movements Other Small Catastrophe Events And Attritional Loss Movements [Member] Other Small Catastrophe Events And Attritional Loss Movements [Member] Unearned premiums Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve Derivative Assets Derivative Asset [Abstract] Designated as Hedging Instrument Designated as Hedging Instrument [Member] SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract] SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract] Net income (loss) available (attributable) to RenaissanceRe common shareholders Net income (loss) available (attributable) to RenaissanceRe common shareholders Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Accident Year 2024 Short-Duration Insurance Contract, Accident Year 2024 [Member] Total assets Assets Cumulative Paid Claims and Claim Expenses, Net of Reinsurance Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net 5.750% Senior Notes due 2033 5.750% Senior Notes due 2033 [Member] 5.750% Senior Notes due 2033 Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Statutory Accounting Practice, Jurisdiction [Domain] Statutory Accounting Practice, Jurisdiction [Domain] Commitments and contingencies (Note 20) Commitments and Contingencies Stock Incentive Compensation Share-Based Payment Arrangement [Policy Text Block] Capital Support Agreement Capital Support Agreement [Member] Statutory capital and surplus Statutory Accounting Practices, Statutory Capital and Surplus, Balance Non-U.S. government Foreign Government Debt [Member] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Related Party Transaction [Table] Related Party Transaction [Table] 2037 2037 [Member] 2037 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Mortgage-backed Collateralized Mortgage-Backed Securities [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Expected tax rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate, Dividend Withholding Tax, Percent Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate, Dividend Withholding Tax, Percent 2025 Long-Term Debt, Maturity, Year One Other liabilities Other Liabilities Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Schedule of Gain (Loss) on Securities [Table] Schedule of Gain (Loss) on Securities [Table] Deferred tax assets Deferred Tax Assets, Gross [Abstract] Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Consumer Consumer Sector [Member] Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Discount on closing price Business Acquisition, Closing Share Price, Discount Business Acquisition, Closing Share Price, Discount Reinsurance balances payable Reinsurance Payable Audit Information [Abstract] Audit Information Net income (loss) attributable to RenaissanceRe Net income (loss) Net Income (Loss) Attributable to Parent Other income (loss) Other income (loss) Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, U.S. state regulatory authorities Assets Held by Insurance Regulators IBNR Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Foreign statutory income tax rate Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent Letter of credit aggregate commitment Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Income Tax [Table] Income Tax [Table] Income Tax [Table] Secured Letter of Credit Facility Secured Letter Of Credit Facility [Member] Secured Letter Of Credit Facility Total expenses Benefits, Losses and Expenses Entity File Number Entity File Number Net realized and unrealized gains (losses) on investments Net realized and unrealized gains (losses) on investments Nonoperating Gains (Losses) Consolidated Entities [Domain] Consolidated Entities [Domain] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Effect of exchange rate changes on foreign currency cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Dividends on common shares (Note 12) Dividends on common shares Dividends, Common Stock Name Forgone Recovery, Individual Name Operating lease, weighted average lease term Operating Lease, Weighted Average Remaining Lease Term Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Provision for (release of) allowance Reinsurance Recoverable, Credit Loss Expense (Reversal) Premium Receivable, Allowance for Credit Loss [Roll Forward] Premium Receivable, Allowance for Credit Loss [Roll Forward] PFZW PFZW [Member] PFZW Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Lessee, finance lease, term of contract Lessee, Finance Lease, Term of Contract Average annual percentage payout, year two Short-Duration Insurance Contracts, Historical Claims Duration, Year Two Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Member] This item represents that portion of equity (net assets) in redeemable noncontrolling interests not attributable, directly or indirectly to the parent. Accident Year 2018 Short-Duration Insurance Contracts, Accident Year 2018 [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Derivative Liabilities Derivative Liability [Abstract] Foreign currency forward contracts Foreign Currency Forward Contracts, Investment Operations [Member] Foreign Currency Forward Contracts, Investment Operations Foreign Currency Contracts [Member] Other investments, maximum exposure to loss Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount 2019 Large Loss Events 2019 Large Loss Events [Member] 2019 Large Loss Events [Member] Reduction in gross other intangible assets Other Intangible Assets, Gross, Change In Classification, Amount Other Intangible Assets, Gross, Change In Classification, Amount Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] RREAG RenaissanceRe Europe AG [Member] RenaissanceRe Europe AG Assumed and ceded (re)insurance contracts Assumed And Ceded Re Insurance Contracts, Liabilities, Fair Value Assumed And Ceded Re Insurance Contracts, Liabilities, Fair Value Schedule of Statutory Net (Loss) Income Schedule of Statutory Net Income (Loss) [Table Text Block] Schedule of Statutory Net Income (Loss) [Table Text Block] Related Party Transactions, by Related Party [Axis] Related and Nonrelated Parties [Axis] Denominator for basic income (loss) per RenaissanceRe common share - weighted average common shares (in shares) Weighted Average Number of Shares Outstanding, Basic Investor Investor [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Intangible assets acquired Identifiable indefinite lived intangible assets (insurance

licenses) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Redemption of preference shares Payments for Repurchase of Preferred Stock and Preference Stock Combined ratio Combined Ratio Entity Filer Category Entity Filer Category Weighted average life Debt Securities Weighted Average Life This item represents the weighted average life in years of debt securities. Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Acquired Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Reinsurer Concentration Risk Reinsurer Concentration Risk [Member] Vوبا Deferred Tax Liabilities, Value Of Business Acquired Deferred Tax Liabilities, Value Of Business Acquired Bilateral Facility Participants Bilateral Facility Participants [Member] Bilateral Facility Participants [Member] Customer One Customer One [Member] Customer One Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] 2021 Weather-Related Large Loss Events 2021 Large Loss Events [Member] 2021 Large Loss Events [Member] Schedule of Computation of Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock incentive compensation, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Accident Year 2017 Short-Duration Insurance Contracts, Accident Year 2017 [Member] Accident Year 2022 Short-Duration Insurance Contract, Accident Year 2022 [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Income taxes paid (refunded) Income Taxes Paid, Net Adjustments Goodwill, Measurement Period Adjustment Common share price of RenaissanceRe (in dollars per share) Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Share Price Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Share Price Investments in other ventures, under equity method (Note 5) CarryingA Value Equity Method Investments Pay vs Performance Disclosure [Line Items] Redeemable noncontrolling interests (Note 10) Redeemable noncontrolling interests Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Residential mortgage-backed Residential Mortgage-Backed Securities [Member] Allowance for Reinsurance Recoverable SEC Schedule, 12-09, Allowance, Reinsurance Recoverable [Member] Derivative [Table] Derivative [Table] Large and small catastrophe events and attritional loss movements Large and Small Catastrophe Events And Attritional Loss Movements [Member] Large and Small Catastrophe Events And Attritional Loss Movements [Member] Goodwill and other intangible assets (Note 4) Total goodwill and other intangible assets Goodwill and other intangible assets Intangible Assets, Net (Including Goodwill) Foreign exchange and other Liability for Unpaid Claims and Claims Adjustment Expense, Foreign Currency Translation Gain (Loss) Citibank Europe Citibank Europe [Member] Citibank Europe Number of segregated accounts Number Of Segregated Accounts Number Of Segregated Accounts Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Management Fee Financial Service [Member] Schedule of Share-based Compensation, Cash Settled Restricted Stock Units and Performance Shares Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Common shares, shares outstanding (in shares) Shares outstanding - beginning balance (in shares) Shares outstanding - ending balance (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Proceeds from sales of equity investments Proceeds From Trading Securities, Short-Term Proceeds From Trading Securities, Short-Term Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Redemption of shares from redeemable noncontrolling interests Redemption of shares from redeemable noncontrolling interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Industry Sector [Domain] Industry Sector [Domain] Finance lease, interest expense Finance Lease, Interest Expense Due in less than one year Trading Securities, Debt Maturities, Within One Year, Amortized Cost Basis This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one year of the balance sheet date and are categorized as trading securities. 2023 Large Loss Events 2023 Large Loss Events [Member] 2023 Large Loss Events Proceeds from issuance of equity Proceeds from Issuance or Sale of Equity Liquidation preference (in usd per share) Preferred Stock, Liquidation Preference Per Share Ceded Credit Risk, Collateralization [Domain] Ceded Credit Risk, Collateralization [Domain] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets [Table] Entity Tax Identification Number Entity Tax Identification Number Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Stichting Pensioenfonds Zorg en Welzijn Stichting Pensioenfonds Zorg en Welzijn [Member] Stichting Pensioenfonds Zorg en Welzijn Gross Amounts Offset in the Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Offset Retirement Plan Type [Axis] Retirement Plan Type [Axis] \$100 Million Principal At Risk Variable Rate Note One Hundred Million Principal At Risk Variable Rate Note [Member] One Hundred Thousand Principal At Risk Variable Rate Note SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items] Deferred acquisition costs and value of business acquired Deferred Policy Acquisition Cost Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Numerator: Earnings Per Share Reconciliation [Abstract] U.S. treasury U.S Treasury Securities [Member] Rated lower than A- Standard & Poor's, BBB+ Rating [Member] Plan Name [Axis] Plan Name [Axis] After 2029 Finance Lease, Liability, to be Paid, after Year Five Equity Components [Axis] Equity Components [Axis] Future minimum lease payments under existing leases Finance Lease, Liability, to be Paid Accumulated Impairment Losses Intangible Assets (Excluding Goodwill), Accumulated Impairment Loss Intangible Assets (Excluding Goodwill), Accumulated Impairment Loss Trade Names [Member] Payments of capital distributions Payments of Capital Distribution Net income (loss) available (attributable) to RenaissanceRe common shareholders Business Acquisition, Pro Forma Net Income (Loss) Industry insured loss Loss Contingency, Industry Amount Incurred, Amount Loss Contingency, Industry Amount Incurred, Amount Net deferred tax asset (liability) before valuation allowance Deferred Tax Asset (Liability) Before Valuation Allowance, Net The sum of the tax effects as of the balance sheet date of deferred tax assets and deferred tax liabilities, before consideration of the valuation allowance recorded as of the balance sheet date pertaining to the specified deferred tax asset for which an assessment was made that it is more likely than not that all or a portion of such deferred tax asset will not be realized through related deductions on future tax returns. Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Gross Amounts Offset in the Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Other Short Term Investments Other Short Term Investments [Member] Other Short Term Investments Net investment income Investment Income [Member] Direct Gross Amounts Direct Premiums Earned Investment Type Categorization [Domain] Investments [Domain] Business acquisition, common shares (in shares) Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Basic materials Basic Materials Sector [Member] Basic Materials Sector [Member] Patents and intellectual property Developed Technology Rights [Member] Statement, Geographical [Axis] Geographical [Axis] Fixed maturity investments trading, amortized cost Amortized cost Debt Securities, Trading, Amortized Cost Net deferred tax assets Net deferred tax asset (liability) Deferred Tax Assets, Net 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Increase (decrease) in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Recognition of Bermuda net deferred tax asset Effective Income Tax Rate Reconciliation, Recognition Of Bermuda Net Deferred Tax Asset Effective Income Tax Rate Reconciliation, Recognition Of Bermuda Net Deferred Tax Asset Goodwill and Intangible Assets [Line Items] Schedule of Goodwill and Intangible Assets [Line Items] Schedule of Goodwill and Intangible Assets [Line Items] Weighted Average or Actual Weighted Average [Member] Reinsurance recoverable Increase (Decrease) in Reinsurance Recoverable Repurchase of shares (Note 12) Value of shares repurchased Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other Liabilities [Member] Other Liabilities [Member] Chief Executive Officer Chief Executive Officer [Member] Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Operating lease, expense Operating Lease, Expense Net undiscounted cash flows Measurement Input, Undiscounted Cash Flows [Member] Measurement Input, Undiscounted Cash Flows [Member] Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Vesting maximum as a percentage of target if performance goal are achieved Vesting Maximum, as a Percentage of Target, if Performance Goals are Achieved Vesting Maximum, as a Percentage of Target, if Performance Goals are Achieved Equity investments, at fair value (Notes 5 and 6) Total Equity investments Equity Securities, FV-NI, Current Unrecognized compensation costs related to restricted stock awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Reinsurance balances payable Reinsurance Balances Payable [Member] Reinsurance Balances Payable [Member] Consolidation Items [Axis] Consolidation Items [Axis] Healthcare Healthcare Sector [Member] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Fair Value Option Fair Value of Financial Instruments, Policy [Policy Text Block] Due after five through ten years Trading Securities, Debt Maturities, after Five Through Ten Years, Amortized Cost Basis This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one through 5 years of the balance sheet date and are categorized as trading securities. 2024 2024 [Member] 2024 Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Net sales (purchases) of short term investments Payments For (Proceeds From) Other Short Term Investments The net amount paid (received) by the reporting entity through acquisition (sale/maturities) of short-term investments with an original maturity that is one year or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Ordinary dividend capacity Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Awards vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Prior years Net claims and claim expenses incurred æ¸ prior accident years Prior Year Claims and Claims Adjustment Expense Average annual percentage payout, year seven Short-Duration Insurance Contracts, Historical Claims Duration, Year Seven \$250 Million Principal-At-Risk Note Two Hundred And Fifty Million Principal At Risk Variable Rate Note [Member] Two Hundred And Fifty Million Principal At Risk Variable Rate Note Direct Direct Premiums Written Preference shares, shares outstanding (in shares) Preferred Stock, Shares Outstanding Underwriting income (loss) Underwriting Income (Loss) Net Net premiums earned less net claims and claim expenses incurred, acquisition expenses and operational expenses directly related to underwriting activities. Warrants Warrant [Member] Security Exchange Name Security Exchange Name Schedule of Finite and Indefinite-lived Intangible Assets [Table] Schedule of Finite and Indefinite-lived Intangible Assets [Table] Schedule of Finite and Indefinite-lived Intangible Assets [Table] Financials Financial Services Sector [Member] Schedule of Provision for Current Expected Credit Losses of Premiums Receivable Premium Receivable, Allowance for Credit Loss [Table Text Block] Fontana Fontana Holdings L.P. [Member] Fontana Holdings L.P. [Member] Fixed maturity investments trading Fixed Maturities [Member] Gain (Loss) on Securities [Line Items] Gain (Loss) on Securities [Line Items] Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Fair Value SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value Short-term debt Short-Term Debt SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Table] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Table] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Prepaid reinsurance premiums (Note 7) Prepaid Reinsurance Premiums Withholding tax Effective Income Tax Rate Reconciliation, Withholding Tax Effective Income Tax Rate Reconciliation, Withholding Tax Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Incurred Claims and Claim Expenses, Net of Reinsurance Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net Losses recoverable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Losses Recoverable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Losses Recoverable Common shares, shares issued (in shares) Shares issued - beginning balance (in shares) Shares issued - ending balance (in shares) Common Stock, Shares, Issued Other assets Other Assets [Member] Premium Revenue SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities) Derivative, Weighted Average U.S. Dollar Equivalent Of Foreign Denominated Net Assets Derivative, Weighted Average U.S. Dollar Equivalent Of Foreign Denominated Net Assets 4.750% Senior Notes due 2025 (DaVinci) 4.750% Senior Notes Due May 1, 2025 4.750% Senior Notes Due May 1, 2025 [Member] 4.75% Senior Notes Due May 1, 2025 [Member] Entity [Domain] Entity [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Concentration risk , percentage Percent of gross premiums received Concentration Risk, Percentage SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract] Gross premiums written (Note 7) Premiums Written, Gross Derivative liabilities Net Amounts of Liabilities Presented in the Balance Sheet Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Liquidating period Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Liquidating Investment, Remaining Period Europe Europe [Member] Authorized common shares (in shares) Common Stock, Shares Authorized Fontana Fontana Third-Party Investors [Member] Fontana Third-Party Investors Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Net purchase of Validus Payments to Acquire Businesses, Net of Cash Acquired Debt to capital ratio Ratio of Indebtedness to Net Capital Insurance [Abstract] Ceded Credit Risk [Table] Ceded Credit Risk [Table] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Entity Voluntary Filers Entity Voluntary Filers Related Party Related Party [Member] Amortization period majority Acquired Finite-Lived Intangible Assets, Majority Amortization Period Acquired Finite-Lived Intangible Assets, Majority Amortization Period Net Investment Income SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income Hedging Designation [Domain] Hedging Designation [Domain] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense (Note 9) Interest expense Interest expense Interest Expense, Nonoperating Deferred Deferred Income Tax Expense (Benefit) Short-term investments, amortized cost Other Short-Term Investments, Amortized Cost Other Short-Term Investments, Amortized Cost Investments Deferred Tax Assets, Equity Method Investments, Available For Sale Investments and Derivatives Deferred Tax Assets, Equity Method Investments, Available For Sale Investments and Derivatives Taxation, Uncertainties Income Tax Uncertainties, Policy [Policy Text Block] Proceeds from sales of short term investments Proceeds from Sale of Short-Term Investments Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Entity Address, Country Entity Address, Country Excess windfall tax benefit Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Net Written Premiums SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Standby Letter of Credit Agreement Standby Letter of Credit Agreement [Member] Standby Letter of Credit Agreement Parent company ownership in redeemable noncontrolling interest Subsidiary, Ownership Percentage, Parent Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Platinum Underwriters Holdings, Ltd. Platinum [Member] Platinum [Member] Debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Plan assets at fair value Defined Benefit Plan, Plan Assets, Amount After 2029 Long-Term Debt, Maturity, after Year Five Worldwide (excluding U.S.) Worldwide, Excluding U.S. [Member] Worldwide, Excluding U.S. [Member] Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Investment Income [Table] Investment Income [Table] Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward] Business Combination, Recognized Identifiable Assets

Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward] Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Shares repurchased, average price per share (in usd per share) Shares Acquired, Average Cost Per Share Investment expenses Investment Income, Investment Expense Investments in subsidiaries Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Document Annual Report Document Annual Report Prepaid reinsurance premiums Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Reinsurance Premiums Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Reinsurance Premiums 2027 Finance Lease, Liability, to be Paid, Year Three Awards vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Multi-Beneficiary Reduced Collateral Reinsurance Trust Multi-Beneficiary Reduced Collateral Reinsurance Trust [Member] Multi-Beneficiary Reduced Collateral Reinsurance Trust [Member] Amortization of intangible assets Amortization of Intangible Assets Agent relationships - top four Agent Relationships - Top Four [Member] Agent Relationships - Top Four Accounting Policies [Abstract] Accounting Policies [Abstract] Liabilities Liabilities [Abstract] Revenues Revenues [Abstract] Impairment of indefinite-lived intangible asset Impairment of Intangible Assets, Indefinite-Lived Impairment of Intangible Assets, Indefinite-Lived Liquidity discount Measurement Input, Liquidity [Member] Measurement Input, Liquidity [Member] Net (income) loss attributable to redeemable noncontrolling interests (Note 10) Net income (loss) attributable to redeemable noncontrolling interest Net (income) loss attributable to redeemable noncontrolling interests Net Income (Loss) Attributable to Redeemable Noncontrolling Interest ACQUISITION OF VALIDUS Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Catastrophic Event [Axis] Catastrophic Event [Axis] Reserves for Unpaid Claims and Claim Adjustment Expenses SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Reserve for Unpaid Claim and Claim Adjustment Expense Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] PEO Name PEO Name Award Type [Domain] Award Type [Domain] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Issuance of performance share and restricted stock awards (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Licenses Licensing Agreements [Member] BSCR ratio Bermuda Capital And Solvency Ratio Bermuda Capital And Solvency Ratio Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Liability for Catastrophe Claims [Line Items] Liability for Catastrophe Claims [Line Items] Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Deferred tax asset Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Finite-lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Fixed maturity investments trading, at fair value - amortized cost \$23,750,540 at DecemberÂ 31, 2024 (2023 - \$20,872,450) (Notes 5 and 6) Fixed maturity investments trading Fixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil) Debt Securities, Trading Consolidated Subsidiaries SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Consolidated Property and Casualty Insurance Entity [Member] Additional paid-in capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Expected future benefit from goodwill Business Acquisition, Goodwill, Expected Tax Deductible Amount, Future Benefit Business Acquisition, Goodwill, Expected Tax Deductible Amount, Future Benefit Class of Stock [Line Items] Class of Stock [Line Items] Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Net Premiums Written SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Premium Written Provision for (release of) allowance Premium Receivable, Credit Loss Expense (Reversal) Title and Position [Domain] Title and Position [Domain] Amortization and depreciation Deferred Tax Assets, Amortization And Depreciation Deferred Tax Assets, Amortization And Depreciation Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] 2028 Finance Lease, Liability, to be Paid, Year Four Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS SEC Schedule, 12-17, Insurance Companies, Reinsurance [Text Block] Gross realized gains on fixed maturity investments trading Debt Securities, Trading, Realized Gain Canada CANADA Net claims and claim expenses incurred (Notes 7 and 8) Net claims and claim expenses incurred Net claim and claim expenses decrease Net claims and claim expenses incurred Policyholder Benefits and Claims Incurred, Net Three Brokers Three Brokers [Member] Three Brokers [Member] Value of in-force business Deferred Tax Assets, Value Of In Force Business Deferred Tax Assets, Value Of In Force Business Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Switzerland SWITZERLAND Valuation Technique, Quoted Prices Valuation Technique, Quoted Prices [Member] Valuation Technique, Quoted Prices Equity method investment, dividends and distributions Proceeds from Equity Method Investment, Sum of Distributions Amount of distribution received from equity method investee for return of investment and return on investment. Total stock compensation expense recognized Share-Based Payment Arrangement, Noncash Expense 2017 Large Loss Events 2017 Large Loss Events [Member] 2017 Large Loss Events [Member] Value of business acquired Intangible Assets Arising from Insurance Contracts Acquired in Business Combination [Member] Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Australia AUSTRALIA Actuarial methods - actual reported claims less than expected claims Reported Claims Less than Expected [Member] Reported Claims Less than Expected [Member] California Wildfires California Wildfires [Member] California Wildfires Interest rate Debt Instrument, Interest Rate, Stated Percentage Other Segment Reporting, Reconciling Item, Corporate Nonseignment [Member] Ceded Ceded premiums written Ceded Premiums Written Schedule of Investments [Line Items] Schedule of Investments [Line Items] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Due after one through five years Trading Securities, Debt Maturities, after One Through Five Years, Amortized Cost Basis This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one year of the balance sheet date and are categorized as trading securities. Series C Preferred Stock Series C Preferred Stock [Member] Maturity period Investment Owned, Maturity Period Investment Owned, Maturity Period Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Dividend rate, percentage Preferred Stock, Dividend Rate, Percentage Foreign branch adjustments Effective Income Tax Rate Reconciliation, Foreign Branch Adjustments, Amount Effective Income Tax Rate Reconciliation, Foreign Branch Adjustments, Amount Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Bermuda BERMUDA Credit Rating, Standard & Poor's [Axis] Credit Rating, Standard & Poor's [Axis] Cash consideration funded by net proceeds from the issuance of Senior Notes Business Combination, Consideration Transferred, Proceeds From Issuance Of Senior Notes Business Combination, Consideration Transferred, Proceeds From Issuance Of Senior Notes Auditor Firm ID Auditor Firm ID Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets \$350 Million Principal At Risk Variable Rate Note Three Hundred And Fifty Million Principal At Risk Variable Rate Note [Member] Three Hundred And Fifty Million Principal At Risk Variable Rate Note Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Customer Three Customer Three [Member] Customer Three Total liabilities, noncontrolling interests and shareholdersâ€™ equity Liabilities and Equity Percentage of Amount Assumed to Net SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net SUBSEQUENT EVENTS Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Ceded Ceded premiums earned Ceded to Other Companies Ceded Premiums Earned Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Investments Marketable Securities, Policy [Policy Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Fund investments Senior Secured Bank Loan Funds [Member] An investment that primarily invests in bank loans and other senior debt instruments. Corporate expenses associated with the acquisition Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Unearned Premiums SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Unearned Premium DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] 2026 Finance Lease, Liability, to be Paid, Year Two Outstanding liabilities from accident year 2014 and prior, net of reinsurance Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented Supplemental Information for Property, Casualty Insurance Underwriters, by Affiliation with Registrant [Axis] SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Affiliation with Registrant [Axis] Payments of dividends Payments of Dividends Percentage of maximum aggregate amount to be secured Line of Credit Facility, Percentage Of Maximum Aggregate Amount To Be Secured Line of Credit Facility, Percentage Of Maximum Aggregate Amount To Be Secured Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Share-based Compensation, Restricted Stock Awards Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of Aggregate Amount of Maturities Related to the Company's Debt Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Average annual percentage payout, year nine Short-Duration Insurance Contracts, Historical Claims Duration, Year Nine Industry Sector [Axis] Industry Sector [Axis] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Small catastrophe events and attritonal loss movements Small Catastrophe Events And Attritonal Loss Movements [Member] Small Catastrophe Events And Attritonal Loss Movements [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Product and Service [Axis] Product and Service [Axis] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Quarterly liquidation preference (in usd per share) Preferred Stock, Liquidation Preference Per Share, Quarterly Preferred Stock, Liquidation Preference Per Share, Quarterly Vermeer Vermeer Reinsurance Ltd. [Member] Vermeer Reinsurance Ltd. [Member] Citibank Europe plc Citibank Europe plc [Member] Citibank Europe plc [Member] Schedule of Other Investments Measured Using Net Asset Valuations Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block] Total identifiable net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Deferred Policy Acquisition Costs SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Deferred Policy Acquisition Cost Average annual percentage payout, year ten Short-Duration Insurance Contracts, Historical Claims Duration, Year 10 Total purchase price Total purchase price Total purchase price Business Combination, Consideration Transferred Depository Shares, each representing a 1/1,000th interest in a Series F 5.7500% Preference Share, Par Value \$1.00 per share Depository Shares, each representing a 1/1,000th interest in a Series F 5. [Member] Depository Shares, each representing a 1/1,000th interest in a Series F 5. [Member] Reduction in goodwill Goodwill, Gross, Change In Classification, Amount Goodwill, Gross, Change In Classification, Amount Derivatives Derivatives, Policy [Policy Text Block] Mandatory capital contribution in the event of capital and surplus reduction below a specified level Estimate of pre tax loss Loss Contingency, Estimate of Possible Loss Unamortized discount and debt issuance expenses Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] Related Party Transactions [Abstract] Gross Premiums Written, Benchmark Gross Premiums Written, Benchmark [Member] Gross Premiums Written, Benchmark Aon plc Aon plc [Member] Aon plc [Member] U.K. UNITED KINGDOM Noncatastrophic Event [Domain] Noncatastrophic Event [Domain] Acquisition expenses Deferred Policy Acquisition Costs, Amortization Expense Large catastrophe events Large Catastrophe Events [Member] Large Catastrophe Events [Member] Adjustment for unallocated loss adjustment expenses Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claims Adjustment Expense, Accumulated Unallocated Claim Adjustment Expense Other income (loss) Other Operating Income (Expense) [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Wells Fargo Wells Fargo [Member] Wells Fargo [Member] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Investment in participating notes Variable Interest Entity, Investment In Participating Notes Variable Interest Entity, Investment In Participating Notes Total revenues Business Acquisition, Pro Forma Revenue Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Ceded Credit Risk, Secured Ceded Credit Risk, Secured [Member] Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, various counterparties Assets held in trust Asset, Held-in-Trust Total Long-Term Debt, Gross Return of investments in other ventures Proceeds from Equity Method Investment, Distribution, Return of Capital Exercise Price Award Exercise Price Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Arrangement Duration Trading Arrangement Duration Non-Employee Director Stock Incentive Plan Non-Employee Director Stock Incentive Plan [Member] Non-Employee Director Stock Incentive Plan [Member] Operating loss carryforwards Operating Loss Carryforwards GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Variable Interest Entity [Table] Variable Interest Entity [Table] Shareholdersâ€™ Equity Shareholdersâ€™ Equity Equity Equity, Attributable to Parent [Abstract] Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Bermuda Domestic Tax Jurisdiction [Member] Total investments Investments Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Required statutory capital and surplus Statutory Accounting Practices, Statutory Capital and Surplus Required Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Finance lease, liability Finance Lease, Liability 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Claims and claim expenses recovered Net reinsurance costs and recoveries Policyholder Benefits and Claims Incurred, Assumed and Ceded Third-Party Investors Third-Party Investors [Member] Third-Party Investors [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Goodwill, gross Goodwill, Gross Other intangible assets, net Net Intangible Assets, Net (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Accident Year 2015 Short-Duration Insurance Contracts, Accident Year 2015 (Member) Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items] Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items] Alpha Cat entities AlphaCat Managers Ltd [Member] AlphaCat Managers Ltd Uncommitted Letter of Credit Facility Uncommitted Letter of Credit Facility [Member] Uncommitted Letter of Credit Facility [Member] Schedule of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Reinsurance Recoverable Reinsurance Recoverable Including Reinsurance Premium Paid [Member] Operational expenses Operating Costs and Expenses IBNR and ACR Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Net incurred related to: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Lender Name [Axis] Lender Name [Axis] Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Amortization Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Amortization Decrease (increase) in unearned premiums (Increase) Decrease in Unearned Premiums, Net Related Party [Domain] Related and Nonrelated Parties [Domain] 3.700% Senior Notes due 2025 3.700% Senior Notes Due April 1, 2025 [Member] 3.700% Senior Notes Due April 1, 2025 [Member] Deferred acquisition costs and value of business acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Acquisition Costs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Acquisition Costs Schedule of Identifiable Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Assumed reinsurance contract Assumed and ceded (re)insurance contracts, group two Assumed and Ceded Re Insurance Contracts, Group Two [Member] Assumed and Ceded Re Insurance Contracts, Group Two [Member] Liability Class [Axis] Liability Class [Axis] Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Short-duration Insurance Contracts, Historical Claims Duration [Line Items] Short-Duration Insurance Contracts, Historical Claims Duration [Line

Items] Net unrealized gains (losses) included in net investment income Unrealized Gain (Loss) on investments Deferred revenue Deferred Tax Liabilities, Tax Deferred Income Gross claims and claim expenses incurred Policyholder Benefits and Claims Incurred, Direct Interest Expense Interest Expense [Member] Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Share repurchase program, shares repurchased (in shares) Repurchase of shares (in shares) Stock Repurchased During Period, Shares Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Prepaid reinsurance premiums Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Secured Bilateral Facility Secured Bilateral Facility [Member] Secured Bilateral Facility [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] COMMITMENTS, CONTINGENCIES AND OTHER ITEMS Commitments and Contingencies Disclosure [Text Block] Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed 2030 and thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Committed amount Investment Owned, Balance, Principal Amount Asset management contracts Asset Management Contracts [Member] Asset Management Contracts Measure: Measure [Axis] Unearned premiums Unearned Premiums Issuance of performance share and restricted stock awards Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Benefits, Claims, Losses and Settlement Expenses SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Asset Class [Domain] Asset Class [Domain] Covenants not-to-compete Noncompete Agreements [Member] Authorized preference shares (in shares) Preferred Stock, Shares Authorized Issuance of shares (in shares) Stock Issued During Period, Shares, New Issues Credit default swaps Credit Default Swap [Member] Unfunded Commitments Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Entity Emerging Growth Company Entity Emerging Growth Company Net realized and unrealized gains (losses) on other investments Debt Securities, Gain (Loss) Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Commodity options Commodity Option [Member] Other Investments Total other investments Other Investments [Member] 2029 Long-Term Debt, Maturity, Year Five Short Short [Member] Redeemable noncontrolling interest, redemption requirement, maximum percentage of shares held Redeemable Noncontrolling Interest, Redemption Requirement, Percentage of Aggregate Shares Held, Maximum Redeemable Noncontrolling Interest, Redemption Requirement, Percentage of Aggregate Shares Held, Maximum Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Investments in other ventures, under equity method Investments In Other Ventures [Member] Investments In Other Ventures [Member] Finance lease, right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Component [Domain] Equity Component [Domain] Preference shares, par value (in dollars per share) Par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Fulfilled commitments Private Equity Investments and Other Entities, Commitments Fulfilled Private Equity Investments and Other Entities, Commitments Fulfilled Bridge Loan Bridge Loan [Member] Japan JAPAN Reinsurance recoverable (Notes 7 and 8) Reinsurance recoverable, end of period Reinsurance Recoverable Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments Payable for investments purchased Broker-Dealer, Payable to Other Broker-Dealer and Clearing Organization Net realized and unrealized gains (losses) on fixed maturity investments trading Debt Securities, Trading, Gain (Loss) Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Net claims and claim expense ratio â€” calendar year Loss Ratio Schedule of Fair Value of Fixed Maturity Investments Trading Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Commodity futures Commodity Futures [Member] Commodity Futures Net unrealized gain (loss) recognized in earnings due to change in estimate Net Investment Income, Change In Estimate Net Investment Income, Change In Estimate Statement [Table] Statement [Table] Ireland IRELAND Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Schedule of Variable Interest Entities Summary of the Principal-at-risk Variable Notes Schedule of Variable Interest Entities [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Reserve for unearned premiums Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Unearned Premiums Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Unearned Premiums Purchases of equity investments Payments To Acquire Trading Securities, Short-Term Payments To Acquire Trading Securities, Short-Term Unearned Premiums SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium Due after one through five years Trading Securities, Debt Maturities, after One Through Five Years, Fair Value This item represents the fair value of debt securities which are expected to mature after one through five years of the balance sheet date and are categorized as trading securities. Accumulated other comprehensive income (loss) Derivative gains (losses) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Outstanding receivable Due from subsidiaries Accounts Receivable, before Allowance for Credit Loss Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Beginning Expiration Year [Axis] Beginning Expiration Year [Axis] Beginning Expiration Year Senior Notes Senior Notes [Member] Income Tax Expense (Benefit) Income Tax Expense (Benefit), Continuing Operations [Abstract] 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Validus Holdings, Ltd and Talbot Underwriting Limited Validus Holdings, Ltd And Talbot Underwriting Limited [Member] Validus Holdings, Ltd And Talbot Underwriting Limited Private credit funds Private Credit Funds [Member] Private Credit Funds Statutory Net Income (Loss) Statutory Accounting Practices, Statutory Net Income Amount Deferred tax liability related to VOBA and other adjustments Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Tax Liabilities, Value Of Business Acquired And Other Adjustments Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Tax Liabilities, Value Of Business Acquired And Other Adjustments Identifiable intangible assets Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023 Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024 Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Short-duration Insurance Contracts, Accident Year [Axis] Short-Duration Insurance Contracts, Accident Year [Axis] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Other intangible assets Other Intangible Assets [Member] Total net paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid TAXATION Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Nondeductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Due after five through ten years Trading Securities, Debt Maturities, after Five Through Ten Years, Fair Value This item represents the fair value of debt securities which are expected to mature after five through ten years of the balance sheet date and are categorized as trading securities. Deferred finance charges Deferred Tax Assets, Other Tax Carryforwards Agencies Agency Securities [Member] Paid Claims and Claim Adjustment Expenses SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Paid Claim and Claim Adjustment Expense Repayments of long-term lines of credit Repayments of Long-Term Lines of Credit Discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Net Investment Income [Line Items] Net Investment Income [Line Items] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items] Schedule of Goodwill and Other Intangible Assets Included In Equity Method Investments Schedule of Goodwill and Other Intangible Assets Included in Equity Method Investments [Table Text Block] Tabular disclosure of the aggregate amount of goodwill and intangible assets included in Investment in other ventures, under equity method. Non-cash consideration Noncash or Part Noncash Divestiture, Amount of Consideration Paid Noncash or Part Noncash Divestiture, Amount of Consideration Paid Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Depository Shares, each representing a 1/1,000th interest in a Series G 4.20% Preference Share, Par Value \$1.00 per share Depository Shares, each representing a 1/1,000th interest in a Series G 4 [Member] Depository Shares, each representing a 1/1,000th interest in a Series G 4 Proceeds from sales of investments in other ventures Proceeds from Sale of Equity Method Investments Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Credit Facility [Axis] Credit Facility [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Fair Value Long-term debt Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Commercial mortgage-backed Commercial Mortgage-Backed Securities [Member] Total cash consideration paid by RenaissanceRe as acquisition consideration Total cash consideration paid by RenaissanceRe as acquisition consideration Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Decrease to losses recoverable Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs Fair Value, Net Asset (Liability) Carrying Amount Other Investments, Funded Commitments [Member] Other Investments, Funded Commitments Net realized and unrealized gains (losses) on investments-related derivatives Derivative Instruments Not Designated As Hedging Instruments Investment Portfolio Gain Loss Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments and relating to the entity's investment portfolio. Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Segment, Geographical [Domain] Geographical [Domain] Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets Issuance of shares (Note 12) Stock Issued During Period, Value, New Issues Investments in other ventures, under equity method Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments in Other Ventures, Under Equity Method Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments in Other Ventures, Under Equity Method Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common shares: \$1.00 par value â€” 50,180,987 shares issued and outstanding at December 31, 2024 (2023 â€” 52,693,887) (Note 12) Common shares: \$1.00 par value â€” 50,180,987 shares issued and outstanding at December 31, 2024 (2023 â€” 52,693,887) (Note 12) Common Stock, Value, Issued Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Unsecured Bilateral Facility Unsecured Bilateral Facility [Member] Unsecured Bilateral Facility [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Reserve for claims and claim expenses Deferred Tax Assets, Other Term loans Term Loan [Member] Term Loan Claims and Claim Expenses Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block] Rollforward of Common Stock Issued and Outstanding Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Intangible asset impairment Impairment of Intangible Assets (Excluding Goodwill) Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Preference shares: \$1.00 par value â€” 30,000 shares issued and outstanding at December 31, 2024 (2023 â€” 30,000) (Note 12) Preference shares: \$1.00 par value â€” 30,000 shares issued and outstanding at December 31, 2024 (2023 â€” 30,000) (Note 12) Preferred Stock, Value, Issued Deferred tax liabilities Deferred Tax Liabilities, Gross Statutory Accounting Practices [Table] Statutory Accounting Practices [Table] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share â€” basic (in dollars per share) Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share â€” basic (in dollars per share) Earnings Per Share, Basic RenaissanceRe common share issuance, net of expenses Proceeds from Issuance of Common Stock Cash and cash equivalents Cash and Cash Equivalents [Member] \$85 Thousand Principal At Risk Variable Rate Note Eighty-Five Thousand Principal At Risk Variable Rate Note [Member] Eighty-Five Thousand Principal At Risk Variable Rate Note Finite and Indefinite-lived Intangible Assets [Axis] Finite and Indefinite-lived Intangible Assets [Axis] Finite and Indefinite-lived Intangible Assets [Axis] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Ownership [Domain] Ownership [Domain] Trademarks and trade names Trademarks [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Short term investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short Term Investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short Term Investments Accident Year 2019 Short-Duration Insurance Contract, Accident Year 2019 [Member] Multi-Beneficiary Reinsurance Trust Multi-Beneficiary Reinsurance Trust [Member] Multi-Beneficiary Reinsurance Trust [Member] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract] SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Issued or Drawn Credit facilities outstanding Long-Term Line of Credit Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Noncontrolling interest, value subscribed Sale of limited partner interest to redeemable noncontrolling interest Noncontrolling Interest, Increase from Subsidiary Equity Issuance Net foreign exchange gains (losses) Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Foreign Exchange Gains (Losses) Schedule of Quantitative Information Used as Level 3 Inputs Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Luxembourg LUXEMBOURG Insurance licenses Insurance Licenses [Member] Insurance Licenses [Member] 2027 2027 [Member] 2027 Investors of Upsilon RFO Diversified I, II and III Investors Of Upsilon RFO Diversified I, II and III [Member] Investors Of Upsilon RFO Diversified I, II and III Direct private equity investments Direct private equity investments Private equity funds Private Equity Funds [Member] Due after ten years Trading Securities, Debt Maturities, after Ten Years, Amortized Cost Basis This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature after ten years of the balance sheet date and are categorized as trading securities. Assumed Assumed Premiums Written Total revenues Total revenues Revenues Singapore SINGAPORE STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS Share-Based Payment Arrangement [Text Block] Dividends paid â€” preference shares Payments of Ordinary Dividends, Preferred Stock and Preference Stock Accordion feature, maximum borrowing capacity Line Of Credit Facility, Accordion Feature, Maximum Borrowing Capacity Line Of Credit Facility, Accordion Feature, Maximum Borrowing Capacity Entity Address, City or Town Entity Address, City or Town Deferred Policy Acquisition Costs SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost Reinsurance Trust Fund [Axis] Reinsurance Trust Fund [Axis] Reinsurance Trust Fund [Axis] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Assets: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Awards forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Other Intangible Assets By Major Class Schedule of Finite-Lived Intangible Assets [Table Text Block] Net premiums written (Note 7) Net premiums written Net premiums written Premiums Written, Net Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Assumed and ceded (re)insurance contracts Assumed And Ceded Re Insurance Contracts [Member] Assumed and ceded (re)insurance contracts accounted for at fair value. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign DaVinci DaVinci DavinciRe Third-Party Investors [Member] DavinciRe Third-Party Investors 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Variable interest entity, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Proceeds from noncontrolling interests Proceeds from Noncontrolling Interests

[illegible]

[illegible]

[illegible]

[illegible]

(The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or heavily obfuscated document. It contains no meaningful information.)

[illegible]

[illegible]

4HIJ2D*1Z"NAK;D6AW+J.D.7HB3:5(SIJZYH-B"J]H#J%O#7B7I74.M"UUDMK*POK=98+F"12CO2(X*NC*2I4@=@D\$5"S.Y.P1| MXNZ9V:V?@#30V/ I|^>FV2)H?A#2HM@EVZ4% CNM1>I!^8XP8&+VM@D MFI ^B2VJO^&E&E JSQUV@5^S7\$S-6^-7Q+&^BS;IX6I|^9M: WCT.14.M.35:R^NB(K6V/FI.00D<I\$1-L LX21.14.X8.%3X=%S6 C P##06@ P+ M2 @&W%IWOCl>+&F&ZETU^>H?>I74I16CQ+6% .1X18I+ +8I2NEOQ@O&E&V.M.#/ (.1I9^>G69M1^0V/ TW9P.98.6E0>C=B\$)Y\$B1@GUOFOIAEX8M1^?^A@I/H/PJ7A?Q:U/P1/ A-W1Z296B3VM& A^H P^V9?>^97O1/I2JW+20Q%Z13?#N8I@+XO-W^1XJ1^0E-2U+ @.EM M^PA9QVWP/T75:73C1I/ W5+M&K2TECE/AOQBHV5Y EOKI^F88/^FW@51=M? M8.LN2L1/^4A?2%?@V1/ U/QOY/AQK=EX+U24:19YM^AELL229CJGRG MI@B^F+AI+@-D\$ V/WV/OV;71MKJD+X M2867@J3PY&XV1I.K^HOKB@ HHHH **** MBBB@ HHHH *5_1 @HW %&S OI/C_>P#?S7D1 P##%SQA19+V=3# MF@6&C&T7414+V1=3^P^K03K9C.RF29-G4D@545?2W.15: FFE= P31 I^9XL J3BT.Z 6 P""SWOD.90I2.* I2O @F7X1^!@O7=8@TJ^XDCOEI/B.1=-NI MF^O2VA+ITA-G\$S\$+YK!@ "IG R1IZ(Z2OIV^*PRK Y1%? 7100>G I M1^7H:XC&V&GOI #F1BMO M9&TWLVBV. O :S: I^?CFO@301X^N &+XFP2M LV2L M? 3XV \$1PXA 8 I # C.O1I A1P^V=IXAU^9H1R^H1W MEG.M^O1M9>B5=RL X/VTHK1=?@G1:YVON\$ _C1: I#1D+X3W?7X%?X@ MSWJ@C#X=2L1J. 7PWXP1LHUM80IMNW^Q31R^?V0^VAG^XOUBH/CIP=^TJ6@Z^XQOU?IHC5O&H:@I@Y1Y)YGG^18BCV+Q/MJ/3%?2@ P#P7:UVX^3V^VCH71 P37^C I^E)S8ZG#+I: (=TY:F6QCNC3.2 M%M%HC+N2Q5H8R^29P7O@>22EY2Z9:Z/1+JFK7ILEE^+1H. 217O1/2W86^XCDXIR80/FGD72R&_1D@*QD07#21.31M/O/PQ P %*V41. 01% #>^1Z3^O:M8Z=I^F72RWALIZ.U2:3JB-Y%B ME.O+ +=IXW@O^SYX< 9^ X*?LL2 KJ/4OV2=(N1%M8?FF^?I^AYHP8.O2Z M P\$=FDL75 BM^AEAF4F-9.'3M^U.UTV#31^M^I M^+&I^P2.^UA.AIM.&+N^H=&N2I60 VUOVIO2OV?^?C2M72?K3+J2\$-O.K.MX<+1&B1W7B3O=1+V.L.BZ>JCSKAID@&\$(C#2^_T.L D. V4O^?FGAIX^T M+O&B31&X@C/MK/P41^PETE+62\$WA3Q10M&VZ^?CR12Z17LOBNK7\$U.VN.M4OL^K#?ZC^F2^T16A1 Z^UXK^ 8^C^AKI?E3%4EIQOUP#7=9H+6XN! M.VVJW>D^ P.UJM."25EQ.O1^C.#O0^QOXP?LP M7Z1L2?M?I.13I/KCPV.MG4.XG.%GX.KH.AKX:>?<5<=>=>2AGFG^X5N%Y9%I0.-M P\$&7 @UJU80?90I% X92TC@R18I0I Y1JIEV.1I#K1XH I.W.&LO^C6^MK21^IHC0N^OV.V9-?>O.USPP B=YL.Z.KEG15EHVAKJIG%>VWVEP7M M@T<^"KL4Y^"LSX^16X?7_ "OD?IJKX7I&X&7I/VG1/J08I^&KF M1^PT^2V2DN8+ZTN:4M? VIL<3&CPO= NWDY+9OB:IK?J^ 012L #>#H I M^JH^PNM120S?PIT^PHFC:1H7B7BKA0I.V%ETTT151Z<^"I/Q# #>73X=6^A2. TW1PY X+I+M1RGXI7 (ITNIN+L+V1I14: 0TB^0W@I^N98R0W.RIU^4EE#2YD1ZUSMCO2I.21M1Z=>0V4I4X1: "RC%\$S.M76B6X3I\$? I<LH21+2TMK^TBL^%*8X88XCBQ08 M^M1^>P H DHHHH **** BBBB@ HHHH **** SD^G 6D .:J^J^W^F^VMSY<^OZ^P4YSCFOIC@M1 @.H0I^U^V^M\$15:1J/UB7P1^NKU107&+GCG>O6V21P=NL\$%5F62 M&55=HIE.UPIXI11 X-F2I E%CIO 93/%>IJO/CY<1^ 9R X+2^2MF M.M^ 3X.N.X^O1^ M1^B^H^?@WPI^RCHW MO%1: "21 \$%UL>K^"1NEM4YKJ25IKJ^T^BLPHEH196 U%KYW :? M1% @^R^XQO1? OX: 72BG16YD1>2D>CX?>I^WLS: 1.1K+&=WMX=IW^*^MSMH29^U^RD.MJ1^WTG@V368KFYME*%="VQ19K1=13&9%1E: 2RD@T>22L72%I M&F BCX9 .9I^ P.UWX3?OX=065YBA=J7EKJ\$H^XN5-VRIJX.XD:#.MME752TCE0\$63P3I@72 C5^SL P6A>I?P3 .C1M76/Q^*GQ<^%5IXGI.%S1+4.=9KH&G77V4Z&*86)CED:>J9?&S^I^*N.M2M1LZ?GJG# @.H^POX? ^/PGT7PQ190&61^RNCV^O1X^I.H.SRW-PX^M>5F8_Y8XP<Z1UE^&GA.X^?I7^CGG6H= T30-N-1UC4@.D1VM MKI&T81K8YVIBLO16A1577^T70/HMXY:12Z:ZAIVH6LEM?V%I.K+I M^I157925?D\$SS@B@#X\$E X+&C \$f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

Redeemable noncontrolling interests (Note 10)	6,977,749	6,100,831
Shareholders' Equity		
Preference shares: \$1.00 par value – 30,000 shares issued and outstanding at December 31, 2024 (2023 – 30,000) (Note 12)	750,000	750,000
Common shares: \$1.00 par value – 50,180,987 shares issued and outstanding at December 31, 2024 (2023 – 52,693,887) (Note 12)	50,181	52,694
Additional paid-in capital (Note 12)	1,512,435	2,144,459
Accumulated other comprehensive income (loss)	(14,756)	(14,211)
Retained earnings (Note 12)	8,276,152	6,522,016
Total shareholders' equity attributable to RenaissanceRe	10,574,012	9,454,958
Total liabilities, noncontrolling interests and shareholders' equity	\$ 50,707,550	\$ 49,007,105

XML 23 R4.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets		
(Parenthetical) - USD	Dec. 31, 2024	Dec. 31, 2023
(\$)		
\$ in Thousands		

[Statement of Financial Position \[Abstract\]](#)

Fixed maturity investments trading, amortized cost	\$ 23,750,540	\$ 20,872,450
Short-term investments, amortized cost	\$ 4,532,166	\$ 4,603,340
Preference shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Preference shares, shares issued (in shares)	30,000	30,000
Preference shares, shares outstanding (in shares)	30,000	30,000
Common shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Common shares, shares issued (in shares)	50,180,987	52,693,887
Common shares, shares outstanding (in shares)	50,180,987	52,693,887

XML 24 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Revenues](#)

Gross premiums written (Note 7)	\$ 11,733,066	\$ 8,862,366	\$ 9,213,540
Net premiums written (Note 7)	9,952,216	7,467,813	7,196,160
Decrease (increase) in unearned premiums	143,544	3,320	(862,171)
Net premiums earned (Note 7)	10,095,760	7,471,133	6,333,989
Net investment income (Note 5)	1,654,289	1,253,110	559,932
Net foreign exchange gains (losses)	(76,076)	(41,479)	(56,909)
Equity in earnings (losses) of other ventures (Note 5)	47,087	43,474	11,249
Other income (loss)	1,928	(6,152)	12,636
Net realized and unrealized gains (losses) on investments	(27,840)	414,522	(1,800,485)
Total revenues	11,695,148	9,134,608	5,060,412

[Expenses](#)

Net claims and claim expenses incurred (Notes 7 and 8)	5,332,981	3,573,509	4,338,840
Acquisition expenses	2,643,867	1,875,034	1,568,606
Operational expenses	496,588	375,182	276,691
Corporate expenses	134,784	127,642	46,775
Interest expense (Note 9)	93,768	73,181	48,335
Total expenses	8,701,988	6,024,548	6,279,247
Income (loss) before taxes	2,993,160	3,110,060	(1,218,835)
Income tax benefit (expense) (Note 15)	(32,628)	510,067	59,019
Net income (loss)	2,960,532	3,620,127	(1,159,816)
Net (income) loss attributable to redeemable noncontrolling interests (Note 10)	(1,090,172)	(1,058,995)	98,613
Net income (loss) attributable to RenaissanceRe	1,870,360	2,561,132	(1,061,203)
Dividends on preference shares (Note 12)	(35,375)	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 1,834,985	\$ 2,525,757	\$ (1,096,578)
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic (in dollars per share)	\$ 35.31	\$ 52.40	\$ (25.50)
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – diluted (in dollars per share)	\$ 35.21	\$ 52.27	\$ (25.50)

XML 25 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Income (Loss) - USD	12 Months Ended		
(\$)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands			

[Comprehensive income \(loss\)](#)

Net income (loss)	\$ 2,960,532	\$ 3,620,127	\$ (1,159,816)
Change in net unrealized gains (losses) on investments, net of tax	1,045	1,082	(4,923)
Foreign currency translation adjustments, net of tax	(1,590)	169	370
Comprehensive income (loss)	2,959,987	3,621,378	(1,164,369)
Comprehensive (income) loss attributable to redeemable noncontrolling interests	(1,090,172)	(1,058,995)	98,613
Comprehensive income (loss) attributable to RenaissanceRe	\$ 1,869,815	\$ 2,562,383	\$ (1,065,756)

XML 26 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Shareholders' Equity - USD (\$)	Total	Preference shares	Common shares	Additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings
\$ in Thousands						
Beginning balance at Dec. 31, 2021		\$ 750,000	\$ 44,445	\$ 608,121	\$ (10,909)	\$ 5,232,624
Statement of Changes in Stockholders' Equity						
Repurchase of shares (Note 12)			(1,051)	(161,788)		
Issuance of performance share and restricted stock awards			324	34,863		
Change in redeemable noncontrolling interest				(5,549)		
Change in net unrealized gains (loss) on investments, net of tax	\$ (4,923)				(4,923)	
Foreign currency translation adjustments, net of tax	370					
Net income (loss)	(1,159,816)					
Net (income) loss attributable to redeemable noncontrolling interests (Note 10)	98,613					98,613
Dividends on common shares (Note 12)	(64,700)					(64,675)
Dividends on preference shares (Note 12)	(35,375)					(35,375)
Ending balance at Dec. 31, 2022	5,325,274	750,000	43,718	475,647	(15,462)	4,071,371
Statement of Changes in Stockholders' Equity						
Issuance of shares (Note 12)			8,568	1,628,209		
Issuance of performance share and restricted stock awards			408	42,007		
Change in redeemable noncontrolling interest				(1,404)		
Change in net unrealized gains (loss) on investments, net of tax	1,082				1,082	
Foreign currency translation adjustments, net of tax	169				169	
Net income (loss)	3,620,127					
Net (income) loss attributable to redeemable noncontrolling interests (Note 10)	(1,058,995)					(1,058,995)
Dividends on common shares (Note 12)	(75,100)					(75,112)
Dividends on preference shares (Note 12)	(35,375)					(35,375)

Ending balance at Dec. 31, 2023	9,454,958	750,000	52,694	2,144,459	(14,211)	6,522,016
Statement of Changes in Stockholders' Equity						
Repurchase of shares (Note 12)			(2,711)	(675,453)		
Issuance of performance share and restricted stock awards			198	48,458		
Change in redeemable noncontrolling interest				(5,029)		
Change in net unrealized gains (loss) on investments, net of tax	1,045				1,045	
Foreign currency translation adjustments, net of tax	(1,590)				(1,590)	
Net income (loss)	2,960,532					
Net (income) loss attributable to redeemable noncontrolling interests (Note 10)	(1,090,172)					(1,090,172)
Dividends on common shares (Note 12)	(80,800)					(80,849)
Dividends on preference shares (Note 12)	(35,375)					(35,375)
Ending balance at Dec. 31, 2024	\$ 10,574,012	\$ 750,000	\$ 50,181	\$ 1,512,435	\$ (14,756)	\$ 8,276,152

XML 27 R8.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows provided by (used in) operating activities			
Net income (loss)	\$ 2,960,532	\$ 3,620,127	\$ (1,159,816)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities			
Amortization, accretion and depreciation	258,456	(134,753)	(26,950)
Equity in undistributed (earnings) losses of other ventures	9,035	(7,642)	10,723
Net realized and unrealized (gains) losses on investments	(29,439)	(482,794)	1,635,192
Change in:			
Premiums receivable	(9,546)	(126,852)	(1,357,929)
Prepaid reinsurance premiums	36,445	223,385	(166,690)
Reinsurance recoverable	862,896	663,909	(442,256)
Deferred acquisition costs and value of business acquired	199,078	37,301	(322,578)
Reserve for claims and claim expenses	816,622	(34,656)	2,597,943
Unearned premiums	(185,720)	(227,001)	1,027,894
Reinsurance balances payable	(381,830)	(1,040,110)	67,318
Other	(371,707)	(579,280)	(259,168)
Net cash provided by (used in) operating activities	4,164,822	1,911,634	1,603,683
Cash flows provided by (used in) investing activities			
Proceeds from sales and maturities of fixed maturity investments trading	23,515,450	21,796,577	22,086,168
Purchases of fixed maturity investments trading	(26,296,842)	(24,771,411)	(24,923,131)
Proceeds from sales of equity investments	463	566,040	659,199
Purchases of equity investments	(205)	(1,715)	(861,508)
Proceeds from sales of short term investments	31,772,072	41,152,880	26,612,585
Purchases of short term investments	(31,597,588)	(39,309,700)	(25,972,174)
Proceeds from sales of other investments	1,087,445	489,658	408,944
Purchases of other investments	(1,525,665)	(1,291,508)	(1,027,734)
Proceeds from sales of investments in other ventures	0	0	3,545
Purchases of investments in other ventures	(57,335)	(25,265)	(4,318)
Return of investments in other ventures	41,349	5,554	2,248
Net purchase of Validus	0	(2,433,746)	0
Net cash provided by (used in) investing activities	(3,060,856)	(3,822,636)	(3,016,176)
Cash flows provided by (used in) financing activities			
Dividends paid - RenaissanceRe common shares	(80,849)	(75,112)	(64,675)
Dividends paid - preference shares	(35,375)	(35,375)	(35,396)
RenaissanceRe common share repurchases	(666,921)	0	(166,664)
RenaissanceRe common share issuance, net of expenses	0	1,351,608	0
Issuance of debt, net of expenses	0	740,581	0
Repayment of Medici Revolving Credit Facility	(150,000)	(30,000)	0
Drawdown of Medici Revolving Credit Facility	75,000	75,000	0
Subscriptions of third-party redeemable noncontrolling interest shares	537,433	982,914	1,277,945
Redemptions of third-party redeemable noncontrolling interest shares	(943,223)	(400,458)	(274,957)
Taxes paid on withholding shares	(23,580)	(20,518)	(10,911)
Net cash provided by (used in) financing activities	(1,287,515)	2,588,639	725,342
Effect of exchange rate changes on foreign currency cash	(17,365)	5,542	22,471
Net increase (decrease) in cash and cash equivalents	(200,914)	683,179	(664,680)
Cash and cash equivalents, beginning of year	1,877,518	1,194,339	1,859,019
Cash and cash equivalents, end of year	1,676,604	1,877,518	1,194,339
Supplemental disclosure of cash flow information			
Income taxes paid (refunded)	99,535	26,777	3,129
Interest paid	88,046	73,543	46,247
Non-cash consideration	[1] \$ 0	\$ 285,168	\$ 0

[1] Represents the non-cash component of the total Validus Acquisition consideration. Refer to "Note 3. Acquisition of Validus" for additional information related to the Validus Acquisition.

XML 28 R9.htm IDEA: XBRL DOCUMENT

ORGANIZATION	12 Months Ended Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
ORGANIZATION	ORGANIZATION
RenaissanceRe Holdings Ltd. ("RenaissanceRe" or the "Company") was formed under the laws of Bermuda on June 7, 1993. Through its wholly owned and majority-owned subsidiaries, joint ventures and managed funds, the Company provides property, casualty and specialty reinsurance and certain insurance solutions to its customers.	
These consolidated financial statements include the results of the Company, its subsidiaries, and all variable interest entities in which the Company is considered to be the primary beneficiary.	

XML 29 R10.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended Dec. 31, 2024
Accounting Policies [Abstract]	
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES
Basis Of Presentation	
These consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the United States ("GAAP"). All significant intercompany accounts and transactions have been eliminated from these statements.	
Certain comparative information has been reclassified to conform to the current presentation.	
Use Of Estimates In Financial Statements	
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. The major estimates reflected in the Company's consolidated financial statements include, but are not limited to, the reserve for claims and claim expenses; reinsurance recoverable and premiums receivable, including provisions for reinsurance recoverable and premiums receivable to reflect expected credit losses; estimates of written and earned premiums; fair value, including the fair value of investments, financial instruments and derivatives; impairment charges; deferred acquisition costs, the value of business acquired ("VOBA") and the fair value of other assets acquired and liabilities assumed in acquisitions; and the Company's deferred tax valuation allowance.	
Premiums and Related Expenses	
Premiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are	

determined. Unearned premiums represent the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written.

Acquisition costs are incurred when a contract or policy is issued and only the costs directly related to the successful acquisition of new and renewal contract or policies are deferred and amortized over the same period in which the related premiums are earned. Acquisition costs consist principally of commissions, brokerage and premium tax expenses and are shown net of commissions earned on ceded reinsurance. Certain of the Company's assumed contracts contain profit sharing provisions or adjustable commissions that are estimated based on the expected loss and loss adjustment expense on those contracts. Acquisition costs include accruals for such estimates of commissions. Certain of the Company's ceded contracts contain profit sharing provisions which accrue to the benefit of the Company. Acquisition costs are shown net of such commissions and profit commissions earned on ceded reinsurance. In addition, certain of the

Company's ceded contracts contain override and management fees which are recorded as an offset against operational expenses. Deferred policy acquisition costs are limited to their estimated realizable value based on the related unearned premiums. Anticipated claims and claim expenses, based on historical and current experience, and anticipated investment income related to those premiums are considered in determining the recoverability of deferred acquisition costs.

Claims and Claim Expenses

The reserve for claims and claim expenses includes estimates for unpaid claims and claim expenses on reported losses as well as an estimate of losses incurred but not reported. The reserve is based on individual claims, case reserves and other reserve estimates reported by insureds and ceding companies as well as management estimates of ultimate losses. Inherent in the estimates of ultimate losses are expected trends in claim severity and frequency and other factors which could vary significantly as claims are settled. In addition, the Company does not have the benefit of a significant amount of its own historical experience in certain casualty and specialty and insurance lines of business. Accordingly, the reserving for incurred losses in these lines of business could be subject to greater variability.

Ultimate losses may vary materially from the amounts provided in the consolidated financial statements. These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, are reflected in the consolidated statements of operations in the period in which they become known and are accounted for as changes in estimates.

Reinsurance

Amounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, the Company accrues amounts (either assets or liabilities) that are due to or from retrocessionaires based on estimated contract experience. If the Company determines that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. Reinsurance recoverable on dual trigger reinsurance contracts require the Company to estimate its ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. Amounts recoverable from reinsurers are recorded net of a provision for current expected credit losses to reflect expected credit losses.

Assumed and ceded reinsurance contracts that lack significant transfer of risk are treated as deposits.

Certain assumed and ceded reinsurance contracts that do not meet all of the criteria to be accounted for as reinsurance in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 944, *Financial Services - Insurance* have been accounted for at fair value under the fair value option in accordance with FASB ASC Topic 825, *Financial Instruments*.

Investments

Fixed Maturity Investments

Investments in fixed maturities are classified as trading and are reported at fair value. Investment transactions are recorded on the trade date with balances pending settlement reflected in the balance sheet as a receivable for investments sold or a payable for investments purchased. Net investment income includes interest and dividend income together with amortization of market premiums and discounts and is net of investment management and custody fees. The amortization of premium and accretion of discount for fixed maturity securities is computed using the effective yield method. For mortgage-backed securities and other holdings for which there is prepayment risk, prepayment assumptions are evaluated quarterly and revised as necessary. Any adjustments required due to the change in effective yields and maturities are recognized on a prospective basis through yield adjustments. Fair values of investments are based on quoted market prices, or when such prices are not available, by reference to broker or underwriter bid indications and/or internal pricing valuation techniques. The net unrealized appreciation or depreciation on fixed maturity investments trading is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations. Realized gains or losses on the sale of investments are determined on the basis of the first in first out cost method.

Short Term Investments

Short term investments, which are managed as part of the Company's investment portfolio and have a maturity of one year or less when purchased, are carried at fair value. The net unrealized appreciation or depreciation on short term investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Equity Investments

Equity investments are accounted for at fair value in accordance with FASB ASC Topic 825, *Financial Instruments*. Fair values are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. Dividend income is included in net investment income and net realized and unrealized appreciation or depreciation on equity investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Other Investments

The Company accounts for its other investments at fair value in accordance with FASB ASC Topic 825, *Financial Instruments* with interest and dividend income included in net investment income. Realized and unrealized gains and losses on other investments are included in net realized and unrealized gains (losses) on investments. The fair value of the Company's fund investments, which include private equity funds, private credit funds and hedge funds, is generally established on the basis of the net asset value ("NAV") per share (or its equivalent) established by each respective fund investments manager, if applicable. The net asset value established by the respective fund investments manager is determined in accordance with the governing documents of such fund investments. The Company applies the practical expedient provided by the FASB ASC Topic 825, *Financial Instruments* relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of the fund investments based on that NAV per share, or its equivalent. Fund investments are recorded on the consolidated balance sheets in other investments. Fund investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy.

Certain of the Company's fund investment managers, or their fund administrators, are unable to provide final fund valuations as of the Company's current reporting date. The Company typically experiences a reporting lag to receive a final net asset value report of one month for hedge funds and three months for both private equity funds and private credit funds, although the Company has occasionally experienced delays of up to six months, particularly at year end.

In circumstances where there is a reporting lag between the current period end reporting date and the reporting date of the latest fund valuation, the Company estimates the fair value of these funds by starting with the prior month or quarter-end fund valuations, adjusting these valuations for actual capital calls, redemptions or distributions, as well as the impact of changes in foreign currency exchange rates, and then estimating the return for the current period. In circumstances in which the Company estimates the return for the current period, all information available to the Company is utilized. This principally includes using preliminary estimates reported to the Company by its fund managers, where available, and estimating returns based on the performance of broad market indices or other valuation methods. Actual final fund valuations may differ, perhaps materially so, from the Company's estimates and these differences are recorded in the Company's statement of operations in the period in which they are reported to the Company as a change in estimate.

The Company's other investments also include investments in catastrophe bonds, direct private equity investments and term loans which are recorded at fair value. The fair value of catastrophe bonds is based on broker or underwriter bid indications. The fair value of direct private equity investments is based on quoted prices for similar assets, where available, or on the use of internal valuation models.

Investments in Other Ventures, Under Equity Method

Investments in which the Company has significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, the Company records its proportionate share of income or loss from such investments in its statements of operations for the period. Additionally, the Company records its portion of any changes to the accumulated other comprehensive income or loss of the investee in the Company's statements of comprehensive income (loss). If the Company's proportionate

share of loss from such investment is in excess of the carrying value of such investment, the Company suspends the application of the equity method when the carrying value of the investment is reduced to zero, unless the Company has committed to provide further financial support to the investee. If the investee subsequently reports net income, the Company resumes applying the equity method only after its proportionate share of net income equals the proportionate share of net losses not recognized during the period the equity method was suspended. Any decline in value of investments in other ventures, under equity method considered by management to be other-than-temporary is charged to income in the period in which it is determined.

Cash and Cash Equivalents

Cash equivalents include money market instruments with a maturity of ninety days or less when purchased.

Stock Incentive Compensation

The Company is authorized to issue restricted stock awards and units, performance shares, stock options and other equity-based awards to its employees and directors. The fair value of the compensation cost is measured at the grant date and expensed over the period for which the employee or director is required to provide services in exchange for the award.

The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.

Derivatives

From time to time, the Company enters into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company accounts for its derivatives in accordance with FASB ASC Topic 815, *Derivatives and Hedging*, which requires all derivatives to be recorded at fair value on the Company's balance sheet as either assets or liabilities, depending on their rights or obligations, with changes in fair value reflected in current earnings. The Company has adopted hedge accounting for certain of its derivative instruments used as hedges of a net investment in a foreign operation, as discussed below. The fair value of the Company's derivatives is estimated by reference to quoted prices or broker quotes, where available, or in the absence of quoted prices or broker quotes, the use of industry or internal valuation models.

Hedges of a Net Investment in a Foreign Operation

Changes in the fair value of derivative instruments used to hedge the net investment in a foreign operation, to the extent effective as a hedge, are recorded as a component of accumulated other comprehensive income (loss) in foreign currency translation adjustments, net of tax. Cumulative changes in fair value recorded in accumulated other comprehensive income (loss) are reclassified into earnings upon the sale, or complete or substantially complete liquidation, of the foreign operation. Any hedge ineffectiveness is recorded immediately in current period earnings as net foreign exchange gains (losses).

Hedge Documentation and Effectiveness Testing

To qualify for hedge accounting treatment, a derivative must be highly effective in mitigating the designated changes in value or cash flow of the hedged item. At the inception of a hedge, the Company formally documents relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking each hedge transaction. The documentation process includes linking derivatives that are designated as net investment hedges to specific assets or liabilities on the consolidated balance sheets. The Company also formally assesses, both at the hedge's inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the net investment in a foreign operation. The Company will discontinue hedge accounting prospectively if it determines that the derivative is no longer highly effective in offsetting changes in the net investment in a foreign operation, the derivative is no longer designated as a hedging instrument, or the derivative expires or is sold, terminated or exercised. If hedge accounting is discontinued, the derivative continues to be carried at fair value on the consolidated balance sheets with changes in its fair value recognized in current period earnings through net realized and unrealized gains (losses) on investments.

Fair Value Option

The Company has elected to account for certain of its assets and liabilities at fair value in accordance with FASB ASC Topic 820, *Fair Value Measurement*. The Company recognizes the change in unrealized gains and losses arising from changes in fair value in its statements of operations.

Business Combinations, Goodwill and Other Intangible Assets

The Company accounts for business combinations in accordance with FASB ASC Topic 805, *Business Combinations*, and goodwill and other intangible assets that arise from business combinations in accordance with FASB ASC Topic 350, *Intangibles - Goodwill and Other*. A purchase price that is in excess of the fair value of the net assets acquired arising from a business combination is recorded as goodwill, and is not amortized. Other intangible assets with a finite life are amortized over the estimated useful life of the asset. Other intangible assets with an indefinite useful life are not amortized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining the fair value of net assets acquired. The significant assumptions include the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges.

Goodwill and other intangible assets are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, goodwill is assigned to the applicable reporting unit of the acquired entities giving rise to the goodwill. Goodwill and other intangible assets recorded in connection with investments accounted for under the equity method, are recorded as investments in other ventures, under equity method on the Company's consolidated balance sheets.

The Company has established the second half of the year as the period for performing its annual impairment tests. The Company may determine to perform additional impairment testing at other times in the year if it is deemed necessary. The Company has elected to use the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. Under this option, the Company is not required to calculate the fair value of a reporting unit unless the Company determines, based on its qualitative assessment, that it is more likely than not that a reporting unit's fair value is less than its carrying amount. If goodwill or other intangible assets are impaired, they are written down to their estimated fair value with a corresponding expense reflected in the Company's consolidated statements of operations.

Noncontrolling Interests

The Company accounts for redeemable noncontrolling interests in the mezzanine section of the Company's consolidated balance sheets in accordance with United States Securities and Exchange Commission ("SEC") guidance which is applicable to SEC registrants. The share classes related to the redeemable noncontrolling interest portion of the issuer are accounted for in accordance with SEC guidance, which requires that shares not required to be accounted for in accordance with FASB ASC Topic 480, *Distinguishing Liabilities from Equity*, and having redemption features that are not solely within the control of the issuer, to be classified outside of permanent equity in the mezzanine section of the balance sheet. The SEC guidance does not impact the accounting for redeemable noncontrolling interest on the consolidated statements of operations; therefore, the provisions of FASB ASC Topic 810, *Consolidation* with respect to the consolidated statements of operations still apply, and net (income) loss attributable to redeemable noncontrolling interests is presented separately in the Company's consolidated statements of operations.

Variable Interest Entities

The Company accounts for variable interest entities (“VIEs”) in accordance with FASB ASC Topic 810, *Consolidation*, which requires the consolidation of all VIEs by the primary beneficiary, that being the investor that has the power to direct the activities of the VIE and that will absorb a portion of the VIE’s expected losses or residual returns that could potentially be significant to the VIE. When the Company determines it has a variable interest in a VIE, it determines whether it is the primary beneficiary of that VIE by performing an analysis that principally considers: (i) the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders; (ii) the VIE’s capital structure; (iii) the terms between the VIE and its variable interest holders and other parties involved with the VIE; (iv) which variable interest holders have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; (v) which variable interest holders have the obligation to absorb losses or the

right to receive benefits from the VIE that could potentially be significant to the VIE; and (vi) related party relationships. The Company reassesses its determination of whether the Company is the primary beneficiary of a VIE upon changes in facts and circumstances that could potentially alter the Company’s assessment.

Earnings Per Share

The Company calculates earnings per share in accordance with FASB ASC Topic 260, *Earnings per Share*. Basic earnings per share are based on weighted average common shares and exclude any dilutive effects of options and restricted stock. Diluted earnings per share assumes the exercise of all dilutive stock options and restricted stock grants.

The two-class method is used to determine earnings per share based on dividends declared on common shares and participating securities (i.e., distributed earnings) and participation rights of participating securities in any undistributed earnings. Each unvested restricted share granted by the Company is considered a participating security and the Company uses the two-class method to calculate its net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic and diluted.

Foreign Exchange

Monetary assets and liabilities denominated in a currency other than the functional currency of the Company’s subsidiaries in which those monetary assets and liabilities reside are revalued into such subsidiary’s functional currency at the prevailing exchange rate on the balance sheet date. Revenues and expenses denominated in a currency other than the functional currency of the Company’s subsidiaries, are valued at the exchange rate on the date on which the underlying revenue or expense transaction occurred. The net effect of these revaluation adjustments are recognized in the Company’s consolidated statements of operations as part of net foreign exchange gains (losses).

The Company’s functional currency is the U.S. dollar. One of the Company’s subsidiaries has a functional currency other than the U.S. dollar. Assets and liabilities of the foreign operation whose functional currency is not the U.S. dollar are translated into the Company’s U.S. dollar reporting currency at prevailing balance sheet-date exchange rates, while revenue and expenses of such foreign operation are translated into the Company’s U.S. dollar functional currency at monthly average exchange rates during the year. The net effect of these translation adjustments, as well as any gains or losses on intercompany balances for which settlement is not planned or anticipated in the foreseeable future, net of applicable deferred income taxes, is included in the Company’s consolidated balance sheets as currency translation adjustments and reflected within accumulated other comprehensive income (loss).

Taxation

Income taxes have been provided for in accordance with the provisions of FASB ASC Topic 740, *Income Taxes*. Deferred tax assets and liabilities result from temporary differences between the amounts recorded in the consolidated financial statements and the tax basis of the Company’s assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, deferred acquisition expenses, VOBA, intangible assets, value of in-force business, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances.

Uncertain tax positions are also accounted for in accordance with FASB ASC Topic 740, *Income Taxes*. Uncertain tax positions must meet a more likely than not recognition threshold to be recognized.

Recently Adopted Accounting Pronouncements

Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued ASU No. 2023-07, *Improvements to Reportable Segment Disclosures* (“ASU 2023-07”). Among other things, ASU 2023-07 improves the disclosures about a public entity’s reportable segments and addresses investor requests for additional, more detailed information about a reportable segment’s expenses. The amendments in ASU 2023-07 are effective for public business entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the annual reporting period beginning January 1, 2024. The adoption of ASU 2023-07 did not have a material impact on the Company’s reportable segment disclosures.

Recently Issued Accounting Pronouncements Not Yet Adopted

Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, *Improvements to Income Tax Disclosures* (“ASU 2023-09”). Among other things, ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in ASU 2023-09 are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this guidance.

Disaggregation of Income Statement Expenses

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses* (“ASU 2024-03”). Among other things, ASU 2024-03 addresses investor requests for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly presented expense captions (such as cost of sales; selling, general and administrative expenses and research and development). The amendments in ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance.

[XML 30 R11.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF
VALIDUS

Business
Combination, Asset
Acquisition, and Joint
Venture Formation
[Abstract]

ACQUISITION OF
VALIDUS

12 Months Ended
Dec. 31, 2024

ACQUISITION OF VALIDUS

On November 1, 2023, the Company completed its acquisition in accordance with the Stock Purchase Agreement, dated May 22, 2023 (as amended, the “Stock Purchase Agreement”), between RenaissanceRe and American International Group, Inc., (“AIG”), pursuant to which, upon the terms and subject to the conditions thereof, RenaissanceRe, or one of its subsidiaries, purchased, acquired and accepted from certain subsidiaries of AIG, all of their right, title and interest in the shares of Validus Holdings, Ltd. (“Validus Holdings”), and Validus Specialty, LLC (“Validus Specialty”). Substantially all of the assets of Validus Holdings was comprised of its equity interest in its wholly-owned subsidiary, Validus Reinsurance, Ltd. (“Validus Re”). The Company also acquired the renewal rights, records and customer relationships of the assumed treaty reinsurance business of Talbot Underwriting Limited, an affiliate of AIG (“Talbot”), a specialty (re)insurance group operating within the Lloyd’s market. The acquisitions under the Stock Purchase Agreement, together with the other transactions contemplated in the Stock Purchase Agreement, are referred to herein as the “Validus Acquisition.” Validus Holdings, Validus Specialty, and their respective subsidiaries that were acquired in the Validus Acquisition (including Validus Re and Validus Holdings (UK) Ltd) collectively are referred to herein as “Validus.” Pursuant to the Validus Acquisition, the Company acquired 100% voting equity interest in each of Validus Holdings and Validus Specialty.

In connection with the Validus Acquisition, on November 1, 2023, the Company paid to AIG aggregate consideration of \$2.985 billion, consisting of the following: (i) cash consideration of \$2.735 billion; and (ii) 1,322,541 common shares, which were valued at approximately \$250.0 million based on a value of \$189.03 per share at signing, pursuant to the Stock Purchase Agreement. The value of the acquisition consideration was \$3.020 billion as of the closing date. The parties determined that no post-closing adjustment was required to the value of the acquisition consideration as of the closing date.

In connection with the closing of the Validus Acquisition, the Company entered into a reserve development cover whereby the Validus risk-bearing entities agreed to cede to AIG substantially all of their adverse or favorable development on stated reserves at the time of the closing, subject to certain terms and conditions. Under the reserve development agreement AIG assumes substantially all of any favorable or adverse development on the stated reserves, on a whole-account basis, and takes into consideration adverse or favorable performance across the Company’s reportable segments. To the extent the combined performance of the acquired reserve for claims and claim expenses is worse than expected on an aggregate basis across reportable segments, the Company is indemnified under the terms of the reserve development agreement and would expect to collect substantially all of the adverse development under the reserve development agreement. To the extent the combined performance of the acquired reserve for claims and claim expenses is better than expected on an aggregate basis across reportable segments, the Company would expect to pay substantially all of the favorable development to AIG under the reserve development agreement.

The Company recorded \$61.9 million of corporate expenses associated with the acquisition of Validus during 2024 (2023 - \$76.4 million). Included in these expenses are compensation, transaction and integration-related costs.

Acquisition Consideration

The Company’s total consideration for Validus was calculated as follows:

<i>RenaissanceRe Common Shares</i>			
Common shares issued by RenaissanceRe to AIG		1,323	
Common share price of RenaissanceRe ⁽¹⁾	\$	215.62	
Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG			\$ 285,168
<i>Cash Consideration</i>			
Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market	\$	1,351,608	
Cash consideration funded by net proceeds from the issuance of Senior Notes		740,581	
Cash consideration funded by available cash resources		642,811	
Total cash consideration paid by RenaissanceRe as acquisition consideration			2,735,000
Total purchase price			\$ 3,020,168

(1) The common share price of RenaissanceRe is based on the closing price of \$226.97 per RenaissanceRe common share on the closing date of the Validus Acquisition, November 1, 2023 with a 5% discount to reflect restrictions on the transfer of those shares.

Fair Value of Net Assets Acquired and Liabilities Assumed

The purchase price was allocated to the acquired assets and liabilities of the Company based on estimated fair values on November 1, 2023, the date the transaction closed, as detailed in the table below:

Assets:		
Cash and cash equivalents	\$	301,253
Investments trading		3,248,242
Short term investments		1,659,902
Investments in other ventures, under equity method		3,997
Reinsurance premiums receivable		2,014,359
Prepaid reinsurance premiums		126,750
Losses recoverable ⁽¹⁾		1,297,270
Accrued investment income		21,441
Deferred acquisition costs and value of business acquired		617,000
Other assets		70,557
Identifiable intangible assets		460,884
Total assets		9,821,655
Liabilities:		
Reserve for claims and claim expenses ⁽¹⁾		4,628,952
Reserve for unearned premiums		1,804,029
Reinsurance balances payable		298,003
Accounts payable and accrued liabilities		120,994
Deferred tax liability		39,157
Total liabilities		6,891,135
Total identifiable net assets acquired		2,930,520
Total purchase price		3,020,168
Goodwill	\$	89,648

(1) Includes the net fair value adjustment of \$192.0 million to net claims and claim expenses on November 1, 2023, which was made up of a \$76.8 million decrease to losses recoverable and a \$268.9 million decrease to reserve for claims and claim expenses.

The goodwill represents the excess of the purchase price over the fair value of the underlying net assets acquired and liabilities assumed.

The significant fair value adjustments and related future amortization are as follows:

- Deferred acquisition costs and VOBA - to reflect the elimination of Validus' net deferred acquisition costs, and the establishment of the value of business acquired asset, which represents the present value of the expected underwriting profit within the unearned premiums liability, net of reinsurance, less costs to service the related policies and a risk premium. The fair value of VOBA was determined after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio and related expenses. The adjustment for VOBA will be amortized to acquisition expenses over approximately two years, as the contracts for business in-force as of the acquisition date expire;
- Net reserve for claims and claim expenses - to reflect a decrease related to the present value of the net unpaid claims and claim expenses based on the estimated payout pattern, partially offset by an increase in net claims and claim expenses related to the estimated market based risk margin. The risk margin represents the estimated cost of capital required by a market participant to assume the net claims and claim expenses. The fair value of net reserve for claims and claim expenses was determined using certain key assumptions, including the estimated cost of capital and investment yield. This will be amortized using the projected discount and risk margin patterns of the net claims and claim expenses as of the acquisition date;
- Identifiable indefinite lived and finite lived intangible assets - to establish the fair value of identifiable intangible assets related to the acquisition of Validus described in detail below; and
- Deferred tax liability - to reflect the net deferred tax liability on the intangible assets and the other fair value adjustments.

Identifiable indefinite lived and finite lived intangible assets consisted of the following and are included in goodwill and other intangible assets on the Company's consolidated balance sheet:

	Amount	Economic Useful Life
Agent relationships - top four	\$ 195,000	15 years
Agent relationships - other	9,000	5 years
Managing General Agent ("MGA") relationships	3,000	15 years
Trade name	5,000	0.5 years
Renewal rights	215,000	15 years
Asset management contracts	20,000	4 years
Insurance licenses	13,884	Indefinite
Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023	460,884	
Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange	60,489	
Impairment loss on insurance licenses	13,767	
Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024	\$ 386,628	

Amortization from the acquisition date, November 1, 2023, through December 31, 2023 was included in the Company's consolidated statements of operations for the year ended December 31, 2023.

An explanation of the identifiable indefinite and finite intangible assets is as follows:

- Agent relationships - top four - the value of Validus' relationships with their top four brokers (Marsh & McLennan Companies, Inc., Aon Benfield Group Ltd., Willis Towers Watson Plc and Arthur J. Gallagher & Co.) after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years;
- Renewal rights - the value of policy renewal rights was determined after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges that would impact the expected cash flows from these renewals over the expected life of these policies. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years; and
- Insurance licenses - the value of acquired insurance licenses.

Financial Results

The following table summarizes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. Operating activities of Validus from the acquisition date, November 1, 2023, through December 31, 2023 are included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023.

The unaudited net contribution of the acquisition and integration of Validus is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that may be achieved in the future. These results are not used as a part of management's analysis of the financial performance of the Company's business. These results primarily reflect items recorded directly by Validus from November 1, 2023 through December 31, 2023, including: 1) net premiums earned and net underwriting income on the in-force portfolio acquired with the acquisition of Validus and previously retained on Validus entities' balance sheets; 2) net premiums earned and net underwriting income for those contracts which renewed post-acquisition on one of the acquired Validus entities' balance sheets; 3) net investment income and net realized and unrealized gains recorded directly by Validus; and 4) certain direct costs incurred directly by Validus. In addition, these results, where possible, were adjusted for transaction and integration related costs incurred by the Company. However, these results do not reflect on-going operating costs incurred by the Company in supporting Validus unless such costs were incurred directly by Validus. These results also do not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may be achieved in the future. These results involve significant estimates and are not indicative of the future results of the acquired Validus entities which have been, and will continue to be impacted by potential changes in targeted business mix, investment management strategies, and synergies recognized from changes in the combined entity's operating structure, as well as the impact of changes in other business and capital management strategies.

	Year ended December 31, 2023 ⁽¹⁾
Total revenues	\$ 696,888
Net income (loss) available (attributable) to RenaissanceRe common shareholders ⁽²⁾	\$ 307,802

(1) Includes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) through December 31, 2023.

(2) Includes \$76.4 million of corporate expenses associated with the acquisition and integration of Validus for the year ended December 31, 2023.

Taxation

At the date of the acquisition the Company established a net deferred tax asset of \$73.0 million and recorded a valuation allowance against Validus' deferred tax assets of \$66.0 million resulting in a net acquired deferred tax asset of \$7.0 million. A net deferred tax liability of \$46.2 million was also recorded related to the estimated fair value of intangible assets recorded, VOBA and other adjustments to the fair values of the assets acquired and liabilities assumed. This resulted in a net deferred tax liability of \$39.2 million recorded in conjunction with the acquisition of Validus. The Company estimated that goodwill related to the acquisition of Validus Specialty of approximately \$24 million will be deductible for U.S. tax purposes resulting in an estimated future tax benefit of approximately \$5 million.

Supplemental Pro Forma Information

The following table presents unaudited pro forma consolidated financial information for the years ended December 31, 2023 and 2022, respectively, and assumes the acquisition of Validus occurred on January 1, 2022. The unaudited pro forma consolidated financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the transaction been completed as of January 1, 2022 or that may be achieved in the future. The unaudited pro forma consolidated financial information does not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may result from the acquisition of Validus. In addition, unaudited pro forma consolidated financial information does not include the effects of costs associated with any restructuring or integration activities resulting from the acquisition of Validus, as they are nonrecurring.

Year ended December 31,	2023	2022
Total revenues	\$ 11,611,682	\$ 7,169,338
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 2,926,518	\$ (1,552,425)

Among other adjustments, and in addition to the fair value adjustments and recognition of goodwill, VOBA and identifiable intangible assets noted above, other material nonrecurring pro forma adjustments directly attributable to the acquisition of Validus principally included certain adjustments to recognize transaction related costs, align accounting policies, and amortize fair value adjustments, VOBA, and identifiable definite lived intangible assets, net of related tax impacts.

Defined Benefit Pension Plan

The Validus group entities have a contributory defined benefit pension plan for employees, which was not material to RenaissanceRe's results of operations, financial condition or cash flows for the year ended December 31, 2024.

The plan offers mandatory benefits as prescribed by the applicable law, as well as voluntary benefits. These mandatory benefits include guarantees regarding the level of interest paid annually on accrued pension savings. The Validus group entities and the members of the plan contribute a defined percentage of salary to the pension arrangement and credit accumulation is granted on these contributions. At retirement, the accumulated contributions are converted into a pension. A full independent actuarial valuation is prepared annually.

At December 31, 2024, the net balance sheet liability was \$1.6 million, comprising \$10.5 million of projected benefit obligation and \$8.8 million of plan assets at fair value (2023 - \$1.1 million, \$9.8 million, and \$8.7 million, respectively).

[XML 31 R12.htm IDEA: XBRL DOCUMENT](#)

GOODWILL AND OTHER INTANGIBLE ASSETS

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)
[GOODWILL AND OTHER INTANGIBLE ASSETS](#)

12 Months Ended
Dec. 31, 2024

GOODWILL AND OTHER INTANGIBLE ASSETS

The following tables show an analysis of goodwill and other intangible assets, net of foreign currency translation adjustments, included in goodwill and other intangible assets on the Company's consolidated balance sheets:

At December 31,	Goodwill and Other Intangible Assets	
	2024	2023
Goodwill, net	\$ 300,507	\$ 300,542
Other intangible assets, net	403,625	474,810
Total goodwill and other intangible assets	\$ 704,132	\$ 775,352

Included in goodwill and other intangible assets on the Company's consolidated balance sheet at December 31, 2024 was gross goodwill of \$302.8 million (2023 - \$302.8 million, 2022 - \$213.2 million). Included in goodwill, net at December 31, 2024 was accumulated impairment losses of \$2.3 million (2023 - \$2.3 million).

In addition, the Company has also recorded goodwill and other intangible assets included in investments in other ventures, under equity method on the Company's consolidated balance sheets:

At December 31,	Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method	
	2024	2023
Goodwill, net	\$ 8,724	\$ 10,808
Other intangible assets, net	207	7,260
Total goodwill and other intangible assets	\$ 8,931	\$ 18,068

Included in investments in other ventures, under equity method on the Company's consolidated balance sheet at December 31, 2024 was gross goodwill of \$13.2 million (2023 - \$15.3 million, 2022 - \$14.4 million). Included in gross goodwill and gross other intangible assets was a reduction of \$2.1 million and \$6.9 million, respectively, related to a change in the classification of the Company's investment in TWFG, from investment in other ventures, under equity method to fair value, as a result of TWFG, Inc's initial public

offering in 2024. Included in goodwill, net at December 31, 2024, was accumulated impairment losses of \$4.5 million (2023 - \$4.5 million).

Goodwill

The following table shows a roll forward of goodwill included in goodwill and other intangible assets and goodwill included in investments in other ventures, under equity method on the Company's consolidated balance sheets:

	Goodwill	
	Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets included in Investments in Other Ventures, Under Equity Method
Balance at December 31, 2022, net	\$ 210,894	\$ 9,903
Acquired	89,648	905
Balance at December 31, 2023, net	300,542	10,808
Adjustments	—	(2,084)
Foreign currency translation	(35)	—
Balance at December 31, 2024, net	\$ 300,507	\$ 8,724

Other Intangible Assets

The gross carrying value, accumulated amortization and accumulated impairment losses by major category of other intangible assets included in goodwill and other intangible assets and investments in other ventures, under equity method on the Company’s consolidated balance sheets are shown below:

	Other Intangible Assets			
	Gross Carrying Value	Accumulated Amortization	Accumulated Impairment Losses	Net
At December 31, 2024				
Customer relationships and customer lists	\$ 530,528	\$ (150,051)	\$ (1,403)	\$ 379,074
Licenses ⁽¹⁾	30,951	—	(20,567)	10,384
Value of business acquired	20,200	(20,200)	—	—
Asset management contracts	20,000	(5,833)	—	14,167
Software	12,230	(12,230)	—	—
Patents and intellectual property	4,500	(1,875)	(2,625)	—
Covenants not-to-compete	4,030	(4,030)	—	—
Trademarks and trade names	6,710	(6,503)	—	207
	<u>\$ 629,149</u>	<u>\$ (200,722)</u>	<u>\$ (24,595)</u>	<u>\$ 403,832</u>

(1) Licenses is comprised of \$10.4 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2024

	Other Intangible Assets			
	Gross Carrying Value	Accumulated Amortization	Accumulated Impairment Losses	Net
At December 31, 2023				
Customer relationships and customer lists	\$ 530,704	\$ (101,659)	\$ (1,550)	\$ 427,495
Licenses ⁽¹⁾	37,663	—	(6,653)	31,010
Value of business acquired	20,200	(20,200)	—	—
Asset management contracts	20,000	(833)	—	19,167
Software	12,230	(12,230)	—	—
Patents and intellectual property	4,500	(1,875)	(2,625)	—
Covenants not-to-compete	4,030	(4,030)	—	—
Trademarks and trade names	6,710	(2,312)	—	4,398
	<u>\$ 636,037</u>	<u>\$ (143,139)</u>	<u>\$ (10,828)</u>	<u>\$ 482,070</u>

(1) Licenses is comprised of \$31.0 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2023

During 2023, the Company recorded \$460.9 million of gross identifiable intangible assets identified in connection with the Validus Acquisition. See “Note 3. Acquisition of Validus” for additional information regarding the Validus Acquisition.

The Company recorded amortization expense of \$57.6 million and an impairment loss of \$13.8 million related to other intangible assets during 2024 (2023 - \$13.6 million and \$Nil, respectively).

In accordance with the Company’s established accounting policy, the Company reviewed its finite lived intangible assets for indicators of impairment throughout 2024, testing for impairment as appropriate. During 2024, the Company amalgamated and merged certain Validus Re entities into the Company. As a result of management’s review and analysis, it was determined that certain licenses associated with these entities were either cancelled upon amalgamation or merger, or that there was no new business written using these licenses in 2024, and no new business would be incepting using these licenses on a go forward basis. Accordingly, and in connection with the Company’s impairment testing performed, it was determined that the licenses associated with these acquired Validus entities, which was initially reflected as an indefinite lived intangible asset of \$13.9 million at the time of the acquisition of Validus, should be written down to \$Nil. The Company recorded an intangible asset impairment charge of \$13.8 million during the year ended December 31, 2024.

In performing the impairment assessment, the Company first assessed qualitative factors to determine whether it was necessary to perform a quantitative impairment test. Based on its qualitative assessment, the Company determined it was not more likely than not that the fair value of the goodwill and other intangible assets in question were less than their respective carrying amounts. The qualitative assessment included the following factors which the Company determined had not significantly deteriorated given specific facts and circumstances: macroeconomic conditions; industry and market conditions; costs factors; and overall financial performance. Other than the intangible assets impaired as noted above, and normal course amortization of intangible assets, in accordance with the Company’s established accounting policy, there were no adjustments to carried goodwill and other intangible assets during the year ended December 31, 2024.

The remaining useful life of intangible assets with finite lives ranges from 0.2 to 13.8 years, with a weighted-average amortization period of 12.7 years. Expected amortization of the other intangible assets, including other intangible assets recorded in investments in other ventures, under equity method, is shown below:

	Other Intangibles Assets	Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method	Total
2025	\$ 70,210	\$ 24	\$ 70,234
2026	61,622	24	61,646
2027	53,737	24	53,761
2028	42,661	24	42,685
2029	34,495	24	34,519
2030 and thereafter	130,516	87	130,603
Total remaining amortization expense	393,241	207	393,448
Indefinite lived	10,384	—	10,384
Total	<u>\$ 403,625</u>	<u>\$ 207</u>	<u>\$ 403,832</u>

[XML 32 R13.htm IDEA: XBRL DOCUMENT](#)

INVESTMENTS

[Investments, Debt and Equity Securities \[Abstract\]](#)

INVESTMENTS

INVESTMENTS

Fixed Maturity Investments Trading

The following table summarizes the fair value of fixed maturity investments trading:

	2024	2023
At December 31,		
U.S. treasuries	\$ 11,001,893	\$ 10,060,203
Corporate ⁽¹⁾	7,862,423	6,499,075
Residential mortgage-backed	1,707,056	1,420,362
Asset-backed	1,422,393	1,491,695
Agencies	623,489	489,117
Non-U.S. government	618,809	483,576
Commercial mortgage-backed	326,451	433,080
Total fixed maturity investments trading	<u>\$ 23,562,514</u>	<u>\$ 20,877,108</u>

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

Contractual maturities of fixed maturity investments trading are described in the following table. Expected maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

	At December 31, 2024		At December 31, 2023	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in less than one year	\$ 1,374,089	\$ 1,373,838	\$ 587,720	\$ 582,519
Due after one through five years	12,139,153	12,131,114	11,439,510	11,468,263
Due after five through ten years	6,339,563	6,246,506	5,182,667	5,188,716
Due after ten years	387,413	355,156	307,392	292,473
Mortgage-backed	2,094,190	2,033,507	1,864,520	1,853,442
Asset-backed	1,416,132	1,422,393	1,490,641	1,491,695
Total	<u>\$ 23,750,540</u>	<u>\$ 23,562,514</u>	<u>\$ 20,872,450</u>	<u>\$ 20,877,108</u>

Equity Investments

The following table summarizes the fair value of equity investments:

	2024	2023
At December 31,		
Financials	\$ 116,400	\$ 106,542
Basic materials	595	—
Industrial, utilities and energy	312	—
Communications and technology	263	12
Consumer	154	212
Healthcare	32	—
Total	<u>\$ 117,756</u>	<u>\$ 106,766</u>

Pledged Investments

At December 31, 2024, \$10.3 billion (2023 - \$10.5 billion) of cash and investments at fair value were on deposit with, or in trust accounts for the benefit of, various counterparties, including with respect to the Company’s letter of credit facilities. Of this amount, \$3.1 billion (2023 - \$2.9 billion) is on deposit with, or in trust accounts for the benefit of, U.S. state regulatory authorities.

Reverse Repurchase Agreements

At December 31, 2024, the Company held \$169.4 million (2023 - \$159.7 million) of reverse repurchase agreements. These loans are fully collateralized, are generally outstanding for a short period of time and are presented on a gross basis as part of short term investments on the Company’s consolidated balance sheets. The required collateral for these loans typically includes high-quality, readily marketable instruments. Upon maturity, the Company receives principal and interest income.

Net Investment Income

The components of net investment income are as follows:

Year ended December 31,	2024	2023	2022
Fixed maturity investments trading	\$ 1,116,649	\$ 744,457	\$ 382,165
Short term investments	183,153	213,303	41,042
Equity investments	2,460	7,261	20,864
Other investments			
Catastrophe bonds	238,844	200,572	94,784
Other	82,457	87,296	37,497
Cash and cash equivalents	54,241	23,123	5,197
	1,677,804	1,276,012	581,549
Investment expenses	(23,515)	(22,902)	(21,617)
Net investment income	\$ 1,654,289	\$ 1,253,110	\$ 559,932

Net Realized and Unrealized Gains (Losses) on Investments

Net realized and unrealized gains (losses) on investments are as follows:

Year ended December 31,	2024	2023	2022
Gross realized gains on fixed maturity investments trading	\$ 142,243	\$ 80,905	\$ 38,781
Gross realized losses on fixed maturity investments trading	(206,172)	(473,946)	(771,342)
Net realized gains (losses) on fixed maturity investments trading	(63,929)	(393,041)	(732,561)
Net unrealized gains (losses) on fixed maturity investments trading	(182,494)	685,095	(636,762)
Net realized and unrealized gains (losses) on fixed maturity investments trading	(246,423)	292,054	(1,369,323)
Net realized and unrealized gains (losses) on investment-related derivatives ⁽¹⁾	(57,279)	(68,272)	(165,293)
Net realized gains (losses) on equity investments	355	(27,492)	43,035
Net unrealized gains (losses) on equity investments	10,621	73,243	(166,823)
Net realized and unrealized gains (losses) on equity investments	10,976	45,751	(123,788)
Net realized and unrealized gains (losses) on other investments - catastrophe bonds	62,353	101,897	(130,335)
Net realized and unrealized gains (losses) on other investments - other	202,533	43,092	(11,746)
Net realized and unrealized gains (losses) on investments	\$ (27,840)	\$ 414,522	\$ (1,800,485)

(1) Net realized and unrealized gains (losses) on investment-related derivatives includes fixed maturity investments related derivatives, equity investments related derivatives and commodity related derivatives. See "Note 19. Derivative Instruments" for additional information.

Other Investments

The table below shows the fair value of the Company's portfolio of other investments:

At December 31,	2024	2023
Fund investments	\$ 2,128,499	\$ 1,415,804
Catastrophe bonds	1,984,396	1,942,199
Direct private equity investments	211,866	59,905
Term loans	—	97,658
Total other investments	\$ 4,324,761	\$ 3,515,566

During 2024, the Company recorded a net loss of \$9.7 million (2023 - loss of \$3.0 million, 2022 - income of \$19.8 million), representing the change between the Company's fair value estimate for funds as at the prior year end, and the final reported net asset values provided by the Company's fund investment managers, as discussed in "Note 2. Significant Accounting Policies." This net loss was included between net investment income and net realized and unrealized gains (losses) on investments for the year ended December 31, 2024.

The Company has committed capital to direct private equity investments, fund investments, term loans and investments in other ventures of \$4.5 billion, of which \$2.5 billion has been contributed at December 31, 2024 (2023 - \$3.6 billion and \$2.0 billion, respectively). The Company's remaining commitments to these investments at December 31, 2024 totaled \$2.0 billion (2023 - \$1.6 billion). In the future, the Company may enter into additional commitments for such investments.

Fund Investments

Fund investments are limited partnership or similar interests in private equity funds, private credit funds and hedge funds managed by unrelated third parties.

Catastrophe Bonds

Catastrophe bonds are non-investment grade bonds generally issued by unrelated third parties that generally mature within 1 to 5 years.

Direct Private Equity Investments

Direct private equity investments are the Company's direct equity investments in companies that are not traded on any nationally recognized equity markets.

Term Loans

Term loans represent the Company's participation interest in a senior secured term loan facility, which the Company disposed of during 2024. The Company had committed to a loan participation interest of \$100.0 million which was fully funded as at December 31, 2023. This facility paid interest, had a 5-year maturity and was fully secured by a diversified pool of primarily private equity assets.

Investments in Other Ventures, under Equity Method

The table below shows the Company's portfolio of investments in other ventures, under equity method:

At December 31,	2024		2023	
	Ownership %	Carrying Value	Ownership %	Carrying Value
Investments in other ventures, under equity method	0.1% - 50.0%	\$ 102,770	0.1% - 50.0%	\$ 112,624

The table below shows the Company's equity in earnings (losses) of other ventures:

Year ended December 31,	2024	2023	2022
Equity in earnings (losses) of other ventures	\$ 47,087	\$ 43,474	\$ 11,249

During 2024, the Company received \$109.8 million of distributions from its investments in other ventures, under equity method (2023 - \$41.4 million, 2022 - \$24.2 million). The equity in earnings (losses) of Top Layer Reinsurance Ltd. ("Top Layer"), a managed joint venture formed by the Company to write high excess non-U.S. property catastrophe reinsurance, is recorded on a current quarter basis. The equity in earnings (losses) of the Company's investments in other ventures are reported one quarter in arrears.

[XML 33 R14.htm IDEA: XBRL DOCUMENT](#)

FAIR VALUE MEASUREMENTS

[Fair Value Disclosures](#)
[\[Abstract\]](#)

[FAIR VALUE MEASUREMENTS](#)

**12 Months Ended
Dec. 31, 2024**

FAIR VALUE MEASUREMENTS

The use of fair value to measure certain assets and liabilities with resulting unrealized gains or losses is pervasive within the Company's consolidated financial statements. Fair value is defined under accounting guidance currently applicable to the Company as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between open market participants at the measurement date. The Company recognizes the change in unrealized gains or losses arising from changes in fair value in its consolidated statements of operations.

FASB ASC Topic 820, *Fair Value Measurement* prescribes a fair value hierarchy that prioritizes the inputs to the respective valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to valuation techniques that use at least one significant input that is unobservable (Level 3). The three levels of the fair value hierarchy are described below:

- Fair values determined by Level 1 inputs utilize unadjusted quoted prices obtained from active markets for identical assets or liabilities for which the Company has access at the measurement date. The fair value is determined by multiplying the quoted price by the quantity held by the Company;
- Fair values determined by Level 2 inputs utilize inputs (other than quoted prices included in Level 1) that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, such as interest rates and yield curves that are observable at commonly quoted intervals, broker quotes and certain pricing indices; and
- Level 3 inputs are based all or in part on significant unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. In these cases, significant management assumptions can be used to establish management's best estimate of the assumptions used by other market participants in determining the fair value of the asset or liability.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement of the asset or liability. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and the Company considers factors specific to the asset or liability.

In order to determine if a market is active or inactive for a security, the Company considers a number of factors, including, but not limited to, the spread between what a seller is asking for a security and what a buyer is bidding for the same security, the volume of trading activity for the security in question, the price of the security compared to its par value (for fixed maturity investments), and other factors that may be indicative of market activity.

There have been no material changes in the Company's valuation techniques, nor have there been any transfers between Level 1 and Level 2, or Level 2 and Level 3 during the period represented by these consolidated financial statements.

Below is a summary of the assets and liabilities that are measured at fair value on a recurring basis and also represents the carrying amount on the Company's consolidated balance sheets:

	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2024				
Fixed maturity investments trading				
U.S. treasuries	\$ 11,001,893	\$ 11,001,893	\$ —	\$ —
Corporate ⁽¹⁾	7,862,423	—	7,862,423	—
Residential mortgage-backed	1,707,056	—	1,707,056	—
Asset-backed	1,422,393	—	1,422,393	—
Agencies	623,489	—	623,489	—
Non-U.S. government	618,809	—	618,809	—
Commercial mortgage-backed	326,451	—	326,451	—
Total fixed maturity investments trading	23,562,514	11,001,893	12,560,621	—
Short term investments	4,531,655	99,343	4,432,312	—
Equity investments	117,756	117,756	—	—
Other investments				
Catastrophe bonds	1,984,396	—	1,984,396	—
Direct private equity investments	211,866	—	168,089	43,777
	2,196,262	—	2,152,485	43,777
Fund investments ⁽²⁾	2,128,499	—	—	—
Total other investments	4,324,761	—	2,152,485	43,777
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts ⁽³⁾	(405)	—	—	(405)
Derivative assets ⁽⁴⁾	34,538	10,614	23,924	—
Derivative liabilities ⁽⁴⁾	(75,878)	(7,872)	(68,006)	—
Total other assets and (liabilities)	(41,745)	2,742	(44,082)	(405)
	\$ 32,494,941	\$ 11,221,734	\$ 19,101,336	\$ 43,372

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

(2) Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

(3) Included in assumed and ceded (re)insurance contracts at December 31, 2024 was \$2.0 million of other assets and \$2.4 million of other liabilities.

(4) Refer to "Note 19. Derivative Instruments" for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.

	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2023				
Fixed maturity investments trading				
U.S. treasuries	\$ 10,060,203	\$ 10,060,203	\$ —	\$ —
Corporate ⁽¹⁾	6,499,075	—	6,499,075	—
Asset-backed	1,491,695	—	1,491,695	—
Residential mortgage-backed	1,420,362	—	1,420,362	—
Agencies	489,117	—	489,117	—
Non-U.S. government	483,576	—	483,576	—
Commercial mortgage-backed	433,080	—	433,080	—
Total fixed maturity investments trading	20,877,108	10,060,203	10,816,905	—
Short term investments	4,604,079	130,232	4,473,847	—
Equity investments	106,766	106,766	—	—
Other investments				
Catastrophe bonds	1,942,199	—	1,942,199	—
Term loans	97,658	—	—	97,658
Direct private equity investments	59,905	—	—	59,905
	2,099,762	—	1,942,199	157,563
Fund investments ⁽²⁾	1,415,804	—	—	—
Total other investments	3,515,566	—	1,942,199	157,563
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts ⁽³⁾	(515)	—	—	(515)
Derivative assets ⁽⁴⁾	44,724	16,701	28,023	—
Derivative liabilities ⁽⁴⁾	(29,992)	(10,372)	(19,620)	—
Total other assets and (liabilities)	14,217	6,329	8,403	(515)
	\$ 29,117,736	\$ 10,303,530	\$ 17,241,354	\$ 157,048

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

(2) Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

(3) Included in assumed and ceded (re)insurance contracts at December 31, 2023 was \$2.2 million of other assets and \$2.7 million of other liabilities.

(4) Refer to "Note 19. Derivative Instruments" for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.

Level 1 and Level 2 Assets and Liabilities Measured at Fair Value

Fixed Maturity Investments

Fixed maturity investments included in Level 1 consist of the Company's investments in U.S. treasuries. Fixed maturity investments included in Level 2 are agencies, corporate (including non-U.S. government-backed corporate), non-U.S. government, residential mortgage-backed, commercial mortgage-backed and asset-backed.

The Company's fixed maturity investments are primarily priced using pricing services, such as index providers and pricing vendors, as well as broker quotations. In general, the pricing vendors provide pricing for a high volume of liquid securities that are actively traded. For securities that do not trade on an exchange, the pricing services generally utilize market data and other observable inputs in matrix pricing models to determine month end prices. Observable inputs include benchmark yields, reported trades, broker-dealer quotes, issuer spreads, bids, offers, reference data and industry and economic events. Index pricing generally relies on market traders as the primary source for pricing; however, models are also utilized to provide prices for all index eligible securities. The models use a variety of observable inputs such as benchmark yields, transactional data, dealer runs, broker-dealer quotes and corporate actions. Prices are generally verified using third-party data. Securities which are priced by an index provider are generally included in the index.

In general, broker-dealers value securities through their trading desks based on observable inputs. The methodologies include mapping securities based on trade data, bids or offers, observed spreads, and performance on newly issued securities. Broker-dealers also determine valuations by observing secondary trading of similar securities. Prices obtained from broker quotations are considered non-binding, however they are based on observable inputs and by observing secondary trading of similar securities obtained from active and non-distressed markets.

The Company considers these broker quotations to be Level 2 inputs as they are corroborated with other market observable inputs. The techniques generally used to determine the fair value of the Company's fixed maturity investments are detailed below by asset class.

U.S. Treasuries

Level 1 - At December 31, 2024, the Company's U.S. treasuries fixed maturity investments were primarily priced by pricing services and had a weighted average yield to maturity of 4.4% and a weighted average credit quality of AA (2023 - 4.1% and AA, respectively). When pricing these securities, the pricing services utilize daily data from many real time market sources, including active broker-dealers. Certain data sources are regularly reviewed for accuracy to attempt to ensure the most reliable price source is used for each issue and maturity date.

Corporate

Level 2 - At December 31, 2024, the Company's corporate fixed maturity investments principally consisted of U.S. and international corporations and non-U.S. government-backed corporations and had a weighted average yield to maturity of 5.5% and a weighted average credit quality of BBB (2023 - 5.7% and BBB, respectively).

The Company's corporate fixed maturity investments, other than non-U.S. government-backed corporations, are primarily priced by pricing services. When evaluating these securities, the pricing services gather information from market sources regarding the issuer of the security and obtain credit data, as well as other observations, from markets and sector news. Evaluations are updated by obtaining broker-dealer quotes and other market information including actual trade volumes, when available. The pricing services also consider the specific terms and conditions of the securities, including any specific features which may influence risk. In certain instances, securities are individually evaluated using a spread which is added to the U.S. treasury curve or a security specific swap curve as appropriate.

Non-U.S. government-backed corporate fixed maturity investments are primarily priced by pricing services that employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high quality credits. The pricing services then apply a credit spread to the respective curve for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets.

Agencies

Level 2 - At December 31, 2024, the Company's agency fixed maturity investments had a weighted average yield to maturity of 4.7% and a weighted average credit quality of AA (2023 - 4.6% and AA, respectively). The issuers of the Company's agency fixed maturity investments primarily consist of the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and other agencies. Fixed maturity investments included in agencies are primarily priced by pricing services. When evaluating these securities, the pricing services gather information from market sources and integrate other observations from markets and sector news. Evaluations are updated by obtaining broker-dealer quotes and other market information

including actual trade volumes, when available. The fair value of each security is individually computed using analytical models which incorporate option adjusted spreads and other daily interest rate data.

Non-U.S. Government

Level 2 - At December 31, 2024, the Company's non-U.S. government fixed maturity investments had a weighted average yield to maturity of 4.5% and a weighted average credit quality of AA (2023 - 4.4% and AA, respectively). The issuers of securities in this sector are non-U.S. governments and their respective agencies as well as supranational organizations. Securities held in these sectors are primarily priced by pricing services that employ proprietary discounted cash flow models to value the securities. Key quantitative inputs for these models are daily observed benchmark curves for treasury, swap and high issuance credits. The pricing services then apply a credit spread for each security which is developed by in-depth and real time market analysis. For securities in which trade volume is low, the pricing services utilize data from more frequently traded securities with similar attributes. These models may also be supplemented by daily market and credit research for international markets.

Residential Mortgage-backed

Level 2 - At December 31, 2024, the Company's residential mortgage-backed fixed maturity investments had a weighted average yield of maturity of 5.4%, a weighted average credit quality of AA, and a weighted average life of 7.7 years (2023 - 5.1%, AA and 7.7 years, respectively). Residential mortgage-backed securities include both agency and non-agency mortgage-backed securities. The Company's agency mortgage-backed fixed maturity investments are primarily priced by pricing services using a mortgage pool specific model which utilizes daily inputs from the active to-be-announced market which is very liquid, as well as the U.S. treasury market. The model also utilizes additional information, such as the weighted average maturity, weighted average coupon and other available pool level data which is provided by the sponsoring agency. Valuations are also corroborated with active market quotes.

Non-agency mortgage-based securities are primarily priced by pricing services using an option adjusted spread model or other relevant models, which principally utilize inputs including benchmark yields, available trade information or broker quotes, and issuer spreads. The pricing services also review collateral prepayment speeds, loss severity and delinquencies among other collateral performance indicators for the securities valuation, when applicable.

Commercial Mortgage-backed

Level 2 - At December 31, 2024, the Company's commercial mortgage-backed fixed maturity investments had a weighted average yield to maturity of 5.7%, a weighted average credit quality of AAA, and a weighted average life of 3.8 years (2023 - 8.8%, AAA and 2.2 years, respectively). Securities held in these sectors are primarily priced by pricing services. The pricing services apply dealer quotes and other available trade information such as bids and offers, prepayment speeds which may be adjusted for the underlying collateral or current price data, the U.S. treasury curve and swap curve as well as cash settlement. The pricing services discount the expected cash flows for each security held in this sector using a spread adjusted benchmark yield based on the characteristics of the security.

Asset-backed

Level 2 - At December 31, 2024, the Company's asset-backed fixed maturity investments had a weighted average yield to maturity of 5.9%, a weighted average credit quality of AAA and a weighted average life of 4.7 years (2023 - 7.0%, AA and 3.9 years, respectively). The underlying collateral for the Company's asset-backed fixed maturity investments primarily consists of collateralized loan obligations and other

receivables. Securities held in these sectors are primarily priced by pricing services. The pricing services apply dealer quotes and other available trade information such as bids and offers, prepayment speeds which may be adjusted for the underlying collateral or current price data, the U.S. treasury curve and swap curve as well as cash settlement. The pricing services determine the expected cash flows for each security held in this sector using historical prepayment and default projections for the underlying collateral and current market data. In addition, a spread is applied to the relevant benchmark and used to discount the cash flows noted above to determine the fair value of the securities held in this sector.

Short Term Investments

Level 1 - At December 31, 2024, the Company's short term investments in U.S. treasuries were primarily priced by pricing services and had a weighted average yield to maturity of 4.2% and a weighted average credit quality of AA (2023 - 5.3% and AAA, respectively). When pricing these securities, the pricing services utilize daily data from many real time market sources, including active broker-dealers. Certain data sources are regularly reviewed for accuracy to ensure the most reliable price source is used for each issue and maturity date.

Level 2 - At December 31, 2024, the Company's other short term investments had a weighted average yield to maturity of 4.4% and a weighted average credit quality of AAA (2023 - 5.3% and AAA, respectively). Amortized cost approximates fair value for the majority of the remainder of the Company's short term investments portfolio and, in certain cases, fair value is determined in a manner similar to the Company's fixed maturity investments noted above.

Equity Investments

Level 1 - The fair value of the Company's portfolio of equity investments are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. When pricing these securities, the pricing services utilize daily data from many real time market sources, including applicable securities exchanges. All data sources are regularly reviewed for accuracy to attempt to ensure the most reliable price source was used for each security.

Other Investments

Catastrophe Bonds

Level 2 - The Company's other investments include investments in catastrophe bonds which are recorded at fair value based on broker or underwriter bid indications.

Direct Private Equity Investments

Level 2 - At December 31, 2024, the Company's other investments included \$168.1 million (2023 - \$Nil) of direct private equity investments which are recorded at fair value based on quoted prices for similar assets.

Other Assets and Liabilities

Derivatives

Level 1 and Level 2 - Other assets and liabilities include certain derivatives entered into by the Company. The fair value of these transactions includes certain exchange traded futures and options contracts which are considered Level 1, and foreign currency contracts and certain credit derivatives, determined using standard industry valuation models and considered Level 2, as the inputs to the valuation model are based on observable market inputs. For credit derivatives, these inputs include credit spreads, credit ratings of the underlying referenced security, the risk-free rate and the contract term. For foreign currency contracts, these inputs include spot rates and interest rate curves.

Level 3 Assets and Liabilities Measured at Fair Value

Below is a summary of quantitative information regarding the significant unobservable inputs (Level 3) used in determining the fair value of assets and liabilities measured at fair value on a recurring basis:

At December 31, 2024	Fair Value (Level 3)	Valuation Technique	Unobservable Inputs	Weighted Average or Actual
Other investments				
Direct private equity investments	\$ 43,777	Internal valuation model	Discount rate	10.0 %
			Liquidity discount	15.0 %
Total other investments	43,777			
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts	(405)	Internal valuation model	Net undiscounted cash flows	\$ 12,657
			Expected loss ratio	1.2 %
			Discount rate	4.4 %
Total other assets and (liabilities)	(405)			
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	\$ 43,372			

At December 31, 2023	Fair Value (Level 3)	Valuation Technique	Unobservable Inputs	Weighted Average or Actual
Other investments				
Direct private equity investments	\$ 59,905	Internal valuation model	Discount rate	10.0 %
			Liquidity discount	15.0 %
Term loans	97,658	Discounted cash flow	Credit spread adjustment	0.2 %
			Risk premium	2.6 %
Total other investments	157,563			
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts	(515)	Internal valuation model	Net undiscounted cash flows	\$ 12,478
			Expected loss ratio	2.3 %
			Discount rate	3.8 %
Total other assets and (liabilities)	(515)			
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	\$ 157,048			

Below is a reconciliation of the beginning and ending balances, for the periods shown, of assets and liabilities measured at fair value on a recurring basis using Level 3 inputs.

	Other Investments		Other Assets and (Liabilities)		Total
	Direct Private Equity Investments	Term Loans			
Balance - January 1, 2024	\$ 59,905	\$ 97,658	\$ (515)	\$	157,048
Net investment income	258	—	—		258
Net realized and unrealized gains (losses) on investments	(16,686)	—	—		(16,686)
Other income (loss)	—	—	252		252
Net foreign exchange gains (losses)	(7)	—	—		(7)
Purchases	577	—	3,640		4,217
Sales	(270)	(94,321)	(3,626)		(98,217)
Settlements	—	(3,337)	(156)		(3,493)
Balance - December 31, 2024	\$ 43,777	\$ —	\$ (405)	\$	43,372

	Other Investments		Other Assets and (Liabilities)		Total
	Direct Private Equity Investments	Term Loans			
Balance - January 1, 2023	\$ 66,785	100,000	(1,832)		164,948
Net investment income	250	—	—		250
Net realized and unrealized gains (losses) on investments	(7,120)	—	—		(7,120)
Other income (loss)	—	—	(492)		(492)
Net foreign exchange gains (losses)	(5)	—	—		(5)
Purchases	—	—	1,809		1,809
Settlements	—	(2,342)	—		(2,342)
Balance - December 31, 2023	\$ 59,905	97,658	(515)		157,048

Other Investments

Direct Private Equity Investments

Level 3 - At December 31, 2024, the Company's other investments included \$43.8 million (2023 - \$59.9 million) of direct private equity investments which are recorded at fair value, with the fair value obtained through the use of internal valuation models. The Company measured the fair value of these investments using multiples of net tangible book value of the underlying entities. The significant unobservable inputs used in the fair value measurement of these investments are liquidity discount rates applied to each of the net tangible book value multiples used in the internal valuation models, and discount rates applied to the expected cash flows of the underlying entities in various scenarios. These unobservable inputs in isolation can cause significant increases or decreases in fair value. Generally, an increase in the liquidity discount rate or discount rates would result in a decrease in the fair value of these private equity investments.

Term Loans

Level 3 - During 2024, the Company disposed of its investment in a term loan. At December 31, 2023, the Company's other investments included a \$97.7 million investment which was recorded at fair value, with the fair value obtained through the use of a discounted cash flow model. The significant unobservable inputs used in the discounted cash flow model were the cash flow projection of the associated term loan, and the discount rate. The discount rate used was based on the Secured Overnight Financing Rate ("SOFR"), which was then adjusted for credit risk and a risk premium. These adjustments may be impacted by market movements implied by transactions of similar or related assets, loan-to-value, tenor, liquidity, credit risk adjustment or other risk factors. Assumptions used in the valuation process may significantly impact the resulting fair value.

Other Assets and Liabilities

Assumed and Ceded (Re)insurance Contracts

Level 3 - At December 31, 2024, the Company had a \$0.4 million net liability (2023 - \$0.5 million net liability) related to assumed and ceded (re)insurance contracts accounted for at fair value, with the fair value obtained through the use of an internal valuation model. The inputs to the internal valuation model are principally based on proprietary data as observable market inputs are generally not available. The most significant unobservable inputs include the assumed and ceded expected net cash flows related to the contracts, including the expected premium, acquisition expenses and losses; the expected loss ratio and the relevant discount rate used to present value the net cash flows. The contract period and acquisition expense ratio are considered an observable input as each is defined in the contract. Generally, an increase in the net expected cash flows and expected term of the contract and a decrease in the discount rate, expected loss ratio or acquisition expense ratio, would result in an increase in the expected profit and ultimate fair value of these assumed and ceded (re)insurance contracts.

Financial Instruments Disclosed, But Not Carried, at Fair Value

The Company uses various financial instruments in the normal course of its business. The Company's (re)insurance contracts are excluded from the fair value of financial instruments accounting guidance, unless the Company elects the fair value option, and therefore, are not included in the amounts discussed herein. The carrying values of cash and cash equivalents, accrued investment income, receivables for investments sold, certain other assets, payables for investments purchased, certain other liabilities, and other financial instruments not included herein approximated their fair values.

Debt

Included on the Company's consolidated balance sheet at December 31, 2024 were debt obligations of \$1.9 billion (2023 - \$2.0 billion). At December 31, 2024, the fair value of the Company's debt obligations was \$1.9 billion (2023 - \$1.9 billion).

The fair value of the Company's debt obligations is determined using indicative market pricing obtained from third-party service providers, which the Company considers Level 2 in the fair value hierarchy. There have been no changes during the period in the Company's valuation technique used to determine the fair value of the Company's debt obligations. Refer to "Note 9. Debt and Credit Facilities" for additional information related to the Company's debt obligations.

The Fair Value Option for Financial Assets and Financial Liabilities

The Company has elected to account for certain financial assets and financial liabilities at fair value using the guidance under FASB ASC Topic 825, *Financial Instruments* as the Company believes it represents the most meaningful measurement basis for these assets and liabilities. Below is a summary of the balances the Company has elected to account for at fair value:

At December 31,	2024		2023	
Other investments	\$	4,324,761	\$	3,515,566
Other assets	\$	2,029	\$	2,227
Other liabilities	\$	2,434	\$	2,742

The change in fair value of other investments resulted in net unrealized gains on investments in 2024 of \$243.8 million (2023 - gains of \$137.3 million, 2022 - losses of \$181.2 million).

Measuring the Fair Value of Other Investments Using Net Asset Valuations

The table below shows the Company's portfolio of other investments measured using net asset valuations as a practical expedient:

At December 31, 2024	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period (Minimum Days)	Redemption Notice Period (Maximum Days)
Private credit funds	\$ 1,181,146	\$ 1,284,699	See below	See below	See below
Private equity funds	609,105	664,234	See below	See below	See below
Hedge funds	338,248	—	See below	See below	See below
Total other investments measured using net asset valuations	\$ 2,128,499	\$ 1,948,933			

At December 31, 2023	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period (Minimum Days)	Redemption Notice Period (Maximum Days)
Private credit funds	\$ 982,016	\$ 949,135	See below	See below	See below
Private equity funds	433,788	673,778	See below	See below	See below
Total other investments measured using net asset valuations	\$ 1,415,804	\$ 1,622,913			

Private Credit Funds

The Company's investments in private credit funds include limited partnership or similar interests that invest in certain private credit asset classes, including U.S. direct lending funds, secondaries, mezzanine investments, distressed securities and senior secured bank loan funds. The Company generally has no right to redeem its interest in any of these private credit funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the liquidation or maturity of the underlying private credit assets of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership.

Private Equity Funds

The Company's investments in private equity funds include limited partnership or similar interests that invest in certain private equity asset classes including U.S. and global leveraged buyouts. The Company generally has no right to redeem its interest in any of these private equity funds in advance of dissolution of the applicable limited partnerships. Instead, distributions are received by the Company in connection with the exit from the underlying private equity investments of the fund. It is estimated that the majority of the underlying assets of the limited partnerships would liquidate over 5 to 10 years from inception of the limited partnership.

Hedge Funds

The Company's investments in hedge funds are primarily focused on global multi-strategy opportunities. These investments are generally redeemable at the option of the Company, at less than a month's notice. Certain restrictions on redemptions, including initial lock-up periods or redemption gates, may also apply to the Company, as defined by each fund's governing documents. Redemption gates allow the investment manager of a fund to defer part or all of a redemption request so as to not negatively impact the value of the redemption or the value of any interests that remain in the fund.

Limited Partnerships Entities

The Company's fund investments, included within other investments, are primarily variable interests in limited partnerships entities with unaffiliated fund managers in the normal course of business. The Company determined that certain of these interests represent investments in the VIEs and that it is not required to

consolidate these investments because it is not the primary beneficiary of these VIEs. The Company's maximum exposure to loss with respect to these VIEs is limited to the carrying amounts reported in the Company's consolidated balance sheets and any unfunded commitment.

The following table summarizes the aggregate carrying amount of the unconsolidated fund investments in VIEs, as well as the Company's maximum exposure to loss associated with these VIEs:

Other Investments	Carrying Amount		Maximum Exposure to Loss	
	Unfunded Commitments		Total	
At December 31, 2024	\$ 1,993,362	\$ 1,863,142	\$ 3,856,504	
At December 31, 2023	\$ 1,251,799	\$ 1,550,452	\$ 2,802,251	

[XML 34 R15.htm IDEA: XBRL DOCUMENT](#)

REINSURANCE

[SEC Schedule, 12-17, Insurance Companies, Reinsurance \[Abstract\]](#)
[REINSURANCE](#)

12 Months Ended Dec. 31, 2024

REINSURANCE

The Company purchases reinsurance and other protection to manage its risk portfolio and to reduce its exposure to large losses. The Company currently has in place contracts that provide for recovery of a portion of certain claims and claim expenses, generally in excess of various retentions or on a proportional basis. In addition to loss recoveries, certain of the Company's ceded reinsurance contracts provide for payments of additional premiums, for reinstatement premiums and for lost no-claims bonuses, which are incurred when losses are ceded to the respective reinsurance contracts. The Company remains liable to the extent that any reinsurer fails to meet its obligations.

The following table sets forth the effect of reinsurance and retrocessional activity on premiums written and earned and on net claims and claim expenses incurred:

Year ended December 31,	2024	2023	2022
Premiums Written			
Direct	\$ 1,197,360	\$ 865,771	\$ 1,264,410
Assumed	10,535,706	7,996,595	7,949,130
Ceded	(1,780,850)	(1,394,553)	(2,017,380)
Net premiums written	\$ 9,952,216	\$ 7,467,813	\$ 7,196,160
Premiums Earned			
Direct	\$ 1,097,726	\$ 1,013,372	\$ 1,105,164
Assumed	10,815,336	8,072,193	7,079,632
Ceded	(1,817,302)	(1,614,432)	(1,850,807)
Net premiums earned	\$ 10,095,760	\$ 7,471,133	\$ 6,333,989
Claims and Claim Expenses			
Gross claims and claim expenses incurred	\$ 5,629,756	\$ 3,950,362	\$ 5,851,140
Claims and claim expenses recovered	(296,775)	(376,853)	(1,512,300)
Net claims and claim expenses incurred	\$ 5,332,981	\$ 3,573,509	\$ 4,338,840

In assessing an allowance for reinsurance assets, which includes premiums receivable and reinsurance recoverable, the Company considers historical information, financial strength of reinsurers, collateralization amounts, and counterparty credit ratings to determine the appropriateness of the allowance. In assessing future default for reinsurance assets, the Company evaluates the provision for current expected credit losses under the probability of default and loss given default method. The Company utilizes its internal capital and risk models, which use counterparty ratings from major rating agencies, and assesses the current market conditions for the likelihood of default. The Company updates its internal capital and risk models for counterparty credit ratings and current market conditions on a periodic basis. Historically, the Company has not experienced material credit losses from reinsurance assets.

Premiums receivable reflect premiums written based on contract and policy terms and include estimates based on information received from both insureds and ceding companies, supplemented by the Company's estimates of premiums that are written but not reported. Due to the nature of reinsurance, ceding

companies routinely report and remit premiums subsequent to the contract coverage period, although the time lag involved in the process of reporting and collecting premiums is typically shorter than the lag in reporting losses.

At December 31, 2024, the Company's premiums receivable balance was \$7.3 billion (2023 - \$7.3 billion). Of the Company's premiums receivable balance as of December 31, 2024, the majority are receivable from highly rated counterparties. The provision for current expected credit losses on the Company's premiums receivable was \$4.6 million at December 31, 2024 (2023 - \$3.5 million). The following table provides a roll forward of the provision for current expected credit losses of the Company's premiums receivable:

Year ended December 31,	2024	2023
Beginning balance	\$ 3,514	\$ 4,606
Provision for (release of) allowance	1,117	(2,788)
Amounts acquired ⁽¹⁾	—	1,696
Ending balance	\$ 4,631	\$ 3,514

(1) Represents Validus' provision for current expected credit losses on premiums receivable, acquired November 1, 2023.

Reinsurance recoverable reflects amounts due from reinsurers based on the claim liabilities associated with the reinsurance policy. The Company accrues amounts that are due from reinsurers based on estimated ultimate losses applicable to the contracts.

At December 31, 2024, the Company's reinsurance recoverable balance was \$4.5 billion (2023 - \$5.3 billion). Of the Company's reinsurance recoverable balance at December 31, 2024, 55.7% is fully collateralized by the Company's reinsurers, 43.2% is recoverable from reinsurers rated A- or higher by major rating agencies and 1.0% is recoverable from reinsurers rated lower than A- by major rating agencies (2023 - 60.6%, 38.5% and 0.9%, respectively). The reinsurers with the three largest balances accounted for 12.6%, 11.0% and 8.3%, respectively, of the Company's reinsurance recoverable balance at December 31, 2024 (2023 - 17.6%, 14.3% and 8.7%, respectively). The provision for current expected credit losses was \$11.7 million at December 31, 2024 (2023 - \$13.3 million). The three largest company-specific components of the provision for current expected credit losses represented 23.9%, 7.2% and 5.9%, respectively, of the Company's total provision for current expected credit losses at December 31, 2024 (2023 - 10.9%, 10.7% and 8.1%, respectively). The following table provides a roll forward of the provision for current expected credit losses of the Company's reinsurance recoverable:

Year ended December 31,	2024	2023
Beginning balance	\$ 13,279	\$ 12,169
Provision for (release of) allowance	(1,549)	(3,644)
Amounts acquired ⁽¹⁾	—	4,754
Ending balance	\$ 11,730	\$ 13,279

(1) Represents Validus' provision for current expected credit losses on reinsurance recoverable, acquired November 1, 2023.

[XML 35 R16.htm IDEA: XBRL DOCUMENT](#)

RESERVE FOR CLAIMS AND CLAIM EXPENSES

[Insurance Loss Reserves \[Abstract\]](#)
[RESERVE FOR CLAIMS AND CLAIM EXPENSES](#)

12 Months Ended Dec. 31, 2024

RESERVE FOR CLAIMS AND CLAIM EXPENSES

The Company believes the most significant accounting judgment made by management is its estimate of claims and claim expense reserves. Claims and claim expense reserves represent estimates, including actuarial and statistical projections at a given point in time, of the ultimate settlement and administration costs for unpaid claims and claim expenses arising from the insurance and reinsurance contracts the Company sells. The Company's reserve for claims and claim expenses are a combination of case reserves, additional case reserves ("ACR") and incurred but not reported losses and incurred but not enough

reported losses (collectively referred to as “IBNR”). Case reserves are losses reported to the Company by insureds and ceding companies, but which have not yet been paid. If deemed necessary and in certain situations, either the Company establishes, or the Company’s clients report, ACR. Client reported ACR represents the client’s estimate of additional contract specific claims in excess of the case reserves they have reported to the Company. ACR established by the Company represents the Company’s estimates for claims related to specific contracts which the Company believes may not be adequately estimated by the client as of that

date or is not within the IBNR. The Company establishes IBNR using actuarial techniques and expert judgment to represent the anticipated cost of claims which have not been reported to the Company yet, or where the Company anticipates increased reporting. The Company’s reserving committee, which includes members of the Company’s senior management, reviews, discusses, and assesses the reasonableness and adequacy of the reserving estimates included in the audited consolidated financial statements.

The following table summarizes the Company’s reserve for claims and claim expenses by segment, allocated between case reserves, ACR and IBNR:

	Case Reserves	Additional Case Reserves	IBNR	Total
At December 31, 2024				
Property	\$ 1,845,228	\$ 1,905,553	\$ 2,821,958	\$ 6,572,739
Casualty and Specialty	3,081,081	295,074	11,354,597	14,730,752
Total	\$ 4,926,309	\$ 2,200,627	\$ 14,176,555	\$ 21,303,491
At December 31, 2023				
Property ⁽¹⁾	\$ 2,461,580	\$ 2,401,911	\$ 2,970,129	\$ 7,833,620
Casualty and Specialty ⁽¹⁾	2,801,016	331,345	9,520,888	12,653,249
Total	\$ 5,262,596	\$ 2,733,256	\$ 12,491,017	\$ 20,486,869

(1) The previously reported amount has been adjusted to reclassify certain reserves from IBNR to ACR.

Activity in the reserve for claims and claim expenses is summarized as follows:

Year ended December 31,	2024	2023	2022
Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period	\$ 15,142,583	\$ 11,181,648	\$ 9,025,961
Net incurred related to:			
Current year	6,184,315	4,024,116	4,586,422
Prior years	(851,334)	(450,607)	(247,582)
Total net incurred	5,332,981	3,573,509	4,338,840
Net paid related to:			
Current year	488,450	364,793	105,885
Prior years	3,109,360	2,630,885	1,924,271
Total net paid	3,597,810	2,995,678	2,030,156
Foreign exchange and other ⁽¹⁾	(55,653)	62,902	(152,997)
Amounts acquired ⁽²⁾	—	3,320,202	—
Reserve for claims and claim expenses, net of reinsurance recoverable, end of period	16,822,101	15,142,583	11,181,648
Reinsurance recoverable, end of period	4,481,390	5,344,286	4,710,925
Reserve for claims and claim expenses, end of period	\$ 21,303,491	\$ 20,486,869	\$ 15,892,573

(1) Reflects the impact of the foreign exchange revaluation of the reserve for claims and claim expenses, net of reinsurance recoverable, denominated in non-U.S. dollars as at the balance sheet date, as well as reinsurance transactions accounted for under retroactive reinsurance accounting.

(2) Represents the fair value of Validus’ reserve for claims and claim expenses, net of reinsurance recoverable, acquired on November 1, 2023.

During 2024, the Company incurred losses related to Hurricane Milton, Hurricane Helene, the Baltimore Bridge Collapse, a series of severe convective storms that impacted the Southern and Midwest United States, the Hualien earthquake which impacted Taiwan in April 2024, a severe hailstorm which impacted Calgary in August 2024, Hurricane Debby, Hurricane Beryl, and certain aggregate loss contracts triggered during 2024 (collectively, the “2024 Large Loss Events”).

The Company’s reserving methodology for each line of business uses a loss reserving process that calculates a point estimate for its ultimate settlement and administration costs for claims and claim expenses. The Company does not calculate a range of estimates and does not discount any of its reserves for claims and claim expenses. The Company uses this point estimate, along with paid claims and case reserves, to record its best estimate of ACR and IBNR in its consolidated financial statements. Under GAAP, the Company is not permitted to establish estimates for catastrophe claims and claim expense reserves until an event occurs that gives rise to a loss.

Reserving involves other uncertainties, such as the dependence on information from ceding companies, the time lag inherent in reporting information from the primary insurer to the Company or to the Company’s ceding companies, and differing reserving practices among ceding companies. The information received from ceding companies is typically in the form of bordereaux, broker notifications of loss and/or discussions with ceding companies or their brokers. This information may be received on a monthly, quarterly or transactional basis and normally includes paid claims and estimates of case reserves. The Company sometimes also receives an estimate or provision for IBNR. This information is updated and adjusted periodically during the loss settlement period as new data or facts in respect of initial claims, client accounts, industry or event trends may be reported or emerge in addition to changes in applicable statutory and case laws.

The Company’s estimates of large losses are based on factors including currently available information derived from claims information from certain customers and brokers, industry assessments of losses, proprietary models, and the terms and conditions of the Company’s contracts. The uncertainty of the Company’s estimates for large losses is also impacted by the preliminary nature of the information available, the magnitude and relative infrequency of the events, the expected duration of the respective claims development period, inadequacies in the data provided to the relevant date by industry participants and the potential for further reporting lags or insufficiencies; and in certain large losses, significant uncertainty as to the form of the claims and legal issues, under the relevant terms of insurance and reinsurance contracts. In addition, a significant portion of the net claims and claim expenses associated with certain large losses can be concentrated with a few large clients and therefore the loss estimates for these large losses may vary significantly based on the claims experience of those clients. The contingent nature of business interruption and other exposures will also impact losses in a meaningful way, which may give rise to significant complexity in respect of claims handling, claims adjustment and other coverage issues, over time. Given the magnitude of certain events, there can be meaningful uncertainty regarding total covered losses for the insurance industry and, accordingly, several of the key assumptions underlying the Company’s loss estimates. Loss reserve estimation in respect of the Company’s retrocessional contracts poses further challenges compared to directly assumed reinsurance. In addition, the Company’s actual net losses from these events may increase if the Company’s reinsurers or other obligors fail to meet their obligations.

The Company reevaluates its actuarial reserving assumptions on a periodic basis. Typically, the quarterly review procedures include reviewing paid and reported claims in the most recent reporting period, reviewing the development of paid and reported claims from prior periods, and reviewing the Company’s overall experience by underwriting year and in the aggregate. The Company monitors its expected ultimate claims and claim expense ratios and expected claims reporting assumptions on a quarterly basis and compares them to its actual experience. These actuarial assumptions are generally reviewed annually, based on input from the Company’s actuaries, underwriters, claims personnel and finance professionals, although adjustments may be made more frequently if needed. Assumption changes are made to adjust for changes in the terms of coverage the Company provides, changes in industry results for similar business, as well as its actual experience to the extent the Company has enough data to rely on its own experience. If the Company determines that adjustments to an earlier estimate are appropriate, such adjustments are recorded in the period in which they are identified.

Because of the inherent uncertainties discussed above, the Company has developed a reserving philosophy that attempts to incorporate prudent assumptions and estimates, and the Company has generally experienced favorable development on prior accident years net claims and claim expenses in the last several years. However, there is no assurance that this favorable development on prior accident years net claims and claim expenses will occur in future periods.

The Company establishes a provision for unallocated loss adjustment expenses (“ULAE”) when the related reserve for claims and claim expenses is established. ULAE are expenses that cannot be associated with a specific claim but are related to claims paid or in the process of settlement, such as internal costs of the claims function, and are included in the reserve for claims and claim expenses. The determination of the ULAE provision is subject to judgment.

Incurred and Paid Claims Development and Reserving Methodology

The information provided herein about incurred and paid accident year claims development for the years ended prior to December 31, 2024 on a consolidated basis and by segment is presented as supplementary information. The Company has applied a retrospective approach with respect to its acquisitions, presenting all relevant historical information for all periods presented. In addition, included in the incurred claims and claim expenses and cumulated paid claims and claim expenses tables below are reconciling items that represent the unamortized balance of fair value adjustments recorded in connection with the acquisition of TMR and Validus to reflect an increase in net claims and claim expenses due to the addition of a market based risk margin that represented the cost of capital required by a market participant to assume the net claims and claim expenses of TMR and Validus, partially offset by a decrease from discounting in connection with the acquisition of TMR and Validus, to reflect the time value of money.

For incurred and paid accident year claims denominated in currencies other than USD, the Company used the current year-end balance sheet foreign exchange rate for all periods provided, thereby eliminating the effects of changes in foreign currency translation rates from the incurred and paid accident year claims development information included in the tables below.

The following table details the Company’s consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance												At December 31, 2024
Accident Year	For the year ended December 31,										IBNR and ACR	
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024		
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)		
2015	\$ 1,670,190	\$ 1,603,613	\$ 1,572,065	\$ 1,527,011	\$ 1,505,261	\$ 1,494,406	\$ 1,497,311	\$ 1,489,897	\$ 1,487,053	\$ 1,485,686	\$ 51,310	
2016	—	1,872,508	1,882,586	1,843,984	1,811,320	1,734,299	1,752,579	1,784,035	1,762,581	1,768,120	31,713	
2017	—	—	3,606,410	3,423,131	3,340,805	3,262,344	3,230,732	3,168,653	3,160,015	3,171,839	106,741	
2018	—	—	—	2,912,949	3,132,829	3,065,222	2,934,773	2,926,168	2,965,944	2,980,818	178,549	
2019	—	—	—	—	2,706,854	2,680,637	2,591,017	2,554,243	2,564,553	2,620,761	249,622	
2020	—	—	—	—	—	4,393,340	4,392,922	4,397,548	4,370,007	4,301,296	761,291	
2021	—	—	—	—	—	—	5,534,493	5,388,056	5,176,255	4,906,690	1,018,009	
2022	—	—	—	—	—	—	—	5,902,647	5,627,982	5,128,208	2,231,524	
2023	—	—	—	—	—	—	—	—	5,277,384	5,200,462	3,144,564	
2024	—	—	—	—	—	—	—	—	—	6,077,913	5,042,190	
Total	—	—	—	—	—	—	—	—	—	\$ 37,641,793	\$ 12,815,513	
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance												
Accident Year	For the year ended December 31,											
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024		
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)		
2015	\$ 456,673	\$ 787,860	\$ 1,009,810	\$ 1,137,612	\$ 1,239,336	\$ 1,303,717	\$ 1,353,866	\$ 1,391,122	\$ 1,417,548	\$ 1,430,775		
2016	—	469,972	895,958	1,103,921	1,280,778	1,416,750	1,522,045	1,586,304	1,615,296	1,653,636		
2017	—	—	922,620	1,503,737	1,864,661	2,229,595	2,416,297	2,579,980	2,726,059	2,850,754		
2018	—	—	—	672,825	1,190,862	1,593,543	1,900,077	2,118,511	2,238,238	2,382,009		
2019	—	—	—	—	382,173	1,350,356	1,678,643	1,996,128	2,225,414	2,339,789		
2020	—	—	—	—	—	756,409	1,810,464	2,323,405	2,795,075	3,239,789		
2021	—	—	—	—	—	—	886,330	2,092,957	2,922,881	3,356,124		
2022	—	—	—	—	—	—	—	280,032	1,446,448	2,260,464		
2023	—	—	—	—	—	—	—	—	516,063	1,289,115		
2024	—	—	—	—	—	—	—	—	—	475,609		
Total	—	—	—	—	—	—	—	—	—	\$ 21,163,689		
Outstanding liabilities from accident year 2014 and prior, net of reinsurance											386,060	
Adjustment for unallocated loss adjustment expenses											114,425	
Unamortized fair value and other adjustments recorded in connection with acquisitions											(156,488)	
Liability for claims and claim expenses, net of reinsurance											\$ 16,822,101	

Property Segment

Within the Property segment, the Company writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes. Under these contracts, the Company indemnifies an insurer or reinsurer when its aggregate paid claims and claim expenses from a single occurrence of a covered peril exceeds the attachment point specified in the contract, up to an amount per loss specified in the contract. Generally, the Company’s most significant exposure is to losses from hurricanes, earthquakes and other windstorms, although the Company is also exposed to claims arising from other man-made and natural catastrophes, such as tsunamis, winter storms, freezes, floods, fires, tornadoes, explosions and acts of terrorism. The Company’s predominant exposure under such coverage is to property damage. However, other risks, including business interruption and other non-property losses, may also be covered under the Company’s catastrophe contracts when arising from a covered peril. The Company’s coverages are offered on either a worldwide basis or are limited to selected geographic areas.

Coverage can also vary from “all property” perils to limited coverage on selected perils, such as “earthquake only” coverage. The Company also enters into retrocessional contracts that provide property catastrophe coverage to other reinsurers or retrocedants. This coverage is generally in the form of excess of loss

retrocessional contracts and may cover all perils and exposures on a worldwide basis or be limited in scope to selected geographic areas, perils and/or exposures. The exposures the Company assumes from retrocessional business can change within a contract term as the underwriters of a retrocedant may alter their book of business after the retrocessional coverage has been bound. The Company also offers dual trigger reinsurance contracts which require the Company to pay claims based on claims incurred by insurers and reinsurers in addition to the estimate of insured industry losses as reported by referenced statistical reporting agencies.

Also included in the Property segment is property per risk, property (re)insurance, delegated authority arrangements and regional U.S. multi-line reinsurance. The Company's predominant exposure under such coverage is to property damage. However, other risks, including business interruption and other non-property losses, may also be covered when arising from a covered peril. The Company's coverages are offered on either a worldwide basis or are limited to selected geographic areas. Principally all of the business is reinsurance, although the Company also writes insurance business primarily through delegated authority arrangements. The Company offers these products principally through proportional reinsurance coverage or in the form of delegated authority arrangements. In a proportional reinsurance arrangement (also referred to as quota share reinsurance or pro rata reinsurance), the reinsurer shares a proportional part of the original premiums and losses of the reinsured.

Claims and claim expenses in the Company's Property segment are generally characterized by losses of low frequency and high severity. Initial reporting of paid and incurred claims in general, tends to be relatively prompt, particularly for less complex losses. The Company considers this business "short-tail" as compared to the reporting of claims for "long-tail" products, which tends to be slower. However, the timing of claims payment and reporting also varies depending on various factors, including: whether the claims arise under reinsurance of primary insurance companies or reinsurance of other reinsurance companies; the nature of the events (e.g., hurricanes, earthquakes or terrorism); the geographic area involved; post-event inflation which may cause the cost to repair damaged property to increase significantly from current estimates, or for property claims to remain open for a longer period of time, due to limitations on the supply of building materials, labor and other resources; complex policy coverage and other legal issues; and the quality of each client's claims management and reserving practices. Management's judgments regarding these factors are reflected in the Company's reserve for claims and claim expenses.

Reserving for most of the Company's Property segment, in particular catastrophe exposure, generally does not involve the use of traditional actuarial techniques, although for certain classes, such as proportional Property classes, traditional actuarial techniques are applied. Rather, claims and claim expense reserves are estimated by management by completing an in-depth analysis of the individual contracts which may potentially be impacted by the loss. The in-depth analysis generally involves: 1) estimating the size of insured industry losses; 2) reviewing reinsurance contract portfolios to identify contracts which are exposed; 3) reviewing information reported or otherwise provided by customers and brokers; 4) discussing the loss with customers and brokers; and 5) estimating the ultimate expected cost to settle all claims and administrative costs arising from the loss on a contract-by-contract basis and in aggregate for the event. Once a loss has occurred, during the then current reporting period, the Company records its best estimate of the ultimate expected cost to settle all claims arising from the loss. The Company's estimate of claims and claim expense reserves is then determined by deducting cumulative paid losses from its estimate of the ultimate expected loss. The Company's estimate of IBNR is determined by deducting cumulative paid losses, case reserves and ACR from its estimate of the ultimate expected loss. Once the Company receives a valid notice of loss or payment request under a catastrophe reinsurance contract, it is generally able to process and pay such claims promptly.

Because losses from which claims arise under policies written within the Property segment are typically prominent, public events such as hurricanes and earthquakes, the Company is often able to use independent reports as part of its loss reserve estimation process. The Company also reviews catastrophe bulletins published by various statistical reporting agencies to assist in determining the size of the industry loss, although these reports may not be available for some time after an event. For smaller events including localized severe weather events such as windstorms, hail, ice, snow, flooding, freezing and tornadoes, which are not necessarily prominent, public occurrences, the Company uses standard actuarial techniques to set reserves as it does in other property. The assumptions used are monitored and reviewed through the year to ensure they reflect the level of small cat activity experienced through the year and the exposure to the geographic regions involved. For these small events, the IBNR is run-off over time using Bornhuetter-

Ferguson actuarial method, a standard actuarial technique. The loss development factors for the reported Bornhuetter-Ferguson actuarial method are selected based on a review of the Company's historical experience. The reported loss development factors are typically reviewed annually.

In general, reserves for the Company's more recent large losses are subject to greater uncertainty and, therefore, greater potential variability, and are likely to experience material changes from one period to the next. This is due to the uncertainty as to the size of the industry losses, uncertainty as to which contracts have been exposed, uncertainty due to complex legal and coverage issues that can arise out of large or complex losses, and uncertainty as to the magnitude of claims incurred by the Company's customers. As the Company's claims age, more information becomes available and the Company believes its estimates become more certain.

The following table details the Company's Property segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance												At December 31, 2024
Accident Year	For the year ended December 31,											
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	IBNR and ACR	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
2015	\$ 506,243	\$ 456,920	\$ 414,379	\$ 397,750	\$ 388,076	\$ 383,214	\$ 374,258	\$ 376,457	\$ 375,420	\$ 373,895	\$ 511	
2016	—	572,814	592,915	564,880	544,624	517,878	532,556	522,917	522,370	522,370	3,361	
2017	—	—	1,951,429	1,813,187	1,687,873	1,670,648	1,613,614	1,550,274	1,521,356	1,496,890	76,065	
2018	—	—	—	1,271,912	1,348,628	1,286,032	1,158,452	1,147,450	1,098,897	1,072,994	64,246	
2019	—	—	—	—	1,162,088	1,135,337	1,042,748	976,162	934,252	932,496	35,810	
2020	—	—	—	—	—	1,966,826	2,075,320	2,076,315	2,010,634	1,972,883	265,855	
2021	—	—	—	—	—	—	2,759,175	2,758,871	2,655,570	2,440,274	143,701	
2022	—	—	—	—	—	—	—	2,544,022	2,431,989	2,045,341	597,038	
2023	—	—	—	—	—	—	—	—	1,469,539	1,376,749	577,889	
2024	—	—	—	—	—	—	—	—	—	1,928,913	1,407,007	
Total	—	—	—	—	—	—	—	—	—	\$ 14,142,805	\$ 3,171,483	

Cumulative Paid Claims and Claim Expenses, Net of Reinsurance												At December 31, 2024
Accident Year	For the year ended December 31,											
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	IBNR and ACR	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
2015	\$ 141,410	\$ 277,662	\$ 322,118	\$ 344,855	\$ 356,090	\$ 360,172	\$ 362,864	\$ 365,875	\$ 369,874	\$ 370,585	\$ 370,585	
2016	—	144,973	324,607	405,317	438,693	465,432	476,483	481,117	477,703	480,030	480,030	
2017	—	—	619,039	935,017	1,115,451	1,223,434	1,243,652	1,291,080	1,313,624	1,323,316	1,323,316	
2018	—	—	—	453,864	675,404	838,513	872,831	917,391	952,022	953,609	953,609	
2019	—	—	—	—	164,785	457,281	632,491	718,321	777,272	818,617	818,617	
2020	—	—	—	—	—	284,033	878,467	1,139,605	1,332,331	1,517,898	1,517,898	
2021	—	—	—	—	—	—	585,175	1,371,613	1,852,117	1,984,325	1,984,325	
2022	—	—	—	—	—	—	—	76,656	764,636	1,157,016	1,157,016	
2023	—	—	—	—	—	—	—	—	232,849	536,495	536,495	
2024	—	—	—	—	—	—	—	—	—	224,606	224,606	
Total	—	—	—	—	—	—	—	—	—	\$ 9,266,497	\$ 9,266,497	
Outstanding liabilities from accident year 2014 and prior, net of reinsurance											\$ 49,601	
Adjustment for unallocated loss adjustment expenses											\$ 15,115	
Unamortized fair value and other adjustments recorded in connection with acquisitions											\$ (34,183)	
Liability for claims and claim expenses, net of reinsurance											\$ 4,906,841	

Casualty and Specialty Segment

The Company offers its casualty and specialty reinsurance products principally on a proportional basis, and it also provides excess of loss coverage. The Company offers casualty and specialty reinsurance products to insurance and reinsurance companies and provides coverage for specific geographic regions or on a worldwide basis. Principally all of the business is reinsurance, although the Company also writes insurance business.

As with the Company's Property segment, its Casualty and Specialty segment reinsurance contracts can include coverage for relatively large limits or exposures. As a result, the Company's casualty and specialty reinsurance business can be subject to significant claims volatility. In periods of low claims frequency or severity, the Company's results will generally be favorably impacted while in periods of high claims frequency or severity the Company's results will generally be negatively impacted.

The Company's processes and methodologies in respect of loss estimation for the coverages offered through its Casualty and Specialty segment differ from those used for its Property segment. For example, the Company's casualty and specialty coverages are more likely to be impacted by factors such as long-term inflation and changes in the social and legal environment, which the Company believes gives rise to greater uncertainty in its reserves for claims and claim expenses. The Company believes this makes its Casualty and Specialty segment reserving subject to greater uncertainty than its Property segment.

The Company calculates multiple point estimates for claims and claim expense reserves using a variety of actuarial reserving techniques for many, but not all, of its classes of business for each underwriting year within the Casualty and Specialty segment. The Company does not believe that these multiple point estimates are, or should be considered, a range. Rather, the Company considers each class of business and determines the most appropriate point estimate for each underwriting year based on the characteristics of the particular class including: (1) loss development patterns derived from historical data; (2) the credibility of the selected loss development pattern; (3) the stability of the loss development patterns; (4) how developed the underwriting year is; and (5) the observed loss development of other underwriting years for the same class. The Company also considers other relevant factors, including: (1) historical ultimate loss ratios; (2) the presence of individual large losses; and (3) known occurrences that have not yet resulted in reported losses. The Company makes determinations of the most appropriate point estimate of loss for each class based on an evaluation of relevant information and does not ascribe any particular portion of the estimate to a particular factor or consideration. In addition, the Company believes that a review of individual contract information improves the loss estimates for some classes of business.

When developing claims and claims expense reserves for its Casualty and Specialty segment, the Company considers several actuarial techniques such as the expected loss ratio method, the Bornhuetter-Ferguson actuarial method and the paid and reported chain ladder actuarial method.

For classes of business and underwriting years where the Company has limited historical claims experience, estimates of ultimate losses are generally initially determined based on the loss ratio method applied to each underwriting year and to each class of business. Unless the Company has credited claims experience or unfavorable development, it generally selects an ultimate loss based on its initial expected loss ratio. The selected ultimate losses are determined by multiplying the initial expected loss ratio by the earned premium. The initial expected loss ratios are key inputs that involve management judgment and are based on a variety of factors, including: (1) contract by contract expected loss ratios developed during the Company's pricing process; (2) historical loss ratios and combined ratios adjusted for rate change and trend; and (3) industry benchmarks for similar business. These judgments take into account management's view of past, current and future factors that may influence ultimate losses, including: (1) market conditions; (2) changes in the business underwritten; (3) changes in timing of the emergence of claims; and (4) other factors that may influence ultimate loss ratios and losses.

The determination of when reported losses are sufficient and credible to warrant selection of an ultimate loss ratio different from the initial expected loss ratio also requires judgment. The Company generally makes adjustments for reported loss experience indicating unfavorable variances from initial expected loss ratios sooner than reported loss experience indicating favorable variances. This is because the reporting of losses in excess of expectations tends to have greater credibility than an absence or lower than expected level of reported losses. Over time, as a greater number of claims are reported and the credibility of reported losses improves, actuarial estimates of IBNR are typically based on the Bornhuetter-Ferguson actuarial method or the reported chain ladder actuarial method.

The Bornhuetter-Ferguson actuarial method allows for greater weight to be applied to expected results in periods where little or no actual experience is available, and, hence, is less susceptible to the potential pitfall of being excessively swayed by experience of actual paid and/or reported loss data, compared to the

chain ladder actuarial method. The Bornhuetter-Ferguson actuarial method uses the initial expected loss ratio to estimate IBNR, and it assumes that past experience is not fully representative of the future. As the Company's reserves for claims and claim expenses age, and actual claims experience becomes available, this method places less weight on expected experience and places more weight on actual experience. This experience, which represents the difference between expected reported claims and actual reported claims, is reflected in the respective reporting period as a change in estimate. The utilization of the Bornhuetter-Ferguson actuarial method requires the Company to estimate an expected ultimate claims and claim expense ratio and select an expected loss reporting pattern. The Company selects its estimates of the expected ultimate claims and claim expense ratios as described above and selects its expected loss reporting patterns by utilizing actuarial analysis, including management's judgment, and historical patterns of paid losses and reporting of case reserves to the Company, as well as industry loss development patterns. The estimated expected claims and claim expense ratio may be modified to the extent that reported losses at a given point in time differ from what would be expected based on the selected loss reporting pattern.

The reported chain ladder actuarial method utilizes actual reported losses and a loss development pattern to determine an estimate of ultimate losses that is independent of the initial expected ultimate loss ratio and earned premium. The Company believes this technique is most appropriate when there are a large number of reported losses with significant statistical credibility and a relatively stable loss development pattern. Information that may cause future loss development patterns to differ from historical loss development patterns is considered and reflected in the Company's selected loss development patterns as appropriate. For certain reinsurance contracts, historical loss development patterns may be developed from ceding company data or other sources.

In addition, certain specialty coverages may be impacted by natural and man-made catastrophes. The Company estimates reserves for claim and claim expenses for these losses, following a process that is similar to its Property segment described above.

The following table details the Company's Casualty and Specialty segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance											
Accident Year	For the year ended December 31,										At December 31, 2024
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	IBNR and ACR
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
2015	\$ 1,163,947	\$ 1,146,693	\$ 1,157,686	\$ 1,129,261	\$ 1,117,185	\$ 1,111,192	\$ 1,123,053	\$ 1,113,440	\$ 1,111,633	\$ 1,111,791	\$ 50,799
2016	—	1,299,694	1,289,671	1,279,104	1,266,696	1,216,421	1,238,316	1,251,479	1,239,664	1,245,750	28,352
2017	—	—	1,654,981	1,609,944	1,652,932	1,591,696	1,617,118	1,618,379	1,638,639	1,674,949	30,676
2018	—	—	—	1,641,037	1,784,201	1,778,190	1,776,321	1,778,718	1,867,047	1,907,824	114,303
2019	—	—	—	—	1,544,766	1,545,300	1,548,269	1,578,081	1,650,301	1,708,265	213,812
2020	—	—	—	—	—	2,426,514	2,317,602	2,321,233	2,359,373	2,328,413	495,436
2021	—	—	—	—	—	—	2,775,318	2,629,185	2,520,688	2,466,416	874,308
2022	—	—	—	—	—	—	—	3,358,625	3,195,993	3,082,867	1,634,486
2023	—	—	—	—	—	—	—	—	3,807,845	3,823,713	2,566,675
2024	—	—	—	—	—	—	—	—	—	4,149,000	3,635,183
Total	—	—	—	—	—	—	—	—	—	\$ 23,498,988	\$ 9,644,030

Cumulative Paid Claims and Claim Expenses, Net of Reinsurance											
Accident Year	For the year ended December 31,										
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
2015	\$ 315,263	\$ 510,198	\$ 687,692	\$ 792,757	\$ 883,246	\$ 943,545	\$ 991,002	\$ 1,025,247	\$ 1,047,674	\$ 1,060,190	
2016	—	324,999	571,351	698,604	842,085	951,318	1,045,562	1,105,187	1,137,593	1,173,606	
2017	—	—	303,581	568,720	749,410	1,006,161	1,172,645	1,288,900	1,412,435	1,527,438	
2018	—	—	—	218,961	515,458	755,030	1,027,246	1,201,120	1,386,216	1,528,400	
2019	—	—	—	—	217,388	533,656	737,865	960,322	1,218,856	1,406,797	
2020	—	—	—	—	—	472,376	931,997	1,183,800	1,462,744	1,721,891	
2021	—	—	—	—	—	—	301,155	721,344	1,070,764	1,371,799	
2022	—	—	—	—	—	—	—	203,376	681,812	1,103,448	
2023	—	—	—	—	—	—	—	—	283,214	752,620	
2024	—	—	—	—	—	—	—	—	—	251,003	
Total	—	—	—	—	—	—	—	—	—	\$ 11,897,192	
Outstanding liabilities from accident year 2014 and prior, net of reinsurance										336,459	
Adjustment for unallocated loss adjustment expenses										89,310	
Unamortized fair value and other adjustments recorded in connection with acquisitions										(122,305)	
Liability for claims and claim expenses, net of reinsurance										\$ 11,915,260	

Prior Year Development of the Reserve for Net Claims and Claim Expenses

The Company's estimates of claims and claim expense reserves are not precise in that, among other things, they are based on predictions of future developments and estimates of future trends and other variable factors. Some, but not all, of the Company's reserves are further subject to the uncertainty inherent in actuarial methodologies and estimates. Because a reserve estimate is simply an insurer's estimate at a point in time of its ultimate liability, and because there are numerous factors that affect reserves and claims payments that cannot be determined with certainty in advance, the Company's ultimate payments will vary, perhaps materially, from its estimates of reserves. If the Company determines in a subsequent period that adjustments to its previously established reserves are appropriate, such adjustments are recorded in the period in which they are identified. On a net basis, the Company's cumulative favorable or unfavorable development is generally reduced by offsetting changes in its reinsurance recoverable, as well as changes to loss related premiums such as reinstatement premiums and redeemable noncontrolling interest, all of which generally move in the opposite direction to changes in the Company's ultimate claims and claim expenses.

The following table details the Company's prior year net development by segment of its net claims and claim expenses:

Year ended December 31,	(Favorable) Adverse Development		
	2024	2023	2022
Property	\$ (818,852)	\$ (408,905)	\$ (205,741)
Casualty and Specialty	(32,482)	(41,702)	(41,841)
Total net (favorable) adverse development of prior accident years net claims and claim expenses	<u>\$ (851,334)</u>	<u>\$ (450,607)</u>	<u>\$ (247,582)</u>

Changes to prior year estimated net claims and claim expenses increased net income by \$851.3 million during the year ended December 31, 2024 (2023 - increased net income by \$450.6 million, 2022 - increased net income by \$247.6 million), excluding the consideration of changes in reinstatement, adjustment or other premium changes, profit commissions, redeemable noncontrolling interests - DaVinci, Fontana and Vermeer and income tax.

Property Segment

The following tables detail the prior year net development of the Company's liability for net unpaid claims and claim expenses for its Property segment, allocated between large catastrophe events and other small catastrophe events and attritional loss movements:

Year ended December 31,	2024	
	(Favorable) adverse development	
Catastrophe net claims and claim expenses		
Large catastrophe events		
2023 Large Loss Events ⁽¹⁾	\$	(31,899)
2022 Weather-Related Large Losses ⁽²⁾		(284,327)
2021 Weather-Related Large Losses ⁽³⁾		(180,028)
2020 Weather-Related Large Loss Events ⁽⁴⁾		(47,512)
2019 Large Loss Events ⁽⁵⁾		(14,445)
2018 Large Loss Events ⁽⁶⁾		(38,295)
2017 Large Loss Events ⁽⁷⁾		(25,692)
Total large catastrophe events		(622,198)
Small catastrophe events and attritional loss movements		
Other small catastrophe events and attritional loss movements		(206,616)
Total small catastrophe events and attritional loss movements		(206,616)
Total catastrophe and attritional net claims and claim expenses		(828,814)
Actuarial assumption changes		9,962
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$	(818,852)

- "2023 Large Loss Events" includes earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Ciaran, and certain aggregate loss contracts triggered during 2023.
- "2022 Weather-Related Large Losses" includes Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contracts.
- "2021 Weather-Related Large Losses" includes Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contracts.
- "2020 Weather-Related Large Loss Events" includes Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contracts.
- "2019 Large Loss Events" includes Hurricane Dorian and Typhoons Faxai and Hagibis and certain losses associated with aggregate loss contracts.
- "2018 Large Loss Events" includes Typhoons Jebi, Mangkhut and Trami, Hurricane Florence, wildfires in California, Hurricane Michael and certain losses associated with aggregate loss contracts.
- "2017 Large Loss Events" includes Hurricanes Harvey, Irma and Maria, the Mexico City Earthquake, wildfires in California and certain losses associated with aggregate loss contracts.

The net favorable development of prior accident years net claims and claim expenses on the large catastrophe events was driven by better than expected loss emergence across the 2017 to 2023 accident years.

The net favorable development on other small catastrophe events and attritional loss movements was primarily related to lines of business where the Company principally estimates net claims and claim expenses using traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes.

Year ended December 31,	2023	
	(Favorable) adverse development	
Catastrophe net claims and claim expenses		
Large catastrophe events		
2022 Weather-Related Large Losses	\$	(85,653)
2021 Weather-Related Large Losses		(36,949)
2020 Weather-Related Large Loss Events		(42,577)
2019 Large Loss Events		(43,850)
2018 Large Loss Events		(40,050)
2017 Large Loss Events		(46,404)
Other		(14,337)
Total large catastrophe events		(309,820)
Small catastrophe events and attritional loss movements		
Other small catastrophe events and attritional loss movements		(99,925)
Total small catastrophe events and attritional loss movements		(99,925)
Total catastrophe and attritional net claims and claim expenses		(409,745)
Actuarial assumption changes		840
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$	(408,905)

The net favorable development of prior accident years net claims and claim expenses was driven by better than expected loss emergence.

The net favorable development on other small catastrophe events and attritional loss movements was related to lines of business where the Company principally estimates net claims and claim expenses using traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes.

Year ended December 31,	2022	
	(Favorable) adverse development	
Catastrophe net claims and claim expenses		
Large catastrophe events		
2021 Weather-Related Large Loss Events	\$	(12,387)
2020 Weather-Related Large Loss Events		(24,589)
2019 Large Loss Events		(97,034)
2018 Large Loss Events		(20,318)
2017 Large Loss Events		(39,481)
Other		(4,755)
Total large catastrophe events		(198,564)
Small catastrophe events and attritional loss movements		
Other small catastrophe events and attritional loss movements		(31,024)
Total small catastrophe events and attritional loss movements		(31,024)
Total catastrophe and attritional net claims and claim expenses		(229,588)
Actuarial assumption changes		23,847
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$	(205,741)

The net favorable development of prior accident years net claims and claim expenses was largely driven by better than expected loss emergence.

The net favorable development on other small catastrophe events and attritional loss movements was related to lines of business where the Company principally estimates net claims and claim expenses using

traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes.

Casualty and Specialty Segment

The following table details the net development of the Company’s prior accident years net claims and claim expenses for its Casualty and Specialty segment:

Year ended December 31,	(Favorable) Adverse Development		
	2024	2023	2022
Actuarial methods - actual reported claims less than expected claims	\$ (67,595)	\$ (44,612)	\$ (63,353)
Actuarial assumption changes	35,113	2,910	21,512
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (32,482)	\$ (41,702)	\$ (41,841)

The Company principally estimates net claims and claim expenses for the Casualty and Specialty segment using traditional actuarial methods.

The net favorable development of prior accident years net claims and claim expenses during the three-year period ended December 31, 2024 was primarily due to reported losses generally coming in lower than expected on attritional net claims and claim expenses and was driven by favorable experience within the Company’s other specialty, credit and professional liability classes of business, partially offset by adverse experience in general liability.

Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses

The reconciliation of the net incurred and paid claims development tables to the reserve for claims and claim expenses in the consolidated balance sheet is as follows:

At December 31, 2024		
Net Reserve for Claims and Claim Expenses		
Property		\$ 4,906,841
Casualty and Specialty		11,915,260
Total net reserve for claims and claim expenses		16,822,101
Reinsurance Recoverable		
Property		\$ 1,665,898
Casualty and Specialty		2,815,492
Total reinsurance recoverable		4,481,390
Total reserve for claims and claim expenses		\$ 21,303,491

Historical Claims Duration

The following is unaudited supplementary information about average historical claims duration by segment:

At December 31, 2024	Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (Number of Years)									
	1	2	3	4	5	6	7	8	9	10
Property	20.7 %	28.8 %	16.4 %	6.9 %	5.5 %	0.9 %	0.9 %	0.4 %	0.7 %	0.2 %
Casualty and Specialty	12.3 %	16.3 %	12.4 %	12.9 %	10.6 %	8.4 %	6.3 %	4.5 %	2.5 %	1.1 %

Claims Frequency

Both of the Company’s reportable segments are broadly considered to be reinsurance, where multiple claims are often aggregated, perhaps multiple times through retrocessional reinsurance, before ultimately being ceded to the Company. The nature, size, terms and conditions of contracts entered into by the Company changes from one accident year to the next, as do the quantum of contractual or policy limits, and accordingly the potential amount of claims and claim expenses associated with a reported claim, can range from nominal, to significant. These factors can impact the amount and timing of the claims and claim expenses to be recorded and accordingly, developing claim frequency information is highly subjective and is not prepared or utilized for internal purposes. In recent years, the Company has grown its Casualty and Specialty segment where a significant amount of the premium and net reserves come from proportional contracts. The Company does not have direct access to claim frequency information underlying certain of its proportional contracts given the nature of that business. In addition, the Company completed the acquisition of Validus on November 1, 2023. Historically, Validus has not kept nor had access to claim count and frequency information. As providing any claim count and frequency information would exclude the entirety of the legacy Validus portfolio as well as all proportional contracts for the Company, the Company has determined that it is impracticable to provide this information.

Assumed Reinsurance Contracts Classified As Deposit Contracts

Included in other income (loss) during 2024 was \$0.2 million related to income earned on assumed reinsurance contracts that were classified as deposit contracts with underwriting risk only (2023 - \$0.2 million, 2022 - \$0.2 million). Deposit liabilities of \$3.5 million are included in reinsurance balances payable at December 31, 2024 (2023 - \$3.7 million).

XML 36 R17.htm IDEA: XBRL DOCUMENT

DEBT AND CREDIT FACILITIES

Debt Disclosure

[Abstract]

DEBT AND CREDIT FACILITIES

12 Months Ended

Dec. 31, 2024

DEBT AND CREDIT FACILITIES

The agreements governing the Company’s debt obligations and credit facilities contain certain customary representations, warranties and covenants. At December 31, 2024, the Company believes that it was in compliance with its debt covenants.

Debt Obligations

A summary of the Company’s debt obligations on its consolidated balance sheets is set forth below:

	December 31, 2024		December 31, 2023	
	Fair Value	Carrying Value	Fair Value	Carrying Value
5.750% Senior Notes due 2033	\$ 755,693	\$ 742,068	\$ 758,783	\$ 741,124
3.600% Senior Notes due 2029	376,816	396,051	371,276	395,137
3.450% Senior Notes due 2027	290,070	298,765	283,350	298,270
3.700% Senior Notes due 2025	299,550	299,908	293,154	299,537
4.750% Senior Notes due 2025 (DaVinci) ⁽¹⁾	149,363	149,897	147,489	149,587
Total senior notes	1,871,492	1,886,689	1,854,052	1,883,655
Medici Revolving Credit Facility ⁽²⁾	—	—	75,000	75,000
Total debt	\$ 1,871,492	\$ 1,886,689	\$ 1,929,052	\$ 1,958,655

- (1) RenaissanceRe owns a noncontrolling economic interest in its joint venture DaVinci. Because RenaissanceRe controls a majority of DaVinci’s issued voting shares, the consolidated financial statements of DaVinci are included in the consolidated financial statements of RenaissanceRe. However, RenaissanceRe does not guarantee or provide credit support for DaVinci and RenaissanceRe’s financial exposure to DaVinci is limited to its investment in DaVinci’s shares and counterparty credit risk arising from reinsurance transactions.
- (2) RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici’s issued voting shares, the financial statements of Medici are included in RenaissanceRe’s consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe’s financial exposure to Medici is limited to its investment in Medici’s shares and counterparty credit risk arising from reinsurance transactions.

5.750% Senior Notes due 2033

On June 5, 2023, the Company issued \$750.0 million of its 5.750% Senior Notes due June 5, 2033, with interest on the notes payable on June 5 and December 5 of each year, commencing on December 5, 2023. The notes are redeemable at the applicable redemption price, subject to the terms described in the indenture for the notes. However, the notes (i) may not be redeemed at any time prior to June 5, 2026 without approval of the Bermuda Monetary Authority (the “BMA”) and (ii) may not be redeemed or repaid at any time if enhanced capital requirements, as established by the BMA, would be breached immediately before or after giving effect to the redemption or repayment of such notes, unless, in each case, RenaissanceRe replaces the capital represented by the notes to be redeemed or repaid with capital having equal or better capital treatment as the notes under applicable BMA rules. The notes contain various covenants including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries. The Company received net proceeds of approximately \$741.0 million from the offering of senior notes after deducting the underwriting discounts and estimated offering expenses payable by the Company. The Company used the net proceeds from this offering to fund a portion of the cash consideration for the Validus Acquisition, which closed on November 1, 2023, to pay related costs and expenses, and for general corporate purposes. See “Note 3. Acquisition of Validus” for additional information regarding the Validus Acquisition.

3.600% Senior Notes Due 2029

On April 2, 2019, RenaissanceRe issued \$400.0 million principal amount of its 3.600% Senior Notes due April 15, 2029, with interest on the notes payable on April 15 and October 15 of each year, commencing on October 15, 2019. The notes are redeemable at the applicable redemption price, subject to the terms described in the indenture for the notes. However, the notes may not be redeemed at any time prior to their maturity if enhanced capital requirements, as established by the BMA, would be breached immediately before or after giving effect to the redemption of such notes, unless, in each case, RenaissanceRe replaces the capital represented by the notes to be redeemed with capital having equal or better capital treatment as the notes under applicable BMA rules. The notes contain various covenants including limitations on mergers

and consolidations, and restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries. The net proceeds from this offering were used to repay, in full, the \$200.0 million outstanding under the Company’s revolving credit facility at March 31, 2019, which the Company used to partially fund the purchase price for the TMR Stock Purchase, and the remainder of the net proceeds was used for general corporate purposes.

3.450% Senior Notes due 2027 of RenaissanceRe Finance

On June 29, 2017, RenaissanceRe Finance Inc. (“RenaissanceRe Finance”) issued \$300.0 million principal amount of its 3.450% Senior Notes due July 1, 2027, with interest on the notes payable on July 1 and January 1 of each year. The notes are fully and unconditionally guaranteed by RenaissanceRe and may be redeemed by RenaissanceRe Finance prior to maturity, subject to the payment of a “make-whole” premium if the notes are redeemed prior to April 1, 2027. The notes contain various covenants, including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, stock of designated subsidiaries.

3.700% Senior Notes due 2025 of RenaissanceRe Finance

On March 24, 2015, RenaissanceRe Finance issued \$300.0 million principal amount of its 3.700% Senior Notes due April 1, 2025, with interest on the notes payable on April 1 and October 1 of each year. The notes are fully and unconditionally guaranteed by RenaissanceRe and may be redeemed by RenaissanceRe Finance prior to maturity, subject to the payment of a “make-whole” premium if the notes are redeemed prior to January 1, 2025. The notes contain various covenants, including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, stock of designated subsidiaries.

The net proceeds from the offering of the notes (together with cash on hand) were applied by RenaissanceRe to repay in full a \$300.0 million bridge loan that Barclays Bank PLC provided to RenaissanceRe on February 25, 2015 in order to finance a portion of the cash consideration paid by RenaissanceRe in connection with the acquisition of Platinum.

DaVinci Senior Notes

On May 4, 2015, DaVinciRe Holdings Ltd. (“DaVinci”) issued \$150.0 million principal amount of its 4.750% Senior Notes due May 1, 2025, with interest on the notes payable on May 1 and November 1, commencing with November 1, 2015 (the “DaVinci Senior Notes”). The DaVinci Senior Notes, which are senior obligations, may be redeemed prior to maturity, subject to the payment of a “make-whole” premium if the notes are redeemed before February 1, 2025. The DaVinci Senior Notes contain various covenants including restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries, limitations on mergers, amalgamations and consolidations, limitations on third-party investor redemptions, a leverage covenant and a covenant to maintain certain ratings. The net proceeds from this offering were used to repay, in full, \$100.0 million outstanding under the loan agreement, dated as of March 30, 2011, between DaVinci and RenaissanceRe, and the remainder of the net proceeds were used for general corporate purposes.

Scheduled Debt Maturity

The following table sets forth the scheduled maturity of the Company’s aggregate amount of its debt obligation reflected on its consolidated balance sheet at December 31, 2024:

2025	\$ 450,000
2026	—
2027	300,000
2028	—
2029	400,000
After 2029	750,000
Unamortized discount and debt issuance expenses	(13,311)
	\$ 1,886,689

Credit Facilities

The outstanding amounts issued or drawn under each of the Company’s significant credit facilities is set forth below:

At December 31, 2024	Issued or Drawn
Revolving Credit Facility ⁽¹⁾	\$ —
Medici Revolving Credit Facility ⁽²⁾	—
Bilateral Letter of Credit Facilities	
Secured	262,168
Unsecured	357,443
	<u>\$ 619,611</u>

- (1) At December 31, 2024, no amounts were issued or drawn under this facility.
- (2) RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici’s voting shares, the financial statements of Medici are included in RenaissanceRe’s consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe’s financial exposure to Medici is limited to its investment in Medici’s shares and counterparty credit risk arising from reinsurance transactions. The drawn amount of the Medici revolving credit facility is included on the Company’s consolidated balance sheets under debt.

RenaissanceRe Revolving Credit Facility

RenaissanceRe, Renaissance Reinsurance Ltd. (“Renaissance Reinsurance”), RenaissanceRe Specialty U.S. Ltd. (“RenaissanceRe Specialty U.S.”), Renaissance Reinsurance U.S. Inc. (“Renaissance Reinsurance U.S.”) and RenaissanceRe Europe AG (“RREAG”) are parties to a third amended and restated credit agreement dated November 18, 2022 (the “Revolving Credit Agreement”) with various banks, financial institutions and Wells Fargo Bank, National Association (“Wells Fargo”) as administrative agent, which amended and restated a previous credit agreement. The Revolving Credit Agreement provides for a revolving commitment to RenaissanceRe of \$500.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$700.0 million. Amounts borrowed under the Revolving Credit Agreement bear interest at a rate selected by RenaissanceRe equal to the Base Rate or Term SOFR (each as defined in the Revolving Credit Agreement) plus a margin. In addition to revolving loans, the Revolving Credit Agreement provides that the entire facility will also be available for the issuance of standby letters of credit, subject to the terms and conditions set forth therein, and swingline loans, which are capped at \$50.0 million for each of the swingline lenders. At December 31, 2024, RenaissanceRe had \$Nil outstanding under the Revolving Credit Agreement.

The Revolving Credit Agreement contains representations, warranties and covenants customary for bank loan facilities of this type, including limits on the ability of RenaissanceRe and its subsidiaries to merge, consolidate, sell a substantial amount of assets, incur liens and declare or pay dividends under certain circumstances. The Revolving Credit Agreement also contains certain financial covenants which generally provide that the ratio of consolidated debt to capital shall not exceed 0.35:1 and that the consolidated net worth of RenaissanceRe shall equal or exceed approximately \$4.0 billion, subject to an annual adjustment.

If certain events of default occur, in some circumstances the lenders’ obligations to make loans may be terminated and the outstanding obligations of RenaissanceRe under the Revolving Credit Agreement may be accelerated. The scheduled commitment maturity date of the Revolving Credit Agreement is November 18, 2027.

RenaissanceRe Finance guarantees RenaissanceRe’s obligations under the Revolving Credit Agreement. Subject to certain exceptions, additional subsidiaries of RenaissanceRe are required to become guarantors if such subsidiaries issue or incur certain types of indebtedness.

Bilateral Letter of Credit Facilities

Uncommitted, Secured Standby Letter of Credit Facility with Wells Fargo

RenaissanceRe and certain of its subsidiaries and affiliates, including Renaissance Reinsurance, DaVinci Reinsurance Ltd. (“DaVinci Reinsurance”), Renaissance Reinsurance U.S., RREAG and RenaissanceRe Specialty U.S. are parties to an Amended and Restated Standby Letter of Credit Agreement dated June 21,

2019, as amended, with Wells Fargo, which provides for a secured, uncommitted facility under which letters of credit may be issued from time to time for the respective accounts of the subsidiaries. Pursuant to the agreement, the applicants may request secured letter of credit issuances up to an aggregate amount of \$200.0 million. RenaissanceRe has unconditionally guaranteed the payment obligations of the applicants other than DaVinci Reinsurance.

The agreement contains representations, warranties and covenants that are customary for facilities of this type. Under the agreement, each applicant is required to pledge eligible collateral having a value sufficient to cover all of its obligations under the agreement with respect to secured letters of credit issued for its account. In the case of an event of default under the agreement, Wells Fargo may exercise certain remedies, including conversion of collateral of a defaulting applicant into cash.

At December 31, 2024, there were \$20.1 million of secured letters of credit outstanding and \$Nil of unsecured letters of credit outstanding under this agreement.

Secured Letter of Credit Facility with Citibank Europe

Certain subsidiaries and affiliates of RenaissanceRe, including Renaissance Reinsurance, DaVinci Reinsurance, Renaissance Reinsurance of Europe Designated Activity Company (“Renaissance Reinsurance of Europe DAC”) and RenaissanceRe Specialty U.S., are parties to a facility letter, dated December 19, 2022, as amended, with Citibank Europe plc (“Citibank Europe”), pursuant to which Citibank Europe has established a letter of credit facility under which Citibank Europe provides a commitment to issue letters of credit for the accounts of the participants in multiple currencies. On November 1, 2023, the aggregate committed amount of the facility was increased from \$180.0 million to \$320.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$350.0 million.

The letter of credit facility is scheduled to expire on December 31, 2026. At all times during which it is a party to the facility, each participant is obligated to pledge to Citibank Europe securities with a value that equals or exceeds the aggregate face amount of its then-outstanding letters of credit. In the case of an event of default under the facility with respect to a participant, Citibank Europe may exercise certain remedies, including terminating its commitment to such participant and taking certain actions with respect to the collateral pledged by such participant (including the sale thereof). In the facility letter, each participant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other undertakings.

At December 31, 2024, \$232.6 million aggregate face amount of letters of credit was outstanding and \$87.4 million remained unused and available to the participants under this facility.

Uncommitted, Unsecured Letter of Credit Facility with Citibank Europe

Renaissance Reinsurance, RenaissanceRe Specialty U.S., Renaissance Reinsurance U.S. and RREAG are parties to a Master Agreement for Issuance of Payment Instruments and a Facility Letter for Issuance of Payment Instruments with Citibank Europe dated March 22, 2019, as amended, which established an uncommitted, unsecured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of one or more of the applicants. The obligations of the applicants under this facility are guaranteed by RenaissanceRe.

Pursuant to the master agreement, each applicant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other customary undertakings. The master agreement contains events of default customary for facilities of this type. In the case of an event of default under the facility, Citibank Europe may exercise certain remedies, including requiring that the relevant applicant pledge cash collateral in an amount equal to the maximum actual and contingent liability of the issuing bank under the letters of credit and similar instruments issued for such applicant under the facility, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof). In addition, Citibank Europe may require that the relevant applicant pledge cash collateral if certain minimum ratings are not satisfied.

At December 31, 2024, the aggregate face amount of the payment instruments issued and outstanding under this facility was \$293.0 million.

Unsecured Letter of Credit Facility with Credit Suisse

RREAG, Renaissance Reinsurance and RenaissanceRe were parties to a letter of credit facility agreement with Credit Suisse (Switzerland) Ltd. (“Credit Suisse”) dated December 16, 2021, as amended, and which provided for a \$200.0 million committed, unsecured letter of credit facility pursuant to which Credit Suisse (or any other fronting bank acting on behalf of Credit Suisse) may issue letters of credit or similar instruments in multiple currencies for the account of RREAG or Renaissance Reinsurance. The obligations of RREAG and Renaissance Reinsurance under the agreement were guaranteed by RenaissanceRe. The facility was allowed to expire in accordance with its terms on December 31, 2024.

At December 31, 2024, letters of credit issued by Credit Suisse under the agreement were outstanding in the face amount of \$19.1 million.

Uncommitted, Unsecured Standby Letter of Credit Facility with Nordea

RREAG, Renaissance Reinsurance and RenaissanceRe are parties to a standby letter of credit agreement with Nordea Bank Abp, New York Branch (“Nordea”) dated October 3, 2024 which provides for an uncommitted, unsecured facility pursuant to which Nordea may issue standby letters of credit in multiple currencies for the accounts of RREAG and Renaissance Reinsurance. Pursuant to the agreement, RREAG and Renaissance Reinsurance may request letters of credit up to an aggregate amount of \$250.0 million. The obligations of RREAG and Renaissance Reinsurance under the agreement are guaranteed by RenaissanceRe.

At December 31, 2024, letters of credit issued by Nordea under the agreement were outstanding in the face amount of \$45.3 million.

Uncommitted Letter of Credit Facility with Société Générale

Renaissance Reinsurance is party to a letter of credit reimbursement agreement with Société Générale, New York Branch (“SocGen”), dated September 8, 2022, which provides for a \$250.0 million uncommitted letter of credit facility under which Renaissance Reinsurance may request either secured or unsecured letters of credit in multiple currencies for the account of Renaissance Reinsurance, subject to secured letters of credit comprising at least 40% of the maximum aggregate amount.

In the agreement, Renaissance Reinsurance makes representations, warranties and covenants that are customary for facilities of this type, and agrees to comply with certain informational and other customary undertakings. The agreement also contains certain financial covenants applicable to the Renaissance Reinsurance customary for facilities of this type.

The agreement contains events of default customary for facilities of this type. At any time on or after the occurrence of an event of default, SocGen may exercise remedies, including requiring that Renaissance Reinsurance pledge cash collateral in an amount equal to the maximum liability of the issuing bank under the unsecured letters of credit and similar instruments issued under the agreement, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof).

At December 31, 2024, letters of credit issued by SocGen under the agreement were outstanding in the face amount of \$Nil.

Vermeer Letter of Credit Facility with Citibank Europe

Vermeer Reinsurance Ltd. (“Vermeer”) is party to an uncommitted, secured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of the applicant. The obligations of Vermeer under this facility are not guaranteed by RenaissanceRe.

At December 31, 2024, the aggregate face amount of letters of credit outstanding under this facility was \$9.4 million.

Medici

RenaissanceRe Medici Fund Ltd. (“Medici”) and RenaissanceRe Fund Management Ltd. (“RFM”) are parties to a revolving credit facility, as amended, pursuant to which National Australia Bank Limited provides for a revolving commitment to Medici of \$75.0 million. The obligations of Medici and RFM under this facility are not guaranteed by RenaissanceRe.

At December 31, 2024, the face amount of the outstanding revolving credit facility was \$Nil.

Top Layer

Renaissance Reinsurance is party to a collateralized letter of credit and reimbursement agreement in the amount of \$37.5 million that supports the Company’s Top Layer joint venture. Renaissance Reinsurance is obligated to make a mandatory capital contribution of up to \$50.0 million in the event that a loss reduces Top Layer’s capital below a specified level.

XML 37 R18.htm IDEA: XBRL DOCUMENT

NONCONTROLLING INTERESTS

Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest [Abstract] NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS

A summary of the Company’s redeemable noncontrolling interests on its consolidated balance sheets is set forth below:

At December 31,	2024	2023
Redeemable noncontrolling interest - DaVinci	\$ 3,061,708	\$ 2,541,482
Redeemable noncontrolling interest - Medici	1,646,745	1,650,229
Redeemable noncontrolling interest - Vermeer	1,799,857	1,555,297
Redeemable noncontrolling interest - Fontana	469,439	353,823
Redeemable noncontrolling interests	<u>\$ 6,977,749</u>	<u>\$ 6,100,831</u>

A summary of the Company’s redeemable noncontrolling interests on its consolidated statements of operations is set forth below:

Year ended December 31,	2024	2023	2022
Redeemable noncontrolling interest - DaVinci	\$ 627,055	\$ 545,812	\$ (65,514)
Redeemable noncontrolling interest - Medici	202,941	239,250	(70,504)
Redeemable noncontrolling interest - Vermeer	244,560	239,457	43,058
Redeemable noncontrolling interest - Fontana	15,616	34,476	(5,653)
Net income (loss) attributable to redeemable noncontrolling interests	\$ 1,090,172	\$ 1,058,995	\$ (98,613)

Redeemable Noncontrolling Interest - DaVinci

DaVinci is a managed joint venture formed by RenaissanceRe principally to write property catastrophe reinsurance and certain casualty and specialty reinsurance lines of business on a global basis through its wholly-owned subsidiary, DaVinci Reinsurance. RenaissanceRe owns a noncontrolling economic interest in DaVinci; however, because RenaissanceRe controls a majority of DaVinci's outstanding voting rights, the Company consolidates DaVinci and all significant intercompany transactions have been eliminated. The portion of DaVinci's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company's noncontrolling economic ownership in DaVinci was 25.4% at December 31, 2024 (2023 - 27.8%).

DaVinci shareholders are party to a shareholders' agreement which provides DaVinci shareholders, excluding RenaissanceRe, with certain redemption rights that enable each shareholder to notify DaVinci of such shareholder's desire for DaVinci to repurchase up to half of such shareholder's initial aggregate number of shares held, subject to certain limitations, such as limiting the aggregate of all share repurchase requests to 25% of DaVinci's capital in any given year and satisfying all applicable regulatory requirements. If total shareholder requests exceed 25% of DaVinci's capital, the number of shares repurchased will be reduced among the requesting shareholders pro-rata, based on the amounts desired to be repurchased. Shareholders desiring to have DaVinci repurchase their shares must notify DaVinci before March 1 of each year. The repurchase price will be based on GAAP book value as of the end of the year in which the shareholder notice is given, and the repurchase will be effective as of December 31 of that year. The repurchase price can be subject to a holdback and true-up for potential development on outstanding loss reserves. Similarly, when shares are issued by DaVinci and sold to DaVinci shareholders, the sale price is based on GAAP book value and can be subject to a true-up for potential development on outstanding loss reserves.

2024

During 2024, RenaissanceRe sold an aggregate of \$300.0 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$225.9 million of shares from other third-party investors. In addition, DaVinci distributed \$180.6 million to third-party investors and \$69.4 million to the Company. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 25.4%.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received cash inflows of \$69.7 million from subscriptions of shares in DaVinci by third-party investors, and paid \$225.9 million as a result of redemptions of shares from and distributions to third-party investors.

Refer to "Note 21. Subsequent Events" for additional information related to the Company's noncontrolling economic ownership in DaVinci subsequent to December 31, 2024.

2023

During 2023, DaVinci completed an equity capital raise of \$250.0 million, comprised of \$102.2 million from third-party investors and \$147.8 million from RenaissanceRe. In addition, RenaissanceRe sold an aggregate of \$275.0 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$123.3 million of shares from other third-party investors. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 27.8%.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$300.0 million subscriptions of shares in DaVinci by third-party investors, and paid \$123.3 million as a result of redemptions of shares from third-party investors.

The Company expects its noncontrolling economic ownership in DaVinci to fluctuate over time.

The activity in redeemable noncontrolling interest - DaVinci is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 2,541,482	\$ 1,740,300
Redemption of shares from redeemable noncontrolling interests	(406,849)	(123,272)
Sale of shares to redeemable noncontrolling interests, net of adjustments	300,020	378,642
Net income (loss) attributable to redeemable noncontrolling interest	627,055	545,812
Ending balance	\$ 3,061,708	\$ 2,541,482

Redeemable Noncontrolling Interest - Medici

Medici is an exempted company, incorporated in Bermuda and registered as an institutional fund. Medici invests, primarily on behalf of third-party investors, in various instruments that have returns primarily tied to property catastrophe risk. RenaissanceRe owns a noncontrolling economic interest in Medici; however, because RenaissanceRe controls all of Medici's issued voting shares, the Company consolidates Medici and all significant intercompany transactions have been eliminated. The portion of Medici's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. Any shareholder may redeem all or any portion of its shares as of the last day of any calendar month, upon at least 30 calendar days' prior irrevocable written notice to Medici.

2024

During 2024, investors subscribed for \$250.2 million, including \$50.6 million from the Company. In addition, investors redeemed \$382.0 million, of the participating, non-voting common shares of Medici, including \$0.3 million from the Company. Third party investors also received \$24.6 million in dividends. As a result of these transactions, the Company's noncontrolling economic ownership in Medici was 15.8% at December 31, 2024.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received cash inflows of \$163.6 million from subscriptions of shares in Medici by third-party investors and paid \$361.8 million as a result of redemptions of shares from and dividends to third-party investors.

Refer to "Note 21. Subsequent Events" for additional information related to the Company's noncontrolling economic ownership in Medici subsequent to December 31, 2024.

2023

During 2023, investors subscribed for \$527.3 million, including \$45.2 million from the Company, and redeemed \$117.5 million, including \$10.0 million from the Company, of the participating, non-voting common shares of Medici. As a result of these net subscriptions, the Company's noncontrolling economic ownership in Medici was 11.7% at December 31, 2023.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$531.4 million from subscriptions of shares in Medici by third-party investors, and paid \$102.2 million as a result of redemptions of shares from third-party investors.

The Company expects its noncontrolling economic ownership in Medici to fluctuate over time.

The activity in redeemable noncontrolling interest - Medici is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 1,650,229	\$ 1,036,218
Redemption of shares from redeemable noncontrolling interests	(406,644)	(107,549)
Sale of shares to redeemable noncontrolling interests	200,219	482,310
Net income (loss) attributable to redeemable noncontrolling interest	202,941	239,250
Ending balance	\$ 1,646,745	\$ 1,650,229

Redeemable Noncontrolling Interest - Vermeer

Vermeer is a managed joint venture formed by RenaissanceRe to provide capacity focused on risk remote layers in the U.S. property catastrophe market. RenaissanceRe owns 100% of the voting non-participating shares of Vermeer, while the sole third-party investor, Stichting Pensioenfonds Zorg en Welzijn ("PFZW"), a pension fund represented by PGGM Vermogensbeheer B.V., a Dutch pension fund manager, owns 100% of the non-voting participating shares of Vermeer and retains all of the economic benefits. The Company has concluded that Vermeer is a VIE as it has voting rights that are not proportional to its participating rights, and the Company is the primary beneficiary of Vermeer, as it has power over the activities that most significantly impact the economic performance of Vermeer. As a result, the Company consolidates Vermeer and all significant inter-company transactions have been eliminated. As PFZW owns all of the economics of Vermeer, all of Vermeer's earnings are allocated to PFZW in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company has not provided any financial or other support to Vermeer that it was not contractually required to provide.

2024

During 2024, Vermeer declared and paid \$175.0 million of dividends to PFZW. In addition, PFZW subscribed for \$175.0 million of participating, non-voting common shares of Vermeer.

2023

During 2023, Vermeer declared and paid \$175.0 million of dividends to PFZW.

The Company does not expect its noncontrolling economic ownership in Vermeer to fluctuate over time.

The activity in redeemable noncontrolling interest - Vermeer is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 1,555,297	\$ 1,490,840
Dividends on common shares	(175,000)	(175,000)
Sale of shares to redeemable noncontrolling interest	175,000	—
Net income (loss) attributable to redeemable noncontrolling interest	244,560	239,457
Ending balance	\$ 1,799,857	\$ 1,555,297

Redeemable Noncontrolling Interest - Fontana

Fontana Holdings L.P. and its subsidiaries (collectively, "Fontana") are a managed joint venture formed by the Company to assume casualty and specialty risks in line with the Company's book of business. RenaissanceRe owns a noncontrolling economic interest in Fontana and controls a majority of Fontana's outstanding voting rights. The Company concluded that Fontana meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with Fontana and concluded it is the primary beneficiary of Fontana, as it has power over the activities that most significantly impact the economic performance of Fontana. As a result, the Company consolidates Fontana and all significant inter-company transactions have been eliminated. The portion of Fontana's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. The Company may be obligated to repurchase all or a portion of the limited partner interest held by shareholders of Fontana upon request, subject to certain restrictions. The Company has not provided any financial or other support to Fontana that it was not contractually required to provide.

2024

During 2024, investors subscribed for \$100.0 million of the limited partner interest of Fontana, including \$50.0 million from the Company. In addition, RenaissanceRe sold an aggregate of \$50.0 million of its limited partner interest in Fontana to other third-party investors. As a result of these transactions, the Company's noncontrolling economic ownership in Fontana was 26.5% at December 31, 2024.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received \$129.2 million subscriptions of shares in Fontana by third-party investors.

Refer to "Note 21. Subsequent Events" for additional information related to the Company's noncontrolling economic ownership in Fontana subsequent to December 31, 2024.

2023

During 2023, investors subscribed for \$75.0 million of the limited partner interest of Fontana, including \$23.7 million from the Company. As a result of these subscriptions, the Company's noncontrolling economic ownership in Fontana remained at 31.6% at December 31, 2023.

The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$151.3 million from subscriptions of shares in Fontana by third-party investors.

The Company's investment in Fontana may fluctuate, perhaps materially, in future quarters.

The activity in redeemable noncontrolling interest - Fontana is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 353,823	\$ 268,031
Sale of limited partner interest to redeemable noncontrolling interest	100,000	51,316
Net income (loss) attributable to redeemable noncontrolling interest	15,616	34,476
Ending balance	\$ 469,439	\$ 353,823

[XML 38 R19.htm IDEA: XBRL DOCUMENT](#)

VARIABLE INTEREST ENTITIES

[Organization](#),
[Consolidation and Presentation of Financial Statements](#)
[\[Abstract\]](#)

VARIABLE INTEREST ENTITIES

12 Months Ended
Dec. 31, 2024

VARIABLE INTEREST ENTITIES

Upsilon RFO

Upsilon RFO Re Ltd. (“Upsilon RFO”) is an exempted company incorporated in Bermuda. It is registered as a segregated accounts company and as a collateralized insurer. Upsilon RFO currently has four segregated accounts (Upsilon RFO Diversified I, II, III and IV). RenaissanceRe indirectly owns a portion of the participating non-voting preference shares of three of the existing segregated accounts of Upsilon RFO (Upsilon RFO Diversified I, II and III) and all of Upsilon RFO’s voting Class A shares. The shareholders (other than the voting Class A shareholder) participate in all of the profits or losses of Upsilon RFO while their shares remain outstanding. The shareholders (other than the voting Class A shareholder) indemnify

Upsilon RFO against losses relating to insurance risk, and therefore these shares have been accounted for as prospective reinsurance under FASB ASC Topic 944, *Financial Services - Insurance*.

Upsilon RFO is considered a VIE as it has insufficient equity capital to finance its activities without additional financial support. The Company is the primary beneficiary of Upsilon RFO Diversified I, II and III as it has the power over the activities that most significantly impact the economic performance of those segregated accounts and has the obligation to absorb expected losses and the right to receive expected benefits that could be significant to those segregated accounts, in accordance with the accounting guidance. As a result, the Company consolidates Upsilon RFO Diversified I, II and III and all significant inter-company transactions have been eliminated.

The Company has determined that it is not the primary beneficiary of Upsilon RFO Diversified IV, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to that segregated account, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of Upsilon RFO Diversified IV. The Company does not have, and does not expect to have, a material investment in Upsilon RFO Diversified IV. In addition, the Company expects its absolute and relative ownership in Upsilon RFO Diversified IV to remain minimal.

Other than its equity investments in Upsilon RFO, the Company has not provided financial or other support to Upsilon RFO that it was not contractually required to provide.

2024

During 2024, and following the release of collateral that was previously held by cedants associated with prior underwriting years’ contracts, Upsilon RFO returned \$397.6 million of capital to investors of Upsilon RFO Diversified I, II and III, including \$59.8 million to the Company. At December 31, 2024, the Company’s participation in the risks assumed by Upsilon RFO Diversified I, II and III was 12.7%.

At December 31, 2024, the Company’s consolidated balance sheet included total assets and total liabilities of Upsilon RFO Diversified I, II and III of \$1.9 billion and \$1.9 billion, respectively (December 31, 2023 - \$2.4 billion and \$2.4 billion, respectively). Of the total assets and liabilities of Upsilon RFO Diversified I, II and III, a net amount of \$60.5 million (December 31, 2023 - \$74.2 million) is attributable to the Company, and \$282.2 million (December 31, 2023 - \$500.0 million) is attributable to third-party investors. Of the total assets and liabilities of Upsilon RFO Diversified IV, a net amount of \$115.9 million (December 31, 2023 - \$88.3 million) is attributable to third-party investors.

2023

During 2023, and following the release of collateral that was previously held by cedants associated with prior underwriting years’ contracts, Upsilon RFO returned \$988.5 million of capital to investors of Upsilon RFO Diversified I, II and III, including \$125.5 million to the Company. In addition, Upsilon RFO issued \$39.8 million of non-voting preference shares to existing investors, including \$10.2 million to the Company, and \$1.4 million of non-voting preference shares to external investors of Upsilon RFO Diversified IV. At December 31, 2023, the Company’s participation in the risks assumed by Upsilon RFO Diversified I, II and III was 14.3%.

Upsilon Diversified

RenaissanceRe Upsilon Diversified Fund (“Upsilon Diversified”) is a segregated account of RenaissanceRe Upsilon Fund Ltd., (“Upsilon Fund”), an exempted company incorporated in Bermuda which is registered as a segregated accounts company and a Class A Professional Fund. Upsilon Diversified provides a fund structure through which investors can invest in reinsurance risk managed by the Company, which includes investments in Upsilon RFO and Medici. The Company concluded that Upsilon Diversified meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with Upsilon Diversified and concluded it is not the primary beneficiary of Upsilon Diversified, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to Upsilon Diversified, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of Upsilon Diversified. Upsilon Diversified meets the definition of an investment company in accordance with accounting guidance, and accordingly, is required to account for all of its investments, including its investments in Upsilon RFO and Medici, at fair value. The Company does

not have, has not previously had, and does not expect to have, a material investment in Upsilon Diversified. In addition, the Company expects its absolute and relative ownership in Upsilon Diversified to remain minimal. Other than its current equity investment in Upsilon Diversified, the Company has not provided financial or other support to Upsilon Diversified that it was not contractually required to provide. The total assets of Upsilon Diversified principally reflect its investment in Upsilon RFO.

2024

During 2024, and following the release of collateral from Upsilon RFO, Upsilon Diversified returned \$333.4 million of capital to investors, including \$0.5 million to the Company. In addition, third-party investors subscribed for \$16.9 million of non-voting preference shares. The fair value of the Company’s indirect equity ownership in Upsilon Diversified is included in investments in other ventures and was \$0.5 million at December 31, 2024 (December 31, 2023 - \$0.8 million). At December 31, 2024, the total assets and total liabilities of Upsilon Diversified were \$440.6 million and \$140.9 million, respectively (December 31, 2023 - \$600.8 million and \$108.0 million, respectively). Upsilon Diversified’s investment in Upsilon RFO was valued at \$304.0 million at December 31, 2024 (December 31, 2023 - \$503.1 million).

2023

During 2023, and following the release of collateral from Upsilon RFO, Upsilon Diversified returned \$844.1 million of capital to investors, including \$1.2 million to the Company. In addition, Upsilon Diversified issued \$30.0 million of non-voting preference shares to existing investors, including \$0.1 million to the Company.

NOC1

NOC1 is a segregated account of Upsilon Fund formed in 2023, that provides a fund structure through which investors can invest in a portfolio of insurance-linked securities, principally catastrophe bonds. The Company concluded that NOC1 meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with NOC1 and concluded it is not the primary beneficiary of NOC1, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to NOC1, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of NOC1. The Company does not have, and does not expect to have, a material investment in NOC 1 and expects its absolute and relative ownership in NOC1 to remain minimal. Other than its current equity investment in NOC1, the Company has not provided financial or other support to NOC1 that it was not contractually required to provide.

2024

During 2024, NOC1 issued \$20.0 million of non-voting preference shares to existing investors, including \$0.2 million to the Company. During the year ended December 31, 2024, NOC1 redeemed \$48.8 million of non-voting preference shares to existing investors, including \$0.5 million to the Company. The fair value of the Company’s indirect equity ownership in NOC1 is included in investments in other ventures and was \$1.7 million at December 31, 2024 (December 31, 2023 - \$1.7 million). At December 31, 2024, the total assets and total liabilities of NOC1 were \$173.4 million and \$2.2 million, respectively (December 31, 2023 - \$196.5 million and \$22.8 million, respectively).

2023

During 2023, NOC1 issued \$161.5 million of non-voting preference shares to existing investors, including \$1.6 million to the Company.

Vermeer

Vermeer provides capacity focused on risk remote layers in the U.S. property catastrophe market. Refer to “Note 10. Noncontrolling Interests” for additional information regarding Vermeer.

At December 31, 2024, the Company’s consolidated balance sheet included total assets and total liabilities of Vermeer of \$1.9 billion and \$93.0 million, respectively (2023 - \$1.7 billion and \$102.7 million, respectively). In addition, the Company’s consolidated balance sheet included redeemable noncontrolling interests associated with Vermeer of \$1.8 billion at December 31, 2024 (2023 - \$1.6 billion).

Fontana

Fontana provides reinsurance capacity focused on business written within the Company’s Casualty and Specialty segment. Refer to “Note 10. Noncontrolling Interests” for additional information regarding Fontana.

At December 31, 2024, the Company’s consolidated balance sheet included total assets and total liabilities of Fontana of \$2.2 billion and \$1.6 billion, respectively (2023 - \$1.5 billion and \$968.5 million, respectively). In addition, the Company’s consolidated balance sheet included redeemable noncontrolling interests associated with Fontana of \$469.4 million at December 31, 2024 (2023 - \$353.8 million).

Mona Lisa Re Ltd.

Mona Lisa Re Ltd. (“Mona Lisa Re”), a Bermuda domiciled special purpose insurer (“SPI”), provides reinsurance capacity to subsidiaries of RenaissanceRe through reinsurance agreements which are collateralized and funded by Mona Lisa Re through the issuance of one or more series of principal-at-risk variable rate notes to third-party investors.

Upon issuance of a series of notes by Mona Lisa Re, all of the proceeds from the issuance are deposited into collateral accounts, separated by series, to fund any potential obligation under the reinsurance agreements entered into with Renaissance Reinsurance and/or DaVinci Reinsurance underlying such series of notes. The outstanding principal amount of each series of notes generally will be returned to holders of such notes upon the expiration of the risk period underlying such notes, unless an event occurs which causes a loss under the applicable series of notes, in which case the amount returned will be reduced by such noteholder’s pro rata share of such loss, as specified in the applicable governing documents of such notes. In addition, holders of such notes are generally entitled to interest payments, payable quarterly, as determined by the applicable governing documents of each series of notes.

The Company concluded that Mona Lisa Re meets the definition of a VIE as it does not have sufficient equity capital to finance its activities. The Company evaluated its relationship with Mona Lisa Re and concluded it is not the primary beneficiary of Mona Lisa Re as it does not have the power over the activities that most significantly impact the economic performance of Mona Lisa Re, in accordance with the accounting guidance. As a result, the financial position and results of operations of Mona Lisa Re are not consolidated by the Company.

The only transactions related to Mona Lisa Re that are recorded in the Company’s consolidated financial statements are the ceded reinsurance agreements entered into by Renaissance Reinsurance and DaVinci Reinsurance which are accounted for as prospective reinsurance under FASB ASC Topic 944, *Financial Services - Insurance*, and the fair value of the principal-at-risk variable rate notes owned by the Company. Other than its investment in the principal-at-risk variable rate notes of Mona Lisa Re, the Company has not provided financial or other support to Mona Lisa Re that it was not contractually required to provide.

Renaissance Reinsurance and DaVinci Reinsurance have together entered into ceded reinsurance contracts with Mona Lisa Re with ceded premiums written of \$45.2 million and \$11.7 million, respectively, during 2024 (2023 - \$32.8 million and \$8.2 million, respectively, 2022 - \$39.6 million and \$9.9 million, respectively). In addition, Renaissance Reinsurance and DaVinci Reinsurance recognized ceded premiums earned related to the ceded reinsurance contracts with Mona Lisa Re of \$39.5 million and \$10.3 million, respectively, during 2024 (2023 - \$32.8 million and \$8.2 million, respectively, 2022 - \$39.4 million and \$9.8 million, respectively).

The following table is a summary of the principal-at-risk variable notes, outstanding at December 31, 2024, Mona Lisa Re issued to investors:

Effective Date	Total Principal Amount
December 3, 2024	\$ 350,000
June 13, 2024	150,000
December 20, 2022	85,000
December 20, 2022	100,000
June 29, 2021	250,000

At December 31, 2024, the total assets and total liabilities of Mona Lisa Re were \$936.1 million and \$936.1 million, respectively (2023 - \$436.9 million and \$436.9 million, respectively).

The fair value of the Company’s investment in the principal-at-risk variable rate notes of Mona Lisa Re is included in other investments. Net of third-party investors, the fair value of the Company’s investment in Mona Lisa Re was \$7.0 million at December 31, 2024 (2023 - \$2.2 million).

Tailwind Re Ltd.

Tailwind Re Ltd. (“Tailwind Re”), a Bermuda domiciled SPI provides reinsurance capacity to subsidiaries of RenaissanceRe through reinsurance agreements which are collateralized and funded by Tailwind Re through the issuance of one or more series of principal-at-risk variable rate notes to third-party investors and the Company.

Upon issuance of a series of notes by Tailwind Re, all of the proceeds from the issuance were deposited into collateral accounts, separated by series, to fund any potential obligation under the reinsurance agreements entered into with Validus underlying such series of notes. The outstanding principal amount of each series of notes generally will be returned to holders of such notes upon the expiration of the risk period underlying such notes, unless an event occurs which causes a loss under the applicable series of notes, in which case the amount returned will be reduced by such noteholder's pro rata share of such loss, as specified in the applicable governing documents of such notes. In addition, holders of such notes are generally entitled to interest payments, payable quarterly, as determined by the applicable governing documents of each series of notes.

The Company concluded that Tailwind Re meets the definition of a VIE as it does not have sufficient equity capital to finance its activities. The Company evaluated its relationship with Tailwind Re and concluded it is not the primary beneficiary of Tailwind Re as it does not have the power over the activities that most significantly impact the economic performance of Tailwind Re, in accordance with the accounting guidance. As a result, the financial position and results of operations of Tailwind Re are not consolidated by the Company.

The only transactions related to Tailwind Re that are recorded in the Company's consolidated financial statements are the ceded reinsurance agreements entered into by certain former Validus entities, which are accounted for as prospective reinsurance under FASB ASC Topic 944, *Financial Services - Insurance*, and, as at December 31, 2023, the fair value of the principal-at-risk variable rate notes owned by the Company. Other than its investment in the principal-at-risk variable rate notes of Tailwind Re, which were held as at December 31, 2023 but were fully redeemed in the first quarter of 2024, the Company has not provided financial or other support to Tailwind Re that it was not contractually required to provide.

The Company recognized ceded premiums written related to the ceded reinsurance contracts with Tailwind Re of \$42.7 million during 2024 (2023 - \$Nil). In addition, the Company recognized ceded premiums earned related to the ceded reinsurance contracts with Tailwind Re of \$42.7 million during 2024 (2023 - \$6.5 million). At December 31, 2024, the total assets and total liabilities of Tailwind Re were \$416.8 million and \$416.8 million, respectively (2023 - \$417.1 million and \$417.1 million, respectively).

The fair value of the Company's investment in the principal-at-risk variable rate notes of Tailwind Re is included in other investments. Net of third-party investors, the fair value of the Company's investment in Tailwind Re was \$Nil at December 31, 2024 (2023 - \$0.8 million).

AlphaCat

In connection with the Validus Acquisition, the Company acquired AlphaCat Managers Ltd. ("AlphaCat Managers"), which manages third-party capital in various forms, including through closed-end and open-end Bermuda mutual funds and one managed account (collectively, the "AlphaCat Funds"), which currently generates fee income. The AlphaCat Funds are primarily funded by third-party capital investors. The AlphaCat Funds are invested in various risk-linked instruments through variable funding notes issued by AlphaCat Reinsurance Ltd. ("AlphaCat Re"), AlphaCat Master Fund Ltd. and OmegaCat Reinsurance Ltd. ("OmegaCat Re"), which give investors access to a range of property catastrophe risks. Prior to the Validus Acquisition, substantially all of the AlphaCat Funds had received full redemption requests from their investors and capital was being released accordingly, subject to certain constraints. The Company expects to run off the business over a period of time.

The Company concluded that the AlphaCat Funds, AlphaCat Re and OmegaCat Re meet the definition of VIEs as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns.

The Company evaluated its relationship with the AlphaCat Funds, AlphaCat Re and OmegaCat Re and concluded it is not the primary beneficiary as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to the AlphaCat Funds, AlphaCat Re and OmegaCat Re, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of the AlphaCat Funds, AlphaCat Re and OmegaCat Re. The Company has not provided financial or other support to the AlphaCat Funds, AlphaCat Re and OmegaCat Re that it was not contractually required to provide. The total assets of the AlphaCat Funds, AlphaCat Re and OmegaCat Re principally reflect their investments in OmegaCat Re and AlphaCat Re.

The fair value of the Company's direct equity ownership in the AlphaCat Funds and AlphaCat Re is included in other investments and was \$3.6 million at December 31, 2024 (2023 - \$4.4 million). At December 31, 2024, the total assets and total liabilities of the AlphaCat Funds, AlphaCat Re and OmegaCat Re were \$3.0 billion and \$1.3 billion, respectively (2023 - \$5.0 billion and \$2.4 billion, respectively).

Fund Investments

The Company's fund investments represent variable interests in limited partnerships entities with unaffiliated fund managers in the normal course of business. Refer to "Note 6. Fair Value Measurements" for additional information.

[XML 39 R20.htm IDEA: XBRL DOCUMENT](#)

SHAREHOLDERS' EQUITY
[Stockholders' Equity Note \[Abstract\]](#)
[SHAREHOLDERS' EQUITY](#)

12 Months Ended
Dec. 31, 2024

SHAREHOLDERS' EQUITY

Authorized Capital

The aggregate authorized capital of RenaissanceRe is 325 million shares consisting of 225 million common shares and 100 million preference shares. The following table is a summary of changes in common shares issued and outstanding:

Year ended December 31, (thousands of shares)	2024	2023	2022
Beginning balance	52,694	43,718	44,445
Issuance of shares	—	8,568	—
Repurchase of shares	(2,711)	—	(1,051)
Issuance of performance share and restricted stock awards	198	408	324
Ending balance	50,181	52,694	43,718

Common Shares

On May 26, 2023, the Company completed an offering of 7,245,000 of its common shares at the public offering price of \$192.00 per share. The Company received net proceeds of approximately \$1,352 million from the equity offering after deducting the underwriting discounts and estimated offering expenses payable by the Company. The Company used the net proceeds from this offering to fund a portion of the cash consideration for the Validus Acquisition, which closed on November 1, 2023, to pay related costs and expenses, and for general corporate purposes.

On November 1, 2023, the Company issued 1,322,541 of its common shares to AIG pursuant to the Stock Purchase Agreement, as a part of the total consideration for the Validus Acquisition.

See "Note 3. Acquisition of Validus" for additional information regarding the Validus Acquisition.

Preference Shares

Series F Preference Shares

In June 2018, RenaissanceRe raised \$250.0 million through the issuance of 10,000 shares of its 5.75% Series F Preference Shares, \$1.00 par value and liquidation preference \$25,000 per share (equivalent to 10,000,000 Depositary Shares, each of which represents a 1/1,000th interest in a 5.75% Series F

Preference Share). The 5.75% Series F Preference Shares may be redeemed at a redemption price of \$25,000 per share (equivalent to \$25.00 per Depositary Share), plus declared and unpaid dividends, at RenaissanceRe's option on or after June 30, 2023, provided that no redemption may occur prior to June 30, 2028 unless certain redemption requirements are met.

Series G Preference Shares

In July 2021, RenaissanceRe raised \$500.0 million through the issuance of 20,000 shares of its 4.20% Series G Preference Shares, \$1.00 par value and liquidation preference \$25,000 per share (equivalent to 20,000,000 Depositary Shares, each of which represents a 1/1,000th interest in a 4.20% Series G Preference Share). The 4.20% Series G Preference Shares have no stated maturity date and may be redeemed at a redemption price of \$25,000 per share (equivalent to \$25.00 per Depositary Share), plus declared and unpaid dividends, at RenaissanceRe's option on or after July 15, 2026, provided that no redemption may occur prior to July 15, 2026 unless certain redemption requirements are met.

The preference shares have no stated maturity and are not convertible into any other securities of RenaissanceRe. Generally, the preference shares have no voting rights. Whenever dividends payable on the preference shares are in arrears (whether or not such dividends have been earned or declared) in an amount equivalent to dividends for six full dividend periods (whether or not consecutive), the holders of the preference shares, voting as a single class regardless of class or series, will have the right to elect two directors to the Board of Directors of RenaissanceRe.

Dividends

The Board of RenaissanceRe declared quarterly dividends of \$0.39 per common share, payable to common shareholders of record on March 15, 2024, June 14, 2024, September 13, 2024 and December 13, 2024, and the Company paid the dividends on March 29, 2024, June 28, 2024, September 30, 2024 and December 31, 2024.

The Board of Directors approved the payment of quarterly dividends on each of the series of RenaissanceRe's preference shares to preference shareholders of record in the amounts and on the quarterly record dates and dividend payment dates set forth in the prospectus supplement and Certificate of Designation for the applicable series of preference shares, unless and until further action is taken by the Board of Directors. The dividend payment dates for the preference shares will be the first day of March, June, September and December of each year (or if this date is not a business day, on the business day immediately following this date). The record dates for the preference share dividends are one day prior to the dividend payment dates.

The amount of the dividend on the 5.750% Series F Preference Shares is an amount per share equal to 5.750% of the liquidation preference per annum (the equivalent to \$1,437.50 per 5.750% Series F Preference Share per annum, or \$359.375 per 5.750% Series F Preference Share per quarter, or \$1.4375 per Depositary Share per annum, or \$0.359375 per Depositary Share per quarter). The amount of the dividend on the 4.20% Series G Preference Shares is an amount per share equal to 4.20% of the liquidation preference per annum (the equivalent to \$1,050 per 4.20% Series G Preference Share per annum, or \$262.50 per 4.20% Series G Preference Share per quarter, or \$1.05 per Depositary Share per annum, or \$0.2625 per quarter).

During 2024, the Company paid \$35.4 million in preference share dividends (2023 - \$35.4 million, 2022 - \$35.4 million) and \$80.8 million in common share dividends (2023 - \$75.1 million, 2022 - \$64.7 million).

Share Repurchases

The Company's share repurchase program may be effected from time to time, depending on market conditions and other factors, through open market purchases and privately negotiated transactions. On November 6, 2024, RenaissanceRe's Board approved an increase in its authorized share repurchase program to an aggregate amount of up to \$750.0 million. Unless terminated earlier by RenaissanceRe's Board, the program will expire when the Company has repurchased the full value of the common shares authorized. During 2024, the Company repurchased 2,711,234 common shares at an aggregate cost of \$677.6 million and an average price of \$249.93 per common share. At December 31, 2024, \$287.7 million remained available for repurchase under the share repurchase program. In the future, the Company may authorize additional purchase activities under the currently authorized share repurchase program, increase the amount authorized under the share repurchase program, or adopt additional trading plans. The

Company's decision to repurchase common shares will depend on, among other matters, the market price of the common shares and the capital requirements of the Company.

Refer to Note 21. "Subsequent Events" for additional information related to the share repurchase program subsequent to December 31, 2024.

[XML 40 R21.htm IDEA: XBRL DOCUMENT](#)

EARNINGS PER SHARE
[Earnings Per Share \[Abstract\]](#)
[EARNINGS PER SHARE](#)

12 Months Ended
Dec. 31, 2024

The following table sets forth the computation of basic and diluted earnings per common share:

Year ended December 31, (common shares in thousands)	2024	2023	2022
Numerator:			
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 1,834,985	\$ 2,525,757	\$ (1,096,578)
Amount allocated to participating common shareholders ⁽¹⁾	(27,472)	(37,308)	(1,079)
Net income (loss) allocated to RenaissanceRe common shareholders	\$ 1,807,513	\$ 2,488,449	\$ (1,097,657)
Denominator:			
Denominator for basic income (loss) per RenaissanceRe common share - weighted average common shares ⁽²⁾	51,186	47,493	43,040
Per common share equivalents of non-vested shares ⁽²⁾	153	114	—
Denominator for diluted income (loss) per RenaissanceRe common share - adjusted weighted average common shares and assumed conversions ⁽²⁾	51,339	47,607	43,040
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - basic	\$ 35.31	\$ 52.40	\$ (25.50)
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - diluted	\$ 35.21	\$ 52.27	\$ (25.50)

(1) Represents earnings and dividends attributable to holders of unvested shares issued pursuant to the Company's stock compensation plans.
(2) In periods for which the Company has net loss allocated to RenaissanceRe common shareholders, the denominator used in calculating net loss attributable to RenaissanceRe common shareholders per common share - basic is also used in calculating net loss attributable to RenaissanceRe common shareholders per common share - diluted. For the year ended December 31, 2022, per common share equivalents of non-vested shares of 90 thousand could potentially be dilutive in future periods if the Company reports net income allocated to RenaissanceRe common shareholders.

RELATED PARTY
TRANSACTIONS AND
MAJOR CUSTOMERS

[Related Party
Transactions
\[Abstract\]](#)

RELATED PARTY
TRANSACTIONS AND
MAJOR CUSTOMERS

12 Months Ended

Dec. 31, 2024

RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS

Tower Hill

The Company has entered into reinsurance and other arrangements with certain subsidiaries and affiliates of Tower Hill and has also entered into reinsurance arrangements with respect to business produced by the Tower Hill Companies.

During 2024, the Company recorded \$115.1 million (2023 - \$96.8 million, 2022 - \$82.0 million) of gross premiums written assumed from the Tower Hill Companies and its subsidiaries and affiliates. Gross premiums earned totaled \$119.0 million (2023 - \$83.3 million, 2022 - \$80.0 million) and expenses incurred were \$14.2 million (2023 - \$12.7 million, 2022 - \$15.8 million) for 2024. The Company had a net related outstanding receivable balance of \$31.9 million as of December 31, 2024 (2023 - receivable of \$37.0 million). During 2024, the Company assumed net claims and claim expenses of \$94.5 million (2023 - recovered net claims and claim expenses of \$9.8 million, 2022 - assumed net claims and claim expenses of \$68.6 million) and, as of December 31, 2024, had a net reserve for claims and claim expenses of \$95.2 million (2023 - \$50.2 million).

In addition, the Company received distributions of \$34.4 million from the Tower Hill Companies during 2024 (2023 - \$22.6 million, 2022 - \$10.5 million).

Top Layer

During 2024, the Company received distributions from Top Layer of \$16.8 million (2023 - \$7.8 million, 2022 - \$8.7 million), and recorded a management fee of \$3.0 million (2023 - \$3.4 million, 2022 - \$2.4 million). The management fee reimburses the Company for services it provides to Top Layer.

Broker Concentration

During 2024, the Company received 82.1% of its gross premiums written (2023 - 84.3%, 2022 - 82.2%) from three brokers. Subsidiaries and affiliates of Aon plc, Marsh & McLennan Companies, Inc. and Arthur J. Gallagher accounted for 32.0%, 36.5% and 13.6%, respectively, of the Company's gross premiums written in 2024 (2023 - 36.1%, 33.2% and 15.0%, respectively).

TAXATION

[Income Tax
Disclosure \[Abstract\]](#)
[TAXATION](#)

12 Months Ended

Dec. 31, 2024

TAXATION

Through December 31, 2024 RenaissanceRe and its Bermuda subsidiaries were not subject to any income or capital gains taxes in Bermuda. A 15% corporate income tax applies to the Company's Bermuda operations, except for the Bermuda operations of the Company's joint ventures and managed funds, starting in 2025 as a result of the enactment of the Bermuda Corporate Income Tax Act 2023 ("CIT") on December 27, 2023. Furthermore, the Company generally expects that the profits generated in Bermuda on or after January 1, 2025 by the Company's joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the global anti-base erosion model rules ("GloBE Rules") by many of the jurisdictions in which the Company operates. As a result, the Company expects its income taxes to increase beginning in 2025.

RenaissanceRe Finance and its subsidiaries are subject to income taxes imposed by U.S. federal and state authorities and file a consolidated U.S. federal income tax return. Should the U.S. subsidiaries pay a dividend to RenaissanceRe, withholding taxes would apply to the extent of current year or accumulated earnings and profits at an expected tax rate of 5.0%. The Company has not accrued withholding taxes on the unremitted earnings of RenaissanceRe Finance to date as there is no intention to remit such earnings. The cumulative amount that would be subject to withholding tax, if distributed, is not practicable to compute. The Company also has operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, Canada and Australia which are subject to income taxes imposed by the respective jurisdictions in which they operate. Withholding taxes would not be expected to apply to dividends paid to RenaissanceRe from its operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, and Australia.

The following is a summary of the Company's income (loss) before taxes allocated between domestic and foreign operations:

Year ended December 31,	2024	2023	2022
Domestic			
Bermuda	\$ 2,704,721	\$ 2,622,066	\$ (672,950)
Foreign			
Singapore	61,570	64,003	112
Ireland	2,650	1,730	6
U.S.	93,606	308,768	(367,799)
Australia	14,487	7,570	(29,214)
Switzerland	57,585	(22,016)	(72,773)
Luxembourg	(50)	(16)	—
Canada	(3,501)	2,040	—
U.K.	62,092	125,915	(76,217)
Income (loss) before taxes	\$ 2,993,160	\$ 3,110,060	\$ (1,218,835)

Income tax benefit (expense) is comprised as follows:

Income tax benefit (expense)	Current	Deferred	Total
Year ended December 31, 2024	\$ (56,718)	\$ 24,090	\$ (32,628)
Year ended December 31, 2023	\$ (57,422)	\$ 567,489	\$ 510,067
Year ended December 31, 2022	\$ (3,078)	\$ 62,097	\$ 59,019

The Company's expected income tax provision computed on pre-tax income (loss) at the weighted average tax rate has been calculated as the sum of the pre-tax income (loss) in each jurisdiction multiplied by that jurisdiction's applicable statutory tax rate. Statutory tax rates of 0.0% in Bermuda, 21.0% in the U.S., 12.5% in Ireland, 25.0% in the U.K., 17.0% in Singapore, 19.7% in Switzerland, 24.9% in Luxembourg, 26.5% in Canada and 30.0% in Australia have been used.

The Company's effective income tax rate, which it calculates as income tax benefit (expense) divided by income (loss) before taxes, may fluctuate significantly from period to period depending on the geographic distribution of pre-tax income (loss) in any given period between different jurisdictions with comparatively higher tax rates and those with comparatively lower tax rates. The geographic distribution of pre-tax income (loss) can vary significantly between periods due to, but not limited to, the following factors: the business mix of net premiums written and earned; the geographic location, the size and the nature of net claims and claim expenses incurred; the amount and geographic location of operational expenses, net investment income, net realized and unrealized gains (losses) on investments; outstanding debt and related interest expense; and the amount of specific adjustments to determine the income tax basis in each of the Company's operating jurisdictions. In addition, a significant portion of the Company's gross and net premiums are currently written and earned in Bermuda, which does not currently have a corporate income tax, including the majority of the Company's catastrophe business, which can result in significant volatility to its pre-tax net income (loss) in any given period. The Company expects its consolidated effective tax rate will increase in 2025 as a result of the enactment of the CIT in Bermuda and the implementation of the GloBE Rules in certain jurisdictions where it operates. In addition, it is possible the Company could be adversely affected by other future changes in tax laws, regulation, or enforcement, any of which could increase the effective tax rate more rapidly or steeply than currently anticipated.

A reconciliation of the difference between the provision for income taxes and the expected tax provision at the weighted average tax rate is as follows:

Year ended December 31,	2024	2023	2022
Expected income tax benefit (expense)	\$ (60,684)	\$ (103,963)	\$ 114,721
Non deductible expenses	(1,671)	(535)	(508)
Reinsurance adjustment	4,384	4,746	(1,265)
Effect of change in tax rate	(160)	(729)	7,461
OECD Pillar Two global minimum tax	(16,603)	—	—
GAAP to statutory accounting difference	(1,113)	(1,781)	(6,019)
Withholding tax	(1,614)	(1,078)	(2,154)
Recognition of Bermuda net deferred tax asset	8,339	593,765	—
Change in valuation allowance	66,198	45,192	(62,133)
Foreign branch adjustments	(30,998)	(25,908)	11,656
Other	1,294	358	(2,740)
Income tax benefit (expense)	\$ (32,628)	\$ 510,067	\$ 59,019

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below:

At December 31,	2024	2023
Deferred tax assets		
Intangible assets	\$ 420,143	\$ 408,654
Value of in-force business	167,599	167,599
Tax loss carryforwards	152,864	197,498
Reserve for claims and claim expenses	131,121	95,685
Unearned premiums	59,441	68,408
Amortization and depreciation	23,877	16,386
Deferred finance charges	17,832	19,442
Accrued expenses	4,336	2,849
Investments	2,687	37,044
Deferred underwriting results	1,548	9,373
	981,448	1,022,938
Deferred tax liabilities		
Deferred acquisition expenses	(125,347)	(112,157)
VOBA	(17,540)	(46,109)
Deferred revenue	(8,685)	—
U.S. tax accounting method change	(7,312)	—
	(158,884)	(158,266)
Net deferred tax asset (liability) before valuation allowance	822,564	864,672
Valuation allowance	(147,079)	(213,277)
Net deferred tax asset (liability)	\$ 675,485	\$ 651,395

A substantial amount of the Company's net deferred tax asset is separately reflected as an asset in the consolidated balance sheets with the remaining net deferred tax liability recorded in other liabilities.

The Company's net deferred tax asset primarily relates to net operating loss and capital loss carryforwards, unrealized losses in the U.S. investment portfolio, and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, value of in-force business, intangible assets, VOBA, deferred acquisition expenses and amortization and depreciation. The Company's valuation allowance assessment is based on all available information including projections of future GAAP taxable income from each tax-paying component in each tax jurisdiction. During 2024, the Company recorded a net decrease to the valuation allowance of \$66.2 million (2023 - increase of \$19.6 million, 2022 - increase of \$62.1 million).

A valuation allowance has been provided against certain deferred tax assets in the U.S., Canada, Ireland, the U.K., Luxembourg and Switzerland. These deferred tax assets relate primarily to net operating loss carryforwards, deferred finance charges, capital loss carryforwards and unrealized losses in the U.S. investment portfolio.

In the U.S. and Switzerland, the Company has net operating loss carryforwards of \$97.3 million and \$350.0 million respectively. Under applicable law, the U.S. and Swiss net operating loss carryforwards will

begin to expire in 2037 and 2025 respectively. The Company has net operating loss carryforwards of \$141.2 million in the U.K., \$8.3 million in Ireland, and \$155.7 million in Luxembourg. Under applicable law, the U.K., Ireland and Luxembourg net operating losses can be carried forward for an indefinite period. The Company has capital loss carryforwards of \$131.6 million in the U.S. that begin to expire in 2027. The Company has unrealized losses in the U.S. investment portfolio of \$60.6 million. These unrealized investment losses do not expire. However, if realized, these losses may only offset realized capital gains and would expire, if unused, at the end of the fifth taxable year following their realization.

The Company made net payments for U.S. federal and state, Canada, Ireland, U.K., Singapore, Switzerland and Australia income taxes of \$99.5 million for the year ended 2024 (2023 - net payments of \$26.8 million, 2022 - net payments of \$3.1 million).

The Company had no unrecognized tax benefits at December 31, 2024 and December 31, 2023. Interest and penalties related to unrecognized tax benefits would be recognized in income tax expense. At December 31, 2024 and December 31, 2023, there were no interest or penalties accrued on unrecognized tax benefits.

The following filed income tax returns are open for examination with the applicable tax authorities: tax years 2018 through 2023 with the U.S.; 2020 through 2023 with Ireland; 2022 through 2023 with the U.K.; 2020 through 2023 with Singapore; 2021 through 2023 with Switzerland; 2020 through 2023 with Australia; 2020 through 2023 with Canada; and 2019 through 2023 with Luxembourg. The Company does not expect the resolution of these open years to have a significant impact on its consolidated statements of operations and financial condition.

[XML 43 R24.htm IDEA: XBRL DOCUMENT](#)

SEGMENT REPORTING

[Segment Reporting.](#)
[Measurement](#)
[Disclosures](#)
[\[Abstract\]](#)

SEGMENT REPORTING

The Company's reportable segments are defined as follows: (1) Property, which is comprised of catastrophe and other property (re)insurance written on behalf of the Company's consolidated operating subsidiaries, joint ventures and managed funds, and (2) Casualty and Specialty, which is comprised of casualty and specialty (re)insurance written on behalf of the Company's consolidated operating subsidiaries, joint ventures and managed funds. In addition to its reportable segments, the Company has an Other category, which primarily includes its investments unit, strategic investments, corporate expenses, capital servicing costs, noncontrolling interests and certain expenses related to acquisitions and dispositions.

The Company's reportable segments each have executive leadership who are responsible for the overall performance of their respective segments and who are directly accountable to the Company's chief operating decision maker ("CODM"), the Chief Executive Officer of RenaissanceRe, who is ultimately responsible for reviewing the business to assess performance, make operating decisions and allocate resources. The Company reports the results of its operations consistent with the manner in which the CODM reviews the business.

The Company does not manage its assets by segment; accordingly, net investment income and total assets are not allocated to the segments.

A summary of the significant components of the Company's revenues and expenses by segment is as follows:

Year ended December 31, 2024	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 4,823,731	\$ 6,909,335	\$ —	\$ 11,733,066
Net premiums written	\$ 3,833,636	\$ 6,118,580	\$ —	\$ 9,952,216
Net premiums earned	\$ 3,850,352	\$ 6,245,408	\$ —	\$ 10,095,760
Net claims and claim expenses incurred	\$ 1,141,726	\$ 4,191,255	\$ —	\$ 5,332,981
Acquisition expenses	758,554	1,885,313	—	2,643,867
Operational expenses	302,360	194,228	—	496,588
Underwriting income (loss)	\$ 1,647,712	\$ (25,388)	\$ —	\$ 1,622,324
Net investment income	—	—	1,654,289	1,654,289
Net foreign exchange gains (losses)	—	—	(76,076)	(76,076)
Equity in earnings (losses) of other ventures	—	—	47,087	47,087
Other income (loss)	—	—	1,928	1,928
Net realized and unrealized gains (losses) on investments	—	—	(27,840)	(27,840)
Corporate expenses	—	—	(134,784)	(134,784)
Interest expense	—	—	(93,768)	(93,768)
Income (loss) before taxes	—	—	—	2,993,160
Income tax benefit (expense)	—	—	(32,628)	(32,628)
Net (income) loss attributable to redeemable noncontrolling interests	—	—	(1,090,172)	(1,090,172)
Dividends on preference shares	—	—	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	—	—	—	\$ 1,834,985
Net claims and claim expenses incurred - current accident year	\$ 1,960,578	\$ 4,223,737	\$ —	\$ 6,184,315
Net claims and claim expenses incurred - prior accident years	(818,852)	(32,482)	—	(851,334)
Net claims and claim expenses incurred - total	\$ 1,141,726	\$ 4,191,255	\$ —	\$ 5,332,981
Net claims and claim expense ratio - current accident year	50.9 %	67.6 %	—	61.3 %
Net claims and claim expense ratio - prior accident years	(21.2)%	(0.5)%	—	(8.5)%
Net claims and claim expense ratio - calendar year	29.7 %	67.1 %	—	52.8 %
Underwriting expense ratio	27.5 %	33.3 %	—	31.1 %
Combined ratio	57.2 %	100.4 %	—	83.9 %

Year ended December 31, 2023	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 3,562,414	\$ 5,299,952	\$ —	\$ 8,862,366
Net premiums written	\$ 2,967,309	\$ 4,500,504	\$ —	\$ 7,467,813
Net premiums earned	\$ 3,090,792	\$ 4,380,341	\$ —	\$ 7,471,133
Net claims and claim expenses incurred	799,905	2,773,604	—	3,573,509
Acquisition expenses	600,127	1,274,907	—	1,875,034
Operational expenses	251,433	123,749	—	375,182
Underwriting income (loss)	\$ 1,439,327	\$ 208,081	\$ —	\$ 1,647,408
Net investment income	—	—	1,253,110	1,253,110
Net foreign exchange gains (losses)	—	—	(41,479)	(41,479)
Equity in earnings (losses) of other ventures	—	—	43,474	43,474
Other income (loss)	—	—	(6,152)	(6,152)
Net realized and unrealized gains (losses) on investments	—	—	414,522	414,522
Corporate expenses	—	—	(127,642)	(127,642)
Interest expense	—	—	(73,181)	(73,181)
Income (loss) before taxes	—	—	—	3,110,060
Income tax benefit (expense)	—	—	510,067	510,067
Net (income) loss attributable to redeemable noncontrolling interests	—	—	(1,058,995)	(1,058,995)
Dividends on preference shares	—	—	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	—	—	—	\$ 2,525,757
Net claims and claim expenses incurred - current accident year	\$ 1,208,810	\$ 2,815,306	\$ —	\$ 4,024,116
Net claims and claim expenses incurred - prior accident years	(408,905)	(41,702)	—	(450,607)
Net claims and claim expenses incurred - total	\$ 799,905	\$ 2,773,604	\$ —	\$ 3,573,509
Net claims and claim expense ratio - current accident year	39.1 %	64.3 %	—	53.9 %
Net claims and claim expense ratio - prior accident years	(13.2)%	(1.0)%	—	(6.1)%
Net claims and claim expense ratio - calendar year	25.9 %	63.3 %	—	47.8 %
Underwriting expense ratio	27.5 %	31.9 %	—	30.1 %
Combined ratio	53.4 %	95.2 %	—	77.9 %

Year ended December 31, 2022	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 3,734,241	\$ 5,479,299	\$ —	\$ 9,213,540
Net premiums written	\$ 2,847,659	\$ 4,348,501	\$ —	\$ 7,196,160
Net premiums earned	\$ 2,770,227	\$ 3,563,762	\$ —	\$ 6,333,989
Net claims and claim expenses incurred	2,044,771	2,294,069	—	4,338,840
Acquisition expenses	547,210	1,021,396	—	1,568,606
Operational expenses	194,355	82,336	—	276,691
Underwriting income (loss)	\$ (16,109)	\$ 165,561	\$ —	\$ 149,852
Net investment income	—	—	559,932	559,932
Net foreign exchange gains (losses)	—	—	(56,909)	(56,909)
Equity in earnings (losses) of other ventures	—	—	11,249	11,249
Other income (loss)	—	—	12,636	12,636
Net realized and unrealized gains (losses) on investments	—	—	(1,800,485)	(1,800,485)
Corporate expenses	—	—	(46,775)	(46,775)
Interest expense	—	—	(48,335)	(48,335)
Income (loss) before taxes	—	—	—	(1,218,835)
Income tax benefit (expense)	—	—	59,019	59,019
Net (income) loss attributable to redeemable noncontrolling interests	—	—	98,613	98,613
Dividends on preference shares	—	—	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	—	—	—	\$ (1,096,578)
Net claims and claim expenses incurred - current accident year	\$ 2,250,512	\$ 2,335,910	\$ —	\$ 4,586,422
Net claims and claim expenses incurred - prior accident years	(205,741)	(41,841)	—	(247,582)
Net claims and claim expenses incurred - total	\$ 2,044,771	\$ 2,294,069	\$ —	\$ 4,338,840
Net claims and claim expense ratio - current accident year	81.2 %	65.2 %	—	72.2 %
Net claims and claim expense ratio - prior accident years	(7.4)%	(1.3)%	—	(3.9)%
Net claims and claim expense ratio - calendar year	73.2 %	64.2 %	—	68.5 %
Underwriting expense ratio	26.2 %	30.2 %	—	29.2 %
Combined ratio	100.6 %	95.3 %	—	97.2 %

The following is a summary of the Company's gross premiums written allocated to the territory of coverage exposure:

Year ended December 31,	2024		2023		2022	
	Gross Premiums Written	Percentage of Gross Premiums Written	Gross Premiums Written	Percentage of Gross Premiums Written	Gross Premiums Written	Percentage of Gross Premiums Written
Property						
U.S. and Caribbean	\$ 2,996,981	25.5 %	\$ 2,303,013	26.0 %	\$ 2,343,830	25.5 %
Worldwide	1,063,292	9.1 %	798,623	9.0 %	1,053,369	11.4 %
Europe	244,523	2.1 %	163,500	1.9 %	62,998	0.7 %
Worldwide (excluding U.S.) ⁽¹⁾	180,688	1.5 %	70,646	0.8 %	37,436	0.4 %
Japan	106,533	0.9 %	85,823	1.0 %	104,767	1.1 %
Australia and New Zealand	101,976	0.9 %	70,107	0.8 %	86,080	0.9 %
Other	129,738	1.1 %	70,702	0.8 %	45,761	0.5 %
Total Property	4,823,731	41.1 %	3,562,414	40.3 %	3,734,241	40.5 %
Casualty and Specialty						
Worldwide	3,217,662	27.3 %	2,280,687	25.7 %	2,328,030	25.3 %
U.S. and Caribbean	2,986,956	25.5 %	2,333,096	26.3 %	2,556,466	27.7 %
Europe	353,863	3.0 %	197,228	2.2 %	327,831	3.6 %
Worldwide (excluding U.S.) ⁽¹⁾	195,489	1.7 %	130,334	1.5 %	177,746	1.9 %
Australia and New Zealand	43,183	0.4 %	27,397	0.3 %	35,973	0.4 %
Other	112,182	1.0 %	331,210	3.7 %	53,253	0.6 %
Total Casualty and Specialty	6,909,335	58.9 %	5,299,952	59.7 %	5,479,299	59.5 %
Total gross premiums written	\$ 11,733,066	100.0 %	\$ 8,862,366	100.0 %	\$ 9,213,540	100.0 %

(1) The category "Worldwide (excluding U.S.)" consists of contracts that cover more than one geographic region (other than the U.S.).

[XML 44 R25.htm IDEA: XBRL DOCUMENT](#)

STOCK INCENTIVE
COMPENSATION
AND EMPLOYEE
BENEFIT PLANS

[Share-Based Payment
Arrangement
\[Abstract\]](#)

[STOCK INCENTIVE
COMPENSATION AND
EMPLOYEE BENEFIT
PLANS](#)

STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS

Stock Incentive Compensation Plans and Awards

The Company is authorized to issue restricted stock awards, restricted stock units, performance share awards, stock options and other share-based awards to its employees and directors pursuant to various stock incentive compensation plans.

On May 16, 2022, the Company’s shareholders approved the Company’s First Amended and Restated 2016 Long-Term Incentive Plan, which amended and restated the plan initially approved by the shareholders in May 2016 (as amended from time to time, the “2016 Long-Term Incentive Plan”). The Company is authorized to issue up to 3,060,092 common shares pursuant to the 2016 Long-Term Incentive Plan. The 2016 Long-Term Incentive Plan permits the grant of restricted stock awards, restricted stock units, performance share awards (including cash-based performance awards), stock options and other share-based awards to employees, officers, non-employee directors and consultants or advisors of the Company and its affiliates.

In November 2016, the Company instituted a cash settled restricted stock unit (“CSRSU”) plan, the 2016 Restricted Stock Unit Plan, which allows for the issuance of equity awards in the form of CSRSUs. There are currently no outstanding awards under this plan.

Restricted Stock Awards

Restricted stock awards granted to employees under the 2016 Long-Term Incentive Plan generally vest ratably over a four-year period. Restricted stock awards granted to non-employee directors generally vest ratably over a three-year period.

Performance Share Awards

Performance share awards granted to certain of the Company’s executive officers pursuant to the 2016 Long-Term Incentive Plan are subject to vesting conditions based on both continued service and the attainment of pre-established performance goals. If performance goals are achieved, the performance

share awards will vest up to a maximum of 200% of target. Performance share awards generally cliff vest at the end of a three-year vesting period based on the attainment of performance goals over the three-year performance period.

Performance Share Awards Granted in March 2019

Performance share awards granted in March 2019 had a performance condition, which was the percentage change in the Company’s tangible book value per common share plus change in accumulated dividends, or, in the event of a change in control, a market condition, which was the Company’s total shareholder return relative to its peer group.

Performance Share Awards Granted Beginning in March 2020

Beginning with awards granted in March 2020, performance share awards have performance conditions, which are the average percentage change in the Company’s book value per common share plus change in accumulated dividends over three years and the three-year average underwriting expense ratio rank compared to peers, or, in the event of a change in control, a market condition, which is the Company’s total shareholder return relative to its peer group. The performance conditions are calculated in accordance with the terms of the applicable award agreement.

Performance Share Awards Granted to CEO in November 2023

On November 7, 2023, the Board of Directors granted performance-based restricted stock awards to the Company’s Chief Executive Officer. The performance condition is the average percentage change in the Company’s tangible book value per common share plus change in accumulated dividends over four years, commencing on January 1, 2023 and ending on December 31, 2026, or, in the event of a change in control, a market condition, which is the Company’s total shareholder return relative to its peer group. The performance conditions are calculated in accordance with the terms of the applicable award agreement.

Valuation Assumptions

Performance Share Awards Granted in March 2019

For performance share awards granted in March 2019, the performance metric related to the percentage change in tangible book value per share plus change in accumulated dividends which is classified as a performance condition under FASB ASC Topic 718, *Compensation - Stock Compensation*. As a result, the fair value of the performance share awards was determined based on the fair market value of RenaissanceRe’s common shares on the grant date. The estimated fair value of performance share awards was amortized as an expense over the requisite service period.

Performance Share Awards Granted Beginning in March 2020

For performance share awards granted beginning in March 2020, the performance metrics relate to (i) the percentage change in book value per share plus change in accumulated dividends and (ii) average underwriting expense ratio rank compared to peers, both of which are classified as performance conditions under FASB ASC Topic 718, *Compensation - Stock Compensation*. As a result, the fair value of the performance share awards is determined based on the fair market value of RenaissanceRe’s common shares on the grant date. The estimated fair value of performance share awards is amortized as an expense over the requisite service period.

Restricted Stock Awards

The fair value of restricted stock awards is determined based on the fair market value of RenaissanceRe’s common shares on the grant date. The estimated fair value of restricted stock awards is amortized as an expense over the requisite service period. The Company has elected to recognize forfeitures as they occurred rather than estimating service-based forfeitures over the requisite service period.

Summary of Stock Compensation Activity

Performance Share Awards

The following table provides a roll forward of the Company’s unvested performance share awards:

	Number of Shares ⁽¹⁾	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	141,068	\$ 163.98
Awards granted	69,548	145.49
Awards forfeited	(19,352)	—
Nonvested at December 31, 2022	191,264	\$ 159.07
Awards granted	160,796	211.18
Awards vested	(38,846)	170.40
Awards forfeited	(26,994)	—
Nonvested at December 31, 2023	286,220	\$ 185.73
Awards granted	50,654	223.35
Awards vested	(53,083)	162.61
Awards forfeited	(2,793)	—
Nonvested at December 31, 2024	280,998	\$ 197.11

(1) For performance share awards, the number of shares is stated at the maximum number that can be attained if the performance conditions are fully met. Forfeitures represent shares forfeited due to vesting below the maximum attainable as a result of the Company not fully meeting the performance conditions.

Restricted Stock Awards

The following table provides a roll forward of the Company’s unvested restricted stock awards:

	Employee Restricted Stock Awards		Non-Employee Director Restricted Stock Awards		Total Restricted Stock Awards	
	Number of Shares	Weighted Average Grant Date Fair Value	Number of Shares	Weighted Average Grant Date Fair Value	Number of Shares	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	623,332	\$ 153.02	20,601	\$ 162.60	643,933	\$ 153.32
Awards granted	354,887	143.86	12,721	145.77	367,608	143.92
Awards vested	(242,628)	148.30	(12,307)	159.20	(254,935)	148.83
Awards forfeited	(22,795)	—	—	—	(22,795)	—
Nonvested at December 31, 2022	712,796	\$ 150.19	21,015	\$ 154.40	733,811	\$ 150.31
Awards granted	378,994	199.24	9,064	215.79	388,058	199.65
Awards vested	(279,363)	151.15	(11,861)	161.56	(291,224)	151.57
Awards forfeited	(15,278)	—	—	—	(15,278)	—
Nonvested at December 31, 2023	797,149	\$ 172.74	18,218	\$ 180.70	815,367	\$ 172.91
Awards granted	260,209	234.94	8,645	223.66	268,854	234.69
Awards vested	(293,175)	164.67	(10,749)	177.16	(303,924)	165.11
Awards forfeited	(17,694)	—	—	—	(17,694)	—
Nonvested at December 31, 2024	746,489	\$ 197.26	16,114	\$ 207.95	762,603	\$ 197.49

There were 0.8 million shares available for issuance under the 2016 Long-Term Incentive Plan at December 31, 2024.

The aggregate fair value of restricted stock awards and performance share awards vested during 2024 was \$82.8 million (2023 - \$70.0 million, 2022 - \$38.8 million). In connection with share vestings, there was a \$2.0 million excess windfall tax benefit realized by the Company in 2024 (2023 - \$1.7 million, 2022 - \$0.1 million).

The total stock compensation expense recognized in the Company’s consolidated statements of operations during 2024 was \$71.4 million (2023 - \$60.3 million, 2022 - \$45.2 million). As of December 31, 2024, there was \$107.6 million of total unrecognized compensation cost related to restricted stock awards and \$17.8 million related to performance share awards, which will be recognized on a weighted average basis during the next 1.8 years and 1.8 years, respectively.

All of the Company’s employees are eligible for defined contribution pension plans. Contributions are primarily based upon a percentage of eligible compensation. The Company contributed \$12.0 million to its

XML 45 R26.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS
Insurance [Abstract]
STATUTORY REQUIREMENTS

12 Months Ended
Dec. 31, 2024

STATUTORY REQUIREMENTS

The Company's (re)insurance operations are subject to insurance laws and regulations in the jurisdictions in which they operate, the most significant of which currently include Bermuda, Switzerland, the U.K. and the U.S. These regulations include certain restrictions on the amount of dividends or other distributions, such as loans or cash advances, available to shareholders without prior approval of the respective regulatory authorities.

The following table summarizes the statutory capital and surplus and required minimum statutory capital and surplus of the Company's primary regulated insurance operations in its most significant regulatory jurisdictions:

At December 31,	Bermuda ⁽¹⁾		Switzerland ⁽²⁾		U.K. ⁽³⁾		U.S. ⁽⁴⁾	
	2024	2023	2024	2023	2024	2023	2024	2023
Statutory capital and surplus	\$ 11,793,261	\$ 12,141,907	\$ 1,908,106	\$ 2,644,998	\$ 952,309	\$ 935,776	\$ 1,255,304	\$ 1,044,010
Required statutory capital and surplus	2,686,108	2,284,208	1,049,922	987,707	952,309	935,776	967,735	794,061

- (1) Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). The Company's primary Bermuda-domiciled insurance subsidiaries' required statutory capital and surplus is based on the minimum solvency margin. On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated. The previously reported statutory capital and surplus and required statutory capital and surplus at December 31, 2023 have been updated to actual amounts filed and reflect guidance received by the BMA on February 23, 2024 related to the impact of the CIT in the statutory financial statements.
- (2) Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland (which was acquired on November 1, 2023) and its Bermuda branch. On June 21, 2024, Validus Switzerland merged into RREAG.
- (3) Includes Syndicate 1458. With respect to statutory capital and surplus and required statutory capital and surplus, underwriting capacity of a member of Lloyd's must be supported by providing a deposit in the form of cash, securities or letters of credit, which are referred to as FAL. Syndicate 1458 is capitalized by its FAL, with the related assets not held on its balance sheet.
- (4) Includes Renaissance Reinsurance U.S.

The following table summarizes the statutory net income (loss) of the Company's primary regulated insurance operations in its most significant regulatory jurisdictions:

	Statutory Net Income (Loss)			
	Bermuda ⁽¹⁾	Switzerland ⁽²⁾	U.K. ⁽³⁾	U.S. ⁽⁴⁾
Year ended December 31, 2024	\$ 2,056,265	\$ 312,000	\$ 89,169	\$ (87,897)
Year ended December 31, 2023	2,699,083	225,751	158,258	(17,618)
Year ended December 31, 2022	(706,676)	(244,035)	(24,573)	35,344

- (1) Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated.
- (2) Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland and its Bermuda branch (which was acquired on November 1, 2023). On June 21, 2024 Validus Switzerland merged into RREAG.
- (3) Includes Syndicate 1458.
- (4) Includes Renaissance Reinsurance U.S.

The difference between statutory financial statements and statements prepared in accordance with GAAP varies by jurisdiction; however, the primary difference is that for the Company's regulated entities the statutory financial statements generally do not reflect goodwill and intangible assets. Also, in the U.S., fixed maturity investments are generally recorded at amortized cost and deferred income tax is charged directly to equity. In the U.S. and Bermuda, deferred acquisition costs are generally not reflected in the statutory financial statements. In Switzerland, currency translation adjustment losses are directly charged to net income (loss), while translation gains are not admissible and reflected as translation reserve on the statutory balance sheet. In addition, fixed maturity investments are carried at the lower of amortized cost and market value and recognition of equalization reserves is allowed. The prudence principle standard also allows for valuating certain assets below their nominal value. None of the Company's insurance subsidiaries used permitted practices that prevented the trigger of a regulatory event during the years ended December 31, 2024, 2023 and 2022.

Dividend Restrictions of RenaissanceRe

As a Bermuda-domiciled holding company, RenaissanceRe has limited operations of its own. Its assets consist primarily of investments in subsidiaries and cash and securities. As a result, the Company relies primarily on dividends and distributions (and other statutorily permissible payments) from its subsidiaries, investment income and fee income to meet its liquidity requirements, which primarily include making principal and interest payments on its debt, and dividend payments to its preference and common shareholders.

The payment of dividends by the Company's subsidiaries is, under certain circumstances, limited by the applicable laws and regulations in the various jurisdictions in which the subsidiaries operate, including Bermuda, the U.S., the U.K., Switzerland, Australia, Singapore and Ireland. In addition, insurance laws require the Company's insurance subsidiaries to maintain certain measures of solvency and liquidity.

Bermuda

Bermuda-registered insurance companies are regulated under the Bermuda Insurance Act 1978, as amended, and related regulations (collectively, the "Insurance Act"), which impose various requirements depending on a company's classification under the Insurance Act. The Company and certain of its Bermuda-registered insurers are generally required to maintain available statutory economic capital and surplus at a level at least equal to their enhanced capital requirement ("ECR"), which is established by reference to the Bermuda Capital and Solvency Ratio ("BSCR") model. The ECR may be adjusted by the BMA if it concludes that the insurer's risk profile deviates significantly from the assumptions underlying its ECR or the insurer's assessment of its risk management policies and practices used to calculate the ECR. The BMA has established a target capital level applicable to certain registration categories, and to insurance groups, equal to 120% of the applicable ECR. Failure to maintain statutory capital at least equal to the target capital level would likely result in increased BMA regulatory oversight. The Company and

certain of its Bermuda-registered insurers are generally required to file an annual BSCR with the BMA. The Company's 2023 group BSCR was filed with the BMA on May 31, 2024 with a BSCR ratio of 263%.

Renaissance Reinsurance and DaVinci Reinsurance are registered as Class 4 general business insurers, RenaissanceRe Specialty U.S. and Vermeer are registered as Class 3B general business insurers, and Fontana Reinsurance Ltd. and Fontana Reinsurance U.S. Ltd. are registered as Class 3A general business insurers under the Insurance Act. Class 4, Class 3B and Class 3A insurers are required to maintain available statutory economic capital and surplus at a target capital level equal to 120% of the ECR. Unlike other (re)insurers, special purpose insurers and collateralized insurers are fully funded to meet their (re)insurance obligations. RenaissanceRe Europe AG, Bermuda Branch, a Class 3B general business insurer, has modified requirements, which are addressed under Switzerland, below.

Class 4, Class 3B and Class 3A insurers are prohibited from declaring or paying any dividends if in breach of the required minimum solvency margin or minimum liquidity ratio, or if the declaration or payment of such dividend would cause the insurer to fail to meet the required minimum solvency margin or minimum liquidity ratio. Further, certain categories of insurers are prohibited to declare or pay dividends over certain thresholds without the BMA's approval. These restrictions on declaring or paying dividends and distributions under the Insurance Act are in addition to the solvency requirements under the Bermuda Companies Act 1981.

Switzerland

RREAG is a reinsurance company licensed and supervised by the Swiss Financial Market Supervisory Authority FINMA ("FINMA").The minimum capital requirement for a Swiss reinsurance company under the Insurance Supervisory Act for reinsurance license class C1 is CHF 10 million. RREAG must further maintain adequate solvency and provide for sufficient free and unencumbered capital in relation to its activities in accordance with the Swiss Solvency Test ("SST"). The solvency requirement is met if the available risk-bearing capital exceeds the required target capital. It is then assessed whether the identified available capital can meet the SST requirements and is sufficient to cover the company's obligations in less favorable scenarios. RREAG maintains branch operations in Australia, Bermuda, the U.K. and the U.S., each in accordance with applicable local regulations, which may include statutory capital requirements.

RREAG may only distribute dividends out of its retained earnings or distributable reserves based on the audited annual accounts of the company. Any distribution of dividends remains subject to the approval of FINMA (as a change of the regulatory business plan) if they have a bearing on the solvency of the reinsurer and/or the interests of the insured. The solvency and capital requirements must still be met following any distribution.

U.K.

The underwriting capacity of a member of Lloyd's must be supported by providing a deposit, referred to as "Funds at Lloyd's" or "FAL," in the form of cash, securities or letters of credit in an amount determined under the capital adequacy regime of the U.K. Prudential Regulatory Authority ("PRA"). The amount of such deposit is calculated for each member through the completion of a quarterly capital adequacy exercise. Under these requirements, Lloyd's must demonstrate that each member has sufficient assets to meet its underwriting liabilities plus a required solvency margin. The amount of FAL for Syndicate 1458 is determined by Lloyd's and is based on Syndicate 1458's solvency and capital requirement as calculated through its internal model.

Dividends from a Lloyd's managing agent and a Lloyd's corporate member can be declared and paid provided the relevant company has sufficient profits available for distribution.

U.S.

Renaissance Reinsurance U.S. is required to meet certain minimum statutory capital and surplus requirements under Maryland law. Renaissance Reinsurance U.S. is also subject to risk-based capital ("RBC") requirements under Maryland law, and must file an annual report of its RBC levels. If the report shows Renaissance Reinsurance U.S.'s statutory capital and surplus or total adjusted capital is below certain levels, Renaissance Reinsurance U.S. may be required to take certain corrective action or the Maryland Insurance Administration ("MIA") may be permitted or required to take certain regulatory action.

Maryland law places limitations on the amounts of dividends or distributions payable by Renaissance Reinsurance U.S. At December 31, 2024, Renaissance Reinsurance U.S. had an ordinary dividend capacity of \$125.5 million which can be paid in 2025. Payment of ordinary dividends by Renaissance Reinsurance U.S. requires notice to the MIA. Declaration of an extraordinary dividend, which must be paid out of earned surplus, generally requires thirty days' prior notice to and approval or non-disapproval of the MIA. An extraordinary dividend includes any dividend whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the lesser of (1) ten percent of the insurer's surplus as regards policyholders as of December 31 of the preceding year or (2) the insurer's net investment income, excluding realized capital gains (as determined under statutory accounting principles), for the twelve month period ending December 31 of the preceding year and pro rata distributions of any class of the insurer's own securities, plus any amounts of net investment income (subject to the foregoing exclusions), in the three calendar years prior to the preceding year which have not been distributed.

Multi-Beneficiary Reinsurance Trusts

Each of Renaissance Reinsurance, DaVinci Reinsurance, and RREAG was approved as a Trustee Reinsurer and established a multi-beneficiary reinsurance trust ("MBRT") to collateralize its (re)insurance liabilities. The MBRTs are subject to rules and regulations including but not limited to certain minimum capital funding requirements, investment guidelines, capital distribution restrictions and regulatory reporting requirements.

The following table summarizes the assets held under trust and minimum amount required with respect to the MBRTs:

At December 31,	2024		2023	
	Assets Held Under Trust	Minimum Amount Required	Assets Held Under Trust	Minimum Amount Required
Renaissance Reinsurance ⁽¹⁾	\$ 954,114	\$ 554,119	\$ 1,209,808	910,646
DaVinci Reinsurance	179,849	47,179	174,352	114,203
RREAG ⁽²⁾	1,463,275	1,312,796	1,342,339	1,298,712

(1) Renaissance Reinsurance and Validus Re amalgamated on October 1, 2024. Comparative information for 2023 has been reclassified to include Validus Re.

(2) RREAG and Validus Switzerland merged on June 21, 2024, with RREAG being the successor to the MBRTs held by Validus Switzerland.

Multi-Beneficiary Reduced Collateral Reinsurance Trusts

Each of Renaissance Reinsurance, RREAG and DaVinci Reinsurance has been approved as a "certified reinsurer" eligible for collateral reduction in certain states, and are authorized to provide reduced collateral equal to 20%, 20% and 50%, respectively, of their net outstanding insurance liabilities to insurers domiciled in each of those states. Each of Renaissance Reinsurance, RREAG and DaVinci Reinsurance has established a multi-beneficiary reduced collateral reinsurance trust to collateralize its (re)insurance liabilities associated with cedants domiciled in those states. The reduced collateral reinsurance trusts are subject to rules and regulations including but not limited to certain minimum capital funding requirements, investment guidelines, capital distribution restrictions and regulatory reporting requirements.

The following table summarizes the assets held under trust and minimum amount required with respect to the reduced collateral reinsurance trusts:

At December 31,	2024		2023	
	Assets Held Under Trust	Minimum Amount Required	Assets Held Under Trust	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

XML 46 R27.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS
Summary of
Derivative
Instruments
[Abstract]
DERIVATIVE

12 Months Ended
Dec. 31, 2024

DERIVATIVE INSTRUMENTS

INSTRUMENTS

From time to time, the Company may enter into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company's derivative instruments can be exchange traded or over-the-counter, with over-the-counter derivatives generally traded under International Swaps and Derivatives Association master agreements, which establish the terms of the transactions entered into with the Company's derivative counterparties. In the event a party becomes insolvent or otherwise defaults on its obligations, a master agreement generally permits the non-defaulting party to accelerate and terminate all outstanding transactions and net the transactions' marked-to-market values so that a single sum in a single currency will be owed by, or owed to, the non-defaulting party. Effectively, this contractual close-out netting reduces credit exposure from gross to net exposure. Where the Company has entered into master netting agreements with counterparties, or the Company has the legal and contractual right to offset positions, the derivative positions are generally netted by counterparty and are reported accordingly in other assets and other liabilities.

The Company is not aware of the existence of any credit-risk related contingent features that it believes would be triggered in its derivative instruments that are in a net liability position at December 31, 2024.

The tables below show the gross and net amounts of recognized derivative assets and liabilities at fair value, including the location on the consolidated balance sheets of the Company's principal derivative instruments:

At December 31, 2024	Derivative Assets					
	Gross Amounts of Recognized Assets	Gross Amounts Offset in the Balance Sheet	Net Amounts of Assets Presented in the Balance Sheet	Balance Sheet Location	Collateral Received	Net Amount
Derivative instruments not designated as hedges						
Interest rate futures	\$ 4,198	\$ —	\$ 4,198	Other assets	\$ —	\$ 4,198
Foreign currency forward contracts ⁽¹⁾	16,275	—	16,275	Other assets	—	16,275
Foreign currency forward contracts ⁽²⁾	4,085	—	4,085	Other assets	—	4,085
Commodity futures	5,933	—	5,933	Other assets	—	5,933
Commodity options	483	—	483	Other assets	—	483
Total derivative instruments not designated as hedges	30,974	—	30,974		—	30,974
Derivative instruments designated as hedges						
Foreign currency forward contracts ⁽³⁾	3,564	—	3,564	Other assets	—	3,564
Total	\$ 34,538	\$ —	\$ 34,538		\$ —	\$ 34,538

At December 31, 2024	Derivative Liabilities					
	Gross Amounts of Recognized Liabilities	Gross Amounts Offset in the Balance Sheet	Net Amounts of Liabilities Presented in the Balance Sheet	Balance Sheet Location	Collateral Pledged	Net Amount
Derivative instruments not designated as hedges						
Interest rate futures	\$ 6,178	\$ —	\$ 6,178	Other liabilities	\$ 5,408	\$ 770
Foreign currency forward contracts ⁽¹⁾	53,160	—	53,160	Other liabilities	5,632	47,528
Foreign currency forward contracts ⁽²⁾	13,171	—	13,171	Other liabilities	—	13,171
Credit default swaps	1,675	—	1,675	Other liabilities	1,675	—
Equity futures	1,694	—	1,694	Other liabilities	—	1,694
Total derivative instruments not designated as hedges	75,878	—	75,878		12,715	63,163
Total	\$ 75,878	\$ —	\$ 75,878		\$ 12,715	\$ 63,163

(1) Contracts used to manage foreign currency risks in underwriting and non-investment operations.

(2) Contracts used to manage foreign currency risks in investment operations.

(3) Contracts designated as hedges of net investments in a foreign operation.

At December 31, 2023	Derivative Assets					
	Gross Amounts of Recognized Assets	Gross Amounts Offset in the Balance Sheet	Net Amounts of Assets Presented in the Balance Sheet	Balance Sheet Location	Collateral Received	Net Amount
Derivative instruments not designated as hedges						
Interest rate futures	\$ 13,162	\$ —	\$ 13,162	Other assets	\$ —	\$ 13,162
Foreign currency forward contracts ⁽¹⁾	16,827	—	16,827	Other assets	—	16,827
Foreign currency forward contracts ⁽²⁾	10,448	—	10,448	Other assets	—	10,448
Credit default swaps	749	—	749	Other assets	—	749
Commodity options	3,538	—	3,538	Other assets	—	3,538
Total derivative instruments not designated as hedges	44,724	—	44,724		—	44,724
Total	\$ 44,724	\$ —	\$ 44,724		\$ —	\$ 44,724

At December 31, 2023	Derivative Liabilities					
	Gross Amounts of Recognized Liabilities	Gross Amounts Offset in the Balance Sheet	Net Amounts of Liabilities Presented in the Balance Sheet	Balance Sheet Location	Collateral Pledged	Net Amount
Derivative instruments not designated as hedges						
Interest rate futures	\$ 5,768	\$ —	\$ 5,768	Other liabilities	\$ 5,720	\$ 48
Foreign currency forward contracts ⁽¹⁾	11,890	—	11,890	Other liabilities	—	11,890
Foreign currency forward contracts ⁽²⁾	2,603	—	2,603	Other liabilities	—	2,603
Credit default swaps	1,248	—	1,248	Other liabilities	1,248	—
Commodity options	3,162	—	3,162	Other liabilities	—	3,162
Commodity futures	1,441	—	1,441	Other liabilities	—	1,441
Total derivative instruments not designated as hedges	26,112	—	26,112		6,968	19,144
Derivative instruments designated as hedges						
Foreign currency forward contracts ⁽³⁾	3,879	—	3,879	Other liabilities	—	3,879
Total	\$ 29,991	\$ —	\$ 29,991		\$ 6,968	\$ 23,023

(1) Contracts used to manage foreign currency risks in underwriting and non-investment operations.

(2) Contracts used to manage foreign currency risks in investment operations.

(3) Contracts designated as hedges of net investments in a foreign operation.

The location and amount of the gain (loss) recognized in the Company's consolidated statements of operations related to its principal derivative instruments are shown in the following table:

Year ended December 31,	Location of Gain (Loss) Recognized on Derivatives	Amount of Gain (loss) Recognized on Derivatives		
		2024	2023	2022
Derivative instruments not designated as hedges				
Interest rate futures ⁽¹⁾	Net realized and unrealized gains (losses) on investments	\$ (81,400)	\$ 3,877	\$ (86,863)
Foreign currency forward contracts ⁽²⁾	Net foreign exchange gains (losses)	(27,918)	(877)	(51,401)
Foreign currency forward contracts ⁽³⁾	Net foreign exchange gains (losses)	(32,687)	(11,761)	21,689
Credit default swaps ⁽¹⁾	Net realized and unrealized gains (losses) on investments	(54,757)	(70,924)	(9,084)
Total return swaps ⁽¹⁾	Net realized and unrealized gains (losses) on investments	—	(1,928)	(6)
Equity futures ⁽⁴⁾	Net realized and unrealized gains (losses) on investments	3,379	(1,928)	(69,972)
Warrants	Net realized and unrealized gains (losses) on investments	(1,046)	—	632
Commodity options	Net realized and unrealized gains (losses) on investments	(4,517)	(4,553)	—
Commodity futures	Net realized and unrealized gains (losses) on investments	81,062	5,256	—
Total derivative instruments not designated as hedges		(117,884)	(80,910)	(195,005)
Derivative instruments designated as hedges				
Foreign currency forward contracts ⁽⁵⁾	Accumulated other comprehensive income (loss)	6,194	205	6,466
Total		\$ (111,690)	\$ (80,705)	\$ (188,539)

(1) Fixed income related derivatives included in net realized and unrealized gains (losses) on investment-related derivatives. See "Note 5. Investments" for additional information.

(2) Contracts used to manage foreign currency risks in underwriting and non-investment operations.

(3) Contracts used to manage foreign currency risks in investment operations.

(4) Equity related derivatives included in net realized and unrealized gains (losses) on investment-related derivatives. See "Note 5. Investments" for additional information.

(5) Contracts designated as hedges of net investments in a foreign operation.

Derivative Instruments Not Designated as Hedges

Interest Rate Derivatives

The Company uses interest rate futures within its portfolio of fixed maturity investments to manage its exposure to interest rate risk, which may result in increasing or decreasing its exposure to this risk.

Interest Rate Futures

The fair value of interest rate futures is determined using exchange traded prices. At December 31, 2024, the Company had \$7.1 billion of notional long positions and \$3.1 billion of notional short positions of primarily U.S. treasury and non-US government bond futures contracts (2023 - \$5.9 billion and \$2.7 billion, respectively).

Foreign Currency Derivatives

The Company's functional currency is the U.S. dollar. The Company writes a portion of its business in currencies other than U.S. dollars and may, from time to time, experience foreign exchange gains and losses in the Company's consolidated financial statements. The impact of changes in exchange rates on the

Company's assets and liabilities denominated in currencies other than the U.S. dollar, excluding non-monetary assets and liabilities, are recognized in the Company's consolidated statements of operations.

Underwriting and Non-investments Operations Related Foreign Currency Contracts

The Company's foreign currency policy with regard to its underwriting operations is generally to enter into foreign currency forward and option contracts for notional values that approximate the foreign currency liabilities, including claims and claim expense reserves and reinsurance balances payable, net of any cash, investments and receivables held in the respective foreign currency. The Company's use of foreign currency forward and option contracts is intended to minimize the effect of fluctuating foreign currencies on the value of non-U.S. dollar denominated assets and liabilities associated with its underwriting operations. The Company may determine not to match a portion of its projected underwriting related assets or liabilities with underlying foreign currency exposure with investments in the same currencies, which would increase its exposure to foreign currency fluctuations and potentially increase the impact and volatility of foreign exchange gains and losses on its results of operations. The fair value of the Company's underwriting operations related foreign currency contracts is determined using indicative pricing obtained from counterparties or broker quotes. At December 31, 2024, the Company had outstanding underwriting related foreign currency contracts of \$1.0 billion in notional long positions and \$508.8 million in notional short positions, denominated in U.S. dollars (2023 - \$805.2 million and \$496.4 million, respectively).

Investment Portfolio Related Foreign Currency Forward Contracts

The Company's investment operations are exposed to currency fluctuations through its investments in non-U.S. dollar fixed maturity investments, short term investments and other investments. From time to time, the Company may employ foreign currency forward contracts in its investment portfolio to either assume foreign currency risk or to economically hedge its exposure to currency fluctuations from these investments. The fair value of the Company's investment portfolio related foreign currency forward contracts is determined using an interpolated rate based on closing forward market rates. At December 31, 2024, the Company had outstanding investment portfolio related foreign currency contracts of \$345.0 million in notional long positions and \$107.0 million in notional short positions, denominated in U.S. dollars (2023 - \$420.7 million and \$130.0 million, respectively).

Credit Derivatives

The Company's exposure to credit risk is primarily due to its fixed maturity investments, short term investments, premiums receivable and reinsurance recoverable. From time to time, the Company may purchase credit derivatives to manage its exposures in the insurance industry, and to assist in managing the credit risk associated with ceded reinsurance. The Company also employs credit derivatives in its investment portfolio to either assume credit risk or manage its credit exposure.

Credit Default Swaps

The fair value of the Company's credit default swaps is determined using industry valuation models, broker bid indications or internal pricing valuation techniques. The fair value of these credit default swaps can change based on a variety of factors including changes in credit spreads, default rates and recovery rates, the correlation of credit risk between the referenced credit and the counterparty, and market rate inputs such as interest rates. At December 31, 2024, the Company had outstanding credit default swaps of \$1.4 billion in notional positions to protect the investment portfolio against increasing credit risk and \$Nil in notional positions to assume credit risk, denominated in U.S. dollars (2023 - \$1.5 billion and \$22.1 million, respectively).

Equity Derivatives

Equity Futures

From time to time, the Company uses equity derivatives in its investment portfolio to either assume equity risk or hedge its equity exposure. The fair value of the Company's equity futures is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had \$437.2 million of notional long positions of equity futures (2023 - \$Nil notional long positions).

Commodity Derivatives

The Company uses commodity derivatives within its investments portfolio to assume risk and manage its exposures in the insurance industry. Commodity derivatives expose the Company to potentially unfavorable price changes to the underlying commodities.

Commodity Futures

The fair value of the Company's commodity futures is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had a \$684.3 million of notional long positions of commodity futures, denominated in U.S. dollars (2023 - \$255.2 million of notional long positions).

Commodity Options

The fair value of these derivatives is determined using market-based prices from pricing vendors. At December 31, 2024, the Company had \$0.5 million of notional long positions of exchange traded commodity option contracts (2023 - \$0.4 million of notional long positions). The notional amounts for options are based on the fair value of the underlying commodities as if the options were exercised at the reporting date.

Derivative Instruments Designated as Hedges of Net Investments in Foreign Operations

Foreign Currency Derivatives

Hedges of Net Investments in Foreign Operations

One of the Company's subsidiaries currently uses a non-U.S. dollar functional currency. The Company, from time to time, enters into foreign exchange forwards to hedge non-U.S. dollar functional currencies, on an after-tax basis, from changes in the exchange rate between the U.S. dollar and these currencies.

As of December 31, 2024 and 2023, this included the Australian dollar net investment in a foreign operation. These foreign exchange forward contracts were formally designated as hedges of its investment in subsidiaries with non-U.S. dollar functional currencies and there was no ineffectiveness in these transactions.

The table below provides a summary of derivative instruments designated as hedges of net investments in a foreign operation, including the weighted average U.S. dollar equivalent of foreign denominated net assets (liabilities) that were hedged and the resulting derivative gains (losses) that are recorded in foreign currency translation adjustments, net of tax, within accumulated other comprehensive income (loss) on the Company's consolidated statements of changes in shareholders' equity:

Year ended December 31,	2024		2023	
Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities)	\$	61,120	\$	59,664
Derivative gains (losses)	\$	6,194	\$	205

XML 47 R28.htm IDEA: XBRL DOCUMENT

COMMITMENTS,
CONTINGENCIES
AND OTHER ITEMS

Commitments and
Contingencies
Disclosure [Abstract]

COMMITMENTS,
CONTINGENCIES AND
OTHER ITEMS

12 Months Ended

Dec. 31, 2024

COMMITMENTS, CONTINGENCIES AND OTHER ITEMS

Concentration of Credit Risk

Instruments which potentially subject the Company to concentration of credit risk consist principally of investments, including the Company's equity method investments, cash, premiums receivable and reinsurance balances. The Company limits the amount of credit exposure to any one financial institution and, except for the securities of the U.S. Government and U.S. Government related entities, and money market securities, none of the Company's fixed maturity and short term investments exceeded 10% of shareholders' equity at December 31, 2024. Refer to "Note 7. Reinsurance," for information with respect to reinsurance recoverable.

Employment Agreements

The Board has authorized the execution of employment agreements between the Company and certain officers. These agreements provide for, among other things, severance payments under certain circumstances, as well as accelerated vesting of options and certain restricted stock grants, upon a change in control, as defined in the employment agreements and the Company's stock incentive plan.

Letters of Credit and Other Commitments

At December 31, 2024, the Company's banks have issued secured and unsecured letters of credit totaling \$619.6 million in favor of certain ceding companies. In connection with the Company's Top Layer joint venture, Renaissance Reinsurance has committed \$37.5 million of collateral to support a letter of credit and is obligated to make a mandatory capital contribution of up to \$50.0 million in the event that a loss reduces Top Layer's capital and surplus below a specified level.

Refer to "Note 9. Debt and Credit Facilities" for additional information related to the Company's debt and credit facilities.

Investment Commitments

The Company has committed capital to direct private equity investments, fund investments and investments in other ventures of \$4.5 billion, of which \$2.5 billion has been contributed at December 31, 2024. The Company's remaining commitments to these investments at December 31, 2024 totaled \$2.0 billion. These commitments do not have a defined contractual commitment date. In the future, we may enter into additional commitments in respect of these investments or individual portfolio company investment opportunities.

Indemnifications and Warranties

In the ordinary course of its business, the Company may enter into contracts or agreements that contain indemnifications or warranties. Future events could occur that lead to the execution of these provisions against the Company. Based on past experience, management currently believes that the likelihood of such an event is remote.

Leases

The Company's operating leases primarily relate to office space for its global underwriting platforms principally in Bermuda, Australia, Ireland, Singapore, Switzerland, the U.K. and the U.S. These leases expire at various dates through 2039 with a weighted average lease term of 5.9 years. Included in other assets and other liabilities at December 31, 2024 is a right-of-use asset of \$83.8 million and a lease liability of \$114.3 million, respectively, associated with the Company's operating leases (2023 - \$72.9 million and \$103.9 million, respectively). During 2024, the Company recorded an operating lease expense of \$14.8 million included in operational expenses (2023 - \$12.8 million).

The Company's financing leases primarily relate to office space in Bermuda with an initial lease term of 20 years, ending in 2028, and a bargain renewal option for an additional 30 years. Included in other assets and other liabilities at December 31, 2024 is a right-of-use asset of \$16.1 million and a lease liability of \$21.0 million, respectively, associated with the Company's finance leases (2023 - \$16.6 million and \$21.5 million, respectively). During 2024, the Company recorded interest expense of \$2.1 million associated with its finance leases (2023 - \$2.2 million) included in interest expense and amortization of its finance leases right-to-use asset of \$0.5 million included in operational expenses (2023 - \$0.5 million).

Future minimum lease payments under existing operating and finance leases are detailed below, excluding the bargain renewal option on the finance lease related to office space in Bermuda:

	Future Minimum Lease Payments			
	Operating Leases		Finance Leases	
2025	\$	15,657	\$	2,661
2026		16,461		2,661
2027		16,439		2,661
2028		16,328		2,146
2029		15,199		—
After 2029		70,656		—
Future minimum lease payments under existing leases	\$	150,740	\$	10,129

Legal Proceedings

The Company and its subsidiaries are subject to lawsuits and regulatory actions in the normal course of business that do not arise from or directly relate to claims on reinsurance treaties or contracts or direct surplus lines insurance policies. In the Company's industry, business litigation may involve allegations of underwriting or claims-handling errors or misconduct, disputes relating to the scope of, or compliance with, the terms of delegated underwriting agreements, employment claims, regulatory actions or disputes arising from the Company's business ventures. The Company's operating subsidiaries are subject to claims litigation involving, among other things, disputed interpretations of policy coverages. Generally, the Company's direct surplus lines insurance operations are subject to greater frequency and diversity of claims and claims-related litigation than its reinsurance operations and, in some jurisdictions, may be subject to direct actions by allegedly injured persons or entities seeking damages from policyholders. These lawsuits, involving or arising out of claims on policies issued by the Company's subsidiaries which are typical to the insurance industry in general and in the normal course of business, are considered in its loss and loss expense reserves. In addition, the Company may from time to time engage in litigation or arbitration related to its claims for payment in respect of ceded reinsurance, including disputes that challenge the Company's ability to enforce its underwriting intent. Such matters could result, directly or indirectly, in providers of protection not meeting their obligations to the Company or not doing so on a timely basis. The Company may also be subject to other disputes from time to time, relating to operational or other matters distinct from insurance or reinsurance claims. Any litigation or arbitration, or regulatory process, contains an element of uncertainty, and the value of an exposure or a gain contingency related to a dispute is difficult to estimate. The Company believes that no individual litigation or arbitration to which it is presently a party is likely to have a material adverse effect on its financial condition, business or operations.

XML 48 R29.htm IDEA: XBRL DOCUMENT

SUBSEQUENT
EVENTS

Subsequent Events
[Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

Share Repurchase Program

Subsequent to December 31, 2024 and through the period ended February 7, 2025, the Company repurchased 928,880 common shares at an aggregate cost of \$227.7 million and an average price of \$245.10 per common share.

On February 5, 2025, the Board approved a renewal of the authorized share repurchase program for an aggregate amount of up to \$750 million.

DaVinci

Effective January 1, 2025, RenaissanceRe sold an aggregate of \$69.7 million of its shares in DaVinci to third-party investors and purchased an aggregate of \$26.9 million of shares from third-party investors. At December 31, 2024, \$69.7 million, representing the net amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in DaVinci subsequent to these transactions was 24.3%.

Fontana

Effective January 1, 2025, Fontana completed an equity capital raise of \$100.0 million, comprised of \$29.2 million from third-party investors and \$70.8 million from RenaissanceRe. In addition, RenaissanceRe sold an aggregate of \$100.0 million of its limited partner interest in Fontana to third-party investors and purchased an aggregate of \$72.0 million of limited partner interest in Fontana from third-party investors. At December 31, 2024, \$129.2 million, representing the net amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in Fontana subsequent to these transactions was 28.7%.

Medici

Effective in January and February 2025, Medici issued an aggregate of \$107.9 million of non-voting preference shares to investors, including \$50.1 million to the Company, and redeemed an aggregate of \$16.5 million of non-voting preference shares to investors, including \$Nil to the Company. In January 2025, Medici declared a dividend of \$15.2 million, all of which is payable to third-party investors. At December 31, 2024, \$39.0 million, representing the amount received from investors other than the Company prior to January 1, 2025, is included in other liabilities on the Company's consolidated balance sheet, and also included in cash flows provided by financing activities on the Company's consolidated statements of cash flows for the year ended December 31, 2024. The Company's noncontrolling economic ownership in Medici subsequent to these transactions was 17.7% effective February 1, 2025.

California Wildfires

The California wildfires, commencing in January 2025, have led to a range of publicly available industry insured loss estimates. The Company expects its pre-tax net negative impact to be approximately 1.5% of the California wildfires' aggregate industry insured loss. Based on a \$50 billion aggregate industry insured loss, the Company estimates a pre-tax net negative impact on net income (loss) available (attributable) to common shareholders of approximately \$750 million in the first quarter of 2025. The Company expects the wildfires will primarily impact its Property segment and, to a lesser extent, the Casualty and Specialty segment.

Net negative impact on underwriting result includes the sum of (1) net claims and claim expenses incurred, (2) assumed and ceded reinstatement premiums earned and (3) earned and lost profit commissions. Net negative impact on net income (loss) available (attributable) to RenaissanceRe common shareholders is the sum of (1) net negative impact on underwriting result and (2) redeemable noncontrolling interest, both before consideration of any related income tax benefit (expense).

The Company's assessment of the impact from the California wildfires is preliminary, and is based on, among other things, initial industry insured loss estimates, market share analysis, the application of modeling techniques, a review of in-force contracts and potential uncertainties relating to reinsurance recoveries. It is difficult at this time to provide an accurate estimate of the financial impact of the California wildfires, including as a result of the preliminary nature of the information provided thus far by industry participants, the magnitude and recency of the California wildfires, and other factors. The Company's actual net negative impact from this event will be reflected in the first quarter 2025 results of operations, when reported.

Crash of American Airlines Flight 5342

On January 29, 2025, a helicopter collided with a commercial airline flight near Ronald Reagan Washington National Airport. The Company is in the preliminary stage of assessing the impact of this event on the Company's financial results for the first quarter of 2025, and expects any impact would primarily be in the Casualty and Specialty segment. It is difficult at this time to provide an accurate estimate of the financial impact of this event given the preliminary nature of the information available, and other factors.

[XML 49 R30.htm IDEA: XBRL DOCUMENT](#)

**SCHEDULE I.
SUMMARY OF
INVESTMENTS
OTHER THAN
INVESTMENTS IN
RELATED PARTIES**

[SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties \[Abstract\]](#)

[SUMMARY OF INVESTMENTS, OTHER THAN INVESTMENTS IN RELATED PARTIES](#)

12 Months Ended

Dec. 31, 2024

**SCHEDULE I
RENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIES
SUMMARY OF INVESTMENTS
OTHER THAN INVESTMENTS IN RELATED PARTIES
(THOUSANDS OF UNITED STATES DOLLARS)**

	December 31, 2024	
	Amortized Cost or Cost	Fair Value
Amount at Which Shown in the Balance Sheet		
Type of investment:		
Fixed maturity investments trading		
U.S. treasuries	\$11,062,641	\$11,001,893
Corporate	7,919,470	7,862,423
Residential mortgage-backed	1,761,607	1,707,056
Asset-backed	1,416,132	1,422,393
Agencies	633,726	623,489
Non-U.S. government	624,381	618,809
Commercial mortgage-backed	332,583	326,451
Total fixed maturity investments trading	23,750,540	23,562,514
Short term investments	\$ 4,532,166	4,531,655
Equity investments		117,756
Other investments		
Fund investments		2,128,499
Catastrophe bonds		1,984,396
Direct private equity investments		211,866
Total other investments		4,324,761
Investments in other ventures, under equity method		102,770
Total investments	\$32,639,456	\$ 32,639,456

[XML 50 R31.htm IDEA: XBRL DOCUMENT](#)

**SCHEDULE II.
CONDENSED
FINANCIAL
INFORMATION OF
REGISTRANT**

[Condensed Financial Information Disclosure \[Abstract\]](#)
[CONDENSED FINANCIAL INFORMATION OF REGISTRANT](#)

12 Months Ended

Dec. 31, 2024

**SCHEDULE II
RENAISSANCERE HOLDINGS LTD.
CONDENSED FINANCIAL INFORMATION OF REGISTRANT
RENAISSANCERE HOLDINGS LTD.
BALANCE SHEETS
AT DECEMBER 31, 2024 AND 2023
(PARENT COMPANY)
(THOUSANDS OF UNITED STATES DOLLARS)**

	At December 31,	
	2024	2023
Assets		
Fixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil)	\$ 153,504	\$ —
Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917)	131,236	277,917
Total investments	284,740	277,917
Cash and cash equivalents	20,054	45,080
Investments in subsidiaries	10,732,129	9,632,226
Due from subsidiaries	7,919	52,816
Accrued investment income	1,052	—
Deferred tax asset	10,334	33,646
Receivable for investments sold	1,329	2,849
Other assets	681,322	660,818
Goodwill and other intangible assets	98,662	101,509
Total assets	\$ 11,837,541	\$ 10,806,861
Liabilities and Shareholders' Equity		
Liabilities		
Debt	\$ 1,138,119	\$ 1,136,260
Due to subsidiaries	17,051	136,729
Other liabilities	108,359	78,915
Total liabilities	1,263,529	1,351,904
Shareholders' Equity		
Preference shares: \$1.00 par value - 30,000 shares issued and outstanding at December 31, 2024 (2023 - 30,000)	750,000	750,000
Common shares: \$1.00 par value - 50,180,987 shares issued and outstanding at December 31, 2024 (2023 - 52,693,887)	50,181	52,694
Additional paid-in capital	1,512,435	2,144,459
Accumulated other comprehensive income (loss)	(14,756)	(14,211)
Retained earnings	8,276,152	6,522,015
Total shareholders' equity attributable to RenaissanceRe	10,574,012	9,454,957
Total liabilities and shareholders' equity	\$ 11,837,541	\$ 10,806,861

**SCHEDULE II
RENAISSANCERE HOLDINGS LTD.
CONDENSED FINANCIAL INFORMATION OF REGISTRANT - CONTINUED
RENAISSANCERE HOLDINGS LTD.
STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022
(PARENT COMPANY)
(THOUSANDS OF UNITED STATES DOLLARS)**

	Year ended December 31,		
	2024	2023	2022
Revenues			
Net investment income	\$ 58,166	\$ 97,395	\$ 46,966
Net foreign exchange gains (losses)	(23,916)	1,129	(46,796)
Other income (loss)	(95)	(907)	—
Net realized and unrealized gains (losses) on investments	(4,840)	(73,572)	(3,017)
Total revenues	29,315	24,045	(2,847)
Expenses			
Operational expenses	15,866	32,066	14,818
Corporate expenses	86,314	98,493	39,614
Interest expense	59,384	40,416	15,315
Total expenses	161,564	170,975	69,747
Income (loss) before equity in net income (loss) of subsidiaries	(132,249)	(146,930)	(72,594)
Equity in net income (loss) of subsidiaries	2,017,805	2,708,061	(988,610)
Income (loss) before taxes	1,885,556	2,561,131	(1,061,204)
Income tax benefit (expense)	(15,196)	—	—
Net income (loss)	1,870,360	2,561,131	(1,061,204)
Dividends on preference shares	(35,375)	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 1,834,985	\$ 2,525,756	\$ (1,096,579)

**RENAISSANCERE HOLDINGS LTD.
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022
(PARENT COMPANY)
(THOUSANDS OF UNITED STATES DOLLARS)**

	Year ended December 31,		
	2024	2023	2022
Comprehensive income (loss)			
Net income (loss)	\$ 1,870,360	\$ 2,561,131	\$ (1,061,204)
Change in net unrealized gains (losses) on investments, net of tax	1,045	1,082	(4,923)
Foreign currency translation adjustments, net of tax	(1,590)	169	370
Comprehensive income (loss) attributable to RenaissanceRe	\$ 1,869,815	\$ 2,562,382	\$ (1,065,757)

**SCHEDULE II
RENAISSANCERE HOLDINGS LTD.
CONDENSED FINANCIAL INFORMATION OF REGISTRANT - CONTINUED**

**RENAISSANCERE HOLDINGS LTD.
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022
(PARENT COMPANY)
(THOUSANDS OF UNITED STATES DOLLARS)**

	Year ended December 31,		
	2024	2023	2022
Cash flows provided by (used in) operating activities:			
Net income (loss)	\$ 1,870,360	\$ 2,561,131	\$ (1,061,204)
Less: equity in net income (loss) of subsidiaries	(2,017,805)	(2,708,061)	988,610
	(147,445)	(146,930)	(72,594)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities			
Net realized and unrealized (gains) losses on investments	334	67,868	2,051
Other	142,051	72,691	36,601
Net cash provided by (used in) operating activities	(5,060)	(6,371)	(33,942)
Cash flows provided by (used in) investing activities:			
Proceeds from sales and maturities of fixed maturity investments trading	309,490	1,613,740	198,341
Purchases of fixed maturity investments trading	(387,276)	(1,505,160)	(375,804)
Net sales (purchases) of short term investments	147,296	(211,370)	(21,037)
Dividends and return of capital from subsidiaries	1,079,438	1,097,301	1,009,108
Contributions to subsidiaries	(247,147)	(169,204)	(349,336)
Due to (from) subsidiary	(115,041)	(7,088)	(178,470)
Due to (from) subsidiary for the purchase of Validus Specialty	—	(45,467)	—
Purchase of Validus Holdings and Talbot Treaty Renewal Rights	—	(2,689,533)	—
Net cash provided by (used in) investing activities	786,760	(1,916,781)	282,802
Cash flows provided by (used in) financing activities:			
Dividends paid – RenaissanceRe common shares	(80,850)	(75,112)	(64,675)
Dividends paid – preference shares	(35,375)	(35,375)	(35,396)
RenaissanceRe common share repurchases	(666,921)	—	(166,664)
RenaissanceRe common share issuance, net of expenses	—	1,351,608	—
Issuance of debt, net of expenses	—	740,581	—
Taxes paid on withholding shares	(23,580)	(20,518)	(10,911)
Net cash provided by (used in) financing activities	(806,726)	1,961,184	(277,646)
Effect of exchange rate changes on foreign currency cash	—	—	—
Net increase (decrease) in cash and cash equivalents	(25,026)	38,032	(28,786)
Cash and cash equivalents, beginning of year	45,080	7,048	35,834
Cash and cash equivalents, end of year	\$ 20,054	\$ 45,080	\$ 7,048

[XML 51 R32.htm IDEA: XBRL DOCUMENT](#)

**SCHEDULE III.
SUPPLEMENTARY
INSURANCE
INFORMATION**

[SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information \[Abstract\]](#)

[Supplementary Insurance Information](#)

12 Months Ended

Dec. 31, 2024

**SCHEDULE III
RENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIES
SUPPLEMENTARY INSURANCE INFORMATION
(THOUSANDS OF UNITED STATES DOLLARS)**

	December 31, 2024			Year ended December 31, 2024					
	Deferred Policy Acquisition Costs	Future Policy Benefits, Losses, Claims and Expenses	Unearned Premiums	Premium Revenue	Net Investment Income	Benefits, Claims, Losses and Settlement Expenses	Amortization of Deferred Policy Acquisition Costs	Other Operating Expenses	Net Written Premiums
Property	\$ 234,652	\$ 6,572,739	\$ 1,193,695	\$ 3,850,352	\$ —	\$ 1,141,726	\$ 758,554	\$ 302,360	\$ 3,833,636
Casualty and Specialty	1,317,707	14,730,752	4,756,720	6,245,408	—	4,191,255	1,885,313	194,228	6,118,580
Other	—	—	—	—	1,654,289	—	—	—	—
Total	\$ 1,552,359	\$ 21,303,491	\$ 5,950,415	\$ 10,095,760	\$ 1,654,289	\$ 5,332,981	\$ 2,643,867	\$ 496,588	\$ 9,952,216

	December 31, 2023			Year ended December 31, 2023					
	Deferred Policy Acquisition Costs	Future Policy Benefits, Losses, Claims and Loss Expenses	Unearned Premiums	Premium Revenue	Net Investment Income	Benefits, Claims, Losses and Settlement Expenses	Amortization of Deferred Policy Acquisition Costs	Other Operating Expenses	Net Written Premiums
Property	\$ 274,288	\$ 7,833,620	\$ 1,158,294	\$ 3,090,792	\$ —	\$ 799,905	\$ 600,127	\$ 251,433	\$ 2,967,309
Casualty and Specialty	1,477,149	12,653,249	4,977,841	4,380,341	—	2,773,604	1,274,907	123,749	4,500,504
Other	—	—	—	—	1,253,110	—	—	—	—
Total	\$ 1,751,437	\$ 20,486,869	\$ 6,136,135	\$ 7,471,133	\$ 1,253,110	\$ 3,573,509	\$ 1,875,034	\$ 375,182	\$ 7,467,813

	December 31, 2022			Year ended December 31, 2022					
	Deferred Policy Acquisition Costs	Future Policy Benefits, Losses, Claims and Loss Expenses	Unearned Premiums	Premium Revenue	Net Investment Income	Benefits, Claims, Losses and Settlement Expenses	Amortization of Deferred Policy Acquisition Costs	Other Operating Expenses	Net Written Premiums
Property	\$ 202,999	\$ 7,535,832	\$ 1,002,149	\$ 2,770,227	\$ —	\$ 2,044,771	\$ 547,210	\$ 194,355	\$ 2,847,659
Casualty and Specialty	968,739	8,356,741	3,556,958	3,563,762	—	2,294,069	1,021,396	82,336	4,348,501
Other	—	—	—	—	559,932	—	—	—	—
Total	\$ 1,171,738	\$ 15,892,573	\$ 4,559,107	\$ 6,333,989	\$ 559,932	\$ 4,338,840	\$ 1,568,606	\$ 276,691	\$ 7,196,160

[XML 52 R33.htm IDEA: XBRL DOCUMENT](#)

**SCHEDULE IV.
SUPPLEMENTAL
SCHEDULE OF
REINSURANCE**

12 Months Ended

Dec. 31, 2024

SCHEDULE IV
RENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIES
SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS
(THOUSANDS OF UNITED STATES DOLLARS)

Property and Liability Premiums Earned	Gross Amounts	Ceded to Other Companies	Assumed From Other Companies	Net Amount	Percentage of Amount Assumed to Net
Year ended December 31, 2024	\$1,097,726	\$1,817,302	\$10,815,336	\$10,095,760	107 %
Year ended December 31, 2023	\$1,013,372	\$1,614,432	\$8,072,193	\$7,471,133	108 %
Year ended December 31, 2022	\$1,105,164	\$1,850,807	\$7,079,632	\$6,333,989	112 %

XML 53 R34.htm IDEA: XBRL DOCUMENT

SCHEDULE VI.
SUPPLEMENTARY
INSURANCE
INFORMATION
CONCERNING
PROPERTY-
CASUALTY
INSURANCE
OPERATIONS

12 Months Ended

Dec. 31, 2024

SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract]
SUPPLEMENTAL INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS

SCHEDULE VI
RENAISSANCERE HOLDINGS LTD. AND SUBSIDIARIES
SUPPLEMENTARY INSURANCE INFORMATION CONCERNING
PROPERTY-CASUALTY INSURANCE OPERATIONS
(THOUSANDS OF UNITED STATES DOLLARS)

Affiliation with Registrant	Deferred Policy Acquisition Costs	Reserves for Unpaid Claims and Claim Adjustment Expenses	Discount, if any Deducted	Unearned Premiums	Earned Premiums	Net Investment Income
Consolidated Subsidiaries						
Year ended December 31, 2024	\$1,552,359	\$21,303,491	\$—	\$5,950,415	\$10,095,760	\$1,654,289
Year ended December 31, 2023	\$1,751,437	\$20,486,869	\$—	\$6,136,135	\$7,471,133	\$1,253,110
Year ended December 31, 2022	\$1,171,738	\$15,892,573	\$—	\$4,559,107	\$6,333,989	\$559,932

Affiliation with Registrant	Claims and Claim Adjustment Expenses Incurred Related to		Amortization of Deferred Policy Acquisition Costs	Paid Claims and Claim Adjustment Expenses	Net Premiums Written
Consolidated Subsidiaries	Current Year	Prior Year			
Year ended December 31, 2024	\$6,184,315	\$(851,334)	\$2,643,867	\$3,597,810	\$9,952,216
Year ended December 31, 2023	\$4,024,116	\$(450,607)	\$1,875,034	\$2,995,678	\$7,467,813
Year ended December 31, 2022	\$4,586,422	\$(247,582)	\$1,568,606	\$2,030,156	\$7,196,160

XML 54 R35.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD (\$) \$ in Thousands
12 Months Ended
Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

Pay vs Performance Disclosure
Net income (loss) \$1,870,360 \$2,561,132 \$(1,061,203)

XML 55 R36.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024

Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false

XML 56 R37.htm IDEA: XBRL DOCUMENT

Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024

Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted true

XML 57 R38.htm IDEA: XBRL DOCUMENT

Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

Our business and support functions utilize information systems that provide critical services to both our employees and our customers. We have an integrated team of professionals who manage and support our communication platforms, transaction-management systems, and analytics and reporting capabilities, including the development of proprietary solutions like REMS®. We use both cloud-based platforms and services and off-site, secure data centers in North America and Europe for our core applications.

Information security and privacy are important concerns, with an escalating cyber-threat environment and evolving regulatory requirements driving continued investment in this area. Our information security program is designed to meet or exceed industry best practices and is integrated into our broader ERM framework. We are subject to a number of cybersecurity and data privacy laws and regulations, such as those promulgated by the BMA, Office of the Privacy Commission, NYDFS, MIA, and the EU. Pursuant to applicable regulations, we have established and maintain a cybersecurity program designed to protect our information technology systems and customer data. Our program is designed to comply with all applicable cybersecurity regulatory requirements, including disclosure requirements, and we continue to evaluate and assess our compliance in the changing regulatory environment. It is likely that we will be subject to new regulations that could adversely affect our operations or ability to write business profitably in one or more jurisdictions. We cannot predict what, if any, regulatory actions may be taken with regard to “big data” or emerging technologies, such as artificial intelligence, but any actions could have a material impact on our business, business processes, financial condition, and results of operations.

We have in place, and seek to continuously improve, a comprehensive system of security controls, managed by a dedicated staff. We also engage reputable third parties to perform a variety of services, including continuous monitoring of our information systems, incident response or management services, cyber-forensic investigation services, and periodic security penetration testing. In addition, we are subject to independent assessment and review by regulators and external auditors, as well as periodic audits of our security controls by our independent internal audit team. We provide regular security risk education and awareness training sessions for all staff. We maintain an ongoing internal third-party cybersecurity risk assessment program to identify potential cybersecurity threats associated with our use of third-party service providers, and consider these assessments when selecting and engaging service providers with periodic re-evaluations. See “Part I, Item 1A. Risk Factors” for additional information on information technology and cybersecurity related risks that may impact us and our financial results.

Cybersecurity Risk Management Processes Integrated [Flag] true

Cybersecurity Risk Management Processes Integrated [Text Block]

Cybersecurity Risk Management Third Party Engaged [Flag] true

Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true

Cybersecurity Risk Materially Affected or Reasonably Likely to false

[Materially Affect Registrant \[Flag\]](#)
[Cybersecurity Risk Board of Directors Oversight \[Text Block\]](#)
[Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight \[Text Block\]](#)
[Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight \[Text Block\]](#)
[Cybersecurity Risk Role of Management \[Text Block\]](#)

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

Our Board and its Audit Committee are supported in their oversight of information technology and cybersecurity matters and risks by two management committees, the Operational Risk and Resilience Committee and the Information Security Steering Committee (the "ISSC"), both of which regularly report to the Audit Committee. The ISSC is responsible for providing management oversight for our cybersecurity risk management program, and its membership includes our Chief Technology Officer and Chief Information Security Officer, among other members of senior management.

true

[Cybersecurity Risk Management Positions or Committees Responsible \[Flag\]](#)
[Cybersecurity Risk Management Expertise of Management Responsible \[Text Block\]](#)
[Cybersecurity Risk Process for Informing Management or Committees Responsible \[Text Block\]](#)
[Cybersecurity Risk Management Positions or Committees Responsible Report to Board \[Flag\]](#)

Our Board and its Audit Committee are supported in their oversight of information technology and cybersecurity matters and risks by two management committees, the Operational Risk and Resilience Committee and the Information Security Steering Committee (the "ISSC"), both of which regularly report to the Audit Committee. The ISSC is responsible for providing management oversight for our cybersecurity risk management program, and its membership includes our Chief Technology Officer and Chief Information Security Officer, among other members of senior management.

Our Chief Technology Officer and Chief Information Security Officer have each served in various roles in information technology and/or information security for many years, and have extensive information technology and cybersecurity experience. The Chief Technology Officer, and Chief Information Security Officer, alongside other multidisciplinary teams across the Company, work to monitor the prevention, detection, mitigation and remediation of cybersecurity incidents. The broad, cross-functional management team leverages significant experience and expertise across a range of areas, including risk management, technology, and legal and regulatory affairs, among others, for assessing and managing cybersecurity risks.

The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

true

XML 58 R39.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)
[Accounting Policies \[Abstract\]](#)
[Basis Of Presentation](#)

12 Months Ended
Dec. 31, 2024

Basis Of Presentation

These consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the United States ("GAAP"). All significant intercompany accounts and transactions have been eliminated from these statements.

Certain comparative information has been reclassified to conform to the current presentation.

Use Of Estimates In Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. The major estimates reflected in the Company's consolidated financial statements include, but are not limited to, the reserve for claims and claim expenses; reinsurance recoverable and premiums receivable, including provisions for reinsurance recoverable and premiums receivable to reflect expected credit losses; estimates of written and earned premiums; fair value, including the fair value of investments, financial instruments and derivatives; impairment charges; deferred acquisition costs, the value of business acquired ("VOBA") and the fair value of other assets acquired and liabilities assumed in acquisitions; and the Company's deferred tax valuation allowance.

Premiums and Related Expenses

Premiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are determined. Unearned premiums represent the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written.

Acquisition costs are incurred when a contract or policy is issued and only the costs directly related to the successful acquisition of new and renewal contract or policies are deferred and amortized over the same period in which the related premiums are earned. Acquisition costs consist principally of commissions, brokerage and premium tax expenses and are shown net of commissions earned on ceded reinsurance. Certain of the Company's assumed contracts contain profit sharing provisions or adjustable commissions that are estimated based on the expected loss and loss adjustment expense on those contracts. Acquisition costs include accruals for such estimates of commissions. Certain of the Company's ceded contracts contain profit sharing provisions which accrue to the benefit of the Company. Acquisition costs are shown net of such commissions and profit commissions earned on ceded reinsurance. In addition, certain of the

Company's ceded contracts contain override and management fees which are recorded as an offset against operational expenses. Deferred policy acquisition costs are limited to their estimated realizable value based on the related unearned premiums. Anticipated claims and claim expenses, based on historical and current experience, and anticipated investment income related to those premiums are considered in determining the recoverability of deferred acquisition costs.

Claims and Claim Expenses

The reserve for claims and claim expenses includes estimates for unpaid claims and claim expenses on reported losses as well as an estimate of losses incurred but not reported. The reserve is based on individual claims, case reserves and other reserve estimates reported by insureds and ceding companies as well as management estimates of ultimate losses. Inherent in the estimates of ultimate losses are expected trends in claim severity and frequency and other factors which could vary significantly as claims are settled. In addition, the Company does not have the benefit of a significant amount of its own historical experience in certain casualty and specialty and insurance lines of business. Accordingly, the reserving for incurred losses in these lines of business could be subject to greater variability.

Ultimate losses may vary materially from the amounts provided in the consolidated financial statements. These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, are reflected in the consolidated statements of operations in the period in which they become known and are accounted for as changes in estimates.

Reinsurance

Amounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, the Company accrues amounts (either assets or liabilities) that are due to or from retrocessionaires based on estimated contract experience. If the Company determines that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. Reinsurance recoverable on dual trigger reinsurance contracts require the Company to estimate its ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. Amounts recoverable from reinsurers are recorded net of a provision for current expected credit losses to reflect expected credit losses.

Assumed and ceded reinsurance contracts that lack significant transfer of risk are treated as deposits.

Certain assumed and ceded reinsurance contracts that do not meet all of the criteria to be accounted for as reinsurance in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 944, *Financial Services - Insurance* have been accounted for at fair value under the fair value option in accordance with FASB ASC Topic 825, *Financial Instruments*.

Investments

Fixed Maturity Investments

Investments in fixed maturities are classified as trading and are reported at fair value. Investment transactions are recorded on the trade date with balances pending settlement reflected in the balance sheet as a receivable for investments sold or a payable for investments purchased. Net investment income includes interest and dividend income together with amortization of market premiums and discounts and is net of investment management and custody fees. The amortization of premium and accretion of discount for fixed maturity securities is computed using the effective yield method. For mortgage-backed securities and other holdings for which there is prepayment risk, prepayment assumptions are evaluated quarterly and revised as necessary. Any adjustments required due to the change in effective yields and maturities are recognized on a prospective basis through yield adjustments. Fair values of investments are based on quoted market prices, or when such prices are not available, by reference to broker or underwriter bid indications and/or internal pricing valuation techniques. The net unrealized appreciation or depreciation on fixed maturity investments trading is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations. Realized gains or losses on the sale of investments are determined on the basis of the first in first out cost method.

Short Term Investments

Short term investments, which are managed as part of the Company's investment portfolio and have a maturity of one year or less when purchased, are carried at fair value. The net unrealized appreciation or depreciation on short term investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Equity Investments

Equity investments are accounted for at fair value in accordance with FASB ASC Topic 825, *Financial Instruments*. Fair values are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. Dividend income is included in net investment income and net realized and unrealized appreciation or depreciation on equity investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Other Investments

The Company accounts for its other investments at fair value in accordance with FASB ASC Topic 825, *Financial Instruments* with interest and dividend income included in net investment income. Realized and unrealized gains and losses on other investments are included in net realized and unrealized gains (losses) on investments. The fair value of the Company's fund investments, which include private equity

Other Investments

funds, private credit funds and hedge funds, is generally established on the basis of the net asset value (“NAV”) per share (or its equivalent) established by each respective fund investments manager, if applicable. The net asset value established by the respective fund investments manager is determined in accordance with the governing documents of such fund investments. The Company applies the practical expedient provided by the FASB ASC Topic 825, *Financial Instruments* relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of the fund investments based on that NAV per share, or its equivalent. Fund investments are recorded on the consolidated balance sheets in other investments. Fund investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy.

Certain of the Company’s fund investment managers, or their fund administrators, are unable to provide final fund valuations as of the Company’s current reporting date. The Company typically experiences a reporting lag to receive a final net asset value report of one month for hedge funds and three months for both private equity funds and private credit funds, although the Company has occasionally experienced delays of up to six months, particularly at year end.

In circumstances where there is a reporting lag between the current period end reporting date and the reporting date of the latest fund valuation, the Company estimates the fair value of these funds by starting with the prior month or quarter-end fund valuations, adjusting these valuations for actual capital calls, redemptions or distributions, as well as the impact of changes in foreign currency exchange rates, and then estimating the return for the current period. In circumstances in which the Company estimates the return for the current period, all information available to the Company is utilized. This principally includes using preliminary estimates reported to the Company by its fund managers, where available, and estimating returns based on the performance of broad market indices or other valuation methods. Actual final fund valuations may differ, perhaps materially so, from the Company’s estimates and these differences are recorded in the Company’s statement of operations in the period in which they are reported to the Company as a change in estimate.

The Company’s other investments also include investments in catastrophe bonds, direct private equity investments and term loans which are recorded at fair value. The fair value of catastrophe bonds is based on broker or underwriter bid indications. The fair value of direct private equity investments is based on quoted prices for similar assets, where available, or on the use of internal valuation models.

Investments in Other Ventures, Under Equity Method

Investments in Other Ventures, Under Equity Method

Investments in which the Company has significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, the Company records its proportionate share of income or loss from such investments in its statements of operations for the period. Additionally, the Company records its portion of any changes to the accumulated other comprehensive income or loss of the investee in the Company’s statements of comprehensive income (loss). If the Company’s proportionate share of loss from such investment is in excess of the carrying value of such investment, the Company suspends the application of the equity method when the carrying value of the investment is reduced to zero, unless the Company has committed to provide further financial support to the investee. If the investee subsequently reports net income, the Company resumes applying the equity method only after its proportionate share of net income equals the proportionate share of net losses not recognized during the period the equity method was suspended. Any decline in value of investments in other ventures, under equity method considered by management to be other-than-temporary is charged to income in the period in which it is determined.

Cash and Cash Equivalents

Cash equivalents include money market instruments with a maturity of ninety days or less when purchased.

Stock Incentive Compensation

The Company is authorized to issue restricted stock awards and units, performance shares, stock options and other equity-based awards to its employees and directors. The fair value of the compensation cost is measured at the grant date and expensed over the period for which the employee or director is required to provide services in exchange for the award.

The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.

Derivatives

From time to time, the Company enters into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company accounts for its derivatives in accordance with FASB ASC Topic 815, *Derivatives and Hedging*, which requires all derivatives to be recorded at fair value on the Company’s balance sheet as either assets or liabilities, depending on their rights or obligations, with changes in fair value reflected in current earnings. The Company has adopted hedge accounting for certain of its derivative instruments used as hedges of a net investment in a foreign operation, as discussed below. The fair value of the Company’s derivatives is estimated by reference to quoted prices or broker quotes, where available, or in the absence of quoted prices or broker quotes, the use of industry or internal valuation models.

Hedges of a Net Investment in a Foreign Operation

Changes in the fair value of derivative instruments used to hedge the net investment in a foreign operation, to the extent effective as a hedge, are recorded as a component of accumulated other comprehensive income (loss) in foreign currency translation adjustments, net of tax. Cumulative changes in fair value recorded in accumulated other comprehensive income (loss) are reclassified into earnings upon the sale, or complete or substantially complete liquidation, of the foreign operation. Any hedge ineffectiveness is recorded immediately in current period earnings as net foreign exchange gains (losses).

Hedge Documentation and Effectiveness Testing

To qualify for hedge accounting treatment, a derivative must be highly effective in mitigating the designated changes in value or cash flow of the hedged item. At the inception of a hedge, the Company formally documents relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking each hedge transaction. The documentation process includes linking derivatives that are designated as net investment hedges to specific assets or liabilities on the consolidated balance sheets. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the net investment in a foreign operation. The Company will discontinue hedge accounting prospectively if it determines that the derivative is no longer highly effective in offsetting changes in the net investment in a foreign operation, the derivative is no longer designated as a hedging instrument, or the derivative expires or is sold, terminated or exercised. If hedge accounting is discontinued, the derivative continues to be carried at fair value on the consolidated balance sheets with changes in its fair value recognized in current period earnings through net realized and unrealized gains (losses) on investments.

Fair Value Option

The Company has elected to account for certain of its assets and liabilities at fair value in accordance with FASB ASC Topic 820, *Fair Value Measurement*. The Company recognizes the change in unrealized gains and losses arising from changes in fair value in its statements of operations.

The use of fair value to measure certain assets and liabilities with resulting unrealized gains or losses is pervasive within the Company’s consolidated financial statements. Fair value is defined under accounting guidance currently applicable to the Company as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between open market participants at the measurement date. The Company recognizes the change in unrealized gains or losses arising from changes in fair value in its consolidated statements of operations.

FASB ASC Topic 820, *Fair Value Measurement* prescribes a fair value hierarchy that prioritizes the inputs to the respective valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to valuation techniques that use at least one significant input that is unobservable (Level 3). The three levels of the fair value hierarchy are described below:

- Fair values determined by Level 1 inputs utilize unadjusted quoted prices obtained from active markets for identical assets or liabilities for which the Company has access at the measurement date. The fair value is determined by multiplying the quoted price by the quantity held by the Company;
- Fair values determined by Level 2 inputs utilize inputs (other than quoted prices included in Level 1) that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, such as interest rates and yield curves that are observable at commonly quoted intervals, broker quotes and certain pricing indices; and
- Level 3 inputs are based all or in part on significant unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. In these cases, significant management assumptions can be used to establish management’s best estimate of the assumptions used by other market participants in determining the fair value of the asset or liability.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement of the asset or liability. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and the Company considers factors specific to the asset or liability.

In order to determine if a market is active or inactive for a security, the Company considers a number of factors, including, but not limited to, the spread between what a seller is asking for a security and what a buyer is bidding for the same security, the volume of trading activity for the security in question, the price of the security compared to its par value (for fixed maturity investments), and other factors that may be indicative of market activity.

There have been no material changes in the Company’s valuation techniques, nor have there been any transfers between Level 1 and Level 2, or Level 2 and Level 3 during the period represented by these consolidated financial statements.

Business Combinations

The Company accounts for business combinations in accordance with FASB ASC Topic 805, *Business Combinations*, and goodwill and other intangible assets that arise from business combinations in accordance with FASB ASC Topic 350, *Intangibles – Goodwill and Other*.

A purchase price that is in excess of the fair value of the net assets acquired arising from a business combination is recorded as goodwill, and is not amortized. Other intangible assets with a finite life are amortized over the estimated useful life of the asset. Other intangible assets with an indefinite useful life are not amortized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining the fair value of net assets acquired. The significant assumptions include the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges.

Goodwill and other intangible assets are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, goodwill is assigned to the applicable reporting unit of the acquired entities giving rise to the goodwill. Goodwill and other intangible assets recorded in connection with investments accounted for under the equity method, are recorded as investments in other ventures, under equity method on the Company’s consolidated balance sheets.

The Company has established the second half of the year as the period for performing its annual impairment tests. The Company may determine to perform additional impairment testing at other times in the year if it is deemed necessary. The Company has elected to use the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. Under this option, the Company is not required to calculate the fair value of a reporting unit unless the Company determines, based on its qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If goodwill or other intangible assets are impaired, they are written down to their estimated fair value with a corresponding expense reflected in the Company’s consolidated statements of operations.

Noncontrolling Interests

Noncontrolling Interests

The Company accounts for redeemable noncontrolling interests in the mezzanine section of the Company’s consolidated balance sheets in accordance with United States Securities and Exchange Commission (“SEC”) guidance which is applicable to SEC registrants. The share classes related to the redeemable noncontrolling interest portion of the issuer are accounted for in accordance with SEC guidance, which requires that shares not required to be accounted for in accordance with FASB ASC Topic 480, *Distinguishing Liabilities from Equity*, and having redemption features that are not solely within the control of the issuer, to be classified outside of permanent equity in the mezzanine section of the balance sheet. The SEC guidance does not impact the accounting for redeemable noncontrolling interest on the consolidated statements of operations; therefore, the provisions of FASB ASC Topic 810, *Consolidation* with respect to the consolidated statements of operations still apply, and net (income) loss attributable to redeemable noncontrolling interests is presented separately in the Company’s consolidated statements of operations.

Variable Interest Entities

The Company accounts for variable interest entities (“VIEs”) in accordance with FASB ASC Topic 810, *Consolidation*, which requires the consolidation of all VIEs by the primary beneficiary, that being the investor that has the power to direct the activities of the VIE and that will absorb a portion of the VIE’s expected losses or residual returns that could potentially be significant to the VIE. When the Company determines it has a variable interest in a VIE, it determines whether it is the primary beneficiary of that VIE by performing an analysis that principally considers: (i) the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders; (ii) the VIE’s capital structure; (iii) the terms between the VIE and its variable interest holders and other parties involved with the VIE; (iv) which variable interest holders have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; (v) which variable interest holders have the obligation to absorb losses or the

right to receive benefits from the VIE that could potentially be significant to the VIE; and (vi) related party relationships. The Company reassesses its determination of whether the Company is the primary beneficiary of a VIE upon changes in facts and circumstances that could potentially alter the Company’s assessment.

Earnings Per Share

The Company calculates earnings per share in accordance with FASB ASC Topic 260, *Earnings per Share*. Basic earnings per share are based on weighted average common shares and exclude any dilutive effects of options and restricted stock. Diluted earnings per share assumes the exercise of all dilutive stock options and restricted stock grants.

The two-class method is used to determine earnings per share based on dividends declared on common shares and participating securities (i.e., distributed earnings) and participation rights of participating securities in any undistributed earnings. Each unvested restricted share granted by the Company is considered a participating security and the Company uses the two-class method to calculate its net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic and diluted.

Foreign Exchange

Foreign Exchange

Monetary assets and liabilities denominated in a currency other than the functional currency of the Company’s subsidiaries in which those monetary assets and liabilities reside are revalued into such subsidiary’s functional currency at the prevailing exchange rate on the balance sheet date. Revenues and expenses denominated in a currency other than the functional currency of the Company’s subsidiaries, are valued at the exchange rate on the date on which the underlying revenue or expense transaction occurred. The net effect of these revaluation adjustments are recognized in the Company’s consolidated statements of operations as part of net foreign exchange gains (losses).

The Company’s functional currency is the U.S. dollar. One of the Company’s subsidiaries has a functional currency other than the U.S. dollar. Assets and liabilities of the foreign operation whose functional currency is not the U.S. dollar are translated into the Company’s U.S. dollar reporting currency at prevailing balance sheet-date exchange rates, while revenue and expenses of such foreign operation are translated into the Company’s U.S. dollar functional currency at monthly average exchange rates during the year. The net effect of these translation adjustments, as well as any gains or losses on

intercompany balances for which settlement is not planned or anticipated in the foreseeable future, net of applicable deferred income taxes, is included in the Company’s consolidated balance sheets as currency translation adjustments and reflected within accumulated other comprehensive income (loss).

Taxation

Taxation

Income taxes have been provided for in accordance with the provisions of FASB ASC Topic 740, *Income Taxes*. Deferred tax assets and liabilities result from temporary differences between the amounts recorded in the consolidated financial statements and the tax basis of the Company’s assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, deferred acquisition expenses, VOBA, intangible assets, value of in-force business, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances.

Uncertain tax positions are also accounted for in accordance with FASB ASC Topic 740, *Income Taxes*. Uncertain tax positions must meet a more likely than not recognition threshold to be recognized.

Recently Adopted Accounting Pronouncements

Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued ASU No. 2023-07, *Improvements to Reportable Segment Disclosures* (“ASU 2023-07”). Among other things, ASU 2023-07 improves the disclosures about a public entity’s reportable segments and addresses investor requests for additional, more detailed information about a reportable segment’s expenses. The amendments in ASU 2023-07 are effective for public business entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the annual reporting period beginning January 1, 2024. The adoption of ASU 2023-07 did not have a material impact on the Company’s reportable segment disclosures.

Recently Issued Accounting Pronouncements Not Yet Adopted

Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, *Improvements to Income Tax Disclosures* (“ASU 2023-09”). Among other things, ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in ASU 2023-09 are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this guidance.

Disaggregation of Income Statement Expenses

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses* (“ASU 2024-03”). Among other things, ASU 2024-03 addresses investor requests for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly presented expense captions (such as cost of sales; selling, general and administrative expenses and research and development). The amendments in ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance.

XML 59 R40.htm IDEA: XBRL DOCUMENT

ACQUISITION OF VALIDUS (Tables)

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of Acquisition Purchase Price and Financial Results

12 Months Ended Dec. 31, 2024

The Company’s total consideration for Validus was calculated as follows:

<i>RenaissanceRe Common Shares</i>			
Common shares issued by RenaissanceRe to AIG		1,323	
Common share price of RenaissanceRe ⁽¹⁾	\$	215.62	
Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG			\$ 285,168
<i>Cash Consideration</i>			
Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market	\$	1,351,608	
Cash consideration funded by net proceeds from the issuance of Senior Notes		740,581	
Cash consideration funded by available cash resources		642,811	
Total cash consideration paid by RenaissanceRe as acquisition consideration			2,735,000
Total purchase price			\$ 3,020,168

(1) The common share price of RenaissanceRe is based on the closing price of \$226.97 per RenaissanceRe common share on the closing date of the Validus Acquisition, November 1, 2023 with a 5% discount to reflect restrictions on the transfer of those shares.

The following table summarizes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company’s consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. Operating activities of Validus from the acquisition date, November 1, 2023, through December 31, 2023 are included in the Company’s consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023.

The unaudited net contribution of the acquisition and integration of Validus is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that may be achieved in the future. These results are not used as a part of management’s analysis of the financial performance of the Company’s business. These results primarily reflect items recorded directly by Validus from November 1, 2023 through December 31, 2023, including: 1) net premiums earned and net underwriting income on the in-force portfolio acquired with the acquisition of Validus and previously retained on Validus entities’ balance sheets; 2) net premiums earned and net underwriting income for those contracts which renewed post-acquisition on one of the acquired Validus entities’ balance sheets; 3) net investment income and net realized and unrealized gains recorded directly by Validus; and 4) certain direct costs incurred directly by Validus. In addition, these results, where possible, were adjusted for transaction and integration related costs incurred by the Company. However, these results do not reflect on-going operating costs incurred by the Company in supporting Validus unless such costs were incurred directly by Validus. These results also do not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may be achieved in the future. These results involve significant estimates and are not indicative of the future results of the acquired Validus entities which have been, and will continue to be impacted by potential changes in targeted business mix, investment management strategies, and synergies recognized from changes in the combined entity’s operating structure, as well as the impact of changes in other business and capital management strategies.

	Year ended December 31, 2023 ⁽¹⁾
Total revenues	\$ 696,888
Net income (loss) available (attributable) to RenaissanceRe common shareholders ⁽²⁾	\$ 307,802

(1) Includes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company’s consolidated statements of operations and comprehensive income (loss) through December 31, 2023.

(2) Includes \$76.4 million of corporate expenses associated with the acquisition and integration of Validus for the year ended December 31, 2023.

Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed

The purchase price was allocated to the acquired assets and liabilities of the Company based on estimated fair values on November 1, 2023, the date the transaction closed, as detailed in the table below:

Assets:		
Cash and cash equivalents	\$	301,253
Investments trading		3,248,242
Short term investments		1,659,902
Investments in other ventures, under equity method		3,997
Reinsurance premiums receivable		2,014,359
Prepaid reinsurance premiums		126,750
Losses recoverable ⁽¹⁾		1,297,270
Accrued investment income		21,441
Deferred acquisition costs and value of business acquired		617,000
Other assets		70,557
Identifiable intangible assets		460,884
Total assets		9,821,655
Liabilities:		
Reserve for claims and claim expenses ⁽¹⁾		4,628,952
Reserve for unearned premiums		1,804,029
Reinsurance balances payable		298,003
Accounts payable and accrued liabilities		120,994
Deferred tax liability		39,157
Total liabilities		6,891,135
Total identifiable net assets acquired		2,930,520
Total purchase price		3,020,168
Goodwill	\$	89,648

(1)Includes the net fair value adjustment of \$192.0 million to net claims and claim expenses on November 1, 2023, which was made up of a \$76.8 million decrease to losses recoverable and a \$268.9 million decrease to reserve for claims and claim expenses.

Schedule of Identifiable Intangible Assets Acquired

Identifiable indefinite lived and finite lived intangible assets consisted of the following and are included in goodwill and other intangible assets on the Company’s consolidated balance sheet:

	Amount	Economic Useful Life
Agent relationships - top four	\$ 195,000	15 years
Agent relationships - other	9,000	5 years
Managing General Agent (“MGA”) relationships	3,000	15 years
Trade name	5,000	0.5 years
Renewal rights	215,000	15 years
Asset management contracts	20,000	4 years
Insurance licenses	13,884	Indefinite
Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023	460,884	
Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange	60,489	
Impairment loss on insurance licenses	13,767	
Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024	\$ 386,628	

Schedule of Pro Forma Information

XML 60 R41.htm IDEA: XBRL DOCUMENT

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

The following table presents unaudited pro forma consolidated financial information for the years ended December 31, 2023 and 2022, respectively, and assumes the acquisition of Validus occurred on January 1, 2022. The unaudited pro forma consolidated financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the transaction been completed as of January 1, 2022 or that may be achieved in the future. The unaudited pro forma consolidated financial information does not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may result from the acquisition of Validus. In addition, unaudited pro forma consolidated financial information does not include the effects of costs associated with any restructuring or integration activities resulting from the acquisition of Validus, as they are nonrecurring.

Year ended December 31,	2023	2022
Total revenues	\$ 11,611,682	\$ 7,169,338
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 2,926,518	\$ (1,552,425)

12 Months Ended

Dec. 31, 2024

The following tables show an analysis of goodwill and other intangible assets, net of foreign currency translation adjustments, included in goodwill and other intangible assets on the Company’s consolidated balance sheets:

At December 31,	Goodwill and Other Intangible Assets	
	2024	2023
Goodwill, net	\$ 300,507	\$ 300,542
Other intangible assets, net	403,625	474,810
Total goodwill and other intangible assets	\$ 704,132	\$ 775,352

In addition, the Company has also recorded goodwill and other intangible assets included in investments in other ventures, under equity method on the Company’s consolidated balance sheets:

At December 31,	Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method	
	2024	2023
Goodwill, net	\$ 8,724	\$ 10,808
Other intangible assets, net	207	7,260
Total goodwill and other intangible assets	\$ 8,931	\$ 18,068

The following table shows a roll forward of goodwill included in goodwill and other intangible assets and goodwill included in investments in other ventures, under equity method on the Company’s consolidated balance sheets:

	Goodwill	
	Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method
Balance at December 31, 2022, net	\$ 210,894	\$ 9,903
Acquired	89,648	905
Balance at December 31, 2023, net	300,542	10,808
Adjustments	—	(2,084)
Foreign currency translation	(35)	—
Balance at December 31, 2024, net	\$ 300,507	\$ 8,724

The gross carrying value, accumulated amortization and accumulated impairment losses by major category of other intangible assets included in goodwill and other intangible assets and investments in other ventures, under equity method on the Company’s consolidated balance sheets are shown below:

At December 31, 2024	Other Intangible Assets			
	Gross Carrying Value	Accumulated Amortization	Accumulated Impairment Losses	Net
Customer relationships and customer lists	\$ 530,528	\$ (150,051)	\$ (1,403)	\$ 379,074
Licenses ⁽¹⁾	30,951	—	(20,567)	10,384
Value of business acquired	20,200	(20,200)	—	—
Asset management contracts	20,000	(5,833)	—	14,167
Software	12,230	(12,230)	—	—
Patents and intellectual property	4,500	(1,875)	(2,625)	—
Covenants not-to-compete	4,030	(4,030)	—	—
Trademarks and trade names	6,710	(6,503)	—	207
	\$ 629,149	\$ (200,722)	\$ (24,595)	\$ 403,832

(1) Licenses is comprised of \$10.4 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2024

At December 31, 2023	Other Intangible Assets			
	Gross Carrying Value	Accumulated Amortization	Accumulated Impairment Losses	Net
Customer relationships and customer lists	\$ 530,704	\$ (101,659)	\$ (1,550)	\$ 427,495
Licenses ⁽¹⁾	37,663	—	(6,653)	31,010
Value of business acquired	20,200	(20,200)	—	—
Asset management contracts	20,000	(833)	—	19,167
Software	12,230	(12,230)	—	—
Patents and intellectual property	4,500	(1,875)	(2,625)	—
Covenants not-to-compete	4,030	(4,030)	—	—
Trademarks and trade names	6,710	(2,312)	—	4,398
	\$ 636,037	\$ (143,139)	\$ (10,828)	\$ 482,070

(1) Licenses is comprised of \$31.0 million of indefinite lived other intangible assets, included in other intangible assets, net, as of December 31, 2023

Expected amortization of the other intangible assets, including other intangible assets recorded in investments in other ventures, under equity method, is shown below:

	Other Intangibles Assets	Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method	Total
2025	\$ 70,210	\$ 24	\$ 70,234
2026	61,622	24	61,646
2027	53,737	24	53,761
2028	42,661	24	42,685
2029	34,495	24	34,519
2030 and thereafter	130,516	87	130,603
Total remaining amortization expense	393,241	207	393,448
Indefinite lived	10,384	—	10,384
Total	\$ 403,625	\$ 207	\$ 403,832

XML 61 R42.htm IDEA: XBRL DOCUMENT

INVESTMENTS (Tables)

Investments, Debt and Equity Securities [Abstract]

Schedule of Fair Value of Fixed Maturity Investments Trading

12 Months Ended

Dec. 31, 2024

The following table summarizes the fair value of fixed maturity investments trading:

At December 31,	2024	2023
U.S. treasuries	\$ 11,001,893	\$ 10,060,203
Corporate ⁽¹⁾	7,862,423	6,499,075
Residential mortgage-backed	1,707,056	1,420,362
Asset-backed	1,422,393	1,491,695
Agencies	623,489	489,117
Non-U.S. government	618,809	483,576
Commercial mortgage-backed	326,451	433,080
Total fixed maturity investments trading	\$ 23,562,514	\$ 20,877,108

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

The following table summarizes the fair value of equity investments:

At December 31,	2024	2023
Financials	\$ 116,400	\$ 106,542
Basic materials	595	—
Industrial, utilities and energy	312	—
Communications and technology	263	12
Consumer	154	212
Healthcare	32	—
Total	\$ 117,756	\$ 106,766

Contractual maturities of fixed maturity investments trading are described in the following table. Expected maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

Schedule of Contractual Maturities of Fixed Maturity Investments

	At December 31, 2024		At December 31, 2023	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in less than one year	\$ 1,374,089	\$ 1,373,838	\$ 587,720	\$ 582,519
Due after one through five years	12,139,153	12,131,114	11,439,510	11,468,263
Due after five through ten years	6,339,563	6,246,506	5,182,667	5,188,716
Due after ten years	387,413	355,156	307,392	292,473
Mortgage-backed	2,094,190	2,033,507	1,864,520	1,853,442
Asset-backed	1,416,132	1,422,393	1,490,641	1,491,695
Total	\$ 23,750,540	\$ 23,562,514	\$ 20,872,450	\$ 20,877,108

Schedule of Net Investment Income

The components of net investment income are as follows:

Year ended December 31,	2024	2023	2022
Fixed maturity investments trading	\$ 1,116,649	\$ 744,457	\$ 382,165
Short term investments	183,153	213,303	41,042
Equity investments	2,460	7,261	20,864
Other investments			
Catastrophe bonds	238,844	200,572	94,784
Other	82,457	87,296	37,497
Cash and cash equivalents	54,241	23,123	5,197
	1,677,804	1,276,012	581,549
Investment expenses	(23,515)	(22,902)	(21,617)
Net investment income	\$ 1,654,289	\$ 1,253,110	\$ 559,932

Schedule of Net Realized and Unrealized Gains (Losses) On Investments and Net Other-Than-Temporary Impairments

Net realized and unrealized gains (losses) on investments are as follows:

Year ended December 31,	2024	2023	2022
Gross realized gains on fixed maturity investments trading	\$ 142,243	\$ 80,905	\$ 38,781
Gross realized losses on fixed maturity investments trading	(206,172)	(473,946)	(771,342)
Net realized gains (losses) on fixed maturity investments trading	(63,929)	(393,041)	(732,561)
Net unrealized gains (losses) on fixed maturity investments trading	(182,494)	685,095	(636,762)
Net realized and unrealized gains (losses) on fixed maturity investments trading	(246,423)	292,054	(1,369,323)
Net realized and unrealized gains (losses) on investment-related derivatives ⁽¹⁾	(57,279)	(68,272)	(165,293)
Net realized gains (losses) on equity investments	355	(27,492)	43,035
Net unrealized gains (losses) on equity investments	10,621	73,243	(166,823)
Net realized and unrealized gains (losses) on equity investments	10,976	45,751	(123,788)
Net realized and unrealized gains (losses) on other investments - catastrophe bonds	62,353	101,897	(130,335)
Net realized and unrealized gains (losses) on other investments - other	202,533	43,092	(11,746)
Net realized and unrealized gains (losses) on investments	\$ (27,840)	\$ 414,522	\$ (1,800,485)

(1) Net realized and unrealized gains (losses) on investment-related derivatives includes fixed maturity investments related derivatives, equity investments related derivatives and commodity related derivatives. See "Note 19. Derivative Instruments" for additional information.

The table below shows the fair value of the Company's portfolio of other investments:

At December 31,	2024	2023
Fund investments	\$ 2,128,499	\$ 1,415,804
Catastrophe bonds	1,984,396	1,942,199
Direct private equity investments	211,866	59,905
Term loans	—	97,658
Total other investments	\$ 4,324,761	\$ 3,515,566

Schedule of Equity Method Investments

The table below shows the Company's portfolio of investments in other ventures, under equity method:

At December 31,	2024		2023	
	Ownership %	Carrying Value	Ownership %	Carrying Value
Investments in other ventures, under equity method	0.1% - 50.0%	\$ 102,770	0.1% - 50.0%	\$ 112,624

Schedule of Equity In Earnings of Equity Method Investments

The table below shows the Company's equity in earnings (losses) of other ventures:

Year ended December 31,	2024	2023	2022
Equity in earnings (losses) of other ventures	\$ 47,087	\$ 43,474	\$ 11,249

XML 62 R43.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis

12 Months Ended

Dec. 31, 2024

Below is a summary of the assets and liabilities that are measured at fair value on a recurring basis and also represents the carrying amount on the Company's consolidated balance sheets:

	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2024				
Fixed maturity investments trading				
U.S. treasuries	\$ 11,001,893	\$ 11,001,893	\$ —	\$ —
Corporate ⁽¹⁾	7,862,423	—	7,862,423	—
Residential mortgage-backed	1,707,056	—	1,707,056	—
Asset-backed	1,422,393	—	1,422,393	—
Agencies	623,489	—	623,489	—
Non-U.S. government	618,809	—	618,809	—
Commercial mortgage-backed	326,451	—	326,451	—
Total fixed maturity investments trading	23,562,514	11,001,893	12,560,621	—
Short term investments	4,531,655	99,343	4,432,312	—
Equity investments	117,756	117,756	—	—
Other investments				
Catastrophe bonds	1,984,396	—	1,984,396	—
Direct private equity investments	211,866	—	168,089	43,777
	2,196,262	—	2,152,485	43,777
Fund investments ⁽²⁾	2,128,499	—	—	—
Total other investments	4,324,761	—	2,152,485	43,777
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts ⁽³⁾	(405)	—	—	(405)
Derivative assets ⁽⁴⁾	34,538	10,614	23,924	—
Derivative liabilities ⁽⁴⁾	(75,878)	(7,872)	(68,006)	—
Total other assets and (liabilities)	(41,745)	2,742	(44,082)	(405)
	\$ 32,494,941	\$ 11,221,734	\$ 19,101,336	\$ 43,372

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

(2) Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

(3) Included in assumed and ceded (re)insurance contracts at December 31, 2024 was \$2.0 million of other assets and \$2.4 million of other liabilities.

(4) Refer to "Note 19. Derivative Instruments" for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.

		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2023	Total			
Fixed maturity investments trading				
U.S. treasuries	\$ 10,060,203	\$ 10,060,203	\$ —	\$ —
Corporate ⁽¹⁾	6,499,075	—	6,499,075	—
Asset-backed	1,491,695	—	1,491,695	—
Residential mortgage-backed	1,420,362	—	1,420,362	—
Agencies	489,117	—	489,117	—
Non-U.S. government	483,576	—	483,576	—
Commercial mortgage-backed	433,080	—	433,080	—
Total fixed maturity investments trading	20,877,108	10,060,203	10,816,905	—
Short term investments	4,604,079	130,232	4,473,847	—
Equity investments	106,766	106,766	—	—
Other investments				
Catastrophe bonds	1,942,199	—	1,942,199	—
Term loans	97,658	—	—	97,658
Direct private equity investments	59,905	—	—	59,905
	2,099,762	—	1,942,199	157,563
Fund investments ⁽²⁾	1,415,804	—	—	—
Total other investments	3,515,566	—	1,942,199	157,563
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts ⁽³⁾	(515)	—	—	(515)
Derivative assets ⁽⁴⁾	44,724	16,701	28,023	—
Derivative liabilities ⁽⁴⁾	(29,992)	(10,372)	(19,620)	—
Total other assets and (liabilities)	14,217	6,329	8,403	(515)
	\$ 29,117,736	\$ 10,303,530	\$ 17,241,354	\$ 157,048

(1) Corporate fixed maturity investments include non-U.S. government-backed corporate fixed maturity investments.

(2) Fund investments, which may include private equity funds, private credit funds, and hedge funds are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and have not been classified in the fair value hierarchy. The fair value presented in this table is provided to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

(3) Included in assumed and ceded (re)insurance contracts at December 31, 2023 was \$2.2 million of other assets and \$2.7 million of other liabilities.

(4) Refer to "Note 19. Derivative Instruments" for additional information related to the fair value, by type of contract, of derivatives entered into by the Company.

Below is a summary of quantitative information regarding the significant unobservable inputs (Level 3) used in determining the fair value of assets and liabilities measured at fair value on a recurring basis:

At December 31, 2024	Fair Value (Level 3)	Valuation Technique	Unobservable Inputs	Weighted Average or Actual
Other investments				
Direct private equity investments	\$ 43,777	Internal valuation model	Discount rate	10.0 %
			Liquidity discount	15.0 %
Total other investments	43,777			
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts	(405)	Internal valuation model	Net undiscounted cash flows	\$ 12.657
			Expected loss ratio	1.2 %
			Discount rate	4.4 %
Total other assets and (liabilities)	(405)			
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	\$ 43,372			

At December 31, 2023	Fair Value (Level 3)	Valuation Technique	Unobservable Inputs	Weighted Average or Actual
Other investments				
Direct private equity investments	\$ 59,905	Internal valuation model	Discount rate	10.0 %
			Liquidity discount	15.0 %
Term loans	97,658	Discounted cash flow	Credit spread adjustment	0.2 %
			Risk premium	2.6 %
Total other investments	157,563			
Other assets and (liabilities)				
Assumed and ceded (re)insurance contracts	(515)	Internal valuation model	Net undiscounted cash flows	\$ 12.478
			Expected loss ratio	2.3 %
			Discount rate	3.8 %
Total other assets and (liabilities)	(515)			
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	\$ 157,048			

Below is a reconciliation of the beginning and ending balances, for the periods shown, of assets and liabilities measured at fair value on a recurring basis using Level 3 inputs.

	Other Investments		Other Assets and (Liabilities)	Total
	Direct Private Equity Investments	Term Loans		
Balance - January 1, 2024	\$ 59,905	\$ 97,658	\$ (515)	\$ 157,048
Net investment income	258	—	—	258
Net realized and unrealized gains (losses) on investments	(16,686)	—	—	(16,686)
Other income (loss)	—	—	252	252
Net foreign exchange gains (losses)	(7)	—	—	(7)
Purchases	577	—	3,640	4,217
Sales	(270)	(94,321)	(3,626)	(98,217)
Settlements	—	(3,337)	(156)	(3,493)
Balance - December 31, 2024	\$ 43,777	\$ —	\$ (405)	\$ 43,372

	Other Investments		Other Assets and (Liabilities)	Total
	Direct Private Equity Investments	Term Loans		
Balance - January 1, 2023	\$ 66,786	100,006	(1,832)	164,948
Net investment income	250	—	—	250
Net realized and unrealized gains (losses) on investments	(7,120)	—	—	(7,120)
Other income (loss)	—	—	(492)	(492)
Net foreign exchange gains (losses)	(5)	—	—	(5)
Purchases	—	—	1,809	1,809
Settlements	—	(2,342)	—	(2,342)
Balance - December 31, 2023	\$ 59,905	\$ 97,658	\$ (515)	\$ 157,048

Below is a reconciliation of the beginning and ending balances, for the periods shown, of assets and liabilities measured at fair value on a recurring basis using Level 3 inputs.

	Other Investments		Other Assets and (Liabilities)	Total
	Direct Private Equity Investments	Term Loans		
Balance - January 1, 2024	\$ 59,905	\$ 97,658	\$ (515)	\$ 157,048
Net investment income	258	—	—	258
Net realized and unrealized gains (losses) on investments	(16,686)	—	—	(16,686)
Other income (loss)	—	—	252	252
Net foreign exchange gains (losses)	(7)	—	—	(7)
Purchases	577	—	3,640	4,217
Sales	(270)	(94,321)	(3,626)	(98,217)
Settlements	—	(3,337)	(156)	(3,493)
Balance - December 31, 2024	\$ 43,777	\$ —	\$ (405)	\$ 43,372

	Other Investments		Other Assets and (Liabilities)	Total
	Direct Private Equity Investments	Term Loans		
Balance - January 1, 2023	\$ 66,786	100,006	(1,832)	164,948
Net investment income	250	—	—	250
Net realized and unrealized gains (losses) on investments	(7,120)	—	—	(7,120)
Other income (loss)	—	—	(492)	(492)
Net foreign exchange gains (losses)	(5)	—	—	(5)
Purchases	—	—	1,809	1,809
Settlements	—	(2,342)	—	(2,342)
Balance - December 31, 2023	\$ 59,905	\$ 97,658	\$ (515)	\$ 157,048

Below is a summary of the balances the Company has elected to account for at fair value:

At December 31,	2024	2023
Other investments	\$ 4,324,761	\$ 3,515,566
Other assets	\$ 2,029	\$ 2,227
Other liabilities	\$ 2,434	\$ 2,742

The table below shows the Company's portfolio of other investments measured using net asset valuations as a practical expedient:

[Schedule of Quantitative Information Used as Level 3 Inputs](#)

[Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs](#)

[Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs](#)

[Schedule of the Balances the Company has Elected to Account for at Fair Value](#)

[Schedule of Other Investments Measured Using Net Asset Valuations](#)

At December 31, 2024	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period (Minimum Days)	Redemption Notice Period (Maximum Days)
Private credit funds	\$ 1,181,146	\$ 1,284,699	See below	See below	See below
Private equity funds	609,105	664,234	See below	See below	See below
Hedge funds	338,248	—	See below	See below	See below
Total other investments measured using net asset valuations	\$ 2,128,499	\$ 1,948,933			

At December 31, 2023	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period (Minimum Days)	Redemption Notice Period (Maximum Days)
Private credit funds	\$ 982,016	\$ 949,135	See below	See below	See below
Private equity funds	433,788	673,778	See below	See below	See below
Total other investments measured using net asset valuations	\$ 1,415,804	\$ 1,622,913			

Schedule of Variable Interest Entities

The following table summarizes the aggregate carrying amount of the unconsolidated fund investments in VIEs, as well as the Company's maximum exposure to loss associated with these VIEs:

Other Investments	Maximum Exposure to Loss		
	Carrying Amount	Unfunded Commitments	Total
At December 31, 2024	\$ 1,993,362	\$ 1,863,142	\$ 3,856,504
At December 31, 2023	\$ 1,251,799	\$ 1,550,452	\$ 2,802,251

The following table is a summary of the principal-at-risk variable notes, outstanding at December 31, 2024, Mona Lisa Re issued to investors:

Effective Date	Total Principal Amount
December 3, 2024	\$ 350,000
June 13, 2024	150,000
December 20, 2022	85,000
December 20, 2022	100,000
June 29, 2021	250,000

XML 63 R44.htm IDEA: XBRL DOCUMENT

REINSURANCE (Tables)

12 Months Ended Dec. 31, 2024

SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]

Schedule of Effect of Reinsurance and Retrocessional Activity on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred

The following table sets forth the effect of reinsurance and retrocessional activity on premiums written and earned and on net claims and claim expenses incurred:

Year ended December 31,	2024	2023	2022
Premiums Written			
Direct	\$ 1,197,360	\$ 865,771	\$ 1,264,410
Assumed	10,535,706	7,996,595	7,949,130
Ceded	(1,780,850)	(1,394,553)	(2,017,380)
Net premiums written	\$ 9,952,216	\$ 7,467,813	\$ 7,196,160
Premiums Earned			
Direct	\$ 1,097,726	\$ 1,013,372	\$ 1,105,164
Assumed	10,815,336	8,072,193	7,079,632
Ceded	(1,817,302)	(1,614,432)	(1,850,807)
Net premiums earned	\$ 10,095,760	\$ 7,471,133	\$ 6,333,989
Claims and Claim Expenses			
Gross claims and claim expenses incurred	\$ 5,629,756	\$ 3,950,362	\$ 5,851,140
Claims and claim expenses recovered	(296,775)	(376,853)	(1,512,300)
Net claims and claim expenses incurred	\$ 5,332,981	\$ 3,573,509	\$ 4,338,840

Schedule of Provision for Current Expected Credit Losses of Premiums Receivable

The following table provides a roll forward of the provision for current expected credit losses of the Company's premiums receivable:

Year ended December 31,	2024	2023
Beginning balance	\$ 3,514	\$ 4,606
Provision for (release of) allowance	1,117	(2,788)
Amounts acquired ⁽¹⁾	—	1,696
Ending balance	\$ 4,631	\$ 3,514

(1) Represents Validus' provision for current expected credit losses on premiums receivable, acquired November 1, 2023.

The following table provides a roll forward of the provision for current expected credit losses of the Company's reinsurance recoverable:

Year ended December 31,	2024	2023
Beginning balance	\$ 13,279	\$ 12,169
Provision for (release of) allowance	(1,549)	(3,644)
Amounts acquired ⁽¹⁾	—	4,754
Ending balance	\$ 11,730	\$ 13,279

(1) Represents Validus' provision for current expected credit losses on reinsurance recoverable, acquired November 1, 2023.

XML 64 R45.htm IDEA: XBRL DOCUMENT

RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables)

Insurance Loss Reserves [Abstract]

Schedule of Claims and Claim Expenses

12 Months Ended

Dec. 31, 2024

The following table summarizes the Company's reserve for claims and claim expenses by segment, allocated between case reserves, ACR and IBNR:

At December 31, 2024	Case Reserves	Additional Case Reserves	IBNR	Total
Property	\$ 1,845,228	\$ 1,905,553	\$ 2,821,958	\$ 6,572,739
Casualty and Specialty	3,081,081	295,074	11,354,597	14,730,752
Total	\$ 4,926,309	\$ 2,200,627	\$ 14,176,555	\$ 21,303,491
At December 31, 2023				
Property ⁽¹⁾	\$ 2,461,580	\$ 2,401,911	\$ 2,970,129	\$ 7,833,620
Casualty and Specialty ⁽¹⁾	2,801,016	331,345	9,520,888	12,653,249
Total	\$ 5,262,596	\$ 2,733,256	\$ 12,491,017	\$ 20,486,869

(1) The previously reported amount has been adjusted to reclassify certain reserves from IBNR to ACR.

Activity in the reserve for claims and claim expenses is summarized as follows:

Year ended December 31,	2024	2023	2022
Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period	\$ 15,142,583	\$ 11,181,648	\$ 9,025,961
Net incurred related to:			
Current year	6,184,315	4,024,116	4,586,422
Prior years	(851,334)	(450,607)	(247,582)
Total net incurred	5,332,981	3,573,509	4,338,840
Net paid related to:			
Current year	488,450	364,793	105,885
Prior years	3,109,360	2,630,885	1,924,271
Total net paid	3,597,810	2,995,678	2,030,156
Foreign exchange and other ⁽¹⁾	(55,653)	62,902	(152,997)
Amounts acquired ⁽²⁾	—	3,320,202	—
Reserve for claims and claim expenses, net of reinsurance recoverable, end of period	16,822,101	15,142,583	11,181,648
Reinsurance recoverable, end of period	4,481,390	5,344,286	4,710,925
Reserve for claims and claim expenses, end of period	\$ 21,303,491	\$ 20,486,869	\$ 15,892,573

(1) Reflects the impact of the foreign exchange revaluation of the reserve for claims and claim expenses, net of reinsurance recoverable, denominated in non-U.S. dollars as at the balance sheet date, as well as reinsurance transactions accounted for under retroactive reinsurance accounting.

(2) Represents the fair value of Validus' reserve for claims and claim expenses, net of reinsurance recoverable, acquired on November 1, 2023.

The following table details the Company's prior year net development by segment of its net claims and claim expenses:

Year ended December 31,	(Favorable) Adverse Development		
	2024	2023	2022
Property	\$ (818,852)	\$ (408,905)	\$ (205,741)
Casualty and Specialty	(32,482)	(41,702)	(41,841)
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (851,334)	\$ (450,607)	\$ (247,582)

The following tables detail the prior year net development of the Company's liability for net unpaid claims and claim expenses for its Property segment, allocated between large catastrophe events and other small catastrophe events and attritional loss movements:

Year ended December 31,	2024 (Favorable) adverse development
Catastrophe net claims and claim expenses	
<i>Large catastrophe events</i>	
2023 Large Loss Events ⁽¹⁾	\$ (31,899)
2022 Weather-Related Large Losses ⁽²⁾	(284,327)
2021 Weather-Related Large Losses ⁽³⁾	(180,028)
2020 Weather-Related Large Loss Events ⁽⁴⁾	(47,512)
2019 Large Loss Events ⁽⁵⁾	(14,445)
2018 Large Loss Events ⁽⁶⁾	(38,295)
2017 Large Loss Events ⁽⁷⁾	(25,692)
<i>Total large catastrophe events</i>	(622,198)
<i>Small catastrophe events and attritional loss movements</i>	
Other small catastrophe events and attritional loss movements	(206,616)
<i>Total small catastrophe events and attritional loss movements</i>	(206,616)
Total catastrophe and attritional net claims and claim expenses	(828,814)
Actuarial assumption changes	9,962
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (818,852)

- (1) "2023 Large Loss Events" includes earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Ciaran, and certain aggregate loss contracts triggered during 2023.
- (2) "2022 Weather-Related Large Losses" includes Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contracts.
- (3) "2021 Weather-Related Large Losses" includes Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contracts.
- (4) "2020 Weather-Related Large Loss Events" includes Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contracts.
- (5) "2019 Large Loss Events" includes Hurricane Dorian and Typhoons Faxai and Hagibis and certain losses associated with aggregate loss contracts.
- (6) "2018 Large Loss Events" includes Typhoons Jebi, Mangkhut and Trami, Hurricane Florence, wildfires in California, Hurricane Michael and certain losses associated with aggregate loss contracts.
- (7) "2017 Large Loss Events" includes Hurricanes Harvey, Irma and Maria, the Mexico City Earthquake, wildfires in California and certain losses associated with aggregate loss contracts.

Year ended December 31,	2023 (Favorable) adverse development
Catastrophe net claims and claim expenses	
<i>Large catastrophe events</i>	
2022 Weather-Related Large Losses	\$ (85,653)
2021 Weather-Related Large Losses	(36,949)
2020 Weather-Related Large Loss Events	(42,577)
2019 Large Loss Events	(43,850)
2018 Large Loss Events	(40,050)
2017 Large Loss Events	(46,404)
Other	(14,337)
<i>Total large catastrophe events</i>	(309,820)
<i>Small catastrophe events and attritional loss movements</i>	
Other small catastrophe events and attritional loss movements	(99,925)
<i>Total small catastrophe events and attritional loss movements</i>	(99,925)
Total catastrophe and attritional net claims and claim expenses	(409,745)
Actuarial assumption changes	840
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (408,905)

Year ended December 31,	2022 (Favorable) adverse development
Catastrophe net claims and claim expenses	
<i>Large catastrophe events</i>	
2021 Weather-Related Large Loss Events	\$ (12,387)
2020 Weather-Related Large Loss Events	(24,589)
2019 Large Loss Events	(97,034)
2018 Large Loss Events	(20,318)
2017 Large Loss Events	(39,481)
Other	(4,755)
<i>Total large catastrophe events</i>	(198,564)
<i>Small catastrophe events and attritional loss movements</i>	
Other small catastrophe events and attritional loss movements	(31,024)
<i>Total small catastrophe events and attritional loss movements</i>	(31,024)
Total catastrophe and attritional net claims and claim expenses	(229,588)
Actuarial assumption changes	23,847
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (205,741)

The following table details the net development of the Company's prior accident years net claims and claim expenses for its Casualty and Specialty segment:

Year ended December 31,	(Favorable) Adverse Development		
	2024	2023	2022
Actuarial methods - actual reported claims less than expected claims	\$ (67,595)	\$ (44,612)	\$ (63,353)
Actuarial assumption changes	35,113	2,910	21,512
Total net (favorable) adverse development of prior accident years net claims and claim expenses	\$ (32,482)	\$ (41,702)	\$ (41,841)

The reconciliation of the net incurred and paid claims development tables to the reserve for claims and claim expenses in the consolidated balance sheet is as follows:

At December 31, 2024	
Net Reserve for Claims and Claim Expenses	
Property	\$ 4,906,841
Casualty and Specialty	11,915,260
Total net reserve for claims and claim expenses	16,822,101
Reinsurance Recoverable	
Property	\$ 1,665,898
Casualty and Specialty	2,815,492
Total reinsurance recoverable	4,481,390
Total reserve for claims and claim expenses	\$ 21,303,491

Schedule of Short-duration Insurance Contracts, Claims Development

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance											At December 31, 2024
Accident Year	For the year ended December 31,										IBNR and ACR
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
2015	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	
2016	\$ 1,670,190	\$ 1,603,613	\$ 1,572,065	\$ 1,527,011	\$ 1,505,261	\$ 1,494,406	\$ 1,497,311	\$ 1,489,897	\$ 1,487,053	\$ 1,485,686	\$ 51,310
2017	—	1,872,508	1,882,586	1,843,984	1,811,320	1,734,299	1,752,579	1,784,035	1,762,581	1,768,120	31,713
2018	—	—	3,606,410	3,423,131	3,340,805	3,262,344	3,230,732	3,168,653	3,160,015	3,171,839	106,741
2019	—	—	—	2,912,949	3,132,829	3,065,222	2,934,773	2,926,168	2,965,944	2,980,818	178,549
2020	—	—	—	—	2,706,854	2,680,637	2,591,017	2,554,243	2,564,553	2,620,761	249,622
2021	—	—	—	—	—	4,393,340	4,392,922	4,397,548	4,370,007	4,301,296	761,291
2022	—	—	—	—	—	—	5,534,493	5,388,056	5,176,258	4,906,690	1,018,009
2023	—	—	—	—	—	—	—	5,902,647	5,627,982	5,128,208	2,231,524
2024	—	—	—	—	—	—	—	—	5,277,384	5,200,462	3,144,564
2024 Total	—	—	—	—	—	—	—	—	—	6,077,913	5,042,190
										\$ 37,641,793	\$ 12,815,513
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance											
For the year ended December 31,											
Accident Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	
2015	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)
2016	\$ 456,673	\$ 787,860	\$ 1,009,810	\$ 1,137,612	\$ 1,239,336	\$ 1,303,717	\$ 1,353,866	\$ 1,391,122	\$ 1,417,548	\$ 1,430,775	
2017	—	469,972	895,958	1,103,921	1,280,778	1,416,750	1,522,045	1,586,304	1,615,296	1,653,636	
2018	—	—	922,620	1,503,737	1,864,861	2,229,595	2,416,297	2,579,800	2,726,059	2,850,754	
2019	—	—	—	672,825	1,190,862	1,593,543	1,900,077	2,118,511	2,238,238	2,382,009	
2020	—	—	—	—	382,173	991,137	1,350,356	1,678,643	1,996,128	2,225,414	
2021	—	—	—	—	—	756,409	1,810,464	2,323,405	2,795,075	3,239,789	
2022	—	—	—	—	—	—	886,330	2,092,957	2,922,881	3,356,124	
2023	—	—	—	—	—	—	—	280,032	1,446,448	2,260,464	
2024	—	—	—	—	—	—	—	—	516,063	1,289,115	
2024 Total	—	—	—	—	—	—	—	—	—	475,609	
										\$ 21,163,689	
										Outstanding liabilities from accident year 2014 and prior, net of reinsurance	386,060
										Adjustment for unallocated loss adjustment expenses	114,425
										Unamortized fair value and other adjustments recorded in connection with acquisitions	(156,488)
										Liability for claims and claim expenses, net of reinsurance	\$ 16,822,101

The following table details the Company's Property segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance											At December 31, 2024 IBNR and ACR													
Accident Year	For the year ended December 31,																							
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024														
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)														
2015	\$	506,243	\$	456,920	\$	414,379	\$	397,750	\$	388,076	\$	383,214	\$	374,258	\$	376,457	\$	375,420	\$	373,895	\$	511		
2016	—	—	—	572,814	—	592,915	—	564,880	—	544,624	—	517,878	—	514,263	—	532,556	—	522,917	—	522,370	—	3,361		
2017	—	—	—	—	—	1,951,429	—	1,813,187	—	1,687,873	—	1,670,648	—	1,613,614	—	1,550,274	—	1,521,356	—	1,486,890	—	76,065		
2018	—	—	—	—	—	—	—	1,348,628	—	1,286,032	—	1,158,452	—	1,147,450	—	1,098,897	—	1,072,994	—	1,072,994	—	64,246		
2019	—	—	—	—	—	—	—	—	—	1,162,088	—	1,135,337	—	1,042,748	—	976,162	—	914,252	—	912,496	—	35,810		
2020	—	—	—	—	—	—	—	—	—	—	—	—	—	2,075,320	—	2,076,315	—	2,010,634	—	1,972,883	—	265,855		
2021	—	—	—	—	—	—	—	—	—	—	—	—	—	2,759,175	—	2,758,871	—	2,655,570	—	2,440,274	—	143,701		
2022	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2,544,022	—	2,431,989	—	2,045,341	—	597,038		
2023	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1,469,539	—	1,376,749	—	577,889		
2024	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1,938,913	—	1,407,007		
Total																				\$	14,142,805	\$	3,171,483	
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance											At December 31, 2024													
Accident Year	For the year ended December 31,																							
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024														
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)														
2015	\$	141,410	\$	277,662	\$	322,118	\$	344,855	\$	356,090	\$	360,172	\$	362,864	\$	365,875	\$	369,874	\$	370,585				
2016	—	—	—	144,973	—	324,607	—	405,317	—	438,693	—	465,432	—	476,483	—	481,117	—	477,703	—	480,030				
2017	—	—	—	—	—	619,039	—	935,017	—	1,115,451	—	1,223,434	—	1,243,652	—	1,291,080	—	1,313,624	—	1,323,316				
2018	—	—	—	—	—	—	—	453,864	—	675,404	—	838,513	—	872,831	—	917,391	—	852,022	—	853,609				
2019	—	—	—	—	—	—	—	—	—	164,785	—	457,281	—	632,491	—	718,321	—	777,272	—	818,617				
2020	—	—	—	—	—	—	—	—	—	—	—	284,033	—	878,467	—	1,139,605	—	1,332,331	—	1,517,898				
2021	—	—	—	—	—	—	—	—	—	—	—	—	—	585,175	—	1,371,613	—	1,852,117	—	1,984,325				
2022	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	76,656	—	764,636	—	1,157,016				
2023	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	232,849	—	536,495				
2024	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	224,606				
Total																				\$	9,266,497	\$	4,906,841	
Outstanding liabilities from accident year 2014 and prior, net of reinsurance												49,601												
Adjustment for unallocated loss adjustment expenses												15,115												
Unamortized fair value and other adjustments recorded in connection with acquisitions												(34,183)												
Liability for claims and claim expenses, net of reinsurance												\$	4,906,841											

The following table details the Company's Casualty and Specialty segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

Incurred Claims and Claim Expenses, Net of Reinsurance												At December 31, 2024
Accident Year	For the year ended December 31,											
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	IBNR and ACR	
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)		
2015	\$ 1,163,947	\$ 1,146,693	\$ 1,157,686	\$ 1,129,261	\$ 1,117,185	\$ 1,111,192	\$ 1,123,053	\$ 1,113,440	\$ 1,111,633	\$ 1,111,791	\$ 50,799	
2016	—	1,299,694	1,289,671	1,279,104	1,266,696	1,216,421	1,238,316	1,251,479	1,239,664	1,245,750	28,352	
2017	—	—	1,654,981	1,609,944	1,652,932	1,591,696	1,617,118	1,618,379	1,638,659	1,674,949	30,676	
2018	—	—	—	1,641,037	1,784,201	1,779,190	1,776,321	1,778,718	1,867,047	1,907,824	114,303	
2019	—	—	—	—	1,544,766	1,545,300	1,548,269	1,578,081	1,650,301	1,708,265	213,812	
2020	—	—	—	—	—	2,426,514	2,317,602	2,321,233	2,359,373	2,328,413	495,436	
2021	—	—	—	—	—	—	2,775,318	2,629,185	2,520,688	2,466,416	874,308	
2022	—	—	—	—	—	—	—	3,358,625	3,195,993	3,082,867	1,634,486	
2023	—	—	—	—	—	—	—	—	3,807,845	3,823,713	2,566,675	
2024	—	—	—	—	—	—	—	—	—	—	3,635,183	
Total	—	—	—	—	—	—	—	—	—	\$ 23,498,988	\$ 9,644,030	
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance												
Accident Year	For the year ended December 31,											
	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024		
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)		
2015	\$ 315,263	\$ 510,198	\$ 687,692	\$ 792,757	\$ 883,246	\$ 943,545	\$ 991,002	\$ 1,025,247	\$ 1,047,674	\$ 1,060,190		
2016	—	324,999	571,351	688,604	842,085	851,318	1,045,562	1,105,187	1,137,593	1,173,606		
2017	—	—	303,581	568,720	749,410	1,006,161	1,172,645	1,288,900	1,412,435	1,527,438		
2018	—	—	—	218,961	515,458	755,030	1,027,246	1,201,120	1,386,216	1,528,400		
2019	—	—	—	—	217,388	533,856	717,865	960,322	1,218,856	1,406,797		
2020	—	—	—	—	—	472,376	931,997	1,183,800	1,462,744	1,721,891		
2021	—	—	—	—	—	—	301,155	723,344	1,070,764	1,371,799		
2022	—	—	—	—	—	—	—	203,376	681,812	1,103,448		
2023	—	—	—	—	—	—	—	—	283,214	752,620		
2024	—	—	—	—	—	—	—	—	—	251,003		
Total	—	—	—	—	—	—	—	—	—	\$ 11,897,192		
Outstanding liabilities from accident year 2014 and prior, net of reinsurance											336,459	
Adjustment for unallocated loss adjustment expenses											99,310	
Unamortized fair value and other adjustments recorded in connection with acquisitions											(122,305)	
Liability for claims and claim expenses, net of reinsurance											\$ 11,915,260	

The following is unaudited supplementary information about average historical claims duration by segment:

Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (Number of Years)											
At December 31, 2024	1	2	3	4	5	6	7	8	9	10	
Property	20.7 %	28.8 %	16.4 %	6.9 %	5.5 %	0.9 %	0.9 %	0.4 %	0.7 %	0.2 %	
Casualty and Specialty	12.3 %	16.3 %	12.4 %	12.9 %	10.6 %	8.4 %	6.3 %	4.5 %	2.5 %	1.1 %	

[XML 65 R46.htm IDEA: XBRL DOCUMENT](#)

DEBT AND CREDIT FACILITIES (Tables)

[Debt Disclosure \[Abstract\]](#)

[Schedule of Carrying Values and Estimated Fair Values of Debt Instruments](#)

A summary of the Company's debt obligations on its consolidated balance sheets is set forth below:

	December 31, 2024						December 31, 2023			
	Fair Value		Carrying Value				Fair Value		Carrying Value	
5.750% Senior Notes due 2033	\$	755,693	\$	742,068	\$	758,783	\$	741,124		
3.600% Senior Notes due 2029		376,816		396,051		371,276		395,137		
3.450% Senior Notes due 2027		290,070		298,765		283,350		298,270		
3.700% Senior Notes due 2025		299,550		299,908		293,154		299,537		
4.750% Senior Notes due 2025 (DaVinci) ⁽¹⁾		149,363		149,897		147,489		149,587		
Total senior notes		1,871,492		1,886,689		1,854,052		1,883,655		
Medici Revolving Credit Facility ⁽²⁾		—		—		75,000		75,000		
Total debt	\$	1,871,492	\$	1,886,689	\$	1,929,052	\$	1,958,655		

- (1) RenaissanceRe owns a noncontrolling economic interest in its joint venture DaVinci. Because RenaissanceRe controls a majority of DaVinci's issued voting shares, the consolidated financial statements of DaVinci are included in the consolidated financial statements of RenaissanceRe. However, RenaissanceRe does not guarantee or provide credit support for DaVinci and RenaissanceRe's financial exposure to DaVinci is limited to its investment in DaVinci's shares and counterparty credit risk arising from reinsurance transactions.
- (2) RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici's issued voting shares, the financial statements of Medici are included in RenaissanceRe's consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions.

[Schedule of Aggregate Amount of Maturities Related to the Company's Debt Obligations](#)

The following table sets forth the scheduled maturity of the Company's aggregate amount of its debt obligation reflected on its consolidated balance sheet at December 31, 2024:

2025	\$ 450,000
2026	—
2027	300,000
2028	—
2029	400,000
After 2029	750,000
Unamortized discount and debt issuance expenses	(13,311)
	\$ 1,886,689

[Schedule of Credit Facilities](#)

The outstanding amounts issued or drawn under each of the Company's significant credit facilities is set forth below:

At December 31, 2024	Issued or Drawn
Revolving Credit Facility ⁽¹⁾	\$ —
Medici Revolving Credit Facility ⁽²⁾	—
Bilateral Letter of Credit Facilities	
Secured	262,168
Unsecured	357,443
	\$ 619,611

- (1) At December 31, 2024, no amounts were issued or drawn under this facility.
- (2) RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici's voting shares, the financial statements of Medici are included in RenaissanceRe's consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions. The drawn amount of the Medici revolving credit facility is included on the Company's consolidated balance sheets under debt.

[XML 66 R47.htm IDEA: XBRL DOCUMENT](#)

NONCONTROLLING INTERESTS (Tables)

[Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest \[Abstract\]](#)

[Schedule of Redeemable Noncontrolling Interest](#)

12 Months Ended Dec. 31, 2024

A summary of the Company's redeemable noncontrolling interests on its consolidated balance sheets is set forth below:

At December 31,	2024	2023
Redeemable noncontrolling interest - DaVinci	\$ 3,061,708	\$ 2,541,482
Redeemable noncontrolling interest - Medici	1,646,745	1,650,229
Redeemable noncontrolling interest - Vermeer	1,799,857	1,555,297
Redeemable noncontrolling interest - Fontana	469,439	353,823
Redeemable noncontrolling interests	<u>\$ 6,977,749</u>	<u>\$ 6,100,831</u>

A summary of the Company's redeemable noncontrolling interests on its consolidated statements of operations is set forth below:

Year ended December 31,	2024	2023	2022
Redeemable noncontrolling interest - DaVinci	\$ 627,055	\$ 545,812	\$ (65,514)
Redeemable noncontrolling interest - Medici	202,941	239,250	(70,504)
Redeemable noncontrolling interest - Vermeer	244,560	239,457	43,058
Redeemable noncontrolling interest - Fontana	15,616	34,476	(5,653)
Net income (loss) attributable to redeemable noncontrolling interests	<u>\$ 1,090,172</u>	<u>\$ 1,058,995</u>	<u>\$ (98,613)</u>

The activity in redeemable noncontrolling interest - DaVinci is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 2,541,482	\$ 1,740,300
Redemption of shares from redeemable noncontrolling interests	(406,849)	(123,272)
Sale of shares to redeemable noncontrolling interests, net of adjustments	300,020	378,642
Net income (loss) attributable to redeemable noncontrolling interest	627,055	545,812
Ending balance	<u>\$ 3,061,708</u>	<u>\$ 2,541,482</u>

The activity in redeemable noncontrolling interest - Medici is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 1,650,229	\$ 1,036,218
Redemption of shares from redeemable noncontrolling interests	(406,644)	(107,549)
Sale of shares to redeemable noncontrolling interests	200,219	482,310
Net income (loss) attributable to redeemable noncontrolling interest	202,941	239,250
Ending balance	<u>\$ 1,646,745</u>	<u>\$ 1,650,229</u>

The activity in redeemable noncontrolling interest - Vermeer is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 1,555,297	\$ 1,490,840
Dividends on common shares	(175,000)	(175,000)
Sale of shares to redeemable noncontrolling interest	175,000	—
Net income (loss) attributable to redeemable noncontrolling interest	244,560	239,457
Ending balance	<u>\$ 1,799,857</u>	<u>\$ 1,555,297</u>

The activity in redeemable noncontrolling interest - Fontana is detailed in the table below:

Year ended December 31,	2024	2023
Beginning balance	\$ 353,823	\$ 268,031
Sale of limited partner interest to redeemable noncontrolling interest	100,000	51,316
Net income (loss) attributable to redeemable noncontrolling interest	15,616	34,476
Ending balance	<u>\$ 469,439</u>	<u>\$ 353,823</u>

XML 67 R48.htm IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES (Tables)

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

[Summary of the Principal-at-risk Variable Notes](#)

**12 Months Ended
Dec. 31, 2024**

The following table summarizes the aggregate carrying amount of the unconsolidated fund investments in VIEs, as well as the Company's maximum exposure to loss associated with these VIEs:

Other Investments	Maximum Exposure to Loss		
	Carrying Amount	Unfunded Commitments	Total
At December 31, 2024	\$ 1,993,362	\$ 1,863,142	\$ 3,856,504
At December 31, 2023	\$ 1,251,799	\$ 1,550,452	\$ 2,802,251

The following table is a summary of the principal-at-risk variable notes, outstanding at December 31, 2024, Mona Lisa Re issued to investors:

Effective Date	Total Principal Amount
December 3, 2024	\$ 350,000
June 13, 2024	150,000
December 20, 2022	85,000
December 20, 2022	100,000
June 29, 2021	250,000

XML 68 R49.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Tables)

[Stockholders' Equity Note \[Abstract\]](#)

[Rollforward of Common Stock Issued and Outstanding](#)

**12 Months Ended
Dec. 31, 2024**

The following table is a summary of changes in common shares issued and outstanding:

Year ended December 31,	2024	2023	2022
(thousands of shares)			
Beginning balance	52,694	43,718	44,445
Amount allocated to participating common shareholders	—	8,568	—
Issuance of shares	—	—	(1,051)
Repurchase of shares	(2,711)	408	324
Issuance of performance share and restricted stock awards	198	—	—
Ending balance	<u>50,181</u>	<u>52,694</u>	<u>43,718</u>

XML 69 R50.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

[Earnings Per Share \[Abstract\]](#)

[Schedule of Computation of Basic and Diluted Earnings Per Common Share](#)

**12 Months Ended
Dec. 31, 2024**

The following table sets forth the computation of basic and diluted earnings per common share:

Year ended December 31,	2024	2023	2022
(common shares in thousands)			
Numerator:			
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 1,834,985	\$ 2,525,757	\$ (1,096,578)
Amount allocated to participating common shareholders ⁽¹⁾	(27,472)	(37,308)	(1,079)
Net income (loss) allocated to RenaissanceRe common shareholders	<u>\$ 1,807,513</u>	<u>\$ 2,488,449</u>	<u>\$ (1,097,657)</u>
Denominator:			
Denominator for basic income (loss) per RenaissanceRe common share - weighted average common shares ⁽²⁾	51,186	47,493	43,040
Per common share equivalents of non-vested shares ⁽²⁾	153	114	—
Denominator for diluted income (loss) per RenaissanceRe common share - adjusted weighted average common shares and assumed conversions ⁽²⁾	<u>51,339</u>	<u>47,607</u>	<u>43,040</u>
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - basic	\$ 35.31	\$ 52.40	\$ (25.50)
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - diluted	<u>\$ 35.21</u>	<u>\$ 52.27</u>	<u>\$ (25.50)</u>

(1) Represents earnings and dividends attributable to holders of unvested shares issued pursuant to the Company's stock compensation plans.

(2) In periods for which the Company has net loss allocated to RenaissanceRe common shareholders, the denominator used in calculating net loss attributable to RenaissanceRe common shareholders per common share - basic is also used in calculating net loss attributable to RenaissanceRe common shareholders per common share - diluted. For the year ended December 31, 2022, per common share equivalents of non-vested shares of 90 thousand could potentially be dilutive in future periods if the Company reports net income allocated to RenaissanceRe common shareholders.

XML 70 R51.htm IDEA: XBRL DOCUMENT

TAXATION (Tables)

[Income Tax Disclosure \[Abstract\]](#)

[Schedule of Income before Income Tax, Domestic and Foreign](#)

The following is a summary of the Company's income (loss) before taxes allocated between domestic and foreign operations:

**12 Months Ended
Dec. 31, 2024**

Year ended December 31,	2024	2023	2022
Domestic			
Bermuda	\$ 2,704,721	\$ 2,622,066	\$ (672,950)
Foreign			
Singapore	61,570	64,003	112
Ireland	2,650	1,730	6
U.S.	93,606	308,768	(367,799)
Australia	14,487	7,570	(29,214)
Switzerland	57,585	(22,016)	(72,773)
Luxembourg	(50)	(16)	—
Canada	(3,501)	2,040	—
U.K.	62,092	125,915	(76,217)
Income (loss) before taxes	<u>\$ 2,993,160</u>	<u>\$ 3,110,060</u>	<u>\$ (1,218,835)</u>

Schedule of Components of Income Tax (Expense) Benefit

Income tax benefit (expense) is comprised as follows:

Income tax benefit (expense)	Current	Deferred	Total
Year ended December 31, 2024	\$ (56,718)	\$ 24,090	\$ (32,628)
Year ended December 31, 2023	\$ (57,422)	\$ 567,489	\$ 510,067
Year ended December 31, 2022	\$ (3,078)	\$ 62,097	\$ 59,019

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the difference between the provision for income taxes and the expected tax provision at the weighted average tax rate is as follows:

Year ended December 31,	2024	2023	2022
Expected income tax benefit (expense)	\$ (60,684)	\$ (103,963)	\$ 114,721
Nondeductible expenses	(1,671)	(535)	(508)
Reinsurance adjustment	4,384	4,746	(1,265)
Effect of change in tax rate	(160)	(729)	7,461
OECD Pillar Two global minimum tax	(16,603)	—	—
GAAP to statutory accounting difference	(1,113)	(1,781)	(6,019)
Withholding tax	(1,614)	(1,078)	(2,154)
Recognition of Bermuda net deferred tax asset	8,339	593,765	—
Change in valuation allowance	66,198	45,192	(62,133)
Foreign branch adjustments	(30,998)	(25,908)	11,656
Other	1,294	358	(2,740)
Income tax benefit (expense)	<u>\$ (32,628)</u>	<u>\$ 510,067</u>	<u>\$ 59,019</u>

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below:

At December 31,	2024	2023
Deferred tax assets		
Intangible assets	\$ 420,143	\$ 408,654
Value of in-force business	167,599	167,599
Tax loss carryforwards	152,864	197,498
Reserve for claims and claim expenses	131,121	95,685
Unearned premiums	59,441	68,408
Amortization and depreciation	23,877	16,386
Deferred finance charges	17,832	19,442
Accrued expenses	4,336	2,849
Investments	2,687	37,044
Deferred underwriting results	1,548	9,373
	<u>981,448</u>	<u>1,022,938</u>
Deferred tax liabilities		
Deferred acquisition expenses	(125,347)	(112,157)
VOBA	(17,540)	(46,109)
Deferred revenue	(8,685)	—
U.S. tax accounting method change	(7,312)	—
	<u>(158,884)</u>	<u>(158,266)</u>
Net deferred tax asset (liability) before valuation allowance	822,564	864,672
Valuation allowance	(147,079)	(213,277)
Net deferred tax asset (liability)	<u>\$ 675,485</u>	<u>\$ 651,395</u>

XML 71 R52.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING (Tables)

Segment Reporting, Measurement Disclosures [Abstract]

Schedule of Significant Components of the Company's Revenues and Expenses

12 Months Ended Dec. 31, 2024

A summary of the significant components of the Company's revenues and expenses by segment is as follows:

Year ended December 31, 2024	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 4,823,731	\$ 6,909,335	\$ —	\$ 11,733,066
Net premiums written	\$ 3,833,636	\$ 6,118,580	\$ —	\$ 9,952,216
Net premiums earned	\$ 3,850,352	\$ 6,245,408	\$ —	\$ 10,095,760
Net claims and claim expenses incurred	1,141,726	4,191,255	—	5,332,981
Acquisition expenses	758,554	1,885,313	—	2,643,867
Operational expenses	302,360	194,228	—	496,588
Underwriting income (loss)	<u>\$ 1,647,712</u>	<u>\$ (25,388)</u>	<u>\$ —</u>	<u>1,622,324</u>
Net investment income	—	—	1,654,289	1,654,289
Net foreign exchange gains (losses)	—	—	(76,076)	(76,076)
Equity in earnings (losses) of other ventures	—	—	47,087	47,087
Other income (loss)	—	—	1,928	1,928
Net realized and unrealized gains (losses) on investments	—	—	(27,840)	(27,840)
Corporate expenses	—	—	(134,784)	(134,784)
Interest expense	—	—	(93,768)	(93,768)
Income (loss) before taxes	—	—	—	2,993,160
Income tax benefit (expense)	—	—	(32,628)	(32,628)
Net (income) loss attributable to redeemable noncontrolling interests	—	—	(1,090,172)	(1,090,172)
Dividends on preference shares	—	—	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	—	—	—	<u>\$ 1,834,985</u>
Net claims and claim expenses incurred - current accident year	\$ 1,960,578	\$ 4,223,737	\$ —	\$ 6,184,315
Net claims and claim expenses incurred - prior accident years	(818,852)	(32,482)	—	(851,334)
Net claims and claim expenses incurred - total	<u>\$ 1,141,726</u>	<u>\$ 4,191,255</u>	<u>\$ —</u>	<u>\$ 5,332,981</u>
Net claims and claim expense ratio - current accident year	50.9 %	67.6 %	—	61.3 %
Net claims and claim expense ratio - prior accident years	(21.2) %	(0.5) %	—	(8.5) %
Net claims and claim expense ratio - calendar year	29.7 %	67.1 %	—	52.8 %
Underwriting expense ratio	27.5 %	33.3 %	—	31.1 %
Combined ratio	<u>57.2 %</u>	<u>100.4 %</u>	<u>—</u>	<u>83.9 %</u>

Year ended December 31, 2023	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 3,562,414	\$ 5,299,952	\$ —	\$ 8,862,366
Net premiums written	\$ 2,967,309	\$ 4,500,504	\$ —	\$ 7,467,813
Net premiums earned	\$ 3,090,792	\$ 4,380,341	\$ —	\$ 7,471,133
Net claims and claim expenses incurred	799,905	2,773,604	—	3,573,509
Acquisition expenses	600,127	1,274,907	—	1,875,034
Operational expenses	251,433	123,749	—	375,182
Underwriting income (loss)	<u>\$ 1,439,327</u>	<u>\$ 208,081</u>	<u>\$ —</u>	<u>1,647,408</u>
Net investment income	—	—	1,253,110	1,253,110
Net foreign exchange gains (losses)	—	—	(41,479)	(41,479)
Equity in earnings (losses) of other ventures	—	—	43,474	43,474
Other income (loss)	—	—	(6,152)	(6,152)
Net realized and unrealized gains (losses) on investments	—	—	414,522	414,522
Corporate expenses	—	—	(127,642)	(127,642)
Interest expense	—	—	(73,181)	(73,181)
Income (loss) before taxes	—	—	—	3,110,060
Income tax benefit (expense)	—	—	510,067	510,067
Net (income) loss attributable to redeemable noncontrolling interests	—	—	(1,058,995)	(1,058,995)
Dividends on preference shares	—	—	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	—	—	—	<u>\$ 2,525,757</u>
Net claims and claim expenses incurred - current accident year	\$ 1,208,810	\$ 2,815,306	\$ —	\$ 4,024,116
Net claims and claim expenses incurred - prior accident years	(408,905)	(41,702)	—	(450,607)
Net claims and claim expenses incurred - total	<u>\$ 799,905</u>	<u>\$ 2,773,604</u>	<u>\$ —</u>	<u>\$ 3,573,509</u>
Net claims and claim expense ratio - current accident year	39.1 %	64.3 %	—	53.9 %
Net claims and claim expense ratio - prior accident years	(13.2) %	(1.0) %	—	(6.1) %
Net claims and claim expense ratio - calendar year	25.9 %	63.3 %	—	47.8 %
Underwriting expense ratio	27.5 %	31.9 %	—	30.1 %
Combined ratio	<u>53.4 %</u>	<u>95.2 %</u>	<u>—</u>	<u>77.9 %</u>

Year ended December 31, 2022	Property	Casualty and Specialty	Other	Total
Gross premiums written	\$ 3,734,241	\$ 5,479,299	\$ —	\$ 9,213,540
Net premiums written	\$ 2,847,659	\$ 4,348,501	\$ —	\$ 7,196,160
Net premiums earned	\$ 2,770,227	\$ 3,563,762	\$ —	\$ 6,333,989
Net claims and claim expenses incurred	2,044,771	2,294,069	—	4,338,840
Acquisition expenses	547,210	1,021,396	—	1,568,606
Operational expenses	194,355	82,336	—	276,691
Underwriting income (loss)	\$ (16,109)	\$ 165,961	\$ —	\$ 149,852
Net investment income			559,932	559,932
Net foreign exchange gains (losses)			(56,909)	(56,909)
Equity in earnings (losses) of other ventures			11,249	11,249
Other income (loss)			12,636	12,636
Net realized and unrealized gains (losses) on investments			(1,800,485)	(1,800,485)
Corporate expenses			(46,775)	(46,775)
Interest expense			(48,335)	(48,335)
Income (loss) before taxes				(1,218,835)
Income tax benefit (expense)			59,019	59,019
Net (income) loss attributable to redeemable noncontrolling interests			98,613	98,613
Dividends on preference shares			(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders			\$	\$ (1,096,578)
Net claims and claim expenses incurred – current accident year	\$ 2,250,512	\$ 2,335,910	\$ —	\$ 4,586,422
Net claims and claim expenses incurred – prior accident years	(205,741)	(41,841)	—	(247,582)
Net claims and claim expenses incurred – total	\$ 2,044,771	\$ 2,294,069	\$ —	\$ 4,338,840
Net claims and claim expense ratio – current accident year	81.3%	65.5%		72.4%
Net claims and claim expense ratio – prior accident years	(7.4)%	(1.1)%		(3.9)%
Net claims and claim expense ratio – calendar year	73.8%	64.4%		68.5%
Underwriting expense ratio	26.8%	30.9%		29.2%
Combined ratio	100.6%	95.3%		97.7%

[Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure](#)

The following is a summary of the Company's gross premiums written allocated to the territory of coverage exposure:

Year ended December 31,	2024		2023		2022	
	Gross Premiums Written	Percentage of Gross Premiums Written	Gross Premiums Written	Percentage of Gross Premiums Written	Gross Premiums Written	Percentage of Gross Premiums Written
Property						
U.S. and Caribbean	\$ 2,996,981	25.5 %	\$ 2,303,013	26.0 %	\$ 2,343,830	25.5 %
Worldwide	1,063,292	9.1 %	798,623	9.0 %	1,053,369	11.4 %
Europe	244,523	2.1 %	163,500	1.9 %	62,998	0.7 %
Worldwide (excluding U.S.) ⁽¹⁾	180,688	1.5 %	70,646	0.8 %	37,436	0.4 %
Japan	106,533	0.9 %	85,823	1.0 %	104,767	1.1 %
Australia and New Zealand	101,976	0.9 %	70,107	0.8 %	86,080	0.9 %
Other	129,738	1.1 %	70,702	0.8 %	45,761	0.5 %
Total Property	4,823,731	41.1 %	3,562,414	40.3 %	3,734,241	40.5 %
Casualty and Specialty						
Worldwide	3,217,662	27.3 %	2,280,687	25.7 %	2,328,030	25.3 %
U.S. and Caribbean	2,986,956	25.5 %	2,333,096	26.3 %	2,556,466	27.7 %
Europe	353,863	3.0 %	197,228	2.2 %	327,631	3.6 %
Worldwide (excluding U.S.) ⁽¹⁾	195,489	1.7 %	130,334	1.5 %	177,746	1.9 %
Australia and New Zealand	43,183	0.4 %	27,397	0.3 %	35,973	0.4 %
Other	112,182	1.0 %	331,210	3.7 %	53,253	0.6 %
Total Casualty and Specialty	6,909,335	58.9 %	5,299,952	59.7 %	5,479,299	59.5 %
Total gross premiums written	\$ 11,733,066	100.0 %	\$ 8,862,366	100.0 %	\$ 9,213,540	100.0 %

(1) The category "Worldwide (excluding U.S.," consists of contracts that cover more than one geographic region (other than the U.S.).

[XML 72 R53.htm IDEA: XBRL DOCUMENT](#)

**STOCK INCENTIVE
COMPENSATION
AND EMPLOYEE
BENEFIT PLANS
(Tables)**

[Share-Based Payment Arrangement \[Abstract\]](#)
[Schedule of Share-based Compensation, Cash Settled Restricted Stock Units and Performance Shares](#)

12 Months Ended

Dec. 31, 2024

Performance Share Awards

The following table provides a roll forward of the Company's unvested performance share awards:

	Number of Shares ⁽¹⁾	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	141,068	\$ 163.98
Awards granted	69,548	145.49
Awards forfeited	(19,352)	—
Nonvested at December 31, 2022	191,264	\$ 159.07
Awards granted	160,796	211.18
Awards vested	(38,846)	170.40
Awards forfeited	(26,994)	—
Nonvested at December 31, 2023	286,220	\$ 185.73
Awards granted	50,654	223.35
Awards vested	(53,083)	162.61
Awards forfeited	(2,793)	—
Nonvested at December 31, 2024	280,998	\$ 197.11

(1) For performance share awards, the number of shares is stated at the maximum number that can be attained if the performance conditions are fully met. Forfeitures represent shares forfeited due to vesting below the maximum attainable as a result of the Company not fully meeting the performance conditions.

Restricted Stock Awards

The following table provides a roll forward of the Company's unvested restricted stock awards:

	Employee Restricted Stock Awards		Non-Employee Director Restricted Stock Awards		Total Restricted Stock Awards	
	Number of Shares	Weighted Average Grant Date Fair Value	Number of Shares	Weighted Average Grant Date Fair Value	Number of Shares	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2021	623,332	\$ 153.02	20,601	\$ 162.60	643,933	\$ 153.32
Awards granted	354,887	143.86	12,721	145.77	367,608	143.92
Awards vested	(242,628)	148.30	(12,307)	159.20	(254,935)	148.83
Awards forfeited	(22,795)	—	—	—	(22,795)	—
Nonvested at December 31, 2022	712,796	\$ 150.19	21,015	\$ 154.40	733,811	\$ 150.31
Awards granted	378,994	199.24	9,064	215.79	388,058	199.65
Awards vested	(279,363)	151.15	(11,861)	161.56	(291,224)	151.57
Awards forfeited	(15,278)	—	—	—	(15,278)	—
Nonvested at December 31, 2023	797,149	\$ 172.74	18,218	\$ 180.70	815,367	\$ 172.91
Awards granted	260,209	234.94	8,645	223.66	268,854	234.69
Awards vested	(293,175)	164.67	(10,749)	177.16	(303,924)	165.11
Awards forfeited	(17,694)	—	—	—	(17,694)	—
Nonvested at December 31, 2024	746,489	\$ 197.26	16,114	\$ 207.95	762,603	\$ 197.49

[XML 73 R54.htm IDEA: XBRL DOCUMENT](#)

**STATUTORY
REQUIREMENTS
(Tables)**

[Insurance \[Abstract\]](#)
[Schedule of Actual and Required Statutory Capital and Surplus](#)

The following table summarizes the statutory capital and surplus and required minimum statutory capital and surplus of the Company's primary regulated insurance operations in its most significant regulatory jurisdictions:

At December 31,	Bermuda ⁽²⁾		Switzerland ⁽²⁾		U.K. ⁽³⁾		U.S. ⁽⁴⁾	
	2024	2023	2024	2023	2024	2023	2024	2023
Statutory capital and surplus	\$ 11,793,261	\$ 12,141,907	\$ 1,908,106	\$ 2,644,998	\$ 952,309	\$ 935,776	\$ 1,255,304	\$ 1,044,010
Required statutory capital and surplus	2,686,108	2,284,208	1,049,922	987,707	952,309	935,776	967,735	794,061

- (1) Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). The Company's primary Bermuda-domiciled insurance subsidiaries' required statutory capital and surplus is based on the minimum solvency margin. On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated. The previously reported statutory capital and surplus and required statutory capital and surplus at December 31, 2023 have been updated to actual amounts filed and reflect guidance received by the BMA on February 23, 2024 related to the impact of the CIT in the statutory financial statements.
- (2) Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland (which was acquired on November 1, 2023) and its Bermuda branch. On June 21, 2024, Validus Switzerland merged into RREAG.
- (3) Includes Syndicate 1458. With respect to statutory capital and surplus and required statutory capital and surplus, underwriting capacity of a member of Lloyd's must be supported by providing a deposit in the form of cash, securities or letters of credit, which are referred to as FAL. Syndicate 1458 is capitalized by its FAL, with the related assets not held on its balance sheet.
- (4) Includes Renaissance Reinsurance U.S.

[Schedule of Statutory Net \(Loss\) Income](#)

The following table summarizes the statutory net income (loss) of the Company's primary regulated insurance operations in its most significant regulatory jurisdictions:

	Statutory Net Income (Loss)			
	Bermuda ⁽¹⁾	Switzerland ⁽²⁾	U.K. ⁽³⁾	U.S. ⁽⁴⁾
Year ended December 31, 2024	\$ 2,056,265	\$ 312,000	\$ 89,169	\$ (87,897)
Year ended December 31, 2023	2,699,083	225,751	158,258	(17,618)
Year ended December 31, 2022	(706,676)	(244,035)	(24,573)	35,344

- (1) Includes Renaissance Reinsurance, DaVinci Reinsurance, RenaissanceRe Specialty U.S., Vermeer, Fontana and Validus Re (which was acquired in on November 1, 2023). On October 1, 2024, Renaissance Reinsurance and Validus Re were amalgamated.
- (2) Includes RREAG and its branches in Australia, Bermuda, the U.K. and the U.S., and Validus Switzerland and its Bermuda branch (which was acquired on November 1, 2023). On June 21, 2024 Validus Switzerland merged into RREAG.

- (3) Includes Syndicate 1458.
(4) Includes Renaissance Reinsurance U.S.

Summary of Reinsurance Trusts

The following table summarizes the assets held under trust and minimum amount required with respect to the MBRTs:

At December 31,	2024		2023	
	Assets Held Under Trust	Minimum Amount Required	Assets Held Under Trust	Minimum Amount Required
Renaissance Reinsurance ⁽¹⁾	\$ 954,114	\$ 554,119	\$ 1,209,808	\$ 910,646
DaVinci Reinsurance	179,849	47,179	174,352	114,203
RREAG ⁽²⁾	1,463,275	1,312,796	1,342,339	1,298,712

- (1) Renaissance Reinsurance and Validus Re amalgamated on October 1, 2024. Comparative information for 2023 has been reclassified to include Validus Re.
(2) RREAG and Validus Switzerland merged on June 21, 2024, with RREAG being the successor to the MBRTs held by Validus Switzerland.

The following table summarizes the assets held under trust and minimum amount required with respect to the reduced collateral reinsurance trusts:

At December 31,	2024		2023	
	Assets Held Under Trust	Minimum Amount Required	Assets Held Under Trust	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	\$ 129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

XML 74 R55.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS (Tables)

Summary of Derivative Instruments [Abstract]

Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments

12 Months Ended

Dec. 31, 2024

The tables below show the gross and net amounts of recognized derivative assets and liabilities at fair value, including the location on the consolidated balance sheets of the Company's principal derivative instruments:

At December 31, 2024	2024		2023	
	Gross Amounts of Recognized Assets	Minimum Amount Required	Gross Amounts of Recognized Assets	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	\$ 129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

At December 31, 2024	2024		2023	
	Gross Amounts of Recognized Assets	Minimum Amount Required	Gross Amounts of Recognized Assets	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	\$ 129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

- (1) Contracts used to manage foreign currency risks in underwriting and non-investment operations.
(2) Contracts used to manage foreign currency risks in investment operations.
(3) Contracts designated as hedges of net investments in a foreign operation.

At December 31, 2023	2023		2022	
	Gross Amounts of Recognized Assets	Minimum Amount Required	Gross Amounts of Recognized Assets	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	\$ 129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

At December 31, 2023	2023		2022	
	Gross Amounts of Recognized Assets	Minimum Amount Required	Gross Amounts of Recognized Assets	Minimum Amount Required
Renaissance Reinsurance	\$ 187,742	\$ 83,622	\$ 193,922	\$ 129,380
DaVinci Reinsurance	220,542	73,210	215,560	125,184
RREAG	101,252	67,671	103,632	75,380

- (1) Contracts used to manage foreign currency risks in underwriting and non-investment operations.
(2) Contracts used to manage foreign currency risks in investment operations.
(3) Contracts designated as hedges of net investments in a foreign operation.

Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments

The location and amount of the gain (loss) recognized in the Company's consolidated statements of operations related to its principal derivative instruments are shown in the following table:

Year ended December 31,	2024		2023		2022	
	Location of Gain (Loss) Recognized on Derivatives	Amount of Gain (loss) Recognized on Derivatives	Location of Gain (Loss) Recognized on Derivatives	Amount of Gain (loss) Recognized on Derivatives	Location of Gain (Loss) Recognized on Derivatives	Amount of Gain (loss) Recognized on Derivatives
Derivative instruments not designated as hedges						
Interest rate futures ⁽¹⁾	Net realized and unrealized gains (losses) on investments	\$ (81,400)	\$ 3,877	\$ (86,863)		
Foreign currency forward contracts ⁽²⁾	Net foreign exchange gains (losses)	(27,918)	(877)	(51,401)		
Foreign currency forward contracts ⁽³⁾	Net foreign exchange gains (losses)	(32,687)	(11,761)	21,689		
Credit default swaps ⁽¹⁾	Net realized and unrealized gains (losses) on investments	(54,757)	(70,924)	(9,084)		
Total return swaps ⁽¹⁾	Net realized and unrealized gains (losses) on investments	—	—	(6)		
Equity futures ⁽⁴⁾	Net realized and unrealized gains (losses) on investments	3,379	(1,928)	(69,972)		
Warrants	Net realized and unrealized gains (losses) on investments	(1,046)	—	632		
Commodity options	Net realized and unrealized gains (losses) on investments	(4,517)	(4,553)	—		
Commodity futures	Net realized and unrealized gains (losses) on investments	81,062	5,256	—		
Total derivative instruments not designated as hedges		(117,884)	(80,910)	(195,005)		
Derivative instruments designated as hedges						
Foreign currency forward contracts ⁽⁵⁾	Accumulated other comprehensive income (loss)	6,194	205	6,466		
Total		\$ (111,690)	\$ (80,705)	\$ (188,539)		

- (1) Fixed income related derivatives included in net realized and unrealized gains (losses) on investment-related derivatives. See "Note 5. Investments" for additional information.
(2) Contracts used to manage foreign currency risks in underwriting and non-investment operations.
(3) Contracts used to manage foreign currency risks in investment operations.
(4) Equity related derivatives included in net realized and unrealized gains (losses) on investment-related derivatives. See "Note 5. Investments" for additional information.
(5) Contracts designated as hedges of net investments in a foreign operation.

The table below provides a summary of derivative instruments designated as hedges of net investments in a foreign operation, including the weighted average U.S. dollar equivalent of foreign denominated net assets (liabilities) that were hedged and the resulting derivative gains (losses) that are recorded in foreign currency translation adjustments, net of tax, within accumulated other comprehensive income (loss) on the Company's consolidated statements of changes in shareholders' equity:

Year ended December 31,	2024	2023
Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities)	\$ 61,120	\$ 59,664
Derivative gains (losses)	\$ 6,194	\$ 205

XML 75 R56.htm IDEA: XBRL DOCUMENT

COMMITMENTS,
CONTINGENCIES
AND OTHER ITEMS
(Tables)

Commitments and Contingencies Disclosure
[Abstract]

Schedule of Future Minimum Payments, Operating
Leases

12 Months Ended

Dec. 31, 2024

	Future Minimum Lease Payments	
	Operating Leases	Finance Leases
2025	\$ 15,657	\$ 2,661
2026	16,461	2,661
2027	16,439	2,661
2028	16,328	2,146
2029	15,199	—
After 2029	70,656	—
Future minimum lease payments under existing leases	\$ 150,740	\$ 10,129

	Future Minimum Lease Payments	
	Operating Leases	Finance Leases
2025	\$ 15,657	\$ 2,661
2026	16,461	2,661
2027	16,439	2,661
2028	16,328	2,146
2029	15,199	—
After 2029	70,656	—
Future minimum lease payments under existing leases	\$ 150,740	\$ 10,129

XML 76 R57.htm IDEA: XBRL DOCUMENT

ACQUISITION OF
VALIDUS - Overview
(Details) - Validus -
USD (\$)
\$ / shares in Units, \$
in Thousands

Business Acquisition [Line Items]

Percentage of voting interests acquired

Total purchase price

Total cash consideration paid by RenaissanceRe as acquisition consideration

Shares issued (in shares)

Business acquisition, common shares (in shares)

Business acquisition, share price (in dollars per share)

Corporate expenses associated with the acquisition

Agent relationships - top four

Business Acquisition [Line Items]

Amortization period majority

Renewal rights

Business Acquisition [Line Items]

Amortization period majority

XML 77 R58.htm IDEA: XBRL DOCUMENT

ACQUISITION OF
VALIDUS - Schedule
of Purchase Price
(Details) - Validus -
USD (\$)
\$ / shares in Units, \$
in Thousands

Business Acquisition [Line Items]

Common shares issued by RenaissanceRe to AIG (in shares)

Common share price of RenaissanceRe (in dollars per share)

Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG

Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market

Cash consideration funded by net proceeds from the issuance of Senior Notes

Cash consideration funded by available cash resources

Total cash consideration paid by RenaissanceRe as acquisition consideration

Total purchase price

Business acquisition, share price (in dollars per share)

Discount on closing price

XML 78 R59.htm IDEA: XBRL DOCUMENT

ACQUISITION OF
VALIDUS - Schedule
of Fair Value of Net
Assets Acquired and
Liabilities Assumed
(Details) - USD (\$)
\$ in Thousands

Liabilities:

Net fair value adjustment

Validus

Assets:

Cash and cash equivalents

Investments trading

Short term investments

Investments in other ventures, under equity method

Reinsurance premiums receivable

Prepaid reinsurance premiums

Losses recoverable

Accrued investment income

Deferred acquisition costs and value of business acquired

Other assets

Identifiable intangible assets

Total assets

Liabilities:

Reserve for claims and claim expenses

Reserve for unearned premiums

Reinsurance balances payable

Accounts payable and accrued liabilities

Deferred tax liability

Total liabilities

Total identifiable net assets acquired

Total purchase price

Goodwill

12 Months Ended

Nov. 01, 2023 May 22, 2023 Dec. 31, 2024 Dec. 31, 2023

100.00%
\$ 3,020,168 \$ 2,985,000
\$ 2,735,000
1,322,541
\$ 285,168 \$ 250,000
\$ 226.97 \$ 189.03
\$ 61,900 \$ 76,400

10 years

10 years

Nov. 01, 2023 May 22, 2023

1,322,541
\$ 215.62
\$ 285,168 \$ 250,000
1,351,608
740,581
642,811
2,735,000
\$ 3,020,168 \$ 2,985,000
\$ 226.97 \$ 189.03
5.00%

Nov. 01, 2023 May 22, 2023 Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021

\$ 16,822,101 \$ 15,142,583 \$ 11,181,648 \$ 9,025,961

\$ 301,253
3,248,242
1,659,902
3,997
2,014,359
126,750
1,297,270
21,441
617,000
70,557
460,884 \$ 386,628
9,821,655

4,628,952
1,804,029
298,003
120,994
39,157
6,891,135
2,930,520
3,020,168 \$ 2,985,000

89,648

Net fair value adjustment	192,000
Decrease to losses recoverable	76,800
Decrease to reserve for claims and claim expense	\$ 268,900

[XML 79 R60.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details) - Validus - USD (\$) \$ in Thousands	2 Months Ended		12 Months Ended	
	Nov. 01, 2023	Dec. 31, 2023	Dec. 31, 2024	

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023			\$ 386,628	
Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange		\$ 60,489		
Impairment loss on insurance licenses			13,767	
Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024	\$ 460,884	\$ 386,628		

[Insurance licenses](#)

[Business Acquisition \[Line Items\]](#)

[Intangible assets acquired](#)13,884

[Agent relationships - top four](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 195,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)15 years

[Agent relationships - other](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 9,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)5 years

[Managing General Agent \("MGA"\) relationships](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 3,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)15 years

[Trade name](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 5,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)6 months

[Renewal rights](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 215,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)15 years

[Asset management contracts](#)

[Business Acquisition \[Line Items\]](#)

[Prepaid reinsurance premiums](#)\$ 20,000

[Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill](#)
[\[Roll Forward\]](#)

[Economic Useful Life](#)4 years

[XML 80 R61.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF VALIDUS - Schedule of Financial Results (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Business Acquisition \[Line Items\]](#)

[Total revenues](#)\$ 11,695,148\$ 9,134,608\$ 5,060,412

[Net income \(loss\) available \(attributable\) to RenaissanceRe common shareholders](#)1,834,9852,525,757\$ (1,096,578)

[Validus](#)

[Business Acquisition \[Line Items\]](#)

[Total revenues](#)696,888

[Net income \(loss\) available \(attributable\) to RenaissanceRe common shareholders](#)307,802

[Corporate expenses associated with the acquisition](#)\$ 61,900\$ 76,400

[XML 81 R62.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF VALIDUS - Taxation (Details) - USD (\$) \$ in Thousands	12 Months Ended	
	Nov. 01, 2023	Dec. 31, 2023

[Business Acquisition \[Line Items\]](#)

[Net deferred tax assets](#)\$ 675,485\$ 651,395

[Deferred tax asset, valuation allowance](#)\$ 147,079\$ 213,277

[Validus](#)

[Business Acquisition \[Line Items\]](#)

[Net deferred tax assets](#)\$ 73,000

[Deferred tax asset, valuation allowance](#)66,000

[Deferred tax assets](#)7,000

[Deferred tax liability related to VOBA and other adjustments](#)46,200

[Deferred tax liability](#)39,157

[Expected future benefit from goodwill](#)5,000

[Validus Specialty](#)

[Business Acquisition \[Line Items\]](#)

[Expected tax deductible amount](#)\$ 24,000

[XML 82 R63.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF VALIDUS - Schedule of Supplemental Pro forma Information (Details) - Validus - USD (\$) \$ in Thousands	12 Months Ended	
	Dec. 31, 2023	Dec. 31, 2022

[Business Acquisition \[Line Items\]](#)

[Total revenues](#)\$ 11,611,682\$ 7,169,338

[Net income \(loss\) available \(attributable\) to RenaissanceRe common shareholders](#)\$ 2,926,518\$ (1,552,425)

[XML 83 R64.htm IDEA: XBRL DOCUMENT](#)

ACQUISITION OF
VALIDUS - Defined
Benefit Pension Plan
(Details) - Pension
Plan - Validus - USD
(\$)
\$ in Millions

Dec. 31, 2024Dec. 31, 2023

Business Acquisition [Line Items]

Net balance sheet liability	\$ 1.6	\$ 1.1
Projected benefit obligation	10.5	9.8
Plan assets at fair value	\$ 8.8	\$ 8.7

XML 84 R65.htm IDEA: XBRL DOCUMENT

GOODWILL AND
OTHER INTANGIBLE
ASSETS - Schedule of
Intangible Assets and
Goodwill (Details) -
USD (\$)
\$ in Thousands

Dec. 31, 2024Dec. 31, 2023Dec. 31, 2022

Goodwill and Intangible Assets [Line Items]

Other intangible assets, net	\$ 403,832	\$ 482,070	
Total goodwill and other intangible assets	704,132	775,352	
Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method			
Goodwill and Intangible Assets [Line Items]			
Goodwill, net	8,724	10,808	\$ 9,903
Other intangible assets, net	207	7,260	
Total goodwill and other intangible assets	8,931	18,068	
Goodwill and Other Intangible Assets			
Goodwill and Intangible Assets [Line Items]			
Goodwill, net	300,507	300,542	\$ 210,894
Other intangible assets, net	403,625	474,810	
Total goodwill and other intangible assets	\$ 704,132	\$ 775,352	

XML 85 R66.htm IDEA: XBRL DOCUMENT

GOODWILL AND
OTHER INTANGIBLE
ASSETS - Narrative
(Details) - USD (\$)

12 Months Ended

	Dec. 31, 2024	Dec. 31, 2023	Nov. 01, 2023	Dec. 31, 2022
Goodwill and Intangible Assets [Line Items]				
Amortization of intangible assets	\$ 57,600,000	\$ 13,600,000		
Impairment of indefinite-lived intangible asset	\$ 13,800,000	0		
Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag	intangible asset impairment charge			
Intangible asset impairment	\$ 13,800,000			
Validus				
Goodwill and Intangible Assets [Line Items]				
Identifiable intangible assets		386,628,000	\$ 460,884,000	
Validus Insurance licenses				
Goodwill and Intangible Assets [Line Items]				
Identifiable indefinite lived intangible assets (insurance licenses)			\$ 13,884,000	
Goodwill and Other Intangible Assets				
Goodwill and Intangible Assets [Line Items]				
Goodwill, gross	302,800,000	302,800,000		\$ 213,200,000
Goodwill, accumulated impairment loss	2,300,000	2,300,000		
Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method				
Goodwill and Intangible Assets [Line Items]				
Goodwill, gross	13,200,000	15,300,000		\$ 14,400,000
Goodwill, accumulated impairment loss	4,500,000	\$ 4,500,000		
Reduction in goodwill	2,100,000			
Reduction in gross other intangible assets	\$ (6,900,000)			
Minimum				
Goodwill and Intangible Assets [Line Items]				
Finite-lived intangible assets, useful life	2 months 12 days			
Maximum				
Goodwill and Intangible Assets [Line Items]				
Finite-lived intangible assets, useful life	13 years 9 months 18 days			
Weighted Average or Actual				
Goodwill and Intangible Assets [Line Items]				
Finite-lived intangible assets, useful life	12 years 8 months 12 days			

XML 86 R67.htm IDEA: XBRL DOCUMENT

GOODWILL AND
OTHER INTANGIBLE
ASSETS - Schedule of
Goodwill and Other
Intangible Assets
Included in Equity
Method Investments
(Details) - USD (\$)
\$ in Thousands

12 Months Ended

	Dec. 31, 2024	Dec. 31, 2023
Goodwill		
Acquired	\$ 89,648	
Adjustments	\$ 0	
Foreign currency translation	(35)	
Goodwill and Other Intangible Assets		
Goodwill		
Goodwill beginning balance	300,542	210,894
Goodwill ending balance	300,507	300,542
Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method		
Goodwill		
Goodwill beginning balance	10,808	9,903
Acquired		905
Adjustments	(2,084)	
Foreign currency translation	0	
Goodwill ending balance	\$ 8,724	\$ 10,808

XML 87 R68.htm IDEA: XBRL DOCUMENT

GOODWILL AND
OTHER INTANGIBLE
ASSETS - Schedule of
Finite-Lived
Intangible Assets by
Major Class (Details)
- USD (\$)

Dec. 31, 2024Dec. 31, 2023

\$ in Thousands		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	\$ 629,149	\$ 636,037
Accumulated Amortization	(200,722)	(143,139)
Accumulated Impairment Losses	(24,595)	(10,828)
Net	403,832	482,070
Licenses		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	30,951	37,663
Accumulated Impairment Losses	(20,567)	(6,653)
Net	10,384	31,010
Customer relationships and customer lists		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	530,528	530,704
Accumulated Amortization	(150,051)	(101,659)
Accumulated Impairment Losses	(1,403)	(1,550)
Net	379,074	427,495
Value of business acquired		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	20,200	20,200
Accumulated Amortization	(20,200)	(20,200)
Accumulated Impairment Losses	0	0
Net	0	0
Asset management contracts		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	20,000	20,000
Accumulated Amortization	(5,833)	(833)
Accumulated Impairment Losses	0	0
Net	14,167	19,167
Software		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	12,230	12,230
Accumulated Amortization	(12,230)	(12,230)
Accumulated Impairment Losses	0	0
Net	0	0
Patents and intellectual property		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	4,500	4,500
Accumulated Amortization	(1,875)	(1,875)
Accumulated Impairment Losses	(2,625)	(2,625)
Net	0	0
Covenants not-to-compete		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	4,030	4,030
Accumulated Amortization	(4,030)	(4,030)
Accumulated Impairment Losses	0	0
Net	0	0
Trademarks and trade names		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Value	6,710	6,710
Accumulated Amortization	(6,503)	(2,312)
Accumulated Impairment Losses	0	0
Net	\$ 207	\$ 4,398
<i><u>XML 88 R69.htm IDEA: XBRL DOCUMENT</u></i>		
GOODWILL AND		
OTHER INTANGIBLE		
ASSETS - Schedule of		
Expected Impairment		Dec. 31, 2024
Charges and		USD (\$)
Amortization Expense		
(Details)		
\$ in Thousands		
Other intangible assets		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Total		\$ 403,832
Other intangible assets Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Total		207
Other intangible assets Goodwill and Other Intangible Assets		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Total		403,625
Other intangible assets		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Indefinite lived		10,384
Other intangible assets Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Indefinite lived		0
Other intangible assets Goodwill and Other Intangible Assets		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
Indefinite lived		10,384
Other intangible assets		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
2025		70,234
2026		61,646
2027		53,761
2028		42,685
2029		34,519
2030 and thereafter		130,603
Total remaining amortization expense		393,448
Other intangible assets Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method		
Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
2025		24
2026		24
2027		24
2028		24
2029		24
2030 and thereafter		87
Total remaining amortization expense		207
Other intangible assets Goodwill and Other Intangible Assets		

Schedule of Finite and Indefinite-lived Intangible Assets [Line Items]		
2025		70,210
2026		61,622
2027		53,737
2028		42,661
2029		34,495
2030 and thereafter		130,516
Total remaining amortization expense		\$ 393,241

[XML 89 R70.htm IDEA: XBRL DOCUMENT](#)

INVESTMENTS -		
Schedule of Fair		
Value of Fixed		
Maturity Investments	Dec. 31, 2024	Dec. 31, 2023
Trading (Details) -		
USD (\$)		
\$ in Thousands		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	\$ 23,562,514	\$ 20,877,108
U.S. treasuries		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	11,001,893	10,060,203
Corporate		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	7,862,423	6,499,075
Asset-backed		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	1,422,393	1,491,695
Residential mortgage-backed		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	1,707,056	1,420,362
Agencies		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	623,489	489,117
Non-U.S. government		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	618,809	483,576
Commercial mortgage-backed		

Schedule of Investments [Line Items]		
Fixed maturity investments trading	\$ 326,451	\$ 433,080

[XML 90 R71.htm IDEA: XBRL DOCUMENT](#)

INVESTMENTS -		
Schedule of		
Contractual		
Maturities of Fixed		Dec. 31, 2024
Maturity Investments		Dec. 31, 2023
(Details) - USD (\$)		
\$ in Thousands		

Amortized Cost		
Due in less than one year	\$ 1,374,089	\$ 587,720
Due after one through five years	12,139,153	11,439,510
Due after five through ten years	6,339,563	5,182,667
Due after ten years	387,413	307,392
Amortized cost	23,750,540	20,872,450

Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]		
Due in less than one year	1,373,838	582,519
Due after one through five years	12,131,114	11,468,263
Due after five through ten years	6,246,506	5,188,716
Due after ten years	355,156	292,473
Fixed maturity investments trading	23,562,514	20,877,108

Mortgage-backed		
Amortized Cost		
Amortized cost	2,094,190	1,864,520

Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]		
Fixed maturity investments trading	2,033,507	1,853,442
Asset-backed		

Amortized Cost		
Amortized cost	1,416,132	1,490,641
Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]		

Fixed maturity investments trading	\$ 1,422,393	\$ 1,491,695

[XML 91 R72.htm IDEA: XBRL DOCUMENT](#)

INVESTMENTS -		
Schedule of Fair		
Value of Equity		
Investments (Details)	Dec. 31, 2024	Dec. 31, 2023
- USD (\$)		
\$ in Thousands		

Schedule of Investments [Line Items]		
Total	\$ 117,756	\$ 106,766
Financials		

Schedule of Investments [Line Items]		
Total	116,400	106,542
Basic materials		

Schedule of Investments [Line Items]		
Total	595	0
Industrial, utilities and energy		

Schedule of Investments [Line Items]		
Total	312	0
Communications and technology		

Schedule of Investments [Line Items]		
Total	263	12
Consumer		

Schedule of Investments [Line Items]		
Total	154	212
Healthcare		

Schedule of Investments [Line Items]		
Total	\$ 32	\$ 0

[XML 92 R73.htm IDEA: XBRL DOCUMENT](#)

INVESTMENTS -		
Pledged Investments		
and Reverse		
Repurchase		Dec. 31, 2024
		Dec. 31, 2023

Agreements (Details)
- USD (\$)
\$ in Billions

Investments, Debt and Equity Securities [Abstract]

Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, various counterparties	\$ 10.3	\$ 10.5
Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, U.S. state regulatory authorities	\$ 3.1	\$ 2.9

XML 93 R74.htm IDEA: XBRL DOCUMENT

INVESTMENTS - Reverse Purchase Agreements	Dec. 31, 2024	Dec. 31, 2023
(Narrative) (Details) - USD (\$) \$ in Millions		

Investments, Debt and Equity Securities [Abstract]

Reverse repurchase agreements	\$ 169.4	\$ 159.7

XML 94 R75.htm IDEA: XBRL DOCUMENT

INVESTMENTS - Schedule of Net Investment Income (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Net Investment Income [Line Items]

Investment income before investment expenses	\$ 1,677,804	\$ 1,276,012	\$ 581,549
Investment expenses	(23,515)	(22,902)	(21,617)
Net investment income	1,654,289	1,253,110	559,932

Fixed maturity investments trading

Net Investment Income [Line Items]

Investment income before investment expenses	1,116,649	744,457	382,165

Short term investments

Net Investment Income [Line Items]

Investment income before investment expenses	183,153	213,303	41,042

Equity investments

Net Investment Income [Line Items]

Investment income before investment expenses	2,460	7,261	20,864

Catastrophe bonds

Net Investment Income [Line Items]

Investment income before investment expenses	238,844	200,572	94,784

Other

Net Investment Income [Line Items]

Investment income before investment expenses	82,457	87,296	37,497

Cash and cash equivalents

Net Investment Income [Line Items]

Investment income before investment expenses	\$ 54,241	\$ 23,123	\$ 5,197

XML 95 R76.htm IDEA: XBRL DOCUMENT

INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Gain (Loss) on Securities [Line Items]

Net realized and unrealized gains (losses) on fixed maturity investments trading	\$ (246,423)	\$ 292,054	\$ (1,369,323)

Net realized and unrealized gains (losses) on equity investments	10,976	45,751	(123,788)

Net realized and unrealized gains (losses) on investments	(27,840)	414,522	(1,800,485)

Fixed maturity investments trading

Gain (Loss) on Securities [Line Items]

Gross realized gains on fixed maturity investments trading	142,243	80,905	38,781

Gross realized losses on fixed maturity investments trading	(206,172)	(473,946)	(771,342)

Net realized gains (losses) on fixed maturity investments trading	(63,929)	(393,041)	(732,561)

Net unrealized gains (losses) on fixed maturity investments trading	(182,494)	685,095	(636,762)

Investments-related derivatives

Gain (Loss) on Securities [Line Items]

Net realized and unrealized gains (losses) on investments-related derivatives	(57,279)	(68,272)	(165,293)

Equity investments

Gain (Loss) on Securities [Line Items]

Net realized gains (losses) on equity investments	355	(27,492)	43,035

Net unrealized gains (losses) on equity investments	10,621	73,243	(166,823)

Catastrophe bonds

Gain (Loss) on Securities [Line Items]

Net realized and unrealized gains (losses) on other investments	62,353	101,897	(130,335)

Other

Gain (Loss) on Securities [Line Items]

Net realized and unrealized gains (losses) on other investments	\$ 202,533	\$ 43,092	\$ (11,746)

XML 96 R77.htm IDEA: XBRL DOCUMENT

INVESTMENTS - Schedule of Other Investments (Details) - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Schedule of Investments [Line Items]

Other investments	\$ 4,324,761	\$ 3,515,566

Initial commitments	4,500,000	3,600,000

Fulfilled commitments	2,500,000	2,000,000

Unfunded commitments	\$ 2,000,000	1,600,000

Maturity period	5 years	

Other Investments

Schedule of Investments [Line Items]

Net unrealized gain (loss) recognized in earnings due to change in estimate	\$ (9,700)	(3,000)	\$ 19,800

Fund investments

Schedule of Investments [Line Items]

Other investments	2,128,499	1,415,804

Catastrophe bonds

Schedule of Investments [Line Items]

Other investments	\$ 1,984,396	1,942,199

Catastrophe bonds | Minimum

Schedule of Investments [Line Items]

Maturity period	1 year	

Catastrophe bonds | Maximum

Schedule of Investments [Line Items]	5 years		
Maturity period			
Direct private equity investments			
Schedule of Investments [Line Items]			
Other investments	\$ 211,866	59,905	
Term loans			
Schedule of Investments [Line Items]			
Other investments	\$ 0	\$ 97,658	
XML 97 R78.htm IDEA: XBRL DOCUMENT			
INVESTMENTS -	12 Months Ended		
Term Loans (Details)	Dec. 31, 2024		
	USD (\$)		
Investments, Debt and Equity Securities [Abstract]			
Committed amount	\$ 100,000,000		
Maturity period	5 years		
XML 98 R79.htm IDEA: XBRL DOCUMENT			
INVESTMENTS -			
Schedule of			
Investments in Other			
Ventures, under	Dec. 31, 2024	Dec. 31, 2023	
Equity Method			
(Details) - USD (\$)			
\$ in Thousands			
Schedule of Equity Method Investments [Line Items]			
Carrying Value	\$ 102,770	\$ 112,624	
Investments in other ventures, under equity method			
Schedule of Equity Method Investments [Line Items]			
Carrying Value	\$ 102,770	\$ 112,624	
Minimum Investments in other ventures, under equity method			
Schedule of Equity Method Investments [Line Items]			
Ownership %	0.10%	0.10%	
Maximum Investments in other ventures, under equity method			
Schedule of Equity Method Investments [Line Items]			
Ownership %	50.00%	50.00%	
XML 99 R80.htm IDEA: XBRL DOCUMENT			
INVESTMENTS -	12 Months Ended		
Schedule of Equity in			
(Losses) Earnings of			
Other Ventures,			
Under Equity Method	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
(Details) - USD (\$)			
\$ in Thousands			
Investments, Debt and Equity Securities [Abstract]			
Equity in earnings (losses) of other ventures	\$ 47,087	\$ 43,474	\$ 11,249
Equity method investment, dividends and distributions	\$ 109,800	\$ 41,400	\$ 24,200
XML 100 R81.htm IDEA: XBRL DOCUMENT			
FAIR VALUE			
MEASUREMENTS -			
Schedule of Assets			
and Liabilities			
Measured at Fair			
Value on a Recurring	Dec. 31, 2024 Dec. 31, 2023		
Basis (Details) - USD			
(\$)			
\$ in Thousands			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fixed maturity investments trading		\$ 23,562,514	\$ 20,877,108
Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)		4,531,655	4,604,079
Equity investments		117,756	106,766
Other investments		4,324,761	3,515,566
Derivative assets		34,538	44,724
Derivative liabilities		(75,878)	(29,991)
Other liabilities		(2,434)	(2,742)
Other assets		2,029	2,227
Fair Value, Measurements, Recurring			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fixed maturity investments trading		23,562,514	20,877,108
Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)		4,531,655	4,604,079
Equity investments		117,756	106,766
Other investments		4,324,761	3,515,566
Assumed and ceded (re)insurance contracts		(405)	(515)
Derivative assets		34,538	44,724
Derivative liabilities		(75,878)	(29,992)
Other liabilities		(41,745)	
Other assets			14,217
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs		32,494,941	29,117,736
Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fixed maturity investments trading		11,001,893	10,060,203
Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)		99,343	130,232
Equity investments		117,756	106,766
Other investments		0	0
Assumed and ceded (re)insurance contracts		0	0
Derivative assets		10,614	16,701
Derivative liabilities		(7,872)	(10,372)
Other assets		2,742	6,329
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs		11,221,734	10,303,530
Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fixed maturity investments trading		12,560,621	10,816,905
Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)		4,432,312	4,473,847
Equity investments		0	0
Other investments		2,152,485	1,942,199
Assumed and ceded (re)insurance contracts		0	0
Derivative assets		23,924	28,023
Derivative liabilities		(68,006)	(19,620)
Other liabilities		(44,082)	
Other assets			8,403
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs		19,101,336	17,241,354
Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			

Fixed maturity investments trading	0	0
Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)	0	0
Equity investments	0	0
Other investments	43,777	157,563
Assumed and ceded (re)insurance contracts	(405)	(515)
Derivative assets	0	0
Derivative liabilities	0	0
Other liabilities	(405)	(515)
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	43,372	157,048
Fair Value, Measurements, Recurring Fair Value, Inputs, Level 1, 2 and 3		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Other investments	2,196,262	2,099,762
U.S. treasuries Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	11,001,893	10,060,203
U.S. treasuries Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	11,001,893	10,060,203
U.S. treasuries Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
U.S. treasuries Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Corporate Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	7,862,423	6,499,075
Corporate Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Corporate Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	7,862,423	6,499,075
Corporate Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Residential mortgage-backed Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	1,707,056	1,420,362
Residential mortgage-backed Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Residential mortgage-backed Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	1,707,056	1,420,362
Residential mortgage-backed Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Asset-backed Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	1,422,393	1,491,695
Asset-backed Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Asset-backed Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	1,422,393	1,491,695
Asset-backed Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Agencies Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	623,489	489,117
Agencies Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Agencies Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	623,489	489,117
Agencies Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Non-U.S. government Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	618,809	483,576
Non-U.S. government Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Non-U.S. government Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	618,809	483,576
Non-U.S. government Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Commercial mortgage-backed Fair Value, Measurements, Recurring		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	326,451	433,080
Commercial mortgage-backed Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Commercial mortgage-backed Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	326,451	433,080
Commercial mortgage-backed Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Fixed maturity investments trading	0	0
Catastrophe bonds Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		

Other investments	0	0	
Catastrophe bonds Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	1,984,396	1,942,199	
Catastrophe bonds Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	0	0	
Catastrophe bonds Fair Value, Measurements, Recurring Fair Value, Inputs, Level 1, 2 and 3			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	1,984,396	1,942,199	
Direct private equity investments Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	0	0	
Direct private equity investments Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	168,089	0	
Direct private equity investments Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	43,777	59,905	
Direct private equity investments Fair Value, Measurements, Recurring Fair Value, Inputs, Level 1, 2 and 3			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	211,866	59,905	
Fund investments Fair Value, Measurements, Recurring Fair Value Measured at Net Asset Value Per Share			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments	2,128,499	1,415,804	
Term loans Fair Value, Measurements, Recurring Quoted Prices in Active Markets for Identical Assets (Level 1)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments		0	
Term loans Fair Value, Measurements, Recurring Significant Other Observable Inputs (Level 2)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments		0	
Term loans Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments		97,658	
Term loans Fair Value, Measurements, Recurring Fair Value, Inputs, Level 1, 2 and 3			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other investments		97,658	
Assumed and ceded (re)insurance contracts Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3) Other assets			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other assets	2,000	2,200	
Assumed and ceded (re)insurance contracts Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3) Other Liabilities [Member]			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Other liabilities	\$ (2,400)	\$ (2,700)	
<i><u>XML 101 R82.htm IDEA: XBRL DOCUMENT</u></i>			
FAIR VALUE MEASUREMENTS - Narrative (Details) - USD (\$)	12 Months Ended		
\$ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	\$ 4,324,761	\$ 3,515,566	
Other liabilities	(2,434)	(2,742)	
Debt	1,886,689	1,958,655	
Fair Value	1,900,000	1,900,000	
Other Investments Net investment income			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Net unrealized gains (losses) included in net investment income	243,800	137,300	\$ (181,200)
Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	4,324,761	3,515,566	
Other liabilities	(41,745)		
Significant Other Observable Inputs (Level 2) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	2,152,485	1,942,199	
Other liabilities	(44,082)		
Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	43,777	157,563	
Other liabilities	(405)	(515)	
Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring Internal valuation model Assumed reinsurance contract			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other liabilities	(405)	(515)	
Direct private equity investments Significant Other Observable Inputs (Level 2) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	168,089	0	
Direct private equity investments Significant Other Observable Inputs (Level 2) Fair Value, Measurements, Recurring Valuation Technique, Quoted Prices			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	168,100	0	
Direct private equity investments Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	43,777	59,905	
Direct private equity investments Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring Internal valuation model			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments	\$ 43,777	59,905	
Term loans Significant Other Observable Inputs (Level 2) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments		0	
Term loans Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments		97,658	
Term loans Significant Unobservable Inputs (Level 3) Fair Value, Measurements, Recurring Internal valuation model			
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]			
Other investments		\$ 97,700	
U.S. treasuries			

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	4.40%	4.10%
Corporate		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	5.50%	5.70%
Agencies		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	4.70%	4.60%
Non-U.S. government		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	4.50%	4.40%
Residential mortgage-backed		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	5.40%	5.10%
Weighted average life	7 years 8 months 12 days	7 years 8 months 12 days
Commercial mortgage-backed		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	5.70%	8.80%
Weighted average life	3 years 9 months 18 days	2 years 2 months 12 days
Asset-backed		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	5.90%	7.00%
Weighted average life	4 years 8 months 12 days	3 years 10 months 24 days
Short term investments		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	4.20%	5.30%
Other Short Term Investments		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Weighted average yield to maturity	4.40%	5.30%
Private credit funds Minimum		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Liquidating period	5 years	
Private credit funds Maximum		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Liquidating period	10 years	
Direct private equity investments		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Other investments	\$ 211,866	\$ 59,905
Direct private equity investments Minimum		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Liquidating period	5 years	
Direct private equity investments Maximum		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Liquidating period	10 years	
<i>XML 102 R83.htm IDEA: XBRL DOCUMENT</i>		
FAIR VALUE		
MEASUREMENTS -		
Schedule of		
Quantitative		
Information Used as		
Level 3 Inputs		
(Details)		
\$ in Thousands		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments	\$ 4,324,761	\$ 3,515,566
Other liabilities	(2,434)	(2,742)
Fair Value, Measurements, Recurring		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments	4,324,761	3,515,566
Other liabilities	(41,745)	
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	32,494,941	29,117,736
Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments	43,777	157,563
Other liabilities	(405)	(515)
Total assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs	43,372	157,048
Fair Value, Measurements, Recurring Significant Unobservable Inputs (Level 3) Assumed and ceded (re)insurance contracts		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other liabilities	(405)	(515)
Fair Value, Measurements, Recurring Internal valuation model Significant Unobservable Inputs (Level 3) Assumed and ceded (re)insurance contracts, group two		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other liabilities	(405)	(515)
Fair Value, Measurements, Recurring Direct private equity investments Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments	43,777	59,905
Fair Value, Measurements, Recurring Direct private equity investments Internal valuation model Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments	\$ 43,777	59,905
Fair Value, Measurements, Recurring Term loans Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments		97,658
Fair Value, Measurements, Recurring Term loans Internal valuation model Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments		97,700
Fair Value, Measurements, Recurring Term loans Discounted cash flow Significant Unobservable Inputs (Level 3)		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Other investments		\$ 97,658
Fair Value, Measurements, Recurring Discount rate Internal valuation model Significant Unobservable Inputs (Level 3) Assumed and ceded (re)insurance contracts, group two Weighted Average or Actual		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs	0.044	0.038
Fair Value, Measurements, Recurring Discount rate Direct private equity investments Internal valuation model Significant Unobservable Inputs (Level 3) Weighted Average or Actual		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs	0.100	0.100
Fair Value, Measurements, Recurring Liquidity discount Direct private equity investments Internal valuation model Significant Unobservable Inputs (Level 3) 		

Weighted Average or Actual

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant observable and unobservable inputs	0.150	0.150
Fair Value, Measurements, Recurring Credit spread adjustment Term loans Discounted cash flow Significant Unobservable Inputs (Level 3) Weighted Average or Actual		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs		0.002
Fair Value, Measurements, Recurring Risk premium Term loans Discounted cash flow Significant Unobservable Inputs (Level 3) Weighted Average or Actual		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs		0.026
Fair Value, Measurements, Recurring Net undiscounted cash flows Internal valuation model Significant Unobservable Inputs (Level 3) Assumed and ceded (re)insurance contracts, group two Weighted Average or Actual		
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs		
Fair Value, Measurements, Recurring Expected loss ratio Internal valuation model Significant Unobservable Inputs (Level 3) Assumed and ceded (re)insurance contracts, group two Weighted Average or Actual	12,657,000	12,478,000
Fair Value Measurement Inputs and Valuation Techniques [Line Items]		
Significant observable and unobservable inputs	0.012	0.023

XML 103 R84.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) - Fair Value, Measurements, Recurring - USD (\$) \$ in Thousands	12 Months Ended Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Beginning balance	\$ 157,048	\$ 164,948
Net investment income		
Net foreign exchange gains (losses)	(7)	(5)
Purchases	4,217	1,809
Sales	(98,217)	
Settlements	(3,493)	(2,342)
Ending balance	\$ 43,372	\$ 157,048
Net investment income		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net investment income (Note 5)	Net investment income (Note 5)
Net investment income		
Net in earnings (loss)	\$ 258	\$ 250
Net realized and unrealized gains (losses) on investments		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net realized and unrealized gains (losses) on investments	Net realized and unrealized gains (losses) on investments
Net investment income		
Net in earnings (loss)	\$ (16,686)	\$ (7,120)
Other income (loss)		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (loss)	Other income (loss)
Net investment income		
Net in earnings (loss)	\$ 252	\$ (492)
Direct private equity investments		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Beginning balance	59,905	66,780
Net investment income		
Net foreign exchange gains (losses)	(7)	(5)
Purchases	577	0
Sales	(270)	
Settlements	0	0
Ending balance	43,777	59,905
Direct private equity investments Net investment income		
Net investment income		
Net in earnings (loss)	258	250
Direct private equity investments Net realized and unrealized gains (losses) on investments		
Net investment income		
Net in earnings (loss)	(16,686)	(7,120)
Direct private equity investments Other income (loss)		
Net investment income		
Net in earnings (loss)	0	0
Term loans		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		
Beginning balance	97,658	100,000
Net investment income		
Net foreign exchange gains (losses)	0	0
Purchases	0	0
Sales	(94,321)	
Settlements	(3,337)	(2,342)
Ending balance	0	97,658
Term loans Net investment income		
Net investment income		
Net in earnings (loss)	0	0
Term loans Net realized and unrealized gains (losses) on investments		
Net investment income		
Net in earnings (loss)	0	0
Term loans Other income (loss)		
Net investment income		
Net in earnings (loss)	0	0
Other Assets and (Liabilities)		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]		

Forward]		
Beginning balance	(515)	(1,832)
Net investment income		
Net foreign exchange gains (losses)	0	0
Purchases	3,640	1,809
Sales	(3,626)	
Settlements	(156)	0
Ending balance	(405)	(515)
Other Assets and (Liabilities) Net investment income		
Net investment income		
Net in earnings (loss)	0	0
Other Assets and (Liabilities) Net realized and unrealized gains (losses) on investments		
Net investment income		
Net in earnings (loss)	0	0
Other Assets and (Liabilities) Other income (loss)		
Net investment income		
Net in earnings (loss)	\$ 252	\$ (492)

XML 104 R85.htm IDEA: XBRL DOCUMENT

FAIR VALUE		
MEASUREMENTS -		
Schedule of Balances		
Elected to Account	Dec. 31, 2024	Dec. 31, 2023
for at Fair Value		
(Details) - USD (\$)		
\$ in Thousands		

Fair Value Disclosures [Abstract]

Other investments	\$ 4,324,761	\$ 3,515,566
Other assets	2,029	2,227
Other liabilities	\$ 2,434	\$ 2,742

XML 105 R86.htm IDEA: XBRL DOCUMENT

FAIR VALUE		
MEASUREMENTS -		
Schedule of Other		
Investments		
Measured Using Net		
Asset Valuations	Dec. 31, 2024	Dec. 31, 2023
(Details) - Fair Value		
Measured at Net		
Asset Value Per Share		
- USD (\$)		
\$ in Thousands		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Fair Value	\$ 2,128,499	\$ 1,415,804
Unfunded Commitments	1,948,933	1,622,913
Private credit funds		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Fair Value	1,181,146	982,016
Unfunded Commitments	1,284,699	949,135
Private equity funds		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Fair Value	609,105	433,788
Unfunded Commitments	664,234	\$ 673,778
Hedge funds		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Fair Value	338,248	
Unfunded Commitments	\$ 0	

XML 106 R87.htm IDEA: XBRL DOCUMENT

FAIR VALUE		
MEASUREMENTS -		
Schedule of Variable		
Interest Entities	Dec. 31, 2024	Dec. 31, 2023
(Details) - USD (\$)		
\$ in Thousands		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Other investments, maximum exposure to loss	\$ 3,856,504	\$ 2,802,251
Carrying Amount		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Other investments, maximum exposure to loss	1,993,362	1,251,799
Unfunded Commitments		

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]

Other investments, maximum exposure to loss	\$ 1,863,142	\$ 1,550,452

XML 107 R88.htm IDEA: XBRL DOCUMENT

REINSURANCE -			
Schedule of Effect of			
Reinsurance and			
Retrocessional			
Activity on Premiums			
Written and Earned	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
and on Net Claims			
and Claim Expenses			
Incurred (Details) -			
USD (\$)			
\$ in Thousands			

Premiums Written

Direct	\$ 1,197,360	\$ 865,771	\$ 1,264,410
Assumed	10,535,706	7,996,595	7,949,130
Ceded	(1,780,850)	(1,394,553)	(2,017,380)
Net premiums written	9,952,216	7,467,813	7,196,160

Premiums Earned

Direct	1,097,726	1,013,372	1,105,164
Assumed	10,815,336	8,072,193	7,079,632
Ceded	(1,817,302)	(1,614,432)	(1,850,807)
Net premiums earned (Note 7)	10,095,760	7,471,133	6,333,989

Claims and Claim Expenses

Gross claims and claim expenses incurred	5,629,756	3,950,362	5,851,140
Claims and claim expenses recovered	(296,775)	(376,853)	(1,512,300)
Net claims and claim expenses incurred	\$ 5,332,981	\$ 3,573,509	\$ 4,338,840

XML 108 R89.htm IDEA: XBRL DOCUMENT

REINSURANCE -			
Narrative (Details) -			
USD (\$)			
\$ in Thousands			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Ceded Credit Risk [Line Items]

Premiums receivable	\$ 7,290,228	\$ 7,280,682	
Premium receivable, allowance for credit loss	4,631	3,514	\$ 4,606
Reinsurance recoverable	4,500,000	5,300,000	
Reinsurance recoverable, allowance for credit loss	\$ 11,730	\$ 13,279	\$ 12,169

Reinsurance Recoverable | Reinsurer Concentration Risk | Customer One

Ceded Credit Risk [Line Items]

Concentration risk , percentage	12.60%	17.60%	
Reinsurance Recoverable Reinsurer Concentration Risk Customer Two			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	11.00%	14.30%	
Reinsurance Recoverable Reinsurer Concentration Risk Customer Three			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	8.30%	8.70%	
Allowance for Reinsurance Recoverable Customer Concentration Risk Customer One			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	23.90%	10.90%	
Allowance for Reinsurance Recoverable Customer Concentration Risk Customer Two			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	7.20%	10.70%	
Allowance for Reinsurance Recoverable Customer Concentration Risk Customer Three			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	5.90%	8.10%	
Ceded Credit Risk, Secured Reinsurance Recoverable Reinsurer Concentration Risk			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	55.70%	60.60%	
Rated A- or higher Ceded Credit Risk, Unsecured Reinsurance Recoverable Reinsurer Concentration Risk			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	43.20%	38.50%	
Rated lower than A- Ceded Credit Risk, Unsecured Reinsurance Recoverable Reinsurer Concentration Risk			

Ceded Credit Risk [Line Items]

Concentration risk , percentage	1.00%	0.90%	

XML 109 R90.htm IDEA: XBRL DOCUMENT

REINSURANCE -	12 Months Ended		
Schedule of Provision			
for Current Expected			
Credit Losses of			
Premiums Receivable	Dec. 31, 2024	Dec. 31, 2023	
(Details) - USD (\$)			
\$ in Thousands			

Premium Receivable, Allowance for Credit Loss [Roll Forward]

Beginning balance	\$ 3,514	\$ 4,606	
Provision for (release of) allowance	1,117	(2,788)	
Amounts acquired	0	1,696	
Ending balance	\$ 4,631	\$ 3,514	

XML 110 R91.htm IDEA: XBRL DOCUMENT

REINSURANCE -	12 Months Ended		
Schedule of Provision			
for Current Expected			
Credit Losses of			
Reinsurance			
Recoverable (Details)	Dec. 31, 2024	Dec. 31, 2023	
- USD (\$)			
\$ in Thousands			

Reinsurance Recoverable, Allowance for Credit Loss [Roll Forward]

Beginning balance	\$ 13,279	\$ 12,169	
Provision for (release of) allowance	(1,549)	(3,644)	
Acquired	0	4,754	
Ending balance	\$ 11,730	\$ 13,279	

XML 111 R92.htm IDEA: XBRL DOCUMENT

RESERVE FOR			
CLAIMS AND CLAIM			
EXPENSES - Schedule			
of Reserve for Claims			
and Claim Expenses	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
by Segment (Details)			
- USD (\$)			
\$ in Thousands			

Liability for Claims and Claims Adjustment Expense [Line Items]

Case Reserves	\$ 4,926,309	\$ 5,262,596	
Additional Case Reserves	2,200,627	2,733,256	
IBNR	14,176,555	12,491,017	
Total	21,303,491	20,486,869	\$ 15,892,573

Property | Operating Segments

Liability for Claims and Claims Adjustment Expense [Line Items]

Case Reserves	1,845,228	2,461,580	
Additional Case Reserves	1,905,553	2,401,911	
IBNR	2,821,958	2,970,129	
Total	6,572,739	7,833,620	

Casualty and Specialty | Operating Segments

Liability for Claims and Claims Adjustment Expense [Line Items]

Case Reserves	3,081,081	2,801,016	
Additional Case Reserves	295,074	331,345	
IBNR	11,354,597	9,520,888	
Total	\$ 14,730,752	\$ 12,653,249	

XML 112 R93.htm IDEA: XBRL DOCUMENT

RESERVE FOR	12 Months Ended		
CLAIMS AND CLAIM			
EXPENSES - Schedule			
of Liability for Unpaid			
Claims and Claim			
Expenses (Details) -	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
USD (\$)			
\$ in Thousands			

Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]

Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period	\$ 15,142,583	\$ 11,181,648	\$ 9,025,961

Net incurred related to:

Current year	6,184,315	4,024,116	4,586,422
Prior years	(851,334)	(450,607)	(247,582)
Total net incurred	5,332,981	3,573,509	4,338,840

Net paid related to:

Accident Year 2018 | Property

Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,072,994	1,098,897	1,147,450	1,158,452	1,286,032	1,348,628	1,271,912
IBNR and ACR	64,246						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	853,609	852,022	917,391	872,831	838,513	675,404	453,864
Accident Year 2018 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,907,824	1,867,047	1,778,718	1,776,321	1,779,190	1,784,201	1,641,037
IBNR and ACR	114,303						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,528,400	1,386,216	1,201,120	1,027,246	755,030	515,458	\$ 218,961
Accident Year 2019							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	2,620,761	2,564,553	2,554,243	2,591,017	2,680,637	2,706,854	
IBNR and ACR	249,622						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	2,225,414	1,996,128	1,678,643	1,350,356	991,137	382,173	
Accident Year 2019 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	912,496	914,252	976,162	1,042,748	1,135,337	1,162,088	
IBNR and ACR	35,810						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	818,617	777,272	718,321	632,491	457,281	164,785	
Accident Year 2019 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,708,265	1,650,301	1,578,081	1,548,269	1,545,300	1,544,766	
IBNR and ACR	213,812						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,406,797	1,218,856	960,322	717,865	533,856	\$ 217,388	
Accident Year 2020							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	4,301,296	4,370,007	4,397,548	4,392,922	4,393,340		
IBNR and ACR	761,291						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	3,239,789	2,795,075	2,323,405	1,810,464	756,409		
Accident Year 2020 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,972,883	2,010,634	2,076,315	2,075,320	1,966,826		
IBNR and ACR	265,855						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,517,898	1,332,331	1,139,605	878,467	284,033		
Accident Year 2020 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	2,328,413	2,359,373	2,321,233	2,317,602	2,426,514		
IBNR and ACR	495,436						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,721,891	1,462,744	1,183,800	931,997	\$ 472,376		
Accident Year 2021							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	4,906,690	5,176,258	5,388,056	5,534,493			
IBNR and ACR	1,018,009						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	3,356,124	2,922,881	2,092,957	886,330			
Accident Year 2021 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	2,440,274	2,655,570	2,758,871	2,759,175			
IBNR and ACR	143,701						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,984,325	1,852,117	1,371,613	585,175			
Accident Year 2021 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	2,466,416	2,520,688	2,629,185	2,775,318			
IBNR and ACR	874,308						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,371,799	1,070,764	721,344	\$ 301,155			
Accident Year 2022							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	5,128,208	5,627,982	5,902,647				
IBNR and ACR	2,231,524						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	2,260,464	1,446,448	280,032				
Accident Year 2022 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	2,045,341	2,431,989	2,544,022				
IBNR and ACR	597,038						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,157,016	764,636	76,656				
Accident Year 2022 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	3,082,867	3,195,993	3,358,625				
IBNR and ACR	1,634,486						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,103,448	681,812	\$ 203,376				
Accident Year 2023							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	5,200,462	5,277,384					
IBNR and ACR	3,144,564						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	1,289,115	516,063					
Accident Year 2023 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,376,749	1,469,539					
IBNR and ACR	577,889						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	536,495	232,849					
Accident Year 2023 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	3,823,713	3,807,845					
IBNR and ACR	2,566,675						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	752,620	\$ 283,214					
Accident Year 2024							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	6,077,913						
IBNR and ACR	5,042,190						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	475,609						
Accident Year 2024 Property							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	1,928,913						
IBNR and ACR	1,407,007						
Cumulative Paid Claims and Claim Expenses, Net of Reinsurance	224,606						
Accident Year 2024 Casualty and Specialty							
Claims Development [Line Items]							
Incurred Claims and Claim Expenses, Net of Reinsurance	4,149,000						

IBNR and ACR3,635,183

Cumulative Paid Claims and Claim Expenses, Net of Reinsurance\$ 251,003

XML 114 R95.htm IDEA: XBRL DOCUMENT

RESERVE FOR CLAIMS AND CLAIM EXPENSES - Prior Year Development of the Reserve for Net Claims and Claim Expenses (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	\$ (851,334)	\$ (450,607)	\$ (247,582)

Actuarial assumption changes

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years		840	

Property

Net claims and claim expenses incurred - prior accident years	(818,852)	(408,905)	(205,741)

Property | Actuarial assumption changes

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	9,962		23,847

Property | Large and small catastrophe events and attritional loss movements

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(828,814)	(409,745)	(229,588)

Property | Large catastrophe events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(622,198)	(309,820)	(198,564)

Property | 2023 Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(31,899)	(85,653)	

Property | 2022 Weather-Related Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(284,327)		

Property | 2021 Weather-Related Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(180,028)	(36,949)	(12,387)

Property | 2020 Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(47,512)	(42,577)	(24,589)

Property | 2019 Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(14,445)	(43,850)	(97,034)

Property | 2018 Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(38,295)	(40,050)	(20,318)

Property | 2017 Large Loss Events

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(25,692)	(46,404)	(39,481)

Property | Other

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years		(14,337)	(4,755)

Property | Small catastrophe events and attritional loss movements

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(206,616)	(99,925)	(31,024)

Property | Other small catastrophe events and attritional loss movements

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(206,616)	(99,925)	(31,024)

Property | Operating Segments

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(818,852)	(408,905)	(205,741)

Casualty and Specialty

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(32,482)	(41,702)	(41,841)

Casualty and Specialty | Actuarial methods - actual reported claims less than expected claims

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	(67,595)	(44,612)	(63,353)

Casualty and Specialty | Actuarial assumption changes

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	35,113	2,910	21,512

Casualty and Specialty | Operating Segments

Liability for Catastrophe Claims [Line Items]

Net claims and claim expenses incurred - prior accident years	\$ (32,482)	\$ (41,702)	\$ (41,841)

XML 115 R96.htm IDEA: XBRL DOCUMENT

RESERVE FOR CLAIMS AND CLAIM EXPENSES - Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021			

Liability for Claims and Claims Adjustment Expense [Line Items]				
Net Reserve for Claims and Claim Expenses	\$ 16,822,101	\$ 15,142,583	\$ 11,181,648	\$ 9,025,961
Reinsurance Recoverable	4,481,390	5,344,286	4,710,925	
Total reserve for claims and claim expenses	21,303,491	\$ 20,486,869	\$ 15,892,573	
Property				
Liability for Claims and Claims Adjustment Expense [Line Items]				
Net Reserve for Claims and Claim Expenses	4,906,841			
Reinsurance Recoverable	1,665,898			
Casualty and Specialty				
Liability for Claims and Claims Adjustment Expense [Line Items]				
Net Reserve for Claims and Claim Expenses	11,915,260			
Reinsurance Recoverable	\$ 2,815,492			

XML 116 R97.htm IDEA: XBRL DOCUMENT

RESERVE FOR
CLAIMS AND CLAIM
EXPENSES -
Historical Claims
Duration (Details)

Dec. 31, 2024

Property

Short-duration Insurance Contracts, Historical Claims Duration [Line Items]

Average annual percentage payout, year one	20.70%
Average annual percentage payout, year two	28.80%
Average annual percentage payout, year three	16.40%
Average annual percentage payout, year four	6.90%
Average annual percentage payout, year five	5.50%
Average annual percentage payout, year six	0.90%
Average annual percentage payout, year seven	0.90%
Average annual percentage payout, year eight	0.40%
Average annual percentage payout, year nine	0.70%
Average annual percentage payout, year ten	0.20%

Casualty and Specialty

Short-duration Insurance Contracts, Historical Claims Duration [Line Items]

Average annual percentage payout, year one	12.30%
Average annual percentage payout, year two	16.30%
Average annual percentage payout, year three	12.40%
Average annual percentage payout, year four	12.90%
Average annual percentage payout, year five	10.60%
Average annual percentage payout, year six	8.40%
Average annual percentage payout, year seven	6.30%
Average annual percentage payout, year eight	4.50%
Average annual percentage payout, year nine	2.50%
Average annual percentage payout, year ten	1.10%

XML 117 R98.htm IDEA: XBRL DOCUMENT

RESERVE FOR CLAIMS AND CLAIM EXPENSES - Additional Information (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]

Other income (loss)	\$ 1,928	\$ (6,152)	\$ 12,636
Net claim and claim expenses decrease	(5,332,981)	(3,573,509)	(4,338,840)
Reinsurance balances payable			
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]			
Aggregate deposit liabilities	3,500	3,700	
Deposit Contracts, Underwriting Risk Only			
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]			
Other income (loss)	\$ 200	\$ 200	
Net claim and claim expenses decrease			\$ 200

XML 118 R99.htm IDEA: XBRL DOCUMENT

DEBT AND CREDIT FACILITIES - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) - USD (\$) \$ in Thousands							
	Dec. 31, 2024	Dec. 31, 2023	Jun. 05, 2023	Apr. 02, 2019	Jun. 29, 2017	May 04, 2015	Mar. 24, 2015

Debt Instrument [Line Items]

Long-term debt	\$ 1,900,000	\$ 1,900,000					
Fair Value							
Debt Instrument [Line Items]							
Long-term debt	1,871,492	1,929,052					
Carrying Value							
Debt Instrument [Line Items]							
Long-term debt	\$ 1,886,689	1,958,655					
3.600% Senior Notes due 2029							
Debt Instrument [Line Items]							
Interest rate	3.60%			3.60%			
3.450% Senior Notes due 2027							
Debt Instrument [Line Items]							
Interest rate	3.45%				3.45%		
3.700% Senior Notes due 2025							
Debt Instrument [Line Items]							
Interest rate	3.70%						3.70%
DaVinci 4.750% Senior Notes due 2025 (DaVinci)							
Debt Instrument [Line Items]							
Interest rate	4.75%					4.75%	
Senior Notes 5.750% Senior Notes due 2033							
Debt Instrument [Line Items]							
Interest rate	5.75%		5.75%				
Senior Notes RenaissanceRe Finance, Inc. 5.750% Senior Notes due 2033 Fair Value							
Debt Instrument [Line Items]							
Long-term debt	\$ 755,693	758,783					
Senior Notes RenaissanceRe Finance, Inc. 5.750% Senior Notes due 2033 Carrying Value							
Debt Instrument [Line Items]							
Long-term debt	742,068	741,124					
Senior Notes RenaissanceRe Finance, Inc. 3.600% Senior Notes due 2029 Fair Value							
Debt Instrument [Line Items]							
Long-term debt	376,816	371,276					
Senior Notes RenaissanceRe Finance, Inc. 3.600% Senior Notes due 2029 Carrying Value							
Debt Instrument [Line Items]							
Long-term debt	396,051	395,137					
Senior Notes RenaissanceRe Finance, Inc. 3.450% Senior Notes due 2027 Fair Value							
Debt Instrument [Line Items]							
Long-term debt	290,070	283,350					
Senior Notes RenaissanceRe Finance, Inc. 3.450% Senior Notes due 2027 Carrying Value							
Debt Instrument [Line Items]							
Long-term debt	298,765	298,270					
Senior Notes RenaissanceRe Finance, Inc. 3.700% Senior Notes due 2025 Fair Value							

Debt Instrument [Line Items]									
Long-term debt			299,550				293,154		
Senior Notes RenaissanceRe Finance, Inc. 3.700% Senior Notes due 2025 Carrying Value									
Debt Instrument [Line Items]									
Long-term debt			299,908				299,537		
Senior Notes DaVinci Fair Value									
Debt Instrument [Line Items]									
Long-term debt			1,871,492				1,854,052		
Senior Notes DaVinci Carrying Value									
Debt Instrument [Line Items]									
Long-term debt			1,886,689				1,883,655		
Senior Notes DaVinci 4.750% Senior Notes due 2025 (DaVinci) Fair Value									
Debt Instrument [Line Items]									
Long-term debt			149,363				147,489		
Senior Notes DaVinci 4.750% Senior Notes due 2025 (DaVinci) Carrying Value									
Debt Instrument [Line Items]									
Long-term debt			149,897				149,587		
Line of Credit DaVinci Fair Value Revolving Credit Facility									
Debt Instrument [Line Items]									
Long-term debt			0				75,000		
Line of Credit DaVinci Carrying Value Revolving Credit Facility									
Debt Instrument [Line Items]									
Long-term debt			\$ 0				\$ 75,000		
<i><u>XML 119 R100.htm IDEA: XBRL DOCUMENT</u></i>									
DEBT AND CREDIT		12 Months Ended							
FACILITIES - Debt									
Obligations Narrative									
(Details) - USD (\$)		Jun. 05, 2023	Apr. 02, 2019	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jun. 29, 2017	May 04, 2015	Mar. 24, 2015
									Feb. 25, 2015
Debt Instrument [Line Items]									
Issuance of debt, net of expenses				\$ 0	\$ 740,581,000	\$ 0			
Bridge Loan Platinum Underwriters Holdings, Ltd.									
Debt Instrument [Line Items]									
Short-term debt									\$ 300,000,000.0
3.600% Senior Notes due 2029									
Debt Instrument [Line Items]									
Interest rate			3.60%	3.60%					
3.450% Senior Notes due 2027									
Debt Instrument [Line Items]									
Interest rate				3.45%			3.45%		
3.700% Senior Notes due 2025									
Debt Instrument [Line Items]									
Interest rate				3.70%				3.70%	
Senior Notes 5.750% Senior Notes due 2033									
Debt Instrument [Line Items]									
Interest rate		5.75%		5.75%					
Face amount		\$ 750,000,000.0							
Issuance of debt, net of expenses		\$ 741,000,000							
Senior Notes 3.600% Senior Notes due 2029									
Debt Instrument [Line Items]									
Face amount			\$ 400,000,000.0						
Repayments of long-term lines of credit									
			\$ 200,000,000.0						
RenaissanceRe Finance, Inc. 3.700% Senior Notes due 2025									
Debt Instrument [Line Items]									
Face amount								\$ 300,000,000.0	
RenaissanceRe Finance, Inc. Senior Notes 3.450% Senior Notes due 2027									
Debt Instrument [Line Items]									
Face amount						\$ 300,000,000.0			
DaVinci									
Debt Instrument [Line Items]									
Loan agreement with related party							\$ 100,000,000.0		
DaVinci 4.750% Senior Notes Due May 1, 2025									
Debt Instrument [Line Items]									
Interest rate				4.75%			4.75%		
Face amount							\$ 150,000,000.0		
<i><u>XML 120 R101.htm IDEA: XBRL DOCUMENT</u></i>									
DEBT AND CREDIT		Dec. 31, 2024							
FACILITIES-		USD (\$)							
Schedule of									
Maturities of Long-term Debt (Details)									
\$ in Thousands									
Debt Disclosure [Abstract]									
2025			\$ 450,000						
2026			0						
2027			300,000						
2028			0						
2029			400,000						
After 2029			750,000						
Unamortized discount and debt issuance expenses			(13,311)						
Total			\$ 1,886,689						
<i><u>XML 121 R102.htm IDEA: XBRL DOCUMENT</u></i>									
DEBT AND CREDIT		Dec. 31, 2024							
FACILITIES -		USD (\$)							
Schedule of Credit									
Facilities (Details)									
Line of Credit Facility [Line Items]									
Issued or Drawn			\$ 619,611,000						
Revolving Credit Facility									
Line of Credit Facility [Line Items]									
Issued or Drawn			0						

Revolving Credit Facility Medici									
Line of Credit Facility [Line Items]									
Issued or Drawn		0							
Revolving Credit Facility Line of Credit									
Line of Credit Facility [Line Items]									
Issued or Drawn		0							
Revolving Credit Facility Line of Credit Medici									
Line of Credit Facility [Line Items]									
Issued or Drawn		0							
Letter of Credit Line of Credit Secured Bilateral Facility									
Line of Credit Facility [Line Items]									
Issued or Drawn		262,168,000							
Letter of Credit Line of Credit Unsecured Bilateral Facility									
Line of Credit Facility [Line Items]									
Issued or Drawn		\$ 357,443,000							
XML 122 R103.htm IDEA: XBRL DOCUMENT									
DEBT AND CREDIT									
FACILITIES - Credit		Dec. 31, 2024	Oct. 03,	Nov. 01,	Oct. 31,	Nov. 18,	Sep. 08,	Dec. 16,	Jun. 21,
Facilities Narrative		USD (\$)	2024	2023	2023	2022	2022	2021	2019
(Details)			USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)
Line of Credit Facility [Line Items]									
Credit facilities outstanding		\$ 619,611,000							
Top Layer Reinsurance Ltd. Letter of Credit									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity		37,500,000							
Top Layer Reinsurance Ltd. Letter of Credit Capital Support Agreement									
Line of Credit Facility [Line Items]									
Mandatory capital contribution in the event of capital and surplus reduction below a specified level		50,000,000.0							
Revolving Credit Facility									
Line of Credit Facility [Line Items]									
Credit facilities outstanding		0							
Revolving Credit Facility Medici									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity		75,000,000.0							
Credit facilities outstanding		\$ 0							
Revolving Credit Facility									
Line of Credit Facility [Line Items]									
Letter of credit aggregate commitment						\$ 500,000,000.0			
Line of credit facility, maximum borrowing capacity						700,000,000.0			
Debt to capital ratio		0.35							
Minimum net worth requirements		\$ 4,000,000,000.0							
Revolving Credit Facility Bridge Loan									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity						\$ 50,000,000.0			
Secured Bilateral Facility Letter of Credit Wells Fargo									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity									\$ 200,000,000.0
Credit facilities outstanding		20,100,000							
Secured Bilateral Facility Letter of Credit Citibank Europe plc									
Line of Credit Facility [Line Items]									
Credit facilities outstanding		232,600,000							
Secured Bilateral Facility Letter of Credit Citibank Europe plc Bilateral Facility Participants									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity				\$ 320,000,000.0	\$ 180,000,000				
Accordion feature, maximum borrowing capacity				\$ 350,000,000					
Loan agreement, remaining borrowing capacity		87,400,000							
Unsecured Bilateral Facility Letter of Credit Wells Fargo									
Line of Credit Facility [Line Items]									
Credit facilities outstanding		0							
Unsecured Bilateral Facility Letter of Credit Citibank Europe plc									
Line of Credit Facility [Line Items]									
Credit facilities outstanding		293,000,000.0							
Unsecured Bilateral Facility Letter of Credit Credit Suisse (Switzerland) Ltd.									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity									\$ 200,000,000.0
Credit facilities outstanding		19,100,000							
Standby Letter of Credit Agreement Letter of Credit Nordea Bank Abp, New York Branch									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity				\$ 250,000,000.0					
Credit facilities outstanding		45,300,000							
Uncommitted Letter of Credit Facility Letter of Credit Société Générale, New York Branch ("SocGen")									
Line of Credit Facility [Line Items]									
Line of credit facility, maximum borrowing capacity						\$ 250,000,000.0			
Credit facilities outstanding									
Percentage of maximum aggregate amount to be secured						40.00%			
Secured Letter of Credit Facility Letter of Credit Citibank Europe									
Line of Credit Facility [Line Items]									
Credit facilities outstanding		\$ 9,400,000							
XML 123 R104.htm IDEA: XBRL DOCUMENT									
NONCONTROLLING INTERESTS - Summary of Redeemable Noncontrolling Interest (Details) - USD (\$)		12 Months Ended							
\$ in Thousands									
Redeemable Noncontrolling Interest [Line Items]									
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022					

Redeemable noncontrolling interests	\$ 6,977,749	\$ 6,100,831	
Net income (loss) attributable to redeemable noncontrolling interest	1,090,172	1,058,995	\$ (98,613)
DaVinci			
Redeemable Noncontrolling Interest [Line Items]			
Redeemable noncontrolling interests	3,061,708	2,541,482	1,740,300
Net income (loss) attributable to redeemable noncontrolling interest	627,055	545,812	(65,514)
Medici			
Redeemable Noncontrolling Interest [Line Items]			
Redeemable noncontrolling interests	1,646,745	1,650,229	1,036,218
Net income (loss) attributable to redeemable noncontrolling interest	202,941	239,250	(70,504)
Vermeer			
Redeemable Noncontrolling Interest [Line Items]			
Redeemable noncontrolling interests	1,799,857	1,555,297	1,490,840
Net income (loss) attributable to redeemable noncontrolling interest	244,560	239,457	43,058
Fontana			
Redeemable Noncontrolling Interest [Line Items]			
Redeemable noncontrolling interests	469,439	353,823	268,031
Net income (loss) attributable to redeemable noncontrolling interest	\$ 15,616	\$ 34,476	\$ (5,653)
XML 124 R105.htm IDEA: XBRL DOCUMENT			
NONCONTROLLING INTERESTS - Narrative (Details) - USD (\$)		12 Months Ended	
\$ in Thousands		Dec. 31, 2024	Dec. 31, 2023
DaVinci Reinsurance			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		\$ 300,000	\$ 275,000
Proceeds from noncontrolling interests		69,700	
Third-Party Investors			
Redeemable Noncontrolling Interest [Line Items]			
Redemption of shares from redeemable noncontrolling interests		225,900	123,300
DaVinci			
Redeemable Noncontrolling Interest [Line Items]			
Payments to noncontrolling interests		225,900	123,300
Proceeds from noncontrolling interests			300,000
Medici			
Redeemable Noncontrolling Interest [Line Items]			
Payments to noncontrolling interests		361,800	102,200
Proceeds from noncontrolling interests		163,600	531,400
Fontana			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		50,000	
Proceeds from noncontrolling interests		129,200	151,300
DaVinci			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed			250,000
Redemption of shares from redeemable noncontrolling interests		\$ 406,849	123,272
DaVinci Redeemable Noncontrolling Interest			
Redeemable Noncontrolling Interest [Line Items]			
Redeemable noncontrolling interest, redemption requirement, maximum percentage of shares held	50.00%		
DaVinci Third-Party Investors			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed			102,200
Payments to noncontrolling interests		\$ 180,600	
DaVinci RenaissanceRe Holdings Ltd.			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed			147,800
Payments to noncontrolling interests		69,400	
Medici			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		200,219	482,310
Redemption of shares from redeemable noncontrolling interests		\$ 406,644	107,549
Written notice period for redemption		30 days	
Medici Third-Party Investors			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		\$ 250,200	527,300
Redemption of shares from redeemable noncontrolling interests		382,000	117,500
Payments of dividends		24,600	
Medici RenaissanceRe Holdings Ltd.			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		50,600	45,200
Redemption of shares from redeemable noncontrolling interests		300	10,000
Vermeer			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		175,000	0
Vermeer Stichting Pensioenfonds Zorg en Welzijn			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		175,000	
Payments of dividends		175,000	175,000
Fontana			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		100,000	51,316
Fontana Third-Party Investors			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		100,000	75,000
Fontana RenaissanceRe Holdings Ltd.			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling interest, value subscribed		\$ 50,000	\$ 23,700
Maximum DaVinci			
Redeemable Noncontrolling Interest [Line Items]			
Share repurchase requests, limit		25.00%	
DaVinci Reinsurance			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling ownership percentage		25.40%	27.80%
Medici			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling ownership percentage		15.80%	11.70%
Vermeer Medici Voting, Non-participating Shares			

Redeemable Noncontrolling Interest [Line Items]			
Parent company ownership in redeemable noncontrolling interest	100.00%		
Vermeer PFZW Participating, Non-voting Common Shares			
Redeemable Noncontrolling Interest [Line Items]			
Parent company ownership in redeemable noncontrolling interest	100.00%		
Fontana			
Redeemable Noncontrolling Interest [Line Items]			
Noncontrolling ownership percentage	26.50%	31.60%	

XML 125 R106.htm
IDEA: XBRL DOCUMENT

NONCONTROLLING INTERESTS - Schedule of Redeemable Noncontrolling Interest Activity (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Activity in redeemable noncontrolling interest			
Beginning balance	\$ 6,100,831		
Net income (loss) attributable to redeemable noncontrolling interest	1,090,172	\$ 1,058,995	\$ (98,613)
Ending balance	6,977,749	6,100,831	
DaVinci			
Activity in redeemable noncontrolling interest			
Beginning balance	2,541,482	1,740,300	
Redemption of shares from redeemable noncontrolling interests	(406,849)	(123,272)	
Sale of limited partner interest to redeemable noncontrolling interest		250,000	
Net income (loss) attributable to redeemable noncontrolling interest	627,055	545,812	(65,514)
Ending balance	3,061,708	2,541,482	1,740,300
DaVinci Third-Party Investors And RenaissanceRe			
Activity in redeemable noncontrolling interest			
Sale of limited partner interest to redeemable noncontrolling interest	300,020	378,642	
Medici			
Activity in redeemable noncontrolling interest			
Beginning balance	1,650,229	1,036,218	
Redemption of shares from redeemable noncontrolling interests	(406,644)	(107,549)	
Sale of limited partner interest to redeemable noncontrolling interest	200,219	482,310	
Net income (loss) attributable to redeemable noncontrolling interest	202,941	239,250	(70,504)
Ending balance	1,646,745	1,650,229	1,036,218
Vermeer			
Activity in redeemable noncontrolling interest			
Beginning balance	1,555,297	1,490,840	
Dividends on common shares	(175,000)	(175,000)	
Sale of limited partner interest to redeemable noncontrolling interest	175,000	0	
Net income (loss) attributable to redeemable noncontrolling interest	244,560	239,457	43,058
Ending balance	1,799,857	1,555,297	1,490,840
Fontana			
Activity in redeemable noncontrolling interest			
Beginning balance	353,823	268,031	
Sale of limited partner interest to redeemable noncontrolling interest	100,000	51,316	
Net income (loss) attributable to redeemable noncontrolling interest	15,616	34,476	(5,653)
Ending balance	\$ 469,439	\$ 353,823	\$ 268,031

XML 126 R107.htm
IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES - Narrative (Details) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
	USD (\$)	USD (\$)	USD (\$)
	account		
Variable Interest Entity [Line Items]			
Number of segregated accounts account	4		
Assets	\$ 50,707,550	\$ 49,007,105	
Liabilities	33,155,789	33,451,316	
Investments in other ventures, under equity method (Note 5)	102,770	112,624	
Redeemable noncontrolling interests	6,977,749	6,100,831	
Ceded premiums written	1,780,850	1,394,553	\$ 2,017,380
Ceded premiums earned	1,817,302	1,614,432	1,850,807
Vermeer			
Variable Interest Entity [Line Items]			
Redeemable noncontrolling interests	1,799,857	1,555,297	1,490,840
Fontana			
Variable Interest Entity [Line Items]			
Redeemable noncontrolling interests	469,439	353,823	268,031
Primary Beneficiary Upsilon RFO Re Ltd.			
Variable Interest Entity [Line Items]			
Assets	1,900,000	2,400,000	
Liabilities	1,900,000	2,400,000	
Net assets	60,500	74,200	
Primary Beneficiary Investors of Upsilon RFO Diversified I, II and III Upsilon RFO Re Ltd.			
Variable Interest Entity [Line Items]			
Payments of capital distributions	397,600	988,500	
Net assets	282,200	500,000	
Primary Beneficiary RenaissanceRe Holdings Ltd. Upsilon RFO Re Ltd.			
Variable Interest Entity [Line Items]			
Payments of capital distributions	\$ 59,800	\$ 125,500	
Variable interest entity, ownership percentage	12.70%	14.30%	
Primary Beneficiary RenaissanceRe Holdings Ltd. Upsilon RFO Re Ltd. Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity		\$ 10,200	
Primary Beneficiary Investor Upsilon RFO Re Ltd. Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity		39,800	
Not Primary Beneficiary RenaissanceRe Upsilon Diversified Fund			
Variable Interest Entity [Line Items]			
Investments in other ventures, under equity method (Note 5)	\$ 500	800	
Not Primary Beneficiary NOC1			
Variable Interest Entity [Line Items]			
Investments in other ventures, under equity method (Note 5)	1,700	1,700	
Not Primary Beneficiary Alpha Cat entities			
Variable Interest Entity [Line Items]			
Investments in other ventures, under equity method (Note 5)	3,600	4,400	

Not Primary Beneficiary RenaissanceRe Upsilon Diversified Fund			
Variable Interest Entity [Line Items]			
Assets	440,600	600,800	
Liabilities	140,900	108,000	
Not Primary Beneficiary RenaissanceRe Upsilon Diversified Fund Upsilon RFO Re Ltd.			
Variable Interest Entity [Line Items]			
Investment owned, fair value	304,000	503,100	
Not Primary Beneficiary NOC1			
Variable Interest Entity [Line Items]			
Assets	173,400	196,500	
Liabilities	2,200	22,800	
Not Primary Beneficiary Vermeer			
Variable Interest Entity [Line Items]			
Assets	1,900,000	1,700,000	
Liabilities	93,000	102,700	
Redeemable noncontrolling interests	1,800,000	1,600,000	
Not Primary Beneficiary Fontana			
Variable Interest Entity [Line Items]			
Assets	2,200,000	1,500,000	
Liabilities	1,600,000	968,500	
Redeemable noncontrolling interests	469,400	353,800	
Not Primary Beneficiary Mona Lisa Re			
Variable Interest Entity [Line Items]			
Assets	936,100	436,900	
Liabilities	936,100	436,900	
Not Primary Beneficiary Mona Lisa Re Other Investments			
Variable Interest Entity [Line Items]			
Investment in participating notes	7,000	2,200	
Not Primary Beneficiary Tailwind Re Ltd			
Variable Interest Entity [Line Items]			
Assets	416,800	417,100	
Liabilities	416,800	417,100	
Not Primary Beneficiary Tailwind Re Ltd Other Investments			
Variable Interest Entity [Line Items]			
Investment in participating notes	0	800	
Not Primary Beneficiary Alpha Cat entities			
Variable Interest Entity [Line Items]			
Assets	3,000,000	5,000,000	
Liabilities	1,300,000	2,400,000	
Not Primary Beneficiary RenaissanceRe Holdings Ltd. RenaissanceRe Upsilon Diversified Fund			
Variable Interest Entity [Line Items]			
Payments of capital distributions	500	1,200	
Not Primary Beneficiary RenaissanceRe Holdings Ltd. RenaissanceRe Upsilon Diversified Fund Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity		100	
Not Primary Beneficiary RenaissanceRe Holdings Ltd. NOC1 Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity	200	1,600	
Redemption of preference shares	500		
Not Primary Beneficiary RenaissanceRe Holdings Ltd. Tailwind Re Ltd			
Variable Interest Entity [Line Items]			
Ceded premiums written	42,700	0	
Ceded premiums earned	42,700	6,500	
Not Primary Beneficiary Investors of Upsilon RFO Diversified IV Upsilon RFO Re Ltd.			
Variable Interest Entity [Line Items]			
Net assets	115,900	88,300	
Not Primary Beneficiary Investors of Upsilon RFO Diversified IV Upsilon RFO Re Ltd. Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity		81,400	
Not Primary Beneficiary Investor RenaissanceRe Upsilon Diversified Fund			
Variable Interest Entity [Line Items]			
Payments of capital distributions	333,400	844,100	
Not Primary Beneficiary Investor RenaissanceRe Upsilon Diversified Fund Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity	16,900	30,000	
Not Primary Beneficiary Investor NOC1 Preference shares			
Variable Interest Entity [Line Items]			
Investment in variable interest entity	20,000	161,500	
Redemption of preference shares	48,800		
Not Primary Beneficiary Renaissance Reinsurance Mona Lisa Re			
Variable Interest Entity [Line Items]			
Ceded premiums written	45,200	32,800	39,600
Ceded premiums earned	39,500	32,800	39,400
Not Primary Beneficiary DaVinci Reinsurance Mona Lisa Re			
Variable Interest Entity [Line Items]			
Ceded premiums written	11,700	8,200	9,900
Ceded premiums earned	\$ 10,300	\$ 8,200	\$ 9,800

XML 127 R108.htm

IDEA: XBRL DOCUMENT

VARIABLE INTEREST ENTITIES - Summary of the Principal-at-risk Variable Notes (Details) - Not Primary Beneficiary - Mona Lisa Re - USD (\$)

\$ in Millions

\$350 Million Principal At Risk Variable Rate Note

[Variable Interest Entity \[Line Items\]](#)

Face amount

\$ 350.0

[\\$150 Million Principal-At-Risk Note](#)

[Variable Interest Entity \[Line Items\]](#)

Face amount

\$ 150.0

[\\$85 Thousand Principal At Risk Variable Rate Note](#)

[Variable Interest Entity \[Line Items\]](#)

Face amount

\$ 85.0

[\\$100 Million Principal At Risk Variable Rate Note](#)

[Variable Interest Entity \[Line Items\]](#)

Face amount

\$ 100.0

SHAREHOLDERS' EQUITY - Narrative (Details)	1 Months Ended				3 Months Ended				12 Months Ended			
	Nov. 01, 2023	May 26, 2023	Jul. 31, 2021	Jun. 30, 2018	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 06, 2024
	shares	\$ / shares	\$ / shares	\$ / shares	USD (\$) period director \$ / shares	\$ / shares	\$ / shares	\$ / shares	USD (\$) period director \$ / shares	USD (\$) \$ / shares	USD (\$) \$ / shares	USD (\$) \$ / shares
Class of Stock [Line Items]												
Aggregate authorized shares (in shares) shares					325,000,000				325,000,000			
Authorized common shares (in shares) shares					225,000,000				225,000,000			
Authorized preference shares (in shares) shares					100,000,000				100,000,000			
Par value (in usd per share)					\$ 1.00				\$ 1.00	\$ 1.00		
Dividends declared per common share (in usd per share)					0.39	\$ 0.39	\$ 0.39	\$ 0.39				
Dividends on preference shares \$									\$	\$	\$	
									35,375,000	35,375,000	35,375,000	
Dividends on common shares \$									\$	\$	\$	
									80,800,000	75,100,000	64,700,000	
Validus												
Class of Stock [Line Items]												
Shares issued (in shares) shares	1,322,541											
Public Offering												
Class of Stock [Line Items]												
Sale of stock, number of shares issued (in shares) shares		7,245,000										
Sale of stock, price per share (in usd per share)		\$ 192.00										
Sale of stock, consideration received on transaction \$		\$										
		1,352,000,000										
Series F Preferred Stock												
Class of Stock [Line Items]												
Sale of stock, number of shares issued (in shares) shares				10,000								
Proceeds from issuance of equity \$				\$								
				250,000,000								
Dividend rate, percentage				5.75%					5.75%			
Par value (in usd per share)				\$ 1.00								
Liquidation preference (in usd per share)				25,000								
Liquidation preference per annum (in usd per share)					1,437.5				\$ 1,437.5			
Quarterly liquidation preference (in usd per share)					359.375				\$ 359.375			
Series F Preferred Stock Redemption period one												
Class of Stock [Line Items]												
Redemption price per share (in usd per share)				\$ 25,000								
Depository Shares, each representing a 1/1,000th interest in a Series F 5.750% Preference Share, Par Value \$1.00 per share												
Class of Stock [Line Items]												
Sale of stock, number of shares issued (in shares) shares				10,000,000								
Depository Shares												
Class of Stock [Line Items]												
Percentage interest in underlying shares			0.10%	0.10%								
Depository Shares Redemption period one												
Class of Stock [Line Items]												
Redemption price per share (in usd per share)			\$ 25.00	\$ 25.00								
Series G Preferred Stock												
Class of Stock [Line Items]												
Sale of stock, number of shares issued (in shares) shares				20,000								
Proceeds from issuance of equity \$				\$								
				500,000,000								
Dividend rate, percentage				4.20%					4.20%			
Par value (in usd per share)				\$ 1.00								
Liquidation preference (in usd per share)				25,000								
Liquidation preference per annum (in usd per share)					1,050				\$ 1,050			
Quarterly liquidation preference (in usd per share)					\$ 262.50				\$ 262.50			
Series G Preferred Stock Redemption period one												
Class of Stock [Line Items]												
Redemption price per share (in usd per share)			\$ 25,000									
Depository Shares, each representing a 1/1,000th interest in a Series G 4.20% Preference Share, Par Value \$1.00 per share												
Class of Stock [Line Items]												
Sale of stock, number of shares issued (in shares) shares				20,000,000								
Series C Preferred Stock												
Class of Stock [Line Items]												
Right to elect directors, required number of dividend periods in arrears period					6				6			
Right to elect directors, number of directors director					2				2			
Series F Preferred Shares, Depository Shares												
Class of Stock [Line Items]												
Liquidation preference per annum (in usd per share)					\$ 1.4375				\$ 1.4375			
Quarterly liquidation preference (in usd per share)					0.359375				0.359375			
Series G Preferred Shares, Depository Shares												
Class of Stock [Line Items]												
Liquidation preference per annum (in usd per share)					1.05				1.05			
Quarterly liquidation preference (in usd per share)					\$ 0.2625				\$ 0.2625			
Common shares												
Class of Stock [Line Items]												
Share repurchase program, authorized aggregate amount \$												\$ 750,000,000.0
Share repurchase program, shares repurchased (in shares) shares									2,711,234			
Value of shares repurchased \$									\$			
									677,600,000			
Shares repurchased, average price per share (in usd per share)									\$ 249.93			

Remaining authorized repurchase amount \$		\$	287,700,000	\$	287,700,000
<u>XML 129 R110.htm IDEA: XBRL DOCUMENT</u>					
SHAREHOLDERS' EQUITY - Rollforward of Shares Issued and Outstanding (Details) - shares		12 Months Ended			
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Shares issued - beginning balance (in shares)		52,693,887			
Shares outstanding - beginning balance (in shares)		52,693,887			
Shares issued - ending balance (in shares)		50,180,987	52,693,887		
Shares outstanding - ending balance (in shares)		50,180,987	52,693,887		
Common shares					
Increase (Decrease) in Stockholders' Equity [Roll Forward]					
Shares issued - beginning balance (in shares)		52,694,000	43,718,000	44,445,000	
Shares outstanding - beginning balance (in shares)		52,694,000	43,718,000	44,445,000	
Issuance of shares (in shares)		0	8,568,000	0	
Repurchase of shares (in shares)		(2,711,000)	0	(1,051,000)	
Issuance of performance share and restricted stock awards (in shares)		198,000	408,000	324,000	
Shares issued - ending balance (in shares)		50,181,000	52,694,000	43,718,000	
Shares outstanding - ending balance (in shares)		50,181,000	52,694,000	43,718,000	
<u>XML 130 R111.htm IDEA: XBRL DOCUMENT</u>					
EARNINGS PER SHARE - Computation of Basic and Diluted Earnings Per Common Share (Details) - USD (\$)		12 Months Ended			
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Numerator:					
Net income (loss) available (attributable) to RenaissanceRe common shareholders		\$ 1,834,985	\$ 2,525,757	\$ (1,096,578)	
Amount allocated to participating common shareholders		(27,472)	(37,308)	(1,079)	
Net income (loss) allocated to RenaissanceRe common shareholders		\$ 1,807,513	\$ 2,488,449	\$ (1,097,657)	
Denominator:					
Denominator for basic income (loss) per RenaissanceRe common share - weighted average common shares (in shares)		51,186	47,493	43,040	
Per common share equivalents of non-vested shares (in shares)		153	114	0	
Denominator for diluted income (loss) per RenaissanceRe common share - adjusted weighted average common shares and assumed conversions (in shares)		51,339	47,607	43,040	
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - basic (in dollars per share)		\$ 35.31	\$ 52.40	\$ (25.50)	
Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share - diluted (in dollars per share)		\$ 35.21	\$ 52.27	\$ (25.50)	
Potentially dilutive securities (in shares)				90	
<u>XML 131 R112.htm IDEA: XBRL DOCUMENT</u>					
RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS (Details) - USD (\$)		12 Months Ended			
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Related Party Transaction [Line Items]					
Gross premiums written (Note 7)		\$ 11,733,066	\$ 8,862,366	\$ 9,213,540	
Gross premiums earned		10,815,336	8,072,193	7,079,632	
Acquisition expenses		2,643,867	1,875,034	1,568,606	
Net reinsurance costs and recoveries		(296,775)	(376,853)	(1,512,300)	
Total reserve for claims and claim expenses		21,303,491	20,486,869	15,892,573	
Equity method investment, dividends and distributions		\$ 109,800	\$ 41,400	\$ 24,200	
Gross premiums written Three Brokers Customer Concentration Risk					
Related Party Transaction [Line Items]					
Percent of gross premiums received		82.10%	84.30%	82.20%	
Gross premiums written Aon plc Customer Concentration Risk					
Related Party Transaction [Line Items]					
Percent of gross premiums received		32.00%	36.10%		
Gross premiums written Marsh & McLennan Companies, Inc. Customer Concentration Risk					
Related Party Transaction [Line Items]					
Percent of gross premiums received		36.50%	33.20%		
Gross premiums written Arthur J Gallagher Customer Concentration Risk					
Related Party Transaction [Line Items]					
Percent of gross premiums received		13.60%	15.00%		
Related Party Tower Hill Companies					
Related Party Transaction [Line Items]					
Gross premiums written (Note 7)		\$ 115,100	\$ 96,800	\$ 82,000	
Gross premiums earned		119,000	83,300	80,000	
Acquisition expenses		14,200	12,700	15,800	
Outstanding receivable		31,900	37,000		
Net reinsurance costs and recoveries		94,500	(9,800)	68,600	
Total reserve for claims and claim expenses		95,200	50,200		
Equity method investment, dividends and distributions		34,400	22,600	10,500	
Related Party Top Layer Reinsurance Ltd.					
Related Party Transaction [Line Items]					
Equity method investment, dividends and distributions		16,800	7,800	8,700	
Related Party Management Fee Top Layer Reinsurance Ltd.					
Related Party Transaction [Line Items]					
Revenue recorded		\$ 3,000	\$ 3,400	\$ 2,400	
<u>XML 132 R113.htm IDEA: XBRL DOCUMENT</u>					
TAXATION - Narrative (Details) - USD (\$)		12 Months Ended			
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	
Operating Loss Carryforwards [Line Items]					
Increase (decrease) in valuation allowance		\$ (66,200,000)	\$ 19,600,000	\$ 62,100,000	
Unrealized losses in the US investment portfolio		60,600,000			
Income taxes paid (refunded)		99,535,000	26,777,000	\$ 3,129,000	
Unrecognized tax benefits		0	0		
Interest and penalties accrued on unrecognized tax benefits		\$ 0	\$ 0		
Bermuda					
Operating Loss Carryforwards [Line Items]					
Statutory income tax rate U.S.		0.00%			
Operating Loss Carryforwards [Line Items]					
Expected tax rate		5.00%			
Foreign statutory income tax rate U.S. 2037		21.00%			

Operating Loss Carryforwards [Line Items]	
Operating loss carryforwards	\$ 97,300,000
U.S. 2027	
Operating Loss Carryforwards [Line Items]	
Operating loss carryforwards	\$ 131,600,000
Ireland	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	12.50%
Operating loss carryforwards	\$ 8,300,000
U.K.	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	25.00%
Operating loss carryforwards	\$ 141,200,000
Singapore	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	17.00%
Switzerland	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	19.70%
Switzerland 2024	
Operating Loss Carryforwards [Line Items]	
Operating loss carryforwards	\$ 350,000,000.0
Luxembourg	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	24.90%
Operating loss carryforwards	\$ 155,700,000
Canada	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	26.50%
Australia	
Operating Loss Carryforwards [Line Items]	
Foreign statutory income tax rate	30.00%

XML 133 R114.htm IDEA: XBRL DOCUMENT

TAXATION - Income		12 Months Ended		
(Loss) Before Income				
Taxes, Foreign and				
Domestic (Details) -		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
USD (\$)				
\$ in Thousands				
Income Tax Expense (Benefit)				
Income (loss) before taxes		\$ 2,993,160	\$ 3,110,060	\$ (1,218,835)
Bermuda				
Income Tax Expense (Benefit)				
Domestic		2,704,721	2,622,066	(672,950)
Singapore				
Income Tax Expense (Benefit)				
Foreign		61,570	64,003	112
Ireland				
Income Tax Expense (Benefit)				
Foreign		2,650	1,730	6
U.S.				
Income Tax Expense (Benefit)				
Foreign		93,606	308,768	(367,799)
Australia				
Income Tax Expense (Benefit)				
Foreign		14,487	7,570	(29,214)
Switzerland				
Income Tax Expense (Benefit)				
Foreign		57,585	(22,016)	(72,773)
Luxembourg				
Income Tax Expense (Benefit)				
Foreign		(50)	(16)	0
Canada				
Income Tax Expense (Benefit)				
Foreign		(3,501)	2,040	0
U.K.				
Income Tax Expense (Benefit)				
Foreign		\$ 62,092	\$ 125,915	\$ (76,217)

XML 134 R115.htm IDEA: XBRL DOCUMENT

TAXATION -		12 Months Ended		
Components of				
Income Tax Benefit				
(Expense) (Details) -		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
USD (\$)				
\$ in Thousands				
Income Tax Expense (Benefit)				
Current	\$ (56,718)	\$ (57,422)	\$ (3,078)	
Deferred	24,090	567,489	62,097	
Income tax benefit (expense)	\$ (32,628)	\$ 510,067	\$ 59,019	

XML 135 R116.htm IDEA: XBRL DOCUMENT

TAXATION- Income		12 Months Ended		
Tax Reconciliation				
(Details) - USD (\$)		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands				
Income Tax Disclosure [Abstract]				
Expected income tax benefit (expense)	\$ (60,684)	\$ (103,963)	\$ 114,721	
Nondeductible expenses	(1,671)	(535)	(508)	
Reinsurance adjustment	4,384	4,746	(1,265)	
Effect of change in tax rate	(160)	(729)	7,461	
OECD Pillar Two global minimum tax	(16,603)	0	0	
GAAP to statutory accounting difference	(1,113)	(1,781)	(6,019)	
Withholding tax	(1,614)	(1,078)	(2,154)	
Recognition of Bermuda net deferred tax asset	8,339	593,765	0	
Change in valuation allowance	66,198	45,192	(62,133)	
Foreign branch adjustments	(30,998)	(25,908)	11,656	
Other	1,294	358	(2,740)	
Income tax benefit (expense)	\$ (32,628)	\$ 510,067	\$ 59,019	

XML 136 R117.htm IDEA: XBRL DOCUMENT

TAXATION - Deferred
Tax Assets and

Liabilities (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets		
Tax loss carryforwards	\$ 152,864	\$ 197,498
Unearned premiums	59,441	68,408
Reserve for claims and claim expenses	131,121	95,685
Deferred finance charges	17,832	19,442
Deferred underwriting results	1,548	9,373
Accrued expenses	4,336	2,849
Investments	2,687	37,044
Amortization and depreciation	23,877	16,386
Value of in-force business	167,599	167,599
Intangible assets	420,143	408,654
Deferred tax assets	981,448	1,022,938
Deferred tax liabilities		
Deferred acquisition expenses	(125,347)	(112,157)
VOBA	(17,540)	(46,109)
Deferred revenue	(8,685)	0
U.S. tax accounting method change	(7,312)	0
Deferred tax liabilities	(158,884)	(158,266)
Net deferred tax asset (liability) before valuation allowance	822,564	864,672
Valuation allowance	(147,079)	(213,277)
Net deferred tax asset (liability)	\$ 675,485	\$ 651,395

[XML 137 R118.htm IDEA: XBRL DOCUMENT](#)

SEGMENT REPORTING - Schedule of Significant Components of the Company's Revenues and Expenses (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

[Segment Reporting Information \[Line Items\]](#)

Gross premiums written (Note 7)	\$ 11,733,066	\$ 8,862,366	\$ 9,213,540
Net premiums written	9,952,216	7,467,813	7,196,160
Net premiums earned	10,095,760	7,471,133	6,333,989
Net claims and claim expenses incurred	5,332,981	3,573,509	4,338,840
Acquisition expenses	2,643,867	1,875,034	1,568,606
Operational expenses	496,588	375,182	276,691
Underwriting income (loss)	1,622,324	1,647,408	149,852
Net investment income	1,654,289	1,253,110	559,932
Net foreign exchange gains (losses)	(76,076)	(41,479)	(56,909)
Equity in earnings (losses) of other ventures	47,087	43,474	11,249
Other income (loss)	1,928	(6,152)	12,636
Net realized and unrealized gains (losses) on investments	(27,840)	414,522	(1,800,485)
Corporate expenses	(134,784)	(127,642)	(46,775)
Interest expense	(93,768)	(73,181)	(48,335)
Income (loss) before taxes	2,993,160	3,110,060	(1,218,835)
Income tax benefit (expense)	(32,628)	510,067	59,019
Net (income) loss attributable to redeemable noncontrolling interests	(1,090,172)	(1,058,995)	98,613
Dividends on preference shares	(35,375)	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	1,834,985	2,525,757	(1,096,578)
Net claims and claim expenses incurred - current accident year	6,184,315	4,024,116	4,586,422
Net claims and claim expenses incurred - prior accident years	(851,334)	(450,607)	(247,582)
Total net incurred	\$ 5,332,981	\$ 3,573,509	\$ 4,338,840
Net claims and claim expense ratio - current accident year	61.30%	53.90%	72.40%
Net claims and claim expense ratio - prior accident years	(8.50%)	(6.10%)	(3.90%)
Net claims and claim expense ratio - calendar year	52.80%	47.80%	68.50%
Underwriting expense ratio	31.10%	30.10%	29.20%
Combined ratio	83.90%	77.90%	97.70%

Other

[Segment Reporting Information \[Line Items\]](#)

Gross premiums written (Note 7)	\$ 0	\$ 0	\$ 0
Net premiums written	0	0	0
Net premiums earned	0	0	0
Net claims and claim expenses incurred	0	0	0
Acquisition expenses	0	0	0
Operational expenses	0	0	0
Underwriting income (loss)	0	0	0
Net investment income	1,654,289	1,253,110	559,932
Net foreign exchange gains (losses)	(76,076)	(41,479)	(56,909)
Equity in earnings (losses) of other ventures	47,087	43,474	11,249
Other income (loss)	1,928	(6,152)	12,636
Net realized and unrealized gains (losses) on investments	(27,840)	414,522	(1,800,485)
Corporate expenses	(134,784)	(127,642)	(46,775)
Interest expense	(93,768)	(73,181)	(48,335)
Income tax benefit (expense)	(32,628)	510,067	59,019
Net (income) loss attributable to redeemable noncontrolling interests	(1,090,172)	(1,058,995)	98,613
Dividends on preference shares	(35,375)	(35,375)	(35,375)
Net claims and claim expenses incurred - current accident year	0	0	0
Net claims and claim expenses incurred - prior accident years	0	0	0
Total net incurred	0	0	0

Property

[Segment Reporting Information \[Line Items\]](#)

Gross premiums written (Note 7)	4,823,731	3,562,414	3,734,241
Net claims and claim expenses incurred - prior accident years	(818,852)	(408,905)	(205,741)

Property | Operating Segments

[Segment Reporting Information \[Line Items\]](#)

Gross premiums written (Note 7)	4,823,731	3,562,414	3,734,241
Net premiums written	3,833,636	2,967,309	2,847,659
Net premiums earned	3,850,352	3,090,792	2,770,227
Net claims and claim expenses incurred	1,141,726	799,905	2,044,771
Acquisition expenses	758,554	600,127	547,210
Operational expenses	302,360	251,433	194,355
Underwriting income (loss)	1,647,712	1,439,327	(16,109)
Net claims and claim expenses incurred - current accident year	1,960,578	1,208,810	2,250,512
Net claims and claim expenses incurred - prior accident years	(818,852)	(408,905)	(205,741)
Total net incurred	\$ 1,141,726	\$ 799,905	\$ 2,044,771

Net claims and claim expense ratio – current accident year	50.90%	39.10%	81.20%
Net claims and claim expense ratio – prior accident years	(21.20%)	(13.20%)	(7.40%)
Net claims and claim expense ratio – calendar year	29.70%	25.90%	73.80%
Underwriting expense ratio	27.50%	27.50%	26.80%
Combined ratio	57.20%	53.40%	100.60%
Casualty and Specialty			
Segment Reporting Information [Line Items]			
Gross premiums written (Note 7)	\$ 6,909,335	\$ 5,299,952	\$ 5,479,299
Net claims and claim expenses incurred – prior accident years	(32,482)	(41,702)	(41,841)
Casualty and Specialty Operating Segments			
Segment Reporting Information [Line Items]			
Gross premiums written (Note 7)	6,909,335	5,299,952	5,479,299
Net premiums written	6,118,580	4,500,504	4,348,501
Net premiums earned	6,245,408	4,380,341	3,563,762
Net claims and claim expenses incurred	4,191,255	2,773,604	2,294,069
Acquisition expenses	1,885,313	1,274,907	1,021,396
Operational expenses	194,228	123,749	82,336
Underwriting income (loss)	(25,388)	208,081	165,961
Net claims and claim expenses incurred – current accident year	4,223,737	2,815,306	2,335,910
Net claims and claim expenses incurred – prior accident years	(32,482)	(41,702)	(41,841)
Total net incurred	\$ 4,191,255	\$ 2,773,604	\$ 2,294,069
Net claims and claim expense ratio – current accident year	67.60%	64.30%	65.50%
Net claims and claim expense ratio – prior accident years	(0.50%)	(1.00%)	(1.10%)
Net claims and claim expense ratio – calendar year	67.10%	63.30%	64.40%
Underwriting expense ratio	33.30%	31.90%	30.90%
Combined ratio	100.40%	95.20%	95.30%

XML 138 R119.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING - Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 11,733,066	\$ 8,862,366	\$ 9,213,540
Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	100.00%	100.00%	100.00%
Property			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 4,823,731	\$ 3,562,414	\$ 3,734,241
Property Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	41.10%	40.30%	40.50%
Property U.S. and Caribbean			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 2,996,981	\$ 2,303,013	\$ 2,343,830
Property U.S. and Caribbean Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	25.50%	26.00%	25.50%
Property Worldwide			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 1,063,292	\$ 798,623	\$ 1,053,369
Property Worldwide Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	9.10%	9.00%	11.40%
Property Europe			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 244,523	\$ 163,500	\$ 62,998
Property Europe Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	2.10%	1.90%	0.70%
Property Worldwide (excluding U.S.)			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 180,688	\$ 70,646	\$ 37,436
Property Worldwide (excluding U.S.) Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	1.50%	0.80%	0.40%
Property Japan			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 106,533	\$ 85,823	\$ 104,767
Property Japan Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	0.90%	1.00%	1.10%
Property Australia and New Zealand			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 101,976	\$ 70,107	\$ 86,080
Property Australia and New Zealand Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	0.90%	0.80%	0.90%
Property Other			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 129,738	\$ 70,702	\$ 45,761
Property Other Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	1.10%	0.80%	0.50%
Casualty and Specialty			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 6,909,335	\$ 5,299,952	\$ 5,479,299
Casualty and Specialty Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk . percentage	58.90%	59.70%	59.50%
Casualty and Specialty U.S. and Caribbean			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 2,986,956	\$ 2,333,096	\$ 2,556,466

Casualty and Specialty U.S. and Caribbean Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	25.50%	26.30%	27.70%
Casualty and Specialty Worldwide			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 3,217,662	\$ 2,280,687	\$ 2,328,030
Casualty and Specialty Worldwide Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	27.30%	25.70%	25.30%
Casualty and Specialty Europe			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 353,863	\$ 197,228	\$ 327,831
Casualty and Specialty Europe Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	3.00%	2.20%	3.60%
Casualty and Specialty Worldwide (excluding U.S.)			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 195,489	\$ 130,334	\$ 177,746
Casualty and Specialty Worldwide (excluding U.S.) Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	1.70%	1.50%	1.90%
Casualty and Specialty Australia and New Zealand			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 43,183	\$ 27,397	\$ 35,973
Casualty and Specialty Australia and New Zealand Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	0.40%	0.30%	0.40%
Casualty and Specialty Other			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Gross premiums written (Note 7)	\$ 112,182	\$ 331,210	\$ 53,253
Casualty and Specialty Other Gross Premiums Written, Benchmark Geographic Concentration Risk			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Concentration risk , percentage	1.00%	3.70%	0.60%

XML 139 R120.htm
IDEA: XBRL DOCUMENT

STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD (\$)				
\$ in Millions				
12 Months Ended				
	Nov. 07, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
May 16, 2022				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total fair value of shares and share units vested		\$ 82.8	\$ 70.0	\$ 38.8
Excess windfall tax benefit		2.0	1.7	0.1
Total stock compensation expense recognized		71.4	60.3	45.2
Contributions to defined contribution pension plans		12.0	\$ 9.5	\$ 6.7
Restricted stock awards				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Unrecognized compensation costs related to restricted stock awards		\$ 107.6		
Periods for recognition of compensation costs not yet recognized		1 year 9 months 18 days		
Performance Shares				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Stock incentive compensation, vesting period		3 years		
Unrecognized compensation costs related to restricted stock awards		\$ 17.8		
Periods for recognition of compensation costs not yet recognized		1 year 9 months 18 days		
Performance Shares Chief Executive Officer				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Performance period	4 years			
2016 Long-Term Incentive Plan				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Shares reserved for issuance (in shares)				3,060,092
Number of shares available for grant (in shares)		800,000		
2016 Long-Term Incentive Plan Restricted stock awards				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Stock incentive compensation, vesting period		4 years		
Granted May 2018 Performance Shares				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Vesting maximum as a percentage of target if performance goal are achieved		200.00%		
Non-Employee Director Stock Incentive Plan Restricted stock awards				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Stock incentive compensation, vesting period		3 years		

XML 140 R121.htm
IDEA: XBRL DOCUMENT

STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Equity Compensation Other than Options (Details) - \$ / shares			
12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Performance Shares			
Number of Shares [Roll Forward]			
Nonvested, beginning balance (in shares)	286,220	191,264	141,068
Awards granted (in shares)	50,654	160,796	69,548
Awards forfeited (in shares)	(2,793)	(26,994)	(19,352)
Awards vested (in shares)	(53,083)	(38,846)	
Nonvested, ending balance (in shares)	280,998	286,220	191,264
Weighted Average Grant Date Fair Value			
Nonvested, beginning balance (in usd per share)	\$ 185.73	\$ 159.07	\$ 163.98
Awards granted (in usd per share)	223.35	211.18	145.49
Awards forfeited (in usd per share)	0	0	0
Awards vested (in usd per share)	162.61	170.40	
Nonvested, ending balance (in usd per share)	\$ 197.11	\$ 185.73	\$ 159.07
Total Restricted Stock Awards			
Number of Shares [Roll Forward]			
Nonvested, beginning balance (in shares)	815,367	733,811	643,933
Awards granted (in shares)	268,854	388,058	367,608
Awards forfeited (in shares)	(17,694)	(15,278)	(22,795)
Awards vested (in shares)	(303,924)	(291,224)	(254,935)
Nonvested, ending balance (in shares)	762,603	815,367	733,811

Weighted Average Grant Date Fair Value			
Nonvested, beginning balance (in usd per share)	\$ 172.91	\$ 150.31	\$ 153.32
Awards granted (in usd per share)	234.69	199.65	143.92
Awards forfeited (in usd per share)	0	0	0
Awards vested (in usd per share)	165.11	151.57	148.83
Nonvested, ending balance (in usd per share)	\$ 197.49	\$ 172.91	\$ 150.31
Employee Restricted Stock Awards			
Number of Shares [Roll Forward]			
Nonvested, beginning balance (in shares)	797,149	712,796	623,332
Awards granted (in shares)	260,209	378,994	354,887
Awards forfeited (in shares)	(17,694)	(15,278)	(22,795)
Awards vested (in shares)	(293,175)	(279,363)	(242,628)
Nonvested, ending balance (in shares)	746,489	797,149	712,796

Weighted Average Grant Date Fair Value			
Nonvested, beginning balance (in usd per share)	\$ 172.74	\$ 150.19	\$ 153.02
Awards granted (in usd per share)	234.94	199.24	143.86
Awards forfeited (in usd per share)	0	0	0
Awards vested (in usd per share)	164.67	151.15	148.30
Nonvested, ending balance (in usd per share)	\$ 197.26	\$ 172.74	\$ 150.19
Non-Employee Director Restricted Stock Awards			
Number of Shares [Roll Forward]			
Nonvested, beginning balance (in shares)	18,218	21,015	20,601
Awards granted (in shares)	8,645	9,064	12,721
Awards forfeited (in shares)	0	0	0
Awards vested (in shares)	(10,749)	(11,861)	(12,307)
Nonvested, ending balance (in shares)	16,114	18,218	21,015

Weighted Average Grant Date Fair Value			
Nonvested, beginning balance (in usd per share)	\$ 180.70	\$ 154.40	\$ 162.60
Awards granted (in usd per share)	223.66	215.79	145.77
Awards forfeited (in usd per share)	0	0	0
Awards vested (in usd per share)	177.16	161.56	159.20
Nonvested, ending balance (in usd per share)	\$ 207.95	\$ 180.70	\$ 154.40

XML 141 R122.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS -	
Statutory Capital and Surplus (Details) - USD (\$)	Dec. 31, 2024Dec. 31, 2023
\$ in Thousands	

Statutory Accounting Practices [Line Items]			
Statutory capital and surplus	\$ 11,793,261	\$ 12,141,907	
Required statutory capital and surplus	2,686,108	2,284,208	

Switzerland

Statutory Accounting Practices [Line Items]			
Statutory capital and surplus	1,908,106	2,644,998	
Required statutory capital and surplus	1,049,922	987,707	

U.K.

Statutory Accounting Practices [Line Items]			
Statutory capital and surplus	952,309	935,776	
Required statutory capital and surplus	952,309	935,776	

U.S.

Statutory Accounting Practices [Line Items]			
Statutory capital and surplus	1,255,304	1,044,010	
Required statutory capital and surplus	\$ 967,735	\$ 794,061	

XML 142 R123.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS -		12 Months Ended		
Statutory Net Income (Loss) (Details) - USD (\$)		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
\$ in Thousands				

Statutory Accounting Practices [Line Items]			
Statutory Net Income (Loss)	\$ 2,056,265	\$ 2,699,083	\$ (706,676)

Switzerland

Statutory Accounting Practices [Line Items]			
Statutory Net Income (Loss)	312,000	225,751	(244,035)

U.K.

Statutory Accounting Practices [Line Items]			
Statutory Net Income (Loss)	89,169	158,258	(24,573)

U.S.

Statutory Accounting Practices [Line Items]			
Statutory Net Income (Loss)	\$ (87,897)	\$ (17,618)	\$ 35,344

XML 143 R124.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS -		12 Months Ended	
Narrative (Details) -			
USD (\$)		Dec. 31, 2024	Dec. 31, 2023
\$ in Millions			

Statutory Accounting Practices [Line Items]			
Target percentage of ECR		120.00%	
BSCR ratio			263.00%

Multi-Beneficiary Reduced Collateral Reinsurance Trust Renaissance Reinsurance			
Statutory Accounting Practices [Line Items]			
Multi-beneficiary reduced collateral reinsurance trust collateral reduction		20.00%	
Multi-Beneficiary Reduced Collateral Reinsurance Trust RREAG			
Statutory Accounting Practices [Line Items]			
Multi-beneficiary reduced collateral reinsurance trust collateral reduction		20.00%	
Multi-Beneficiary Reduced Collateral Reinsurance Trust DaVinci Reinsurance			
Statutory Accounting Practices [Line Items]			
Multi-beneficiary reduced collateral reinsurance trust collateral reduction		50.00%	

U.S.

Statutory Accounting Practices [Line Items]			
Ordinary dividend capacity		\$ 125.5	

XML 144 R125.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS -		12 Months Ended	
Schedule Of Assets Held Under Trust And	Dec. 31, 2024Dec. 31, 2023		

Minimum (Details) -
USD (\$)
\$ in Thousands

Statutory Accounting Practices [Line Items]

Assets held in trust	\$ 10,300,000	\$ 10,500,000
Multi-Beneficiary Reinsurance Trust Renaissance Reinsurance		
Statutory Accounting Practices [Line Items]		
Assets held in trust	954,114	1,209,808
Multi-Beneficiary Reinsurance Trust Renaissance Reinsurance Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	554,119	910,646
Multi-Beneficiary Reinsurance Trust DaVinci Reinsurance		
Statutory Accounting Practices [Line Items]		
Assets held in trust	179,849	174,352
Multi-Beneficiary Reinsurance Trust DaVinci Reinsurance Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	47,179	114,203
Multi-Beneficiary Reinsurance Trust RREAG		
Statutory Accounting Practices [Line Items]		
Assets held in trust	1,463,275	1,342,339
Multi-Beneficiary Reinsurance Trust RREAG Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	\$ 1,312,796	\$ 1,298,712

XML 145 R126.htm IDEA: XBRL DOCUMENT

STATUTORY REQUIREMENTS- Schedule Of Multi- Beneficiary Reduced Collateral Reinsurance Trusts (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023

Statutory Accounting Practices [Line Items]

Assets held in trust	\$ 10,300,000	\$ 10,500,000
Multi-Beneficiary Reduced Collateral Reinsurance Trust Renaissance Reinsurance		
Statutory Accounting Practices [Line Items]		
Assets held in trust	187,742	193,922
Multi-Beneficiary Reduced Collateral Reinsurance Trust Renaissance Reinsurance Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	83,622	129,380
Multi-Beneficiary Reduced Collateral Reinsurance Trust DaVinci Reinsurance		
Statutory Accounting Practices [Line Items]		
Assets held in trust	220,542	215,560
Multi-Beneficiary Reduced Collateral Reinsurance Trust DaVinci Reinsurance Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	73,210	125,184
Multi-Beneficiary Reduced Collateral Reinsurance Trust RREAG		
Statutory Accounting Practices [Line Items]		
Assets held in trust	101,252	103,632
Multi-Beneficiary Reduced Collateral Reinsurance Trust RREAG Minimum		
Statutory Accounting Practices [Line Items]		
Assets held in trust	\$ 67,671	\$ 75,380

XML 146 R127.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS - Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details) - USD (\$) \$ in Thousands	Dec. 31, 2024	Dec. 31, 2023

Derivative Assets

Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Gross Amounts of Recognized Assets	\$ 34,538	\$ 44,724
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	34,538	44,724
Collateral Received	0	0
Net Amount	\$ 34,538	\$ 44,724

Derivative Liabilities

Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Gross Amounts of Recognized Liabilities	\$ 75,878	\$ 29,991
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	75,878	29,991
Collateral Pledged	12,715	6,968
Net Amount	63,163	23,023

Not Designated as Hedging Instrument

Derivative Assets

Gross Amounts of Recognized Assets	30,974	44,724
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	30,974	44,724
Collateral Received	0	0
Net Amount	30,974	44,724

Derivative Liabilities

Gross Amounts of Recognized Liabilities	75,878	26,112
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	75,878	26,112
Collateral Pledged	12,715	6,968
Net Amount	63,163	19,144

Interest rate futures | Not Designated as Hedging Instrument

Derivative Assets

Gross Amounts of Recognized Assets	4,198	13,162
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	4,198	13,162
Collateral Received	0	0
Net Amount	4,198	13,162

Derivative Liabilities

Gross Amounts of Recognized Liabilities	6,178	5,768
Gross Amounts Offset in the Balance Sheet	0	0

Net Amounts of Liabilities Presented in the Balance Sheet	6,178	5,768
Collateral Pledged	5,408	5,720
Net Amount	770	48
Foreign currency forward contracts Not Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets	16,275	16,827
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	16,275	16,827
Collateral Received	0	0
Net Amount	16,275	16,827
Derivative Liabilities		
Gross Amounts of Recognized Liabilities	53,160	11,890
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	53,160	11,890
Collateral Pledged	5,632	0
Net Amount	47,528	11,890
Foreign currency forward contracts Not Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets	4,085	10,448
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	4,085	10,448
Collateral Received	0	0
Net Amount	4,085	10,448
Derivative Liabilities		
Gross Amounts of Recognized Liabilities	13,171	2,603
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	13,171	2,603
Collateral Pledged	0	0
Net Amount	13,171	2,603
Foreign currency forward contracts Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets	3,564	
Gross Amounts Offset in the Balance Sheet	0	
Net Amounts of Assets Presented in the Balance Sheet	3,564	
Collateral Received	0	
Net Amount	3,564	
Derivative Liabilities		
Gross Amounts of Recognized Liabilities		3,879
Gross Amounts Offset in the Balance Sheet		0
Net Amounts of Liabilities Presented in the Balance Sheet		3,879
Collateral Pledged		0
Net Amount		3,879
Commodity futures Not Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets	5,933	
Gross Amounts Offset in the Balance Sheet	0	
Net Amounts of Assets Presented in the Balance Sheet	5,933	
Collateral Received	0	
Net Amount	5,933	
Derivative Liabilities		
Gross Amounts of Recognized Liabilities		1,441
Gross Amounts Offset in the Balance Sheet		0
Net Amounts of Liabilities Presented in the Balance Sheet		1,441
Collateral Pledged		0
Net Amount		1,441
Commodity options Not Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets	483	3,538
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets Presented in the Balance Sheet	483	3,538
Collateral Received	0	0
Net Amount	483	3,538
Derivative Liabilities		
Gross Amounts of Recognized Liabilities		3,162
Gross Amounts Offset in the Balance Sheet		0
Net Amounts of Liabilities Presented in the Balance Sheet		3,162
Collateral Pledged		0
Net Amount		3,162
Credit default swaps Not Designated as Hedging Instrument		
Derivative Assets		
Gross Amounts of Recognized Assets		749
Gross Amounts Offset in the Balance Sheet		0
Net Amounts of Assets Presented in the Balance Sheet		749
Collateral Received		0
Net Amount		749
Derivative Liabilities		
Gross Amounts of Recognized Liabilities	1,675	1,248
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	1,675	1,248
Collateral Pledged	1,675	1,248
Net Amount	0	\$ 0
Equity futures Not Designated as Hedging Instrument		
Derivative Liabilities		
Gross Amounts of Recognized Liabilities	1,694	
Gross Amounts Offset in the Balance Sheet	0	
Net Amounts of Liabilities Presented in the Balance Sheet	1,694	
Collateral Pledged	0	
Net Amount	\$ 1,694	

XML 147 R128.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS - Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details)	12 Months Ended	
- USD (\$)		
\$ in Thousands		
	Dec. 31, 2024	Dec. 31, 2023
		Dec. 31, 2022

Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	\$ (111,690)	\$ (80,705)	\$ (188,539)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			
Net foreign exchange gains (losses), Net realized and unrealized gains (losses) on investments			
Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	\$ (117,884)	\$ (80,910)	\$ (195,005)
Interest rate futures Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(81,400)	3,877	(86,863)
Foreign currency forward contracts Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(27,918)	(877)	(51,401)
Foreign currency forward contracts Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(32,687)	(11,761)	21,689
Foreign currency forward contracts Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Accumulated other comprehensive income (loss)	6,194	205	6,466
Credit default swaps Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(54,757)	(70,924)	(9,084)
Total return swaps Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	0	0	(6)
Equity futures Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	3,379	(1,928)	(69,972)
Warrants Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(1,046)	0	632
Commodity options Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	(4,517)	(4,553)	0
Commodity futures Not Designated as Hedging Instrument			
Derivative Instruments, Gain (Loss) [Line Items]			
Amount of Gain (loss) Recognized on Derivatives	\$ 81,062	\$ 5,256	\$ 0

XML 148 R129.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS -		
Narrative (Details) -		
Not Designated as		
Hedging Instrument -	Dec. 31, 2024	Dec. 31, 2023
USD (\$)		
\$ in Millions		

Long | Interest rate futures

Derivative [Line Items]

Derivative, notional amount \$ 7,100.0 \$ 5,900.0

Long | Foreign currency forward contracts

Derivative [Line Items]

Derivative, notional amount 1,000.0 805.2

Long | Foreign currency forward contracts

Derivative [Line Items]

Derivative, notional amount 345.0 420.7

Long | Credit default swaps

Derivative [Line Items]

Derivative, notional amount 1,500.0

Long | Equity futures

Derivative [Line Items]

Derivative, notional amount 437.2 0.0

Long | Commodity futures

Derivative [Line Items]

Derivative, notional amount 684.3 255.2

Long | Commodity options

Derivative [Line Items]

Derivative, notional amount 0.5 0.4

Short | Interest rate futures

Derivative [Line Items]

Derivative, notional amount 3,100.0 2,700.0

Short | Foreign currency forward contracts

Derivative [Line Items]

Derivative, notional amount 508.8 496.4

Short | Foreign currency forward contracts

Derivative [Line Items]

Derivative, notional amount 107.0 130.0

Short | Credit default swaps

Derivative [Line Items]

Derivative, notional amount \$ 1,400.0 \$ 22.1

XML 149 R130.htm IDEA: XBRL DOCUMENT

DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation (Details) - Foreign Exchange Forward - Designated as Hedging Instrument - Net Investment Hedging - USD (\$) \$ in Thousands	12 Months Ended								
Derivative Instruments and Hedging Activities Disclosures [Line Items]									
Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities)	\$ 61,120				\$ 59,664				
Derivative gains (losses)	\$ 6,194				\$ 205				
<u>XML 150 R131.htm IDEA: XBRL DOCUMENT</u>									
COMMITMENTS, CONTINGENCIES AND OTHER ITEMS - Narrative (Details) - USD (\$) \$ in Millions	12 Months Ended								
Commitments and Contingencies [Line Items]									
Initial commitments	\$ 4,500.0				\$ 3,600.0				
Fulfilled commitments	2,500.0				2,000.0				
Unfunded commitments	\$ 2,000.0				\$ 1,600.0				
Operating lease, weighted average lease term	5 years 10 months 24 days								
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets				Other assets				
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Other liabilities				Other liabilities				
Operating lease, right-of-use asset	\$ 83.8				\$ 72.9				
Operating lease, liability	114.3				103.9				
Operating lease, expense	\$ 14.8				\$ 12.8				
Lessee, finance lease, term of contract	20 years								
Lessee, finance lease, renewal term	30 years								
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets				Other assets				
Finance Lease, Liability, Statement of Financial Position [Extensible List]	Other liabilities				Other liabilities				
Finance lease, right-of-use asset	\$ 16.1				\$ 16.6				
Finance lease, liability	21.0				21.5				
Letter of Credit									
Commitments and Contingencies [Line Items]									
Letters of credit outstanding	619.6								
Letter of Credit Top Layer Reinsurance Ltd.									
Commitments and Contingencies [Line Items]									
Line of credit facility, maximum borrowing capacity	37.5								
Letter of Credit Capital Support Agreement Top Layer Reinsurance Ltd.									
Commitments and Contingencies [Line Items]									
Mandatory capital contribution in the event of capital and surplus reduction below a specified level	50.0								
Interest Expense									
Commitments and Contingencies [Line Items]									
Finance lease, interest expense	2.1				2.2				
Other income (loss)									
Commitments and Contingencies [Line Items]									
Finance lease, right-of-use asset, amortization	\$ 0.5				\$ 0.5				
<u>XML 151 R132.htm IDEA: XBRL DOCUMENT</u>									
COMMITMENTS, CONTINGENCIES AND OTHER ITEMS - Schedule of Future Minimum Payments, Operating and Finance Leases (Details) \$ in Thousands	Dec. 31, 2024								
Operating Leases									
2025	\$ 15,657								
2026	16,461								
2027	16,439								
2028	16,328								
2029	15,199								
After 2029	70,656								
Future minimum lease payments under existing leases	150,740								
Lessee, Operating Lease, Liability, Undiscounted Excess Amount Not Disclosed	0								
Finance Leases									
2025	2,661								
2026	2,661								
2027	2,661								
2028	2,146								
2029	0								
After 2029	0								
Future minimum lease payments under existing leases	10,129								
Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed	\$ 0								
<u>XML 152 R133.htm IDEA: XBRL DOCUMENT</u>									
SUBSEQUENT EVENTS (Details) - USD (\$)	1 Months Ended		12 Months Ended						
California Wildfires Forecast									
Subsequent Event [Line Items]									
Estimate of pre tax loss							\$ 750,000,000		
Fontana									
Subsequent Event [Line Items]									
Noncontrolling interest, value subscribed					\$ 100,000,000	\$ 51,316,000			
Medici									
Subsequent Event [Line Items]									
Noncontrolling interest, value subscribed					200,219,000	482,310,000			
Redemption of shares from redeemable noncontrolling interests					\$ 406,644,000	\$ 107,549,000			
DaVinci Reinsurance									
Subsequent Event [Line Items]									
Noncontrolling ownership percentage					25.40%	27.80%			

Fontana			
Subsequent Event [Line Items]			
Noncontrolling ownership percentage	26.50%	31.60%	
Medici			
Subsequent Event [Line Items]			
Noncontrolling ownership percentage	15.80%	11.70%	
DaVinci			
Subsequent Event [Line Items]			
Proceeds from noncontrolling interests			\$ 300,000,000
Third-Party Investors			
Subsequent Event [Line Items]			
Redemption of shares from redeemable noncontrolling interests	\$ 225,900,000	123,300,000	
Third-Party Investors Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	100,000,000.0	75,000,000.0	
Third-Party Investors Medici			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	250,200,000	527,300,000	
Redemption of shares from redeemable noncontrolling interests	382,000,000.0	117,500,000	
Payments of dividends	24,600,000		
DaVinci Reinsurance			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	300,000,000.0	275,000,000.0	
Proceeds from noncontrolling interests	69,700,000		
RenaissanceRe Holdings Ltd. Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	50,000,000.0	23,700,000	
RenaissanceRe Holdings Ltd. Medici			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	50,600,000	45,200,000	
Redemption of shares from redeemable noncontrolling interests	300,000	10,000,000.0	
Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	50,000,000.0		
Proceeds from noncontrolling interests	129,200,000	\$ 151,300,000	
Medici Third-Party Investors			
Subsequent Event [Line Items]			
Proceeds from noncontrolling interests	\$ 39,000,000.0		
Subsequent Event California Wildfires			
Subsequent Event [Line Items]			
Loss contingency incurred percentage	1.50%		
Industry insured loss	\$ 50,000,000,000		
Subsequent Event Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	\$ 100,000,000.0		
Subsequent Event DaVinci Reinsurance			
Subsequent Event [Line Items]			
Noncontrolling ownership percentage	24.30%		
Subsequent Event Fontana			
Subsequent Event [Line Items]			
Noncontrolling ownership percentage	28.70%		
Subsequent Event Medici			
Subsequent Event [Line Items]			
Noncontrolling ownership percentage	17.70%		
Subsequent Event DaVinci			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	\$ 69,700,000		
Subsequent Event Third-Party Investors			
Subsequent Event [Line Items]			
Redemption of shares from redeemable noncontrolling interests	26,900,000		
Subsequent Event Third-Party Investors Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	29,200,000		
Subsequent Event Third-Party Investors Medici			
Subsequent Event [Line Items]			
Redemption of shares from redeemable noncontrolling interests	16,500,000		
Noncontrolling interest, increase from sale of parent equity interest	107,900,000		
Payments of dividends	15,200,000		
Subsequent Event RenaissanceRe Holdings Ltd. Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	70,800,000		
Subsequent Event RenaissanceRe Holdings Ltd. Medici			
Subsequent Event [Line Items]			
Redemption of shares from redeemable noncontrolling interests			
Noncontrolling interest, increase from sale of parent equity interest	50,100,000		
Subsequent Event Fontana			
Subsequent Event [Line Items]			
Noncontrolling interest, value subscribed	100,000,000.0		
Redemption of shares from redeemable noncontrolling interests	\$ 72,000,000.0		
Common shares			
Subsequent Event [Line Items]			
Share repurchase program, shares repurchased (in shares)	2,711,234		
Value of shares repurchased	\$ 677,600,000		
Shares repurchased, average price per share (in usd per share)	\$ 249.93		
Share repurchase program, authorized aggregate amount			\$ 750,000,000.0
Common shares Subsequent Event			
Subsequent Event [Line Items]			
Share repurchase program, shares repurchased (in shares)	928,880		
Value of shares repurchased	\$ 227,700,000		
Shares repurchased, average price per share (in usd per share)	\$ 245.10		
Share repurchase program, authorized aggregate amount			\$ 750,000,000

SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES (Details) \$ in Thousands	Dec. 31, 2024 USD (\$)	
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	\$ 32,639,456	
Amount at Which Shown in the Balance Sheet	32,639,456	
Fixed maturity investments trading		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	23,750,540	
Fair Value	23,562,514	
Amount at Which Shown in the Balance Sheet	23,562,514	
U.S. treasuries		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	11,062,641	
Fair Value	11,001,893	
Amount at Which Shown in the Balance Sheet	11,001,893	
Corporate		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	7,919,470	
Fair Value	7,862,423	
Amount at Which Shown in the Balance Sheet	7,862,423	
Residential mortgage-backed		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	1,761,607	
Fair Value	1,707,056	
Amount at Which Shown in the Balance Sheet	1,707,056	
Asset-backed		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	1,416,132	
Fair Value	1,422,393	
Amount at Which Shown in the Balance Sheet	1,422,393	
Agencies		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	633,726	
Fair Value	623,489	
Amount at Which Shown in the Balance Sheet	623,489	
Non-U.S. government		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	624,381	
Fair Value	618,809	
Amount at Which Shown in the Balance Sheet	618,809	
Commercial mortgage-backed		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	332,583	
Fair Value	326,451	
Amount at Which Shown in the Balance Sheet	326,451	
Short term investments		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Amortized Cost or Cost	4,532,166	
Fair Value	4,531,655	
Amount at Which Shown in the Balance Sheet	4,531,655	
Equity investments		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	117,756	
Amount at Which Shown in the Balance Sheet	117,756	
Total other investments		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	4,324,761	
Amount at Which Shown in the Balance Sheet	4,324,761	
Fund investments		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	2,128,499	
Amount at Which Shown in the Balance Sheet	2,128,499	
Catastrophe bonds		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	1,984,396	
Amount at Which Shown in the Balance Sheet	1,984,396	
Direct private equity investments		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	211,866	
Amount at Which Shown in the Balance Sheet	211,866	
Investments in other ventures, under equity method		
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]		
Fair Value	102,770	
Amount at Which Shown in the Balance Sheet	\$ 102,770	
<u>XML 154 R135.htm IDEA: XBRL DOCUMENT</u>		
SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Balance sheets (Details) - USD (\$) \$ in Thousands		
Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022		
Assets		
Fixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil)	\$ 23,562,514	\$ 20,877,108
Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917)	4,531,655	4,604,079
Total investments	32,639,456	29,216,143
Cash and cash equivalents	1,676,604	1,877,518
Accrued investment income	238,290	205,713
Deferred tax asset	701,053	685,040
Receivable for investments sold	91,669	622,197
Other assets	444,037	323,960
Goodwill and other intangible assets	704,132	775,352
Total assets	50,707,550	49,007,105

Liabilities			
Debt	1,886,689	1,958,655	
Other liabilities	1,060,129	1,021,872	
Total liabilities	33,155,789	33,451,316	
Shareholders' Equity			
Preference shares: \$1.00 par value – 30,000 shares issued and outstanding at December 31, 2024 (2023 – 30,000) (Note 12)	750,000	750,000	
Common shares: \$1.00 par value – 50,180,987 shares issued and outstanding at December 31, 2024 (2023 – 52,693,887) (Note 12)	50,181	52,694	
Additional paid-in capital (Note 12)	1,512,435	2,144,459	
Accumulated other comprehensive income (loss)	(14,756)	(14,211)	
Retained earnings (Note 12)	8,276,152	6,522,016	
Total shareholders' equity attributable to RenaissanceRe	10,574,012	9,454,958	\$ 5,325,274
Total liabilities, noncontrolling interests and shareholders' equity	50,707,550	49,007,105	
Parent Company			

Assets			
Fixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil)	153,504	0	
Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917)	131,236	277,917	
Total investments	284,740	277,917	
Cash and cash equivalents	20,054	45,080	
Investments in subsidiaries	10,732,129	9,632,226	
Due from subsidiaries	7,919	52,816	
Accrued investment income	1,052	0	
Deferred tax asset	10,334	33,646	
Receivable for investments sold	1,329	2,849	
Other assets	681,322	660,818	
Goodwill and other intangible assets	98,662	101,509	
Total assets	11,837,541	10,806,861	

Liabilities			
Debt	1,138,119	1,136,260	
Due to subsidiaries	17,051	136,729	
Other liabilities	108,359	78,915	
Total liabilities	1,263,529	1,351,904	

Shareholders' Equity			
Preference shares: \$1.00 par value – 30,000 shares issued and outstanding at December 31, 2024 (2023 – 30,000) (Note 12)	750,000	750,000	
Common shares: \$1.00 par value – 50,180,987 shares issued and outstanding at December 31, 2024 (2023 – 52,693,887) (Note 12)	50,181	52,694	
Additional paid-in capital (Note 12)	1,512,435	2,144,459	
Accumulated other comprehensive income (loss)	(14,756)	(14,211)	
Retained earnings (Note 12)	8,276,152	6,522,015	
Total shareholders' equity attributable to RenaissanceRe	10,574,012	9,454,957	
Total liabilities, noncontrolling interests and shareholders' equity	\$ 11,837,541	\$ 10,806,861	

XML 155
R136.htm
IDEA: XBRL DOCUMENT

SCHEDULE II.		
CONDENSED		
FINANCIAL		
INFORMATION OF		
REGISTRANT -		
Balance Sheets	Dec. 31, 2024	Dec. 31, 2023
Additional		
Information (Details)		
- USD (\$)		
\$ / shares in Units, \$		
in Thousands		

Condensed Financial Statements, Captions
[Line Items]

Fixed maturity investments trading, amortized cost	\$ 23,750,540	\$ 20,872,450
Short-term investments, amortized cost	\$ 4,532,166	\$ 4,603,340
Preference shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Preference shares, shares issued (in shares)	30,000	30,000
Preference shares, shares outstanding (in shares)	30,000	30,000
Common shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Common shares, shares issued (in shares)	50,180,987	52,693,887
Common shares, shares outstanding (in shares)	50,180,987	52,693,887
Parent Company		

Condensed Financial Statements, Captions
[Line Items]

Fixed maturity investments trading, amortized cost	\$ 153,742	
Short-term investments, amortized cost	\$ 131,232	\$ 277,917
Preference shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Preference shares, shares issued (in shares)	30,000	30,000
Preference shares, shares outstanding (in shares)	30,000	30,000
Common shares, par value (in dollars per share)	\$ 1.00	\$ 1.00
Common shares, shares issued (in shares)	50,180,987	52,693,887
Common shares, shares outstanding (in shares)	50,180,987	52,693,887

XML 156
R137.htm
IDEA: XBRL DOCUMENT

SCHEDULE II.			12 Months Ended
CONDENSED			
FINANCIAL			
INFORMATION OF			
REGISTRANT -			
Statements of	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operations (Details) -			
USD (\$)			
\$ in Thousands			

Revenues

Net investment income	\$ 1,654,289	\$ 1,253,110	\$ 559,932
Net foreign exchange gains (losses)	(76,076)	(41,479)	(56,909)
Other income (loss)	1,928	(6,152)	12,636
Net realized and unrealized gains (losses) on investments	(27,840)	414,522	(1,800,485)
Total revenues	11,695,148	9,134,608	5,060,412

Expenses

Operational expenses	496,588	375,182	276,691
Corporate expenses	134,784	127,642	46,775
Interest expense	93,768	73,181	48,335
Total expenses	8,701,988	6,024,548	6,279,247
Income (loss) before taxes	2,993,160	3,110,060	(1,218,835)
Income tax benefit (expense)	(32,628)	510,067	59,019
Net income (loss) attributable to RenaissanceRe	1,870,360	2,561,132	(1,061,203)
Dividends on preference shares	(35,375)	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	1,834,985	2,525,757	(1,096,578)
Parent Company			

Revenues

Net investment income	58,166	97,395	46,966
Net foreign exchange gains (losses)	(23,916)	1,129	(46,796)

Other income (loss)	(95)	(907)	0
Net realized and unrealized gains (losses) on investments	(4,840)	(73,572)	(3,017)
Total revenues	29,315	24,045	(2,847)
Expenses			
Operational expenses	15,866	32,066	14,818
Corporate expenses	86,314	98,493	39,614
Interest expense	59,384	40,416	15,315
Total expenses	161,564	170,975	69,747
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total	(132,249)	(146,930)	(72,594)
Equity in net income (loss) of subsidiaries	2,017,805	2,708,061	(988,610)
Income (loss) before taxes	1,885,556	2,561,131	(1,061,204)
Income tax benefit (expense)	(15,196)	0	0
Net income (loss) attributable to RenaissanceRe	1,870,360	2,561,131	(1,061,204)
Dividends on preference shares	(35,375)	(35,375)	(35,375)
Net income (loss) available (attributable) to RenaissanceRe common shareholders	\$ 1,834,985	\$ 2,525,756	\$ (1,096,579)

XML 157 R138.htm IDEA: XBRL DOCUMENT

SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Comprehensive Income (Loss) (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Condensed Financial Statements, Captions [Line Items]

Net income (loss)	\$ 1,870,360	\$ 2,561,132	\$ (1,061,203)
Change in net unrealized gains (losses) on investments, net of tax	1,045	1,082	(4,923)
Foreign currency translation adjustments, net of tax	(1,590)	169	370
Comprehensive income (loss) attributable to RenaissanceRe Parent Company	1,869,815	2,562,383	(1,065,756)
Condensed Financial Statements, Captions [Line Items]			
Net income (loss)	1,870,360	2,561,131	(1,061,204)
Change in net unrealized gains (losses) on investments, net of tax	1,045	1,082	(4,923)
Foreign currency translation adjustments, net of tax	(1,590)	169	370
Comprehensive income (loss) attributable to RenaissanceRe	\$ 1,869,815	\$ 2,562,382	\$ (1,065,757)

XML 158 R139.htm IDEA: XBRL DOCUMENT

SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT- Statements of Cash Flows (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022

Net Cash Provided by (Used in) Operating Activities [Abstract]

Net income (loss) attributable to RenaissanceRe	\$ 1,870,360	\$ 2,561,132	\$ (1,061,203)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities			
Net realized and unrealized (gains) losses on investments	(29,439)	(482,794)	1,635,192
Other	(371,707)	(579,280)	(259,168)
Net cash provided by (used in) operating activities	4,164,822	1,911,634	1,603,683

Net Cash Provided by (Used in) Investing Activities [Abstract]

Proceeds from sales and maturities of fixed maturity investments trading	23,515,450	21,796,577	22,086,168
Purchases of fixed maturity investments trading	(26,296,842)	(24,771,411)	(24,923,131)
Return of investments in other ventures	41,349	5,554	2,248
Net purchase of Validus	0	(2,433,746)	0
Net cash provided by (used in) investing activities	(3,060,856)	(3,822,636)	(3,016,176)

Cash flows provided by (used in) financing activities

Dividends paid – RenaissanceRe common shares	(80,849)	(75,112)	(64,675)
Dividends paid – preference shares	(35,375)	(35,375)	(35,396)
RenaissanceRe common share repurchases	(666,921)	0	(166,664)
RenaissanceRe common share issuance, net of expenses	0	1,351,608	0
Issuance of debt, net of expenses	0	740,581	0
Taxes paid on withholding shares	(23,580)	(20,518)	(10,911)
Net cash provided by (used in) financing activities	(1,287,515)	2,588,639	725,342
Effect of exchange rate changes on foreign currency cash	(17,365)	5,542	22,471
Net increase (decrease) in cash and cash equivalents	(200,914)	683,179	(664,680)
Cash and cash equivalents, beginning of year	1,877,518	1,194,339	1,859,019
Cash and cash equivalents, end of year	1,676,604	1,877,518	1,194,339

Parent Company

Net Cash Provided by (Used in) Operating Activities [Abstract]

Net income (loss) attributable to RenaissanceRe	1,870,360	2,561,131	(1,061,204)
Less: equity in net income (loss) of subsidiaries	(2,017,805)	(2,708,061)	988,610
Loss before equity in net income of subsidiaries	(147,445)	(146,930)	(72,594)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities			
Net realized and unrealized (gains) losses on investments	334	67,868	2,051
Other	142,051	72,691	36,601
Net cash provided by (used in) operating activities	(5,060)	(6,371)	(33,942)

Net Cash Provided by (Used in) Investing Activities [Abstract]

Proceeds from sales and maturities of fixed maturity investments trading	309,490	1,613,740	198,341
Purchases of fixed maturity investments trading	(387,276)	(1,505,160)	(375,804)
Net sales (purchases) of short term investments	147,296	(211,370)	(21,037)
Return of investments in other ventures	1,079,438	1,097,301	1,009,108
Contributions to subsidiaries	(247,147)	(169,204)	(349,336)
Due to (from) subsidiary	(115,041)	(7,088)	(178,470)
Net cash provided by (used in) investing activities	786,760	(1,916,781)	282,802

Cash flows provided by (used in) financing activities

Dividends paid – RenaissanceRe common shares	(80,850)	(75,112)	(64,675)
Dividends paid – preference shares	(35,375)	(35,375)	(35,396)
RenaissanceRe common share repurchases	(666,921)	0	(166,664)
RenaissanceRe common share issuance, net of expenses	0	1,351,608	0
Issuance of debt, net of expenses	0	740,581	0
Taxes paid on withholding shares	(23,580)	(20,518)	(10,911)
Net cash provided by (used in) financing activities	(806,726)	1,961,184	(277,646)
Effect of exchange rate changes on foreign currency cash	0	0	0
Net increase (decrease) in cash and cash equivalents	(25,026)	38,032	(28,786)
Cash and cash equivalents, beginning of year	45,080	7,048	35,834
Cash and cash equivalents, end of year	20,054	45,080	7,048

Net Cash Provided by (Used in) Investing Activities [Abstract]

Due to (from) subsidiary
Parent Company | Validus Holdings, Ltd and Talbot Underwriting Limited
Net Cash Provided by (Used in) Investing Activities [Abstract]

Net purchase of Validus

XML 159 R140.htm IDEA: XBRL DOCUMENT

SCHEDULE III.
SUPPLEMENTARY
INSURANCE
INFORMATION
(Details) - USD (\$)
\$ in Thousands

SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]

Deferred Policy Acquisition Costs
Future Policy Benefits, Losses, Claims and Loss Expenses
Unearned Premiums
Premium Revenue
Net Investment Income
Benefits, Claims, Losses and Settlement Expenses
Amortization of Deferred Policy Acquisition Costs
Other Operating Expenses
Net Written Premiums
Other

SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]

Deferred Policy Acquisition Costs
Future Policy Benefits, Losses, Claims and Loss Expenses
Unearned Premiums
Premium Revenue
Net Investment Income
Benefits, Claims, Losses and Settlement Expenses
Amortization of Deferred Policy Acquisition Costs
Other Operating Expenses
Net Written Premiums
Property | Operating Segments

SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]

Deferred Policy Acquisition Costs
Future Policy Benefits, Losses, Claims and Loss Expenses
Unearned Premiums
Premium Revenue
Net Investment Income
Benefits, Claims, Losses and Settlement Expenses
Amortization of Deferred Policy Acquisition Costs
Other Operating Expenses
Net Written Premiums
Casualty and Specialty | Operating Segments

SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]

Deferred Policy Acquisition Costs
Future Policy Benefits, Losses, Claims and Loss Expenses
Unearned Premiums
Premium Revenue
Net Investment Income
Benefits, Claims, Losses and Settlement Expenses
Amortization of Deferred Policy Acquisition Costs
Other Operating Expenses
Net Written Premiums

XML 160 R141.htm IDEA: XBRL DOCUMENT

SCHEDULE IV.
SUPPLEMENTAL
SCHEDULE OF
REINSURANCE
PREMIUMS (Details)
- USD (\$)
\$ in Thousands

SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]

Gross Amounts
Ceded to Other Companies
Assumed
Net premiums earned (Note 7)
Percentage of Amount Assumed to Net

XML 161 R142.htm IDEA: XBRL DOCUMENT

SCHEDULE VI.
SUPPLEMENTARY
INSURANCE
INFORMATION
CONCERNING
PROPERTY-
CASUALTY
INSURANCE
OPERATIONS
(Details) - USD (\$)
\$ in Thousands

SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]

Current year
Prior years
Consolidated Subsidiaries

SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]

Deferred Policy Acquisition Costs
Reserves for Unpaid Claims and Claim Adjustment Expenses
Discount, if any, Deducted
Unearned Premiums
Earned Premiums
Net Investment Income
Current year
Prior years
Amortization of Deferred Policy Acquisition Costs
Paid Claims and Claim Adjustment Expenses
Net Premiums Written

EXCEL 162 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L.#!10 (\$2"3%H"04UB@0 + \$ 0 9&ICA'Q<' Q87!P+GAM
M:\$V,/0L" ,1\$!IQQ:=!P4B0-!2L+(!>OLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJO<&4GPZ4A!0W_J=0U!R:UEA_6)#MI7E!+
P04 M " !s@DQ:15ZIA^X K @ \$0 &108U!R:W!S+Y-O&ULS9+! M2!0Ps(9?17)O!G!"J&;B^))07!;!1:2V=U@DX9DI-VW-ZVI740?P&-F GSS M#4QKHC!JPN?4!TSD,%^~
O@M9FKAA!Z(H :YH->Y+HE0FKL^>4WEF?80M?G0 M>P31-&QP2-!JTC !J!@0F6JMD2:AICZ=1-8L^/B9NAEF#6""@-EX#4!J!) M!3AV+5P \$XPP^?Q=0+L0Y^!2V+D#
D0621A^~ 1580RY8-(9)-NIL!"SI^!Y%1^?H.'GS!BYBZG:(E)/X M8-DOVI:[MR >X%#BVR!]*+ M41B1%GI@M MNNO1+.5)#3(3/PB=AI4J4!P'I

0 (45,467) 0
\$ 0 \$ (2,689,533) \$ 0

12 Months Ended

Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

1,552,359 1,751,437 1,171,738
21,303,491 20,486,869 15,892,573
5,950,415 6,136,135 4,559,107
10,095,760 7,471,133 6,333,989
1,654,289 1,253,110 559,932
5,332,981 3,573,509 4,338,840
2,643,867 1,875,034 1,568,606
496,588 375,182 276,691
9,952,216 7,467,813 7,196,160

0 0 0
0 0 0
0 0 0
0 0 0
1,654,289 1,253,110 559,932
0 0 0
0 0 0
0 0 0
0 0 0

234,652 274,288 202,999
6,572,739 7,833,620 7,535,832
1,193,695 1,158,294 1,002,149
3,850,352 3,090,792 2,770,227
0 0 0
1,141,726 799,905 2,044,771
758,554 600,127 547,210
302,360 251,433 194,355
3,833,636 2,967,309 2,847,659

1,317,707 1,477,149 968,739
14,730,752 12,653,249 8,356,741
4,756,720 4,977,841 3,556,958
6,245,408 4,380,341 3,563,762
0 0 0
4,191,255 2,773,604 2,294,069
1,885,313 1,274,907 1,021,396
194,228 123,749 82,336
\$ 6,118,580 \$ 4,500,504 \$ 4,348,501

12 Months Ended

Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

1,097,726 1,013,372 1,105,164
1,817,302 1,614,432 1,850,807
10,815,336 8,072,193 7,079,632
\$ 10,095,760 \$ 7,471,133 \$ 6,333,989
107.00% 108.00% 112.00%

12 Months Ended

Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2022

\$ 6,184,315 \$ 4,024,116 \$ 4,586,422
(851,334) (450,607) (247,582)

1,552,359 1,751,437 1,171,738
21,303,491 20,486,869 15,892,573
0 0 0
5,950,415 6,136,135 4,559,107
10,095,760 7,471,133 6,333,989
1,654,289 1,253,110 559,932
6,184,315 4,024,116 4,586,422
(450,607) (247,582)
2,643,867 1,875,034 1,568,606
3,597,810 2,995,678 2,030,156
\$ 9,952,216 \$ 7,467,813 \$ 7,196,160

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

[+T\$5%GR)-1I2J3YGVZ+4JG;-TJUP-MD\$%22M-MB803%-2(-1C2%-5)+D3<4-L0@97@OPQYV-Z-B-M\$00%<@2I5M"+N1NLM-M%<@NYG9%
H449#1@128C0"-2="#37PIL@B+MM@+VQ08@CC186@P45-D8@72E3Y5I6@+@UHU4%-A8">./=-6THA.Y38Q-M(-<+H-F>@JQ-IH988Z\$-DC@SH)4%j0EA)3ICD<f=-S9%#
%<ZIA%-6% MRA.%W08IK2M+1LE@2N(1K6A0(9<)2G@.4F:6OG@V%2H-X0N%60P"M1K&52WH4<+!%\$0C1+Y11%Q0Y)BN9)PEI%5163H
M19.Y%N&ZJ2I2P-?2I&4H15U0PDHIA)6W6F?PR-M@IYUD555LI9M@T<1MAR0TP-NH%CA5D7C\$IC#-O4G-MQD14%UE@A-Q&W-
E-0Q6360UM#K#->D\$-6L1MU0PM80"/186AG-72-O-M?B-4%M8B(9H%1+R0T+EP0C6G)2P8.9ZG<E*+T-4ZA5&JH DUUY+1+TH-M-O-(O\$y+T&JBB0^U
>=-+4#4%CS\$64ADQ)100H53AM-QW-ABTQ0.-4Y2-M0-6D.102QQ>V<3-H0FCU@DY.007M%2)2REDQ^JH-V>OR7B-MOX@-NTA.G+G-MY)SH0%6C@B%#<154B26W*
M3YD7HOHYH(CJG=-K)T-X5A.M.IF*HP(D)-1C95M-M0>0Y<+>?I8G.0-X2D1C645-%0H+1M18L7%51H+H1FQTQZD-D..S032-Z80-D13ZD-H162%=(5=1).HDBD
j0)DUZR=XSU5#U<=RI-MHTD/<8CTI?MMUPZ?K1+K0I4BMKB1Y^O(3IQ)MVOIX1&@UBXK(1^%O#1-M&-M#YJXFLX*Z\$SIK2W70=(4IFLH#04..UV=JBY"
M1)Y7-Y0VW+..BF1I05H&JPE(-A0-M&@=00-ZA-V)TWL/H14M1(-XQ)M#K8BDN(-1C6-MF=NWD&MCHPHQH/L@<56-5.FFNC&K2&?I-MICK?
LXG%JAHF51W1+>A-10%9%-9T(-3I&T&K1S1G)4)K\$R&-S&-@C90-941335JR-N8KG-3L-1%LN!G!B?X0IKM(DC)RDZPC3E-DV\AY:6P9%=<0/M-
-5U9T2C&P2GD1+P8CC=UWF<4-M%2+?1C8L@WY%N2QJF3DSN0FUMI&FR&S&U/RGT<3H>@EY2NC-D12)3>E-M&1#6GD-RH2.8%=<FQS.1^=>9/M-
51^8ZQQ-Y>469LE6@<EJF4YTW>2+V-M@HISWYK14HYTS@IY-Z-M%TWEJ2Y10ZJQRRJ?<48C+7#T0-M1HDS\$8?=(9NG6\$R\$K54Y+>6@J4
9N-LW03T^O.F@S23EBX^C-#0R1M45\$R00%FM\$6-@T+T?M6F35V2P6S16C^U2%\$S)@<7109JRS/H2U/M1H&C-H4^A0Q>24H^HCE.AH(2XTS
C:000.142J+1+UH%08IPN+40-)=M\$5H%..D18<B^ILW+V)7D-H8FE(ES4L1T0LQ.^?T%<G9194H7J90+M16.8(0W0.12Z>?>5X9W+@B0Q.1+6C.59?/2
B&\$5\$L2.G@ELH>M^/=9T%B-M0&D^T?IO=X\$%P.M3Q^UX%=-M#A+FFS^WF.V.ZK6Q^6V3STAR=-)2JH89.M.9KHBO+U&3?3JB-U?38726Y>@>Y
%0\$2?>4192F&14^0)1)4<=<1-M?TDEY-HRULM@A0A0A?2.NJ-7<5HE0T)+9<-IN-020J=ZV.L6LE-M^JENC(1)1HA98DLL@:S.T^N7ID^#2V)WLO.LG2-MLB-
J6F%1J&+&X.#MF600.ESSF.2I63D5EY9XRE8Y9

[illegible]

!5U9I(8V6'ZB'Z+GEOE#-IK>V-55D6I0(=B4CT6B)5N7H5*CB.61 Me:Q@GB)9EH:U5:8AF^W6EK+BA84+^D58=HX(2U=13%96M)X8OX)S2G-M6OZ)2BVS=U4
L1L6%?2C>T.&=LBP4L1/10%#2.-8Z1=BN-(6# GENZZH# M1=1 ZPBUDSPR'R'JWW8X@1Q>=H=^LF12Z1@GZ1=DE:S-8#>#F3T0YFO5R
M&TXMYNM&H90R6<^C60AN4CA-VF/H1+6 H8-H#S2IO#M-#JASBFOOV3L6ZG25M5-MRCHW-6 O1W5M01<AWY^N-1J#67 20I16 M&# NKP'M/OBBOW?XNN?
M7QFHX&5JIDQGV.HV/H1-?>1=0J971=1W4 M56BYV17A7A16H#W374D@C@-OJ1?+P04 1\$@D0. PDZHYV0 M'&Q &Q'AL+W=ODGLL?F=182H MSR JE98BMX>6Y87G-
%4A35R0YENGIO MXHT1?12%&#HX>+EY68ROMH1/47RZ&CD056=>JHN7AOX MN:2U<UHL6:BEHJ5<BL-XL7)D)R<=>6Y50=RDZ>DAEJH5M7W2I@UO
M8I418V1P-B1+KV2?&F/H0.1X(7?2LW<OJ#EELLWPHB7S16Z9YV1@QHI.M6%:M:3175&24&Z/QML YL+=>QRI7-IWCR.1^((RO=9=A5>1C1P6? M8Q14918UNZIR663N-G
SM>S1XKIRC<S'>ES'X@1PQ#M-31XE7 MW(BUKI.WGRI0=N)S1@#P2H1<=(S20P9Z1&VMO@N<9)@&Y MS4:8=>Y44U9I<+R6-J1#2)R.FI>RBM?F?E&3HM2@TNO
E(FV19FEN>O1 M%#B:HFYE?T?#Z3RZ4L\$\$.S6L1<=SSYK:75+4. IZ3YCK9+ZL A M3N1PS .9:2572@LCV.EIOF?>1XN0?B09R19P19M.R+1?>HFI1HY MD5CL5AGL>EB14
@#2%&XZ.TP>?>1/22.O-AHZQJHUK1.O)QV1>C9ROV1.M9X+1^ALM#0G81B5/H:1+1<1>ZD0A134C.C6#9.3YF&1&1A:M@Y6Q5Q0L1K50?>T (93M.K&1&1T5)ITUV?
+Q&K1+KLD7TP>?>PM1= (7 M&TE.FK) >J.N.W. &BIE>#G'JBR92-(HJ/L<F>PR3FL7D M1.6%&L1P.Z1A9.7%\$574NK9JF7.2N2KMHMP#R@>ZR&KE2HXH
MD31B9@GTU(RL.F)@&E41.HY6GB8W4 40413.EK3.C08M#GK@>219D?M8A1^UD2@<JG'Q10'>M<101Y56#B:02&B J=<+HHH'T'>0@10L1.N.M:0109W=W@4N".
f>3JOET<#<2PKY<1"Y9SLBNP2SA.& BZVRI3&H&8-H#K.H156 T(HJL90+(9'Y#E+B&C:KLGAB-R/O?19N.O191Z9XT1
MRC.&#>GNKY<#>YPV9 MJ8HBY>?>1V:121<@>H1C0-/#HAF'W1M1.HBHHCW-HZ 05H>H85>=R/O?E.BC1H0C1&6&07F?/(9%271T2R7R(A>BDR(C)C&H-AF 4T<@N
MEZ4>1LBV+Y&6&YH1<DPD14.(2F#7.ZL1L1A#72&#&PG85JK1F>41N.M.GB&X<C@GD>=BWKFMKCS#E<#>SEW+OOLXXK MW710
YU>E1A)LSR@ZQH1U 7X9+Y.61EIN36C1@TAXWEG3M<#E MN1MXT1+U-8D#U976NV1L=YL-R.CZ04:G59 B4/SP(CS#&+R1Y(01.0%&.(82FR1 W30-D>=>R^MY((@*+)
MSXM F==W68(4.RY(8Q&9+1+1YUOGP1)=8&2%515.58HAIUW1H1X18.34W#1.N1L=9+N<CXK1+8A'BY Z1XDA&KNW<2R
MOZ8 -\$AP'SO#>YCU\$WR8:5YJHT=>D58C92VH1><90>5124W60D^PT1#>ML+O@<9VVE1E8.BCH4&D75C1O>=EOMV1Y2161G1HLKJ E1#>BN6B&K(PD4
MBGZ<@<N1.S7:V.658H1WR.D+SJOH C>T>74 HJ30+FE#1M21&147QX M@<?>J4D4TK1G4MN1CFUR>.621&VKNNH31&HDV7F67>#S@#G4#ZA
MD1HHC01G1O?>O?A13Q1>139K622E MKV19<C71>+L1F74E(5N1)>5%>QHJ417 N K9B141=1C@C9@T151BFC4513H6:87L1(1Z.O:OY.FE31JKN.O)ZN#1<7G5%7FZ#DX
MW9T7=>=F&U.C.W>R 41ZJ8H03H.W8HCB M1#>#>#KJ47GU<1H1<61V1AMDB86C1V1O#>DR\$Z9N/1H.70->+6+>
M#OZMPT2>1P<#&MX&X&E@>T+>1HL@5UM1.RY71K1SP&#>#B4#1.M+1A.BB.CQ 2H.9MKN81=>HQH14YV7W8)99IKCY'ESG'POHUM1OZKHV>A1-M6LWH@.VJTLX
C1+M@<#>6D1.9/G:OYGVX/SJO?>@>BNC1<#>H1MJH1.M5G1C1N-N.SG143K5V6+1H.GPHE.8&L&H #51>91&YFCM#>@1<1H7B08#1
M.G4TF2#QB.(PFFOZ=HUTV1H1UEKW17RV)>1K'M'P(H5S1A\$BD=NW-MA' C1903&9>7#>C6&AN44H70B M1VZG>6#O?F
T1G'&K\$>+X1C96W81M5713+AFB&L1&Q+@CW/K1@<U1H8 MKGZ&A5U.7+2&E6A40GBH4V.UO2HWN4>S>IHJN1RC&6&7=HDDN12H156 MT3<M1#>A1YF<K4M4\$10Y1
18Q (<Z16>01<K7QW410<8TV1Y WMYPD12 M0F0TE52>#>#>#D1Q'8=>41Y3D1X1QCBUS5JY?>T.16>2N4=>742F1P M.Y18893K1TH6BVP1#MB#>8
+<1N01'>80>0POT0B0CAAZJ6OLK+R7.M1H4A1H.WJBI.N01=1&NPN81EN'JF.KD211&N0&8H1ME.1#>1LNW00E1.6381>+((MLD3.SBE/BA2>GQ 2MSYKTM1YV6.LR>1
EOPC.MCLB1K1Y1.55 EY>?>1L1F1K'F>'XX594M# SAWZ7X /G+JRPFKP(MG'&M2XOS<6-A SP>2>C.N'DB@OU4 80G<29G/CW3.7?ETM.7)SBIGPI-M<@UAN?
'EV>OWWUV7KI<^>Y1.ZR1'G1SX/REA<+SE22@>14# M>3T#C3SG0Y:6F)YDT8B1@<P1#>2H'D'M%>?>P1?>2BW#>@>718>=>1XOEZ1M3Y44L
KMSY4<@>JX.R.B5)1BBH7A2. UNB5(SZ K=KTS5DN.M0)BQO22.M0QL85(E'Y+7B15?2 C2:1#>=BL 1X&OT<?>W-PHX&P?TGWOFZ4Q7'R5. M'C%>K@Y.V5>0D<=>D1B.
91W<D1>=B1>BV+J1 M1501RHU E5\$A\$J>'HPL=P=U=P2%&X.8-D'X&M2#>BM81>+1+TOU? C3W M1K&GAI+E9&E124.>@13H.TC6G&41X(41+SU8'HPD7<8BF#L2.31<M'F#41
<N801TA54>5>0Y6GLGV.Y2.RQ>W1FA161UW=0P&EN1<1%>39&S M'14#0.N8YB1<C&41H1OQ=O\$&6K.OXO<K14B881XO&SOQPD?>P>Z&91L1+N1Y4H1E1UQ
NMJM<7KEU.9.DIRG1PD143Q1HU J1>H.OO4\$&WR/3+1&7&B&B9 M1A#O4:1SR<8.12J@S.140LECR1TK'1.3AS'H'<14SB'>921>BUN1 M.1+8B.<#>1E1L14#D%OA3P+>
KI+>1ACV/D53 AX)03Q?> 959HMD?>) MWN6T B40QMSD F=&121'>?G1@2 N4CN#K(K<1@O461UHL13D0<+&6>)59<M1AVY2+5E51DC?>C.ENBF&61W1)>1KOGKM
&VJ+>11.(HCC<+1J4H1 M154.KMDQV1H1B X1#1#>1>1214N2B>G8PNK8M2+24B<@>#RW>?>T18A MHA&1EK4>17C.MF3<B1V12P1H1<1L12?>
Q21&4HBM&1E=>53419 3 M1+>M1L 1YGYZ1H18M+MAA>Y=XW44#1>+>1&K&00\$1AF87X<Z-KCM&1A MHA-EVY26<100 H1M1+P1P&@>11<R1H2Z(H-HY&?>
YH=ETRGHH3HFF M9-0&52<X)HD.SCSY1KWRF&W5*#>#>Y.MP+BBF1K7?<S<+L5>@>LEP3.S11@&B:5F4J1H1L.C5XF99.72U1Y1# M056ZIE11'>
M1Q.O1#>#&amp

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

KRI/AI?7IS%B3(KF)HB~\$5H~?7T4P;A6~!->PG:WPIIF.M.YB>FE MAIVBI7JAWO#H4!#OG.1AW;U(=>A X^T 4RF.HE5?^9<0I3E.%US(B5I 2 M#508Jc"13B)7.^Z5ISIMN14?KCG MJ.CX1.E3D^>_PX^S1&06QI4R&+UG M^*32?>E.F3CPTVAIF.BX^FRY.I0.B1L928.WB#01?T~"IEG.1c"1#K1^1#>+G M?2^PG675E^<C50>AW.J0~M#W1^24>+&9IS(D^YBQE" <9QH^>+E\$E~.4DU.%G1/GI^QI>JGWKB.IBR.^1+1-0H6P^D">= MY^X?7D0.0D (DRH<=<?CXAG4DXNV.I4:0G+<5N93QI.M\$S^<80#RQ(3.MG.I5^50^&B) <+~>5A(.%2C.Y6.X5.0.<4V^>U3R^L6.F6IQ9RPK.R.M^ZRC6Q#NWIOQAT.VX.OX)< "T5I2N^P_.R9WK5T.A^YMMJ+BL.8.2.MEQ?>IU^I~.YA^?S622A?3IA1^%%(PG ^LUE1^F>7B.?P2K8W-W.T129ZFFS<(U.M\$1>+>IL<+&IS.&+K!R7MOH^<@8U>.<6<=>#H.9K^R~:44?>3OWE.LM.D\$G.I.N^O7CV.C^>#ZM\$CNW=@.R.C.YU!U^T.H&I^X>M;PI H8^9HX.C.K.T.^IDALYS1^7@>2I=P1+!+I|B>RH\$577UM+! Z^=9A4!2^MH6^"+S">+~>=DX0ZP.)%L|B^"OB8|3W<6%U^160FI9YXTH.M^C^T.A^Y^4!>=>1^J5P\$^ZR^I^" (67;GK.^/L.MHM^NW4SJA.NJ\$1^2BO.MC=5J>+>D>E?2>GMY8~+8+2L!4L.G.Q03W^H^1/(67+3L8.N.YTP.O>ZQO1.M.^%<+&WN91FV1<5#1%AO!#4\$1L^H0<+32^3%H2P> ^21.G.4.M^9>P=VIR.W.H665T.966G?1^19C8W1.2^96P^T^< "4Q.Z29F^AP439IHW18.L\$K^+M^R^?D.KX1^<+JHUOM^K.TK1Y<1>OZL.GFHKKW.L5LGBH^<+V19G)<C+W4U^M^5>.>6WK8BV^=YD4N?7.G.U.S04.FV1=%4ZIV1=I^X^<MZX^I=IW.L7FI4)<XHMS.O.M.IBR0Y.K.1HD?Y3).7^S=7I2B1H^YNT.EP<Z!>0^B^Q=IQ?> ^+HUGK>5GU3<QK<NXG.G>_.3O2L3^5^RCR.M^E^>#WFBDBE!&1#4!>VO+OS+U^M^<E!>U+N^K7Z&G!>3L^H0<I^C^A>+9.M\$E.EHHW0B\$<MIJ94XK.O.E5=PAO^9TYF0!&? ^F@+1|H3Z^B1N4<5#H4=>=O.M.PG|H0+>#K1.SZ4E2^M.M?7W112V71H^0^E39IH6L.L5GE4M=53^UGA8V.BH^YV(VH2ZC%6AUH^@7C+Z1)!>+>?2M7HL^E=U+N^= I^XV!>D0\$1L.A6^NL^Q<4U>B^3^2%PWI^LW^KOIZ.N4.M+!<+&S!0I6\$5YR.PJ^8^BWCN!Q09.RE^>1\$10~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~>+>?7^<O0I^U^>5L2^>7\$1L^>V^2BQ.^1^M7BTB^<P^LD7H6L.M^>0%9ZM^HA^82\$4K1^>A!>A!>R5^88^V4^>R^R6K MZ^N1\$F^>Y^B\$3^5A.NV7>~>NM>^!^BV^O.^!>GAM5B.N2CRKD<|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i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

[illegible]

[The following output contains extremely dense, non-readable strings that appear to be corrupted or encoded text from a document page.]

41Y#G**&F3MNMZ/GX:1FUHC8V7%Z>6Y2:1147%*C*Q(KIS^@)& MK*3(RPPPD*M\$;%U-EB-17-9^QHB006#;@%N%8& @&%LC*=L33%70:M?<...>

Z:V7PY7K687PNE2G^LHD<+!+!LO T^T4V9FAC,KT^F^U M2N78,17|@4ZP3YK?IR^2R0QKNKT4+172U:7E:B7UNS^K8LM3T>:JOV4UOM
M+7Tt==MQ<+%&Bj?%#0Z0R/GZ4UEHFH(CS4XP.0.3)>5+DGL\$F^0#5:~B^Q^0-U&K&(GK&6 M.O^X% C.6U/IQ4N6O98L\$M9361N9D0:6D0:@!:=!OPFIEQ^S(UHIO^&V
MU7H10:RXHK6:7+1-RIEBAY^X4:IK^K0X00:7W2L+10\$=IL^<5%\$803AP1 M.7XVRU<@<6H&@:PEN2:OJ=@IQ<>XIN^C:R4:FK^*SV^1V\$G0-QW&\$+MU+M^G
M=@C^~R:"6P%W\$~JV#C%E80V1^4K109%6A1A.CY0A5:VYTX+G^6GYE.M940FAAX4^T^X450KUFU2UPV:UK<|<#ZHHL1ZK:1PHK6@1^!^YPIH1@YVZ340E
M#=-RCR+7F1LGS?) P#UOXC8CP#T&^3P%15TXIMNB:3^6L^UGTG/V-P8>@ \$ M&:6@:(C1,,\$>"0<@#IKOH\$J175BK^N%I!>^=-N^1-VH:@IVT1309NV!?!M?UG
8B^YU1635G^R776D?7N=K5:~@^0S@SNJH8BBBK1L[SOP8&1010I2?LHFPV86V.M5\$&D^?P^<G=11%:TF2^L.M1BE4:Q M1Z14L@FRAD^K^SHC6LW\$S-K1@E6,
fQ^#B+1A1@FT^?QB2M^1+>F+69K88Q&MME90^71^J^L^Y^T^Q.M0 MNKK16 GZSD?29JRTI6@>5J5_VVM7V7710/P=NMM>JF^XFA:59J68@-01M3G
O4-5%93T0KULK5EK:HLX^Q0TKA&H^D=B^1441N^QWISL^R\$S:NB MUMN:Q95E1^U^UHHIO^Q^5C=<@10.9RW=<6%<V>S1IOM^MU_EGB701&B40^ETW
MA:F9U9^P951^5H^&N1Z?^0T2^59K241^3%T^L7L^&@R\$)=ZJPEB31 I00: M79:51^Q^06H1UG2/PW.VY^OV=6SP6.TX<:4.RSR=680B CF@I@:R4S:NETFO^XHHQ9:
zKE8%A0%77W/V^W(AC)HCE.7L1B9R5KY-MV.3RW)H9JDWT^CAENI&PIBB)J^E M:DI/1RV0Z2DH6Z^I[E4#4U^D8A1.W8.S1>E9E^WJ6%9=-2^VW^TFID0D^Y.UQ)9E:1?
Q=ZBUD)@ENUM9 G&6520+BBW+VLZRE^RJA3R M78VUA<:SN^TXI&OPYLA^NFTF70^@_JYDJS^?B<@>70@N0L&51^@:8^&J&U^M^&413P:2%?1\$<2^B1 Q09%
T6-B8NT9)601H23Y9Q07^\$E:F94?<@#FSB:~01^P^?2Z&N2):M:JHICA^?#<4<@<@Q13H1B0NT^72^N.NM7V7EUL2L&S1P^I^H1N<+!+!JBI^? MM\$5^7YDX21>:=R8W1^HB2RFI=+U:6UH?
MJ:M^4Q^17J07#>+!<H6M0=2QZ3:BN01^1SS=8A^1P?^+7^BD\$ M3IA84X&D1^T8ZRO=-J1C<7^MO@X0:172:S641@/6L1P%GK\$,"YNC@QF7 M071)@?
NBG=6C^H19Z>KBW742^_YAON,+C+98=N>NR^9^QD61+^<F&1.T.MVT->X@H&A1-P936S-2>:C4\$JvX%_F0CF39IGCLO6@:8BGA&N12^0.9T@ M2MSP=F-8CJ#1^XZK
1LYM^#J@>5>UY00.)J\$V,?>0 K7&#=-D:1

S0f)%56/B)5A^S@<\$K:8>1,8IDN 6T&>O!>E1ZS 00#^C0:~1H&#5 M0.6!>^Q\$>=\$>KB.L/H2/^HGT3Q&AFIM^0KD7L>1 M^G1S.(^%+5F&T3MY0K.)N+VK190BE^<U^I\$0DU^X
JZKC1RVEZ(E1G0+>MLTUP9.CW19116AX8X). W^IZIT\$ VKX MH4^QHS+IG13Z1T1-TP#1J19%-27%PF?<|<^HBJS M4K\$TB8#0SESPR.E^I0JYS&(4)\$H^F:=<3XFID(NL0^@<95%~
ME1+<CQ&+MKVM(M81U^U4I@<X)K10Q^01.AJ.\$&9TZ@NRIC^8VDI?F\$10#9%>Z M802GH#^3R-UCR GL73+TB33LHH^H6=67Y.PZ6.~#Q.66Z2Z2P^W6F
MT6XSSVZA<=&^WNI^Q") 57.HX@ S5H14AS75:5IL^IV-15^E^W1VW&K\$3\$+M=PLXMG.H^H^?20010^E1^PO#4^P07M\$S 2475\$V5A^\$R^YJ2 MBH1=XYT1%&
fA:2.0016IRSH^Q=X)=BLN\$7W19/9U:7=>4S.8K5N121>432N M8#V1H^S1.IXE6.R?7310H2)Q9<@<0@V1P@J<1<~9Y2010:V M\$1UA4/G L1L3Z2X.ZJ.^T1R6-TE&F.S#
MF<1+ HDNGL@<1YXGMMH\$D\$G>B^J27%YU?G?>B7YRBZ4HJ8Q3?>Q10A0R M10^>S2Q^N1KV9+5XG=7BHI-E^".3\$U MPOVXNI.S&
Z9J1:~<@2.SW<~1=916#~2^&U1\$&J^CB114&L.IPQ1=<5V MCGFWJ1>1Q^4C&10^5%B1#5Y31E1T22)1\$&1E>GR1(51(CWAB6Q\$S0
Q^6T6ZKC21^HJL30IK+>HE.SBMIGNW MG^Q?<X^7E8\$&Q9L M^1M^?4X^4K^X^QORR&CKXTE1E1HFF@1(INZLY1M^ MK^N^<~110-MVLT?>
4CNE)E?718^910.NK&P0=VJR.W.H965T^H2M41\$D4K623Q6#AA13^HJZ MNH20B0ZC^S3IG^>D+ C7.\$KRUP>+HEB^>#L@X6.13V.E\$+IR?
8E&@FJHRD?164148FRE4>OK^C^M1&H176<M-1W7XQ14?QR:NEE.L6=PNKS^TCELJTS^621F72^FNA1NRRB5201KGZ7W7<4# M^1HYD<~U8G 0ATGU^H6@MAG
117<5.WM9^B1EP4XN15EMZSC&~#&CVHHZK\$ M8^Y.Z%9NB@RC=(85YV1+Z 91L WMO?L>?715>WUQ?N^&QIOV.BCF\$0R^WU^M7^>7GLY^4#H^H^KGFKC+&?<
1%1^=>A1F093129295H1 325YD41^1JYV(FGU MDR3>9\$0121^X8D#). ^ER MM4<@<LNR1HWH&X+9^%E/W61H0121+PZR1>IR7.002)\$<@>01FAC^<~1D4@<R91A.MY^B:
<@<@13^R^S3)801^43\$ BA36G\$3S1^PQ#@8^W2W3X92.0KS1L^P>+&1A.MTQ1RPH1W=1WJOL^YR1369HMT1PQTH@<GH9 XW.ZD.4 C0>H^AC@JG1>9L MNL&L1+^ZR0
M6.Q&QDL:U(CU\$AV=>RT6&9D1M^?JRXDNYN.MANH+N3>S=3F1010XVYU.MQ1F<E.QONH1^3HD^H1AUFEXC.YL0^YKE^UM61^A=N0 M.^W-9.56QDPF#
HGG(61)MR(U1G00&20U9-09C=TO MPF1^0 M1AM^12S&M2 X2.L4&Z24HA^9-0P^F#(GLZPM^3Y=@<R8F10<4>2^*=\$RHO0%<@<B
M2D@<ZHJH1^BEJG@<07F#U^>ZE#61^<@1\$71=9FE=R^M1BYHN1C4OT1=91B^&0CW4 MUBJ1=12=TRPMB=TC&^L1E:SM^P^Y^M.N0K3\$RA^BPR3^H&1^JKY9N
MM2^<K310@ Q.ZW50 X^>X6B^<@Q=P&MIUF6%BK5L1U=V(Q+7Y^UMWXA3H^<@<R3L9.1.CRI+H+30M.M9?
M1NNO/GWHK(N\$KG(HHVV1Y1V52:IA&6^1JH89^2YB:5^K4TEA^L^>MVR MU60?7L>LEZPIBE=&HAW1YWEHPP62?@%2=WB0QLC15R1F.GL(G LXPZ^AI
M4130K^V^WA1^FPRI^T02^+12NY.1JU^2E0M524YX6^0C^&7 L1L1\$91V.MPX.M10BF 51ZP5^1JTS^E1M(O6G&@<YD+01VS>@>HJ3L624N1M HB68W5^MSF^+V10HJVLH.T
M:@NSG0=<+3NK067UK@JN1H1EQ13U1A.EGBDEQ6^CYT1=7WQ510^H7 M510U@O65C1TM237^WM1ZJMCZ^?K@<^X12TP^MWVL@OZHM0^A1+SOVH0SRG3+
<DE1\$Y4FO:F7V7VNTA^M^&K&L1PV^CR(=M M/M^H^G^RA8)=O9+PG1Z0^F@USC1^CLLD18Y1S3!%#^A108S9^WU41)^PP MA=GN^NDW-RE+Z6@JRR;
MHX92QU^H1WZ1L^M2K35V1Y.YE&K^&4W=1NW1T\$1U@<3^2W+J3THR.D M.24^LZU3MU.VZF3RZM9RK0E^H93LXNHRF^M3%EGEY1^MO26P
MLSV1^NIDBNCQ\$MW>=1H^A1V70A1U0@OXLR6LLU#>B^?27+5.ZZ4B& M&K^4^1J&X&S1^/WOK@IPZIAMR&XBJ^B1K3W6&WB@IN&7-5^N1HJ
M312^493>S1G6Z99.41C1M.^8KZC9251P^0Q11^L1R5X^XU>XVH<H^Z.MY#1>^ACP1^21D8^HW.SN-55WL^LGO+V@4B13^Y9FN.3Q3<2Z^NZZGEO MP1R1@<:QX6L19:
=PR1^Z1\$+>5X90.LR M58=7B1B1^I^OPIYG1^H9NG<^Y M^#WKH^K1V1>H^DZ.MR PT X>6=-+81P\$F.2%<1PUSR.8 M^241H1+ZWU1265B1H1D=0UZZ^JY1P1T^A812^BW<:
B(1%5E>5;X90.LR MS>QEI<@>3B:QB7^F1 M^#B^8G^RJKN\$^TB14Q. #8D&+SH0Z1H1.48A1E2G1^L@C3X.M^MTCG\$&@UNK.T@U009C.I/M=GYW3OE5^NFTF;
^Y(MQ1R101^EXF MD&A^OU^WM@NXKBDX1^P=PTH582XKWH^HFM1 2CCL2^X^U10.9483.Y1+<1=U^S9H 1CCY^#102P.\$%>10.6M107DZ71^MJ0T^ID
1\$1^W^W&K&U10^M=H1V\$AKA^4 M1M^<#%<G6701AP7&K1L^TQ>PS10\$A1^E42L7^AV^>L^DF76\$N^210Y1TR MH1G^H&66^1^C^67ZGGRK^X>S D8.KYCG9H M3T1^PCO5U9
^03RL9.D.1N^<1J.S07.566K&@VQZ1H6YONE1Q3F8L^VX%9 M.^>MT.#>R>N+03H^A5K1@>5>F@Q.KZ0A\$&^7E26.9 M^08D7UNGLZ9&1E
MT.Z7WIH2W12=1P191019.C@ZBX.P.G1&G&QZ^MIR(71H1H1%:IRM?>RR^>8&99TKBT1=(M5F2.LZ1TWPD5.8CJZR7S1Y1=81G SSS^410\$KZ767813GOX\$84^IR.%415Z:7^X1
M.^&N^VY-(C1-6&490D5^01V&D^%90^1TFP.\$HE M.8VR^TPHTP\$9^0PA&C21K0-L.T1992^@<U1.(6^8SC^CXJP&N2T2SB ME1^H(2&<4)3K\$-(DH=>A410>A0
H8P0N^2H2^A1+BC=>PGD^<^A&3 M6^0A1@<@>1)1H1=1R121MP3R14 C1VPD^ID^R@92W^<@<MNR84Q.E1=D8^I^E=X MGL1\$X(51G^F+L^1QHD^1^<M^>95REIS9G1^V^Q^=H
1Q^OR^E1&K2.^8 M23&3G141^<CEZ311G?>MU^1Y^UW7D^<2.B43^SVH1G 7XKKV7@0UB=>MAYGR18^29)56.OM1 8Z1451N2 W<@>0:5.0L6C@ZH1.Y5&16^MQ <1E
M4.B6@<^&^>4N^1^<SOL.U2^P^9Y@<I^<V^1Y27^M3F&^H6\$8 HTB0V1B MX6^6A1B1X^5Y&5^E^>F=>O>NS1ARM X5 5X/2>12?>C 72N1^U^1Y^W
M^S^O1816U1H1@&K PGT=>=<+03J1972RN^SSMO.F\$;REE<^+1HVP=M^>T=<C7X^4\$1L^1101{ \$2^3%HR^K@<R14 <^9>+&PQ=VJR.W.H M965TCVTEY110
(A^1L2\$(<#&@<TOW1^N01?#DG)EB.S8?1H8OHY^UISWU^7HW6 MS<~M=5EVZM^I9.9^?7#=>=37=3.M.OS97+UHL^YJR M&N@Z>2%25/ 8E14LX-77E1W1M7717S;E+RO>:-N?
3=>=>5MNI16K1E^672^1X.Y.W0V0Y^KRRH15^V1ZU/PH\$;EY?2?^<U1^2EL^Y<~U9.6 M10U^H61Z\$;SMJNGP^H18^K<^1.BUX\$^QOE@<@<IMT01^M773%JZ<^<E8U
M(HW91)^CREALK16Q14ZHD1KCM^G915^GYH1521>>%G7Q^W.SX&S^WOM?E&AE.E\$F.7^P^2 F2 IEG^E^V8H1M9.V^>V=A4 MW1=MPH^MFO^<50UW1^>7=>
1^YGVZG1>WY2E1^1N.8E1^?01D0D70WE M3HJG7^19L5WNY.Z=>4Y11GY21OE0GDZ^MH8C^NF.0T51M619^1YUVM19^J27^J1LY=>109E^K(H1.5^1(GX2%)^XK9W5^<@
(S.OY\$51^&C&5 M.4^4 JARVIRIN5^M>0.RH168?U1Y5A=E^UM6<14^CVP^A^U^F^M1Q1Y(A1^@4Z?>A1^IPTPK.GNU# EDV1=8DR0 M=DO=>X&R&MDFP^<2052N13EYLD\$R+CG1
<3>3^3Y\$P21^LB0 F6^12>DN55^M^FSB0SNT1A9^TR1W9EG1E^>@1D1B@+ 2X3^WNP^8ZQVK.L0F2+1\$1KWM M7^G1\$>ZNV81XDV7^M^019AK73703@53HH1781PUJ9
M=2H1F1J1^<@H1DWB7^<@<Y\$E&1P4^IKY9C^1.1%501^#P84M0^<C^>+G\$>M D21AM7\$S=G^1V4Y1YV.WGLTY=>6^>7GHQ1^1AYT3171JVNK031Q^MVF7^#N1JR1^+1661
(1^1Y^P1WOE31 51:~1E8 M56A^K@<O S.(K1B^3JHET^T2U^LEU1X121E0W^>PDD^CDA171^5.1QZS72=6^08^1CLW=>6^K=D0\$1RD.<@QB9G2D.@0W^E
MLD2G^X1B.GUV19X1D713^3 SA-221 5H1A&G&10XU1@AB&>^<MO1H9.IX& L2AVGC1+CL^2%EF0.BH1C10H1H1M^#R.P0
M1VWHR&@O1^R1XW6PVH21^1E\$K9\$S1G1^L1^1Y1YX.M1^GM1C^<F^IR^665N1M4E.9&9%<#>W>6.C<~750AVX^H1 8Z\$1MX.Z2Z1^1D1^Z^KP7R1MUS1+99>2J#S9
M1@<+<+57%AZ701#ZOZ&R71HWS^%11+SV15=<OBEHJV27\$<C^P01^710P M@5B1910C5>(<191)=+1#YV1HZ^UO^Y1>4CMYQ4Q44UH6(E>W0?^8PNWNG1A:7=)
1CY448.4H1^EG611@PU@2P1\$2UAN M1QB1V1T01^>2<GX4&1SE1^INAD1:WH1+1KB.01^5O^X1N M^K=>#1^3\$+<QGS9^>@F1X1S0RQJ1M161X&GBHOFN^?
1G1^<=&G5(H1F\$1\$ W1\$ M1% N2C0^V10@<M0C^Q06^B.\$1K1^83L2^CSY0 K^1+14^<K8 8%>T1^C6E2L2^# M0T^<M1W&S01 C 7#81B(3K UBHTU\$ H1P=SV^Q0P1^X1^N1T2?
S.49C<@<1Z^/B M9YKB.W5>5WE7L1Z7Q8&<@<1P.WXN1O1U1+>2.6X^JH7FBLRT1E=CPET MHK<^PNR1E10.31B=0F01=#<4X.NLW7:HX^KF^GBYC&V E C1>QA:25
M+9L.P61^<@<68EM^1YCM8M&^60031>3V1F9XN1M1&K^ZMND+1H9.H2 UG.M6U15HKKZ45R.BAF^6X.15^<1^Z^@<9.LG50&UG2371^A0Q=554UAVH^E.M105
A:0R4U1U=552G0 6#6G41^&T=K7T71@<1^S\$":.@%#3KCP^#Q5H\$K H&HYX&? M/F+HT2>+KY^#CGXKV&D\$ Z73.%>1V\$R+ PT4?F/5^>6T^MK5^GF@3U16^R&6SV:0\$B
S63N>2D0%\$A^>20@?14 11T71V^N0Q MH1AC=<@<D1YCGSDPDP0?YB1(+>73).GF1T^1J3^8^RDNIU1^1U+15 M+=+0^L2D ZHP&A1U^3M@<=<+S^W(ORT1
H2WS1M^V67B6 MALU1R1^1V.RV=>5&#>YX1^24C/60C=23^PTE&0^YB<C71^TQ><4@F9\$ M1P^XZT51@<B1M1A1^XW41^K9Z^OM1Z.PC&<H1ZS^SLHH1%>=2GYL=1K
M1P+1M1^G&?>AN1Q01M1MLZV621:UL^S16ZRN^Y7@>?A^K>91&Q80R^WH1851V2H7^M2P^<V1^F1P.O01^K0H4A3A861^XK35AWE98L^?A0<61\$1L^#X
MDN55^TZ^ED G4.LMP13M087R21 8=>YX>9.1^H1DH3D?^00&U^Z3^M@<AV1#0 M02H.O\$E^E1M1V1^D3B8@<K^J6 .9\$1@>1A7#XP4BP8AP.51+MC.DX7Q6S;
<51^1G1Z6+8KHL98A1GT0N^U).E0^/U711G M8#U101^>2&A:1L(B401T.YA00W?1S@#1.1^<NRH0V^+1^1RQ\$?)1HD=>\$ M\$F.EP.V.E.07HD1B0&RQ9+0\$
(=>F\$Q.C6X1ND+2^A87 M7.7ZHF@1142 MCI^XHP9.AY>O6&V36? 080-10=>B.P2B8.E1C15HOR1&O1\$&82T^H29=0IKT1.M78MM55HR1P13N Q<@<F^A74\$16@<XT
MM52P21H41HC6M8^<N1^>N>?>1L>8)Q\$S^<7%>DQ1AP7^P>23P7KE^4.MU>D5EL^G1^7DH18.L<@<812=C^0>7 P6CKT(NHHR MJ1@<134L^<^&Y60P1W1\$)^#.#Y?
6YBZP6.SFD^U1@<11^>N^%<XZ MJOY^KQ&X\$M.6^9^FF1K1^H6101F93D.K^6(11^>1XZ1>=1ZL^1H2H G1M^K1M15 11S1+2.XBH.G1^WJDR3A^>#&H13&N5A12NTP%>
<0\$0T0^0.1^3 M&S59Z1EQO^E^H1R1>2^UF9YK.3^@ASU+X16 G01^<1.CD# 2.03BXZ01^B^<1T1V^21Y5Y90P2171&#<M4.L430.99F(G\$;SV13DWD37>430T^A21@<Z1
(2)2:Z70)R^AU9#@1 M3F^1X^DIS3C75@&#>TQ01G>A+8>>D1A/6C.A1H10W=-1J1NX07H1 M>1#1AWG7=L OVLV+ HUJ41.YX7B2KV\$0M(KW5H^E 6>(X7;SN)+171@155
MN89\$7(K51Y4G07/LZ1YB7T32=EE&0^<21NLZ&P1P^SYL^1KKF^45X\$R.^ZMR M\$B1JMDNHK1X^>9\$1F>WRE^<K^495L1>8 MT5 W68B1U(GR9@<D@<Q9H208H).
<0%<HCAH^X#^?31#18 QV6TBYN^<QO^A1^1P^P4 MZ^1U.D17N 33P\$N.M\$ MXFD+Y.G@<K&0E&J6\$A85KH1^>F&S(D0>6.ABP1L MK1R1^16197616Z^<CH+ZRT1F1^&Z
Z1U8P6PM&PNM<^P2&010^PYM6 6X56G.M_YA>D^C^S^VF-6.212C2Z1K10^SMW^01U?<G^#NB1W1G1E12+0RP1U1@<2G/L1M8D# M^#7#00R19R6A^>P=#
MN.U1U71^U1U3 4@<F1H1^Q11AY>\$45^8TOW1+6CE1682G4.5^#B&CQY10F^3K138Z&JAMR^<3JFR.G1C^ETUP1O6^YH1F=&1^NVP^Y17F64 9=>U1^#Q:5SZ0>1A \$N+8A
+OUPZR^003.%MC2^1NT 7.@7JA#3U1H1>^1L^FLX>9S&11898XBRNBN^55>787)R1Y1 MZ78H1^KB8501TB1/^RG.C.MGO50^0A&0^
7F1L^&D1^F^31X0205G1^1W1K N1H1+XV.H1012M^24 M0.CC&W?1P=0061612261F4 M0.C.N1S10&@<5>E X5DS RC80<3KVZQ^\$8F.IAF^<1^>(M4.G2^H330)=A7(QP
ME8\$XO1^88WRV1A^D10\$@<# Q.O1X1H1Q13UHRG^&4C29P881@<+S10^W1FC.716=>5 M21EMD^#B1>6.O6.91Y.(2%61^ZBK^%AL1>=<#UZB
M8F.S13Y1^>8+846C71S1Z1X3G90XP1L1^<F=VNOV>67G.CY8F6^<1@<2L1 M01.MT1L G6B7200.1Q^WBR91B1<@<TDKPK^K1U\$<G1^Y9CN\$S281^F^<G\$ MR7.Y1^1B2YK1D1D
Y^YH10^H5Z32EY41^EHN122@1V1020P1H0Q491.M051Z1V^3C16X&X1JG&X1^<91^?2L C68>^E1B1B1<3XU1Y1D1<S1DL8\$S21HD MNX1H10N1015Q101
101^%<@<8#>@J+&GG7UX<@<+Q0\$U>2A1TFT1BURS>G3W1 M1C^>S^<Y1Y16H#B=S(>S1)^+H^#TOW^>Q8+<@CY8X^D1^U^Y1^LOY1^MF>Q^M^S198R.67KX%Z%2=??
X1+18<+101L33&HY.H1+AKH1N61#12L1Z=>@2 M1^C^9.00&B^U1\$1N21>1E#>?>M1^>D0>4>W 91PG@#>E Q\$B^D@<\$6.FX M0131W#1.X%24A<@<Q>1+2P22+1R+WX141^U1Q?
36.P7>RO1G1^1\$K01.Q<=<M3PX21PS(PY1^E16\$<EXL^@<QE70 6M).G7<K0>7P.LED M1^>M1^>S2LDLXU314Q1Y\$0^U@.18^<C89.S742%<Q1H1T^<#>R87H1 M1H1
ASU^H1FMA<1J1+P01BR\$RH1^1 3Q#10P^2&=<E191J5>5L^>Y2391M1= MFC.A1=>GH1>MCPGF01Y1A1^T^>N2Q10.PY^X^D^D4\$0A07@<0L^ERA5\$ MA1%4GB1+1
(BC \$ M8.P1P#2E50Q111E0X11J\$1F149.EE=99 EN1 M1P125GR\$H1K40A=>6%10.151>@<Q22A55HBN6KG.S<3J1TM&QZ.C21LOL
M6+H1^3X1Z1VN2G61VLZB^%QE(NURM^CH20Q1.8RS =E1^+45125=YP1^08 M0<XXZMRH18?><7S8B0674/M.NA@13%PIY13 307%RIA5LL>D1HGZR3P
M1.#1^R+^#W41=L>01.WX>5W1K^21N161^163^?>1@9A1P.MH.CCX1P.MK.05EBR1EL2^7G>S8BNT1^FW1YDK^015KY>#91N1#OGMCH1?^>.&K5 M0?
~W6Y1^Y013\$)R\$D^Q^@<FOY2P05>=/6~11N1BKZ1DPTKM7^L@>?>7 M=2M N^R1K1N^51+P04 1^>M0Q:1P0A32P\$1^<S@<0^AL M1W=OACW\$<FVSE4B1/QF?
~WN^#EO4MM.AD1V180Y1^N=M.HGGV15 M.FP6G^OX4A2G^<6UBUY>SV3+7G13%31^C1107UG.Z(W.EFS.M1G1L R0<=<5KJ>2BY1@<10^SV7EG^O1>13>?>H^<
H58\$DF2KUF17^7G.M1^<N1X1^DE^R1M^>D14&\$5^2M^W(N1.5655\$1410M8C11^H1X3D7P9N1 MZ^?G1\$1^<1^>5&C2=1FHT<@<ZVPA.2#^*K=7X5>1.Y1<7=SI^T\$+F^N
M1M=W1&H>?WF^N1ZZA1^HBTX.DK&>1\$1W090W1BY1HN(=H\$1)>W^P17 M>?Z80 11MG##A18T O.L61^+UH+V1A8DP6.%13G1
M.9X1H1^#MHE1AVKOYL6A55P4#X9^K#>SF^CZRH1 SF<10R51\$1A0>@>.\$W7^P\$ H1E=H1\$H1 MNP01\$1^54B90<=<+E6Y91+Q2 #.1B1.C1R\$>1^S%G&+
(5H^P1C1E^E0PE.M110Q251P^<21Q10^Q1 M10(MET1)^#F= #SDZ^<W187&H.T7>=>M^2M N^R1K1N^51+P04 1^>M0Q:1P0A32P\$1^<S@<0^AL M1W=OACW\$<FVSE4B1/QF?
MKTJ1Q^>R^Q^K41R1G^E191^Q1A^T4A.GMX.(1951F51^4\$>4M^<1^<FL7D^06^<1RW4 M^YK^7Q016^5.GK1(G.SPE2169A1@<C3L619.10MAY1P/E3+1^<1G^<YH1U1^<
M5S0X&GNT0Q6G19>ZWFZ.LB3N1P.EPTP80RYX&T&T1B1E1^1\$15^>061XK40A M1P^ZU\$51\$1NH14^W#A2.6YKK1TGNP0^K0R9VAGG\$<U.H^X1+51B1P915FT1U7\$>45L1^<1(G
M4JW@<#X^XEV6==1HJH1^%>*>01^#GNDO^%7\$1^#?1H2 M>@>#J^E<~MD142F^OT.M71AGO2@<GEL M1.Z01.SOPU+N^1S=1RWK1^CS^<@0H=MQ4ZP6^%1_G MFE.UY#
N^9\$<S&18V.6 7T^U7Z1H1N8GTG0Q^XNY(X1^>1Q41Z1H13E0H1YKZ1^>P331H1L1Y>M&K&UG121= K3KUW\$<QCF^T^MU M31M^<M1018.ETM^0^725L^<7.61+<0^<SHDC1FDS?
Y161G16M.B7>GNT1==3HF YG471 MJE1JR91P51@M411).TP3KYX CZYX@MQ906\$1^1C1R1A111+Z01 MNN&1&J6E6ZGX SAT01VE&KZ219\$1U16GT+1U1 P04^1\$@<DQ.NQ?>=
MM^<#>#M^P&0^AL1W=>OV^1L.E.91PNY1^YBMK/5 M>C^SR1\$3=0167M11V6<#6^UC^#N1VH87DJ1G@<T^>O1L1^1H3&U6(SES>U&N.MG.&0^M^>Y1>31Y1KR^?
GY1>1W1.M^#KM1^PIBYD>1H1A/QZDJPC>

13R5L1<0A0089?PI0^@W M.FKPH@<PCE<61ZVR\$<U1U52U1^XFGU^*N:8^S^<3W\$+4\$%(^%1+9.T(M3^0101^N+1A^U1Y1X1V

[illegible]

MNTGFEZ, B9HAODS>C#VC<5<-798.D,1J9R)EJ5dC(L18B&<:HH10R B2\$0L M,MSiQO<VY43 (KSWR3QIG<W<KJY#>U4B3<GF1RZCZ1?IDURGLP<+G^H
MNTQ>Z2G6G0&GZB5;TB25.5,OP324>XJ1D2>O67?<+I108R37J,9L E.NQBJMHH MSKGFERU<05:VAIC686&K2%A+<B3<X3Y01<?2#<0525F6B4U9./95X:#A
M/I^<R4%<C^E^B9JH%<C8NH8M^E<YKN^7V+>0P9KI>V>53;RH8D-8MIZIT)O<MY\$%<6P9=O<^?WBAHO<3L=j6.XDO<HDQEF1A3P^BJ1?IPR9P
M^PG648I54(S<C<0RW4<+<SEH<CZQ^<I<Q<M^CUI^<R5HJ0.1<2YB?<?B1Q18>STD3J2I<O>9^<I^<HJ19^<CC5<MSA3N8S9H6<#?1<^<KJ12>GJH51+BC<Z7Y4+2N)
(YL1R4Q?7E<C0<MI0&ITAC5<OX<1.1^F&?P4LH)LDN:<TCQ0R1<0<Z1A>0JQTF12N1R<5G5.MI+YGV.MI<08RP^FQ04<H&8?<+<UEH2<PABM25X&019P<C<C:0
M#<+R<+9L5><P1P^8?<?Y3YF<+<1%J17?<T^B<4FYHGMV1E<=2IO<0<5.MI5R^<F+<I96P<I&9M<IDS)T2>0<0<LKR04K45;JCS<^KS&D<^<XV
M=9IQ&K1214X2TB2.5<B^WM6<47FJ&JL<ABRRHGWMV1M<=P<1.12E<TGPH6G<+8U0R^1H1+<1.2H2>+<C<Z7Y4+2N&H/MJDI<IR&^<HJ6XN<=O3Y?<
N)##U(XMB:UKJYK6YVLAQ/4A0R<=^Z%<H73D<M:594>Y^70<+<1OX5(X^<J^V^<J16W4X1L8PYDYKCI)<4ZBYE<+L:D78?8JP M&Q7<#V.2M,8D41N3;S<=^?>#%<Y^A3?T)74#
(P<=7N3<0#2JH+2Y5<+?#T7K MZJHJL9E<E:P7H<+<K12^<N^<O<K<+<?<H7>K&HJ UG&XJ7F<+<U^A5;S<2M<UW MBR ZMUI<A1:ONE#DZ\$121Q<=TG?B^<W8+
I0R0<4JH?20<A%UEM#8PD45N1MM3?V119L5<1>SX2^8GD7I(4<+<AR<JHJ.CRRIFJG<ASL59W<^*03XSGI>14RL1<1<JCNHIV1UUG<57P<+<U^<M5%ZS22M<<X9D^<RA(O.M:
(4V^K^AN,BPK>>+<U^<D&1B<+BC<Z7Y4+3NDVYRMB:BKK<55<60G<J<C^TE MZ(SU<Y^HM42F1H4ET^D<J9<+HJF.8.21>U.O<M^F6A6<J9>GPB<ZVYRON<=^*0ZWW<
GJJR0<Z<X5RIG)0A<+<L^<XQUL+<P04 M<^I\$<DQ<0V.K<5P<5<6Q<+<AL+W<0^IR M^<3<474N<4Y4E<Y<5%<HOG6:R15&ZP M<B19>SEHC RWZ<55>
<075A.9RC(Q3N5>Z&_%RC>Z.WE%UCO.E5(4WS MP^Y8?<=^NA<?<P6LLTB<^7Y4ZU>?<+Z9.YIOBY<^<U<RL<6BAB&UHJL<ML2B+U24+?1^\$6?
E72HC<5%<PS)>9Z/<+<X6GU2W<4JPS<+<U<P.SI M^<CH@<+<K0V0<0J0.ZJ3<5J90<3%KH%<2+19+<5JTM6^C<+<U?Z.T&+<U)25>KN/4<+<3OHWH<=OQY<DC<+00>?1F1&<
I6<0^NM49N1AQQV<^QA%<1^69JP M>J<7OZFBZ9907B2.L8RI#<I0X1RN/L4<+<HJ3&ADPOW<T2>=Z#Z<+U<S<6Z9R+<U M:HEIVVE>UVTW0KIEFY4<0<+<HCIE4C5+<
+JA<+<N^>YJW<2U740A<+<G M^YBI<C^8^1+<U+8P3Z<G^<0N4<YGP M<O.XFV^<24&I^<W50<SOQ27<MT(5<IGE<B^<EXA<H^Y8*81<KJ>3K<+<WWW.NJA>N>+<U^<+<G^<8N
MUM,D<J2.U9U^M 470H1+7<YJ5.TO<+<HMOLSD<MY5E+7<KXZ<P3XJMI MBBRFZ<2<5DA<K2^<Q M^R7EYOLRNI<YHJ<K1E&+<01Z>SEGEY<INSOK<+<48J
ML7X1542A1V&PZ7PX+31B<O<=VEQUVGQ^SS)1GB&4EWIM>6Z3NM^E^+<Y(258J<9V.E>+<NYOJ+<S<MX&HJ3.424)6RIVERSYGR<
D2K6A<=O<Q45<WYTFN2IB^<0<U+09KJAG M3ME=78(4V58<5T^<CW^<LW9V^<ZU^<Z1P^<G&5<I+<V<I6H8V^<M?2YU.SOL M.G.N7PFI3NSUXX3<XW4VRPM<+<3K%GY9
381<+<A0C0&^<6=R<+<H?Z>=W

0*#2D<NB#DCGSR1,0HDZ,R-2D)>0*#>+P.MOIM.FHN5*>RT390 M6 %5(UJMU)A;S^BH55#142P#J\$2@UVT.#.KX;G=6N5;UG2742*=@09*MS;((W.3*Y0H814X*52-0*#2-1-0Y5UCZ136V0>90IAAHXZ1N62_10K6FE-EH+2%>@:5S M,3-TA?>=60B4MD#5512;I>A+10Q+6WB=MH+U&N9N=&+&+L%V;+62MFLA44M*U*U2-0*G90V=8",PUA89%VNY0W7V;Q^LA0UK83=K798T8BBE2;+&H&@JD;M&U&SC#%KA/;5/D4K4#4446;f=>PZ(57D>KAD>ID9WFM?7:(4-6N&7C588 M%*U*U0B4FOT6D&S&K^MMLCT4*=>7X1@TH6T&IV7A9M@K<6CD6GAD4H6 M.Q8V5SC^WP.Z0+H523Y2;9XAF;0J2_5A.H&H#2L U>@>8H.TG18?>#PLDI&4F4#44168;G6&F.9M.LBXE.D=NK-2<_>FP#13 ML.7_4T4BHJLX;?>=NTPTK2<5A F4H4#44168;1@IV-#1;H&H1 L M/PU#1%#;PS#B;ZA0H1&5&IVX9B1 U>@>D0#H1 J@H;@U.R7U@U5>6<@HM;M9W.9L=1741E10U.M#+S0/RJZ5XHJ9R<>9HO&104>44(1KA0 M-+1&D&S^4S1#10U (<S23*H1 U@QI@+>-9>G&PO=VIR.W.H M965F1T DCTES% M#&FIE)MKT01Q^GD15VP+M#47ESRCPGADWY40.#B2I0^EYAFIC9DHY88R U=HM.MP193?P.U^HLSQSP@=0L9V(L.RGA2N#F15>L\$<=>S=D0N0YM;KF9FPY+0 M^H68\$XK\$&Q+J,+*P1E<4CA9TX&=>R1^QHWRH3T8&UAYH4K4\$50MC# M+--RHF?>U^CV5.#312/4#>=51J81\$P8JE7FLAT9(0&2F%RDS>L=U7L-(MTWPORT3UBW916CYR@N122V7NPB;G1T7D3WLA#<@6 P+ W@L44#1 L#9 Y5? M.MPI+V4J4L=(B0..A9S0M.6S.BTXK\$S JMPI>+M^M7D1N9W5>D>#>+V^&M^JOWQ&7V10X<3/GI8H.IHH44Y9F.V.K-T(4249J0@.A1H7H@)>1^BN.ME?>Z(0(7IR1T0+>)>R4I B\$4-3^Q^TDFI=L5;N^V^X(HEHT^LD^E7QB0 M)>@>SIHJH<-1K;+Y&YQ;U.HG3?751N18;L(4%5%>-M^L7 F^7G/KDZ1LHGL23W6G+D-1M8A?Z.ZD.XZCN>I^K%KV8W=421>5>SGX7&215)H64A1J5G\$<5^H72AD1P<=>MK521%#H1C0%0F3>?>NG<3#(R6Y3VR3M;C22W1LUG#G+;M&+P3B00?>#>OP^B1L.M682M16A4YR3)3%05W>15:ON&SRJP.FTPJGG+6+1MIYZ1=1TNOU42I2^5S8&OJRN4I>+B+&3=>#6KS:5C4C7?>M321V16N2?/5= MYA/A.UH(E.%4>#K0V0?>TJ?>2;J&=>ULM9C0;YLX&?>%0N.IDW.%0P\$FYB1ZL-%Y67H.V M^?>P&P&XKB?>#JL.DV71YD>P1/25D^W/PD.FUL9>@F4 M3VME+LKTQ31W6L=(7+>3M6=>)>DJDK-Z.8<BSB0107H18TSP28U@403= M6#M^DEB)NIX\$%F2(1S&E.VF1K0>KX0C9;F7>BP62)6G)YA74^XHHCPQ0.DUR=9.781R5B16E^L(41S^W0.L0 MC<=>BTFM0\$>96K4,7A^263?Z97?>@D19.02&LOM+@T0(513R#R^50)MB.N\$B(E&K&B)Q\$N1=18 %\$F)JLH910M+R^QTK&S<^Z^X^L^N^L^514P^F MUKP<C2N.69.14^Q&ADBB8<8 /14M^W^/F4.S5NF3^N2I637)TLC-WY8 M+1^WBJL(-C^NZW M1.HC<Z&E&HFN91955&ORZCY^U^O^Y^61^M^L.W29#>44ACBZ41W#K<G0GX M^OFSZ?5S.TX9VX>I>X>=>=4CDA#&F&B2(MWVJH^RPSD37-LDIE=MM ME.^J P%#&9X.CD+S28^1^C^H&R8Q0\$7N.A\$-06=M^U+7-1#&)IF T=V>+(R0J M^>#>(^@CCK2^Q^TJ^ZC0+9DU@DU.\$_KN/1^G3+1DEUB^HRAI7.N.MWVKY<=>RK.02F?>=&JTD&DUF&S&5-YO774VLEL?>5W1M4KWA4Y+29-8@U^MCO>ZGGO.OBT^AM^Z2A4+29-1^ZU1>6J^0=IE.S4KD3-7%0>)>QEXO+U M-55&B.WF.42U>5K.RI2.97A32^TVBV# K(RBU.76946HL^P.3^FS1 M<=<PPY#>GTOM0.U^DTZL(G1A.DP1^GJZ&36F^ONFM6P1E.P16G#N=+^C^DN2%6G<14G^H1^Y92)53@U.U^U6A@*0 ME.^#8(12D2A>=>BIVN1<=>PVT.T5T?>=4 1X^E=N^N^WGP.D0M.V.#2MPK.MZ)F8Z2(43A50V9)60Y^RF@D7^P07H1=>PF#^9297RLD1F40<QDD01^MIA4&5C&2@>5C^S^BFI8RQ<=>KUDA.X.IZ7\$K0Z5&5-8PD.V2D.6IKD>2 M6^2FEZY810D13P.R1M^@4Y5163^Y V80<0>=X A.M.M H00&C^H&4Y5.V4M.CF4WU.EU&C.MP<=>0Z(08^XHSH.M0YR)I2O-Q M^#Y9Y^YR>T.N+IGX&HFR2IB1\$1>#>D1^#D0N8R^PL^@YX=H9R9P^2^HFX10Z5 MRO-E4@KJAF92921 KI2P2I>=>PZW082@NXQB240C%GTC8#>#>D@_#@>? MD150O YON<OF&L;(U&21)>=>f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

L4D:#PBF.3&19CAG3,\$#FH+>973H94Q&8<+N4B"R",+MRU<6>+W8@,+P8IPM9,Y,W,RVM,5FS,YO\$M2H,MOID[F]EJOT,^X%4P^0^VT^DD?^#M=U8&1^!8!\$!0NYM:UE@(\$4F)
l+94@#?>=WTFN\$W@.T,IU0Z+AL13JYO[!H-IF^~W=I/P^F8J5D29I\$#M?DN>2>3E>6.1N^SRBP-9F]H:~4GZ=TC27Q38MSJD4?/T?T?80+NUSP3-G&R\$2=OYQH
K%K6KX,l+V,K%<IUD569\$U>ZKVYU3H&K^X^C7\$<16M,H440F\$0UBDZ^>SRAI5\$<Y&YOUAM&#JH\$=IEF%FKR1=\$%TSUJR]LTF:7%Q,M1+&B-
#FWI0QCTD,X>L+I=EY<5>=EDIKZ5I@=>D]J3&57.PC4>WXNCVN9-0!~#!P15-MIX0DAID,1HREKS:ADL,^!HJ2>-KR=UBU!+&F&EBCB]JHK9FAL53,Y\$++ZZ>+UU+87TQO
ME^ZN5"M,l+>109H>?8BO%=LAD(ICKQ@0C0.4-U(P-Y%M,%EQM,l+<,\$%X\$-IQT6#>@?H,C<5!K6H!&A#IV+4F(9:0]R,*B?ANA@M3!^J^0A44#>@%Q!D^JAL9]!&#-
%Y=K1@.6X@?9)S\$N,^M3J213J0U!+P04~!\$@D:ZO9]BM(1%&1%&0^!&W=O@N^(\$U13J/KMAP,L^E^=NWF1FQ?.,=-Q
M<=>2>3XICE9L+0!0ID^K,FBFHV3AN,0!6,AY,Y]!,0XQ@?B]!^DQNOV14,F^WMD6A533?>ZP>2T32!4!O^MBQOTLITL1,1#>W!V62Y(MA1C5ZH418W!<WY!#<0?7,^#OD>Y@PIX
M1^3A01ON^FSj=7Q\$!>@W^XFGHT2_ZKPI\$>,9JYME!@3>+>Y1+FEJ02^U^!+@#<="ZY1H139],66UN1K^~!MS^+<(DM.6%):8VB+4,0DV+OKIKB0Q3D!+B=<82UF-
(L)YH&K5U1W8,@P7E==57L>76%I^N5K^0%\$8,6YMR-MFQ@A28]H1^G^S6N^P=L,B]FRHMM^KPS^R^T9T,FM.L4+K5L2!#R,UV^K8,6MVB+400HV=>@(&
XZ.O14.#@UX.3W.KIN^IY?@-))K^#H3,P/EE^2VSM-M3^6Z-7&HWP6VU/+&U!C,\$!^XIO=IL,0U/X6#PX6Y<9P878,6SUZG^TC
MX<14+>@KJ3&NOB]URC?UWMV]0MBMV]9]R8E2X9+6-E&UQJ5513HPS/KKIPQ3-J,^E18VTDJ,BX^ZBBPZT,M,C)!#PXF!6OCW,R>A^U^F80P>9YWO^WR^C~;W:
H~<4>=>SE1M=>3JLFO\$<0^>RQV]L,F\$2F6JVF,BC2E0H9PR^0H0J3B4,V,^>U(IZD-MB3,MBX^81Y,4.GUVIMXCPN7ZKF,&+73)94E%F\$B@QF,M8^IX<@#09.0_&X4,BVFL
P3W9:WKC-1^T^4N(528D)H<0%>CA)H5R@3B-NRZF-MSMSG2,^GGC!<~R9TFL6SG&CUO2,4CWV]J28B5K15Y,OXH!@8N7&86+ZPI
M3M!#1+DBPL&12R,\$<QW^EP1@,7P\$&2^12R^H!%#M,VLH345!>+>R6P7PMSINC4FC38-F,KQFM5Y@GPIN2<1227=RX0F,1QZHV2<U,D(97]P!&NYU8W!>+>R!+,%5W9
MD4^~%K-M^OWIHP=37%"CRNE=+>D]YIC41I)\$S^<~%Y8,E^~0793,X;ISW#(R)M)\$C^EOT>")LWB@M^N\$@J2P\$JH&H%?M:(J5MI^XH^GO@3:N(LAP2?/373M,~
R%>@#%\$9:8L.0^>HPW4M<6&SA^FZ,K6^T^&K^WNKU@.,IX-T@>PPW,X,T^C]V17H^2,0NN-R5,M1Q0^>24ZL^>=DDQ?>SRZ>@>^?2>Q>2.5@15)7!<~%V8I2PL^T8%~4,M-VUG:
W25<=>@JX5373G!F)P#H!>V=J24^&M7FQI3,IE!+P04~!\$M@DQ:@MIE~!>0&^&AL+W=O]SGL0<K>9YMCDCP6J[C2#H,ACT@!W\$M05SFY~>@#)4J2!JN3X2CL6,.RP:
^78-1!O3^XZ?>@19G\$OYXDKNW6\$R2,6T!>+>K8Y3^XJ(980^W,6C@G1K^2CHC>+&DY@Y+!P>]!BOO7?6,6,61UK!MDG^A!W,~X\$+6B>]W^B>8!>7.671!9M,A1
5E02100F@>@19.G.OVOJP!M!>?20?GTF#164!2-KQ585,9E546!>+>G16P+H09W,]HX]L1L,N%>=>D4R-MCM,NP>=KZ7GR^AR9TQ>=>+!F2GWPISVC)\$S^,PUW0>SKTDJH!+>
+!XXNMA?>F!G!4\$!L#1!0<(\$2^3%\$!PR&5U0^#0=>9>+>PQ=VIR:W-H,M965T>1WB,>+>I4X/5^VC<>5"~<M3F7&,&0VRO3Y^N89"~0+K&?&1W@5%PDE!%2
>+>+!HN@D]J\$>=BY\$>,&3Q10R!E-M^U\$>00E0Q3QB830N2O<0^>1HKEDDT^T,T^#53J68YJ3!4W_3B(1SP\$?1%9_MAJM4~!T/MR^EX^YKR,BXU+&6
58F+!FA6]10X^!^A!UX4X2H^BN014-MZ!<^CZ18<+>HJF3!<U0EMJLDH3!>@(\$!S!>@_KHB6MV^B+669+4E>+>E-M8]L(O\$!<+>JZWR!>]F,G\$]WLE^U+!+B6
KL&S!>29Y2P(HSL,F&B0%<0M-R+>),709/2790>@>OGP^WH,D^XQW?2P^C4%\$>^>KJYJN^ANKH!>,<(>C!<W-M^!T>^VZK4@/7I^!M38-M53,R2YVJ,+=<60~!+>+>T%
MNM;QWKA:68)U;K16>@>P^ZIC4M^QB^T!7#,>+>S6THUJ5+1^2N>+>S125!^HWZ+>0MD>U^I2=>88F5E^>RZT!%<+>HJ4W480.G-8Z,F\$N,+=<IR-T,CB\$>,
M#:#5DS,~+D36!<N^>~HM^TRS^UE MG,~!ZQ32I^H7!>=>764N=L\$3K%+>+25+>R47GQDK+,@HZ=VOH06Z,-TB^EE^M>(<@JZ&Z^H3%NBB=0N^VH^BBS?>
>@JTGVI^Q^>XUGRQ@>N>Y>G&I@>Y^#Y^X-MZ8-MC&6CUF^>WW?7!%JM^J+72EVT,@>M^PKO)3O!U^+75=M\$7K500-MUB?>
55QOE!>1Y0L+1&OU^>X&G1257IKM,P,~>YJY_HNM9PW\$004R6_6CVURJ^MHZ?>T^>299XIG;1%ZU!OQ^123,25LVNE;H]W8^VMAY,~MF2,SL^V^BV^MI^<^!@J\$K(016Q0:1/G,?>
>H<Y,CCKC!&BDQ,HKG7KV^!T=(E,M54BK8I)=>W31N@5M^3N^H-FLA C!&8,78:AB\$>H0Z+G8H&HJG^BTG981M-MRF4Y^E9TEJMX#>8YVBS12P27Q^K^K^<44\$W^M9A]!>
JQJLDYR,E^XFT/GC2^M^D]B]L,\$7L+!EH412%>H5F1G)(P^C^P+D^3Z6V^EFG6N\$S4^K_#U!+P04~!\$M@DQ:@OSS54~!Y^@<0^&AL+W=O^M7L52>=63Q(016PSXBI@EB7%TQ
9ACV@>@S^IC8?9M0DBW?2,08IE6=^?20GMI-1STA!^<R%2E\$@MR#6)HA1^MCN-G=HKGYDFIAZ_HG^*R\$LRSP\$GUS3Z,YR)Y:CGH!>S<U^!H]L^&4#-MG-
(9W_1MH,U@?>F^ZYH+!<I^<01P^?>@H]B!>@Q10D?>@7A@>EDDF,35^+>@N+>5C?>+>M^Q_MF&<+>+>0LCKA!%\$&D,?M^X^H^WISZ=RL,P,2KKF\$XL,D-!<H^8
M^N@,RE!>]H]P3G!F^D^X~9D\$D=8^D)EIS!^_KU(GHP-D\$>.,\$2!<D^PPT^M7RZJ4C^WZ?>T^>299XIG;1%ZU!OQ^123,25LVNE;H]W8^VMAY,~MF2,SL^V^BV^MI^<^!@J\$K(016Q0:1/G,?>
843MB&H!>+>0<OX42693C?>5UA-3A]S]B;00QVU^MLJW?7J50!BK^Z]PQ^T^R-NN^Z6B_Y^E7KTF&P8)9^Q4RN,Y^N7A,00<9-G0^W>H\$>@#>=>T^>JNRK^AT^FACMH,YC2N^QO3?7
M4Y39YFX^XND^&6E=ZHI\$>QY5H&,BRHVGZ^QWB?P^>43RU^%>Y,~M=J]MF197K/R58^Y,3JOVQ@H]SL^>?CG6?58G\$H\$>N^C+!P^ZK14^0JN3
MU8KFZT^KJUF968C!#&G3,Y9%>UHOZFZT,JB5K88Z03^X1L^6N%L+0#G^O+M%176AU_20C#9US35^M-MJELKFL+K2YJYH&5C12%U!>O!>+>WBF^H,Z?>
>OJNHS^W6AU46M^LZ^M^F^M^P+>D]L+!PHB8CFVJN44A5T^NYSOFT^N^N^V7IV=>=4.764=,~RME_MHV2@U9_KI^12H=4UJSJP,170QH4CA;R?>+!+!5MG^X3(6<+>7:X)(%<
M%0A0Z<40%ZDCZ^W?>P!02P^>+>10.6G16%>=C!0_8B0_1D-M^X;^!W^W&K&UL51=^<X%?>T%?CM:=1MP28^M\$N^HGA&4V&G,K89YV&U^URDQ8\$UB,19#V17^<4^FA
2%#2F#R4)J]YXG.0Z^MYQ^KGXG(9\$>^21TQ>=>99^KZ173E;DCB0%WQ@F^YTSQ4^+!+TK^EY28B@MLZ0XZ?>S^O&66=12@!<B^>VZHB^R+X!X&C@0KJES=>
>IW7+5%>SA^F^>D^E5YQ.IQ.A\$!^I(Y0IRXUMD^Y^MXQO^NG,37G5Z3841&18)A0CQVY121E2^HBDW^D)MGPZ^JN559]@<9D^2^>+>O^>#D1G@>SLGL^W8,8P=>^!P2J7<^>L1
M0)3EG!>+<1&01V^>^B6TG,^#L2^D5^>^!>ITAP,F5R^ID.,%#>+>3X.OH^MM\$9+>S(O!VQ-GI+TND^5T^I2G,?>W?>T?T?C,74S!9CJVRL@<+>X/RI^MED2^&8F4ND+K20XPT0^>)<?>
>=>3C%>S^Q!>H?>9>NCR1^8E^,NFF,~N\$~MX057^?G1C0^>#&X&4T(L,K0A^6_KB93,DI0C^Z\$1&3V07HP!^ZB&G94^3MP]!>+>G^X^!D8,-OKT^P^OOP^N
(07XN!>="X4226,12IGJL^CIG^H^M5!&7,75T^>K6)!>=>2H^I04OTFV^#8\$E4,3^4T5&AC~!F8ZMD670PPR
MB3^>7!>=>G/G&^AQUYU^N,~Z+G1=SZ0?>,0WBD68^0FI!L(CW^H,1&X&EYGN-MHR#>+>N4W51ZMT6Y&=>?W6N^P<5^>0LR5E^TCY2D^>~*11,]H^T&G=>1^N86N^MUT,~^QWDAZ4I
>S^>HILGJ3YSYL@>8IYVE,FAF4T^VJCBY=W<EIR^LZW,M^>4H5!>1@8JEB1M^X+>T7DD6Y62,&1JG35!>=5!DN1~F0!0SG&G=>59A,MH1,6P^>28N=>IE3?
JG>346!>#M0J&K,%5I=TPVY^X_>XUTUN9A,D,~+>ZNEJ^MH3L3LUU@L^#&ML#>+>T,R)HCEDKPU9^!ZK?15D9@ML^!A6VAU_2JG^#W3%>^EJUQCA~
M^T^K2UKY>+>@VH<58M&Z^>2T>+>H4JL?&^>+>VQ6+5F+!>NG+RT,SS&X4M^M,~>WE^>XB50YVY3G\$ZMHV19,7PBH9M!>5?>U9=>#?>ZD^XZ^MS^T!>
>61%607YMMJ80!>F!F2615R^J]MB,~NPM9Q4^Y^T^K^UDU!>M=MH(IH!>^!AJV45^7M&H^D,~>U33Q@>3#ZR)SYM%>G:(70!40@,RI^>X8U@>M)>A=>I^F^>Q2V?
98\$<F/T?>>331L^ZUN9J5E!<~3W!>18Q^>#66G^M^L^F^>#XK8L^Y^T^K^>5,T%&I^Z^>P^V&5,1L^V^TNJ15DX\$>5%A7_GYC^+>?>W
>+>X7Z6E_7W18!>3C,0B6G^0BPBP6G,6K&G,JCX^>63HERCJWCU_2YM3^M^AUM^OIGED@0A56F^GL_MN7K^24H0<@,~P!02P^%>@10.6AKI@416@/404D^X;^HW
M,W&K&UL^25173HPS^HVR:0&(D35N86!P)TDX@_MK0A18_3^MSDVEY\$>K^O^2WVLYT^TZZ32^O^>+>H^WQ^>5YV2C!>@!\$>G=12C,*M^J+!>+>Q5H!>YEQ5\$>W^4FG;R(9Z%9I^>
>^M]MD2C#,>HNO&L&C^>+>SS\$W^>SU^ME55SGK^M^P93^!>V=HREVHR^7K">+>Q2M^P^>G^F856^>5EDP@>P^>_55D^>M^P^R^?>+>ZIS>UN<76CQ>8J+>X^VR,~MW^E\$&K^2K3%>A9<
E_YWNH^R>9431BQ-M^J=>M6DS0VA_553IMQ?^T^FJ\$M(X^>=BTL#>1@>GKTPPF(5D^MEQUF+>+>XP8P_P,S%>S,2%>+>3F6?>^!H78JXVY>?>P4<8+>9,2H19Q0!>+>MYQ,X^?>QZL+22
N>HWA^T^#=>BDS1N^K)>@#>#3Z,0^>0MSS&K^B,~!W!+>M0]H^>H\$>+>I^A!\$>S!>+>U^U92J6X2BP,6-0K\$>M(OWSJ743?PS@8=>XK0H13&R4\$>M)!>0
M5HNNK4)2%>6Q0\$>+>Y86\$0<0NP^XOE!>=X^BZ\$^U!+>P04~!\$M@DQ:G8WU,B^<H^&0^&AL+W=O^GGL^VTFB95FD^!>1^H^F9@FMOK&K!>L0@>+>Y+>PRWC=>
<D,0A#>#&8;Z4T8EIBJ4^!18M%>@%53L,~MAUBJ*5>+>X^N^0004H9C63T\$O!<J^C^Y=>G=(8ME0^A<V!>Z0,\$5IV3^A&*>+>J0^M^"W4_8@CE/L34_NX^>?>05SD^!ST.<?>2\$P!>
>@B^H^N8J!>G@>SUH1+78H&I^M^X^F5\$GK^M^M044N5Z>E>3!>+>T^M^H&Q@Y^>+>Y^>=>O^WJ&L^>.,67J!>3-3K\$>@>WIT!>=DC0V!>0&@&#>?3HMG
M2^T2H^>R&DASMT^YV^!HOIP^>SKL^>="S!\$%4%9RR1L,6_679N+!E!06T^PA_M2ZDGLY>]ONF(L&E,GF2G-LD=]H\$R9L^>M!#>#H9E4!M6N!M6<~D97DZ,9R-M=>
~!PM7Y6B(K^>U>Y>CUXB^>M9N^!>LQ!>+!>E^>G80DD84^COHF^VUO>+>MNLN1^064F802LXW^>KA2C&L(2G^>JFJ3M^L^N-M6^169H3!>17PTHV^M&A^JMS)>^>3!S&
>P>P^>94Y!<T^MOQ^6Y^G49=>N8R,R=>9Q27J!>20KP2EZF9%K@<0^Q1PP7U4JA^>257.M0=>C03J1^!SVU!>L^>H^>Q,035<0JX#>E\$3X)XG>L<^<+>PQ=VIR,W
H965TG^3JBU^P0Y)%(S8.5,P#7DN292,K54C%9SI,~NGU?L^XQV166^M^5RS_!D9>=WSBVA4PA27N;OGRY10Z\$S,)BP2YHN6M;UCH,04DA4U6^E0\$>K!M6L^AS6>+>I8^X-4^O!O!^X<~
%#4@<1^H)BXA!CB,0~LR7BVQI0Z8\$>MID\$K^83J^QJ+K&P!>GLGHY09L^X8#6!PON@<C=6K2LL<=N^BX4M^Y!LB^5^>M,2%?>#S^FAZ&W2L,~H^"DL^X4@PTE3-1
>9,92UE!E8H!XZ>+>H^M<~>06&AXR5-M44+94(K0K=Ed!>+>C<108X^JH0Q^>XJH8!>ENL^T@>MK4(P^YDQ^>SYL^YIC\$>S^UHQ^K^!<B6PCMD\$3V^>
CIN@D6^5^0V1\$>0V1\$>5LRD^>B,~P,M5001021+!B<+>LYY^H07Z^>JL^>7%>7K1U^>N^>X77^16&S^PHC<+>N(O!>+>GD^MY,44H6)63LN8H140!<G!>+>UN\$>K=1
>+>F!9H\$>X^>0NU9>X^>0U^>M55+MM218^>9,B0EJHJHVJK0\$8^>ZK4Z,WU^6ID5^>HYZFZC^>S^Y315,M^Y3WG&G^Y2322,FUH185!>C,65\$>K&W4_100N9KH
YK^>OT^4\$!>L#1!0M^<52^3%>K>W+>+>Q!>...>9>+>PQ=VIR,W-H965T^>LENO-MBZ,IKGI^2ITLICAJY+5K+KE^>O5U6!^AKO^WUINKFMS^7&YN^VNUW^50S^Y7
M!>D^>GN<+>IM^I=GS^MLLR\$7_5\$>+>16I5U^>^PP25U=>Z,C4+>S7ZUS=>@>G^M9!0BVM^>SINO^M^YH=>OHY+>G^T\$OW^>F59>+5Y>+>2PHM^Y^TN^M054U?>
VEW>+>XJIBU2^Y(NFU\$&G^<X^!Y7&4467^>K8!>0H!>U?>+>T>+>V^>L^7^<I^X?M^>+>1QD148KMMJ7^>8F^JES?>UGL?>=>@&B^Q?>05X!5D2P^9W^B19;0
M>EFTQ>G\$N0H@>U^VTF+>H!>H^>Q>+>6Z+>+>B05E!>XL+LIEV9H^M\$WW@Q69,~NH~>W5^>JW5^>QO7+>K,A^C&FTT2^>V=5VNKZ^BDYH8Y^ZG8EYLG^M0077!>
I4H!H^>B^>XUW\$Q+>+>H^M81C3^V700!>+>E?>2BK<^>A+>A+>O^>AGS3Y?<G5H)T^>DM5^G1^>C^>W15>=<I^F^>MWHL^>XU?>+>7YM^DHH190LS7M^>#686VQX<^>110>^W^C!^>A?>
\$XK^>97.5)M6<=>OY^%Q!>+>IKJ!0!A\$Q,2V+>H_Q,2XXYMS^<R\$^>YZN9!>=>W^>O!46S,(QEF^HCA!>.,R831~!H#>Y\$>=5W40-KU>JRL+>+>AJ
MR+>+>A!H^FEX,K^>B^>M^>5^>L^>F^>HD^>30A^>BAAK)>4DY^>+>7M^H^V\$R!H^>MG!37^M^F\$6DZ>@>QD^>BXXI5<^>90LH(OH(G)>=<+>56;4A(02Y>+>2PQR+>9QF!HDCQ^M^>H!N;W;6!
348FVH9HJLGYHYGYB<V6!>@H2-B^>M\$)52+>8Q3+YOB,L^!<G>+>6L!<G>+>XLDQ3&Z8I^Q^AD@>+>FLL+!WMH^X!M^E!>F4MK60^EQK^L#F=>+>2HJH3^>24HK3?
66K^DIF=10BK<^>5.GM,~TF^B1W\$S(!^>MID@<Y10:3B)Q<@>E,215<I(30,BM^>=M,LG,~>+>8+>2BE^>JJYDW(M^>S^>E^>F^>E^>H!>+>D^Y^G!A,~W!<H^<+>MYG!<@>^Y^5G=1A&0
1GK^>2,X^>X^&3(BB9^>KA^>MFHO_Q^>MJD@R3,V!>Q0RG+>2R\$R\$>+>10QCS^>90%>^QBFCQFB(81^M!)U9RBBR\$B^G^HOTG0P3^HG<+>K^>^D1M<+>@>WDDDU\$>4=8^>5R)>^P9^>
M(EW,)!>U@F&8,8D6L^XMF,R32W=256\$>@K!E^B43&C&@>AZN08RE!<~9&X^M0E!<+>4~!>+>DS1+>=<10@QB^23H0!>08^>8&1Q^>96Q\$>^ZA,5WCQ=BA\$!<H^>D^MR@8^S^T_>+>@>
>60!>OVT\$>O3HQB4E^A!>X3^>(\$WB>S^>R0TOG^Y6ZO(H^PM&ZB-M^V!>+>I^>F^>7&F43TWT^<+>S^!>VLA^!>UOSNRIM79_JW\$Z268\$15^>5V7F>M6=>+>P^>P^QO!569G^CA,4H!>
>16LDX0R158^>B^>0^>F^>+>F^>C^>F^>Z^>S^>R0TMO^>P^>MOD006-213A,8Y+>B^>X4QB^>ZHP6BC^M9^>X^>=>E^>JZ5YRP3^>R!>18^>1%>#>1D80^>M0\$>56!>1G0!>^V\$K^>G57Q
M(4^>5N^>8^>F^>H^>N^>F^>M^>H^>K^>X^>H^>K^>H^>K^>367!>#1^>EA59^>C&8^>B43,6^>9H!>M^>L^>G^>O^>59L^>K0S^>9B^>5T^>Z,05T^>SN^>O25077Q^>+>#H^K^>0^>13@>ISY,V^>MKO,D^>5^>H^>A^>73!>C2-
5,2!>518H^>2^>HJ^>(MT!>^DH^>K^>B^>DIF^>B^>M7,~D^>F^>1CWN^>8,~>@Y^>I^>T^>3^>O^>V^>=>I^>D&G^>K^>I^>K^>L^>D^>D^>H^>G^>YB^>D^>C50J2^>H6G^>4Y252^>MA^>E^>D^>@!>A!>1^>=>REBA^>=>2!>+>MZ
M16%0!>+>LQKH8D0,5W62=QA,X,YXWRF\$IS^<W^3)@>+>G^>G^>83^>F03J&@>+>84E^>ML+>G^>IR+>3A&3P,^F563^>O^>X!>+>=6-9Z\$>21BR!<+>C(Q2<+>H7R)!>+>J4^>U^>M^>M^>V^>I^>G^>+>H^>B^>Z^>E
<+>7SVYGHB7^>FEL^>NIR3^>L^>A!>3H^>K!>=>V5Z,A^>@>1M^>M^>L^>M^>+>L^>M^>250W&V2M^>X^>K&2>+>F?>7JHJSL^>FLUJ^>2C4H5!>HJPT^>Z^>H^>MUUC^>F8G,^>FJ^>+>K^>J^>BX9^>71C^>G^>
>+>@>+>QH!>+>760E&+>5T^>H^>W^>HJ^>5=M^>M^>K^>U^>E^>TXOABON^>9!>LD,~>C=>+>Y45PE^>P2!>@>+>P^>+>M!>+>B!>+>I^>L^>MG^>ESUC^>252X153^>VKKR^>G!>T^>K\$>MY^>F^>DNEO4UIOR
>H]U,DFP^>C^>A4>+>M!>M^>C^>1U7HJZ0L^>FLWKR^>J95KUL^>W&Y^>F68@>OZV^>TVJ2>=2_8294936?>M^>+>OBBF!<@>(MOXA8F+UK@>G\$W0>5A!H^>FYG^>UVQ>+>12,95T^>KUM^>W^>M^>
F168@>B^>SP^>C^>YU^>C^>I^>MD^>B^>+>UYS^>0^>9C^>@>A?>9^>F^>M^>L^>K^>X^>F5!>R!>6MZSO^>MAF&3LQO,RE^>J!>P@>I229Q3^>@>ONK@>A0ULH^>OP^>M^>+>16!>AS^>W^>Q^>A0^>Y5!>UL^>W^>F^>X>84^>@>
SP,~>M^>8FDR^>4K&^>5^>E^>ZCBG^>B^>M0YLG,T^>+>MFEDL^>SN^>EWC^>WRL^>~M^>6=>JDX#>+>J^>?Y2O2S^>RC2-5R^>ZS^>M&Z&Y^>UL^>P!>B^>X&MD^>52^>GYO^>
>Y^>YU^>U9>VPO,DN>8A7MOG^>CMYD1-MC(I^>80G^>SEBN^>9!>0^>#1+>F9@>6YV6I^>G^>4A2KQY^>Z^>7^>@>SV>=>7<+>1^>MRE&1^>8@7^>1H9P^>R^>O^>HKIUN^>N\$>73P>L8BUB^>NXOHD<~
~>8>=STGE^>M

HEIKJ04D25XMDXZGGS0:U-M2W/OHJ>AG5U?PL<1?>@P.#PPW+PFH84?7FBM..XKOCWMXK^L^UFQOY5U-H
MUJ?42JPU<=>QK72<0566C6&JHJR1H?>4+>E7(UN9<+U+UJ51<?M>+JG241PNVY(E^XHS7A\$HJ>>69IEA-?)(3R/FB62>|LXR|O|23HK|47^1)
MIG^A^KE.XYAEFLY9Q\$0:K01910+1376D1JW8?I04:D58UBJF^<E3UBH^M7+UMMU127#>TJVRLEJBD>YI=K/=5@1FD?66\$>PJPEVTHYNYC(BOE5E^F^MFZAX##YO)9>X^1
11(X9S#L515+Q 5:-8JJK0?ZX Y^>N^C^<AF?M^LVD M&O<8VRN&N10?W^O/XJ>=5&WTF392?0>3P&3B23K0X+V1U?P@(<1=3D&V42M48W)BY9H
1916(N^O^R1>#1=W^B^3DAX451R8<1^<N|JZ^E5^>ZD0?>1MY6G<KDJ81V0^A?>1^<@&F7T2L1?9?G23QX^>P^M3>+98BV762718R^F@JESL
=65D62@<=NW/32+50UBJ6@F^E^XBC=<1=JM^M9=>1=L4=#N^YU?2?>3<1QHFDR=55E&F9N^G^RLDWE11D>JF&CK4.0&45 M5^6^1.8Z4J^
S^K<^BL@JH&1=14WTM6I616<13^62S@>1?Q2M64:D6M^<M^M<6N1L5U6+7#7UENH28WR8&916?>S^>#7@EUGJH.05)3G2FAQA^XLM^M92%4-8JEIFOI>L1|FXRT6-410Y
RYN&MG:QV^76Q@+SY+>P>YUYNH1 M#H:Q5)3-2EIRH(KC9)2=4-8JEIFOI>DU^YHYRA^N1F^W^Q^F8?CUVZ?P^M^KMIOCM
#2FOR&A<=>1JRONJG2<3.078EIKJ64L1L^U8USX^>KJ42PU MU^<1>S1Z=>2H3<1@B#0?>X1?1?QC4Q0(XC)E17#75MY99JQISF4Y828MR1>L
MYT26KA<=>2JFIMW&M@<OR@>UJMY|JRCFP>12IG<6?>P MU>VIR>W H965T1R=A^Q2:MKGI MXR14P+1L>DQ11MB>JZVE#<4>VM+10QIR(HZ>4K2+1W&4?2HC#FHV9
M5^W_3X356<A1^>D3FARRIDH1@(<C^F15?>F^WY^W^R^D63XP^>E4=5 M05H240< RSH.0H^>36&451-WN5?>L7C^>COR1+Q0S&ZG6H2V3.3G0^M/32FDR
+06WR1L^M&K<3?>DY.7^Z^DHL-70^B2B2SH^MCHJX+<W^K^>4UEPBH8N.RN=>1&(8^B2)DHSAM+MRBX^H+50XKRP|T0I^M^Y6RGAB^>JN34>KAIN7^X8T1_0&WQ&^<
MTAU1^<P^CU^T?7^K M^O^>FES@.DWT?20%GX(PH^>B&CO+JHSBXID^>3BOR571W0TBIG7C^>T0I7^M05>^1OS^DZ6-R7U-1V5_9_@O\$H4GIXMNMZWJH< M#B
904BYVB#D2+>F6?T_LBEA^>Y1QM+1(685T1G^>Z^>Q5?3XQ?>C?>J#N^M^<C1^>B65K^H13?HJG:IMQO 0F-9>15^>KPN>9#1(1%|<QK05=>90C.Q2 MC6V6.VKL>17C>X:JY4#
1FIJX21^>S3?Wd6+5C8&S^22^4^>XG9J#F1Z2 MM0H0H165: MZY.O=>8VHL1^DWGJ^>1^YFK<N4P|H>D<=>D&WW^<K-6B^>6HIOKXW
MFF^ZIN>TS&PEZNMQIS0>T0J88^>UGKLUV>2>3FS-D2H0(MM-BE^>3KJLLA MCN^C1090?1=8^FAB8K^3V0I(C^>S&R1F^7N1B<^>G7B(FEU4%>71-80@?Q M^M1%>5HM4:CKKZ9
UEH^K^>MF>#>T:U&QJH-B^>ME:UE^WH14-HU4W-10 M4ZHYE1R5^>KJL>T4Q+1(9F323XBF190S(UV7_MJL EFLVHJH=>6&1TIZYD+3.R7
^56^>SJH0^1R7&^>SJH^16H(ZO^>9ZH^U M=>^D2BK0^&6+0%>SOV9^?>ZFUVL13G^>UNF@?>@?>7^>F8=9.Q@TV9J2-GAI7M MO 19.IQ^>N1<4TO^>S^>PFK2AC^>D@>H>ET^>1+W4YD-M
V1^>H=17CJH04:CM25L0H1H1F^>C^>K^>YV^>PB2<@>U1C^>T^>M^>F<@>JTY60Q<24&@>Z1YH8G^>V1#1=Y11=#2 MCH61K66F^
M2Q@>4JZKLK5<?>E1J2F0F1^>P^>C^>D1H78K5NF<4<+>YE M=>(65^>G?>3D?>IK151=N^>Z7G^>C^>A13>+1 MM4T1@G9R>#?>1^>YAY?6TW^>EQOEQUY(4R67W^>9R^>RBU M^>S^>2
6&S^>S216^>K0I=<C-Q+1^>N0^>Y^>E6^>4^>C4E2L M^>WQIBAR6513^>MSJKGNVYH^>GQ^>C^>W0<1^>D^>23KMA^>DF+>1^>L15^>Z 6RZ6L^>@>YNI
M1^>S1^>DRT^KI^>FGZ2ZS^>TWO^>X2<+>V3^>QW1N@>KFKE^>(N1Z65^>WK^>UEF5^>569S^>K^>14^>9JUSYH^>C^>14H^>HF0H7^>C^>14H^>LH0R>2 DP<1^>L2H+1^>310^>@>8K2R)HSS<
1^>5^>TU5^>D^>WY^>MAQOR^>SCW16YOCJ^>O^>NYNKIZI.66G)1<6-FZTB0Y^>(<9YF0&0GB^>?D81O=A M%109.1^>1-DZ%3.22(1^>R-8C6^>H^>#>KD1TW6:AO&<7 19F&1^>+143R^
M5B^>R(5ZM^>#>1191&504TP^>ASLJHN.CNN0)YONM1+Y1UL^>2^>OFQZVZ^>DNLDEH7.45.31^>L61T 29T14^>#Q M4D5?S^>N8<S^>J^KD642QA^>#>01+>ERV1^>
5^>AYX9+16@>62^>D+DIN.Y5^>MIO^>C7JN7^>L M^>IW+3L^>4G54^>LDO^>K&7^>1X8R^>Y7R^>IX9X^>TMUZH72Q00<B^>L^>9QHKI(KB^>M^>19N^>X^>P^>1^>3Z<1^>N3^>F5^>H8=1^>F5.4
^>ZNAH^>ZD7K^>W8P^>H1^>M^>K^>C^>E^>M^>P08X^>5^>EATC.MQ95^>Y^>JOJ^>J20^>5^>M^>N^>C^>B^>N255^>54SDV2<VS M^>S1^>Z^>Y^>XOX3^>R^>M^>A^>U^>JZL^>ZOY62H^>6^>4HYC?
5^>Y5J14^>W^>@>Y%=>M^>J^>6^>R^>IGR^>HU6T0V34^>UATPS.MU^>M^>K^>S^>A^>W150<1K<1^>N^>M^>4^>M^>4^>Y^>H^>H^>S^>H^>V^>Q^>1^>M42Y^>U^>Y59Z^>KZ0^>A^>436GAE11^>E23<1^>N83W?
TLXCMH13P^>FK^>K^>OKO65^>9^>L^>M^>F^>BZPT^>SRKJ^>...ONYZ6.JY4TD...>FEPX8.6M>Y^>L^>VQ0PE24HFR5^>9L^>A7\$8^>B^>?>?K|H|>)<<@BI>+T5:(J#M^>MEO37(T^>S^>N+9^>LH\$=>
^>A68GCHM3^>1^>Y0Y62<=>SAH1M6:13@<02BMBJ^>M^>K^>N^>S^>H^>T^>V1^>4^>E0E^>F^>6EM^>X1^>L^>D^>D^>M^>G^>M^>Q^>H^>M^>50(C^>M^>H^>A^>1^>U^&gt

[illegible]

W1%\$1R-D-M-PF%{6T6}12U&1D&F6GDOP6A1K%5<K<2-#A)GJPFSSG.#8)I-U.MRW858ML17V%Y9-WA-H(W1\$+I-C-I-1M-SNB23>Z5#K0V4EJ(TB=(42M,4
MSL.P3I}MFE1B+H8+V@M1E292F4J)+F+BS<CBL1OK14-K-E=BB<Jf8.R?>.MKG&QWIZM6+<GU/LHJ->TA1-TQ3%HKO&D-WU1SV>X^N1-X5N>BA4IJ6E.M+BW-(72-
6S6Q6OCYCMBA2B#<9^SR&M16D2F24BF4)+4.C800.84.O<M1^C.F7BK567NSD8OEUNMHFB#BVTH.T@t12U&1&D-MJ6P9D00.IB1P3-8DVDFHD/TB16SVOU?2
Z>>..%1HEFDFFI+9.M0CS<0^3YV%<M%CUK=<(52DM1FDH155BF8V+V(2>=094)=#10F44^MTB144RA4SL&L%>B-RG.Y/MLN#L=M-LIAHX7.WFUU<G6U/<KF:TA=TF
ML%>BKR&R&R%M%>M272TXNNH~0^0E12A-HC2TC194-Q9LR.F.WFK%>V-MISHS%UM%1=F^92F9HM06-Q4GL&NSYQ<P.P.MGO(C/LN>XH198-AN(M-72.65IG6)/IA7R-3
?O-.WDW/LZ>X^I.4H3:(TA=<T1F5DI+RF&WE.M%\$.TH3^?UM%1=F^92F9HM06>.PO.IR2&X^I(B57V=>L>&X&U/7-Y5R-GOMV%IVY.W29QO.JQCQVFGLG/K292GHS^ICF
MI%>Q.3B-D.3C4I4T@>12E9F15DJF+9SC2N00S2%DIO=F>F9F<JNT.MTHWCQE&I#POWAH+L+WHHS2%TC1LX5B.OIOKPY.T-Z/6-BYYZ06D-L4H.M3:(TA=CFI:
E.YRF.W.%61SH3^UM%.1=F^92F9HEP<18\$.E+P+S8EV-V8MFA0IF8PB.L1+I2775WA/H^I.1=F^90F9JHME7.49#L.OI62U-OI9V7>=6L.MWN&KN1=E+FOZRPE6%Y&UGIM5:
Z>>S&E606KH2>433^8U3%NGQI51.MV19-6I.H12(2ITE4)<GE:OFF.HMD2-9%IM(G3UR.YAL/GCN^P.P.RAK.V+RIOGUPU>=1N1MG.F272MOJB+NHL7X7-LIU5U.O.VSHJO<#6A?>
ET4L.#03J174V0N.MWO+7/2D1.GRRERDR&32WSH.UZX%CG>+PI(U-MWO2EP^YA..I=>M(XC13AZ6ZS)>O).I6.7VYI=N."P.AT/I-B4ISEC<O7GB.MWK<HJU/CMS\$K^MM<
<7=-.6ZT4^U^<NT=QBPM^CO.T&F1Y2G&/6INH.7.M.PX7V>JV=I4C4<1<20.S515H10<Q^NT^>I=D>=C.MDOBDSN%>%VNP.M./IS^IK14BD.73FR1<4(FQ2.X5JUD.M^<S/
FCHCX>LR3.^C9.95/GWTB=QH<I(3H72WXIXW/Q^<OOU%&+M2GU:AIN<2.42.B2^>2FOSD2PCU<G<6^2SWRTH.OAED<OH5I&L>#>J.M.MIW&=RW85NC>=MWVV3/
PPNPWKINTQAWMJWB>N78X<C.WXYXVOLO.D.E^M^M90MM6&5SGSO4VWP55=IO/+LOQEU1O^L^-MV6/K7FTIBL01.8C.9K&S^+I+C2SP<P.OG^MDH8FIB-
^GDUUW0317J1R/JR/MVL2EY=W.(GZFD.6414V8R.1H#H82.S.8Y.2R1476>#>+>7596G1.K.MVD).EJ206(RYZAR)^20F09B6GZ-#7HZ>3E+PL52D7=Q8^OY.ZGZ=>SNPWY
MG.LDIB>=T.XPS4/F=5%1C4(U#0.5)M%SK3RZ-NSIO&EN<+1.T.PSS05HFYSV.3J=1.T.805&-0C4.UPT7-JE.IA1HRN
MYVKY^WW>XZG=S-IJBRX<?>.OG&L^N.O=JS85I/E2CA4(U#015523^8YO.MEKUL4AI)T30%CM4Z&..14H5&-0C4.U=4D2M/+H<X5VA.V6XLD77CA<H.NMBFIHTFFFPB7=1XI?
->MIFGM=>CT^12I/8%>#7/(9IE24CA(U#015523^8U/LHDAIPJGI7^M%\$>LDE1-KEA6H^S^0C4SU#M455).H32<NLO&K-MDHX.7IL.MISN^AMEF25?
*A&H1J#>ARI^>F49J1>773UI<=>INM>U0S8-J/E2CA4(U#015523^8M^*TOCJH/D8IR.M.\$>QY5V/LGIT&4.4ZM&.U2A48U^0SA4U21TU.I.MH(PYI.)4OV^%9IH3%WL(ZCI:
I<1>YG8V+T).9JIGE058=I+M^%HOI.AFHJ15I72V5WAFWS^S=HLV.TWKJRIS=<=MPJ.H9I/E2CA4(VYYPN#SX=<15233^U/LIWI9HIU/P6QG-P8TA.<M
MH9HU7RUHJ1<YVHHUJ16KL5LEQRZ&GO-NQM^MFJ7K<9>MOJOZNM^I=>2.MRTL^MHC1(Z7ZLI1+U^C^U/LR.XUU<BT.MFPWV>FCF054UIAXX^IY=PKLYGF7<
LI49I>4WVS5WTLZN90EA<WGWOD1M18JL<SO^>9N3IGBL>N(N55.A&H5J^*IQJ^>FDHJ:KW4.6I7>X^I%IK8MAFH>5.A&H5J^*IQJ^>FDHJ:GG46GW72SIUJZF>
IUP.TDUUH<2^*K<=ME8.2ZS<V7H15LBH-?E9G<=U=O^Q.KYNG.0/O4.YI.A2I.6GW&2.M=UJ.I>BOYLGI5T^>U<PINH9>5G76C(IER55H2>IOZNF77GCQI/72LM
MW=>(LE.VH)V1R3+<SK6CWGD70-2I(LK.5YV7)F+FPH^Q5D6/V^*O4L.M5%(LD/^<IW+HGQ0^<WY.P=02P.\$%<10.6EYTS^>@:<0<M.HH
IX^IYW/KD2UIQ7Q.O&P/BN<BSZGZ.0N(P/=IX6GMAB>R&B-=7=53.M^KIX45MXZ2LIRS9E(O11..20IHYG>6+PPV>F=,HS^5.L9P^IZM^<ZHL2S/HM9P
YS.2.CQOS.H4S.M<2%OVN3I23F5^I).99E9F&IS(IG.M.#<DIQI<FU^ILOE572WV2SW>LY)VTDPE6YR)JHG?>W^<N#<0^<1
MH1I=<4J734TBHNJ(UUCMVBY3JIUBJP.M<+0^>U1I=WHH35BM&4LIV+FBG295I.IJFRJK>VOLAUUTVT-HU.MK7V%<C^I6EX05L.ZM2<SBEOFM6GY4VO.UO:
I434M6<6EFFCA.Z5K4=4ZI>M&VBIH7H22NI=<%1VG<4=1=1902I>G55.YHYK<N52&8^%2&LA^&M8^<CZL28EH7U1X170^0V>=,WMJM+VVS.IZT-INHM.DTE#?
V&&<O.M6PH^LHIP.2W6F<IAZH&KIA^8<6DN<IRPHX3X).M@M/I^\$N1I)-WA2X2\$2R&S&IP8I/M=<=&BD/GRUG>EIZ.66.M\$7^(M86<YFI+8^<#<(AD>WPI0KIOI
?C^AT7>+8AZH&C<GJAST^S.M6=U1=BJPZ^I74I7BRXRGI+L1JCT4.Y0621L4I^<OL5?>HZO<P&S.D@M10^>=>I8J3FTEDS^<DUMT&PC6VHW/ZV.P\$M/T%>=>JF<".R%
I#F7EJAYI>1IND^H'W5E=<EM^66=KI7IBRG6JHRJQN.M10.FG.975H=<KEI+TYMS2MN&P&SZIN.M0ZZFH.I9QIO3IN>S=<E.N5.PW86.M/4.6E17A.GR.
V%N/(C1+2.60+WGLA0H+&WM%>EQ9>W9I2YUM<+JOIHL(SMIG65H14QD6>9KI^I7L4EBD6.Q+7+GBU0C.Q.E&P=QI2V.WH65T.MUVT^>OI.992>JH4<+>FDJ>I.Y%>5>I
MG4IWP214L)K867L^RVG<+>=PIDO.VKV).RS.CDBP/BI/QCYVR/OOQ2U.MFORYP^>G%>LZ^6I2K^BW^E%7QI2VEY66WG-ID6LRYOYK^<L=I2.M.M%<H19RD02>3^FN2
L/3^7G2.H^YZ14+I9Q.GBAYMG#6<K/Y7W42S^T47P.L^M^N<GRWF&K17^MOR^050U.I.MJA.EJLN^5S2DI^PWJIZFIN)KHBX<O^M5I7DGEG_BC07N::NAVY.ZS<
MXCR=YZD5=B0=5Y<R6Y27.GPSESY%Y/(+C>I7PCYD5HOBOWY7^MANUKH^M.8.83=<8K.M-THS7ZO>N>?WFCP^>NPD^<Q1).0&S<BHE\$&=<C\$7^ITV.IWA
MMER=<#&I.FDZ.OQFCNNAN615..<#P#>P.EHN887B5DOQ81VC^B4D09B7W>^<8IP.H.S29.O.M=#PGUZOE.LLU>3^>E5JHM7OXNRZLS:B45CI(QAL0XS&A<3(CP^>GER2
M&3Q<0<+>D1A^&O(E^<2OFD)>#85.HS1W>D>HGB.G^40XAK4UR6US4R)^%&SLU.M2GX3-27SIC(QAL0XA&A<3(CP^>K^<PI0H.M.V780ZCLY>+22^U.BQ&GU?
6I#<4BJS.A&HJ^>HJ9J9I1FWFK3K0A.M^MKS^1P49I552CA4(U#015523^8T.MJD^6=UTIU<SMU<3598IHRLOXA99.M4(U#015523^8V.D7/<7<C^I@00%I9?
F^2M64762Y=0+8)I%>HQI.A.MFHJ15I79I3.EH1<9EDP.ONAG<35%1C4(U#015523^8SISUYU.OI.9XJIZEF.6.MI<5&T/LK^F@>24HU^>034.U014DR<
SK^T^CUW51A

2#T81+TC1.15:KUY7MY#726*E71.M2+52BXTW1#ADGBF451.9=K3S.N9N@Q@NYIY"HTITRO.R.M"*=ZST?MK_X)+435_VWUJ(J7Z
MG*E74Z9.0YF3.WXJ74KU1M1+>2Z?F6.KJ#E616:(QZ3P4*VRELYEB8 MG7D&U00N IO<D.P)QV#>GIR(3@4T9+HS>+>#>FWG19R&BD<X/K/9).
M1335047N1&BD<X/KJ4330NGOP1A.MF>1+31FKN7.#4#>1PG RN#>IN65+SRXN=85EXA+15N12M@RG7X>1+.M1==S*P&L-C-07ISCU>21TRIN4.DX2.SEZ6=N/2
126L1JMNFF6MNR19.C01+S.G.LV0#P1/181<1.0R4HK.S4.X6:.9619F3X#>.Q6G8IA9H1ME9K&E#&A'<C'ON69W.ZS+>S.6@O.NT.S+>V4239/5.E>42/U5H1H=A<P27A
M320UT(C)NRRXNM1.P0PFPV.5N6(T)U>UC+FE MEV<99ZMPV>.>..V1V25+17E=H17.VL=WNK*SR M<7+7#TVYDS<161ETJ3.P=UR3B=>6WBI<1GGH+VW8UG1FVCVY?>
148L#>M110<S2?3%HS10L00...>+>KPO=VJR.W+H965TA1F<R-XR56FEVZ MKHR6<RQ'HHH1HNSB(DTQYJ5&1N14GLHJ7<1/4F78M.O0#@URIF M*#T72Z3A(B?>
553FEK.C.ZIDN0PQ.ZE1HD5MOXBRAJ601.M18N1H1O1LQPL&C1..>E1K5FEY1+>..C<S<QSI7&E?>C<C>+>7<X-M25+JQSJ#>..876IE75+EXOYT#>
>LWCOH<+>0=STP%SNB#K6S WXYD<+>ZAM M>L&TPV+OFGYH.BM50IR<72A*69K-D1UZ(DL1O1H1\$N2 X5-#1S16R.IZB1IMG=>+>@725%IX*E\$5N1N\$%40S*YCIZ1
M8.0Q1NB."RK11Y JPF+Y660UW.P.B.PBN.T@6+7.FENH3N<G33#>53JH7P1BZ M<#89G2&6HE16Q_K<D?U72<692W2C?M7V4*0/L?>0.8?>U1J@P=WA.MKNS2CQ5H0<
VO/RH#>V.MH9#>DXIMS2(R1W5.5NWB#>Y7G.24.7Q0C5&=5.PBPG16J7J21.228:YK?VW=YTXT41A60L(P M*53&S.OPIE71#>W5802QD15+>#S7.CE2#>WYKWN2HFPM1.<6UA<+>
M50K+>@K.K@G6P0.ML1.2AH#>6*ZAA3?>111K1A8HK.RS.UVP+121*87M070U<=1KH1F2 MKR5Y1JKEO1Q'>EAX2D#>..10X=>X=<=>1+182#D+>..1LXHW0=>M1
M15W051+>U016G13RG7213R3D?>612JAGWVWAE.M1S1Z7<+>D+00E(A.M.66WMLN1YVYF7250EA4%#H+1212MZM.VY29K1+>K MUD29.W1>20UK?>
>91%L=7CWUZ+>#M<@-Q%J1S<#1IHD#>K01Z6#H#0.M1.LZM&W\$=>1>LV.FVX06DA*WGM+>+>N06_K<83YOW1+>OQ%>8KK0 M*N<1J74V1>C*#XRGX2>>1#>
<1N+BF94VJ?>..<775=>4/C168KO=>1%>M P041?>1\$@D0.THDK0321"MO0S<+>@>+>AL+W=O&LUO=UM<H8FH7HKZ+R15YU5V5M>#>P.XFK.M.3D71F.O.U.VUM
M10L09M10JXADLE42.>1%L<=>#>XZJ60H1H1F06<KIRPK.MC07N1Y105<XNGLGQ>+>W6UFQCEBW1U13IGR<H0WZ2Q.OJO<+>O.Q5<9.ETN1B.M2P41F.K1317MR<VJ
17U1AE1Z+>6R92.RT.U7J2(MO.D1Y.O71A7G0G.MV>3.N.GCZO=>=<H8W6T+112B JGJU=U.EMDR141701O1P<+>X75K1S.FP6V.MK.AUEGU1=1TV-B-E.M3K56W<RX2.M#J
17U0R&L15W7RT.YUS*73S.M2.Y7+710<U&N5N&PBL5V671>NGL#BMMSIF.Z57A*1L'>UCFB06L<=>K01.M1Y10=>KV.2=>1+13&M8+>1LXN.01.<+>3?X5H4+>HYL<+>X7F#>
<=>8K M>HKK@O7L? M.OS)>..<6N-ZG<S>..Z=HROW1QO+>..(OIK2XS<Z.D6Z25C1S<WXR.M?C'N.O'TZ<K=>#V..S=LS-IP<X>#>G1@PUL70>?>3WL91U795QIA9<S819/
MC>FLL.X.OA47-7N1<+>7UY15<162ZP1H1H1QXESX&B1BK1C>..S7&W&UON.M271.Q021+1+185T1H1C@>0UHM.Y<23MK6N?>..FZ6IE7.>79E2C?>Z<E>M.X&R6Z5<S>?>
MAAPV9ALLR7Y=06<3N1416J6UBH0F07MW.DSD..5MS&KQ.ME01S0+>..1QD.03B44D180F(C2P13.DYV.E'GW.11#>ADCV7F&S>FZ21J.MV<Z7L6=>1R7CH1W051NAW1
8B2Z>23FH1+>M101+WZ3M2UGLWU.MW=67.5XGR8D1D<LZKO.QK10L7(C2PH1S<EX.Y=5W2QML.H19719V0LVYKE2358<?>..V1A.T&HFF.571+S2.S38>JIS<A1
MLY1E0A(G1)=71QV4.20+>NV.>H1L<?2PRX<6P.YO=N..M22PA.0E42M?>O=>3<+>NPK1L.OU=>J.M@13FG7H1V.L<S0<S>O@.11A.D.M.M1T<?>
FS70L&=>GU@T061\$GH=2E..>+>17WME04Q1UH23W8MR=1S44U.M#1515 M0+40U66HK1UW707@NFU1L6181=>1>6321L1C1<S5R2\$F1K4H1(I.MIK81?TWGL<FZ12B.7L6>?>
441+1P1L.C6H1H15(M0+4+>U1-4D1.D1.S4.M.YY@ABU1CQ@21S#>M9Z05.IMV.C6H1H1@19E.<#XWEW<N1J1.OU5J&CV4H1H6HE.M0K481U14
MDY2F=6J3131+UGN1J1.SY<3XV1+53L6GZUMC6H1U1#>0.5%0+14=U-84J M5.K#>D1.FJ0T1M7>..6H1H1O1.P+U5V1H1M#>114.U1443Z6H51L>@FJ2H3.MQX\$FV&7JDUWWZ35#>
K33#>PQEBN1YU<S8G01+>T&H>0#SCM.L1&OUFEN&A M161510 M0+40U66H1H1H1E1#11U<#>28.8<#>G8P1#P71TG6>#>Z9E+17.HW.M3DLENZ.8Z.HF
89J1H1H1.BFD.U1..5B55M035#>VO1<..W4H1S.FGZ2+1+>S.M.#8Y2WPL<0DFW1L1.NQ7MLB17J2W6J1F1P.1M1:TONU8.1E7ZWLH9J1M.<@JA<F4'U'>M1C5\$E23F*8.
4TRSM1X<ZS8E9M320&QVTLA<.(W1X.<UQ.M1&S<BZ1>..CFHU.F.B&1'52+14.U6M035?>6L.ZHT030K01X'M<4HY1A.MEH1J1#>90+14U<425).4HX#3>+>TB2?>X<.
<F1JPD018A71F>G9&H.MJGX<S>4U1H1C@>6H51L>@FJ2413X.F.F=18T6W'XMADE73E701Q(MMNZ>+>M1V21S21Q1W161CMU1Z1G>W7.V7L#8XFNU.M1#517%75=PC)9<
4&U2FMH36S1D7.#>D>A.H=>ZMR<11MN.CFU91F.>@>1B@6H1F4B5(M1+14\$U26E1=S71L1.85HRJ5.WH0QX9Z.M141MCU1H1T.TE.U1443Z6H51L>@D16#5.M1#61A&JQ.B6H1JD
+7=>E.R<1>2.MGGC639NGR<5Z770T=>P1#FJH1Y1<7VN.ZV3.381A1XV1X1T1(A1@E4BYK..M.<8K1H1@FJ27M1A1)UECY1L=U6H19.21FS.07W.T4X<+1+1JY1.7FFGM1
81MY1<2M5+>#>Z(GH5)M<ULGPW1PDT1H1JDE14.NZ1L'FBE1G&ZZ>V1J2 M<3Y3.21Y15U5041SC<#>#>M'1A10+14U<H1S1G&J>..@F4UM<2819<0#>M1)FRS'K7E.6 M.
ZK17WN1B>Z1@RT1O.F.Y1.KIRN1W1P1..0100#>S=ZAFHM1J.KY1J1L1@6H1M4B5(M1+14\$U26G1..S1&QTACX.3>AFHM1J.KY1J1L1@6H1M
M4B5(M1+14\$U26G1+1W5=0S..2067U1M=1C1OAS1?J2V3+>8>=>ZJ'P

R--6MDHE211-Q00K3-3FGV15WPWZ-1(A1Y1DN-NB4-B12\$-5\$Y1K18-MOV40A3TN7-2&GN>9P-3#3N9-S\FX9XY+>AVMK5WVS(QK\$UI=>,%*HJ-24=C'-M-
 <20=2PM,*B>IXU3G+0BB-/L2-%>3\$AW:3-4G>+Y-ME@9-43-0-3YABY3,N)H3823/R9RH-7*0TZ0PKH319T1PWIG=>XFRTGC
 M1M#3-1MN@>0PYL3N1FL1BJW-ABAL9-1H116-01C<-1/RG9>=>Q<-SDVLI0-MKVY@>E,M,K:60-VY)A#YKJ01FAJR,S5X1HMQLB=Y00R0NDE-HF/>OAUf3,
 USD9>->RYZOJH3-MDX05=66YK99,*MBHW>G&S<0UB1B7278>17-FHJL>18>4K>Q>22C,KO-M90>=>AP0-0YAWFO>17VTE7C@XW1H1LB:6D-O,QIC3-53=FE/SZ0
 M26:87>1+KVV3+O<=>K'ACI14HXCF@>IY>HVSFG0>=>7MT>FHO7YGIK;>1<@>6L52%K%:DGD-M15N<D3R74>OV121JPZW1-L2E0V^9DR>GY30MHW0?_51+P04
 M-1\$@DQ:TV5F&D->#C6@&@>AL-1W=O&UQ05=<1N%>7TK-1V2514-O5-911/0TSAPWFI&S14,G#1H1VYR52">11-MV4FG/IX@>01B<
 %26GJ9QMD/KCDN00N%N%>=>1K-ZKH-LB:ZNE97H1N2<-M-1Y>7U54-MLE=>G54-6Z+7-M:IK3E7>7-HULR+P-5U>05>P^0<0%SL1=>
 PLEIE56U?FQ13Y2V<-P-0Z4-1MT>=>D6=1-(IG)5R4Y- MM51<+M2>Q-T=9>0'S MD1:9K%S>=UTV1VY3FTR&31Y1*1-EFTT1>=>O%S6W?>CIRTV/HGFZHH-M5IO&<@Y6>+Y<-
 YZ<-1+101?>Y>B:4\$1&LFU-QC@>VP=>JRV15H1&F3-M7KZIRJ-H:M-60N45-FNNV567U1-/S<TPY2H0XG67Z2Z-M2/ST3J+GK7G61R7653>1MP792?
 VT-3>9N7HHBZ0Q80576-9(GW-V-M1U298U-LLS1BT7T-JONEK7<-Q-61/2>=>56P57F=0261G)H0X+3W-D/O@>0Y-M3+1Y>4307R<8PK/>1YHJ>9:2R\$-9-7EQ
 M%WTL-0&A-E?<K&N&1Q>=>#7<+1QC=>=>Z7HD-ZSMR+QC1V2C63&2LYU-ZRD-6-145U66&JWRHJ-G*F-K(A-75-%HE7-MD-WID3GLV-Y<CY<(<4)B5M1-LBQ(+5/
 M>FZOB44-E,X-N45P0C9=>RPV% MS=>513,45@>T00K2R+1HX@&3A,72(NCB%#2<QK7W&4H0L<S713P74>O>9G-M7A=Z5P-D8&6&AAT-QICD-83HJT=>3SRT-6=8&V70;1<
 >MBC1+38NC-B&)<=>(N#<-L%>(YH)BHPWBOM?101M3&G45T9RM7672ZU*\$0-MC'A:BSV7-3JH1-L1-3/BX M54:05#6G<@902BV-E
 Q10B/D18<=>#G01KX5N-Y1+FIVE0E75W60G7FV>6-M09X=>NIG3<-18<=<U<=<1%7>=<@>1H3?>1<-2@XPU<=>UX&B<=>=>QS:LZOY1+>+5RM,
 IZMQT3>W635PQ091@>T15THX@>S(SHHWFGS=>6&@>GJ:90&DN-17&ZT-MPX-N-7VX?>J-(V#>#8Y103Y81%FA86<->3LHYH1U0>1YF1
 M#0H0-F/SU4-9UGL3T1SBL,YL=>=>23CF&KXFG6T11-J-D&9E>2V-F1R-M6@>0JQG-D1YTHF75<=>10-HJ>D2?>D2?>4%&B&2?R-31<PJD12>=>5<=>M-1T-F20
 G<=>7&201-A?13&1H8&A26-L-WOU97D15-VK2KY2G1<=>Z:HIH01-M8I0-8Q0N8>#1&1&47F612?P->A2TV0TKR<95OH-OX<=>C&X&9ZC-SR1>5-MIZTH-HHG<YV-B63>1%GRVY<
 <89B04MVMLS6-DDWH59#D10-K)I09-72<0-MT8+>#HB7?>-%5BSI-ECF-USKAE7-3#>=OIC1&4?>4Z-M-TWVQI21-^T1-*X(HC6B0ER\$"(0B3)&1W\$1@>0-Z-O+H66R\$S X+H0-I
 M#>E9=7-WAY-P-8DDF510V1N1-LW-G-P1-63/A<8-83#<NE+V>AU9+9-M-Z5-M:PF8<N1H00BM&P#BWULE5>3C-XFK4K9RZ-2-2R^T=10Q->@1P1P=DY-A-
 D-8%HL-9AY8ELO<Z>S&A91T1WUHW1^>EL5&B7-ME09HQ<SXX>0E0P2PD&R08P(2EF7=>=AUD&S&QW<=>UE2F0E15-ZLZC-ZC<=>7K%\$>
 M0231GHW26C5M-MYGV1+>#K1%1XJ-W-LK>7ML0-0)CJDS>D-PK&P7F>=>Y-M:G1<000H,C1Q1037-4HXJ-B*#D10Z1J-P1THHK 755B-MO1H12?>SHD-2<=>C/>E7N-TW1
 IGG21&G26FJL1=UF1<C1+Y478T1<1-KI6H2-M3&6MH1B3>1A(2957HT>1Y)DEJAY1<1+L&=>1D=>#09C0-R+Y+H1MGLG(CZ111+27C2?>1H8K1M15X1K1&KPN.F&A>
 <<<<+1MOTBAXIV-\$\$MDPO->WBT3&DMF%Z9B&W<1-D@K-M/(LLJ0G'Y>=>8UY<44@D2PF3JB@>H)921A>=>6<@88T-%DOMOR8-W:OU7-M%10KH0J9-SX%R@4J=>#P
 ESI<=>41%=>7%1<1-BX7H-9IKH-JL9&K1<Y>YZ0-MXC&MS1<=>17J15-QB085Y"E<=>1000AVAL2L#F0=>=>500%\$2D\$>#E2-M:E04>3Z&1QJWAMT\$>=<SAU@71=>7^AD&K4^P^CKEY?
 R-2H4K-EL89C?>3A-M-M*F1<1N&F&3CC@>=W3D31^YYP=OX16P&B-R-BYH-17G<+P741A)8H1-MX1VZM%V6=2FUW<=>1&W(LB1/>3QW<=>=<DEPE+KL-V6V13H9Z&XQ(C
 M&E1&7(FPNK)>-KTED0&K-18R5166\$H-3&80&86MR2-1M=>@>UTV7C7#>#JCT5PAY1)1H1-OR8ZP-SK" T4E"K102-VW-MIF<03DNOV\$
 B)-B2B-11AB0@>G1\$1&+>#6K2P-DFFV1SU/6N7IE-O&N&8" M00A<OQ7V1+9G-60<X&R-195@>X&A1DN=>R-2(O&C@>0.12151%F16<M-SO\$9) VFD6\$A9+1/8=>\$\$1
 (JF6<U(HTE.\$1829TOE=<1- M0?>@U\$D&H91ZA3"0>H4OGG5J30-2HLS?>2F%LC8CB@NDI/0-6-H8"JC'A1
 MD-7M10-W-HLZBRU>UOXLMMIROWT?M&3)>#=<N61Y&W>74U1VUN1TX-M93IGU1S4R720U-6"LS%<6&73TIRSGP5/76^P215EE-J2P5
 MF+AG10W>#AD31>G^HXR6G4<YOL&4Y>=>DY^T<30<CXYVRRD<G1YVU<6-M1-I55MUUJURC7?>Q<@W&F\$S=KIN3FG-1SB>V7G<^7B>AY-F&G&A^Z-X9NR-E7MYMO107
 MVUUK23D-45L#10<0<S2?3HDBBW&PO>VIR-W-HM965TW(KJR<1J1-1Y3>=>R6V20?>HEXNQ0B15ISE41=>+<1
 M11A<=>#KKVY<MSS-WKQY1D8T>B-BD85PTBJ-LY\$>OGS>D>C<-LX-1M-9-M:GX<A2IKYO&UXWY15BE<-SB-51&0+>R1N.061<HF2-RV24H.GCC2%YN-M-NJ
 IF1+@3>=>EUG<V&U<1VHS3<F-W8>)>@>X1->@AW&X32H1E1+>@>R1M0-3<1D9NM431YX5F67YT7-Z15=>=>SUK7F2R2N-FZ.OYLV15WY2JH-51KMZLN-M:Z>?>SZL
 IRL:K<X>S^T-OO<1VHS3=9SX>5WWKL+TOONA<+V7H1>E^+>M656H2=F1L-624F715U151XG751-RDO?>C8-C74<21QK0ZLOIS0V1ZV1^JW1YOWFS?
 9HFZ>3LK5&54WFFH7BWZV>WNOY=>CTC-MOR-YLH6W1M5CB8H8%CG89>3-3"NO&8KB6I?>71OZ42&B6&95:1315<H03KMW1>7>2^JMAKIDMZ-LA

[illegible]

[illegible]

[R23.htm 9952171 - Disclosure - TAXATION](http://www.renre.com/role/TAXATION) Sheet <http://www.renre.com/role/TAXATION> Notes 23 false false R24.htm 9952172 - Disclosure - SEGMENT REPORTING Sheet <http://www.renre.com/role/SEGMENTREPORTING> SEGMENT REPORTING Notes 24 false false R25.htm 9952173 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS Sheet <http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANS> STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS Notes 25 false false R26.htm 9952174 - Disclosure - STATUTORY REQUIREMENTS Sheet <http://www.renre.com/role/STATUTORYREQUIREMENTS> STATUTORY REQUIREMENTS Notes 26 false false R27.htm 9952175 - Disclosure - DERIVATIVE INSTRUMENTS Sheet <http://www.renre.com/role/DERIVATIVEINSTRUMENTS> DERIVATIVE INSTRUMENTS Notes 27 false false R28.htm 9952176 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS Sheet <http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMS> COMMITMENTS, CONTINGENCIES AND OTHER ITEMS Notes 28 false false R29.htm 9952177 - Disclosure - SUBSEQUENT EVENTS Sheet <http://www.renre.com/role/SUBSEQUENTEVENTS> SUBSEQUENT EVENTS Notes 29 false false R30.htm 9952178 - Disclosure - SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES Sheet <http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIES> SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES Notes 30 false false R31.htm 9952179 - Disclosure - SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT Sheet <http://www.renre.com/role/SCHEDULEIICONDENSEDFINANCIALINFORMATIONOFREGISTRANT> SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT Notes 31 false false R32.htm 9952180 - Disclosure - SCHEDULE III. SUPPLEMENTARY INSURANCE INFORMATION Sheet <http://www.renre.com/role/SCHEDULEIIISUPPLEMENTARYINSURANCEINFORMATION> SCHEDULE III. SUPPLEMENTARY INSURANCE INFORMATION Notes 32 false false R33.htm 9952181 - Disclosure - SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS Sheet <http://www.renre.com/role/SCHEDULEIVSUPPLEMENTALSCHEDULEOFREINSURANCEPREMIUMS> SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS Notes 33 false false R34.htm 9952182 - Disclosure - SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS Sheet <http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONS> SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS Notes 34 false false R35.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet <http://xbrl.sec.gov/ecd/role/PyvDisclosure> Pay vs Performance Disclosure Notes 35 false false R36.htm 995445 - Disclosure - Insider Trading Arrangements Sheet <http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements> Insider Trading Arrangements Notes 36 false false R37.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet <http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc> Insider Trading Policies and Procedures Notes 37 false false R38.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet <http://xbrl.sec.gov/cvd/role/CybersecurityRiskManagementAndStrategyDisclosure> Cybersecurity Risk Management and Strategy Disclosure Notes 38 false false R39.htm 9955511 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet <http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES> Policies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 39 false false R40.htm 9955512 - Disclosure - ACQUISITION OF VALIDUS (Tables) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUS> Tables ACQUISITION OF VALIDUS (Tables) Tables <http://www.renre.com/role/ACQUISITIONOFVALIDUS> 40 false false R41.htm 9955513 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETS> Tables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETS> 41 false false R42.htm 9955514 - Disclosure - INVESTMENTS (Tables) Sheet <http://www.renre.com/role/INVESTMENTSTables> INVESTMENTS (Tables) Tables <http://www.renre.com/role/INVESTMENTS> 42 false false R43.htm 9955515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables> FAIR VALUE MEASUREMENTS (Tables) Tables <http://www.renre.com/role/FAIRVALUEMEASUREMENTS> 43 false false R44.htm 9955516 - Disclosure - REINSURANCE (Tables) Sheet <http://www.renre.com/role/REINSURANCETables> REINSURANCE (Tables) Tables <http://www.renre.com/role/REINSURANCE> 44 false false R45.htm 9955517 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables) Sheet <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESTables> RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables) Tables <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSES> 45 false false R46.htm 9955518 - Disclosure - DEBT AND CREDIT FACILITIES (Tables) Sheet <http://www.renre.com/role/DEBTANDCREDITFACILITIES> Tables DEBT AND CREDIT FACILITIES (Tables) Tables <http://www.renre.com/role/DEBTANDCREDITFACILITIES> 46 false false R47.htm 9955519 - Disclosure - NONCONTROLLING INTERESTS (Tables) Sheet <http://www.renre.com/role/NONCONTROLLINGINTERESTSTables> VARIABLE INTEREST ENTITIES (Tables) Sheet <http://www.renre.com/role/VARIABLEINTERESTENTITIESTables> VARIABLE INTEREST ENTITIES (Tables) Tables <http://www.renre.com/role/VARIABLEINTERESTENTITIES> 48 false false R49.htm 9955521 - Disclosure - SHAREHOLDERS??? EQUITY (Tables) Sheet <http://www.renre.com/role/SHAREHOLDERSEQUITYTables> SHAREHOLDERS??? EQUITY (Tables) Tables <http://www.renre.com/role/SHAREHOLDERSEQUITY> 49 false false R50.htm 9955522 - Disclosure - EARNINGS PER SHARE (Tables) Sheet <http://www.renre.com/role/EARNINGSPERSHARETables> EARNINGS PER SHARE (Tables) Tables <http://www.renre.com/role/EARNINGSPERSHARE> 50 false false R51.htm 9955523 - Disclosure - TAXATION (Tables) Sheet <http://www.renre.com/role/TAXATIONTables> TAXATION (Tables) Tables <http://www.renre.com/role/TAXATION> 51 false false R52.htm 9955524 - Disclosure - SEGMENT REPORTING (Tables) Sheet <http://www.renre.com/role/SEGMENTREPORTINGTables> SEGMENT REPORTING (Tables) Tables <http://www.renre.com/role/SEGMENTREPORTING> 52 false false R53.htm 9955525 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS (Tables) Sheet <http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANS> 53 false false R54.htm 9955526 - Disclosure - STATUTORY REQUIREMENTS (Tables) Sheet <http://www.renre.com/role/STATUTORYREQUIREMENTSTables> STATUTORY REQUIREMENTS (Tables) Tables <http://www.renre.com/role/STATUTORYREQUIREMENTS> 54 false false R55.htm 9955527 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet <http://www.renre.com/role/DERIVATIVEINSTRUMENTSTables> DERIVATIVE INSTRUMENTS (Tables) Tables <http://www.renre.com/role/DERIVATIVEINSTRUMENTS> 55 false false R56.htm 9955528 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS (Tables) Sheet <http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSTables> COMMITMENTS, CONTINGENCIES AND OTHER ITEMS (Tables) Tables <http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMS> 56 false false R57.htm 9955529 - Disclosure - ACQUISITION OF VALIDUS - Overview (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails> ACQUISITION OF VALIDUS - Overview (Details) Details 57 false false R58.htm 9955530 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Purchase Price (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails> ACQUISITION OF VALIDUS - Schedule of Purchase Price (Details) Details 58 false false R59.htm 9955531 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails> ACQUISITION OF VALIDUS - Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed (Details) Details 59 false false R60.htm 9955532 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails> ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details) Details 60 false false R61.htm 9955533 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Financial Results (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails> ACQUISITION OF VALIDUS - Schedule of Financial Results (Details) Details 61 false false R62.htm 9955534 - Disclosure - ACQUISITION OF VALIDUS - Taxation (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails> ACQUISITION OF VALIDUS - Taxation (Details) Details 62 false false R63.htm 9955535 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Supplemental Pro Forma Information (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails> ACQUISITION OF VALIDUS - Schedule of Supplemental Pro Forma Information (Details) Details 63 false false R64.htm 9955536 - Disclosure - ACQUISITION OF VALIDUS - Defined Benefit Pension Plan (Details) Sheet <http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails> ACQUISITION OF VALIDUS - Defined Benefit Pension Plan (Details) Details 64 false false R65.htm 9955537 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets and Goodwill (Details) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails> GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets and Goodwill (Details) Details 65 false false R66.htm 9955538 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails> GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 66 false false R67.htm 9955539 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill and Other Intangible Assets Included in Equity Method Investments (Details) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails> GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill and Other Intangible Assets Included in Equity Method Investments (Details) Details 67 false false R68.htm 9955540 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets by Major Class (Details) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails> GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets by Major Class (Details) Details 68 false false R69.htm 9955541 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Expected Impairment Charges and Amortization Expense (Details) Sheet <http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails> GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Expected Impairment Charges and Amortization Expense (Details) Details 69 false false R70.htm 9955542 - Disclosure - INVESTMENTS - Schedule of Fair Value of Fixed Maturity Investments Trading (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails> INVESTMENTS - Schedule of Fair Value of Fixed Maturity Investments Trading (Details) Details 70 false false R71.htm 9955543 - Disclosure - INVESTMENTS - Schedule of Contractual Maturities of Fixed Maturity Investments (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails> INVESTMENTS - Schedule of Contractual Maturities of Fixed Maturity Investments (Details) Details 71 false false R72.htm 9955544 - Disclosure - INVESTMENTS - Schedule of Fair Value of Equity Investments (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails> INVESTMENTS - Schedule of Fair Value of Equity Investments (Details) Details 72 false false R73.htm 9955545 - Disclosure - INVESTMENTS - Pledged Investments and Reverse Repurchase Agreements (Details) Sheet <http://www.renre.com/role/INVESTMENTSPledgedInvestmentsandReverseRepurchaseAgreementsDetails> INVESTMENTS - Pledged Investments and Reverse Repurchase Agreements (Details) Details 73 false false R74.htm 9955546 - Disclosure - INVESTMENTS - Reverse Purchase Agreements (Narrative) (Details) Sheet <http://www.renre.com/role/INVESTMENTSReversePurchaseAgreementsNarrativeDetails> INVESTMENTS - Reverse Purchase Agreements (Narrative) (Details) Details 74 false false R75.htm 9955547 - Disclosure - INVESTMENTS - Schedule of Net Investment Income (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails> INVESTMENTS - Schedule of Net Investment Income (Details) Details 75 false false R76.htm 9955548 - Disclosure - INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails> INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details) Details 76 false false R77.htm 9955549 - Disclosure - INVESTMENTS - Schedule of Other Investments (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails> INVESTMENTS - Schedule of Other Investments (Details) Details 77 false false R78.htm 9955550 - Disclosure - INVESTMENTS - Term Loans (Details) Sheet <http://www.renre.com/role/INVESTMENTSTermLoansDetails> INVESTMENTS - Term Loans (Details) Details 78 false false R79.htm 9955551 - Disclosure - INVESTMENTS - Schedule of Investments in Other Ventures, under Equity Method (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofInvestmentsinOtherVenturesunderEquityMethodDetails> INVESTMENTS - Schedule of Investments in Other Ventures, under Equity Method (Details) Details 79 false false R80.htm 9955552 - Disclosure - INVESTMENTS - Schedule of Equity in (Losses) Earnings of Other Ventures, Under Equity Method (Details) Sheet <http://www.renre.com/role/INVESTMENTSScheduleofEquityinLossesEarningsofOtherVenturesUnderEquityMethodDetails> INVESTMENTS - Schedule of Equity in (Losses) Earnings of Other Ventures, Under Equity Method (Details) Details 80 false false R81.htm 9955553 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails> FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 81 false false R82.htm 9955554 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails> FAIR VALUE MEASUREMENTS - Narrative (Details) Details 82 false false R83.htm 9955555 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information Used as Level 3 Inputs (Details) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails> FAIR VALUE MEASUREMENTS - Schedule of Quantitative Information Used as Level 3 Inputs (Details) Details 83 false false R84.htm 9955556 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails> FAIR VALUE

MEASUREMENTS – Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (Details) Details 84 false false R85.htm 9955557 – Disclosure – FAIR VALUE MEASUREMENTS – Schedule of Balances Elected to Account for at Fair Value (Details) Sheet <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofBalancesElectedtoAccountforFairValueDetails> **FAIR VALUE MEASUREMENTS – Schedule of Balances Elected to Account for at Fair Value (Details) Details 85 false false R86.htm 9955558 – Disclosure – FAIR VALUE MEASUREMENTS – Schedule of Other Investments Measured Using Net Asset Valuations (Details) Sheet** <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails> **FAIR VALUE MEASUREMENTS – Schedule of Other Investments Measured Using Net Asset Valuations (Details) Details 86 false false R87.htm 9955559 – Disclosure – FAIR VALUE MEASUREMENTS – Schedule of Variable Interest Entities (Details) Sheet** <http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofVariableInterestEntitiesDetails> **FAIR VALUE MEASUREMENTS – Schedule of Variable Interest Entities (Details) Details 87 false false R88.htm 9955560 – Disclosure – REINSURANCE – Schedule of Effect of Reinsurance and Retrocessional Activity on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred (Details) Sheet** <http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurredD> **REINSURANCE – Schedule of Effect of Reinsurance and Retrocessional Activity on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred (Details) Details 88 false false R89.htm 9955561 – Disclosure – REINSURANCE – Narrative (Details) Sheet** <http://www.renre.com/role/REINSURANCENarrativeDetails> **REINSURANCE – Narrative (Details) Details 89 false false R90.htm 9955562 – Disclosure – REINSURANCE – Schedule of Provision for Current Expected Credit Losses of Premiums Receivable (Details) Sheet** <http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails> **REINSURANCE – Schedule of Provision for Current Expected Credit Losses of Premiums Receivable (Details) Details 90 false false R91.htm 9955563 – Disclosure – REINSURANCE – Schedule of Provision for Current Expected Credit Losses of Reinsurance Recoverable (Details) Sheet** <http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofReinsuranceRecoverableDetails> **REINSURANCE – Schedule of Provision for Current Expected Credit Losses of Reinsurance Recoverable (Details) Details 91 false false R92.htm 9955564 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Reserve for Claims and Claim Expenses by Segment (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Reserve for Claims and Claim Expenses by Segment (Details) Details 92 false false R93.htm 9955565 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Liability for Unpaid Claims and Claim Expenses (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Liability for Unpaid Claims and Claim Expenses (Details) Details 93 false false R94.htm 9955566 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Incurred and Paid Claims Development (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Schedule of Incurred and Paid Claims Development (Details) Details 94 false false R95.htm 9955567 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Prior Year Development of the Reserve for Net Claims and Claim Expenses (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Prior Year Development of the Reserve for Net Claims and Claim Expenses (Details) Details 95 false false R96.htm 9955568 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Reconciliation of the Disclosure of Incurred and Paid Claims Development to the Reserve for Claims and Claim Expenses (Details) Details 96 false false R97.htm 9955569 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Historical Claims Duration (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Historical Claims Duration (Details) Details 97 false false R98.htm 9955570 – Disclosure – RESERVE FOR CLAIMS AND CLAIM EXPENSES – Additional Information (Details) Sheet** <http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails> **RESERVE FOR CLAIMS AND CLAIM EXPENSES – Additional Information (Details) Details 98 false false R99.htm 9955571 – Disclosure – DEBT AND CREDIT FACILITIES – Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) Sheet** <http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails> **DEBT AND CREDIT FACILITIES – Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) Details 99 false false R100.htm 9955572 – Disclosure – DEBT AND CREDIT FACILITIES – Debt Obligations Narrative (Details) Sheet** <http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails> **DEBT AND CREDIT FACILITIES – Debt Obligations Narrative (Details) Details 100 false false R101.htm 9955573 – Disclosure – DEBT AND CREDIT FACILITIES – Schedule of Maturities of Long-term Debt (Details) Sheet** <http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails> **DEBT AND CREDIT FACILITIES – Schedule of Maturities of Long-term Debt (Details) Details 101 false false R102.htm 9955574 – Disclosure – DEBT AND CREDIT FACILITIES – Schedule of Credit Facilities (Details) Sheet** <http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails> **DEBT AND CREDIT FACILITIES – Schedule of Credit Facilities (Details) Details 102 false false R103.htm 9955575 – Disclosure – DEBT AND CREDIT FACILITIES – Credit Facilities Narrative (Details) Sheet** <http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails> **DEBT AND CREDIT FACILITIES – Credit Facilities Narrative (Details) Details 103 false false R104.htm 9955576 – Disclosure – NONCONTROLLING INTERESTS – Summary of Redeemable Noncontrolling Interest (Details) Sheet** <http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails> **NONCONTROLLING INTERESTS – Summary of Redeemable Noncontrolling Interest (Details) Details 104 false false R105.htm 9955577 – Disclosure – NONCONTROLLING INTERESTS – Narrative (Details) Sheet** <http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails> **NONCONTROLLING INTERESTS – Narrative (Details) Details 105 false false R106.htm 9955578 – Disclosure – NONCONTROLLING INTERESTS – Schedule of Redeemable Noncontrolling Interest Activity (Details) Sheet** <http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails> **NONCONTROLLING INTERESTS – Schedule of Redeemable Noncontrolling Interest Activity (Details) Details 106 false false R107.htm 9955579 – Disclosure – VARIABLE INTEREST ENTITIES – Narrative (Details) Sheet** <http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails> **VARIABLE INTEREST ENTITIES – Narrative (Details) Details 107 false false R108.htm 9955580 – Disclosure – VARIABLE INTEREST ENTITIES – Summary of the Principal-at-risk Variable Notes (Details) Notes** <http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails> **VARIABLE INTEREST ENTITIES – Summary of the Principal-at-risk Variable Notes (Details) Details 108 false false R109.htm 9955581 – Disclosure – SHAREHOLDERS’ EQUITY – Narrative (Details) Sheet** <http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails> **SHAREHOLDERS’ EQUITY – Narrative (Details) Details 109 false false R110.htm 9955582 – Disclosure – SHAREHOLDERS’ EQUITY – Rollforward of Shares Issued and Outstanding (Details) Sheet** <http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails> **SHAREHOLDERS’ EQUITY – Rollforward of Shares Issued and Outstanding (Details) Details 110 false false R111.htm 9955583 – Disclosure – EARNINGS PER SHARE – Computation of Basic and Diluted Earnings Per Common Share (Details) Sheet** <http://www.renre.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails> **EARNINGS PER SHARE – Computation of Basic and Diluted Earnings Per Common Share (Details) Details 111 false false R112.htm 9955584 – Disclosure – RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS (Details) Sheet** <http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORMCUSTOMERSDetails> **RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS (Details) Details 112 false false R113.htm 9955585 – Disclosure – TAXATION – Narrative (Details) Sheet** <http://www.renre.com/role/TAXATIONNarrativeDetails> **TAXATION – Narrative (Details) Details 113 false false R114.htm 9955586 – Disclosure – TAXATION – Income (Loss) Before Income Taxes, Foreign and Domestic (Details) Sheet** <http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails> **TAXATION – Income (Loss) Before Income Taxes, Foreign and Domestic (Details) Details 114 false false R115.htm 9955587 – Disclosure – TAXATION – Components of Income Tax Benefit (Expense) (Details) Sheet** <http://www.renre.com/role/TAXATIONComponentsofIncomeTaxBenefitExpenseDetails> **TAXATION – Components of Income Tax Benefit (Expense) (Details) Details 115 false false R116.htm 9955588 – Disclosure – TAXATION – Income Tax Reconciliation (Details) Sheet** <http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails> **TAXATION – Income Tax Reconciliation (Details) Details 116 false false R117.htm 9955589 – Disclosure – TAXATION – Deferred Tax Assets and Liabilities (Details) Sheet** <http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails> **TAXATION – Deferred Tax Assets and Liabilities (Details) Details 117 false false R118.htm 9955590 – Disclosure – SEGMENT REPORTING – Schedule of Significant Components of the Company’s Revenues and Expenses (Details) Sheet** <http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails> **SEGMENT REPORTING – Schedule of Significant Components of the Company’s Revenues and Expenses (Details) Details 118 false false R119.htm 9955591 – Disclosure – SEGMENT REPORTING – Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details) Sheet** <http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails> **SEGMENT REPORTING – Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details) Details 119 false false R120.htm 9955592 – Disclosure – STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS – Narrative (Details) Sheet** <http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails> **STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS – Narrative (Details) Details 120 false false R121.htm 9955593 – Disclosure – STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS – Equity Compensation Other than Options (Details) Sheet** <http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails> **STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS – Equity Compensation Other than Options (Details) Details 121 false false R122.htm 9955594 – Disclosure – STATUTORY REQUIREMENTS – Statutory Capital and Surplus (Details) Sheet** <http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails> **STATUTORY REQUIREMENTS – Statutory Capital and Surplus (Details) Details 122 false false R123.htm 9955595 – Disclosure – STATUTORY REQUIREMENTS – Statutory Net Income (Loss) (Details) Sheet** <http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails> **STATUTORY REQUIREMENTS – Statutory Net Income (Loss) (Details) Details 123 false false R124.htm 9955596 – Disclosure – STATUTORY REQUIREMENTS – Narrative (Details) Sheet** <http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails> **STATUTORY REQUIREMENTS – Narrative (Details) Details 124 false false R125.htm 9955597 – Disclosure – STATUTORY REQUIREMENTS – Schedule of Assets Held Under Trust and Minimum (Details) Sheet** <http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleofAssetsHeldUnderTrustandMinimumDetails> **STATUTORY REQUIREMENTS – Schedule of Assets Held Under Trust and Minimum (Details) Details 125 false false R126.htm 9955598 – Disclosure – STATUTORY REQUIREMENTS – Schedule of Multi-Beneficiary Reduced Collateral Reinsurance Trusts (Details) Sheet** <http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails> **STATUTORY REQUIREMENTS – Schedule of Multi-Beneficiary Reduced Collateral Reinsurance Trusts (Details) Details 126 false false R127.htm 9955599 – Disclosure – DERIVATIVE INSTRUMENTS – Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details) Sheet** <http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails> **DERIVATIVE INSTRUMENTS – Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details) Details 127 false false R128.htm 9955600 – Disclosure – DERIVATIVE INSTRUMENTS – Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details) Sheet** <http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails> **DERIVATIVE INSTRUMENTS – Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details) Details 128 false false R129.htm 9955601 – Disclosure – DERIVATIVE INSTRUMENTS – Narrative (Details) Sheet** <http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails> **DERIVATIVE INSTRUMENTS – Narrative (Details) Details 129 false false R130.htm 9955602 – Disclosure – DERIVATIVE INSTRUMENTS – Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation (Details) Sheet** <http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails> **DERIVATIVE INSTRUMENTS – Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation (Details) Details 130 false false R131.htm 9955603 – Disclosure – COMMITMENTS, CONTINGENCIES AND OTHER ITEMS – Narrative (Details) Sheet** <http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails> **COMMITMENTS, CONTINGENCIES AND OTHER ITEMS – Narrative (Details) Details 131 false false R132.htm 9955604 – Disclosure – COMMITMENTS, CONTINGENCIES AND OTHER ITEMS – Schedule of Future Minimum Payments, Operating and Finance Leases (Details) Sheet** <http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails> **COMMITMENTS, CONTINGENCIES AND OTHER ITEMS – Schedule of Future Minimum Payments, Operating and Finance Leases (Details) Details 132 false false R133.htm 9955605 – Disclosure**

[SUBSEQUENT EVENTS \(Details\) Sheet](#) http://www.renre.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details
[http://www.renre.com/role/SUBSEQUENTEVENTS-133>false>false-R134.htm-9955606-Disclosure-SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES \(Details\)](#) Sheet http://www.renre.com/role/SCHEDULEIISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails
SCHEDULE I. SUMMARY OF INVESTMENTS OTHER THAN INVESTMENTS IN RELATED PARTIES (Details) Details
[http://www.renre.com/role/SCHEDULEIISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIES-134>false>false-R135.htm-9955607-Disclosure-](#)
[SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Balance sheets \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIHCNDESEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails SCHEDULE II. CONDENSED FINANCIAL INFORMATION](#)
[OF REGISTRANT - Balance sheets \(Details\)](#) Details 135 false false R136.htm-9955608-Disclosure-SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT
[- Balance Sheets Additional Information \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIHCNDESEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails SCHEDULE II. CONDENSED](#)
[FINANCIAL INFORMATION OF REGISTRANT - Balance Sheets Additional Information \(Details\)](#) Details 136 false false R137.htm-9955609-Disclosure-SCHEDULE II.
[CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Operations \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIHCNDESEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails SCHEDULE II. CONDENSED FINANCIAL](#)
[INFORMATION OF REGISTRANT - Statements of Operations \(Details\)](#) Details 137 false false R138.htm-9955610-Disclosure-SCHEDULE II. CONDENSED FINANCIAL
[INFORMATION OF REGISTRANT - Statements of Comprehensive Income \(Loss\) \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIHCNDESEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfComprehensiveIncomeLossDetails SCHEDULE II. CONDENSED](#)
[FINANCIAL INFORMATION OF REGISTRANT - Statements of Comprehensive Income \(Loss\) \(Details\)](#) Details 138 false false R139.htm-9955611-Disclosure-SCHEDULE II.
[CONDENSED FINANCIAL INFORMATION OF REGISTRANT - Statements of Cash Flows \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIHCNDESEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails SCHEDULE II. CONDENSED FINANCIAL](#)
[INFORMATION OF REGISTRANT - Statements of Cash Flows \(Details\)](#) Details 139 false false R140.htm-9955612-Disclosure-SCHEDULE III. SUPPLEMENTARY INSURANCE
[INFORMATION \(Details\)](#) Sheet http://www.renre.com/role/SCHEDULEIIISUPPLEMENTARYINSURANCEINFORMATIONDetails SCHEDULE III. SUPPLEMENTARY INSURANCE
[INFORMATION \(Details\)](#) Details http://www.renre.com/role/SCHEDULEIIISUPPLEMENTARYINSURANCEINFORMATION-140>false>false-R141.htm-9955613-Disclosure-
[SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE PREMIUMS \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEIVSUPPLEMENTALSCHEDULEOFREINSURANCEPREMIUMSDetails SCHEDULE IV. SUPPLEMENTAL SCHEDULE OF REINSURANCE](#)
[PREMIUMS \(Details\)](#) Details http://www.renre.com/role/SCHEDULEIVSUPPLEMENTALSCHEDULEOFREINSURANCEPREMIUMS-141>false>false-R142.htm-9955614-Disclosure
[SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS \(Details\)](#) Sheet
[http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails SCHEDULE VI.](#)
[SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS \(Details\)](#) Details
[http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONS-142>false>false-All](#)
[Reports Book All Reports rnr-20241231.htm rnr-20241231.sxd rnr-20241231_cal.xml rnr-20241231_def.xml rnr-20241231_lab.xml rnr-20241231_pre.xml rnr-20241231-q1.jpg](#)
[http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 169 MetaLinks.json](#)
[IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rnr-20241231.htm": { "nsPrefix": "rnr", "nsuri": "http://www.renre.com/20241231", "dts": { "inline": { "local": { "rnr-](#)

```

"xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R14": f "role": "http://www.renre.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952162 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R15": f "role": "http://www.renre.com/role/REINSURANCE", "longName": "9952163 - Disclosure - REINSURANCE", "shortName": "REINSURANCE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:ReinsuranceTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:ReinsuranceTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R16": f "role": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSES", "longName": "9952164 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES", "shortName": "RESERVE FOR CLAIMS AND CLAIM EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R17": f "role": "http://www.renre.com/role/DEBTANDCREDITFACILITIES", "longName": "9952165 - Disclosure - DEBT AND CREDIT FACILITIES", "shortName": "DEBT AND CREDIT FACILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R18": f "role": "http://www.renre.com/role/NONCONTROLLINGINTERESTS", "longName": "9952166 - Disclosure - NONCONTROLLING INTERESTS", "shortName": "NONCONTROLLING INTERESTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R19": f "role": "http://www.renre.com/role/VARIABLEINTERESTENTITIES", "longName": "9952167 - Disclosure - VARIABLE INTEREST ENTITIES", "shortName": "VARIABLE INTEREST ENTITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R20": f "role": "http://www.renre.com/role/SHAREHOLDERSEQUITY", "longName": "9952168 - Disclosure - SHAREHOLDERSEQUITY", "shortName": "SHAREHOLDERSEQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R21": f "role": "http://www.renre.com/role/EARNINGSPEERSHARE", "longName": "9952169 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R22": f "role": "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERS", "longName": "9952170 - Disclosure - RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS", "shortName": "RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": f "contextRef": "c-1", "name": "rnr:RelatedPartyTransactionsAndMajorCustomersDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "rnr:RelatedPartyTransactionsAndMajorCustomersDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R23": f "role": "http://www.renre.com/role/TAXATION", "longName": "9952171 - Disclosure - TAXATION", "shortName": "TAXATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R24": f "role": "http://www.renre.com/role/SEGMENTREPORTING", "longName": "9952172 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R25": f "role": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANS", "longName": "9952173 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS", "shortName": "STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "R26": f "role": "http://www.renre.com/role/STATUTORYREQUIREMENTS", "longName": "9952174 - Disclosure - STATUTORY REQUIREMENTS", "shortName": "STATUTORY REQUIREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": f "contextRef": "c-1", "name": "rnr:DividendRestrictionsandStatutoryRequirementsDisclosureTextBlock", "unitRef": null, "xmlns": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "div", "body", "html" l, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } l, "uniqueAnchor": f "contextRef": "c-1", "name": "rnr:DividendRestrictionsandStatutoryRequirementsDisclosureTextBlock", "unit
```

body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R34": { "role": "http://www.renre.com/role/SCHEDULEVISUALLYSUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONS", "longName": "9952182 - Disclosure - SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY CASUALTY INSURANCE OPERATIONS", "shortName": "SCHEDULE VI. SUPPLEMENTARY INSURANCE INFORMATION CONCERNING PROPERTY CASUALTY INSURANCE OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "Srt:ScheduleOfSupplementalInformationForPropertyCasualtyInsuranceUnderwritersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "Srt:ScheduleOfSupplementalInformationForPropertyCasualtyInsuranceUnderwritersTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R35": { "role": "http://xbrl.sec.gov/ecd/role/PyvDisclosure", "longName": "9954110 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R36": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R37": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTradingPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTradingPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R38": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R39": { "role": "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "longName": "995511 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R40": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSTables", "longName": "995512 - Disclosure - ACQUISITION OF VALIDUS (Tables)", "shortName": "ACQUISITION OF VALIDUS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R41": { "role": "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "995513 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R42": { "role": "http://www.renre.com/role/INVESTMENTSTables", "longName": "995514 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R43": { "role": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "995515 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R44": { "role": "http://www.renre.com/role/REINSURANCETables", "longName": "995516 - Disclosure - REINSURANCE (Tables)", "shortName": "REINSURANCE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectsOfReinsuranceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectsOfReinsuranceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R45": { "role": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESTables", "longName": "995517 - Disclosure - RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables)", "shortName": "RESERVE FOR CLAIMS AND CLAIM EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiability

body": "html", "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R54": { "role": "http://www.renre.com/role/STATUTORYREQUIREMENTSTables", "longName": "9955526 - Disclosure - STATUTORY REQUIREMENTS (Tables)", "shortName": "STATUTORY REQUIREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "rnr:ScheduleofStatutoryCapitalSurplusandUnrestrictedNetAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rnr:ScheduleofStatutoryCapitalSurplusandUnrestrictedNetAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R55": { "role": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9955527 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R56": { "role": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSTables", "longName": "9955528 - Disclosure - COMMITMENTS, CONTINGENCIES AND OTHER ITEMS (Tables)", "shortName": "COMMITMENTS, CONTINGENCIES AND OTHER ITEMS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R57": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails", "longName": "9955529 - Disclosure - ACQUISITION OF VALIDUS - Overview (Details)", "shortName": "ACQUISITION OF VALIDUS - Overview (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-46", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R58": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "longName": "9955530 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Purchase Price (Details)", "shortName": "ACQUISITION OF VALIDUS - Schedule of Purchase Price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-48", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-48", "name": "rnr:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableSharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R59": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9955531 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed (Details)", "shortName": "ACQUISITION OF VALIDUS - Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R60": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails", "longName": "9955532 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details)", "shortName": "ACQUISITION OF VALIDUS - Schedule of Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-66", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "rnr:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R61": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails", "longName": "9955533 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Financial Results (Details)", "shortName": "ACQUISITION OF VALIDUS - Schedule of Financial Results (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R62": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "longName": "9955534 - Disclosure - ACQUISITION OF VALIDUS - Taxation (Details)", "shortName": "ACQUISITION OF VALIDUS - Taxation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R63": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalPro Forma Information Details", "longName": "9955535 - Disclosure - ACQUISITION OF VALIDUS - Schedule of Supplemental Pro Forma Information (Details)", "shortName": "ACQUISITION OF VALIDUS - Schedule of Supplemental Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-51", "name": "us-gaap:BusinessAcquisitionsPro Forma Revenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:BusinessAcquisitionPro Forma Information TableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:BusinessAcquisitionsPro Forma Revenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:BusinessAcquisitionPro Forma Information TableTextBlock", "ix:continuation": "body", "html": 1, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R64": { "role": "http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails", "longName": "9955536 - Disclosure - ACQUISITION OF VALIDUS - Defined Benefit Pension Plan (Details)", "shortName": "ACQUISITION OF VALIDUS - Defined Benefit Pension Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "


```

subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-107", "name": "rnr:ExpectedAmortizationOfOtherIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "rnr:ExpectedAmortizationOfOtherIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R70": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails", "longName": "9955542 - Disclosure - INVESTMENTS - Schedule of Fair Value of Fixed Maturity Investments Trading (Details)", "shortName": "INVESTMENTS - Schedule of Fair Value of Fixed Maturity Investments Trading (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:TradingSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:TradingSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R71": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "longName": "9955543 - Disclosure - INVESTMENTS - Schedule of Contractual Maturities of Fixed Maturity Investments (Details)", "shortName": "INVESTMENTS - Schedule of Contractual Maturities of Fixed Maturity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-8", "name": "rnr:TradingSecuritiesDebtMaturitiesWithinOneYearAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R72": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails", "longName": "9955544 - Disclosure - INVESTMENTS - Schedule of Fair Value of Equity Investments (Details)", "shortName": "INVESTMENTS - Schedule of Fair Value of Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R73": { "role": "http://www.renre.com/role/INVESTMENTSPledgedInvestmentsandReverseRepurchaseAgreementsDetails", "longName": "9955545 - Disclosure - INVESTMENTS - Pledged Investments and Reverse Repurchase Agreements (Details)", "shortName": "INVESTMENTS - Pledged Investments and Reverse Repurchase Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:AssetsHeldByInsuranceRegulators", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R74": { "role": "http://www.renre.com/role/INVESTMENTSReversePurchaseAgreementsNarrativeDetails", "longName": "9955546 - Disclosure - INVESTMENTS - Reverse Purchase Agreements (Narrative) (Details)", "shortName": "INVESTMENTS - Reverse Purchase Agreements (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:SecuritiesForReverseRepurchaseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:SecuritiesForReverseRepurchaseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R75": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails", "longName": "9955547 - Disclosure - INVESTMENTS - Schedule of Net Investment Income (Details)", "shortName": "INVESTMENTS - Schedule of Net Investment Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:InvestmentIncomeTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R76": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails", "longName": "9955548 - Disclosure - INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details)", "shortName": "INVESTMENTS - Schedule of Net Realized and Unrealized Gains (Losses) on Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesTradingGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesTradingGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R77": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "longName": "9955549 - Disclosure - INVESTMENTS - Schedule of Other Investments (Details)", "shortName": "INVESTMENTS - Schedule of Other Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:OtherLongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:SecuritiesOwnedAndOtherInvestmentsNotReadilyMarketableDisclosureTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "rnr:NetInvestmentIncomeChangeInEstimate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R78": { "role": "http://www.renre.com/role/INVESTMENTSTermLoansDetails", "longName": "9955550 - Disclosure - INVESTMENTS - Term Loans (Details)", "shortName": "INVESTMENTS - Term Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "R79": { "role": "http://www.renre.com/role/INVESTMENTSScheduleofInvestmentsinOtherVenturesunderEquityMethodDetails", "longName": "9955551 - Disclosure - INVESTMENTS - Schedule of Investments in Other Ventures, Under Equity Method (Details)", "shortName": "INVESTMENTS - Schedule of Investments in Other Ventures, Under Equity Method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-172", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "rnr-202412
```

[illegible]

"Details","order": "99", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0"},
ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-654",
name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-
gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "rnr-
20241231.htm", "unique": true } }, "R100": { "role": "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "longName": "9955572 -
Disclosure - DEBT AND CREDIT FACILITIES - Debt Obligations Narrative (Details)", "shortName": "DEBT AND CREDIT FACILITIES - Debt Obligations Narrative (Details)",
isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "us-
gaap:ProceedsFromIssuanceOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-667", "name": "us-gaap:ShortTermBorrowings", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true } },
"R101": { "role": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesoffLongtermDebtDetails", "longName": "9955573 - Disclosure - DEBT AND
CREDIT FACILITIES - Schedule of Maturities of Long-term Debt (Details)", "shortName": "DEBT AND CREDIT FACILITIES - Schedule of Maturities of Long-term Debt
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-8", "name": "us-
gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td",
tr": "table", "div": "us-gaap:ScheduleOfMaturitiesOffLongTermDebtTableTextBlock", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm",
"first": true, "unique": true } }, "R102": { "role":
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails", "longName": "9955574 - Disclosure - DEBT AND CREDIT FACILITIES - Schedule
of Credit Facilities (Details)", "shortName": "DEBT AND CREDIT FACILITIES - Schedule of Credit Facilities (Details)", "isDefault": "false", "groupType": "disclosure",
subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOffLineOfCreditFacilitiesTextBlock", "ix: continuation": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-670", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false",
lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOffLineOfCreditFacilitiesTextBlock", "ix: continuation": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true } }, "R103": { "role":
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "longName": "9955575 - Disclosure - DEBT AND CREDIT FACILITIES - Credit
Facilities Narrative (Details)", "shortName": "DEBT AND CREDIT FACILITIES - Credit Facilities Narrative (Details)", "isDefault": "false", "groupType": "disclosure",
subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang":
"en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOffLineOfCreditFacilitiesTextBlock", "ix: continuation": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-693", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-
20241231.htm", "unique": true } }, "R104": { "role": "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails",
longName": "9955576 - Disclosure - NONCONTROLLING INTERESTS - Summary of Redeemable Noncontrolling Interest (Details)", "shortName": "NONCONTROLLING
INTERESTS - Summary of Redeemable Noncontrolling Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
order": "104", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix: continuation": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": null }, "R105": { "role":
"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "longName": "9955577 - Disclosure - NONCONTROLLING INTERESTS - Narrative (Details)",
shortName": "NONCONTROLLING INTERESTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"105", "firstAnchor": { "contextRef": "c-719", "name": "us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "5", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": {
"contextRef": "c-723", "name": "us-gaap:PaymentsToMinorityShareholders", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div",
ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true } }, "R106": { "role":
"http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "longName": "9955578 - Disclosure -
NONCONTROLLING INTERESTS - Schedule of Redeemable Noncontrolling Interest Activity (Details)", "shortName": "NONCONTROLLING INTERESTS - Schedule of
Redeemable Noncontrolling Interest Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106",
firstAnchor": { "contextRef": "c-9", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix: continuation": "body", "html": "1",
reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-730", "name": "us-
gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr":
table", "div": "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true } }, "R107": { "role":
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "longName": "9955579 - Disclosure - VARIABLE INTEREST ENTITIES - Narrative (Details)",
shortName": "VARIABLE INTEREST ENTITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"107", "firstAnchor": { "contextRef": "c-8", "name": "rnr:NumberOfSegregatedAccounts", "unitRef": "account", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
{ "span": "div", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8",
name": "rnr:NumberOfSegregatedAccounts", "unitRef": "account", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation": "body",
html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } }, "R108": { "role":
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "longName": "9955580 - Disclosure - VARIABLE INTEREST
ENTITIES - Summary of the Principal at-risk Variable Notes (Details)", "shortName": "VARIABLE INTEREST ENTITIES - Summary of the Principal at-risk Variable Notes
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-800", "name": "us-
gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix: continuation":
ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-800", "name": "us-
gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix: continuation":
ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true } }, "R109": { "role":
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "longName": "9955581 - Disclosure - SHAREHOLDERSu2019 EQUITY - Narrative (Details)",
shortName": "SHAREHOLDERSu2019 EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"109", "firstAnchor": { "contextRef": "c-8", "name": "rnr:StockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span":
div", "ix: continuation": "body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-
gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation":
body", "html": "1", reportCount": 1, "baseRef": "rnr-20241231.htm", "unique

"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R117", "http://www.renre.com/role/TAXATIONDeferredTaxAssetsAndLiabilitiesDetails", "longName": "9955589 - Disclosure - TAXATION - Deferred Tax Assets and Liabilities (Details)", "shortName": "TAXATION - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R118", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails", "longName": "9955590 - Disclosure - SEGMENT REPORTING - Schedule of Significant Components of the Company's Revenues and Expenses (Details)", "shortName": "SEGMENT REPORTING - Schedule of Significant Components of the Company's Revenues and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsWrittenGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rnr:UnderwritingIncomeLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R119", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "longName": "9955591 - Disclosure - SEGMENT REPORTING - Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details)", "shortName": "SEGMENT REPORTING - Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsWrittenGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-985", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R120", "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "longName": "9955592 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Narrative (Details)", "shortName": "STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R121", "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "longName": "9955593 - Disclosure - STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Equity Compensation Other than Options (Details)", "shortName": "STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS - Equity Compensation Other than Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-998", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-994", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R122", "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails", "longName": "9955594 - Disclosure - STATUTORY REQUIREMENTS - Statutory Capital and Surplus (Details)", "shortName": "STATUTORY REQUIREMENTS - Statutory Capital and Surplus (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-1022", "name": "us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "rnr:ScheduleOfStatutoryCapitalSurplusandUnrestrictedNetAssetsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R123", "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails", "longName": "9955595 - Disclosure - STATUTORY REQUIREMENTS - Statutory Net Income (Loss) (Details)", "shortName": "STATUTORY REQUIREMENTS - Statutory Net Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-1030", "name": "us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "rnr:ScheduleOfStatutoryNetIncomeLossTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R124", "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "longName": "9955596 - Disclosure - STATUTORY REQUIREMENTS - Narrative (Details)", "shortName": "STATUTORY REQUIREMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-1", "name": "rnr:TargetPercentageOfEnhancedCapitalRequirement", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rnr:TargetPercentageOfEnhancedCapitalRequirement", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "role": "R125", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails", "longName": "9955597 - Disclosure - STATUTORY REQUIREMENTS - Schedule of Assets Held Under Trust and Minimum (Details)", "shortName": "STATUTORY REQUIREMENTS - Schedule of Assets Held Under Trust and Minimum (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1042", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "rnr:ScheduleOfReinsuranceTrustsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R126", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails", "longName": "9955598 - Disclosure - STATUTORY REQUIREMENTS - Schedule of Multi-Beneficiary Reduced Collateral Reinsurance Trusts (Details)", "shortName": "STATUTORY REQUIREMENTS - Schedule of Multi-Beneficiary Reduced Collateral Reinsurance Trusts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1057", "name": "us-gaap:AssetsHeldInTrust", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R127", "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleOfLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails", "longName": "9955599 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Location on Consolidated Balance Sheets and Fair Value of Principal Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R128", "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails", "longName": "9955600 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Gain (Loss) Recognized in Consolidated Statements of Operations Related to Principal Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R129", "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "longName": "9955601 - Disclosure - DERIVATIVE INSTRUMENTS - Narrative (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-1119", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1119", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "rnr-20241231.htm", "unique": true }, "role": "R130", "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails", "longName": "9955602 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation

[illegible]

{ "en-us": { "role": { "terseLabel": "2018 Large Loss Events", "label": "2018 Large Loss Events [Member]", "documentation": "2018 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2019LargeLossEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2019LargeLossEventsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2019 Large Loss Events", "label": "2019 Large Loss Events [Member]", "documentation": "2019 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2020LargeLossEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2020LargeLossEventsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2020 Large Loss Events", "label": "2020 Large Loss Events [Member]", "documentation": "2020 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2021LargeLossEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2021LargeLossEventsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2021 Weather-Related Large Loss Events", "label": "2021 Large Loss Events [Member]", "documentation": "2021 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2022LargeLossEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2022LargeLossEventsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2022 Weather-Related Large Loss Events", "label": "2022 Large Loss Events [Member]", "documentation": "2022 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2023LargeLossEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2023LargeLossEventsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2023 Large Loss Events", "label": "2023 Large Loss Events [Member]", "documentation": "2023 Large Loss Events [Member]" } } }, { "auth_ref": { "rnr_A2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2024Member", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "2024 [Member]", "documentation": "2024" } } }, { "auth_ref": { "rnr_A2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2027Member", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "2027 [Member]", "documentation": "2027" } } }, { "auth_ref": { "rnr_A2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A2037Member", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "2037", "label": "2037 [Member]", "documentation": "2037" } } }, { "auth_ref": { "rnr_A3.450SeniorNotesDueJuly12027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A3.450SeniorNotesDueJuly12027Member", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "3.450% Senior Notes Due 2027", "label": "3.450% Senior Notes Due July 1 2027 [Member]", "documentation": "3.450% Senior Notes Due July 1 2027 [Member]" } } }, { "auth_ref": { "rnr_A3.600SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A3.600SeniorNotesDue2029Member", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "3.600% Senior Notes Due 2029", "label": "3.600% Senior Notes Due 2029 [Member]", "documentation": "3.600% Senior Notes Due 2029 [Member]" } } }, { "auth_ref": { "rnr_A3.700SeniorNotesDueApril12025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A3.700SeniorNotesDueApril12025Member", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "3.700% Senior Notes Due 2025", "label": "3.700% Senior Notes Due April 1, 2025 [Member]", "documentation": "3.700% Senior Notes Due April 1, 2025 [Member]" } } }, { "auth_ref": { "rnr_A4.750SeniorNotesDueMay12025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A4.750SeniorNotesDueMay12025Member", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "4.750% Senior Notes due 2025 (DaVinci)", "terseLabel": "4.750% Senior Notes Due May 1, 2025", "label": "4.750% Senior Notes Due May 1, 2025 [Member]", "documentation": "4.75% Senior Notes Due May 1, 2025 [Member]" } } }, { "auth_ref": { "rnr_A5.750SeniorNotesDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "A5.750SeniorNotesDue2033Member", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "5.750% Senior Notes due 2033", "label": "5.750% Senior Notes due 2033 [Member]", "documentation": "5.750% Senior Notes due 2033" } } }, { "country": "AU", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "AU", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Australia", "label": "AUSTRALIA" } } }, { "auth_ref": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, { "auth_ref": { "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Due to subsidiaries", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, { "auth_ref": { "r213", "r1749" }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding receivable", "verboseLabel": "Due from subsidiaries", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, { "auth_ref": { "r342", "r460", "r461", "r1757" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AccruedInvestmentIncomeReceivable", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued investment income", "label": "Accrued Investment Income Receivable", "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments." } } }, { "auth_ref": { "r209", "r983", "r1558" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss) and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, { "auth_ref": { "r4", "r20", "r31", "r902", "r805", "r873", "r1062", "r1063", "r1560", "r1561", "r1562", "r1581", "r1582", "r1583", "r1585" }, "rnr_AcquiredFiniteLivedIntangibleAssetsMajorityAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AcquiredFiniteLivedIntangibleAssetsMajorityAmortizationPeriod", "presentation": { "http://www.renre.com/role/ACQUISITIONOFFVALIDUSOverviewDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization period majority", "label": "Acquired Finite-Lived Intangible Assets, Majority Amortization Period", "documentation": "Acquired Finite-Lived Intangible Assets, Majority Amortization Period" } } }, { "auth_ref": { "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": { "http://www.renre.com/role/ACQUISITIONOFFVALIDUScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Economic Useful Life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, { "auth_ref": { "r532", "r1286" }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, { "auth_ref": { "r1455" }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital (Note 12)", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, { "auth_ref": { "r150", "r1358", "r1908" }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofChangesinShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, { "auth_ref": { "r1893", "r1581", "r1582", "r1583", "r1585", "r1703", "r1810" }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, { "auth_ref": { "r1468" }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } }, { "auth_ref": { "r1468" }, "ecd_AdjToNonPeeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, { "auth_ref": { "r1468" }, "ecd_AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]" } } }, { "auth_ref": { "r1468" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://flash.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": { "lang": { "en-us": { "role": { "terseLabel":

"Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } } , "auth_ref": "f" } , "us-gaap_AgencySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AgencySecuritiesMember", "presentation": "f" } } } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Agencies" } , "label": "Agency Securities [Member]" } , "documentation": "Securities issued by government sponsored entities." } } } , "auth_ref": "f" } , "r1598": "r1600" } } } , "rnr_AgentRelationshipsOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AgentRelationshipsOtherMember", "presentation": "f" } } } , "http://www.renre.com/role/ACQUISITIONOFVALIDUScheduleofIdentifiableIntangibleAssetsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Agent relationships - other" } , "label": "Agent Relationships - Other [Member]" } , "documentation": "Agent Relationships - Other" } } } , "auth_ref": "f" } } , "rnr_AgentRelationshipsTopFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AgentRelationshipsTopFourMember", "presentation": "f" } } } , "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails": "http://www.renre.com/role/ACQUISITIONOFVALIDUScheduleofIdentifiableIntangibleAssetsDetails" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Agent relationships - top four" } , "label": "Agent Relationships - Top Four [Member]" } , "documentation": "Agent Relationships - Top Four" } } } , "auth_ref": "f" } } , "ecd_AggtChngPnsnValInSummryCompstnTblForApblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblyrMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } , "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } } , "auth_ref": "f" } , "r1513": "r1513" } , "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Aggregate Erroneous Compensation Amount" } , "label": "Aggregate Erroneous Compensation Amount" } } } , "auth_ref": "f" } , "r1426": "r1437" } , "r1447": "r1480" } } } , "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } , "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } } , "auth_ref": "f" } , "r1429": "r1440" } , "r1450" } , "r1483" } } } , "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Aggregate Pension Adjustments Service Cost" } , "label": "Aggregate Pension Adjustments Service Cost [Member]" } } } , "auth_ref": "f" } , "r1514": "r1514" } , "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "All Adjustments to Compensation" } , "label": "All Adjustments to Compensation [Member]" } } } , "auth_ref": "f" } , "r1468": "r1468" } , "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "All Executive Categories" } , "label": "All Executive Categories [Member]" } } } , "auth_ref": "f" } , "r1475": "r1475" } , "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "All Individuals" } , "label": "All Individuals [Member]" } } } , "auth_ref": "f" } , "r1430": "r1441": "r1451" } , "r1475": "r1484" } , "r1489": "r1496" } } } , "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": "f" } } } , "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "All Trading Arrangements" } , "label": "All Trading Arrangements [Member]" } } } , "auth_ref": "f" } , "r1494": "r1494" } , "us-gaap_AllowanceForReinsuranceRecoverableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForReinsuranceRecoverableMember", "presentation": "f" } } } , "http://www.renre.com/role/REINSURANCENarrativeDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Allowance for Reinsurance Recoverable" } , "label": "SEC Schedule, 12-09, Allowance, Reinsurance Recoverable [Member]" } , "documentation": "Allowance for portion expected to be uncollectible of recoverable from reinsurer for paid and unpaid claims and claim settlement expense." } } } , "auth_ref": "f" } , "r1576": "r1577" } , "r1578": "r1579" } , "r1580": "r1580" } } , "rnr_AlphaCatManagersLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AlphaCatManagersLtdMember", "presentation": "f" } } } , "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Alpha Cat entities" } , "label": "Alpha Cat Entities [Member]" } , "documentation": "Alpha Cat Managers Ltd [Member]" } , "documentation": "Alpha Cat Managers Ltd" } } } , "auth_ref": "f" } , "us-gaap_AlternativeInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestment", "presentation": "f" } } } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Fair Value" } , "label": "Alternative Investment" } , "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund." } } } , "auth_ref": "f" } , "r812": "r830" } , "r1345": "r1349" } , "r1350": "r1705" } , "r1707": "r1708" } , "r1709": "r1709" } } , "us-gaap_AlternativeInvestmentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestmentMeasurementInput", "presentation": "f" } } } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Significant observable and unobservable inputs" } , "label": "Alternative Investment Measurement Input" } , "documentation": "Value of input used to measure alternative investment." } } } , "auth_ref": "f" } , "r1349": "r1707": "r1708" } , "r1709": "r1709" } } , "dei_AmendementFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": "f" } } } , "http://www.renre.com/role/COVERPage": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Amendment Flag" } , "label": "Amendment Flag" } , "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } , "auth_ref": "f" } } , "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "presentation": "f" } } } , "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Amortization of intangible assets" } , "label": "Amortization of Intangible Assets" } , "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } , "auth_ref": "f" } , "r12": "r529" } , "r536": "r1316" } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": "f" } } } , "http://www.renre.com/role/EARNINGSPEPERSHAREComputationsOfBasicandDilutedEarningsPerCommonShareDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Potentially dilutive securities (in shares)" } , "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } , "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } , "auth_ref": "f" } , "r412": "r412" } , "rnr_AonPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AonPlcMember", "presentation": "f" } } } , "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Aon plc" } , "label": "Aon plc [Member]" } , "documentation": "Aon plc [Member]" } } } , "auth_ref": "f" } , "rnr_ArthurJGallagherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ArthurJGallagherMember", "presentation": "f" } } } , "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Arthur J Gallagher" } , "label": "Arthur J Gallagher [Member]" } , "documentation": "Arthur J Gallagher" } } } , "auth_ref": "f" } , "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": "f" } } } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsTradingDetails": "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Asset-backed" } , "label": "Asset-Backed Securities [Member]" } , "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } } , "auth_ref": "f" } , "r1327": "r1359" } , "r1599": "r1601" } , "r1602": "r1602" } } , "rnr_AssetManagementContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AssetManagementContractsMember", "presentation": "f" } } } , "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Asset management contracts" } , "label": "Asset Management Contracts [Member]" } , "documentation": "Asset Management Contracts" } } } , "auth_ref": "f" } } , "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "presentation": "f" } } } , "http://www.renre.com/role/ConsolidatedBalanceSheets": "f" } , "parentTag": "null" } , "weight": "null" } , "order": "null" } , "root": "true" } , "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": "f" } , "parentTag": "null" } , "weight": "null" } , "order": "null" } , "root": "true" } , "presentation": "f" } , "http://www.renre.com/role/ConsolidatedBalanceSheets": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "totalLabel": "Total assets" } , "terseLabel": "Assets" } , "label": "Assets" } , "documentation": "Amount of asset recognized for present right to economic benefit." } } } , "auth_ref": "f" } , "r210": "r230" } , "r337": "r376" } , "r422": "r430" } , "r448": "r452" } , "r500": "r566" } , "r567": "r569" } , "r570": "r571" } , "r572": "r573" } , "r575": "r576" } , "r792": "r796" } , "r844": "r972" } , "r1140": "r1306" } , "r1307": "r1358" } , "r1404": "r1647" } , "r1648": "r1733" } } } , "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": "f" } } } , "http://www.renre.com/role/ConsolidatedBalanceSheets": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Assets" } , "label": "Assets [Abstract]" } } } , "auth_ref": "f" } } , "us-gaap_AssetsHeldByInsuranceRegulators": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldByInsuranceRegulators", "presentation": "f" } } } , "http://www.renre.com/role/INVESTMENTSPledgedInvestmentsandReverseRepurchaseAgreementsDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "verboseLabel": "Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, U.S. state regulatory authorities" } , "label": "Assets Held by Insurance Regulators" } , "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements." } } } , "auth_ref": "f" } , "r1078": "r1078" } , "us-gaap_AssetsHeldInTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldInTrust", "presentation": "f" } } } , "http://www.renre.com/role/INVESTMENTSPledgedInvestmentsandReverseRepurchaseAgreementsDetails": "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustandMinimumDetails": "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "verboseLabel": "Cash and investments at fair value on deposit with, or in trust accounts for the benefit of, various counterparties" } , "label": "Assets held in trust" } , "label": "Asset, Held in Trust" } , "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations." } } } , "auth_ref": "f" } , "r1574": "r1574" } , "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "presentation": "f" } } } , "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "terseLabel": "Net assets" } , "label": "Net Assets" } , "documentation": "Amount of net assets (liabilities)." } } } , "auth_ref": "f" } , "r16": "r16" } , "rnr_AssumedAndCededReinsuranceContractsLiabilitiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AssumedAndCededReinsuranceContractsLiabilitiesFairValue", "presentation": "f" } } } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": "f" } , "parentTag": "us-gaap_OtherAssetsFairValueDisclosure" } , "weight": "-1.0" } , "order": "3.0" } } , "presentation": "f" } , "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": "f" } , "lang": "f" } , "en-us": "f" } , "role": "f" } , "negatedTerseLabel": "Assumed and ceded (re)insurance contracts" } , "label": "Assumed And Ceded Re Insurance Contracts, Liabilities, Fair Value" } , "documentation": "Assumed

And Ceded Re Insurance Contracts, Liabilities, Fair Value" } }, {"auth_ref": "I" }, {"rnr_AssumedAndCededReInsuranceContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AssumedAndCededReInsuranceContractsMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Assumed and ceded (re)insurance contracts", "label": "Assumed And Ceded Re Insurance Contracts [Member]", "documentation": "Assumed and ceded (re)insurance contracts accounted for at fair value." } } }, "auth_ref": "I" }, {"us_gaap_AssumedPremiumsEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssumedPremiumsEarned", "crdr": "credit", "calculation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SCHEDULEFVSVSUPPLEMENTALSCHEDULEOFREINSURANCEPREMIUMSDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Assumed", "terseLabel": "Gross premiums earned", "label": "Assumed Premiums Earned", "documentation": "Amount of earned premiums assumed from other entities." } } }, "auth_ref": { "r1019", "r1073", "r1076", "r1759" } }, {"us_gaap_AssumedPremiumsWritten": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssumedPremiumsWritten", "crdr": "credit", "calculation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "parentTag": "us-gaap_PremiumsWrittenNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "lang": { "en-us": { "role": { "verboseLabel": "Assumed", "label": "Assumed Premiums Written", "documentation": "Amount of written premiums assumed from other entities." } } }, "auth_ref": { "r1073" } }, {"rnr_AssumedandCededReInsuranceContractsGroupTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AssumedandCededReInsuranceContractsGroupTwoMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Assumed reinsurance contract", "verboseLabel": "Assumed and ceded (re)insurance contracts, group two", "label": "Assumed and Ceded Re Insurance Contracts, Group Two [Member]", "documentation": "Assumed and Ceded Re Insurance Contracts, Group Two [Member]" } } }, "auth_ref": "I" }, {"rnr_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": "I" }, {"dei_AuditorFirmID": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmID", "presentation": { "http://www.renre.com/role/AuditInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": { "r1409", "r1410", "r1433" } }, {"dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": { "http://www.renre.com/role/AuditInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": { "r1409", "r1410", "r1433" } }, {"dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": { "http://www.renre.com/role/AuditInformation", "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": { "r1409", "r1410", "r1433" } }, {"rnr_AustraliaandNewZealandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "AustraliaandNewZealandMember", "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "lang": { "en-us": { "role": { "terseLabel": "Australia and New Zealand", "label": "Australia and New Zealand [Member]", "documentation": "Australia and New Zealand [Member]" } } }, "auth_ref": { "I", "ecd_AwardExcrPrice": { "xbrltype": "perShareItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcrPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r1491" } }, {"ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": { "r1492" } }, {"ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "auth_ref": { "r1487" } }, {"ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r1487" } }, {"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r1487" } }, {"ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r1487" } }, {"ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r1487" } }, {"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r1487" } }, {"us_gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSeparativeDetails", "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724" } }, {"ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r1490" } }, {"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r1489" } }, {"ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": { "r1488" } }, {"country_BM": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "BM", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails", "lang": { "en-us": { "role": { "terseLabel": "Bermuda", "label": "BERMUDA" } } }, "auth_ref": { "I" }, {"us_gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r551", "r1767", "r1768" } }, {"us_gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": { "r100", "r103", "r551", "r1767", "r1768" } }, {"rnr_BasicMaterialsSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BasicMaterialsSectorMember", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Basic materials", "label": "Basic Materials Sector [Member]", "documentation": "Basic Materials Sector [Member]" } } }, "auth_ref": { "I" }, {"us_gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "terseLabel": "Basis Of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, HFS)." } } }, "auth_ref": { "I" }, {"rnr_BeginningExpirationYearAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BeginningExpirationYearAxis", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Beginning Expiration Year [Axis]", "label": "Beginning Expiration Year [Axis]", "documentation": "Beginning Expiration Year" } } }, "auth_ref": { "I" }, {"rnr_BeginningExpirationYearDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BeginningExpirationYearDomain", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Beginning Expiration Year [Domain]", "label": "Beginning Expiration Year [Domain]", "documentation": "Beginning Expiration Year [Domain]" } } }, "auth_ref": { "I" }, {"us_gaap_BenefitsLossesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BenefitsLossesAndExpenses", "crdr": "debit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTSStatementsofOperationsDetails", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 1.0 }, {"http://www.renre.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTSStatementsofOperationsDetails", "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Benefits, Losses and Expenses", "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs." } } }, "auth_ref": { "r1001" } }, {"us_gaap_BenefitsLossesAndExpensesAbstract": { "xbrltype":

"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BenefitsLossesAndExpensesAbstract", "presentation": {
"http://www.renre.com/role/ConsolidatedStatementsOfOperations",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails", "lang": { "en-us": { "role": { "terseLabel":
"Expenses", "label": "Benefits, Losses and Expenses [Abstract]" } } }, "auth_ref": { "rnr_BermudaCapitalAndSolvencyRatio": { "xbrltype": "percentItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "BermudaCapitalAndSolvencyRatio", "presentation": {
"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "BSCR ratio", "label": "Bermuda Capital And Solvency
Ratio", "documentation": "Bermuda Capital And Solvency Ratio" } } }, "auth_ref": { "rnr_BilateralFacilityParticipantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "BilateralFacilityParticipantsMember", "presentation": {
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Bilateral Facility Participants", "label":
"Bilateral Facility Participants [Member]", "documentation": "Bilateral Facility Participants [Member]" } } }, "auth_ref": { "us-gaap_BridgeLoanMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BridgeLoanMember", "presentation": {
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Bridge Loan", "label": "Bridge Loan
[Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan bridges the gap in time when otherwise no financing
would be in place." } } }, "auth_ref": { "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionAcquireeDomain", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails",
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label":
"Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business
combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": { "r530", "r531", "r532", "r533", "r534", "r786", "r1331", "r1334",
"us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails", "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails",
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition
[Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": { "r70", "r73", "r530", "r531",
"r532", "r533", "r534", "r786", "r1331", "r1334" } } }, "rnr_BusinessAcquisitionClosingSharePriceDiscount": { "xbrltype": "percentItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "BusinessAcquisitionClosingSharePriceDiscount", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "lang": { "en-us": { "role": { "terseLabel": "Discount on closing price", "label":
"Business Acquisition, Closing Share Price, Discount", "documentation": "Business Acquisition, Closing Share Price, Discount" } } }, "auth_ref": { "us-
gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": { "en-
us": { "role": { "terseLabel": "Shares issued (in shares)", "verboseLabel": "Common shares issued by RenaissanceRe to AIG (in shares)", "label": "Business Acquisition, Equity
Interests Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": { "r198" } } },
"rnr_BusinessAcquisitionGoodwillExpectedTaxDeductibleAmountFutureBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"BusinessAcquisitionGoodwillExpectedTaxDeductibleAmountFutureBenefit", "crdr": "credit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "lang": { "en-us": { "role": { "terseLabel": "Expected future benefit from goodwill", "label": "Business
Acquisition, Goodwill, Expected Tax Deductible Amount, Future Benefit", "documentation": "Business Acquisition, Goodwill, Expected Tax Deductible Amount, Future Benefit"
} } }, "auth_ref": { "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionLineItems", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business
Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r786" } } }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired":
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails", "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired", "label":
"Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business
combination." } } }, "auth_ref": { "r71" } } }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSTables", "lang": {
"en-us": { "role": { "terseLabel": "Schedule of Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular
disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
} } }, "auth_ref": { "r1530", "r1531" } } }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "lang": { "en-us": { "role": { "terseLabel": "Expected tax deductible amount", "label": "Business
Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for
tax purposes." } } }, "auth_ref": { "r60" } } }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionSharePrice", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, share price (in
dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a
business combination." } } }, "auth_ref": { "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)
available (attributable) to RenaissanceRe common shareholders", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net income
or loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": { "r784", "r785" } } }, "us-
gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProFormaInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Total revenues",
"label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been
completed at the beginning of the period." } } }, "auth_ref": { "r784", "r785" } } }, "us-
gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combination,
Acquisition of Less than 100 Percent, Noncontrolling Interest [Abstract]", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest
[Abstract]" } } }, "auth_ref": { "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation
[Abstract]" } } }, "auth_ref": { "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "totalLabel": "Total
purchase price", "verboseLabel": "Total purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred,
consisting of acquisition date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref":
{ "r1", "r2", "r18" } } }, "rnr_BusinessCombinationConsiderationTransferredAvailableCashResources": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "BusinessCombinationConsiderationTransferredAvailableCashResources", "crdr": "credit", "calculation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order":
1.0 } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "lang": { "en-us": { "role": { "terseLabel": "Cash
consideration funded by available cash resources", "label": "Business Combination, Consideration Transferred, Available Cash Resources", "documentation": "Business
Combination, Consideration Transferred, Available Cash Resources" } } }, "auth_ref": { "us-
gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "calculation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight":
1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails",
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails", "lang": { "en-us": { "role": { "verboseLabel": "Business acquisition, common shares
(in shares)", "terseLabel": "Market value of RenaissanceRe common shares issued by RenaissanceRe to AIG", "label": "Business Combination, Consideration Transferred,"

Equity Interests Issued and Issuable"}}, "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": { "r1": "r2" } } }, "rnr_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableSharePrice": { "xbrltype": "perShareItem", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableSharePrice", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common share price of RenaissanceRe (in dollars per share)", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Share Price", "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Share Price" } } } }, "auth_ref": { } } }, "rnr_BusinessCombinationConsiderationTransferredProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationConsiderationTransferredProceedsFromIssuanceOfCommonStock", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market", "label": "Business Combination, Consideration Transferred, Proceeds from Issuance of Common Stock", "documentation": "Business Combination, Consideration Transferred, Proceeds from Issuance of Common Stock" } } } }, "auth_ref": { } } }, "rnr_BusinessCombinationConsiderationTransferredProceedsFromIssuanceOfSeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationConsiderationTransferredProceedsFromIssuanceOfSeniorNotes", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "parentTag": "us-gaap_PaymentsToAcquireBusinessesGross", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofPurchasePriceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash consideration funded by net proceeds from the issuance of Senior Notes", "label": "Business Combination, Consideration Transferred, Proceeds From Issuance Of Senior Notes", "documentation": "Business Combination, Consideration Transferred, Proceeds From Issuance Of Senior Notes" } } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUS": { "lang": { "en-us": { "role": { "terseLabel": "ACQUISITION OF VALIDUS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } } }, "auth_ref": { "r191": "r787" } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable and Accrued Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accounts Payable and Accrued Liabilities" } } } }, "auth_ref": { } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedInvestmentIncome", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued investment income", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Investment Income", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Investment Income" } } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } } }, "auth_ref": { "r75": "r75" } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": { "r75": "r75" } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredAcquisitionCosts", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred acquisition costs and value of business acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Acquisition Costs", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Acquisition Costs" } } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } } }, "auth_ref": { "r75": "r75" } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } } }, "auth_ref": { "r75": "r75" } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesValueOfBusinessAcquiredAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesValueOfBusinessAcquiredAndOtherAdjustments", "crdr": "credit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability related to VOBA and other adjustments", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Value Of Business Acquired And Other Adjustments", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Tax Liabilities, Value Of Business Acquired And Other Adjustments" } } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Identifiable indefinite lived intangible assets (insurance licenses)", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } } }, "auth_ref": { "r75": "r75" } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssetsImpairmentLoss", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment loss on insurance licenses", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Impairment Loss", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Impairment Loss" } } } }, "auth_ref": { } } }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 11.0 } } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets", "periodStartLabel": "Gross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023", "periodEndLabel": "Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } } }, "auth_ref": { "r75": "r75" } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAmortization", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Amortization", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill, Amortization" } } } }, "auth_ref": { } } }, "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillRollForward", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward]", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward]", "documentation": "Business Combination, Recognized

Identifiable Assets Acquired And Liabilities Assumed, Intangible Assets, Other Than Goodwill [Roll Forward] } } } , "auth_ref": {} } } , "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" : { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid reinsurance premiums", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } } , "auth_ref": { "r74", "r75" } } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInOtherVenturesUnderEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsInOtherVenturesUnderEquityMethod", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments in other ventures, under equity method", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments in Other Ventures, Under Equity Method", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments in Other Ventures, Under Equity Method" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsTrading": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInvestmentsTrading", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments trading", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Trading", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Trading" } } } } } , "auth_ref": {} } } , "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } } } , "auth_ref": { "r75" } } } , "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLossesRecoverable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLossesRecoverable", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Losses recoverable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Losses Recoverable", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Losses Recoverable" } } } } } , "auth_ref": {} } } , "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total identifiable net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } } } } , "auth_ref": { "r74", "r75" } } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidReinsurancePremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPrepaidReinsurancePremiums", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 9.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid reinsurance premiums", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Reinsurance Premiums", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Prepaid Reinsurance Premiums" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReinsuranceBalancesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReinsuranceBalancesPayable", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reinsurance balances payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Balances Payable", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Balances Payable" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReinsurancePremiumsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReinsurancePremiumsReceivable", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reinsurance premiums receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Premiums Receivable", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reinsurance Premiums Receivable" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReserveForClaimsAndClaimExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReserveForClaimsAndClaimExpenses", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reserve for claims and claim expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Claims and Claim Expenses", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Claims and Claim Expenses" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReserveForUnearnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReserveForUnearnedPremiums", "crdr": "credit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reserve for unearned premiums", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Unearned Premiums", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Reserve for Unearned Premiums" } } } } } , "auth_ref": {} } } , "rnr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShortTermInvestments", "crdr": "debit", "calculation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 10.0 } } , "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short term investments", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short Term Investments", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short Term Investments" } } } } } , "auth_ref": {} } } , "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "documentation": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } } } } , "auth_ref": {} } } , "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate expenses associated with the acquisition", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } } } } , "auth_ref": { "r72" } } } , "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } } } } , "auth_ref": { "r192", "r193", "r194", "r195" } } } , "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } } } } , "auth_ref": {} } } , "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CH", "presentation": {


```

http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails",
"http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails", "http://www.renre.com/role/TAXATIONNarrativeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Switzerland", "label": "SWITZERLAND" } } }, {"auth_ref": { "r1": "CaliforniaWildfiresMember", "domainItemType": "nsuri", "presentation": { "http://www.renre.com/20241231", "localname": "CaliforniaWildfiresMember", "presentation": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "California Wildfires", "label": "California Wildfires [Member]", "documentation": "California Wildfires" } } }, {"auth_ref": { "r1": "us-gaap_CapitalSupportAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalSupportAgreementMember", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Capital Support Agreement", "label": "Capital Support Agreement [Member]", "documentation": "A Capital Support Agreement provides for cash infusions, to maintain a specific credit rating." } } }, {"auth_ref": { "r1": "us-gaap_CarryingReportedAmountFairValueDisclosureMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, {"auth_ref": { "r1": "r113", "r114": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, {"auth_ref": { "r1": "r39", "r333", "r1292": "us-gaap_CashAndCashEquivalentsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": { "r1": "us-gaap_CashAndCashEquivalentsPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" }, {"lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, {"auth_ref": { "r1": "r40": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails" }, {"lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of year", "periodEndLabel": "Cash and cash equivalents, end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": { "r1": "r39", "r175", "r372": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "parentTag": null, "weight": null, "order": null, "root": true } }, {"presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails" }, {"lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": { "r1": "r39", "r175": "rnr_CasualtyandSpecialtySegmentMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CasualtyandSpecialtySegmentMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails", "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Casualty and Specialty", "label": "Casualty and Specialty Segment [Member]", "documentation": "Casualty and Specialty Segment [Member] } } }, {"auth_ref": { "r1": "rnr_CatastropheBondsMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CatastropheBondsMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Catastrophe bonds", "verboseLabel": "Catastrophe bonds", "label": "Catastrophe Bonds [Member]", "documentation": "An investment that invests in catastrophe bonds." } } }, {"auth_ref": { "r1": "r1": "us-gaap_CatastropheEventDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CatastropheEventDomain", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Catastrophe Event [Domain]", "label": "Catastrophic Event [Domain]", "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, {"auth_ref": { "r1": "r1375": "us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]", "label": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": { "r1": "r1375": "us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTable", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claim and Claim Adjustment Expense, Change [Table]", "label": "Liability for Unpaid Claim and Claim Adjustment Expense, Change [Table]", "documentation": "Disclosure of information about change in incurred claim and claim adjustment expenses recognized in statement of income and attributable to insured event from prior year. Includes, but is not limited to, reason for change and disclosure of fact whether additional or return premium was accrued as result of prior-year effect." } } }, {"auth_ref": { "r1": "r23", "r1375": "us-gaap_CededCreditRiskCollateralizationAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CededCreditRiskCollateralizationAxis", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Ceded Credit Risk, Collateralization [Axis]", "label": "Ceded Credit Risk, Collateralization [Axis]", "documentation": "Information by collateralization of reinsurance recoverable." } } }, {"auth_ref": { "r1": "r1529": "us-gaap_CededCreditRiskCollateralizationDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CededCreditRiskCollateralizationDomain", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Ceded Credit Risk, Collateralization [Domain]", "label": "Ceded Credit Risk, Collateralization [Domain]", "documentation": "Collateralization of reinsurance recoverable." } } }, {"auth_ref": { "r1": "us-gaap_CededCreditRiskLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CededCreditRiskLineItems", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Ceded Credit Risk [Line Items]", "label": "Ceded Credit Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": { "r1": "r1079": "us-gaap_CededCreditRiskSecuredMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "
```


"r1018","r1070","r1071","r1074","r1076","r1759"}}, {"us-gaap_CededPremiumsWritten": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CededPremiumsWritten", "crdr": "debit", "calculation": {"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"parentTag": "us-gaap_PremiumsWrittenNet", "weight": 1.0, "order": 3.0}}, "presentation": {"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Ceded", "terseLabel": "Ceded premiums written", "label": "Ceded Premiums Written", "documentation": "Amount of written premiums ceded to other entities."}}}, "auth_ref": {"r225", "r226"}}, "rnr_ChangeInActuarialAssumptionMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ChangeInActuarialAssumptionMember", "presentation": {"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Actuarial assumption changes", "label": "Change in Actuarial Assumption [Member]", "documentation": "Change in Actuarial Assumption [Member]"}}, "auth_ref": {"r11}, "ecd_ChangedPeerGroupFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Changed Peer Group Footnote", "label": "Changed Peer Group Footnote", "documentation": "Footnote [Text Block]"}}, "auth_ref": {"r1466"}}, "srt_ChiefExecutiveOfficerMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": {"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer."}}}, "auth_ref": {"r1594"}}, "ecd_ChngInFrValAsOfVstngDtOPrrYrEqtyAwrdsVstdInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"}}, "auth_ref": {"r1463"}}, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"}}, "auth_ref": {"r1461"}}, "rnr_CitibankEuropeMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CitibankEuropeMember", "presentation": {"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Citibank Europe", "label": "Citibank Europe [Member]", "documentation": "Citibank Europe"}}, "auth_ref": {"r11}, "rnr_CitibankEuropePlcMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CitibankEuropePlcMember", "presentation": {"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Citibank Europe plc", "label": "Citibank Europe plc [Member]", "documentation": "Citibank Europe plc [Member]"}}, "auth_ref": {"r11}, "dei_CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": {"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city"}}, "auth_ref": {"r11}, "us-gaap_ClaimsDevelopmentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClaimsDevelopmentLineItems", "presentation": {"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": {"lang": {"en-us": {"role": {"terseLabel": "Claims Development [Line Items]", "label": "Claims Development [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r1052", "r1053", "r1055", "r1056", "r1381"}}, "us-gaap_ClassOfStockDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": {"http://www.renre.com/role/CoverPage": {"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails": {"http://www.renre.com/role/SHAREHOLDERSECURITYNarrativeDetails": {"http://www.renre.com/role/SUBSEQUENTEVENTSDetails": {"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."}}}, "auth_ref": {"r253", "r339", "r340", "r341", "r376", "r404", "r408", "r412", "r416", "r424", "r425", "r500", "r566", "r569", "r570", "r571", "r575", "r576", "r608", "r609", "r612", "r615", "r622", "r844", "r1086", "r1087", "r1088", "r1089", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1128", "r1149", "r1171", "r1261", "r1262", "r1263", "r1264", "r1265", "r1519", "r1572", "r1586"}}, "us-gaap_ClassOfStockLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": {"http://www.renre.com/role/SHAREHOLDERSECURITYNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r339", "r340", "r341", "r424", "r608", "r609", "r610", "r612", "r615", "r620", "r622", "r1086", "r1087", "r1088", "r1089", "r1323", "r1519", "r1572"}}, "ecd_CoSelectedMeasureAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount"}}, "auth_ref": {"r1467"}}, "ecd_CoSelectedMeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name"}}, "auth_ref": {"r1467"}}, "us-gaap_CombinedRatio": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CombinedRatio", "calculation": {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {"lang": {"en-us": {"role": {"totalLabel": "Combined ratio", "label": "Combined Ratio", "documentation": "Ratio of non-life losses and loss expenses, non-life acquisition expenses and non-life general and administrative expenses, to non-life net premiums earned."}}}, "auth_ref": {"r11}, "us-gaap_CommercialAndIndustrialSectorMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialAndIndustrialSectorMember", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Industrial, utilities and energy", "label": "Commercial and Industrial Sector [Member]", "documentation": "Sector of the economy consisting of companies engaged in commercial and industrial business activities."}}}, "auth_ref": {"r1312", "r1812", "r1814", "r1815", "r1816"}}, "us-gaap_CommercialMortgageBackedSecuritiesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": {"http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": {"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": {"http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commercial mortgage-backed", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans."}}}, "auth_ref": {"r1345", "r1347", "r1349", "r1599", "r1601", "r1602", "r1658"}}, "us-gaap_CommitmentsAndContingencies": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": {"http://www.renre.com/role/ConsolidatedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0}}, "presentation": {"http://www.renre.com/role/ConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"verboseLabel": "Commitments and contingencies (Note 20)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."}}}, "auth_ref": {"r144", "r216", "r975", "r1277"}}, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": {"en-us": {"role": {"terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]"}}, "auth_ref": {"r11}, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": {"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMS": {"lang": {"en-us": {"role": {"terseLabel": "COMMITMENTS, CONTINGENCIES AND OTHER ITEMS", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies."}}}, "auth_ref": {"r181", "r555", "r556", "r1273", "r1634", "r1639"}}, "rnr_CommitmentsAndContingenciesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CommitmentsAndContingenciesLineItems", "presentation": {"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commitments and Contingencies [Line Items]", "label": "Commitments and Contingencies [Line Items]", "documentation": "Commitments and Contingencies [Line Items]"}}, "auth_ref": {"r11}, "rnr_CommitmentsAndContingenciesTable": {"xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CommitmentsAndContingenciesTable", "presentation": {"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commitments and Contingencies [Table]", "label": "Commitments and Contingencies [Table]", "documentation": "Commitments and Contingencies [Table]"}}, "auth_ref": {"r11}, "rnr_CommodityFuturesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CommodityFuturesMember", "presentation": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commodity futures", "label": "Commodity Futures [Member]", "documentation": "Commodity Futures"}}, "auth_ref": {"r11}, "us-gaap_CommodityOptionMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityOptionMember", "presentation": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Commodity options", "label": "Commodity Option [Member]", "documentation": "Option contract in which the underlying asset is a commodity."}}}, "auth_ref": {"r11}, "us-gaap_CommonStockDividendsPerShareDeclared": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": {"http://www.renre.com/role/SHAREHOLDERSECURITYNarrativeDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Dividends declared per common share (in usd per share)", "label": "Common Stock Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."}}}, "auth_ref": {"r189"}}, "us-gaap_CommonStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": {"http://www.renre.com/role/ConsolidatedStatementsofChangesinShareholdersEquity": {"http://www.renre.com/role/CoverPage": {"http://www.renre.com/role/SHAREHOLDERSECURITYNarrativeDetails": {"http://www.renre.com/role/SHAREHOLDERSECURITYRollforwardofSharesIssuedandOutstandingDetails": {"http://www.renre.com/role/SUBSEQUENTEVENTSDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Common Shares, Par Value \$1.00 per share", "terseLabel": "Common shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer."}}}, "auth_ref": {"r1389", "r1390", "r1391", "r1393", "r1394", "r1395", "r1398", "r1581", "r1582", "r1585", "r1703", "r1805", "r1810"}}, "us-gaap_CommonStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {"http://www.renre.com/role/ConsolidatedBalanceSheetsParenthetical": {"http://www.renre.com/role/SCHEDULECONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Common shares, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock."}}}, "auth_ref": {"r149}}}, "us-gaap_CommonStockSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "CommonStockSharesAuthorized", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Authorized common shares (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r149", "r128" }, "us-gaap": "CommonStockSharesIssued", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Common shares, shares issued (in shares)", "periodStartLabel": "Shares issued - beginning balance (in shares)", "periodEndLabel": "Shares issued - ending balance (in shares)", "label": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r149" }, "us-gaap": "CommonStockSharesOutstanding", { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Common shares, shares outstanding (in shares)", "periodStartLabel": "Shares outstanding - beginning balance (in shares)", "periodEndLabel": "Shares outstanding - ending balance (in shares)", "label": "Common Stock, Shares Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r21", "r149", "r128", "r146", "r1910", "r1811" }, "us-gaap": "CommonStockValue", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Common shares: \$1.00 par value in2013 50,180,987 shares issued and outstanding at Decemberu00a031, 2024 (2023 u2013 52,693,887) (Note 12)", "terseLabel": "Common shares: \$1.00 par value in2013 50,180,987 shares issued and outstanding at Decemberu00a031, 2024 (2023 u2013 52,693,887) (Note 12)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r149", "r977", "r1358" }, "ecd": "CompActuallyPaidVsCoSelectedMeasureTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r1472" }, "ecd": "CompActuallyPaidVsNetIncomeTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r1471" }, "ecd": "CompActuallyPaidVsOtherMeasureTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r1473" }, "ecd": "CompActuallyPaidVsTotalShareholderRtnTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r1470" }, "us-gaap": "ComprehensiveIncomeNetOfTax", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfComprehensiveIncomeLossDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) attributable to RenaissanceRe", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r32", "r351", "r353", "r361", "r960", "r994", "r996" }, "us-gaap": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap:ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Comprehensive (income) loss attributable to redeemable noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r0", "r63", "r94", "r351", "r353", "r360", "r959", "r994", "r995" }, "us-gaap": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap:ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r94", "r200", "r351", "r353", "r359", "r958", "r994" }, "us-gaap": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": { "us-gaap:ComputerSoftwareIntangibleAssetMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": { "r1286", "r1290", "r1622", "r1623", "r1624", "r1625", "r1627", "r1629", "r1632", "r1633" }, "us-gaap": "ConcentrationRiskBenchmarkDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r44", "r46", "r115", "r116", "r459", "r1272" }, "us-gaap": "ConcentrationRiskByBenchmarkAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r44", "r46", "r115", "r116", "r459", "r1079", "r1272" }, "us-gaap": "ConcentrationRiskByTypeAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": { "r44", "r46", "r115", "r116", "r459", "r1272", "r1529" }, "us-gaap": "ConcentrationRiskPercentage1", { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "verboseLabel": "Percent of gross premiums received", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": { "r44", "r46", "r115", "r116", "r459" }, "us-gaap": "ConcentrationRiskTypeDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r44", "r46", "r115", "r116", "r459", "r1272" }, "srt": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Condensed Financial Information Disclosure [Abstract]", "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "auth_ref": { "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANT", "lang": { "en-us": { "role": { "terseLabel": "CONDENSED FINANCIAL INFORMATION OF REGISTRANT", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document." } } }, "auth_ref": { "r384", "r1524" }, "srt": "CondensedFinancialStatementsCaptionsLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedFinancialStatementsCaptionsLineItems", "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfComprehensiveIncomeLossDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Condensed Financial Statements, Captions [Line Items]", "label": "Condensed Financial Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r255", "r323", "r324", "r325", "r384", "r1524" }, "srt": "ConsolidatedEntitiesAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": {

http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofComprehensiveIncomeLossDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": { "r255", "r305", "r384", "r792", "r793", "r796", "r797", "r798", "r1278", "r1544", "r1547", "r1548", "r1646", "r1649", "r1650" } }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": {
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofComprehensiveIncomeLossDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": { "r255", "r305", "r384", "r792", "r793", "r796", "r797", "r798", "r1278", "r1544", "r1547", "r1548", "r1646", "r1649", "r1650" } }, "srt_ConsolidatedPropertyAndCasualtyInsuranceEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedPropertyAndCasualtyInsuranceEntityMember", "presentation": {
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consolidated Subsidiaries", "label": "SEC Schedule 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Consolidated Property and Casualty Insurance Entity [Member]", "documentation": "Controlled entity included in financial statements of registrant with liability for property-casualty insurance claim." } } }, "auth_ref": { "r286", "r1023" } }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails",
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r228", "r255", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r384", "r422", "r432", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r566", "r567", "r568", "r569", "r571", "r572", "r573", "r574", "r575", "r1306", "r1307", "r1545", "r1546", "r1647", "r1648" } }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails",
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r228", "r255", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r384", "r422", "r432", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r566", "r567", "r568", "r569", "r571", "r572", "r573", "r574", "r575", "r1306", "r1307", "r1545", "r1546", "r1647", "r1648" } }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": {
"http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions or any noncontrolling interest." } } }, "auth_ref": { "r240" } }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": {
"http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": { "r81", "r87", "r89" } }, "us-gaap_ConsumerSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsumerSectorMember", "presentation": {
"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails" | "lang": { "en-us": { "role": { "terseLabel": "Consumer", "label": "Consumer Sector [Member]", "documentation": "Sector of economy consisting of companies engaged in business activity related to consumer product and service." } } }, "auth_ref": { "r1812", "r1814", "r1815", "r1816" } }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": {
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails",
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": { "r1327", "r1329", "r1345", "r1359", "r1386", "r1802" } }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": {
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": { "r25", "r447", "r448", "r449", "r450", "r453", "r1590" } }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": {
"http://www.renre.com/role/REINVESTMENTSScheduleofReceivableNoncontrollingInterestActivityDetails",
"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" | "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": { "r321", "r322", "r381", "r382", "r581", "r610", "r877", "r901", "r966", "r1294", "r1297" } }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { } }, "us-gaap_CreditDefaultSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditDefaultSwapMember", "presentation": {
"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails",
"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails" | "lang": { "en-us": { "role": { "terseLabel": "Credit default swaps", "label": "Credit Default Swap [Member]", "documentation": "Credit derivative contract between credit default swap buyer and third party in which credit default swap buyer makes periodic payment to third party and third party guarantees to reimburse credit default swap buyer if original borrower defaults." } } }, "auth_ref": { "r1396", "r1397" } }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": {
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails" | "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { "r565", "r1

"http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": "I",
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails" }, {"lang": "en-us", "role": "verboseLabel", "Customer relationships and customer lists", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } }, {"auth_ref": "r78", "r1622", "r1623", "r1624", "r1625", "r1627", "r1629", "r1632", "r1633" } }, {"rnr_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "CustomerThreeMember", "presentation": "I",
"http://www.renre.com/role/REINSURANCENarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Customer Three", "label": "Customer Three [Member]",
"documentation": "Customer Three" } }, {"auth_ref": "I", "rnr_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231",
"localname": "CustomerTwoMember", "presentation": "I", "http://www.renre.com/role/REINSURANCENarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer Two" } }, {"auth_ref": "I",
"cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } }, {"auth_ref": "r1418", "r1507" } }, {"cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Board of Directors Oversight [Text Block]" } }, {"auth_ref": "r1418", "r1507" } }, {"cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } }, {"auth_ref": "r1420", "r1509" } }, {"cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } }, {"auth_ref": "r1420", "r1509" } }, {"cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } }, {"auth_ref": "r1422", "r1511" } }, {"cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } }, {"auth_ref": "r1420", "r1509" } }, {"cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } }, {"auth_ref": "r1413", "r1502" } }, {"cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Processes Integrated [Flag]" } }, {"auth_ref": "r1414", "r1503" } }, {"cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Processes Integrated [Text Block]" } }, {"auth_ref": "r1414", "r1503" } }, {"cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Strategy and Governance [Abstract]" } }, {"auth_ref": "r1412", "r1501" } }, {"cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Strategy and Governance [Line Items]" } }, {"auth_ref": "r1412", "r1501" } }, {"cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Strategy and Governance [Table]" } }, {"auth_ref": "r1412", "r1501" } }, {"cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Management Third Party Engaged [Flag]" } }, {"auth_ref": "r1415", "r1504" } }, {"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } }, {"auth_ref": "r1417", "r1506" } }, {"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } }, {"auth_ref": "r1417", "r1506" } }, {"cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } }, {"auth_ref": "r1418", "r1507" } }, {"cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } }, {"auth_ref": "r1421", "r1510" } }, {"cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Role of Management [Text Block]" } }, {"auth_ref": "r1419", "r1508" } }, {"cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": "I",
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" }, {"lang": "en-us", "role": "label", "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } }, {"auth_ref": "r1416", "r1505" } }, {"rnr_DaVinciReinsuranceLtd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DaVinciReinsuranceLtd.Member", "presentation": "I",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" }, {"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails",
"http://www.renre.com/role/SUBSEQUENTEVENTSDetails" }, {"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "DaVinci Reinsurance", "label": "DaVinci Reinsurance Ltd. [Member]", "documentation": "DaVinci Reinsurance Ltd. [Member]" } }, {"auth_ref": "I",
"rnr_DavinciReThirdPartyInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DavinciReThirdPartyInvestorsMember", "presentation": "I", "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails" }, {"lang": "en-us", "role": "verboseLabel", "DaVinci", "terseLabel": "DaVinci", "label": "DavinciRe Third-Party Investors [Member]", "documentation": "DavinciRe Third-Party Investors" } }, {"auth_ref": "I", "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } }, {"auth_ref": "I", "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": "I",
"http://www.renre.com/role/DEBTANDCREDITFACILITIES" }, {"lang": "en-us", "role": "terseLabel", "DEBT AND CREDIT FACILITIES", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } }, {"auth_ref": "r182", "r374", "r546", "r547", "r548", "r549", "r550", "r564", "r565", "r577", "r583", "r584", "r585", "r586", "r587", "r588", "r593", "r600", "r601", "r603", "r862" } }, {"us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": "I", "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails" }, {"lang": "en-us", "role": "terseLabel", "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } }, {"auth_ref": "r29", "r137", "r138", "r211", "r215", "r384", "r578", "r579", "r580", "r581", "r582", "r584", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r599", "r1318", "r1319", "r1320", "r1321", "r1322", "r1356", "r1573", "r1635", "r1636", "r1637", "r1724", "r1725" } }, {"us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": "I",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, {"presentation": "I", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails" }, {"lang": "en-us", "role": "totalLabel", "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } }, {"auth_ref": "r29", "r29", "r215", "r604" } }, {"us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": "I", "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails" }, {"lang": "en-us", "role": "verboseLabel", "Face amount", "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } }, {"auth_ref": "r579", "r862", "r863", "r1319", "r1320", "r1356" } }, {"us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": "I

"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails";
"label": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": { "r140", "r579" } }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails";
"label": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r384", "r578", "r579", "r580", "r581", "r582", "r584", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r599", "r602", "r1318", "r1319", "r1320", "r1321", "r1322", "r1356", "r1573", "r1724", "r1725" } }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails";
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails";
"label": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r29", "r384", "r578", "r580", "r581", "r582", "r584", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r599", "r1318", "r1319", "r1320", "r1321", "r1322", "r1356", "r1573", "r1635", "r1636", "r1637", "r1724", "r1725" } }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails";
"Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": { "r224" } }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails";
"label": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": { "r224" } }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails";
"label": "Debt Instrument, Redemption, Period One [Member]", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": { "r224" } }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails";
"label": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": { "r29", "r61", "r65", "r123", "r187", "r188", "r384", "r578", "r579", "r580", "r581", "r582", "r584", "r589", "r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r599", "r602", "r1318", "r1319", "r1320", "r1321", "r1322", "r1356", "r1573", "r1724", "r1725" } }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails";
"label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": { "r589", "r605", "r661", "r862", "r863", "r1319", "r1320", "r1356" } }, "us-gaap_DebtSecuritiesGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesGainLoss", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails";
"label": "Debt Securities, Gain (Loss)", "label": "Debt Securities, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": { "r1000", "r1563", "r1564" } }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails";
"label": "Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]", "documentation": "Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]" } } }, "auth_ref": { "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025", "r2026", "r2027", "r2028", "r2029", "r2030", "r2031", "r2032", "r2033", "r2034", "r2035", "r2036", "r2037", "r2038", "r2039", "r2040", "r2041", "r2042", "r2043", "r2044", "r2045", "r2046", "r2047", "r2048", "r2049", "r2050", "r2051", "r2052", "r2053", "r2054", "r2055", "r2056", "r2057", "r2058", "r2059", "r2060", "r2061", "r2062", "r2063", "r2064", "r2065", "r2066", "r2067", "r2068", "r2069", "r2070", "r2071", "r2072", "r2073", "r2074", "r2075", "r2076", "r2077", "r2078", "r2079", "r2080", "r2081", "r2082", "r2083", "r2084", "r2085", "r2086", "r2087", "r2088", "r2089", "r2090", "r2091", "r2092", "r2093", "r2094", "r2095", "r2096", "r2097", "r2098", "r2099", "r2100", "r2101", "r2102", "r2103", "r2104", "r2105", "r2106", "r2107", "r2108", "r2109", "r2110", "r2111", "r2112", "r2113", "r2114", "r2115", "r2116", "r2117", "r2118", "r2119", "r2120", "r2121", "r2122", "r2123", "r2124", "r2125", "r2126", "r2127", "r2128", "r2129", "r2130", "r2131", "r2132", "r2133", "r2134", "r2135", "r2136", "r2137", "r2138", "r2139", "r2140", "r2141", "r2142", "r2143", "r2144", "r2145", "r2146", "r2147", "r2148", "r2149", "r2150", "r2151", "r2152", "r2153", "r2154", "r2155", "r2156", "r2157", "r2158", "r2159", "r2160", "r2161", "r2162", "r2163", "r2164", "r2165", "r2166", "r2167", "r2168", "r2169", "r2170", "r2171", "r2172", "r2173", "r2174", "r2175", "r2176", "r2177", "r2178", "r2179", "r2180", "r2181", "r2182", "r2183", "r2184", "r2185", "r2186", "r2187", "r2188", "r2189", "r2190", "r2191", "r2192", "r2193", "r2194", "r2195", "r2196", "r2197", "r2198", "r2199", "r2200", "r2201", "r2202", "r2203", "r2204", "r2205", "r2206", "r2207", "r2208", "r2209", "r2210", "r2211", "r2212", "r2213", "r2214", "r2215", "r2216", "r2217", "r2218", "r2219", "r2220", "r2221", "r2222", "r2223", "r2224", "r2225", "r2226", "r2227", "r2228", "r2229", "r2230", "r2231", "r2232", "r2233", "r2234", "r2235", "r2236", "r2237", "r2238", "r2239", "r2240", "r2241", "r2242", "r2243", "r2244", "r2245", "r2246", "r2247", "r2248", "r2249", "r2250", "r2251", "r2252", "r2253", "r2254", "r2255", "r2256", "r2257", "r2258", "r2259", "r2260", "r2261", "r2262", "r2263", "r2264", "r2265", "r2266", "r2267", "r2268", "r2269", "r2270", "r2271", "r2272", "r2273", "r2274", "r2275", "r2276", "r2277", "r2278", "r2279", "r2280", "r2281", "r2282", "r2283", "r2284", "r2285", "r2286", "r2287", "r2288", "r2289", "r2290", "r2291", "r2292", "r2293", "r2294", "r2295", "r2296", "r2297", "r2298", "r2299", "r2300", "r2301", "r2302", "r2303", "r2304", "r2305", "r2306", "r2307", "r2308", "r2309", "r2310", "r2311", "r2312", "r2313", "r2314", "r2315", "r2316", "r2317", "r2318", "r2319", "r2320", "r2321", "r2322", "r2323", "r2324", "r2325", "r2326", "r2327", "r2328", "r2329", "r2330", "r2331", "r2332", "r2333", "r2334", "r2335", "r2336", "r2337", "r2338", "r2339", "r2340", "r2341", "r2342", "r2343", "r2344", "r2345", "r2346", "r2347", "r2348", "r2349", "r2350", "r2351", "r2352", "r2353", "r2354", "r2355", "r2356", "r2357", "r2358", "r2359", "r2360", "r2361", "r2362", "r2363", "r2364", "r2365", "r2366", "r2367", "r2368", "r2369", "r2370", "r2371", "r2372", "r2373", "r2374", "r2375", "r2376", "r2377", "r2378", "r2379", "r2380", "r2381", "r2382", "r2383", "r2384", "r2385", "r2386", "r2387", "r2388", "r2389", "r2390", "r2391", "r2392", "r2393", "r2394", "r2395", "r2396", "r2397", "r2398", "r2399", "r2400", "r2401", "r2402", "r2403", "r2404", "r2405", "r2406", "r2407", "r2408", "r2409", "r2410", "r2411", "r2412", "r2413", "r2414", "r2415", "r2416", "r2417", "r2418", "r2419", "r2420", "r2421", "r2422", "r2423", "r2424", "r2425", "r2426", "r2427", "r2428", "r2429", "r2430", "r2431", "r2432", "r2433", "r2434", "r2435", "r2436", "r2437", "r2438", "r2439", "r2440", "r2441", "r2442", "r2443", "r2444", "r2445", "r2446", "r2447", "r2448", "r2449", "r2450", "r2451", "r2452", "r2453", "r2454", "r2455", "r2456", "r2457", "r2458", "r2459", "r2460", "r2461", "r2462", "r2463", "r2464", "r2465", "r2466", "r2467", "r2468", "r2469", "r2470", "r2471", "r2472", "r2473", "r2474", "r2475", "r2476", "r2477", "r2478", "r2479", "r2480", "r2481", "r2482", "r2483", "r2484", "r2485", "r2486", "r2487", "r2488", "r2489", "r2490", "r2491", "r2492", "r2493", "r2494", "r2495", "r2496", "r2497", "r2498", "r2499", "r2500", "r2501", "r2502", "r2503", "r2504", "r2505", "r2506", "r2507", "r2508", "r2509", "r2510", "r2511", "r2512", "r2513", "r2514", "r2515", "r2516", "r2517", "r2518", "r2519", "r2520", "r2521", "r2522", "r2523", "r2524", "r2525", "r2526", "r2527", "r2528", "r2529", "r2530", "r2531", "r2532", "r2533", "r2534", "r2535", "r2536", "r2537", "r2538", "r2539", "r2540", "r2541", "r2542", "r2543", "r2544", "r2545", "r2546", "r2547", "r2548", "r2549", "r2550", "r2551", "r2552", "r2553", "r2554", "r2555", "r2556", "r2557", "r2558", "r2559", "r2560", "r2561", "r2562", "r2563", "r2564", "r2565", "r2566", "r2567", "r2568", "r2569", "r2570", "r2571", "r2572", "r2573", "r2574", "r2575", "r2576", "r2577", "r2578", "r2579", "r2580", "r2581", "r2582", "r2583", "r2584", "r2585", "r2586", "r2587", "r2588", "r2589", "r2590", "r2591", "r2592", "r2593", "r2594", "r2595", "r2596", "r2597", "r2598", "r2599", "r2600", "r2601", "r2602", "r2603", "r2604", "r2605", "r2606", "r2607", "r2608", "r2609", "r2610", "r2611", "r2612", "r2613", "r2614", "r2615", "r2616", "r2617", "r2618", "r2619", "r2620", "r2621", "r2622", "r2623", "r2624", "r2625", "r2626", "r2627", "r2628", "r2629", "r2630", "r2631", "r2632", "r2633", "r2634", "r2635", "r2636", "r2637", "r2638", "r2639", "r2640", "r2641", "r2642", "r2643", "r2644", "r2645", "r2646", "r2647", "r2648", "r2649", "r2650", "r2651", "r2652", "r2653", "r2654", "r2655", "r2656", "r2657", "r2658", "r2659", "r2660", "r2661", "r2662", "r2663", "r2664", "r2665", "r2666", "r2667", "r2668", "r2669", "r2670", "r2671", "r2672", "r2673", "r2674", "r2675", "r2676", "r2677", "r2678", "r2679", "r2680", "r2681", "r2682", "r2683", "r2684", "r2685", "r2686", "r2687", "r2688", "r2689", "r2690", "r2691", "r2692", "r2693", "r2694", "r2695", "r2696", "r2697", "r2698", "r2699", "r2700", "r2701", "r2702", "r2703", "r2704", "r2705", "r2706", "r2707", "r2708", "r2709", "r2710", "r2711", "r2712", "r2713", "r2714", "r2715", "r2716", "r2717", "r2718", "r2719", "r2720", "r2721", "r2722", "r2723", "r2724", "r2725", "r2726", "r2727", "r2728", "r2729", "r2730", "r2731", "r2732", "r2733", "r2734", "r2735", "r2736", "r2737", "r2738", "r2739", "r2740", "r2741", "r2742", "r2743", "r2744", "r2745", "r2746", "r2747", "r2748", "r2749", "r2750", "r2751", "r2752", "r2753", "r2754", "r2755", "r2756", "r2757", "r2758", "r2759", "r2760", "r2761", "r2762", "r2763", "r2764", "r2765", "r2766", "r2767", "r2768", "r2769", "r2770", "r2771", "r2772", "r2773", "r2774", "r2775", "r2776", "r2777", "r2778", "r2779", "r2780", "r2781", "r2782", "r2783", "r2784", "r2785", "r2786", "r2787", "r2788", "r2789", "r2790", "r2791", "r2792", "r2793", "r2794", "r2795", "r2796", "r2797", "r2798", "r2799", "r2800", "r2801", "r2802", "r2803", "r2804", "r2805", "r2806", "r2807", "r2808", "r2809", "r2810", "r2811", "r2812", "r2813", "r2814", "r2815", "r2816", "r2817", "r2818", "r2819", "r2820", "r2821", "r2822", "r2823", "r2824", "r2825", "r2826", "r2827", "r2828", "r2829", "r2830", "r2831", "r2832", "r2833", "r2834", "r2835", "r2836", "r2837", "r2838", "r2839", "r2840", "r2841", "r2842", "r2843", "r2844", "r2845", "r2846", "r2847", "r2848", "r2849", "r2850", "r2851", "r2852", "r2853", "r2854", "r2855", "r2856", "r2857", "r2858", "r2859", "r2860", "r2861", "r2862", "r2863", "r2864", "r2865", "r2866", "r2867", "r2868", "r2869", "r2870", "r2871", "r2872", "r2873", "r2874", "r2875", "r2876", "r2877", "r2878", "r2879", "r2880", "r2881", "r2882", "r2883", "r2884", "r2885", "r2886", "r2887", "r2888", "r2889", "r2890", "r2891", "r2892", "r2893", "r2894", "r2895", "r2896", "r2897", "r2898", "r2899", "r2900", "r2901", "r2902", "r2903", "r2904", "r2905", "r2906", "r2907", "r2908", "r2909", "r2910", "r2911", "r2912", "r2913", "r2914", "r2915", "r2916", "r2917", "r2918", "r2919", "r2920", "r2921", "r2922", "r2923", "r2924", "r2925", "r2926", "r2927", "r2928", "r2929", "r2930", "r2931", "r2932", "r2933", "r2934", "r2935", "r2936", "r2937", "r2938", "r2939", "r2940", "r2941", "r2942", "r2943", "r2944", "r2945", "r2946", "r2947", "r2948", "r2949", "r2950", "r2951", "r2952", "r2953", "r2954", "r2955", "r2956", "r2957", "r2958", "r2959", "r2960", "r2961", "r2962", "r2963", "r2964", "r2965", "r2966", "r2967", "r2968", "r2969", "r2970", "r2971", "r2972", "r2973", "r2974", "r2975", "r2976", "r2977", "r2978", "r2979", "r2980", "r2981", "r2982", "r2983", "r2984", "r2985", "r2986", "r2987", "r2988", "r2989", "r2990", "r29

"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails";
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails";
"Acquisition expenses", "label": "Deferred Policy Acquisition Costs, Amortization Expense", "documentation": "Amount of amortization expense (reversal of expense) for deferred policy acquisition costs." } } }, "auth_ref": { "r236", "r1002", "r1038", "r1039", "r1065", "r1372", "r1570", "r1745" } }, "us-gaap-DeferredPolicyAcquisitionCosts": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCosts", "crdr": "debit", "calculation": {
"http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.renre.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Deferred acquisition costs and value of business acquired", "label":
"Deferred Policy Acquisition Cost", "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force." } } }, "auth_ref": { "r237",
"r984", "r1039", "r1040", "r1065", "r1372" } }, "rnr-DeferredTaxAssetLiabilityBeforeValuationAllowanceNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "DeferredTaxAssetLiabilityBeforeValuationAllowanceNet", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax asset (liability)
before valuation allowance", "label": "Deferred Tax Asset (Liability) Before Valuation Allowance, Net", "documentation": "The sum of the tax effects as of the balance sheet
date of deferred tax assets and deferred tax liabilities, before consideration of the valuation allowance recorded as of the balance sheet date pertaining to the specified
deferred tax asset for which an assessment was made that it is more likely than not that all or a portion of such deferred tax asset will not be realized through related
deductions on future tax returns." } } }, "auth_ref": { } }, "rnr-DeferredTaxAssetsAmortizationAndDepreciation": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "DeferredTaxAssetsAmortizationAndDepreciation", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization and depreciation",
"label": "Deferred Tax Assets, Amortization And Depreciation", "documentation": "Deferred Tax Assets, Amortization And Depreciation" } } }, "auth_ref": { } }, "us-
gaap-DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDeferredIncome",
"crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight",
1.0, "order": 6.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred
underwriting results", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable
to deductible temporary differences from deferred income." } } }, "auth_ref": { "r1692" } },
"rnr-DeferredTaxAssetsEquityMethodInvestmentsAvailableForSaleInvestmentsandDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231",
"localname": "DeferredTaxAssetsEquityMethodInvestmentsAvailableForSaleInvestmentsandDerivatives", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Deferred
Tax Assets, Equity Method Investments, Available For Sale Investments and Derivatives", "documentation": "Deferred Tax Assets, Equity Method Investments, Available For
Sale Investments and Derivatives" } } }, "auth_ref": { } }, "us-gaap-DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
"rnr-DeferredTaxAssetLiabilityBeforeValuationAllowanceNet", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets", "label": "Deferred Tax Assets,
Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } },
"auth_ref": { "r761" } }, "us-gaap-DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsGrossAbstract", "presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": { } }, "rnr-DeferredTaxAssetsIntangibleAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DeferredTaxAssetsIntangibleAssets", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label":
"Deferred Tax Assets, Intangible Assets", "documentation": "Deferred Tax Assets, Intangible Assets" } } }, "auth_ref": { } }, "us-gaap-DeferredTaxAssetsLiabilitiesNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Net deferred tax assets", "totalLabel": "Net deferred tax asset (liability)", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after
allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } },
"auth_ref": { "r1690" } }, "us-gaap-DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": {
"parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Tax loss carryforwards", "label": "Deferred Tax
Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss
carryforwards." } } }, "auth_ref": { "r1692" } }, "us-gaap-DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-
gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": {
"en-us": { "role": { "terseLabel": "Reserve for claims and claim expenses", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation
allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": { "r1692" } }, "us-
gaap-DeferredTaxAssetsOtherTaxCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsOtherTaxCarryforwards", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag":
"us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": {
"en-us": { "role": { "terseLabel": "Deferred finance charges", "label": "Deferred Tax Assets, Other Tax Carryforwards", "documentation": "Amount, before allocation of
valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other." } } }, "auth_ref": { "r1692" } }, "us-
gaap-DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label":
"Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax
asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": { "r1692" } }, "us-
gaap-DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unearned premiums", "label":
"Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve", "documentation": "Amount before allocation of valuation allowances of
deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve." } } }, "auth_ref": { "r1692" } }, "us-
gaap-DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance",
"crdr": "credit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsLiabilitiesNet",
"weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails":
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset, valuation allowance",
"negatedTerseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely
than not that a tax benefit will not be realized." } } }, "auth_ref": { "r762" } }, "rnr-DeferredTaxAssetsValueOfInForceBusiness": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "DeferredTaxAssetsValueOfInForceBusiness", "crdr": "debit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Value of in-force business",
"label": "Deferred Tax Assets, Value Of In Force Business", "documentation": "Deferred Tax Assets, Value Of In Force Business" } } }, "auth_ref": { } }, "us-
gaap-DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Tax
Liabilities, Gross [Abstract]" } } }, "auth_ref": { } }, "rnr-DeferredTaxLiabilitiesDeferredExpenseDeferredAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredAcquisitionCosts", "crdr": "credit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred acquisition
expenses", "label": "Deferred Tax Liabilities, Deferred Expense, Deferred Acquisition Costs", "documentation": "Deferred Tax Liabilities, Deferred Expense, Deferred
Acquisition Costs" } } }, "auth_ref": { } }, "us-gaap-DeferredTaxLiabilitiesTaxDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxLiabilitiesTaxDeferredIncome", "crdr": "credit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": {
"parentTag": "us-gaap-DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred revenue", "label": "Deferred Tax
Liabilities, Tax Deferred Income", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income
classified as other." } } }, "auth_ref": { "r1692" } }, "rnr-DeferredTaxLiabilitiesU.S.TaxAccountingMethodChange": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "DeferredTaxLiabilitiesU.S.TaxAccountingMethodChange", "crdr": "credit", "calculation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap-DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } },
"presentation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "U.S. tax accounting
method change", "label": "Deferred Tax Liabilities, U.S. Tax Accounting Method Change", "documentation": "Deferred Tax Liabilities, U.S. Tax Accounting Method Change" } } },
"auth_ref": { } }, "rnr-DeferredTaxLiabilitiesValueOfBusinessAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"DeferredTaxLiabilitiesValueOfBusinessAcquired", "crdr": "credit", "calculation": { "http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": {
"parentTag": "us-gaap-DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.renre.com/role/TAXATIONDeferredTaxAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "VOBA", "label": "Deferred Tax Liabilities,
Value Of Business Acquired", "documentation": "Deferred Tax Liabilities, Value Of Business Acquired" } } }, "auth_ref": { } }, "us-gaap-DefinedBenefitPlanBenefitObligation": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label":
"Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit
plan." } } }, "auth_ref": { "r627" } }, "us-gaap-DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": {
"http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan assets at fair value", "label":
"Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is
not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": { "r638", "r649", "r650", "r651",


```

"1328", "r1328", "r1329" } }, "us-gaap:DefinedBenefitPlanFundedStatusOffPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOffPlan", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFFVALIDUSDefinedBenefitPensionPlanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net balance sheet liability", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth ref": { "r626", "r647", "r1329" } }, "us-gaap:DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": { "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contributions to defined contribution pension plans", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth ref": { "r685" } } }, "us-gaap:DepositContractsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositContractsLiabilities", "crdr": "credit", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Aggregate deposit liabilities", "label": "Deposit Contracts, Liabilities", "documentation": "Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred." } } }, "auth ref": { "r515", "r516" } }, "rnr:DepositContractsUnderwritingRiskOnlyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DepositContractsUnderwritingRiskOnlyMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Deposit Contracts, Underwriting Risk Only", "label": "Deposit Contracts, Underwriting Risk Only [Member]", "documentation": "Deposit Contracts, Underwriting Risk Only [Member]" } } }, "auth ref": { "rnr:DepositarySharesEachRepresentingA11000thInterestInASeriesG4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DepositarySharesEachRepresentingA11000thInterestInASeriesG4Member", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Depositary Shares, each representing a 1/1,000th interest in a Series G 4.20% Preference Share, Par Value $1.00 per share", "label": "Depositary Shares, each representing a 1/1,000th interest in a Series G 4 [Member]", "documentation": "Depositary Shares, each representing a 1/1,000th interest in a Series G 4" } } }, "auth ref": { "rnr:DepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DepositarySharesMember", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Depositary Shares, each representing a 1/1,000th interest in a Series F 5. [Member]", "label": "Depositary Shares, each representing a 1/1,000th interest in a Series F 5.750% Preference Share, Par Value $1.00 per share", "label": "Depositary Shares, each representing a 1/1,000th interest in a Series F 5. [Member]", "documentation": "Depositary Shares, each representing a 1/1,000th interest in a Series F 5. [Member]" } } }, "auth ref": { "us-gaap:DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Amortization, accretion and depreciation", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth ref": { "r12" } } }, "us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetCollateralObligationToReturnCashOffset", "crdr": "credit", "calculation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "parentTag": "us-gaap:DerivativeAssets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Offset in the Balance Sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets." } } }, "auth ref": { "r13", "r24" } } }, "us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth ref": { "r798" } } } }, "us-gaap:DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Derivative Assets", "crdr": "debit", "calculation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap:OtherAssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Assets", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth ref": { "r345", "r347", "r813", "r814", "r827", "r843", "r1105", "r1106", "r1107", "r1109", "r1110", "r1112", "r1113", "r1115", "r1117", "r1118", "r1134", "r1135", "r1226", "r1229", "r1232", "r1233", "r1234", "r1235", "r1297", "r1345", "r1349", "r1391", "r1707", "r1708", "r1709", "r1806" } } }, "us-gaap:DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsAbstract", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative Assets", "label": "Derivative Asset [Abstract]", "documentation": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "auth ref": { "us-gaap:DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "parentTag": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collateral Received", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth ref": { "r28", "r110", "r346", "r1295" } } } }, "us-gaap:DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "parentTag": "us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collateral Pledged", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth ref": { "r28", "r110", "r346", "r1295" } } } }, "us-gaap:DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract Type [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth ref": { "r1115", "r1118", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1141", "r1142", "r1143", "r1144", "r1159", "r1159", "r1160", "r1161", "r1164", "r1165", "r1166", "r1167", "r1226", "r1227", "r1232", "r1234", "r1389", "r1391", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1717", "r1718" } } } }, "us-gaap:DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "parentTag": "us-gaap:DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts of Recognized Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth ref": { "r27", "r155", "r205", "r206", "r344", "r1297" } } } }, "us-gaap:DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral":
```

"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "totalLabel":-f "Net Amount","label":-f "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction". "documentation":-f "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement."-l } },"auth_ref":-f "r28". "r109"-l },"us-gaap_DerivativeGainLossOnDerivativeNet":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeGainLossOnDerivativeNet","crdr":-f "credit","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "verboseLabel":-f "Amount of Gain (loss) Recognized on Derivatives","label":-f "Derivative, Gain (loss) on Derivative, Net","documentation":-f "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."-l } },"auth_ref":-f "r1700"-l },"us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration":-f "xbrltype":-f "enumerationSetItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "terseLabel":-f "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]","label":-f "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]","documentation":-f "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative."-l } },"auth_ref":-f "r1700"-l },"us-gaap_DerivativeInstrumentRiskAxis":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentRiskAxis","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails","http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails","http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails","http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Instrument Risk [Axis]","label":-f "Derivative Instrument [Axis]","documentation":-f "Information by type of derivative contract."-l } },"auth_ref":-f "r101","r104","r105","r207","r115","r118","r133","r134","r135","r136","r137","r138","r139","r141","r142","r143","r144","r158","r159","r160","r161","r164","r165","r166","r167","r126","r127","r1232","r1234","r1297","r1389","r1391","r1710","r1711","r1712","r1713","r1714","r1715","r1717","r1718"-l },"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock":-f "xbrltype":-f "textBlockItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTS"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "DERIVATIVE INSTRUMENTS","label":-f "Derivative Instruments and Hedging Activities Disclosure [Text Block]","documentation":-f "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."-l } },"auth_ref":-f "r203","r800","r807"-l },"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Instruments and Hedging Activities Disclosures [Line Items]","label":-f "Derivative Instruments and Hedging Activities Disclosures [Line Items]","documentation":-f "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."-l } },"auth_ref":-f "r101","r104","r105","r207","r115","r118","r133","r134","r135","r136","r137","r138","r139","r141","r142","r143","r144","r158","r159","r160","r161","r164","r165","r166","r167","r126","r127","r1232","r1234","r1297","r1389","r1391","r1710","r1711","r1712","r1713","r1714","r1715","r1717","r1718"-l },"us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Instruments and Hedging Activities Disclosures [Table]","label":-f "Derivative Instruments and Hedging Activities Disclosures [Table]","documentation":-f "Disclosure of information about derivatives and hedging activities."-l } },"auth_ref":-f "r203","r800","r807"-l },"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsGainLossByHedgingRelationshipAxis","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Hedging Relationship [Axis]","label":-f "Hedging Relationship [Axis]","documentation":-f "Information by type of hedging relationship."-l } },"auth_ref":-f "r22","r101","r104","r105","r111","r112","r799"-l },"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Instruments, Gain (Loss) [Table]","label":-f "Derivative Instruments, Gain (Loss) [Table]","documentation":-f "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."-l } },"auth_ref":-f "r22","r101","r104","r105","r111","r112","r799"-l },"us-gaap_DerivativeInstrumentsGainLossLineItems":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeInstrumentsGainLossLineItems","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Instruments, Gain (Loss) [Line Items]","label":-f "Derivative Instruments, Gain (Loss) [Line Items]","documentation":-f "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."-l } },"auth_ref":-f "r799"-l },"rnr_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsInvestmentPortfolioGainLoss":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://www.renre.com/20241231","localname":-f "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsInvestmentPortfolioGainLoss","crdr":-f "debit","calculation":-f "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails"-f "parentTag":-f "us-gaap_NonoperatingGainsLosses","weight":-f 1.0,"order":-f 2.0 },"presentation":-f "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Net realized and unrealized gains (losses) on investments-related derivatives","label":-f "Derivative Instruments Not Designated As Hedging Instruments Investment Portfolio Gain Loss","documentation":-f "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments and relating to the entity's investment portfolio."-l } },"auth_ref":-f "r22","r101","r104","r105","r111","r112","r799"-l },"us-gaap_DerivativeLiabilities":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeLiabilities","crdr":-f "credit","calculation":-f "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"-f "parentTag":-f "us-gaap_OtherLiabilitiesFairValueDisclosure","weight":-f 1.0,"order":-f 3.0 },"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-f "parentTag":-f "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral","weight":-f 1.0,"order":-f 2.0 },"presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails","http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "negatedTerseLabel":-f "Derivative liabilities","totalLabel":-f "Net Amounts of Liabilities Presented in the Balance Sheet","label":-f "Derivative Liability","documentation":-f "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."-l } },"auth_ref":-f "r345","r347","r813","r814","r827","r843","r1105","r1106","r1107","r1109","r1112","r1113","r1115","r1117","r1118","r1141","r1143","r1144","r1227","r1228","r1229","r1232","r1233","r1234","r1235","r1297","r1707","r1708","r1709","r1806"-l },"us-gaap_DerivativeLiabilitiesAbstract":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeLiabilitiesAbstract","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Liabilities","label":-f "Derivative Liability [Abstract]"-l } },"auth_ref":-f "r203","r800","r807"-l },"us-gaap_DerivativeLiabilityCollateralRightToReclaimCashOffset":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeLiabilityCollateralRightToReclaimCashOffset","crdr":-f "debit","calculation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-f "parentTag":-f "us-gaap_DerivativeLiabilities","weight":-f 1.0,"order":-f 2.0 },"presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Gross Amounts Offset in the Balance Sheet","label":-f "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Offset","documentation":-f "Amount of right to receive cash collateral under master netting arrangements offset against derivative liabilities."-l } },"auth_ref":-f "r13","r24"-l },"us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration":-f "xbrltype":-f "enumerationSetItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative Liability, Statement of Financial Position [Extensible Enumeration]","label":-f "Derivative Liability, Statement of Financial Position [Extensible Enumeration]","documentation":-f "Indicates line item in statement of financial position that includes derivative liability."-l } },"auth_ref":-f "r798"-l },"us-gaap_DerivativeLineItems":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeLineItems","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative [Line Items]","label":-f "Derivative [Line Items]","documentation":-f "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."-l } },"auth_ref":-f "r807"-l },"us-gaap_DerivativeMember":-f "xbrltype":-f "domainItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeMember","presentation":-f "http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Investments-related derivatives","label":-f "Derivative [Member]","documentation":-f "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required. (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)." } },"auth_ref":-f "r204","r1347"-l },"us-gaap_DerivativeNotionalAmount":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeNotionalAmount","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative, notional amount","label":-f "Derivative, Notional Amount","documentation":-f "Nominal or face amount used to calculate payment on derivative."-l } },"auth_ref":-f "r1698","r1699"-l },"us-gaap_DerivativeTable":-f "xbrltype":-f "stringItemType","nsuri":-f "http://fasb.org/us-gaap/2024","localname":-f "DerivativeTable","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Derivative [Table]","label":-f "Derivative [Table]","documentation":-f "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."-l } },"auth_ref":-f "r22","r95","r96","r97","r99","r102","r104","r106","r108","r112","r807"-l },"rnr_DerivativeWeightedAverageU.S.DollarEquivalentOfforeignDenominatedNetAssets":-f "xbrltype":-f "monetaryItemType","nsuri":-f "http://www.renre.com/20241231","localname":-f "DerivativeWeightedAverageU.S.DollarEquivalentOfforeignDenominatedNetAssets","crdr":-f "debit","presentation":-f "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails"-l,"lang":-f "en-us":-f "role":-f "role":-f "terseLabel":-f "Weighted average of U.S. dollar equivalent of foreign denominated net assets (liabilities)","label":-f "Derivative, Weighted Average U.S. Dollar Equivalent Of Foreign Denominated Net Assets","documentation":-f "Derivative, Weighted Average U.S. Dollar Equivalent Of Foreign Denominated Net Assets"-l } },"auth_ref":-

["us-gaap-DerivativesFairValueLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [{"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}}, {"auth_ref": [{"us-gaap-DerivativesPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [{"http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": {"lang": {"en-us": {"role": {"terseLabel": "Derivatives", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."}}}}, {"auth_ref": [{"r22": "r95", "r96": "r99", "r107": "r383", "r398"}]}]}, {"us-gaap-DesignatedAsHedgingInstrumentMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [{"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsOfOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": {"en-us": {"role": {"terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."} }}, {"auth_ref": [{"r22"}]}, {"us-gaap-DevelopedTechnologyRightsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [{"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Patents and intellectual property", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."}}}}, {"auth_ref": [{"r197": "r1622", "r1623", "r1624", "r1625", "r1627", "r1629", "r1632", "r1633"}]}]}, {"us-gaap-DirectPremiumsEarned": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectPremiumsEarned", "crd": "credit", "calculation": [{"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"parentTag": "us-gaap-PremiumsEarnedNet", "weight": 1.0, "order": 1.0}}, {"presentation": [{"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"http://www.renre.com/role/SCHEDULEIVSUPPLEMENTALSCHEDULEOFREINSURANCEPREMIUMSDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Direct", "terseLabel": "Gross Amounts", "label": "Direct Premiums Earned", "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned."}}}}, {"auth_ref": [{"r1017": "r1072", "r1075", "r1759"}]}]}, {"us-gaap-DirectPremiumsWritten": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DirectPremiumsWritten", "crd": "credit", "calculation": [{"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"parentTag": "us-gaap-PremiumsWrittenNet", "weight": 1.0, "order": 1.0}}, {"presentation": [{"http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": {"lang": {"en-us": {"role": {"verboseLabel": "Direct", "label": "Direct Premiums Written", "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums written."}}}}, {"auth_ref": [{"r1072"}]}]}, {"us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [{"http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANS": {"lang": {"en-us": {"role": {"terseLabel": "STOCK INCENTIVE COMPENSATION AND EMPLOYEE BENEFIT PLANS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement."}}}}, {"auth_ref": [{"r691": "r695", "r725", "r726", "r728", "r1338"}]}]}, {"us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "label": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]"}}]}, {"auth_ref": [{"rnr-DividendRestrictionsandStatutoryRequirementsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.renre.com/20241231", "localname": "DividendRestrictionsandStatutoryRequirementsDisclosureTextBlock", "presentation": [{"http://www.renre.com/role/STATUTORYREQUIREMENTS": {"lang": {"en-us": {"role": {"terseLabel": "STATUTORY REQUIREMENTS", "label": "Dividend Restrictions and Statutory Requirements Disclosure [Text Block]", "documentation": "Dividend Restrictions and Statutory Requirements Disclosure [Text Block]"}}}}, {"auth_ref": [{"r7": "r189"}]}]}, {"us-gaap-DividendsCommonStock": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crd": "debit", "presentation": [{"http://www.renre.com/role/ConsolidatedStatementsofChangesinShareholdersEquity": {"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": {"lang": {"en-us": {"role": {"negatedLabel": "Dividends on common shares (Note 12)", "verboseLabel": "Dividends on common shares", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."} }}, {"auth_ref": [{"r7": "r189"}]}]}, {"us-gaap-DividendsPreferredStock": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crd": "debit", "calculation": [{"http://www.renre.com/role/ConsolidatedStatementsofOperations": {"parentTag": "us-gaap-NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0}}, {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {"parentTag": "us-gaap-NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0}}, {"presentation": [{"http://www.renre.com/role/ConsolidatedStatementsofChangesinShareholdersEquity": {"http://www.renre.com/role/ConsolidatedStatementsofOperations": {"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails": {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Dividends on preference shares (Note 12)", "terseLabel": "Dividends on preference shares", "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."} }}, {"auth_ref": [{"r7": "r189"}]}]}, {"dei-DocumentsAnnualReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report."}}}}, {"auth_ref": [{"r1409": "r1433"}]}]}, {"dei-DocumentsFinStmntErrorCorrectionFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmntErrorCorrectionFlag", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."}}}}, {"auth_ref": [{"r1409": "r1410", "r1433", "r1476"}]}]}, {"dei-DocumentsFiscalPeriodFocus": {"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."}}}}, {"auth_ref": [{"dei-DocumentsFiscalYearFocus": {"xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."}}}}, {"auth_ref": [{"dei-DocumentsPeriodEndDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."}}}}, {"auth_ref": [{"dei-DocumentsTransitionReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report."}}}}, {"auth_ref": [{"r1454"}]}]}, {"dei-DocumentsSubmissionTypeItemType": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."}}}}, {"auth_ref": [{"dei-DocumentsIncorporatedByReferenceTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [{"http://www.renre.com/role/CoverPage": {"lang": {"en-us": {"role": {"terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference."}}}}, {"auth_ref": [{"r1407"}]}]}, {"us-gaap-DomesticCountryMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [{"http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": {"http://www.renre.com/role/TAXATIONNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Bermuda", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."}}}}, {"auth_ref": [{"r744"}]}]}, {"ecd-DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInThCompForCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdInThCompForCvrdYrMember", "presentation": [{"http://xbrl.sec.gov/cd/role/PrpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"}}}}, {"auth_ref": [{"r1465"}]}]}, {"us-gaap-EarningsPerShareAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": {"en-us": {"role": {"terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]"}}}}, {"auth_ref": [{"us-gaap-EarningsPerShareBasic": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [{"http://www.renre.com/role/ConsolidatedStatementsofOperations": {"http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share lu2013 basic (in dollars per share)", "terseLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share lu2013 basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."}}}}, {"auth_ref": [{"r362": "r390", "r391", "r392", "r393", "r394", "r395", "r404", "r412", "r415", "r416", "r421", "r782", "r790", "r810", "r811", "r961", "r997", "r1299"}]}]}, {"us-gaap-EarningsPerShareDiluted": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [{"http://www.renre.com/role/ConsolidatedStatementsofOperations": {"http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share lu2013 diluted (in dollars per share)", "terseLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share lu2013 diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."}}}}, {"auth_ref": [{"r362": "r390", "r391", "r392", "r393", "r394", "r395", "r404", "r412", "r415", "r416", "r421", "r782", "r790", "r810", "r811", "r961", "r997", "r1299"}]}]}, {"us-gaap-EarningsPerSharePolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [{"http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": {"lang": {"en-us": {"role": {"verboseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."}}}}, {"auth_ref": [{"r42", "r43", "r418"}]}]}, {"us-gaap-EarningsPerShareReconciliationAbstract": {"xbrltype":

```

stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": {
  "http://www.renre.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails", "lang": { "en-us": { "role": { "verboseLabel":
    "Numerator", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": { "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
    "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.renre.com/role/EARNINGSPEERSHARE", "lang": { "en-us": { "role": {
      "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r400",
      "r417", "r419", "r420" } } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri":
      "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": {
        "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-
        gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } } }, "presentation": {
        "http://www.renre.com/role/ConsolidatedStatementsofCashFlows",
        "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": { "en-us": { "role": { "terseLabel":
          "Effect of exchange rate changes on foreign currency cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents,
          Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents
          restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency
          on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not
          limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of
          changes in value because of changes in interest rates." } } }, "auth_ref": { "r852" } } }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
          "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
          "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Statutory income tax rate", "label": "Effective Income
            Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income
            (loss)." } } }, "auth_ref": { "r378", "r744", "r772", "r1341" } } }, "renr_EffectiveIncomeTaxRateReconciliationAtForeignStatutoryIncomeTaxRatePercent": { "xbrltype":
            "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAtForeignStatutoryIncomeTaxRatePercent",
            "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Foreign statutory income tax rate", "label": "Effective
              Income Tax Rate Reconciliation, at Foreign Statutory Income Tax Rate, Percent", "documentation": "Effective Income Tax Rate Reconciliation, at Foreign Statutory Income
              Tax Rate, Percent" } } }, "auth_ref": { "us-gaap_EffectiveIncomeTaxRateReconciliationBeatAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
              gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationBeatAmount", "crdr": "debit", "calculation": {
                "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } } }, "presentation": {
                "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "OECD Pillar Two global minimum tax", "label":
                  "Effective Income Tax Rate Reconciliation, BEAT, Amount", "documentation": "Amount of reported income tax expense from difference to expected income tax expense
                  (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to base erosion and anti-abuse tax
                  (BEAT)." } } }, "auth_ref": { "r1341", "r1687", "r1689" } } }, "renr_EffectiveIncomeTaxRateReconciliationForeignBranchAdjustmentsAmount": { "xbrltype": "monetaryItemType",
                  "nsuri": "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationForeignBranchAdjustmentsAmount", "crdr": "debit", "calculation": {
                    "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } } }, "presentation": {
                    "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign branch adjustments", "label": "Effective
                      Income Tax Rate Reconciliation, Foreign Branch Adjustments, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Foreign Branch Adjustments, Amount" } } },
                      "auth_ref": { "renr_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDividendWithholdingTaxPercent": { "xbrltype": "percentItemType", "nsuri":
                        "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDividendWithholdingTaxPercent", "presentation": {
                          "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Expected tax rate", "label": "Effective Income Tax Rate Reconciliation,
                          Foreign Income Tax Rate, Dividend Withholding Tax, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate, Dividend Withholding
                          Tax, Percent" } } }, "auth_ref": { "renr_EffectiveIncomeTaxRateReconciliationGAAPToStatutoryAccountingDifferenceAmount": { "xbrltype": "monetaryItemType", "nsuri":
                          "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationGAAPToStatutoryAccountingDifferenceAmount", "crdr": "credit", "calculation": {
                            "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } } }, "presentation": {
                            "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "terseLabel": "GAAP to statutory accounting difference", "label":
                              "Effective Income Tax Rate Reconciliation, GAAP To Statutory Accounting Difference, Amount", "documentation": "Effective Income Tax Rate Reconciliation, GAAP To
                              Statutory Accounting Difference, Amount" } } }, "auth_ref": { "renr_EffectiveIncomeTaxRateReconciliationRecognitionOfBermudaNetDeferredTaxAsset": { "xbrltype":
                              "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationRecognitionOfBermudaNetDeferredTaxAsset", "crdr":
                              "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order":
                                9.0 } } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognition of Bermuda
                                net deferred tax asset", "label": "Effective Income Tax Rate Reconciliation, Recognition Of Bermuda Net Deferred Tax Asset", "documentation": "Effective Income Tax Rate
                                Reconciliation, Recognition Of Bermuda Net Deferred Tax Asset" } } }, "auth_ref": { "renr_EffectiveIncomeTaxRateReconciliationReinsuranceAdjustmentAmount": {
                                  "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationReinsuranceAdjustmentAmount", "crdr":
                                  "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order":
                                    8.0 } } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Reinsurance
                                    adjustment", "label": "Effective Income Tax Rate Reconciliation, Reinsurance Adjustment, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Reinsurance
                                    Adjustment, Amount" } } }, "auth_ref": { "renr_EffectiveIncomeTaxRateReconciliationWithholdingTax": { "xbrltype": "monetaryItemType", "nsuri":
                                      "http://www.renre.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTax", "crdr": "credit", "calculation": {
                                        "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } } }, "presentation": {
                                        "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails", "lang": { "en-us": { "role": { "terseLabel": "Withholding tax", "label": "Effective Income Tax Rate
                                        Reconciliation, Withholding Tax", "documentation": "Effective Income Tax Rate Reconciliation, Withholding Tax" } } }, "auth_ref": { "us-
                                        gaap_EffectsOfReinsuranceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectsOfReinsuranceTableTextBlock",
                                        "presentation": { "http://www.renre.com/role/REINSURANCETables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Reinsurance and Retrocessional Activity
                                        on Premiums Written and Earned and on Net Claims and Claim Expenses Incurred", "label": "Effects of Reinsurance [Table Text Block]", "documentation": "Tabular disclosure
                                        of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance." } } }, "auth_ref": { "r17" } } },
                                        "renr_EightyFiveThousandandPrincipalAtRiskVariableRateNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
                                        "EightyFiveThousandandPrincipalAtRiskVariableRateNoteMember", "presentation": {
                                          "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": { "en-us": { "role": { "terseLabel": "85 Thousand and
                                          Principal At Risk Variable Rate Note", "label": "Eighty-Five Thousand and Principal At Risk Variable Rate Note [Member]", "documentation": "Eighty-Five Thousand and Principal At
                                          Risk Variable Rate Note" } } }, "auth_ref": { "renr_EmployeeRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231",
                                          "localname": "EmployeeRestrictedStockMember", "presentation": {
                                            "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": { "en-us": { "role": {
                                              "terseLabel": "Employee Restricted Stock Awards", "label": "Employee Restricted Stock [Member]", "documentation": "Employee Restricted Stock [Member]" } } }, "auth_ref": {
                                              "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri":
                                              "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit",
                                              "presentation": { "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel":
                                                "Unrecognized compensation costs related to restricted stock awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
                                                "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": { "r727" } } }, "us-
                                              gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition": { "xbrltype": "durationItemType",
                                              "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition",
                                              "presentation": {
                                                "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Periods for
                                                recognition of compensation costs not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
                                                "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in
                                                PnYnMnDnInMns format, for example, P1Y5M13D, represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r727" } } }, "us-
                                                gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
                                                "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": {
                                                  "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Excess windfall
                                                  tax benefit", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-
                                                  based payment arrangement." } } }, "auth_ref": { "r245" } } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
                                                  "localname": "EmployeeStockOptionMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "
```

"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports) and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails": { "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails": { "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails": { "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r1406": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r1406": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r1516": { "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "cldr": "credit", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r1406": { "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r1406": { "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r1406": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r1406": { "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-O, N-1A." } } }, "auth_ref": { "r1517": { "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]", "auth_ref": { "r1459": { "ecd_EqtyAwrdsAdjsExclgValRprtInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "auth_ref": { "r1512": { "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments [Member]", "label": "Equity Awards Adjustments [Member]", "auth_ref": { "r1512": { "ecd_EqtyAwrdsInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "auth_ref": { "r1512": { "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails": { "http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r21": { "r330": { "r355": { "r357": { "r385": { "r386": { "r387": { "r389": { "r394": { "r396": { "r398": { "r423": { "r501": { "r502": { "r543": { "r623": { "r770": { "r771": { "r779": { "r780": { "r781": { "r783": { "r789": { "r790": { "r801": { "r802": { "r803": { "r804": { "r805": { "r806": { "r809": { "r854": { "r855": { "r856": { "r857": { "r858": { "r859": { "r864": { "r865": { "r873": { "r889": { "r1062": { "r1063": { "r1064": { "r1093": { "r1171": { "us-gaap_EquityContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityContractMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsOfOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity futures", "label": "Equity futures", "documentation": "Derivative instrument whose primary underlying risk is tied to share prices." } } }, "auth_ref": { "r1297": { "r1327": { "r1344": { "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofInvestmentsinOtherVenturesunderEquityMethodDetails": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r497": { "r498": { "r499": { "r778": { "r1521": { "r1522": { "r1523": { "r1694": { "r1695": { "r1696": { "r1697": { "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": { "r332": { "r376": { "r500": { "r844": { "r921": { "r922": { "r927": { "r934": { "r941": { "r942": { "r953": { "r955": { "r1360": { "r1361": { "r1362": { "r1363": { "r1364": { "r1365": { "r1366": { "r1367": { "r1368": { "r1369": { "r1370": { "r1371": { "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets Included in Investments in Other Ventures, Under Equity Method", "label": "Equity Method Investment, Nonconsolidated Investee or Group of

[illegible]

defined in one or many axes to the table." } } } , "auth_ref": { "r815", "r816", "r817", "r1349" } } , "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisValuationTechniquesTable", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } } , "auth_ref": { "r815", "r816", "r817", "r1349" } } , "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings", "crdr": "credit", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net in earnings (loss)", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3)." } } } , "auth_ref": { "r1711" } } , "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Net investment income", "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings [Abstract]" } } } , "auth_ref": { "r1711" } } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } } , "auth_ref": { "r818", "r819", "r820", "r821", "r822", "r823", "r828", "r1347" } } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } , "auth_ref": { "r1711" } } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } } , "auth_ref": { "r819", "r823", "r828", "r1347" } } , "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r1711" } } , "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } } , "auth_ref": { "r818", "r819", "r820", "r821", "r822", "r823", "r828", "r1347" } } , "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } } , "auth_ref": { "r113", "r114" } } , "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } } , "auth_ref": { "r591", "r650", "r651", "r652", "r653", "r654", "r655", "r812", "r814", "r815", "r816", "r817", "r826", "r827", "r830", "r885", "r886", "r887", "r1319", "r1320", "r1327", "r1328", "r1329", "r1345", "r1349" } } , "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } } , "auth_ref": { "r818", "r819", "r820", "r821", "r822", "r823", "r828" } } , "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFAHTESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } } , "auth_ref": { "r591", "r1319", "r1320" } } , "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } } , "auth_ref": { "r813", "r814", "r815", "r817", "r1345", "r1708", "r1719" } } , "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFAHTESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } } , "auth_ref": { "r591", "r1319", "r1320" } } , "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } } , "auth_ref": { "r1711" } } , "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTS": { "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election, (7) all other required (as defined) and desired information." } } } , "auth_ref": { "r822", "r824", "r825", "r826", "r830", "r833", "r834", "r835", "r836", "r956", "r1345", "r1350" } } , "us-gaap_FairValueInputsLevel1And3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1And3Member", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)." } } } , "auth_ref": { "r1345", "r1659", "r1706", "r1717" } } , "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical or Similar Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } , "auth_ref": { "r591", "r650", "r655", "r814", "r822", "r885", "r1327", "r1328", "r1329", "r1345" } } , "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } } , "auth_ref": { "r591", "r650", "r655", "r814", "r815", "r827", "r886", "r1319", "r1320", "r1327", "r1328", "r1329", "r1345" } } , "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {

```

http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails }, { "lang": "en-us", "role": "terseLabel", "label": "Significant Unobservable Inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth_ref": "r591", "r650", "r651", "r652", "r653", "r654", "r655", "r814", "r815", "r816", "r817", "r827", "r887", "r1319", "r1320", "r1327", "r1328", "r1329", "r1345", "r1349" }, { "us-gaap FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofVariableInterestEntitiesDetails", "lang": "en-us", "role": "terseLabel", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]", "documentation": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, { "auth_ref": "r812", "r830", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355" }, { "us-gaap FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentRemainingPeriod", "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentRemainingPeriod", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "label": "Liquidating period", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Liquidating Investment, Remaining Period", "documentation": "Remaining period of expected liquidation by investee of underlying asset of investment measured at net asset value per share or unit. In 'PnYmNdThHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." }, { "auth_ref": "r831", "r1355" }, { "us-gaap FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofVariableInterestEntitiesDetails", "lang": "en-us", "role": "terseLabel", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]", "documentation": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]", "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis." }, { "auth_ref": "r812", "r830", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355" }, { "us-gaap FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Other Investments Measured Using Net Asset Valuations", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block]", "documentation": "Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis." }, { "auth_ref": "r812", "r829", "r840", "r1350" }, { "us-gaap FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitments", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitments", "crdr": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "lang": "en-us", "role": "terseLabel", "label": "Unfunded Commitments", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments", "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments)." }, { "auth_ref": "r832", "r1350" }, { "us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." }, { "auth_ref": "r818", "r819", "r820", "r821", "r822", "r823", "r828" }, { "us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." }, { "auth_ref": "r818", "r823", "r828" }, { "us-gaap FairValueMeasuredAtNetAssetValuePerShareMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "lang": "en-us", "role": "terseLabel", "label": "Fair Value Measured at Net Asset Value Per Share", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." }, { "auth_ref": "r650", "r812", "r830", "r1345" }, { "us-gaap FairValueMeasurementFrequencyDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." }, { "auth_ref": "r813", "r814", "r815", "r817", "r1345", "r1708", "r1719" }, { "us-gaap FairValueMeasurementInputsDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables", "lang": "en-us", "role": "terseLabel", "label": "Schedule of Quantitative Information Used as Level 3 Inputs", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." }, { "auth_ref": "r208" }, { "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth_ref": "r821", "r828", "r1347" }, { "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Sales", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth_ref": "r821", "r828", "r1347" }, { "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "crdr": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Settlements", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth_ref": "r821", "r828", "r1347" }, { "us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Beginning balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." }, { "auth_ref": "r818", "r828", "r1347" }, { "rmr FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisForeignExchangeGainsLosses", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisForeignExchangeGainsLosses", "crdr": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "label": "Net foreign exchange gains (losses)", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Foreign Exchange Gains (Losses)", "documentation": "" }, { "auth_ref": "r818", "r828", "r1347" }, { "us-gaap FairValueMeasurementsFairValueHierarchyDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvest
```

assets and (liabilities) measured at fair value on a recurring basis using Level 3 inputs", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability.", "auth_ref": "r1705", "r1706", "us-gaap_FairValueOfFinancialInstrumentsPolicy", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "lang": "en-us", "role": "verboselabel", "Fair Value Option", "label": "Fair Value of Financial Instruments, Policy", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "auth_ref": "r15", "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionQuantitativeDisclosuresTextBlock", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTS", "lang": "en-us", "role": "terseLabel", "Schedule of the Balances the Company has Elected to Account for at Fair Value", "label": "Fair Value Option, Disclosures", "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option.", "auth_ref": "r118", "r1720", "r1722", "r1723", "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetLiabilityGainLossStatementOfIncomeExtensibleList", "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetLiabilityGainLossStatementOfIncomeExtensibleList", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income", "label": "Fair Value, Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset (liability), measured at fair value using unobservable input (level 3).", "auth_ref": "r1711", "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails", "lang": "en-us", "role": "terseLabel", "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument.", "auth_ref": "r100", "r102", "r111", "us-gaap_FinanceLeaseInterestExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance lease, interest expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability.", "auth_ref": "r069", "r070", "r1357", "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "Finance Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity", "auth_ref": "us-gaap_FinanceLeaseLiability", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance lease, liability", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "auth_ref": "r067", "r072", "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSTables", "lang": "en-us", "role": "terseLabel", "Schedule of Future Minimum Payments, Finance Leases", "label": "Finance Lease, Liability, to be Paid, Maturity", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability, includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "auth_ref": "r1728", "us-gaap_FinanceLeaseLiabilityPaymentsDue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "totalLabel", "Future minimum lease payments under existing leases", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments from finance lease.", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "After 2029", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "2029", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0, "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r072", "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Statement of Financial Position", "label": "Finance Lease, Liability, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes finance lease liability.", "auth_ref": "r068", "rnr_FinanceLeaseLiabilityUndiscountedExcessAmountNotDisclosed", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmountNotDisclosed", "crdr": "credit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed", "label": "Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed", "documentation": "Finance Lease, Liability, Undiscounted Excess Amount, Not Disclosed", "auth_ref": "us-gaap_FinanceLeaseRightOfUseAsset", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance lease, right-of-use asset", "label": "Finance Lease, Right of Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "auth_ref": "r066", "us-gaap_FinanceLeaseRightOfUseAssetAmortization", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance lease, right-of-use asset, amortization", "label": "Finance Lease, Right of Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "auth_ref": "r069", "r070", "r1357", "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Finance Lease, Right of Use Asset, Statement of Financial Position", "label": "Finance Lease, Right of Use Asset, Statement of Financial Position", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "auth_ref": "r068", "us-gaap_FinancialInstrumentAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Financial Instrument", "label": "Financial Instrument", "documentation": "Information by type of financial instrument.", "auth_ref": "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r504", "r505", "r509", "r510", "r511", "r512", "r513", "r514", "r602", "r620", "r807", "r837", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892",

```

"r993","r994","r995","r999","r002","r003","r004","r005","r006","r007","r008","r009","r010","r011","r012","r013","r014","r015","r016","r090","r1314","r1345","r1347","r1349","r1350","r1351","r1352","r1353","r1354","r1355","r1359","r1532","r1533","r1534","r1535","r1536","r1537","r1538","r1603","r1605","r1606","r1607","r1704","r1707","r1708","r1709","r1716","r1719"}}, {"us-gaap": "FinancialServiceMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialServiceMember", "presentation": {"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": {"lang": {"en-us": {"role": {"terseLabel": "Management Fee", "label": "Financial Service [Member]", "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance."}}}, {"auth_ref": {"r1657"}}, {"us-gaap": "FinancialServicesSectorMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialServicesSectorMember", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Financials", "label": "Financial Services Sector [Member]", "documentation": "Sector of the economy consisting of companies engaged in financial services."}}}, {"auth_ref": {"r1345"}, {"r1391"}, {"r1812"}, {"r1814"}, {"r1815"}, {"r1816"}}, {"rmr": "FiniteAndIndefiniteLivedIntangibleAssetsAxis": {"xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FiniteAndIndefiniteLivedIntangibleAssetsAxis", "presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "Finite and Indefinite-lived Intangible Assets [Axis]", "label": "Finite and Indefinite-lived Intangible Assets [Axis]", "documentation": "Finite and Indefinite-lived Intangible Assets [Axis]"}}, {"auth_ref": {}}, {"rmr": "FiniteAndIndefiniteLivedIntangibleAssetsDomain": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FiniteAndIndefiniteLivedIntangibleAssetsDomain", "presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "Finite and Indefinite-lived Intangible Assets [Domain]", "label": "Finite and Indefinite-lived Intangible Assets [Domain]", "documentation": "Finite and Indefinite-lived Intangible Assets [Domain]"}}, {"auth_ref": {}}, {"us-gaap": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of identifiable Intangible Assets Acquired", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination."}}}, {"auth_ref": {}}, {"us-gaap": "FiniteLivedIntangibleAssetUsefulLife": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Finite-lived intangible assets, useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."}}}, {"auth_ref": {}}, {"us-gaap": "FiniteLivedIntangibleAssetsAccumulatedAmortization": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": {"parentTag": "us-gaap: IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."}}}, {"auth_ref": {"r335"}, {"r517"}, {"r535"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2030 and thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r1630"}, {"r1817"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r537"}, {"r1286"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r537"}, {"r1286"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r537"}, {"r1286"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r537"}, {"r1286"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"parentTag": "us-gaap: FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": {"r537"}, {"r1286"}, {"r1316"}}, {"us-gaap": "FiniteLivedIntangibleAssetsByMajorClassAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": {"lang": {"en-us": {"role": {"terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets."}}}, {"auth_ref": {"r528"}, {"r530"}, {"r531"}, {"r532"}, {"r534"}, {"r535"}, {"r539"}, {"r540"}, {"r1286"}}, {"us-gaap": "FiniteLivedIntangibleAssetsMajorClassDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassDomain", "presentation": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": {"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": {"lang": {"en-us": {"role": {"terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc
```

"documentation": "Fontana Holdings L.P. [Member]" } } }, "auth_ref": "F", "rnr_FortanaThirdPartyInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FontanaThirdPartyInvestorsMember", "presentation": { "http://www.renre.com/role/NonControllingInterestsNarrativeDetails": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fontana", "label": "Fontana Third-Party Investors [Member]", "documentation": "Fontana Third-Party Investors" } } }, "auth_ref": "F", "rnr_ForeignCurrencyForwardContractsInvestmentOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ForeignCurrencyForwardContractsInvestmentOperationsMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsRelatedtoPrincipalDerivativeInstrumentsDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Foreign Currency Forward Contracts, Investment Operations [Member]", "documentation": "Foreign Currency Forward Contracts, Investment Operations Foreign Currency Contracts [Member]" } } }, "auth_ref": "F", "rnr_ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsRelatedtoPrincipalDerivativeInstrumentsDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Foreign Currency Forward Contracts, Underwriting and Non-Investment Operations [Member]", "documentation": "Foreign Currency Forward Contracts, Underwriting Operations Related Foreign Currency Contracts [Member]" } } }, "auth_ref": "F", "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 }, "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net foreign exchange gains (losses)", "verboseLabel": "Net foreign exchange gains (losses)", "label": "Gain (Loss) Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": "r846", "r848", "r850", "r851", "r1168" } } }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": "r845" } } }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgedsofaNetInvestmentinaForeignOperationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": "r1134", "r1138", "r1143", "r1160", "r1166", "r1230", "r1231", "r1232", "r1391" } } }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtMember", "presentation": { "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-U.S. government", "label": "Foreign Government Debt [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": "r1598", "r1600" } } }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-U.S. government", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": "r1359", "r1658", "r1802" } } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": "r1430", "r1441", "r1451", "r1484" } } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": "r1430", "r1441", "r1451", "r1484" } } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": "r1430", "r1441", "r1451", "r1484" } } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": "r1430", "r1441", "r1451", "r1484" } } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": "r1430", "r1441", "r1451", "r1484" } } }, "ecr_FValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ecr_FValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": "r1464" } } }, "rnr_FundInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "FundInvestmentsMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fund investments", "label": "Fund Investments [Member]", "documentation": "Fund Investments" } } }, "auth_ref": "F", "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails": { "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "U.K.", "label": "UNITED KINGDOM" } } }, "auth_ref": "F", "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlowsDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Net realized and unrealized (gains) losses on investments", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": "r167", "r170", "r1518" } } }, "us-gaap_GainLossOnInvestmentsMember1": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsMember1", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net realized and unrealized gains (losses) on investments", "label": "Gain (Loss) on Investments [Member]", "documentation": "Primary financial statement caption encompassing gain (loss) on investments." } } }, "auth_ref": "F", "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": { "http://www.renre.com/role/INVESTMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Realized and Unrealized Gains (Losses) On Investments and Net Other Than Temporary Impairments", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": "r1563", "r1564" } } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri":

"r1358", "r1618", "r1620" } }], "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Acquired", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": { "r521", "r1315" } } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure Abstract", "label": "Goodwill and Intangible Assets Disclosure Abstract" } } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETS": { "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure Text Block", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": { "r1617", "r1621" } } }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Policy Text Block", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": { "r1617", "r1621" } } }, "rnr_GoodwillAndOtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "GoodwillAndOtherIntangibleAssetsMember", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill And Other Intangible Assets Member", "documentation": "Goodwill And Other Intangible Assets" } } }, "auth_ref": { "r1", "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r525" } } }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillGross", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill, gross", "label": "Goodwill, Gross", "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r520", "r527", "r1315" } } }, "rnr_GoodwillGrossChangeInClassificationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "GoodwillGrossChangeInClassificationAmount", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Reduction in goodwill", "label": "Goodwill, Gross, Change In Classification, Amount", "documentation": "Goodwill, Gross, Change In Classification, Amount" } } }, "auth_ref": { "r1", "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill, accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r520", "r527", "r1315" } } }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": { "r0", "r1619" } } }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofGoodwillandOtherIntangibleAssetsIncludedinEquityMethodInvestmentsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r1", "us-gaap_GrossInvestmentIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossInvestmentIncomeOperating", "crdr": "credit", "calculation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment income before investment expenses", "label": "Gross Investment Income, Operating", "documentation": "Amount, before investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": { "r991", "r1402", "r1809" } } }, "rnr_GrossPremiumsWrittenBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "GrossPremiumsWrittenBenchmarkMember", "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Premiums Written, Benchmark", "label": "Gross Premiums Written, Benchmark Member", "documentation": "Gross Premiums Written, Benchmark" } } }, "auth_ref": { "r1", "rnr_GrossPremiumsWrittenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "GrossPremiumsWrittenMember", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross premiums written", "label": "Gross Premiums Written Member", "documentation": "Gross Premiums Written Member" } } }, "auth_ref": { "r1", "us-gaap_HealthcareSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthcareSectorMember", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Healthcare", "label": "Healthcare Sector Member", "documentation": "Sector of the economy consisting of companies engaged in healthcare-related business activities." } } }, "auth_ref": { "r1345", "r1347", "r1349", "r1391", "r1812", "r1814", "r1815", "r1816" } } }, "us-gaap_HedgeFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgeFundsMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Hedge funds", "label": "Hedge Funds Member", "documentation": "Investments in registered hedge funds." } } }, "auth_ref": { "r1345", "r1347", "r1658" } } }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsOfOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": { "r22", "r799" } } }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": { "r22" } } }, "country IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND", "documentation": "Ireland" } } }, "auth_ref": { "r1", "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": { "r1409", "r1410", "r1433" } } }, "rnr_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag", "label": "Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag", "documentation": "Impairment Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration Not Disclosed Flag" } } }, "auth_ref": { "r1", "us-gaap_ImpairmentOffIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOffIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": { "r12", "r529", "r541" } } }, "rnr_ImpairmentOffIntangibleAssetsIndefiniteLived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ImpairmentOffIntangibleAssetsIndefiniteLived", "crdr": "debit", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment of indefinite-lived intangible asset", "label": "Impairment of Intangible Assets, Indefinite-Lived", "documentation": "Impairment of Intangible Assets, Indefinite-Lived" } } }, "auth_ref": { "r1", "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": { "r377", "r743" } } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 4.0 } }, "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }


```
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r160": "r221", "r229": "r962", "r986": "r1301", "r1306": "r1588", "r1589": "r1591", "r1592": "r1593" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": { "r377": "r743" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": { "r229": "r1003", "r1301": "r1588", "r1589": "r1591", "r1592": "r1593" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet", "crdr": "credit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Loss before equity in net income of subsidiaries", "label": "Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Noncontrolling Interests, Net", "documentation": "Amount of income (loss) from continuing operations, nonoperating income (expense) and income (loss) from equity method investments, before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of interest income (expense)." } } }, "auth_ref": { "r1": "r229", "r1003": "r1301", "r1588": "r1589", "r1591": "r1592", "r1593" } }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": "http://www.renre.com/role/INVESTMENTScheduleofEquityInLossesEarningsOfOtherVenturesUnderEquityMethodDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Equity in earnings (losses) of other ventures (Note 5)", "terseLabel": "Equity in earnings (losses) of other ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": { "r12": "r161", "r220": "r422", "r437": "r452", "r495": "r985" } }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Equity in undistributed (earnings) losses of other ventures", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities." } } }, "auth_ref": { "r12": "r12", "r12": "r12" } }, "us-gaap_IncomeLossFromSubsidiariesNetOffTax": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromSubsidiariesNetOffTax", "crdr": "credit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Equity in net income (loss) of subsidiaries", "negatedLabel": "Less: equity in net income (loss) of subsidiaries", "label": "Income (Loss) from Subsidiaries, Net of Tax", "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity." } } }, "auth_ref": { "r1": "r12", "r12": "r12" } }, "us-gaap_IncomeStatementAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Abstract", "label": "Income Statement Abstract", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r371": "r744", "r745": "r755", "r766": "r1341", "r1691" } }, "us-gaap_IncomeTaxJurisdiction": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxJurisdiction", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r544": "r551", "r552": "r819", "r823": "r828", "r1059", "r1061", "r1154", "r1286", "r1348", "r1769" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r551": "r552", "r819", "r823", "r828", "r1059", "r1061", "r1154", "r1286", "r1348", "r1769" } }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r371": "r744", "r745": "r755", "r766": "r1341", "r1691" } }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure Abstract", "label": "Income Tax Disclosure Abstract", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r371": "r744", "r745": "r755", "r766": "r1341", "r1691" } }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": { "r371": "r744", "r745": "r755", "r766": "r1341", "r1691" } }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.renre.com/role/TAXATION": { "lang": { "en-us": { "role": { "terseLabel": "TAXATION", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": { "r378": "r735", "r744": "r751", "r752": "r753", "r757": "r764", "r773", "r775", "r776", "r777", "r1091", "r1341" } }, "us-gaap_IncomeTaxExpenseBenefit": {
```

"http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": { "r748", "r1341", "r1687" } }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Effect of change in tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": { "r737", "r744", "r747", "r1341" } }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Expected income tax expense (benefit)", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": { "r744", "r1341" } }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Nondeductible expenses", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": { "r749", "r750", "r1687" } }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/TAXATIONIncomeTaxReconciliationDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": { "r1344", "r1687", "r1688" } }, "rnr_IncomeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "IncomeTaxTable", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Tax [Table]", "label": "Income Tax [Table]", "documentation": "Income Tax [Table]", "auth_ref": { "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Taxation, Uncertainties", "label": "Income Tax Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": { "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid (refunded)", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": { "r41", "r371", "r765", "r766" } }, "us-gaap_IncreaseDecreaseInDeferredPolicyAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredPolicyAcquisitionCosts", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Deferred acquisition costs and value of business acquired", "label": "Increase (Decrease) in Deferred Policy Acquisition Costs", "documentation": "The increase (decrease) during the reporting period in the balance sheet value of capitalized sales costs that are associated with acquiring a new insurance customers." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Reserve for claims and claim expenses", "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve", "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Change in", "label": "Increase (Decrease) in Operating Capital [Abstract]", "auth_ref": { "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTSStatementsOfCashFlowsDetails": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTSStatementsOfCashFlowsDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInPremiumsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPremiumsReceivable", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Premiums receivable", "label": "Increase (Decrease) in Premiums Receivable", "documentation": "The change in the premium receivable balance on the balance sheet." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInPrepaidReinsurancePremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidReinsurancePremiums", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid reinsurance premiums", "label": "Increase (Decrease) in Prepaid Reinsurance Premiums", "documentation": "The change in prepaid reinsurance premiums recorded on the balance sheet, which is needed to adjust net income to arrive at net cash flows provided by or used in operations." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInReinsurancePayables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReinsurancePayables", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Reinsurance balances payable", "label": "Increase (Decrease) in Reinsurance Payables", "documentation": "The increase (decrease) during the reporting period in the amount due to other insurance companies when the reporting entity has assumed a portion of the cedant's insurance risk which has resulted in insurance losses." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInReinsuranceRecoverable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReinsuranceRecoverable", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reinsurance recoverable", "label": "Increase (Decrease) in Reinsurance Recoverable", "documentation": "The increase (decrease) during the reporting period in the amount of benefits the ceding insurer expects to recover on insurance policies ceded to other insurance entities as of the balance sheet date for all guaranteed benefit types." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "http://www.renre.com/role/SHAREHOLDERSEQUITYRollForwardofSharesIssuedandOutstandingDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Statement of Changes in Stockholders' Equity", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Activity in redeemable noncontrolling interest", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "us-gaap_IncreaseDecreaseInUnearnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInUnearnedPremiums", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Unearned premiums", "label": "Increase (Decrease) in Unearned Premiums", "documentation": "Amount of increase (decrease) unearned premiums written. Excludes portion of unearned premiums amortized into income." } } }, "auth_ref": { "r11" } }, "us-gaap_IncreaseDecreaseInUnearnedPremiumsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInUnearnedPremiumsNet", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in unearned premiums", "label": "(Increase) Decrease in Unearned Premiums, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of decrease (increase) in unearned premiums." } } }, "auth_ref": { "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberofDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Per common share equivalents of non-vested shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share-based payment arrangements using the treasury stock method." } } }, "auth_ref": { "r405", "r406", "r407", "r416", "r694" } }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALUABLEUSScheduleofIdentifiableIntangibleAssetsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r528", "r533", "r538", "r1316" } }, "us-

gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "parentTag": "rnr_ExpectedAmortizationOfOtherIntangibleAssets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite lived", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r517", "r538", "r1316" } }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofExpectedImpairmentChargesandAmortizationExpenseDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": { "r528", "r533", "r538", "r1316" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PydDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]", "auth_ref": { "r1430", "r1441", "r1451", "r1475", "r1484", "r1488", "r1496" } } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "auth_ref": { "r1494" } } } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "auth_ref": { "r1411", "r1500" } } } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]", "auth_ref": { "r1411", "r1500" } } } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "auth_ref": { "r1411", "r1500" } } } }, "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Insurance [Abstract]", "label": "Insurance [Abstract]", "auth_ref": { "rnr_InsuranceLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "InsuranceLicensesMember", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Insurance Licenses", "label": "Insurance Licenses [Member]", "documentation": "Insurance Licenses [Member]", "auth_ref": { "us-gaap_InsuranceLossReservesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceLossReservesAbstract", "lang": { "en-us": { "role": { "label": "Insurance Loss Reserves [Abstract]", "auth_ref": { "us-gaap_IntangibleAssetsArisingFromInsuranceContractsAcquiredInBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsArisingFromInsuranceContractsAcquiredInBusinessCombinationMember", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Value of business acquired", "label": "Intangible Assets Arising from Insurance Contracts Acquired in Business Combination [Member]", "documentation": "An intangible asset that arises from measuring the difference between (a) the fair value of the contractual insurance and reinsurance assets acquired and liabilities assumed and (b) the assets and liabilities measured in accordance with the acquirer's policies for insurance and reinsurance contracts that it issues or holds. This element is used for business combinations entered into on or after December 15, 2008." } } }, "auth_ref": { "r133" } } }, "rnr_IntangibleAssetsExcludingGoodwillAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "IntangibleAssetsExcludingGoodwillAccumulatedImpairmentLoss", "crdr": "credit", "calculation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Impairment Losses", "label": "Intangible Assets (Excluding Goodwill), Accumulated Impairment Loss", "documentation": "Intangible Assets (Excluding Goodwill), Accumulated Impairment Loss", "auth_ref": { "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": { "r334" } } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r528", "r1629", "r1631" } } }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofIntangibleAssetsandGoodwillDetails": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Goodwill and other intangible assets (Note 4)", "totalLabel": "Total goodwill and other intangible assets", "terseLabel": "Goodwill and other intangible assets", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } } }, "auth_ref": { "r1616" } } }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": { "r26" } } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "http://www.renre.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofOperations": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense (Note 9)", "negatedLabel": "Interest expense", "verboseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r434", "r1565" } } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r365", "r369", "r370" } } }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsofOperationsRelatedtoPrincipalDerivativeInstrumentsDetails": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest rate futures", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": { "r1287", "r1297", "r1327", "r1345" } } } }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalRevenueServiceIRSMember", "presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails": { "http://www.renre.com/role/TAXATIONNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": { "rnr_InternalValuationModelValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "InternalValuationModelValuationTechniqueMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Internal valuation model", "label": "Internal Valuation Model Valuation Technique [Member]", "documentation": "Internal Valuation Model Valuation Technique [Member]", "auth_ref": { "us-gaap_InvestmentIncomeInvestmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInvestmentExpense", "crdr": "debit", "calculation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Investment expenses", "label": "Investment Income, Investment Expense", "documentation": "Amount of expenses related to the generation of investment income." } } }, "auth_ref": { "r171", "r1402", "r1760" } } } }, "us-gaap_InvestmentIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net investment income", "label": "Investment Income [Member]", "documentation": "Primary financial statement caption encompassing investment income." } } }, "auth_ref": { "r26" } } } }, "us-gaap_InvestmentIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeTextBlock", "presentation": { "http://www.renre.com/role/INVESTMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Income", "label": "Investment Income [Table Text Block]", "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and

dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }
"auth_ref": { "r165", "r166", "r169", "r171", "r1761" } }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" }, "lang": { "en-us":
{ "role": { "terseLabel": "Investment owned, fair value", "label": "Investment Owned, Fair Value", "documentation": "Fair value of investment in security owned." } } }
"auth_ref": { "r1084", "r1105", "r1106", "r1107", "r1109", "r1111", "r1112", "r1113", "r1116", "r1119", "r1120", "r1131", "r1132", "r1177", "r1186", "r1187", "r1196", "r1208",
"r1209", "r1222", "r1223", "r1224", "r1241", "r1244", "r1250", "r1252", "r1255", "r1391", "r1404", "r1806" } }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": {
"http://www.renre.com/role/INVESTMENTSTermLoansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Committed amount", "label": "Investment Owned, Balance,
Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": { "r1105", "r1116", "r1184", "r1212", "r1249", "r1391" } }
"rnr_InvestmentOwnedMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.renre.com/20241231", "localname": "InvestmentOwnedMaturityPeriod",
"presentation": { "http://www.renre.com/role/INVESTMENTSScheduleOfOtherInvestmentsDetails", "http://www.renre.com/role/INVESTMENTSTermLoansDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Maturity period", "label": "Investment Owned, Maturity Period", "documentation": "Investment Owned, Maturity Period" } } }, "auth_ref": {
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleOfOtherInvestmentsMeasuredUsingNetAssetValuationsDetails",
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleOfVariableInterestEntitiesDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfNetInvestmentIncomeDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfNetRealizedandUnrealizedGainsLossesonInvestmentsDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfOtherInvestmentsDetails",
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOTHERTHANINVESTMENTSINRELATEDPARTIESDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": { "r1106", "r1108", "r1109", "r1112",
"r1116", "r1177", "r1186", "r1201", "r1209", "r1222", "r1236", "r1252", "r1256", "r1257", "r1258", "r1259", "r1391" } }, "us-gaap_InvestmentTypeCategorizationMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": {
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails",
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleOfOtherInvestmentsMeasuredUsingNetAssetValuationsDetails",
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleOfVariableInterestEntitiesDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfNetInvestmentIncomeDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfNetRealizedandUnrealizedGainsLossesonInvestmentsDetails",
"http://www.renre.com/role/INVESTMENTSScheduleOfOtherInvestmentsDetails",
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOTHERTHANINVESTMENTSINRELATEDPARTIESDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Investment Type Categorization [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": {
"r1106", "r1108", "r1109", "r1112", "r1116", "r1177", "r1186", "r1201", "r1209", "r1222", "r1236", "r1252", "r1256", "r1257", "r1258", "r1259", "r1391" } }, "us-
gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": {
"http://www.renre.com/role/ConsolidatedBalanceSheets", { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0,
"order": 7.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total
investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": { "r966", "r969",
"r1385", "r1388" } }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": { "http://www.renre.com/role/INVESTMENTSTables" }, "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Contractual Maturities of Fixed Maturity Investments", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
"documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": {
"http://www.renre.com/role/INVESTMENTS", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments Debt and Equity Securities Abstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt
and Equity Securities [Abstract]" } } }, "auth_ref": {
"http://fasb.org/us-gaap/2024", "localname": "Investments In Affiliates Subsidiaries Associates And Joint Ventures", "crdr": "debit", "calculation": {
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0,
"order": 2.0 } }, "presentation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Investments in subsidiaries", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation":
"Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": { "r1554" } }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": {
"http://www.renre.com/role/INVESTMENTS", "lang": { "en-us": { "role": { "terseLabel": "INVESTMENTS", "label": "Investments in Debt and Marketable Equity Securities (and
Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r223",
"r254", "r462", "r463", "r838", "r839", "r1742" } }, "rnr_InvestmentsInOtherVenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231",
"localname": "InvestmentsInOtherVenturesMember", "presentation": {
"http://www.renre.com/role/INVESTMENTSScheduleOfInvestmentsInOtherVenturesUnderEquityMethodDetails", "lang": { "en-us": { "role": { "terseLabel": "Investments in
other ventures, under equity method", "label": "Investments In Other Ventures [Member]", "documentation": "Investments In Other Ventures [Member]" } } }, "auth_ref": {
"http://www.renre.com/role/INVESTMENTS", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestorMember", "presentation": {
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Investor", "label": "Investor [Member]",
"documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or
appreciation in value." } } }, "auth_ref": { "r1729", "r1730" } }, "rnr_InvestorsOfUpsilonRFO Diversified III And III Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "InvestorsOfUpsilonRFO Diversified III And III Member", "presentation": {
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Investors of Upsilon RFO Diversified I, II and III",
"label": "Investors Of Upsilon RFO Diversified I, II and III [Member]", "documentation": "Investors Of Upsilon RFO Diversified I, II and III" } } }, "auth_ref": {
"rnr_InvestorsOfUpsilonRFO Diversified IV Member": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"InvestorsOfUpsilonRFO Diversified IV Member", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": {
"terseLabel": "Investors of Upsilon RFO Diversified IV", "label": "Investors Of Upsilon RFO Diversified IV [Member]", "documentation": "Investors Of Upsilon RFO Diversified
IV" } } }, "auth_ref": { "country JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleOfGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "lang": { "en-us": { "role": {
"terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": { "country LU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "LU",
"presentation": { "http://www.renre.com/role/TAXATIONIncomeLossBeforeIncomeTaxesForeignandDomesticDetails", "http://www.renre.com/role/TAXATIONNarrativeDetails",
"lang": { "en-us": { "role": { "terseLabel": "Luxembourg", "label": "LUXEMBOURG" } } }, "auth_ref": { "rnr_LargeCatastropheEventsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "LargeCatastropheEventsMember", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails", "lang": { "en-us": {
"role": { "terseLabel": "Large catastrophe events", "label": "Large Catastrophe Events [Member]", "documentation": "Large Catastrophe Events [Member]" } } }, "auth_ref": {
"rnr_LargeandSmallCatastropheEventsAndAttritionalLossMovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"LargeandSmallCatastropheEventsAndAttritionalLossMovementsMember", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails", "lang": { "en-us": {
"role": { "terseLabel": "Large and small catastrophe events and attritional loss movements", "label": "Large and Small Catastrophe Events And Attritional Loss Movements
[Member]", "documentation": "Large and Small Catastrophe Events And Attritional Loss Movements [Member]" } } }, "auth_ref": { "dei LegalEntityAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails",
"http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails",
"http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails",
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": { "en-us": { "role": { "terseLabel": "Legal Entity
[Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { "us-gaap_LesseeFinanceLeaseRenewalTerm1":
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseRenewalTerm1", "presentation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, finance lease, renewal
term", "label": "Lessee, Finance Lease, Renewal Term", "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D',
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1727" } }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseTermOfContract1", "presentation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, finance lease, term of
contract", "label": "Lessee, Finance Lease, Term of Contract", "documentation": "Term of lessee's finance lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D',
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1727" } }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments,
Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of
lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial
position." } } }, "auth_ref": { "r1728" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": { "en-us":
{ "role": { "totalLabel": "Future minimum lease payments under existing leases", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r872" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "After 2029", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r872": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r872": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r872": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2020", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r872": { "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } }, "auth_ref": { "r872": { "rnr_LesseeOperatingLeaseLiabilityUndiscountedExcessAmountNotDisclosed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmountNotDisclosed", "crdr": "credit", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed", "documentation": "Lessee, Operating Lease, Liability, Undiscounted Excess, Amount Not Disclosed"} } }, "auth_ref": { "r1": { "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."} } }, "auth_ref": { "r1": { "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": { "r1": { "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r29": { "r137": { "r138": { "r139": { "r142": { "r143": { "r144": { "r147": { "r376": { "r500": { "r566": { "r567": { "r569": { "r570": { "r571": { "r572": { "r573": { "r575": { "r576": { "r793": { "r796": { "r797": { "r844": { "r1126": { "r1300": { "r1404": { "r1647": { "r1733": { "r1734": { "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]", "documentation": "Liabilities [Abstract]" } } }, "auth_ref": { "r1": { "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, noncontrolling interests and shareholders' equity 2019", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r154": { "r217": { "r981": { "r1358": { "r1574": { "r1610": { "r1721": { "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Noncontrolling Interests and Shareholders' Equity 2019", "label": "Liabilities and Shareholders' Equity", "documentation": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { "r1": { "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Catastrophe Event [Axis]", "label": "Catastrophe Event [Axis]", "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": { "r1375": { "r1801": { "us-gaap_LiabilityForCatastropheClaimsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsLineItems", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Catastrophe Claims [Line Items]", "label": "Liability for Catastrophe Claims [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1069": { "us-gaap_LiabilityForCatastropheClaimsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsTable", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Catastrophe Claims [Table]", "label": "Liability for Catastrophe Claims [Table]", "documentation": "Disclosure of information about claim for unexpected natural or man-made disaster of substantial extent causing significant physical damage or destruction, loss of life, or permanent change to natural environment. Includes, but is not limited to, earthquake, windstorm, fire, and explosion." } } }, "auth_ref": { "r1801": { "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Reserve for claims and claim expenses (Note 8)", "totalLabel": "Total", "netLabel": "Net", "label": "Reserve for claims and claim expenses, end of period", "terseLabel": "Total reserve for claims and claim expenses", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": { "r1375": { "r1381": { "r1748": { "r1773": { "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or

many axes to the table." } } }, "auth_ref": "I", "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails", "lang": { "en-us": { "role": {
"terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "documentation":
"Disclosure of information about the liability for claims and claims adjustment expense." } } }, "auth_ref": "I", "us-
gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "presentation": -1 "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSES", "lang":
{ "en-us": { "role": { "verboseLabel": "RESERVE FOR CLAIMS AND CLAIM EXPENSES", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text
Block]", "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments." } } }, "auth_ref": "r1043", "r1045"
I }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "crdr": "credit", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails", "lang": { "en-us": { "role": {
"terseLabel": "Amounts acquired", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "documentation": "Amount of increase
(decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which
have been incurred but not reported." } } }, "auth_ref": "I", "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails", "lang": { "en-us": { "role": {
"verboseLabel": "Net paid related to", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "auth_ref": "I", "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear", "crdr": "credit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-
gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-
gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of
reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": "r1048", "r1375"} }, "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears", "crdr": "credit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-
gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of
reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": "r1048", "r1375"} }, "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Foreign exchange and other", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Foreign Currency Translation Gain (Loss)",
"documentation": "Amount of foreign currency gain (loss) which decreases (increases) the cost of settling unpaid claims after deduction of reinsurance recoveries. Includes,
but is not limited to, claims which have been incurred but not reported." } } }, "auth_ref": "I", "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount", "crdr": "credit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "parentTag": "us-
gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 3.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "lang": { "en-us": { "role": {
"terseLabel": "IBNR", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount", "documentation": "Estimated
costs as of the balance sheet date of settling incurred claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance
company for reimbursement." } } }, "auth_ref": "I", "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims", "crdr": "debit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "totalLabel":
"Total net incurred", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of
expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": "r1375", "r1771"} }, "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"verboseLabel": "Net incurred related to", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "auth_ref": "I", "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "crdr": "credit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": -1 "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Net fair value adjustment", "periodStartLabel": "Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period", "periodEndLabel":
"Reserve for claims and claim expenses, net of reinsurance recoverable, end of period", "totalLabel": "Net Reserve for Claims and Claim Expenses", "label": "Liability for
Unpaid Claims and Claims Adjustment Expense, Net", "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid
claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been
incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims." } } }, "auth_ref": "r1046", "r1049",
"r1749"} }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll
Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": "I", "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments", "crdr": "credit", "presentation": -1
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Decrease to reserve for claims and claim expense", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments", "documentation": "Sum of
adjustments to the estimated reserve for unpaid claims and claims adjustment expense." } } }, "auth_ref": "r1770"} }, "us-
gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount", "crdr": "credit", "calculation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "parentTag": "us-
gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Case Reserves", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Reported Claims, Amount", "documentation": "Costs of settling insured
claims and costs incurred in the claims settlement process for the specified year specifically for claims that have already been submitted to the insurance company for
reimbursement." } } }, "auth_ref": "I", "rnr_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAdditionalCaseReservesAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.renre.com/20241231", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAdditionalCaseReservesAmount", "crdr": "credit",
"calculation": -1 "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "parentTag": "us-
gaap_LiabilityForClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": -1
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Additional Caseu00a0Reserves", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Additional Case Reserves, Amount", "documentation":
"Liability for Unpaid Claims and Claims Adjustment Expense, Additional Case Reserves, Amount"} } }, "auth_ref": "I", "us-gaap_LicensingAgreementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": -1
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails": { "lang": { "en-us": { "role": {
"verboseLabel": "Licenses", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to
sell or otherwise utilize specified products or processes in a specified territory." } } }, "auth_ref": "r79", "r734", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627",
"r1629", "r1631", "r1632", "r1633", "r1686"} }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCredit", "crdr": "credit", "presentation": -1 "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails",
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Issued or Drawn", "verboseLabel":
"Credit facilities outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions
of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the
application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a
maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term
obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term
obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a
long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively
determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the
agreement." } } }, "auth_ref": "r29", "r215", "r1751"} }, "rnr_LineOfCreditFacilityAccordionFeatureMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "LineOfCreditFacilityAccordionFeatureMaximumBorrowingCapacity", "crdr": "credit", "presentation": -1
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accordion feature, maximum
borrowing capacity", "label": "Line Of Credit Facility, Accordion Feature, Maximum Borrowing Capacity", "documentation": "Line Of Credit Facility, Accordion Feature,
Maximum Borrowing Capacity"} } }, "auth_ref": "I", "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityAxis", "presentation": -1 "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": {


```

"terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0, "presentation": "table", "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "auth_ref": "r136", "r141", "r1573", "r1644", "r1645", "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "auth_ref": "r136", "r141", "r1573", "r1644", "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r565", "r1573", "r1644", "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": "http://www.renre.com/role/COMMITMENTSContingenciesAndOtherItemsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "auth_ref": "r136", "r141", "r1573", "r1644", "us-gaap_LineOfCreditFacilityPercentageOfMaximumAggregateAmountToBeSecured": { "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "LineOfCreditFacilityPercentageOfMaximumAggregateAmountToBeSecured", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Percentage of maximum aggregate amount to be secured", "label": "Line of Credit Facility, Percentage Of Maximum Aggregate Amount To Be Secured", "documentation": "Line of Credit Facility, Percentage Of Maximum Aggregate Amount To Be Secured", "auth_ref": "r136", "r141", "r1573", "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Loan agreement, remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "auth_ref": "r136", "r141", "r1573", "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement.", "auth_ref": "r136", "r141", "r1573", "r1644", "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Line of Credit, Member", "label": "Line of Credit, Member", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "auth_ref": "r136", "r141", "r1573", "r1644", "us-gaap_LoansAndLeasesReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableRelatedParties", "crdr": "debit", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Loan agreement with related party", "label": "Loans and Leases Receivable, Related Parties", "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.", "auth_ref": "r120", "r219", "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": "http://www.renre.com/role/CoverPage", "lang": "en-us", "role": "terseLabel", "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity.", "auth_ref": "r136", "r141", "us-gaap_LongTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermMember", "presentation": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Long", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of a security.", "auth_ref": "r136", "r141", "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0, "presentation": "table", "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0, "presentation": "table", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "auth_ref": "r29", "r215", "r590", "r606", "r1319", "r1320", "r1356", "r1751", "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Fair Value", "verboseLabel": "Long-term debt", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "auth_ref": "r1705", "r1707", "r1708", "r1709", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0, "presentation": "table", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "After 2029", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r14", "r384", "r1652", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0, "presentation": "table", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r14", "r384", "r595", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0, "presentation": "table", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r14", "r384", "r595", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0, "presentation": "table", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel", "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": "r14", "r384", "r595", "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0, "presentation": "table", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofMaturitiesofLongtermDebtDetails", "lang": "en-us", "role": "terseLabel",
```

"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails"; "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type {Domain}", "label": "Long-Term Debt, Type {Domain}", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": { "r29", "r55", "r1635", "r1636", "r1637" } }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": { "http://www.renre.com/role/COMMITMENTSContingenciesAndOtherItemsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails"; "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Loss-Contingency Nature {Axis}", "label": "Loss-Contingency Nature {Axis}", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": { "r557", "r559", "r563", "r733", "r1069", "r1317", "r1640", "r1641" } }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": { "http://www.renre.com/role/COMMITMENTSContingenciesAndOtherItemsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails"; "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Mandatory capital contribution in the event of capital and surplus reduction below a specified level", "verboseLabel": "Estimate of pre-tax loss", "label": "Loss-Contingency Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": { "r558", "r559", "r562", "r563", "r733", "r1317" } }, "rnr_LossContingencyIndustryAmountIncurredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "LossContingencyIndustryAmountIncurredAmount", "crdr": "debit", "presentation": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Industry-insured loss", "label": "Loss-Contingency Industry Amount Incurred, Amount", "documentation": "Loss-Contingency Industry Amount Incurred, Amount" } } }, "auth_ref": { "rnr_LossContingencyIndustryAmountIncurredPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "LossContingencyIndustryAmountIncurredPercentage", "presentation": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Loss-Contingency incurred percentage", "label": "Loss-Contingency Industry Amount Incurred, Percentage", "documentation": "Loss-Contingency Industry Amount Incurred, Percentage" } } }, "auth_ref": { "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": { "http://www.renre.com/role/COMMITMENTSContingenciesAndOtherItemsNarrativeDetails";
"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails"; "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Loss-Contingency Nature {Domain}", "label": "Loss-Contingency Nature {Domain}", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": { "r557", "r558", "r559", "r563", "r733", "r1069", "r1317", "r1640", "r1641" } }, "us-gaap_LossRatio": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossRatio", "calculation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails"; "parentTag": "us-gaap_CombinedRatio", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails"; "lang": { "en-us": { "role": { "totalLabel": "Net claims and claim expense ratio in 2013 calendar year", "label": "Loss Ratio", "documentation": "Ratio of non-life losses and loss expenses to non-life net premiums earned." } } }, "auth_ref": { "rnr_MGARelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MGARelationshipsMember", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Managing General Agent (in 2012 MGA in 2014) relationships", "label": "MGA Relationships {Member}", "documentation": "MGA Relationships" } } }, "auth_ref": { "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails"; "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Major Customers {Axis}", "label": "Customer {Axis}", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": { "r459", "r1326", "r1373", "r1380", "r1656", "r1763", "r1774", "r1775", "r1777", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803", "r1804" } }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"; "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Marketable Securities, Policy {Policy Text Block}", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": { "r122" } }, "rnr_MarshMcLennanCompaniesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MarshMcLennanCompaniesIncMember", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Marsh & McLennan Companies, Inc.", "label": "Marsh & McLennan Companies, Inc. {Member}", "documentation": "Marsh & McLennan Companies, Inc. {Member}" } } }, "auth_ref": { "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails";
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails";
"http://www.renre.com/role/INVESTMENTSScheduleofInvestmentsinOtherVenturesunderEquityMethodDetails";
"http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails"; "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails"; "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum {Member}", "documentation": "Upper limit of the provided range." } } }, "auth_ref": { "r256", "r258", "r260", "r261", "r263", "r328", "r329", "r558", "r559", "r560", "r561", "r688", "r733", "r817", "r917", "r1058", "r1060", "r1069", "r1117", "r1118", "r1180", "r1199", "r1205", "r1206", "r1246", "r1284", "r1285", "r1311", "r1323", "r1337", "r1349", "r1350", "r1354", "r1355", "r1374", "r1651", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740" } }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure {Axis}" } } }, "auth_ref": { "r1467" } }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"; "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": { "r1467" } }, "us-gaap_MeasurementInputCreditSpreadMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputCreditSpreadMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Credit spread adjustment", "label": "Measurement Input, Credit Spread {Member}", "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality." } } }, "auth_ref": { "r170", "r178", "r179" } }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountRateMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate {Member}", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": { "r1707", "r1708", "r1709" } }, "rnr_MeasurementInputExpectedLossRatioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MeasurementInputExpectedLossRatioMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Expected loss ratio", "label": "Measurement Input, Expected Loss Ratio {Member}", "documentation": "Measurement Input, Expected Loss Ratio {Member}" } } }, "auth_ref": { "rnr_MeasurementInputLiquidityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MeasurementInputLiquidityMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Liquidity discount", "label": "Measurement Input, Liquidity {Member}", "documentation": "Measurement Input, Liquidity {Member}" } } }, "auth_ref": { "rnr_MeasurementInputRiskPremiumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MeasurementInputRiskPremiumMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Risk premium", "label": "Measurement Input, Risk Premium {Member}", "documentation": "Measurement Input, Risk Premium" } } }, "auth_ref": { "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type {Axis}", "label": "Measurement Input Type {Axis}", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": { "r815", "r816", "r817", "r1349" } }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type {Domain}", "label": "Measurement Input Type {Domain}", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": { "r815", "r816", "r817", "r1349" } }, "rnr_MeasurementInputUndiscountedCashFlowsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MeasurementInputUndiscountedCashFlowsMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Net undiscounted cash flows", "label": "Measurement Input, Undiscounted Cash Flows {Member}", "documentation": "Measurement Input, Undiscounted Cash Flows {Member}" } } }, "auth_ref": { "rnr_MediciThirdPartyInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MediciThirdPartyInvestorsMember", "presentation": { "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"; "lang": { "en-us": { "role": { "terseLabel": "Medici Third-Party Investors", "label": "Medici Third-Party Investors {Member}", "documentation": "Medici Third-Party Investors" } } }, "auth_ref": { "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails";
"http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails";
"http://www.renre.com/role/INVESTMENTSScheduleofInvestmentsinOtherVenturesunderEquityMethodDetails";
"http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails";
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails";
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails"; "lang": { "en-us": { "role": { "terseLabel": "Minimum", "verboseLabel": "Minimum", "label": "Minimum {Member}", "documentation": "Lower limit of the provided range." } } }, "auth_ref": { "r256", "r258", "r260", "r261", "r263", "r328", "r329", "r558", "r559", "r560", "r561", "r688", "r733", "r817", "r917", "r1058", "r1060", "r1069", "r1117", "r1118", "r1180", "r1199", "r1205", "r1206", "r1246", "r1284", "r1285", "r1311", "r1323", "r1337", "r1349", "r1350", "r1354", "r1374", "r1651", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740" } }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinimumNetWorthRequiredForCompliance", "crdr": "credit", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails"; "lang": { "en-us": { "role": { "terseLabel": "Minimum net worth requirements", "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum", "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework." } } }, "auth_ref": { "r1267", "r1268", "r1269", "r1270" } }, "rnr_MinorityInterestAggregateShareRepurchaseRequestLimitAsPercentOfCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MinorityInterestAggregateShareRepurchaseRequestLimitAsPercentOfCapital", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails"; "lang": { "en-us": { "role": { "terseLabel": "Share repurchase requests, limit", "label": "Minority Interest, Aggregate Share Repurchase Request, Limit As Percent Of Capital", "documentation": "This item limits the aggregate of all share repurchase requests to 25% of DaVinciRe's capital in any given year and satisfying all applicable regulatory requirements. If total shareholder requests exceed 25% of DaVinciRe's capital, the number of shares repurchased will be reduced among the requesting shareholders pro-rata, based on the amounts desired to be repurchased." } } }, "auth_ref": { "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype":

```

"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSchedueofRedeemableNoncontrollingInterestActivityDetails", "lang": "en-us", "role": "negatedTerseLabel": "Dividends on common shares", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "auth_ref": "r189", "us-gaap_MinorityInterestDecreaseFromRedemptions": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromRedemptions", "crdr": "debit", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSchedueofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": "en-us", "role": "terseLabel": "Redemption of shares from redeemable noncontrolling interests", "negatedTerseLabel": "Redemption of shares from redeemable noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)", "auth_ref": "r84", "r189", "201", "us-gaap_MinorityInterestDisclosureTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTS", "lang": "en-us", "role": "terseLabel": "NONCONTROLLING INTERESTS", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net income or loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "auth_ref": "r199", "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": "en-us", "role": "terseLabel": "Noncontrolling ownership percentage", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity", "auth_ref": "r84", "r189", "201", "us-gaap_MinorityInterestOwnershipPercentageByParent": "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Parent company ownership in redeemable noncontrolling interest", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage", "auth_ref": "r84", "r189", "201", "us-gaap_MinorityInterestPeriodIncreaseDecrease": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestPeriodIncreaseDecrease", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "lang": "en-us", "role": "terseLabel": "Change in redeemable noncontrolling interest", "label": "Noncontrolling Interest, Period Increase (Decrease)", "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period", "auth_ref": "r82", "ecd_MnpiDiscTimedForCompValFlag": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "auth_ref": "r1487", "rnr_MonaLisaReMember": "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MonaLisaReMember", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalriskVariableNotesDetails", "lang": "en-us", "role": "terseLabel": "Mona Lisa Re", "label": "Mona Lisa Re [Member]", "documentation": "Mona Lisa Re [Member]", "auth_ref": "r84", "r189", "201", "us-gaap_MortgageBackedSecuritiesMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageBackedSecuritiesMember", "presentation": "http://www.renre.com/role/INVESTMENTSSchedueofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": "en-us", "role": "verboseLabel": "Mortgage-backed", "label": "Collateralized Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by mortgage loans", "auth_ref": "r1327", "r1328", "r1329", "r1598", "r1599", "r1600", "r1601", "r1602", "r1802", "ecd_MtrTermsOfTrdArrTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]", "auth_ref": "r1495", "rnr_MultiBeneficiaryReducedCollateralReinsuranceTrustCollateralReduction": "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MultiBeneficiaryReducedCollateralReinsuranceTrustCollateralReduction", "presentation": "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Multi-beneficiary reduced collateral reinsurance trust collateral reduction", "label": "Multi-Beneficiary Reduced Collateral Reinsurance Trust Collateral Reduction", "documentation": "Reduction in collateral requirements of multi-beneficiary reinsurance trust to the percentage noted of the net outstanding insurance liabilities", "auth_ref": "r84", "rnr_MultiBeneficiaryReducedCollateralReinsuranceTrustMember": "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MultiBeneficiaryReducedCollateralReinsuranceTrustMember", "presentation": "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSSchedueOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails", "lang": "en-us", "role": "terseLabel": "Multi-Beneficiary Reduced Collateral Reinsurance Trust", "label": "Multi-Beneficiary Reduced Collateral Reinsurance Trust [Member]", "documentation": "Multi-Beneficiary Reduced Collateral Reinsurance Trust [Member]", "auth_ref": "r84", "rnr_MultiBeneficiaryReinsuranceTrustMember": "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "MultiBeneficiaryReinsuranceTrustMember", "presentation": "http://www.renre.com/role/STATUTORYREQUIREMENTSSchedueOfAssetsHeldUnderTrustAndMinimumDetails", "lang": "en-us", "role": "terseLabel": "Multi-Beneficiary Reinsurance Trust", "label": "Multi-Beneficiary Reinsurance Trust [Member]", "documentation": "Multi-Beneficiary Reinsurance Trust [Member]", "auth_ref": "r84", "rnr_NOCIMember": "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NOCIMember", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel": "NOCI", "label": "NOCI [Member]", "documentation": "NOCI", "auth_ref": "r84", "rnr_NameOfMajorCustomerDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": "http://www.renre.com/role/REINSURANCENarrativeDetails", "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORGUSTOMERSDetails", "lang": "en-us", "role": "terseLabel": "Name of Major Customer", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers", "auth_ref": "r459", "r1326", "r1373", "r1380", "r1656", "r1763", "r1774", "r1775", "r1777", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803", "r1804", "ecd_NamedExecutiveOfficersFnTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]", "auth_ref": "r1468", "us-gaap_NetCashProvidedByUsedInFinancingActivities": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "lang": "en-us", "role": "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit", "auth_ref": "r368", "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "lang": "en-us", "role": "terseLabel": "Cash flows provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "auth_ref": "r84", "us-gaap_NetCashProvidedByUsedInInvestingActivities": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0, "presentation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "lang": "en-us", "role": "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets", "auth_ref": "r368", "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "lang": "en-us", "role": "terseLabel": "Cash flows provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": "r84", "rnr_NetClaimsAndClaimExpenseRatioPriorYears": "xbrltype": "
```

```

NetClaimsAndClaimsExpenseRatioCurrentYear": { "xbrlType": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NetClaimsAndClaimsExpenseRatioCurrentYear", "calculation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_LossRatio", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net claims and claim expense ratio in 2013 current accident year", "label": "Net Claims and Claims Expense Ratio Current Year", "documentation": "Net claims and claim expense ratio - current accident year is derived by dividing net claims and claim expense - current accident year by net premiums earned." } } }, "auth_ref": { "r163", "r177", "r222", "r332", "r350", "r352", "r357", "r376", "r388", "r390", "r391", "r392", "r393", "r394", "r397", "r398", "r409", "r500", "r566", "r567", "r569", "r570", "r571", "r572", "r573", "r575", "r576", "r792", "r790", "r811", "r844", "r988", "r1148", "r1169", "r1170", "r1402", "r1647" } }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 }, "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Net (income) loss attributable to redeemable noncontrolling interests (Note 10)", "terseLabel": "Net income (loss) attributable to redeemable noncontrolling interest", "negatedTerseLabel": "Net (income) loss attributable to redeemable noncontrolling interests", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest" } } }, "auth_ref": { "r162" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.renre.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": 1.0, "order": 1.0 }, "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "http://www.renre.com/role/EARNINGSPEERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "http://www.renre.com/role/SCHEДУЕHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders", "terseLabel": "Net income (loss) available (attributable) to RenaissanceRe common shareholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": { "r363", "r390", "r391", "r392", "r393", "r401", "r402", "r411", "r416", "r790" } }, "us-gaap_NetInvestmentHedgingMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofDerivativeInstrumentsDesignatedasHedgesofaNetInvestmentinaForeignOperationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": { "r98" } }, "us-gaap_NetInvestmentIncome": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentIncome", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 }, "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 }, "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": { "http://www.renre.com/role/SCHEДУЕHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net investment income (Note 5)", "totalLabel": "Net investment income", "verboseLabel": "Net investment income", "label": "Net Investment Income", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": { "r239", "r992", "r993", "r1155", "r1402" } }, "rnr_NetInvestmentIncomeChangeInEstimate": { "xbrlType": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NetInvestmentIncomeChangeInEstimate", "crdr": "credit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) recognized in earnings due to change in estimate", "label": "Net Investment Income, Change In Estimate", "documentation": "Net Investment Income, Change In Estimate" } } }, "auth_ref": { "r98" } }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES": { "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "r98" } }, "rnr_NonEmployeeDirectorRestrictedStockMember": { "xbrlType": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NonEmployeeDirectorRestrictedStockMember", "presentation": { "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-Employee Director Restricted Stock Awards", "label": "Non-employee Director Restricted Stock [Member]", "documentation": "Non-employee Director Restricted Stock [Member]" } } }, "auth_ref": { "r98" } }, "rnr_NonEmployeeDirectorStockIncentivePlanMember": { "xbrlType": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NonEmployeeDirectorStockIncentivePlanMember", "presentation": { "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-Employee Director Stock Incentive Plan", "label": "Non-Employee Director Stock Incentive Plan [Member]", "documentation": "Non-Employee Director Stock Incentive Plan [Member]" } } }, "auth_ref": { "r98" } }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "r1467" } }, "ecd_NonPeoNeoMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r1430", "r1441", "r1451", "r1475", "r1484" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": { "r1458" } }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": { "r1457" } }, "ecd_NonPeoNeoMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": { "r1475" } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r1495" } }, "ecd_NonRule10b51ArrTrmndFlag": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r1495" } }, "rnr_NoncashOrPartNoncashDivestitureAmountOfConsiderationPaid": { "xbrlType": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationPaid", "crdr": "credit", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash consideration", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Paid", "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Paid" } } }, "auth_ref": { "r98" } }, "us-gaap_Noncatast
```

"http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails",
"http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest, value subscribed", "verboseLabel": "Sale of limited partner interest to redeemable noncontrolling interest", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": { "r19", "r66", "r201" } },
"nrnr NoncontrollingInterestRedemptionProvisionNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"NoncontrollingInterestRedemptionProvisionNoticePeriod", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Written notice period for redemption", "label": "Noncontrolling Interest, Redemption Provision, Notice Period", "documentation": "Noncontrolling Interest, Redemption Provision, Notice Period" } } }, "auth_ref": { "us-gaap_NondesignatedMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": { "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails",
"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsOfOperationsRelatedtoPrincipalDerivativeInstrumentsDetails",
"http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofLocationonConsolidatedBalanceSheetsandFairValueofPrincipalDerivativeInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "auth_ref": { "r22" } }, "us-gaap_NonoperatingGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingGainsLosses", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 5.0 },
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 7.0 },
"http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations",
"http://www.renre.com/role/INVESTMENTSScheduleofNetRealizedandUnrealizedGainsLossesonInvestmentsDetails",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", "lang": { "en-us": { "role": { "terseLabel": "Net realized and unrealized gains (losses) on investments", "totalLabel": "Net realized and unrealized gains (losses)", "verboseLabel": "Net realized and unrealized gains (losses) on investments", "label": "Nonoperating Gains (Losses)", "documentation": "The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).", "auth_ref": { "r168", "r171" } },
"nrnr NordeaBankAbpNewYorkBranchMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"NordeaBankAbpNewYorkBranchMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Nordea Bank Abp, New York Branch", "label": "Nordea Bank Abp, New York Branch [Member]", "documentation": "Nordea Bank Abp, New York Branch", "auth_ref": { "nrnr NumberOfSegregatedAccounts": { "xbrltype": "integerItemType", "nsuri": "http://www.renre.com/20241231", "localname": "NumberOfSegregatedAccounts", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Number of segregated accounts", "label": "Number Of Segregated Accounts", "documentation": "Number Of Segregated Accounts" } } }, "auth_ref": { "nrnr OneHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OneHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": { "en-us": { "role": { "terseLabel": "\$150-Million Principal-At-Risk Note", "label": "One Hundred And Fifty-Million Principal At Risk Variable Rate Note [Member]", "documentation": "One Hundred And Fifty-Million Principal At Risk Variable Rate Note" } } }, "auth_ref": { "nrnr OneHundredMillionPrincipalAtRiskVariableRateNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OneHundredMillionPrincipalAtRiskVariableRateNoteMember", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": { "en-us": { "role": { "terseLabel": "\$100-Million Principal At Risk Variable Rate Note", "label": "One Hundred Million Principal At Risk Variable Rate Note [Member]", "documentation": "One Hundred Thousand Principal At Risk Variable Rate Note" } } }, "auth_ref": { "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 },
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", { "parentTag": "nrnr UnderwritingIncomeLossNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfOperations",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfOperationsDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", "lang": { "en-us": { "role": { "terseLabel": "Operational expenses", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "auth_ref": { "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income.", "auth_ref": { "r1726" } }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSScheduleofFutureMinimumPaymentsOperatingandFinanceLeasesDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": { "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "auth_ref": { "r867" } }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease liability.", "auth_ref": { "r868" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "auth_ref": { "r868" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnTnFnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": { "r871", "r1357" } }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "auth_ref": { "r767" } }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Loss Carryforwards [Table]", "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization.", "auth_ref": { "r767" } },
"nrnr OperatingLossCarryforwardsUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OperatingLossCarryforwardsUnrealizedGainLoss", "crdr": "credit", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": { "en-us": { "role": { "negatedLabel": "Unrealized losses in the US investment portfolio", "label": "Operating Loss Carryforwards, Unrealized Gain (Loss)", "documentation": "Operating Loss Carryforwards, Unrealized Gain (Loss)" } } }, "auth_ref": { "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails",
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails",
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "auth_ref": { "r446", "r447", "r448", "r449", "r450", "r453", "r1306", "r1307" } }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "presentation": { "http://www.renre.com/role/ORGANIZATION", "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "auth_ref": { "r134", "r199", "r1082", "r1083" } }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets",
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other.", "auth_ref": { "r209", "r336", "r971", "r1307", "r1404" } }, "us-gaap_OtherAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",

"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofBalancesElectedtoAccountforatFairValueDetails" }, {"lang": "en-us", {"role": "totalLabel": "Other assets", "terseLabel": "Other assets", "label": "Other Assets, Fair Value Disclosure", "documentation": "Fair value portion of other assets." } } }, {"auth_ref": "r1705", "r1706", "r1716" } }, {"nrn_OtherAssetsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OtherAssetsLiabilitiesMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails" }, {"lang": "en-us", {"role": "terseLabel": "Other u00a0Assets and (Liabilities)", "label": "Other Assets (Liabilities) Member", "documentation": "The fair value of other assets and liabilities included in the Company's total other assets and liabilities." } } }, {"auth_ref": "r11", "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" }, {"lang": "en-us", {"role": "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, {"auth_ref": "r100", "r111" } }, {"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", {"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsofChangesInShareholdersEquity", "http://www.renre.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofComprehensiveIncomeLossDetails" }, {"lang": "en-us", {"role": "terseLabel": "Foreign currency translation adjustments, net of tax", "verboseLabel": "Foreign currency translation adjustments, net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, {"auth_ref": "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r192

"Other income (loss)": "verboseLabel": "Other income (loss)", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": "I-1", "ecd": "OtherPerfMeasureAmt", "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "OtherPerformance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": "r1467", "us-gaap": "OtherShortTermInvestments", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermInvestments", "crdr": "debit", "calculation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 2.0, "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 4.0, "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails", "lang": "en-us", "role": "terseLabel", "Short term investments, at fair value - amortized cost \$4,532,166 at December 31, 2024 (2023 - \$4,603,340) (Notes 5 and 6)", "netLabel": "Short term investments, at fair value - amortized cost \$131,232 at December 31, 2024 (2023 - \$277,917)", "label": "Other Short-Term Investments", "documentation": "Amount of short-term investments classified as other." } } }, "auth_ref": "r218", "r966", "r968", "r1559", "rnr": "OtherShortTermInvestmentsAmortizedCost", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OtherShortTermInvestmentsAmortizedCost", "crdr": "debit", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Short-term investments, amortized cost", "label": "Other Short-Term Investments, Amortized Cost", "documentation": "Other Short-Term Investments, Amortized Cost" } } }, "auth_ref": "I-1", "rnr": "OtherShortTermInvestmentsMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OtherShortTermInvestmentsMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Other Short-Term Investments", "label": "Other Short-Term Investments [Member]", "documentation": "Other Short-Term Investments" } } }, "auth_ref": "I-1", "rnr": "OtherSmallCatastropheEventsAndAttritionalLossMovementsMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "OtherSmallCatastropheEventsAndAttritionalLossMovementsMember", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails", "lang": "en-us", "role": "terseLabel", "Other small catastrophe events and attritional loss movements", "label": "Other Small Catastrophe Events And Attritional Loss Movements [Member]", "documentation": "Other Small Catastrophe Events And Attritional Loss Movements [Member]" } } }, "auth_ref": "I-1", "ecd": "OutstandingAggtErrCompAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": "r1428", "r1439", "r1449", "r1482", "ecd": "OutstandingRecoveryCompAmt", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": "r1431", "r1442", "r1452", "r1485", "ecd": "OutstandingRecoveryIndName", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": "r1431", "r1442", "r1452", "r1485", "srt": "OwnershipAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": "en-us", "role": "terseLabel", "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": "I-1", "srt": "OwnershipDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": "en-us", "role": "terseLabel", "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": "I-1", "rnr": "PFZWMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PFZWMember", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "PFZW", "label": "PFZW [Member]", "documentation": "PFZW" } } }, "auth_ref": "I-1", "srt": "ParentCompanyMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofComprehensiveIncomeLossDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofOperationsDetails", "lang": "en-us", "role": "verboseLabel": "Parent Company", "label": "Parent Company [Member]", "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary." } } }, "auth_ref": "r255", "r384", "rnr": "ParticipatingNonvotingCommonSharesMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ParticipatingNonvotingCommonSharesMember", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Participating, Non-voting Common Shares", "label": "Participating, Non-voting Common Shares [Member]", "documentation": "Participating, Non-voting Common Shares [Member]" } } }, "auth_ref": "I-1", "ecd": "PayVsPerformanceDisclosureLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": "en-us", "role": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": "r1456", "srt": "PayablesToBrokerDealersAndClearingOrganizations", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PayablesToBrokerDealersAndClearingOrganizations", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0, "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Payable for investments purchased", "label": "Broker-Dealer, Payable to Other Broker-Dealer and Clearing Organization", "documentation": "Amount payable to other broker-dealer and clearing organization, including, but not limited to, security failed to receive, deposit received for security loaned, open transaction, and floor-brokerage payable." } } }, "auth_ref": "r1549", "r1741", "us-gaap": "PaymentsForLossesAndLossAdjustmentExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityforUnpaidClaimsandClaimExpensesDetails", "lang": "en-us", "role": "totalLabel": "Total net paid", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": "r10", "r1375", "r1772", "us-gaap": "PaymentsForProceedsFromBusinessesAndInterestInAffiliates", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromBusinessesAndInterestInAffiliates", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0, "presentation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "negatedTerseLabel": "Due to (from) subsidiary", "label": "Payments for (Proceeds from) Businesses and Interest in Affiliates", "documentation": "The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period." } } }, "auth_ref": "I-1", "rnr": "PaymentsForProceedsFromOtherShortTermInvestments", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PaymentsForProceedsFromOtherShortTermInvestments", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0, "presentation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "negatedTerseLabel": "Net sales (purchases) of short-term investments", "label": "Payments For (Proceeds From) Other Short-Term Investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition (sale/maturities) of short-term investments with an original maturity that is one year or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle." } } }, "auth_ref": "I-1", "us-gaap": "PaymentsForRepurchaseOfCommonStock", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "negatedLabel": "RenaissanceRe common share repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": "r173", "us-gaap": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock", "crdr": "credit", "presentation": "http://www.renre.com/role/VARIABLEINTEENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Redemption of preference shares", "label": "Payments for Repurchase of Preferred Stock and Preference Stock", "documentation": "The cash outflow to reacquire preferred stock during the period." } } }, "auth_ref": "r173", "us-gaap": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedTerseLabel": "Redemptions of third-party redeemable noncontrolling interest shares", "label": "Payments for Repurchase of Redeemable Noncontrolling Interest", "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests." } } }, "auth_ref": "r1569", "us-gaap": "PaymentsOfCapitalDistribution", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfCapitalDistribution", "crdr": "credit", "presentation": "http://www.renre.com/role/VARIABLEINTEENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Payments of capital distributions", "label": "Payments of Capital Distribution", "documentation": "Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends." } } }, "auth_ref": "r173", "us-gaap": "PaymentsOfDividends", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": "en-us", "role": "terseLabel": "Payments of dividends", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": "r173", "us-gaap": "PaymentsOfDividendsCommonStock", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "negatedLabel": "Dividends paid in 2013 RenaissanceRe common shares", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": "r173", "us-gaap": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows",

```

http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"lang": "en-us", "role": "negatedLabel": "Dividends paid in 2013 preference shares", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." }, {"auth_ref": "r173"}, {"us_gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"}, {"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Taxes paid on withholding shares", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." }, {"auth_ref": "r364"}, {"us_gaap_PaymentsToAcquireBusinessesGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": "http://www.renre.com/role/ACQUISITIONOFFVALIDUSScheduleofPurchasePriceDetails"/>, {"parentTag": "us_gaap_BusinessCombinationConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, {"presentation": "http://www.renre.com/role/ACQUISITIONOFFVALIDUSScheduleofPurchasePriceDetails"/>, {"lang": "en-us", "role": "terseLabel": "Total cash consideration paid by RenaissanceRe as acquisition consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." }, {"auth_ref": "r35", "r788"}, {"us_gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"}, {"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Net purchase of Validus", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." }, {"auth_ref": "r35"}, {"us_gaap_PaymentsToAcquireEquityMethodInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Purchases of investments in other ventures", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." }, {"auth_ref": "r35"}, {"us_gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, {"presentation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"}, {"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails"/>, {"lang": "en-us", "role": "terseLabel": "Investment in variable interest entity", "negatedLabel": "Contributions to subsidiaries", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." }, {"auth_ref": "r35"}, {"us_gaap_PaymentsToAcquireOtherInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Purchases of other investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." }, {"auth_ref": "r172"}, {"us_gaap_PaymentsToAcquireShortTermInvestments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 12.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Purchases of short term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." }, {"auth_ref": "r172"}, {"us_gaap_PaymentsToAcquireTradingSecuritiesHeldForInvestment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireTradingSecuritiesHeldForInvestment", "crdr": "credit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlowsDetails"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Purchases of fixed maturity investments trading", "label": "Payment for Acquisition, Trading Security, Held-for-Investment", "documentation": "The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time)." }, {"auth_ref": "r1567"}, {"rnr_PaymentsToAcquireTradingSecuritiesShortTerm": {"xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PaymentsToAcquireTradingSecuritiesShortTerm", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"parentTag": "us_gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, {"presentation": "http://www.renre.com/role/ConsolidatedStatementsOfCashFlows"/>, {"lang": "en-us", "role": "negatedTerseLabel": "Purchases of equity investments", "label": "Payments to Acquire Trading Securities, Short-Term", "documentation": "Payments to Acquire Trading Securities, Short-Term" }, {"auth_ref": "r1"}, {"us_gaap_PaymentsToMinorityShareholders": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails"/>, {"lang": "en-us", "role": "terseLabel": "Payments to noncontrolling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." }, {"auth_ref": "r38"}, {"ecd_PeerGroupIssuersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]"} }, {"auth_ref": "r1466"}, {"ecd_PeerGroupTotalShareholderRtnAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount"} }, {"auth_ref": "r1466"}, {"us_gaap_PensionPlansDefinedBenefitMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": "http://www.renre.com/role/ACQUISITIONOFFVALIDUSScheduleofPurchasePriceDetails"/>, {"lang": "en-us", "role": "terseLabel": "Pension Plan", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." }, {"auth_ref": "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r690", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336"} }, {"ecd_PeoActuallyPaidCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount"} }, {"auth_ref": "r1458"}, {"ecd_PeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "PEO", "label": "PEO [Member]"} }, {"auth_ref": "r1475"}, {"ecd_PeoName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "PEO Name", "label": "PEO Name"} }, {"auth_ref": "r1468"}, {"ecd_PeoTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>, {"lang": "en-us", "role": "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount"} }, {"auth_ref": "r1457"}, {"us_gaap_PerformanceSharesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "
```

```


Policyholder Benefits And Claims Incurred Net, "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap_BenefitsAndExpenses", "weight": 1.0, "order": 1.0 }  

  "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompany'sRevenuesandExpensesDetails", "parentTag": "rnr_UnderwritingIncomeLossNet", "weight": 1.0, "order": 2.0 }  

  "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "parentTag": null, "weight": null, "order": null, "root": true }  

  "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfOperations", "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompany'sRevenuesandExpensesDetails", "lang": "en-us", "role": "verboseLabel": "Net claims and claim expenses incurred (Notes 7 and 8)", "totalLabel": "Net claims and claim expenses incurred", "negatedTerseLabel": "Net claim and claim expenses decrease", "terseLabel": "Net claims and claim expenses incurred", "label": "Policyholder Benefits and Claims Incurred, Net", "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred." } }  

  "auth_ref": "r1762", "us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderBenefitsAndClaimsIncurredNetAbstract", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "lang": "en-us", "role": "verboseLabel": "Claims and Claim Expenses", "label": "Policyholder Benefits and Claims Incurred, Net [Abstract]", "auth_ref": "us-gaap_PortionAtFairValueFairValueDisclosureMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIEScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails", "lang": "en-us", "role": "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } }  

  "auth_ref": "r942", "us-gaap_PositionAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionAxis", "presentation": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } }  

  "auth_ref": "us-gaap_PositionDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain", "presentation": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } }  

  "auth_ref": "us-gaap_PREFERREDStockDividendRatePercentage", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockDividendRatePercentage", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Dividend rate, percentage", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } }  

  "auth_ref": "r609", "r1181", "r1200", "r1204", "r1247", "us-gaap_PREFERREDStockLiquidationPreference", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockLiquidationPreference", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Liquidation preference (in usd per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } }  

  "auth_ref": "r61", "r624", "r148", "r1572", "r1653", "rnr_PREFERREDStockLiquidationPreferencePerSharePerAnnum", "xbrltype": "perShareItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PREFERREDStockLiquidationPreferencePerSharePerAnnum", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Liquidation preference per annum (in usd per share)", "label": "Preferred Stock, Liquidation Preference Per Share, Per Annum", "documentation": "Preferred Stock, Liquidation Preference Per Share, Per Annum" } }  

  "auth_ref": "rnr_PREFERREDStockLiquidationPreferencePerShareQuarterly", "xbrltype": "perShareItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PREFERREDStockLiquidationPreferencePerShareQuarterly", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Quarterly liquidation preference (in usd per share)", "label": "Preferred Stock, Liquidation Preference Per Share, Quarterly", "documentation": "Preferred Stock, Liquidation Preference Per Share, Quarterly" } }  

  "auth_ref": "us-gaap_PREFERREDStockMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockMember", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Preference shares", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } }  

  "auth_ref": "r1389", "r1390", "r1393", "r1394", "r1395", "r1398", "r1805", "r1810", "us-gaap_PREFERREDStockParOrStatedValuePerShare", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockParOrStatedValuePerShare", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheetsParentetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "verboseLabel": "Preference shares, par value (in dollars per share)", "terseLabel": "Par value (in usd per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } }  

  "auth_ref": "r148", "r608", "rnr_PREFERREDStockPercentageInterestInUnderlyingShares", "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PREFERREDStockPercentageInterestInUnderlyingShares", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Percentage interest in underlying shares", "label": "Preferred Stock, Percentage Interest In Underlying Shares", "documentation": "Preferred Stock, Percentage Interest In Underlying Shares" } }  

  "auth_ref": "us-gaap_PREFERREDStockRedemptionPricePerShare", "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockRedemptionPricePerShare", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "verboseLabel": "Redemption price per share (in usd per share)", "label": "Preferred Stock, Redemption Price Per Share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } }  

  "auth_ref": "r60", "r61", "r64", "rnr_PREFERREDStockRightToElectDirectorsNumberOfDirectors", "xbrltype": "integerItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PREFERREDStockRightToElectDirectorsNumberOfDirectors", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Right to elect directors, number of directors", "label": "Preferred Stock, Right To Elect Directors, Number Of Directors", "documentation": "Preferred Stock, Right To Elect Directors, Number Of Directors" } }  

  "auth_ref": "rnr_PREFERREDStockRightToElectDirectorsRequiredNumberOfDividendPeriodsInArrears", "xbrltype": "integerItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PREFERREDStockRightToElectDirectorsRequiredNumberOfDividendPeriodsInArrears", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Right to elect directors, required number of dividend periods in arrears", "label": "Preferred Stock, Right To Elect Directors, Required Number Of Dividend Periods In Arrears", "documentation": "Preferred Stock, Right To Elect Directors, Required Number Of Dividend Periods In Arrears" } }  

  "auth_ref": "us-gaap_PREFERREDStockSharesAuthorized", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockSharesAuthorized", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Authorized preference shares (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } }  

  "auth_ref": "r148", "r128", "us-gaap_PREFERREDStockSharesIssued", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockSharesIssued", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheetsParentetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "lang": "en-us", "role": "verboseLabel": "Preference shares, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } }  

  "auth_ref": "r148", "r608", "us-gaap_PREFERREDStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockSharesOutstanding", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheetsParentetical", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsAdditionalInformationDetails", "lang": "en-us", "role": "verboseLabel": "Preference shares, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } }  

  "auth_ref": "r148", "r1128", "r1146", "r1810", "r1811", "us-gaap_PREFERREDStockValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PREFERREDStockValue", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }  

  "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalanceSheetsDetails", "lang": "en-us", "role": "verboseLabel": "Preference shares: $1.00 par value lu2013 30,000 shares issued and outstanding at Decemberu00a0031, 2024 (2023 lu2013 30,000) (Note 12)", "terseLabel": "Preference shares: $1.00 par value lu2013 30,000 shares issued and outstanding at Decemberu00a0031, 2024 (2023 lu2013 30,000) (Note 12)", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } }  

  "auth_ref": "r148", "r976", "r1358", "us-gaap_PremiumReceivableAllowanceForCreditLossTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumReceivableAllowanceForCreditLossTableTextBlock", "presentation": "http://www.renre.com/role/REINSURANCETables", "lang": "en-us", "role": "terseLabel":


```

```

PremiumsReceivedAllowanceForDoubtfulAccounts", "crdr": "credit", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails", "lang": "en-us", "role": "terseLabel", "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails", "lang": "en-us", "role": "terseLabel", "Premium receivable, allowance for credit loss", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Premium Receivable, Allowance for Credit Loss", "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.", "auth_ref": "r231", "r1595", "r1612", "r1614", "r1757", "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsPeriodIncreaseDecrease", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsReceivableAllowanceForDoubtfulAccountsPeriodIncreaseDecrease", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails", "lang": "en-us", "role": "terseLabel", "Amounts acquired", "label": "Premium Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on premium receivable.", "auth_ref": "r232", "r1611", "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsRollForward", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsReceivableAllowanceForDoubtfulAccountsRollForward", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails", "lang": "en-us", "role": "terseLabel", "Premium Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Premium Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "auth_ref": "us-gaap_PremiumsReceivableAtCarryingValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsReceivableAtCarryingValue", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0, "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofPremiumsReceivableDetails", "lang": "en-us", "role": "terseLabel", "Premiums receivable (Note 7)", "verboseLabel": "Premiums receivable", "label": "Premiums Receivable, Net", "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "auth_ref": "r1754", "r1755", "r1756", "us-gaap_PremiumsWrittenAndEarnedAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsWrittenAndEarnedAbstract", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "lang": "en-us", "role": "verboseLabel", "Premiums Earned", "label": "Premiums Written and Earned [Abstract]", "auth_ref": "us-gaap_PremiumsWrittenGross", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsWrittenGross", "crdr": "credit", "presentation": "http://www.renre.com/role/ConsolidatedStatementsofOperations", "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails", "lang": "en-us", "role": "terseLabel", "Gross premiums written (Note 7)", "label": "Premiums Written, Gross", "documentation": "Amount of direct and assumed premiums written.", "auth_ref": "r17", "us-gaap_PremiumsWrittenNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsWrittenNet", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsofOperations", "parentTag": "us-gaap_PremiumsEarnedNet", "weight": 1.0, "order": 1.0, "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.renre.com/role/ConsolidatedStatementsofOperations", "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails", "lang": "en-us", "role": "terseLabel", "Net premiums written (Note 7)", "totalLabel": "Net premiums written", "verboseLabel": "Net premiums written", "label": "Premiums Written, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums written.", "auth_ref": "r1527", "r1528", "us-gaap_PremiumsWrittenNetConsolidatedAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsWrittenNetConsolidatedAbstract", "presentation": "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "lang": "en-us", "role": "verboseLabel", "Premiums Written", "label": "Premiums Written, Net [Abstract]", "auth_ref": "us-gaap_PrepaidReinsurancePremiums", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidReinsurancePremiums", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0, "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Prepaid reinsurance premiums (Note 7)", "label": "Prepaid Reinsurance Premiums", "documentation": "The unexpired portion of premiums ceded on policies in force as of the balance sheet date.", "auth_ref": "r1042", "r1081", "rnr_PrivateCreditFundsMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PrivateCreditFundsMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "lang": "en-us", "role": "terseLabel", "Private credit funds", "label": "Private Credit Funds [Member]", "documentation": "Private Credit Funds", "auth_ref": "us-gaap_PrivateEquityFundsMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivateEquityFundsMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingLevel3InputsDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofOtherInvestmentsMeasuredUsingNetAssetValuationsDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails", "lang": "en-us", "role": "verboseLabel", "Direct private equity investments", "terseLabel": "Direct private equity investments", "netLabel": "Private equity funds", "label": "Private Equity Funds [Member]", "documentation": "Investments held in private equity funds.", "auth_ref": "r1345", "r1347", "r1658", "rnr_PrivateEquityInvestmentsandOtherEntitiesCommitmentsFulfilled", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PrivateEquityInvestmentsandOtherEntitiesCommitmentsFulfilled", "crdr": "debit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "lang": "en-us", "role": "verboseLabel", "Fulfilled commitments", "label": "Private Equity Investments and Other Entities, Commitments Fulfilled", "documentation": "Private Equity Investments and Other Entities, Commitments Fulfilled", "auth_ref": "rnr_PrivateEquityInvestmentsandOtherEntitiesInitialCommitments", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PrivateEquityInvestmentsandOtherEntitiesInitialCommitments", "crdr": "credit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "lang": "en-us", "role": "verboseLabel", "Initial commitments", "label": "Private Equity Investments and Other Entities, Initial Commitments", "documentation": "Private Equity Investments and Other Entities, Initial Commitments", "auth_ref": "rnr_PrivateEquityInvestmentsandOtherEntitiesUnfundedCommitments", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "PrivateEquityInvestmentsandOtherEntitiesUnfundedCommitments", "crdr": "credit", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "lang": "en-us", "role": "terseLabel", "Unfunded commitments", "label": "Private Equity Investments and Other Entities, Unfunded Commitments", "documentation": "Private Equity Investments and Other Entities, Unfunded Commitments", "auth_ref": "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0, "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "terseLabel", "Return of investments in other ventures", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "auth_ref": "r367", "r1566", "us-gaap_ProceedsFromIssuanceOfCommonStock", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "terseLabel", "RenaissanceRe common share issuance, net of expenses", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity.", "auth_ref": "r6", "us-gaap_ProceedsFromIssuanceOfDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0, "presentation": "http://www.renre.com/role/ConsolidatedStatementsofCashFlows", "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails", "lang": "en-us", "role": "terseLabel", "Issuance of debt, net of expenses", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "auth_ref": "r1568", "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Proceeds from issuance of equity", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "auth_ref": "r6", "r1086", "us-gaap_ProceedsFromLinesOfCredit", "xbrltype": "monetaryItemType", "nsuri": "http
```

gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 }}, "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 10.0 }}, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales and maturities of fixed maturity investments trading", "verboseLabel": "Proceeds from sales and maturities of fixed maturity investments trading", "label": "Proceeds from Sale and Maturity, Debt Security, Trading, and Equity Security, FV-NI, Held-for-Investment", "documentation": "The cash inflow associated with the sale, maturities, repayments and calls of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "auth_ref": { "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 }}, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of investments in other ventures", "label": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "auth_ref": { "r34": { "us-gaap_ProceedsFromSaleOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 }}, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of other investments", "label": "Proceeds from Sale of Other Investments", "documentation": "Amount of cash inflow from the sale of investments classified as other.", "auth_ref": { "r1526": { "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 }}, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of short term investments", "label": "Proceeds from Sale of Short-Term Investments", "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "auth_ref": { "r33": { "rnr_ProceedsFromTradingSecuritiesShortTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ProceedsFromTradingSecuritiesShortTerm", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 }}, "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of equity investments", "label": "Proceeds From Trading Securities, Short-Term", "documentation": "Proceeds From Trading Securities, Short-Term", "auth_ref": { "rnr_ProceedsFromEquityMethodInvestmentSumofDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ProceedsFromEquityMethodInvestmentSumofDistributions", "crdr": "credit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofEquityinLossesEarningsOfOtherVenturesUnderEquityMethodDetails": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, dividends and distributions", "label": "Proceeds from Equity Method Investment, Sum of Distributions", "documentation": "Amount of distribution received from equity method investee for return of investment and return on investment.", "auth_ref": { "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service {Axis}", "label": "Product and Service {Axis}", "documentation": "Information by product and service, or group of similar products and similar services.", "auth_ref": { "r279": "r280", "r281", "r282", "r283", "r284", "r326", "r455", "r918", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1056", "r1288", "r1324", "r1372", "r1374", "r1377", "r1381", "r1387", "r1550", "r1642", "r1643", "r1656", "r1763", "r1774", "r1775", "r1776", "r1777", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025", "r2026", "r2027", "r2028", "r2029", "r2030", "r2031", "r2032", "r2033", "r2034", "r2035", "r2036", "r2037", "r2038", "r2039", "r2040", "r2041", "r2042", "r2043", "r2044", "r2045", "r2046", "r2047", "r2048", "r2049", "r2050", "r2051", "r2052", "r2053", "r2054", "r2055", "r2056", "r2057", "r2058", "r2059", "r2060", "r2061", "r2062", "r2063", "r2064", "r2065", "r2066", "r2067", "r2068", "r2069", "r2070", "r2071", "r2072", "r2073", "r2074", "r2075", "r2076", "r2077", "r2078", "r2079", "r2080", "r2081", "r2082", "r2083", "r2084", "r2085", "r2086", "r2087", "r2088", "r2089", "r2090", "r2091", "r2092", "r2093", "r2094", "r2095", "r2096", "r2097", "r2098", "r2099", "r2100", "r2101", "r2102", "r2103", "r2104", "r2105", "r2106", "r2107", "r2108", "r2109", "r2110", "r2111", "r2112", "r2113", "r2114", "r2115", "r2116", "r2117", "r2118", "r2119", "r2120", "r2121", "r2122", "r2123", "r2124", "r2125", "r2126", "r2127", "r2128", "r2129", "r2130", "r2131", "r2132", "r2133", "r2134", "r2135", "r2136", "r2137", "r2138", "r2139", "r2140", "r2141", "r2142", "r2143", "r2144", "r2145", "r2146", "r2147", "r2148", "r2149", "r2150", "r2151", "r2152", "r2153", "r2154", "r2155", "r2156", "r2157", "r2158", "r2159", "r2160", "r2161", "r2162", "r2163", "r2164", "r2165", "r2166", "r2167", "r2168", "r2169", "r2170", "r2171", "r2172", "r2173", "r2174", "r2175", "r2176", "r2177", "r2178", "r2179", "r2180", "r2181", "r2182", "r2183", "r2184", "r2185", "r2186", "r2187", "r2188", "r2189", "r2190", "r2191", "r2192", "r2193", "r2194", "r2195", "r2196", "r2197", "r2198", "r2199", "r2200", "r2201", "r2202", "r2203", "r2204", "r2205", "r2206", "r2207", "r2208", "r2209", "r2210", "r2211", "r2212", "r2213", "r2214", "r2215", "r2216", "r2217", "r2218", "r2219", "r2220", "r2221", "r2222", "r2223", "r2224", "r2225", "r2226", "r2227", "r2228", "r2229", "r2230", "r2231", "r2232", "r2233", "r2234", "r2235", "r2236", "r2237", "r2238", "r2239", "r2240", "r2241", "r2242", "r2243", "r2244", "r2245", "r2246", "r2247", "r2248", "r2249", "r2250", "r2251", "r2252", "r2253", "r2254", "r2255", "r2256", "r2257", "r2258", "r2259", "r2260", "r2261", "r2262", "r2263", "r2264", "r2265", "r2266", "r2267", "r2268", "r2269", "r2270", "r2271", "r2272", "r2273", "r2274", "r2275", "r2276", "r2277", "r2278", "r2279", "r2280", "r2281", "r2282", "r2283", "r2284", "r2285", "r2286", "r2287", "r2288", "r2289", "r2290", "r2291", "r2292", "r2293", "r2294", "r2295", "r2296", "r2297", "r2298", "r2299", "r2300", "r2301", "r2302", "r2303", "r2304", "r2305", "r2306", "r2307", "r2308", "r2309", "r2310", "r2311", "r2312", "r2313", "r2314", "r2315", "r2316", "r2317", "r2318", "r2319", "r2320", "r2321", "r2322", "r2323", "r2324", "r2325", "r2326", "r2327", "r2328", "r2329", "r2330", "r2331", "r2332", "r2333", "r2334", "r2335", "r2336", "r2337", "r2338", "r2339", "r2340", "r2341", "r2342", "r2343", "r2344", "r2345", "r2346", "r2347", "r2348", "r2349", "r2350", "r2351", "r2352", "r2353", "r2354", "r2355", "r2356", "r2357", "r2358", "r2359", "r2360", "r2361", "r2362", "r2363", "r2364", "r2365", "r2366", "r2367", "r2368", "r2369", "r2370", "r2371", "r2372", "r2373", "r2374", "r2375", "r2376", "r2377", "r2378", "r2379", "r2380", "r2381", "r2382", "r2383", "r2384", "r2385", "r2386", "r2387", "r2388", "r2389", "r2390", "r2391", "r2392", "r2393", "r2394", "r2395", "r2396", "r2397", "r2398", "r2399", "r2400", "r2401", "r2402", "r2403", "r2404", "r2405", "r2406", "r2407", "r2408", "r2409", "r2410", "r2411", "r2412", "r2413", "r2414", "r2415", "r2416", "r2417", "r2418", "r2419", "r2420", "r2421", "r2422", "r2423", "r2424", "r2425", "r2426", "r2427", "r2428", "r2429", "r2430", "r2431", "r2432", "r2433", "r2434", "r2435", "r2436", "r2437", "r2438", "r2439", "r2440", "r2441", "r2442", "r2443", "r2444", "r2445", "r2446", "r2447", "r2448", "r2449", "r2450", "r2451", "r2452", "r2453", "r2454", "r2455", "r2456", "r2457", "r2458", "r2459", "r2460", "r2461", "r2462", "r2463", "r2464", "r2465", "r2466", "r2467", "r2468", "r2469", "r2470", "r2471", "r2472", "r2473", "r2474", "r2475", "r2476", "r2477", "r2478", "r2479", "r2480", "r2481", "r2482", "r2483", "r2484", "r2485", "r2486", "r2487", "r2488", "r2489", "r2490", "r2491", "r2492", "r2493", "r2494", "r2495", "r2496", "r2497", "r2498", "r2499", "r2500", "r2501", "r2502", "r2503", "r2504", "r2505", "r2506", "r2507", "r2508", "r2509", "r2510", "r2511", "r2512", "r2513", "r2514", "r2515", "r2516", "r2517", "r2518", "r2519", "r2520", "r2521", "r2522", "r2523", "r2524", "r2525", "r2526", "r2527", "r2528", "r2529", "r2530", "r2531", "r2532", "r2533", "r2534", "r2535", "r2536", "r2537", "r2538", "r2539", "r2540", "r2541", "r2542", "r2543", "r2544", "r2545", "r2546", "r2547", "r2548", "r2549", "r2550", "r2551", "r2552", "r2553", "r2554", "r2555", "r2556", "r2557", "r2558", "r2559", "r2560", "r2561", "r2562", "r2563", "r2564", "r2565", "r2566", "r2567", "r2568", "r2569", "r2570", "r2571", "r2572", "r2573", "r2574", "r2575", "r2576", "r2577", "r2578", "r2579", "r2580", "r2581", "r2582", "r2583", "r2584", "r2585", "r2586", "r2587", "r2588", "r2589", "r2590", "r2591", "r2592", "r2593", "r2594", "r2595", "r2596", "r2597", "r2598", "r2599", "r2600", "r2601", "r2602", "r2603", "r2604", "r2605", "r2606", "r2607", "r2608", "r2609", "r2610", "r2611", "r2612", "r2613", "r2614", "r2615", "r2616", "r2617", "r2618", "r2619", "r2620", "r2621", "r2622", "r2623", "r2624", "r2625", "r2626", "r2627", "r2628", "r2629", "r2630", "r2631", "r2632", "r2633", "r2634", "r2635", "r2636", "r2637", "r2638", "r2639", "r2640", "r2641", "r2642", "r2643", "r2644", "r2645", "r2646", "r2647", "r2648", "r2649", "r2650", "r2651", "r2652", "r2653", "r2654", "r2655", "r2656", "r2657", "r2658", "r2659", "r2660", "r2661", "r2662", "r2663", "r2664", "r2665", "r2666", "r2667", "r2668", "r2669", "r2670", "r2671", "r2672", "r2673", "r2674", "r2675", "r2676", "r2677", "r2678", "r2679", "r2680", "r2681", "r2682", "r2683", "r2684", "r2685", "r2686", "r2687", "r2688", "r2689", "r2690", "r2691", "r2692", "r2693", "r2694", "r2695", "r2696", "r2697", "r2698", "r2699", "r2700", "r2701", "r2702", "r2703", "r2704", "r2705", "r2706", "r2707", "r2708", "r2709", "r2710", "r2711", "r2712", "r2713", "r2714", "r2715", "r2716", "r2717", "r2718", "r2719", "r2720", "r2721", "r2722", "r2723", "r2724", "r2725", "r2726", "r2727", "r2728", "r2729", "r2730", "r2731", "r2732", "r2733", "r2734", "r2735", "r2736", "r2737", "r2738", "r2739", "r2740", "r2741", "r2742", "r2743", "r2744", "r2745", "r2746", "r2747", "r2748", "r2749", "r2750", "r2751", "r2752", "r2753", "r2754", "r2755", "r2756", "r2757", "r2758", "r2759", "r2760", "r2761", "r2762", "r2763", "r2764", "r2765", "r2766", "r2767", "r2768", "r2769", "r2770", "r2771", "r2772", "r2773", "r2774", "r2775", "r2776", "r2777", "r2778", "r2779", "r2780", "r2781", "r2782", "r2783", "r2784", "r2785", "r2786", "r2787", "r2788", "r2789", "r2790", "r2791", "r2792", "r2793", "r2794", "r2795", "r2796", "r2797", "r2798", "r2799", "r2800", "r2801", "r2802", "r2803", "r2804", "r2805", "r2806", "r2807", "r2808", "r2809", "r2810", "r2811", "r2812", "r2813", "r2814", "r2815", "r2816", "r2817", "r2818", "r2819", "r2820", "r2821", "r2822", "r2823", "r2824", "r2825", "r2826", "r2827", "r2828", "r2829", "r2830", "r2831", "r2832", "r2833", "r2834", "r2835", "r2836", "r2837", "r2838", "r2839", "r2840", "r2841", "r2842", "r2843", "r2844", "r2845", "r2846", "r2847", "r2848", "r2849", "r2850", "r2851", "r2852", "r2853", "r2854", "r2855", "r2856", "r2857", "r2858", "r2859", "r2860", "r2861", "r2862", "r2863", "r2864", "r2865", "r2866", "r2867", "r2868", "r2869", "r2870", "r2871", "r2872", "r2873", "r2874", "r2875", "r2876", "r2877", "r2878", "r2879", "r2880", "r2881", "r2882", "r2883", "r2884", "r2885", "r2886", "r2887", "r2888", "r2889", "r2890", "r2891", "r2892", "r2893", "r2894", "r2895", "r2896", "r2897", "r2898", "r2899", "r2900", "r2901", "r2902", "r2903", "r2904", "r2905", "r2906", "r2907", "r2908", "r2909", "r2910", "r2911", "r2912", "r2913", "r2914", "r2915", "r2916", "r2917", "r2918", "r2919", "r2920", "r2921", "r2922", "r2923", "r2924", "r2925", "r2926", "r2927", "r2928", "r2929", "r2930", "r2931", "r2932", "r2933", "r2934", "r2935", "r2936", "r2937", "r2938", "r2939", "r2940", "r2941", "r2942", "r2943", "r2944", "r2945", "r2946", "r2947", "r2948", "r2949", "r2950", "r2951", "r2952", "r2953", "r2954", "r2955", "r2956", "r2957", "r2958", "r2959", "r2960", "r2961", "r2962", "r2963", "r2964", "r2965", "r2966", "r2967", "r2968", "r2969", "r2970", "r2971", "r2972", "r2973", "r2974", "r2975", "r2976", "r2977", "r2978", "r2979", "r2980", "r2981", "r2982", "r2983", "r2984", "r2985", "r2986", "r2987", "r2988", "r2989", "r2990", "r2991", "r2992", "r2993", "r2994", "r2995", "r2996", "r2997", "r2998", "r2999", "r3000", "r3001", "r3002", "r3003", "r3004", "r3005", "r3006", "r3007", "r3008", "r3009", "r3010", "r3011", "r3012", "r3013", "r3014", "r3015", "r3016", "r3017", "r3018", "r3019", "r3020", "r3021", "r3022", "r3023", "r3024", "r3025", "r3026", "r3027", "r3028", "r3029", "r3030", "r3031", "r3032", "r3033", "r3034", "r3035", "r3036", "r3037", "r3038", "r3039", "r3040", "r3041", "r3042", "r3043", "r3044", "r3045", "r3046", "r3047", "r3048", "r3049", "r3050", "r3051", "r3052", "r3053", "r3054", "r3055", "r3056", "r3057", "r3058", "r3059", "r3060", "r3061", "r3062", "r3063", "r3064", "r3065", "r3066", "r3067", "r3068", "r3069", "r3070", "r3071", "r3072", "r3073", "r3074", "r3075", "r3076", "r3077", "r3078", "r3079", "r3080", "r3081", "r3082", "r3083", "r3084", "r3085", "r3086", "r3087", "r3088", "r3089", "r3090", "r3091", "r3092", "r3093", "r3094", "r3095", "r3096", "r3097", "r3098", "r3099", "r3100", "r3101", "r3102", "r3103", "r3104", "r3105", "r3106", "r3107", "r3108", "r3109", "r3110", "r3111", "r3112", "r3113", "r3114", "r3115", "r3116", "r3117", "r3118", "r3119", "r3120", "r3121", "r3122", "r3123", "r3124", "r3125", "r3126", "r3127", "r3128", "r3129", "r3130", "r3131", "r3132", "r3133", "r3134", "r3135", "r3136", "r3137", "r3138", "r3139", "r3140", "r3141", "r3142", "r3143", "r3144", "r3145", "r3146", "r3147", "r3148", "r3149", "r3150", "r3151", "r3152", "r3153", "r3154", "r3155", "r3156", "r3157", "r3158", "r3159", "r3160", "r3161", "r3162", "r3163", "r3164", "r3165", "r3166", "r3167", "r3168", "r3169", "r3170", "r3171", "r3172", "r3173", "r3174", "r3175", "r3176", "r3177", "r3178", "r3179", "r3180", "r3181", "r3182", "r3183", "r3184", "r3185", "r3186", "r3187", "r3188", "r3189", "r3190", "r3191", "r3192", "r3193", "r3194", "r3195", "r3196", "r3197", "r3198", "r3199", "r3200", "r3201", "r3202", "r3203", "r3204", "r3205", "r3206", "r3207", "r3208", "r3209", "r3210", "r3211", "r3212", "r3213", "r3214", "r3215", "r3216", "r3217", "r3218", "r3219", "r3220", "r3221", "r3222", "r3223", "r3224", "r3225", "r3226", "r3227", "r3228", "r3229", "r3230", "r3231", "r3232", "r3233", "r3234", "r3235", "r3236", "r3237", "r3238", "r3239", "r3240", "r3241", "r3242", "r3243", "r3244", "r3245", "r3246", "r3247", "r3248", "r3249", "r3250", "r3251", "r3252", "r3253", "r3254", "r3255", "r3256", "r3257", "r3258", "r3259", "r3260", "r3261", "r3262", "r3263", "r3264", "r3265", "r3266", "r3267", "r3268", "r3269", "r3270", "r3271", "r3272", "r3273", "r3274", "r3275", "r3276", "r3277", "r3278", "r3279", "r3280", "r3281", "r32

"http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "label", "RecoveryOfErroneously Awarded Compensation Disclosure [Line Items]"} } } } "auth_ref": "r1423", "r1434", "r1444", "r1477"} } } "us-gaap RedeemableNoncontrollingInterestByLegalEntityTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestByLegalEntityTable", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Redeemable Noncontrolling Interest [Table]", "label": "Redeemable Noncontrolling Interest [Table]", "documentation": "Disclosure of information about redeemable noncontrolling interest included in statement of financial position outside of permanent equity." } } } "auth_ref": "us-gaap RedeemableNoncontrollingInterestEquityCarryingAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } } } "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails"} } } } "lang": "en-us", "role": "role", "role": "verboseLabel", "Redeemable noncontrolling interests (Note 10)", "terseLabel": "Redeemable noncontrolling interests", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } } "auth_ref": "r56", "r57", "r184", "r185"} } } "us-gaap RedeemableNoncontrollingInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestLineItems", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Redeemable Noncontrolling Interest [Line Items]", "label": "Redeemable Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } "auth_ref": "rnr RedeemableNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RedeemableNoncontrollingInterestMember", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interest [Member]", "documentation": "This item represents that portion of equity (net assets) in redeemable noncontrolling interests not attributable, directly or indirectly to the parent." } } } "auth_ref": "rnr RedeemableNoncontrollingInterestRedemptionRequirementPercentageOfAggregateSharesHeldMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RedeemableNoncontrollingInterestRedemptionRequirementPercentageOfAggregateSharesHeldMaximum", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Redeemable noncontrolling interest, redemption requirement, maximum percentage of shares held", "label": "Redeemable Noncontrolling Interest, Redemption Requirement, Percentage of Aggregate Shares Held, Maximum", "documentation": "Redeemable Noncontrolling Interest, Redemption Requirement, Percentage of Aggregate Shares Held, Maximum"} } } } "us-gaap RedeemableNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestTableTextBlock", "presentation": { "http://www.renre.com/role/NONCONTROLLINGINTERESTSTables"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Schedule of Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity." } } } "auth_ref": "us-gaap ReinsuranceAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceAccountingPolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Reinsurance", "label": "Reinsurance Accounting Policy [Policy Text Block]", "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy." } } } "auth_ref": "r1383", "r1384"} } } "rnr ReinsuranceBalancesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ReinsuranceBalancesPayableMember", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESAdditionalInformationDetails"} } } } "lang": "en-us", "role": "role", "role": "verboseLabel", "Reinsurance balances payable", "label": "Reinsurance Balances Payable [Member]", "documentation": "Reinsurance Balances Payable [Member]} } } "auth_ref": "us-gaap ReinsuranceCostsAndRecoveriesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceCostsAndRecoveriesNet", "crdr": "credit", "calculation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred": { "parentTag": "us-gaap PolicyholderBenefitsAndClaimsIncurredNet", "weight": -1.0, "order": 2.0 } } } "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofEffectofReinsuranceandRetrocessionalActivityonPremiumsWrittenandEarnedandonNetClaimsandClaimExpensesIncurred", "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails"} } } } "lang": "en-us", "role": "role", "role": "negatedLabel", "Claims and claim expenses recovered", "label": "Net reinsurance costs and recoveries", "label": "Policyholder Benefits and Claims Incurred, Assumed and Ceded", "documentation": "Amount of recovery (expense) related to provision for policy benefits and costs incurred for policies assumed and ceded." } } } "auth_ref": "r1746"} } } "us-gaap ReinsurancePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsurancePayable", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 4.0 } } } "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Reinsurance balances payable", "label": "Reinsurance Payable", "documentation": "The carrying amount as of the balance sheet date of the known and estimated amounts owed to insurers under reinsurance treaties or other arrangements." } } } "auth_ref": "us-gaap ReinsuranceRecoverableAllowanceForCreditLossPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableAllowanceForCreditLossPeriodIncreaseDecrease", "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofReinsuranceRecoverableDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Acquired", "label": "Reinsurance Recoverable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on reinsurance recoverable." } } } "auth_ref": "r1611"} } } "us-gaap ReinsuranceRecoverableAllowanceForCreditLossRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableAllowanceForCreditLossRollForward", "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofReinsuranceRecoverableDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Reinsurance Recoverable, Allowance for Credit Loss [Roll Forward]", "label": "Reinsurance Recoverable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } "auth_ref": "us-gaap ReinsuranceRecoverableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableAllowanceForCreditLossTableTextBlock", "presentation": { "http://www.renre.com/role/REINSURANCETables"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Schedule of Provision for Current Expected Credit Losses of Reinsurance Recoverable", "label": "Reinsurance Recoverable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on reinsurance recoverable." } } } "auth_ref": "r1614"} } } "us-gaap ReinsuranceRecoverableCreditLossExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableCreditLossExpenseReversal", "crdr": "debit", "presentation": { "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofReinsuranceRecoverableDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Provision for (release of) allowance", "label": "Reinsurance Recoverable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on reinsurance recoverable." } } } "auth_ref": "r3072"} } } "us-gaap ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "crdr": "debit", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Decrease to losses recoverable", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer." } } } "auth_ref": "r1046", "r1049", "r1054", "r1375", "r1381", "r147", "r1765", "r1766"} } } "us-gaap ReinsuranceRecoverableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableMember", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Reinsurance Recoverable", "label": "Reinsurance Recoverable Including Reinsurance Premium Paid [Member]", "documentation": "Reinsurance recoverable, after valuation allowance, under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves." } } } "auth_ref": "us-gaap ReinsuranceRecoverables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverables", "crdr": "debit", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails"} } } } "lang": "en-us", "role": "role", "role": "verboseLabel", "Reinsurance recoverable", "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves." } } } "auth_ref": "r1747", "r1758", "r1764"} } } "us-gaap ReinsuranceRecoverablesAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverablesAllowance", "crdr": "credit", "presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails", "http://www.renre.com/role/REINSURANCEScheduleofProvisionforCurrentExpectedCreditLossesofReinsuranceRecoverableDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "Reinsurance recoverable, allowance for credit loss", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Reinsurance Recoverable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on reinsurance recoverable." } } } "auth_ref": "r503", "r506", "r508", "r965", "r1041"} } } "us-gaap ReinsuranceRecoverablesOnPaidAndUnpaidLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverablesOnPaidAndUnpaidLosses", "crdr": "debit", "calculation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExpensesNet": { "parentTag": "us-gaap LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": -1.0, "order": 2.0 } } } "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExpensesDetails"} } } } "lang": "en-us", "role": "role", "role": "verboseLabel", "Reinsurance recoverable (Notes 7 and 8)", "label": "Reinsurance recoverable, end of period", "terseLabel": "Reinsurance Recoverable", "label": "Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts." } } } "auth_ref": "r1080", "r1747", "r1764", "r1765", "r1766"} } } "us-gaap ReinsuranceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceTextBlock", "presentation": { "http://www.renre.com/role/REINSURANCE"} } } } "lang": "en-us", "role": "role", "role": "terseLabel", "REINSURANCE", "label": "Reinsurance [Text Block]", "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts." } } } "auth_ref": "r963", "r964", "r1383", "r1384"} } } "rnr ReinsuranceTrustFundAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ReinsuranceTrustFundAxis", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails"} } } } "lang": "en-us", "role": "role", "role": "terseLabel": }

"Reinsurance Trust Fund [Axis]", "label": "Reinsurance Trust Fund [Axis]", "documentation": "Reinsurance Trust Fund [Axis]"}}, {"auth_ref": []}, {"rnr_ReinsuranceTrustFundDomain": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ReinsuranceTrustFundDomain", "presentation": [{"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Reinsurance Trust Fund [Domain]", "label": "Reinsurance Trust Fund [Domain]", "documentation": "Reinsurance Trust Fund [Domain]"}}, {"auth_ref": []}, {"us-gaap_ReinsurerConcentrationRiskMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsurerConcentrationRiskMember", "presentation": [{"http://www.renre.com/role/REINSURANCENarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Reinsurer Concentration Risk", "label": "Reinsurer Concentration Risk [Member]", "documentation": "Concentration risk of a reinsurer to a specified benchmark, such as reinsurance recoverables"}}, {"auth_ref": []}, {"us-gaap_RelatedPartyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [{"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "lang": {"en-us": {"role": {"terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."}}}, {"auth_ref": [{"r460", "r672", "r874", "r875", "r974", "r982", "r1121", "r1122", "r1123", "r1124", "r1125", "r1145", "r1147"}], {"us-gaap_RelatedPartyMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [{"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "lang": {"en-us": {"role": {"terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."}}}, {"auth_ref": [{"r379", "r380", "r874", "r875", "r876", "r877", "r974", "r982", "r1121", "r1122", "r1123", "r1124", "r1125", "r1145", "r1147", "r1176"}], {"us-gaap_RelatedPartyTransactionLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [{"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": [{"r460", "r1152", "r1153", "r1154"}], {"us-gaap_RelatedPartyTransactionsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": {"en-us": {"role": {"terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]"}}, {"auth_ref": []}, {"rnr_RelatedPartyTransactionsAndMajorCustomersDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RelatedPartyTransactionsAndMajorCustomersDisclosureTextBlock", "presentation": [{"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERS", "lang": {"en-us": {"role": {"terseLabel": "RELATED PARTY TRANSACTIONS AND MAJOR CUSTOMERS", "label": "Related Party Transactions and Major Customers Disclosure [Text Block]", "documentation": "Related Party Transactions and Major Customers Disclosure [Text Block]"}}, {"auth_ref": []}, {"us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [{"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "lang": {"en-us": {"role": {"terseLabel": "Related Party Transactions, by Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."}}}, {"auth_ref": [{"r460", "r672", "r874", "r875", "r974", "r982", "r1121", "r1122", "r1123", "r1124", "r1125", "r1145", "r1147", "r1176", "r1732"}], {"rnr_RenaissanceReEuropeAGMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReEuropeAGMember", "presentation": [{"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails", "RREAG", "label": "RenaissanceRe Europe AG [Member]", "documentation": "RenaissanceRe Europe AG"}}, {"auth_ref": []}, {"rnr_RenaissanceReFinanceInc.Member": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReFinanceInc.Member", "presentation": [{"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleOfCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails", "lang": {"en-us": {"role": {"terseLabel": "RenaissanceRe Finance, Inc.", "label": "RenaissanceRe Finance Inc. [Member]", "documentation": "RenaissanceRe Finance Inc. [Member]"}}, {"auth_ref": []}, {"rnr_RenaissanceReHoldingsLtd.Member": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReHoldingsLtd.Member", "presentation": [{"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "RenaissanceRe Holdings Ltd.", "label": "RenaissanceRe Holdings Ltd. [Member]", "documentation": "RenaissanceRe Holdings Ltd. [Member]"}}, {"auth_ref": []}, {"rnr_RenaissanceReMediciFundLtd.Member": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReMediciFundLtd.Member", "presentation": [{"http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleOfCreditFacilitiesDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleOfRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryOfRedeemableNoncontrollingInterestDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": {"en-us": {"role": {"terseLabel": "Medici", "label": "RenaissanceRe Medici Fund Ltd. [Member]", "documentation": "RenaissanceRe Medici Fund Ltd. [Member]"}}, {"auth_ref": []}, {"rnr_RenaissanceReUpsilonDiversifiedFundMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReUpsilonDiversifiedFundMember", "presentation": [{"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "RenaissanceRe Upsilon Diversified Fund", "label": "RenaissanceRe Upsilon Diversified Fund", "documentation": "RenaissanceRe Upsilon Diversified Fund"}}, {"auth_ref": []}, {"rnr_RenaissanceReInsuranceLtd.Member": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenaissanceReInsuranceLtd.Member", "presentation": [{"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails", "http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Renaissance Reinsurance Ltd. [Member]", "documentation": "Renaissance Reinsurance Ltd. [Member]"}}, {"auth_ref": []}, {"rnr_RenewalRightsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "RenewalRightsMember", "presentation": [{"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails", "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleOfIdentifiableIntangibleAssetsDetails", "lang": {"en-us": {"role": {"terseLabel": "Renewal rights", "label": "Renewal Rights [Member]", "documentation": "Renewal Rights [Member]"}}, {"auth_ref": []}, {"us-gaap_RepaymentsOfLinesOfCredit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": [{"http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0}], "presentation": [{"http://www.renre.com/role/ConsolidatedStatementsOfCashFlows", "lang": {"en-us": {"role": {"negatedLabel": "Repayment of Medici Revolving Credit Facility", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."}}}, {"auth_ref": [{"r174", "r1573"}], {"us-gaap_RepaymentsOfLongTermLinesOfCredit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": [{"http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Repayments of long-term lines of credit", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."}}}, {"auth_ref": [{"r174}], {"rnr_ReportedClaimsLessThanExpectedMember": {"xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ReportedClaimsLessThanExpectedMember", "presentation": [{"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails", "lang": {"en-us": {"role": {"terseLabel": "Actuarial methods - actual reported claims less than expected claims", "label": "Reported Claims Less than Expected [Member]", "documentation": "Reported Claims Less than Expected [Member]"}}, {"auth_ref": [{"srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [{"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleOfRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."}}}, {"auth_ref": [{"r321", "r322", "r381", "r382", "r581", "r610", "r877", "r901", "r966", "r1296", "r1297"}], {"us-gaap_ResidentialMortgageBackedSecuritiesMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResidentialMortgageBackedSecuritiesMember", "presentation": [{"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleOfAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/INVESTMENTSScheduleOfFairValueofFixedMaturityInvestmentsTradingDetails", "http://www.renre.com/role/SCHEDULESUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails", "lang": {"en-us": {"role": {"terseLabel": "Residential mortgage-backed", "label": "Residential Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by residential real estate mortgage loans."}}}, {"auth_ref": [{"r1345", "r1347", "r1349", "r1598", "r1599", "r1600", "r1601", "r1602", "r1658"}], {"ecd_RestatementDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]"}}, {"auth_ref": [{"r1424", "r1435", "r1445", "r1478"}], {"ecd_RestatementDeterminationDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date"}}, {"auth_ref": [{"r1425", "r1436", "r1446", "r1479"}], {"ecd_RestatementDoesNotRequireRecoveryTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]"}}, {"auth_ref": [{"r1432", "r1443", "r1453", "r1486"}], {"us-gaap_RestrictedStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [{"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": {"en-us": {"role": {"verboseLabel": "Restricted stock awards", "terseLabel": "Total Restricted Stock Awards", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."}}}, {"auth_ref": [{"r42}], {"us-gaap_RetainedEarningsAccumulatedDeficit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": [{"http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0}], "presentation": [{"http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails", "lang": {"en-us": {"role": {"terseLabel": "Retained earnings (Note 12)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)."}}, {"auth_ref": [{"r151", "r189", "r979", "r1066", "r1068", "r1090", "r1129", "r1358"}], {"us-gaap_RetainedEarningsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [{"http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "lang": {"en-

us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } }, "auth_ref": { "r330", "r385", "r386", "r387", "r389", "r394", "r396", "r398", "r501", "r502", "r543", "r770", "r771", "r779", "r780", "r781", "r783", "r789", "r790", "r801", "r803", "r804", "r806", "r809", "r864", "r865", "r1062", "r1064", "r1093", "r1810" } }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduledBenefitPensionPlanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": { "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r690", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336" } }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduledBenefitPensionPlanDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": { "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r690", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336" } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONANDMAJORCUSTOMERSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue recorded", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r227", "r228", "r422", "r431", "r432", "r446", "r452", "r455", "r457", "r459", "r624", "r625", "r918" } }, "us-gaap_RevenueRecognitionPremiumsEarnedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPremiumsEarnedPolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Premiums and Related Expenses", "label": "Revenue Recognition, Premiums Earned, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining revenue and timing of recognition as revenue of premiums received from policyholders, insureds and other insurance entities (the effects of ceding and assuming insurance policy risks) for the entity's insurance products." } } }, "auth_ref": { "r131", "r132" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.renre.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANStatementsofOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofFinancialResultsDetails", "http://www.renre.com/role/ConsolidatedStatementsofOperations", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANStatementsofOperationsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "terseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r227", "r228", "r358", "r376", "r422", "r431", "r432", "r436", "r452", "r455", "r457", "r459", "r500", "r566", "r567", "r569", "r570", "r571", "r572", "r573", "r575", "r576", "r844", "r962", "r1306", "r1647" } }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsofOperations": { "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANStatementsofOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]", "documentation": "Revenues from External Customers and Long-Lived Assets Line Items", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r131", "r132" } }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can be continuously obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": { "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778

[illegible]

}}}, "auth_ref": {"r990"}}, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofNetInvestmentIncomeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment Income [Table]", "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."}}}, "auth_ref": {"r165", "r166", "r169", "r990"}}, "us-gaap_ScheduleOfInvestmentsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsTradingDetails": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": {"http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, "auth_ref": {"r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"}}, "us-gaap_ScheduleOfInvestmentsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofEquityInvestmentsTradingDetails": {"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails": {"http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Investment [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company."}}}, "auth_ref": {"r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255"}}, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": {"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESTables": {"lang": {"en-us": {"role": {"verboseLabel": "Schedule of Claims and Claim Expenses", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."}}}, "auth_ref": {"r1045"}}, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": {"http://www.renre.com/role/DEBTANDCREDITFACILITIESTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Credit Facilities", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."}}}, "auth_ref": {"r136", "r141"}}, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": {"http://www.renre.com/role/DEBTANDCREDITFACILITIESTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Aggregate Amount of Maturities Related to the Company's Debt Obligations", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."}}}, "auth_ref": {"r14"}}, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": {"http://www.renre.com/role/DERIVATIVEINSTRUMENTSTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Derivative Instruments Designated as Hedges of a Net Investment in a Foreign Operation", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period."}}}, "auth_ref": {"r1701"}}, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": {"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-based Compensation, Cash Settled Restricted Stock Units and Performance Shares", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."}}}, "auth_ref": {"r190"}}, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": {"http://www.renre.com/role/ACQUISITIONOFVALIDUSTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Fair Value of Net Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."}}}, "auth_ref": {"r196"}}, "rmr_ScheduleOfReinsuranceTrustsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ScheduleOfReinsuranceTrustsTableTextBlock", "presentation": {"http://www.renre.com/role/STATUTORYREQUIREMENTSTables": {"lang": {"en-us": {"role": {"terseLabel": "Summary of Reinsurance Trusts", "label": "Schedule of Reinsurance Trusts [Table Text Block]", "documentation": "Schedule of Reinsurance Trusts"}}, "auth_ref": {}}, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": {"http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction."}}}, "auth_ref": {"r119", "r121", "r1152", "r1153", "r1154"}}, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTableTextBlock", "presentation": {"http://www.renre.com/role/SEGMENTREPORTINGTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Gross Premiums Written Allocated to the Territory of Coverage Exposure", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."}}}, "auth_ref": {"r53", "r159"}}, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."}}}, "auth_ref": {"r53", "r159"}}, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": {"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."}}}, "auth_ref": {"r50", "r51", "r52"}}, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": {"http://www.renre.com/role/SEGMENTREPORTINGTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Significant Components of the Company's Revenues and Expenses", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."}}}, "auth_ref": {"r50", "r51", "r52"}}, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": {"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails": {"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement."}}}, "auth_ref": {"r692", "r693", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724"}}, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": {"http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-based Compensation, Restricted Stock Awards", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."}}}, "auth_ref": {}}, "us-gaap_ScheduleOfStockByClassTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": {"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."}}}, "auth_ref": {"r58", "r59", "r61", "r62", "r63", "r65", "r183", "r187", "r188", "r189", "r339", "r340", "r341", "r424", "r608", "r609", "r610", "r612", "r615", "r620", "r622", "r1086", "r1087", "r1088", "r1089", "r1323", "r1519", "r1572"}}, "srt_ScheduleOfSupplementalInformationForPropertyCasualtyInsuranceUnderwritersTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfSupplementalInformationForPropertyCasualtyInsuranceUnderwritersTextBlock", "presentation": {"http://www.renre.com/role/SCHEDULESUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONS": {"lang": {"en-us": {"role": {"terseLabel": "SUPPLEMENTAL INSURANCE INFORMATION CONCERNING PROPERTY-CASUALTY INSURANCE OPERATIONS", "label": "SEC Schedule 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Table Text Block]", "documentation": "The entire disclosure of supplemental information for registrant, its subsidiary and 50-percent-or-less-owned equity basis investee, with liability for property-casualty insurance claim."}}}, "auth_ref": {"r288", "r300", "r1025", "r1037"}}, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": {"http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt and Equity Securities, FV-NI [Line Items]", "label": "Debt and Equity Securities, FV-NI [Line Items]", "documentation": "Line items represent financial concepts included in a table. These

concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r837" } } } , "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities: Trading, and Equity Securities, FV-NI [Table]", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NB." } } } } , "auth_ref": { "r837" } } } , "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Table]", "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } } } , "auth_ref": { "r85", "r86", "r88", "r91", "r93", "r92", "r93", "r96", "r97", "r96", "r97", "r98", "r99" } } } , "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSTables": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities", "verboseLabel": "Summary of the Principal-at-risk Variable Notes", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE, whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } } } , "auth_ref": { "r85", "r86", "r88", "r91", "r93" } } } , "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } } } , "auth_ref": { "r1316", "r1630" } } } , "rnr_ScheduleofStatutoryCapitalSurplusandUnrestrictedNetAssetsTableTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ScheduleofStatutoryCapitalSurplusandUnrestrictedNetAssetsTableTextBlock", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Actual and Required Statutory Capital and Surplus", "label": "Schedule of Statutory Capital, Surplus and Unrestricted Net Assets [Table Text Block]", "documentation": "Schedule of Statutory Capital, Surplus and Unrestricted Net Assets [Table Text Block]", "auth_ref": { "rnr_ScheduleofStatutoryNetIncomeLossTableTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ScheduleofStatutoryNetIncomeLossTableTextBlock", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Statutory Net (Loss) Income", "label": "Schedule of Statutory Net Income (Loss) [Table Text Block]", "documentation": "Schedule of Statutory Net Income (Loss) [Table Text Block]", "auth_ref": { "rnr_SecuredBilateralFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SecuredBilateralFacilityMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Secured Bilateral Facility", "label": "Secured Bilateral Facility [Member]", "documentation": "Secured Bilateral Facility [Member]", "auth_ref": { "rnr_SecuredLetterOfCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SecuredLetterOfCreditFacilityMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Secured Letter of Credit Facility", "label": "Secured Letter of Credit Facility [Member]", "documentation": "Secured Letter of Credit Facility", "auth_ref": { "us-gaap_SecuritiesForReverseRepurchaseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesForReverseRepurchaseAgreements", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSReversePurchaseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reverse repurchase agreements", "label": "Securities for Reverse Repurchase Agreements", "documentation": "The carrying value of securities purchased to be resold in reverse repurchase transactions as of the balance sheet date." } } } } , "auth_ref": { "us-gaap_SecuritiesOwnedAndOtherInvestmentsNotReadilyMarketableDisclosureTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesOwnedAndOtherInvestmentsNotReadilyMarketableDisclosureTextBlock", "presentation": { "http://www.renre.com/role/INVESTMENTSTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Investments", "label": "Securities Owned and Other Investments Not Readily Marketable Disclosure [Table Text Block]", "documentation": "Tabular disclosure of quantitative and qualitative information related to securities and other investments not readily marketable, including, but not limited to, thinly traded securities or investments, restricted securities and securities in nonpublic entities." } } } } , "auth_ref": { "r1743" } } } , "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.renre.com/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } } , "auth_ref": { "r1405" } } } , "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.renre.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } } , "auth_ref": { "r1408" } } } , "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmenttotheReserveforNetClaimsandClaimExpensesDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimExp": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } } } , "auth_ref": { "r227", "r228", "r229", "r230", "r422", "r427", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r459", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r542", "r553", "r554", "r1003", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1303", "r1306", "r1307", "r1315", "r1379", "r1763", "r1774", "r1775", "r1776", "r1777", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803", "r1804" } } } } , "srst_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srst/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segment, Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } } } , "auth_ref": { "r257", "r259", "r262", "r264", "r301", "r302", "r303", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r457", "r458", "r921", "r923", "r924", "r925", "r926", "r928", "r929", "r930", "r931", "r932", "r933", "r935", "r936", "r937", "r938", "r939", "r940", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r1107", "r1111", "r1113", "r1186", "r1201", "r1222", "r1252", "r1271", "r1274", "r1275", "r1276", "r1277", "r1279", "r1280", "r1281", "r1282", "r1283", "r1289", "r1325", "r1361", "r1362", "r1363", "r1364", "r1366", "r1368", "r1369", "r1370", "r1378", "r1391", "r1656", "r1763", "r1774", "r1775", "r1777", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803", "r1804" } } } , "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "TextBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": { "http://www.renre.com/role/SEGMENTREPORTING": { "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } } } , "auth_ref": { "r230", "r422", "r426", "r427", "r428", "r429", "r430", "r442", "r444", "r445", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r1302", "r1304", "r1305", "r1306", "r1308", "r1309", "r1310" } } } , "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth_ref": { "us-gaap_SegmentReportingMeasurementDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingMeasurementDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Measurement Disclosures [Abstract]", "label": "Segment Reporting, Measurement Disclosures [Abstract]", "auth_ref": { "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } } } , "auth_ref": { "rnr_SeniorSecuredBankLoanFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SeniorSecuredBankLoanFundsMember", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fund investments", "label": "Senior Secured Bank Loan Funds [Member]", "documentation": "An investment that primarily invests in bank loans and other senior debt instruments." } } } } , "auth_ref": { "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Series C Preferred Stock", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } } } , "auth_ref": { "r1556", "r1557", "r1634" } } } , "rnr_SeriesCPreferredSharesDepositorySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SeriesCPreferredSharesDepositorySharesMember", "presentation": { "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": { "lang": { "en-us": { "role": {

"terseLabel": "Series F Preferred Shares, Depositary Shares", "label": "Series F Preferred Shares, Depositary Shares [Member]", "documentation": "Series F Preferred Shares, Depositary Shares", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "Series F Preferred Stock", "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock", "auth_ref": "r1556", "r1557", "r1654", "rnr_SeriesGPreferredSharesDepositarySharesMember": "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SeriesGPreferredSharesDepositarySharesMember", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "Series G Preferred Shares, Depositary Shares", "label": "Series G Preferred Shares, Depositary Shares [Member]", "documentation": "Series G Preferred Shares, Depositary Shares", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "lang": "en-us", "role": "Series G Preferred Stock", "label": "Series G Preferred Stock [Member]", "documentation": "Series G preferred stock", "auth_ref": "r1556", "r1557", "r1654", "us-gaap_ShareBasedCompensation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "Total stock compensation expense recognized", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement", "auth_ref": "r1", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "verboselabel": "Stock incentive compensation, vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnFnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition", "auth_ref": "r1338", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "negatedTerseLabel": "Awards forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period", "auth_ref": "r713", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "TerseLabel": "Awards forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event", "auth_ref": "r713", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "TerseLabel": "Awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)", "auth_ref": "r711", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "TerseLabel": "Awards granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)", "auth_ref": "r711", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "periodStartLabel": "Nonvested, beginning balance (in shares)", "periodEndLabel": "Nonvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date", "auth_ref": "r708", "r709", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "verboselabel": "Number of Shares [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period", "auth_ref": {}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "periodStartLabel": "Nonvested, beginning balance (in usd per share)", "periodEndLabel": "Nonvested, ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options", "auth_ref": "r708", "r709", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "TerseLabel": "Weighted Averageu00a0 Grant Date Fairu00a0Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "auth_ref": {}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "negatedTerseLabel": "Awards vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period", "auth_ref": "r712", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "TerseLabel": "Total fair value of shares and share units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash", "auth_ref": "r715", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "lang": "en-us", "role": "en-us", "role": "TerseLabel": "Awards vested (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement", "auth_ref": "r712", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails", "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "TerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r692", "r693", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "TerseLabel": "Shares reserved for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement", "auth_ref": "r1339", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "TerseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable", "auth_ref": }


```
"r68"]}, {"nmr": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod", "xbrlytpe": "durationItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Performance period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award Performance Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award Performance Period"}], {"auth_ref": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANEquityCompensationOtherthanOptionsDetails"}, {"lang": "en-us", "role": "terseLabel", "Award Type {Domain}", "label": "Award Type {Domain}", "documentation": "Award under share-based payment arrangement"}], {"auth_ref": "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724"}, {"us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy", "xbrlytpe": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"}, {"lang": "en-us", "role": "terseLabel", "Stock Incentive Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."}], {"auth_ref": "r691", "r699", "r718", "r719", "r720", "r721", "r724", "r729", "r730", "r731", "r732"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2019Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2019Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2019", "label": "Short-Duration Insurance Contract Accident Year 2019 [Member]", "documentation": "Accident year 2019 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2020Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2020Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2020", "label": "Short-Duration Insurance Contract Accident Year 2020 [Member]", "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2021Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2021Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2021", "label": "Short-Duration Insurance Contract Accident Year 2021 [Member]", "documentation": "Accident year 2021 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2022Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2022Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2022", "label": "Short-Duration Insurance Contract Accident Year 2022 [Member]", "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2023Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2023Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2023", "label": "Short-Duration Insurance Contract Accident Year 2023 [Member]", "documentation": "Accident year 2023 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractAccidentYear2024Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractAccidentYear2024Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2024", "label": "Short-Duration Insurance Contract Accident Year 2024 [Member]", "documentation": "Accident year 2024 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1051"}, {"us-gaap_ShortDurationInsuranceContractsAccidentYear2017Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractsAccidentYear2017Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2017", "label": "Short-Duration Insurance Contracts Accident Year 2017 [Member]", "documentation": "Accident year 2017 in which a covered event occurs under the terms of the short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortDurationInsuranceContractsAccidentYear2018Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortDurationInsuranceContractsAccidentYear2018Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2018", "label": "Short-Duration Insurance Contracts Accident Year 2018 [Member]", "documentation": "Accident year 2018 in which covered event occurs under terms of short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortTermBorrowings", "xbrlytpe": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": "http://www.renre.com/role/DEBTANDCREDITFACILITIESDebtObligationsNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-term Debt", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."}], {"auth_ref": "r135", "r211", "r1358", "r1750"}, {"us-gaap_ShortTermDebtTypeAxis", "xbrlytpe": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-term Debt Type {Axis}", "label": "Short-Term Debt Type {Axis}", "documentation": "Information by type of short-term debt arrangement."}], {"auth_ref": "r137", "r1635", "r1636", "r1637"}, {"us-gaap_ShortTermDebtTypeDomain", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": "http://www.renre.com/role/COMMITMENTSCONTINGENCIESANDOTHERITEMSNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-term Debt Type {Domain}", "label": "Short-Term Debt Type {Domain}", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."}], {"auth_ref": "r135", "r1635", "r1636", "r1637"}, {"us-gaap_ShortTermInvestmentsMember", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-term Investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."}], {"auth_ref": "r1257", "r1258", "r1259", "r1291"}, {"us-gaap_ShortDurationInsuranceContractsAccidentYear2015Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsAccidentYear2015Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2015", "label": "Short-Duration Insurance Contracts Accident Year 2015 [Member]", "documentation": "Accident year 2015 in which a covered event occurs under the terms of the short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortdurationInsuranceContractsAccidentYear2016Member", "xbrlytpe": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsAccidentYear2016Member", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Accident Year 2016", "label": "Short-Duration Insurance Contracts Accident Year 2016 [Member]", "documentation": "Accident year 2016 in which a covered event occurs under the terms of the short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055"}, {"us-gaap_ShortdurationInsuranceContractsAccidentYearAxis", "xbrlytpe": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-duration Insurance Contracts Accident Year {Axis}", "label": "Short-Duration Insurance Contracts Accident Year {Axis}", "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract."}], {"auth_ref": "r1052", "r1053", "r1055", "r1381"}, {"us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable", "xbrlytpe": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails"}, {"lang": "en-us", "role": "terseLabel", "Short-duration Insurance Contracts Claims Development {Table}", "label": "Short-Duration Insurance Contracts Claims Development {Table}", "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts."}], {"auth_ref": "r1052", "r1053", "r1055", "r1056", "r1381"}, {"us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "xbrlytpe": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock", "presentation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESTables"}, {"lang": "en-us", "role": "terseLabel", "Schedule of Short-duration Insurance Contracts Claims Development", "label": "Short-Duration Insurance Contracts Claims Development [Table Text Block]", "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts."}], {"auth_ref": "r1051", "r1381", "r1777", "r1778"}, {"us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "xbrlytpe": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "crdr": "debit", "calculation": "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaims
```

"http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationTable", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-duration Insurance Contracts, Historical Claims Duration [Table]", "label": "Short-Duration Insurance Contracts, Historical Claims Duration [Table]", "documentation": "Disclosure of information about average annual percentage payout of incurred claims by age, after reinsurance, for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearEight": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearEight", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year eight", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Eight", "documentation": "Percentage of average annual payout, after reinsurance, in the eighth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearFive": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearFive", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year five", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Five", "documentation": "Percentage of average annual payout, after reinsurance, in the fifth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearFour": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearFour", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year four", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Four", "documentation": "Percentage of average annual payout, after reinsurance, in the fourth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearNine": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearNine", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year nine", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Nine", "documentation": "Percentage of average annual payout, after reinsurance, in the ninth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year one", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year One", "documentation": "Percentage of average annual payout, after reinsurance, in the first year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearSeven": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearSeven", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year seven", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Seven", "documentation": "Percentage of average annual payout, after reinsurance, in the seventh year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearSix": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearSix", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year six", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Six", "documentation": "Percentage of average annual payout, after reinsurance, in the sixth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearTen": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearTen", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year ten", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Ten", "documentation": "Percentage of average annual payout, after reinsurance, in the tenth year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearThree": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearThree", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year three", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Three", "documentation": "Percentage of average annual payout, after reinsurance, in the third year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearTwo": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearTwo", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Average annual percentage payout, year two", "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year Two", "documentation": "Percentage of average annual payout, after reinsurance, in the second year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts." } } }, "auth_ref": { "r1057", "r1302" } }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIBNRClaimsLiabilityNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIBNRClaimsLiabilityNet", "crdr": "credit", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "IBNR and ACR", "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "documentation": "Undiscounted amount, after reinsurance, of incurred but not reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense." } } }, "auth_ref": { "r1055", "r1056", "r1301" } }, "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet", "crdr": "credit", "calculation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Incurred Claims and Claim Expenses, Net of Reinsurance", "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net", "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense." } } }, "auth_ref": { "r1052", "r1301" } }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "crdr": "credit", "calculation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "totalLabel": "Liability for claims and claim expenses, net of reinsurance", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net", "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense." } } }, "auth_ref": { "r1051", "r1054", "r1301" } }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNetNotSeparatelyPresented", "crdr": "credit", "calculation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding liabilities from accident year 2014 and prior, net of reinsurance", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented", "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts for accident years not separately presented in claim development information. Excludes unallocated claim adjustment expense." } } }, "auth_ref": { "r1051", "r1301" } }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAccumulatedUnallocatedClaimAdjustmentExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAccumulatedUnallocatedClaimAdjustmentExpense", "crdr": "credit", "calculation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment for unallocated loss adjustment expenses", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claims Adjustment Expense, Accumulated Unallocated Claim Adjustment Expense", "documentation": "Amount of liability for unallocated claim adjustment expense for short-duration insurance contracts." } } }, "auth_ref": { "r1301", "r1776" } }, "rnr_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsandClaimAdjustmentExpenseUnamortizedFairValueAdjustmentsAssociatedWithAcquisition": { "xbrltype": "monetaryItem", "nsuri": "http://www.renre.com/20241231", "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsandClaimAdjustmentExpenseUnamortizedFairValueAdjustmentsAssociatedWithAcquisition", "crdr": "credit", "calculation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unamortized fair value and other adjustments recorded in connection with acquisitions", "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Unamortized Fair Value Adjustments Associated With Acquisition", "documentation": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Unamortized Fair Value Adjustments Associated With Acquisition" } } }, "auth_ref": { "r1776" } }, "us-gaap_ShortdurationInsuranceContractsScheduleOffHistoricalClaimsDurationTableTextBlock": { "xbrltype": "textBlock", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsScheduleOffHistoricalClaimsDurationTableTextBlock", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-duration Insurance Contracts, Schedule of Historical Claims Duration", "label": "Short-Duration Insurance Contracts, Schedule of Historical Claims Duration [Table Text Block]", "documentation": "Tabular disclosure of average annual percentage payout of incurred claims by age, after reinsurance, for short-duration insurance contracts." } } }, "auth_ref": { "r1302", "r1779" } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlock", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {
"http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIES": { "lang": { "en-us": { "role": { "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r178", "r373" } }, "rnr_SmallCatastropheEventsAndAttritionalLossMovementsMember": { "xbrltype": "domainItem", "nsuri": "http://www.renre.com/20241231", "localname": "SmallCatastropheEventsAndAttritionalLossMovementsMember", "presentation": {
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "lang": { "en-us": {

```
"role": "Small Catastrophe Events And Attritional Loss Movements", "label": "Small Catastrophe Events And Attritional Loss Movements [Member]",  
"documentation": "Small Catastrophe Events And Attritional Loss Movements [Member]"} } } , { "auth_ref": "rmr.SocieteGeneraleNewYorkBranchSocGenMember", {  
  "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "SocieteGeneraleNewYorkBranchSocGenMember", "presentation": {  
    "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Sociu00e9nu00e9  
Glu00e9nu00e9rale-New York Branch (u201cSocGenu201d)", "label": "Sociu00e9nu00e9 Glu00e9nu00e9rale-New York Branch (u201cSocGenu201d) [Member]",  
"documentation": "Sociu00e9nu00e9 Glu00e9nu00e9rale-New York Branch (u201cSocGenu201d) [Member]" } } }, "auth_ref": { } } ,  
"srtsStandardPoorsAMinusRatingMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StandardPoorsAMinusRatingMember",  
"presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Rated A- or higher", "label": "Standard & Poor's A-  
Rating [Member]", "documentation": "A- credit rating as defined by the external credit rating agency. Standard & Poor's." } } }, "auth_ref": { } } ,  
"srtsStandardPoorsBBBPlusRatingMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StandardPoorsBBBPlusRatingMember",  
"presentation": { "http://www.renre.com/role/REINSURANCENarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Rated lower than A-", "label": "Standard & Poor's  
BBB+ Rating [Member]", "documentation": "BBB+ credit rating as defined by the external credit rating agency. Standard & Poor's." } } }, "auth_ref": { } } ,  
"rmr.StandbyLetterOfCreditAgreementMember", { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "  
StandbyLetterOfCreditAgreementMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails", "lang": { "en-us": {  
"role": { "terseLabel": "Standby Letter of Credit Agreement", "label": "Standby Letter of Credit Agreement [Member]", "documentation": "Standby Letter of Credit Agreement"  
} } }, "auth_ref": { } } , "us-gaap.StatementBusinessSegmentsAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
StatementBusinessSegmentsAxis", "presentation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESHistoricalClaimsDurationDetails",  
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails",  
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESReconciliationoftheDisclosureofIncurredandPaidClaimsDevelopmenttotheReserveforClaimsandClaimEx  
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofIncurredandPaidClaimsDevelopmentDetails",  
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofReserveforClaimsandClaimExpensesbySegmentDetails",  
"http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails",  
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails",  
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails", "lang": { "en-us": { "role": { "terseLabel":  
"Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": { "r227", "r228", "r229", "r230", "r331", "r422", "r427",  
"r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r453",  
"r454", "r459", "r459", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r542", "r545", "r553", "r554", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010",  
"r1011", "r1012", "r1013", "r1014", "r1015", "r1303", "r1306", "r1307", "r1315", "r1379", "r1763", "r1774", "r1775", "r1776", "r1777", "r1779", "r1780", "r1781", "r1782",  
"r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803",  
"r1804" } } }, "us-gaap.StatementClassOfStockAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis",  
"presentation": { "http://www.renre.com/role/CoverPage", "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails",  
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails", "http://www.renre.com/role/SUBSEQUENTEVENTSDetails",  
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]",  
"documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r253", "r339", "r340", "r341", "r376", "r404", "r408", "r412", "r416", "r424",  
"r425", "r500", "r566", "r569", "r570", "r571", "r575", "r576", "r608", "r609", "r612", "r615", "r622", "r844", "r1086", "r1087", "r1088", "r1089", "r1093", "r1094", "r1095",  
"r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1128", "r1149", "r1171", "r1261", "r1262", "r1263", "r1264", "r1265", "r1519", "r1572",  
"r1586" } } }, "us-gaap.StatementEquityComponentsAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "  
StatementEquityComponentsAxis", "presentation": { "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",  
"http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails",  
"http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails", "lang": { "en-us": { "role": { "terseLabel": "Equity Components  
[Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r21", "r149", "r152", "r153", "r330", "r355", "r356",  
"r357", "r385", "r386", "r387", "r389", "r394", "r396", "r398", "r423", "r501", "r502", "r543", "r623", "r770", "r771", "r779", "r780", "r781", "r783", "r789", "r790", "r801",  
"r802", "r803", "r804", "r805", "r806", "r809", "r854", "r855", "r856", "r857", "r858", "r859", "r864", "r865", "r873", "r889", "r1062", "r1063", "r1064", "r1093", "r1171" } } ,  
"srtsStatementGeographicalAxis", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": {  
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails", "lang": { "en-us": { "role": {  
"terseLabel": "Statement Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": { "r257", "r259",  
"r262", "r264", "r301", "r302", "r303", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r457", "r458", "r921", "r923", "r924", "r925", "r926", "r928", "r929", "r930",  
"r931", "r932", "r933", "r935", "r936", "r937", "r938", "r939", "r940", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955",  
"r1107", "r1111", "r1113", "r1186", "r1201", "r1222", "r1252", "r1271", "r1274", "r1275", "r1276", "r1277", "r1279", "r1280", "r1281", "r1282", "r1283", "r1289", "r1325",  
"r1361", "r1362", "r1363", "r1364", "r1366", "r1368", "r1369", "r1370", "r1378", "r1391", "r1656", "r1763", "r1774", "r1775", "r1776", "r1777", "r1779", "r1780", "r1781", "r1782",  
"r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1803",  
"r1804" } } }, "us-gaap.StatementLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": {  
"http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",  
"http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails", "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]",  
"label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information  
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r385", "r386", "r387", "r423", "r865", "r918", "r1084", "r1104", "r1119",  
"r1121", "r1122", "r1123", "r1124", "r1125", "r1128", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r11
```

```
"http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfAssetsHeldUnderTrustAndMinimumDetails","http://www.renre.com/role/STATUTORYREQUIREMENTSScheduleOfMultiBeneficiaryReducedCollateralReinsuranceTrustsDetails","http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails","http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryNetIncomeLossDetails"}}, {"lang": "en-us", "role": "terseLabel", "Statutory Accounting Practices [Table]", "documentation": "Disclosure of information about statutory financial reporting and difference between reporting under Generally Accepted Accounting Principles (GAAP) and result based on prescribed and permitted accounting practice of state or country of domicile in which statutory financial statements are required or National Association of Insurance Commissioners (NAIC) prescribed practice, or both."}, {"auth_ref": "r124", "r127", "r128", "r129", "r130", "r1753"}, {"nr": "Stichting Pensioenfonds Zorg en Welzijn Member", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "Stichting Pensioenfonds Zorg en Welzijn Member", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Stichting Pensioenfonds Zorg en Welzijn", "label": "Stichting Pensioenfonds Zorg en Welzijn [Member]", "documentation": "Stichting Pensioenfonds Zorg en Welzijn"}, {"auth_ref": "I", "ecd": "StkPrCrOrTsrEstimationMethodTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCrOrTsrEstimationMethodTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}, {"lang": "en-us", "role": "terseLabel", "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]", "auth_ref": "r1427", "r1438", "r1448", "r1481"}, {"us-gaap": "StockAppreciationRightsSARSMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": "http://xbrl.sec.gov/ecd/AwardTimingDisclosure"}, {"lang": "en-us", "role": "terseLabel", "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."}, {"auth_ref": "I", "us-gaap": "StockIssuedDuringPeriodSharesNewIssues", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": "http://xbrl.sec.gov/ShareholderEquityRollforwardofSharesIssuedandOutstandingDetails"}, {"lang": "en-us", "role": "terseLabel", "Issuance of shares (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period."}, {"auth_ref": "r21", "r148", "r149", "r189", "r1086", "r1171", "r1262"}, {"us-gaap": "StockIssuedDuringPeriodSharesShareBasedCompensation", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails"}, {"lang": "en-us", "role": "terseLabel", "Issuance of performance share and restricted stock awards (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."}, {"auth_ref": "r21", "r148", "r149", "r189"}, {"us-gaap": "StockIssuedDuringPeriodValueNewIssues", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}, {"lang": "en-us", "role": "terseLabel", "Issuance of shares (Note 12)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."}, {"auth_ref": "r21", "r148", "r149", "r189", "r1093", "r1171", "r1262", "r1403"}, {"us-gaap": "StockIssuedDuringPeriodValueShareBasedCompensation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}, {"lang": "en-us", "role": "terseLabel", "Issuance of performance share and restricted stock awards", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."}, {"auth_ref": "r69", "r148", "r149", "r189"}, {"srt": "StockRepurchaseProgramAuthorizedAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount", "crdr": "debit", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"us-gaap": "StockRepurchaseProgramAuthorizedAmount", "crdr": "credit", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "verboseLabel", "Share repurchase program, authorized aggregate amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."}, {"auth_ref": "r1655"}, {"us-gaap": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount", "crdr": "credit", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"lang": "en-us", "role": "verboseLabel", "Remaining authorized repurchase amount", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."}, {"auth_ref": "I", "us-gaap": "StockRepurchasedDuringPeriodShares", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"http://www.renre.com/role/SHAREHOLDERSEQUITYRollforwardofSharesIssuedandOutstandingDetails"}, {"http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "terseLabel", "Share repurchase program, shares repurchased (in shares)", "negatedLabel": "Repurchase of shares (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."}, {"auth_ref": "r21", "r148", "r149", "r189", "r1089", "r1171", "r1264"}, {"us-gaap": "StockRepurchasedDuringPeriodValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": "http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}, {"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "negatedLabel", "Repurchase of shares (Note 12)", "terseLabel": "Value of shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."}, {"auth_ref": "r21", "r148", "r149", "r189", "r1093", "r1171", "r1264"}, {"nr": "StockSharesAuthorized", "xbrltype": "sharesItemType", "nsuri": "http://www.renre.com/20241231", "localname": "StockSharesAuthorized", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails"}, {"lang": "en-us", "role": "terseLabel", "Aggregate authorized shares (in shares)", "label": "Stock, Shares Authorized", "documentation": "The maximum number of common shares and nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."}, {"auth_ref": "I", "us-gaap": "StockholdersEquity", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": "http://www.renre.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap:LiabilitiesAndStockholdersEquity", "weight": "1.0", "order": "4.0", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets"}, {"http://www.renre.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"}, {"http://www.renre.com/role/SCHEDULEDHECONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails"}, {"lang": "en-us", "role": "totalLabel", "Total shareholders' equity attributable to Renaissance Re", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."}, {"auth_ref": "r149", "r152", "r153", "r180", "r1130", "r1146", "r1172", "r1173", "r1358", "r1404", "r1574", "r1610", "r1721", "r1810"}, {"us-gaap": "StockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": "http://www.renre.com/role/ConsolidatedBalanceSheets"}, {"http://www.renre.com/role/SCHEDULEDHECONDENSEDFINANCIALINFORMATIONOFREGISTRANTBalancesheetsDetails"}, {"lang": "en-us", "role": "terseLabel", "Shareholders' equity", "verboseLabel": "Shareholders' equity", "label": "Equity, Attributable to Parent [Abstract]", "auth_ref": "I", "us-gaap": "StockholdersEquityNoteAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": "en-us", "role": "terseLabel", "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]", "auth_ref": "I", "us-gaap": "StockholdersEquityNoteDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": "http://www.renre.com/role/SHAREHOLDERSEQUITY"}, {"lang": "en-us", "role": "verboseLabel", "SHAREDOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity."}, {"auth_ref": "r186", "r375", "r607", "r609", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r621", "r623", "r808", "r1174", "r1175", "r1266"}, {"us-gaap": "SubsequentEventLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "terseLabel", "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."}, {"auth_ref": "r860", "r880"}, {"us-gaap": "SubsequentEventMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "terseLabel", "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."}, {"auth_ref": "r860", "r880"}, {"us-gaap": "SubsequentEventTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": "http://www.renre.com/role/SUBSEQUENTEVENTSDetails"}, {"lang": "en-us", "role": "terseLabel", "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."}, {"auth_ref": "r860", "r880"}, {"us-gaap": "SubsequentEventTypeAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": "http://www.renre.com/role/SUBSEQUENTEVENTSDetails
```

gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesCost", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost or Cost", "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost", "documentation": "Cost of investment held by insurance company, excluding investment in related party." } } }, "auth_ref": { "r1257": 1 } }, "us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesFairValue", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value", "documentation": "Fair value of investment held by insurance company, excluding investment in related party." } } }, "auth_ref": { "r1258": 1 } },
"srt_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesReportableDataLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesReportableDataLineItems", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]", "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r265", "r1260": 1 } },
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTable", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": { "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Table]", "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Table]", "documentation": "Disclosure of information about investment held by insurance company, excluding investment in related party." } } }, "auth_ref": { "r265", "r1260": 1 } },
"srt_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOOTHERTHANINVESTMENTSINRELATEDPARTIES": { "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF INVESTMENTS, OTHER THAN INVESTMENTS IN RELATED PARTIES", "label": "SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Text Block]", "documentation": "The entire disclosure of information about investment held by insurance company, excluding investment in related party." } } }, "auth_ref": { "r265", "r1260": 1 } },
"us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": -1 }
"http://www.renre.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": 1 } } },
"srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract]", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Abstract]", "auth_ref": 1 } } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersAmortizationOfDeferredPolicyAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersAmortizationOfDeferredPolicyAcquisitionCosts", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Amortization of Deferred Policy Acquisition Costs", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Amortization of Deferred Policy Acquisition Cost", "documentation": "Amount of amortization expense on deferred policy acquisition cost for property-casualty insurance underwriter." } } }, "auth_ref": { "r1034": 1 } },
"srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersByAffiliationWithRegistrantAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersByAffiliationWithRegistrantAxis", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental Information for Property-Casualty Insurance Underwriters, by Affiliation with Registrant [Axis]", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Affiliation with Registrant [Axis]", "documentation": "Information by affiliation to property-casualty insurance underwriter." } } }, "auth_ref": { "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r1023", "r1024", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityForUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": -1 }
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityForUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } },
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityForUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } },
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Current year", "terseLabel": "Net claims and claim expenses incurred in 2013 current accident year", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": { "r1047", "r1375": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersDeferredPolicyAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersDeferredPolicyAcquisitionCosts", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred Policy Acquisition Costs", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Deferred Policy Acquisition Cost", "documentation": "Amount of deferred policy acquisition cost related to property-casualty insurance policy written." } } }, "auth_ref": { "r1027": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersDiscountDeductedFromReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersDiscountDeductedFromReserves", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Discount, if any, Deducted", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Discount Deducted from Reserve", "documentation": "Amount of discount deducted from reserve for unpaid claim and claim adjustment expense by property-casualty insurance underwriter." } } }, "auth_ref": { "r1029": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersEarnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersEarnedPremiums", "crdr": "credit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Earned Premiums", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Earned Premium", "documentation": "Amount of premium revenue earned by property-casualty insurance underwriter." } } }, "auth_ref": { "r1031": 1 } },
"srt_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersLineItems", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r1023", "r1024", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersNetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersNetInvestmentIncome", "crdr": "credit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Investment Income", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Net Investment Income", "documentation": "Amount of net investment income earned by property-casualty insurance underwriter." } } }, "auth_ref": { "r1032": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPaidClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Paid Claims and Claim Adjustment Expenses", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Paid Claim and Claim Adjustment Expense", "documentation": "Amount of loss reported and paid for claim and claim adjustment expense by property-casualty insurance underwriter." } } }, "auth_ref": { "r1035": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPremiumsWritten": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPremiumsWritten", "crdr": "credit", "presentation": -1 }
"http://www.renre.com/role/SCHEDULEVISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net Premiums Written", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Premium Written", "documentation": "Amount of premium written by property-casualty insurance underwriter." } } }, "auth_ref": { "r1036": 1 } },
"us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityForUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": -1 }
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESPriorYearDevelopmentoftheReserveforNetClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } },
"http://www.renre.com/role/RESERVEFORCLAIMSANDCLAIMEXPENSESScheduleofLiabilityForUnpaidClaimsandClaimExpensesDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } },
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompaniesRevenuesandExpensesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Prior years", "terseLabel": "Net claims and claim expenses incurred in 2013 prior accident years", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Reserve for Unpaid Claim and Claim Adjustment Expense", "documentation": "Amount of reserve, policy claim payable and loss expense incurred by


```
"property-casualty-insurance-underwriter:" + "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails" + "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Table]", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Table]", "documentation": "Disclosure of information about registrant, its subsidiary, and 50-percent-or-less-owned equity basis investee, with liability for property-casualty insurance claim that is supplementary." } }, "auth ref": { "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r1023", "r1024", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036" } }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersUnearnedPremiums": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersUnearnedPremiums", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONCONCERNINGPROPERTYCASUALTYINSURANCEOPERATIONSDetails" + "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Unearned Premium", "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Unearned Premium", "documentation": "Amount of premium written but not yet earned by property-casualty insurance underwriter." } }, "auth ref": { "r1030" } } }, "srt_SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementalScheduleOfReinsurancePremiumsForInsuranceCompaniesAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]", "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Abstract]", "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue." } }, "auth ref": { "r285", "r1022" } } }, "srt_SupplementaryInsuranceInformationAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementaryInsuranceInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract]", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Abstract]", "documentation": "The entire disclosure for the supplemental schedule of reinsurance information. Reinsurance schedule includes, but is not limited to, the type of insurance, gross amount of premiums, premiums ceded to other entities, premiums assumed from other entities, net amount of premium revenue, and the percentage of the premiums assumed to net premium revenue." } }, "auth ref": { "r285", "r1022" } } }, "us-gaap_SupplementaryInsuranceInformationAmortizationOfDeferredPolicyAcquisitionCosts": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationAmortizationOfDeferredPolicyAcquisitionCosts", "crdr": "debit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Amortization of Deferred Policy Acquisition Costs", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost", "documentation": "Amount of amortization of deferred policy acquisition cost recognized, as disclosed in supplementary insurance information." } }, "auth ref": { "r1013" } } }, "us-gaap_SupplementaryInsuranceInformationBenefitsClaimsLossesAndSettlementExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationBenefitsClaimsLossesAndSettlementExpense", "crdr": "debit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Benefits, Claims, Losses and Settlement Expenses", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses", "documentation": "Amount of insurance benefit, claim, loss and settlement expenses incurred, as disclosed in supplementary insurance information." } }, "auth ref": { "r1012" } } }, "srt_SupplementaryInsuranceInformationBySegmentLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementaryInsuranceInformationBySegmentLineItems", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth ref": { "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015" } } }, "srt_SupplementaryInsuranceInformationBySegmentTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementaryInsuranceInformationBySegmentTable", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Table]", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information [Table]", "documentation": "Disclosure of information about supplementary insurance information by segment. Includes, but is not limited to, deferred policy acquisition cost; future policy benefit; loss, claim and loss expenses; unearned premium; other policy claim and benefit payable; premium revenue; net investment income; benefit, claim, loss and settlement expenses; amortization of deferred policy acquisition cost; other operating expense; and premium written." } }, "auth ref": { "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r277", "r278", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015" } } }, "us-gaap_SupplementaryInsuranceInformationDeferredPolicyAcquisitionCosts": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationDeferredPolicyAcquisitionCosts", "crdr": "debit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "verboseLabel": "Deferred Policy Acquisition Costs", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost", "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force, as disclosed in supplementary insurance information." } }, "auth ref": { "r1006" } } }, "srt_SupplementaryInsuranceInformationForInsuranceCompaniesDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SupplementaryInsuranceInformationForInsuranceCompaniesDisclosureTextBlock", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATION" + "lang": { "en-us": { "role": { "terseLabel": "Supplementary Insurance Information", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Disclosure [Text Block]", "documentation": "The entire disclosure for supplementary insurance information by segment. Includes, but is not limited to, deferred policy acquisition cost; future policy benefit; loss, claim and loss expenses; unearned premium; other policy claim and benefit payable; premium revenue; net investment income; benefit, claim, loss and settlement expenses; amortization of deferred policy acquisition cost; other operating expense; and premium written." } }, "auth ref": { "r247", "r248", "r272", "r276" } } }, "us-gaap_SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationLiabilityForFuturePolicyBenefitsLossesClaimsAndLossExpenseReserves", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "verboseLabel": "Future Policy Benefits, Losses, Claims and Loss Expenses", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense", "documentation": "Amount of reserve for future policy claim payable and loss expense to be incurred, disclosed in supplementary insurance information." } }, "auth ref": { "r1007" } } }, "us-gaap_SupplementaryInsuranceInformationNetInvestmentIncome": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationNetInvestmentIncome", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Net Investment Income", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income", "documentation": "Amount of net investment income earned, disclosed in supplementary insurance information." } }, "auth ref": { "r1011" } } }, "us-gaap_SupplementaryInsuranceInformationOtherOperatingExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationOtherOperatingExpense", "crdr": "debit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Other Operating Expenses", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense", "documentation": "Amount of operating expense classified as other, disclosed in supplementary insurance information." } }, "auth ref": { "r1014" } } }, "us-gaap_SupplementaryInsuranceInformationPremiumRevenue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationPremiumRevenue", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Premium Revenue", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue", "documentation": "Amount of premium revenue earned, disclosed in supplementary insurance information." } }, "auth ref": { "r1010" } } }, "us-gaap_SupplementaryInsuranceInformationPremiumsWritten": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationPremiumsWritten", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "terseLabel": "Net Written Premiums", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written", "documentation": "Amount, after premiums ceded and assumed, of premium written, disclosed in supplementary insurance information." } }, "auth ref": { "r1015" } } }, "us-gaap_SupplementaryInsuranceInformationUnearnedPremiums": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementaryInsuranceInformationUnearnedPremiums", "crdr": "credit", "presentation": { "http://www.renre.com/role/SCHEDULEHISUPPLEMENTARYINSURANCEINFORMATIONDetails" + "lang": { "en-us": { "role": { "verboseLabel": "Unearned Premiums", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium", "documentation": "Amount of premium not yet earned, disclosed in supplementary insurance information." } }, "auth ref": { "r1008" } } }, "ecd_TabularListTableTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDcIdMember" + "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } }, "auth ref": { "r1474" } } }, "tnr_TailwindReltdMember": { "xbrlType": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TailwindReltdMember", "presentation": { "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails" + "lang": { "en-us": { "role": { "terseLabel": "Tailwind Re Ltd", "label": "Tailwind Re Ltd [Member]", "documentation": "Tailwind Re Ltd" } }, "auth ref": { "rnr_TargetPercentageOfEnhancedCapitalRequirement" } } }, "rnr_TargetPercentageOfEnhancedCapitalRequirement": { "xbrlType": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TargetPercentageOfEnhancedCapitalRequirement", "presentation": { "http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails" + "lang": { "en-us": { "role": { "terseLabel": "Target percentage of ECR", "label": "Target Percentage Of
```


"\$350 Million Principal At Risk Variable Rate Note", "label": "Three Hundred And Fifty Million Principal At Risk Variable Rate Note [Member]", "documentation": "Three Hundred And Fifty Million Principal At Risk Variable Rate Note" } } }, "auth_ref": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": { "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": { "r1594", "r1731" } }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": { "http://www.renre.com/role/STOCKINGENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Domain]", "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": { "rnr_TopLayerReMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TopLayerReMember", "presentation": { "http://www.renre.com/role/COMMITMENTSCONFINGENCIESANDOTHERITEMSNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Total return swaps", "label": "Total return swaps [Member]", "documentation": "Contracts in which one party makes payments at a fixed or variable rate while the counterparty makes payments based on an asset, including the income and capital gains derived therefrom." } } }, "auth_ref": { "r204", "r1396", "r1397" } }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": { "r1466" } }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]", "documentation": "Total Shareholder Return Vs Peer Group [Text Block]", "auth_ref": { "r1473" } }, "rnr_TowerHillMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TowerHillMember", "presentation": { "http://www.renre.com/role/RELATEDPARTYTRANSACTIONSANDMAJORCUSTOMERSDetails", "lang": { "en-us": { "role": { "terseLabel": "Tower Hill Companies", "label": "Tower Hill [Member]", "documentation": "Tower Hill [Member]", "auth_ref": { "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofIdentifiableIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Trade name", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": { "r76", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1629", "r1631", "r1632", "r1633" } }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": { "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsbyMajorClassDetails", "lang": { "en-us": { "role": { "terseLabel": "Trademarks and trade names", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": { "r76", "r1316", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1629", "r1631", "r1632", "r1633" } }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]", "auth_ref": { "r1494" } }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]", "auth_ref": { "r1496" } }, "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock", "presentation": { "http://www.renre.com/role/INVESTMENTSTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Fixed Maturity Investments Trading", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": { "r837" } }, "us-gaap_TradingSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 }, "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheets", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANFBalancesheetsDetails", "lang": { "en-us": { "role": { "verboseLabel": "Fixed maturity investments trading, at fair value - amortized cost \$23,750,540 at December 31, 2024 (Notes 5 and 6)", "terseLabel": "Fixed maturity investments trading", "netLabel": "Fixed maturity investments trading, at fair value - amortized cost \$153,742 at December 31, 2024 (2023 - \$Nil)", "label": "Debt Securities, Trading", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": { "r338", "r813", "r1293", "r1596", "r1707", "r1708", "r1709" } }, "us-gaap_TradingSecuritiesDebtAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecuritiesDebtAmortizedCost", "crdr": "debit", "presentation": { "http://www.renre.com/role/ConsolidatedBalanceSheetsParentetical", "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANFBalancesheetsAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity investments trading, amortized cost", "verboseLabel": "Amortized cost", "label": "Debt Securities, Trading, Amortized Cost", "documentation": "Amortized cost of investments in debt securities classified as trading." } } }, "auth_ref": { "r970", "r1555" } }, "rnr_TradingSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after five through ten years", "label": "Trading Securities, Debt Maturities, after Five Through Ten Years, Amortized Cost Basis", "documentation": "This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one through 5 years of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "rnr_TradingSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after five through ten years", "label": "Trading Securities, Debt Maturities, after Five Through Ten Years, Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature after five through ten years of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "rnr_TradingSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after one through five years", "label": "Trading Securities, Debt Maturities, after One Through Five Years, Amortized Cost Basis", "documentation": "This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one year of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "rnr_TradingSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after one through five years", "label": "Trading Securities, Debt Maturities, after One Through Five Years, Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature after one through five years of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "rnr_TradingSecuritiesDebtMaturitiesAfterTenYearsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterTenYearsAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Trading Securities, Debt Maturities, after Ten Years, Amortized Cost Basis", "documentation": "This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature after ten years of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Trading Securities, Debt Maturities, after Ten Years, Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature after ten years of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "rnr_TradingSecuritiesDebtMaturitiesWithinOneYearAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesWithinOneYearAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due in less than one year", "label": "Trading Securities, Debt Maturities, Within One Year, Amortized Cost Basis", "documentation": "This item represents debt securities, at cost, net of adjustments including accretion, amortization and collection of cash, if any, which are expected to mature within one year of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "http://www.renre.com/20241231", "localname": "TradingSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": { "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Due in less than one year", "label": "Trading Securities, Debt Maturities, within One Year, Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature within one year of the balance sheet date and are categorized as trading securities." } } }, "auth_ref": { "dei_TradingSymbol": { "xbrltype": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.renre.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": { "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/INVESTMENTSScheduleofContractualMaturitiesofFixedMaturityInvestmentsDetails", "http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails", "http://www.renre.com/role/INVESTMENTSScheduleofOtherInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": { "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r602", "r620", "r807", "r837", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r899", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r990", "r1345", "r1347", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1359", "r1532", "r1533",

"r1534","r1535","r1536","r1537","r1538","r1603","r1605","r1606","r1607","r1704","r1707","r1708","r1709","r1716","r1719"}}, "ecd_TrdrArrAdoptionDate": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }
"auth_ref": { "r1497" } }, "ecd_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }
"auth_ref": { "r1498" } } }, "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement
Expiration Date" } } } }, "auth_ref": { "r1498" } } }, "ecd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement Individual
Name" } } } }, "auth_ref": { "r1496" } } }, "ecd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement Individual
Title" } } } }, "auth_ref": { "r1496" } } }, "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdrArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Aggregate Available",
"label": "Trading Arrangement Securities Aggregate Available Amount" } } } }, "auth_ref": { "r1499" } } }, "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } } }, "auth_ref": { "r1497" } } }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
"xbrltype": "perShareItemtype", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": {
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": "http://www.renre.com/role/SUBSEQUENTEVENTSDetails", "lang": { "en-us": { "role": { "terseLabel":
"Shares repurchased, average price per share (in-usd per share)", "label": "Shares Acquired Average Cost Per Share", "documentation": "Total cost of shares repurchased
divided by the total number of shares repurchased." } } } }, "auth_ref": { "r67" } } }, "rnr_TwoHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "TwoHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember", "presentation": {
"http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalAtRiskVariableNotesDetails": {
"lang": { "en-us": { "role": { "terseLabel": "\$250 Million
Principal At Risk Note", "label": "Two Hundred And Fifty Million Principal At Risk Variable Rate Note [Member]", "documentation": "Two Hundred And Fifty Million Principal
At Risk Variable Rate Note" } } } }, "auth_ref": { "rnr_U.S.andCaribbeanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"U.S.andCaribbeanMember", "presentation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofGrossPremiumsWrittenAllocatedtotheTerritoryofCoverageExposureDetails": {
"lang": { "en-us": { "role": {
"terseLabel": "U.S. and Caribbean", "label": "U.S. and Caribbean [Member]", "documentation": "U.S. and Caribbean [Member]" } } } }, "auth_ref": { "country-US": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": {
"http://www.renre.com/role/STATUTORYREQUIREMENTSNarrativeDetails": "http://www.renre.com/role/STATUTORYREQUIREMENTSStatutoryCapitalandSurplusDetails",
"http://www.renre.com/role/STATUTORYREQUIREMENTSSStatutoryNetIncomeLossDetails": {
"lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } } },
"auth_ref": { "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USTreasurySecuritiesMember", "presentation": { "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails":
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
"http://www.renre.com/role/INVESTMENTSScheduleofFairValueofFixedMaturityInvestmentsTradingDetails":
"http://www.renre.com/role/SCHEDULEISUMMARYOFINVESTMENTSOTHERTHANINVESTMENTSINRELATEDPARTIESDetails": {
"lang": { "en-us": { "role": { "terseLabel":
"U.S. treasuries", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States
Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury
notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years." } } } }, "auth_ref": { "r1298", "r1327", "r1329", "r1345",
"r1744" } } }, "rnr_UncommittedLetterOfCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname":
"UncommittedLetterOfCreditFacilityMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Uncommitted Letter of Credit Facility", "label": "Uncommitted Letter of Credit Facility [Member]", "documentation": "Uncommitted Letter of Credit
Facility [Member]" } } } }, "auth_ref": { "us-gaap_UnderwritingExpenseRatio": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnderwritingExpenseRatio", "calculation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-gaap_CombinedRatio",
"weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {
"lang": { "en-us": { "role": { "terseLabel":
"Underwriting expense ratio", "label": "Underwriting Expense Ratio", "documentation": "Ratio of non-life acquisition expenses and certain non-life general and administrative
expenses to non-life net premiums earned." } } } }, "auth_ref": { "rnr_UnderwritingIncomeLossNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "UnderwritingIncomeLossNet", "calculation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": {
"http://www.renre.com/role/SEGMENTREPORTINGScheduleofSignificantComponentsoftheCompanysRevenuesandExpensesDetails": {
"lang": { "en-us": { "role": { "totalLabel":
"Underwriting income (loss)", "label": "Underwriting Income (Loss) Net", "documentation": "Net premiums earned less net claims and claim expenses incurred, acquisition
expenses and operational expenses directly related to underwriting activities." } } } }, "auth_ref": { "us-gaap_UndistributedEarnings": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarnings", "crdr": "credit", "calculation": {
"http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root":
true } }, "presentation": { "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": {
"lang": { "en-us": { "role": { "totalLabel": "Net income (loss) allocated to RenaissanceRe common shareholders", "label": "Undistributed Earnings, Basic", "documentation": "The earnings that is allocated
to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed." } } } },
"auth_ref": { "r410", "r414" } } }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "calculation": {
"http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": "us-gaap_UndistributedEarnings",
"weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails": {
"lang": { "en-us": { "role": { "negatedLabel": "Amount allocated to participating common shareholders", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities,
Basic", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the
two-class method." } } } }, "auth_ref": { "r410", "r413", "r414" } } }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardHoldingDisclosure": {
"lang": { "en-us": { "role": { "terseLabel":
"Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } } }, "auth_ref": { "r1493" } } }, "us-gaap_UnearnedPremiums": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnearnedPremiums", "crdr": "credit", "calculation": {
"http://www.renre.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.renre.com/role/ConsolidatedBalanceSheets": {
"lang": { "en-us": { "role": { "terseLabel": "Unearned premiums", "label": "Unearned Premiums", "documentation":
"Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date." } } } }, "auth_ref": { "r250" } } }, "us-
gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": {
"lang": { "en-us": { "role": { "terseLabel": "Claims and Claim Expenses", "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]", "documentation": "Disclosure
of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the
statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to
the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim
adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record,
process, and adjust claims." } } } }, "auth_ref": { "r1044", "r1050", "r1376" } } }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": {
"http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Net unrealized gains (losses) included in net
investment income", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } } }, "auth_ref": { "r12" } } }, "us-
gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit",
"presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax
Benefits", "documentation": "Amount of unrecognized tax benefits." } } } }, "auth_ref": { "r736", "r756", "r1340" } } }, "us-
gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": { "http://www.renre.com/role/TAXATIONNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Interest and penalties accrued on unrecognized tax benefits", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
"documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax
return." } } } }, "auth_ref": { "r754", "r1340" } } }, "rnr_UnsecuredBilateralFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231",
"localname": "UnsecuredBilateralFacilityMember", "presentation": { "http://www.renre.com/role/DEBTANDCREDITFACILITIESCreditFacilitiesNarrativeDetails":
"http://www.renre.com/role/DEBTANDCREDITFACILITIESScheduleofCreditFacilitiesDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Unsecured Bilateral Facility", "label":
"Unsecured Bilateral Facility [Member]", "documentation": "Unsecured Bilateral Facility [Member]" } } } }, "auth_ref": { "rnr_UpsilonRFOReLtd.Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "UpsilonRFOReLtd.Member", "presentation": {
"http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Upsilon RFO Re Ltd.", "label": "Upsilon RFO Re Ltd.
[Member]", "documentation": "Upsilon RFO Re Ltd. [Member]" } } } }, "auth_ref": { "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.renre.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies": {
"lang": { "en-us": { "role": { "verboseLabel": "Use Of Estimates in Financial Statements", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting
policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } } }, "auth_ref": { "r47", "r48", "r49",
"r241", "r242", "r243", "r244" } } }, "rnr_ValidusHoldingsLtdAndTalbotUnderwritingLimitedMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.renre.com/20241231", "localname": "ValidusHoldingsLtdAndTalbotUnderwritingLimitedMember", "presentation": {
"http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsofCashFlowsDetails": {
"lang": { "en-us": { "role": { "terseLabel":
"Validus Holdings, Ltd and Talbot Underwriting Limited", "label": "Validus Holdings, Ltd And Talbot Underwriting Limited [Member]", "documentation": "Validus Holdings,
Ltd And Talbot Underwriting Limited" } } } }, "auth_ref": { "rnr_ValidusHoldingsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231",
"localname": "ValidusHoldingsLtdMember", "presentation": { "http://www.renre.com/role/ACQUISITIONOFVALIDUSDefinedBenefitPensionPlanDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSOverviewDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleoffFairValueofNetAssetsAcquiredandLiabilitiesAssumedDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleoffFinancialResultsDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleoffIdentifiableIntangibleAssetsDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleoffPurchasePriceDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSScheduleofSupplementalProformaInformationDetails":
"http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails": "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails":
"http://www.renre.com/role/SHAREHOLDERSEQUITYNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Validus", "label": "Validus Holdings, Ltd [Member]",

"documentation": "Validus Holdings, Ltd", "id": "1", "auth_ref": "1", "rnr": "rnr_ValidusSpecialtyMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ValidusSpecialtyMember", "presentation": "http://www.renre.com/role/ACQUISITIONOFVALIDUSTaxationDetails", "http://www.renre.com/role/SCHEDULEHCONDENSEDFINANCIALINFORMATIONOFREGISTRANTStatementsOfCashFlowsDetails", "lang": "en-us", "role": "terseLabel", "Validus Specialty", "label": "Validus Specialty [Member]", "documentation": "Validus Specialty", "auth_ref": "1", "us-gaap": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "credit": "credit", "presentation": "http://www.renre.com/role/TAXATIONNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Increase (decrease) in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset", "auth_ref": "759", "us-gaap": "us-gaap_ValuationTechniqueAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique", "auth_ref": "r15", "r16", "r1349", "r1709", "us-gaap": "us-gaap_ValuationTechniqueDiscountedCashFlowMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "Discounted cash flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows", "auth_ref": "r1349", "r1708", "r1709", "us-gaap": "us-gaap_ValuationTechniqueDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "lang": "en-us", "role": "terseLabel", "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique", "auth_ref": "r15", "r16", "r1349", "r1709", "rnr": "rnr_ValuationTechniqueQuotedPricesMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "ValuationTechniqueQuotedPricesMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Valuation Technique, Quoted Prices", "label": "Valuation Technique, Quoted Prices [Member]", "documentation": "Valuation Technique, Quoted Prices", "auth_ref": "1", "us-gaap": "us-gaap_VariableInterestEntityDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIES", "lang": "en-us", "role": "terseLabel", "VARIABLE INTEREST ENTITIES", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss", "auth_ref": "r199", "us-gaap": "us-gaap_VariableInterestEntityMaximumLossExposureAmount", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityMaximumLossExposureAmount", "credit": "credit", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofVariableInterestEntitiesDetails", "lang": "en-us", "role": "terseLabel", "Other investments, maximum exposure to loss", "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount", "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)", "auth_ref": "r92", "r202", "rnr": "rnr_VariableInterestEntityInvestmentInParticipatingNotes", "xbrltype": "monetaryItemType", "nsuri": "http://www.renre.com/20241231", "localname": "VariableInterestEntityInvestmentInParticipatingNotes", "credit": "debit", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Investment in participating notes", "label": "Variable Interest Entity, Investment in Participating Notes", "documentation": "Variable Interest Entity, Investment in Participating Notes", "auth_ref": "1", "us-gaap": "us-gaap_VariableInterestEntityLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": "en-us", "role": "terseLabel", "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": "r792", "r793", "r796", "r797", "r996", "r997", "r998", "us-gaap": "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESSummaryofthePrincipalatRiskVariableNotesDetails", "lang": "en-us", "role": "terseLabel", "Not Primary Beneficiary", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity", "auth_ref": "1", "us-gaap": "us-gaap_VariableInterestEntityOwnershipPercentage", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Variable interest entity, ownership percentage", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)", "auth_ref": "r90", "us-gaap": "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity", "auth_ref": "r85", "r792", "r793", "r796", "r797", "rnr": "rnr_VermeerReinsuranceLtd.Member", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "VermeerReinsuranceLtd.Member", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSScheduleofRedeemableNoncontrollingInterestActivityDetails", "http://www.renre.com/role/NONCONTROLLINGINTERESTSSummaryofRedeemableNoncontrollingInterestDetails", "http://www.renre.com/role/VARIABLEINTERESTENTITIESNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Vermeer", "label": "Vermeer Reinsurance Ltd. [Member]", "documentation": "Vermeer Reinsurance Ltd. [Member]", "auth_ref": "1", "rnr": "rnr_VestingMaximumAsPercentageOfTargetIfPerformanceGoalsAreAchieved", "xbrltype": "percentItemType", "nsuri": "http://www.renre.com/20241231", "localname": "VestingMaximumAsPercentageOfTargetIfPerformanceGoalsAreAchieved", "presentation": "http://www.renre.com/role/STOCKINCENTIVECOMPENSATIONANDEMPLOYEEBENEFITPLANSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Vesting maximum as a percentage of target if performance goal are achieved", "label": "Vesting Maximum, as a Percentage of Target, if Performance Goals are Achieved", "documentation": "Vesting Maximum, as a Percentage of Target, if Performance Goals are Achieved", "auth_ref": "1", "rnr": "rnr_VotingNonparticipatingSharesMember", "xbrltype": "domainItemType", "nsuri": "http://www.renre.com/20241231", "localname": "VotingNonparticipatingSharesMember", "presentation": "http://www.renre.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Voting, Non-participating Shares", "label": "Voting, Non-participating Shares [Member]", "auth_ref": "1", "ecd": "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr.Member", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr.Member", "presentation": "http://xbrl.sec.gov/ecd/role/PrpDisclosure", "lang": "en-us", "role": "terseLabel", "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "auth_ref": "r1462", "us-gaap": "us-gaap_WarrantMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": "http://www.renre.com/role/DERIVATIVEINSTRUMENTSScheduleofGainLossRecognizedinConsolidatedStatementsOfOperationsRelatedtoPrincipalDerivativeInstrumentsDetails", "lang": "en-us", "role": "terseLabel", "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount", "auth_ref": "r1389", "r1390", "r1393", "r1394", "r1395", "r1398", "srt": "srt_WeightedAverageMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": "http://www.renre.com/role/FAIRVALUEMEASUREMENTSScheduleofQuantitativeInformationUsedasLevel3InputsDetails", "http://www.renre.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Weighted Average", "label": "Weighted Average or Actual", "documentation": "Average of a range of values, calculated with consideration of proportional relevance", "auth_ref": "r817", "r900", "r1284", "r1285", "r1349", "r1735", "r1737", "r1740", "us-gaap": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails", "lang": "en-us", "role": "terseLabel", "Denominator for diluted income (loss) per Renaissance Re common share - adjusted weighted average common shares and assumed conversions (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period", "auth_ref": "r403", "r416", "us-gaap": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": "http://www.renre.com/role/EARNINGSPEPERSHAREComputationofBasicandDilutedEarningsPerCommonShareDetails

EndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdgAndUnvstdMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "Member": "auth-ref", "1460", "std-ref", "0", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16", "r1": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7", "r2": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8", "r3": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r4": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r5": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r6": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r7": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2", "r8": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r9": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D", "r10": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25", "r11": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r12": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r13": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5", "r14": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1", "r15": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1", "r16": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1", "r17": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "605", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1", "r18": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r19": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r20": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r21": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r22": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2", "r23": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3", "r24": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3", "r25": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4", "r26": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D", "r27": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D", "r28": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-13", "r29": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480366/210-10-50-1", "r30": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14", "r31": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A", "r32": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5", "r33": "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "2

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#3&U0/35EAFF55UWJWM01C2%5-YI*G#YIE:FC52H(TXJUX?2J9D&?2M""H6G2YWK^G8)BXVTR EM45>:QHBBD00-8>5HCITZC^+HDX K:1VZX>X M&:/>V'QO)U:N>
=<#1>#>#1V5B2P4+>#5E2L2^48<J@C%A5S1*P2+1^UG73,M9?F1H&HNN 171-8M6@16+>#KQBFO<2,2,W""3HC^A+G1&1BQAI&GPPDV5Y7XF0 M,Q^+YVYH?
N#880H10JBJ2<+>YIY:8GE5E2^C^E U6*MI9R&ED7P1R6K73K51#M_K1H1R&R+R+00X^F2H1L1,08Y3Y&+1&3J41&F2B\$X4&5:850Y91N)Z0W7^G2<5BECMH\$Y58^/6I
M=7:1P1&6^P0:DEQF^1H1TH^+>T4Q0 4N1W)RPL^+>E=OEOKT(9K)<W859 M4R7T5W0(83^>SFR15)SD1B9+N>16V>2H1J^1^2W&5-91^>P9R7R14-H M,0LO5NVT5&+>U
L,RV,N5&J27U19@DH:<X^H7H^>@<CD<84NNEJRK&6BQ55RD M+R81DMJ7>8V510V0D)SCT'SJLH;B6(1?^>M,C2M;W15:DIG<^>DL F1?3-W1TE:19H04LOA:PF6NN">*6KP?
323M%0LEN2P% MMXP1,PNR1^VR9P1Q40440%T0LE 16:DLX,ZS1P11 4G1^2835^*#YPN5&N^M^>@41:RS1YU1U(X&:WVF2,EUK,+16T+4+Z1AE+1:G:AH^AL^MGTV@V8_PV
M:JUZ)WS(VT,W7Z0OP<5CK(L1NGC^@18<+>RJPV&5%21L1H9E01^L9^Q^M8@ERAH6-1+6^<^G=2^5Z^>9N1510D(3E^V^X\$>=>10^HAC50<M^E1&=85?
(3:B#J1L(2073N50)=1A1>14E-FOP>173)21V81GZ3VTPVZU1+>D M854+>41JGRFAO^&Q6-0^3%BD^#4N5>0^%2M2^C^>16^F1H1 VY71^>F+W0^E5NA1Q^1A1&18H9+M^
Z=>=>N,N,OUMVYQ1%0U^PL=>SZZK(Z^K29^M&8:51Z MO^88->=>^%>FTTQK1&8Z-9M^88X55DXT0E6W9Z9R1RHQ92^QMB8BL6:CL245
MKC921^95B0:HZP2SCT+1E:D55&9TF&S:SAZQ^993Z0>3H1J9:WQC^<WJL3B M1HML2FCB:QOLM8 Z6QWUZR>=>5Y^CN74-SKMMO1H1=F0(07C3F+ROSEQ.U
/9N8<^<6^N215K9 M&+A-\$N671U^U 6LW2> KM01H6%3X?1UFHJZQ:EP16^X^762179+>16^M1&6AW+Q2L(M1)P1A Q1D(R^B9BP29(12&5:5IZN+7GXQ15:YZAR<^<6D MCE
71&R^>1 P1H1W=M2/E4^U^M101S1J>2T9-C&H1FV8Z07VPR6 M""548:8P1R<+>OC9C1M789+>1Q=5>F+>NTIPLZ1&#MFIH=EPC2FHH1Q)WW1^MVJ53BQ\$=8:1Q:DOQ
MCG=65747 N66&2& ,DT.0.P1^+>=>3%#1)O&#04%P/6S291G^7^#B1B(1^M1M&M0Q(2^1B^>8^5G2M14=KRUCF1Q(SN^X^R^Y^H1+>#E2AZ1A>R^1 ZYHS
MAXR^1717,(0Q(A3F1):1581EL8:8-WW-6EXR)R^C(AH6N)1G4U5Y1P313^15 M15 MN(4COP157&1 M8>=>F144V/GYJMC,P1D9K M&^R^1@>81121^M=V^>)<^>+>#KK>+>((S1F9L?=>
F1L^Y=83+714D:28RYM1^<2^X01^D^C^M1^GM1^6^<V^>+>0 7R^KW1P<#<1^>O:0111="795;M1C^KH1RM(1910FR1P+1^V^K00BP1R^>+>CQN
M-X^>11M00QLX^CXG0^<K1L^U^D^E^Y^M^X^+>E6F1ER^152R MZ<="E5%0:CSJE7B+>1^C^B,Y04M1>1Z^28N5W9V^>U&^PZ01^C7V&^8S^D1TX^M2AF1W?
R^K1G&A4^<D8<C2,E:XHZ>U<+>O=R^B^>PXJ1Z.O.N1.P1P(F8 M^YB80>+>MOJFPMMA1HDSNR8V,ZP31^L70QA278C=2Y7^>W+R4^#(1H MOT6T>8^E>M^2)JH R^WZ1<^
D^MXH7&X.T3+2^#C.1^M^K1<ZM\$E^817^#M^26HH8V5W71SK^X2>A&E^BK^VX^7C5^V@=>17D^8&E+U1 M9^/H04<0)FSVDC1@QB^OF^PVEBJK^B6)C1^>#W156V^3X^C^M
M^+1^%>O>381KK C&AG&N^0MTU^>V>F6E9ZP5<K2P7>PEPAK&OAF.Z:PIW ME.65^>B^1^36:>#M^AHUEBS=>1P^T1U190L5>22^RPG?
>Y>00W.0FLY.LK^C17&#^/KPL^G1OD_S1601N^Q5:1^MPLH1Q^>29%>1^>Z5^>=>V^>1^>1M6U1H2M^00D2>4#0>9>1#1U1U0^>F01ST># MKATLH1:Y+T&
1^>Z3W1Y4C0200Z3Z1H2^>7R^>7EV.K1751>1^>G1:CSU>7H>+>MBW+>C^>0Z>+>H6:IEJW^>1Y+QVW^>C^>8^>7UZ^K3Y1U0^>7 M1R^>31^>2W1U>23>1^>Y11^>#8#>S^>YH094
16:PPHY451MS^016=>+># M^>X1^>91V=>=>GJ231P2^>Q@<N1CRO1TY=>2JX^>3^>Q>X325^>QO.P1Y M1D50R^2SA=>OHB-03OE1FZ-G8N419O4C1:YH630B^5&B^<1L5M?&br/>&07 M^K^1=>CCS3^80XX^=>PX 1L6^>1^>51+P0A^1^>1&@DQ:1^>EC 2#X0^1 MZ0^>@&S.R.64M86UE:F1M96YT:FR.V9\$=>=&1C:W1U+>FAT>U=>5;N1^>1^>M?G^>+>1W>#3>1^>F1
>@<Y&GD^06WHD&RYW846R9^>1LKR:397V^>1M^>Q00<71,M^>Q59H1W^>K^>M7&1NS^>7D6_V1A1^1D01^>2H19:G\$<K^>T4F150Q/GK1N1Q1<^>QNF^>F^>
M&1D14.GKVKZSZGZ1A+>B6.3DY1&^>1^>1&=>S^>W^>1^>MOS^>518Y111^>W1.AH^>1^>1DWH1^>JH8_3^>P9C&ACADY4W5^>310NK^>1U=>#U^>C6 M2V1^>1U=>801Z^>A8T21Z1J4E5CPY<@<L>#>
1PG_H1.OVSN^>P-H M=U1^>#>32X1H1+IE1^>V2TR<+>UV7^>SN1^>1B\$>ZVL28^>3^>X5&1L^>H6T30R^>X MJ.6^>1^>KMYNRR^>1289Y^>1^>F610Y7=>AS00^>0^>815P51M^>5^>FN1V1\$<@>M3^>
#X1+1WY1N>2>BUUHX6CT3>?>D^>4Y 7E0X1T^>M.M^>1^>1^>C1N^>2ZSPL M.MBR1&5^>F1B^>6>8R51BMORA^>2&X8RW1^>1J1A^>NE1&6S1U^>1^>G^>6^>GF&2TQC M21.NT>2^>Z^>N^>L^>H^>C1
<1>43.N4V%N:15Y^>N^>R6LW5JMD+A:YFOA(BOPB^>P_M^>=>N^>F7T.\$2-1ME1M.B61)1^>1N^KCF1H\$S.Y1N^>?%N>XZS^>1K^>F^>YXL1^>3^>M30^>9031\$3@B1>>1^>L&+D1W.7A?^>S1
/M85P0JR3C52B07E#1E=U0A1L<=>B&Q)^<^>XC^>P1^>L^>E^>C^>M^>0^>H^>J^>=>1&X^>F^>1^>E^>C^>H^>K^>R^>3^>DL^>N^>XBD^>42YH.53B1^>D4S^>E^>+>C^>H1W9^>F1^>MX5:7U8^>+>N^>V41^>91Q^>S^>

[illegible]

[illegible]

[illegible]

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

[illegible]

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

2232HVJ2<=YI.MPI<8M.I.O-WZS%ODIUP%>#BPP%<-RAGFGPAZI<N6K0.NHDKJ.YYH15.PEPIZ-Y.MJ>O7OH.GRXN=ABUEF8=>^3H&MN
%MX.<9QDEFBOIC&C3QH=UEFR74L+S.C.8JW.D)P.WH/M+I.TGJO0M.M(+.A.6+50CSMM.LX3*.8QJ3N7.+Y+PSAJTES^U!U8-IFE8.6NV-%B.M16AS:
AZMPR=Z>3G2IOA8UYH1ZTFL+DXMR73P//JLHW3+.4+9JISF=C.%S8>7K45T0?>.UFN.W97J3.B2D9J.H6P8R5Z&2YM
f/FZU4IO9EQ4V+L4LS..0F.S..&TS5DEHEJKNBP@TIN/JY+Y"W7">K5H50.%1.Q.92GHG.SGC=E3=M0(C9YG2"6X"l<+7NL(ONU.^?RVH16&5IXQ">.LIP"5#+2SV4.J#921
M.TN10RW.9QFA.C4Q.>?>L5B.M3.TF8(T.">NFE.)9Y83.4.DEKV9IL#6QN.IKJAL.NFFPJH?">L3DM.JM.<LR.A7N18I&NR65HMUN.^?>L3DM.JM.<LR.A7N18I&NR65HMUN.^?
ML-L1.U#WRGOHL(@.O.).W./A.(SP+)%EW/L0IKB2NM)V\$>WR.R4M.R9\$9-MKD(CJF=#<4/.>+Y47RRBC&EPQ\$2.2@?>48GI.LD8+01/T0J9&SU-EK\$Q
MV(XP<+TME,>=>{UVRD/DHN>ISEK8XP%P.5}HB6.F=Z?D9KM.?0E.FOJ.#MBG.C5PG4Y8L?>LCPI.VUC:>IH79OZ/@.A.EI=F?>MIEB&SNV->G.MZ&46+RJX&T/B#)Z&OR
HYZ4M-J/DWK#@08L.<HD)YYM.MA2UOSRJCE7EKDP3=>(SP&Z?6Y?>4V.O.MG-OIG?>3JWRV+&#VVX&OC\$52NI<=>HJP&Z.0S?>F/T5>9T95V-VJE0-QH#.M/Q0#7Q6HTE.
A=55L.PV%K6.2(IY>VRIS>55SLGKT7E/L+02BKBE."/LOF5=.IVLO6AI.MWNX<(<3.663QI/%TARM055(C\PF0ILG/I/26+1IC134?>2L/Z2?>#G8EY#
MH-L3U<+L1?>QUDH&DL+HNBQ(ZQ=Q24I)<-K+NNU.DVL+FOQ?>P.M63?OI/%GJ8&S2+TB#PS5=>5G8(G->1UN+1FTF?>9-K8O.9?>R6NIYU<=<9H.MWS
^2NX0.4JOA4W28XIW=W@E.CYVM-C+L.PI684I0QOEWL.M66G<ISA4.I.V/>XFKJ5&246.%>VYR+Q>05FMON/WB.2XRMEF7W&>7.M(R.N&JM.W%>25NK/7IL
.MYM6EIUY7IG.#?>LBBRI&L(H82H.IFS&24D=48%YW2LIC2BMIL6-&ES&YHI.MMO)FC7C8?>#?>V5MT?>QXJ+I-N1PMLZ.9XIK3(IACQCHYBZO?>13E&#>M&63HY6.X&H&SF(F
%U9HHO(QX&A4H61WP270?>0P=P(MO-?)>EJ<BL%W%BKI+MTD.2=D@IG.IA\$>=735F=IFL'A<?>CAKIZ20BJN2=>2W+C&SUPH030%.(HO?>Z.>NOF%G+6-F4%FA:
(4U4VMDJSJQE?>7RIO4IYI.M+FE+VG7?>KO10ZA?>#2W#CPJH&+CKK0K&3&KL+M&)2OX9VOY5OD%>E45F.78H4MFU7Q
(4I7.ZAMXOP8>#ALBY.M(L7+KJ37)COVT2@QU=>??>B)SD.4J9C0.M0.M50I46.34\$V9(D0A@H4UA+1=QZ)79S.U#M2JO.A>S)IBOL.MPTA03\$>?>H.A
EJO1>P>5H+BT7X@>0Q2>L?>7IN(40.M&S.-EL+>+1\$>ME.HI?>Q2JB68=A15W.5CFHGDBHC%>JL2.C5&5&2PLA&BSPR-BHP?>Q&E.M%>EEFYH&G500%GHHJ%-2^X+>_L-
A0^H&MON061+>3J509304E+>UC.HGE504H1&OXPS#M&9ID4IJG43J?(UUD0EKJKB.E.Y-IH.MBIY#ZKAPl&VX/HI?>@9.O.VYQM.G?>H).YM#SHCYU3
MNG&ETB&%8&4&"E=LFBIS?>ABR=&WWT9K<=>%"FO%/VAC3AC.KBZ5YX=<)<MP%WH?>6B.I/P<9-I&E&PS#>ZH/E.9K0GLP/R+I+TH->2AIFKP&SIX.MP%E/CJH?>0.82?
HR7JV.S(S)9U4Q>=>4VSU953?>J72FSFVL7+/JYX3UZOG0GF4=U3MFPW.#1L4ME.8B7?>6@?>EV=KQ@>H\$9I3=5G6IKSAH?>L+INBRE.HI@IMJST+>B&OF6?>#3
MBSS4UQ<L1.N004XG.G+>E.L+Y-G.B.#EITFIYHGSJRJNZOJGEWF(K-E.N.M28EKI84M.EY&JAPGGR-/>J.O.MWYX80)QG-D&F&SAH?>YL>+I7H.GH.M3HJL+16EST+>=H2
(01J28XUY&A/NQO?>Z&NZTO&S-WE">M4Q-PLY=<(&XBD.MW+>UPV1-.55&JRGRO(JH795LEH7RA.MSIJX&L/07054A8I7?>AG36Z.MO.V&ORRH&S/V=>H1.28TEM<1H07F7W?>Z.
H5.;>A.GIB\$&S&A&@BYLV&K+?>XA?>SND+H.H&SKD.JL.DXDJ.@TL.MI@B0)Q2C&EAD0?>@J9Q.MOV&ELC&CR6G.\$&VYM+>C5-Z&KH&7F26?>BOH131&\$>5BWX&E+>E-EV
MI.">4?>9DR45IESZ79.(SL>7(Z@>1086G+>+>5H?>F)?>MOE?>V1.1WOVGTU.M9+LH?>WWA.E(753P)RI&E52I7<=>6-S5Z55T0=>JOT?>?>K&X.%1?>C.(Z.B%Z3?>2=56YN.5YBZICN
CTP?>Q.Z2IG&M@>SOY4.RDXRP00)ZAKGCI(50?>Z10?>T10?>S&84C?>2A>QV-M.M2AUUS.MQ(M&9.N1XH-10U?>PM-V2&24?>E&FL4782LUV9M-DL?>F&6L?>*<8%
81
6?>F0?>6V5(.SYN)4A.S04R&K&2M+&F&E(3.A)=XJ5T+>NJKFA?>LHHV.<A.PRF&X3?>L%>MJIG2.U9Y23&0FTK3?>2&MIB7M15-03VB?>F&S40T&S1?>#>ZAB?>4=<LID!
P6V+>ZPP>82WDW@<H14.M.0GL1.H?>74XJH?>CIB093?>1CDV?>L1?>5?>E7FH6L&A=PA2)H0?>HT&V&M1P&M&P.B.F4HC(1+H&J&X&GBRNA?>A?>Y&B&K?>L?>5N.0?><ARY?>#
M1+8T2J?>NY?>L/GG&8063IY+>I&P.GF2.&AN=<Q3&S?>L?>@U66?>1.6.M?>H@>XZOTFM01CR?>K(5+&K.S06UIY+>EO40W5.IE+>2&X.H.E7H?>OG7PSIA.M3U5B;
I9?TKI.60H15Z&21C260/T@&COL&DBF5OR&?>I(P+22;#A3S9J&MR&SB3?>@-HYUL#>46NC.DL?>@55.)>(5X340&AWS2H#@>MH?>26KNL\$)BWT%3-(891?>*8M6?
&SM&FW=>@+>IM2&Q&MP26X8/DM?>@-MH<6&5&MG#<C?>Q3&F&P?>L?>G9&V?>L?>8?>P4?>VXWTONU5&9Q3BQ?>P&A24.2AY&MTP?>M#>=>G3/TR-2+E&ANI&F&SGM?>QI.EVES4
%GZR(JIY3IHHG)?>2BP>@>6&Z7R7WHU3I4H4DCOT.MQ01YG7&?>L?>MW99>R1\$8&4?>GR?>ZL50&Q&23&VX&S-N.MIBTWCDJI0&HQH6V&U&LE75330104BZU+I&SKNN
K&L&LD&CKP?>L?>9(2I2J.M&94PA.MTPI>HVCL.MBX+>H&K/H&C3?>2BOHTAK<=>ZTH?>M7IACGD55A1=>E&I8?>7ARIE?>FT7M7I?>30E4?>J5H&S&N?>?>MU?>P?>Y?>J
(LBOQJ&I&K=>MGOU)+HPACP&C6X=3I.M&06+I&G&Z22<=>Q&A&V&I6?>J?>+O&L&C.H&F&S&24H&I&812/TL.M&H&I&N&C&03?>Y+1OO.2OIS(I&@&CB32R?>J2;WW9X?>3<8R7MJ
LF#H9?>MXBT?>QLT&Y&J2W?>KM6;/&S&43N&G#>JNK0&8?>ZV1."4J."4+PIP5DR.S3S/#>MV:NS.4.LP76?>7N+>A?>9#>JX.SP?>99<8<3TT98/HI?>I-XZ-AQQ1
M?>K.3AWM+>JRM&WC&2&CBC&GK&S?>B&UP&F6H?>M.D.C(2JU@>W152DVL5?>MHA?>+>V&amp

[illegible]

[illegible]

[illegible]

Q=4*4+R.RZEKC+M<@
ZJND55*5GMYKD*5MN(M=C(YKJG,X98)0*WBE>A6NQE5-0MB1-K=56-B-90/H*62-BU@Z1>T2+4NDHF4/KN*Q*M#H1V2WV13YQ>=RS5&996&TS;6*2%XYHC(O?
7AN#H#71>P5>H4#W1-MTLKNR8<SV29D8BULE(=W15>92>0BH62&K/IRU/LT,UZU/L>TB2RV-M1K(6&5>U<@&98WH/VJFFH73781#<C<OK*MKU<9/5&-79V/#>4Y
M2XA@OJK<U0ODI25&1VYRNMHM6VCIOBY>1VY241S9R7ZU8U54VB8FMOY#OVN1NS&F-Z<UUT6E0>P<QOQ3IC&LS&B<=>8#F<R2SV1>K1L-MR-X8M<UE1<
HH>R<R322CM5>+M+R#<@<JEB1M4>+2K=<#XDV1&#&566NW4H4MRZ24>#7E60G3,V1S454574>95XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ<GB7Z0>=12>JG3BIO&1>+S135J1-B1M29%Z57(V4#B)&#1<X-OF-O*LP2CFH38=IBU12H1N3:DI5HUTCLM2<6(T>@OSLMH2L@3MHC-
Z2VNH8-D206BS/HXVFA&Z1J0&2404QAUSHSYVY#<LY3>APDD-61G7<45>#XD05D4M*->F3JUM#X@<14W7V1=>Y59&M*+&6MRL/PI=
(=IE;SHD3/MZ@<180A-MJL(G;M(EF5;CV:QVDS)F2K<L9RO129RFMRQ<E1A;A3DKAWM"PBO-M53LUC5F5";9%>1HU3K4AS7JOYO-E2CDBHCE&L5O+)=<Q1-Y/JM8
MO@A16-A657-4Q3YB-D2,K0%EX828N9J9U15B-WWTRU5U0WVYPLF9PD MR<1>0KB>319Y9-46H(VLLF)>=>FJ1V131J4PGRH8SOY@48L1+>
MU+AM-KR=>G6GF1Y#CZS5;&BPKF<6(Z9A-PI#>T0U5U0LH1@6C-NA5GC&PV4J-1S1M-G5)H80<@45YKY<=>RBE19Z224AQ07JHW2+958WH-NH32UOK1@49*MY#B
M2JXU1>T1P-IMP4P20G17VZ&lt

99:ISJC..IFZPFI:RWHL&X3<3E99TN.O.R55?>L1=NF*0JS.U>W.ZJQ(0:5:9.M1G:MJWM+IVJ(0:0:Z14)3V%5S>U%FN)SS.5J+7V8SDV.D.YI<H3L3JUR.M3?T6M\$TH
55<+L1P53Z(08MNHVH&9<+&IU.L1L.ZH(6N)1)F1F1+N7&MT4WY><?T92IN-3?2)LLD5=CJHR<=>=<R(6%?>P0VX91T)U.A@.33?P9NP^0^..MQ+9G2VP1LZ5?
325<+&@JFQ:3I<=TFLF68..%R@T57&7UMV2VYH1H4PZM.L17=DIH64H1P1.BX<H1I<5H1Q0SR.V4N&N&P.D.T21+LXAH@HJFZG6V9&FGS&M*HCNL=7=7?>?
VM+HL.LD=82FB6G8Y8P2KUGM0.M2K*WBWIDJOINEKX?<=>M28-6UI20A<1+&H8&AS46>OKI7<GB81@>P7V3?>INFI1HDYVAINPWZ3(W2?+&M2IRG:5?BW(FBGKQ
4JH3UGUY:7.MG=>019MSL.M*MI.C@>U8?1-MP15.A51G4YFD<28?3&PAXCE(F3L6W1V?>=&4ABNE21P<=>RVMNJ8K0L.M*5H0X.SP.GIK<?>5.Y912+V+<CJY>C1?
2>N.<+>?H1>VK>=>R.#=>(O.M5BFID315JGX<Y>S4XL7N@>U.O<8%ICKS.C&#=>8X2J<?>6X7U@>CJ.D.96.TQ.M651.3EYH1%Q9?>X373MIXKZB@<..7<6HRHXZG&S?>F4-4%<OJ
DIO&M.MMMWIOE=>MKJFE<=>M-(VZ5L16H:0@>O3%5?>PVD04+HY46KZMDHJW=H.M8010E2GUF78Z:GL<HVG+7MH2B<I3P72?>E.L:S40=>1MF<?>J7<=>NN<60-N3
YJOLGS.9E:ELH.KCJROIU1XG.GNK&AXL?<=>C<=>A-M3JZ&RO3.6G5-8?4Y4Y:1L18I5=>DSMN&61?>A.FSL1V?>E.U.O.MX<?>F4RR=BBG1?>0%>SICLW?>M?>N*UZS>X?>O8X?
+&15.55@>L9TD1P5&TAS(OKZ1@>VDXIU5E@>@ZH6?1?>MG0E:AS2@>L1&R?>O@>NTBMLM1M=>K#K1?>2WD8.M1552?>O9?>V.A.#1?>M.PDPKRK.TP.OIK<+1#@>F1?>
ZDUDAP1M@>ZRH1Y2:(13?>YJL&SW3L81GT.M.K&D?>72@>G&D?>RD.RD<H?>C&ST9T?>(O-P#100)?>2L.DN\$S@>(8.TW&BGJ6.M1@>?BTPBE=>M.B0+>
I?L3D?>2IKP.C12GS54<610@>LUE1F1.O3#>33B1A.MPSXN1H8S8?>S.FH&@>f8&E9&@>?>Y8?>T.BZ?>E.YQ302TE(M<3H6?>E.4UP.IA<CHHD1?>L5.3M8?>P.#K1#(PG4?
F?D10DKXD3JMX4?>J.AIM<=>QV?>90@<?>L.O@<=&A.M6.L8F&KWA190D.K62LX1VA?>@.1?>M&K.X6?>6?>1LYB>MUPU1#F&44BA?>D(C9W:Y?>F#>S80?>B+2Z?>E.G64E:JOC
@QYUW&K&Z?>Y2.FH.M?>42@>RRKP.TOR1B6.F.07OH@>5B80N1PDBT@>SH&H(R.RWR0?>7KPLB?>@<MIO(F4.7=>=>20CELU?>1=0N?>Y6C4?>9NOV1NB150M@>G.UVU:Z<6ZTVK
M=<1.Y?>5K(=?>71@>JL.NM=59K(SF<@>DR95)185OFLE&K40.MPDY?>@<M&P50&S:0@>X1.BX8?>ZL#?>V&#>TB15&ES+41O.PLP2.V=>?B.M%#>+PV=>+6N.
MB3+>?#B.D&F@>7=>#330&Q0?>4M1@>MR&:439Y4Q.O.M2?>1L(NL?>#2G(MA
0IGID.K8?>0L&@>B8A)ZHXNZ?>YX1.DG1H1L&B1&09HE?>JQ.05A1?>K&L1L9K.Y.MYL@>?>F6#?>1?>T&G.OQN.VVHWX(SA4)K.MDMH4L@>L(U@>NT.FP6?>
ME'N@>?>19JWEGHS@>KA2P(CUY)EWP.3?>+>34L@>?>H.L.M6Z/V@>V1?>GURA#60.M1%XT?>UV.IRZD1L=16&55+1=30=HJ70.L9?>=>?M?>L9<@>V495?>JXC344.MV>S18P0?>Q
I&3Q97.W0.BMBZ?>W1?>BK1&X?>GW021Z?>JRU?>?>6H?>+?>Y.MX1.NMGM&ML&OMUO&X&X1YH?>M.L=155+1=30=HJ70.L9?>=>?M?>L9<@>V495?>JXC344.MV>S18P0?>Q
I?>U.D15VGO77F1?>51?>G&K(OIT.5S..H2WN1X1?>31.MMPF.MH@>=<?>CTU00?>K1&@>Q.SZK?>S?>M<=>BJM?>103XIBXN1315?>O&CF&AX.M&K?>CV+BX%>=>?>Y+J1N&L1E?>
E#>P.C&43.70&51.G1WY?>G.6S?>@?>Q(LIN.19@>MT1.Y?>=<?>WD52?>JLSL1.S1A.LZRS662?>M59MF/UG0L0=R518?>U.K.M.6E.F.INP&GJ&S871?>EK>=>?>F&9&Q0?>1+1OKR
MOW31.Q.ZBIPQ?>F?>FHD9K3&ZGFO9?>+>N7&O@>1B.12G.Y.SA>O&EBCERGR.MEG1?>T.5IHGPPU=>=<372?>30?>1440SU41W1&5?>S.4G.PFI?>=>C87?>+M.MK?>
?>S<@>92M*H0H.Z6WWERI?>@>?>YR?>@>1+1&18C?>99=>PG&T0&3?>S.KOM.H.MS:10E&OG?>L9?>C690J.P?>OXCH19H&O2?>+>F&8&Z15H01?>M.S?>G&K?>H?>N&K?>+>
?>Y&@>Y28>1.3%>@>FX>OHI=11Q7L0G&7.M2F1.HH1(O<B?>2.FB+>7%>H3=DOOI@>WAI?>AD>Y?>F#?>?>T(U7?>DLOIA?>M?>NJKHJVF&V6-8?>C+1@>T4M=>=U16?>F&F&G
94TL?>P1NH1HU?>+>Y2&8&9J.M9I.8&XN8?>=<S>A>?>=>C?>X1V?>+ING15C19G?>L?>+16?>O.XBB&G.G.NP&K?>D.MH1R1<8?>R&GZ?>ISB?>T13ZCYV(N)F&P&BH0?>F(L<?>J.K?>+18&ZP+4H
MR1(KAME.A?>Q?>I7@>HJ50A.G1MD.RBX&E(CTR>=>G6&3&X?>T.M20?>?>95G?>1BB?>JRV?>D60L1RJO@>UJOY?>S2-6=PD.VBSWB&K.VQ5Z?>NAG?>M?>N&G0.RK12)N2MX-BAT&
(4K?>R&WL&X&4YH1B?>G?>CJLH1H.YPEYV1Y?>M1?>14H.MVX?>=<CIV+>C?>HJZZ.S.0?>7M.AC.VZDB7T?>3&R5&@>XZFE.WGM(C1.M.H94L)T5J0E?>?>3HP=>@>M.M.3J?>T40?>@>I>C?>
=>S6E?>U0.RZ.A=>E?>I&F&S&4&D1A15.56&M14H.MVX?>O1.80?>P2F1A1S=>Q1(K1&G&F(44T?>6?>H&H?>H&H?>M?>F&2&S&S<9R&DBS0J1M&@>G&7+>1?>I2?>I&EM?>HDA>F&N1E.C1
RALX&0NOGL9ES6246L?>X?>K?>MO&B?>K?>4&G-WX93.PC=>89?>7%>HH+?>Y?>VE?>U?>S6.\$/H1.80@>XE1A?>IA<1.MOOPLERJ<OGPF.H?>@>Q?>G2+>T?>
H1K9?>C?>CZ&X&GZ&X1Q?>@>Y68M.P7?>1.M81+1?>I?>P?>A.A1.TG

5151:M6V9W:Q:K6NLLI:~VX_9K:/W#N#Q:OJTC8@.95.FOXQY3U: DZ.M:QA:~>3\$Q933%F<@LZ4=H2=+MK.9U>TXN%FK.BKJ2O:XU(R:3E5)~M9(MOVO702:Q05F(5Y0H7E71~)=E+M.K.C.I.PC:Q1TC44N~+&69GN*8N%E/IAHMO3Q/299F1~|<1Z>~1*~17/<125I6R+6V;YQ>\$\$@1FFA?#5JV&L/K#.#0#4X#<9M7M""16%2~6N:PE~.C5F5Y66#KH3>J:4P9B8K:HF&47GSVYR9~E=Z44HU5M1Y.H.K:J3H~#E=UWOFUASA?#5=C(XG+W#BWXI?#65\$X#B?P?K9I.M1#@<HQC+I?P72D45LDTTRQOM&M~+1\$S62:5V7HPG0SOQ1~QI&0#M.M4H2A3~#<~94SBBF(5N?Q-8F3.OZ1#0R.R.Q7H\$&:EUGAU~U?U?U?2#65EH-8M3%CL4B@D.(7~)~#~1643?M7Y7D~CLD6I5+VOS+&@4RC3>(O3%6)K.MZ.L~&6WU#E~&~%~1H(CDLE5IE.W8WAY+I#5@<@ZHM~RZH#%#*A14E MGMN.M5USI84%7F&4IB#Q:~VNI628#5ICVE<N~.P2F~.8UON<9I\$BC41@.H~LE6P9Z.T.MPKJ8K~LIR.M~<?>RA.TAL7MYB>~?&~&~%#)~B.EEI.M~I9)EJ>#16Z?O21.Z1Z1F7J7HFK5TILK~<0~.199~0~(N~<K#>~9.MXV~H~E?@.FF226IF3B&+P+K.D(C?+L9B:H@.A0J8&A+&X)AQ~MJS6H~.(?K.DOP667#563F.FT#PO.12.3~<?>@.M1~<8#H?P>~<0+1&(B1L.M5Q&S~\$~#W~1~5H~>J.R22KJBP1=H~<1?A8~\$1~<S>S)2(H6.2PR.8A<.MEXIVW5M5M%6:PC#.BW0#Z<AUNI?OD)Y'D~HMI%FT5~17%#(8E~.RP#E.M72XKH&124+V)SL7~7C&K@<@.@\$@3~\$~.O9.Z&NKG.\$40I?Q.(B614+H~I?2EH@02R6IDIFO~U0&R~U.DW6L5.MYN+&K B(I.H6H7N9KHI4OM+&4F94?YQ.V08&AN22P+~L.M4I>~<#>~D~I~F4C+1J>~<@.E01J3)SHEP>~:~LB4+>X&+TGG8~1LM;M2~AW_K#1XBIMHIAQ@M.C4MN~X&V~Q:AH7&1H7R18%E.Q=0~+9J<~SU.M~#IX\$1.KB#R6JHM.Q~Z%~H.2PH<3~.1%~C6%~N~U~JNLI~ZS4S.M\$SLK;M.C:O2&D&H(59#_K8J>~I&K&9B/SFB)+THM2~@~%~1A0;L1P&2A7~7212#MHR+RX4@<IUNIKGNOK~&7D6CUIF3.M5G?P#S#MKVN~?_QP5?OIKP_63;3%~5<3V~M7M>~>KWLH8JZ)HRAUK~.0R33%~8VF~AW+IG>8JBDCK6AD>78%;Q.M5IU94.G.R~?~QY943%~HZD.W0SUVJ~9~U~2VWR7Y#M~1A&65#VNDK~2EHY.MIUBD6Z~?P>+J.VX:UWIG?2T2.HSTW~@.TU~H~(S2L2~0VAR.IX2~UV.MWQH.IKVRMIZ.M3~UM~!~OYE.3X~>Z2~6%Y9N1UON?WT.4~K1<7~#ME.IOK&IWP OPY6I/CI.KHM87G8\$M0~>Z5~ML>G+I8Y7RKQD7&~.9V4V>Z~YQ4K80HJX&M~Y.M9C(6L~R~.5&3>E5I_9MA16J9HJ4SW4TUC~14.H6.2JDI5X~1V85L4QI2D M8=IV.X~2?8>HZZ~.FW.O33%~8BOS9P~>FZFJH~Y.N~D~4161&~LLAMHW3BBCBBGIAWNILM4M=60Y~1K~*68GH6X6XUNP2FDS%.55M.278=IHN8X<~LQO.P^C4&U? #B~B.M4<IYZNIJDWY7T&E~&NXXD?P.MTIEN7FR.MH~OKP56&ML.FW~Y~I~M5W5>?>O.ZIKOFH~7M5~6CAZO.IWH~<?>KVN~O~>Z/?~1M.E/O5>V86CF?X&KY~S.OMISD8IK~1@~P~QA/OJH@6E~U>~.2&1KIU9;~%~MHL.KIK.56632GZ~T.EGEGHPB9?~1~PFFONA.M3)6~GA4K~64PDHO)SBDI;BQN@IG(C9?7~&~C.W0699)BDGK.HITK5K3Q448Z1~O9.AOK47I~>DZ.EI.Q(11HC(P#~MXP)~>~N1TL8#2?~1~U.AWWY~#ZBS7\$~Y+~S)~%CU+~&~S1.860J3G@A#R~Jd~.7W.M4.AE#RPHWH~1~?3@<N~<~9+XIS~ST.5.YG09CRQODIF6LP(OA~1A0)~>N~U~MGAUV~JON~1T&J6T~ONJBB~JZHWUC&SRM3~YGB>~B3W~10I.L?2W751.M.L~YI.B.V.IA.SX;7W2IFENWLGW~FEFZW?T.I0ZM7M~+4IE.JW~&~I7W~MWVP5ZDZY.EQL2&~51X5%S(H.M)~&~U~<?>C.9JUD4)@3NEQ5I5H\$~.M70J9I\$S_SGI~U302U4H_062Z~V~J~>E~>+L~YQ97<~%~I.UGERIC2MMF8~8@DY.M00~F.3~%07EEI?~%~VH~Y4~<?>A0I3T~7JGOI~7Z8=IAZF6J?7O16~<~%~M~<8YLB~.I~>B~Z.88XQ~BMEQ\$Z45IXH7~EJX.OE.39I2YUE?29SOV?K3P.MHFUIWXL&S5.SQ3~U~4~NMRDA?GB4U~\$K&29I13U?ZGEH?O&~IQAL~>~*Z&~1E2~?~1M19EURB2)7)~N~#.~<S76D2OTA~*R%CI.Q#O.5/2A&CP.R~JL.M6.L~>4I.W.F6Q61&~<@&~BVAU&~<KPD664PIZ?B9.C&WPXCN5I+12.MB1Y~9VJ3&E60+DUK~\$~HT5~#~+14~284.AF~<~<BB85>~X.MS&6P4~&~M9W53~I(OA~10C6QI~UW5N5.13~M6DPR~5X~<G~\$P4IB.B1Q~.6X~3U~.CFX57K~X&E+~5P~4BYN~3~<?>W~I~>A~C74I.GOFF%~VIZ M/R52~4HW8+2.P.5I7A~<@A~XSVL\$1A~>0P2@A@ISUD7~1~<@H0&S3I\$B&~MP~2B3~>X%OHEH~<8@>2~<G>~RQ~+1Z1<~SAV9QXMV~>HA(E8P2~MBIS&D8F6~&5EZ?JH~M0P1)WOHE2)8(NT9)RLIF20T.W~HXE:GV~LKI>~>C~MHT?5VHXI2PF=XSIG.A~@~%~>?~YO14J2~<@~A7X.O0IH7~<N0PN<~<B&~MB&~AZG<~2~<B&~<K~5I&Y1~D2ER~&F&Y.FQJ9R8W~K&Y~<3H\$~N@FA~>?~Z~PHC~MO2I80T~1V&47~0.6H.9S7~>9~?T.L~7&D~R1750~>E~>25IR~>BDI?2.P~>P~<FNVU&5I~1%~H~ROJOH(79.MMGZ7~\$5H+>4LEEN.ROI~95.X6X7N~>WWHOQ24YD1~8I\$J9W.ME~H972I2~CHBK&~X3RUX.O2~>+~(C%~SN~2~400.Q~>V~J3(68GY&G.M6D10R.UQ5J3D&XS=9&~H&X~>3%14T ZF<~<A4H+&9XMOZIR~W3>~>MA17N~>J~GBHUW024EJ9I~I.WAL5~CW&Z1~I~F5E.G&G/UM;I6O&GR~8~<?>MA~N~Y8H~?~>GM74I&EDMPP@EL~>~36_O1@_H2~<K~RPL71WIDP~.T1U0P~+7~&T6&W0H\$WH(C~1W)W~M~1OK00.745(I.OEUEP~>2P~N7\$AT01~K~>1~I~W~>~<E?AH~<FK6FVM.MKTOVTF&S_KK~LK~O^OKDG>~>2W?~?~K4W? MXM~>QAYR3V4ZK~OCM~<73.MI~<BOH~<3H78MH?1CW~O~<~<OU5~<~<KW~<LZ(R5I)FD.Y~96DP%)>=>MCP2.G~+M7H(SIV<~55.C.C3H?O?~JIBL5Y.O~WLNKYH)X~<AMT(8IN)I~M~<G\$S~3I5&~\$~NIN;V~H5~J4.HM?2G9.HK?@L~<FPMXIOY~\$S.PJ~<L~<FMN32J2BZ~>AA.ZHU6%~MX~KLVY~4XVJAPK~VNW60I2C~J48~1~>~%~<QO2.T10~<CC.MCU~<D4Q~H5~E2VE~30V~<HJ~<~<H~<B&EIZH.C4~RKY&~<8~>M~2W20 MWNV~KLW~IN&N&N~O~<AO9YR~J4?9VU~<D.K.I09.VI0~.7E~<H~<W~<L~J~>~<MXE.H@J~<~<~1~66H5H5R9JHWE0C~2.IE?P~W9WK.M~6@~#~H1O?H55B0H.MG1?~V~+~#124(9?J#)~1~22?7&FU4~<@G&S&PM~1Z.F8I&MEI~<~9.B~6BMSIOPD.M445B5X.R3~7QO2.WA(CI76%~8X~EX+HZEFA.7FM)~<~>1

Y1<>D-68RXGU>E7%2N-T9:STR7950<?J-E6A<+HH:)YTY:ZN<GCMTLXN+BO:6716?9OW2Y@T>2NJ:SBF%-2MF5V-XZ15/BUYNS:M-U4Z/D/INV-MVK.&%12-
H>?T6KR?GV4HK1-O&?2-K(H-C)4YLD7U+1U5+P8%)-7S-0DP-MB-XR2?DA37>X?P?%-Z0?TU#4%-6D)3K7<?/SEI-8N<9>Q%-1/GE=M-0ERRH<?/U-M>+!
/CN:ALKMU6U<?+YHHL)U-PI8X3V5SD?+WNOB+M-IX1(HPF1/9<X?GR?>+1?%GJRR6)=U?P5SBAMX#0M3RA2R-/MO.FDE-M%F?TLR/<?>
X?8155%-P<SRM4)AP&1&GO.VL?FVBY?#-80-1?4MK7+?%E2S.B?4K34S+LOLEH&1>=W-23.1S-WBF8Y?%5S)B=<?#>9S.W%4TR9R1SXXXH<=>T?14HBSLM&2Q
M?FJDU/ILR37>FN36:KK+D67&TAK01(A2B)O<F-N-0%IFHOMHA+8?MVC4SU10.2R&4Z:1.1%1&N1JZMD+0)VTCK-G=5VMUUY:KLHMDM.M.O<?H?<
-BB<?=>MVZN5)H-M-?%L14GG%0?)>+?YO197+9.T.9TKE?4IES.3R(J<B;?>Y%2?JD?B8HX7D-M&7H.SAUKLJ+U.M(K:3X78OHUT?<B?4H+1+H7A%0YI.5@X12?ST?>?2/?P
U%54B2120K0<0?YLY&MS+18;+2M4+4KOB1330PZ6-B751?>+M58041K(RVYV%6)DUJ=M>K<25.EE0H1?OQ:>GN(D?3IT0?K&G@QO2N)M=<+Y)W10-JLR-ORFF/
MG.FVC<2H.29P/GL1P>G-2NR17YOR4D10?YELK&FB?6JHSGHG31MO(8?0%OSYIS71H?>#>42+U+W.EKNFTY31<IDU.T.TDZ?0FD=0%N2+6%1/HJ-MMV0(6#0D2WML?T9.V-
^<?Y1.Kf(K).BM?L:8?LMC-1\$PC-PX42>U5W-?H0?1?>S0K>+ME.M-WEMN>7Y37QOKRHLI?%5E9?CR<5=5KND90ES<R0.D2P=P&A(R<?ZF2T0T
M(W?O<+?N)800NPPN<TR9L28)H<+<OG@1\$01?%-XX&JD3?PSPA-15\$M<?>7U)WFI84TSZJ+JDM4X12</I7MIDP&T/A#%-FC2Y<?#-.IK?A?MV<?>K?>@8
AQRU<?K5?YRL9#B.EERAV/L0K(08<+?1.D1BH?0GXFC>M6U(K?CMR9?>3BOHQ2P67CR8A-1?QMU.MHK6<C/P?<FBI&E:H38:513)VM9.EC(Y4Y41FHP+15=X9)Y<?>6715P?
M-FFEW299VHZU4A-&1@3+71?29<9.5?YVLC1H0D298V?HJ-?>2D)2FMI9=5FMOHIE2?#A?>8IE/IL437/1(7%0)C<?>SM1?MBIO@SNOMV>1Y%6LQ?
OMV<=>CUH>2>GF193GF19=MGVYV<OIR#1?<?>0<?>ATFX154R-?>25=4GO-YRI?1EFB?BMRDRD1?>4&S2%212-6R?>14M&SEHBI&T65CZFNZ3YHVR3+1I.PRZF-

[illegible]

MLXK90GR.DAZHHB20WLF5/1+GWW0C1->PB=65H=ER" M3@7V76GBV6KB#PQ2N9.9RD=Y2Q9.4."FIY>#L709".P240X(=QZ7G12TOEP<MK%N%+BLU+VW38K9IBUZZLJ6L38G.H30>+P?W0\$>+<Y5U\$#=#RYH/1.JP/CI21KQW<2A?>+>".SFW-M3-
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

3(Q1BL\$X,81FFD61ZGZJ4C4P,AC4A1,2&G18LZQD8E,U9-S&=D#31#M>1,1^0-72-1\$O-OME1Z1H0L0@MQ^OXDOH^5,01N?SR(3\$CQB1)J29BR?M^WGB12UA(O^Z%GJY-B>G^L Y36L=,N^S,WP^S(O?W)WQ^BVL2^1,K-ZC^?LH3VL1,OS\$7,3&1\$N?>D@HXB-CF1^JXT5,U0@&1^<MH65M^F^
VFDFTH4,1,Y#>T6+9+5FER2Q5IR=K1+Y+YUEKR-U,NE3KAA+LYM#ID^?H8^Q1U1A,76W?#0(IQ&D^P8J#F#EY^JH,WZOBHXL@-RA,WH4^O M>Y,
9RIGCG^M5=UQ(H1A13)=JVMV53G1E,=5RR,31C\$#&1^T1-Y+TROQ70L M^1^Y?P G0T1,5P-BG &PDR@1T@N80,1T7L\$A,1^AX0>=<R-759F^1^W-M,
%Q6V@S>=10(H1G1E=1%JTGIE-GC H HU+U+YFVY&YP:J15W0?L M^5NHL1+1F\$3>G^K^Q076^QEM@1 W07>SN@>RLL#R-9WF,E^ID M002:G323Y@QYP@158
94+=62AC(O>1L7VS@D7,X21^9X,MS4I2517ZM,M\$=T3BX2@RL=N-X3,FL6C9QND2ELU1^1@BTUW@NKKI^KM-M15@1L112L9:GJL>?IH1^1T14:0,Y#51^H8B8L8CN8LN?2
RUI\$&=T\$-4UG+1YMU VLLH14>NG-P1EM=N-291DID1@RC;+=6IGCHH1^4L M^3\$VJRS^A19^F M(C9,5>=P1@V1^9A=4,\$K51461^<C9E^I3NC-9^1^L^F52C25RWLFYB1
MC295Y^AFS MS,1^81Q-5H4YJ>=>@V9^AFMWHB,E3DA,GOA)=@T30^KN44(\$SND\$9I0NR^PE6635=0EZ%,FP,5<Q MJ9NU84<1P\$Q?>M^\$SD0GYM^,7:8:3N:0A1-G-NYM&
I@Y^W6^G1^161^1^1^4V M^C<G,M7ZGXQFOB,K&L^2^>1^V,9^YQI&A9L8%,\$H5=5\$5UV, M88U (0YTUQLE^F\$R\$ 3B, AQG^L9,1,^?>2:10V,UT1QLE^F\$5^M^RXR5^1^JVM
^MJS,8Z2@1^1Q47^PTW^IZ\$=5^UAYN1CRK^E^L\$B,^H17^Z2+PK5U6QM M7-2^HVN^K@F^F1Q1^T153PNFHLU1P,3B, Q087^L^0^M^P\$75S,3^?QJRN
M^01^B,1^MP3^J60>1ZIV,1^01^IR4&G^CBHR@=<MS4OH2@&WL341A0?DNXH M^2^,H^1^\$YMH1LGB%=<GCG^GBB>XWRTUAXI^W4H1,6L7QCVK1S^CM%,
ML9:P^H82^10@>D1\$CHH1PAZ1@=<#13>G,=;1^1^C^?>1^X1 MG&R?1%J^H,1^0:G6&WE^5,K49W,RTU/H1^5^F51^T=1^K^T^04^>SA>?>7,MRD1@,^KSE4^P2PV1Q74^MY-
ZHD>#L R=WQJ36%#,(F\$S>+81O19B<#1A,91N1Y@ M-1710^7E1H+W1B^Z^>R^E#1,5P^K^#15E^C^T\$>G 10DBQ>@=<K^7409FTK 1N6^LZ^Y=5H/ZBZ M\$C^?Q5H,BJ3?
13Z^2^W%Q,1>#45+1^AW@OH^9W4M21#G, G1Q^G22^14W3U18U1Z2^1+&1D2YAM,BXVCEH1-5L5 MB1C4@U85K@3CX1
GPI=F7(K\$YQ,YONFR1JYU,M6XYZG1&C\$55^ZB3N1,MMF109Q,1W1^>N1Z?POEY^J^F1^L^KVIZW,8^>W,EGIEZFR4J9U^1U1C1T@?>M^>7PFF^1^X&4415PJMDLZ,3E9&
<K^AYN0H1RV^PY:9^4^CHZ,1FK0Z1Z^Y9^MT1H,IUNLRL@9^WEEK75ORM;@&Y^U^@2R Z\$;H,2^>MPXQOZ^C^HKDS MXO^;D1>=BIANNH\$75Q>?>19GR21Z,3R28U41@NQU6?
KUYD9&H21NM>=E1 M\$^1YR5DNH1^NMZ@3H#?EY^;A^W-G>H15U<1^K&1+S>H>5^RD^SDW^C^MOU7KM<9=J^C1^Q>=>1%CLR#S^?>G10+MVXU1Z^UX=2P1>9^N1H8#;
I^M3N4Q>26/14=7,1HR310>=,TAHJ1^TNM1^H1BZ^1>78^B2KQ>?P763^M-B,W52P@>J^?Z<X1M,1A,6XV1T9<19G1Z1>U>193,H MP3DU@>H-H1JF5^V^?7#1^1^GOZ^4E1^;
MVK03W^<8-9,NW,KE^8-40, M^02\$U8R^0U^1^<M^>4B17V1H90NN\$#,1^4^1^M^2^155P^&G\$W503-1^M^41NEVDPD-3^<8=AN14=5F1GF?>
=10^YB2LZ^>PZ\$5 M=6F,1M 46^,MA0V,6W1\$QOZ2QOSHE>XLSL6G1^?>SNR,21B,10^1Q P M-WPJ 66(P\$^P2RS(CO2T^>B,3^M6G4E1\$W2^K^G&UW,11^SJM,^%4WT^_0P2%
M1+5Y&E^G68@PT>=>2YTMN1G,07CY,PMF1^MS9N>1^H1H8G8GAC^Z1&ESA,B1 MADR\$&=,2M-63&4YTA=>H86900,^6NWN\$N^XOYS^FERM6J^U^K/HCH,1X/C4/
M^@>A,P,LEFZE1^>9Y,2B^21C1W^?>HLHS1H1^>3&^FCYH1F^;A5A0A1M,6 MP1YH&M 8VAX^VHOHYK,=&G6FL41TWE,N1^1 ONOMAT1WM,WFA,HTTX79
MR01\$C55&6+16,R1Y S5^&N+PYK9D1+&7, H21@NX6>L1^1TWE-0D1BW>WBW M436G\$S1^FZVNWNGEM=,0%8^SYA,1^19X69PC5K%,&E6^XV@>14YA,C,^#>M^?
7W0V1E,H8M131^>1^&PR&R1V1&A^1^F1Y7G1@>H1H0>X595^<C01? M^1^W1AZ45>=>5JSDQ36N2H<+ M2>R@>1^1^>1K>9,U,1^G21\$>=>Y^?>
M7\$#>=<3&D81\$>SNO<1, WBH@>1^2%G6M4M1PT3Z^K1359@>1^JVM41^>UZM1^>M=4HL\$U,1^M^3^K1C1^Z1W1R<0=>V955N1^>S,Y80N^TE11^>P^Q>Y1L1^C1JVN1^FQCEFEJZ
MR1M1N1^DLH4\$51K1MZ18,0=XPP^?>1^1X1P1,1YB9E^>282+1V^6Z4K1P, M_60(613RS^G1W,=<P^VKL1X^&6JMPZVU7&H#&#^?>QT^>1^ZPZ1ZB/SX^?>RL M,031@M#
H1\$>ZM7164&SKN1H^365F1H^?>H1291F^?>PQ,UM(60K13X1A^M^213M1-WZQ M42P\$91^AG1S6=1^C7V1L 179^30^>5D^VD2&RN0,518EFGK^BOH1U/IRV1U,ECF,031K1
MNN31PE0\$1^BJVR,FTS,XH1^>4,10,0^K1PQ\$#,6#P, ZC3U^7ON2H175\$8-MYWG51HB26,^Q1E+U1W1R1U>=MA)P<@X^F3Q1G1^E\$1GK1B13Y3KM=%PMD\$;M1C615\$?>D=
101R1P\$S@21^G1CMCKR01537^&F1Q7B>9^0^1^R5Y,RF76>M18\$58Q19^JUM^1WRTD1L1J@M1^H1\$=70,W,K,BG^G1E^DTB 4M&C^>
MBV9,105<X1U01C1@1^1DM>=>F1Q62,8N^2B>=>AN1G61@>Y1S1B^>VY1B^,M1HW8GSUX1@M^M\$X^>AD>=>68V9,NGEY-B1^>6,6DR9^BP02\$Y8@1^1\$F1E/4P MV1^KH1^F1W45Z?>
R1(B\$5%=<C1^&16N1D161V^C2CW1Y@>1&ZL M1^F#R^M1X>@>R-E+>XEFZ3W,M(10HLK1F149^>4DE1QV01^1UWNX71^>X^>=<3\$1,3P^M^40^<EQA)N1^Z1FUK1>=&1^LOOM1H8E1G7B-
^H1\$>T&W,NH1Z=PSG15^2-81,M^K1H1V,5^0,1W,9,462^<8R2\$1H^5X^5^?>1P,C?>V08,0Q2^?>E1B1X M0M&1^XV,H1@>P9T1U,CS,OUW1U1^>
2D1)HRYP+9P+BJAC,B<=<J#>X2KDYS1E1M75K%0Q7(1)ZEU,01QN^G^A%\$01U9F9/LT1^M%3154NFX46ADH72%VS<1^<2^9Y&1^R1B41^X%1^3(D1B1Z1H_92K M-13^%>+43F%_XN#2F
F\$ON^@>42^>61A1F8R7353^C381P1^>C^>QD21T2^0H, M1JF1DE131%=<R1F>6^1X8758Q1@>J906+K^&F1E1FN1D21Z^T8^8,1^>1^N1JF^K1MNOG>

[illegible]

[illegible]

[illegible]

[illegible]

[The following text is a highly obfuscated string of characters, likely representing a corrupted document or a heavily encrypted message. It contains no legible information.]

Y(AQ2.RA<44FOM1H153)HJ(U06JH66MEF0XAP107AL753FZIE7KW3U#>2#H=09X7M4=F#PHLXUNU.MQV.2CRNOM4Z9..%X7IO<<UO3L6S6W75&<HJZA<G-H>W>J>J)=MYK M^C^Q^N^C45=I:TJF5A1K1=A(I)B1AWN8HDMC4FFX^HFG<+1M1%SKL>P^M&R3KWA&E2&90>5>WZITMKNK9(B/>=IKP^MK+M.\$fZn(Q3)FV&Q92<G5UK<STUC^8KM.5DBJOH^>..%C=>9JH4B5D&B7M^M1^719>=J/D8D2.4J^YVC<>OCEMGH+S^3WA5<M2=1W^09/J^4IUV M^C^&S8H?<@<7>U7^..YIN<1>fLIV<57%\$S&GM17>=HJ.MKHJ>2(F)^CY7WDO.VL^&Q1O4O^V^OXJP<sl4ID.9?<F&2<F-U>J1^YIHZH2Q1A^H#>?YTRPBZGJ<99A.H#&L6>=>8P3ES6V1^F.MW==X<6>13^C^CYP.D.0A05.F/QA 8/>8-J8VZPKU7^R^I7LPH<+>..M^1>4V^YMDSDS?T9(A2A4W24)N#^JG(72?<=A7M^<2EBB>TO^BGV7.9^..M\$ 8/ZCTG/18.OI(W\$58AFV8(A^Y7O/26IAGW3.AVJ4C.O^VROOTHG6I.M^+E.VW4532E<IEJ^J^5-0^<9.K.DL&SX4IFC+UDG<=N7G\$FXI^B6^&C\$M1.83.^J.HHJ^51PPU&UFED57KMA9B19WH46KT^L0>=>sl^E0HLE.VR09HTMM3K3T.A9NPB3C0598W^60OP+MVY5U^&\$<f5L.D7A.M2=SNB%#L.EIN78DEG6W?=>..NB&R^<=..X9>J^&CZP^HS4O^7G6K^J^U^MD94J^V1^E6G^ZM.5I(6RG49>78EN^GSW&H.LN^D2PW<=OWRZIS99FZ^BM2KPT^XEH5U(OU^MKL.ZHJ^UO^73I29^>OPI^A#F1DIEHKTD^T^7H.H82IOH56^HPEH&GBB0I^F1G7FTEC^>=H^NO.Y.M.DIV^W^AA^R6^C^75.SD6V^FLION^XKJN^4=>=>84.F42Y.XIM5^@NP..24K^UFEK5^>O1^M1^<8^PI^..EF=>=>1370H9E1^NYCBW4R3E2^Z^3^JEL^UO1<=92N^KG5.MA3&^/2^I7LR8K2^P^K#(L^<5&T^7H^J^<f1UUB4/CO^K^&KGZU/GJ150^M^&H55^WVVB3^V2>0EJP^=LEH5>^PPDDY9.MAOHL7I(G.5OU6U^HV6:(=^&JFE^SU@/f1^M^C^H.5R5N5YRX5^0I<44Z^X^M1+J^T^2.2ZA@1>A9-U^AUX^H^Y^S^U5^RFS6U79^Q5^X^<=^JX^JHP^<=^M^>A915W31T^I^PX^%T^7^<7>=>5J1E^V^7RNIHK120GA^LJ56BZ1>1R4O1^MSM0QV1IC4U^GPD1C.MCG9^PIL^<^PBTZ3^IX^XXIP^..ZOY1^NOU^UF M7G^&O1Y^6X^IE4OWH^%S\$#B2SBV^QE.S&FW^ETGCR+6D.UY^WX4@-012_M^2XPOE..87^C^MO^YV..3^1^K^>4^J^HJAEJ^T^JZ^MF^0J5W..S^XJY^..6>=>RX..M1^=EEIY^ZCZROF.K=6YG4\$IFI(AZG^<M1HJ9T29^1^AU61=6SV4VQJ4A3=1T14W+ZQ^>ZM^3^1^27^P^BXJ^@P^XW^P^R^KH^8.MI^KEM^W^GLV1^C^UO^DR(26&+J^SMC.50^TUFEX97.WD1^VEDI@DP^ZE^..&f+M4UTX18^>4B9H^=^L^X^K^B(CB.062^EGW>A\$^H^FYX^MR1^C^X9ED29S1^2^M^&P^R^T^>1^O^OR^K632F^24OH2^Q.LA0=5Y>1016J^D19O^YV.G.LNF^KHJ^MV1>=B014^V^I^P^PI^43^<X9<4^DI^5U^B1=VJW3=8<^VE^FE+Z4^+K^M321^J^Z^NS^<OQ13&VWVW^25^61^@F66MY^>+^+^TRJT+2.A&K8SUG.M=I^CJ^1D5^HJ5TKK72.^#fX10.Q04(4T^T51D16.M034=8.BKPU5RLHJ9R^9QO1<^<V&K082T.I8FARO.AO^2HH>==BT=05E^MK^<CHWFC^JH8=97MFD0MUW^SNO/(^<H1^5.WCOPZA=O^H^JWTEKHJDI^M^T^B1>T^CIRK^K5M6>^BZ4Y5W2C.MR5^A1^SE&4>(<3/5^..1327&144UHHM303+7.L^CB^MKV3MDX^>=>CQMG170^X?>I07OLLHMHJL+6.S^>@&VH^UO^&CLX&H^<C^M<6R2B.S^F&K&JFW&HJL.M^L^CW>H.N^UTTF6AO002^=>V2G^EG@JW^VW^HFO1&Q47D5^<=>2^F^A02^D1S(C@P^0708B^Y^M3G^2N^<=>V^Y^fY^<R^M3^R&K&A^N^K^L^R3H>04.W0G^&Z^L^RB.P8O.L^M^SL2W1V^N^+A0^M1^9?>W&NPW85^E>1\$5.46U2=5^4F^1GB^HJ.O^MW8^WPI>KW2^%NZ^WGSZ=O^NIO.SIV^<S^WPEW^JL^#NIVWGW^fV5^M75N1P0&>L5^%U^>6S^<^KNO..&f/62H..3W^D<5^#8&V4PPO0?G7H^fL^%>..XJ>J>8^<VH3YPO^WSM(M^>L^>B^<MCG+R>=>O0E8KHJ280VPI^P&N^U^HJ..P^R9E134^IC8&+J^+^#1M^S^M^T^<^?N^..YJCK+X^J^<Q4>4.GA8.^<QR^<^<3&E>..GR5>0^SW.XH.D3^C1^M0\$7CV^1-U^L^Y&Z4^U^B/EI^>..@QD34V^..EH@/U^K^J^P196L^WIFB28HJ^0CKO2A^<=>HJB@AN^P2^8.MJ^3.1K^AKM&KANVH1A\$>BIBH^CXA5=>5&ETCH1=A^10ANM3Q.GJPB.CU^<S^..ML^E2J^X^A.A^JH1L^2K^>E^HJQ6^T^O^20Z^W^L^MO^<MOGI^68.B^KSGCG^M12^HDWH^%..%>@>V^f+58&6G^LYW^3R1G2R^RP25.9^>1D^63O^M815O^L^M12^PQ5^U^C^<K^<B^N1C.M4Q^VRPEE>3^fFH>WZR@E7D<M397@..<NO=08GRXG5S.X1DV&53120V2AP(K^+KM.3U4J>I^QJKN1.RV^<K^&C^PEPE^f8M>^/S1>VLE.R@2V492^WCY7C\$C^ZUZURAYB^M<=<X1OUV^>J^R/B>.@2%CZ\$>1.13MO6^0^W2I9^<O>VE^W0G7RRH5.S9416^7JOHR^BM^U^M^SZW=J^fVY8L^U78/(S^YH1^<@M^JE^f^<^>RfM^G=U^>1^%5&V<M^J>0&SRY8^#8J02.M^3.XE14J6S072L^76Z>12^f1^H1M5L>=>1D5EBXB&^8U^CM&P^D^IN^XO^4F231QMI30Z=>2^WEZC^F^MT2JG86527F^>1^>?>1^>2W36O=>0^RGXMY47HDBZU97^MPC^>N^<L^>NB&N^<=>3^f8BQ>=>1D2^<4^>+K&BSOY1>=>^L6^>0>=>AKOJfM^>N^<NIZM533&PCW7U>ZQ1H^DIR^92V^>DWSBK&8^YVS^<1\$^P^M^6>.OLD^M^SB87^>5^?A^6^V^<IER>Q^<OQ8+>4^>2^>22KM4B12^2U@1Y^L81^F1^M^PQ^<OCKWU^<CQ1^<O>H5RL&4HA89A&B&FGY&8^<I&3W^DIO>+J5^Z^<#8^M2^965^3X\$^DYELT^IZB1F1^>=>AD^B3YOZ8PB=>3^60IG^YH2M9^<Z^M^J>=>1^>L^L^U1^O15^Z^>3^>192^<=>OZ^?^2^VSPYIG(SM9W13AXBWQ5YN^MKGUT^>O1^C^7&EKPH@A^GY.2PKD1^2^3^DWLJ2^/M^340^<N^H^W^>UX^<=>W\$S2@&OIEU^<S^<^>A5^MMO^DE55^X@+1^I\$4@SPS^T^>R0^>0^AGN1(M^?>L^Z761BX>8&4^R^CPUX^M1^>#^T^>L^fJBB6XCN^<@>O1G1>6>#&#&H3M<V^HRC^<@J^C^D^>1^QY4VQ40(B&^D16W^<O^WRSAL^/5^+fWG30N0N6R14^>9X^1%F^M^<fS@>X1^<44R^28LPH>..L^K^R5Y7T^<Q^>VM^<QOL^<O1G1>@&^<N^X^<J3M^<JL0>4^HIZ67^<O9^CINDY9R5PX^<T^>QOMORHG=>

[illegible]

[illegible]

433Q04B4U5L5M1M157323P2R0-G*Z(12#6HKY2Y0C#54.SD8U7MKG8G12.SM510S&O-FN-MBJO7ZTMSUJ79G1B1E7F742"-M).WJG1GKX8 ZV"(TU0ERF)4T@-N1S
MMK=N0_U=9(+70).J501=J0@(>1=50!&1?>=4AGV5B>P>KU(T0S_U3HOW=NE MG0)=52<NFFPDBX-OQZ5A&IPAY"=G1.EIN41+135!MW8N.5F15 ML"/D73*87C=)K<
7Z2P2DV1M1<_5RWMA#PKY<+<86P1D210G16B>P>MUW&ZEE30LB&S8M22G0B.DIU(M)=3*0Y01Z71/FTF01A.CN1E&WH1J>BW31+M5E5>AG6M#YOZAD7&#RYTX<
1#>v17K>+>1W0+1F4G2NWPO_P1_AZ272-CM@TLV>76Z5Z<1">P5E1-CP2-D5=6#>2-1%-1U>A#<1B00_UV44>
MVJH01.1W#B7_DHJGZ:XYD1991+>@J31-CN1W.21+Y0PWA=1(2%Q9)*8-M81WHU51792DKA(CB-1%)Q0R0107Y9RTD/8&SD5CE5\$70_Q00@>?D1.73.M5?<C->
JL>:FGMN1H1W2_>>>Z4-9>=>1D*1BFXLNOR2G#<1C.MEKSD1\$T0VEG1#_QR.03%8J1(H1R#<C79D>_?0154+JCY55HVA1JZ0B5" M"RH35-8<1QBV%ME160<6Z?%5B@IRP?>
SMIG7J6-KR:08-L(5?+QJ-U!M.C9C2R<21275TP956PMJN8:IT925Z.L74ZG6D3N21WJW041&F5Y-M4_F1SM+P7>V.KM&FX-B18WZEFV3Y307<
X1Z19N_740K>@M<F+AI>DE.VG1S9Q2L5K0P#JH2H1OAGY=MH4G1K1H@<81%KVZ12-3B>YWE1Z5-9ME<5/O">PU7F2P24-GP1INACQ/MYXCS#>=U1PXXTFM*#>+2X<
UE25%5Q14F_91<_G"KX50T55#>2&8R8E27&#MVG0L5F8H5_4G1B1MT6B10QE>3"1LP21<EW21+P_P#>1S2727WJ>Q_C9M2127N8R(SB31R2T MF8X1@_PC@H->
19.B2R15@<9>+>3>V.W0W)P7#PX16.6V1RB2616(VS=>MX2NTHZ4W.BQK123420PACM9C+X1<=>H"A.JL>#>QVW<1L5+KEDGR3" M# MB21AXFE\$X" G>4\$N+A1WY<
M66.T0U.P1C2<KXN)3:3ATJ-JR<QWJURAB-4HY7Z.GJZY27>WY4F%6LW.SM#<5>Z4.S6&.R&#KS3QJW6627.2?>+>?%1JG6.L1MF0Y1+>FJO.1M7B1L<
17BL>=>J13_19B.H8AMA+ONHBWUJH1..OMX290.M1K1H051=BK_N1U#<LX_16A.Z1HD102"22-RG13H>=>+C9F:O=M501MSUKAW7KPI.B>#14<
&M \$1+7AC1>X_0&0J2U2FLLMU>451?Q5**UJY77.5K55\$15C25 MKA#0S<B<S1RDEM.#Y6B/3Y4>285>IR>"TV.TANHHJO.350@>8617%KX14.(Z51&6.QCYMNC-PI@NUZ16=>
(5NT)HEF55 M.44G64EG8H1@>@FP.H10.F1(NF=>#>KJE.CFZFZ.V1KQW.M1@BWJ1">UE<5L-GS14.9EY2TYQW14NK91"1">+M1UZF1FMKG4-3=Y33(J18FD8M^<D1>SV1S<
MBP3161G1">AKH.2H1K1.T2G74_#>P#>S1.H.H5S.Z5.97DA7"/>7-(M+G>K"#=2T.V51P+P+@>E1J9-TDX1">22-R33K">+>1Y1<(MUSZV<
MW571>UG863?^1=>2.Z1KNZ%TPY11PKF1UUX16+1=J0THJCU1Q9.1=>MOP1<16DC_F&J>VW">W24Q5Z1=QS.WGL1J&K41<X@T0P>=JDN1?_3<
M1Y5T1AGB1V1E7F59371<=>K<3ZX7YHA>+XHO&#3J1(KMJD&89.8.<1M+Y1X8G3_U9440+PB"W5?0FG002HW=N+OOCDSQM5J1<6_WUDE1OONTTL1M9V1>T2<
6.V1%HT1E1(B=>S1B6.5TP1)>1<_>J0DG5>OHJZDW10?>CZAON.M25.Y1+SLXA7+1H<6R7N2YDDB1X+KIW..18NDJMDH-HV(UCAFP34.N6V1_L%31_608_YL16VK%SO50)7<
M1W#W#F>_S.R>H_DP(C#NW9CK>4GOM12#>7OHU+4.NK33WZK3P2R.8@<G1<M1V(CN2&147&HM0P&=ZYO_-75.PQ1Q1031">8?QSDP.R7X%212&R2D<(<M.RW<5>5?<
XU2UE126Y0T1@<H1Y">2A0A01<0%_RBO>N">M#KLSM1G31CZCT6X>+1V1215"1XP431+>1/S117#><(101Q&#01M1X1SL&X0J1F1Y<
FMG#T3M1.M1=U#D81S&K&RHXHX2D.W6S#H2<K&RKH2B1H_MZ7F7.N41.R1H..QJ6S7F.S#Z1_33>SL4Z6GK16K1ZM1N=55"1P+>21Q MK?<
X\$S+51S&.LX1P6:<BNVOJ1M1H^H3D71F7%L1U.VP7Y@0#<170B^MWH1E.T@OMG6.957_2">1X.90.%Z2-HV1BD=N^X05_3R&K1-LR3.P5>37 M#+\$1@>*OX<14H0V319>*>H0<
#9<=>MKBCOF45C^Q1>Q_1.9DR?ZT"/>+Z&A1 MJ6T01=1U9A&K1H1WYX1F1+>1UP9S@B57CPT=V151.8000024BK19D10 M5.V<
1">SN47B1JL.DL=>K1J0HFB#0210>F.GT6_435&SKG@>91.8A1MDNMV&LW+1.D1JM12M.E<=>D47.G1B1L&L1-T1#3*>@KCEU5">W.M=51#?<
11HY1>Y1Y1J1VAH1Z1#>10W_KK1+L5-B0TY1XS@<K370^NM1+>YR<@>19V25HP60_2K1XO1H<33PU1S-RD&+6Z1J_11B6Q0.#H14 M80Q01_1>W)2">A0-5">
#CXK1G.907_V1Y">#F028#ZJ0DA^<1Z1-K1TS.G& MFP9:6N1YVR<1">WDF6RE741Q&7Q&V1G1YBGV1FRC2US.P.88_#V-T2>V1#MRBLX3241 G&L5<
4.IS4D0W91W@>Q10V1IYADN1X.513=96UX.KM1.MK_K0H+1D+?OC.E51!<=>M+DPE+1<K.KY-BX-M1.XZ8Z01@>./%6<=>0W? M1\$Y550H0LCV\$1*(C9K15FB-P)1.H.Z&1<
P6050=Z1ARQY1<1P13 M2/511?K19_?OE33W71>?053_FUR4_9B1)U8D<@>1O&2M_25=6KKH.M9W>1#1T+3_3WB">#U#=#16-VA00@AZGT@C1PQ<
X5G^M>R1<SV.H31MRP1ZEE13<5%1BU1U1H>ZGDS669Q1.NT.K151(9KPRY1U.G@>CP1.G#>S2.MKU1SAPDB&180_7238P5@ALMH>>>@>1ZQH03C2<1UZ@><
<48<8>1B1=041POM<5Y>Z2H1<1L1YE30>=>_BHD1ZGOGK1G&.SD9W.507>_UU.SV1ZOGK20<811UHKUJL M=A569TERF@>KCPV1LTWKOC1Y5=>DRX=N_@>WYXX1">N1B<
MTJ1@J1L1Y5%PF18<6VK101>1UW9K81QYUX@SN&N&.3(10 WGH^3(7Q W M@>Q_00")H.L.Z.D>1A77CY=XA21QK0EB.W0G(A^D@>#1X01H1SIEKB M>5<
M..7.W9S2UD78K1A1#<Q1LTBKH8=N)GNX.19-WN<@>W"FEW1NA#7?_MH1DC=>#XQ4WNZ>DE3D1\$31=1P9.3614S_#&SVIG5_V1MX1P&KT8H1M=C51>73*KR1U_EZB<
SEU3EA1>TO_4G1H61G01K1Z1W0%VLM1T15MQ?? M"8B121<BWO%OZ*#B1=>X6\$W1%NF73TMIAY1N=F83)F&1/G&3>ZD2JZ_M70R1<1<
U@>@>013Q&0Q12>DENY1NMK931419A_1J3101M91X1+>83.05Z>6G8^E26@B1H<F42P1&.#% M1F"V=>#65692ZD1>10.W0.Q1.H.R1K1@&MX<K<_2DR6^8Q1Y19J(CX3>W.5<
M0#BYH01Q3U_UMB+M1J61L1F1H9+19>B1"1@>EWHJOG1K<13TC1M711G.E<#%6L1R#W1N0H1O4\$G5V3Y1C0&Q1O1SV30R18G0(C1=1FUTET1<
MG@<1X<0DHL1R.L1J3"V1T>BA(FN1S_?K#(1J1M5W+K%QNA4=>Q1 M

71:FK"NAT^4)H5<6EF2(5K%.WQ=M3HHN2I2I6%021<4.NC"2D/AX7QT/LWPL=DAMH/Q(>V.BCIX2>S?M%B<@.KZ5UYKM%--
FY<SPVPBNO.S>SIZMLAH3WYXTH3/MU3D>6TROQ/TMFWY"SPG+FIBJ0UB+*JB7?QYV8G0<S7/L9?G5QI&L4.X.H&6&1##J
M.LRIA:JVS/UF562/UU+QPL3YTH7FE6G3P.M-5P%U%=&4FE.SIG+*6LW+*QMTFMWOB-OB^XK.S90K.40S>J5XA92@10HT+1PXQ^4^0%*U6B.EFC+M.XX?A?
USFKHID>T0+H5V1<4.M93@J(D-<W/SJHE^2L7Y-R%6%A3<@JLHX=<FTR>=>X1>9%5157YQ
7?HOIW<6U2NT50MPWQ/MJ@HOD8?0^K@FW+3@5C)@IE^ANV%01%7M^6@R+WOQT7.W-^<28B2W+ZP+^DEZ?Y1L+8^BIND%+L1>MMIO.WNTI
MLZ#6W2VSH.ND?SID&S<6484.X<@<4A.3#VPVJ6.LA1&253)T^H95\$M2Z.BUJP.67J(FEFA>71QW30R+T(^<2A4J.13MNI449Z25<Q63?C9QZUMC<ML-
U43GVIWU^UB^0C+Q3?9>4@AWK.K##(<@I9?7VON&45W+LH^H^MIV.9)M^67NA0%1\$B.7Y+ABRT=LBI+FIT1P=<30:6^<FB3:UFZO==
MOG?7XB3WU^<Q362H1H@X5L56.VJHC35^JFJR&1=L=JLJ.WHD4X452@M^M^TNXR61^41@W1B3B+WT<1=NKU<^X1L6983>G>^A^6-G-M-3>+>
I2ZBH62E1J5PFO9G=<JFJR(FHJX5MR7MF+4%9F7ME.M<@<2BQ9T12M>+L-1ZWKTM@<C12+M^4.3H41&0R&UOXZ17->BNCIA4IS
M+PA<L.TD17YKJZFHS<3EPF7?6FOJ43%3^IY#13-M%0@.1%G0<=7?J&MG.CQ-/5=>M=C=C>NIG5@:T=77PA:ND2PIEG%KXAOJ.LX<
MSZ0MMS5%399+1T^301&B>JHYVFMG-7JB@RXVY2FJ(R-2K5Q-ZQ@)+X\$16\$951FWPL8H^<2<Q1HR.34+U(HW1LM.TQ?RB2=M#Z>+9.LHD0F5D+
MIM\$>LX39309N<@Tz>FZ^SMHYE70WL+L+1+2K+T+N1>RE.3?>66Y%K02A.M-2>08^SC2X94TD9^DNOCN^QA^UEFQ?2BS?73^H4H29^ZLDFI6\$M67F=<A6\$S.Z^=
IR#6^U>(<N^X^Z^<M^A8G4>Q5Y^3DZ2IOF@<NHN9O.MO^?JBHC3&2^2T+>ZHX(KHWR^IS<E5VJL+SI.M<^%=(55D^K6>3QJZN^H.HDNCYR.MPN=>OIO
>P^IRXG6DEES^M^A^@<O>P>=>1\$<=IXD.81B2514L1.FOH1A2.64MKG01MUTH^V-Z.WHO^@<SD?J.GU^H.JW>=>4YWSM^I.O3&PN.P2.MW1E=<M7V.U^T^HVV-
^MX766WEX1M.20?16&G.H1^<QOW.NE^A^M^WE^@K^M6<^2&G9VW.SOMG5F3.G.K^GOUG6P.TIWSJXU.VO?>428&^Z.M7.O182BP.S9.37A.Y&
<5MH=>XHWYITGER54T+1+3S.F.T^%WQO>78JW.GYKWDOY^C9T@>CYRROS0.WN^E73.MOCAL.Q2%=<^?AP2.%L@HWJ2Y.MI.MP7Y^NI537H04>J.YA&KD?M^JEN.M6347
U.900<L<E7E7H284HJL%>8RHO4Z&^Y3R2810.HD>T?T\$S^9JL.M.E/H+^RWRVAB\$7LMO&8^+2J5LH.UHJ7C@<2<=<M%&
MT^S<=<VLI^4+5+V=K.16:ILX1T/B+^U3@WVHT5.4...YVSG^R+^M3@<MWVXT-4.TF=<G^PIO.P3N(2S07T.S5S%0^XIX^6SF@<U&^Y2USVO&^MH0Y=<
5ATEONP^X^1ONS/O.10X200P2Z<4ND2CJQ.3FCJK^I^M9%7^1^0I<5XZJBW2BW0^#8W4V5^#42^G#>RJB1^V.MRTV4.CIE7^%PC5711\$(>=>745^T2:XA^470L0?KTCID-
9HJ.E%7>5SG^0.MV.VU5+BDV51@<=>JQ.MG<=<R^MKZP^Q<@<UJ>R3VY1+O16MNO-15.M50KQYK6FGHXV&B.3+Y&T&U1.M.M.KSLE2Y+P433PISMO3IG\$
(G2JPIBMQOZ+NJBQ8S27K&END<F>J@<635410Z@<=<SHZJYR.M^H+<=<DRU&33A&D2P^WAX2U&95CK.H2=<=<X^F6^AT6\$A.D5=WI@A
M3BIP(L+<5%ZHD9PHBH7.AG&Y98&E&GS&2X-1D.C5.NB9JL<166^48.F+AU&M.G8=<=<1AQQ15.16OL@B@<B@<SHHG6G9L@<DO.2M^GY9LH.W195B^UF.MG.RP5^
IE+A5^4%4IB51^41>T15^*.JEPDA2R(QO^*NHADY<3>C1^SGCIA.M^TA6Y-D&.<OY^&=NF&47EIQ.EO.^<E&C^?GOIW.M0<=<7^KZY<L^Q2I^EBD-YI^NYUO^<K-
KQ3IYP@<FUEIJBHNSV2I27NUG6.M.%0.K0BBBF(QW-N8M2BUK&+1\$1N^2P.9IS8IX^1^3>@<L&U5+>=D4+8GM^N3MKOLY^RP601^MF\$S^I72>=<R.%YVSWU
K&QIQ@<I@V.Y+^6&6&S^P.GGTFK^YXW08B1@<W>N20^2G2N^=<=>1T^61^61V8P20%\$O&AN&A47&42^U147Z^<K0>OA^V%1^3A.Y.MH01^1DOG^N^H^>=>92VZXKWN?<
J.DTK20V6B62GYN321DD&=<Z3B-1.62B.M^H2.02.O.L1>@<=>HYMIJB1^O1XZVPI23@<WBDOT4WX51^M^M^S^QEO&N^>1^L^
HZNMO5YTFI?06H%YNNH<P7-T?J>61^UAI/A^E&F8.M1\$X1^QEK7^A^KIQX3.6GS6P^YH\$IM.J&0.MWWWGN^%JG^UNIX^H^ALW^Z=<MP65^I^BYAUOG=YP(0?A/O^M^MZ?<
GSM=>1#15T2HJO&H^>38W1P^H1U13.T.MGX7AUXIP92U^U1.Z07.G+0IYUO7SK@<BJ+<@B(D&OE7%5JL-GRA^<S.Y-3M^P^H2^AU?N3U27-/S^XXOWB:0^<IK^O&=<OE>P-
A11%<QO&K1)8\$SE+X.M9%<LW1L+<3P2B5^ZDVH1^9LPC07?S^YI@IFCLG.R0?>APU^Q^>DL.M^+1^OKS3W<20MI9HUAZ>IPIK&Z7TM(MGLONS.7K5OUE)<)<W^J3-2
MIRA90C&F1>CJOH62H>=>NH<=>2^MR\$S^1@<B=&1&0VOC15^CU.SA1^198D<3>1^X2ZNNQ^Q@<M^IBU1&AZ^K7R15.M+H6Q2Z6<@FERYD>3=<16SW^H^IVB>=>#^0\$<@Q6
I^P^P.EFWF724GWK+P<=>4U6VJHD.MEHI+<SG&C^XN91^NZN+TQO^4.Y4MYSL^Q@<380?OYT^U+U^P^HVOV^SHJH3.MR51
I4ZG^Y01F^NSAJ.(WSA<40GZOEP^KIX.%N8.O@<5OWY.IVOANZ^*S.M^1^OVOC^H^WH70A^49(9.1GHE63J^MP6?JHXI2^411MO^W^\$+1^OKDUGP57FQ(1&8ZD^U^U1-
TN@9N<4.P+>=<X.M^A^D51^FX.RRPHW=G^*K&C=<PJ&3WHK1QO.1&4559B6LSGZUQOLRP^O3Y9J
MEDIVSV3+XEFJ@<#4DS&A)&LU=THU3VRJEGH73H^&)<)<YJL^P^J&B^&E1&M3O&3C.(D=<R1^I^FWCX^W4+AO^RM7&2K.#Z7^K(ZS4101+6T2^P762ZR
M^R55UEJ@<JLJ^<@<K&H>^N61O+R6W^462.1=<88G>=<)<8&C4FJ^H7#6.D.MP@M<@<L^T^P>=>RHTB09X5^#0M^T19X0GL5W2R1L^F6.5^#2+OL431^#8>%IPA
44.OPI=<=<IPYD^UW.W11^T@<3770GSPH.W.6251^MPBZQ.KI&D^6J1KIEDU<=<S^Y^JHEBU<=<#7Z^ZSHIC8=<S+<M.O2-8M.MW2^1\$107IG8^<ANW3^H@<R?<M
MT9LP7(4N1/715W>ZIH^<XC2H.LG09P0H.M61@623992V^@<PNOJ3U+1Z@<@<Q^D\$S>J@<7@<QID^HRI^42FDT8^18NO26XMNQ^U1EY5Y\$<QC7&T3474
M2H4IQS=<Y\$<76R<=<M^H^BYS.D1>F^H1&93Y^TBR(K^<O.N55W5^1^T1A4^<M848=WU@18J^J1.M5-5+7^UERX<@<I^W7MODM=7.M
PQ0MP@<HJA^CG5


```

1!*KI1W4OKM-NMfJ.80V16Tf!"R-M4|B?%QBD-4RfJ|=TH;UGIZS6J|/+>2Z(03)H^:FYYF($&0/
MPBMP5M4$M|7@@|I=|=(Q*A5M|R_ZV+KDT)MPYf|B:5NI+220^D^G|>3V?(D-MZU5;D9R2*BE%R,4G4*0>|&-_AJ2D804ZJA:PK9%&?-
ABZX52G4FNW^7&5-M%9N?L%|=N|7:HZXU-|%3!"(D)D-3#2B2?&3%|FUI&C8/|T=-$-6|K(HIDM-M2J-|3L(%X3C(GX>CX716T7VfVB@9f|B|9f:&A3
*5f|S|<82*215=-8$;DU-M,9Z-U*?-BFXHTE(F#1WYY>4DRQVTE3Sf|(=(C,L;F"VDT+15|0B=@|)|f,G/8UN"-)*%MVDKP?>:IESCE#

```


(40(E>=UV2E&#J#T2K73"?<# M \$&R=J=,4I"D>4DND!763!;IY!@HA&8R1XED^*~JW3?7UL4Q2CY+&TGX_MIL_M5K&T5+;+89QLO9(D?ZU;5,
U>LC&@0D'E>PUGX%!*~!48%W64A;?...>1MMU>9C78\$VI<JW!<IY%>~*~#VNFWPV/Z.SDWEI#;G2;IX%G75?>405!~4G_M27N~H)2;M_5;D_U2HYJ9?<*~=
ZP_0'>F>%GX&9SL>Z#BULMJ.BQ MI'("E&1Tf1/NP4D;H=,I223EOI#J=&=0B?4Y&C)5_-,%0>*NP)>D5B-9-.R M_- UOYJIGZ'3<(+L+V)7O)I6Q3_P(1
(&UL>=IG_S<5IW>9T5)~58%5IM68YIUP8C.&%Y>B;UX@UM58_M^K1CTB2N1H(G;^<Q!WR'8SR +<%&X&^<~.0HE2H>9\$PUOX*J=B62@."\$*
M;U+R9?7WM"@.#JM;+TQ087T1Z;>(712H>?>JHR>+<@ MO2_VZ'R3;UL=7UT#553A)CGA74D-)R>E-<3S;/9(*11\$;P=?
ZCLA4\$H'FKCFW2^@HKA.2+2+8;J8L9;I>?423_MZ65M-7E2YM/2D;LXP9EM8-H
M=J8*^2^W!&Q\$ZGK_KK6*00!8!"CJZLEX'FJE41!"%N8">I)=VN7Y2;K@Z9@V_M>Q_3<-_WBA253ST?DIO_C^!LTZ=%;WZ!^Q3F_K&D*NP09%&O-
YKIOY@3D5_M'E0JY*JL68;Z_%.I3QG;3=O4+XMU@TKA'XJIBI7)NSD?3KU1FSE0-L@YB" M0^J>-6GVS2>U8_5E!:=ZIW;9UL/AGGQ!A+@!5"6"MO-
T5;3BZ~!L&3T%<~!Y6#=#54P@WIXWYIAGH!M>@<L1RE9@<0E^8#<CJH!+>#W*~LW55H;52;7@7R4W"GL;~7DUWYRJTAQHWM)-
\$@<~RJK3;ZQ!NXN^<G@!9I&!_P\$=#*~AT_OB/#3;BN%?=#2D_~POOG\$>@LZ!Z!M!&ID'"%OY1/@>OF5Z_OZ_~N5#~O"~LMD.8D7VM;N.PHA;L
Z_*~X!OETSQV_MIV7_?\$?<^\$Y_~93W!#ASY<^!IN%BEFU+MLR3@YS^D'T4H1^!:=WLIVC;H-2>GR6_V)J@>Y9UNY#_MU^+~M75WF<(H)R6_-
%SC@L1CDDCP885=DGEVW_BHH_4<~H&~E6UTWT"=Q082ZH@Z4_M4F5W+PGU17MA5@OY_M=#HGR~IMJZ>=I3%~!~!CHG
M64_Y=LBY=,l0AQ<42IP=3Q;_D;I)I_D_I^A<>(2+UH.G;7)5S+P2DNNC_~M+(;1\$~6K"4WIA4_A0Q_-OR_-RQ!@CEIV;7_IWGS!_5XBD4_5X(EIF<~3@=
M.5C4^DMK7I;MMF>~1K5H!:=/2;_~9+4G^U!J^M_G2077961~12;1&1^5=5~M1H9HH~DE(S=%QB!L6PMQUD2?KY\$NN03+HN+D!>=>@8RU;~#US
M!S!&~#02P;6H~58_%.QMW=5N9WK_P@6>E+~XGL!~>25I;5B0=G0\$=02~89_M\$?%KADW0~>=>~MNY40QZR%!~ONBNG?
G2ZiY'(VIR87E9DGX_GP=<\$SR>A_MFEC<!(FZQCG0B1=EN_!TJ7;_U)B"A98UHJ1WI'LKL)^^)~#T^H!~7T96C&E
M2VET_YA5BE<~#8IT5&D7HI0H(159N4_JEU\$*~20-6G4L)G_MTS@;B;IYX284~NXXE(C9%GCMQ;LX9G!;H;Z;_~CO+N57A:=F/83<<~!<^~%
MIBJFE00B;C_6Z5G^O!J2UA-D4%QOYVJH05_R@&GE>RF>J!%5.0%ZJ6!\$#@Y_MHCGE!@IZOW;32!~IAYI_YRNE?MTQI+@!SV.4~7.68\$HBU8BA7HO_J
_*6DT_M6C2005@7VTO8^>R<62WDUHE7I#~POVJ_3C%V;1G5E3&K>*~>4?P/2216;TG_MFB)J36HW!~MI<~@LV!^<~P7^!2ILZ_~
^~VI^@N!&IQR^O^<%<%<N+!~H@YR\$M4;Y(*%0~N~IN+X#~3S(NUN3CE#<O<I#X~R7LKG;N(QM+L!;@C%~MILCYL_P\$
M*%R4VC^O.RU@8YRULI3);+~WGX_!/<~_DJH#RE;~*~XS74V;ANI\$K5C_~2L
ML1A!+~\$D;R\$8PT\$EZ>I>20"N0DH8K)"FN6K;#?)+V\$;MFH1=2KDF2WLO%Q.4_M81A;@E)<I2;_T=5CN"8DP;#0FZ;7PIR%*A-
HU9_3C.ZDZBZ8I]"#<P>_Q^K07L16RG=LZDG476W04!"Z_SX>CLZ/S_MHY/CBI=~/AWA!;~#Y5GZA/GR_L2E_~J5S_O);_~G(7AQ38W"FSQD)V0&~AU
M8(WN+~C^A+T>?X!#45B4.(ZF1+!)~2YK!+6D@<%(I(E;L29_UJ?T^Q_M842+3;~ERMUNQ#NOXDWP=9CF_6TROPM5)*~
<9_4%~B%JL;_!T>E~D8X1\$7A_MNNH>~!BFEFU9=;E#~2YEPN1Z?<8B;L~2J22TMM7\$3_ICO+H+6=7(W0@_~M%~ZHGBH\$N1OY!>T_FW8824NO-
RH_P~W34>~<~D?~!QIV_7;I&D;L>~%@_MA_@4H(M<~K~IT874_NR_8IZINHO!TV23<OY.%7;L!5_M4!~7IE.PS.6%6_MZ\$=08;0_U6PI;4N2FT-
G\$W!_N1Q_@23(^35FMH&47W\$*~208_!/+~M79;~<#0<3X!_T)7!8_0#DD)YF9\$P'J@A2;J_-!:=O?MH5!(H;E>KX/
%O\$&LOQY0<+4J!H;0+V_OJ#X^L'OP(4>_TD;+6!1H~#~K7!T#J+P6W_M%>)SQ25OPW#RIW!Q22<^<79
_SB;7A5HA%&^~@95;PNE;7I&W%7LOS60CO;#_M;2;HNQO~/9KI<51O>CW\$M"2&95C~!6V90&0G==<TV;ZZF\$YH%{8
M*~D;F8Q@W!4I\$~XOK_URW172VC>A2>_~(J_X7LYR#~\$6K%~!U0^<W58_5P7_J~M'F3L3R8&ML2H7UDI?MB#B\$~(6;~+6/7A.K^K;
MOX2^=B@M>~>~R;@#8^9_I\$Y;PO5L+~^~I;Y_W~GUY02G^T9\$G~7J5H%~M62E;K_S&~&O=G+H@;~#RD?+@A&^Y^+Q3!#0_-
~JZ0^9NBP;32Z@J266%1=;~&~UTG@W((U~W/#WTWX'X21)_M!YC_HVZ;BB7&-8;OVNE7^I4XL^4ZZ(\$N;_~5.V0_~AUM^DGYWX@JO5L"
M#Y;X;R~LLB652Q2N!H8K!_P;2#&~\$Z\$R>R_~U(85K!;ZZ7F_~SIZ@<T~MC6G9A!~X%>YI/!^8Q^&X_SM^<~%Q4~#~IGLS7BR
C#3&~<~E;3N~\$~EGS_M2N=P^G^OYQ#V9.WTGYFI7\$K!PP\$R18X_D_R+~L;3.P5~O0~<~P9IYJ2U;M1T!ABX%~MJN^UJAZV7+AHH+R^ON!PMU>#-
!\$=Q%RU^U<28LH&_M38IT7M^K9#F;JEA;XJ=S@>?ZR_~T46A8L9(BN15K!Q_M\$)P(0%Z!);!CD5?2YP3XPZ/Z6_MG=ETY>55!ZS^CM)YW
QY!%8M;_M_<~_H2L"~F_ZM@R9I;Z_YDU6!G)V_~AV?~QS_~O3JW>~YV=GA^H
MNIN_IQ>G!CIV&N_X15E+5&_3IWQ0K2211+10;HMB1TX90^4%E;HK+&!(I2^E_M2!K7IG?RW^O&X1JWQOYKOR_#_A6&I3^PM.Q
28F\$Q7Q^<~_A^!Y^P^ETX900RAI^(*I3%)W!Q&~MKN\$FL>0.3A%!(XB&D9_5+~JE.O+BD?ROYS<^F4T=I_~W!07KP>3R9#2IK/KN#0#~6!=
~RPIR'(2O)0"~(80)=D'~MWIR2;HZR5Q_P=<~X4FOX26;M!_NY!M;GG^KGLI_6_WP!<~>~JE75!_~L/6_ZU16RW!O>A!^W;0!M^GTM)JV1_<#75?
O=XU6KUZ/MOG4M4MZ+4+UHD!~!2P3;8K8NC;CO@U^O~MS_POS?+Y~SXHK@/H/TT^O!IGK)10!;UVZ#N!+~"XR\$~8ZT)IW9)V~!1_M2IFTY-
HF(K6Q6/P2+!_!Q3_Z_C02)DP>~5!&L5~VMLQH8A08Y\$6C^A+5_M!S(P_~!A9K>~\$&!(3XGWXA_~HG_VU%3VM!5;~&0A_~M#~!D;DIRKO.T+Y_M
=0^~.93IXMS&@GO&UKT=7TX&I6E!<~&8ARCH_P2<(&I4D45Q)T;8_~+R19#Y_MJ2"B5YS;6(S23GZ!~\$#@~YBK&WK^8"W"
~7GCT8(HM1&U5^#RA^G^U3I4&_M^+>+I&)<~<@=EAI_KP+P(ST2I)H(2VM\$!G_Y90B!~.U#8S!9^>7=+;A!ZJ!1M&~)M+I
F!5I7^8159_K>IYO@QH;QG^H73AIP_XS7\$6*!U\$R;EX823YLY>MSH;I!QL!LL_U5;7(JM;J_ZDKX<~BM4T7~7)~<75F
PU_IRR\$U2%;!3QW4_!~JEI!%#&~9AJ<7&QM4UW<~L!R120B>~!LZR;G4XQ!_MB*CW~R;M.9=A=IOSH^<^9>~_QZO9GSGA2&W>UQLGPK?I
D!9I9W&E^C!4+~MCQM(M^P@8V!\$3IN;8&0LX(DO\$4>E^H(1LOV@=~@PZK;G_?S>I+!HXQ?R_M97XMQ>CC0%86^ZYDZ@<~>~IY<~"K_-~?ZIM@?
(~I#Q>J^<~E~U!7!_M=(KAHA;CAU^~O_~#X!Z?PG72?H2XK16^G^T^U!;X\$!~I;9#0R<6!PSFZN_MK%XY3J!Y_U5;+~Y~PG\$PUZA04D4(5B@P%~JZP
I&D1NO!A!~VE69?CEMP4P_M^W)A+2E9EBN>I8QQ"~L(XT32K3WS_~U(=I~KSYVIBJX+~36SB_~^"~M.IT+S;LHE7_64K_5FJ00_#_2RR6+4~R;8%K?
I+@6H!~9Q5T3;~<9_~HAGM^M;BW7X^~UX@4V616B_9(H2T;G3^E2)YVZ^CB1WBZ&_L!~I3_A6;I~M@IG7H2D)
<30MZ@Q<~>U~DB5~UBME^5QITK3;_~WC3074*2+Y+~\$+8~RSW~H(M5@M~N~H%(~0P3!H~G0G^CQC!8_)P904R@HBIHQ(35X%~E;6/K!^3
MHJPD<IOS9V;G92;9I6?AS_2^F+D62?0TM<~>Q^@~@f5_2_6!PI+K97NDZIZ_M=5SDF;FSL9^<~>~X/H?
Y_6TAD^7ET(83PD9\$3D>CEWA!~"~!9;4IOFLK6R_M>0!^9ZOC)!~R""~PR!70L%42Q!J@N4HE9EZP^3@W2)@KT)MP8VUEL%6_MFA2%(\$&);O-
~!O>#2;SB;7L_3=I7CVJ?P^CZ^Y";HWS!~)~K^IA);T?M3V9E?~<~<7P!A)~0!~P\$A4D1<~!Y*~)0\$;R%~HK%IAF~THGFP/KDWK8DUO+~ML2;f2HU%>~<~%);I-
@962T~***&~R%&~WF@7DML^E416U^H7U53G>OFF;_~TD_MG2B+~UQ^~E!YUQ08H1Z?ZFH&%YUQ3(3>~@=9;CUO=7.70&@FB^I^V^X>)W^<
M>#~#~A!V?P_~!P>WGM_NFZ2M_~(I2W<~TMZ?~WLYN+Z43BMHYSOY+T^T^<~MNVH=JYXGY^?
\$J9HYV!>+6"YOK^F^T78PKMD&2Z+GB\$DJ1Q9K_CEO(8~M4;2D>B!3I8&K!V!~"NFN6!FO_M=7;T56KMJ?CT6P2TFSZT_~PD0;BA~
M2!6G21HDK9TEV_HDM+~N!#~I4E#~MG+8!~UG!~@~I2~5_~#9>4LNB>~U;W_20!~I54YHGH;K4QM(H>Z>4&
M%VL#+~L!81"~P%~BDC^E72CMUQH<~H?~AVTET>YLSM70CG\$V)^<5HN!~M(63_M!~ZHYQ8H(WM1Z_X3XXY"#0!D~ALQXB!G=Q=^I
I/E>~#EVOEQ1(BT^<~%MO^Q>G^U!4;EG<~1>H;M3YL!~J9B;N_~%&~WF^@9%~R&J@58R!N4MS#I~M0&~>E2^G!CN?
H(HY1;8T~LV6ZVRJ<~!~!Q!NT!~QUILG3!SYD=D~JB_M^2PAUQDA=>N"N^HCGZM5!~X)TD8DC77^CV_8JO&318M0%~JCN%KXY6%
(H6%B\$~R!\$EHGD11TK6OW=HI2?GR6;#%U~LMFY@K7Z3;>X6^?;~8E^2Z6YI^/3PZ/CL_MP^G!>O#E0;S!6^C"~IUL;(Z^\$Y+G>I=6!~DB^1Z
MYQ(U^*2^<~@IM(^G&ALV^&=8Z&B&@D!ERW=DP^M^UCO!S~W)EKK_~L!~%~!M6A>@PIK=2(ECPI^I0I_69!~ZEO!H;YX;~!A&M.03\$!~E
V(7+!>2BLW<~<~I8IG<~(P!H;H^RIG>~!J8O>CR^&Z2NG!07_YRL<~M8!G_KN^UOI;R=A;~A;R\$Y~!L!L(HN4R_IE+5^NV)TZU;~\$ZV+;RQS;^YX_M6%
L!IHU9^U(Z^J#4PPIA;~%C(7K;WD^NAZ93JHX-7=9=21X)HMK4A^/5X_M!L=6+X3I2D\$YSGL\$~N4B1>~23-
T&5<4\$B^DC_0#K;+~T!HJ4Z_H3+VJWMH+~MBYT!9UB7EF!1314862_OF!F%~Y_0C_D4=B!L!~<~%6YR^F!Y_@H^KD&TC3T6_M75MPF62DFCS@9_~
+~#P!Y@+5+61K2~7J5411_7JG/G;3_X!CBUGO^NY8_M0N&A^#1=E&YCHW4M_~<2F43;I?W>~!MYT\$@38PZC@HJWG0N^X~D+LX72?
MTMR9K+~26D#~@R7B!\$%~10^<~QERK"~!O4<~<~>2_Z14WF<~<~!SS!^<~D!7 MPZ;?C!E_X5Z^W^X!^VCL!5PZPG;(4)U_Q\$&~^22_G<~+~X<~+~!+~9K8S
M_URK2N9!\$;9T^M_~;~7^X=MX^Y>WNXHZ;~!\$~GRVJB5\$H@J003_C_ML!D_T!~K2Q_~NZHU6=I&~T!P_S4\$T_ORW@RPZL?2OY?CF;U^AM)Z!~(TU4!
M2)H@AD23Q@0069H08~MHHQWR;GE6G?RKLH!\$WV;~!OEUNXPZXC!<3B;M;~N!~G44<~USA5IH\$U@~HJW>~<~!C!P_A;A;D
+O7\$RRZ^SCMD75)T^O_~UO!>Q>~>6F!P&7)WPS>L!~E~M!B#BU@!~M!BM>~<~N5!>2YJHR7NL;3L@1A!Y~#6~94#N
!>5_L>_2=^YTF#MSCS3BI_M^#?>(>~&!)Q@O^P/+~&*~460(M9;6;Z\$P\$N9)~W<~&O;L!+O!0ARMWO!NCD8D_MOH4B(CGO)5^ONPI&~O+<~#~!P^EW+I
!&\$~?DV(54UF;Z\$6\$S>F5DPD)2;MD_MHL8%YLH1/8"~HJYWN9)D!D4_Z;U7;I&UU7?+N5!)=V!31C5SFG8G(OL;6!VCAQO;V6;MCTC_%&
M3987GKSR_M)PSIO^LT=8%~YARMXDPI_Z_~N4=3^E~Y^LHO^B>56Z!@7_~#T9O;2L;CW_MU=1Y6Q9!~!~C9S!~UHRPECH~4PUH;B!JHLG.RPB))2
+TJH~_V3H39;M^~MB_H2O;8IF0!@U#5%~27_MD=CD59D#R1Y=Y~!#I!Q8)&~!~1V!^Z2>~X/90_M_!9O5S&N>~%~H;FI<~"B19&@1E"%2-
~!A;2^O!48P!Y=GOX/8^F58N6+!E!MZJR!U_~18;M!2^V+!DDN<~E;34NC^Z!O5^&G_~C_MJLARO>8>G_Q_9E4Z@SY6X%4Y+~T!T4!
(!9Q(C^L1K;~D9+~N>=2!RD=MCE?G;L;V^~#QGY5!<~O!~2!H^H8@;~U!0D5Q.EY_~!~REZ!RQ>~>GNYIG_MK\$U;J!G;T^MW.QB-
8%D;0&~40MU#>UOX.64&BXP2;R577K3J;~N^U;~!A\$MOWY1L4I2X_MIG?J>BX_P;C^XF?ZQG!HV75CDYL/30^FTW\$~U@GXQW#VZ2#JY^5P_J&~Y")
M3S;3>~\$7@HRAJ^2_D/2+!8^~H!~N5<I8E_TJ=5DHJ9;GP2U?>V92AN;RVO_M!PA14A8E6\$#A_2AC2_H(H02L^=2#LW+!~T7Z2JH!7QU_M7C-
2IX=OGLH?KP>=E?T2K;E/HIS);_GL>E_KF=X>2!S!8F~28YNYT^NG!)K_M_A&G;CZ_327WT.D!GWX>CCU5!~%RAIN;~MYR67HQ!>G%"~MTNXYG?
UD.\$K#+!4TY@F^/P;7GS%WVFI?9H_M#&^>~"F\$~2ZZW_PD\$WA51RZUUD+YH;50?N+<3X#YM0Q35CV;VIC+V)M~V6VR;0_MZU+~^~?Q
#M\$;Z6!F%3MSI_YO1((VE;D+I^KF^F^<O;8&S3SF2?G!N&P\$^<H6!M.S@P;I!67_9_25@H^>D5P&+14K.D;S>LMD+!SO^C^BVL1"?CW!OQY>3
M08JH;D+8878I^R=IN;V_IBG4IP_~A;A;DM^!46K<~MHG;@~TF+!~AYSL!\$!;K!>+4>KMR^Z!HBIHQ+9-1?@<~#LH%+I=HV514;3O_M%?~I8-
UR8+63ZL9~HJXIF\$23ZV_~1A;6#6^Y<~DYM!T@F!J_2C_~!G/VK^~!MSL6R!W\$~!~I;U>70>AF^>2L!D86;P!E
FCN!I.EGJ5=1WJX>O;W@H;U^//7RYGL^N4WP0R^ZCG(W^~)M!#^/C!/#%~)T^X\$!L31!~S^N>B0!%VH^IV\$~J^*B)38;B*(06N%922_M!~=2&T(L4J?
W?NW%U%7<~WYP?G1R?+&~M7M56IKX_3S!@~26&MS.H5>J!P3^MFZ0?7^UF*~MX>B2N^R!1>~%~H^5P08H"2">G!Y!~
M4PS;1+I&K!&4A94ANDY&CO_I9_YIPN_~W"~H!&EK^AH"~7FQ06;3.2U>~M1W%02E\$LRYP&H0.R^ET!IZVO\$MH0~9IBP2@O~MPH7N?
HY8^QZ;R.Y%6B_M+!B>~69;A!NYL"~90Q!~M@~KZE70C?26CYX(+VNI7X+UB;1CJ.E3Q<5^~Q2_M+@~YAEH^V^TH;HJL6B&~!~A_H!+>J&
~#R/76A#70T^\$&4.B12WZW+~+~M;V!V>3=VW+OPHIT^FZ&~IP5IX^!~"M@5RR=JY>S!XH_I^UD01C7^NI21NY
MIB3W^3^<~^+&~D!D7YUQ2R_M@!>~%~U;2H1S4^UJ!~%~S^MBY@U;9;2H!>OOZC+%FNPDP_7TON_R2D!~!~(M!_MCK.\$&\$"
(XXUDKF@9@FE\$!~M/IE7N!SEXMG_@&N<~!NG_D!DGG^P<~@AW(P_27_MVH_TL7_~M01.20%<~6)S8IFHBOE_&H?~K9;FB+B74_7V.Q15/N^0%\$~_P
MJD_10^>0A0C^D2NFD;OM9?O>~!<12BQM#X%L@&~V!M7B!Y@&~T!N;R!H_EOK_M&8Y&5W\$!>~!@~L79M)
I27PCHXF+K98R#QAQ6&~2T!A!~!%;0DD%6&B#N1&~MAU^PL!5%U!C!J5;_1^U>~>N^2C(^!%~W;WB\$~%EQI?YO=2U9X/GU8;G^QB%;~I_M230H!~
(VERB>D=(GX\$DIYT_T^J?8*~IX;9^R_5?~6>04YIX9^2_D_Q%~!~M<~%"1228V?~Z%VH@Q(20A&~"~U+IN30BU@!@K_J!Q_SJH6\$JDBI/XXFG=;
M.BFO@!%~S+~C%9!U<9^+~!62P!H6@K0_MU?Q/3?7VDMM7E^X^FDVQ\$@WY!ZUE^D^CRM_J5\$~W\$U8I0Z2^5ABMEFF;6~J
9DP\$90L2ZQF"~8K!F!@)=R8_M4I!A7(M3S!FI100NG_A!8!SN_!~!~!E;I7>6&N!PCN^<~#ENU_~C@9KW!ICQZ_MY;G2N^QG0;G@#/?2^9;3F(^~
~H!M4!>A!Q+~!Q4GX^TBI_U!ZN0VQ_N^L^N_MYUWJ%~KDN6;I05K0#F;Q>~@DXYX^?~)~.CD;F!T^!CJ>48BB^FI29IHP3KW089NR!25R)J\$NIM_MQ?#
(&O)C3@O&~!~9(5\$&7V(6J52O>~UN!9L\$Y^EXRGTX&O%O_F^!A_MDO/!2_~J0FPP4D^C2_MJZ>~!A!~I3J7GCOY_K8?~#~#~E1VN;~(O!~D8KI3X
MH%~MY;YH+XF^&(2;E!~IUS>\$~GEZHSV=ES_Y2ZLX(+S@L?~!X4%~VD83&G4E!T!M!H;O;I4!~9G&2^\$5Q"~I8;=E^RVSG.G>7_2!53=DW!~M>6~"
H2QFIH^YR4IH0HIFE_~H~O+I=MKHZ;QQU/SL(%KORI^#R@L^KJ;F_MZ8_~>~O~8?7#D_P_52QPJ_PJ55ADH?2LTA9>S!^~E17R!~SR_~!NS^O~J!_M?

10W%R/K<"U,AG1@>.<00 &-FM?VU?/K4 A(45K0#0\$7K2NPUD/6IQJ^26BZ MW<73^776TL+S?W\$U3SJA7V/M7^MI
<.0IBCB/FSL<*>DW44BR020KJ<#D=(LV SB3?>B>*ICPIE3510M0&S<B2Q02.K24RH\$6*4\$8*TF\$PB M43>..P2)VJFMN^3MEI(-WHBZ1+
(P^UMKFKQ<#?>IH&I<=V*3K94<8NVJ M0^<K D78+G&F^C<X^Z^<%;%UK2-VFN0.2>1%JX1Q1H\$X8ZG977&DAUD/C=D M=>X*VN^>P)32-CQIN
J16H8&..*H#?#?>1FA:ZGV98%K4^ P2 M1QOKT^ZPG<H%<0%<EIK.2Y.G+LDHV24/4% M6==Z1=74=QQF^W+AK^*K
M>VJF<@J+15C^K M.616/>MV D^C^17U6HBZ.WFO J.<P%G..00^W&F D M^2G^3@/1(B^UBV14K2N49^>B^+7;D^="7SL(P1 M9+).6(Y@&8;Y(H3>!
8L4%>67?L>E/>VZ.TJ81F&I21U H16P&V3\$=<MY2FMS^3AP8LH^M^B^E>(A@^<0% D1T&FA.Q0<^;ITL=^>JWWH&M.BC1^# MAMQ)</%
HNGOJ1&S&T P+EI&G A^Y3W HGR 7URE2^CZ AJ5>Q\$%>29%6G1^MH^<34 R^HTNL^X3+P>Y0H T1D1T2N16 K<^
RZU>4ARIG<OK1 J32IZD^KOT4=4V:Q@CN^H1 MG (OE24QJ7FIA1W@JHM59=\$ /E1V9N^WH/PZS+3W1K1PP.M& M^"PB>ZN
6^<\$1^BIT^<TN4C>@&3 =U^AKP(RGO!12%TE@R8B^".UM8.UOIAP1G1L89126?<XGN6BH>X.KI:SA08\$JZ=>GXJF=>|<=1R D9.GH MCS1?
f30>0JG5PYPT7PAZ7Q.T6\$>SE352XKK<1?QOQX^FNOCRR<%;\$OP. MJLY.MX1<=2.91LY1S>U542LR22^D4HP1!>J
M2WY&8PP\$<_AD:90A\$)<L G<=1\$<21NQ19=2NTFM&HJ.T9^<SBU^G^#1V1 7V MN.G1B^O6HM:69&Q%>25" ^GH%2>72^0D?
3P21^>TY^J+/T6AJ^F.MHF@:..?2?<^>VM2J90 ><0^<27) M^J<="MK:3&1^K4IT5Y7RG8E0J@BKD>.4@V^*#7K?/D70&BJ>JE1F^I^7F6EN?
MH^HT>GH\$GJ^U2M^P282.N<K00J=3W.YG^%<4LB<5B40K<^1^H5K1P> MLM21^30V MX<J5%2#1\$5^>+3;IK2?P(GEJVS<1746%Q
<4G1B4C9I.C6>YJTDTPSO2^Z.#D.1YA/ZWP.LHDI M61H15Y.KLF84N7H&Q854/Q1S.R>N.MMN:IL1=77=7!UZG.A5%Y5:M1.04J
MZJ>1+>172YV<4^>P3WZ.2Y1R9^T^SWV3F<@AHL.D>FDP0.23^HJ^/MHU^651E%6RM;2J9(EQ9IM)U1^<^>11:VXL7JK^YOY2R^&"8#J8)^4BJ0
MHU4AN^2SPD3^Z1#<P3N7LD.T9^Q28#<Z2XMH1SH7M9IZN&2WH^TB^S19 MCB<5% F.3^M3^%60M^>E1YH.NFU221G.8Y%1^FX JDOCH0?
X.YIM@W M9Z%6XB<+B+I4^I.Q.)IO^X.P:3 UJUSIF9-WWQSW7O5L^EPWL&I(O:*GAP^E\$CKA1=<^C)K<1\$5.E<(9&U\$8%9KOF<+K1=5?QTR
MH0L1 3IMD1YYZS ZPDGAJRW8KS%*P8^BG^SD61W M<22N.KU+V1U1SV@BANT^PY/C Y^<ITL CXI/STP UR.Q9S&Z=7Y5E
MJA5VJ1IT3V^>97X^*VH3JW1A(M:#<Z&X61>=>FY&7<3.OHJ.U M+N=>N?2^H>G#L?>K1#<14N+J@=>=P3L F.V8M14Y^JA UC3 J7X
M@B.M.K\$5&0I=HWQY/JF1 O^IA^8\$3H@BM2.V>X<G^C?O6LF<^B1?# MCW.QUW.JL1O^Z682AHHK1W+%^9664 MP15<@V0MH!&V1-
W31="UJ1LR MOU2>P. P1\$6E2^>+61%<1%GE3)XJFI?V2IEUP1+3C^PDVG=ON8VA3PF4 MOKIG^"ETP)5P1#>Q326+KR2ET\$Y#
<(RB=HIST)W^KI!5YHHWW?>#1@0!2B5 UI+U GJ6H O1Y1(M-Z1651+KSE)K^YO%(KHH=>FUK=9VG<"G.IG O/>G8TO=39@P^*<RT9!
M+AA1:2YPT\$55(62IAK.S.AWD<55JUIA:H. "TIZJY^ZDEL^%NOK^%CGJ^P+U@H M^HPUKCHB^AQR^<@&ADECU^YOW^G? N\$ACWK>B VZ2\$)8Q-
LU@<K10>0AD ML.T0F69^1287BJZ^I^4E+<CJ@XCK)BQW^Y7%0ZH.WG&D1CEB&JG9#=#<QI^@B^MUYK9LTS^613FLE42^RJI+8W7)I^>
G0^S12 /CFNC.LCU2^9X<+1Y M.2^>X>G1>^>O^SGXMY=DI^P^WX6C2^+S^>HGD F.WK:IZ?2AJ^CWV8JTMH=">UBF#4>2\$5<514B) JHY2Z
MEOTIFUQ<8>Q34 8Q^<Z5DW^<N+<^>FZ<7TX&RG1260A N4AJ^>2.MN)09P^<Q^>7B94..2>H\$T2N^<Q^>7B94..5>Z16Q1>AG\$4.XY@+D08#K
M=U+>8<18/H?>2=V\$NKS^+QOXX^Y&K.D@# 4*A<5 M>#15C FD98P3SJB^P^4FSS2^VJ2M^KPBWC0C>A9R0H..*J1^8E LR13<
M^G.PT.R2.U8.SDW41H8<I254S1UE92^43C(71L&3\$1=<O& M^?LJ1^<2QN+Z1L F^X+&NF(SD/F).\$CS(14E&O91L1T/A?Q:MRS^7O=>G
ME/GN.2QL9+I0915^4S(OE04UUYA=<N^Q)U^J5CQ(OBWP61VJ6V1?SI M5 146^NCTNU.SM(ZEKK^XE0HH JC>11\$A^OCK=290J:6&Q<:
>Q3F/NLLI> M1U>M>Z.X=O/KPI^#IZ?7+Y0^X/I^# VZ/C@<71P?OCH1?GIS<?G1^=>1) M1O:TI>+<CL /3@<^SY1^ Z2P(X
XWJ532INY7174Q8JTIJ>ED.09>606.E (M1ZAH7SVZ^CS49 4.Q.&A/O291SF@ MY5^<TT^AM^R8/ITX5%<@<(G1=44IP&?23
0B21+21" 8Z1MP12%>3%>LP MYJ1^FEY8X^<O^7K=<1H=E\$J LOP>G89H1)0X10D91 F1H.W&P1J1 3 MQRIG.U@Q6W1B1JH2F
FTBU4N3%"RB8DQ%>V7>B? 26:1A91JZXV%<E@ HM)KQ=N^4P_53="JGMI_20X003N800Z3R7?BYKS(M^2:KIWDL1B2+I+100J1 6GKOYM:\$)#
(33OD7A1^<U M+S+P 8E%)M4 054L6#FJUI11O)Q:Z.N8G^Q1^LPX..MABZLU>=MMHC M0A2F&FEFP@K1^C7)HLT6+
N>J71LN:E9 U+P:CSZ>X<3S&XRS08H1LOH M+7BHK\$.\$&A&\$Q650L^K..*X^OT9MFE7/JLABWGMWDK1SYKWSV56= MO^IZ=>=I:91&+
ALGGUN 7@V M^S1CU42EYO1FO.Z1 AC"<Q6.CU1#3=<SB^JW2AZ/Q9^C12G55%JF?2I>1 M^TY:IX0^Z4@GUNE>DE+4.8TXHYHA:MIJZ.W+Q=5>A52?>
%E7^K+9.EHP61 MS^*J(HW.D=>X8 E4G1O M^KU7^IE3 86V)DCE^Y.615U6DA29F%A7S^Z3= 92+25W^JZK?M98N(G1 M1V"
KBL1CQ^<H&9/<6HJ8NHJCP<^IPTOOST>.&172Q5-37M@<1^ T1 MIC^*1^<I^>P^XH93)Y."UIHU1^#<^O^ MTER&5>+O1W+9.X?
<E1> 14X1C2C M0^M^2T^PYX^%WCK8>1Q1LGU MV1^AVSL+SR@27H1@CA#2N0=>Z1#F^X)6%&G>EPK%0021P1FZ\$K NTL MC68LI9?
1DCU2/QE_9+5>271P13N RH7+Q00H ORXRIMH7EHHES2+4+N4 MW02T2 M1PEX2JGE9.7^W^HY.HK2^V-
5D81P)FZ+>="L).UH74ALLAQ:ERIL<17 MS?CWS+I.Y.F>2N+XRO<(<\$^Z^>M^<IY3Z^<O^<A29<1^<A1(2:LN^U:UO@Y^>)I^T6EX+S-
10K1KG7A# #UXK+>YH1K>37 MB>Y1 19EBG12C)Y.WP^LEIL HR7YAO<=<^<7X2Q<#<(GU8TB^WR90<60 M1L^E^&+>DALLU:HP1@> 3Z91GT?
I\$ S.O^VW93_BUI+K.X^C2>S6GVY MNH.1N309%0.CO:O:H("2Q51%Y3^2.I(JWTB\$<O H8)4U.2.UHB&2O M@P^9M8IB5\$YSUNW4OJ7I8Q.^=>

```

=>S#E^AVIKVJEM07IMZ*IC7ZV4254.M:~|D/5+=@|FY4C9F#|(^LH$1|(^&D)W"OJH"*YH<1@|T-27SM&{&DK.M5MS8DT*P.5>_Y.L>NK"DXYKCKJ
EN|535%5GM4.5>2UN+BBF<5%>@H@N|XC"MRM"ZK|3JKWQJ|~^54|4=8.A)S.BB5|V;#.58U"J|N(6+>|KCKQJER=+U+^MJB?&{CDG+|^S)YB-
M8+>+%;M.8:81$XZL@>K>NH$PRI53|U|TNW&E<7|>E.F2&98CQK|9<4.6.3B:IC^<H.M+=+3.N:@N2|C.IQCC%|67<@>C-|@.(H|L^HH5C.P|>N-
27O=-3DO="E6T.MY7T"2W^XO719-8=##ZB5$%IQ5^X.Q%DB)!'Y)4#L:"|XYD-.5|HY)Y'D-MJ+WBBG;|^T+@8)N7HP_V-#|6Z|LS?
AKGLW4U|3K&2.H|X=3%K|^4.^^M@~O*03|6%91A*Q6L.KZE?2ZWQ(AOY+P|9>V>3R73<4|KRUQ4)CBFFL
M2FHR|D5)Q+D|TU"ET4Y<QF>G+Y$F^EXRHO*~M:O|9Q08C+GW^GKYAKA
M|S%)>EX^EN>GTS2P"HOB.T<@G29L.#U'DC4Y"~Y0&>.$Z|H^R7H(|SN_&4.M^~
==W2.Z8A^QV.16#WZBYM|AV>F_|BN3O5=#S+Y^X;#Q*BWK&$@O|K.MJ.YV@:R^X$=IDORH_|K|5^7>M1"WJ44AK0EH.5"?
<6XTV+M+|C|YX|+X|+6|S6R.L^;|V74|H|WQ|D|&M|S5D6^B|G$E11-94>|^2+>GD|G4UKWC9H>+HSX?
>5%ST5GI98WLN+JAW.B9XCNO*QK18|7(EM^4J8^IK2.Q6%OC|OCP+BUYD_HH.M|+&^Z7>+2|H6"6W|H4Z4L)G"99;
<5>=>JQ(C)<KQXKG=V/6+*S^<VF.MK31Q|H|YU+>W_|L@Q6*T="^|E+53.8E|<6U&C+E2|P|OX|S3|>+..9Y|D+S*VZ*#FB5M5)9^UQ&M|T
D|K3*7(3;=@#H2FF?WX|H9L<Q>%=|R|K|@|J|ZO|D^+<6QCO93.3.0$Y^|M@LH@O=(KWDR^F70|J_|R|H^9_YO|2LV..RN^XZ)UPN2SZG8M|Q|5?93L
M3+4HR:519@O<3|G|D2|H6|.C)^4="5Y|^9UX$HS|<9>RS3|9_S$Q@H|M8S:2U9<8O2|J>9.(H-L;:>?ZQ=";^75Z^JNG<==|FK$#+S@>$|S
M4H5P.%HG-G>?HF|_5K|H^N=RNQBV";4D-6.H>G:4.OOLQ3Q(HI=ML2.M-1KE6|45065?P(OHZL|HQ8)9&A=8|<82|H
|TS|0;@~|U)AUX|_U|J2HX.M63A9F(PG2Z|C(%FEJ^H|W616EC6FFK^WM+L.8#U8X|U?C^?TYW|^?&B.MO.X4LL9L8|8_EU6+T4?
ZNXQ|9I62&5RK|1W|AN|C&|MW>K^X|Y2|S|N5|_U.MU=|HJW62VYV|WV|ZJW^T@W*16XXQ|B$|4Y|P4P|PN&66NU|J|O|B|H|D|K^<7&
M1:T^K5-6<^F&DRVA|^#N+16R5|L.C|XDHUZX|D|X^T|74#9ET|K|RL|^>WP.MZ|V^X%^&^8;_Q2B:H9772D|T+0L90|^+P8|^>|T59|
|X|^1>6R/AW2=1#O.MR3T|T423R7?>Q3?GZP.B7@GZ^D|O>U>N(FY+7|B|KJ|^L|H^Q|ZQ9KAM=@T.M$|Z8R)4&^|2M4_HLN_|C|<X>JY2F|O:~?
9(<^H|95D7N|K7-|X=TSGL8|6.MP=9R2^#|H|DR<O|Y22B|VZ|1L>ZQ4_HF7@4^FGH|H^C|G3|K^K)<|HAC.MMN|H|K|1|^1AYT?
5>TQ2V|U|^&1Z21SK(E8=.#0.QQB.|9@S2LE560QX.M:P_YD6|25|>W_??CVZ(=.%1+22|QQ$|03H)Q|0|8M%&E(F.ZB|:O44___M|L.%N8$Y>TBJUOZ?
N:|N4Y="O-ET>B<3C|E9Q|Z7H)O|U9O#P2TQNG3|T+<A.NM|^OU@|T|G|P).QOZ<Q^T^U|8U=|R.(+&|%2>C|P'9&|H|T|B|H|9UP6ZQ|C|P|MFMZD?
#N+|4D27*~|QD>T<C%DGQO(ZY7|V|O|D05M|2|9;91B=7|N^<A.M^CM&T^1|MP$)HJ|>YQ^#="AA3|2|100>+>K.P.O|MP2@A@6D3|O|1|X^&|M8"ADP+C
MQV?K2+@|ZC.SE^V^L&X#@|X|&=6|SY.^0.2SDMR0(&$8)@~5B.#|TM-AP&M4=8KL|J.MHS|JZ^#|QQE>F6&S@L|M.MD|^X?0|H|SGH&B9K5%F:
*^GT|G|O<5C<+&2FPX|LKQKGQ=..MBCWN|9H|F|D|H|63Z|T|3C7F$T^>^|956MXY|^IXQ1=|S=59B|OQ.MH42:2Q@E^E|S|B0%Q
(|LZD|VHWY^H^1|)QO2U|^1|RK|2|5K^C^PPI^Q81<=<G2|W4^L.N.MP%@A|T0+V|QOEK@1F2RYC|Y.^85T^FFG@CAY|^E^6K-3|F2<=U+^M2|WB
M@|L_|DBNL|JAYQ^X3|^5B.70|BH8|F(L|5^G4XPX%|TT6/50Y?Q?|^L.M$WM-B;7^U^<|"%|E.Y)QA-D.5BX*UZWWY|^+W
N8W|N98Z>X#U7.X89U@C.M<4=2R>=>KEL|GR8O|Z>ED^&D^B2|H|2KFZ>P7G.WC@N<#PU|Z$A|U^0.H.MD$&3C|E0SZA6=3?U=9Y|Q2M(-
L.MB0?T2@#&L|Y^<P2.M23SE|FOA.M^G+|^T|T05<^|.NS;AW&S^CGXM|MX|T(WO|4N)|$T|C6@28T8|IND.U:8
M9W|H|26#&LB.$AA0|BT$|W87|9.2.T.M@(|>@=>C|KSG"$S+V+^"(M.K6|W.M|EH7Q>=>|SMZP+*OD?|K$|E2M1@O+OT.8O8^1*TB?
T45=GR|E.Y|^|Z.M+Z|^#&L|W|P|B|T$.TKS.4W>_EK8^#3@B#A0NALX|H3.W73@|YB1|TM48|/RVE|T|^HO#9|@9P-H_|@1P;">&YB.M3F|X^D12K#_
YC_QC(84^&L^B6C)M^#D49(15^TAOMXX|1$H&O;V^$9V@UZEN^<K>D-WH%|4VDGFSNY8G|ENAH.M=0E^P2;
VT(P|&7^&4&+1UGPH6$;)|QBI^PU0&|^GM*^|ZFYRY|W8>S:3S!M6?XP^<9<3^X6|CE59>_FXSSQ3|>YG06YXN|H|>3L.%H%3.S)E^YBK(S1U
M@H|=K-UZDA"Z%Q>Y4+Z^<@D+K;|H9AQ^KK|1^UA.P@|^NS<=DT_Y^A^M|P(N2|F>D|R/7$1%@P^E7("HCC?2?>EQE^D4#40Z-8;L
Y=YYN|N2_3H.N7-M|Z0ECCY|^|ZGTU^L|R|U?>V^|SH_MM_4>NL?1OE$|U)GC=|$+|^V|^L.N.M|4CNH|H|Q?
1E>^U^<^42^B2E$EAM^#CT^N@E.F8|H>^Q6=^YU|HD4377BR.M^66|H|H|>D$0^9^C>0SFU2M.C.OE2DPF^M^T.FVU|^O|CRB4|PKU@^T06&
MG63^5Q|PN7RB.Y2=T^<KX+3PKA@T6@2KPI>+&J^7L^|FQY(K|LB|5#<^|BR
M9OE&OSSIHOYME4_8Z^5R#744G5'6#YOZ1RX|TL$E89.^M+&G6|8|7RBBPZW.M.QUA=ND07-S|&8CDL_#1D8B1B)|T|^|U>7XB")16XU8B1+?
Y@Y^MYM^#86X.P.M99|H2|OQF^Z|&3C.M$OPZ748E|O.QS|DPTK|J4W^4|^6CD#&.CK;4J^&=|Z|9.G.V|D^82M#(5_ZM.M|SHLE^3|1&Z@7_G2OK&
|3@3|<5ZL^16$6NGN(NH|FTFW|^L|^P>I<(&2M|F.M^#CP^6L9P>5^)|EP.D+T|6C_Y0E5D2A:Y|S|<C(95M|>5;_%294H.MR-
&WN=00D015%"W7Y^CC1-D|BZ;D>+<1?AB^H+4|4|R>|^JUPH^|J=T.D|9.M_&CCL)^633|8NLP0E.S|?
%5M4$F4|D60T=H8M|P1|H|C7S5Q%>DDR|QC9+&C+6*>%1&^%G>P

```


E^V18Y="0.54X1|K6W?T E=EL&L|G7=SFJ428 M4DQ*SETN8H&LA:~9WD"Ts(NV%1:~(901P-1WU'5\$Z7^6F>UM:6%HS(C@HEB
MOBL0N%\$5\$#L\$TGW.FI@5A.Z734ER+X19W~>_>D|>#5EK8:ID97 M*2|>K>9)>VD0_L(I(AUE/81&E> Z27<~(HA)G*HUV\$ M^M6\$
AJ(3\$^5_QR6:G5^=N+9&P89 I/@P^4Q1^@7+ W|).Y/MV_1^N|J4_066I2.(FEQPOQ:WT M6XW76MM|)I/-0#3UT:5H|\$&|JX3 MYA)G/XC3^ZF?
K3:7L|N^H^E^KQ:2P IQ:~4F0Q@|WYV&S^VFH.ML1:12>+= M|SE7:DR8I>HClO|@F=I:P^JMK_IR~9M91FHQ09\$#%Q:5106H0VRIJFG02YV(ZD
M|H8EZ\$P^(:R9)7P1?057DMQ~%H#0J_+EY%GR60?BQI-G~)=IY|29X5AWE\$ M^HGR^*J8C3Q7=;<=78%|H2H^A7K:VYX^@7AF3QXN^@:~?
>305..WN^W>0. M&ZJH0C)K %M^CA4I@7N>1Y+SA^*HQ050A4V|J2NV2GIV8^~B_~H:;+~#10 MBT2NS)*IVB>?>P?NE"W(I&7?
M_LB+5/-WLL3KWZ3^AU# XS^I8:JG<(V^YY54A)%%ROV0^FT ZJ@:1~*SIW@ M8^(\W2D&*VYBBV|2A/C>3R1:~+5R\$W6..2D M^U8R.Y2V
_XDD?309ECNJ2>LGG8^&MX=N35S+^I8SI+XX.5/7 <49L1EF^4 MP_9-1#+=K O)WXO^1Q>=>|H^DV:V)_F_B1F4VfV6F76A?3\$.ELE@^5>@~M4
MP4#UK@&17%6(MXH F.U)Q^I82N^129G4Q678^<_1N>AE^..8Z>?~1 #N.MI|)=~#07&D26&^?>R=R:R(N8M%T2I("2CP.
(Q>)\$@A>ENF7GQX^1=1%W>~ MHG&SG3A>17YGIVA@UFQ1HMZM8|;L^4A(KW_Y8N<26I_75L\$S@QM|).7@H2N-M-
&>&>J^!^IT2R75)N#2#F~LTSOG0+PS-PCU^G^GFAFRJ^VJO3+;+!
MOA>1#^+DYI|V(NQFBXA4).X8ZIDGBZ=JMF9=U^M)F5_6^8^XM#^*K_8S<3YTR_A3^C+T6=-KS|3I99 M^IYV70%1>_3R1=F-
Y^6H7#^M1=P*DOBJGOX^H2NJ8UOL9Q.43G6*!:%0N-MY@W24<~9U/E/EP<@K'=TC46&I_1JG\$KBD-(MXD2=X#-
VU#4#2^Z^@~"XVF>@D_SB&ZFROU|JK4P/K MX_~P:OPY>3V2C(0 CQ+BR76ZY_5N^GK^1|C_@)7>0J19^0RJDD54&8@FJDQ_M9=4ZK|=-JM:90:%_M_1?
M^|BRPKH2^LHC^@B^XT9&5RQ>?RE_N1C8<>(O M(OPCE^A< BOWT2_DZEM^PC|/FV<~P9KN(6A/#5@O:~""W+L.O/I MW_K@^_9-
/J+0NYH(A8Y%9H|US_#QF#4COAZ%8U77TM@ (ESP|Y_?L% MF+?7G:Z_VAF^_U9_SASBJVR:B3&0@-GL54!=(>62:H>O^21VXUAQPZGY)-
MQ3W3\$6V|>=N9Q_1^D5U1BW>LX3_~ANZU^C=G-4:125RRF)AZFJ%>_Y# MZ|71OR.38I9^WCC4C4Z4\$~IQBQFV/VYIL+^I|H)5U5*^<21?
+&42_~%ZK M3#8I^T6&L4^SG05@D8^8#< M%|YRYI02W~#~6I?24_W^V96B4T47E M^QI49_~YK=U:Q|H5G&USFP2J8WIP<H4UH,\$YJU\$7/8?
H&_BF/DK49YIL_MX0Z/8M|?JK=1=46B^LB#^M-RI40:P^5^|JB6S1:3_M%HB.5?FCW/N67;YA58PP^TR>~_WCAWFR>^_&6RUBU-
W7ZB=JYV12QD&D2@TS4T\$:"|H^~K&|YPM/KO^+?2D U<~%Z+^?|Q_(UB2_ML(2UCYPTSTO_SZZX_~GNL^PT^6Y6>|S@;=&^G8JB@5JAD<=W:X_~NTS-
0G|_MEPRSQZPHF^%XH(R)J0_~#4|<~(040CMM2R\$5\$7D:3+D|J8^C.VG.D4 M4OD40^MW3>WA@=J8:E:C0SDV5&H0&00.MAV/L6?
WE50%^X6EV^R6..75=Y M_VU|XJ|G\$C2^1D0^_W>#^OJ4^B1.ZP#ZW|C^7)EDIV;Z^CKQ=7L^ZLYRA M.?
OS|X.K2R3^TPI|QH|HGSLOYOKR|_B<7=^@0EXREU^PQ2^%M@U(ZD^CO M_~X)J^T5%3HL.G.V#E1-B_1Y?2(9_Y_9H&JD:~^3NE^?6Q0^S8_1@
M&17#|BBH^BK^9>6Q0^1^3LY_C^|DK9|N>HLQ2HAX79>RV0_W/U_#?E&^5|>_3INM1+KDQ|V7^-YAN8L^FWFN-M)P_~OE^6_TO58A^|VFA^~^I-
SE.F^CL2VYK3EYGP2SO^M3<~<L\$N5N.#1 MQG-7^TPI|OXUXO|K^+4~1\$1^|JDN|NK<4>~*72@C|J2:OGVOF9B^=Q0G M^1+V\$YN<~>ZJNAD?
ZJL_G/WY|_JMK|OB#(Q^2LH_~@GO^Q^4VM^J93E@<2_LK6T4^~1U)29\$>|H:U<9K|)1\$DEK;L0% M<1EX^*)CS@/4_4^Q:K9|H^?S
MOCHMW4_LB@_M^1 ALU|U)K_X@|JX|_#>D:~(00X92.CSG\$%^TOO_ZT0I<9I^YH MB84G+~*JQ05/J0C=J3AO^ZW/E^K^YLU=^GS>? Y1+KF4S^?
O@=PSI6YTL2B M^J0IR3W^1_1=(|L^T63Y@NDN^NR%3X&S^MIUKU^#~KW16U8>I2|GH1D2A MSA^SIY3ED+ECHRMAI02M1T_KCIL:MH-
&>^8I*_V47@;H_Q(4V&^6B)1IG MOZ(K9F>XW=J&1>6UP_1O6XMWL_&1% X_+2&+722.PC95569HTQ^* MB2O>U.O2^EON4M_WDC_~UG?Y2&W/3W"-
ORXCK_OAGU+?G_YG^0_5D\$^%8P M|5D92^4Y#~*KPDAB_&BGKZB^N:0|V6A^H^P0=AA^|V7|&~8_7 M60I46_ZD94XG_A|P(H8^TM
1^1ATMVG6S=3^RSQKN^7^IDE0W+293?2CC M^~|IQP3|ZPIRHXH&AFH^60=Q8ID46RDI0I4|_34^X#X9_0TJZ^E_4R M^J^8>/3(41D\$~@?
L_1&DX_32%3#=~^I^A|^"%<6-(\$S9@Y?I?)8EZ(DWY_518 MOQO?B9G8;|9Y5^3EP(^7RNH^+H@9B#K6#09&|AJ^"N8>58!|: KB:& \$PN MJ+M!#K%D#1
<2@TS3>_@7YW^~%>DH^KOX|X^02V3\$3S7X23^="7^W@W_~X^LH MJWS^8^COD=3MD^BUMWGX^P:BOX^UH^<4KRCEI64HTKO_D_2^?>U^5.64XBGP
M1ABYID6<I03G^BNW^"MB=W_~W^@L(2=5-N^HS/OEV^4&(RYECA|YGGH;H^M|D28_&H96^W4N9V?7^1%Z2YB7^~^C+V-
^#YTA^/W^DK^=AP>D^X0|MP_Y M/3\$;L.P.@75|=DAF#;/P/BC^%S_VH_O^CBV5+WI<3/CILIC3W\$^"C^~^~(X1 M+SO^~V M+UNAWAY^O9|HFFVT
_WZZM7>_1^H2Q4E:5WBU@P^0.ZQ+1(IKT6%\$6(5X^N@)~%PXP2_L^W00.7SLVYKM^&OX5^A502I22_MEA+1_HU^M@85I2S=
O^1.57ZYWJ<H>DUXK^G^=@VH&5D^BNY_5IG/_YF24_O MH:SU/14.3^WVQ.C.TH:S8E^AK\$R>~2/DYE\$M;?A6=G9@#6\$K<8R3I2~
M^U79;T+H|H0E) 40>~"TN9.NV:TY@2ZJEQ^T7G6QD:S2D-04.A=^OY8N>/_MYE&N6MFX^~1EM.LB|J^D^?<MP|PV0GL6
MT.835CR_A%|ZYI_HQ2N|J3W00T6#R>_HJYXL2P5DW3Q:9IQY@=.%SN4 M0GA2L_3_KDA^\$S;12~""4XSI2IG5KOT_SIFQM.\$(B|:EL0P6^TY@3SH>R
M^ABGN+7&Z.G^V&N_VXVJ;4ZQV1^"I6=0B9/C9+2+1WPVK^Q^M^=V_<\$ (M|6D|>J6U1B^ODK6(D6^|IGR1=8V2&0J1Z^1)THY0XBICC
K^50.KRVGTZ^PF M^%B0V&E:173>Y6CO_1^Z2W_~(K+R)WPTI^TFS0^Q5R^P^Y#P&S_5S MJHV%11IR.WI^6U(6I784?^C_Y\$K^?Q91T11.E^H^CKUQ?
Y+OQPA.OH|=~M98E3+LXIVWF7DR@DMHP(S9^1+&_#W@O#R9I<^B^?2YM9ILX#@^C^ZM^C^7\$+^ZG@^SIS_N6=NRJCI M=~%J_2)Z\$^#VB+BV2
=NR&YWR>B;~\$BWI\$BY^B6^9Q8H^H?>OIVDW56N+9.%89R^@Q_T2|RJEL4V0%IZ_K@#2T MQ39I
1AX T^HONEDVZBRI0|JLU@A^1^Y=M\$0<2_514R|H/6VXKO^P<~1 MK13P62DZU9^F_N=N^"~*U\$=(S)JLK?2T9G=~VOZ~FP15,%RI_1W^T(7Q
M7GK:K^\$(VXQ\$^/OR#15Z=;LG&KL6SIYP_#D=5IU^(#ONC:~5M.3@~1\$=&>\$ MTE9I22F_\$\$E80^JA?TRVG-4IN6_G:~T^F=R+
(&V%Y%2^~_1H.KJTSJ24W^4J^E2KCG\$MIRNY6DH|G^P)T9;H&=.% M/1<7P2C^E^J^~V/XG^4SEE0^R5U^M3\$SDFR|JM.U7_A@9/3C(PC).ES>_M<~&#
8HZ^14C^~FRRAYM15\$?7=CLIB^U^+B2^1 M_M.YS353@>|T^8&=1L DLVS_~=W^YW|ZLBT5M#BD3;~<G\$SAXF\$S#2 MHB_~<IG6HLE
+84ZE.6_D&J3E^DG4W1>I?>>|A_1.94#NMS_M5;6)G+M(2ARAKKG#<9_75|8S)0(1C|M=-43+I8=-(W72OZO5T^@VW^X13X_M.PUW^~%G?
=I3@3D45T2IY8Z;\$KN\$60|PR98^?>D?T1H_F%AQ+I|C:FY53_U MEGC:I5S^BM|I\$>TNE%~57IPM<9&9QJD+@W&E=J0^56%VE^NCZ%
/66^ZZMYR32^M%14S%~#^M)DI>SNGCFB2^U^+|JB774I|K_M2T0Q_L>3^M3VEJP+0A&WU33^VAL^8 M06M^+DY_Z2I@5V)I^
_96F_YGQ^A) L_0RUH#10YK0\$P_1H@;+?07J24 ML_<4^1:F^S.09XI5RU^&CX_1D_O15VGI+^J^DP8#PA7%VWM_AQ_7V|8O
MB5;_ODUF7^L0R|H^?2^X4ELJ^X)IWC12W4CBMQR9_P6S3J3;2AUP^K5CTV M^W+4E^12G^I_L^D^W>~JP@W^P_1AL_9_MR.O&2%MEYT?
W|H_17M^R^FJ51_XV1@BH^M95W^%WAKSSA>~^HVQ|XTW4_K MOGBOEY\$A\$^0N1_X\$19)W^S|_X^F^QB^C|9+@.8^ZNZJ923-SIW.SYG(5?YI)W_VD~CY
MJN21#<~<1(G^0)P@&^I^U^T#^1%=8AK%OCGD1THOZ@U^4:T|UGV16|BRNP^P^LGTG|BG_M^G|H61=^~%+&
H|H.OL_G>ZKR_F3H=N7^1JTB^HBT^E2UK|""4WY^"H@XO_MDL3_1@~>J|^"DWG3=K\$;ZN^9_6I8CZ<05;^0Q09(V4TG)C6D9^\$SQ3
M^\$+^)*#=:Z9:RAJ?V^MON|TK%6#@>7&IW^T@>WOR3+K^STTDQV/S3?JFK#@OK|QWDT88-AZ#QOU8WNP3G"=~<<7SG^0M5_M2^LYN\$_1?
5CBF+^#51OHT5<~>HX8^+9.M2IGRW7CR2EMCP.88M17^5;IG
MR^7JHC/2&N9B0MG6>=Y8Y9&\$&=B5\$S_U^IQ^1^N0AF3M9S=X_D2J^T^R^H@13435_O10I_4G45HF%h_M9.E@IA)5<~&16IUU\$^6R|1^2&#^
F^X<13CST>~&W_5+0\$7;1T LE8YR|71M^A^R0_VF.D^P^Y^4UAADS146R070.W>@|M4:PH(K9<~&08/R_HJK_?3_?6OR\$^TK^F|@&K MIEF7TC
MHJ#P@<P^X)4#;6/SX3M42^0J0_M0\$^1 DIAOT^R@I^W|VJSU3S^9IU.7.W_814YR)3&LUE0W\$^K_K_@J|F@ MEFFJ^P_2XS81^&D)I^@#_O_8>~
XZ^ZW_IQAD68U^R3\$^J20N1;0(22JA MB^E4DE1)J#%^A!36K0:42E^ID^FL5:J119.ELE9P)XV3.G/F=>7_NI^?S M7N|/?7>WWOYW?2WA?
EC>CQ&SKGM5S71WI>K12PUNHJ9^U^+A\$M_M1 OMNQ0U0790_4Q0=|H|HK^+FPN.C^0|^XG(FI_(QK6.R0R0IA^C3^7I MQ0=%U+?
5JM^CL1N^TYIY9HH_U^%V4H^4>W^AMK%20(JA^?C487I2\$1^##&@ MS_O\$Q^?T&B>=D_7=I9^Q.5)1613^1Z^?BNJO2IG+EX@I&4EPLH^PE-Q
MQI+5%U^Y:4%~1ZX&^1)FX?R%301#%Y(FQ9&^?>9RT2_(EB>NJS<8UX:\$N&4^_MU&^PR#%~8I:U=6A.V8O6DIY>2^W23;W0KX4S^W?
O_~\$SIWD_M>AIFR3XS M^Y<H6^L^I^F15&:(=)9^5\$;F^L_7\$;0^T^E.F5:QP^8^Z6.2L^AW>R|> MWNJ:G15>^~1+VYM&6>F_EKR6Z>I%3H5S9)#
8EYI^B2F^12%28F|QD.C M4Y^"RG60D^6:970 JD+>2^EN3U@Z(6^W=3E61\$=QV^21M<6NTHT/H6 M5?>ZDRI4;~>D4H69(5I^@MNB2I^
P^"KW4^C(3VTH5L^?2NY%7(1CNE^IQZ^P MU+Z^Z^MYW(4ZZ;MS+WVC52HA^AF6^ZUP^NY_LW13+;QM(JEC^X9M^QH0I
MTOVC^BDT@0^~&4^4SAQ_1^M2H)2%~+LKNFD=9E\$@<7AL104U_1_B9EGET<=OE74(0TL@E#W6%WK%K>~(MXL_V33MX&_FB6\$
M4S1HG:~O^ZAVB^0^YN:M2LR>|TX|04_>X_R2OOD^/L#1L_6D.WLJ7^669? M6#B^LOC^AYIYREL^4053_MF8G)^I7_OL^4W0X0+H1_57I
D>D^N^V:BJO+|OD2>3MR70QKNY_V_87T2/T+^9^NOZ^TM^1^1M_V=9MS5_S_R7+G2H20^R^LM^2V^1045%5N_MNY-GN&B6:6YQ?
KI9%|H6SCQ=ZL^1\$SB3T4_R2:GPOG_U_W2QW^3XW^N^+@_M^HOQ^U^~2YHH_HUM^VH_1AXQ29WTHO0+^TM;16IX^N72L2F/013X1V^/M^B^'KK"
>&KBOF^S8Q308MSY|O^B_1\$COP4C7T\$|T.M^1.(GD|:CVB KG^1^I9A\$3^=\$B9YN#~+|RFWW66|:Z?HY^UCXPU0W9^CH
MH37I#H16>~"T^~+KC7I^Q0481^HJHA8= MEC7Z_~+=+&UO#%~2.M13P.I7>~L^3^P^147KAP&=J.RD>~H6^L^H^UR=IR^FV3>~:KJP;=JUI^T+GKL9F|V|^08
M9NZ@W^\$%^VBP93>B@NTLZD3Q|Z M:)~L@#(D-7X%\$@;7LC_~<DM^OI^F^U@EGIS:(KHMGY^UL+V^G9ORT5SK4E6
MLTK(I&Z^NU@IAC^SRYS86C1^1_29K015JZ\$KMXFZ9^37IV%P%P_1+1+&Q\$ MUC^1%7FVQ14KEOH3>XIK6_B6CC.P^)>~&@Q^G1M^=U/V)^FN3LZ?
8N&24N_MLK9QF\$D221A.\$Z:MBO16A^>E23E_7862A>A^1Z3>2)>13@K\$5%K&X^J^M7ZQP2JR^X^UWV73DNL3P^O>~<K_X58\$72"
FI_19)N_8PX^~T))C^MR1O@P&JN?9?_JIP4YH;IR6)4_X&KA9KCVCS^Y_)\$TCI/|TJ9=GDERN0>W_M69I+<(#M|H0|D51H@N^9LSB=4HJ_YLC
TMU>D&^WTH2\$ M\$1716#54F49IDA=5L\$Y4IC1GF%@%MN_N\$6I\$6.19Q8Y09>5WTZ7W5M<~S SX M0LHY9JM_~^P6E91(WX2^~FQ+^#C5\$V^Y
B^REFXQ(8^9C;Z^NJBEEF0\$ M\$1M<1V2^I(H2_W_YNGH50E_Y49EY@^3^1=W^K_M85D^SO@C_43W.K@|JHJK@I^I^K;FV.846;="WY+TX
^X?2^VW0B0^~^I)Y M4>K3^XIOQ_#O@IM^+~%Q_0|Z|^H^L+!<9&T5NA^?C>@>|JT+E|~L:&PS30^~M6_1Q-
>_W=H&=JYZN6MN38Y_W^3Y_LX^|Y_G_0+@T#Z^L^SYSPGME^PR^<H>~5I.TP^""JCLZ+P@G^I^G^26) H^_S&PAY M.6#3EZI^PI+H^MKP&X;#>U|~
O#~+7^>6V^YQY^G(Z^TJAT^M&2^1H^Y&G_DF M2B3L5M1(GE^B^*4J9^VBOA^D^J^PX1_M.YX8.)>~5(L^N\$%FG#UTK^1<~#L^1
@+|YE|H|@RK>Q18NID0W\$1DQ?7IV4K6M9V=,SNO.S4T^~GJ7^TP&A^1^I%0@_M|P^~>Q?#W1^#7B039^1^3F4@S^~<@^@^#30:
<7M)(&T^#>+TJPS^V1L(42 M3UVXY^6_1)O00)AQJUA.6#H9/K8KPY_XS_V1^H\$Z4H6I9VJ=J MW0:LY^T#E
X!S+2S4_O^T8T.RR2;Z^Y^4=XNO^U_SX78R0SCXH>B(P^M K3G=B^8TJH^>(>B^VL>@P|:I4<0DMOYIP7^#N?YX^%8SO&M>~(I<~\$^:V@I#_HM2
2T1^~*HB5&\$^KQZ^=QOP+&RMFU_V&+OUC^L^~2% M2TYENG @~|NTVMH|I@>G9LU\$7\$55=7CZM_E>2;2%JYC_SJ>2G6BT2^RRK
MEFW9^OFUP+~>9TI^M^ZK1Z>#IXT^TWIURW923XM6U4MOI^LIG|H^|B^<~MB5_K:5P5LV5G65I8%SA^#I?
A4N1H6)H6H7D60BPWQ\$0+^CE^Z^T^8J29_~OT M^I8GNW0L8ZIVTX1QA">L^DIE^H^1^CG8_~@8?SIG1Z_~>9F@/P>KV.59E^5 MY7\$XW8^K.S.^?L?
1^T^R^OZILK3#~PW\$GPOWD9P\$^L^C^#2_~H2P_OG%&Z#1 M6_0NHP6^M^>1CG^#JYU_GX_IPO@|>D+V9V<13D^KFUN\$LSU^HVH6SL^D79NV
MGIE3R+~%K^IAM#+5A|H^3JIV7LL4_9ZQ5M|SO+G+N^YR74B_1SORM;BYGM5WL_M24V/-6:(DO5.1:6XB!8^V^T|F\$P7IL3OZX3^~@%3F.(I+K@?F_1+
0?7 M27VTDK^%7VG7<62>BZNIS9YY7B|^0A M2RS+LV^ES^FG121+ODIN+5L4U^10T=3N^R) MNPH_3C.XXI.MN;@~1UY57 MOISW(OG<~
K1NLE_U|V1D1=WI^K6_1^Y=JOXOQ.WO73^9RTGBC?T=K1 M^= M^>QTO)ESOC^1#I^ED&234P_X=COI^A958IR^~YI25^K16N7VNI&K2|S|U|
MLJLK2K?2_2M^9LP9)>9@~CMCOZ^DIHXC(A^~)G6=RZPIGD4A^J>2MVT^N MPHIOQ.TNV^9_K=)^.59K#^D3TA\$+I6+V(Z0JHMN^2#
I^MYU:QQ6^Z^2TB>=2BIV52 MWY&I>L+1%0U9^R2H2IG|I^"~<QS(EL1K69LVHN7^HSYHJAL^WID106V&ICA MIGHW;~\$&RE=W-
#QI>HB\$6&XHELZ_U@^C|A4CR&MKYB;L^1^7^40EL+WA MT^~T^470>RTQI+FIKT?
9S@!N=:XUY.#IX^&C_L|^~T_K_A265G29^PMZ3IEVZD0D0@;QS2^FL2^I(HF.GVG)O.CS85WQI/QZ>OBB^KECF^PJMB
M4^FOH4O0^C^@6E>14@B^JU21&NPTH4^EGGA_R&@&C^C^Q^Q^L\$S1#IF4
MH^D#~%WOXGP^NF64) LZ#1>2P?1#~+Z)>=0SF^&^DV\$^M&0FM^JTZ@I>~%3_ M9?3B7^KDA^JZ;%_2SN?AWBB8CXL5)T(KRKCF(I-
^DZD4>~6(O)0:8^77M^>~?PDI0A75RX:(%C\$P^PIE^%N0G^?Q8Q#5+9V|JB^8H4HI^A^X^V>V1 M&^\$&3FV6_2.C^5,B

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

MFE%<4&T*9+5@^YI.6/WZ#_2P>J3.WCR7N#*AJ/K6<4%U;ISE0Y MC.V:OLXE<^:!!JHHC\$^C G3>DBS5_!*<^A^L L Q>5I/KU&H?&DF> *=%
MA&GYD032?P0I M#HA T2U M#M#DT.#A Q> 37QW.7/3**W5R JF6 .R/OGIQ M9F22< M6 MD&MIM20% %5G0?>
LQ2\$TCQD>M.LZSZ+J#=-DJZ4ZU)HPP50)" MZTY-5Z/^>)JTS.XS.35+&=Q9/G#XW4W=J7WEK59PB:@B.1AJ(C^A+YA1.,
MN^Y3JYPN0.MAE+P^X@f(C)!"4:0IQ8*!5LZZ SYG2_KK MUH90Q03.V8GV\$D[XUYU.GQDE2!<.% 2(+DX0@/^2TKX!Z)WQFNU8E2M4-7
M2^>I%2>12)1KH0*1XSUX",MCOQ%<N;^>94NV\F:5DM"MI%0*6W M^7 Z=5U/ATN8MIQC)HK\$N)FJLY&U2YPE8A.C22WBPL6L=-^M.
<#I^+V44JH.70_9_ E207K16#.3SIT^F5T^O M(36IS2!:#3D)^!\$T%67L+O7J@1Y9H!^ 2YIL.E576& M7HA!"#M3\$5H MUTS+&
NR/O_302<#J^VHR7/AL/OEDX#ZZWM6IC>XZRT^<#.#.31%~27CR80#2 M^5AQQ:PG/^Z@JG<11H#25+&P/K^8VYV7KZ.D0Z4/J^5LZ@.)SD>O64
MT179L0\$4X(ZRIF&97>64C9XKM&1< >TJZ-2#6.161^17>-(H#D1-7\$G5H^U-M-B.7&YV?P_3#;^=-.f.F6IVKA+P7>+?(*9^>4>I7ZO=+3Q.?<
G8-66CJ4JH8H2TZU7741 M;D3C2H.L-D^&C/)22Y-OF+&O6U&8#OHNSN-IL<^2ZIFVVKU!<U(C0Q3Q=)M)4^2IPQW^7ZX.^S:HOVZR.T-H?
Q<^&E5KK.G+&+OC63BZZL/>S5K MN7=S3L.)K@F.LKB)3BIA%!"*%< %N/YB7GVBT>27R&9BX.C=-R=UZH M^WWT?
M^<^RLDO>XA6^3(ROC=NG<G(CA^L.2FLOWOQT)>.IX?/!S;T769L M^Z9+/KWLXLU\$5@5^W:08P "78UPE^!QOM&CBY_#9J1^=HM1B0NIZPU-
R.MJE=YMJ196M-JHVHJ3F9#=(1C67#AU8HST=&*P70P.D@JH8\$WKW7KA+2R.M;Y)P-D-X!-O_2L/42H M^5+8N%<^A^C?
F*1\$V:43.67KNHA607Y.8D\$+L/I#<2V#^+Y0^%<,\$T.MHATSS33+?@D*^XZ>68M\$RJE.%OK(EH.7VN MX&A?J9=LC3U\$GCA[K2O^A-7%G+?
FV57AT.MP.RFM>24-QYU M18.R7R(HH>I2-O0^0I48&F^@&6V:QT!"L-Q:\$LN^VGLJ6>?71^2VQ8H)2 MIM\$=^<3;
(<^>Y0%GHI>170N.RBIO/UFWOGIF<^<F MQUJBCZFVGM-75U M^<L!P%GKR89IHREMM9<6DUHQ@P!%;D9\$4KK.#/(<752XJH7Y4V_NRXKJ>@/
MG26KRR(>?7A<0VK^<Y/YZZC-&T7Z&ZZO)\$JZ+I!<=#.6..6R6)4#=-LAF M/6JG4QK> /-6>XF.RW!W?%NIRN7);N:7/K2Q^1?
PZ%&=0H+^P^C8LGE%96A:H222W5N^0M TSW.N^+L\$@P/J8^LA_780!)JMXHJ.FN MF1<(-@2(4EUBH-H^4D6:"A0(2(^EV@G13%#15%"8F(I^8@H"
%042E25=-M0D<%(04H0H)%(%)=(R8P@LOGGESYG026=-WV/L\$GVO^JDBD?7K6GM:IR M^JUKK<O^>!)GJZ.C5N@>13X^
Z8@H%ZY=6>S)OO_+57I6!3_M8C&1HPI\$%:LV\$ _M9(6I#/+>OJO.3PR5U!L(V7%UWX=OO*W^K+*FB>SC!\$")J#7>+HGR42-
M.AZ86T<^<ER19/TMOX(RAJ)(OVC=/!<..2IU.EPNR_5.3!INL/CU\$ZWE^M.FR&JXY.V5+USIQO_#JIS?^<ITE-7E>=-DCQ9_53+S^<RV!%TX
/M.EV1/SPSY11QI#)-GJVN=-OG>HIW0>2B5"\$Y_VU!\$5%?IG M_Q_2\$ _EQ_0_9+7831XYE^:Q(OQIZ>%ZMI\$%)G<+>+B98QD92IVMK#.
MG;ZUQ)LE7/FBC*F:9505OK&SW_!J3ZQM5VMZ.J^X+!^?)@fM@L/<^=UD^A M#21^QY+ZIZW^5IFU)HWW%IS4:I5KG Y7HJEXT>U99^FA4EIT#
M4;%(6-^9I<537R_S<1_7=8R^<V.@Y#&RON&QIE8=*Y GVC3<604T!HP=-MIZ^KSQ G>AKP3.^YF3.UV9%0@^CG3>@E2.OJ3Y(MTFHB%<6P-%J.
P^O2FM.MZMLKW@.D@.10_6^<N:NJG4-484GG.#.8KSKD/I\$K<=&fFU^AIGKUPTHZTY
MBHH^A41_655J?M!P_7=2OLYV#OE.KUHL=&GJAWN:HL@<R%JHE^<CP0B2P M.HP76".MUA2XJB(2B@WK/&PGJG0K+24NYYUGL.D2E^1E>..\$?
>9TB"00#^MT2?Y.FCF.AW#5ZM^# Q085-IEQH1302J87.RRSP_*FMD#2PHB!24ZZ=<6 MD@R266TDW>)W81Z120RIPNARKN1G<+13/L64NH!
L^<^3+4#9(I-Q0LP7 M3+!7=-DAIHDA!V0G.PI.#NO=H1^90A_@^I9^26;_*S&A^U62_#F^WJ MHS;+80UJU^OX8_NSC:SNPJ>+U%8!"XJKOK@?
I0H4.3Z<0E^<X-P@I&S&2 M52I0V?FXCP\$UI@<Q8D.QO#515UJUO=^# W_X2IK2IHU5HUICWH.YG>!D0 M^E0Q9?
(*31(TI7A>BR4C3MALBM\$&UM-UB@.IY).M+UYDT>V#4D&Y2H^M4.T.VGNE06=C-GUC^C3VS>)M8+(V6Z!26IE3H1@0Y513_)Y^<I))YYOI/FW
MN^OUF.^+>Q^5LCOTX^<1QI0H#E!LYQMS@.((KHIOZ^T^U!FHV+5.B M&:QIY?33I%I%_IZ#*89K#T.Y=I^<C.3J)M0@.D9PU0>R!M
LJ\$6&TB^90)"IN:TI.EAG:OS!H)H@P^2\$M5Q3*V.BY8?<F-DJ&P=IQK8BN8A!<M#W/SY^<H.XGI&L_@G5<="S13H(36)"R="41")!%OG".M<+HJ-
J-ZHEH41PGI>7NG8ML?FTY-JCN6_0J92@F/MC9^QI%&5?H.VZ6T!M4_T(EBZWA.V#?L>GVEZ!A#Y#K/J#I->>I3JFE ("Q&& %K27"B46X:AM-M-
9@N^9.C.YQ/FH\$C<=<5>AQPI5.IY53KJ3ZL2QGG6#RJR.Q^R^<EZN^N^M-KFER.M!@5.AY4L+IP-JYLL2WJM.D925SIV)(2THRGX5!W22N?
@273ERMLO MX>=<+&^P^IV5\$0E#NB&3Z<1L^(<#2GE.9A0!\$J2R+J0E.#4.1-P#(222 M_2@&4Y+R)7NTDY<+RFQBGCLGU8IU_8Y<>LY^XJ=VKQ(#
G+FA5Q3(-MK_KT+B.6N2_0_Q&GN7^K7U-O_X8^IDJ#X+^ M^<%YINIU\$B!_MINZ<1R9U^2DIMYOF8L!<VB?RMT%Q:6ACS#7.0#Y+
S&>AVDW)HK.SZ&L^M V22F28K 45_X>1@0@Q=3=(5@2^EQF&^IG1P5_!<0XIE+EGRT!LU3PZ.MXOCT.A8CB/B5>FL02.%MQQ3!2,3#=-
ELX&^PS0VHS.ET4.P^LTD\$WV4YP3^M_&7U!AEF:615RC!RG^<R&7U^V=EZZ_2GR^2>JZ%!"F3/4&^;.=G^G@B M>
JHJ6GKDHTAKW!#8.N%AWYN9P#^/J=>Q081H>527WCFM26^KJ_=-BBT74.M:JHIM46X0\$P^MEEEY2.7&RRCMDS(PDP+XJH:8)8\$3H&)<K!<
\$D=^JBR%TJ=R\$ MMA+OI=6!JKGC.*&>1).X+OD=>7MVZ9.LAQ0!8MQ!"8T^&URY.V4W#O=I9 M6+^&L25+GPH@FGHP6FBIZ>?Q: A6N2S?
D8BP?_*VPO&X<7!BOT^UI&^/3R MKL_BRN^X R=("^A+<4+TF4_"<G^>26<^BZ&^ID /Z!VOT!9C?2ER=I+ MFB/47TWAVYUD5(?
J8&\$4JOWGZ5F? CAHSR0\$H\$#.7FX&W#U#(Z^O.Y%M MN1M961^16W2F0\$2@2VPB>+I+6I@N%+@&W)C^<! NOW2G4!GH^A.2.VSD>Q^YS
M(@:D0M2?RUH-Z%:SQ+V-QH!TJ:H^8/3RT&K@<7E#51RSIAXH4_9KT#CWJH^GY+ M0580N9Q2382744:OH0+!/"&B>F^Q=KFR^<
^M0+!>WCH\$S^9^F2L=IK_-M@K=AZNP.)M^Z=EM^<PQ11^3S!N4/8_A?>&EB5^*O?EY>S.BW^IE%4=MU)7H.VR>#>XSEPQ_?0(6-
G9F2%>UVI3AIEG!7H=HJ_)T.J/86<^YX_M.:7 QKX5#KYWODS!QJN+!#H3.PU6C5W4DA73F.I7LZ)A@Y>_V8M.VL.^93>
MMV2R:106S.NGGW.0^Y(I>KMP.BAX7LB!^HMH.J_4D=39<1.X+FCJQ9-56 M^!EPQ)(TJJE98I8VY<~%J8IQ*Y4LKZ.?Q!AH?YHISEA@)H^<JC.DZ#_4I
M8I2HHH^ZF/L@X:73>+JW9?P.#ZL NOI^VO.GF&2Z5FWXIOXLZ.R.KM&4 MFFY2_7..2.VZ2^&O&V+G&E!>6;X93.&A/K^<1.4H9P6+>3WB&5SC^9C?Z
M@11T3T!<YI.K&K^<+<U.2.5>^OKWTD_#J.D.BDWXW2.Z.EOU/9\$+E.L ME^=78^VY2^50D.D.DPKE/0D>B_*#KJHUE<3J87^L^1I^G+^5K#<L9G^<
M.EX>9-1XK^TA\$F^D^IV\$RX8./.%25H:10%I^C!)%<EXI83VVS^P^SYI_Y MO9=LM0M%4RM>99XF/7NT9H!J9?^2^"X#C.TI/_MA.G;(&DT^+&5FM-A%
!IIV#ARNVH(3?8K0H0):H^WK# M@%9Q_2AN:10_4IX+=+&D\$<10G2^<95>+?%5JW6V^J78_<B_VMZA^K?
M86U!1Y68##=5Y638A!A\$+6*8<^A.F01E^QY(GWY(2Z6)&\$+A MMX^/UXVZ^7F18^&K!&_AV9.CSC?B_VO% M6\$8CJ#_E@?@J2?
Q>:Q2\$;L9!)#*^<Z_*TS^KMI#01E<17E!\$1@A(0V7R^MP&MCM:QT(Q2O2(1LH^ER!78NC3\$NQL?<W_S8>^NA.V.OA78:(^Q90^I1^M+;?<
^M&AIWR6#BUY2\$<4_3YDBI_/_M=^Y&HUD=D)JHHA+GO.7-!JQMVO0!>FH=JWVT_XSMBEJH8CH_<LIV<1>3L ME6)ZNGD&029S3@&
I9JG>_*A^<#&_#OW-TRUKY CHX_-25NJ_+>.\$9L=MQ9^<@3R^5(524+9 MP%5BBORX_!09DSU:R!<LW&S?AU#%3%7/X>\$_O-U
M8W0!)KL_8I5#M8EA MJ&V 8Z8<C^Q^QIS+!>P8AIVP81G>D?H2\$TMJWF7YA.3^UNBZ5T7H5U^8WZ MLCC_*RZ(T:P7XXS(6.2ZL_IYYA.G:J16A5-
D=C29201T0FGTR^DS):V.MIL\$.F21WWP@>S8JS4O<C9W UPKC^Y\$J7Q5W57A_G&85_EOT84_Y&QRQ
M^M^H^K3H(8)JXA\$R.N)T41AIZTWN^>M@2TCL>_E_&U M^!5PMXHX7DD_GUV_H0:U<2D:NATTYCJA+W6RN=RRZMZM-
KG05+<CKX8KYHR^<J^BN4PIHAW02#>_W0\$=<40^D#1A+Z=M2V^<P.TJF>O^<QV8IA)M.6_W:N
2P.NA0K>R4@IGU/V.X0R@<C.M%_A4@4^<^O!&I3(9DDDCRI?F&:4UY M2N^1Z.D:0DN^XHI^Q.AQF_-EM?
Z_JIT^E=^03HNV5B31NBZ@<^NU/ICL ML-2I^0%>?AT?JE2UAF3DPX!<I84V.HFO:<^VROU06!7^8*S^G_E6+AJ7 M^MA5PBW?-
Q4L^<S=IHJINNWE005:O!O@<^U/JU_KH.LC79C0<1&K_1E)0(6+DT)2_YW3_F2!MR@H6=9WY^3.CX_GFDK/DBIHI/4%T
N^_WHED0!2WGVV544\$V M\$IPXIM-BB9I6>G37^FG-V^Y+*QK6!YES(7+^JOI7SKT4;_T)!-8!G_K@<M)R&)F6\$?#E(WW-PN?1(4L)CYJ.V6P)C-IR#^T:
GXTHU(AWV2\$-Q5Z^G^G M2J!P@<Y^<^C2&FN\$5K76O!/<C5YRVB)1GE9>U_10+2D.692^QF^0020AHX M2D2
=ZBQ^5M8/01#QNJ1N^H@IY=^VVO<^<L^K.R^SHX1^28H8^FTT.R2.MO.23UM(QH1(4#<^XNR\$IZI_&0E4 MD:U%:+=>PZ_Q3;I-
=<^\$OFKNBBVMW7P^CIGRTI>TY0C" MF0+N W:U.(+>R0B9=T^RBUQ9B.^/I/\$\$<53/PI+ERWY0I^<O2%F%.2GOOS>EY/SN&0VN^W&+D/J7M3M
MMKJ!8D^B22M=<ZRU^H^YIOQV\$9.P.FCG9N T^>YX!_23JX>I>U>A2C M6+^BF2N^1)WV^<#ZNAVO_U#>179_#+3/(K7F1WX:ZN^2N%
MF<168I^1#92C^_2_B&+Z1)VRGWO0PZCKI^"2K.A(YE.(L0!^4Q%)>M>B_02ID^<DR41-C7S12@.%"E18D-B1TA!9?7Q4T/DHRZ<^7O M
PM4M<^\$ESI^E@NKXA@WT.L!\$3BK=JH^D9JIGIVS7C_#EX4).6!&KYF MA!#M:SDM^IM9&PC>6&N8L5
N\$Q.6I=1\$^CH5PD!P9F!W#^G^WJZ@S09^T M?T.GAU=&WGCC^J\$33;YI^+5^IRXIKPZ28H(IQ.MRUYG942\$C_V5<^%YT!<^M>I^<^C?<W=C^T)8D(H
512YDQ.9!RN/9\$SW6 MU5^C.11_06_08M@<^IY%.*OX^<F6Y59Q OT0Z<KUKO??;=<W02IG:7# M_7I5/LI^<Q^P^A^OM)HO/HJHJQB@?<
^SPKVL_052E^"7Z1>UWEMZ6IDB#<^<H<_R.#50>1G/K1G_JW.IN&H4!^2-B(ME(LG4)=#IT M2&4X<@5:1XF_3K75UAVVZ:B6Y>>HF=&^>)(3AQ
K9IKT4V0#%&#ZZZF&N MEAV%F<(<%.1IS/7A6\$@<M^LGD_I&+X.JYYSJHM_J0Z2UE.KS)M)M90:P.M4^<=&@B>1%G=&UOTHH+NS9CDOT2=
IUV6J4IG>F^*NC.ND=IK^%U)&A1RBJU MBB#;BIEH=PKX51XG@Y(CYI_K_8:8?F:8H%/0&5O.WB#26KJ!)H!V5D M
H5+D@BY90D^L.XDW=GJ^GY^M25UDQ1DVB195M5FJL92TWH5TYIK\$C47^TMI=TL M3>1SG.YIKT^H.H0&1^VC.%1L32<0I0U26 M
2&D9FS8=ANP^*LGWRNK MAYH.BV.D#K9.NI+>+63^FC\$JIR-3>_VL!\$TBB.&U@U^!J!<JN@&\$U=^*YLE(&H^Z(F9J&=>G M
M+HLRCGXQRM5M3Z372NRX!>@D^M^F7V9>X^"1^U>^?2FK_7A99M^<^F8^M^IK7E7P(>+6AKV16DA^YX.N.F
URAT^U086@<IL_07R.KMZ+\$5Y@^+&#&+ MCTZEN^HJPKER0(7A5U/LI M1^<F^H)EUXXP<9>_>E.G.#(K+)<1L8*7<E!+>U09.JYIQ+<F884(O
M2>WJH_=#48B+5D<)E08#F.MYY:H2!H2ZW*!<Q0S^JHUG4\$&-2585WN9^<QDZ9(H\$;93^Z#7W!TCOL+T@<
MGKJ^0M.QI.PW6JGS_K4W@.00H%5>Z M_Y>7S1J!<^KDP85>0WDDQ^J6K^<22Y4@5Z2LNLZZTC=FF7@.P^%I_L_Y>I8)O M3NU%
!MYGS.1!>X^KET92? M^P.3.\$DHTEK^OAF^RL2&L12!J!1A+TRJ3^!HMX^E_U#>JY>MXNIOBQ
MN6133=U:KV^\$2#93>N#NOKLAVA^%N&:48DTMAZIAN^C:9-PG>PH.K80.T7&M-0M0)&TFKE%7AD8!+OGYN^FOKY.^8P_ZC>4GCW4?
9\$QUPUS^3P!>L9^G1 M(2L.CSV>UH4.OKNA>7^P\$BVQFQWME.W!@-1^<@="M=1HDXIFQIZV_!57\$ M^GW7&(H)
(SMSXEY7TJ=WL^T)ISZ&IK5%C2_IG_TUH7^WIV:AFNVJ>2^A M^#_NO7_83WCAT5JAYON+HHE^8-"L^EF)OD%W0<1X&FT!(H3R^"++=ILK%
M37>Z_VPH.W8I^9V+K5R2PW1)ZW^U^6I2I+AYI6IO2PQ:2.3.K_#<9Q3%<@ M^BA+&OV&Y>5+5R=7I
W^NQ2KT+HGI0G@B9#2H^F8ZGJG=>O>G.FY=9B.R# MZ5UM6^/7H&8AHL!\$P/9R^4^8SS\$.YI8I#<S:T#_8@#P0422S^\$!^C^2J M&K<8BIK<+<O2W?<
W6-PWT^P@<#>1.13^<!(CU)N.L^P3B4Y^QV M^>W^23\$2D M6Q^SY^NK0!KKTY_#RYM@%SSR61K.C.D_C14BQ+U!H>1&CZ_B8C>9R64
M!>6Y0KQ^H<+<2!<KEGI_61NR^HSE^780C^>W^PQ0=QM(NY="8AIB/F10 M38X9)NNU3)2_2GN@<^M2M1CAMJ^MSXIZ&5^N\$OIS MJ88Y^08M\$K
MP=HBW_U<L\$2X(!#<^<^<J<^<X<1P+1^*V^038I&2^U9I:81TNM^WAM2Y^K MJHK_16N+^URX&225:C#9I=3WEE^..0V K9!_<+<+4
^U95V\$;PFZ5M^ZD^AX M^TI=ZOFX^K\$J<K^<7>22);31O@.9!AMN(!^B4B3SJRBR^RC^_#<+41) MA&\$_E_I9NBCW.EP=5C.FFVN=?."T:J2895BAL-
GA59C6!PHZM/AIU_A9 MBJH^H8-ISM0FMR@CBF..M&@f7EV^%C^X A^X^Q8I/GH8/UJ5<19.<#4
MM="7Y^>K8^*WKNB#G6_Z2RWD\$;_!WO@D_!^JAVKOB9RIMJH8VNRGC=I<M_&XS^HCL!"02A_"PZ2JOEJHY4A:OX6H_#OOHH&H5=5^/L4%0
M537&G8L10GQ)GUD#W1<^>QXHD22(46)HKTJ7DKR\$ED1HUZY1^M.VLXIE=;^<QO#15^U^7WV2\$@H.&(<Q2^1728>@QJ MNMWHJ:UOW%5I
(2#%<GC.LI3I CV.A15L10W9:3W/XUHW2X^1 A_O47 M5UAPDAN8F<K_7V&G83^TI) _W:R:/(+<W).3(72R!<1KH R@X9G
M2GF#^H1K^N7XB#5TH9/FUWM@W^#1\$CN=*DB_JXJAI9S!_!0ABZ_."1/7UT(8H!N\$B+NGY)M6?@<B90?D)%<71O:A M^/AJA-5HF:234 ^TQ3E!2
31=1EQI\$+H51B>EZC23T?YZ=5K&^X^<4L^N4G^M=HM8H^MK^AZ<I>^<H!&H&5.FN5W3_WU^>AJOWK^<=>IR4F(H9J)DNO_N+>Z:QNY#2(I_7^<K?
Q7 M^MEY^<N!K\$Y(G:/4K7K9L!<8N^YWI79^OX=(E_O<1 Q5H0V9I_QP^<F M^<+<W32^<#H\$XBCR.D22E>+<8^9A8HF6%#M?
4IVL IVUXZ19RR^GGUQIK%&5^):NOTWKA^<+>@.S.C4=8<!KZ/>+Y=# M^N^!TULFY=#T# SM^I@_J0^?T^R5.7>HJ#X=XB-2).4E>KC58CXUA(3)H!
<UH_#39=/L13# M^/Q38J6ZS#74+H0HB^X^2LJ MXYO.GD2OYWX_1^<5TJ2U>2(SD^QB)B MHEWJOAL_75KR>W^AF7G&3=-GREX:9D&4JGEQ-
9CIE+9>6R)!>W@<HJ>Q>M^M5C^3^V-)RI0IHJY(QP^TOR00JF6M!<56EJ7LH^C^2UJ!+0GNZ M^2I0YFW52Q@-I(HGT^4UD0A0@<^V KJD?
GKLC^UD_W2X0?NS!^TI^>=46" M^P.FN!#<3E&+<EDMUGUR+<=>66REJR0RX.9R.0R.RM\$!<=<SZAVU+N>TR) M-(22=971^!QC^VHJ2J^

T#22=>O,D:1:HLT)=PC-C*8*P512%B!2N7ZWS M=#^^^5UJ5/CW1:NJ7U60U*ORUP?]?5X2DJE3&?U>>C"!#?O>8SLLPV*FPZV^' MH4#JL-ZP.1HK/(-)QKEI98.ATIF^#RIZI>52B(IV.194.N<[S]^-5V78.MTAX8H+JLB^FD^G.6:IKS1GL-9M[<Y^-8X(-S:GD:YAF+HR6U00R9+@L+0-M :XQS3DC"C">P|G>BD!4"1J;K111\$RKW9DB8K7R5_V22U+FXNHQ0<[MVIF M?^VI=8+G*H0W/P!_JIV;!"Z\$!&39"*-<@.VHP+&1T*0.:O>6HUJ2VJ MQ-&HJ.W95VJA145ZLL1NJ4.O^&ROH3#<=&=9PUUO+1FH1P!=HK#HX9:X>&D:7E M4:=0?_M24:=<_&L:1QRJ M^*ZNZPS85K7/>S\$4@X:SL=(SB) ID^CIR4^!C0 M^6"N0.XS)I.AGJ<@N#D4IV? MKGC%Y8JV3.;Z0&-QI:5H:Z?_5YIMKVY XQZ64ZK+@/U%)X%=V&LWOZN MJHO>..5? VZW)KCT@^S^-256H#<^AQIO:B+021^..7<@2A*9#9WYS.A3 MB*YY<+H.NPZ?E;U.@1/(6K) DE:59 1+&Y2DLYZ:Z2L_/_JHKG\$F2> MOQLBAI (O.U*Z9ARQ)=PF=6_YIE0Z.A0=J_IY8N@Q9YFI+JMU_MHU9CU2GINZ8JB:>Q\$KA2N*7B#1+5O!CS4(H^+Y@5LD.UGP=S.5F9L0<^A MJ*0WIF^J2GS.KQ2Y_+J8>+BUA(^+TVJOA9DFK7E^70>||SRHHP>GC MI<+>7;H_?L?=@C99-%\$ VZ4TB-FGC#QVO!H 21XH M57-74? Y%792C2.277 M1D=3.15FI2D (XMN3TUF&B/+B-1SC.Y2 1?>A) L^+1YVY?>Q1R7BS5_I1 MQD_!BIN>JL3DOSIWHJ&RJM3_TH=VD>G\$CQB(= MQJ5>_M:=@/_PW? P.TZ1?NP.ZI?UMY4#DH^O=EI!"^L5(LH7V>Y0+J.MT&^P?? Q+VY*HICR+^C43)."@!W16R8S!^XZMJ6QC.WTVPG.X=BLKBX9V3KR/M^1H69ZG37:OE OPGVG5K@1".OO!S^TM&?P?O=15!X+OV1^W\$ML _=>#* MO*/^7LA+6L20CY^P_#(2XQIF.FR@=H!R^BB*QWMU?/6U/AJ=KONI65_MH8GCCOY.FU22/1IAU^+N #^>4<|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f@G%YEWLLO^QVRIZLJH#474 W;QV!f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f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f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

```

"U!">U!">OR>B$LA"1#IDH%29B3#K-9)IVJ$H9P86ZY4 R(ER+H44HCT NKMUE3.B"TO">I MU<-
/-R=ZD>U"HPZAC@YW,IFZKO"IV#O&N4 M-CX LH2M&F1Z>"V); M%LCV3-8";=*E2U+<2>"A=2|OC03F7$=V1!*G M1,%G=|D>G;.5&;
|BXVYU>42^7V^"UCLK"BF"QX10N0S5W-U5;O=KRW*TS;N M1#W7G*OCE|>N/R;3,Z19K.L'HGN&?>FH740H.VO"5PE5"<25Z6I
M&J6KX|Y@E&H+YQ20B<; KY66Q&S:TsP1(&1Y@2=2GW*AI9+19B1H|6B4.LY M6:C>#JZV1W.W@AWW71ZT"5V8>VDH|60SB$10T@+*6QVX-
>5$=%B1U> M*.$IW%*|LK;#8!7! 3IHWR*9)M/U@I2H|A=86H<SZCQ:S29"BDX12%=N?DZM0E($PB512*8MK" M7:EQ<*M9>8RU5HTCTAN;
(CY8=-45C;$F1^DEFLU^TPWNL|N2N)KVTM|Y3@>Q-YA.L M3.YEOZ3+G'N|6N>6GO&8>4VZ&+!U.R QMXSF">2 L4F"=- MJ&1=2D2AT-
;D718=7@>D41A"TNQYX32"=23G@NVTMTY;E 3$1VQ|H| MI<=UK2E+U.ZYV.MSH(0HA5U&.*#&A6W6%L.V9->9 2"G^Q
M= 8R1=US3N%Y%V*|&ACM#|S^LKUMBT MLJ5^5UTAM M%>6.-= F8(I$795I(H"#MTV"7BMVK5<ZR@##=51+NI D&YEK- 3H|D46
M"=W<(M%02.(4&@=(Z>#2OZ=%|I+P=29R1=%X$B>$6.G=+V)Q6RMW%>V M1RR+WR"6+^G U&D4.C2(N$S97B"R0AX O&0I=B
^=UFZ="JS*U6J21VJ MH^X-T.W;56M^72IRS<58Y3>8-2)WC|ZG> M"V|>O8F8;W(U)DNR-BB%|H.H|H|>L3IE%G|E@WYE;IQ.IZ(:@2
M(%BIEBHGT;XS&IAH C"6UX;|D@.AV/DYR?DG&;KLEK|AH.L1.Y4"1#4# MEZXV;JRSUZ1YLN
5JRSDO^P|J7#;#LHTRLPBG552L)7YRW6.A2@S|QK>| MBDD0.T.U=|A|9.ID^K4V.LWKW(V|>QERIR55PH2H"7L<="WZ1Q4RV+8=900
M%N>|>A17V^6JHIDS.8MPB&KR-Z.GCZ#|ZK)K|J.LH.5TH^VY|J"#*X1 MI(L2^$A.F"E-ATXQ|3PN.1Z^PHYTL7Y;IA-ZALJMRZ^ZT;CMZ/>
M&K90"2.4 4A|S#YD|L^Q1ZL1| (AFKKB3DU.F^ZR>|J5-SN^I2UQ|>2 M7YH8H0JN|GN8R)PLP.Y3 MI VTC 9-0 P502P.5%<18).6F&S.
M(A|A=0C%<17.0 .R;G(M.C.R.#6R.S2>2&B+GAM-2|>7.D)I(G^O|> M^KSNW;8J.Z&#^WA-SIR:4JGLT9CR>5IEF9K>Q8&XI#8"6H249F;CH CPB
M&|<)<5 J9VVV^R61.W.U>KYI<@>B'O<=5|0=-|M?B7@<8)5&M8>2%$-T@>I(60I6D^!3%.-+A7XCOHO>S#T;.(B2(|($PGD*DI"5@4
M1&G=Z#1+^ $OIG27#<5(C;0+^L=^C53W.RZ^200V9I20;1954|.HY M9Q|02V|>^SS_S^<?>L.D^<?>Z^L.COVH&C6_27_O+13H9$X997E&X
MQU)F?U+62_R=D5P5;^JART^K5.D9N*+7XREAQYZAQB5|JT=+2A7E Q|EHY# MF^ZPINZ18
@VO<(<6>K^W^Q0USF=Z|0=B#L|>DUMO59K"JG.C&SV(KJF;R4 M0I@=5_YK/R(8&R+26TU)W3U7VO6QY90U|C0_OIO?O7_6A1YL;@4DY=SBXL
M=K1JR^K08@HLWLGE|6+T^>#<0872B<11(&@<7<@RPED;C&G652+WO| M(RH|LEET>F%$C50Q&KV0E2+G"N|X;Q8>D8
M4*UTNK$|32CPH|J"#N$SWW$F|T/L.JOQ9TNGIAI&U6."+0OF-E561$4./G M:D7^T7YNB|J88AI#-Q|<($H)A6F$0A@F+
(HBDBC)CU6)27HQ+0DU<="J13 MI&PU+4JX(G+J|&6RE#L.Y=4P^EQV02(S;D3ZS*.DSG-3H&7&>K90T2)
M72_R&XJ=FHAM-X/GC|OZMHW|K|Z>LDA|*9G3JU5>92D*RTG&RGN<+MD M<3>Q|""&E/<6*3B3H4U.$SCP|RTJ$ 5V_&YUB.H3-
:9/<@>92712_WA@OP^E2K0CP|?N TM.)Y|S MW5 J3XU-AR7.0U0V^ZODCU^9W2+V7>0<0>X0.XE@L M6"F2>@&@&$1%+L.DQ49|D.JH")615
^XD^?TQ|LLXW>I@<3 B.DZA0^OUW.=2A+LK5@< M5R0QJ66|UAI$Q1+^F6HQ*IN"=4^19W.G;D'7M* K|O&Q.M2W3J@>B9JL>1&
M"NJ|P;05U>X?Q4K+YEF=U+U1$F R#4|2DBK|6G/TOI PA4YU.UAD+H< M(N8Z.W*|AI@<Q10|T.OHE).>G>BI+I7ZHE
8YJP002K713TNA^_R MS_*71.@/GEL#0/H"2EH+&12S/X5000|&SOTR'22.E9CVM?N#T:WNNWC.Y M* QNVGZH?I-J@T^I?
QI.2I=6G6X|U.XDGNB4^0|B|TE4G)7KPI1Y2R*85);9 M+/%Y 2R|0/5&S2(FEY%2I8-F*|S%O|H|I2T+T6>E|7^3E^M"Q@QIR47SW3Z M2W|GK?
M2UAC56+%)@500Q(8NHQ).E.8IG$0|P*D$K31-0N(GJ4Y).N$7H66GD6.Q^M^C27$D|I)P5K91H^? M33>3|NY$U=|H<=
|&@9 NV|_E G+>ZRE(TT^W&RNB.E|P^&GN<K|C|100 M* O-5AVN|>|TXMOHM04Z^>Y(T8)DIS)C=Y6+03K1T=(RVF)G;5LN2-
I43U3|5.5VEF|PG0&L&U* TCKB#JHF|TCX20< M+M#D9CCK.NF2|>^Y Y>8V9L8|VY?^ N|Y M|HRO|BD^|18U Q4 +|>G|L F D1&T|2-
M83U3|>|ATYMY6H^>2MP|UG2^AV443=)3I* ZMY13|CWB|JWWB|C>#Z&S MZ<+<L#&=+8U2|O&G.L3P.OTB|J698V.E9YUR7J=C|N>|J5|+"))
HRI+J.RR MPH&|5<@>6.X?XB<5L> TRK9:XL9Q>|2F+1Y^PRD JAP>OCJ|H MNF@WV.K0M^WG3FXE2F>92%2.%F>XX;MO$?>
D0^WW$3RWFO<3%BAIS&B&7 MQ.$3|B^EL=^%W|TFH=WPIMUU2K.QJA&RBB>|4^E>Y@JU(%O6WUZF6H.MC2| (9P3A'B8|2ST|H-
CU+^LQ.HC8KB3P^DKY4.Y#B)*X MFPKG/H4.(HH83QD00.9H$168$|Z|Y2P/8J^TT>G39WHHBQ(P?>6-L-|C$6.#;TYP^=NZ|3-JRS|H4;
M8-4^CP|(P$&S8|H+DPN0&R<@<10|H=H$JY+08Z3$P2292YQ+Y;BT4 M8.HEF=ZR20.T>+MKHJ29+AE.)#
<|HIA>|L|U|"%4 MHD9#0&B.MTXH3&OPX9Q?7#&F=5(PF=69D6|MI5K1V70|)S&H@%EY=BF$0I M@SR.L<=9+4T6&N4X(FH=>U.| "O1*FI%ZO?I
|UTQ>E$4+36ZL8&|J<C MFA>=73" MN13/MB7BR$ M42^YT#/.9Q$B9>A^4|IYJZ-.RO/33BL+^+4 Q|WK1FC+L TSN.17.T
M|PAZ|F&K&C;TFOACT<Z<|<L'G .<Z7Q|O"IV>?Z#<5$20>7BYV$G.K=C MC3B Q2"1 L=RU-6;|VAT^VTC|T|=6G MN+1|H6QU|MIIX$|FV|V;@
&AUZ_ (OP$-WEIM.S:6 MW2|*PN=18Y5QN.M_6E6OP^4U=69^Q|TGT|BN*W93@KA|B%X4<^HY8Y2?H1!"8=QB&C%|H|P-
|S3QD|OZCENGZVSS0%) MIYY@C|MI<Z$H|HY3L$Y2N|=UP|9>0<1%QYSE=4@0^PCV) (#) P3X0^XPGOV M8B0P3M(T^+V<LC$Q@6.IDK(*Y-
R7#?TJ|V>248^7|Q20^1 C+<3^Q0<8 M@5;3."EYK T^Y>0<."#3|B2Z22|W6Q|&I66W4.ID2^E@<I|LOETQ0 M7?>0<7Q6I9N MWD#|>1B.2?
2(QY|U-7E9%73EDFYB|"?F)Z5^X(XC>/$A|X."R9FJ0>3 MB/AR&><|H<>XHY>1%SDU/%G.F1|J$%V.JPNS5Z+24C F*|<119^QS(IR#F?
%WBXY9A YH>7 M8H#A+1+1CW720Q(HA|1M$GE.XHD0R9Q|O5EM<3^1H4.2YT8D|H|N TN55^IG M63WD|PFEJ^Y E"494>|P*C2Q">H^H F2|U_3LCE2
1-WN-27G 7$UJ3K;LH.MX.6PADA20Q<% QVY%Y) 1U^S1AX+<(E0$E1H^M%<X5|H&S&RK^MNX|0P<^X|XTI607R$%Q2%|>
+PH#W+<KV1V|EB<6V|8#YZKBCG780$H=M
```


WW-KJ=L-Z;ZRFDC9J\$.MD;Y E-TSY(7#X>DF?I<UE/Y M3 GS)7ZV15.ZF=+31156(N=O4I&HFN2=M1#1.8QO@A#BD<D4-KF/K(AQ^V
M(X0Q)Q<Z;+1FKB6%62;R^6D51EP(K7&IMX>+1.2.1M;Y9.4A+0J M5K%PI2(VCFXZ9/4S/U#4-SUDQ3&2O7K<4L<8SY;=,N9M1=N/
M+XVEC.O&PAY8*,BQ3<^IMJOWP&I%@-0\$.*IHS.NG15+P;R@H\$2VG^YV/I=EU(==V7I3-O,IV><^P7,+)M?GY7B-4=RIG+Y?>L7%".
M'=F^1N1X^0#A^!=Q M(8G%Z@9A31.04>\$1-7\$34T^;NHLK2R15N.BJ(6T^#JE.2CK7^LQ@R*8 Z3 M@GV(I/A
\$9W4J/T(C#X#M#00PCB^UL>4&Q@<@K0.I4_9IOZ4=4W>1E)IYI MXTD K989R5CYJ5B164\$%XJM3?>UCL)1%WO4B;^J)J0.C*[KZF:W-K-2;)IM-M%
(NDTOYH4T&:Q08CE71>.W-BOY3E(AN)2^QK#+14)3V11R2Q)1^&21@C MDD+BI^IA(8E105RANT^T/FQC?^17?@IP<,@>
FIQ6LWY0GUVR^MH>2FE=J.M.KG>?)8FKWHF7S2#6/B@17G%QQW+1+ON>=>X1.ZF<<^Y.C2H2R2&:UJF^L1+Q1L12H7%P<^7<>3.U
M4F.(GS:0VE7241.87>3K-S3P1.TCZNI^J.3#9YQ^XV^TD^SLPVL<=^ZPTSA^..UXD!T MI(GKIV.619CIRO*2^'=E25>+G&I^SL)YF7^(-NY^3\$C_Y7ZE
^NIR>Q MSIE(C^6FG+K+IT\$F^2QJXAO.15UNW\$H^G^JVV) 73T1-2Y=52NAB67 MS1MT^>BC51012EU&YJ1X>^08@QU2>=EFL?
@_W/=<Y=BIRX\$KHGVN #/1. M13U&\$1/0H.3Z1^VQ^\$T0=0>S&?11XY^P^_IB^UW^U^L R6=>G^H9%8?C MV+LSI^7@?Q.K6#02M;^ISAJ_A\$?^
D>B/U^JMR7^0^YVIFB^LTIU0^1^T M9ZW1YRV.H0;D)2MG^H1ECV5^HME145+HJ7+^H7;-%(N8BOR4AQ^R-Y^%<M
&18YBF+1/LP3Z19V=BE\$G^3CXH^@J.G^3U1^11F>18>^EB1M^?(9) M0IESH91^/DI=#!C+G4=AI^VN%T\$%3VCP(C^F+36U1QBH4>B2WP6
KVW(B M#F7C+&V.C.N;=1#V?S1+0WU^PWRAN%4K^+VZRLZA6>=KK1DPU.3^EM7^% M7^CN#9RV>MSUL^*PWM#LVIHF^...JZ
DEUG2L1.MSIZZT.Z111^CY0151X8@&L5@&OP1A)PX@0%M%\$^=K^D*)AV.K M&MSYN0:6AX1-HT6V10^K8M#3^H/T>5(LX6^81.48#
fW1)<1&#J4N&ZH MOKPD^D1L>21JLQJ9SX@LU04E7ZAR57LIG3^@H78^ON5H-D-MX<=<B1YU1:TE^QO-N
Q=&J8;+JBL^DEZKBN0IDP6A??R?>03?I&-JA.PWVXB61V7^(\$2A=IQDO@B+V PI03/T(E9D(2^MD^H5>3I?
I:GY0D?H12_6J2TU5\$E1^T U^HDAFAC1Y5M^1227&02_VPMZ2^4 M^T^Q IZ8=H1L.E%F%F+&7JV0C.G1K4X&Z3VLMG^4Y5I9<1)XR2L1+=
M87:8SM&UD4A_1IC^1T1@%\$<4<=>P1P02GOH109@B1061W4F=K\$;FMWR^"U MMT41APWWR8\$1J2U6M@K&I4>VY5-2ULL?
S^1^1^/D1A%VHYLG/Z;CY1Q M7Q\$XS9S2JHV1>9E7F4T6ZZK1^OI+ (FZYO+K1V2YIHR^<Q1(3W=,%1 Y>X MR 63EY1843OZ;7G3-J#U\$YCRX#O:
(88)3%IK.C8C^HB16VEY<615JZH^0 M524ZV1+Y0QH=7E1EGH^U^VNT2-6<6H1^<^JK7Z@4Q#6.01Z*M%)#HE
M@=<^RV;RP5UIV\$MPL;4D:6G8E5^LPI.OJW<^USZ2ID^A1^).8.HH1/5<^XYU18D)N0S17NUC_19ZU21=V7-4CM(C^KWF%27IAJNWK^6;Z@
M<11^8@H7\$P8^YV1\$413K0P^OX11^+W\$D\$G\$ 5>24A>CB^ MCMK^ZSR1J>9G:7.U0S11EA:H1P5>MZ8IC(>7^X+ F@_%>FRI816ZR#1.
MP1M^1-WXYOX(8^@P^(\$10A^J.3>BBDKNI^ZD;FR=14P=^BYE@H(6^DHA M53-1Y^DU\$;BV2;J#<7&U\$8>D-(GB.<1-
G2;#PN81A=KDF.K@H@^("OR5KT2<SD#7>=W4 S LCRH^L.GEF1 MK^GPHV/7=^@-YN62AJM;2)FJ2(P05:L4=&O&OM^%92A#%?2;5B);#P215-'MS?
105-07G+#+(9<KDWK1X0H0B4Q^?81QRZ22KE^XVC MF(9>7>7-C>3T@1(2.BTJRT4T7G0:AYWZ8)6#C0&@MN#BR146L&O%1>C9 M
7Z7EH#6E1^("C^U^F1<^J^TK1W_AA1>FZAY^1@3Q.O525UXRZG-3TBD7C-M:63J^TQ2^?37PLGJ1=62E2SLA:U19@JR3NNV1P_B1#W(>5^*N;-R(X141.
M^CCE+D1HE8M2TGC.U#H0K?S^*=MHH1P^X16^&M50PT^XZ/F@L208WJQFSG<KFI^/U%RL_IHL.S(>73ZNBBD@>5?
JG&S1E1ETGKHJ<+^SH;GH<^C7JAI1^M=-7>+FK23;^2NIW^>^FXL:601HY1%#^)*^"9Q_OVF^Z7(0\$1WIHA1)2YJ=X11B MYG/HU1#1*61S&C^GEGQ-?
J:3.IQ<((2%1CP>Y#!=.Q332:02(?^QKYKQ<W.M&^<89X58CPR/OVCM:
=ZZHF5-0:QNF/N7@QLP+J1D>9I2\$QYY(>1KJW<WC41^0^W%T)CV=U8^J^H1+H\$=)1%\$;>#Q&84^9XQ2XO^0 M^3K+ O.I#2;#3LP^R
<2C8YTND<="J)88+QL L1^<^&T80.H1>LEQ>117JHKTG^0 Q4IBC1^0%1A=L1J MT^6A&S1Q@^F%LZ6UK1.E ME=,FV5E7000&1^JL#OYN-
EGTJ=QE>KLMR1ZW3 MU(NPF\$12/TTA\$CX13\$C0H1XCANY+G=K= *IK5A>^J41
MU(F6;Z;ZDSX<R05)&51OE^1L>=57IG1XQ.4AOMT1^OQPIGD1L &16+M@B M^NE^/ALD1^9R@R^*X\$=#1@^Y5EHT^2^PHH(Q1&4U
^XR71R16CZRXR^R MDKRD7(1^1^4QQ^Y@^*1@Q.8>ZTD(21B3^QYV1^Q6Y1^MW^*C(BTH<^Q&&HCUY0)Y6ZG&K^+O@D;J^ MJ7^AOFWU;M-
O1+)^2^*#;EE&^TV@B^SQ15U5+HXG_MSF>K3(16^8HNA M3-68EP1.N SL=) AA%#;2MQU(OHYA1\$2TIBX1^T<OGUL^IFHX4R2^M7
^T07@3>U1K^N302<8;Z;^1^FJOVHFJG5G96PE1O.P.OAXA^J4A-M^+OE1U)LW^1^@>D=C9B1.EQSKCGA:51100LB>A3D1^69>U98H&1^1@QQ
MB#^#JP031^4QB\$)HB1;M^MM&YD1&5JH^R^K1087G^J)PZT1BZ1^OZ1>D M4P16=0UE2&S=950K M3R9J/J#6RU^MND8%+KJG;^ PFH+^N8NOJ<-PI
^MQLNFU910.EZ8;P> Q_KL=^&DVOL<Y1L9.K1U1M9AW02_<A\$;K\$;Q6C= MP^T_O31PT^ (P07Z.46.MS;GY6UEU5^#L6^+<OQTSN\$1^F MO4-
W56(N1&N 3&+14@4VYHMEY7HF65SSN@U11^MMR1TN61^CBG1^YP.DOWVBLT6N5>3P7PH^RD&HHSF7>KH4^WZOH^YSYE;U7
Y=5CN41^&S+ANBB^20H1<7T84XQ(WL5A MO1W1T.1#&2BDQ.L1+>S+333#)DBJL\$<^D1W^1G^IU>H\$J4N HF07RY
MM00^X#FY1G@G60F.C<HLRZ.P5M.G M62W60PW1N1C@^D%OO61^8^1 L<^7(1)H1^V6HLX-U^UK7^==WKK9PU1^FYV9(D:SU)E5GJT=H^C
M15HTS^Y^N^KIN6"/+^<SK1+)^LGZ4M^Y^2X^X)@/TPYBB\$^.(8H#GV8\$C> MIF.O9P)DQULIP.R(B.2VDICN2);)T>^GY:HL?
P.XJHH175=U^+WP0^Y8 MCK.R^M 7^#X^X^IQEN6(^C15U1T:E1T9^CYSQ?U6E1PD5#@ ESN0=51CQ83
MOH1;RO1^X^D>=1CYMD1/5=X17#1179YBK^1+Z1BW6C<IH&Y+^2VR2:0SD M1:00.HUGIC#3B6)G5V^O^G MA;>Z X9D/9J(R8DDU5RP(M03ST-
B#K.PP0Q&7J;"Q8!W&&^Z%8-4.NON0SZ MMXF 4L^+,@E@9OE/%+XX>/Q; UD)Q)@64WN=^XAF71/ZHD@^U.*IMD0#1CWA
M1^COE1^&F^1T@E5 L1^&71AGL>@>81Z6LE2=SVKY1.1JETFWOLS^T.VD=^*1.O M2.3-9=1%X@7^5T.>3^N&H^X2G=^C.G
%3SX.X#Q2^<="2PE\$+E7H MQ-J1^3UBF6+H W:2DS^QO13U^M^%MIF2_510PX-8121%J59-9.MGYC\$;EE
"@_2W&:MU)V@5^C&6/S1^A#W3)M^CAJ@:4QO=OVK1/TJ^G1H^1X M0X81+CKO+60>Y/W^1^@R66RM1&ZK.T^HFD:(01.G%"^LNA#I
MGB\$^2WR.8T2YK<5^6=PXN&16YZT1^L1:MX>^A^147P1KHJGT97T^QWHQJ1 MO&KGZ^1U/VB^QXX%7^V@1@IMZS=O^*)41X\$.\$XFR#0&NGA>%<+?
VBY:V6YL M\$1^1^="H4=B7ZP.*9.8B\$.4>=FX1ZV80TQ1\$1U1M1K9N7.00(K\$91ML M1+1B 51?>F^14.M%1^10K)E#F17/@QB5GG);#QWFQP?
^1W1RO(UJH^@ M7W17 R^RRM1^L6G.78\$^RNH1=&6K351^1^1^7)O.^C1P1 O1^GM14J1D M^?<1BGT8-27Q1V^B6.
P<1+^1)QHY>0O15)UQ1^DOA.Q^1^D+^ONKZ1^ MY771 B*#2>315/4HMS8^1=51=+L LE\$1L) \$22^DC6G12AIPCY6X1?H^?T
MR+^?2:W6S8VS3FVPT.MV1.3FL^JK5U (>P^NJ#60D)JZZF1H2)4^HZ^Q M/CW@^Y1!#1+/JRG790K9XC;)2UW^KBWEV^Q>0BK1WZNQ7_F*WWW)M;
Z1KU(431V04 7%#JP4UQ^M0NWP2^1M0G; MMW1Q21EY.MB6X1EXH3H9MPGT(N^14.1-3-(1L.GSQ9^8JYQ2U1^<Y1O ML^1ATD^YVCFWY)6Y5-WK-
8KUR1)2UP7MD>W3Z^Q)X<9) 1CP.48@QC^F# MH>L%;HPQ21TTTBDWT5LO&4_<^93VJSS8S8ZTU1PHS25TE9T.H9RHD.N.J1\$H0NK&"4:--
M&N1.LIHUJFT1^7<5UXSX)GEE1055A@L@YU18&^Z1M75Y22^APL1M^2.WR^<1B M^C1GU^1=^WYN^1B @C<55-OP7-
#>^G1O^QZK^1A\$<^>#G1#POFLP1A>3 3 ME12% A^72S<4^21D1P&X^1+0<^%SGLS^2NC.U.L1T\$H&=^% RE8OP#; TS1W MVS>CV1^18JOS-
NEE^YG8%F9RN_VY.O R.PM/ZM17>LN>5&.*X>^DS6W>A M)U1^0T2^W+N1A^Y+H+80PET6210=%SAY0.74Z+F^A;H4V^=XU1LB2@&1X M-
H0Q5_ P^=AHOSLV MJ1A79LVTCTICY<0^9B H.81^%86&8AC^81HE+^WF&S:Z^0Y16M11_Z M>4WQY2M^1N96GF81^X)1^SZB@1^*?
1BA4%1A\$1^1^X22.\$T=^YU^1(0CF M1>GE^YVC0T2H05>S13X% J1EMK1JEN=5^HTD^N^2.Z#L21^ES13 M71V>TBRO^?
^D=5#+@L^WAL:QG/9-A)\$Y12KT?SZD2&JVSEB1^Z8V+H^U MN^H+AY&0QH1@FSAP(^1@K&3.\$@#&5)"B(1516)F5:5J5_W32N%OU
MXT^015>=WJ^GN^Q^W^D^C^KJW<8^@T1Q)S1\$1^UH#^=H=0>^TOG1KN^ITZG MKF2T#G.KFS1^1X19/K.L1Q10401=1DDDZD_2^ZM5O11^8-
M_>&4.O M>#R^N^X26104RQQ^21PSPQ1Z48 M@=7@1..00R4>71J1JY^Z^Q H2MW^64Z6EZH117.1297WJ<129>XJ1^QJ3YFS^QDN69
M_+24D2(RX07_P&6^RQ:7=4_%UP/RZK807R\$^ZIG^5KX2ROWS^18T^XMS MM1^OK0 M#\$D0F+V%(8R5:K1E#W7H1
(H^TE1H0QDPH>J=^6LJPCGXJ6 ME11=^L^YCF DA/SS@KNF2&XMS^MGU+B9.50XN166JLA=FF&453^O^SZBOZ M1/^1J3ZD.DE?
U175T2)3#^1LLZ1W1^@1PB+D11^GQ(TMRI+O@7NSZU^&0XM^#R<=(8L1^Z.D17GL1&B5U50>4 M(9BU1^LCQ N1L^OM;#E712 @Y="9^B\$Z"
<^?2)TY2TC&5&5V33)0>039 M8E11+OY^50<1W1H1BM16RWZ161Q0>)2HQ+G+@^F^L1&18F^%KYH1^02X M>V^1+KUUL0M7>57KB>L>51H1^1^
(8A(P^KE0^AG1E-0\$)HX20_2WY7^<^CQ^MNA(31Z1^1J1^V2W9H41J141^OR1019ZJK4 P^9#YX1^1^1QVCVPJY P^M=M^H81^1^1OIZ1X 6H=D^TV8A;U+I
MU0Q^"##P@P21.3B2Y C^16%80^T121PF)1OE0CE3LXD1R7X6C5H+F\$HU M0^171^%1LWH1@J#J1LCT1Z^SUHH1^BIH\$>1^+&15N>610+6?D;\$\$
MH26T>?1J4192BS1>3H1B2TAGE1VX.R=UF>5.Q.2G(C(31^1N=FP1^1TVTY=614WV1TXWT^1G MA+51^FE1+^C^R^*O.F0K8
YD>91MM&E;^D_11ANS(5^1^1^R1Y1RC M%)@ABO.B1WXS8H0BZ)1^J1R:4ZB5&=9D8K1KT@U=2129.C@?756BFP4U
M1981G1^15.H^1>ZKU5V4U(DET^1^J=2Y^MHK&>LQ.YFM<^Z1+U=H,434^Y
M^X1U3100HW<9KU119NEK/M>9)G^GJORKLZB_QLNZC1LURQ^ZN^>F<3<_MD7#F2.ZP6^5S1R>ET^*(H7<5ZKX=[X]\$1^W0#1I3Z@1(U^1+^*=0X)
MJ8=&41VH(1OM.X^1H1^U JQ@0FH%:M4-8P66:FJ33Y1ZLAID@1/R1^6 MB+^.#76SG=GST;<4<60%IZ&1^1\$S1>09-6(G7.FRV:EG1OBZ-WF5VZ\$NCM
M1^Y1V1+1(12FLK1L1Y<^<70=8.X2)2^Z15Y12=0VL25@51R1E1J.FVU1F^0 M8^3^3R0R5121&1QUWX=DS5P^7L1PSKP^B_1C61&Z^*H)=%M^X)
HP46 PM;<0^N<0-5BY=>W9M9^@GQ M.C06^T1L9-SC^JQLSH+H^R15.Q11E66302REWYK(81&7 MEY=H6V^*6=2617-B^GJ(PY.O1RKH@H
M.*\$X.O5MQ(MTK)41^?UF4=>2JIS^&M>1150=-.80U@IZD7^11&1^1APB% MTF)01AB+T9.\$ \$DIG1)W:8%WB@_FU)U1^Z@/_10^HOK8Z@9^H331TV
MZ.UUV=>7/4H>2) M7TEB1^LZKM^E19V69K^C^F&6%NOY M9C^F7EEQYNZ41^2G.E1S=RL3) 2 ICSE^81^1A=*&5=&6E1G7P^HZ<^141/4V55JH14=
MS2\$HSDPTMWD41^8\$M^2?UW>=)1#1^#1SL1+3-8V>Y#261+VMV^;(MKYU101(EBX.R_O\$^<R^&A1&1(N)SF1B^1U52A AIF>^4A1^
M8XU/IK\$1@UJ>F+>S32KCVXJ>OFH1JL4.0/43M^MN<0N^GKL@.%>H8*+07.Q.6.E1S^28B1UDP>X2Z&1V=AWD1^>OVF197B/MZ7%55&-7S71)F?
1U2101WTN^XT 6^10B1#1A M^3&Q.P.2N@VFNRS1NM9NHL31^1@15(JD(U@O:9X^JY>SPU6GK<66L1.W5Z MA30ZA21^983G+62@XJM^T
F^LQ1V^<D.XNHS3EAE93F1KGWKQ1C)31^M^*^#L^*W=1B5-3#NU211^>?KXJH N (< M9UUVN#0AP4B#4416907)
IH2(^"##4YV\$M&K3 1\$3D1^GB0LS1^C1 M@R+N1\$^6B1K6^X1O131^1^1%T47B1M90UQMZK^R6@O-M^TUP:6D\$5BIH1^H898H_K2<67E1U-
Q1LAX P8R1LO^0T^ZLB21<5HJ>X MR(5W6LH12Y2^N.M.8Q51JVG^=14QW^R(PLGH#PA@0M)DNB1A3E1.7>0D
M5.96<MLT)V1L<Y>J2R54S=M:S.U #NU 1^N^NRNJ\$@OR5)S^7097YVMZC1 M2RQ0&1^CF@4ZVM1^N^1^VEW.C21
+6.1CC^%E1G1.O1=62%60@1L.C MMZ.U.R.N^UF17^XK.E1^ XNW1X.5 R^1ZQ Y16^>Z0192^B^MZO7&W1U6 M5:Y1G6@(@6^VL621J\$HY
U^MWJY4<%.HYB)4VW.%C0Q8E0_+F+LT7.SF^M95;D.B7%41;JMY.P22(H1&,\$ZH^Q^"&.>ZT782AQ_23TL)Z6V61\$X>
M3BH1^39Z7T^N_1M_DD0.5F9W/37=L7P.FEX1P4>191^X 97L=3 VZ+<^C M^FOD^S1=UJME AXU.R@^C^C+9JN17G1U)EW%QV=6U-
ZOD12N<C&1%513XT+ M^F1Z&_F1>F8D&78H41RF 8.P2&S^C5^ML0\$AVU\$FOD^N3&1STA=HMS^20
M5%N#382/17N1\$1LLMOL%&GR7U1H:1JC^PW1^12D2RK&LE TCVET4F3>@1^M8S>Y&(8Y7LHN_441^Y^V7.G>T8>1^R?>
ZTW.H11B&G.G8#&\$6(OXR#1^X M0B1UB>MPI=>1@JG91F.F71N3E>Y1^J1L6 D^E^\$%=>R=R^F7>8Q^571E.6KXT81^12&3^MM5)7AF\$E^
1JTW<4^&^&QV@3Y171%VH%3W(U15E\$2U_LL^Q1U@EL> 5167 M&\$.UUYG.O.R251=2Q>9CFH=A3N4A82GT^Q1^TQ0B1^1P18@+>819@W"
M@U IF=V8H^F#GS9B02T7^"XE@UJT.F+W4U1^16H;.B-9S1^1.D1PRS^0EY M2LR1T8XCQAY\$(X1SK+D(^ADKUES71O1YJ&QW@1A15+^CU&
<4^4WMZJ5A.30BN&EKC1 M.D7L1.Z2GZ UFF@Z1G8ZQ14UEEB71>B40U1^UDH1=L^M1Q1TQ5ZOMK^W 1P1 M^EL<^1#L=A33EKGHD-
G6.V8^S>^C1V&S&F71H1+T^1) MVE1^1^&2)MR^*OM9D(&1Z8%QT_2^G^PY1^19_7B5^Y1^W.VO^1+P1K<1^1 M1^K1C2KMXH-
Q1F12.D1B&00\$A<RAH^1^E<^N^BF#A/MPI.1.3C90^MF+1/M6^2=PDF^08K1<01H8&@/FF7M1/JXE)DJ@=1^/3R4^GY%?
9T^X8K1+9O.M7U8K^BU1^L5R81^CTG1J^1Q1.0111^1 M^1^"RO62<=>(&R3B.21PX<0^QJ+0^4141^1)TB15^1B1#^U=AH%_5^>^C)SNJG.YA M5-
XA24W.P>+MO^77N3;MS-6.R/1 C131B1J.DED<1;@BOYWDPP>U83-8X3^RMY UJ8B>M8K42POD\$G11^7B>WEA3A1M1H^16^&-GBL-
A1^1L1V>X12M^36H1^MO^XK+YMI1A195_K&68X21^E0^Z1E-VJN/ZXH41RL1(1101Z2H^?F>9+2 M\$M^FP-B?

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

M4:VY<J>-KZJM7W-CH#8+2;4/HNS>P<66G8 M-(TT-87ZQIV636AA\AI%ZVMFH-UJG\Z3PI\$.H0-F *7>K%?E<""\J-EEZ>'K2-M"&#>#>; (%IGUG<O4=-M9GL+V)V6.G&\$.KM4XY<I>J-4J3NX>S2712QI?21H12\J0N&OL\A=->L6
MN5K*U79M.-%-9ZOR72L@.Y=LMCARZVYNX^G.0\$O=3M).&M7OT.SP4=-.CYTT MX> H\05;N-D76SFW\9\3\IXN56MM+^2W>7A.VWWF\J9UD=-=I0P)+#IDUV-M(AIDH811UD*(DX1 \$@4)9%F0T*0A@.C:589>7:48\LMJ-^<VWJ_N_@=LOX.;K M7Z^_ /2QV_?7AVPSZ;?DEZZ;.\$&=@V3MB@UKHRTY M8*C.EIO\$S=H:SIUV00+;M2:0@EKK?W:WGGYT6\$2?<=5K19%>GVH>UES*5>
MW*W74IW7DM=E\$>\$.<90NT\X@YYH@0B*GJ0DUKNQ@HQRZF^C^SS2G&@ ME-9+4ZP9Y0IA\$.122 4+MR2)5*8<(004%" MD""A2YF.E52G0>9>H&9G.HM;^C4.MNEMDN@I_U_ZI>F96W>FLIVE.ZNR.HV.M0.
MMYK*W*YS.*C7BPESI.M08FKCEC.92HZH\INTZF.TM<==&YL2INPX""?O-MNMS7U4H8=K5Y@\$.<(:7F0D+(6.99 M"%F0QA2E" (I^2*DAVJ_G=B1I^>Y2Z+&TJ^X/M^@.K5WU_UA=15J6J1 MA>=>=I^DIOSV.L^E0(S4^H\NR4 (T6^GV^FG>.:C^MAS\$Y<3ND^Q^\$EI=-M_? S^Q^W;1H>=2QTGRR02HSIS4\NH&U.E^F*N<IG2XXB4UI+A.BN8\OHLV;?M-MDSXXA^W+6J8Y5T&J%\$S."1A\$W"<4I(33.);1,, (J)B3\$GB1\PRLKYC;S;V\$O^/MFU\@SW9.;1WA+Z)VP4\RW-9V^O.V@K7SM+T^A?GO^VU-6U!;##->6.\$Q
M)7HBO*VYX+UG=1W3P3\Z<E=C>5;2RT.(ZJ^OEEAE4I+>1.K(TSLTIOH@);?2CW.M0.CSH9XKID\3#(LDA(OFGDE-N^Q?OU76^7TI@H\JWYUQ +W2R;=-DZ.M\$SDMS)IN*Z4T@L^_DE;H_PFD.19^J.MA%\$9I(EP;H8J&MI^FQ>6A#0YVU.EY\56+=4F0IENY7;V%J4-U>.&@J079-M4>>9;VU;I3^NL%? *W^I""2EGN15)AT-3<5L+<PD^ZLD^5V)C+^8217^.(X"BOQ^3^16\$5^#.B*)5>=>A-IsG3P3G."SH?NP1+^_M&_G^QIW-J 6+G37.R5J?>V0I^EAG."XH@+SNUN+J&HWJ2VW.EN421+.#-M<(O2I2.X^3.%80Q2).P(RS-8UO&AHO2IE\CHHXRTB=Y3K%#JAN%<#=?H MI^38)JPV_-V>(6E^W/#0^BW@;^ICIC.DH^S^..XV_-4FWF^D^0M.MAOJWYMES1^?2*R.O>W_-L.TQ\$F2<+TU5J;X#84PHRR\$=\$=I^Y2E<78L7F% MI>B1G=VQF\HWLP^V\$QVP.YNU3;.(FI^KJ\$2&BT^>9/2.T4;137CG)0ZP.MRIR6%3.XDI-G^""SU^>Z+HR+;1N.NR3YUTZ9@N8I5F)P3;V(C0 M^H1C@61\YQF@2IE0%Q%SEVZERMIH^FJSD\BP5-1%&O.SRXYV;HGI.MEATFYX;XV^<G_4;U%E@Y>296Q10W^LL3;X;H^2(G.ME^49\$S FPK2L3QFD.L602YDQD\58V+6L^Z+V\$>.;KXGYT8A-#1^5 YT^+3>7 MVJ?) 7KK)@?H(HO4Z\$T.T)2.R=(^YH\;G\$R53;D<*1%>W3;RUJBI MOJU;9PU0C0GAM;I=2&BFX.E7+PN=\$A7.V(K)^ULR9+ISACI^0Q3X.PE29E_MN.O+E+PCIB72QV+U^_WJ_2SI00I3YU%ZM;1.AH&LW\$&CIX M;D.IC9MI.U2I^RMJ;E:T3B^0UL@GX=+S1\$27186^RH@SP;5.9#7E8WZSS.MIE_KLIGK=I_N-6FX>OR@2G.D9\$8@I^R^I#;88)C2DC;1#3T&G? 82MXI&I-M6;-73.%K0P32JEMIT?BHIDY@FKFGI;RO7JQ&V^7?T\$E;PT^M^"HW93CXJBA.I-PX^EG3/^6^USHEFI8^MUQK2I\$3)URI@7& <=>UX_I^"MR#*39UWR^?FQC%#D3_2K&(A+WI69""+U@*^J2IE^V5YX.W>M/OL^TQZ^JZX<^SXIM.%JB0<EJ>_.HUWK#J? QJ43>8.2X2G5&FD2M0^_5OT^AM;[K;V+A#10U4\$8M-MF^2UID600.S+^8PPI2.2\$510;.\$AUQ-2<[KJ\GSI^=XJ2D+^*K1S&L5M+ M;@.P5&0/QADE31H#J3JIR6<+4Q@;V3UK+^M_.\$N%JYH2U5^NKAIK^R-O>=80^0.19IE\$%&J\$+*0B8\$D8<=I^PTRRU4I3F.MUH@=S.9JH6(=#=17X->USOS#16)R.K^<\$YZ=J0C5.S5F.M^_+2QD1UEXIV.MDM+266=C(K^<19C9ZBWVIOX.*V6=4HBD^0EJHIA0^2XI;U_4^)&#^2LI^QI^_M&\$^>@.O.S%N;DO8? YV.YU2.8^3KA;K10^KK;""LH=SU&FPG^L>I>K^R*#+YBH8HIC^?CIT66.MAWOJ&6BV50^N9U.YI=5^I8;H;_S^(<Y%&NEMO5S?P7;8I.Z.TCI3>X.Z? MHWZU-BJZ(=V^>YRE.(2.HA2C^2RT.(^XG^YD@Y@YI^<I.V_169GS^UM8DT.M34U^UD_R=(H^T\$KEWG6P;M^_3K-M^7ID;X_ =9<^/JTP^OIXK4BUN^>09#B^F^=IG+&HBO^V2SDXHK%4ID-37%RIIT\$15_R_ M^<JX^GB29XDZ7^L3>=>I^QTBBE+L08HAB@+0PE3AB^QDA3^62CBQ^ACV22D.MA^*JO^UD64^0.ZM.\$M^_K.B^&I8K6;.4X)R5O=.8I7G_1XID^5Z2O\$Y? Z^HM.MPDW^U;#AW@S2=OQK>>>^SC#H\$80QGS\$S);2OX4Q@<+G^51QJ9^SL3IEK? MW2GIZ0UM.H-B-OGUJB4IME#^ JG8@RBU2+ILF=,B\33887Z2#02SM4T8\W.MC1/&01EOG:"OAKG3IO80_R^2^*1>"JE(2A2ID/" M8@8I#=(.28N)OUK#&W2(S? RRRKIGKW5^H1G4+@4V\$PL^IB/NEJ^F^<H^0QKG<=>8VYVKY%<C=K5Y7@/M#JZQ&G2UUA^<=H7L44AFW22.MQMYKBPY M^R0G\G_N_4^<Q^ZIM^_&PHE592R^8Q9\ZRG6K);&M#=-TFC.MY41B;_I@<T\$X_<65=4W2>@<F^D>AR9)9);"IPEQ^Q^VK+90;0_B MWI_BJFUB>?;M0J^%7AJFSJ^J^ZVMYRNT^D/R^&4(ZI^=G8^2\$<.<W^PY>I=I=W^<(G=YRCTB9@IB4OGA>>45-MJ)E6-I\I_5W0)BONIS^FUJ^AR^6 MQ=-TXUV="I7X_>I@#W26KIL03Q2#P=MY=*\$ELM\3%;6I_KD+PW.T^Y.M6>+&I0GB<5VPU7P4^T^YX\I2K>I^<OU(U^_UE7=IZU? 00;=H@R6G^FWM9R.MCA7=G4U;N.M^N^I^<J^ZIL\$WK.RFQ\$W.YWE&#*C2E46.%CULC^ALUB?^POA-M^SVP;Z2.D_EC7K<I^_ SH^VLDDH^N@I^"33I25I>PHJ2+LRPP_Z@. M&5C0/_16<=MR9G_@=3AZIHPYI(S4U;X%3B^>Z7>.574.NU9)4IM^M>Z@N;+K9DH(7==>NRIW3 MKE+J=K/52K7W_-S1BEGI)("C.L/G/B/X^\$ASZ,*15A\$(LLB;7B=7.RN;#M;L.B7R=#A^HXA+9+S5OL\HXE^_DO&=A<5\$%R?/MKU^L^I^R>U% <""F82M;I^ZJ_T01LP_G_4@3#(L^DVA<I^@."248APG.M+1(8;222ZHQ\MEFFJ)AV0FI=-O>55L\7Q12I3Q6H@52Y=-60;O.Y3N^#O.M15Y52%-2? X&+39L;KV8RI3Z;36M3I6KOCV;E^K(2Z-FYGI>HUGI>YW3XI_M.SW%BI^A@L@V9@AY=00=(>I%G2H+MYI.MP0^MIHQF_ QNISD^RU/TM3B7;I&K_K&8XJ&4I^D)EOE02.EY^?3I+5A.M^@HW.CG=DQB9GV@_.89555).T7P\AYZ>WZ.E&V;^Z6_<^SBT\XVKIO\$%AT M;YX6V4V+^C2DGIK\I^DV^J^_.*26YI^QW7+6_3VOON4.N;55=&Y.S+GG.M%&5\$RED^40L\$4R4@^Y70R4+AR4I=72PYF^F_2IQH9K@K5RVM8- %00.M264.Z^<VP\$IO+;7@KYS^8&5#)_M2^9@I3+I/HFE)<@K_@*^B2OJ_-5;=<=H3#17OL@I>)E^O-RSSOXLV\I@PL.MN#R<4M7MI=J^1R4_ IY^I256J12I52=N1KE2M>P#5=L#0MXUA3_-VI9U^3F6.HI.NG?B#XBYODHTD82.CWFI=Q+=D)XG=SYV2MI^YZ^_6;_B2=I.OJZ#18\$(M&) (OAU2^&#(0EH^#WFI0C\$>^&5N+BP25G\K5\$%&IHD73VA;I^_HIG.MJLT1I\H\B4L;SYM;04I458H6DJLY&V\$H0!>I==BFF_Y.X>@&K.3\$LP MGMI?^J>CIG^<L^;EA_*_CS_?L3S(X(X))P@RA.(GFJBP5\$OL=JGU&&MN%80H\49M84#4W0\$<4U52#)ZNVGTI@_.PTGTAJZ=DT^U=Y\$H (C93)>YMS.MG2SA<D^PIO>(B6VQ4H&Z3C5IHF<^?T^_VA=W+OZ6M.R)ED0^<62GST40^F^MN2^7=7U9&B^<H(D(B;^7IOZDQ1F MGPFTW(SZSY<8WC+Q^2<^&IKRF=6D3HDPY3.TS277;I%\$=BL%_6D@Q>G;Y8/MR8^2DU>J>9DZK4OZE^<YI^Y_+623S7?MSI3OMY+R4_ YIP6)SSGRH(=4TYXX.MI2\$8VD\^P(%N5A\$&EMP(E+I)^C^T?I6NZ_.W&U8@I<^_O2I?ZHQ0_UCP8G MYBE/9/OQO%#.HKBOPIS^<LZ^A^_V0R)H\B.6150=.%@2242N3I&9W0_XR^Z^N^0_&OS1 M\$#>*=IT\$2B>PYT)T_C>)*A/M<(<^_I;_#PC#Z_ R@8!#PY.T+Q@+!^@9M\$ARIVBYD\753D)NIW^&^/O^_MOW5TIDUH4I<^<_W>=VK0F58-I.VY\NJRCD.M/B7\$>W^H276JM+%)6A+PHX3Y&\$35^Y_ RIQJ3I^7+2GSHV\@;MANP.MZ_.\$Q0P7(^WW9F&8I#>+Q^R\$;AFRK^?32I)@.(ZM53>Z4WUX^_T3=C^KE5>UW054QJ(XFF66MUHD?#W%<=<@D.#8U-M\$^MI#7-IC+L^<VJ3M.M&U^>+U^O^I^<I&UEF9D^&4HZG02.MI5M4\$<23I.NMZM=T+^E3 M9(3RT\$;PE7H+JMZ>.\$VB^_8T(2+.%I09#;34YNVR=27M;GEJ^_BI^N^I^M^>+VR_1\$%_GZ^7=PR3YI5QU^M+58^F8YKR((.9NE59^R? JS1X;K+YL&M;MPG&4^S^&I^4C%E=8^I.MED\U5V^I)MHX)^=F\$PY&8&(8ZD=F.035.0PP5&M4PYD@AJ5SYR@.I<+MD<5U&0_ HJ5C.G&Z7I<+^AXM9#;W.DZ+I)4K<^I)4^LNZ.M6X=%/?^UCEQNI.D.P8PI^QVUE? 5BL.PPDTHI\$W\$OR^W>#>8EON.YUOQ^IGS^8^IC03\$(4T@RQD&89^4F8D.M-P+M^/7B^I^XY5Y("B\X-DF^\$!@_I^T^1RVP^ID6R-H?R;9-G)BHFTI MWDO6TU\I^6&53NFMROY.C.%/I50&GS;YV53&0SO\NI02)HIOAC#(\$Y2.M6^4PBS#I.J#)2&MH+O^2^CAHRHDY?_HX+H/FT+ <R+I=I/(P%+/TZWN^MZM^2QC^E^W&(L^%)R^*#_J6;(%IG7RI83(G^_H+N^<M^VDX6+5S7?P5^_K@3V@YV>44@H0=X>X&+IFARI?@A6S? B<=^@_<W;NM^I^H=RBMSIC^89\$2IDF^Q^<O^4PPU^<I^&K^N^ASU+GO^YL^XVOF@=6^>8I^_)*M\A\$+H53^). (D8I^#5\$B\$5E9U2(R\$.(I/<_H KSNJTE88\$^UKD6OVRQ%#_MYVGOGINW44Q>PBOPOSIH^N0X5.O^RKJ8ITTRPV^T\A^VIOERX.F@.)+=EPL^BFF@#1+4U92G+TIGG55MUF_S.MEJ)? -W7I^R53P24Q9)U94%.5%U&G.>"UF<=BC\$<L0F9DZ.R3FSLQJ(AW.MW^L5>34CK67_.(XCJ>OG&^A9EJ&8)A\BM&3TQ7@<)A8LO&" I4\$PH.ZMUE.MI2XD0ASE=I<9Q7436_0MA=K3J\N4M^0^1^#I^YVB<2WV^IQS\$E^6@<9B^RY.M.T4^4Q.ZT(NXHY.4I_3IE7.C^S1JB94.TN& (&L(H^"FQJ3NH.%MY^A\$^_M^*ZC(R15^VAHH73<@I^)=5=-I&WMD0F(##.0)=K\$XTI2A^I&D2>M8I^47U;=+I^XO4\WSC16N0(OF.ML<")BCC\$ 5A#=\$<IQ^2+<+^44Z2>DOTEJIGRI\FBCX#^G.Y^""38FXWTV.MNJIF0182)N\$1I>E4@UGRR99^Y.B.V2RH7&E<@<BIJ^0^<L&C^&D2>8^NC (8B245&021#_M6FT^G0^DH6^<JN0>2#5I<.<.)+VC\63I5I3PD;SN3I&5\$&CDZ^+Y-8I\$SIZ^9MKX^ZPO2^CNOM\N.RI?2=^XKSS=>M6> H6U+@I^J?=%@O^C6I^>5WSX<5?ME?J5K/F%/KQHG2^HQ0RI(41JF7093)?9UF^_.\$L(IY\$D3;#BXURW^ZN^_M.Z\K\H+@%RE^>?UZ!/=^#@^/=8_ 4X3^9Q\$>CPI>0XB&S.S/C\$SK^<5L2I.E7M9)M@R%41.P\K88Q^AE. T2GT8B8@)3E/L%\$^T@BI^55PCR2H;=HE6(Y@IH6&.%GLH&R&^PA@B%F.8T3B^?D2P2%HOI^_U.MV4I.S.OF\$%M?^I+WI^7;4PI^AI/S(8466^ I+B3;^ZAS)2#"5063C4CS\$F>R\$G>7@#A=?M^I/Q^I.R#^IWC.%ENN0%<%D^F+AA<HE^ONW;5&Q76.A778_ D_<I^W.F8CKX&@3=IUV>#EJM<JGL^I)OHPBI.MHRH.5^N^N^U^>2%>RL^"XW\ZOUEHUA=WS^W5S3T^E232L1^8)8Z8.NFQ7 M24Q^7)R5#X^<R^_G3^G>83F-2N3?%LFJ)/454HN5P+M0K_D_<05Y@<45>=>M\3I7PWA8/>)9-0A7WH3;9S\$C^8=^EC"(>\$9@BJ(0QIR%);-I&=> I@S54TIF.MWCQI\J^C.SQ3I21^PIQ+E=QF^<Q^Q^9^QJV.R39BT>G+I08.MC@G7GJH^% MID_@>EG7^QOPY9VMF\W#ZA>BKD^?KB3DQBQI>0)A#^A+49)PEFEMQV\$R.M.VI(1I24A(\$BW^#0S.GH#_ S\NAP(I79=GQ;8)NLH(%OAGYFD!.\$I)P3MDB8.MI0J^"CB4+G3ZYN52AD8%>)V^ZUI1IA/R2TB0\IX&);VTDDB8.RGI+^Z=F&M79? YP<^T5606I0Q^4Q@A@CT2(I9ZD^0>A7X2THPP49HBHVJ3B2S;I>_J.M.M^&^H^&L^&EJ^3G=25_UYWEF>IGCC>^CD+^I^CAA&8;9EW@0 MQ2F9J9;E5^<I^J^<F(W^U7@<=I02&_J3ZFY8^&M+M+9GCN)8JG=8I^&2J\$IA^&^PIBB9S0Q)XS\$15;T^5^<N^+ (<0B1\$&\$4HA^FE.8RI#^4T13X)C7HMC5^<M>>>L>Z;7#-3EMV;=>IPIQ?WI!%!"SC3V(Q@RYUJH.MK\X_06W?7;XK>_OHW.M.IV)>X_X^"V_ <(<9BP2^I^"1.(O4I^CV9I^H\LD@=S+N><I^G752I0IM/M.I9.39FSVQI>46K;R\$IG\$55D9=51^<5^ME=2.M^15_WI@E=-K^A\PI^+ 8I+ISN^40T2P^PDCI)YG4^03ZJ^4QI;MCR.R^I^M^K=>IEN_U>I^DS6^M7)NYQJ7H0%)QQ.EC.MGG\LK3Y&YX-5G8I9X M#8I0K3\$^"KR^_FB<@C5OI^S5P_B;I^<=6Z^X@&\$0&G&NP%>_H^K^9JUE4PI7+I>+KYL=I0W\3MJ?;V57;J=Z5.M&R^Y=^Y9L>_I^H3OGEI9? Y@("S_)\$HOFL^087F^8^&^&D9GL@23)HL^X&R^YR6KN^7L5U2LWSC2PI2^X7V\$LRU;""1^&B.MZK23P.NGL4K^F@HUL^_8Y\IO2.IMFTWW.END)01=IW^/ #B86OTI^M^E@;I^%+I^P_OYH_YTER&N.AS.37I2NPL+I(1S^9KKI.F8;AO^I^EPN+SR5E2I^D@^<(%\$&#I^MG7^D^"6GR^1X8I6\$T9I.HI^H^D;GV^N^KI^>1F @H9T^;S1%=C9^6>4X^""T^CLYVG>.&R;G.Y;I)=9<=Z^66^MLRP3^22IUL^<0.3^_RP(C%TJH3=6<35VC.(RTU)?3-TA>8S;INDTRO M\$&R0@ME9)B<8_*GFIUF^R^F0DA^A^*J4MLN\XU_?+^75^6Q^I5OE^IV<52^M3WQ3^EM>N^I^+IVI(S28H^292YQ? (W)4T2^<KD_IQ\$2;H@E@<Y1KT5)M+M^Q^&^4UJH^<I^<KRN0>=>NRRZ;^F^DIG?=@&R7(4.B2&C^P^XO^""LO3_.P@UOD^6(8QSS3;KIT)H6Y^4M M39)H&A^RTG\$AGIGIT^OBTV^9#%29\$^LUP51RPX<I^U^3CQX.MZ\X^1QH.L\UR9\0A>9ZXI.NPW10RXUUN.V.I3ST.8I2B).6YR0"";8RR M^"615G.G20HSZPU^TIP^X\$0>X_I^CLH^<I^6L\$2^0G^<I^<F^<I@LL9W^>^VY.M&I4Q^_R YGCI0E74QB#;2;4Q2^\$/J_73^H_I=5L=N@N^GM8>0>A1^3G^M^&^.(HH^\$S4I^UE^?ENYV^3WT1.6+5IU6/LPJHU_6GWCX->JV9^92V+ M2EW#FV?P#92<""5;K5)XCMKAT@B2MP&F=KV3QO6I^H^%FA=OU^U^0TK.MJHTW+6 FI+^#%QWH=6D_CY==JZY.O53RW7O6NP)L24_7DE4/I=-S;7&^DW0>I^XJ.W#&Y^+M(\$;12F\$<^R1QPPD7HAA\$N)0X_@J9? HZK8IG.RL^<XO\I=77P\$-Y>W=-I+I=I^G5U.S.NANKZ^<^<K^<^&W\^<XO^<7G7L^<72I^<FPI23SS^>7(72^VH^4G+M+8<= %^_P7A9#W\$<KB7E\$75HJUY+^05-LZ=6V.F;IHL\LMK^HUR.MM1>X6>6W?I^N^6W3;U=5\$OR4Y.B9ST^<FHW7^I5A)3I;8&8;W0(KQYK% M^@BKJIKI25;K_&LL>+H\G.EF6.^+GV\$YMS^B=WG\ZQI>KJLIA1^SDHB\MX9EI^%&4.\$@PI^CD9ID6I1E.6)I+JY^7&M_3^X^OY&?2I.FW TJX^U_2K5.MH.B2M9>L^JN.Z.K.64DLJN23^V.RU9JFLIP5;H.M+<E-U\$U23;=BWO^OT.D^IHR4^Y2\$4F^&G.0GD0#0B^46 ME^Y;PX36I.SI@IXTSI>ZRV_3<MU<=8HX^&HD+O+4AOA^4PI^MBI(P%\$52&I5UOD5DY@W>?H?M^CMHWC\$;Q1^GL24Y@+M5? ABC.TBR&B2U.M(HY9)61617.5%2FU-VXPT5/E4V5U4R=M4)VY&H61^2OYB>I^JHNJ2.C7.M2FKP6C0\$K^X^I+>=53?+JNK%-

K\J\LEIX,89(93)>E:41@1EF6)#IQ MY5G&1#V=(C2SBG1%MNFI;S6"1B12>IO3A?QF&11*=-.B:7HXUZDLRFBWF5, MV- <=>O1ZISC67%>:~6!G&U;T*50*?T2390"Q"S4+K+Q(6);R_SE"1S652R M\$5\$2<68-/B12@3"CL7*HB;N;JVGNI!++3#TB^H0CT>N9@#4=(S- KY@F%0Y>L>N</47"C: C7KF MX P0Z<=>=9H#*+L2D136#;W10%X"IN;:JZ1+X3@M-IWYIO# M?FU^2U7N3J>=//HAR_L14B T>Z4UC*6FO2C%+4 M-B*84U51Y/-@U P^=P0R8.N_A8\$W>Y5.COX1EK2\$5P#;X.1%912SB"HO V_M<+6D95ARV%=-^3%KU&8>F\$> #1NBVX12SC3?)OU2J MEP/0V%GQ&0TS4@=-+W_M1.S;((&+X8/R@+1+18R.M(CV3M3BR&AZ6MS@O'R5E77+;T11+5\$)=(2Y:9 M20-8:1H5:0?9EI>DZBDU&MUTZ14,△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`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|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j&8?M 6<I_7C6.OZEF?0DM8G2^PCGF_0;Z+^_7K@&PW.G.DYQAHOC_M7MV<=>FM M@GT/H8E1JM5>."HVV^T;_ M31TVHJ96GTQI_09X4I0MBZ\$1=3B009R.G^W #104HUS^<98;H6<K56K677X;I_0TV2I2K^NDMA;KH_BJ+VLP_W04NC@J<12RE.22IM(EH%#.#5<<8Y M5NU_AZISPI_9FO_Q^0^I^J7;:@A1%BP_ 2^R^O^I^K2.RG;M5K^Y^M?U+^ MU5V#^!7_>Y+^I39AC&_2YX\$D0^H@^?>G/C\$14^OE^5IVLJ&8^X+^NFM^IW2HO_M?R@WIMVFK^_UJ="G^IWOON^73 FMIKIAJZC;QG^U6&I^4Y.GK@#N=E<7^=MCI M58JH4Y@<^E3=I^P;MMI^K(OW;PP&P^UYE&AWJ3_MF4_8IW=59&SUNP_-NZDS A^#&2! (IEQ6@<I^MORGUOL^RJO_B9U_4^<CTOS;#@<G36_QUSZ>X7%321=A_MJ.A+&O=45LFJ^RFRRO\$&BHXF?<(CZOVFRH1F6N);(C1>9 M15193W(I6J(Z^I^M)>FM_RI7)?_493E/9I^ORD5Q^<^GEQ^PVZ^_EINWU4_E M\$IOK_G&KCPH4AHG60;CC.00^I3#(H@1Y\$%H1PA&J+8_&&_LTXN_ LMF&A.CWS^C MGW&>A^NRO)47^YN3RXC=\$5I< +3#&4081ZHR>Y+I^\$!L:B^#/0_<IV&_8\$9\$!^ M^XBS(DH3^&@B^6_16ID04_HENH N^&^IOFPAIKM+T\$X42@F^H3^%0XK_MQHC8I^+I^VO<H_U.V_@L#;6:5>0#^IDP8^M0#^9JV^I>E_<Y#&P9D^K?T>3 M5.8>W#(FZHG+>? M5M6PGJ^<R2N5R53TV^7I^5RYLWZ0;Z1#&8;I0?>A M@BB^"PBA">^I^?FQ6;^HF8#I^C7IM)O=UT^5;I.KES<=XAA M;8%%L P\$Q2BJ\$A@<28C)C^B5^#A5+I@;^V7UGZ_0SL;C;H^U^YQ)9F>H^<M M=JB+W_9GZ06I^VVEYZ>I9>\$/7P+^WT<=>HQ@UGM6I2U_I60UE)WZL@25+D MH32+^YQ^";_AUC(CZ895>..>6X8T35_).G49N@9^I^_*M29WB(^(.T11^I@2H(COR;M69XR0C@AT^3_8^I^_H_7=^R6+Z10B^>ZZ(Q MGX3N&IELVFZ;C73QI^I^HEQM^Y2X^J9)7G1+^I(O2_3_VN32I^A^GALAD2WU_#A^>D3<I^P^=TIZ5I^R|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l_ Y7PI7Y=;JBVS=0=#97L5V_7C;R0984KIKO8V^Z3_X7Q_7M MI_6ROR(C)C^Q.20_2W>^/CJEY8 M_MQ_WUFT^M_ YN^N!)@<^VH4OGMZ^F;9^U^DI3^3Y@CVYPN^8 M^W^X1%(^<F^H(N5)CUW\$S^Q^S@IPAOKOTZKV_I6#_L&NIO_VH6I>5O^C^F MEI5G^Y@ZB6BM0#NSFULCR;KOMXVSRO&A=7EJD5V_MG>W^YSZLZYQ701<=<AMIR7^I^QFMKS#9_W>^KS""ZA.OMYSQOQFM7F2>766BKQ M;M>EY#5^U^5)>^I125A01%1_&N72<\$E5YU2^<I1\$LODB2.66IDNUS(TL4I0 MI+554I;@XQIH^D^8^I+2^X^O75Z^J^<(DESJHSLFSE?)^I^F@= I;S^%V>^ M^YVYK9G5U\$W&W&QXV=A^I0^U^H^?P6Q3UI5H_JI6R=TTI^24OSI^HJ8^I^M>MCL^+&00N5577^VYQ7.5W^3HD=%9&CXT^CT^"? MKT6 M;#;Y@J1^2_CYX5I>B4>Q>=>DMJ^WFOV5Z99G;3PR1^I7126>9+&DB^B^M^E(\$<A4V8D)ZH>R; (UT1H^KLI&CD^0CFTU=DNVFS91A93> M^TH(@TF(A^IX+RI&&8=A^O.8I9#&G(>MMR_76LNR^QE<568>8MC6R%J^I M^2^R1\$<^AM/CL%ONB;5UOS_<8VA6FDI^IY4L_I0=^T+ITFZNQK)YZN^I MS2BM>3O9F(AIU_ +&Z""I2.FIMDO<ZZY9)>1OCM7W^L@<I^V;SO5C^I_X%F_M8\$A02AD\$2OPGL\$."X&O(I;B;S5^YBHNKW,,>RB^EK_ =0INA5K@>Z>H+7H;6^IZO04I#AV",I3F9E9^C+V;A M^?23DI@F;I;7I\$9B_M,>YKSO>N5K18<3F^L7<#_<5VJ.%\$?&6H^IK? >O^<43YL^K3MW;N^T= M6;(LB8LX&#^JMYBI+7P3I6_Q=^W7^_I M3>WDWDY@49G;GASD35S6PP#2%_4Y^&+ (@CP1B&1&J1K9^964XHT^2IW?+ M2^#H;7PNFZA^I+;3^<=<C_POIXQNA^D^P3<3\$17^R.O.I^CEAQ^P_9I9)= M^F;HAQEIVEX^5- ""CSYDI5O;XO5W^K58LLWL_M2I6?>2^0JZ(RG;S60X4_V#>65TJ_MHIU_M^FN=I3ZLJZ;D\$F=C;IWN&O.OI^FB>?%#E2GX^2KHAGE^U)S)3HJ MM&X^=C^*(K33P>B;6^2^A623W<)/M3J5ZIDYEK24F=VZ4Z_7^ZUW9U^R> M5TWYQ>30_49Y%OHE_&9_KF;IA^@9M^@&@% (<3^T^YFED0D^C.CO#5^ M^M/G1D^3<=<\$J>^OF1^E/IM4#^IBT^J@>^9^3PB?Y<7I+^E6(SUC^I70S^7I1_MW/RZ)(AE9JK^9I8(U_MX^M\$K=3YGJ9U#& <^I^I^V^2V2UT27Q/48J^LDG^NM;D^%YZLT&A^669W1V_<=<MJIHPI79_Y^I^V^I>^/_*WHIO&_#A^*(0<#(I^G_W+I^9%6XI6P^<6K93<5><I^9%WZ<#3I (M\$>=Q9^IYAQO^5^<@>D)P+I2VYXG&AKRP5G4I)N@<@YU_ML^<^KM.QI.7_9UQOGEY=I@G;G2O^H;_D677^D^P@6\$4QQ&DN57I32?>I M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VKI6TT&OYW^JHW3^B+^I6M0\$O^WV+2OWI^R<0^DP;J\$C&G6_X5 ME=LB_KJL+5E;UUVL^B#5#1^1P8R^440BQ^37^_I^QB@6#^I^K9C^6I^8L_G_MV;G^I@O_<IG+9^2>S@2M=&Z^X&F+BP^ZXQI+>CA)CQ\$^O;^<?2 WVN_MZ;ZMJG?_IOR03NRO_/_9KM/6W#VWZ3M;8_Z&PD#2^Y5M?2IGMW^<4+V+^_ M6E;_P^;P;G?>V2+I^M-M^F7^F^<U^H\$H2I^=-%5K?5>5<_<9>_>I^A2Z7^%6/<_B_ MV6M^PI^CB%MC@I^MQ@HJW+^#Y3ZU^#^2HLOPUBDD0(%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N MW^CLO+EIO8W^MI^#N&FM<_I^W;F9J_ H0T^Z\$H(I4 M^RET^FGI^WCVIEM0%+^1)8N@NY^&=>40QQB^I^7D1^4MW34^N M2^#4B2(-_L^"NKZLYZBE=128V_*ZB_GD>XY%?UA5H%;I^L_@OZ1^<4_8^6 M22=VK

[illegible]

UAH,PLLRUN(P@C7&0HI@%E ,M41)RJ8HI@2B+6)9(-\UKUGSO0JZ M?7BHGZO?QZ:375+5N_6I2@1=5T=/(FEIHMRL;- M8TIV73'M-
I-Z=>8<3NA@AI,W-W,O:Y8J=I\JLKW1LZAR@IQ60Z-1N-MYIQNW3CG(S.LV1)H2%N9J#@EE42-LD8P22(\$I@A^(-R.I/(V*5+7>:S,2;JW'M,;I16=Y
2,S4^~ZR>UTA(0UC;%N\$R>#(DS1&:U'L8%/309+GS/EI?Z^KID-MXNT/3K?J+NV3\$~7E_9&5I2(289C1.L0<(EX\$\$.L@&EQ(@XZV>>I!T#*+X5-
@MOMT#R>XZE&HAY141U/;79XJH&@ZCJR8?M=TO&H-Y>1-6I2_9ZA<>?I4_IH34
M)ER*D.M~U@42'KI*8UA7H0I#&\$6=8QIP3'16C4(I136Q#M4P).B99G4@EY MLXA(-TTRLH/OADS)9%T*@;UVI'=L@HH/1?^G-@^?1_?
H^I#A~+G M*T>?SU?SYLWIA?H(G=ISHY^R-T_HH0.HOS,WB"%%(&JFWT;J8_MIZDO-G_%+I55;V3?7O8P3P,29?
+5\$S+5ITB>@IA@#A.>A5%.1I#CR>@MHOQOPWJZIBX*W+ 6S*SAV?~UCI+I;U+#+#1+>L=-D%>0'OQP<X<*MI@*4)VOI:EYFM=JHP'9HW?M9U-
X+>@%N*77JH^A~;HNDW<@-GME0;/2D_M:GQ%QS?OA?R=6-3IYV;KQ#RWU!#<@!<=BTH?C23H;3HSV;X\$R'7#~M>X8-
3>6KWTIEQV&3&W4Y+JWUGBO;OSI_PAE<*~'1+1&:AGC;\$S5V6.MD#9W0-6#HXG\$S8)BZISY6M+86H3G78NM^YI-U@NL4=
MTI@E..JR5L'K537G3I<0.2;VFE@G@Z#M\$Y+>F>8@ARF/40@8A@F%168;3L(BQRMHV
M=IV=8=LE:5MZ<K@JAYX&#\$(RDKAQI@TD)H@((2',HO5)KQ0+1\$+M9C==^M?OPLC^OCP=^RMGSC_RNM@>575;W~Y5Z/AQ5~,C67VO.=
(9KH?I M!~I^K4C?~UU @?2'65E98%(L\$*+U-Q'1\$21QE,"5AF&1:DN\$BLLK4 M4W\$ZL6:XHZIWI-1R&JHC
MG<~\$IV>DTS2/43('N=QVXJ605%*H=#H!CMWQ7NBNT/*W&_D2\$<4NEF3\$I2/PUS\$%_AE?U/(W>%JE;HIOQBQ#1B>J.II")M((>8;HJ
C2)0A\$)D96%>T)N53B(FJ?ST^D#3@&\$.I.M>*M@H-UP@7P1~_0C\$1.W<(LUVX%33LQ%78D-)QB=FBZ;#..QI/LXY/60 MJV/I^IE^@JIBA1PW*F
D+;Y?/RKI>GHIO>+YU.5+I6G?OCGW1S M..16IS3Z5OHWQ~>5A1-D>@3B/BCL,A)"M.8DI#&#<3U.9\$UFX@VX
MOVKGJ)W/Q,S+NEY2NXVW1^=5J>93)X&#"ZP1^B#DV/G#~QUO_(GH.96R\$Y0W3<%A.L_8=^XJ^C_-CM59->F?+Q#HB=NGG>EV?_1BP
M\$<@OIK^W,(<+MOH);X5I>8X5#YI4CIG-696%OR+L3N82LXYIF@K^W8T;EOVZ\$M^4D)K;M^WJHO_N Y96NLGLV2;HJS\$911I(BD5936IAF
M'VC'G;Z8W<8U@Q XQH^TI(-KVS#BOV^AIAUA=IUTZ=2?P~NY+7DITKM.M'XZY16GH&5ZK&J+2^&%%.03LPIPOIEI8THJW.QN?)
<=>^5TKI> MK51#_W;V"=5YYZ5B_D\PH ML~PILO'H")DKE2^EX^IAREL#MH%V^RIUG;Y8P3M*Y*;B1U^E9HZP?:(MHAEE^>C95<8+^X68_16?
HIGO>2R0.E&GDH^IV_9L KW%KJ*4%+396GQ_MCU+IDK1_IJB+CGD;3>U)H^4MJI^XGP*2U*~T_80L/_H?H?2L8@^0V4^M%<@M8H/2IG>LVV=*
<XW1) M4TT7'A=YB\$F(DBX,B-PA")_#3-(P\$S\$ED7%WOK-4)E8I\$5UMCG>+2+18 MQC\$UOS>+>3#TY"6IWK7Q3JBIOYV@=KM_4SAI?
_E#IM;_W\$9ZD+Y/*M^T+53G*HFV^O9=NPVRVO^HOBR.6+>0H5D^I16YWN4APES\$J*HB%'.A^@((MMYQN;LN?2IYZOZNGJH%-
@U=J_.\$%>Y?N8I\$5W-MC=IQ_B0KX)>>&^X^16TW78UOTI@I-1/@I^YKS.EGJXQ^ZX#45B;4T^IW*?RE MYI2K^IE?
7G28%:MRQ?X1Y1Q0%7YI_@C3+1+9MVG@OZMOIOQIVT8+JEOD>M?IEU)~IJ=-E&RKNRPBO0:96AOM-CI(14)3;GZ7W~1~JEJC8>VJ>#FYKAM
MG8;B6ZN.O1LIV32U&I\$Y+YAYPA=ND~2^EPPP;A<73M_8O)C4MCIQX05 M2&CA8E5)%0=C.L96262;M+1%2.21+2#_8TOJHM6PHQ_MH@)RGK
IQ45>Y%5I3LWPO;PIVDE\$%Q08XA0%GIG*IVXZOF2BHE5V_TQO MP^XLWG\$~IJR#>+1/AI>IKL^2JNY<LITIZT.8""\$Z?P.8)G'KRI3?~9 MF-V9/P#-
IQ~9Z#H>@N9KI(KV)I?2^LCC?0%GTF&KJTU@9*O&I^MSZMF-13PIH^P8E;2B5(P%A<.>J;EQ?YI@4+YI=DP@MBY.24MQS/B9
7PHIK?M5D=QV@TJA^">_GHHGZVU^GKG/QIYKWE U=K=4@>+&2*6 Z6>64IHE\$10K40HB+8;YB^A%G;D;2K.URJU#)
M&+&I\$13VA4X#XN^OGKOE>HH;&HUI<8=AO6'0?WDJX1_7U7/CZNM;V@2L%TEUMUN+=7@+~%VCRIOIT6KI0ET/1^~.2RW^O
M2I7)=J2+DU76X8YI0+Q.(P\$*HM3)_JR&/2)BGF4A8FF^ILWHNUBA>@.@D2IGC&EZFVU<_<0Q\$_X&NU.N_V44~9HQI#M#-
#YI0+GXOM-9WXF5_&D8^_WW72JZWKM;X&WX<3UNM;22/WLI?~9+&B M540^3?
=>)Q=E7_HU7RX3P,,@BZ1^07+6Y3%-8X""#;0B\$D&2,MCV\$J&IHY; M=O%Q%7%7RYOW^ICSBIH6;D*<3I1K%BF?;^HW81IZG@I?VXBO2H_L'8(=;V#'
MW+LV>L5>QY1:OQOXX^IQ#918.6MX#LE>S_&2U_IYQ+^3N@I=+ZQ_I2M MF+0_I49^5XK-T^E.B47E_JZHN4C7MULOI3-
Q_I5=>DN+/@_#5<#1^4D)*M25A CE^0HAH3&&?I\$>L4%IDN=28(CJHWXJ^Q.KR2I)0H^<IAN#_IBJ6 M5%-PBZ;5X(^KA?GA=).(TJ^0;
<8D)PIS=HOK.F S2L/7I_~A1=JAFD;XP6FL+U_L9KI^%B<^I^ORLZ&9ZOREK3C>?_Y0 M;A^~TBI?R.MN#P-
*45A^/H+^01<3*8IY3I/VB(0Y5\$>^I^J9VDLID-"6 MJTD?2HLLIOV;BGM5^+^#O3T0\$20G^4Y^HG<^(TC5EMOQ\$Q#PV_10^H4^Y MFN JH=5#9/IU^~
I^VEV>^M7I94DRYP\$>>8RB#>^GSELSR),Q004_M4KOJ@<B#M%I19-WK8T4I4707I#>M@1HKR_MHDU0.L^N+I
_BBE1^B=M7=JL&H0I5_58J806NWBH)929HQ_Y9AE@7A~1.M.TB#8I#%20J+I,@R6(690&5I2+C9HW+IEK.T0#RB?T3+^6@_HJEL.G0R^
M4LG@YH!>80NNUA>Y+;;R<I\$2H+NGZ\$-O.ZDJH_M%Q%71C==BV=US;L_JR26?>&=OY?V#ZC%XI#4>V:8=OHJM^M#*#&DC#F M@I4D-
QKW33VQ_7I7?7FJ M2YPS;10D&^J.AV3C\$)29^ED19CE M_0M8@HUZ+I)TC_&6ZDF^CJ8>.&"VH=MD)Z3OYKHDR4B/^EH MN7D#_L=7;63;5)7?Z?
77Q<_8&^INDT>DWJ3L0LS\$W2-V3O4)3C<0+3 MQCA\$&45RIU\$&0ID1-1(5)A>LGBR;/4&W10\$=KRI>VQRX-9NL)BHL_UY+P.MV2.8_5I+C?
#SHVKN<R_KILL_AW*5DI#E2B.NI2N\$^F<@%PI^M=N78IQ_~%M2LY%WYGOV6BX)>1.6%\$IS^<^RIVI-C>M(NNA?0<2>_WMUA_#I^T@^0YX<
M+E&\$:(HW@23VT+HJ1 M=N^3Z52G)6^H;5I6M.F^JB(O@9/62IQV<4HKHKG&05Q15BL_C1I/>I6 M464EI;DY4.LCICQI(A^D#^AATPV?
3&E+^+4HEQP6PNA=7\$U1Z/7IHDV M7CA3>JRK;WU;6V;#&=A16FELOV;G(GD?_CL>T6-OC_NVAZV8<^UOOL M.6KPLW\$;OF4IX
)=U^DP3L;N5L8KHIZN%N~;OH M-V.MLZ(ORE4IB(W*J2_~*F^IB2I)G..>9I:O^@%VOT2V/JP%\$-WOI.8)@=H(1P R>08V1.=K(Z
MPT7K_Y3I4=^3T4I=CYV^N+I@Q2+6^@5JBTFKEJ2-(94DA2I^F_A\$5LYN;~MJ8Q^M^TIE=Y61^63V^Y;KB>D0TC9GHS.E_U1&1\$W\$;Y2 T(%&P-I
A&Q2_M2~\$W#P#U;FW+OI^R6R;3IM>I>7KKN7=UKI0VZ.N%K;U;I5K^BX7 MXTF@HPUU^F<@=..2Y+DNI15/< WEI?
Z>5D_ORZ6IU@^LYT^QN.@)ARC^M.41"(4ASR6^4)7D1Q3+^J547SEI^D)\$UCQ&KBOO19Z=I^~.80'4/#A6DGA1 MT)PK9?XKS*Z;7CUS8LHC/G;6
8OH_EJ KU2T_ M2U(CLOU;K;9I;LLWZ_HJE)8)X13I1BE%*G&Z>S_1K;Z7-Z5N1(2%ON(5^BYI@M7Y^SBI< M_6W;Q_GL64F^P>Z+I.O_(T01HGW6)
IUMX#>IYV9588TSHS&Z>F7B2K_F9_VH2QWF.8@QY3%*(XH1I6E^I_M99+G_TR@USI\$58&GLOI^VIV&RS.IYIC_6ZFB/>~I2K;NEN8<#&)8ID
MK\$SEYUI^TR&4^OMD!>T4I^IN3~?0."5J_IW20<=U4KN1BKNEI7RWE9IE7 M/V3U=7/S07/_0?Z+I_%.KU458NI_EV\$W9GH3ZIQH^CF^7I.S4^IK?
I<_MH(Q.PWHC@6PRIL\$1L<0.5<M%28&QX-B0#67%ZIF9E<3;35OX4)U%9P/2_MZ;S!_C.R3;ISS+LE_Q73CQ?~%12&\$+I+
<0809ARS%8QED>HG&N1%XI;9G2),<5(42J17NM209&F;Y)Y%BE=5IS(C_S_RJN1 QOZTSYN_MUP(X34_/CON>F+>2UCHRA25CTN% CZ14R^Q10IF-H?
MDH\$X:XI)POIJA>YXUIQOBAG=N3Z^EIH60^<@GZW+1%UK^JDU^NEP^/F_5S MCZ;.)Y^L^&KLMUG6+I42ID>AX7DB8B-
YP7QIOP&209AF\$~9\$12A.MX2_U M7KQOD_ZI^Q*?25@N0_MPCUMI?YAY=6K^J2&V)E_KX+OF3W%9I#^+A3
M+I^&9(1#>W\$+I1KI/X+~#X1YNEA:9S M7M_2.C3R>7V#73>V;6? U&R?F5; D2@BB?2.(YFE^XF8IPD6LG9>I;QKF.HE@0F^LX.O>U^OP?
M;_1.DSSCC#^BBC1@3RPWDNJ9Q)AQ6;HQGO>>L^=KOR6?>I+3? MZIZ&X^6M14^H0Y_UY+I^M6V=MOYV2I/I(A^&T6=>HTK+&R5EDF=^IG>ZES
M^+El;HKLNE7^Q5>L7'9&I>KFIOP?^Y-SI^2U;U)FMWEPMI;MJ9O^~M^R&3XK>IY+T92&::^1ZM@.ELLTSUO";~*WHH;8T@8H(%=1A)BW8H
M5\$Y^UO=MT9QJH>I3GN)WV(ARN+MIHMYT.I=JTG(C^ZYU)W#%??>M^Z#E2I;5/ KIZVDO1 IEYELIY?WZ^LIDXMK&K0.O.GCTI_A3X)C^T?
~30\$ M^TR_4 M7%Y5X)H0 =E Z8R)NI2^@8;B;F8IJA^PGVDH&8;L8ROI>RIG<Z5I2?66H^J_2I3GC-B/KRL^CI<_IHTZ0I.O:MKG2B^B5C,8=8\$;US
M\$!1DA \$<9P@C^<82I<7^I)%\$8^8379A+0FZ+8@H&P6XIG2>BV~IOANC+E MP;MS^94DT+K;W-2%7=4O)=KI?B#O@G9VSC_A?<
*WXXOXWJ8%_2&7CW~9BK_M;IE(C@B&^\$5Z+24)@3I20%\$S2AR3+IVHC^&Q;K>FYHIOQ;EL=Z/C<MW=I43YT6SFENIUID&E-I
I2\$TI058LI^H3)TH0..2 NPWC+OGIZVY MBW8X33V=UE^O\$S.EEISA+OI^M6;K+R=M=6^PU)E)M&6>2_ MSLRX*=
(=CS.PG:"6S69V&D;CEP28&65I;CMKY_O7^P)P/AFTHW7FQ<JW M.^W;EIP;XXO-2&PR#VOX@/KNUA%&=I3+I?BR5Z(I?EJC+Y6>NWC_(# M?
=);6)~UAI_XC;8\$0&+^80"19#QGD_2EPIYD(2%)TS\$22P+^F(Q1PDDV/R3H@A3EN5Q_M9MU+RR^G;(P?T#T S>I9#6-0I\$YOU&A<=N
+>#B;E@80I2AD6^KH MT+I;P+DI_NYNIT_IEL4@D^U&I@+U=Q^MIQH5XM_~7EZ>WJG+>29I@7F^M\$;JL1\$10SU^H\$@C(3DM),<DU8IKEI/+
(V;TB;PTQRR6?)_RPCC?)#>M^M9^N_7^0=OZ?I=UJ_MIDW78L= OLGOQ/WX;T?E4CY238.C=Y37I00^T)E M>N>N>0E?I_V3S-
\$4\$DIED_1^0+O6^T=460N9~48QE?~BG_(87(B^PYE MRKV0%+1CR_5=0+&S_4I@3=LM_J2\$(J8Y^HEC\$;D8)ISA^%>2CF+G&&(6I\$S_OXVH(R2N9I
M99HO;BNT5^6IOH\$PIW?LI%1O*\$S<5.WS+I^B0G8&TQ^01ZS;^F17P.D)HX MZN.TTNA^Q;O3%YOI1@/P9D9%5_MYM<@FU1-
I3I)I_M@VIG4ITKNM&VY9&G-G\$TP>I/O@^\$=IG.1KM_~M^21^MN^G_5;DKL+R5X^QSS6-D^BH<I<10E\$.~V#T429G2(2IAYE<^<=8L
M\$K/Z0.IN7K0C#7H\$&XK\$16%66I%&I^D)T#^G_6_/4OR D<%TOIK_M1I7OV^U^U^FQ+ROI=LI@4EGCHCIS^IS;WUMB&%Z5FRN9@39L;+.5.#J1^
M.P.HIHO.AL5_N6^EXY>0_~H~"15-MA&I/JMD\$Q7RJWX8?="XIKOZ;43IY6 MXF;U^+D>3)LZ_*\$LQ3^&YIOI16^SXYT.C614L?
W#8=ND^19WD;5C193^M0_RH~"6^S1^PLS.#AN2I01%#_~LLH3+>UV^XEN4^/EGY;6MI^Z6V15Z^MLIYCKU-
22:&G*=W>T\$R\$S)4Q)#5QQ^2(H@I0U#E>2^_ZT+4E1^3X=JB?R7S;3>XK MB9N^Z@<\$C TIQOH9WN5GPTWF(CXD1-
/>_#O@_IO7^QNI&5I0LR6YAL2AR M2+I@2A3<3FBEQ^2DBDN&\$6I5"6=>:;WL^>+8I1/I#S<RRO0&FYK MIE^I+C/G
(5A^WQI\$S^T7NM40I4A^6IAP^ONFI_O5I^*KVI^ZNZH^Q3 ML^N^JHXH@_I9BJ@24^GWIHD>XBK>^JC>~*BHM\$J;L&V;@KNR50^WY-
M\$ISAUI M;9=304.9U^1A31MLB7OD(I\$^4JPS\$4^*XI>^_A.F.P#6R\$^I@Y.M#C%9UH&M^V<^MW2^IV+^J4?
G14;EL_4I4ALN1\$F5C9AXFIM9QA^>PHSSIOZ^SY@C;I_ZOI MNS_@OVOO.O>TVIIP3.NN^IWA/AZG%9Y_I+L+LD#08FOFKR^VG_NJL3PC
M8^A3I0RY7;45%KNZC^I46X^IJANZONM^IYE%#%2^3GAG3I)49US2%N2", MH91\$69QYW_ZI#%L_IWQ7^IHQHI=9I?
I0==E.+I=>5HI514<~;XFY8+ ML^EUA5_I^CI^M;7W#S+8P;#>^_10@7MN)">IC^Y2I(^?2RTSF=CIGI2 MUTNA-9X4ALCM2A.YI_EABIB.D-
UT+>E-CDI^F9T&^0F\$F;H^>K^NT^2A&73DPDV)6SD# M;8;3Y^5IK^OIO_U_N_YK2IMA_60(2^*5(4AAE)BDUSU=I^I^4HERPII_MPARZ+I^I^N-
'R+2A;IGFGU;I-Q69+5+5PG(9T7ZE^I_JW_?G78I?Q7NY_MJHX^F+H4430Z86ZZK9L88\$J5^K(IBP3I=4\$VK4<)BD?>2R^053DG@
MAXB.O_IJDEW^LBS^OM5D^>=07@L;TG.%KQ>L1970>+D0&I0MY^I^QI57I(M@)H=RI\$SW86;E@MO^NO~Y8@K=ZB(N2YJN6)R)-
\$I&I=Z.4Z\$0LP4@3@1 M^&GSEPKI=)MYB.C8L5F;^#0T@2\$Z_X;LWB1@NP\$YKMAN^I^6<9_M8O2", BA;JI<C\$M+I.H3;+JFHN^YKL1C1C.>)=KT
MI^2#&E+&E+&E+<ORH@H1F51Y1)^_HFIEUE+&04;TX^W&14R^FW;M+14I.7 M;X2^;=F>6-V2I%2W^<J3?D_39&@&#&^1\$^40Q+TP7XACB^52\$I
I.E5Z;R\$R#N9N9C.D00 MS<=OYI^V<1C@V8YI80N;6_3A&^T;8#>5MYU#^I/Q+I7<@0^N9S;TEH6 M^UY
I^7R^UNY+KI^W_67;ZLD%3S.D(08.P8I1P2^B^8QB+1%F9I4CC5_3E&M&3MU)%(H^I=5/(F6GB\$+(I29LO\$1W5A^GY JD^I(Z2F2QCGQ+VY8(^&S?
MHFUKO-0E7MZ&#&#(USF4^2YD3_C;E^I3^4Q%5%5^TTOASEI^U+SO&^&1 M^@T7?G7;M^PFA;3_0T@6X6;W+I^BON6)EMJH^XW^4<I=NO8?
QM%Z^Y+ MIV^I^Z@QZ4\$^2+ 92P@QIR>=IXX^T^M;J^I^JESR<I+I^I^0^I1LH5N1^J8HQLR M+V D<^\$UQ3FCA4I^3^T^KHU_Q3;M3IJI\$PH
FW;UQI^M+?B6Z9;9B5GL#2V86H39ZQ9B;Z?G&WFOI9=78 M_LO=JMJI8I^I>A9I6TRW%Y6HJF.DT^IB1^I;S_4EXY_I3F^>S^I7LB4657\$
MMRNY^>P^ITUU+>OI?;HF M(K#)^OX@^WI^NMNY2_FQB/BZDIN^R5>3I6AY+4UR@+03_XJ+&4^9GK@RB^I5Y^MXP2I^QR^#J^5>9T-
LY^U^SVTOOYLI=G7_#8IEZ+X&K W#K^GA&=I4 M87I^WJK W^I&^&KXA^I;U6;2US;+>^F^I8.GA=I^W#%I^XIO><6E%#M
MFE&C3SZIOY;WG^F4)4DD^7FOIC0)*<I^CK_V_6I^F M^PU&W7?E+7A+ST+BV?I^U4XWA^?+34LQZVF43LAX^((?M&N4@=K).4 M%=&)>TNY
+2;PP;FVY CC6B^<@H6)9^*E&+&B^U>Y(YOG+X9R1="Z.IN M6DZHE59QKXC^JGKBY@:(H82^Z<\$I
MHDI6=>YG;8%PK\$5IDGB.BT@<Q98BCBIW2GT)QMGBR_DG_YO>G^52^I8 M;M@I^<@I&S?S^CQV4ID.KP^PEQ^I>8(U4Z.MQ
@NJDH^IO.2I#U#QD)KN)G5 M3I W^R; V:@(#E8&^&2.5IX?)_6T;L+KSZ;\$>E4NOI>U M62A2^4L+^B/9A)Q#D^F10XZ%2@5GO!!2
1QLB(ZLEOI=^MW36^M@+1333^A<=&262V1\$A6DD.D7Z<7I4(IYLYVKSK^FCU94.7@CVI MEUK^5)44P?
RXGLE^T+M^UWD^\$TH5UEI2\$41G\$8.YI^9REM9(6_2:QO;C_P.MH3_~I<0(I=I?Z)ZK(9+&#^1:A^I(W3>WX&TH=R69>;Z7)/OYVU^KEKGRX
MT8=IY3LEV>2;OIA<I99QX2^E\$+I(4HER7R&KB M^?2WFD?2K;6?I\$ZRJB>.\$I>=>I^L_OJM M9XIG?@169@.ZL?HD!_!%Q9

A#J#Y0P2(G)3ND:RGJHP59#7_HL6VG MEACXNM2" ZGW#K-R?E#M3%0#J0R1WXB_VA^>7JIR^@#I+ZN;KMB#Z7X@?#G3
 MUD<7IG#GGV,CJ=Z0Z+7IZ>""9>TPXSV3V1'GO#0%G+;=CN8JX3B\$4) M+ 2M<4X)#E#JGRZ0@DBL+;X<&UD#&I+N;4"VDM9#
 H#N#WRYVT_PG;ZM#EJP_X?VZ#G1^S04JA#3WVVG#;+F+^I;=K%6U@B=XEIN;F4_*+,OB>=2 M#H4B;IZ
 810RED6#90(Q1Q(D4I5)H0"?=W;+;#N8IN@?#WASL;#I#E=ZQ_M-L+LX&#;7EW#1A;=#0G-7_W:867IR;@;Z@I7Q<9_Y7TL>*ZM2E25R@
 M.##BQ<GU#XW;#W33IK3+_+M.5%4N>2E%Q=#+IS_DK1ZIT_86JHENIPONXKQ<*#I#O_MWQF,+G;^0<=<
 (OCZ92I#B+Z#F14XOJ4U=TLV;D>=O67E+4+00INJZ1_M4MN_ZE;=7.5H0_B;#27V_F21H4L01C_0B15#DFD32M#XY9BD>786S_M!>
 H9)WY0_4#L_I4V.66_MN_4V8;+Q/7^RLRU2.2.3&80HJ95<M5>NX@>MP8+.9.R-S)D5EIP^Z.2^\$&C-CX_U3OR"WZK5XX/JLISGROS
 M4#YA/HX&D.D5_#I2A14.4YE@#1S#E/B0W1D75E/RZ>/6T<-1@((Z1MLZ1_MHRZT@M1.W84&RDVCA<((Y7_0NC0J01#)%IG<=
 #A#H;Q>N9%M@ENG13+_M#F2ZY+J+E(CT#MUFZ+=+KC(RLEK9;_GJTFH8;93+U_YZ9RW#SSWL4^A0^8^>+R#WDF_M6OYD>_Y^IMZJK=7*
 IN6=ET=2LL^>KJTI200A;=55=-N0MNM9;Z1@6FNL MEQO1_VY5I6W6OK;MCWIIY=16*WT_7BP_K@+=ZQ3IUDN>0R)HJ83CPQU-M
 <28F0UN;TYU9.KSE-L)0-T;IXU&WCZ_L3KKH3_M#13RSOXUD6#R1LI02_IVU^=#H8QC=+I9D1_VN_M50I3(9;OP.L303#V42/K?F3?
 3^NUG;YVE@&10V1+RCY+2;=USUvRT(6_M120U#N)=+8D18S#@CU_IYQZ3_WI7>IVM#I730K;K70KWS+;48VTA9U;X@_MYZ5H=-S(2I/F
 Q3BT#QK%#<C_6P#3>#MEZ8M2>7Z@CXN_U=VA&6#1I_MDLGM95L_DRUM1Z12IUDW5J3G16U5EYJNOA;4W^I#BZW6)1RQO;TF#W.1
 M16D;%3&DDL8081515N^TIK2,,YIK)PJ=2^EE3U#36H) (^H\$14SUP1FC#_M17BH3%3^@UX3_4^*U<@L>UV/W&L9.U-
 =9VGMDQ\$32)1UX6W3(GEIKLYD_MN^E#DGOPEEF744_Y(>U)CNIW145C)=^5N2W7.L3/72BIOI=IE&=9XD4D<#
 MZOI04U#00UQ0A\$O1CA+BP0EB6L7IQ.TK=;=>WAR;#%D66P/D6GZ#WE71DR_GLAB2)C6_M#HK%;Y6_4_R.IB9I\$9X;9_5+>N@XW<,+74&;\$UF
 10KZ3=SH#MN_8I9U#WEB@_0_MVRN+M+7RD2Z;6^UY#&GX0I3SMZP60DUY11_49UW04V/76IWLIRJ3Q;%PX25_#IA
 M#F#F<56^&L+>J0Q+1R>@((DB%088>9>2S@-I#A1^4/3_ZKP9<3ROINU^MM7H#TBI_W<7.0YTF>D81_F4D^428DQ#\$1_ICHNWYO%_Z6WY%
 (>=>=6_M#Z1P3%VQOLS.CS_#FZ19STOS=KJBK4.3.8W5/E0RBS7=M3<7-.82VMQ1L_SM<5+L#F>WIHW3IM6OH7)DCJ2JLY4TEZO:D>FIH_7415
 MVXSLIG>F+BK&UF5\$>4YCG<(>6)ZA4488A9+FE_HPS1511AIFIDUBSE_M9B+<^>Y9;MV56.W9&ORH2=27M7U1K0?
 G;R2;53C+4)W=V1\$00I_HHD;M/@#TD@R_XTLH^=&U^I1Q&UK3PST\$AD+Z+3%3@2>A5^10U.O/6VIT<23_ML9>_#5IWLW80I;E1M9% ^A^&
 <2IK^#YU;_#MVHY7E^?V.DY?8Z_IY>WYG<I^>?7K?WON4Z6Z_7HJM4_U=-2?>F>M_1=QH=5ZP?34F3W+>(0\$Z_M3AKAE(F"
 (Q)YV)W#55;6I7WBH9Y2N;BFFK9_M;E;G>CLC.QP@+@IY=8I%F4X8Q0_Q\$#F8HGB\$UI\$-H)M6M\$+W>B1^ZW_ME1R4H1NN;M;U/B#&GC*
 #BNIOJ^SR1@T.2;H>YA9)W" MPMZ8(HB)G1\$TC\$T8FA2R_?Y10(D)DXEJ+T;1G;5SQM%LY>2%I#+Y9+;2Q_M)<7+>V1*
 #8WCG#8",DH89P1DD4)9#QO);#XUFIJEX_Z+TW5D0>IX(C2)"D_M@H^#JG&#&((1%2F2(A8Z9#_DL#Z(CTCYI8XT=&R-P
 M0<_765W4#A060;G;64.VNOHUI63.WOETPV%Z>Z>K^W^X^D;_Z>J^D^#4B_N2WM_MYU@=#\$GW3L)W+>3LZ^PCH>9W?_2^GM.)W@.#@=-JRVB3G?
 01L.R?>GU>HBI_MKHMBR"8=-N%QI#IYV_IRLU3=T=1(S*+(*OPK&V9JB\$)#2J<->YCG\$BB1@J_M\$-R^UN@B98\$.6;#I.F=\$IM*8,*+N;=NP1C5E\$#_#
 (>=>Q.WP^#8=X^M^>IVGH6.YVYNG_Q#=#H<RR\$+MCS\$SR1&4)(4*ZE>Y@ONK+>Z<C(V;_0_M;KGI^UAH_@#M.6B2/BZHBV#YC\$=C
 M<=9.KL0_QTYMSARC#8_9YHX9+G3\$(<6WC152&#L(J)H\$)5I4NG46K1_M22+Z1.P4.3.\$2C.SI>#9IN7<23159Q_BAU66B17I;8.LA8R^AC^AD
 M;TRIACP2.(LLFFR#)MUY?W2M2KX>(%TCO>P^FP/6H>#L_MYPD_42^7TF<3.HI^@#92T=3B^13(T#2_YOI5E^P1MWNS^XO)J^*(%U#0
 MA)O^Y7I^M^L5_B6GB9Z>OPI/BIH.51_PX^EQ3YVDS10MKD6_JEP<O/BIOYQ2_NIYMZE_M8U7I2W1X/2A=F#3UY0\$;7W<XWR@M>_MNRU^>=<8
 57MH&X\$XIF<&+A5<4I?3_Z%>B_99G&W^AX=#10REB^NE_MJ6E7WM2FA&C1A&2UT537CW11YTW^2I?
 EWKX/ZO2+1+1%L3E\$&4IA@BF&B&08_FD^4K@V-C^<YGC^0J9L95U.8V)M17I9TWU1^)*#&HZ_E@4T/(&S&E;6/UCK^E/5I;T83;=-/27
 MJT00M5;=3BL39UCW2B@9YIM; (QI)Y_+4%20E_3KI9QI_8_#H^%N5X_M11D^59QC.O;G+=+Q2LS5ZSCM2AP#SK01^HJBE\$;<9?U=-0ZA*
 J1C^NOFZA_P9I0Z>K9B#.L<3PGK>UHN_MYUW^Q99#G/354_#&#&#&(-O+4#GJPH_M\$V_YFGQEN-VTA_02X6LIG@%543?
 5I6M6HDG@&R;_INC#BS15.E%#X1<0#PA_E40H9D(DRKY23)6H(DH1R2V<9E=0+D_5=M;7ESI/XV4QJR&_D8>IQ@CY#_OG.0-MR-C
 6P27C\$5TV8W16^O1>12Q_VL316^N@10TIOX1_8W%IQ<=<1G6<+T>=<MF^L.Z6I2JHX(G%DU?
 H#IY55NVF&=KOOU^FWW7M/37_#IA&5PAB>=>KDNIR_MVVO#J1^#7_1NL>\$V%I@H+K^=3_TNV%GUM0^71I.U^T#2&5(S0)6>1O1N_M52E9F@;\$
 \$QK5/M#M&P6R_M0EY_FYU+&Y@B=BR_H3HBF1RESZ@6/HGRNG4D)@EINZTS;E17B_MAU\$RUI\$#P)303+37W4U(3*HGR^E
 ((HEIH502)=3^8WZ_U.C6Q9I0EYI^M90@Y=T2^/(ZRV1YS08+>F>=D+@_M%#;Q8\$_L\$5<WDI&^<0^A%;ZP2L;GAI<-LJYORR4_GJZ=D;W=4+T=EQ-
 BRQ)M^I/LK^@BB^20L_B#.9YH4B197&E9_UYV^D15.O1^F^U1=CRJ^ZXV_MI9MV7_P+W;36I&D3IKY;RG6^00OE/F3B8UC?K#I&+>_H?
 QTUUN99.69_M=ERE@M_M=FQ^R@WAXD^M^HFT=B+85J3D^D_(P&UP<12G;5F5/5A_D1M9\$M6&PH3I=RG<8&2G6.)
 (H8_MD*WU5HTU6T%R8#)#AKB-/15(\$_X0F7>^G_M;7ZYK"W>?%PM3="H7+7W19;.CA>OC;ST#58I_Y>?+W3IR4I+0+X@RA_MW%953YZ_5QX#
 (G@YIEZ>=G9_X0>_JL42)MHW1Q3^2E+I;AX7RH5YBD_M0_10MKT4M7D1@=5Z_XM_M26=#%L7R@%E^WTH>FIC_K_B/JI^XILQK
 _J7J7WY9)HAHMDAK+H+TT_MZ37G6DVL_P_IJZHM_BYTDIBXO?F^K^127D1#17)1.W\$66_6^138M1.27_MY2
 JDI+2A/\$(&9X;BB+X@BOQ^9=4

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f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gt


```

M8B&B$8699F)$%<:01NH_092F811JLFJKUDUDW-4>:UNJ%R:VGL:N:QG-19(RL MG8#2JH8*>39SNJ#5*8J(66FS5-D+1B7GWW%!  

<#X)FR34SR88L#K0_L2N^=EJ$&@)JL^>28G>=CI4M-MOJ!>J9YJFV M9LGLJBO_2C%ADPPYO7R-!U4A_X+Z85IM2/PJ7JZHNJM=4SM_4CDM4MYI  

MQQ(4YPPNBBN@2@F&32+!B+S_XT!MEH4I*5)G@30 M&K>50FEETNSFYGE+ M2GLM:>JDN+FR;G_#;EJSA4AL$&_!@JL%R-  

LYNENSLAMPHX:C^GJDSFK?AIGCE5FGB^J> M7^0+KJ>L%2KW@_2V6^C$RTZ.7.8)2C@F68AS^*(B^E). HBR321XQ+KE5  

M;J^J^J^GW%W=B:#8:5.16L96 K+JDP%$*(DS$40!##%1^C2H_!D_U@%K-$ M2(IC6GL2DQ(A2^W(I^E)FX:92VWGCJTHJLGO_Z_54 G0X^PSISA7W  

M%HL:B)PX#<X3 ZM1C706F32D>H&=<#413A N810Q!1 4AI^IN@33:6D+&S5U_Y9F3)S8_PWL2JG9D2G@<JHJSEF+  

I9G4PLZIK&Q9TYCZ=:RYC^3=:X13 M_9IF5 9DP2B_1^1 ICCR:@W=R)8Q8PE_!$@PLH74AQCFM%#;4QS$W9N=OFIG_-W^^(M=JHXK9^?  

M%51J+GT<2=U_!/"OJ)&$%>82>J2U+>YD5R3JHD21Z43 RT MYNY^4M(XRW$@8418JEQ^DD!)041^A8 P3HV.402ECK16U7$<J$>YJG  

MPJ)U+M@I>K7J5KMU(D$G$RBA#HE_!TV3 SS8KY:XMJ1/SD^YVU:B#?J 21 MD^7IG56 G^H_W FJ15_3CAZ^M^Z+D^H_Y9WKH40A^)*QV7%TK<  

<1C^#B M8LLO81J1EDF0<C^!>J>S+P.FXE9RAS9#24TF(M32JYSM60#>J 10U!2M MGQH^CNO982,@QNS^J 59J_!EJ#M2MJR1M:IVT  

MEXN_1_9S_Z_2T+3_*P$$(D$Q@R)3W1^C/(4X3JB7F<2RDISABIS_2JOHN+7 M^"2KU>WY!^<US8H>J(PID>4A2@^>AEZ#^6)NE_@N^!UJ#<1.01%$<:  

I>ICV^VD:AYDE,IYK+7F+!W3^<_JZJ MN>PIPWSEWECV0!$M94^9>J^S!D_1LFWZKNKVWV6MZOU^&LKA!|ABJ|<1?M MYK)E#8A3BD_@VLF.X>7?  

JH9X85!=2 MOSE9EG>#ON+1XU&M%Q!&5R=IHNUID0!#CIEP4_Z2S05$B6V6MC_!K=5K^2OGIFA(CMTBV3N^T&6!)=WJ GB$SIE  

$JL29U5JSWU?%<@U^%NNU+MW^N^J?EFD_1B^X M&T^>)J:E$GGGALP^!/+<92LBMVTHOHW@C1C_@0#^AE$%&.(4Y($D4  

M$AR57&0EM.NMZDLUFOQJUE5UVP5W9>T^M-B@76J_U^=J^2%T^"S.NJL^IV M_N^13HO:N^!9@POZIO_VNU>_*M^IS5XC^8E!<#<J^<IV#1^N2  

I=5/! M.H($26&B_X_(PS>@A RR^C@#F9XD5:KOE_!EIS2J+35W12YXT28R29YU!M2@C24YVW=66/LK<8<@_VR_X=Q0LS$#F#8V,)!?  

>9Z^R28CW&7WMH6!_ M1RU?%,>+(0NR8R1F35.1Y4(ZIU*(JN5FW^!KED^IA )JLBOFO.9SY_@Q2R-M$=3DJ^AC  

7L#PC$B^N$XB09AGDC3M)HWLJ+L2$&D^<J)K8B!<@) TR@=O5 MMWVH^H0SFH!Q$&P2R17FX1&W$ZYOJSL2U<4S/HHU@55HCB80G$=_H^X^B  

MYJ^!W:LR!C_B^CX7PSBK0_ZNE4@=#84!9IGJF=72JLH_&6H&C8@28 M_!<ITC?PKO^FE5_ B72%+12KK_#6^5ZQ?  

FS&D@=>SO=)DM&>W/X^<EM:Z^ M_Z?H8%$TM:RJ7@:7)3#<7@CO+8J_* M4_00U=7$&_00IQG^8AS8!>9 M21TY2.ED@Y^*9_<N:=J  

IY3:SY1@WP_L@2!4IAQ T2TERU6^JLARIH M2J F5EM3JH4@.94Y4FL PA^!4XF:7A+@ZJ^PYCM^OGDBQG^L_D$2IHJ!$  

ME5XUB0C2D.00!QG&^!9E9DM2V=K4L>W;7J?#G+?7(93MEG+<M,@!$>MG3+P^OMY4)8GQW!@  

M^J^J6QJ7J_U617XCKH+8A$J#J^FR2B(DPAA++%*4A1^S)(4CJL87^ MA7&1D(G D6=IK<^!CT.H#8^!(W0>PF&J$&R)U7W/O&PVX>^X_#0J#<J=J  

M^P_L(##=P+H&=K0X09!^ M^S:USO2K)5YFFO)G$<($Q1^&81Z6(&JH3D.8TCJ18PZ<4GT5U8@ M9>=WU$SJ&UELZB6VFW^<^F?2  

S/!9I=W@J^!PI-VS^D5J!@ MS =M^FJ!>WQ&SU^<S?>S0U^!@3I9Z>5..ON5^Z#M2QD3/RKVX_82>J/D M0@YTO.T4K/3:14X>L^!N^  

W5Q:9ARJ(B8QOIBGV15ZK#7$D^O_ $A21-1/ M_VU7W3%#>A7JMJ20042<964L2 M.SFH8GJN:PHXG^10UIDC0G!U>0_K/U=CXFPV03HEAG:2  

N^Y56H!<+P_MKJ8(^5<JDMZM0.382!T33$<2N3% M=MG=05E_!5>LSI=EI=S7VU%>LJB_ MBQ3EJWHS!W+  

O/>4D&JDXF5X92F&2P3Q.A%HC44Y4.4H@3<^4Q0&2.4ZM MUDE^TL_N-16R=02G;+NAI$R7(CXPL#_OUJ:Q_NFYCE^UH7E#5ML&UBID&L  

M^23MD2YV=WF_F4GR_*ACS+5%_!3^4^9!13$*5DE#MIS;2TJ^ MV^2@N!>W@.5.GHW_&OAF^F^P^R^!JYV!X_1ZNT3W%JPKUH^=,%XSZA  

M-J@RIRIN^"Z=OQ>5>E!+IA9-66/>O)VOXAIB@7&<^<Y$PY=)DJAYYG,22^MT8PE.$Z)4?  

*!X7&W6N65F10C.G+3L>N^!N^>W+BV7FW>=>W&Z+FI^K M7(JL)SX=8JBF=<Y$KZ/QIOC#)XE78IYN&XN!>E* 522+!M^JL.Z7% M-1%4NU?<  

*$S8BE6C 5+1E!B(XA_!18L&L@%QJ^K9@G$@<Y2J^JH!5@/P M7H2)HP$+186H=.6%)M94OR<6=1%HL=5+ VGU9$D!>@Y;Q_G$3!%I83#+1D  

M)6_3.HO=E60#_G9&BG)JIS3MJDKL70!W/87J.FV/HDASNR?=>^?>U?WA MHX2T?>WV MY^=,I4J+RRAY<^MK>  

I^8_!7I7J2HUN_ $4LABO/>3Z>AS?2BE5UYJ3)M3 M^1(HJ+SSRC6GWH2MIS&6UHP.WJB M^@:R92QD+SNOTM%+ 8@ (OHMQ M&.&U9%Q-  

2QOM+1<70L$M_1P2R5^B$@<L$<4.1C3_#%018!R4>EG.FI.MJ.ID=9UMZ?>ABUS5# M67PCZ^>Y)IYWE)BYM^<^KZJ5^5Z^69&&H@B1-D@  

MP8Q#E#*L9F!F89 G.DQ(@^!<4J=O&@U!AF.WIAHY-NN+7P@:KKRF!A^VW5) MITE?D^S7+&43F^=7J6L0-8K!^OI-  

(=V13P>N^>N^JH+4)M!JZY3P^L.H_!4 M_4M4KVOGY42$^JUD:.)^Y7^R5YFHHJ%M_!$!>4>VQ2!8HJ!>R2,*<5,R3$^*4DAX  

MKC#L6^D#B)XVYS_U)L7VJH;(&DZYK)!$JQ731!##ZUMG>5RG98>.<=<I  

MIXWX&6@4!>49VRLK!V!P^G/4XSN#@P.SI3C>J_U4XXAV.R^=<U&E.MB)A)3 #!&UJ P2 BD6&4QH%  

DJ<BY487$!B1>M6*!4Z5DZ5L_@ (PIVFE_0QV4_U2!^RG^K^!GJ:W^2&33NEA0>G!9FKW$X1=%>J2(L ME 0X^@.8A7I^*20AI&4P(03C$.1HD-  

>=>2J!P^>JH+<UGHUU&Y.1..MI9S.7.X/@+Z=SOHH) 3C8K^S1H C2/V^"1%>OVR^Z!&HOTPO/2_@N U MJV_W5>L>?<KWNYS&1>B  

J(N7^400Q2^88(XP)#!DL2TP^58U_B+ MXT8XV$KONH6_F)<@GL%JFV(WZ1(2BR#_HE%="^D/#K<SQ$E2LJAO_M!H793PSP&1UBV&J  

JL4#>JPBUNO226HST?5_WQOQO6>@<KN84=42Z(2G^ M09#%_VR$*)<2DA^R^"K^2.LYTL_87_04L NH#0#^!P!M!Z+G8LJB<@_#J  

/JK_87N^Q.IZ3P&8F981B$<=:9!H7 F 2E M6D_#%C.Y&I7W^JN?_UP^W!UQFXOKN!OIGJYV_M7)#!>+KHJJ!7L^J2L_<  

<HKM1N^B#T4%_="J75BOI4L LRRB94N2!>60LQ8C>Z96+U K-NLGO25_XUV:0! MK$Y5&
```

ENHK-MDPJH6"K2,T@SYG0#,#2'DB81+F-!(SA7%FU*=J-15=-A6MX)H@:M:~L^L^M_M/,LR(D>Wl W^C\$?BIV#Z-0/0JN^M+INW;T(12%>BLJ.M=>W:UA IP.XQ M=1,SS J8S;G.WQ^K:~,"NX/I=-BMLGFC70(#~"~\$3*3)930&TP;3DB>6L-!G MA;S40? JH5I4 7<17%5KN1@=33/21BC.\$#JBYJF.D==="\$((@=VD<\$RXISL^M+39+>,5LWORN65K3/10JN#M!>Q9M^VPP+8JHBWSBYI4UIE0#WJYA=O00 MKR@A:E6@UF4ZK7I("C0&CNBIFOHW-K^>=H+I-0^:A6/G32P7DEUM=Z6G^4MB0<,<19%N:(CRBFGM/WQ^>BFHIL MIUW7-EFF^"H-@581U#K>=E1P\$V)N^H.B.U;O^K-6%>66L64HG=5T=N^H\$-M-JF1=-,1^I^6^J^M&>#QX(I^J^6^TV-R70WU_6J^P>GAI=?APE^I+T(A9B-M#;AFL-&L6JL^I41#ZNR8\$E1Wl-3^CLZ^<\$.Q-6^BY@/LN/R8^C^BIC^F^M0QA>IR+005,1L6R4L.W)>.,I/CJA3^P^I^Z4^J6V^I^TV5^F^XY5FM>_VM1MSZ=>NYL^LZ31^3/1\$)&C@CD.S5GBL5^Q-6\$BM(LRY^X^"JK^I^M^Q^SY^"~M^55^9K.HVSB0ZIX/K&L^H36LX-NFL^L^U^W=1/27ZC@1-B.9DMYMX>>KM(I^V+!DKAEC.D.M.6"@H\$E;=#1#7^J^UY^&GNJ+!DXSH-E(U\$=5Z>)>O@3E2<5R@MH>3(FMS>TQ?Z26Z8YFTM1>/-RSNEP^,3?711%V+G^J^F\$10)EPV)7FT M#Q DB.5I\$,<1Y\$;=24T%CL 90!M^R^P^66I5>6L^HDEJ0F+G7>7H%KUV9J MIBXRZ032S^CNE2DDC(E,IB1+=!^J\$-10) MU_7_0I@E50)=M/X%\$(BPF^F\$5&XR!@B MQM1/\$;&00G&L/&:&4FQ94.L(I^DM^Y\$/@62F9-S8+R=MC^L\$@IW\$&:"70.\$N^H^L5G-6NZ/ZDW!="EZL@8I1-3FL_9Z-18^K^UJHB(JMYSGA640(@4E N)/T<0 Q4CQ3A(L M<812Z91^G^3A(INI^2_C2@M^K-32513^RGCZ^9JP<^<5N^7/LCTA8?>5 MIS>)(H?^PB.B?>GP^4^7>MJ&4JH&H^M^AV^J^1Q@1L=8PZQ+9E5\$33 MKOG3&A.1AID.L53^<(DYL^A^4^0T^<X(2+5H^E&OH2QHXM.GA.IS@6AL^# M)19:1@PIXT.8YCAIB;.(X&#1;<.<14^8=Q-G+W2MA-8G^?D^>X>F1^PHL12R M6%<O-)/91LWKMJ9VM=P%KD\$;J^<^)-N0KXN=#1-#&#+.91DF>A8+G5B8;# M#B/U/9P4ZD\$6FW 3ZU6EGN8+OB>S>V14;_4.S^OC MMM=>X@EIO9X^C(1=AW)MT+UT^74.KU.QOHCXGCMCKB3FZ9ZVJ0.1>158Q5U@6.MTRP.(W3W^3^")_QUAF@ (PHQPD)8RM6J\$X^&R\$Y+O8J9.LMO)S3^_&X-FY M^U/7^&4^C.MBY79IUBD;NLW7Z)=9IZSN!\$33JP@_F%(HDX)2Wl M9JGVZ.2>B=A^6(GC^7%\$&4J6B)E5#^*0^"4Q^1^5AIGB(RQ5RL=LMZHJRI MN0-VBE1NS7F.(6:F52I\$P7)LP_!O!\$ULYCP\$A/GN&8A\$FG-8^)>W-ZZ+!1 MW<12R+!>@F^KQJX4^U^P^K744^SU0T_7ZM4Q.XD.MJ8/GXJG8BUXNH1&+4 M2D^F^X\$674I0&2623GXN^GR;_1+(!DIB.EHF8I<(<(AEG2% MD0&R\$8013%00^E30D.VT.U8P)H^JD^P^U17G&+FQ4)OUB:~<^<5^_<1D.MMGO^DS1<^1YL=R3B.(^3)ZJ_S8-16JL>5#336IOP_9Y9MR/BHD=0^70KJ@0JH-H=LW M2I_8JZ8-84KX\$Z^K>17HS6EP\$=^?7K.3AGIWS/WH^9IBW?MS>CL?7U4^2PB^J-U3 MQ4\$>I2E+(!0TD@HCF^<1&.&18^&1A^&83Q^%F6QXF=4ZL XLJVW0^C)UP7 M9^EG-22<^&IYALCVJRIH/5ZVW3LH?M) UN^UJH>U0#@#ZL1_!BO2^0D M\$AD7_<3&^&0JK<#<:S>\$RORG<%-6/>?%2-O_P@G1V&+!>>J^QINAWXWZ M@C7O1MR!^A^?CG.MO!^V,<1Y;KN9>:(GA7M,V@EXKFEIGEK=PS=Y&IZV M^25>2+IRC=Y+L^L.G6^CA.ACN9.YYLF67E+5:P3F276K^<U2Y6^XF>X^ M^%@OPD^F.8..0\$D^M^CF^"~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~<QIQ^>?DI^PT^PI^I\$ M^HJ3^@P@N.MXWEI^<3^1MHX1?F0%1.GEI=(&LUI^M LAN^# DIYJBM>B+>NWA@>Z12WK;J@_UZ^" M^>0U=17ZC^M^?#KEIG<7T70M^YNTN^L<^9V.G5CL2DX_7+UQ4WG.QX9H% MY<_<17ZY5>Q? ESQ63>NZJ9(NWH8E.G^Y5JMNKWX C0&@L: 7!5CDYHHW=(?>Z0_SS^R= MKO(C^@8>5JN;^9A46FWX!U3 ^!O^>F8&TGH9D^M^P=5.VWV^GEX^N.2D^J MP0\$^_I^S10IKX>T^XM0^2^L1+S;^!P2H+ZD^F TIC0510QO5I@>~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

MLXND&M*)HXOK5ZEN;#LOIO&UST!GH\4JZ#+JCY\!|T%*!M0BZYJXI MY#12@%8.1%LIKY_?
W+Q;E&YYQ_K%HGFI73+1#C7E7L9FX7I2L1..SLC3!
MT1S8L1O#7LW.KM#)KD9+FH.\$X3B1L:"J^6\$W9JJRRKJ_UYQU=S/UA+1#5H_~^VO.P@FWXVOC6B_3A-K&UB_-J2V&L1-M0.H1Q1..1Q"~4\$2!B-
164*M(E\$DQK9:G^4 MQEFL71@.E.K7H2WTR\$Y08U521~1JM.L3V1@AY"DZHTGP:7.0&:JBM.M-TL/4T_S1/*=Q@G^JFTU\$&\$5!#HNX4#~1L85^2QS)
M1XIGU#1#JB_K_)SD1NE7W~?~^=2WE_~^?OU!_7T#Z_/65(EH2K==+LELB.HG.\$F60K1K!+=?^0.2V!NYMF^GGTJNIXDTR559\$&8ASQDLH^AA#Q'
~1L1#(M8 M1(E(QP:12WUT1@!P~*_.1HR)KI&HZA(M1G=//DNIELY.4Y(UN...:FE9^Z%\$ZQW/0&G^K77+&<2C2Q_1XV)U1\$&\$^MC%\$%#1A_1ANQ
GM(R=1GJM_-D.X.L0L0~_..MKX.O641%5)\$Q:ZQ*2.(HH1(1BF\$M24_G-RHJ_B21.Y0723_1648/5\$C.&ZNYH.M1D^1H82.E2:QU?;\$E.N161"XS3-
\$~1^G1+6V/4(V0FH2+^Q^&103SH+_MZZK=UG=?E.WD3HC1B.GFRJXT_QV)JOBN+&5RK-O\$Y51!/=ZH^_KY7&+13C\$
M^124RK4H@_S.FEEL.ZJKCF<3P\$S~WAZ41W..M0.M1LHU\$M^21JSX@W0.9PIQA0ZZ.QUX^A2140W0XE0%PLL&@^217Q1U".U\$*~JG&2AQ51(HD)1:1
QV8)IA5(>^M0.MO.VYXX#~@A2:"KN^X9\$GE^VHR.A^Y>_#_Y41~_1=190W.WD~1^3BY^IK;G.M(=.#0P&3G&C1=(AYGD9T_4T97>O5OR^?+Q?
Y>D>J^<1)PFB1%~CF&141) M3B F(C/M NV7R)1/83(1_9G0Z_O<133INMQVO^G5>/?^TGJH!% 4PR%1QG2C/8120 M#"
(AE&6)3A/TOEFN<+L 77FQ0E6Z^HBU2MR>ZV1VY1G(R)H#G BC2 MK V)1+1+~B#19)Q18LX9V;1^T&R.W291B&F9)QD7WN+RYIQ^1@N"~Y
MU^1Q43O6719%~3YQV^=V8<&7H1LZ?1T7JAR+_F_?YGSZUUD;4TPLH5GY\$P.MEEL\$E1MCJEJ5QVE:A.G.TM.J+7T@/V.OJ90+~_177\$JK.MZ_?
SEFN+K^~1Z1?P7J^~7_WU~(M22TSW~=\$KZ2?2UFMP4-G1\$SG6M"MH^V7_J&:(YVR).D)7B^P1>_12;2;~@31^1W+1E1#>MX^JE=RD^EM15>PFV
ME@=<P52^_U0\$<0X1C~>.\$B\$(M.DT.M52^ON9X1621!:=VM1L7BPNXQL.P.N&2CSG_(H#1%#U1VFAHEK=#G@_M7DB-
A\$~757#C/(H7JY86:FZ#EN^9F#+=~;^PBCKGZGQZOM-RA177.Y<#1 MM!:=A1A#MW9\$&_K^~NQSIR+H1HJ1_91?)UJ4_<=>WG_H_EO>1^~7J17R
MASP2M_ALG-TUQD_415X\$M^1+3J8B;A(BD.&4BC1\$~18J-RJ\$361DD\$91\$JHRMN3U^9ZV4E@XX05O(?!M^TFV^71N)
MH>~=(~WYB01_V4H=HV;18N_A4XYR/C^E89_19HJK4YR/C^SC^&9^Z~1M^P(60D0"7&~>A:(&64XB(S.F>!"HU^QM^3~/4_
SH(*.G"/\$1G9DMEOJZD(@S14 M:8MLHZ.0G3Z(^A#<3BF+_1YN=~1^Y&G/C<K.YR1X3K_:8=276R(1@1YKO'
MJY1~MINS:X13VYXW7J29S)=DVE15K\$1L~5TFW~4FYQ_D9_107ZG2M1-M.MJO_(EH1~)D41~^@M(C.20650AXP7B1Y6A246#671.G=V!>NG7IP1+=U...U
M1HUO&0:HF?N1:YCN3M<6H^7B720T!)K6FQM.MJS0CX01_3A614~#T91Z.YM6U_W\$6.02.Q5&
(^*MOJIZ\$WE8HJON^27JE*~N1.R7:4A^1MRR7Z4BX5D M^1AN&GIUP2J^N6...7?F(1@1^T^0EZGR\$QJOR@1^3YH41_NBAHPSOH.E.WO^V#EOT9;
68>?72 MD0\$T0LRJGSNLR7WQ1^5V10^1>O7_P#~@_"A_.0M9MK1CUM_90VJ1ENEP.MNX2BK4Z)BD_449C#(F1_7B^D2:24MN\$M=6.VGAL373
48S_10YR=BK8(CV62M1>?D_ZT(^P1^K^?176LIA+76W0+3 M2E.ZF^QZ>7^H1Z^189+WQ1U=;H?ZYNE>G8LWWP!SG~_D1Z8
M1Z=DNC:8QU8DYEG171&Y@P)~(M#~.P\$50A\$18B@B~ON6UNJ4H19>4&~H1\$H0F1G<+1H3R2U1U12>9551A1CYV.MCST1#;K4UE)??^Y_14P&9.2?
+D1H^X1F1OC.A&_QC44#\$(68_YE~*M^1s8=4 Q1&~6^EZMU_QTK)GO_1+1@ORU7X."KYVOH.Q1MUH&@51^1ND MEAVH^3F
YC3W1=:8>+15.N2@>Y^K^Z~L_C/V1K4~%GQ4&1^1H2Y8RC(F^0 MID\$N+0V59.MP1V~H^N\$9BX1N@Q_?>K?QY1TDV=
~1K^F1SMK1Y<29MJ_~U1ZM=71+(Z.M_OFZ>S^BJV_~M372ZROO8)NY1QULFHDBZX1G71XOF+_O6F1H1H4^D1M.O.MNV1K.4769N8Y7E6E919.YTW%&-
Y1%::NH^Y1K#JZY6-3%#1KFOIUQBO.D1V"~F7IR/8UIHQM3XZ/1-0H.W.M.LX7_4D4HF>P6NWI>UC^_1.E15LB<2OUT^YVO\$U6_C(MS>J..S3."1)%\$&*
M1CJ2199GL1">21GA(SPM+V40.B1F<1A.MF\$%:5YL&PE^XV=F(HV#BIUF>P;C1M1O6\$13-7Q1UHM1L_K.R1UE9-
39W41USNJ>TA1=<4N1)SPK10^R^K019:Q1L M^X1J)1L&A^P1HDC^92U1\$1CHD0KU9HJ&AB\$D.S\$R^1PO10H&A1A(MD^230&-
LN:Z@~6P..L^D213\$T^M6\$)YDM+1U1<_U2B\$(Y11"?&S.R5*(3PC5_M32\$^1A#91(ZNNVL8A1XX^R;_1N/BPKO:ZW75_1)#5&>1C1/BT5># M+
Z\$~\$V^0@<C51T5U2\$~B74M9ET\$7G\$~1WJWX+1N1\$=1R81\$PT1CQ_041&DQY.M^1P2~1~1R/10726UHC2%2HT7Q1#_1+?
~1^NE6A.H.IWR~762PQ1@_M5\$;=Y6YX^D:~41L26T2C<~KBEDK7C/6B9.Q1O^Q80259~1E721+1N1Q6R^KYH1H&QD:P2L^EXN:U92%#111_01C>4_ZJ<"
M0%P(F<58D09X4\$;(*.W1G96S/2\$W%_DC?&5@S/3-7~HJ8%WBFN?@J2PIV MC(\$=9X1HUD#S0&9.OXKYXNP0US14(F1Q_1Z.31SW/Q2P_3R
P21G_1^XN1E.M11QQ9P@P@QB1\$ M+B;~<~1=N72%~O2.FMI.T2@:N1@UV1_E1K(GY<~80_&1GV1.0^3F@F@O:M.A^""UO1\$S8&%G1R>1387VGYX^F1?
W>R1A9W_4=C1J=M@?V.V:7N5E5R^1Z7K+P_82S=~+DQ.??LW~%~#X%#1G_%.SSB.XK1A%O M^+S(F#2JDA#F620+L:D^D1O@V\$2LHA3GA%F5
GE*(6L11K1HD12HJ1_7W@M2M^UB#19ZES\$JZ=O M6G7UVTF5_19F10M^#1
(Q%\$&_6<0DIRY=>1^~@E9".Q30/2&0M1\$XQ^A.7/3VA+G1Y6Q/O>"V6/^*M51XC=R%N9\$35U7_1)52%72D@10)5A1Q/B67W1U&E=K36^D22-8DYW
M4DUC^<+=S6_(&NVW))RSK3?<DM9+55@IZX;<+~1^Y<_T\$1181+?GZV12ZLB1+;A1JZ.7614.14QB.M1J1F^R^A1E^>@?@T.RL5)41SR1F~1S19KS
MYL1NGT6+254B16>5Q:K1_T\$TEC\$ZDY^X6\$DD_9>6G^Q_M122QO~<68MQH#3F04 M.S.EH2>~) V1_60H&^0HJG
(%3T/(\$~\$X1T&8%3^H1TOW\$SXMX3^T>4S%O1UR?2F%1XO39>G:EZP1&2^14 OUSU1^<1@1.MO/G2A"~Y_A#9+G1L#_F^1@H21X16&1RWMI_M
=5JCO1RXK/HQO_.81CF(<~0Y3%TLH1&8=Q>541P2GR1J:8A@1C.M.SKY1_MZ_~6 U05CWC1<1061L^KYB1<1=16
MG9+G7_G4EPKHUR/DJ65B5YU.IZCG_2QRG^EB#E\$LSYB3C1@O1LQ1G=1 M1XRXFW61&G.538&E2R2Z7AW516>8_V1L.S"UAC_N1Y64MMJGV7
M7#^~N1+U)B:(311+1J01(QF.FH.P_V~ZH6FF1.UBWE1X\$1L5(RAH_V2FJ&_M\$T.OF*(Q1_#^5(U1(S1ZVLM^13M;<59N/F&16V?N?(OMFD14DR71"8Q%\$*
M\$>@_ML^TG@~Q%Q=YO.BBK+W_Y^7+3^LD-A_~SCYN^YQC.WS8W?>DXW1U16@=D49S MG) D\$&_8H2B~\$PIZH+^TN*
D#H1^LY@>4133V51\$1ZMB17L42G(51 MD=NN:5N6^Y1TH<^71 Q1^E&_1^2MRI\$>31^1B7^961^YD(K&Y66G125US8K M10N_0S^U^>P_~4Q161
\$S1\$NPYE^8W4.X_FP%_UR=.B.A611EVLE101T7K.MEG@T>_H^S2?1_F&Q?+_FBL;5_7GZ^C4)A\$18;DK%(1103-5>83\$1_B3-(C M25E3^"7.R1%YDM+
1V1+1&^R^C\$1=3U\$15^2_KS2Z^Q07%.S61\$1^18^R&P.MSUUW15\$VNH_2^PR\$XW\$1\$E171_LGQ5(\$&Z1H^1SAH+^"\$X50^1VW^UW^G^M5?
062AG0~DOPV1G9U3JKZV=1K2FOE&~ON)3V1F1H1+9>K.MJ=F71G1<7^1@R18.BQA^4(#&/_01SU6=711.D^U5US0BA.G&9D1KY^U* MXS50+ M.?
L<0^8CO_~K81<9M0F\$1^6(C:KG151_CEF"W1S^R1O@1H(@C% M18L8A_M^1@1R~
V"~C)H9\$5.2G.K6YQ;#D8>#1/TZ=1L\$Q<91\$COZ;31C8@v;Z_2W5^V_5A3DD41A0GD(2Z.MM6R.H3S#42BRL\$B^@B8H1MJK1
1L+)\$R9>MVISM1G1E7S<3F7)7U^MRG63A+K5 M4(D7RF_N+1^1>_3.C<6Q<+4^4A;?KK82M5#GKZ14VU^1MLO+2\$MF#A ME7IBVX-
TO^FVPUCYUN.7N1+1HSB1H2JEM&U\$Y5LYB@1C(P(MKONU1H1291 M@E71^7N2=KU@HK/YQVQJ^6%XFZK9E.C71=KJQ1K1#^FCX_S1V0(=#
MH%EL_N^K(81N1D1X1YK&19:4RF=XLV62FEG5A1A)>S^P%FN3_Y21^YX1W<~ML6JG_~R=?
7W2L7F1V16RHE75^17U_L.A9ZZ13D\$P_>21P+^FNC1)@R_GB+&1&JAPH1T1F1J\$3454_LWO.M1U^09Q^3SM&O101>1^1R?3ZOV_=7TB2?~2W_?
2-5>^V6N<~RM9EG+51.M1_8L1^J1Q81^61(2^E278KE90ZT^B_KFW1U=1U41.Y+PS^AT_ QO\$E.MM.52V5Y@1U1+@QR0:5_U11#)X?
\$^M032^CSHJ6171X6&A321ZY6_+5=7.M1UX_XH4NO5&:85L1JUP8^OY7^_FNNL1J1O5CIWZ1_1WQUH_~T" MY@&~1T(\$90F5_15B&NK9_Q"1H4!
~<61F04S^1B62%KU+15V10<~5C1" M71-6E1=5G~+PYS_E41C^F@SV9A2K41QF?~1T^1)N22TGC1NYD6^77S8S6?S
MXX3T1+~BL1+U1^Y1T_&~31P*>D+V1P.M.SH&~?513V5U7^QOG1YQ2F1F MS6F1HJZ>41@G^1RO1D1(G+&OB1!:=)BM.<614L\$QF\$?
1O1^L2HT1%5 M:81-E@1E7T\$)C/U.EOX.U6XHP=J@AZ#&LOD1J2^CA"95)?T" _1RW91XVM) M>18%8?1Y6=W>1714<1.5W?B7G^S>13.CZ3E@~
Y*MT\$ M17HP4^P.XFN.^A7H7B1^6T13+T_1ZNOBEG.81(C1_7F0Q11Q^Q.D10JEP6_MY3B~*4J&_D1X1
YCIU(YG4UGB;&9K68>~G7<1#=#H851N(@_RYRR1 M3YK_N0\$TLQ\$16QC5.3.W^U+5%GZK1W5YR119>1H6Q1YZFKM10MMV3B>Q_%.S.M?
1JQ^~C41JW9+5%#0^D_2V&_BGT_1U)~235T.DEOVHY.IN+OM70R?M\$AZ.W.MLVN^J.T=~5#>1501\$68<1AE^_\$.>70XOAT1UB^4<~#0.L>Q>5110?
YBM.71G2XQ>D^1~H92Q_2B^1DO;JY.MDJAP=0&FRP=11418WKK^~0.53.&*KW31_G_L1Z1ZQ)_SLBB13GH^17Q0_B M5)HC4AG1("1%111%Q-
(Y)Y41_9^75X0\$1)E0T_ZB<~1L\$N&Z+1H?CY\$1.M^E+3XRN0D4&TM11:9N1Z7R1>~@?HCB^5R.NC53/VJNQ@727#&.*#B.UAP%
M6^L%.P^6^NWK.N1DJGF.R^V1/608^~HU7_110Q11^1^6JP^Z1W7^EM9R^1M4E1\$;R\$+L1@6PB1O\$D@&3^1
YK3W+1NS5\$J8P=T2+KJ1^@1@Y:T92WR2ICZ.M5:VXW^1H1FED51513DHRH^C_1\$G^T=S4KQN(OXK3^PL%1K&1O;_11^1U)@O M^*?
16JXK^ZYBCY2Y6&0^U4EV.@66Z<MLZ1U=HYD7ZE4FOTX1=>>E1_13<+O740<%C>_1ZX1Y>1U;11@10K.W1L1 MUXN396?31O5114#+ME1
1F+^1_F0=AW7VGD=Y3C.2_Y@411B\$BTA1 M^518^1N^SG1_VYU_1B1MY&U14=51K1^F81Y~19T8^18Y08W&VMQUA_V1F1H
M)>3M5.V620U1S;911.R1L\$1^P8G5<~MR4(31ELGRT@2N1K>D13+T31L.DC_((A1\$1JERY_11WR>1^02+1@11R)>.@7C^*20%HA05_2?
%Y&2RMLMZW&LS.H0G1M517AHO?^1^751U8D\$V4(R4.LR1CD14E9;8U@P61MPQG1K1@36WT M8#^Y1_59KE-
<~+1A^1(1+TWOR1F\$7K71Y^A=P675^F61GD7Q11# M\$FMSL.P1+=~@18T#N1N=EN771P&@1K1>11+1493+19M@_7\$241@+1BCF
H694>V1^5>4GP.VH3V11^YX.8K1N&@T:2SW4^O N#1%BI#%&.65&JM\$_.W.@Z_#(6058^R)P5A11^2-6\$#PDME826N8ZK_BM^7C_~KY9+BI^O2S%.6
MTE\$1^/*<1A"~0AHC^31UV1\$11&D0Q069.Y8.Q#~3#V1W14K13EHZYX1C=051<~MJG1N^?+1^K27(UY1D<~<Y9>P1H1V145^2^KV1_E=11JN.TZ>Z%
1<2S.M1(QOABB1^1.OXY1A=1\$6T?T\$N^@6NT.P1JOA2=1W1=NZ)~55L_NZAT1Q_KO1^6QXTNE_~9BF(8X22&41_Q2#GD M1^Q2B3R5(PS<~O.K;11
VBF:3"~831)%K1W_X.KRH.FA.K^40>1(8QY&?1)<9R1P.M=?A_0SHZ%Y;5NOEHBF3L+T0EX^?KEZ6VMH1R1E@9=7Y5+8C.MU1=1.M%5>?
PMKF1Y6N37.W7.@QUN=?2RPW31=2A7Q.KG1@90C1^1#0E.M.9\$~R88\$K\$@_1@2%1^P^D2B878LH2PY1UK=3GR>5**51>BBSYX/K20K-
Q113ME1>?~(Q1&_MEUN1CZSVFEP1^1D1_572_@1P^2MO15DIYO= R1U1>68H18^62%_1Q.M1:2M5@=1!
11.YOHS>+HY2M.3.2W?18H9;MU>7S\$25>28^M77Z0?OPV9=V MF_Z124V)XB01248@+1@ZA_(\$XCP(8\$ZSL_XHAGBI@&S/71&7FZ:DGf_9Q1@
M_1HBYX1E\$&~.P.C_191P+1H<1^PS_+1^1D%7YGH.Q.M.BMDJGFN7N.2Z3+~9R1^9M8511^1@~\$7B261(CSF.O.FWV217)LGX863H1T_M=8F/76~1>
1+81EH=(8&1\$A+O&61E9Q51QSO1Q11);_WO.^B2_E\$T!9+~(P.M@SSB(41^ZG~LD8=YBCF)4T^*PJ1D1>@SEV?%6W7+J21^GC71/@+1%AT
M#=#NQGPDSC3101077RR:0_JR1=PUSOXQ.SL(3MZ#>=>PY>5^62(CH21N_1M1A/K:15-9N).FR\$\$.1Y2E\$2L@ROB&^180\$DB1+^5JR1/\$\$.=;T1^30
M3G(SC>(DCYU4^*~<18MBO<~WYV1Z^?C3KKX111YN93V.W^~^~^2_1.WO:17E9.M=U1O6T1D0<\$X(Q_G>0)5E#TLY\$E/1_PFD8LY<2J4E1OM;\$W_~Z-
7K.1M0S.M0%(1U1)SA1F^QG=)Z^K^QW^S1P1R6W11^17W0SV1TK1.BWV^7L21@Y<L_5WK
MA^4WON14=3.O>Q^HSC.F1?T^QYY=60P4^@1=QV6P\$~MOFMZV\$Y^Q>9%Y.M0M51B;M^8WK1T2=V1^AYOLQ177H&Z_Z_1#OY;2UW4AN?N1?
YK_?2PA>1_X.MM.V4\$1#110(1\$6^31dB+P^1L1^G%4_7A\$1^1M31_MG1^2EO1PBE7-Q^1^>W17U5R+FN2B39<\$YF"
(SY334^1H&(22=K1_1W1URB\$ MM1X11 ED4XY\$B_ZD132HPRH3E01CR3_M2P1_1Q^078F1^6W_ZG.XO.M1W_H1=??_1SW^\$V?
1C1G77SEFXM>3_11N1^G1V1Y>~<~W7YV1N1MSD>1212RWH1^>C1_+~1CT93>81^XGE121O1Z7SR1K18201UW1NGY1A1E
M.W+S.5)1!@G@OWYCWGZTW_1RR^_K.0QEX1A#(OY>1O9X?W7CF#R051^*~>7 MOY;2_KH_132<^1^%UN6_72S1O_~1GH1OOX1F?291#_4^SR0Q?
R27C1Q?>1 MQW?1M>1=DR^2P1P1L^3U11^P1_8CLRAW1H@16^\$F8P1N1F>1O>A<1M1\$;S M+1<~P^CYTV&17^FYY+TP21Q17
QMXA&B280Q88GT1\$=W\$T@Y<~N95NL1V.MH7E11^1U:82YK_Z31_B1W1MLBA?+6(RM.B#UZ1\$M1O@~1EBM1C1_1^OR%
M1D8+1%HA531\$932JK&LQK21E6:0WC_1@FOGE.T@~T4.MR1W2186:~1A^4M\$~M2^JK=U15UGU_R_3RHS;_7)HML.MWC6WA1?<D1V5MQ^DM2.
M1^1JD3\$X2JHKSR(1&1XTGD1)@N_@1C.P1@1F91L BG<1(P25T1Z^_KW.GX>3 MDMMN16;A\$A1^~91F265FC1GK_GH11K^2-
2FQ@5ER41Z1P3>3_3=1WBS.EYW.M1:EYGV.K^@2G:(O(A^4HH1^121P\$BG^3^Y.69<HWO1/ZYV1N1H1 M5A1C312_1YE<~3%P.E1.=TF^0#~#^1
13T(7K^A2U^O1FXV<94OF5&)N?~M1A>R(R1NO:8.GZ-E8.PNV(Z1L71U^V11^1^1^V^X^~D_~QYR1O1A_1)F^/50# M0Q^K/B;9&L_S2@7TN2_1%Q1)
V^%#_E_1%6R/O^QTOY.A.M1^+1^421B+<7\$P\$&_~@Z^=ED16Q.MOX2A158J101(48B&2K2(014HX^XQ1HHJ1A_MOW0H2YE1UHHH%8>P&+PTF<
MSM^X1+86R/19GUY^K.K^?1\$.0<~BX1^140Y9ERXBA:~1&4L2_Y\$GA(1EY
M1K8^C7U7H^DG1^Y@Z_1<9A^5B1^F4K1US92H128BX^1+X7AF&6>~)1YX_5.X<>1\$S4W00\$1^6\$^1A2_U7\$PX9."&91N60^YD01?)? M9041

0;\$[K&FAYY-7;Y2<:TDXSXAY=H=1>=>,%-(#993B0(W#N#I M0L!!!2[ZUL5R13L<7ZF?@EWBV>M\$ 19B+1)1CA&6. M."OBF="90QJ7<
<:"1+6W;8>#1YJ4W5F>N-7.48GWZ3FXR2D1(D25+A MF>#)Y8J2J25+17G:O1" :JP1+JEDJH(GAUCX1SBU0P%PGXB&"W&.12 M9_@":-.843E&?
\$Z,>(R% XKGP+.(C;"P<:ML!/>4JB-Y DQ%BYFOER\$. JY M&:9C_ \$F&G)(E7DI-4!9 DA!%!"F+UF4CYWV>)E(-QIW78H>"YT=TEV1-S M,/(C?O.3KJ-
Z16Z^2C(Y%JMW)YK92)9JELM:7PMD)F!K=LIXKT.D.QO+ MM1>AQ-I@/!!/:<+Y<+>#GN-YEP-G\JB1KDV-9.\$? R8R!-=HWKPG;D-JC(X MI9Q5?
CWI^NV?P-Y7KK.&L!F!=^F8XR/&QYT#R:#T5WPBDO"#<:Q1(3NLE- M.;\$RB HU85Y"E#9>.UV\$E?>T3R09 MA1#/"J=5T>13RQ*2-
R9&M7ECHI.Z"KVQG3IGW B+;Q4+D8_X-O-#5; M0^N5!BFB2>2R5>."B(#C8\$1W).LIFWLES;H+<1KJ5!SKWRJH(NOL-MP)W.?
@Z5NHHDZ&9M<4GGI=NAX7YGVW:7:"U"^- M7_KQ^/5*4QGPICOEY@D7)A+>9F4B1BE3&X<3+A3.(62UD)!%=>NATHWDL
MM#E4>P&P27.ON+.&DV-7WQ;71Z^=U/2@ZYD2-81NS<#<ID<X%?."EAG0 MUE\$NFV7"GGGY=B/Y+PG26A+&N&"R"
< VKM(CI/!&6.H19?8-15!#A0B9+ M:(2\$1BB1%*(Q)(S0/&DGP3=S6H^1W90>2_YTHRILEMAH^CR2GB<1Y)SK2SS7FQ.
MYH@/+ZOE\$+1ICF:29>+=+0ZX(RY1#-B8U4EDAEE^<C4IG-9W;(>2D)&X\$;RK07 MB#B1"N-1_#B>^1AP.&UL2IIPDS!K=G6A(R#POX!&6^/U;@;7^OE=MJ
M=5>))@(:.WUV5CTI3JX6?>B-7T.NFB2LABL.UOZ7-1.KG4A-YD)H)F6RM\$; MN=:G;-@...K!5I YCUQ4N9W=S<@??AY5BB1280+^&/Q
3-13Y27D.D.BKNE MTRJ@EAOFL-YYHH:3W8SUNF#O9FT3M1/>1/KM;?A@C9FOGOG231"!Y/X?<
MIQ2#D4252QW2X%=-YV>M8W)ZYARC/%V!^@O^=D:TNT50%;1+E9- M_#F"1>+17-\$"=@7\$LN2)=Y\$SY*POK\$X;D0>OW@XDIR5?6T?'"<D#SE(2RY*
M5-12!<=213%(4W+5+NV0(R68E>5Z261ATW7;P>+J9&9WEVU0Y\$;KPD MB75!H:MG@OC0DW7W#;SQRE0-DHCS
M6!LS<33F823)>#Q+R%SY%<3QW!>K>#5D0?C:9YFC&6FEWN6!F="1-CISQ M/C/AR2.T90Y>-S/OIU731>Y:JZMX1W%F/7-GQ%^+<
(0.G.;1JOSH%E@8/(8 MBR1\$)8E@DF4#TB4;FA_ZIK2Z@%DFH_M0C!H2FCZX\$@0S"4<<>1WU1RL)8R-M\$CB&NB;JG"77PC8<2;"OPFYZPI6)<@U\$V
ME2O_Y24L9A+@D<^EZIK!-SG&J;-NO?F11K1+2-."B\$N%_VR?ZV="!">D6.DTT.ZTMYDXG/RP<+X1K/S M!/9X@+029H@/EBF8X?
6IF6=SA)#!ZJH4C1KW(N>X%\$3K8(-S)V>(C-9) M8KJ=WU-1775W0.K- COJU>@(<O^CS^!T.;LL6B!DI#@.#.0AEUYXPEB7
MM=;59U-11D>WPQ8JHJ6QD/MC8HZFDZ<D-1^25W=ULF:2!45"4)\$!I3P5&1M-2&RU.T=-,+N2T#TU3808#-"OR?87%MFM89D8ZR("EWFJ.43X@1
(6A.60 MN>6&Y2Q^V1^2-5#R97)140.P\$NM\$B1B\$Y5\$<K-1N<@/Y=XVVGJW3;\$==3 MN04\$U5==#R\$S-Z0PN1U>71S;
(@R%.6PR)*@1.291XO(BAPB*6&.1H8(#.0)ZJ;E<@N8JB0^<N#INQ^<O#E.OA-YE>SDDFI87\$H!01)DU\$*(DL M6L:E&8-B-14,+85/S-8FVQ%
(3U#33Z!E=A140+!@.X:"1@-GEM-5UWY1"(5R-1G0Z"L6?>Q\$=Q=5Y5OYTCIS"8)((\$P41M P&K\$S
MA/=E9HJLTJ.MTDI3&Y1YV4IZTUUKG=X\$PPIH\$C3M\$MXJ>AQ^N G3OK.?^(M\$OLPFE_X3GWT OG26^A!L&/P_XR3V5<-&?W/4E0SH?8"OU=D3=F@B?<
26DF-D.MTGJAG+NP T8;U3VJ0CMJ/MT^ZY5VWKJ-1B7-7R5T(9@?>) M&6EONYS1.7 MM".&)#WG@%<(3F!(RQ18M(C.&60DAME-7:12SKHQ?
JNGC/M>M0;K:Z\$?2MP=QJ18-5F2G+^%YV-1."I9U5\$Z2^4MTI2+<YR1!>(Q1& MXY51>Z>RRO=WZ9CEJA=2QX^U!E02A@/&T7.NV20P-B:JQ-
C/N>#;ZN\$WR<#ZRFER^C.T3DI^"O*!<@3\$WEL2/"(J?^9^W4-1JS%99
M'WSW&GCPNSO@f\$16MZ6QM1#5McyZ8)16!>JWAFIPQ(JDCFP.MT\$4HL9ND2Y>\$H=0BFLM^ZPTG3J_)AAP2Y-7
M4MA1^7HM+EL1+>+85(KU6KCU&(9C.NCZ-557BQ@1L;D^D^AD16<9#6IY8R>9A9GTS"N/P:IO?T\$157?^ MINMR/@O.#RNYW=3ZIEV6P<-
#9ZD4HO2P#@>17CIN>.)\UR8Z^X(U5(=3>LG:A MLSIO6&M8;%UI00#L1+SW&E?)GIP\$;OE3%6.CS3N12J8\$HZ&^&P7QIT:4#0Z
M%7F3L^XUP=5210_18N@DXLPQ^GF22)9VH1TQ.51 M0- DXRNINW4AT?#?"P"-Q-T+0136A7O%@@;968URT#3QTK127=&.&H07-FF4M MHXS5LTF-
^1H-1!6AHNA=0Y4M1>1HQ^4&PN\$MDW1283@P-."LC@AWT)^5-MLO=^@O2!Q^SYSD+16Q/ZIW\$!AXG15OWT"7@U!H!\$S:GO1BO+1_&1=7:1U1
M1H2.X!M.YJ.?L^K1+7=9CF%QDB-1T.G35_-HPTA(18-R7IBP7G)FJ;H/A+6&MLC)Z ^"@AHJKY0-QLMHSUP- M8\$!L.*E,X!Z9,-+5#NS!)^";M/A+<&GH-!
1D-1)^X=ZJH!)1UEH4CP2T MKJG<153<>2Q%*61XXWK) AS+O4E26V.U5(9F-2/5JUG1LL1A=Z7LL^&L6 M>-1+7-.28-#MYPCEU*2V;M4-%2.
<%D@WNN&Y2L-E-R:U\$JY^YOYM M7>>D6@)02+!N@2M^SN+1+)^"G"MR,C!L:421#3IG.5""16A966(BT\$3 MHJ+P.PDDGTF?
W#P- A1E7>>R6K9+;BG%TG2^WRM!EL>SN=7DG9<=5%-D3; M4J>+8GY20=XUBK1<1N-JA>IZ3IY1:PVED-0874^JQ423&.&P3ZLM
M=B><?H-7+LJH<66S!>M(2VHRLB2X3(ZIT ME.*O+1^0@0) 2!M.KIV/VX\$LKA+1+2.MMFQZM>1&S/M;9.E\$U\$H!0D)DFT-LTR M2&1#H16&4+X6-
EM5N!OESZ1T6RZEIC:60%1UHR7L;BCN=5%6H(14\$*?_MJC<=<T1H:2#DVC?&PJP.ZUOZMMC:E=55-166-G26V-1.GDARN:ZLTRY4<
M1="Z">#)M**<4(UV=-#^1V9D&J2B#(1SB611NV+CI<+T-17 @4NVZL1D-M-#J) @&3J15"2IE"0C=/\$N\$5\$54W17%6S.CG^V7UVWC=IZ;+&<-G3H
M(FX@Y1YX.S>7C-1V&RUP87V:3>2S(><@E3*9*(.K13.\$NT+18-.0DE-2D^<415DK-W.\$) &MSGGJBA^N0>6)^/QOE.QD1VK_#>D-CS8N8G
MIRO32T/F187202?> HJLM\$U\$>4FM2>.&A&249^B;O/-51%5420!%3T1GTAI=B=>27 WPTR^#<4BYE MTD^0LA07)8EM;Z&CU89-/D-
+M1@Z\$CE0080<.-S&C5Y\$;5^9<.-MYFZL;1(\$21P5%9P1Y-GAI<+V4>=5 TG:C AV1@2YB+4 T+T=7N:41D MEVFC-O33^1_ZV=EAU-G2R7>-
1Y3/D<0R L>X-QJ1@E3RBEF1C1WOWH"J8V>@>"NVVYXUXF0M4IW^FY MYP#22J@F\$S2Q%NC2Z1-N+1^O:XS/D-/MN4RIH^JEA1X_ZDE!#8-0.17D
M+7/2EUPM)YJ2XQWPEJKV\$MLM.M1=I=&J00NN- D-6KJ/QJ?H>11^"BP2SM1RC^PCP5). M@LQ64.Y<V40#@15M_KSWX-9YZZ^C5M"9P-
=295+1\$FN\$)=U-0J11.M\$0R82:D02J6+!>L81Q)R9BKCX>=>WNWEL-&E1LCT^M9L=2F=6^QF(W) MU:(TRKZ80M0T-RA!^T118+Y^8C
)01SUBL20.#H4@OJ3:4-D-NMFI<&ZM1^M=1TP70>8^0K#J;3+.-7+9EF!\$VN201>9(*7-VIDV M-%#YDTMRT6!\$H!MO2"XU7AG3M\$NIUNIX/?
CZ^0P/>DL1N2V1W^JZJ@11NR8F+U>X\$85\$QI IF@L4:IT6!-1M;72(DIB WE=9X:5!MJCA1G.0GIG20F>Z1^GYM&30J>>D-1-M^0NVXJE^B1P
5FY9CTI3;O>12L1C=(QO3CE_-O-WPIO&@IFH1QJ@>A:1A%>0%6&A.08 MB137!>Z>MY"GY8V6-E-BIGJH^VDVTOG6.C!D>E;JC%;XGEB^1T1Q4
M9T>S<\$YZY^QM8^E7IFC;0UX00#>TSG>UVBF%RIB4U-7ON FZ<>E&^J?."Z MOM!06#R9W+5JWIN-
YOBK@ZLR5!KJG\$=5TW4YJ.8;3-9Y"GI14KH- B0\$Q\$@ MC\$Z^1J<V.;@Q"11(>R)@- M<3HK8K+75+D<1&XA1W&?B&
H@>HC19F4>P"3092664#1^>2TIN\$DWW784QW-MB-G(K5&44)DCBJ8D-U06)"8;3.S>JXJ0^99@KHJH/GWK21P.48KRZO/J7
MF/HOYAKQDQ0\$R;S!\$S)S)1D(N78^4UMYEX\$M12QO35RW1P.M0^P5K20 M.F>P0-E NBD40>.""Z>#CA;MKRPM0;
(F+!E\$>7\$7&\$M.LH1\$813TFV^O3Z0-M^LB1/ZBYC3^D)2EO?6AHJ0DRO81)F%TRI.G+JK21.8DZT&1;41Y!"GDPJ
MKQBOIR@>D#DX9^0A-FPL^EX^Z^1W/TI&AJY>=B1G^.-H>\$>VF"NK112WA0W&+28-8Z&K^IT\$CRI!N6YN(MH(&-MAX;5/?
#U-1-9RZJM3^P(8UTL^#>1^/1^3);U32:E#1>AW3M0\$=PLFZ@QXA-&4Q&#XIS:7317WD+AIM\$PG&0+1^7Z%+&11>(S49+*
IG/M2P1A>JZKRYTJN" MKH<M""XKEU=1.987;.#172U1- DGIS^HU7J-M\$QQ>3V7G+9JZ80DK+1^9O\$S;#<H<1N"1H%6#&1\$>#@-
J3+*3%)9=M(1!PS MBN3<@-34)OUJY;M^;N1M2:8;\$3?4?ZW=.0G@<(1@<8!HC9ZY813LCH^M^JZ<#&C^VGT4.KVIU&8GJ5?
#>"0T(NH^RWNC43A73^EG-CJDE@<(812KP2^&G241\$K3H32CMAR^Z#B-R6!D^1Y32 MWC(O-11>+L=91OMP=X.CV^ETUJD&Z1JY5_@R-
T>K?IQ<CHOH78FV&NL1KZ!>#H1L6.Y-E@0D8\$P9K22X15N24%(V M<@PT:9-;K;6>SM(=5+2VYU-?1&5;..%0U)1+&#*RE6S8"-
M0@LFZCWN1FGH_1^SB>_EZU8HWM.UNI=?G# MSR1S2<3V^EP>Q@4-UC6CFXDH("Z1P%QEK.H\$1XU1)=<(K-64H5TK6-TNNI
ALSD135;\$>XMFZEN7I2UTE)E@&-Z3P1-14D5!O&*^<9^1-B&1L15HKYT M^YM;ST-GJUCXI^ID).22UW-NH42O&+&1T1GN1!@7T1
<*.PLE.K6TQ"4) MA&U,<G'&=%_M+E^7=9^0F00"!4R(IY^@?"TUL2-ZDH9:GVN<:6Y+6K=WM^D/1D^75V@O MS/1"7:K8.LS+>Z5\ H?<
<*V#Y1G+91-CLHVI+1KK).N1NB<C^E1-1VHU^MHZ%&U-1%\$&C:G:HA-1>Z6V<WR-0QZD4-1YE2XW\$8K>=>N>D1+1^M-7=ZE^<
<4HVDQ178UQJ\$=%MA3N-E=625\$;#U-1=U/@5=-8;T6&21^1.TB(J<1D1U)1+1DB7@TG4@>"U!U;T-6WR5=U!\$B1HJ-MJ!<#C=CR?
QJYB<1.0@")&E-+N^TTFY^G<5F0Y>MMRP^4.XT0 MDPI^601EJ\$>5^XKPOIVK>7M^ER0(-/G7U-MG0WZ-&54H#C(^+7F512N-
K1S&OH(GW7>1#ZSEK1ZX"(B:Q\$@+8_KS-VX MS#-1I2E2Q6/DWQ1^7J+>V4A1-7L1H=#H\$H3(5N-OX4&HV^9)T^7
MO55.H:P3A1HCO1N2W.M1TJ(>E@)C^F;J10-;<K@IQE#FP&6!HGC&G)93-M192C2V12YO-M^OB>RV\$(<%F5I&-&2E-IN0XE3+A\$J%0-PTM.X\$9X-N-
NS=-MZZ6&AEE+PN-0 M-BTY>C-1W+&5!>K(KD6^1+2L+>Y)51)-8-656FZ3J>U2V>W1S!LJRA4U
M=<C^SGO(13O/M1^LU=+DPCI/M4)&96H49CDY\$H(3:D'G.TE1:NY1B-JZ5H-MV^LH^P^GF-V4CHS^BHBK#-
Z5WAE@E-110#@YACZTIMGM#.#63E.Z1N4-MJZK/EG"9-%UGC#-@GB&G-A/REHTK0ZNO.1#.*Y1J!X\$S1)5W9ZL=&X!&RF1 MCI/O-4:9,UDP!"
(7?^PI7&P1T3J^XFB^5+VQJXM\$=7N41TK75-Z2B/ENI M0^1X#&U.(@6TXWKQMRK.R18&Q-7^(@=&66^UT19;S1=M91#;151-E271#)#1
MEU4N@THD"E8+&?MG8=1;T=+PPK&NK6\$-C-32.CW/VU^7-M.UA#A OF2>214Z<1Y1T\$1\$10\$ MN6T+ Q1\$=ZHH^UDR\$;UWV4TM=1=JHU-1PK/?
Q!6^XBC@C)@=<7DR@U3?>D@O=E-9 M\$TQM#U/42+>=JKA&8D-NHR>E&#<^P@-ISO1DW2Z@%1U2P.9/R*N<-85E5C;W"ZL?
H&XT^XOZ^N/1R1^M62^CSH1KJ-LL M^1DB1S\$808(2Z7P@MM1B9JM58(9^17O;U(5"->EJ#75451<+&2)2A-PB+ M8>
R-A9.W^2FEY61+PMREZMEH"VWSK4FHWRS#;A=UN1%223Q/2R&JVS/NL1)Z49.(T199L0X7C.6<^;T1<-E5FW6W+P>761=O.6IFMW71=1
M1HW&Q+1W^>1D+19J1R#H1CHK%<MLB8642%0@C M.&1A1U^XLU-1^WM97U; M:6^FH1YLG1S.2^RF24SREA)F)^2_Y0&\$!EL
<9\$SZO7QJP(ZW1+Y1&1-M-KO-Y>NN7RA&2X.\$E0R1N.5!\$K0&1 M<28^62M0WN1M3ULORG+9^V1+4>""JLRM@<#Y4-MOR#3
AO=YB!>X3N6N\$H(C;L;Z-ZPMU\$<7Y71:EVL^U\$4^20!8TD>@O M06FP%;P/A+@>6^ZK=^?EL.NVCMK92>@R3^FP.DG=-(2EA4NW\$S78W@1.RN?<
Y\$<#N4V^H+141@MN@1B&C)3WN+6Y2"1U M@3A%7-EFCMIHQ+FN1=ITC106L0HQ>UKE^AU6^#8<-7W1^/EZ+TXQM1^DIR M=;Y4N-4-
^WPD^X%..ZZ#^Z2 ^#""1^0#PH3DJK:OL25H>+16T-B&KK1 M@8N1E)TX?^>D2166/SBH+J0@-+&S\$93\$1R11+&MV-
R&LAI=>#SYN1G56^*99)F.H#891+FZ^SY989BE!"3EH39.U^YLVR^A-MXS:2;X^;W67>1<%H.91J9S.3M^N-1F8+21F1&XFL>Y71J;GD-DH+3NU
M3B>#S2%0&1PI&=WU-OY<46>35FVFE M&O+1^=<2CC^RQ-M2Q-5=GD17W4Y1\$W713W#Z;5G2UD-53WO^A-1G
M1^+PY@>^H?1) WE&P2=OU4QZ-8FMJX@3!^D/S6SUB>SKWYR M/2ZX;ZJ6V;<G&S2Y.MLMO-?E-W+10VK/26<^0+CRXU3R7K^3016H#-
M0BA:2;1>#<IG6-B#>8S>X.L2E=1^# N19Y.V>5+1+L4H21;BL=BRQ/MGCD8020Y1\$<0@W2H1X-GS;Y4T\$TF2>WXZ/QQXN+1W?<
+&WQW-RY?CB.MV/G3Z1Y1M;CHS!\$Q-VYUWQ3WGP-B14A2128 M^MY3R.PI=P^1Q1:BAB\$(6H M&K&C^XH1YQ>21
<1V+1U?1W<#;U)2R4+M=;1L%RHS1160.KK=M>Z>A11%E CK M&^4(C1Z<5!&2D&M1+0H-8NMGC.GKKFYT^W:RJC1920^NOG_X1N;PX^V3-MM
^SA1-KB<+1T.&2+M6-BE\$Y0ITXORL3P.8I.(EC^71HGI1(194<-11040YU+1^XG4F^2XZ1H6Q16>O12ZRIAL M;@>DU4-5Q1&J5Z2NBE93D-!
1CBMT1 MWA_L8\$_6-W55\$-(D+0UMQWRYN^4.IZ8(#RD.OB.E<8-0N"&6F:7R:2SK=UH_S\$ZNK\$Y2^185N-AHK1 MJ2DZ-Y\$1-OAX#O1X/C1Y1.%H9
VCI1HJX6.U^H- MFLY+3/7^JOIRU-4OH18.ITS&Z=1#APLA^&8ONGCBH^0VZ&CDPVB- MSC^NJ(1710CU1P-(A61+X.OGN1VE-1\$>7C78
1GL\$^AQ1-C BG6(D-MB(C-1A=6:X2J17352GNNN=K&-1W7&^NSIV>..1X-16158G T.#B1^1NT2-MAU>1%V-123FANWK6BL9-^P/I
(E312%4N)18^XK:6HB^LD0R2^481V#5 M&S013DE3\$W-;J7=0SK)T%>"0;EMH3FO N>B\$Y.Y^R.FYVENH)4KJU-Q7T
MOQVEH:HBIEZ21>E)SV1\$5C2T6+MP=M-9-D C-S=Q3<-892>PBPB-XJWOIG:WAO%N^5)<#-31\$JKB.O2DH@1FPL15=1
M2M3FH.F1^CR:3>+>X2=11J\$11E9-9.00D0-7DL18:UH-1^O3^R7:LO X4F@<MINZ0B+T1R1^AQ4E1Y>1H1K6Q^5H1H>9AY4SK>BGIXFL@9191<8X9V?<
XA(O MJWTT"/@<NCHMNU>G3AKYUA6@315)C.D5@90)TIB M!"VSD^Q26GG5/45+XTZ<1^JPVZTF@F1^T2:7\$1(Y1-62"JT-P"JK\$VLI/
MD1T.TJHX-111XJ(N-1EOWV-1H&IR<1U=-/B-;X2<1-W&XIAV>211W MR=G^E+D1^XZK^2S0U20CQY+1F>1-36215-1611A
M-1A&Z&R(C:FFKHR9D@6\$CQP&E-PS-1>Z.O^L1#>W^1H661)69JZ1^AMN1C^ZXM(61-7-#1#>5:U-H-KEL^7AD1R)F1\$0#>71H^AZQHBQPI="Q.
M27^U2R2?>=>ZM^1Z2E9XJ7E2AF246ZEZ&D=D-1J3#-B6B_Y-7+RI^G1NC@M#B>1>35;1+1G@T-E/1L<1R5GH1D^EV7Q\$A1S-LU35RM#-UY+>X/O
MTUFY1-X92%N^=EC)M;"HS">E.D:2Y64.B54Y^8A1<C3+47V1LH)S1-MV7C.8WB/7D@EG23^N%Q10-T) L6A
@/M/Y1=1.N15D=9VW;PI#&+&YK%273 M0V<1V-GX?2-81Z;1-1KF4+2Y1^0QB1Y1CT1.1A1&@P1AY>G:YAB+1
M57KU.RH8M691U2JHNH7.U8(BE;P+RQ70K.EV(GDMQQT=7;Z1<=8;JKJGEG?OXLO^R=M-D-SLK1Y:Z7

M^AY 3@T+^B)MVN+I>TJDT(RX&"5!A6L5@J%2U3ZU>D!\$DU335 MS(* J7L COJPLZ=9NS-)S? M4Z/ \$7Z:H6A5Y>?7O:S3+B>C7X@G3! <=:87=W? V+CPN+>E(8&,+(-8 TA\$)M5!H DBL=S:Q(M7M3: T=9RKTOQX<27^H/I>?P+>UDPBE&4=+%!\$N&6%P' M41&#(5!)*7LN:YHJ-J&WZZ;PU9V!+ HC9392Z.&=WGPU5_EE)H?GCL7!< M&G'>MIFZ&'S>Q+&[3L3Y>^6\$2[R'ESLF75":J.M;1EALM\$6 2**900PQ2S&? >^7U.V6L6:8SY9YN7K5I7&49HH4(Z5.YL.DI M2)S)=Y>Y\$B\$R6KQ:W^LH!^LM8>M!^VM:~+^W=^9M^HC%0!^V/9VG.M=K^D^RNG^<I<=I /77F!N:~A^HS<=>SDD#9)IB-K\$YV>L3Q+231M4I5_0_Q'R<=>UGI9+I^B+WO:SiH^%XK:=JQ^70C.M=U8P2G7YKM^YCH:6&MR&K+X!K.R%>Q>X!^UC?? =@E5246&8)9Z75H.~%&XB(D1(6F/ M%L%L5XW2DUZT:WF#7%X8VG77KGJML:~%E.XP!VB7IC^HVSZL/YX+<KWA+18N!^V!5:"R& DFH=H>_52/CN7C:UK=UW)3MZ7BF.2M8=UCPP83FEU9"#S!+ MC3Z#U.@S)F7H^VYCEECP%~%+=N2H&9.Z@LO>_3MWZ>_XUAJR>:\$_+K6: M28C>Y>_22Q+H067#&+SL=LSNRSEHKV^M.5@F:D.RGZ0)N3LOUB~2!4!~0&>QU)KFE^PM3(N5R)GE773L.N?<R^ONIVS?IRM.9I/O,%O!W/? S^S!>W+D27 "5LHGHH^RWV441DR(ZM^X M42^'L'G4*08"IX#&+VUVZ2X49:T!N!_N_H:K6KZ(<)X!^U)I(WZRI^M13R07R!@T&6~!> :L227C5>~^=O!6N+YV^W2+@GYN#<~(X9T+I+G=JMN2W/47Z<C>8ARY?>Y:U>@:((\$ 5.BQ6*2(R%0HC.%^YIM61N8I?_#ST?PD.M; [S@<Y^XK^Q)S")ZOXHX7VJH(DTD012.WBGL06>W!1=M1UMJYRJ R8.I M?654LT!0ZU+W.TS8/Y8H3F&.9#I<&5&83H%\$GDJ^4+!19%"!#I8)6I# MZ^XC6T&J8/H^HRO:YQ&E2YDQ^9K8I618M!D=O^CT^C&=EFK^8^N20\$9I&(V@U^M^Z-L^U)=P:J%I32!WNT^!VQHGTU0^4 MAZZ^2/HUM2HS&Q1HAM>SYT8^1^%4Y")8X:74GA&0H9A4F:~XIAJK~HEY/ MY580E!@BTKJP=P7.M<:6!0R^453D3XKDK.9%WN^@)30F9R!D%FWM03W/JD+5P-0I U@M?>27>C4^&H%YS(I355B)H^H"*I2R %>=>18\$X^A5!RK1VL M&233UOR<(W.<%1)~!W~!%R\$7L4HF8:~B8I88>BBA+~!>JU M4PRB<IL7_IJZ=OS"i8^B^DG *DMU&8FE7^XL^P^#9_# !@~:~L.8R5H2^OAR-M(\$!@/DMT!X6U@(%J5KKVU?QG="H^3?:=H^F^~^GJ^IWT_U_<:ORKV/7^COI^M^S82VU)^%~^HD^T!@CQ^!^M^!2^X MKR=SNWQH?26<=>M^M28^DW0W!X!M+^R8YV77G:~%I9T3N>L^K(K0C^FEWO+2=27R>I2_4_K_NAA<9#8_>YB1&EYC&A^UIG\$ MPA%- K3I3VY0J3H!>^FERMV^M41KJ&W&Y)ED8HJ41^AW:~L^Z^M^~^~!0>THYI>@&YSZ^2S<~^+VTHISQR^R.7\$2Y^RQ0B3:928I87 M2.H.8_.E.\$&?/2 0BK/<XG<^HZV3 "M!^B9N#@L?2CM?=W:6^#R)SSJ(@+EL M9\$0)6M! LK_1!D/^N=JGY^L3NOT8W!MIQ_OHK@?6IW:ZS^8704J3@DC\$B6B(MM!QI8(I^J6.N1!X+IVT!G&D.8N M0**Y/N\$H^"3^+>%TW6%"%@M0 MU!*FRL6XB^Y!<@)(3^X0H!^+F=I=A9^C9IM^V?>VJEL^SU TS^OQB^EV72" M7T982R!<^N0PVEJ#_4VE_1\$IT^ Podd^%IT^EG_6KC:"7DOC=JA!T<~K6H MEY>0I0>^N7P_#5U>FWO>#@R.G^R4LVN7FT3!/W!:=%M**ITQ>B2^BUI2 M.K>V%~!C?0W6M9X127 GD8AG^+9G7Q#L:B%=62(4H<4GG.V.PL:~K^N_2^>8>2^J^MQ329">\$R>H!F!4!GM>4 M6D3:@I^ZMI78@HUYO=W!DK\$ _T Z3^4& (8I@)=85UT@:ROEHY~HO\$PPXN^N M+&B\$MCH0~R!APR35P^CB21C:&YI^JUY:49~!NU2=P/OM5=1# M^V! <348+!JK16)WBM@OOO!YOGG0K1SFI47GG4%84I&_!0_Y3JE^?GL2A.M\$72Z=HICLY<~+8VOGI=C6HCK8&ZZ+!@&C^ODD:T/72V/T1!6D."M2(C M:1IRE\$!W)J?2=6JT@.\$IUZDTHL:~D_>^6)W5XJ>T.@MZFZ7H9GGTY.#OYV M>~!T.TWF^&+O^/AAZ^!WOGYX&+W4&W+!S^!VC\$SW7H:6~ !MR:SV "M/90H=ZVH&K!7+L: TOA!709^H=IFCM!@ MVNV!<WDGB!<^\$>+~!OCG^ UEP^8.NJU0&U6>ZWN^T! M6^!>I47W!5_N5LDVU/7U Y>S^P.M3_ZN7B2IE2U">~NKYV=JX(A^QEF6K\$RB1@ZRO@0)~T^F!9>@XJUL^JXGL M>B>)M!C~&2^MJHX>_12N2S8S<2+0XX/AL(U2!\$M^!>H>)%IY? K%IGW74 M+FB!^%ATL!33ECC)9.F1<.\$E&~"U/H^I3VC:CZ:S^<3Y6GJYLVUX^GB#~!&^/!S:VY(2AD+2TP(HM4Q=470V@.@%2YFJ8:)W5 MYTU>^4U07(OX:G.OA%PNUU^U#5#>~UEHHG(XJ>Y^*Y?7N82+!TH\$14&D M%)SM:OZ7J^IVVZ%:X3(JHKI56/BJO#R)6(MS^A!7I#T8X^X!YOE0^XCCG4D~L3L648=J6V7J8^!X=GOVV=1E!FP M= JE_!47CFM5+R^K!>ESMUJ?<(<6!+P 01H=P\$S^OBLNJP5B5^X MZ+P2>G/HUNMN!@!%4 S:MYR>R2_5E_Z&7QY:3J9G)7%~5LYPCL5EPFC6G_MVCCDH5RTA,"(S)X2HY5ES"<~4^T2RZH=)M8K(:(9P!WEC)/7 :UF^9F^5 M^A^M7AT^<JEW^%K08FI2A1SN92G!)1^FE27XV^5!&JBLN\$XFM6(0P)26C MI<#J92? 400LRE88YS^ZLYG@<I^4A:R9(401E15_5B^ZS!R MSR!\$!FL>2&R.@O=9B:QW\$^BNZ3K=UB5JE>JBA?UD22KU^93I?3;AIA= M.BP.JGWM^A^H^?2>+6T^5VIO\$^P7W4_NN5+V7EBU?UA2ICE#S.JLL"\$: MGG!Y^IC^Z!\$!\$X)E8+IV@^E7DMAMAK!H!+>@J^!A<"UQ<==J !N^7^>S!<~P.M^P4 5Y MW>99WR#4%=!O~:BYPR8HE!L2WVT3:>~(N!P 2^)*65LZ^V9:67J>K^R^LM!"DIHJH!W^MS^=IQP2+!P9_/OTV^TXJ(\$CP\$"(0+G8E4^M^+2I2_ZF47^<Y=IRED+FI_H8Y"2LIZAD)S2&U4%8C4^05/FL:2)QER!M9O<3CE-1S.O?1:/9S^FZ/!DH;LE@OAA=E@%7M^<)>Y: 0=G8O6Q0Q?T<^!T>25H0AB^RZ.SQIVQ>N6.455^2\$ 5 MD2\$>@#BIRDJH^I0KA:UGZE^IR7)4QOQX^PBD@ M\$&MMD)D(PR@R^+KY_0Z18^MV#OWXYO/C\$E:QR4!XNK&+6ACN>%!% M1+(L:86BPIW7&TU<:=^0!"^!B:YRFJF\$*<7EY.)NNG5PMY@L_#6T,S! I^M^<#B=>YGF_+7#9.IOD(KJK2OIL\$FZ)(1H\$5^B!9:~N!T^2F^!M6L5_25_MBK!I?72L1OLG1UCB^E^BF^A6(B=3<3^VINN+AL)19VIP?< I<:~!AJ^YY90_MER61+!H2N8\$)P82=>(!0N.U.8\$ 14L14:ZAW^<^Z^0^UER@R5^7 M2&(B)XV^M^OF4>Y^D3CY!H\$K\$K\$YKF5!V:Z!8H.AI !6>TGKJ75WL_7VO#J3= MV3!M/^Y07J_HF!5?M>CM!H+^3!FG.6R^<5L\$8X:~(R^M8?2" BQ&EHJ3_O\$!<7X92 M:C6CB;~H/^U\$075UUVOT MXVY9G0D^#2HV/^0\$0.G4=714=T^J(C\$9>DCH9S:"8K7?)KM>7VOIK?KJKV MP=JR!GN^UH^K!#Q\$JY:9ZP*& !4B8+!W0A^QHUSOX!J\$+F=PL^<5!X6LY M1CB#IV7X.K6JN!QHQ6.W+A!)DN&XPT^4NXV^\$AMRQK3J!K!GT5A26L MV>9HUV8A? _AY_XI^40_I_Z+D_W^!#S>+I4EOPWV3SZ7Z!+W.#>I<^@!G1R3!&@P^# MX!"PXO3H!WCW^A!H^U^J+<8GL5MV.OF3G#\$H!H+0_G2_FRZQX M!^ !G_9H&91P^H!BEAMES^Y(FW0Y>?7R0A25T!^T+>G9NLT\$P^?00RAH12<(!P^!J30:6>Z MM+4K.L!W^E?#YM.FNFTUBHNN7?27G?XQSW!=? (0GNAD18H>T.M.&!(M=2H3?37SN\$5EC\$C!NKH!Q39D^K(B.0=3!3MV7OXLO^R=D_SDAHA^/!\$!MK8!JL26MM? NKW.*0>T>5=XIDQC615J+^B*49050)D DI>MC#L5!A^W_N^<^CTOOH:09I?#7WD_1E.KO^ TU7U4UOG8^SE(90:M@E!A^1DV"= M("RP#+/Q@?W E0JDM/U6H3E^PVK>DMM=3N6K)!^7J!3T^H^%:~YUYV0^ MM4#^A D H5_2!S:YRK^HYIY>?>GGBW^TYL>X^P^YTK9U2\$ITLC_L M^4_X@<W36^~!>4F8Y?247YKR%<O?#K^A!Y.GKH1Z15=#X^H.K M^8!\$X_+LR_!^/GGE:C GS!P^M\$6Y1)JAV MRSD^6CM+!Y>9>(7?I2!J3SZ^L? 66Q%6_W6BBCC&3^1!J^JS^T>5)=@86.SWSJX^YP^RW3GFO M4BR/LG!S+OP!IQ6!HJHJFJLN.O9>84^H^Y1YR!EB26&^#D(A7M^?U4 M8J+C\$Y_4<~RVGN^<Z6/^SIV:~>W&N@OZBK.PZ/CV.FNH!K_0425A M:~!6R9I2_7^Y9M7=>+QA~ M(D^T!ZMWN\$O^0WIZ_H!SSF=IY\$C7W!+9Y3JC.O^V:~!OJTC:U<~BO%<~7/M&L!J2#&5UYB^&BMA^*)RPSWOJQS.N.I0.L.9I(E5\$5V=P.995- &F%3K5^P.2\$!K^H^LKL:SEF5V.7(V=4=,M(P_1!>S!<1F&I^MH.ZZ!>UP!A? G.U.3%!&QDA^!5(D?^!D)H7+FE3EFQ4BW M!@X!\$<="IY7_HKTP.L54_7^>~!OB:YC_3YQJ&KW+H#_2U.XY!>U9:4@QEFB-M(!>@H:=)XG!0Z7M)2HMX+2I!"9^C? YW.)OEJ!6^F=U7M#H7E^AU^C+DIT MR5PD^2EK^E0E2^XHJ#. #3^9O9C_E4\$#_W! F^OAP@7C?G9>^*A<~!VCNN MB#!7^=I%>1:(@? 4R4<~!#&~W0=UGY(P4+!_95C(8Y MK1NK9D32\$!<A4#_Y.0^LGS<~>AZ_7Y!<5CXDA^B8HN.Y1P!>2%5FG!3< M299I2I%7 TE<5@~!H7M^FWW"8VG2L.UYUL9VN9K!<OJT^+!Z!7EPLKS2^MC5)EQW\$5+O\$=(V/BDF0A8N62XW.ZBT!ZL^TRV.IA?08AQ>3PR:CSC^A!9 MQIG!%V+2)FHDZ^064^FF@+T!M^~W^W!FTWY_AU=9^X.F!AQK8IF9NG>C\$.#.N.HD<76;_&/T3/QF_K\$ MN8/=Q-(GQ^X6^H33.O- Z<7YK\$<4J^B#)YR4JXW\$+VZ0#<@4X.ZM!F4:OJM M88F.M!C&F\$>=Q90H(C5!+866T? @O)5KD/@9OFOUCOK/NMSZ!>@IFJ8UPZ^!K^DH.H#6!D9=MCH^H;?K%87F#1LZ_7JWDNJ@=I!U0!H:5%60+^OORUG^\$XVL\$5V)W^I^MHT)\$GN MJ@A.F<~>W^Y4!<K9^H#E!~!XOA#IUY2R3:#3J!&K<~Y1\$!0).H(4D8\$)^#H%6^C)A M^!KKK70I^!CK25JBV!XO!^H P!PP&9<77^N5BA^4Y%!)X/B M!XME^A!6ER:H.8^R^QUR^KWRD!~5+XG20G^!@<^!X^>I=7^WS>Y7+0^30:DR9UT^E!5P+6KJ M27^24E2!BH^HTU0!LHX5C+EP>)<)>ORY2! I%>9W(1(P/0\$!+EUZ# M4R:47EX>8M!TTM:#C^NINFG0+FO^=M+^U^!)?W^Z:JRO0E@TRJHBZB4WNE M%&1KM2@!^MM!S_HUG_6F!89A^1QG06&B^72IX^!H!N^<=S^*U^N22+!LIB!K MCX5W_5PP_K0.GFR&D(& !+45P^1U7^&W^C\$!&2KG^Z7F^%64JP(KKY> M9@C:D\$LE:FH@))UZ!D8AWZ>GJ8XJ(5Z/K2)XYS!ASH^4B(>UMJ/U4>?I M59:%%>+ LPJUCTE8!"I2^&2C^XX MM^VWSC8I09^F6R6G^T^M2^!U^X:67^%=&V%\$4\$ M<#8:\$%QG!S33Y D<~^V^C+!^7P MUAFNZ^NOF>J^V!P9T!&+BILPZ\$!"@!<~KP_G4D_0EYV!G\$=5 (UC.F3#76RI M:/SPL(BJ^HW0Y&O4Z\$!^OBI^DXXC\$5^W^SC;FR+!N^!R^L^T+^X<~(KX.8 M^*&^IY0CJZ.9@2M)QW!H:HO@<@>0^K^RMAZO^SS^#P<)>AM^P^~!K~33/U<~M+ <0434@2!J5544%1U.8%>@~!5!E1440Z0_1R#(6@T0_N!PB!QZ+3QD+!%7 MS1(XZ7=B.YMJSYNJ3 H!<9IYV6=AYKX>\$@&6Y3>#B\$GWTFJYOHJ@BHJD:M^Q^DLJB\$X^5&A.K\$S^R4A:7VDY!X6G4H:6#J^V^UW^Z9_I\$TFUL_*+!SH MVKL_OY+!/? L!S^YL^LHF_54B!RSTQ@UMP@IOB44!5EHHEG/DT0N7QT+M0\$2!J3FGNB+VG4!3>#X!5&_M2^1/J#6D+T/9S5IZ_3DT26_A.K^K2G60A M^<1^>L+2 W4QW@Z\$S@N>J!<T05XYURL_9^42_Z!2=N=E.N.B!\$=2_+!(6 M)=00K2 MEWP!5Y2#~!Q6C<146W+ (!+91^UPCW=DIZ0!8SNR^C86E9W3=^N)LOK!8UG+?WY2X=7:Q=44_!FGK:D9_M7T+D=LT%3!YMK#67A4)9G:3U_D7>^V!+IBC!/=1P_V=<~8J3&T? U>J>^?HTH0!H\$NCGM^M^!7ZNOISHA<^YB^L^A:~T^8^2!>0X^#F4!Q7BCM^M^GQEI^A^9!WW!<^!X!M^<^B&5V0^RDM+VH!F_F? \$53V12F^P^HSH(HSV:10L:92^2L7G^!J76 MI/9V2^<+TL+C^RC^*/K%?FEW9NJN3K)DDMF8@:4ZL:H5^0^N0H1<@%LV7; M%\$<@M8^NA6>Z5I@DG=&O6^9++OW=BE%~,0T>_Z78U"

4+1E7."\$9*!W%M S DA M0.)*~L4ACS6^KV#""!N_9/4%70^MFM_!\$^V5IE6"&PKY0MC:D.\$A0! L M:~X!5R6VWOW=A3;W!>_5=E)Y#J*&Z20+EUG>NI<~MC^9=P)U!+~M!9P+~M^K@M^:M48CSD>"Q_(ZOUOQ^9UJ7I)267UQM MVUF=Z!\$S#EQ MG7+BA(<G<9+&H?76HIN3APW!4S4=9ICD.4\$=IYR(FE^Y MF_Z88UC.U!>EXI9FE.R^CD@KA!^?TH^T^45606(IHM^MH>H<~&_#UN MT%Y(>59WY!<~! AKAYO!7OX_W.9:R323D#F\$^A3R!H!X42C8^R^B_WG4V MX@C4^F5QZ)=G29(<49WY75_Z3Y9D=R7^Y G7KKX4!~R("GRAQ94I\$#4 M9Y\$A!53B8RTS:~SV_00?91%H4=UGYJCYDEVZZ?Q3Z^_I\$<~<83>399D9J M1I7.P.G "TOQG_1ZD2??E^FTIUE/6BHJZV3A^US. I83VP@<~3JF5^A!04 M+ DH>~!M+!H!M^NY+GF:66W!>YB8K!9>_D1Z^Y^CY M.M.I01C\$&71SR!L^FIS4Z0A_A4!PZZ&^!M- 4/4\$SEEX>20G\$6DL^9S^IF\$S^M\$&06A0719YK45BSLA!A0&5:SI^B=^G_Fin_2UH52%6!IZ&DV^D+!#N(16R5Q!HAZULNARI L MIV^W0X37@/P>C?G>^V?2I92V_4N.^ZCHP.70=ODT5**&4\$7?N9E10_M7/89=&8AL:@OUL^A3.F<~7!^FWK M4EH^KC_Z^ATL>YRU)/PF-Q\$XK2X^ T!V^T.R!E_7^TZX3X^!UQ:29E!M6WU>?^N!N^A>38=J!#AL39L^M^Q^N^D0@ZES^A1+W\$BCO38U^&H3+~!>L62C2T!\$X2!904YZ^<=^/Z9I^M^ (@TX&P^KE\$=2XR5^!T:PI?2?FO)2\$KK8Q_#4+8^T)S@>7#~+~M+P!00 MKH?3Q/N3ZQ9/N<~PQG^V>G7Y_@+!HIGU (@KRRMRU)Y>+&F@I25^ZG2W_M.2:7^CITSZ^DJGLOJ3V3RI^W8Y!L2:7RIFZUS)4E4H7(8B^)!VL#0 MN2&S:3P8@39+>760V_06/OXITSZ^LP_!!_QA=<~C?>ZB^9M&39P3^*ENP MJK)= 2\$+!+\$(E^U!IT=R)PV^!5_L_@NK<.)S!>Z!+H.TKH?^H^!&XI M%DT^)=TJY7VQ+!>L05MB^JTRB M!6!G5F_M42_I@623_0?^!K2>+7%P4^090AB=8NKGO:~DZ^_FS.R!09_~M&R5\$PSSHR^YX&RQ!0#H.H(5Q< \$^W@~!I^Y!+!>~&6T3D+!AB~2RS)FEO+ I4_1L!_0^6Z37^CC6%<2^1+^C^N(A_~Q3Y:SI42^6EBK<43^6^@A8(2I2) M.&NMEHDG\$=9DKYU7\$(<6PYS:E.FFEHX@UG:BY>I\$Z!<F0^#3M&+D!J!#&L M35DR5:K8B!T^C^Y=TIR!ZP=9!3L_~_P_&J^!=!~+~# !<~<I08IRIG^~3 M^0+L53J6@0L^*~F0J=WY^U^)!FTP:SVXKVG9B_7)R=O5X!L PS+!>C MAYEY^BA_A4TH=+@!@!%T.IKZ@.OVIX>_H!@#? Y9X<~!12>G:%Y:GOX866 M^R28^FEZ_~!Q4!&L3:Y5+!H64 M8B_X!FYH!3WT5W) L&W!QOZ!IZW^!K\$SI26? D_6.MEB2EUI.8L K^"MZ^WHY^C>V3.SR8"(IPC@3Q_M).S3+!Q!Q_7^V7BS(Q!ZG+G!6QUOFEF!\$1M6+~%)1^0^V.8^B<4@CMR9<2^4=6C3A(H.K\$8? (H=JQ_~B MDIHR^P26BK!7?2>2N^H5I7+^#PA.IVS_6@<T2X337B^!VJ6QNPB7/6_A.M6K^E!+!>~&4Q^%X\$G(C)SSL3^UIER-V\$!H6F_ 3MIM8.H^8D1 R^PLD96QG M.EB:0WGA!(HEWN0C)1^ALB_ZW_U0\$G_Z>P=&I3FO&M^!V^TBQ_WE!+BDB^<N2^SA2^UJ (L!+C_1)6LW3^)*+5JB!T(C.>I!TO M^PIDXEP=858%WRR-U7.BV#YI^L+YV^!A_~N^VC:~.~GSL^O=1VB>JEND MT)H!%(<+ZFL)3C%~@<~G1\$?>

[illegible]

```

%>QATX>25W$N/HP/P^ZR)$X)@%*||T ME1F: 2/HP890TT7JKK=>NO MUJ?>
%->U+>QEX083B7K+>78G9 SIXNO7<#MAI&+>J=M@A4ETGCT$$(00I&V+>MEI)@*%>YU+I/TI^E$6FDA,+T#IX$JPXNXL9I%HOY<%/K.N>=$%IN26:
(MB MX**ID9#>TD2?)>+>Y2D45WGOI#V3;+>W<6=>18KN(AWREF$T$YQ<=>J)@.M.D->5,BJN,"DE:5U/UV33FX)/H$2FR! 5 MG4V"+
IP8KE@/*KVV9PM"/NE2.#Y07HGT3">13ZB,+HYH7BS7QUOKRX*FU.A5 M5YI/3>25B7A"IRB=HJ9?
N&^H3BLCB+6XNK*^DATH>WS2(JYX*EKV.63-JR298R2)4" M@R58RTP2L044C&WHV@KUIA 4,4"MI2@NOA6NNE4&YPO3PZ7F.(I7-$S!&I
M5:0#7D)G#/.E$5^OJ2C."M+N"TAO#>DJA=IMJ^29;S*6ICW>IK=>IM,*>YD>^C^CJ2HMM5I M#M^C(OK3E).(*M)">X<=>J,*>1Y3K1SOHI^J6Y&:
(I0XA)5%>QOBOR M/E P^E MFQJ:5YZU3 13ITLU2E.T+5+E@P.C$S&WIP2.C.YG7DYIHYM.J" MSX8#16%9%+LYK^Z06!4U7RKP!+=.9@<W>:>IR>
(+*31-8)WS2H%(K+<=>PIS&^18>YHHJUIT+4W:*I0J.HSL@>2I^J=>$^1 MO=O EID9EXP&SP600U@."$Y*EEC0I)MZZZ^PA6KKO&:
L%1$T%,"F4ZG6H M$Z6K.KP>I.D#$T75(B!17$IR>7CHMXY9:503#N^A4YI=>VVR6VJRI9@WD= MN+609 ,P3I P=E (L/2R5%+6+G/4=>$O&
($X2->Z^L"HHYTH222.I09I6 M XY6K^I 17H.YBCZYIE4 X2+1+ WFQI *AM.MZKU@;2ZG7Q=2L#YZZ$ M8P44KIV.E@P$&Q:~SI2QHOF5L 2I>D?
UHON@F@%IU(MP-DWTWT7@HECX9 M^CUXPT3M&40.NGYR&(4F9ND=6N^C.ETZ)M.F0LFHM10K" MEN!/:C1W.W 4DRCK<@DI 8^4=Z;
HHJF3 QDI&=>LOOU1 6;+>G4^>OK.121+!$^T6E.LVI M^UFKO)>+113&6L;1.8N/ZC#>MOJ4QF^QQ(CVZ.GGQ)I"/"SOQ^OY^K4
MZV<A2.7BZ^2IU=W0M5)U24A"8KR=2^TC0ILE@I+W+4U%.(M1T&S X MNS^>#B20R5^HMCWGK0.^OC@KLI,SS^QQ^FY 9Y%"UK6@2M4EJ
ME I826CHTJ TZ/CV%LK1P.<^>FHE:<WUD204.7-0@K B@F175=%NWE.XIPFISIV8"SIJF1BBWMSL@L SG_P IK=US.%ODD4!#CC3"@<3UI
MTD4@IS$B RB9J#**YN^>+J+>KTQ H8N *7K.L49DJQ+@N3YV3>OIS7M MLWB@RVEZ@GEP^C) 6HP<49WRUC1CMU7?
32902420$84J9*E>@>BT@TQCQ2.IJ2Z6PKGP66$H82+ MG5NJI&MKYQJ)DUL@IYA%>E=(^*)F>Q%)-S278RWDIC4GK^AIR^>+>M-
M5IXMMLIF.^OW 3U!7U>=>V6ESQ^A^=>%KEQ^>^G.SQ29^>^#B1=25X.18.M2M39Q(ID>M7 I^>7"E+>EQHG:>HFGQ-N2006:@Q.R48!
8ZKKU@Q7K9D M$+EPC(LH6M<3.429T^C7(2AZ^>^YHF9J2I"995U4YQ2$2&E.O0@9HIHQK0R0
M2%>0R6NAXY*HUMEDUT0>=>MDUX^JG&:US5$F2=M.XDJ.NJ= (BE)MB M?>+U=$27V71SH+2F73" XILW? NXCOPI>K39I MN$#G
ZJM=C<@>9.J.RE)F 4I^@PIL8I ^>XZK17R2@ZBC (RCDV3F(&^>T M03IF5"B9HVHIHX%=>9KL A8#&2+K)*(> )SVN+8)VBM5.+ BJO9W2R
MYDF.K2L K;I WMB8HID5<^>C#3.-BE+>#2F5ILPMHJR2>5^H>1&1U%B%Q M4H6062> W)F1&(QZ QZT=VU520M3<)(XLI X@N/DI 4V 7V92?
L=EGZ*MI13EQ**X!@>80R4=09<7<+>6I9) 810AF35Y0Q2=Z=D3OHEFWK475QI&0KH,N2!!U3GCQJL&I&IA:L5FI)C7QX@W@KXORZXR8-XL7
M59QDB&2RY%K08F.I.9C&8T$GJV@KPI18UQ^C^73 I.J-H>P9003299W-MZQ=O/OHQ=L 7KHU!>+3OIQW%9+AAK6NMWVY(G)VM7.
T.PZH.6@SGK!-L M^>JP=H&+>2A8;$DB 9+6.WY*$(=F.#J2LA=.(SO X5)O.EM46FIN2U#6 M2%$70&(-@FLEYJH9$9+7T_F^W>#X=,
N$GKT^G5W I$M/O^HB S^RG MQ 1^00^+>8O+YI9)PCD^H(H4EJL2/7GJS(8BL)!N=L2V8XQ^Q^C^19"J M5GBF.
TYM$N^YD%+>Z5962TINQRCQ$H6I/L0 B@L8BZYM5 25$>0NV3G(I@>N.2^2I%7NQ!>82=F NWBG/YX M4 4 IKJ7@W/AZI4BIE(3^00W
I0RJS^QDP>6.LDPTS3)*8A-WB^>7Y.3C%7T+Z#>9HU.A M.262I(TB@)J2 QTP4PEQ5.F6$S60>76Q$WLMXE2L<L>77I@>8M"H$ M38&HJU
H2Z.O.KOC6C.ME:ICNF.6=3F-HXLD3I E5)9J)Q$RZ J/S9I.SJ3 3M+I@>=ZL<392RW MQ7=V#K4(4IS75UQH.L6AH7Y W22N Y^L0 NU.DBYA
MV5Z@>T"TNW197K.2#6Z&A49=9@H3B$5.CE@>A&A06E8LJ3D.BGBVHYTK MK J.%59$6N2^ID<L>X+X!
J=L.T(4W@>$7Q12>$PIYS2ZE/2.SN^%MJD) MH.=1^!$>XZ4FIN@BD.YVM9054)P53%1>9YUZZS.7CO=1">$W%-K$. MJV3?
7Z.B@M5.N.2).5+>2#2)IYD@ZFRBQM0H%908IM ^9)Q.W0Q^("4P.MH30+!+PNMIGW9&K07F$CUP^KAB@)77EJ2I^Y6JP3YW^
I8T>=>3XP68L% M5$POYODE9LP2B$5RSKDI.5BOBX+>974-HDP(PH&PL$+2QDJWS)!VW
MYU0X.OVIVV^L^%E.9ZD.G"W.CV67W&Y.MI72 S.+FJ>9 ULIM$EYK$PC(G M>LBQ(@2=FN/LGXJ%K/@=R^K*Y>U.:OJFDBO9X N>E
UYVFHCQ^23.SO Z MZ$^0YT@L IEB$QYT7HYA9D=5)QT H#&T&MD5PZA=KJQXVITN>99^&S2I* M2>*>1?
31@>EJEED3.4L6X^HYX.N3L#6"@Q:>@>TOR2M5E^>O^EOVX)***M M/46O^9J^H2(>#53Q>DHB4A6OP6&ZK0>5TR$(Z$>9VTVU$PI9I&EG
4UAT>+>Q@3C$2%91^C 70.COIC FILHUR M.*NGK^XCN=6:XIOZU2BR)*%$G49=UC?FY$GU)ZV#>BIHTKI^Q%R.L%9 M>Q V!+>D)=
(IN.1UDM$HYD(TC.=#6ZC@&S)X#^TZE<5H#2WR>DDN)T$ MZ+M(I%PR>MAFBDH)G!L P4>"YPH4ADI7%R95-
1H0<1HW>=>*8D9PW0+I0G90PQ)BTPC^HEB<8JD=>+>IFK:K" MYG58I>+V9ZOXZUMW^Y:.%L51L 3/WF7R 7!M7F27.28$>0"H
MMIKDQ4+>B$B@G11Q@>Z^I>76 2JOMOH+>HX K.^I2J .&DI^1HZ 2PF8+2#
M&N&N)DOM^OTCG80^9EM.%P@>1THG&FS1^FDL G>+MZI+^>R!W>3IY.N (MJ M=H/PDALIE+I#>PS+SSR.OZ!-
IC)$:RR@H!J>9=HEI8^>+!$UIYA^O M/C.I 1.FI3IX5G*WLFU>.$(UT04+QP5$X#R@<A6Q3K (P2I0.S0<4FFO9(8
M$57&#>T#Z+O^<=>H=NPEHIT$F1 MWI=>#UHO4 77N54: I0D^G)BB LB$($#PQKBEYZ4U M:L6C@G3R.G4Z8"Q>ZD#J^W/CP^?
%INK645FEW.SQ^1DJ 074* Q^>+>6 M76K.5K2NDJ26$Z>4V8")MO 4H.ZS2/IV8 9A7.^EJ^22"AH$5B^M(VY9%H@W/L ROH$ M%L+
CY+LA+E^>4W>T16<L TJWAYC:LK IOB^ACWEO:7W@CLBZUF^>H^C M ICD&C@>2%2RQ^#>+>0JHC/OH$XIC$@JSPTHIYQSQ PJN-
T1X224.KTK@HJ22^>S)T10HQX3IYX&Z M.L R^@>4>2AXD0^V$O09J1YQH:75P6BIGEXVD>0K.HY2@CJ4WYA.PIKZA.M&EEF.P.OEE-
$P2S+S.I@6S.^!%65PP0D)=13QX M.#875WC9@>7M.5i24QF^AJ0HMEM;I$%.N#^3J%D%L3^NZ6J" MJB^DIV<9Q
MAY J55XJ^YH>9KUN17EG.YE.D^23M.6P8M^QI&LHJ8J6^P>E28M/M8D+X 7)8.^B/IOF^UPNU^Q(XQ$S^WIN2)-
B=L.M.BH$O 2R6I.GILUINH0$ MSSD HAP7G3(^I^X OCSGPY92O=L W6YN^Y^WFB5$HWP=8EP UE60^>8+&gt
```


MNOD%)90!1.;!C&M*L(JY^IU.XXPH.1.XI20V&ZX"# = "RXPNSYCWFKYKD^0.M+Q=20LRN.D4YAO."(3B(A5*HDS67);31DNF9;G/;J2!MX3XR, MAEU\$)ZOI^#=<L&R9.ZOENY(I.MG+X.T0)5HCN1PMRNT9;H6G3."K2/N1*06.<3\$Rf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~3.5T.Z65;# I5(=1XC2K!IOQJPI#GLA0.3CK*YD^BU+^NK.E*KJT0^976.M.HHQ.O.W"> SY&&(SR.7E18..9T7FQSK5OS>2\$JL1TGT.D.=1D.B28F!MB1;#K? 7+SIJ.G9)KF.LS*C..85T<@#1^A#2;7.3(DQ62Q&9U7&1H5)"4Q.MCJIKDS^WKV;Y.@J&C.2USOC/;W@5XID6I&5S\$Y")R6@35Y1.F#J431H& MPGN5@G*2A;8/;H!E2Q4WA8^OQN^" S!M^!NE\$C*>NTP..UK+>^>8H9B(B2^M!\$7T0IKOHI0\$3&ZBKW;8N=8HW<5=-.7T;92S(I^*Z&JV@ *7%)30@ESW.9K0=3W3QC;)IOZKO@.MK4;TV80)M^+YH2I^R1IC.LRY1\$VNYA.WTD.E7&7;J76^Q.AW9Q/XZEX;N.M%ZO51982=19T2; (G3T4JA(P1=%^UT&US0RFG1/%^<6J)X.A1<7((^>[K(L.Z.ME3MK^<5BM=JDO<3WFE;K^>)A)"">0<^U.@S85W5O@Z*444%^KV.K8>A""?3.MQ!G *8^7U#UJA^AFEN."9<S^>@;@I932&ND<4>?>2MA33%6B+7)MRZ^WU>VB=.(MIG.<H>YJ^C%>5.KTRZ7ZR;DM5^WY;TX^<W+;V4Z.3)"@.0^0!^Q@P8 M\$N3^ITUD@3#>9!1.4=-18U.NSM.(8VZU1L91W5;7(O4=-5TB*P^7ZS^IG3WFEVZ@.M.GXQKAW>BU4;64Y#<18N^BYI3R)W2L7C@^J^P/PGNVZWZ_ MH/3+!+^N(ROB!;121>15K-;\$@-M(%;3H;5J85)MIB8;Y#..R3%N!;#JZVIL4"+Q>7M4=HB9>;#LIU9BZ=F^*8-(5^0K).M3MX(Q%- <\$XDPI9L3>XCUI7L7.VBJ.#<@<0.PVO#1.^R2+M8^4T6^KOD@I2U.M@.T%3^R;INJ^!TG65;#> !S#(7> >H^W8GS2Y.\$A2M8;2>1J5E8H1 MBDN^X#G3HDY92;EVALTN>O@YFW/IW0^QP9.O^K."5SH4T>8IU/HIARE.RI.M5EM).B2+GL7L;J7N;"Z)UW7^L^0P'6.0WJ.UV(>R; I+FWG@L1OWW_)^CY.M^RI<^IW5<^<D^KW.P^5.A23+SS!@B+1Q!N;5FOH+V6&6(D.FHO5)(?N.LI."4RPG/NFI^W/R/3Q\$=B4P0!ZICW-\$! MQ.XI2VQ>W.L!W.R.N7A=I7U2U=W6;B9/7VD^VEK^@8/7G;.M^TJONLCO!MTP40QIFA.TB!N+Q<_%DU^6VQW^F7TXZ7Z;18I2(HD0)X8330(I0)02B- K4L2.MH5MXKAK3B.XIX.8/2(CMG.+HJ@Y359GBALU^;L#;1!="#&JDK84&+IGMBG MQ9FVT/H4\$=I=AN!H061S9I3*20MG07I6;T.YQHHTYTR\$16%15&%-CZG&5%KT\$6E.M2(I9I%4>.V2CVBU29I%4(URUL/\$KJ^X.J+!++? ZW)1.4\$IA(=^<^E!@45W^QTU..0\$H@.#O^2WY2<=-JL&K4;140F.F.MS2G1X.8P4/KA0=-.6%I42.T%\$1Z0.TU6Z;O1160S3DRIO97H7R;-1;JD- %M0Q""LD.4M)F&J.#(%;TN)W\$A!HSKR4>KL!S!X.AWRP^S6B!N)^JM\$4M^VL@I9.M0BV)(L0Z^9X9=JG8NB\$!^P(41..GZPL>T>T6JZ=-.GB.C+< <TDBQY%MF#I8.XG2IBPH.3*(G#9&J.2EQ9\$2RLXJ!XW<=>.34W>72VCQI0^>=>92.ME.M>7^U\$P2+H/YIS5Y^85AUN@ZIG<6>20IA5FZLPNQY2.- HAL6K2=BM45P4I.M!K^<^Z+^HHH@U!@H4IW^C9^75R^WJ)^2+&RE".NBC"<8V!^*UPJH@0LCT.MYXAM;ZC.86/#10=\$G95Z3;ZEJYJ(^!F? <WL15L.LDRE@<XZP&B\$1Q^X.MCAG&0I^C.GZK>D)4.JH;D&@J19&IV+!>G!H^"XOZS?P4^87)D?D2GHH^5^T.MB4J!ESD RUFO^*J8.O2PODN>KMXKJ^"HF2GIW8ANJH+&6S3;^JBOKG9.R.M""@2L#HJ=Y^Y^<^E.)U. 4EIZA;TV%N.)I.>^6BV^S.H.EU^1Y65%TM9D71ER3)VXH;2F+^#VHSG.07LJGE?X/I3I4^G/0D^6.ONI^/=^LU.M7H>EQE7%-'= />"B1R<4.S\$^H7-) #N1#0L^X!U..@Y8#>^>5K1""%8@Z.A!+EQGIZ=%H1#> />"1^N.2;!!T=5;8R+^N@!"IR";JOY3SC4N;6KZ4BGKV.MMQ5#1+C2F7.- :HW80BQX!^Z%=TPX#39.TD^C.2R\$MU;=8.MI3BH;.8^OXQO\$0=W^1HKM6.1#9+YU@\$&E#J179@2^5949D&#&69?2E(75WJ MBCCM340_R&SCPVZWQ)=^D1J.F+P68LZ5^&O2U+(+8.X9R^Q22663S^+^I^I^MBXA^@#R;HO%IU#14G^A^E;.*6A<@^"P+8=<9.0ZM "UXRZG6G0M2I&F\$!#^1J3IV2WTSPS^IG%U!M.VUKI.M.R.2^I^M>77W97/B0.6I&826.6I>W^C%14&^UY<1AFLK4!@=IH.LMTM@X^6<MHJAZ# I6<^NXWNK@A^4I6HB.^+16HVSZO59L?2>M^*8^H;M.J1+>H^H;PR@21^YFYU@Z.P6^F8C@Y^QEF=F>G-GE\$EYXILLYB!U%=%M25- 1.9SFKLX+8I4^Y1H/6IW)P&FA5%#QIZ^S.%6GKC#1=UR0>CU3;V^1J.MOJO5Q^(@.<=1^?KT9DT^CNA%L.4HW^P3ISWYPR>&P.&6K2TVM2- S.BZQLNK.MIQ1V?OB.XXQ^>R.(G.JG^%YI)Z@398KY;J.I2V@2KHJ^UIBB<^HAT@B8G^*D6T0)F^T^&1T9AEG= M@OKDM^? %B2GB3X.V.XH&S6EN99L-2&.KH3GSX+C44+RQOF5IN&LRN^Z)MSYIPV^@#G^Z\$R.\$&I8.N24L^Z.V(HTT.MMDIN2CT^RL>&@>+#+@LS- @0F9.M.C.R^L81ZA.B1.290WR);P.#G.S9^<^<IQ2EY^PB(^I#2#^1ZYI+0#%;M.M9^FUGKNHZ#)I^WV>>T.2.XGNP.KD0^8? 159>DI5I.GK8EE+SF!^<^\$NM4+Q0.M.F5)D^%U&MIHKJ7.1><\$&4&1.<1&XEB\$)ID8ZY&+I^U!M.MJ@(^F.EL.SUG@(^E)VPDS18%GE%D?% MP)&R8(TOC?^I^@31MS3UJL.B^&FOCL&G.(NEC@3=EY=B^RY.KFUJ).I2B!>RYC&8^LXV.0f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|OWWC+4<8CU,^%>SS00A ME9VNLZ_6=\$ZFG_3YO.FG_#1H6W5^E_24 M.L.77Q:7M99KJ3\$?1LH25:200G5-R3YR39M)-07^ M4RIKY94.D/9NLSRPN6N4>TW\$9DK&ZZA.@_1U4^82D0@D\$UE\$B\$F4YC5O M^3KJ^2L/&@^?T<1W6 P6WJZMNR4V^N)T3.#0(ZA.48=GW(\$74169R)2Z M<^<2\$/FF1>?%H(F8G%!=&2>R1%3!G17G5D\$N\$B>;P\$;.@I8A!VD3F80I6!O_ M&^1G?&&.#-> <^1L.29NFCW2MSNA2<^H8Z7/DR<=.M.BLHT6^" @_A^3FZ)H?W(JEQ^Z3>#**&&U^R:B%(H?29NS080H)3JZKJ>4 M6JPGIJ=W>1FKFSI5(4 NJ. ELPT<9C.Q4I^"LM=UEJZ|>M-MHE74 E_P>^ M82?FGFE|5\$^Q^/E_K_V_3@(&N4RA)O0="Z8".M!A9!_DKEQYE|EZKQZ(M5)^>B@W: (.EX>Y179W05VXXG^U_35Y27TE?<^+1>J\$\$.CMMD M+BE25^CH^\$0100GC^*G5_Y@!=XCTK^M9UR^L_G<^9615V^C3.0-91Q4C1 M99J^ZJ\$%^V.S(X2^J)P&FJHQ=BSS66^!DU(OVDG1D.BU:0RS94N6ESYD+CB1W<0\$ASPR^D91(L.8IC|UB|W|=6N<1V2;=K12J2K6X&=8S7<60:L) Y_.8R)|YME/&90.-LVK4+M>6W_=JTA)CR#=#BV1,|AE@#M!VCBFP(L20^1.R=&=HJ^\$V|5J^J^Q^*!H.M2^N4.2.P18B^#"DE5N\4)? @L.W^QFS3=A;1^+^#2GJ?<^(H9NE.KD0> MH420%^Z=24U0=7_1E58^0DP>K@RXRT49QV8MZN^AZ@/H=^1J<8^F(3V^MUUJ(+^#UMNW5H)^T =>R74U0!)HB3_GBP@SSI+<(^#.#.W@!)<^AYS.JD M>HB&J\$B>#3E_Q#CUE&K38Q2_QE^T^D3J.EK^40E^M!Q M^_X2\$&GH/9W>C^Y.I6;9. (&TJK^" M\$^&@%KR_F1?CW3XSJ.ZO.5.4\$XJO_?/2\$HN6>^!N|=U:2AX5I^>= MYO@,^7A:JPB8S9)B47FNA00^Q^DP- U:~\$LS:1+&P^I0<^M9M<4<^(FT+!0!) MS!F(MW)O2EQE^J^J9X^R54IK@91L0.LK:2R^5#5^G6NG5^6^*1%SS> MEZ\$SJSBVM/MC3H^Q<@^HN5I^ YGFU@A_ZWJVFOT8_HJ8^PQR\$G\$2YA0H^UH MM7^V1ARB^RT^:5X0I2>0IKCSZ06IX4^5+7+9=XN^A&94RH^%K5N^Q2M&=H M4<5^T9H+7JN/E_Y_.\$FGJ+^PO5!P.EP/TR<2+V!K+^DK|H|VB32.ID0&YWS^F&JZ^"UJ\$M^9S.O3%L%| M!D2T4 H^|P!^T_P.YRE9>GJ%&@-^H|UJBSK =|M\$M\$FM2B.I05ZMKFM!MOU M!X+RC6SRZ\$FQ.EGB^N(9A_E62\$\$.VK|Y26JH^U.MLV6U4.K14B)U^U^DVGGH7^GZ_)A1#_ FGU^DM10VD>.#TK5<^7 MRVT0U=X^0^K|H|LE5RN^AS_O!\$Z.GP^3B;H.240^E9FVY.^20R:A^L<+^U MM>=\$80I0T^J0&^2.N@.XU&O^BWJ39VGOG^P8YIJH^Q^WRYO^O)PN9YTM_Z MPS_#J^_05|VYVZ_2.HH\$|4308:F5>7I2-934M<&5"- XHG:3CIG_C>|NEL MJK^+|0Q|L|HY DFOQ_2>MP^_62<0<^>LLH1%|<^G% 69-%4E".OHS1 MRMZ^3_|NF4|^X|X^MM.M\$295IQV^?^#C/KQSWSY+? ^F^H^J7ETAKJH6L21 MA5(9!)&J3SGC.7B@C_!^9IWQ\$^3W15<226=I&I.C.N^+@^ID @YI_ZGEA(QE/M9P!F<^DK2+7=W#FPJ&)(40HR_-2HK0_?1\$R- 2^N^F|H1.3GIEBR4H\$+6FED M8WT#%<@>^ W6Q%(\$MW1^3I2I.^&= OYF_!H.F8<|K0_P_GQ_HJY?JF#1^X|HVC| M^CGX;H_5\$Z_Q)BG15^=F17^RN5G_DJHBDH+C\$SG6JG)\$5PJ@SMA>?% M.=7N>U(D>?>"JCTGJ|2A<1ZYA0.1^ZMWI0Y& NQUCL7G0^MYK90^H^\$JY2 MU.<+?%TL!>.^2+0TI^BLPJ2+&10_2+1=7>^G5O?A/U^T+(QX M^|41YH@^GPO+<^J T9NDI^>0^%\$IO4 Y=K.S2CIR)X^=.8^8CW^XOGM MSO;I2E.I&\$5;J7@/^J\$P20IY5.OB(L560CMBFHQ?>D^W>6P_!PCKHG9.M.PC3J@^D&B^J^*QEJTY.YG+ @9Z(3&H4RAB>7>P2_1J/-ZJ>Y^?9C3\$ MUMVA95.4KY+T3EL&PM6L.4.X;\$^GREMUBH9S^TOWLYBFM\$@W^XSS6B(H3L MR^Z^L.B(%)^K2M_ ^TE+R^G!UDZY^*V2W_Y+U&R^J^K^IWSA8^<^Z62%I2N8G396^"3UU^..0F% MTJ2!^W4HE^NVS09= <0!>T^Y<^7.PJWN_RIF_0K_ F^@&@0!0E;DC40^< M^H|@FENK#(1=1^7Z9KOCY^41^I M^S&R^D0%>QDT8^H^JIHW^D^"9Q!A&4X)\$9 MRID8^SC/H^M^N^A^<A>UGJW%W^W |H|OVFK^E6-3/+DB>0Z75F1T2@%|164)+Z MS.A!;PCO4M\$76;1I2/NJAZ,|@_H_0^==XDD:4Y.P.C(PF)"8\$4#;9^+1. MHK3VLWOKNCO.? 70@KIM^RXU67<^?1^TSL^*M^M\$\$.DCU&P^1J1T+^=^N7TV MO7=WDQ^9WKNI^SB!^T^2<|R@%5_\$.S!^DIO3!#E1A1B^21=JPHJ\$K6.V A M^%.* <^F425^"HJ@<^2Y8>G\$XACL7Y1+16D^G2EL_9N+^M^!EOFO^QK^3_IGGJ3@1E_Y>#1^0G^&O^H.C:PL(8NH^<R^I-34^WRIK^MHFQ!ME- EAC9UA0Y@)H^C;SSG_0O_SF8\$BDLY&K;=PZ_KZE%DYCTV^>^IC M^F82UT^C|A74_CJZG8Q^GOUXLTIO\$=6.C6PY4H<H=1>0TJH6BFM&6AR MW&FHW_!\$S;N4XUOK@MBG\$D\$LR^OW(GRAH&ESF4>^L#;30&=PFH5H SENDK@B(JB2_EO=7QH MX=2Y:3R:9W2%WHHGL^=9^+3CY13? GM/+4Q1KL_N=H67^H7^PSN^QBU(J1 M^JDL+^C+HY.M1B6X7_23I^04UQ\$ UP;2SLA1^65!08RC(T4T1.0C0.T M^M^D^2P!+9HT^H^D3+K;I G^K9HE3I>4^2E^*QD)=TF8^H^H1^U_L^Z^M^G^G^UJGU5M18N40C^=5S195T1=^FFA^U^JPXJFU9_M:=3I6F3_6M^WT&BK2UJS=W\$^1=C9W4B?3? IY3I=.0\$A9_>D9%2#4H9Y3H?T@LYE!^=XB9JU_E_=-14@I2S15A1&61=16:U|XRHH@4\$%+EVU#^%R:QC^ULV>=T MQA9R26I8XRY;|@ DIY_28^VCE\$&IC?CXP0+!\$ LH3^*CHJ7E7PNZJ%\$< MR;|@ PHJ2^"ZVB<15B14^560 Q^1;U4B!TY)T3J_?^>^Q/4A!QBNAS^MZ^10V(718^E M9>+1&+^B9&Z+13\$7SC>^I<^N.Z1&^16I2B2^W1TN+QW>C:A2D(=6^G^PY96 M4IG(CZ^FIME4^TDG1^P^*0KFF^SWE+^637<^7.PJWN RSYWIV5U^FIAG@_M<@M^U^VB3J.O4@N.2XM^?7:U+R2_@%:>BTT.2@TTFX+OG>+G3L5^ M^MJZ37GMZ3P! <5^E^XZX)KWA7V^10J2KG:7_?^1\$WW%&^KPC_RZ>GZ5UQ1 M7FY3.A8L^&8HL5_ZJ2E9S^"(8K)W+^?+LK^U^|U^+< MS8!|^Q92/V32SZ ME_/S> <#%U/M^K)92^O3>6 DJ\$1+^AH\$&\$%_!9@<H23+!>^ZU^C@_0J1M^A_R9_+^J2&PXJ W(>^&JA_FL:3^2E.3\$H^5M%0.^<B?A^IOY_M5S|H4\$ M%_+^U=Z+YDQ:T\$@XX3|(@%M8B#(4K^*I8)2#P#^+4^OT9ZVP4I3IDZ=N^". MWR>2N+ENB5?JH_-8Y^? J4L0529<0M.L^H170EPU@L@YQIU.HD.LT&IE@?7 MZZA8L@ET!F^WU^233I2C=2C_9FUR_5L\$8\$D_@&@AB.M;C(P7=V5^H(CWE M2%.*FSLK M2_2.W3F7|AP|B+MAN+ARA|BQ^U!_MLOAF^*=@I4X7UECHUUBX^X\$=G;1^#WQ:ZZ23Q)H^X%(8L)0GG3AY MDMJR&9VWZ%\$%K;JKDCZH1Z16A^(259JW-1.RNXYP/A38=6H^)KAHBTC M)T:~!^77_@IKSY<&SLR^HE6^*Y3EU3&6B@0-)H+70 IR)PY_4#N=XCL^9J^QD="^T^<QD=30W:60^<Z!<@%9THWH/I0.D M3MLTD^<3(V^F^XYW^QIDQ^MLKIVZD4J8JIV(YWIF@/(@%..)*P5X%\$S M/HX^F7T\$^3U8Q=NIX^8Y7KD\$7L1Y7K_X K8_N^VJ^?K^EUX=ST^F MAPY015_SNSTXS2(PEXV47A3I6U^PZF:=HJK_292+1#G?75TEF^1@10I M^M6@D8(I^L.3!<2\$780/F<@<3.W7JQC@<^!H^XNC_V2IQ\$ S/U M^*RC|_&785FFL_I&^1ITHGWD=H5!^_ MBTQXUSHZ5\$>D+7^6^*G80=3-8= M_K>X_K=HJ2.<>5BQ^EJ_/>R7(GG&G(=)S2@R^J/UW#5!T26^ND^"! M3N^TF)5N^2MBN5HM_ZP9Z/B5?G^<299.242+OHI^JHP:C39^9Z%:U)^B.9 ME4=UT/T=9@|MO|L!@^NB8PZQ=O^_YV<79W;WE9(T31D&L39&4JP^W;2/(<MXIGE9^VXW-SBWX^&#E/V1L-?S0EUAJ9/(I\$|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|f\$UJ_@.XF^M^J2/H(N") HEAI317^=15Z0Q1+L4L_2Z1MJNY.C:75^YQ^+L\$JYTPVMEH8NN2PWWH^MCWA.R.P+58/EU@&W^>2QU^9&V MBZ72Q^OYN^BQ&JYT_#H<106Y_9U(^UP@3B.LY6?)&^7V8!#6;HCD/B\$=%61&ZC) MTM=9L4^5=3)W)W_W Y)U%<18T^Y7NL@6K>|(^@3AH^J^10PN76:60A& MD3/H2S^H5(OAT-OR4)1^4ISH^8N\$>1>7S1F^QEV+IPI4.K9 Z<>ZAA^J M^H^KN@(^H_ U9FOF9^4<3^<V1@>BWT=HRQ\$XV/VIC_0N&LX^D#M.VI&E!(\$3 MZPQ33^*UY@&W^Z=QNTQ51^7O!&C4UAFU^F>=W&HQIA^X18?<N2I0^MDJQ_3W-M(1#PYY^CH3:CTMDMDDBB(MQZ^*@%\$ M1B806^H\$#17.W.M)1_M^|Y^."A^P.7GRJ9Q4EBK4ZGS)J.\$154^L\$\$.Y^8<5)Q0:~!IXP\$^17I#OX MUJ^JY<^>#B2LEH\$H0IKBKJZL2VUE3QJ.\$<6+&COY.K23LB8VGK<4UBW MQ:T^YR86^+DY4J^H4+^K^U:5D1XY;DJ.V.61#%6(EJ4->+^T3^TZ(3^WT? MD2U1^*S12I0<+LW1A9IR)B^XVE-T7F(7F_Y_!SGT24?K0^D>^10 M1O>4ZHL^C^UHK6=MYUOTL^FYHV!+S.K)Y.3M- MU_B43?G<3U4^1+KR;(^+T M9^JE#G27#>E QT69RH3LT_XB16U<^&^+3@^*S6^1EFS3H^+IK_0^UNJG^..IUQ M.T.N^=U<IRX2UIZIO.L.NYTWBO^Y_821+OOG+>DS4IAP==3E!\$%|U_#Z_EYA@?O6GK;JW^!#A0Z^O.9^Q15M^+5N2^J=P&<\$ D<^1^L^U9&7(0_8? >8SC^3.H9D.N^VZH^R M^WK70>H081!@091D:JDZ^U^5D+5OHG7_23^\$66D/L^C^9L^XZ&C^U9YB^M=F MV0^4\$R^<=CH8KP^|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|DE9A!)=P(SR;E)O2C=I@N2N^HC2+1+S^I2^ M^NOK%>QV!>U6VY.IKN>^!%2TMCZ9MX=1^UJDI4X19KT@I^0D0^DBS\$ MF5)T&M+U? D02<ZZX@S&4WE8H2^L/D_!K^TEEPH_O_/SD_66^*==HJQ M^&#V6QJ\$&4^L(I=TG6EA(WEEG.69J2.16&FKZ+1^!@ORZ!ZN)^KQ=Q ME6FOOY(HIYAV&Z@UE\$D^"LM M8YI70_*O?O)@>6>\$6D_H^B=>(9\$^3TB8Q.ZI5:GWU/D53W&D1BAK^9>) M792G_#^ZI^YFKYXNSR? QTOVIGR9R\$Z0SBD10^HJCBYTX6I0R=BI^884V0 M^C^JH^Y^OKX^LCX^NEI^M61^I^ORR_S:15%6L^LR4)H^H^INMQR^0! M^R^S^AZSSY^<9V@+^! <#M^*2.(F4L2 N^!HUDD^_7C^Y.YLGYD_B.W1+!< MA1+L3)HTUL^<77.2>^O1C2L#Z16%0(FER^D4\$\$(5HG_U^QI^@)C7E*) MR4DZ_6AK^NM14^2V^"UTY^*BOOH&G^M^WLRRYG3#F91<1=1;7.R+;+^M)=4%Y%<^AR;2JNF^1AB(>0>|X1B M)^&MDJHE| B>MBYJYJG<|H+QE^C+N9_X^NK+N000^<JH^X69Y_BABH^PKPYR M^0B40.CL4KIGRQ22BO!L^C+N)+W="M^W8>7DR2U/E4:3XT34 RGR8^Y12AVF24 ML_VS9DJP(8^H^M+RPT8U12>W^A(6|20SVH+O1^<^QY<=I:G80;Y^Z M70^G_KXB79L0Q^0>VSCZ5&0^=0J>11&^YLVCM:8J\$U)@_);J5^E^H2#? 0S^9<L3I5Q_MW\$4_7H.UED6P:79L20H^UYD8KX^W\$Y0DG9<^4BRH(3LX_620X^ MG03J^ N^IESOX^H^ANVA^LLC<^9MH2VN5M^LMR=GJ <^9I^UJRH5^14BF2F^"O4_~%IM40#&J=2H_O0.2TZQ^CIK8R^N M^#2OF^ROC^=D41PUHJXQEEGB_6K+^@3^01.#K1^T8G^LH^W^M9NF5\$ _FEMH M^B.C:6<4>@O4.C8\$BE3T^R+IM^W\$QL910(C_A_MJ1LXXH^7_XH\$7F+7IV3)SN0ONTMF@70Y^U/T@_8B+^+I>S^Q0^4V^IQ_M0C F)=R(Q>>=ZZ1S1+P!H^J).XN^NWN6YL>9:2+2K^1^DUJL\$+MIPREF34.T2UGT M2DE|FY^XEA@<X>D8T^ (4Q>~%L^JYPIW^*1B0T^ZILIVT6\$|SIEKQ9H^SR MOYH>^WRXLYKJQ5J5Y_0?T^M^7^MH17^N10>2^H<=>?27@^<^Z!^J3G_6IU M&1\$S^VJH? DG^Y^TIGBZ^R^*JOI&^=^77^8^NYSF>7G76U^GS+^J_5E=K\$ M+1+2HDT^85W3.R^1W1@JMB44YRKY^FA(X2YM+1^LW@ZOCNH/S^<^<^*U^LV2D<^R(MB1E^"^(9E@_U^WLRQ^+122N^3F&HM^>N=XAE3^*GI(I@FHL^T M^#KR>X_2I>K^1E9N2_R(I=YK!^U5_<=H^Q8&Q8\$ E5P^SD%#S3.)0R34#=#PN_M0S!^#3K/EODZ0^YUS(#)\$C^Z^%ZAG^)\$HVS^K M^C.1\$XWN?_H(&PEILGOS/L2I+APV;\$ EIMT.5G2^Q5KIDG3 >O^21G^1^RR M6<=>WL@JDIK^!80W9%88)JY:~AN^0IQ^G2\$G^HGVFCCAPN^ZMBFLN^AKQ36 M700P<DU^K=0KEN^+U_7I+>GX^N12^? Z/G299|3Z|>OR&F^Z1J&C.ADD^MIBTHY@D..TTR)R^H59C^XBT@IOQ^>Z8HL^BM!&^ M2Q(C.GK^408^U^FGI=8#P^1B307\$XISW^4I+^#Q>NB? Y^>|!"R1C^#C14 M7GFMP^DT8^D0=^B78.JV4\$%_?SYCSD?3?OPO^OIFI?6^HS7>J<60VZ^*(4 M9:J|&X@=68R^Z\$4\$.HIWRDV12!\$FGN^#H0^I INF^NK>^IYDTQ14Y^WJ_BIY^=^%NLAV+2^A5+M_<@1^%>36_U4FM^TD<@QLRL&O^9I^*1<=^MYWU^A(E&S>2^H45M(+ M!T<^<92+R^&P^CUH^XO8Y&RWH^XYS^=I:G4FX7^72@JYU^B^I2>K6P_M5OA@T27FI&^&R7 M<+23N^JY<+0+ IR_<^H8U^|NJC^DU@34I7@AX^L3^C^ M5Q^&4\$5_3%KMXHHKXKJ^IV31D8126G9E&41697I=OPJVK_GMXL^JL^L>G MM.^JL_#3QH0Z^ADR_U0^R:ACEPP4Z\$>T+C7\$8.W7_^JH@J3ODU^3^3M.<1@LND.Z5^60^032^<NF33YR<+G_~U70RE^KH/H?Z YR^W.GB04TD_1^JZP_3^<9G)OP!<G.LN M^P=P>GNZ^Z_YV^&?UFD1M.5H_4<~#HU90^H16:\$S^UP^U^V.K.QXB9MRK MX#^#2FWEI &@&M^_61\$^?J2I5^1^EV@_T5@R^B4T1_Z M^+PMW?^F79^H^G^GZNY<IY.B^0^1\$Q8H^CY M^5@AUG^?U^W^QX^A2RIF50^ICGL@:83&:7L(C)^Y@?

#3138S2A_9096TJ+AC MI^N^K7&^YD#IQ1*U,1MDB 2YQ*J9+.#T>^I:CB.390+P4%I64-D&QFGPO-MF5J0,E^4;
(V48G,QT3>PY>^1D%4BYENI=>S^ZLINI^2;66QUO.*G(R(RQ+3YVU&I_QF^S^@(^)^%)9)T^R6,\$\$ MKCTZ,F@7+^XCFCH^/((
VK.P50R.OP^%A)9M^HJMVO\$JGI>=>V9P)T1FOUH)*Z74.0/D#^+M^VICA.F.R%3M%T51.M+^O2R&J9\$U.X M9^~%X\I\0^ZUPHS-1H^2.W\$0UB;2I
A/9@20<@G2^J^J^N^7D^R09F.MA43W..9^D.913^2985^M 70^J2VJ9QY+YLS00/HW\XZTU70)MS((%QERJ83-@R)^IW>T>+J3D)^F#H^W^O
M:REJ15_EB^HFW^MY6^O+ILZ7P28ZT(6<+@9G^+1\$XQI851&#JL M^J1^3>S>Y>WJ.8^F7PR;HK:RZ\$#4.WJT+^+FB%+^_OI_15KEJFK.0=1^*E
MJE.KIT596V?^AIZ+<8(QSOGQIG9IB%NVNJL<=>SYCGPZ-^>J)U)XL<8VVI M^M^G43LLP^J\$>.<PRI51VITF4I^91^Z+IKNQ+00XK.B8U!>=P^/2U^S>
^1.9TM.Y.HZ^>.\$Z&(D)./S<#20NC#7KS.YA=GZW^LYN2G>3^CAI^Q.13841^1BBS40^0G4PJ^J^E7 TCI0<1= MPZ#U+^L(MHJ^1^B^PA79\$3-
&YJ:WTD\$0F\$^%R.G78>5H!#%F=JZICG/60..M^ZS#^P2RO0^1ZB91B^GF4U^L%)F(^<@^J#<4((+T.OE\$%I@- MIX: TK#1G20I<-CH^FSNP^O=?
8R@<M5S^AX.KXIOV3^60RPH^*(<D86A=1 MC3M/A>@CIW=1QL^3^G<14Y=3^156JMHPT2(2JMD:CTIAX(159)<_U85&V<
MJ0^33W2.\$R>^E2LBP&A=>FA+1K\$30^>(^)=^1-8 MBJA=V-2IW2^S6^#=>1L4^UPDR^86JF3F2<^Y\$>YS^8K@K/C6Z7QWJ7@>=>V+V MN0L<.<XH-
OHT^R9J^Z!%^1DVP1=0A?)^E1ZL^B^LJ B^NDU6^QD^IDJ M^3MYU7VH2>^/;O2+1LB>+^L.NG^..?Y2Z2^YCMR>G^X^\$G10^9IC=Y>|>1V
M0L3@<(^G^1+2BLT2M^B^DY.LJ\$;SAH.9;U95\$(*K(VKN8UJ^..3B^GVR460A/NBSXIC(H^U3;G\$W+^TPD^M+NA34^82J@&I
F251\$^W#1J^%K0+W24KNCXV&#J1H(33X^XY#^1DN9=^"Q.M!Q.7391>8^*C0CIGCR=GP%+K^/6)3=-J=LC^W#1D:GRO>2>1^TT9WX7Z7 M^7P?
^W.RX>72WKWY=>6CZ^>Q^O^W76URMZ#^Y2U3J09J.Z^9>+2M^WBC1M.E.#165Y2F!>7I^U^OK.G=^YO^>?<=3\$B+1^%YH^M5+^=Q/QT5+!>=>
T6GJFVG7DUMVG5@<GR.WWD-5^HJ1^8\$>=>19Q^BUK4.PT7> M^JESIN9H3M.G:J81V8>+^V20R1^7W.S03.%
MHHK4Y8<ZO)DJRY-J&LIV>Y<71T7ICIZ6.^11X^R.B3QP213^6N/K3UT.MS16-M^YZ>^INOYBLTK00LO-8J1J8=^10^/Q0^&=1TPT_
M0Q^GMLN>33F>Z71T^T%>@X.MJ.L>2DGUO^Y^@PNX1^#K.^Y2V@&^C.H518N.M.TL.M.Y@&9@=^
=WV.OEV=EE<5.%>FUTR(6XDHD+U)K=CKJ.O.L0.BB^6I(R)29L(YIT06V21^Y)Y6&5..M44KMK&I>^.(A8GJ<6SIP-&\$ISV Z^Y-1?K7?
FTPL4.XXV1.4)X%GW-O^I3.MHE5MZ^X1OPNDIOBNT.^F9.M6Q4K34V18PEXX\$@JEK0K<230P7.L%N)43\$LG?L>^>V\$>)=LB\$C.U.S/VJC+;MWEZ
I=>1JOK8^LJX97>K.YB03L99)092UQ)I.^@A2^C.9^+^UZ/6Q7I^&DI0VX23.P\$ MN0T@U.N^7ERLYXN17FJFWISGUU.Y.S-
6LUCS@<^&^Q4IH8F^4(Q+R).I.VC= MO<14GK)J6I7^>=>Z?PN9R>=%6^PX^30G.F;AV0Q3^XHZ43LE^>GTN)K&B8^8M1#1.300+87(.T?<
S=+^<V^TD7.R?G>^KHKZ^&2I^Z">]^M.M5F.=CISJY>^&166L9RI^BE0HT@<|^|^N#Q0\$B7#^F9P?^YF;PJLUU84RQJ4I^
MURPIX^H^560J^ZJOVZ8OCA.A.IK07Q07I^F2Q0^ZQIZG^>3^I25BF^?+8YN3C^MLES^YW3S.6=099>YL)8FLT.0^T@8^2I.V12(IJTP1@RZ1&?
P/^SE?27^3FO.=P^B.MGW-0)AX^4.PSH+A.A.\$IRV/^DMV^5^Q)(UT.L2Q&^>Q^J^MBKY^X@>=X7=FIC^#G)82.5%SGF@>U!+>?WDR39^66A/=
">I>Y(CE7F15PGF6I)W.E7.WDPJ.MND=SSQ5L6^D8.N.9&5%OR>@Q&R&A^%\$Y1>3)NFW.H\$1.T^Q^M^1ARXIS60Q^>M^Q/QN=7EP+
I<^5^1^4^#ET@ZZ95I.O1&ZG_1I=RHK.BZU7T/Z.YY>^#IH.M^2J4.7^(6&HJ)=DRI.8.218816.ORI:3=(91.BPDRIYXKR)H(4#N809F3+KZ<MOW?
YBTOZ>I9KVGQ.^K14.^>=>#0FIT^H&54.6%HI5<^&(L8P)YIT^L44R=M./SS>^E6Q#1^5/8D(Q.O)H7GR1-S)GSSB>1^T6R00HS@.RC\$|^UEZ3^*
M%676JZUXYY6^9>D90<(<@?>^*T.B6\$ Q7J0.33>T^XDIJ248#<^>R.ZZ.M09.^21X^+1A8^NVIP0MQ+&WQKIE51^256U22.MOU31M7ISF>S)2
T9+U^I# MWF2^1^"LW^<#Z8455^7ZJW_K^=I0IF(4NO11^0K2;SH2^:=25I^"441%Z1.MSIP.^L/0QSS^"X2C.I^"209%(<5>UE^%<)<3^FO-
^91>8+1ZTC^75A.M^#1\$;SE03AE.231^<(X=0MP7^5C2U;3SE.MZ4J2E^UQ7K1^EJAV84S.N1(G&S&A1>D)6M92IVY^%P^V(\$OHS.P2VQ^F12
M&3="JB(+1A0E4.0^4+U-WIB1%62VQM^3U)U#1@.P2%LQ="K32NZX05.MJ1LV39>^FNF&E^"SB^7Z^KIPBA0DS^
M^#H)7\$EG6&6Q#BN=MNI^VF&?9Q^2+KJ\$1^YTO@+^TLR7V)JH3^9<7 M^%G=Q^GZG/XF0K29^R>BJT^S+D(7SOC/(=3^9R%V(
MA6%1HVB)>^78V3^VHYBHU1\$EA730#&D3WH^Q^F&S4R^6488;IA30JF153.M3/HJCF7.G=>7^Q.ZB^YIG)YIG6YH&^7EXX16A85EA
IDZ=>F&F0B^G&5+A.MZ\$5I(P2E6I^ZVJ\$).TOZ8=>3.YD59&G=JLU>OCKI\$&^7K;F>^70N=LOO&CE40\$;N#;5#7Z#1/4^SE.MOED;@N^C)?
MHD&D@V>^JLN^Y0Y@.OUO)M1U0WYI=>(^F.G^M.WI/UEZ)Q^U7%#<@G.NLOYE.R2#YOZWK^4GLY.^>SQ+XXFG_3=Z2.S+>=IU
M^12IRH.M>K(Q@<@N.@T8^PM^H1^MY99Z@<I)HT321^JN2+1^>U>+^EZS.M7)V/ZP.X9(9A1.^%<1M=(.SS5XN^K=)^>MX<^<K^<^&IR3/06
^3%L(2(8&QR^>=)R^<A10\$&+9.MM-V^CHFJ\$235P04ZX.TJLW>10GJ^HL1R76RHP&S^/M^NVX^3LL^R%"2K4.29/KS\$J\$MX^61+^H4&G-
ZV+J1QYD3MM^KMIV\$&^2C^RW:HK^7.F.F.R4U2BV6^7>P.MUJ=BC<^R8ZBJ\$7^>K+P.G:0Q8^6WZM^&^WWJ7+1E#6F.G.T(16R8FNK-^G
M)D^QONARM^TM08^IBJ\$J2KKO+7.12E.4M^7RX>WKMHJ12^JPR95H^KF.MBIO/7192UO.^N.UE2GIU.PK7^4D51>MV7.99'=ONDH=8^<(\$IB)^XT2IBX
ML>^FK>O^W/O=>CLM^Y8).+S7+U8MU1+59D^-FUD6R^VH@<+^E26I(PK1N2C>LHD?JEH@Y.ZS.M9GN1^)^A.S?<
TRVR^MOENOUR3;DSIC1^0894N1^VH4.MR9.FMY\$1.YYHWSX.^65SM1^Y8E^<X&3Y2%\$UH%710>9%2E^AYOVR>?KKY.MGW/ZM^R/J^YG^EIBX^?<
IR1^SS>=[N5VJ+6.1J1KMKIR0\$>A08%T.FAM)MYIRU)WPHS=>H<^V;^M8L8SKTIGN502M+>@A(T.H.0:(\$+^EQ\$2.Z30>M.YO3QJ6G.MQ.I^I?
^2I)A.O)AOZ1.I.8ZTJ)GWL^MWT00C3^YFOX^ER2^&Z.M^?B^YJ^A.MID+FUH8D=>C.(N1.RA.M^H4HJACR9K\$.\$%J1A\$5NUB>)^A47)HFB=GI
3@=>^F@<^<18IRL+M^Z.M^S\$1^>10166)<71XHE.YCR#>^>Q>^>H6+S3U>^>S+R3O10@&+J@Z%MY13GDC-DC9)AK\$S.RUN6^AUJK<+M-
=>GP^I8#3_R<^ZHMOCNI/9\$FT4.M5.9DGKEH<.<)<^<^Y.&P=@^1Q&EMVVPY^#9(I.^%JMEEW=JB98)@4^I;4.M8R2^ICIS63&
Z2UJ&2^P=>^AH1^1^M181^L1P^7=>1\$103.&10125.457.MB4NH2P6G@&@P.^Y2K.VR1@>9=JOV.GKIR^M.M^?>AY=^?S7HO=7^SIN^I^HQ^OUL?
MJM&S1Q2IFD1>=>8JO<^>Y^&^BD.MY2^3S.JW-64B)B1WY.I0JM0Q1^TJ@1^E.^#DY.OYU.J^+HJ.DM-25@6.MGB3R7HH3.\$ITAY^8!&^%H5;E%8U2I?2
B1H8SY-170G5W%TP75PB0^VJ^>M&524D815BIROLIF!#H1Y^RMT51)3^IU^>\$X=1/7WXT/E>51Y-89(K?EU#DK
M#1\$B\$.DRJ\$3^E.^&0&R^YM+51%KZ1=>^WOK4=(?^<Q^81<^SN^SK9^W/D>=>C^H0F1CBA-9.D)0ELN25M^O^FU2^L
IRET^HJMG(9A10\$K.R8ARK^T21^<=>WJL2^8YV.M=S7A21.869LITG8^>UYXMHY.P^J.DG3\$2LY8.X2HB16H^"OD^FT3.W25@M&@731J9W
7(@@SNXB^Z>P+1YWBZW<963R9N@<NFLT%1FT1^9RI7=2=4(HI.MI85K^O)Z/R63X^50\$2^<^IL^#U+Q<+^NK.R=5&\$I.FZW^<^<^XB+^<^7USHI(+
ME<19.R&AU^#>AD4^5SM^LFC1VN=>^IZBJ91W>^JWLUE5&7F+O.S298TEZX.M128^I?
(^B2.3ZCOH&JS+DCE=XZ=>_@JFJ8UJLXB\$EX2^B0=^>9.KNO@-ME^YQ=GZ^ZOY^7E>7#D.Q19N7IVY%BIC^-F0\$;LLS(T^4MT9CWSLVZN\$5
M>H(1)<^F2IQ^T^C2RI7+I^7YHP<^W.E.AH0^V@<@&XFU^8L^Q.0A6XN.M.G^ZHH4127?
E.9^8C^M^>=JP%5SIY.GBWHC42V16UBJ91L%<^JX9N1UE^CMBIP^OP9T.FB.%B&^I^JN.Q.N3U^XEXYV.W.S.6)TXTAZ.UY+^P<^7^1GM.MDQ?
DZ==4%\$S1^KUXFHK)4GT^CTP41^H@1QOH/HBK^<^9^WDD^FW3RPS^<Q1M#A)DIPO225JL=U^ZITF0(Q=9L)1A3F^P)JL=1&
M%3\$R1C.TZ19W9E2T.F4G1>DW6.MF6+U>5.Z.M>7M+VLM.FBYDU<QF1Q8>F>1)880(L^EMBM^29HNDG.X3)2CBYJ2-R
MRS_SZF_STLKKY+^N.SI=71Z71Q^XDY9.J\$2#Z*2M(SOW\$C)MMQBHX^F<1V@YY?MLN<7I^X.23^S151^H>KE^80IK1%5>VR2:QZ5WI7^>#J1.3>J
M^J1^XTE.U1A=7@QSH15.V&KDTA^K@^JMO.PTX^KW61ORV+J4^<L1=^<MF3J.FER^UH^?6^#H0YXOUA?
G)GKJ1B1^4Y2>^FM+^ER4QOSI.FEELZ^MRM4^KX67.9928CMLS<@<KN#6;ML^T.8IL^84.710.MGW+^BXMV5^H>E4H.Y^>K1C+CDOSQ6?
RAS+JES1AOV^%800^&8B>U>9@MBGOH9TBGIZ?)CPXVNI9U7WN0.0B4IEFHEA^ZP^7=UZ.W^<=5_0%<SGPFHR=MSB481^IXYAW=OD.^ONNJ(Q8-
SB\$1^AHBM7^C+1P+^GM&4^%FZ1VIA0^FWUD2101.MYF^&=X^U55%&G6G=RVJF18>N^T8.G)H0E02EISJIBX.HJ@.R=K9H.M3.TUSZ.D32OT/
J26@1A0DS\$RX.P>_UEJFMU6@#15=N>P0E1@HT.1\$9.M/Z9VYUQ&K1^>J^H^E7J^E^P.P1^JFEFX2^Y9&C8O.MQ2PQJ821R^U.MKA4^RH.3RD
^+JONGTF)VRFIA>S^MH^TH8M^1B1V(>O.^<NBR<9^!GK.M.=JPQ>KR2-T3A8LR>^+HG=Q/IQMVE254<1^XYI.\$#L+^1V\$1Y(5%Z^IKZ0
MJ5.O^M+13I^J6Z^<C^V&K^YV^<=>KGS\$^OB.3.Q@JFSIF2D7.E4.H.KC.M9>LS2SLA=1DG&1^JN)P2&G.63JHQO3OMN3.Q1^=S_9^07^X)CQH&
(X(XU.M\$1F7.EN.0C.6=C\$WL9.^>VCO.B(O8=F3AQ1J1^F^J1^570WKZ_SRI>^>M.JZN^@HYZ\$VWMBD=>20V(21P<^<RDGJ6I9>?E1^"?
GJZ=1^>21N=2#D^VQ&MDJX^P9^%G1UEAMU1@<@616124Y^JB^X8^G^9>.ZZ01^61^<^>Y1Z^Z13.MQY0QJ2A80)K&600-
CHRA)CGBR9DKAM.78X^<Q18-UCG&TELGSNN15^3G6.MG+5KK^H^GN=>1^<1H1Y1E^+E.Y.GGOTJ^X9^YMGQ(BU<36+1O3FLY^OJFF
M1Z^UBDJ^R^FO\$1OK>B(T8D3@N1^PC0W40S0J10UVM^S9IP678DRPYTYA.FMG)S.FDG>^J11^I^G.^J1W11SPZPP."CC7RJY-LR<(DISTX80S_/H
&IXZPLM1D)S^<4^>4^>K^S1^YU9.MFL1(WA1C^>S8CZ.11^<IOHGEY^N.T=E/G+3F1IBOH=KU.I^>(^>MS)28?
CW9^761^@7.UXB^<GJRIX3HEED32S3.N=25QVMR%L57H1^K)S/M1V.F@Y1)@S1..QOE^<OFTK2:(Z.^86R<=R/4IK^>C1O^CHIWA9P(MY
I/4)^>C^<LLX^&1^MJ1+(PC=9.090A2XN1.Z8^<C^>G5^>W^V.LG)ZDL(X^S51LU^00^UH)H+M.L7^ZBB^A-1^M.L.NZ.E.^X.T.KG5P.SY0R^I
U=K532A5G1ED1^#HJL1.M^#K18+D(XQ2Z3E3N1UX>^JPGG&01^>M^%X1W1D7^>L>0&#HCU^Y13T2.^1018B#>Z.QZ\$-
MNIS_@35IQZ_JW<@>)>S^Q1&^2G5CP.H851W8K0UMN#(D=Q^PU&DPD)^MEU-M7I>^VX>(24>T.H.MDAV9V^8.T&S\$^I^2N>F5^X\$62=@2K)^L
IC^W61.N^O615^B.AW9&^C8G.S.MORP1A71>1F1^P^K^KY^LE<0B52.%5D.R7.257X0+>1R9V(^72LP<2RR17%L3151IG\$(
MU<^>7^OE+1F7%HS3Z.7Y5<^>BWW&S^<KA2P0>BJ^>J1.BW.BJ^>M^<M61^Q07SQ>2OH.MO%RLKH0Q\$^I<^2\$9I4@T.H^<8S7ZB)(8.MHW
R.WC7V1.5#P6H1Q)1M.RBLSI^7PYNI^S1.151^7FA#6RMND@S2SI2F4172F^LP^>^E%.HIY^NC
M<21R.XF^CP6E>Z\$1OER21X2W&18S61>S1.T@VY^J=5#S356\$C%G)I/

Y2DM^DJ1VRF.MM<=<=>UHH00=96)%\$%#J1.U3(D^9@S+R16E<^/I0FI-QTSQ^5P.J20E(6@LT^I(4E)0HK5^W.M^Z>H\$Z^18G;81O:2>?<
H:Q7M<.&18HR8T^24M2?<2&N0>^>P^>8.&+TPIC.M.U/3V1@IG^3GYPI=KJ6IND^>0.MQBNA^K&B9IVPT^>)<@HJ#K.0B16BC.M/9
65<=<QR\$H.R&@1%U1+2A11>^>GUHM^HJ^O^#61H7-6W\$>E4F.%>#12^Y0P0+^DD
M.^00+^>LAR+&XDV+^71BW1V(N@=>5W=%EW.U^S^WBZKMKB(X-PFK=1F%G.M=;0ZC-1)77G^C>J011JL\$R-10X^F=&(^P>C^HID>@4.;7W(P6Q
MLWBW.DG.2^<J^R.Q/L9(22MD7X.80RLF4^D6L>4R1^<^>M71>+>8BEF^K1C^X/Q6^FQI41G0&0W.AY^%YLJ1.MT81AQ^822^>F2_1Y0Z2E\$
MMDI^Y(W^3F&H&B-O1^E.#6AE1E)R2O/RV01>^3N\$F1G^"1^>C^X.Y0\$0Y2^MY2Z1^8\$;GL&I0JR.^8^W6@.JUC\$1.1&.^JH/Q5257^D2.N<63V^<
J@>JP>M>V^2ZQ.BC+^T^<6.3D.P+H)4.(K/B+J1HC>>5.JB1.^+L^#N.A/L7ALGM3.M^>=>9%79Q<0^W^<SV.U89U^E96O>ED.B5-2^M
^R.MY371M3W02KZIR.7=1L(S8CKO^D6\$D\$M.M7.7G532>^>K(S3Y.R.#7LNDQ)Q^UKU72G7+1QAYG(69.BKR1DE0IE9P?
MM&1%HS599.4.2ZTG@TD1@.^RH.0<^>HD8^W711Z=2\$MZ1<8S5<+1KV.LM^>D1O^>X1SR\$(?ZOF^O1S^>^>O^>C^>O>H=IPI/^5BX+M4B/V
MY=14B1B^&8\$R^HFA=8<15^J^TG4HZ.M.3HJ\$GCMRA70U=PUEQABDPD1C^X.21>1GZ>^DQAVP<5^68\$1^HVO.=MW3PR2.2HXK3-
^#D51XHYD12.M^L.GVUM@1DQ16W31OV32MU^%W.L8V7^N.^YIM.X874^%M6^H1^<7FC^8BFB1<3^>REF91GFI^S919W^Q.ZIF?
^CT&S.G9LK53CS^V.MJN8.C0ZIXJ^F^<^IQN4S9M5LS1X7608^J\$V11+^4H31.O^#UO^A5Q+M&K^J21J1A6^D)DCCIF.HDUV.^#1-\$CL@89
=N1.S=B^3.G74F&8B.M.F)UGFO^M^HJG+FG&7S^B^M^JY.Z41^"1X4Z4MKH1@OF&11^>=>W7Y>HCGN8;OZKSAOJ^>WKZ1Y2J1^>S1@<9)1\$C
M.^H1^WTK.4M1^<27=V58^<^<49I&2.Y7T.F^<VRYK0Y.L=7^NEJP.FF@<1WY77
M54ZYA<7Z.DBK^O^<A13^>HD>=>EDL@<@Q\$<#J1\$MW1^>@IT1^Z&^M4T>19F#<^NC(I^AT)SHE^A4&2IN=1^D.M^140^50C17V\$1S1YOU??
GD3R.M^>B7RS41WV2MYGD.O)YHNC.S1Z.M.K>5(^J8B3Q39F^>2^N0LG^OHVJH52P&9.M/W/MX2UN1<KPN^13.RC^242^1TZ(R.^QQ
&MUR.6G&NH1F+19)\$>L^M@MT6>X>60VVC^<KQEUW)2WC4BCU&D0JDDQ1YR-\$0^"I#9^8XK.C2=\$3.MI#^2FGDGK.6H(44S/Q
>^E/A^IMV)^WM10.N)UFX^1.20XA18.Y.9D\$JUMMK6)27>1AG161\$1U5=EV1FF7.XW59/^..13X^1FRSN^V3(^2%TD.21^M1A/042
P_9NDEHYVQ^EQTLA.HYX^4^6I>IN=KTS^Y.Y.Q=M6DUH1G^QQK41^U.SC7I(G3^214Q&4U1Y^5=>9^UV^VJLX^?>10)M17>+^8
MT3O)G.@^LF>HDXT7^#BED+P^DA&G11^UVS^VM%1^N5430.41MW9\$W.INC.MGLO125.611^20DFA<^K."ORT^J11(0Z>E.F.C2>WVP.F^I

/DT.2@B4IG.MOI|>W2^|>S>^X.GK|_I.BE|2?R(LWSI^CGV31/@YNM|LJY6-U)Y5LWN|NUIN.MYTR7|I.EMB.>."4B4QR5)G7|D+=C|)#M>BUI-
IG^N^G|673.MQN|H^|OMQ8.15|>@SOK|_@|T49H.HD|ZUE.O|AOUD|EN%F.G.U7P\$.+ML(=SUMD*L.VY|ZPCF=C|+9WJ.EQ.H?
#|&8A1>Q|&#/*6PBEPMM%GSRMCL2^M^|H9>4/#X3|JLFF|_M_-I.A8Q<6.Y|6XHL.D6%##.(4O?A\$2-Y|JU^O^M0.#(0*HGV/N0V9O+((M?
EC.OZ7?ZOKQ0\$U2251.1\$!4\$.#.#@Z7\$C"HQ.M|H|U(EHFX=@3IMV*|J\$+>|H.8UN3:RV%>@W>TN5E=HHWIZ5E(B+^YO)C>
MLF+K3)0HC06|V^P1N=-:5X@|LWV2Y7&C<L|Z<C+1&S&L5R?B.FL^I+1.M8AHWDP?0.6U=HR!!N\$+>V^A!^5<?2?ZU<#%0!+J.76X.7.+K8?
W=X8.M#Z|_DB.9|4XGYS^F>+L>5\$U8HX+K4A2I7@C+!+2.OQ2"(KE3\$ZG>?"K3-MJ^@ETT#&|_HHL7%MA6U9|HPT<^|>E.MJ^
\$.M.OK(=|8L:YL@=#3AVT.X">1ZIP^@3KODUR=XSED7W(XEPPAAAFJ2:@HUZU6.K68KE9IMDGO-X)H.#(1^LB.M"(O6@-!
:&*&VH==+V^N(M==#3AF^M>4HKPRZ|N3WF.M%)0RH0\$64O)(.E#-MI9XBL^I)H#IDW.PX.GZ^CRT\$WZ|F^H^|_X9X6?EX9.F?KED_K9VR=4Z+)
M0N84.6%?75-|K/S.100%1.70LX.\$2/2<."SGY.I^AH"\$9KJ|0B138.M_HLM.25>7+CIU^7K62A3P|P|FTE|QHD?0D056W897+8&25OK.0D8F.(J_H76?
A/|9WKW|H.F^J_!(X9AQH|_IAS(CVTH/EE%)JHN4-M2)D477UJ6%|:QV7&AR^@XJL4C>|>%#6)6S/>O-DMOIEHL3|F^|A|_8EVI^<M_>_92JEYD36?
K|_D)AQ>R-#K(ZOACY>V/4K43S0G|OQJ|8REU6\$5|TDJ^M_ZM^ER(=W3?P^7B7(C=BB.Z\$Q|O45MVC^XS.F@P=-1C@.IYTCR:1.DZV9I
ME|A@G=2.PDBD90.H0\$4E(QOD2\$+M_<7|2|CW+9|>@N60Q2A^>WG53SHAA^MLW!UOG^S100K^8EN.BM^8E=-<@<|FCI^!
I^!EADIDQ1.G@|YP#)&F."RZQ^MQ+P>>V&|H<4.)J@%+Z5;I0D^M/M#X.6\$|E|H|J|PJB.N?+6^DL^3)EG.M^B+S.EM.G0@:N4_1X."K+YT&(+?
N#GQC^&ZVN#4.BPG@F=6K\$X^4\$3@C^MQC^0404X^E|F|FKNL|CUI^&MOIO/YM>|^2Y6AV21!%4M^?
RW92\$#R|<R<1_#93)"U|_0R&L9KM)&7EHU^?6604)"#H2|D\$W.1%=-:MOTYGTU(P42|J.7@=%9\$CHR^_WGL^&F9|N.MBT-
33|6(=|P^7<|6J|747ZY\$.MWY&.*7TM7SIP=(ARC.A@0UF4DB.M8.VAD|+WP06.7^A=W^TN=UP>7IO\$<>69#0823G|HUT%I5D^=|MHF\$2.IT4(
H|25/9>0#1^T@F.1N<+5|E1M^M3Y+8#7|G^YPOI.0.L_>77|H^&K^N^G<7=WCW:KZXK@.^+@_1/5M>+DH2JHL.M^=SSYI5G|>_D%IO4K|L4400I2)KSL
ML76)?_OR1RXH.9>5>3?WP.05WVLZ.MD82^K|O?ZBD\$8.0\$T^GK9>^C7K^T=8#N8Z&YH|T7K>^*40CJ3GH7UX.M.W77@RL+1^<=>Y|HB)
.C4*6.1F2AF8J-DKYA13&TA#OD0'9>L|O.3NH.M.SBNCYP^<L.F|N|HY@Y83JCUD3KO-6YP=-A.7@J9D.Z:65EC.2IP2|N6Z
MP>CTWK^&XG@+|URJZ|NLM3(6SE)=>48D@|W^0%#40Q9(EKK^CM\$?_XMYM^<H|O12MQN0&?_VY&^5W3|@0UB|ERTK30|?WTR_HCIU|_I<-
XXD)_HJ.M@|^?#S|Z|^#(R|AOE.O(W88Q6T8^F(OH?^P|N.V8N.L>|J^|_#*)D(C^"M+0A*
(G)4.X@DZFAHEH%VZHKKI26GT.H|>3&TZO^K=1TPM8.ZOK8|_Y^ETI#+_M0^|AH@>6>G8ID@R%"WE_+?M^MU+L|V>|>#Y2|P?A_@HB:@0FJ-
&L&K#A7S.M%CBAD4B2O1==HE7=-WN@:GNW|WXS5K\$7_|JTPREF.967\$JLBW+|+1.\$K3&_M:"E.|PB<5^2O?>#0EYLC=VY^49*^J.GGA?
OY91K_&U.8PW-W^|JLC14I67.E.M7|G^3C.8J^|0RF72WGF2.R7K|86IAP@8K|F\$|>_W-Y|XXOWWZ?7H^|>8M>|<_M-2\$ZFT0@1%4*
|V@&|P&X^T4T|O1=Y=QTH_2400U^90^K^1D.MO^>+B.CG-^K^N|2>_7P|@RLEF\$4Z>_>LW^K^K^U|^>IUR4|_I^|Z|^7<^M<SDF^L|LIC2UU:2.JCX|
(X.SLG29Z(A>=>E4TB48E+2|W|H:7L|7B:O)_DR^XBP^@J80TQ\$U69D0\$M4.M(H|4)7A.X^7^H^&6^PV^2Y|_2N)&^6R_N=4)M^N.TY6S(A+VY.#
(N#9.M97E1N)|ZM%>I3_0^0^N^I^M=IFED3^50.&_&_R&S%D0%326DF%8RYVT_/MK3%.N|QAI\$U7HZ.B77OH+M|>5/^O)25;_="629#>
U&B+0A.B.2H.\$4>#M99G1M|AGEIGM&9PV^C^D|>JX.9|Y^"FW<#^?2Z(SZ^>IUGX|M4M.K.V.MD|T^G^@05.K.2@>^*3K9R|JG<+>UW|>2HJF5
2Y^2URK^JPF?>JF^TI.MUL|/(3<_P.A|<1)|L.P%7B-CF7G^H|7.\$IFL9|@JF+@>^2A=8.X1K|H=J4G.MW6QG|ZH=7M|HZUO(AGB|PR:|D|R6TEEB^.%>2-
KEF^#4J|V|YA^YSH=CH<_1|UV^H06.TK_1Z.M8=4|10@ZJG|CWP4^U@EV^JL6V:EYZ=W^+RW:%Z(H)2%\$|K|>SA76D>=>KTO^?P|A83|
(AWCJL74(QY|P(=FCZ:A|H@|A1PQ1.5BNT|_14T_@.H.LD.MT3|B_12/ZG6W^VEI2N^)|SD.B^5S(5H)QO=PB|F79D>|<1C|I6E6C|S
M_@>8*!^K|IYJ4^M.S7;>_L7_|K=B|_WYZ_>?B.B=L/9^<1/3M_?I=LW//^WV=GS|>G;UZ??|AS-WG|ZYQ:8C|P\$%.P>O6.\$FK>Z^Y6=W5;W
MO.|OYE|I^A>T\$=NEB5.2MQZQ|_IDGQ|MEBA_I>|8RFEW|_D)MGU=LY6CF=^MND7L.Q.R5DF&I8U8>2|HX.(F82+EXH@>
M.ID^7+C9_=\$U\$|N@D6^K^ZEF7A.I33^Z|NWT|Y\$E\$<_M.W5>#%6|&I^SPRB^Q^U3&I&BH<&73<5J4|J\$V^NDX|I@N@J84@X?Z2?2M>
|H|U^P@I|J@H01Y6GQ|O39^T>P|^I^G&G.P|T@CK0*FL2BU_&|_IY2K=C)|M(5^?2."GUFD#^|O|C.SX0.YL|QN^H9|N^>^N^N\$._=1)T2?2
GJDP|UJZ7Q|Q5@M^R^0>ZCA=GHK8I6Z.K4^7UC@A>2H2UMP.HXX^K|Y|_S0WTE>2MC\$^L8UQ0Z.U2V.P@R.M_@G^I-
RM9B&U78Q\$&ZW^VZVR%YYD|9>.\$T14X9.M^>99.5RSIXFK3L2Y^H<VY>^LEI.V.8B^4DTAJD_C5=25F.52LY1C|Y^D+|@>|VN|9@L5+8
MG^T8Y2@O?>R3?GLKQ0NBXQ^N=I2(NM^E<6IPU32|N^%=&86U^D52)SRF5C.ZYH.M65|0HT.XG4+1|SEE|H
MBI<9C3H9K#>@<+|12_Y%*F.%W2.ME.O5@>J&D^.\$XX^VY^\$9^\$M^>RW2V
MOSFBDZBBR41)H+049+02>@K#E%GHA)AROHN:3KU^K|P9|VOR@J|91MCWO&MU_4A|U?
S03K|9|_BI\$0|H(713Z@C^M|)5J3206FOZZ=AWJ4|L9N6|12^MF@Y8-RJM^7T_4\$YM7B7.O.B9N^<K_.BY?|_25LHT#.RV2L5VZZ.M^>
|N\$RH3|2D|_4PC^H2|@8@X@2>#6^<|B(K5|V_..LQVDM=>J^FC^@N^<M7N2)24J+|H|MN^=<3#MW^2SU4Y2GJTF1(EJBTV4|)Y7G^2U3)C9S+FP2\$&F.
M^Q^WT@B^U|DE|)^<|>D5&^<Z|5R4_>10/8W|W3^\$.Z4&D29F\$S2O+HK^\$J6X^@^JZ^4M.L6ZXOE+N_M+I6\$|_K?Z25QQ3FGV?K>#S2.FCA>3
2EM|L.SD4^Q&^V.TJ98N|G18|O|M^3|BPB^1#8C|RE=E8Z>AD|3142D.LGG6.B.BAZI3\$%&:UGM^%3A^)%%&H.Z4.M.09."P=HYPZ|8^|_SU6QT93^Y?
M)5IRL|^+V6H|Q19=E#R61LNSWC@+Q2JH\$.M.X6\$.\$2^EQX?&8TZY1@DFM^1^I4A@KRM^5\$.EK9&#D)W17C.75.TXPZ_2.M|T5&C(QI_>FU^Z|E\$T
R24M.L+|OKK9R^|_J7G|B=K4^+WW\$WX^|_E%M^73&K&J51%2\$>AE>|4Y\$5HHK@/7^K:49G^LXGT&E%P@>+77M|Y\$&X#1^M|N9\$723AQ
R2L@AJ^5C^>JG.6R|N.O.I24M5|>I.R|B^>4M8^>M73@U5L.M%N^K\$|LX1R&8^<P8|S^K^T^G^PT5^&76ANJAYO=GE.Y^>="T|I^<P|G^W0-6N
M48FE9("^^ZUI^Q+KTRIU/01SAPMKY)3|Z_#>|HTO.M(FWD^J^5C=<4)|BM+9FP3/\$S.QFBI|CVIY=9.5&TP<+<#X\$-|MKKK4|3RXF
MDY37P%&9|>T^*#_#5D)D^D^I^|_G.6|E15.7+|(PN(K+K)8ER45G3<_M^XF9623|_I|_6#1^1K|H|V.Z4M^@31Q.L2S^+|L3QG63Z^W3R|29Q?
M7+R+H_>H|I?>#_MF15B^|/H|HKF05(2GIRFO(7M^5=UAXTY92P>+>2R.M8^#U7OKH^|S9|Q^E12F6|28%WK@X<O^D^Y9UQ|6K6K^JO3N^
|^6%YGAD^2BZP6&^7I7H>>|WZ+*#M|ZLXT40IU:6^|YK.XW^4.X.9_>LW2|B=*_+?IGQJ-2>92|Q08D%1Z^*)W^M^X91#
|E\$+A1+|H9FZN.Z^<1\$^Z1^I.X&S.3ZGT+|8VSI+ED^YR2P^*L69J.M8E2(7|L^UJ+&0L^<@&7HM2.0
D6<2.F:3#3JUXSVEMW+|C67)367Q7T)\$%02TP|U@P(1^%CIGP6.2AW.MTU|H7E5C^+A1_>DPJY#P?&7=CV|LVJB4U^4F0B^E\$?
U|_I@+|E|N:8SLM^%M=(((D_N^Y>X0YW+^SI/H=LEE(2-9E\$SR@CQ+Q7\$|SIZU#M|TVDR|0>_>G>H|K3|D^C^10V|L4#P\$E|_>8|EQCC|?
KL_>7A^"F.P|_2Y_>Q^O4FTY^1F|_)(RE+UG8+|_M|^+T.L|Q0SS5EG|U.M_H|Q_2TP|Y_>470PY2RS\$H2A@.DR%PD3|J0|&K
M|C|90|80(5\$4P<79\$X0C|+^|I|Q56C^W5\$|CSPI^L|_<=>2SSI^JX^?L^M|^F|T^?A\$O48|_M^7%6G|2N|O2DT2^YX|1^D
M|C|J\$F32GED0^I^T.EBK|T|65FED3X2|>#&RTH\$S.A|H2V\$;2-WN^MDK.L|L+0B^*1WP+|H|_I^Z45>_>O+NW^>4RL=(D|T|^#0D<E@8^6FCA
M|H_5>|CUX_="1%X^%9ZP|_P8T(R_56%E>3YAG4HFD%15@:#F.F/\$*64A.M^>DU^2F8|U|4EBG|HGG^>YG|A|VO:6Y#<KM=(<#<=<DZ#^P-
/H|7CVHG^>_&CCT@A|N.H2=K&S=E|/U^2^0|MYT|<^M^J\$O^T^|9|6S84|0>DP+|DTCO1M^D^H02W|Q|O^>3^TKS9.%H|T?
MWY=3^2|B(\$P|P|RND|D.WXS^@8J3WEGL400^<U|UQ\$=>J|R^J^2C3^>6D^D8T&H@A^ISRM9I7H^R@|H290.Y&G.MCPO.OUEW!
(C9L0F.P^U3\$1W6W#P#+_R+F9E=\$PD^>#3C5X^/PTT=6C2-Q.M|ZC^"RL|8PQ4HFA^A|S^J\$PAT.P24S2HZMUJ|^&G5Y8.>OAI^X_@&HC8/7H
M=(1\$J94\$|BXAT@|MAX^A^H|^_OSR=1.O:28MGB^6|4I^MC^>+T|L5Q4|A2.T%8^<|T|_I|P^|A|ZL.O_?WR=>#&B9H|Y.C|H^<63&0>
M|H^SRBUX^>1CGW%>Z8>=>0|>0D16.FD.W.FA2|_<P|F7|Z(26|3T.B^<F1^MEK^@QXQ^GLS^SE.NU^Z2|QN^X^>?GGTM2S.1N^7G_>Z^?JH4AXA6
M^G?XE^5Q^<4H^M7O.X+|^#>1U_>(W&^JU0Z%3B&7#&9.F=P^5^801D9LK^M.S0V.D^>_84#V|VP^R\$=|M@=\$B\$|T\$MGM)|^>
(11.6CCR|F^7|L2YXO+Y>K5Y2RN\$XZ_-E>>KHZ_>I\$M(X_1|QT2V6>TD2(LD|8Y|H2NMQAGUNM&K|_3VX-165|H(C^I4@Q.A@M
M^D96\$00.F1\$UNR|BC^OEJ72>P^<|I09#^|O.Q839>G6^BPN\$^N+<K=&#\$.TSADM^>QJ|B182Y|E1)I6GV22O3_2E|H+M6C^A|M^ORX(A@193^)
^V_29W=QAHX=4^46=>Z@%16Q33R^S^K^M^2P|P^FV>^E-U08H^#EK|_I^M|XDCW6C|QRIYODQ#_U|Q^>1SE<#^XYA5X^|KE.73Y;
(H|CLZ|66_Q^<LZV1^<K\$>O^?W^P^<K8\$B^+|Q?Q.M^O|>=A01KY|+&C&A|&S|CC+|Q|Q|KTR|C^>|>AQR7&<5.&^<S|H9.R^=M|Z>S_Y^9<1#
<8^M^J^8&E1^6.Q|FV^CTV.V.3026V.1G>GNG^<|3V-PM7^<K^A^M^\$^*Q#XESG^X^%X%|&#%2|B41G9T>_KM|MZ|1PW%?G^<5W^<|MU6M^S
M|VY2473X|_GBY23|_#9=O5Y^>FJR.SR17|GRPW.DV_2^QO|O|H^+BA9>^M20.J^E&J&P@5|&P@5|&^25"E=|^C.OHL>VHWD^<N^C^Q^K^N|_|RVHF^21
MM2|_O_>H57_>|CH.YC.370R&725APA4|Z^E72/P<_U|^>F=3N|C|^>WB|_M|LZSY3^MEOH%&^&O|H\$0>|Q.Y9|OEUIK=P|HN>QO_0\$Y?
U@B94T^&L.M.LB6>|^<=>V&A-IDUDAPQC#0@<4<6@R.T+T.M|H|_!DETT=MZ(9W%C>AU2.9.MZ^A.TZ7U_8|T+MP|J^?H+MTBRW|M|
MB&F^|PMA_*ULP4|I+YGAH|U^>172_A.R-BEXWRW|O13R/GDKD>1Q|V.M-OWE.T00^0@>N^FM\$W@O07^N^<=>Z^D.B
M_2\$X\$;L&H6+|^5^7XB|T|O_A52_?Y.M.H.33_>K>OCZIGZVC:Q.G<|^M+&EYL+|B|K0\$SFRDC>2G7L|^+M^XB.MHMW^CST%|^_J|5^|X^<=>%"^I^D
%4@>|_C\$1<R^X|CJ|Z|S|D02P2C?>I\$^M+V9+N&132RGH(ZX^6TGTX-WHEL<3_>X4D(C^M6H_>D2=0)|_T^>QGG\$>ENN4GGD1^02_>14D|Z_|&EE^*
(L_>BOP7X.M|EJ\$Y^>D^<132>|5YPGR7Q^032^G8\$PK\$V>29KCM^DYLF2X0U.T^>2^>H38|L.MHR>C|H^>2ZKWU^ER92^*OK@
U|>|O4>=13DR9^4TEA)J0#\$.M\$S\$V|S^MXL23D.S?Y64@GW.P.TYV@<K.G/C\$|L>5(FD0BEYZM|7>88|&69^TEQHZOE.MEC3QNMQ06
<D^>M|H.59&DEB60+G((RG|P^L.D\$^<V&E^V|OZE^>27D|H^>L^>Y\$|F\$F%>0AW^GE%|>TRIR^E1Z>^>FU2^>GH^>L4@CY<S^EX.79.MQ|?
?^>^HGHK|H.O.XOP^>Y2AB1|W^>^>S&2>=>T^>A6^3YW^6|5_>O^E.M(3O<+>YRT4.W<4E_@>H4|I6|H_|&S|HED|
M2\$;98>|W|LA+&^76=Z5U+4LGU_>@%#>WX.2|R_H?7Y&K20R+>29^N_MW50QJ^4|DH|_|X|CIP|C|F|X|L\$0^>?>|U699|V|M9N1+H^Y^H|^C0^A
2MD.M^X|_3|2_V.24JQ.S^1^I(CZ\$S.U\$7@L.H0)4E%&1MZ\$S^F^H^C)YQ8=D^9N8#M^_I_>
|EV_6KMD|F^B(CW|LL8D9F20(6|Z9%Q3\$VJGFSU&S|A^K^?U^!^T^MH_@>@-
/K&7Y66JX^>H^B^>Y09MM<#>9|H4K|8QY|48\$QTT\$K8%&EZG2EA47&TP/M4|_E^Z5^>P0JH_>|H|JODBH|K5|^ZMR<-
_1_2XNU&?>_>L|D9)60Q|HMXA@&I^Z^W+|>AK^#18>DRS-B.M|19+&S>A^I^KTQ1=8Y3A_99.1.P:H8(2L&^&T|>H^<^|AHM\$;YK_7AJ#P0@X|
M>H^|P4K^&E|Q+>?O^H(C=7UZG|UB5^|/C<=>L|(1Z81.M^*!|I^G|9A.8.M0_>1^G#>_>GC1KD^P4H^C9@>IWLXOVW(HWMDK3)S|^70-
M^>#S9^>D9Q.M|H5WB=Q067ZPE.63D\$ZRPD2<#FWL^P\$YN.1T|3E=WFQ^O2G^W^I#2^L^>6G.MP2D|WA.(9|>X^H35VGT2|)%|
|M|DZ80>=7KHJ<#X|O|S|M^>7>+N.1C1<N\$M^E7+17M|J\$S^U6B^#42_RIP4_N5=A<G9^C3PX|H|^>C^<M^QTXB0R|J
M^T^M.ZBP3>U\$|H\$S^GDV7L7.6F^Z9HT&L.RL(K4GH<_<D4|5X>^!T=0^K.M^5.E4|0:0^XDXW^O.3V625^?V\$VO^<4GH|_T|L\$S:CZ+V\$VD>-VR53%
ME9(O|22HRZT^&Y^%295-6D8E^ZUBV@E|H.X.7E^XW^VEEL^>MWX3T97=F&QX\$50|3|3D^Y=X^TQ^2_1B38FV.259T|I2M^XL<9&K^IZ(FP^
MCYM4OYMA\$&IM^9L|(5A|+^T\$@<#|M|C|4LE+7PR3^YU?3&H6|OX.%|B|B^2F>|>LVB9=X.M+5B=
(+LR)4UR0^T1+X^J\$46VE^|_I.M+V@>3%R^6WYYGW|9|.56>|^1.6600^#6@LU>0^H^H46BKP_MU^6V.NOQ="LOT@456K3(P7M<I^>4U>Q|H515-
4|K182M@Y%Y^HVN^273V=T^MY.49G^FL^E|F5.9.ME^>X9^CGRO_>MH2ZQO@_A|Q^>R|Y|H|D|L2EV^F3H_O4|^>=UA98Y.6<71M&|
(2|&4|3.GH38)H21F+V=9^JWJ4H%8+V9J_Y>>^&UQ^KT.U^*@.5@&#T)T(C^EVA2=|X^>XR8H^42.M598^F^=XX^AHP<2<(05)^*&^&^&CD;L-
>THS.^6\$Y36^N2@MW.K>W|9.M^%3.Y7+CIUSN>O&8A|A@E|H7P8&4EP3|13+>E|HHU+|M>^<H^>|N^Y^C.HE<54@>9|_>1^4T>=1^94_UUEI730?
Y3@>HW9^>+4E|I^Q.MUH(QSOLR_2|ZO4.89%N1+HKI^>IAY^#^XEA3^&C^<1D^E.Z2D|ODMDG^M_@&#7K#>V|D^<@HU0?7^>K^>4IFRN^UJ&
&D^<C<0\$CAIKGT^UCN^|@>_M9(PJL.L^M8Z3+6^H3X=|_H^M^EPI|BB1U^F.R+^>STU|DK0B18^10^%S5G-ME)^#7&=5>I7E+OTW&JCP@>@-
_>C^>8^>RSF9&^90T\$(E|V%9OH|R0|GK#2A.MK0RFD^PXU4OBW3M|6%VYU>C4P(L32^6%L0.(I=D&^D22|N^M8)0HRL|
MU_O|>S^WIC^JQMG^ZR2982D=XBCRW\$S51X\$3(D)>W47Y^I26^H_>H(D.TX-MA^>#PFC@BGVH.TDFB@22+&
(6Z#^|C^1X.%1)_>G+^KXVB^A|2+&=>U2&7.M.PW&X^2|Q^IW.23WMES^>SB^0\$|DPF\$B@S-Z_>?>T2^XY94NDOY.05I23

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f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

(/X1A16:.9N;2U<JDU>NR#;K9/7-/NL;78*DD3B*#N404H-1>VDAPMIZ4.P1*ME/5D@U>3/VZ-/;YO*D^I6-AIJSI&*G-I(QS^00!'
MNA=FGQ@99FR0>>DY V26!0N/)/AG/AAG2G3.M.GGF&1.10U1.NJ1.L&+X3(FY(#!G(29H19PH'<#M1MFOY4=G<141L4)BDDQ&%;
(\$LD13\$*B0TV+;C2!O\F>NHTFJL6/OB.M45!"*N=J/(IZG.Z^Q\FB!&=&YF=L)J)*%3L8.4FDC#1.PY@/#\$FEK.>*\$S\$D M\$(4C.W;C1=O+F?)@!#PG6@="=
A6S3K.I6G1.0<J\$3&D<+H!\$N.2QI#M+M+QJU:QI&+1+U^H!H252YV'CA!\$%6BIMS%B49DE6=<=>Y&D@3G8I2131I9>=M\$1RA*QOTUL^\$1P;@9P.
\$7D';G6@EFM6.D#VDH.6!M.B4+!J@SM.I@WHS:SS.MZ2.615>?>XD0=U2@H+K+1+!+1*Y@.6H5-*7;G.S@HRZ2>C.PW5<5L4A\$X.
MGB=Q<#U.LIWR=Y<3.YJ'8'/'7<#;SX7%IR+XL'^%>69RXQ Q#)N8LS<R&IDB M+!X\$!O!3K3.%>@ZNQ9:43L^Z.7=W1%&IVN<#13ZOXNC MF
:SHJ2C.+R'R4BN72\$2U.%#(D&2)\$\$(D= QZ62C&.#DXFEF4H:0615"H0F56BNHJ2!MIA:1/@.M<*!6@B.(P6+!N8"2V%+M^%:2TQ=1ZU2=2J#0
F^V.OPSQ7\$ Q2V!W>9#@.M0^+8(BKV.DR3G=C.;3P>SN?DL!H17672!<C7.OHW#TIGV@G.G0Q+(6JK!M+N1&4PE8E(I+&201):NHJ&
HUU+J=DA;D2KVM+<1GHZ2.RAB2B+;DD.2!^2 MYR!\$//+RXX2421C+J.L.MWQ%^<U74KU63FT/QJ8)&Y'/'K7CZ%UQ!>B<=W(W.MEVJ>1P.
_X@:SF7BRUZO:1E(D!NIAS.ZVQ5<^N;.%0)G3CB M>1*44TJ.0\$45+!+>G7L36D.\$OIW^\$J5.%0Y^@J2/ROV!\$;DSLOODXK
M9=F=W8ZU%!=:@=L*.2Q\$7!AOX1.TIAA2@FAN2TJUF.Y+82?W.<M?GZC!M+.VVGY8JKAG!4.V:>@M&7G62L>3X\$%+!PR.74!
ME0J74L!GCL!SA/7&.P+SEX58HX9^00%(D@A92TMH2S6Q.+G6+N?C7OG6>MNT#68+?>O^XM.G#=I26!D(00T8CS91\$<7Q2"PC(*XR^_"(ZSQW
KI+G>EDL\$*6-CFKFG\$R')\$7.*881#MI=ZTUFZSQW0K9C0^T=Q-Q@MG2=TEB>FIWDGB3<.&8L%A0)V%3"&_A7MY>^GZ3.*1OFIU?
G>3U/0A.FD@Y.F.M0F9MCOHH9^Q!N+AZ*8.TFJH=3.*6C.0<7G3B!O#KN(O&S&U^7=-#2P&FW.MPIS
^5.6B5A:F0&ST.FI<1/0)H.L1'8^<.GH^CQ.N/P1+2L/5!6(HHR@U2.M08C(49(00A%32YA5Q2^!^+E6%+E#U'B)O2@X?VPOHJR9!3E/QO:IU65FT3B
ME-&:(9"!QOB3VR(GJ4^2)AT24#F^T-OJR=2R98^WLDEK.T<"&62&-IU.B.MMH9RL%RXX!Q\$9J:;BUH8F3!CK=(^F>O<9.4E!76?
4S;.*6%Y2XJY1+!B^&4Z4C.(C@)!7%4!+Z&4C5Z@.*M3D)ZGB=L*A.@AN.8J^K'G2\$>M'D4B8*30H^R'RBWM^X^R"V0^AL'G5!1MN5\$6B*91&
B7M\$0&\$X\$P\$XYD0T!(A2:A\$3^@!1TEP>47:3>H.8L8%&XRB#MD8@.#0P3)Q#6CB\$1M8.8!"\$7XIOS3Z@!(H1LMP>47<3A!K31
MWRT7:50WZH/A.HNUBZ19.>"M=0A!H1"W.XGWFN/^8J4IZ.U^4.SY=+/>GEF>B-W/B>1&G COH29SE>?#X9.MYO^C!..IN
V#TC^BA)=!GPU^+!S;^!A<PI&+&0Q/F\$11.K)5@+!F^A!63"MQ^<M?G.GLJ7H93U>9VDTB=V3;B.+Q)QB8".8JD91JY.&7(\$KA\$A\$LL4G-
B'MC#2L4A.EKMWI5S0KXW;T!5?WZ.Y11.9%3>2IER>G8\$JS<#MBIREAFN7O.QKC0O.KTV.)MIU^UA!^!<77;NAQ21.#*#XK
MV85V=X5.6)"LY'E'JM.V?2P.Z.H1C1QD!R4A?O)=0^T>3>7J.95P= P.V.MP&2H!>=#9%YAGX/KB;\$2\$.RB))\$N3.;Z2.CX2D+J6M+UI>EK^" #
MP6JGQ1#(GHCHVH31WMY4NQCZ@I^P08ID/YA\$BZQ/!F\$=F>68.MXPD>KU\$OVJ:Q.WH!P=I>&.>XQO+8I4@B>.&61D0>IDQIR9!#U@9THQ
MDI2!D)*SX:49B!6+/@JCF72E&PP2?3-MH>#B.C6N!V!^FSOE0?A&E!Y.T4LVY.BS!/1<(&T(PK)1&@SFC/2S>0
MYX!>@>O=EMSS#6+!)RPL0JEQ.^DZ<=&6ZN^TVGL5\$=S/^4P>L80!8!\$M8!<X.XJL8@L%CO8G^#B+IRPEADKNWZWR2!M:=7K'9#Z.K?
J5E@!^<AD>G9.MY\$>AS!PMW#ZB+!Y3\$Z2TL2!L!\$>1U(G97.1+\$>.&HTEA^8UP3KTD!S.MQ8BO.RRFHB^P=I.W\$%U!>9!OK!2H:AX?D7A.M
7@.^!4.WFSBUA!<OBZ*YUUYX_6^@F*IE\$@&O.#72M#GGIY@)YQ&PH/P
M5OG:R7BAF<1D15XJ\$PISPIQ2+!KZTUA&E\$4Q6P6T!<BY2Y!92>*D)MQ.R= %<!)\$G!+2)CY^DR@T66:6#66.8MNT:DWH_9#?
35&7K0R0%:"KAV=+!M1*!T6/*4Y42F!+)=!O)R(2IP+!416D8>26FIMCMU=2815-+!GD!KIVE@&=9>M*4@.YHPU(4I23+#!1)!YE\$VV1X/@6/
0!QC#C#D!A.91^&BB74+!TUEZ M<R?C&XLB N&U!S!L.PLLOQUA!E(CGC#M2!VHFH514V&J8OIPYK+N@X
M37D!3.AYD\$C.3%+!21CPLF^966T"N7.;<R!TX3F%G!A=+>6Q.ZRV!M.I.N.VK^A6A.%L2E=I82N!C.G2A@C=CHO:WO3(K^*)7:O6ID
M<\$HH42;\$!E195?Q2WD94DU^VWM2N*\$0M6(\$K&?H0W>Q^6DUMX@*N+O.L.M\$V4;ZOIP%@@WN?3SWJFHR\$OZV6!0Q^*JU/*8OXG>ZAE?
YK<^S#HFW!MD0@LJZ.2^C(W<^B'W#6OG^L!YJ>2!X12E@&AL+!Y^XYM^&9%2%29@9QE!2.D2.MN!+Y+2!HWNW5T^CRBN2.Y5Y.WY2D
8C!QN=<@1^&D60Q@)2F@M^EW97N.MU#49Z>Y+!IWL^K&(XFE^T<_TNE28<KN.%O9\$>+?2_8X6)IX@=<M#WMA^M82A>>1.1/7&J623"
(BPL3/9)!S.#^(@9A>C.%Y7S.CA.ZIGHIU(>HK3V40C\$BD!.\$@9T!>DTKQ<&M+^C^T3RUMR6=V>=MMT![-."^E'9!)Y%7!L.\$(\$XCYQ!9#1.91!\$<
MP<*7+FTL^YMH.@<=D.HOA.C>ZOMHOJM)9.TILC2^Q.QCCJW5\$C(L!3!M.0\$+U/MD^MMN2>QQ.73.XYB7=H\$E/AJ!#2IV.Y#ETI2?
SL!G.YZ^N7R.MY.#3/U^<.G9QIN7JZ9.)&6&KG3_2LG!^GOR5F!XRM2!IR>K+NYICO)M<8G.RX>C%\$JO.6..N0Q>*0#A!%JLNTC!Z^
MGN0!<X>M>C3K.R26V7UP.H\$!<E.NYUT&\$Z!)H0\$2W\$HXPZ//+W<1!<(B!RP5OHLW\$M2P.MHAYBN.<E&E!P!T+WL=)!^<^<@ZC;
P8<=ESBU6!Q.B.\$Y923^F!L^N(#38(Q!MYD78%1!+!+!+!BTID.^K^UOW4SOLJH0UEIUF.JOAP2!C.7=?YZ4BDQ2.6@4AB.M<H!@^X\$MYADPC-
IV^*>=.6S!8H11280<_6Z4.JWQK.Z.-2#Z9607!G.MLPPY23ARRCHPP8B6MK2SLX.4EE1F^XQ?3A(O/^&1!>)!#>A!^+1!ILU
M!"FF424"!G!I\$""K2\$32:P4QM.&TH65:XFV!V.LO.Z4\$7KEJZD?X8KB=<M&\$*Q0D8+N.@H4@3C5&@5LKDMS&6IQ
3/4BK.-7FC8RAOQ%IX#;R^N\$)5W6.ML^7IW9!5>_TIGTRJL4E5.82!OBV.OOY8.U@.)C=2!Q/MH.;B=QP?JL(H!)OF%JOQ^GYH.M!S>Y043^Z7);P
6HR>1!FVBE.S.IP!V3NX^X7.E0=F%>&6.U+9U_P9!M8^C^T;XHUUY#@VSF^C.>CF.L!C.P.W&O)H!#-@<!)1RQO.MC-
B.R!1UJG0^!8XDUF08TDQZ!H=<=C0!Q.F=3P!W>KYQOUEI&\$3.Y=8K^M.5F9.^&1@LYZ&2S^>FA^X2!IMX..00S9F@Y\$S-
@TEH:A&DNQPE4(X>I0IYBH33#2;KBV2HE&B77!<MPO>&^S\$H_2.1!<=VWO&:(.*4.;6!5.CTM=0D;A2*WFG^HWU^Z5E+!L&L
MGO!^ACTH=Y.;.)8#+!HZN8Q^P!@1R(O<L.B^P7X2!E=<5BSE!BQJ2YQ84?A<=3W)S.M/N0QLXC3))&VH(M<2XS!G^6.=^K3W?
TQ!0!H^SU8.PPFT<N^W4ZQ.0!L<O<MV;DE7^<G.Y^G^*>(&R*21.3YU^1G8X%?21T<3SVU.MITLLSV!@&KBW!P?M&\$>LL^Y=21^\$JH5F^0=)LXY!
M!L!ICQ&=!7L2E9KD<9VZ!T9(\$DWM8.=@CT6"DL

• #+JD51.8?W3616V^M^<G)93#N:EP3>UX(!^?2X).3R/>#JDI^*3\$ME%%.211AS^3IX;FAGPF<A!U4X^B;D!A^F!Q>06RKW>AX1%(K\$U7F(?+1+
MV67)3P^S@DJ94PF#^BI+ZYV>C&F6ZNR=I^<Z3;J2K8A!HW=^23S^OY.;Q.M%.\$Z#Z^THJF3(S!A9HLTPAD#UZ&+2Q.MW%8HJ1J5-
TFWHV<=<ML^>N!J!F0%HDZ^W\$4^<^>U.S.Y)YH\$1J!ERGD!K!\$5UEQ1.9H!@V!FP2?P3TPBOW3T6P^E7A>2T>XMFDP^DWD.8.^>0L.MI4AAH6@D<
2HLLUW6FKH!QK\$DKBZU!@O&X\$CQZ!TVPCL7.;Z04S2V3!4.6 M9N-1.;)/@(&A=0H2!VNF2-ZI>+!WMXIG.TGV@!N!L.#=<Z2!9RG5Z2J7Y
MS&)&#A^!+>XX!V!R2W!A.CE&?H:(V7/25S269-965IXLGF0^<5^7!G.JM.MI.T.PD/TWO^X.IO\$SGHIVET3FJJ2QUC-L!R@P8A!Q^G
M7\$2)"2P9#93Q0?G)G<R.HXUJU4!C&A!A5.;>A(ZR8^DT30G\$SDJ3.MY8XQ>J!+MU!H.^+>0U^Q>.\$@CG!G^YGGIGKH2&G.Q6C.Y8S2G.TY0<9K
M#BUCK).C93>C>@<IKX7>LZ.;1<(<R/L.6%5YG&+06!BK.I9PSK^!<27.M2.6(HBI>!)!%CU58A+HJQ#W/7&H6AS_OGA_!E
P^WY%873\$!PNSQ@1&U.M&E.\$()>14Q!PVP^!X25^HKU=MPU4>#!M.N!+S7Z&35Y!E@.DD&6JD#U0G.MI!^<#2BU5+CF(S!ILM.O!<MSIE;
IQ7!D)IAEYUWB=I\$<7&4^B.B.M4T!<=U\$PUD.XY@/C3D8B9Q<H!2!BHJM.!^OYG6IV!YAR.R.6R!X.B6L!Y(A&#M.OQLX>20H@A)8.W#\$X22WKL!AUN
@VY.Y)H@OFTH7ZG.G.T^C.L^XQ^!)M/BR6/G33L^QX+&68PNL!O4.OVUB#TIHR.OHU#8Q>K^DE.68.M%9+H0&LX/P!A.G^PHH630"U+&?
S!25_8\$M7+TE62!O8#1+!O^#18^SS.E0!O49_G30!<E^<#&N^M!V+M0X!ZL5!<IVRS5.2!%!!P^V^CW3=CR0!L.M6K^OFMD/NXF@.8BN8OI
M#WJXRZ:9JP>L!7K.LN==M%&H3O.UM=OP.PI.XTAVT!Q.%W^Y^U^/H2_3= MW>_2.;=W^=2ES^QR-KG0SOZBF.BLLB<^R!<Q^K.;-RO.R-
XC@/THWN6.M!<X+!L.O.S^2SKYGWK8>Y?MHS.K056!7M\$>[RCJ!M!A3M.O= B!7!0KN!A<M?YM.OYY!AUP<!)^U7K5!HHJW\$G(!
RMGTJL4ZZ@O!P!D.#R<I82.E.M#>[EP#E^K!U!AHWR7!A2&H4(214.1G.9Y2.UV7S.N%JAH!^EDM?5=4^
M!JZ09TNE#HXV/5^J6@+HOFBM%&D5E?X)&MGAW70P+9/M#1;LF@HK>+53.M&VOLW^?<
3.59Y^Z.9W.IHL^G9!9H!T^4!3%+!4=Q0.983!F=PO!L/KHN.M!)2N7!5=ZNB^&X\$4!L7X^Q!X<%/'4FG<73Y0+9.TP&6Y56R5\$2X(BXY'
M9!Q3@<B.Y;LEE&Z+J!1=;6A!NX^5X6L.2.^5S!WK0!L^2Y3K7!ID(C!M=206X&B!L#A!@ESTR.C6^B>ISYIG)W62!Q9_8;Q8O82SDAK019XJ@%P_)!;
M.ORD@5!2!VG>A=^OUF!R=+!7!>D.U)=6AJUS:4@DXQH9VM^3XTWW/P0.M&!"X6!V5!9VW^+!7(#^BG%)DMPQ.K>)M6+9>D\$!9ZQ-
6V!%&87!2!Z+M=<@QJ5C7=ADU!HPCEP^R.B2VX^DZ=SI7#!OTG3RL73B3Y?U^!C7!S#%JGVX+H#M^DHWY\$ON:5(C.171
!6SP!(Z^9)Z!+D!5DI8KUB^H!W\$YFL!DH?#E!O-M8\$!DDO4+UN^V@C%>#>Y5G.N!X+X2X2L!V.M5PNH(RAKA!/KN).WC3_Y^?
^DY^X&S.AOR^Y\$F!7V!O:A9QJ^EL=.F&M!>3D!^!#_QC4@^SG;J6TU)!A!BX@/!@:#W3#^Q.O.[P!Z>S0NBN7+2F9=<1
MQ\$W^J.W!E.9LX\$ZV6C!#N.HH&4#J23(H!17+>OMH^Z\$6^1VE.X.L!N3.M!RA^5.O!X&S;0^3L.FR!P2!J^VP#3^C2/Q@9YQMGL7WYX
N^M!Q4??!+>QEH2O.[2Y>D6.;V^<L!P0K0_Y^04/N9V%V2!@8E?J.^/L2.MD.#!+>EA!UR2C!OHQ684^!K#W!H08^KOA.RXGLJZDMVK3Z.E.2H?
NPM!WG9.D9!65JR<?&F.O5.1E^MVN!CUP!E=AKS!>?>D2A!VY.M!@<L.DL3!7^VXMHF!P!<1%2^G!<W
M^@/ETW673J.C)7.#HT+NMMDMRN!O5Z5\$;9^>V5K9R!QOUSB.2A:#4H<.MKKA9O6^H_!L-
HHE!K!94!>C%.DMX&=CZ.R>VW!Z06.P!VP!ROVF=F.MC?-?)N!^V^FTIN^B&Y.MYKMN^YNEU&M4_4!EW?W@M!2^F!M9G^N>H!N
MEU!U03B^<L!33YWLNUJG5!Y7O/K91%28L..S6H!E=WYW80^@&U!E!5#V
MOVN^9&K65.4G=Z!P!C46.AK7K5FMSP&V136V!S!SZA_3^=&S<>VBI3J4.M!&ME.A%0^C.*7MR0!0\$<=<7!>=J+%;!R@!L;.\$H2
2^U^H^Y=N5YCD\$U6V^M!HJ!G71!)@M!@GMS.O.A!F&O@!<@W9)=!>U>Z!3LB?<^XFRMMOXXICYM3?1.;#W!ZAR^EBUD13W^W3!5K.;)W!&X?
43^YH6P!<2B!V!KO.NMNA6?P>3&<=<G!K!7!H!D!S!^M65L!5!Q!UR>1+H9&0^4MYRE9H^9BU6335C_WAW!Y+>MW0G)ED!9^855\$=+!<
M^>0/AOOG!713OM8^8^>?K!T!Q%8^6!O%4!W>6%Y!K!5B!8^Z6.E^Q%\$!M0VTVJ#)!A0!M5XGO^H^&T02@LA_B)3S9XNU
F@EJ@!10W0>9^YJ>J!&S.MSQO.BL&8+Z.;^#X=U7Y6V^9!L\$U!U/H#%180G!FVY?Q.M!&+9#N!JM^+X5!HLL..8^KDK!2R!25.R+84^D!L-
K7V!E@Z=C^LUQ.M5\$>Y.G6H^6HJ!>Q!<H.G.KB5!L50U!>#9>R4J#567G@R^M^*Z2.NURUR<^8;N=N^N
<@_G==K!<N_K#_TX5!MXC6;#^C);Z5FZG.30.MKS+6.(9EJ^VAW6R\$!8^L.BEDJDL;GR^4K7Z^5UMN!7LMP+Y6!V!G!&EJ!MA2^H@O);
J5!N@=<1H^=<E!>^/O!Q@<#N!WU02!7L6!D2.M&G.T!22UP2A^8.M;5BVG6ZL.K!M^MTP3!^+!%BO+GT2!9+H!PE@MPN^!L^T<2!K!JP!G!02;
M=5K!>3P6P0IR?7UR<J&X<W^AG7K8GO!A&V!S^<#Y>#CPR.#Y9.Q!<Y^HD>GH/7LU^?CHUIH2%WX=7K^1HLEP!<6VZE.^!2?
5&GHXWXA.M!6CO^H.A!V!B!M!XMB2U3+R^U<.^?2P/B!<^25.HB!<+V6G!O_K_P.O.M2P\$%^%.4"!\$@DO!<O!YHA^RZP\$@<@<
M83!QBRUS<=&S;6!E.&5T=&5R>E8W!H!YXN!^1M4\$!L!A0#%@10.M6O!8.T@<S>D!X<L!UB\$&S.R.64M86UE.F!M96YT
M;FR.V9S=&J.C!W!U+FA75!+0(4Q0<^2^3%&H!)Z!24^P%0>M>5R!E!>#Y2.U!<G-I9&5R=)A9&EN9W!O!&EG>2YH.M=&U02P\$%^%.4"
!\$@DO!S^G^G2T!<F!BP.#0@<1!M6.97@R.3R.#(T+FA75!+0(4Q0<^2^3%&H)=U4!<R!<T!<4M)=5@<1E^<S(S3!CQ0."UK<=C+FA75!+0(4Q0
M<^2^3%&H)=U4!<R!<T!<4M)=5@<1E^<S(S3!CQ0."UK<=C+FA75!+0(4Q0
!\$@DO.HLNI^C<\$!+M\$#0@<1!M6.97@R.3R.#(T+FA75!+0(4Q0<^2^3%&H)=U4!<R!<T!<4M)=5@<1E^<S(S3!CQ0."UK<=C+FA75!+0(4Q0

#.R.CP.CON.M#1M4\$!L!A0#%@10.6L!^O#67@WPD!X<1MPGL&5X&EB.70R.C\$M&ES=&JFX74!^7%P4^330!0!R!G!M.M.C.R-
#\$R.S%2%&B+GAM;#!+0(4Q0<^2^3%&H)=U4!<R!<T!<4M)=5@<1E^<S(S3!CQ0."UK<=C+FA75!+0(4Q0
20241231.htm.xml!EDA.XBRL DOCUMENT 0000913144 2024-01-01 2024-12-31 0000913144 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000913144
rnr:DepositorySharesEachRepresentingA11000thInterestInASeriesF5.Member 2024-01-01 2024-12-31 0000913144
rnr:DepositorySharesEachRepresentingA11000thInterestInASeriesG4.Member 2024-01-01 2024-12-31 0000913144 2024-06-30 0000913144 2025-
02-07 0000913144 2024-10-01 2024-12-31 0000913144 2024-12-31 0000913144 2023-01-01 2023-12-31 0000913144
2022-01-01 2022-12-31 0000913144 us-gaap:PreferredStockMember 2023-12-31 0000913144 us-gaap:PreferredStockMember 2022-12-31

[0000913144 us-gaap:PreferredStockMember 2021-12-31 0000913144 us-gaap:PreferredStockMember 2024-12-31 0000913144 us-gaap:CommonStockMember 2023-12-31 0000913144 us-gaap:CommonStockMember 2022-12-31 0000913144 us-gaap:CommonStockMember](#)

[2021-12-31 0000913144 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000913144 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000913144 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000913144 us-gaap:CommonStockMember 2024-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000913144 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000913144 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000913144 us-gaap:RetainedEarningsMember 2023-12-31 0000913144 us-gaap:RetainedEarningsMember 2022-12-31 0000913144 us-gaap:RetainedEarningsMember 2021-12-31 0000913144 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000913144 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000913144 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000913144 us-gaap:RetainedEarningsMember 2024-12-31 0000913144 2022-12-31 0000913144 2021-12-31 0000913144 rnr:ValidusHoldingsLtdMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember 2023-05-22 2023-05-22 0000913144 rnr:ValidusHoldingsLtdMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember 2023-05-22 0000913144 rnr:ValidusHoldingsLtdMember 2024-01-01 2024-12-31 0000913144 rnr:ValidusHoldingsLtdMember 2023-01-01 2023-12-31 0000913144 rnr:ValidusHoldingsLtdMember rnr:AgentRelationshipsTopFourMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:AgentRelationshipsTopFourMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:AgentRelationshipsOtherMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:AgentRelationshipsOtherMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:MGARelationshipsMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:MGARelationshipsMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember us-gaap:TradeNamesMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember us-gaap:TradeNamesMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:RenewalRightsMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:RenewalRightsMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:AssetManagementContractsMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:AssetManagementContractsMember 2023-11-01 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember rnr:InsuranceLicensesMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember 2023-11-01 2023-12-31 0000913144 rnr:ValidusHoldingsLtdMember 2023-12-31 0000913144 rnr:ValidusSpecialtyMember 2023-11-01 0000913144 rnr:ValidusHoldingsLtdMember 2022-01-01 2022-12-31 0000913144 rnr:ValidusHoldingsLtdMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000913144 rnr:ValidusHoldingsLtdMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000913144 rnr:GoodwillAndOtherIntangibleAssetsMember 2024-12-31 0000913144 rnr:GoodwillAndOtherIntangibleAssetsMember 2023-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2022-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-01 2023-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-01 2024-12-31 0000913144 us-gaap:CustomerRelationshipsMember 2024-12-31 0000913144 us-gaap:LicensingAgreementsMember 2024-12-31 0000913144 us-gaap:IntangibleAssetsArisingFromInsuranceContractsAcquiredInBusinessCombinationMember 2024-12-31 0000913144 rnr:AssetManagementContractsMember 2024-12-31 0000913144 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-12-31 0000913144 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000913144 us-gaap:NoncompeteAgreementsMember 2024-12-31 0000913144 us-gaap:TrademarksMember 2024-12-31 0000913144 us-gaap:CustomerRelationshipsMember 2023-12-31 0000913144 us-gaap:LicensingAgreementsMember 2023-12-31 0000913144 us-gaap:IntangibleAssetsArisingFromInsuranceContractsAcquiredInBusinessCombinationMember 2023-12-31 0000913144 rnr:AssetManagementContractsMember 2023-12-31 0000913144 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0000913144 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000913144 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000913144 us-gaap:TrademarksMember 2023-12-31 0000913144 rnr:ValidusHoldingsLtdMember rnr:InsuranceLicensesMember 2024-12-31 0000913144 srt:MinimumMember 2024-12-31 0000913144 srt:MaximumMember 2024-12-31 0000913144 srt:WeightedAverageMember 2024-12-31 0000913144 rnr:GoodwillAndOtherIntangibleAssetsMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 rnr:GoodwillAndOtherIntangibleAssetsMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 rnr:GoodwillAndOtherIntangibleAssetsMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000913144 us-gaap:USTreasurySecuritiesMember 2024-12-31 0000913144 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000913144 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0000913144 us-gaap:AssetBackedSecuritiesMember 2024-12-31 0000913144 us-gaap:AgencySecuritiesMember 2024-12-31 0000913144 us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-12-31 0000913144 us-gaap:CommercialMortgageBackedSecuritiesMember 2024-12-31 0000913144 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000913144 us-gaap:MortgageBackedSecuritiesMember 2024-12-31 0000913144 us-gaap:MortgageBackedSecuritiesMember 2023-12-31 0000913144 us-gaap:FinancialServicesSectorMember 2024-12-31 0000913144 rnr:BasicMaterialsSectorMember 2024-12-31 0000913144 rnr:BasicMaterialsSectorMember 2023-12-31 0000913144 us-gaap:CommercialAndIndustrialSectorMember 2024-12-31 0000913144 us-gaap:CommercialAndIndustrialSectorMember 2023-12-31 0000913144 us-gaap:TechnologySectorMember 2024-12-31 0000913144 us-gaap:ConsumerSectorMember 2024-12-31 0000913144 us-gaap:ConsumerSectorMember 2023](#)

[illegible]

[illegible]

gaap:PrivateEquityFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0000913144 rnr:TermLoanMember

us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0000913144 rnr:OtherAssetsLiabilitiesMember us-

gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0000913144 us-gaap:FairValueMeasurementsRecurringMember 2023-01-

01 2023-12-31 0000913144 rnr:TermLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember

rnr:InternalValuationModelValuationTechniqueMember 2023-12-31 0000913144 us-gaap:OtherInvestmentsMember us-

gaap:InvestmentIncomeMember 2024-01-01 2024-12-31 0000913144 us-gaap:OtherInvestmentsMember us-gaap:InvestmentIncomeMember 2023-

01-01 2023-12-31 0000913144 us-gaap:OtherInvestmentsMember us-gaap:InvestmentIncomeMember 2022-01-01 2022-12-31 0000913144 us-

gaap:FairValueMeasuredAtNetAssetValuePerShareMember rnr:PrivateCreditFundsMember 2024-12-31 0000913144 us-

gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:PrivateEquityFundsMember 2024-12-31 0000913144 us-

gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:HedgeFundsMember 2024-12-31 0000913144 us-

gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-12-31 0000913144 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember

rnr:PrivateCreditFundsMember 2023-12-31 0000913144 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-

gaap:PrivateEquityFundsMember 2023-12-31 0000913144 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-12-31 0000913144

srt:MinimumMember rnr:PrivateCreditFundsMember 2024-01-01 2024-12-31 0000913144 srt:MaximumMember rnr:PrivateCreditFundsMember

2024-01-01 2024-12-31 0000913144 srt:MinimumMember us-gaap:PrivateEquityFundsMember 2024-01-01 2024-12-31 0000913144

srt:MaximumMember us-gaap:PrivateEquityFundsMember 2024-01-01 2024-12-31 0000913144 rnr:OtherInvestmentsFundedCommitmentsMember

2024-12-31 0000913144 rnr:OtherInvestmentsUnfundedCommitmentsMember 2024-12-31 0000913144

rnr:OtherInvestmentsFundedCommitmentsMember 2023-12-31 0000913144 rnr:OtherInvestmentsUnfundedCommitmentsMember 2023-12-31

0000913144 us-gaap:CededCreditRiskSecuredMember us-gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember

2024-01-01 2024-12-31 0000913144 srt:StandardPoorsAMinusRatingMember us-gaap:CededCreditRiskUnsecuredMember us-

gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144

srt:StandardPoorsBBBPlusRatingMember us-gaap:CededCreditRiskUnsecuredMember us-gaap:ReinsuranceRecoverableMember us-

gaap:ReinsurerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144 us-gaap:CededCreditRiskSecuredMember us-

gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144

srt:StandardPoorsAMinusRatingMember us-gaap:CededCreditRiskUnsecuredMember us-gaap:ReinsuranceRecoverableMember us-

gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 srt:StandardPoorsBBBPlusRatingMember us-

gaap:CededCreditRiskUnsecuredMember us-gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-

12-31 0000913144 rnr:CustomerOneMember us-gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2024-01-01

2024-12-31 0000913144 rnr:CustomerTwoMember us-gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2024-01-01

2024-12-31 0000913144 rnr:CustomerThreeMember us-gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember

2024-01-01 2024-12-31 0000913144 rnr:CustomerOneMember us-gaap:ReinsuranceRecoverableMember us-

gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 rnr:CustomerTwoMember us-gaap:ReinsuranceRecoverableMember

us-gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 rnr:CustomerThreeMember us-

gaap:ReinsuranceRecoverableMember us-gaap:ReinsurerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 rnr:CustomerOneMember

us-gaap:AllowanceForReinsuranceRecoverableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144

rnr:CustomerTwoMember us-gaap:AllowanceForReinsuranceRecoverableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-

12-31 0000913144 rnr:CustomerThreeMember us-gaap:AllowanceForReinsuranceRecoverableMember us-

gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144 rnr:CustomerOneMember us-

gaap:AllowanceForReinsuranceRecoverableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144

rnr:CustomerTwoMember us-gaap:AllowanceForReinsuranceRecoverableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-

12-31 0000913144 rnr:CustomerThreeMember us-gaap:AllowanceForReinsuranceRecoverableMember us-

gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 us-gaap:OperatingSegmentsMember rnr:PropertySegmentMember

2024-12-31 0000913144 us-gaap:OperatingSegmentsMember rnr:CasualtyandSpecialtySegmentMember 2024-12-31 0000913144 us-

gaap:OperatingSegmentsMember rnr:PropertySegmentMember 2023-12-31 0000913144 us-gaap:OperatingSegmentsMember

rnr:CasualtyandSpecialtySegmentMember 2023-12-31 0000913144 us-gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2015-12-

31 0000913144 us-gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2016-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2017-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2018-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2019-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2020-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2021-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2022-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2015Member 2023-12-31 0000913144 us-

gaap:ShortdurationInsuranceContractsAccidentYear2016Member 2024-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2017-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2018-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2019-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2020-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2021-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2022-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2023-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2017Member 2024-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2018-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2019-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2020-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2021-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2022-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2023-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractsAccidentYear2018Member 2024-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractAccidentYear2019Member 2019-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractAccidentYear2019Member 2020-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractAccidentYear2019Member 2021-12-31 0000913144 us-

gaap:ShortDurationInsuranceContractAccidentYear2019Member 2022-1

[illegible]

[illegible]

0000913144 us-gaap:RevolvingCreditFacilityMember us-gaap:EstimateOffFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember
rnr:DavinciReThirdPartyInvestorsMember 2023-12-31 0000913144 us-gaap:RevolvingCreditFacilityMember us-
gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember rnr:DavinciReThirdPartyInvestorsMember 2023-12-31
0000913144 us-gaap:EstimateOffFairValueFairValueDisclosureMember 2024-12-31 0000913144 us-
gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0000913144 us-gaap:EstimateOffFairValueFairValueDisclosureMember
2023-12-31 0000913144 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0000913144
rnr:A5750SeniorNotesDue2033Member us-gaap:SeniorNotesMember 2023-06-05 0000913144 rnr:A5750SeniorNotesDue2033Member us-
gaap:SeniorNotesMember 2023-06-05 2023-06-05 0000913144 rnr:A3.600SeniorNotesDue2029Member 2019-04-02 0000913144
rnr:A3.600SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2019-04-02 0000913144 rnr:A3.600SeniorNotesDue2029Member us-
gaap:SeniorNotesMember 2019-04-02 2019-04-02 0000913144 rnr:A3.450SeniorNotesDueJuly12027Member 2017-06-29 0000913144
rnr:A3.450SeniorNotesDueJuly12027Member us-gaap:SeniorNotesMember rnr:RenaissanceReFinanceInc.Member 2017-06-29 0000913144
rnr:A3.700SeniorNotesDueApril12025Member 2015-03-24 0000913144 rnr:A3.700SeniorNotesDueApril12025Member
rnr:RenaissanceReFinanceInc.Member 2015-03-24 0000913144 rnr:PlatinumMember us-gaap:BridgeLoanMember 2015-02-25 0000913144
rnr:A4.750SeniorNotesDueMay12025Member rnr:DavinciReThirdPartyInvestorsMember 2015-05-04 0000913144
rnr:DavinciReThirdPartyInvestorsMember 2015-05-04 0000913144 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-12-
31 0000913144 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember rnr:RenaissanceReMediciFundLtd.Member 2024-12-31
0000913144 us-gaap:LetterOfCreditMember rnr:SecuredBilateralFacilityMember us-gaap:LineOfCreditMember 2024-12-31 0000913144 us-
gaap:LetterOfCreditMember rnr:UnsecuredBilateralFacilityMember us-gaap:LineOfCreditMember 2024-12-31 0000913144 us-
gaap:RevolvingCreditFacilityMember 2022-11-18 0000913144 us-gaap:RevolvingCreditFacilityMember us-gaap:BridgeLoanMember 2022-11-18
0000913144 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0000913144 us-gaap:RevolvingCreditFacilityMember 2024-12-31 0000913144 us-
gaap:LetterOfCreditMember rnr:SecuredBilateralFacilityMember rnr:WellsFargoMember 2019-06-21 0000913144 us-gaap:LetterOfCreditMember
rnr:SecuredBilateralFacilityMember rnr:WellsFargoMember 2024-12-31 0000913144 us-gaap:LetterOfCreditMember
rnr:UnsecuredBilateralFacilityMember rnr:WellsFargoMember 2024-12-31 0000913144 rnr:SecuredBilateralFacilityMember
rnr:CitibankEuropePlcMember us-gaap:LetterOfCreditMember rnr:BilateralFacilityParticipantsMember 2023-10-31 0000913144
rnr:SecuredBilateralFacilityMember rnr:CitibankEuropePlcMember us-gaap:LetterOfCreditMember rnr:BilateralFacilityParticipantsMember 2023-
11-01 0000913144 us-gaap:LetterOfCreditMember rnr:SecuredBilateralFacilityMember rnr:CitibankEuropePlcMember 2024-12-31 0000913144
rnr:SecuredBilateralFacilityMember rnr:CitibankEuropePlcMember us-gaap:LetterOfCreditMember rnr:BilateralFacilityParticipantsMember 2024-
12-31 0000913144 us-gaap:LetterOfCreditMember rnr:UnsecuredBilateralFacilityMember rnr:CitibankEuropePlcMember 2024-12-31 0000913144
us-gaap:LetterOfCreditMember rnr:UnsecuredBilateralFacilityMember rnr:CreditSuisseSwitzerlandLtd.Member 2021-12-16 0000913144 us-
gaap:LetterOfCreditMember rnr:UnsecuredBilateralFacilityMember rnr:CreditSuisseSwitzerlandLtd.Member 2024-12-31 0000913144 us-
gaap:LetterOfCreditMember rnr:StandbyLetterOfCreditAgreementMember rnr:NordeaBankAbpNewYorkBranchMember 2024-10-03 0000913144
us-gaap:LetterOfCreditMember rnr:StandbyLetterOfCreditAgreementMember rnr:NordeaBankAbpNewYorkBranchMember 2024-12-31
0000913144 us-gaap:LetterOfCreditMember rnr:UncommittedLetterOfCreditFacilityMember rnr:SocieteGeneraleNewYorkBranchSocGenMember
2022-09-08 0000913144 us-gaap:LetterOfCreditMember rnr:UncommittedLetterOfCreditFacilityMember
rnr:SocieteGeneraleNewYorkBranchSocGenMember 2024-12-31 0000913144 us-gaap:LetterOfCreditMember
rnr:SecuredLetterOfCreditFacilityMember rnr:CitibankEuropeMember 2024-12-31 0000913144 us-gaap:RevolvingCreditFacilityMember
rnr:RenaissanceReMediciFundLtd.Member 2024-12-31 0000913144 us-gaap:LetterOfCreditMember rnr:TopLayerReMember 2024-12-31
0000913144 us-gaap:CapitalSupportAgreementMember us-gaap:LetterOfCreditMember rnr:TopLayerReMember 2024-12-31 0000913144
rnr:DavinciReThirdPartyInvestorsMember 2024-12-31 0000913144 rnr:DavinciReThirdPartyInvestorsMember 2023-12-31 0000913144
rnr:RenaissanceReMediciFundLtd.Member 2024-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2023-12-31 0000913144
rnr:VermeerReinsuranceLtd.Member 2024-12-31 0000913144 rnr:VermeerReinsuranceLtd.Member 2023-12-31 0000913144
rnr:FontanaHoldingsLPMember 2024-12-31 0000913144 rnr:FontanaHoldingsLPMember 2023-12-31 0000913144
rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 rnr:DavinciReThirdPartyInvestorsMember 2023-01-01 2023-12-31
0000913144 rnr:DavinciReThirdPartyInvestorsMember 2022-01-01 2022-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2024-01-01
2024-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2023-01-01 2023-12-31 0000913144
rnr:RenaissanceReMediciFundLtd.Member 2022-01-01 2022-12-31 0000913144 rnr:VermeerReinsuranceLtd.Member 2024-01-01 2024-12-31
0000913144 rnr:VermeerReinsuranceLtd.Member 2023-01-01 2023-12-31 0000913144 rnr:VermeerReinsuranceLtd.Member 2022-01-01 2022-12-
31 0000913144 rnr:FontanaHoldingsLPMember 2024-01-01 2024-12-31 0000913144 rnr:FontanaHoldingsLPMember 2023-01-01 2023-12-31
0000913144 rnr:FontanaHoldingsLPMember 2022-01-01 2022-12-31 0000913144 rnr:DaVinciReinsuranceLtd.Member 2024-12-31 0000913144
rnr:DaVinciReinsuranceLtd.Member 2023-12-31 0000913144 rnr:DaVinciReThirdPartyInvestorsMember 2024-12-31
0000913144 rnr:DaVinciReinsuranceLtd.Member 2024-01-01 2024-12-31 0000913144 rnr:ThirdPartyInvestorsMember 2024-01-01 2024-12-31
0000913144 rnr:ThirdPartyInvestorsMember rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144
rnr:RenaissanceReHoldingsLtd.Member rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144
rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 rnr:ThirdPartyInvestorsMember
rnr:DavinciReThirdPartyInvestorsMember 2023-01-01 2023-12-31 0000913144 rnr:RenaissanceReHoldingsLtd.Member
rnr:DavinciReThirdPartyInvestorsMember 2023-01-01 2023-12-31 0000913144 rnr:DaVinciReinsuranceLtd.Member 2023-01-01 2023-12-31
0000913144 rnr:ThirdPartyInvestorsMember 2023-01-01 2023-12-31 0000913144 rnr:DavinciReThirdPartyInvestorsMember 2023-01-01 2023-12-
31 0000913144 rnr:DavinciReThirdPartyInvestorsMember 2022-12-31 0000913144 rnr:ThirdPartyInvestorsAndRenaissanceReMember
rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 rnr:ThirdPartyInvestorsAndRenaissanceReMember
rnr:DavinciReThirdPartyInvestorsMember 2023-01-01 2023-12-31 0000913144 rnr:ThirdPartyInvestorsMember
rnr:RenaissanceReMediciFundLtd.Member 2024-01-01 2024-12-31 0000913144 rnr:RenaissanceReHoldingsLtd.Member
rnr:RenaissanceReMediciFundLtd.Member 2024-01-01 2024-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2024-12-31
0000913144 rnr:RenaissanceReMediciFundLtd.Member 2024-01-01 2024-12-31 0000913144 rnr:ThirdPartyInvestorsMember
rnr:RenaissanceReMediciFundLtd.Member 2023-01-01 2023-12-31 0000913144 rnr:RenaissanceReHoldingsLtd.Member
rnr:RenaissanceReMediciFundLtd.Member 2023-01-01 2023-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2023-12-31
0000913144 rnr:RenaissanceReMediciFundLtd.Member 2023-01-01 2023-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member 2022-12-
31 0000913144 rnr:VermeerReinsuranceLtd.Member rnr:VotingNonparticipatingSharesMember rnr:RenaissanceReMediciFundLtd.Member 2024-
12-31 0000913144 rnr:VermeerReinsuranceLtd.Member rnr:ParticipatingNonvotingCommonSharesMember rnr:PEZWMember 2024-12-31
0000913144 rnr:StichtingPensioenfondszorgEnWelzijnMember rnr:VermeerReinsuranceLtd.Member 2024-01-01 2024-12-31 0000913144
rnr:StichtingPensioenfondszorgEnWelzijnMember rnr:VermeerReinsuranceLtd.Member 2023-01-01 2023-12-31 0000913144
rnr:VermeerReinsuranceLtd.Member 2022-12-31 0000913144 rnr:ThirdPartyInvestorsMember rnr:FontanaHoldingsLPMember 2024-01-01 2024-
12-31 0000913144 rnr:RenaissanceReHoldingsLtd.Member rnr:FontanaHoldingsLPMember 2024-01-01 2024-12-31 0000913144
rnr:FontanaThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 rnr:FontanaHoldingsLPMember 2024-12-31 0000913144
rnr:ThirdPartyInvestorsMember rnr:FontanaHoldingsLPMember 2023-01-01 2023-12-31 0000913144 rnr:RenaissanceReHoldingsLtd.Member
rnr:FontanaHoldingsLPMember 2023-01-01 2023-12-31 0000913144 rnr:FontanaHoldingsLPMember 2023-12-31 0000913144
rnr:FontanaThirdPartyInvestorsMember 2023-01-01 2023-12-31 0000913144 rnr:FontanaHoldingsLPMember 2022-12-31 0000913144
rnr:RedeemableNoncontrollingInterestMember rnr:DavinciReThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 us-
gaap:VariableInterestEntityPrimaryBeneficiaryMember rnr:InvestorsOfUpsilonRFODiversifiedIIIAndIIIMember rnr:UpsilonRFOReLtd.Member
2024-01-01 2024-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member
rnr:UpsilonRFOReLtd.Member 2024-01-01 2024-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
rnr:UpsilonRFOReLtd.Member 2024-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember rnr:UpsilonRFOReLtd.Member
2023-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember rnr:InvestorsOfUpsilonRFODiversifiedIIIAndIIIMember
rnr:UpsilonRFOReLtd.Member 2024-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
rnr:InvestorsOfUpsilonRFODiversifiedIIIAndIIIMember rnr:UpsilonRFOReLtd.Member 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:InvestorsOfUpsilonRFODiversifiedIVMember rnr:UpsilonRFOReLtd.Member 2024-
12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:InvestorsOfUpsilonRFODiversifiedIVMember
rnr:UpsilonRFOReLtd.Member 2023-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
rnr:InvestorsOfUpsilonRFODiversifiedIIIAndIIIMember rnr:UpsilonRFOReLtd.Member 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member rnr:UpsilonRFOReLtd.Member 2023-01-01 2023-
12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember us-gaap:InvestorMember us-gaap:PreferredStockMember
rnr:UpsilonRFOReLtd.Member 2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
rnr:RenaissanceReHoldingsLtd.Member us-gaap:PreferredStockMember rnr:UpsilonRFOReLtd.Member 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:InvestorsOfUpsilonRFODiversifiedIVMember us-gaap:PreferredStockMember
rnr:UpsilonRFOReLtd.Member 2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-
gaap:InvestorMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-01-01 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member
rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-01-01 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:InvestorMember us-gaap:PreferredStockMember
rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-01-01 2024-12-31 0000913144 us-

gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:UpsilonRFOreLtd.Member rnr:RenaissanceReUpsilonDiversifiedFundMember 2024-
12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:UpsilonRFOreLtd.Member
rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-
gaap:InvestorMember rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member
rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:InvestorMember us-gaap:PreferredStockMember
rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member us-gaap:PreferredStockMember
rnr:RenaissanceReUpsilonDiversifiedFundMember 2023-01-01 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:InvestorMember us-gaap:PreferredStockMember rnr:NOC1Member 2024-01-01
2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member us-
gaap:PreferredStockMember rnr:NOC1Member 2024-01-01 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:NOC1Member 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:NOC1Member 2023-12-31
0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:NOC1Member 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:NOC1Member 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:InvestorMember us-gaap:PreferredStockMember rnr:NOC1Member 2023-01-01
2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member us-
gaap:PreferredStockMember rnr:NOC1Member 2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:VermeerReinsuranceLtd.Member 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:VermeerReinsuranceLtd.Member 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:FontanaHoldingsLPMember 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:FontanaHoldingsLPMember 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:RenaissanceReinsuranceLtd.Member rnr:MonaLisaReMember 2024-01-01 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:DaVinciReinsuranceLtd.Member rnr:MonaLisaReMember 2024-01-01 2024-12-31
0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReinsuranceLtd.Member rnr:MonaLisaReMember
2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:DaVinciReinsuranceLtd.Member
rnr:MonaLisaReMember 2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:RenaissanceReinsuranceLtd.Member rnr:MonaLisaReMember 2022-01-01 2022-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:DaVinciReinsuranceLtd.Member rnr:MonaLisaReMember 2022-01-01 2022-12-31
0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:ThreeHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember rnr:MonaLisaReMember 2024-12-03 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:OneHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember
rnr:MonaLisaReMember 2024-06-13 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:EightyFiveThousandPrincipalAtRiskVariableRateNoteMember rnr:MonaLisaReMember 2022-12-20 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:OneHundredMillionPrincipalAtRiskVariableRateNoteMember
rnr:MonaLisaReMember 2022-12-20 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:TwoHundredAndFiftyMillionPrincipalAtRiskVariableRateNoteMember rnr:MonaLisaReMember 2021-06-29 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:MonaLisaReMember 2024-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:MonaLisaReMember 2023-12-31 0000913144 us-
gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:OtherInvestmentsMember rnr:MonaLisaReMember 2024-12-31 0000913144
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:OtherInvestmentsMember rnr:MonaLisaReMember 2023-12-31 0000913144
us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member rnr:TailwindReLtdMember 2024-01-01
2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:RenaissanceReHoldingsLtd.Member
rnr:TailwindReLtdMember 2023-01-01 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:TailwindReLtdMember 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember rnr:TailwindReLtdMember 2023-
12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:OtherInvestmentsMember rnr:TailwindReLtdMember
2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember us-gaap:OtherInvestmentsMember
rnr:TailwindReLtdMember 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:AlphaCatManagersLtdMember 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:AlphaCatManagersLtdMember 2023-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:AlphaCatManagersLtdMember 2024-12-31 0000913144 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember
rnr:AlphaCatManagersLtdMember 2023-12-31 0000913144 rnr:PublicOfferingMember 2023-05-26 2023-05-26 0000913144
rnr:PublicOfferingMember 2023-05-26 0000913144 us-gaap:SeriesFPreferredStockMember 2018-06-01 2018-06-30 0000913144 us-
gaap:SeriesFPreferredStockMember 2018-06-30 0000913144 rnr:DepositoryShareseachrepresentingA11000thinterestinaSeriesF5.Member 2018-
06-01 2018-06-30 0000913144 us-gaap:DebtInstrumentRedemptionPeriodOneMember rnr:DepositorySharesMember 2018-06-30 0000913144 us-
gaap:SeriesGPreferredStockMember 2021-07-01 2021-07-31 0000913144 us-gaap:SeriesGPreferredStockMember 2021-07-31 0000913144
rnr:DepositorySharesEachRepresentingA11000thInterestInASeriesG4Member 2021-07-01 2021-07-31 0000913144 us-
gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeriesGPreferredStockMember 2021-07-31 0000913144 us-
gaap:DebtInstrumentRedemptionPeriodOneMember rnr:DepositorySharesMember 2021-07-31 0000913144 us-gaap:SeriesCPreferredStockMember
2024-12-31 0000913144 2024-07-01 2024-09-30 0000913144 2024-04-01 2024-06-30 0000913144 2024-01-01 2024-03-31 0000913144 us-
gaap:SeriesFPreferredStockMember 2024-01-01 2024-12-31 0000913144 us-gaap:SeriesFPreferredStockMember 2024-12-31 0000913144
rnr:SeriesFPreferredSharesDepositorySharesMember 2024-12-31 0000913144 us-gaap:SeriesGPreferredStockMember 2024-01-01 2024-12-31
0000913144 us-gaap:SeriesGPreferredStockMember 2024-12-31 0000913144 rnr:SeriesGPreferredSharesDepositorySharesMember 2024-12-31
0000913144 us-gaap:CommonStockMember 2024-11-06 0000913144 us-gaap:CommonStockMember 2024-12-31 0000913144
rnr:DepositorySharesMember 2018-06-30 0000913144 rnr:DepositorySharesMember 2021-07-31 0000913144 rnr:TowerHillMember us-
gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000913144 rnr:TowerHillMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31
0000913144 rnr:TowerHillMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000913144 rnr:TowerHillMember us-
gaap:RelatedPartyMember 2024-12-31 0000913144 rnr:TowerHillMember us-gaap:RelatedPartyMember 2023-12-31 0000913144
rnr:TopLayerReMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000913144 rnr:TopLayerReMember us-gaap:RelatedPartyMember
2023-01-01 2023-12-31 0000913144 rnr:TopLayerReMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000913144
rnr:TopLayerReMember us-gaap:FinancialServiceMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000913144
rnr:TopLayerReMember us-gaap:FinancialServiceMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000913144
rnr:TopLayerReMember us-gaap:FinancialServiceMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000913144
rnr:ThreeBrokersMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144
rnr:ThreeBrokersMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000913144
rnr:ThreeBrokersMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000913144
rnr:AonPleMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000913144
rnr:MarshMcLennanCompaniesIncMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-
31 0000913144 rnr:ArthurJGallagherMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-
12-31 0000913144 rnr:AonPleMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31
0000913144 rnr:MarshMcLennanCompaniesIncMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2023-01-
01 2023-12-31 0000913144 rnr:ArthurJGallagherMember rnr:GrossPremiumsWrittenMember us-gaap:CustomerConcentrationRiskMember 2023-
01-01 2023-12-31 0000913144 us-gaap:InternalRevenueServiceIRSMember 2024-01-01 2024-12-31 0000913144 us-gaap:DomesticCountryMember
2024-01-01 2024-12-31 0000913144 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0000913144 us-gaap:DomesticCountryMember
2022-01-01 2022-12-31 0000913144 country:SG 2024-01-01 2024-12-31 0000913144 country:SG 2023-01-01 2023-12-31 0000913144 country:SG
2022-01-01 2022-12-31 0000913144 country:IE 2024-01-01 2024-12-31 0000913144 country:IE 2023-01-01 2023-12-31 0000913144 country:IE
2022-01-01 2022-12-31 0000913144 us-gaap:InternalRevenueServiceIRSMember 2023-01-01 2023-12-31 0000913144 us-
gaap:InternalRevenueServiceIRSMember 2022-01-01 2022-12-31 0000913144 country:AU 2024-01-01 2024-12-31 0000913144 country:AU 2023-
01-01 2023-12-31 0000913144 country:AU 2022-01-01 2022-12-31 0000913144 country:CH 2024-01-01 2024-12-31 0000913144 country:CH 2023-
01-01 2023-12-31 0000913144 country:CH 2022-01-01 2022-12-31 0000913144 country:LU 2024-01-01 2024-12-31 0000913144 country:LU 2023-
01-01 2023-12-31 0000913144 country:LU 2022-01-01 2022-12-31 0000913144 country:CA 2024-01-01 2024-12-31 0000913144 country:CA 2023-
01-01 2023-12-31 0000913144 country:CA 2022-01-01 2022-12-31 0000913144 country:GB 2024-01-01 2024-12-31 0000913144 country:GB 2023-
01-01 2023-12-31 0000913144 country:GB 2022-01-01 2022-12-31 0000913144 us-gaap:InternalRevenueServiceIRSMember rnr:A2037Member

[illegible]

01-2023-12-31 0000913144 rnr:GrossPremiumsWrittenBenchmarkMember us-gaap:GeographicConcentrationRiskMember
rnr:CasualtyandSpecialtySegmentMember 2022-01-01 2022-12-31 0000913144 rnr:GrossPremiumsWrittenBenchmarkMember us-
gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000913144 rnr:GrossPremiumsWrittenBenchmarkMember us-
gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000913144 rnr:GrossPremiumsWrittenBenchmarkMember us-
gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000913144 rnr:A2016LongTermIncentivePlanMember 2022-05-16
0000913144 us-gaap:RestrictedStockMember rnr:A2016LongTermIncentivePlanMember 2024-01-01 2024-12-31 0000913144 us-
gaap:RestrictedStockMember rnr:NonEmployeeDirectorStockIncentivePlanMember 2024-01-01 2024-12-31 0000913144 us-
gaap:PerformanceSharesMember rnr:A2016LongTermIncentivePlanGrantedMay2018Member 2024-12-31 0000913144 us-
gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000913144 srt:ChiefExecutiveOfficerMember us-gaap:PerformanceSharesMember 2023-
11-07 2023-11-07 0000913144 us-gaap:PerformanceSharesMember 2021-12-31 0000913144 us-gaap:PerformanceSharesMember 2022-01-01
2022-12-31 0000913144 us-gaap:PerformanceSharesMember 2022-12-31 0000913144 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31
0000913144 us-gaap:PerformanceSharesMember 2023-12-31 0000913144 us-gaap:PerformanceSharesMember 2024-12-31 0000913144
rnr:EmployeeRestrictedStockMember 2021-12-31 0000913144 rnr:NonEmployeeDirectorRestrictedStockMember 2021-12-31 0000913144 us-
gaap:RestrictedStockMember 2021-12-31 0000913144 rnr:EmployeeRestrictedStockMember 2022-01-01 2022-12-31 0000913144
rnr:NonEmployeeDirectorRestrictedStockMember 2022-01-01 2022-12-31 0000913144 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31
0000913144 rnr:EmployeeRestrictedStockMember 2022-12-31 0000913144 rnr:NonEmployeeDirectorRestrictedStockMember 2022-12-31
0000913144 us-gaap:RestrictedStockMember 2022-12-31 0000913144 rnr:EmployeeRestrictedStockMember 2023-01-01 2023-12-31 0000913144
rnr:NonEmployeeDirectorRestrictedStockMember 2023-01-01 2023-12-31 0000913144 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31
0000913144 rnr:EmployeeRestrictedStockMember 2023-12-31 0000913144 rnr:NonEmployeeDirectorRestrictedStockMember 2023-12-31
0000913144 us-gaap:RestrictedStockMember 2023-12-31 0000913144 rnr:EmployeeRestrictedStockMember 2024-01-01 2024-12-31 0000913144
rnr:NonEmployeeDirectorRestrictedStockMember 2024-01-01 2024-12-31 0000913144 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31
0000913144 rnr:EmployeeRestrictedStockMember 2024-12-31 0000913144 rnr:NonEmployeeDirectorRestrictedStockMember 2024-12-31
0000913144 us-gaap:RestrictedStockMember 2024-12-31 0000913144 rnr:A2016LongTermIncentivePlanMember 2024-12-31 0000913144
country:BM 2024-12-31 0000913144 country:BM 2023-12-31 0000913144 country:CH 2024-12-31 0000913144 country:CH 2023-12-31
0000913144 country:GB 2024-12-31 0000913144 country:GB 2023-12-31 0000913144 country:US 2024-12-31 0000913144 country:US 2023-12-31
0000913144 country:BM 2024-01-01 2024-12-31 0000913144 country:CH 2024-01-01 2024-12-31 0000913144 country:GB 2024-01-01 2024-12-31
0000913144 country:US 2024-01-01 2024-12-31 0000913144 country:BM 2023-01-01 2023-12-31 0000913144 country:CH 2023-01-01 2023-12-31
0000913144 country:GB 2023-01-01 2023-12-31 0000913144 country:US 2023-01-01 2023-12-31 0000913144 country:BM 2022-01-01 2022-12-31
0000913144 country:CH 2022-01-01 2022-12-31 0000913144 country:GB 2022-01-01 2022-12-31 0000913144 country:US 2022-01-01 2022-12-31
0000913144 rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2024-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2024-12-31 0000913144
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2023-12-31 0000913144 srt:MinimumMember
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2023-12-31 0000913144
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2024-12-31 0000913144 srt:MinimumMember
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2024-12-31 0000913144
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2023-12-31 0000913144 srt:MinimumMember
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2023-12-31 0000913144
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-12-31 0000913144 srt:MinimumMember
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-12-31 0000913144
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2023-12-31 0000913144 srt:MinimumMember
rnr:MultiBeneficiaryReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2023-12-31 0000913144
rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-01-01 2024-12-31 0000913144
rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-01-01 2024-12-31 0000913144
rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2024-01-01 2024-12-31 0000913144
rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2024-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2024-12-31
0000913144 rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2023-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReinsuranceLtd.Member 2023-12-31
0000913144 rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2024-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2024-12-31
0000913144 rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:DaVinciReinsuranceLtd.Member 2023-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2024-12-31 0000913144
srt:MinimumMember rnr:MultiBeneficiaryReducedCollateralReinsuranceTrustMember rnr:RenaissanceReEuropeAGMember 2023-12-31 0000913144
0000913144 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2024-12-31 0000913144
rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember 2024-12-31
0000913144 rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:NondesignatedMember 2024-12-31 0000913144
rnr:CommodityFuturesMember us-gaap:NondesignatedMember 2024-12-31 0000913144 us-gaap:CommodityOptionMember us-
gaap:NondesignatedMember 2024-12-31 0000913144 us-gaap:NondesignatedMember 2024-12-31 0000913144
rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000913144
us-gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember 2024-12-31 0000913144 us-gaap:EquityContractMember us-
gaap:NondesignatedMember 2024-12-31 0000913144 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2023-12-31
0000913144 rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember 2023-12-31
0000913144 rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:NondesignatedMember 2023-12-31 0000913144 us-
gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember 2023-12-31 0000913144 us-gaap:CommodityOptionMember us-
gaap:NondesignatedMember 2023-12-31 0000913144 us-gaap:NondesignatedMember 2023-12-31 0000913144 rnr:CommodityFuturesMember us-
gaap:NondesignatedMember 2023-12-31

gaap:InterestRateContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2023-12-31 0000913144

rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144 rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2024-12-31 0000913144

rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 rnr:ForeignCurrencyForwardContractsUnderwritingAndNonInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2023-12-31 0000913144

rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144

rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:ShortMember 2024-12-31 0000913144

rnr:ForeignCurrencyForwardContractsInvestmentOperationsMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 us-gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember us-gaap:ShortMember 2024-12-31 0000913144 us-gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144 us-gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 us-gaap:CreditDefaultSwapMember us-gaap:NondesignatedMember us-gaap:ShortMember 2023-12-31 0000913144 us-gaap:EquityContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144 us-gaap:EquityContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 rnr:CommodityFuturesMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-12-31 0000913144 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0000913144 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000913144 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-12-31 0000913144 us-gaap:LetterOfCreditMember 2024-12-31 0000913144 us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0000913144 us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000913144 us-gaap:OtherOperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000913144 us-gaap:OtherOperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000913144 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-01 2025-02-07 0000913144 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-02-05 0000913144 rnr:DaVinciReThirdPartyInvestorsMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0000913144

rnr:ThirdPartyInvestorsMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0000913144 rnr:DaVinciReinsuranceLtd.Member us-gaap:SubsequentEventMember 2025-01-01 0000913144 us-gaap:SubsequentEventMember rnr:FontanaHoldingsLPMember 2025-01-01 2025-01-01 0000913144 rnr:ThirdPartyInvestorsMember us-gaap:SubsequentEventMember rnr:FontanaHoldingsLPMember 2025-01-01 2025-01-01 0000913144 rnr:RenaissanceReHoldingsLtd.Member us-gaap:SubsequentEventMember rnr:FontanaHoldingsLPMember 2025-01-01 2025-01-01 0000913144 rnr:FontanaThirdPartyInvestorsMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-01 0000913144

rnr:FontanaHoldingsLPMember us-gaap:SubsequentEventMember 2025-01-01 0000913144 rnr:ThirdPartyInvestorsMember us-gaap:SubsequentEventMember rnr:RenaissanceReMediciFundLtd.Member 2025-01-01 2025-01-01 0000913144

rnr:RenaissanceReHoldingsLtd.Member us-gaap:SubsequentEventMember rnr:RenaissanceReMediciFundLtd.Member 2025-01-01 2025-01-01 0000913144 rnr:MediciThirdPartyInvestorsMember 2024-01-01 2024-12-31 0000913144 rnr:RenaissanceReMediciFundLtd.Member us-gaap:SubsequentEventMember 2025-01-01 0000913144 rnr:CaliforniaWildfiresMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000913144 srt:ScenarioForecastMember rnr:CaliforniaWildfiresMember 2025-03-31 0000913144 us-gaap:ForeignGovernmentDebtMember 2024-12-31 0000913144 us-gaap:FixedMaturitiesMember 2024-12-31 0000913144 us-gaap:EquitySecuritiesMember 2024-12-31 0000913144

rnr:FundInvestmentsMember 2024-12-31 0000913144 us-gaap:OtherInvestmentsMember 2024-12-31 0000913144 us-gaap:EquityMethodInvestmentsMember 2024-12-31 0000913144 srt:ParentCompanyMember 2024-12-31 0000913144 srt:ParentCompanyMember 2023-12-31 0000913144 srt:ParentCompanyMember 2024-01-01 2024-12-31 0000913144 srt:ParentCompanyMember 2023-01-01 2023-12-31 0000913144 srt:ParentCompanyMember 2022-01-01 2022-12-31 0000913144 srt:ParentCompanyMember rnr:ValidusSpecialtyMember 2024-01-01 2024-12-31 0000913144 srt:ParentCompanyMember rnr:ValidusSpecialtyMember 2023-01-01 2023-12-31 0000913144 srt:ParentCompanyMember rnr:ValidusSpecialtyMember 2022-01-01 2022-12-31 0000913144 srt:ParentCompanyMember

rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMember 2024-01-01 2024-12-31 0000913144 srt:ParentCompanyMember rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMember 2023-01-01 2023-12-31 0000913144 srt:ParentCompanyMember rnr:ValidusHoldingsLtdAndTalbotUnderwritingLimitedMember 2022-01-01 2022-12-31 0000913144 srt:ParentCompanyMember 2022-12-31 0000913144 srt:ParentCompanyMember 2021-12-31 0000913144 us-gaap:CorporateNonSegmentMember 2024-12-31 0000913144 us-gaap:CorporateNonSegmentMember 2023-12-31 0000913144 us-gaap:OperatingSegmentsMember rnr:PropertySegmentMember 2022-12-31 0000913144 us-gaap:OperatingSegmentsMember rnr:CasualtyandSpecialtySegmentMember 2022-12-31 0000913144 us-gaap:CorporateNonSegmentMember 2022-12-31 0000913144 srt:ConsolidatedPropertyAndCasualtyInsuranceEntityMember 2024-12-31 0000913144 srt:ConsolidatedPropertyAndCasualtyInsuranceEntityMember 2023-01-01 2023-12-31 0000913144 srt:ConsolidatedPropertyAndCasualtyInsuranceEntityMember 2022-12-31 0000913144

srt:ConsolidatedPropertyAndCasualtyInsuranceEntityMember 2022-01-01 2022-12-31 iso4217:USD shares iso4217:USD shares pure rnr:account rnr:period rnr:director 0000913144 2024 FY false <http://fasb.org/us-gaap/2024#NetInvestmentIncome> <http://fasb.org/us-gaap/2024#NonoperatingGainsLosses> <http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet> <http://fasb.org/us-gaap/2024#OtherAssets> <http://fasb.org/us-gaap/2024#OtherLiabilities> <http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax> <http://fasb.org/us-gaap/2024#NonoperatingGainsLosses> <http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax> <http://fasb.org/us-gaap/2024#NonoperatingGainsLosses> <http://fasb.org/us-gaap/2024#OtherAssets> <http://fasb.org/us-gaap/2024#OtherLiabilities> <http://fasb.org/us-gaap/2024#OtherAssets> <http://fasb.org/us-gaap/2024#OtherLiabilities> 0 0 10-K true 2024-12-31 --12-31 false 001-14428 RENAISSANCE RE HOLDINGS LTD. D0 98-0141974 Renaissance House 12 Crow Lane Pembroke HM 19 BM 441 295-4513 Common Shares, Par Value \$1.00 per share RNR NYSE Depositary Shares, each representing a 1/1,000th interest in a Series F 5.750% Preference Share, Par Value \$1.00 per share RNR PRG NYSE Yes No Yes Yes Large Accelerated Filer false false true false 11500000000 49251139 <div style="margin-top:3pt">Portions of the registrant's definitive proxy statement for the 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this report.</div><div style="margin-top:6pt">Our business and support functions utilize information systems that provide critical services to both our employees and our customers. We have an integrated team of professionals who manage and support our communication platforms, transaction management systems, and analytics and reporting capabilities, including the development of proprietary solutions like REMS®. We use both cloud-based platforms and services and off-site, secure data centers in North America and Europe for our core applications.</div><div style="margin-top:6pt">Information security and privacy are important concerns, with an escalating cyber-threat environment and evolving regulatory requirements driving continued investment in this area. Our information security program is designed to meet or exceed industry best practices and is integrated into our broader ERM framework. We are subject to a number of cybersecurity and data privacy laws and regulations, such as those promulgated by the BMA, Office of the Privacy Commission, NYDFS, MIA, and the EU. Pursuant to applicable regulations, we have established and maintain a cybersecurity program designed to protect our information technology systems and customer data. Our program is designed to comply with all applicable cybersecurity regulatory requirements, including disclosure requirements, and we continue to evaluate and assess our compliance in the changing regulatory environment. It is likely that we will be subject to new regulations that could adversely affect our operations or ability to write business profitably in one or more jurisdictions. We cannot predict what, if any, regulatory actions may be taken with regard to "big data" or emerging technologies, such as artificial intelligence, but any actions could have a material impact on our business, business processes, financial condition, and results of operations.</div>We have in place, and seek to continuously improve, a comprehensive system of security controls, managed by a dedicated staff. We also engage reputable third parties to perform a variety of services, including continuous monitoring of our information systems, incident response or management services, cyber-forensic investigation services, and periodic security penetration testing. In addition, we are subject to independent assessment and review by regulators and external auditors, as well as periodic audits of our security controls by our independent internal audit team. We provide regular security risk education and awareness training sessions for all staff. We maintain an ongoing internal third-party cybersecurity risk assessment program to identify potential cybersecurity threats associated with our use of third-party service providers, and consider these assessments when selecting and engaging service providers with periodic re-evaluations. See "Part I, Item 1A. Risk Factors" for additional information on information technology and cybersecurity related risks that may impact us and our financial results. <div style="margin-top:6pt">Our business and support functions

utilize information systems that provide critical services to both our employees and our customers. We have an integrated team of professionals who manage and support our communication platforms, transaction management systems, and analytics and reporting capabilities, including the development of proprietary solutions like REMS®. We use both cloud-based platforms and services and off-site, secure data centers in North America and Europe for our core applications.

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

Our Board and its Audit Committee are supported in their oversight of information technology and cybersecurity matters and risks by two management committees, the Operational Risk and Resilience Committee and the Information Security Steering Committee (the "ISSC"), both of which regularly report to the Audit Committee. The ISSC is responsible for providing management oversight for our cybersecurity risk management program, and its membership includes our Chief Technology Officer and Chief Information Security Officer, among other members of senior management.

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

Our Board is responsible for overseeing enterprise-wide risk management and is actively involved in the monitoring of risks that could affect us, including cybersecurity risks. Pursuant to its charter, one of the key responsibilities of the Audit Committee of our Board is oversight of our information and cybersecurity programs and it receives regular reports on cybersecurity, information technology and other related matters and risks. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight.

The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight. The Audit Committee regularly briefs the Board on matters relating to its information technology and cybersecurity risk oversight. true

Our Board and its Audit Committee are supported in their oversight of information technology and cybersecurity matters and risks by two management committees, the Operational Risk and Resilience Committee and the Information Security Steering Committee (the "ISSC"), both of which regularly report to the Audit Committee. The ISSC is responsible for providing management oversight for our cybersecurity risk management program, and its membership includes our Chief Technology Officer and Chief Information Security Officer, among other members of senior management.

Our Chief Technology Officer and Chief Information Security Officer have each served in various roles in information technology and/or information security for many years, and have extensive information technology and cybersecurity experience. The Chief Technology Officer, and Chief Information Security Officer, alongside other multidisciplinary teams across the Company, work to monitor the prevention, detection, mitigation and remediation of cybersecurity incidents. The broad, cross-functional management team leverages significant experience and expertise across a range of areas, including risk management, technology, and legal and regulatory affairs, among others, for assessing and managing cybersecurity risks.

1403 PricewaterhouseCoopers Ltd. Hamilton, Bermuda 23750540000 20872450000 23562514000 20877108000 4532166000 4603340000 4531655000 4604079000 117756000 106766000 4324761000 3515566000 102770000 112624000 32639456000 29216143000 1676604000 1877518000 7290228000 7280682000 888332000 924777000 4481390000 5344286000 2382290000 205713000 1552359000 1751437000 701053000 685040000 91669000 622197000 444037000 323960000 704132000 775352000 5070755000 49007105000 21303491000 20486869000 5950415000 6136135000 1886689000 1958655000 2804344000 3186174000 150721000 661611000 1060129000 1021872000 33155789000 33451316000 6977749000 6100831000 1.00 1.00 30000 30000 30000 30000 750000000 750000000 1.00 1.00 50180987 50180987 52693887 52693887 50181000 52694000 1512435000 2144459000 14756000 14211000 8276152000 6522016000 10574012000 9454958000 5070755000 49007105000 11733066000 8862366000 9213540000 9952216000 7467813000 7196160000 143544000 3320000 862171000 10095760000 7471133000 6333989000 1654289000 1253110000 559932000 76076000 41479000 56909000 47087000 43474000 11249000 1928000 6152000 12636000 27840000 414522000 1800485000 11695148000 9134608000 5060412000 5332981000 3573509000 4338840000 2643867000 1875034000 1568606000 496588000 375182000 276691000 134784000 127642000 46775000 93768000 73181000 48335000 8701988000 6024548000 6279247000 2993160000 3110060000 1218835000 32628000 510067000 59019000 2960532000 3620127000 1159816000 1090172000 1058995000 98613000 187036000 2561132000 1061203000 35375000 35375000 35375000 1834985000 2525757000 1096518000 35.31 52.40 25.50 35.21 52.27 25.50 2960532000 3620127000 1159816000 1045000 1082000 4923000 1590000 169000 370000 2959987000 3621378000 1164369000 1090172000 1058995000 98613000 1869815000 2562383000 1065756000 750000000 750000000 750000000 750000000 52694000 43718000 44445000 8568000 2711000 1051000 198000 408000 324000 50181000 52694000 43718000 2144459000 475647000 608121000 1628209000 675453000 161788000 5029000 1404000 5549000 48458000 42007000 34863000 1512435000 2144459000 475647000 14211000 15462000 10909000 1045000 1082000 4923000 1590000 169000 370000 14756000 14211000 15462000 6522016000 4071371000 5232624000 2960532000 3620127000 1159816000 1090172000 1058995000 98613000 80849000 75112000 64675000 35375000 35375000 35375000 8276152000 6522016000 4071371000 10574012000 9454958000 5325274000 2960532000 3620127000 1159816000 258456000 134753000 2695000 9035000 7642000 10723000 29439000 482794000 1635192000 9546000 126852000 1357929000 36445000 223385000 166690000 862896000 663909000 442256000 199078000 37301000 322578000 816622000 34656000 2597943000 18572000 227001000 1027894000 38183000 1040110000 67318000 371707000 579280000 259168000 4164822000 1911634000 1603683000 2351545000 2179657000 22086168000 26296842000 24771411000 24923131000 463000 566040000 659199000 205000 1715000 861508000 31772072000 4115288000 26612585000 31597588000 39309700000 25972174000 1087445000 489658000 408944000 1525665000 1291508000 1027734000 0 0 3545000 57335000 25265000 4318000 41349000 5554000 2248000 0 2433746000 0 3060856000 3822636000 3016176000 80849000 75112000 64675000 35375000 35375000 35396000 666921000 0 166664000 0 1351608000 0 740581000 0 150000000 30000000 0 75000000 75000000 0 537433000 982914000 1277945000 943223000 400458000 274957000 23580000 20518000 10911000 1287515000 2588639000 725342000 17365000 5542000 22471000 200914000 683179000 664680000 1877518000 1194339000 1859019000 1676604000 1877518000 1194339000 99535000 26777000 3129000 88046000 73543000 46247000 0 285168000 0 ORGANIZATION

RenaissanceRe Holdings Ltd. ("RenaissanceRe" or the "Company") was formed under the laws of Bermuda on June 7, 1993. Through its wholly owned and majority-owned subsidiaries, joint ventures and managed funds, the Company provides property, casualty and specialty reinsurance and certain insurance solutions to its customers.

These consolidated financial statements include the results of the Company, its subsidiaries, and all variable interest entities in which the Company is considered to be the primary beneficiary.

SIGNIFICANT ACCOUNTING POLICIES

Basis Of Presentation

Certain comparative information has been reclassified to conform to the current presentation.

Use Of Estimates In Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. The major estimates reflected in the Company's consolidated financial statements include, but are not limited to, the reserve for claims and claim expenses; reinsurance recoverable and premiums receivable, including provisions for reinsurance recoverable and premiums receivable to reflect expected credit losses; estimates of written and earned premiums; fair value, including the fair value of investments, financial instruments and derivatives; impairment charges; deferred acquisition costs, the value of business acquired ("VOBA") and the fair value of other assets acquired and liabilities assumed in acquisitions; and the Company's deferred tax valuation allowance.

Premiums and Related Expenses

Premiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are determined. Unearned premiums represent the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written.

Acquisition costs are incurred when a contract or policy is issued and

only the costs directly related to the successful acquisition of new and renewal contract or policies are deferred and amortized over the same period in which the related premiums are earned. Acquisition costs consist principally of commissions, brokerage and premium tax expenses and are shown net of commissions earned on ceded reinsurance. Certain of the Company's assumed contracts contain profit sharing provisions or adjustable commissions that are estimated based on the expected loss and loss adjustment expense on those contracts. Acquisition costs include accruals for such estimates of commissions. Certain of the Company's ceded contracts contain profit sharing provisions which accrue to the benefit of the Company. Acquisition costs are shown net of such commissions and profit commissions earned on ceded reinsurance. In addition, certain of the Company's ceded contracts contain override and management fees which are recorded as an offset against operational expenses. Deferred policy acquisition costs are limited to their estimated realizable value based on the related unearned premiums. Anticipated claims and claim expenses, based on historical and current experience, and anticipated investment income related to those premiums are considered in determining the recoverability of deferred acquisition costs.

Claims and Claim Expenses

The reserve for claims and claim expenses includes estimates for unpaid claims and claim expenses on reported losses as well as an estimate of losses incurred but not reported. The reserve is based on individual claims, case reserves and other reserve estimates reported by insureds and ceding companies as well as management estimates of ultimate losses. Inherent in the estimates of ultimate losses are expected trends in claim severity and frequency and other factors which could vary significantly as claims are settled. In addition, the Company does not have the benefit of a significant amount of its own historical experience in certain casualty and specialty and insurance lines of business. Accordingly, the reserving for incurred losses in these lines of business could be subject to greater variability.

Ultimate losses may vary materially from the amounts provided in the consolidated financial statements. These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, are reflected in the consolidated statements of operations in the period in which they become known and are accounted for as changes in estimates.

Reinsurance

Amounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, the Company accrues amounts (either assets or liabilities) that are due to or from retrocessionaires based on estimated contract experience. If the Company determines that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. Reinsurance recoverable on dual trigger reinsurance contracts require the Company to estimate its ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. Amounts recoverable from reinsurers are recorded net of a provision for current expected credit losses to reflect expected credit losses.

Assumed and ceded reinsurance contracts that lack significant transfer of risk are treated as deposits.

Certain assumed and ceded reinsurance contracts that do not meet all of the criteria to be accounted for as reinsurance in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 944, Insurance Services

have been accounted for at fair value under the fair value option in accordance with FASB ASC Topic 825.

Financial Instruments

Investments

Fixed Maturity Investments

Investments in fixed maturities are classified as trading and are reported at fair value. Investment transactions are recorded on the trade date with balances pending settlement reflected in the balance sheet as a receivable for investments sold or a payable for investments purchased. Net investment income includes interest and dividend income together with amortization of market premiums and discounts and is net of investment management and custody fees. The amortization of premium and accretion of discount for fixed maturity securities is computed using the effective yield method. For mortgage-backed securities and other holdings for which there is prepayment risk, prepayment assumptions are evaluated quarterly and revised as necessary. Any adjustments required due to the change in effective yields and maturities are recognized on a prospective basis through yield adjustments. Fair values of investments are based on quoted market prices, or when such prices are not available, by reference to broker or underwriter bid indications and/or internal pricing valuation techniques. The net unrealized appreciation or depreciation on fixed maturity investments trading is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations. Realized gains or losses on the sale of investments are determined on the basis of the first in first out cost method.

Short Term Investments

Short term investments, which are managed as part of the Company's investment portfolio and have a maturity of one year or less when purchased, are carried at fair value. The net unrealized appreciation or depreciation on short term investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Equity Investments

Equity investments are accounted for at fair value in accordance with FASB ASC Topic 825.

Financial Instruments

Fair values are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. Dividend income is included in net investment income and net realized and unrealized appreciation or depreciation on equity investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Other Investments

The Company accounts for its other investments at fair value in accordance with FASB ASC Topic 825.

Financial Instruments

with interest and dividend income included in net investment income. Realized and unrealized gains and losses on other investments are included in net realized and unrealized gains (losses) on investments. The fair value of the Company's fund investments, which include private equity funds, private credit funds and hedge funds, is generally established on the basis of the net asset value ("NAV") per share (or its equivalent) established by each respective fund investments manager, if applicable. The net asset value established by the respective fund investments manager is determined in accordance with the governing documents of such fund investments. The Company applies the practical expedient provided by the FASB ASC Topic 825, relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of the fund investments based on that NAV per share, or its equivalent. Fund investments are recorded on the consolidated balance sheets in other investments. Fund investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy.

Certain of the Company's fund investment managers, or their fund administrators, are unable to provide final fund valuations as of the Company's current reporting date. The Company typically experiences a reporting lag to receive a final net asset value report of one month for hedge funds and three months for both private equity funds and private credit funds, although the Company has occasionally experienced delays of up to six months, particularly at year end.

In circumstances where there is a reporting lag between the current period end reporting date and the reporting date of the latest fund valuation, the Company estimates the fair value of these funds by starting with the prior month or quarter end fund valuations, adjusting these valuations for actual capital calls, redemptions or distributions, as well as the impact of changes in foreign currency exchange rates, and then estimating the return for the current period. In circumstances in which the Company estimates the return for the current period, all information available to the Company is utilized. This principally includes using preliminary estimates reported to the Company by its fund managers, where available, and estimating returns based on the performance of broad market indices or other valuation methods. Actual final fund valuations may differ, perhaps materially so, from the Company's estimates and these differences are recorded in the Company's statement of operations in the period in which they are reported to the Company as a change in estimate.

The Company's other investments also include investments in catastrophe bonds, direct private equity investments and term loans which are recorded at fair value. The fair value of catastrophe bonds is based on broker or underwriter bid indications. The fair value of direct private equity investments is based on quoted prices for similar assets, where available, or on the use of internal valuation models.

Investments in Other Ventures, Under Equity

Method of investments in which the Company has significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, the Company records its proportionate share of income or loss from such investments in its statements of operations for the period. Additionally, the Company records its portion of any changes to the accumulated other comprehensive income or loss of the investee in the Company's statements of comprehensive income (loss). If the Company's proportionate share of loss from such investment is in excess of the carrying value of such investment, the Company suspends the application of the equity method when the carrying value of the investment is reduced to zero, unless the Company has committed to provide further financial support to the investee. If the investee subsequently reports net income, the Company resumes applying the equity method only after its proportionate share of net income equals the proportionate share of net losses not recognized during the period the equity method was suspended. Any decline in value of investments in other ventures, under equity method considered by management to be other-than-temporary is charged to income in the period in which it is determined.

Cash and Cash Equivalents

Cash equivalents include money market instruments with a maturity of ninety days or less when purchased.

Stock Incentive Compensation

The Company is authorized to issue restricted stock awards and units, performance shares, stock options and other equity-based awards to its employees and directors. The fair value of the compensation cost is measured at the grant date and expensed over the period for which the employee or director is required to provide services in exchange for the award.

The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.

Derivatives

From time to time, the Company enters into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company accounts for its derivatives in accordance with FASB ASC Topic 815, which requires all derivatives to be recorded at fair value on the Company's balance sheet as either assets or liabilities, depending on their rights or obligations, with changes in fair value reflected in current earnings. The Company has adopted hedge accounting for certain of its derivative instruments used as hedges of a net investment in a foreign operation, as discussed below. The fair value of the Company's derivatives is estimated by reference to quoted prices or broker quotes, where available, or in the absence of quoted prices or broker quotes, the use of industry or internal valuation models.

Hedges of a Net Investment in a Foreign Operation

Changes in the fair value of derivative instruments used to hedge the net investment in a foreign operation, to the extent effective as a hedge, are recorded as a component of accumulated other comprehensive income (loss) in foreign currency translation adjustments, net of tax. Cumulative changes in fair value recorded in accumulated other comprehensive income (loss) are reclassified into earnings upon the sale, or complete or substantially complete liquidation, of the foreign operation. Any hedge ineffectiveness is recorded immediately in current period earnings as net foreign exchange gains (losses).

Hedge Documentation and Effectiveness Testing

To qualify for hedge accounting treatment, a derivative must be highly effective in mitigating the designated changes in value or cash flow of the hedged item. At the inception of a hedge, the Company formally documents relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking each hedge transaction. The documentation process includes linking derivatives that are designated as net investment hedges to specific assets or liabilities on the consolidated balance sheets. The Company also formally assesses, both at the hedge's inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the net investment in a foreign operation. The Company will discontinue hedge accounting prospectively if it determines that the derivative is no longer highly effective in offsetting changes in the net investment in a foreign operation, the derivative is no longer designated as a hedging instrument, or the derivative expires or is sold, terminated or exercised. If hedge accounting is discontinued, the derivative continues to be carried at fair value on the consolidated balance sheets with changes in its fair value recognized in current period earnings through net realized and unrealized gains (losses) on investments.

Fair Value Option

The Company has elected to account for certain of its assets and liabilities at fair value in accordance with FASB ASC Topic 820, Measurement.

The Company recognizes the change in unrealized gains and losses arising from changes in fair value in its statements of operations.

Business Combinations, Goodwill and Other Intangible Assets

The Company accounts for business combinations in accordance with FASB ASC Topic 805, Business Combinations, and goodwill and other intangible assets that arise from business combinations in accordance with FASB ASC Topic 350, Intangibles – Goodwill and Other.

A purchase price that is in excess of the fair value of the net assets acquired arising from a business combination is recorded as goodwill, and is not amortized. Other intangible assets with a finite life are amortized over the estimated useful life of the asset. Other intangible assets with an indefinite useful life are not amortized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining the fair value of net assets acquired. The significant assumptions include the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges.

Goodwill and other intangible assets are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, goodwill is assigned to the applicable reporting unit of the acquired entities giving rise to the goodwill. Goodwill and other intangible assets recorded in connection with investments accounted for under the equity method, are recorded as investments in other ventures, under equity method on the Company's consolidated balance sheets.

The Company has established the second half of the year as the period for performing its annual impairment tests. The Company may determine to perform additional impairment testing at other times in the year if it is deemed necessary. The Company has elected to use the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. Under this option, the Company is not required to calculate the fair value of a reporting unit unless the Company determines, based on its qualitative assessment, that it is more likely than not that a reporting unit's fair value is less than its carrying amount. If goodwill or other intangible assets are impaired, they are written down to their estimated fair value with a corresponding expense reflected in the Company's consolidated statements of operations.

Noncontrolling Interests

The Company accounts for redeemable noncontrolling interests in the mezzanine section of the Company's consolidated balance sheets in accordance with United States Securities and Exchange Commission ("SEC") guidance which is applicable to SEC registrants. The share classes related to the redeemable noncontrolling interest portion of the issuer are accounted for in accordance with SEC guidance, which requires that shares not required to be accounted for in accordance with FASB ASC Topic 480, Distinguishing Liabilities from Equity, and having redemption features that are not solely within the control of the issuer, to be classified outside of permanent equity in the mezzanine section of the balance sheet. The SEC guidance does not impact the accounting for redeemable noncontrolling interest on the consolidated statements of operations; therefore, the provisions of FASB ASC Topic 810, Consolidation, with respect to the consolidated statements of operations still apply, and net (income) loss attributable to redeemable noncontrolling interests is presented separately in the Company's consolidated statements of operations.

Variable Interest Entities

The Company accounts for variable interest

entities (“VIEs”) in accordance with FASB ASC Topic 810, Consolidation, which requires the consolidation of all VIEs by the primary beneficiary, that being the investor that has the power to direct the activities of the VIE and that will absorb a portion of the VIE’s expected losses or residual returns that could potentially be significant to the VIE. When the Company determines it has a variable interest in a VIE, it determines whether it is the primary beneficiary of that VIE by performing an analysis that principally considers: (i) the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders; (ii) the VIE’s capital structure; (iii) the terms between the VIE and its variable interest holders and other parties involved with the VIE; (iv) which variable interest holders have the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; (v) which variable interest holders have the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE; and (vi) related party relationships. The Company reassesses its determination of whether the Company is the primary beneficiary of a VIE upon changes in facts and circumstances that could potentially alter the Company’s assessment.

Earnings Per Share

The Company calculates earnings per share in accordance with FASB ASC Topic 260, Earnings per Share. Basic earnings per share are based on weighted average common shares and exclude any dilutive effects of options and restricted stock. Diluted earnings per share assumes the exercise of all dilutive stock options and restricted stock grants.

The two-class method is used to determine earnings per share based on dividends declared on common shares and participating securities (i.e., distributed earnings) and participation rights of participating securities in any undistributed earnings. Each unvested restricted share granted by the Company is considered a participating security and the Company uses the two-class method to calculate its net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic and diluted.

Foreign Exchange

Monetary assets and liabilities denominated in a currency other than the functional currency of the Company’s subsidiaries in which those monetary assets and liabilities reside are revalued into such subsidiary’s functional currency at the prevailing exchange rate on the balance sheet date. Revenues and expenses denominated in a currency other than the functional currency of the Company’s subsidiaries, are valued at the exchange rate on the date on which the underlying revenue or expense transaction occurred. The net effect of these revaluation adjustments are recognized in the Company’s consolidated statements of operations as part of net foreign exchange gains (losses).

The Company’s functional currency is the U.S. dollar. One of the Company’s subsidiaries has a functional currency other than the U.S. dollar. Assets and liabilities of the foreign operation whose functional currency is not the U.S. dollar are translated into the Company’s U.S. dollar reporting currency at prevailing balance sheet date exchange rates, while revenue and expenses of such foreign operation are translated into the Company’s U.S. dollar functional currency at monthly average exchange rates during the year. The net effect of these translation adjustments, as well as any gains or losses on intercompany balances for which settlement is not planned or anticipated in the foreseeable future, net of applicable deferred income taxes, is included in the Company’s consolidated balance sheets as currency translation adjustments and reflected within accumulated other comprehensive income (loss).

Taxation

Income Taxes

Income taxes have been provided for in accordance with the provisions of FASB ASC Topic 740, Income Taxes. Income Taxes

Deferred tax assets and liabilities result from temporary differences between the amounts recorded in the consolidated financial statements and the tax basis of the Company’s assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, deferred acquisition expenses, VOBA, intangible assets, value of in-force business, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances.

Uncertain tax positions are also accounted for in accordance with FASB ASC Topic 740, Income Taxes.

Uncertain tax positions must meet a more likely than not recognition threshold to be recognized.

Recently Adopted Accounting Pronouncements

Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (“ASU 2023-07”). Among other things, ASU 2023-07 improves the disclosures about a public entity’s reportable segments and addresses investor requests for additional, more detailed information about a reportable segment’s expenses. The amendments in ASU 2023-07 are effective for public business entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the annual reporting period beginning January 1, 2024. The adoption of ASU 2023-07 did not have a material impact on the Company’s reportable segment disclosures.

Recently Issued Accounting Pronouncements Not Yet Adopted

Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). Among other things, ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in ASU 2023-09 are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact of this guidance.

Disaggregation of Income Statement Expenses

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). Among other things, ASU 2024-03 addresses investor requests for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) in commonly presented expense captions (such as cost of sales; selling, general and administrative expenses and research and development). The amendments in ASU 2024-03 are effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance.

Basis Of Presentation

These consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the United States (“GAAP”). All significant intercompany accounts and transactions have been eliminated from these statements.

Certain comparative information has been reclassified to conform to the current presentation.

Use Of Estimates In Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported and disclosed amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. The major estimates reflected in the Company’s consolidated financial statements include, but are not limited to, the reserve for claims and claim expenses; reinsurance recoverable and premiums receivable, including provisions for reinsurance recoverable and premiums receivable to reflect expected credit losses; estimates of written and earned premiums; fair value, including the fair value of investments, financial instruments and derivatives; impairment charges; deferred acquisition costs, the value of business acquired (“VOBA”) and the fair value of other assets acquired and liabilities assumed in acquisitions; and the Company’s deferred tax valuation allowance.

Premiums and Related Expenses

Premiums are recognized as income, net of any applicable reinsurance or retrocessional coverage purchased, over the terms of the related contracts and policies. Premiums written are based on contract and policy terms and include estimates based on information received from both insureds and ceding companies. Subsequent revisions to premium estimates are recorded in the period in which they are determined. Unearned premiums represent the portion of premiums written that relate to the unexpired terms of contracts and policies in force. Amounts are computed by pro rata methods based on statistical data or reports received from ceding companies. Reinstatement premiums are estimated after the occurrence of a significant loss and are recorded in accordance with the contract terms based upon paid losses and case reserves. Reinstatement premiums are earned when written.

Company's ceded contracts contain override and management fees which are recorded as an offset against operational expenses. Deferred policy acquisition costs are limited to their estimated realizable value based on the related unearned premiums. Anticipated claims and claim expenses, based on historical and current experience, and anticipated investment income related to those premiums are considered in determining the recoverability of deferred acquisition costs.

Claims and Claim Expenses

The reserve for claims and claim expenses includes estimates for unpaid claims and claim expenses on reported losses as well as an estimate of losses incurred but not reported. The reserve is based on individual claims, case reserves and other reserve estimates reported by insureds and ceding companies as well as management estimates of ultimate losses. Inherent in the estimates of ultimate losses are expected trends in claim severity and frequency and other factors which could vary significantly as claims are settled. In addition, the Company does not have the benefit of a significant amount of its own historical experience in certain casualty and specialty and insurance lines of business. Accordingly, the reserving for incurred losses in these lines of business could be subject to greater variability.

Ultimate losses may vary materially from the amounts provided in the consolidated financial statements. These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, are reflected in the consolidated statements of operations in the period in which they become known and are accounted for as changes in estimates.

Reinsurance

Amounts recoverable from reinsurers are estimated in a manner consistent with the claims and claim expense reserves associated with the related assumed reinsurance. For multi-year retrospectively rated contracts, the Company accrues amounts (either assets or liabilities) that are due to or from retrocessionaires based on estimated contract experience. If the Company determines that adjustments to earlier estimates are appropriate, such adjustments are recorded in the period in which they are determined. Reinsurance recoverable on dual trigger reinsurance contracts require the Company to estimate its ultimate losses applicable to these contracts as well as estimate the ultimate amount of insured industry losses that will be reported by the applicable statistical reporting agency, as per the contract terms. Amounts recoverable from reinsurers are recorded net of a provision for current expected credit losses to reflect expected credit losses.

Assumed and ceded reinsurance contracts that lack significant transfer of risk are treated as deposits.

Certain assumed and ceded reinsurance contracts that do not meet all of the criteria to be accounted for as reinsurance in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 944, Financial Services – Insurance have been accounted for at fair value under the fair value option in accordance with FASB ASC Topic 825, Financial Instruments.

Fixed Maturity Investments

Investments in fixed maturities are classified as trading and are reported at fair value. Investment transactions are recorded on the trade date with balances pending settlement reflected in the balance sheet as a receivable for investments sold or a payable for investments purchased. Net investment income includes interest and dividend income together with amortization of market premiums and discounts and is net of investment management and custody fees. The amortization of premium and accretion of discount for fixed maturity securities is computed using the effective yield method. For mortgage-backed securities and other holdings for which there is prepayment risk, prepayment assumptions are evaluated quarterly and revised as necessary. Any adjustments required due to the change in effective yields and maturities are recognized on a prospective basis through yield adjustments. Fair values of investments are based on quoted market prices, or when such prices are not available, by reference to broker or underwriter bid indications and/or internal pricing valuation techniques. The net unrealized appreciation or depreciation on fixed maturity investments trading is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations. Realized gains or losses on the sale of investments are determined on the basis of the first in first out cost method.

Short Term Investments

Short term investments, which are managed as part of the Company's investment portfolio and have a maturity of one year or less when purchased, are carried at fair value. The net unrealized appreciation or depreciation on short term investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Equity Investments

Equity investments are accounted for at fair value in accordance with FASB ASC Topic 825, Financial Instruments. Fair values are primarily priced by pricing services, reflecting the closing price quoted for the final trading day of the period. Dividend income is included in net investment income and net realized and unrealized appreciation or depreciation on equity investments is included in net realized and unrealized gains (losses) on investments in the consolidated statements of operations.

Other Investments

The Company accounts for its other investments at fair value in accordance with FASB ASC Topic 825, Financial Instruments. The net asset value established by the respective fund investments manager is determined in accordance with the governing documents of such fund investments. The Company applies the practical expedient provided by the FASB ASC Topic 825, Financial Instruments relating to investments in certain entities that calculate NAV per share (or its equivalent) and therefore measure the fair value of the fund investments based on that NAV per share, or its equivalent. Fund investments are recorded on the consolidated balance sheets in other investments. Fund investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy.

Certain of the Company's fund investment managers, or their fund administrators, are unable to provide final fund valuations as of the Company's current reporting date. The Company typically experiences a reporting lag to receive a final net asset value report of one month for hedge funds and three months for both private equity funds and private credit funds, although the Company has occasionally experienced delays of up to six months, particularly at year end.

In circumstances where there is a reporting lag between the current period end reporting date and the reporting date of the latest fund valuation, the Company estimates the fair value of these funds by starting with the prior month or quarter end fund valuations, adjusting these valuations for actual capital calls, redemptions or distributions, as well as the impact of changes in foreign currency exchange rates, and then estimating the return for the current period. In circumstances in which the Company estimates the return for the current period, all information available to the Company is utilized. This principally includes using preliminary estimates reported to the Company by its

fund managers, where available, and estimating returns based on the performance of broad market indices or other valuation methods. Actual final fund valuations may differ, perhaps materially so, from the Company's estimates and these differences are recorded in the Company's statement of operations in the period in which they are reported to the Company as a change in estimate.

The Company's other investments also include investments in catastrophe bonds, direct private equity investments and term loans which are recorded at fair value. The fair value of catastrophe bonds is based on broker or underwriter bid indications. The fair value of direct private equity investments is based on quoted prices for similar assets, where available, or on the use of internal valuation models.

Investments in Other Ventures, Under Equity Method

Investments in which the Company has significant influence over the operating and financial policies of the investee are classified as investments in other ventures, under equity method, and are accounted for under the equity method of accounting. Under this method, the Company records its proportionate share of income or loss from such investments in its statements of operations for the period. Additionally, the Company records its portion of any changes to the accumulated other comprehensive income or loss of the investee in the Company's statements of comprehensive income (loss). If the Company's proportionate share of loss from such investment is in excess of the carrying value of such investment, the Company suspends the application of the equity method when the carrying value of the investment is reduced to zero, unless the Company has committed to provide further financial support to the investee. If the investee subsequently reports net income, the Company resumes applying the equity method only after its proportionate share of net income equals the proportionate share of net losses not recognized during the period the equity method was suspended. Any decline in value of investments in other ventures, under equity method considered by management to be other than temporary is charged to income in the period in which it is determined.

Cash and Cash Equivalents

Cash equivalents include money market instruments with a maturity of ninety days or less when purchased.

Stock Incentive Compensation

The Company is authorized to issue restricted stock awards and units, performance shares, stock options and other equity-based awards to its employees and directors. The fair value of the compensation cost is measured at the grant date and expensed over the period for which the employee or director is required to provide services in exchange for the award.

The Company has elected to recognize forfeitures as they occur rather than estimating service-based forfeitures over the requisite service period.

Derivatives

From time to time, the Company enters into derivative instruments such as futures, options, swaps, forward contracts and other derivative contracts primarily to manage its foreign currency exposure, obtain exposure to a particular financial market, or for trading and to assume or hedge risk. The Company accounts for its derivatives in accordance with FASB ASC Topic 815, which requires all derivatives to be recorded at fair value on the Company's balance sheet as either assets or liabilities, depending on their rights or obligations, with changes in fair value reflected in current earnings. The Company has adopted hedge accounting for certain of its derivative instruments used as hedges of a net investment in a foreign operation, as discussed below. The fair value of the Company's derivatives is estimated by reference to quoted prices or broker quotes, where available, or in the absence of quoted prices or broker quotes, the use of industry or internal valuation models.

Hedges of a Net Investment in a Foreign Operation

Changes in the fair value of derivative instruments used to hedge the net investment in a foreign operation, to the extent effective as a hedge, are recorded as a component of accumulated other comprehensive income (loss) in foreign currency translation adjustments, net of tax. Cumulative changes in fair value recorded in accumulated other comprehensive income (loss) are reclassified into earnings upon the sale, or complete or substantially complete liquidation, of the foreign operation. Any hedge ineffectiveness is recorded immediately in current period earnings as net foreign exchange gains (losses).

Hedge Documentation and Effectiveness Testing

To qualify for hedge accounting treatment, a derivative must be highly effective in mitigating the designated changes in value or cash flow of the hedged item. At the inception of a hedge, the Company formally documents relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking each hedge transaction. The documentation process includes linking derivatives that are designated as net investment hedges to specific assets or liabilities on the consolidated balance sheets. The Company also formally assesses, both at the hedge's inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the net investment in a foreign operation. The Company will discontinue hedge accounting prospectively if it determines that the derivative is no longer highly effective in offsetting changes in the net investment in a foreign operation, the derivative is no longer designated as a hedging instrument, or the derivative expires or is sold, terminated or exercised. If hedge accounting is discontinued, the derivative continues to be carried at fair value on the consolidated balance sheets with changes in its fair value recognized in current period earnings through net realized and unrealized gains (losses) on investments.

Fair Value Option

The Company has elected to account for certain of its assets and liabilities at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement. The Company recognizes the change in unrealized gains and losses arising from changes in fair value in its statements of operations.

The use of fair value to measure certain assets and liabilities with resulting unrealized gains or losses is pervasive within the Company's consolidated financial statements. Fair value is defined under accounting guidance currently applicable to the Company as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between open market participants at the measurement date. The Company recognizes the change in unrealized gains or losses arising from changes in fair value in its consolidated statements of operations.

FASB ASC Topic 820, Fair Value Measurement

prescribes a fair value hierarchy that prioritizes the inputs to the respective valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to valuation techniques that use at least one significant input that is unobservable (Level 3). The three levels of the fair value hierarchy are described below:

Fair values determined by Level 1 inputs utilize unadjusted quoted prices obtained from active markets for identical assets or liabilities for which the Company has access at the measurement date. The fair value is determined by multiplying the quoted price by the quantity held by the Company.

Fair values determined by Level 2 inputs utilize inputs (other than quoted prices included in Level 1) that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, such as interest rates and yield curves that are observable at commonly quoted intervals, broker quotes and certain pricing indices.

Level 3 inputs are based all or in part on significant unobservable inputs for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. In these cases, significant management assumptions can be used to establish management's best estimate of the assumptions used by other market participants in determining the fair value of the asset or liability.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement of the asset or liability. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and the Company considers factors specific to the asset or liability.

In order to determine if a market is active or inactive for a security, the Company considers a number of factors, including, but not limited to, the spread between what a seller is asking for a security and what a buyer is bidding for the same security, the volume of trading

activity for the security in question, the price of the security compared to its par value (for fixed maturity investments), and other factors that may be indicative of market activity.

There have been no material changes in the Company's valuation techniques, nor have there been any transfers between Level 1 and Level 2, or Level 2 and Level 3 during the period represented by these consolidated financial statements.

The Company accounts for business combinations in accordance with FASB ASC Topic 805, *Business Combinations*. Business combinations in accordance with FASB ASC Topic 350, *Intangibles – Goodwill and Other*, and goodwill and other intangible assets that arise from business combinations in accordance with FASB ASC Topic 350. Intangibles – Goodwill and Other. A purchase price that is in excess of the fair value of the net assets acquired arising from a business combination is recorded as goodwill, and is not amortized. Other intangible assets with a finite life are amortized over the estimated useful life of the asset. Other intangible assets with an indefinite useful life are not amortized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining the fair value of net assets acquired. The significant assumptions include the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges.

Goodwill and other intangible assets are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. For purposes of the annual impairment evaluation, goodwill is assigned to the applicable reporting unit of the acquired entities giving rise to the goodwill. Goodwill and other intangible assets recorded in connection with investments accounted for under the equity method, are recorded as investments in other ventures, under equity method on the Company's consolidated balance sheets.

The Company has established the second half of the year as the period for performing its annual impairment tests. The Company may determine to perform additional impairment testing at other times in the year if it is deemed necessary. The Company has elected to use the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. Under this option, the Company is not required to calculate the fair value of a reporting unit unless the Company determines, based on its qualitative assessment, that it is more likely than not that a reporting unit's fair value is less than its carrying amount. If goodwill or other intangible assets are impaired, they are written down to their estimated fair value with a corresponding expense reflected in the Company's consolidated statements of operations.

Noncontrolling Interests. The Company accounts for redeemable noncontrolling interests in the mezzanine section of the Company's consolidated balance sheets in accordance with United States Securities and Exchange Commission ("SEC") guidance which is applicable to SEC registrants. The share classes related to the redeemable noncontrolling interest portion of the issuer are accounted for in accordance with SEC guidance, which requires that shares not required to be accounted for in accordance with FASB ASC Topic 480, *Distinctions Between Equity and Debt*, and having redemption features that are not solely within the control of the issuer, to be classified outside of permanent equity in the mezzanine section of the balance sheet. The SEC guidance does not impact the accounting for redeemable noncontrolling interest on the consolidated statements of operations; therefore, the provisions of FASB ASC Topic 810, *Consolidation*, as amended, apply, and net (income) loss attributable to redeemable noncontrolling interests is presented separately in the Company's consolidated statements of operations.

Variable Interest Entities. The Company accounts for variable interest entities ("VIEs") in accordance with FASB ASC Topic 810, *Consolidation*, which requires the consolidation of all VIEs by the primary beneficiary, that being the investor that has the power to direct the activities of the VIE and that will absorb a portion of the VIE's expected losses or residual returns that could potentially be significant to the VIE. When the Company determines it has a variable interest in a VIE, it determines whether it is the primary beneficiary of that VIE by performing an analysis that principally considers: (i) the VIE's purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders; (ii) the VIE's capital structure; (iii) the terms between the VIE and its variable interest holders and other parties involved with the VIE; (iv) which variable interest holders have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; (v) which variable interest holders have the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE; and (vi) related party relationships. The Company reassesses its determination of whether the Company is the primary beneficiary of a VIE upon changes in facts and circumstances that could potentially alter the Company's assessment.

Earnings Per Share. The Company calculates earnings per share in accordance with FASB ASC Topic 260, *Earnings Per Share*. Basic earnings per share are based on weighted average common shares and exclude any dilutive effects of options and restricted stock. Diluted earnings per share assumes the exercise of all dilutive stock options and restricted stock grants.

The two-class method is used to determine earnings per share based on dividends declared on common shares and participating securities (i.e., distributed earnings) and participation rights of participating securities in any undistributed earnings. Each unvested restricted share granted by the Company is considered a participating security and the Company uses the two-class method to calculate its net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic and diluted.

Foreign Exchange. Monetary assets and liabilities denominated in a currency other than the functional currency of the Company's subsidiaries in which those monetary assets and liabilities reside are revalued into such subsidiary's functional currency at the prevailing exchange rate on the balance sheet date. Revenues and expenses denominated in a currency other than the functional currency of the Company's subsidiaries, are valued at the exchange rate on the date on which the underlying revenue or expense transaction occurred. The net effect of these revaluation adjustments are recognized in the Company's consolidated statements of operations as part of net foreign exchange gains (losses).

The Company's functional currency is the U.S. dollar. One of the Company's subsidiaries has a functional currency other than the U.S. dollar. Assets and liabilities of the foreign operation whose functional currency is not the U.S. dollar are translated into the Company's U.S. dollar reporting currency at prevailing balance sheet date exchange rates, while revenue and expenses of such foreign operation are translated into the Company's U.S. dollar functional currency at monthly average exchange rates during the year. The net effect of these translation adjustments, as well as any gains or losses on intercompany balances for which settlement is not planned or anticipated in the foreseeable future, net of applicable deferred income taxes, is included in the Company's consolidated balance sheets as currency translation adjustments and reflected within accumulated other comprehensive income (loss).

Taxation. Income taxes have been provided for in accordance with the provisions of FASB ASC Topic 740, *Income Taxes*. Deferred tax assets and liabilities result from temporary differences between the amounts recorded in the consolidated financial statements and the tax basis of the Company's assets and liabilities. Such temporary differences are primarily due to net operating loss and capital loss carryforwards and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, deferred acquisition expenses, VOBA, intangible assets, value of in-force business, and amortization and depreciation, among others. The effect on deferred tax assets and liabilities of a change in tax law or tax rates is recognized in income in the period in which the change is enacted. A valuation allowance against net deferred tax assets is recorded if it is more likely than not that all, or some portion, of the benefits related to net deferred tax assets will not be realized. Significant judgments, assumptions and estimates, which are inherently subjective, are required in determining income tax expense, temporary differences, the deferred tax impact of a change in law, and valuation allowances.

Uncertain tax positions are also accounted for in accordance with FASB ASC Topic 740, *Income Taxes*. Uncertain tax positions must meet a more likely than not recognition threshold to be recognized.

Recently Adopted Accounting Pronouncements. The Company has adopted the following accounting pronouncements:

[illegible]

Cash Consideration

Cash consideration funded by net proceeds from the issuance of common shares of RenaissanceRe to the public market

1,351,608

Cash consideration funded by available cash resources

642,811

Cash consideration funded by available cash resources

Total cash consideration paid by RenaissanceRe as acquisition consideration

2,735,000

Total purchase price

3,020,168

(1) The common share price of RenaissanceRe is based on the closing price of \$226.97 per RenaissanceRe common share on the closing date of the Validus Acquisition, November 1, 2023 with a 5% discount to reflect restrictions on the transfer of those shares.

Fair Value of Net Assets Acquired and Liabilities Assumed

The purchase price was allocated to the acquired assets and liabilities of the Company based on estimated fair values on November 1, 2023, the date the transaction closed, as detailed in the table below:

Assets	301,253
Investments trading	3,248,242
Short term investments	1,659,902
Investments in other ventures, under equity method	3,997

[illegible]

[illegible]

'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;>5,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">0.5 years</td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceceff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 1pt;text-align:left;text-indent: 9pt;vertical-align:bottom">Renewal rights</td><td colspan="3" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">215,000 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:center;vertical-align:bottom">15 years</td><td colspan="3" style="background-color:#ceceff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent: 9pt">Asset management contracts</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">4 years</td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceceff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent: 9pt">Insurance licenses</div></td><td colspan="3" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,884 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:center;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ceceff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent: 9pt">Cross identifiable intangible assets related to the acquisition of Validus, at November 1, 2023 </div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">460,884 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated amortization (from November 1, 2023 through December 31, 2024), net of foreign exchange</div></td><td colspan="3" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,489 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 1pt;text-align:left;text-indent: 9pt;vertical-align:bottom"><div style="padding-left:18pt;text-indent: 9pt">Net identifiable intangible assets related to the acquisition of Validus at December 31, 2024</div></td><td colspan="3" style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">386,628 </td><td style="background-color:#ceceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:center;vertical-align:bottom">Impairment loss on insurance licenses</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,767 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent: 9pt"><div style="padding-left:18pt;text-indent: 9pt">Amortization from the acquisition date, November 1, 2023, through December 31, 2023 was included in the Company's consolidated statements of operations for the year ended December 31, 2023.</div><div style="margin-top:6pt">An explanation of the identifiable indefinite and finite intangible assets is as follows:</div><div style="margin-top:6pt;padding-left:27pt;text-indent: 9pt">Agent relationships – top four – the value of Validus' relationships with their top four brokers (Marsh & McLennan Companies, Inc., Aon Benfield Group Ltd., Willis Towers Watson Pte and Arthur J. Gallagher & Co.) after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years;</div><div style="margin-top:6pt;padding-left:27pt;text-indent: 9pt">Renewal rights – the value of policy renewal rights was determined after taking into consideration certain key assumptions, including the estimated cost of capital, investment yield, loss ratio, related expenses, effective tax rates and capital charges that would impact the expected cash flows from these renewals over the expected life of these policies. These will be amortized based on an economic benefit pattern over its useful life as of the acquisition date, the majority of which is expected to be within the first 10 years; and</div><div style="margin-top:6pt;padding-left:27pt;text-indent: 9pt">Insurance licenses – the value of acquired insurance licenses.</div><div style="margin-top:6pt">Financial Results</div><div style="margin-top:6pt">The following table summarizes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023. Operating activities of Validus from the acquisition date, November 1, 2023, through December 31, 2023 are included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023.</div><div style="margin-top:6pt">The unaudited net contribution of the acquisition and integration of Validus is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that may be achieved in the future. These results are not used as a part of management's analysis of the financial performance of the Company's business. These results primarily reflect items recorded directly by Validus from November 1, 2023 through December 31, 2023, including: 1) net premiums earned and net underwriting income on the in-force portfolio acquired with the acquisition of Validus and previously retained on Validus entities' balance sheets; 2) net premiums earned and net underwriting income for those contracts which renewed post-acquisition on one of the acquired Validus entities' balance sheets; 3) net investment income and net realized and unrealized gains recorded directly by Validus; and 4) certain direct costs incurred directly by Validus. In addition, these results, where possible, were adjusted for transaction and integration related costs incurred

The Company. However, these results do not reflect on-going operating costs incurred by the Company in supporting Validus unless such costs were incurred directly by Validus. These results also do not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may be achieved in the future. These results involve significant estimates and are not indicative of the future results of the acquired Validus entities which have been, and will continue to be impacted by potential changes in targeted business mix, investment management strategies, and synergies recognized from changes in the combined entity's operating structure, as well as the impact of changes in other business and capital management strategies.

	(1)	(2)	Total revenues
Year ended December 31, 2023	\$696,888	\$307,802	\$1,004,690
Year ended December 31, 2022	\$696,888	\$307,802	\$1,004,690

Supplemental Pro Forma Information

The following table presents unaudited pro forma consolidated financial information for the years ended December 31, 2023 and 2022, respectively, and assumes the acquisition of Validus occurred on January 1, 2022. The unaudited pro forma consolidated financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the transaction been completed as of January 1, 2022 or that may be achieved in the future. The unaudited pro forma consolidated financial information does not give consideration to the impact of possible revenue enhancements, expense efficiencies, synergies or asset dispositions that may result from the acquisition of Validus. In addition, unaudited pro forma consolidated financial information does not include the effects of costs associated with any restructuring or integration activities resulting from the acquisition of Validus, as they are nonrecurring.

	(1)	(2)	Total revenues
Year ended December 31, 2023	\$696,888	\$307,802	\$1,004,690
Year ended December 31, 2022	\$696,888	\$307,802	\$1,004,690

At the date of the acquisition the Company established a net deferred tax asset of \$73.0 million and recorded a valuation allowance against Validus' deferred tax assets of \$66.0 million resulting in a net acquired deferred tax asset of \$7.0 million. A net deferred tax liability of \$46.2 million was also recorded related to the estimated fair value of intangible assets recorded, VOBA and other adjustments to the fair values of the assets acquired and liabilities assumed. This resulted in a net deferred tax liability of \$39.2 million recorded in conjunction with the acquisition of Validus. The Company estimated that goodwill related to the acquisition of Validus Specialty of approximately \$24 million will be deductible for U.S. tax purposes resulting in an estimated future tax benefit of approximately \$5 million.

[illegible]

Cash consideration funded by available cash resources

Total cash consideration paid by RenaissanceRe as acquisition consideration

Total purchase price

Total revenues

Net income (loss) available (attributable) to RenaissanceRe common shareholders

Year ended December 31, 2023

Includes the net contribution from the acquisition of Validus since November 1, 2023 that was included in the Company's consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2023.

Includes \$76.4 million of corporate expenses associated with the acquisition and integration of Validus for the year ended December 31, 2023.

The purchase price was allocated to the

[illegible]

[illegible]

[illegible]

Year ended December 31,

	2022	2023
Total revenues	\$11,611,682	\$7,169,338
Net income (loss) available (attributable) to RenaissanceRe common shareholders	(1,552,425)	(1,552,425)

The following tables show an analysis of goodwill and other intangible assets, net of foreign currency translation adjustments, included in goodwill and other intangible assets on the Company's consolidated balance sheets:

	Goodwill	Other Intangible Assets
At December 31,	\$1,611,682,000	\$1,611,682,000
Goodwill, net	\$1,611,682,000	\$1,611,682,000
Other intangible assets, net	\$1,611,682,000	\$1,611,682,000

Other intangible assets, net

	2022	2023
Goodwill, net	\$1,611,682,000	\$1,611,682,000
Other intangible assets, net	\$1,611,682,000	\$1,611,682,000

[illegible]

[illegible]

[illegible]

[illegible]

Net

Customer relationships and customer lists

Licenses

(1)

Asset management contracts

20,000

(833)

19,167

4,500

Patents and intellectual property

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

At December 31, 2023

Financials

Basic materials

Industrial, utilities and energy

Consumer

Healthcare

Total

Pledged Investments

Reverse Repurchase Agreements

Net Investment Income

The components of net investment income are as follows:

[illegible]

[illegible]

[illegible]

[illegible]

211,866

59,905

97,658

4,324,761

3,515,566

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

1980

1979

1978

1977

1976

1975

1974

1973

1972

1971

1970

1969

1968

1967

1966

1965

1964

1963

1962

1961

1960

1959

1958

1957

1956

1955

1954

1953

1952

1951

1950

1949

1948

1947

1946

1945

1944

1943

1942

1941

1940

1939

1938

1937

1936

1935

1934

1933

1932

1931

1930

1929

1928

1927

1926

1925

1924

1923

1922

1921

1920

1919

1918

1917

1916

1915

1914

1913

1912

1911

1910

1909

1908

1907

1906

1905

1904

1903

1902

1901

1900

1899

1898

1897

1896

1895

1894

1893

1892

1891

1890

1889

1888

1887

1886

1885

1884

1883

1882

1881

1880

1879

1878

1877

1876

1875

1874

1873

1872

1871

1870

1869

1868

1867

1866

1865

1864

1863

1862

1861

1860

1859

1858

1857

1856

1855

1854

1853

1852

1851

1850

1849

1848

1847

1846

1845

1844

1843

1842

1841

1840

1839

1838

1837

1836

1835

1834

1833

1832

1831

1830

1829

1828

1827

1826

1825

1824

1823

1822

1821

1820

1819

1818

1817

[illegible]

Table 1: Fair value of fixed maturity investments trading

Investment	2023	2022
U.S. treasuries	11,001,893	1,707,056
Corporate	7,862,423	1,422,393
Asset-backed	1,422,393	1,422,393
Residential mortgage-backed	1,422,393	1,422,393
Agencies	623,489	623,489

The following table summarizes the fair value of fixed maturity investments trading:

Investment	2023	2022
U.S. treasuries	11,001,893	1,707,056
Corporate	7,862,423	1,422,393
Asset-backed	1,422,393	1,422,393
Residential mortgage-backed	1,422,393	1,422,393
Agencies	623,489	623,489

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

At December 31, 2023

Assets (Level 1)	Liabilities (Level 1)
Total	Total
Unobservable Inputs (Level 3)	Unobservable Inputs (Level 3)
Fixed maturity investments trading	Fixed maturity investments trading
U.S. treasuries	U.S. treasuries
Corporate	Corporate
Asset-backed	Asset-backed
Residential mortgage-backed	Residential mortgage-backed
Agencies	Agencies

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Investments

Investment	Cost	Current Value	Gain/Loss
Investment 1	100,000	120,000	20,000
Investment 2	150,000	140,000	(10,000)
Investment 3	200,000	250,000	50,000
Investment 4	250,000	280,000	30,000
Investment 5	300,000	320,000	20,000
Investment 6	350,000	380,000	30,000
Investment 7	400,000	420,000	20,000
Investment 8	450,000	480,000	30,000
Investment 9	500,000	520,000	20,000
Investment 10	550,000	580,000	30,000
Investment 11	600,000	620,000	20,000
Investment 12	650,000	680,000	30,000
Investment 13	700,000	720,000	20,000
Investment 14	750,000	780,000	30,000
Investment 15	800,000	820,000	20,000
Investment 16	850,000	880,000	30,000
Investment 17	900,000	920,000	20,000
Investment 18	950,000	980,000	30,000
Investment 19	1,000,000	1,020,000	20,000
Investment 20	1,050,000	1,080,000	30,000
Investment 21	1,100,000	1,120,000	20,000
Investment 22	1,150,000	1,180,000	30,000
Investment 23	1,200,000	1,220,000	20,000
Investment 24	1,250,000	1,280,000	30,000
Investment 25	1,300,000	1,320,000	20,000
Investment 26	1,350,000	1,380,000	30,000
Investment 27	1,400,000	1,420,000	20,000
Investment 28	1,450,000	1,480,000	30,000
Investment 29	1,500,000	1,520,000	20,000
Investment 30	1,550,000	1,580,000	30,000
Investment 31	1,600,000	1,620,000	20,000
Investment 32	1,650,000	1,680,000	30,000
Investment 33	1,700,000	1,720,000	20,000
Investment 34	1,750,000	1,780,000	30,000
Investment 35	1,800,000	1,820,000	20,000
Investment 36	1,850,000	1,880,000	30,000
Investment 37	1,900,000	1,920,000	20,000
Investment 38	1,950,000	1,980,000	30,000
Investment 39	2,000,000	2,020,000	20,000
Investment 40	2,050,000	2,080,000	30,000
Investment 41	2,100,000	2,120,000	20,000
Investment 42	2,150,000	2,180,000	30,000
Investment 43	2,200,000	2,220,000	20,000
Investment 44	2,250,000	2,280,000	30,000
Investment 45	2,300,000	2,320,000	20,000
Investment 46	2,350,000	2,380,000	30,000
Investment 47	2,400,000	2,420,000	20,000
Investment 48	2,450,000	2,480,000	30,000
Investment 49	2,500,000	2,520,000	20,000
Investment 50	2,550,000	2,580,000	30,000
Investment 51	2,600,000	2,620,000	20,000
Investment 52	2,650,000	2,680,000	30,000
Investment 53	2,700,000	2,720,000	20,000
Investment 54	2,750,000	2,780,000	30,000
Investment 55	2,800,000	2,820,000	20,000
Investment 56	2,850,000	2,880,000	30,000
Investment 57	2,900,000	2,920,000	20,000
Investment 58	2,950,000	2,980,000	30,000
Investment 59	3,000,000	3,020,000	20,000
Investment 60	3,050,000	3,080,000	30,000
Investment 61	3,100,000	3,120,000	20,000
Investment 62	3,150,000	3,180,000	30,000
Investment 63	3,200,000	3,220,000	20,000
Investment 64	3,250,000	3,280,000	30,000
Investment 65	3,300,000	3,320,000	20,000
Investment 66	3,350,000	3,380,000	30,000
Investment 67	3,400,000	3,420,000	20,000
Investment 68	3,450,000	3,480,000	30,000
Investment 69	3,500,000	3,520,000	20,000
Investment 70	3,550,000	3,580,000	30,000
Investment 71	3,600,000	3,620,000	20,000
Investment 72	3,650,000	3,680,000	30,000
Investment 73	3,700,000	3,720,000	20,000
Investment 74	3,750,000	3,780,000	30,000
Investment 75	3,800,000	3,820,000	20,000
Investment 76	3,850,000	3,880,000	30,000
Investment 77	3,900,000	3,920,000	20,000
Investment 78	3,950,000	3,980,000	30,000
Investment 79	4,000,000	4,020,000	20,000
Investment 80	4,050,000	4,080,000	30,000
Investment 81	4,100,000	4,120,000	20,000
Investment 82	4,150,000	4,180,000	30,000
Investment 83	4,200,000	4,220,000	20,000
Investment 84	4,250,000	4,280,000	30,000
Investment 85	4,300,000	4,320,000	20,000
Investment 86	4,350,000	4,380,000	30,000
Investment 87	4,400,000	4,420,000	20,000
Investment 88	4,450,000	4,480,000	30,000
Investment 89	4,500,000	4,520,000	20,000
Investment 90	4,550,000	4,580,000	30,000
Investment 91	4,600,000	4,620,000	20,000
Investment 92	4,650,000	4,680,000	30,000
Investment 93	4,700,000	4,720,000	20,000
Investment 94	4,750,000	4,780,000	30,000
Investment 95	4,800,000	4,820,000	20,000
Investment 96	4,850,000	4,880,000	30,000
Investment 97	4,900,000	4,920,000	20,000
Investment 98	4,950,000	4,980,000	30,000
Investment 99	5,000,000	5,020,000	20,000
Investment 100	5,050,000	5,080,000	30,000

[illegible]

Other Investments

At December 31, 2024, the Company's other investments included \$43.8 million (2023 – \$59.9 million) of direct private equity investments which are recorded at fair value, with the fair value obtained through the use of internal valuation models. The Company measured the fair value of these investments using multiples of net tangible book value of the underlying entities. The significant unobservable inputs used in the fair value measurement of these investments are liquidity discount rates applied to each of the net tangible book value multiples used in the internal valuation models, and discount rates applied to the expected cash flows of the underlying entities in various scenarios. These unobservable inputs in isolation can cause significant increases or decreases in fair value. Generally, an increase in the liquidity discount rate or discount rates would result in a decrease in the fair value of these private equity investments.

Term Loans

During 2024, the Company disposed of its investment in a term loan. At December 31, 2023, the Company's other investments included a \$97.7 million investment which was recorded at fair value, with the fair value obtained through the use of a discounted cash flow model. The significant unobservable inputs used in the discounted cash flow model were the cash flow projection of the associated term loan, and the discount rate. The discount rate used was based on the Secured Overnight Financing Rate ("SOFR"), which was then adjusted for credit risk and a risk premium. These adjustments may be impacted by market movements implied by transactions of similar or related assets; loan-to-value, tenor, liquidity, credit risk adjustment or other risk factors. Assumptions used in the valuation process may significantly impact the resulting fair value.

Assumed and Ceded (Re)insurance Contracts

At December 31, 2024, the Company had a \$0.4 million net liability (2023 – \$0.5 million net liability) related to assumed and ceded (re)insurance contracts accounted for at fair value, with the fair value obtained through the use of an internal valuation model. The inputs to the internal valuation model are principally based on proprietary data as observable market inputs are generally not available. The most significant unobservable inputs include the assumed and ceded expected net cash flows related to the contracts, including the expected premium, acquisition expenses and losses; the expected loss ratio and the relevant discount rate used to present value the net cash flows. The contract period and acquisition expense ratio are considered an observable input as each is defined in the contract. Generally, an increase in the net expected cash flows and expected term of the contract and a decrease in the discount rate, expected loss ratio or acquisition expense ratio, would result in an increase in the expected profit and ultimate fair value of these assumed and ceded (re)insurance contracts.

Financial Instruments Disclosed, But Not Carried, at Fair Value

The Company uses various financial instruments in the normal course of its business. The Company's (re)insurance contracts are excluded from the fair value of financial instruments accounting guidance, unless the Company elects the fair value option, and therefore, are not included in the amounts discussed herein. The carrying values of cash and cash equivalents, accrued investment income, receivables for investments sold, certain other assets, payables for investments purchased, certain other liabilities, and other financial instruments not included herein approximated their fair values.

Debt

Included on the Company's consolidated balance sheet at December 31, 2024 were debt obligations of \$1.9 billion (2023 – \$2.0 billion). At December 31, 2024, the fair value of the Company's debt obligations was \$1.9 billion (2023 – \$1.9 billion).

The fair value of the Company's debt obligations is determined using indicative market pricing obtained from third-party service providers, which the Company considers Level 2 in the fair value hierarchy. There have been no changes during the period in the Company's valuation technique used to determine the fair value of the Company's debt obligations. Refer to "Note 9. Debt and Credit Facilities" for additional information related to the Company's debt obligations.

The Fair Value Option for Financial Assets and Financial Liabilities

The Company has elected to account for certain financial assets and financial liabilities at fair value using the guidance under FASB ASC Topic 825, as the Company believes it represents the most meaningful measurement basis for these assets and liabilities. Below is a summary of the balances the Company has elected to account for at fair value:

	December 31, 2024	December 31, 2023
Assets	\$1.167%	\$1.167%
Liabilities	\$0.588%	\$0.588%

The following table provides a reconciliation of the fair value measurements categorized by level of the fair value hierarchy:

	December 31, 2024	December 31, 2023
Level 1	\$0.000%	\$0.000%
Level 2	\$0.000%	\$0.000%
Level 3	\$0.000%	\$0.000%

The following table provides a reconciliation of the fair value measurements categorized by type of instrument:

	December 31, 2024	December 31, 2023
Equity securities	\$0.000%	\$0.000%
Fixed income securities	\$0.000%	\$0.000%
Derivatives	\$0.000%	\$0.000%
Other	\$0.000%	\$0.000%

[illegible]

[illegible]

Total of other investments measured using net asset valuations

Entity	Investment Type	Investment Amount	Investment Date
Private Credit Funds	Private Credit Funds	1,415,804	1,415,804
Private Equity Funds	Private Equity Funds	1,622,913	1,622,913
Hedge Funds	Hedge Funds	1,863,142	1,863,142
Limited Partnerships	Limited Partnerships	3,856,504	3,856,504
Other Investments	Other Investments	1,993,362	1,993,362
Unfunded Commitments	Unfunded Commitments	1,993,362	1,993,362
Total	Total	11,695,538	11,695,538

At December 31, 2024

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Total other investments

Other assets and (liabilities)

Assumed and ceded (re)insurance contracts

Internal valuation model

Net undiscounted cash flows

Discount rate

Total other assets and (liabilities)

(405)

<table><tr><td colspan=

[illegible]

[illegible]

Direct Private Equity Investments

Year	Investment	Amount
2014	Investment in ABC Corp.	\$100M
2015	Investment in DEF Corp.	\$150M
2016	Investment in GHI Corp.	\$200M
2017	Investment in JKL Corp.	\$250M
2018	Investment in MNO Corp.	\$300M
2019	Investment in PQR Corp.	\$350M
2020	Investment in STU Corp.	\$400M
2021	Investment in VWX Corp.	\$450M
2022	Investment in YZA Corp.	\$500M
2023	Investment in BCD Corp.	\$550M
2024	Investment in EFG Corp.	\$600M

Term Loans

Year	Loan	Amount
2014	Loan to ABC Corp.	\$100M
2015	Loan to DEF Corp.	\$150M
2016	Loan to GHI Corp.	\$200M
2017	Loan to JKL Corp.	\$250M
2018	Loan to MNO Corp.	\$300M
2019	Loan to PQR Corp.	\$350M
2020	Loan to STU Corp.	\$400M
2021	Loan to VWX Corp.	\$450M
2022	Loan to YZA Corp.	\$500M
2023	Loan to BCD Corp.	\$550M
2024	Loan to EFG Corp.	\$600M

Other Assets

Year	Asset	Amount
2014	Asset in ABC Corp.	\$100M
2015	Asset in DEF Corp.	\$150M
2016	Asset in GHI Corp.	\$200M
2017	Asset in JKL Corp.	\$250M
2018	Asset in MNO Corp.	\$300M
2019	Asset in PQR Corp.	\$350M
2020	Asset in STU Corp.	\$400M
2021	Asset in VWX Corp.	\$450M
2022	Asset in YZA Corp.	\$500M
2023	Asset in BCD Corp.	\$550M
2024	Asset in EFG Corp.	\$600M

Liabilities

Year	Liability	Amount
2014	Liability in ABC Corp.	\$100M
2015	Liability in DEF Corp.	\$150M
2016	Liability in GHI Corp.	\$200M
2017	Liability in JKL Corp.	\$250M
2018	Liability in MNO Corp.	\$300M
2019	Liability in PQR Corp.	\$350M
2020	Liability in STU Corp.	\$400M
2021	Liability in VWX Corp.	\$450M
2022	Liability in YZA Corp.	\$500M
2023	Liability in BCD Corp.	\$550M
2024	Liability in EFG Corp.	\$600M

Total

Year	Total	Amount
2014	Total	\$100M
2015	Total	\$150M
2016	Total	\$200M
2017	Total	\$250M
2018	Total	\$300M
2019	Total	\$350M
2020	Total	\$400M
2021	Total	\$450M
2022	Total	\$500M
2023	Total	\$550M
2024	Total	\$600M

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

bottom

Assumed

Ceded

Gross claims and claim expenses incurred

Net premiums earned

Claims and Claim Expenses

Gross claims and claim expenses recovered

Net claims and claim expenses incurred

[illegible]

Reinsurance recoverable reflects amounts due from reinsurers based on the claim liabilities associated with the reinsurance policy. The Company accrues amounts that are due from reinsurers based on estimated ultimate losses applicable to the contracts.

At December 31, 2024, the Company's reinsurance recoverable balance was \$4.5 billion (2023 – \$5.3 billion). Of the Company's reinsurance recoverable balance at December 31, 2024, 55.7% is fully collateralized by the Company's reinsurers, 43.2% is recoverable from reinsurers rated A- or higher by major rating agencies and 1.0% is recoverable from reinsurers rated lower than A- by major rating agencies (2023 – 60.6%, 38.5% and 0.9%, respectively). The reinsurers with the three largest balances accounted for 12.6%, 11.0% and 8.3%, respectively, of the Company's reinsurance recoverable balance at December 31, 2024 (2023 – 17.6%, 14.3% and 8.7%, respectively). The provision for current expected credit losses was \$11.7 million at December 31, 2024 (2023 – \$13.3 million). The three largest company-specific components of the provision for current expected credit losses represented 23.9%, 7.2% and 5.9%, respectively, of the Company's total provision for current expected credit losses at December 31, 2024 (2023 – 10.9%, 10.7% and 8.1%, respectively). The following table provides a roll forward of the provision for current expected credit losses of the Company's reinsurance recoverable:

	2024	2023
Beginning balance	\$13,279	\$12,169
Provision for (release of) allowance	(1,549)	(3,644)
Ending balance	\$11,730	\$8,525

The following table sets forth the effect of reinsurance and retrocessional activity on premiums written and earned and on net claims and claim expenses incurred:

	2024	2023
Validus' provision for current expected credit losses on reinsurance recoverable, acquired November 1, 2023	\$9,842	\$11,498
Effect of reinsurance and retrocessional activity on premiums written and earned and on net claims and claim expenses incurred	\$1,938	\$1,938
Total	\$11,780	\$13,436

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

further challenges compared to directly assumed reinsurance. In addition, the Company's actual net losses from these events may increase if the Company's reinsurers or other obligors fail to meet their obligations.

The Company reevaluates its actuarial reserving assumptions on a periodic basis. Typically, the quarterly review procedures include reviewing paid and reported claims in the most recent reporting period, reviewing the development of paid and reported claims from prior periods, and reviewing the Company's overall experience by underwriting year and in the aggregate. The Company monitors its expected ultimate claims and claim expense ratios and expected claims reporting assumptions on a quarterly basis and compares them to its actual experience. These actuarial assumptions are generally reviewed annually, based on input from the Company's actuaries, underwriters, claims personnel and finance professionals, although adjustments may be made more frequently if needed. Assumption changes are made to adjust for changes in the terms of coverage the Company provides, changes in industry results for similar business, as well as its actual experience to the extent the Company has enough data to rely on its own experience. If the Company determines that adjustments to an earlier estimate are appropriate, such adjustments are recorded in the period in which they are identified.

Because of the inherent uncertainties discussed above, the Company has developed a reserving philosophy that attempts to incorporate prudent assumptions and estimates, and the Company has generally experienced favorable development on prior accident years net claims and claim expenses in the last several years. However, there is no assurance that this favorable development on prior accident years net claims and claim expenses will occur in future periods.

The Company establishes a provision for unallocated loss adjustment expenses ("ULAE") when the related reserve for claims and claim expenses is established. ULAE are expenses that cannot be associated with a specific claim but are related to claims paid or in the process of settlement, such as internal costs of the claims function, and are included in the reserve for claims and claim expenses. The determination of the ULAE provision is subject to judgment.

Incurred and Paid Claims Development and Reserving Methodology

The information provided herein about incurred and paid accident year claims development for the years ended prior to December 31, 2024 on a consolidated basis and by segment is presented as supplementary information. The Company has applied a retrospective approach with respect to its acquisitions, presenting all relevant historical information for all periods presented. In addition, included in the incurred claims and claim expenses and cumulated paid claims and claim expenses tables below are reconciling items that represent the unamortized balance of fair value adjustments recorded in connection with the acquisition of TMR and Validus to reflect an increase in net claims and claim expenses due to the addition of a market based risk margin that represented the cost of capital required by a market participant to assume the net claims and claim expenses of TMR and Validus, partially offset by a decrease from discounting in connection with the acquisition of TMR and Validus, to reflect the time value of money.

For incurred and paid accident year claims denominated in currencies other than USD, the Company used the current year-end balance sheet foreign exchange rate for all periods provided, thereby eliminating the effects of changes in foreign currency translation rates from the incurred and paid accident year claims development information included in the tables below.

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Incurred Claims and Claim Expenses, Net of Reinsurance	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Incurred Claims and Claim Expenses, Net of Reinsurance and ULAE	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Paid Claims and Claim Expenses	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%
ULAE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Paid Claims and Claim Expenses, Net of Reinsurance and ULAE	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%	99.528%

The following table details the Company's consolidated incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2015	2016	2017	2018	2019	2020	2021	2022	2		

[illegible]

[illegible]

[illegible]


```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[illegible]

[illegible]

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```


[illegible]

[illegible]

[illegible]

access and pay such claims promptly. Because losses from which claims arise under policies written within the Property segment are typically prominent, public events such as hurricanes and earthquakes, the Company is often able to use independent reports as part of its loss reserve estimation process. The Company also reviews catastrophe bulletins published by various statistical reporting agencies to assist in determining the size of the industry loss, although these reports may not be available for some time after an event. For smaller events including localized severe weather events such as windstorms, hail, ice, snow, flooding, freezing and tornadoes, which are not necessarily prominent, public occurrences, the Company uses standard actuarial techniques to set reserves as it does in other property. The assumptions used are monitored and reviewed through the year to ensure they reflect the level of small cat activity experienced through the year and the exposure to the geographic regions involved. For these small events, the IBNR is run-off over time using Bornhuetter-Ferguson actuarial method, a standard actuarial technique. The loss development factors for the reported Bornhuetter-Ferguson actuarial method are selected based on a review of the Company's historical experience. The reported loss development factors are typically reviewed annually. In general, reserves for the Company's more recent large losses are subject to greater uncertainty and, therefore, greater potential variability, and are likely to experience material changes from one period to the next. This is due to the uncertainty as to the size of the industry losses, uncertainty as to which contracts have been exposed, uncertainty due to complex legal and coverage issues that can arise out of large or complex losses, and uncertainty as to the magnitude of claims incurred by the Company's customers. As the Company's claims age, more information becomes available and the Company believes its estimates become more certain.

The following table details the Company's Property segment incurred claims and claim expenses and cumulative paid claims and claim expenses as of December 31, 2024, net of reinsurance, as well as IBNR and ACR included within the net incurred claims amounts:

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Incurred Claims and Claim Expenses, Net of Reinsurance	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
IBNR	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
ACR	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000
Total	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000	\$3,000,000

For the year ended December 31, 2024, the Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2023. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2022. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2021. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2020. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2019. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2018. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2017. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2016. The Company's Property segment incurred claims and claim expenses of \$1,000,000, net of reinsurance, for the year ended December 31, 2015.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Casualty and Specialty Segment

The Company offers its casualty and specialty reinsurance products principally on a proportional basis, and it also provides excess of loss coverage. The Company offers casualty and specialty reinsurance products to insurance and reinsurance companies and provides coverage for specific geographic regions or on a worldwide basis. Principally all of the business is reinsurance, although the Company also writes insurance business.

As with the Company's Property segment, its Casualty and Specialty segment reinsurance contracts can include coverage for relatively large limits or exposures. As a result, the Company's casualty and specialty reinsurance business can be subject to significant claims volatility. In periods of low claims frequency or severity, the Company's results will generally be favorably impacted while in periods of high claims frequency or severity the Company's results will generally be negatively impacted.

The Company's processes and methodologies in respect of loss estimation for the coverages offered through its Casualty and Specialty segment differ from those used for its Property segment. For example, the Company's casualty and specialty coverages are more likely to be impacted by factors such as long-term inflation and changes in the social and legal environment, which the Company believes gives rise to greater uncertainty in its reserves for claims and claim expenses. The Company believes this makes its Casualty and Specialty segment reserving subject to greater uncertainty than its Property segment.

The Company calculates multiple point estimates for claims and claim expense reserves using a variety of actuarial reserving techniques for many, but not all, of its classes of business for each underwriting year within the Casualty and Specialty segment. The Company does not believe that these multiple point estimates are, or should be considered, a range. Rather, the Company considers each class of business and determines the most appropriate point estimate for each underwriting year based on the characteristics of the particular class including:

- (1) loss development patterns derived from historical data;
- (2) the credibility of the selected loss development pattern;
- (3) the stability of the loss development patterns;
- (4) how developed the underwriting year is; and
- (5) the observed loss development of other underwriting years for the same class.

The Company also considers other relevant factors, including:

- (1) historical ultimate loss ratios;
- (2) the presence of individual large losses; and
- (3) known occurrences that have not yet resulted in reported losses.

The Company makes determinations of the most appropriate point estimate of loss for each class based on an evaluation of relevant information and does not ascribe any particular portion of the estimate to a particular factor or consideration. In addition, the Company believes that a review of individual contract information improves the loss estimates for some classes of business.

When developing claims and claims expense reserves for its Casualty and Specialty segment, the Company considers several actuarial techniques such as the expected loss ratio method, the Bornhuetter-Ferguson actuarial method and the paid and reported chain ladder actuarial method.

For classes of business and underwriting years where the Company has limited historical claims experience, estimates of ultimate losses are generally initially determined based on the loss ratio method applied to each underwriting year and to each class of business. Unless the Company has credible claims experience or unfavorable development, it generally selects an ultimate loss based on its initial expected loss ratio. The selected ultimate losses are determined by multiplying the initial expected loss ratio by the earned premium. The initial expected loss ratios are key inputs that involve management judgment and are based on a variety of factors, including:

- (1) contract by contract expected loss ratios developed during the Company's pricing process;
- (2) historical loss ratios and combined ratios adjusted for rate change and trend; and
- (3) industry benchmarks for similar business.

These judgments take into account management's view of past, current and future factors that may influence ultimate losses, including:

- (1) market conditions;
- (2) changes in the business underwritten;
- (3) changes in timing of the emergence of claims; and
- (4) other factors that may influence ultimate loss ratios and losses.

The determination of when reported losses are sufficient and credible to warrant selection of an ultimate loss ratio different from the initial expected loss ratio also requires judgment. The Company generally makes adjustments for reported loss experience indicating unfavorable variances from initial expected loss ratios sooner than reported loss experience indicating favorable variances. This is because the reporting of losses in excess of expectations tends to have greater credibility than an absence or lower than expected level of reported losses. Over time, as a greater number of claims are reported and the credibility of reported losses improves, actuarial estimates of IBNR are typically based on the Bornhuetter-Ferguson actuarial method or the reported chain ladder actuarial method.

The Bornhuetter-Ferguson actuarial method allows for greater weight to be applied to expected results in periods where little or no actual experience is available, and, hence, is less susceptible to the potential pitfall of being excessively swayed by experience of actual paid and/or reported loss data, compared to the chain ladder actuarial method. The Bornhuetter-Ferguson actuarial method uses the initial expected loss ratio to estimate IBNR, and it assumes that past experience is not fully representative of the future. As the Company's reserves for claims and claim expenses age, and actual claims experience becomes available, this method places less weight on expected experience and places more weight on actual experience. This experience, which represents the difference between expected reported claims and actual reported claims, is reflected in the respective reporting period as a change in estimate. The utilization of the Bornhuetter-Ferguson actuarial method requires the Company to estimate an expected ultimate claims and claim expense ratio and select an expected loss reporting pattern. The Company selects its estimates of the expected ultimate claims and claim expense ratios as described above and selects its expected loss reporting patterns by utilizing actuarial analysis, including management's judgment, and historical patterns of paid losses and reporting of case reserves to the Company, as well as industry loss development patterns. The estimated expected claims and claim expense ratio may be modified to the extent that reported losses at a given point in time differ from what would be expected based on the selected loss reporting pattern.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Total large catastrophe events and attritional loss movements

(622,198)

Other small catastrophe events and attritional loss movements

(206,616)

Total small catastrophe events and attritional loss movements

(828,814)

Total net (favorable) adverse development of prior accident years net claims and claim expenses

9,962

Actuarial assumption changes

2023 Large Loss Events includes earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other

Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Claran, and certain aggregate loss contracts triggered during 2023.

2022 Weather-Related Large Losses includes Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contracts.

2021 Weather-Related Large Losses includes Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contracts.

2020 Weather-Related Large Loss Events includes Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contracts.

2019 Large Loss Events includes Hurricane Dorian and Typhoons Faxai and Hagibis and certain losses associated with aggregate loss contracts.

2018 Large Loss Events includes Typhoons Jebi, Mangkhut and Trami, Hurricane Florence, wildfires in California, Hurricane Michael and certain losses associated with aggregate loss contracts.

2017 Large Loss Events includes Hurricanes Harvey, Irma and Maria, the Mexico City Earthquake, wildfires in California and certain losses associated with aggregate loss contracts.

The net favorable development of prior accident years net claims and claim expenses on the large catastrophe events was driven by better than expected loss emergence across the 2017 to 2023 accident years.

The net favorable development on other small catastrophe events and attritional loss movements was primarily related to lines of business where the Company principally estimates net claims and claim expenses using traditional actuarial methods. Partially offsetting these net favorable developments was net adverse development related to actuarial assumption changes.

Year ended December 31,	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

	Casualty and Specialty	
Total		
The previously reported amount has been adjusted to reclassify certain reserves from IBNR to ACR.		
Activity in the reserve for claims and claim expenses is summarized as follows:		
(1)		
Year ended December 31,		
2024		
2023		
2022		
Reserve for claims and claim expenses, net of reinsurance recoverable, beginning of period		
"background-color:#e6eef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"		
"background-color:#e6eef;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"		
"background-color:#e6eef;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:center;vertical-align:middle"		
"background-color:#e6eef;border-right:1pt solid #000000;padding:2px 0 2px 1pt;text-align:center;vertical-align:middle"		

[illegible]

[illegible]

[illegible]

[illegible]

#0000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(1)"2023 Large Loss Events" includes earthquakes in Southern and Central Turkey, Cyclone Gabrielle, flooding in northern New Zealand, various wind and thunderstorm events in both the Southern and Midwest U.S., severe weather events in Texas and other</div><div style="margin-top:3pt;padding-left:18pt">Southern and Central U.S. states, wildfires in Hawaii, Hurricanes Idalia and Otis, Storm Ciaran, and certain aggregate loss contracts triggered during 2023.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(2)"2022 Weather-Related Large Losses" includes Hurricanes Ian, Fiona and Nicole, floods in Eastern Australia, Storm Eunice, severe weather in France, typhoons in Asia, Winter Storm Elliott, and loss estimates associated with certain aggregate loss contracts.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(3)"2021 Weather-Related Large Losses" includes Winter Storm Uri, European Floods, Hurricane Ida, hail storm in Europe, wildfires in California, tornadoes in the Central and Midwest U.S., the Midwest Derecho, and losses associated with aggregate loss contracts.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(4)"2020 Weather-Related Large Loss Events" includes Hurricanes Laura, Sally, Isaias, Delta, Zeta and Eta, the California, Oregon and Washington wildfires, Typhoon Maysak, the August 2020 Derecho, and losses associated with aggregate loss contracts.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(5)"2019 Large Loss Events" includes Hurricane Dorian and Typhoons Faxai and Hagibis and certain losses associated with aggregate loss contracts.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(6)"2018 Large Loss Events" includes Typhoons Jebi Mangkhut and Trami, Hurricane Florence, wildfires in California, Hurricane Michael and certain losses associated with aggregate loss contracts.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:18pt">(7)"2017 Large Loss Events" includes Hurricanes Harvey, Irma and Maria, the Mexico City Earthquake, wildfires in California and certain losses associated with aggregate loss contracts.</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.842%"><tr><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:34.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td></tr><tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Year ended December 31,</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="border-right:1pt solid #00000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Catastrophe net claims and claim expenses</td><td colspan="3" style="background-color:#cfeeff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Large catastrophe events</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt">2022 Weather-Related Large Losses</div></td><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">(85,653)</td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom">2021 Weather-Related Large Losses</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36,949)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom">2020 Weather-Related Large Loss Events</td><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(42,577)</td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom">2019 Large Loss Events</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><tr style="border-left:1pt solid #000000;padding:0 1pt"><td colspan="3" style="border-left:1pt solid #0000

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<table><tr><td style="background-color:#c00000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%>2019</span></td><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

limitations on mergers or consolidations, and restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries. The net proceeds from this offering were used to repay, in full, the \$200.0 million outstanding under the Company's revolving credit facility at March 31, 2019, which the Company used to partially fund the purchase price for the TMR Stock Purchase, and the remainder of the net proceeds was used for general corporate purposes.

On June 29, 2017, RenaissanceRe Finance Inc. ("RenaissanceRe Finance") issued \$300.0 million principal amount of its 3.450% Senior Notes due 2027 of RenaissanceRe Finance.

On June 29, 2017, RenaissanceRe Finance Inc. ("RenaissanceRe Finance") issued \$300.0 million principal amount of its 3.450% Senior Notes due July 1, 2027, with interest on the notes payable on July 1 and January 1 of each year. The notes are fully and unconditionally guaranteed by RenaissanceRe and may be redeemed by RenaissanceRe Finance prior to maturity, subject to the payment of a "make-whole" premium if the notes are redeemed prior to April 1, 2027. The notes contain various covenants, including limitations on mergers and consolidations, and restrictions as to the disposition of, and the placing of liens on, stock of designated subsidiaries.

The net proceeds from the offering of the notes (together with cash on hand) were applied by RenaissanceRe to repay in full a \$300.0 million bridge loan that Barclays Bank PLC provided to RenaissanceRe on February 25, 2015 in order to finance a portion of the cash consideration paid by RenaissanceRe in connection with the acquisition of Platinum.

DaVinci Senior Notes

On May 4, 2015, DaVinciRE Holdings Ltd. ("DaVinci") issued \$150.0 million principal amount of its 4.750% Senior Notes due May 1, 2025, with interest on the notes payable on May 1 and November 1, commencing with November 1, 2015 (the "DaVinci Senior Notes"). The DaVinci Senior Notes, which are senior obligations, may be redeemed prior to maturity, subject to the payment of a "make-whole" premium if the notes are redeemed before February 1, 2025. The DaVinci Senior Notes contain various covenants including restrictions as to the disposition of, and the placing of liens on, the stock of designated subsidiaries, limitations on mergers, amalgamations and consolidations, limitations on third-party investor redemptions, a leverage covenant and a covenant to maintain certain ratings. The net proceeds from this offering were used to repay in full, \$100.0 million outstanding under the loan agreement, dated as of March 30, 2011, between DaVinci and RenaissanceRe, and the remainder of the net proceeds were used for general corporate purposes.

Scheduled Debt Maturity

	width:0.1%	width:0.587%	width:0.1%	width:1.0%	width:84.726%	width:0.1%	width:1.0%	width:11.498%	width:0.1%	width:0.1%	width:0.589%	width:0.1%	height:3pt
2025													
450,000													
2026													
—													
2027													
300,000													
2028													
—													
2029													
750,000													
1,886,689													

Unamortized discount and debt issuance expenses

1pt"></td></tr></table></div><div style="margin-top:6pt">Credit Facilities</div><div style="margin-top:6pt">The outstanding amounts issued or drawn under each of the Company's significant credit facilities is set forth below:</div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:99.842%"><tr><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">At December 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Issued or Drawn</td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Revolving Credit Facility(1)</div></td><td colspan="3" style="background-color:#cfeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">Medici Revolving Credit Facility(2)</td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">Bilateral Letter of Credit Facilities</div></td><td colspan="3" style="background-color:#cfeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">Secured</div></td><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">262,168</td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">357,443</td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">Unsecured</div></td><td colspan="3" style="background-color:#cfeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cfeeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">619,611</td><td colspan="3" style="background-color:#cfeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cfeeff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt">(1)At December 31, 2024, no amounts were issued or drawn under this facility.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt">(2)RenaissanceRe owns a noncontrolling economic interest in Medici. Because RenaissanceRe controls all of Medici's voting shares, the financial statements of Medici are included in RenaissanceRe's consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions. The drawn amount of the Medici revolving credit facility is included on the Company's consolidated balance sheets under debt.</div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt">RenaissanceRe Revolving Credit Facility</div><div style="margin-top:6pt">RenaissanceRe, Renaissance Reinsurance Ltd. ("Renaissance Reinsurance"), RenaissanceRe Specialty U.S. Ltd. ("RenaissanceRe Specialty U.S."), Renaissance Reinsurance U.S. Inc. ("Renaissance Reinsurance U.S.") and RenaissanceRe Europe AG ("RREAG") are parties to a third amended and restated credit agreement dated November 18, 2022 (the "Revolving Credit Agreement") with various banks, financial institutions and Wells Fargo Bank, National Association ("Wells Fargo") as administrative agent, which amended and restated a previous credit agreement. The Revolving Credit Agreement provides for a revolving commitment to RenaissanceRe of \$500.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$700.0 million. Amounts borrowed under the Revolving Credit Agreement bear interest at a rate selected by RenaissanceRe equal to the Base Rate or Term SOFR (each as defined in the Revolving Credit Agreement) plus a margin. In addition to revolving loans, the Revolving Credit Agreement provides that the entire facility will also be available for the issuance of standby letters of credit, subject to the terms and conditions set forth therein, and swingline loans, which are capped at \$50.0 million for each of the swingline lenders. At December 31, 2024, RenaissanceRe had \$Nil outstanding under the Revolving Credit Agreement.</div><div style="margin-top:6pt">The Revolving Credit Agreement contains representations, warranties and covenants customary for bank loan facilities of this type, including limits on the ability of RenaissanceRe and its subsidiaries to merge, consolidate, sell a substantial amount of assets, incur liens and declare or pay dividends under certain circumstances. The Revolving Credit Agreement also contains certain financial covenants which generally provide that the ratio of consolidated debt to capital shall not exceed 0.35:1 and that the consolidated net worth of RenaissanceRe shall equal or exceed approximately \$4.0 billion, subject to an annual adjustment.</div><div style="margin-top:6pt">If certain events of default occur, in some circumstances the lenders' obligations to make loans may be terminated and the outstanding obligations of RenaissanceRe under the Revolving Credit Agreement may be accelerated. The scheduled commitment maturity date of the Revolving Credit Agreement is November 18, 2027.</div><div style="margin-top:6pt">RenaissanceRe Finance guarantees RenaissanceRe's obligations under the Revolving Credit Agreement. Subject to certain exceptions, additional subsidiaries of RenaissanceRe are required to become guarantors if such subsidiaries issue or incur certain types of indebtedness.</div><div style="margin-top:6pt">Bilateral Letter of Credit Facilities</div><div style="margin-top:6pt">Uncommitted, Secured Standby Letter of Credit Facility with Wells Fargo</div><div style="margin-top:6pt">RenaissanceRe and certain of its subsidiaries

and affiliates, including Renaissance Reinsurance, DaVinci Reinsurance Ltd. (“DaVinci Reinsurance”), Renaissance Reinsurance U.S., RREAG and RenaissanceRe Specialty U.S. are parties to an Amended and Restated Standby Letter of Credit Agreement dated June 21, 2019, as amended, with Wells Fargo, which provides for a secured, uncommitted facility under which letters of credit may be issued from time to time for the respective accounts of the subsidiaries. Pursuant to the agreement, the applicants may request secured letter of credit issuances up to an aggregate amount of \$200.0 million. RenaissanceRe has unconditionally guaranteed the payment obligations of the applicants other than DaVinci Reinsurance.

The agreement contains representations, warranties and covenants that are customary for facilities of this type. Under the agreement, each applicant is required to pledge eligible collateral having a value sufficient to cover all of its obligations under the agreement with respect to secured letters of credit issued for its account. In the case of an event of default under the agreement, Wells Fargo may exercise certain remedies, including conversion of collateral of a defaulting applicant into cash.

At December 31, 2024, there were \$20.1 million of secured letters of credit outstanding and \$Nil of unsecured letters of credit outstanding under this agreement.

Secured Letter of Credit Facility with Citibank Europe

Certain subsidiaries and affiliates of RenaissanceRe, including Renaissance Reinsurance, DaVinci Reinsurance, Renaissance Reinsurance of Europe Designated Activity Company (“Renaissance Reinsurance of Europe DAC”) and RenaissanceRe Specialty U.S., are parties to a facility letter, dated December 19, 2022, as amended, with Citibank Europe plc (“Citibank Europe”), pursuant to which Citibank Europe has established a letter of credit facility under which Citibank Europe provides a commitment to issue letters of credit for the accounts of the participants in multiple currencies. On November 1, 2023, the aggregate committed amount of the facility was increased from \$180.0 million to \$320.0 million, with a right, subject to satisfying certain conditions, to increase the size of the facility to \$350.0 million.

The letter of credit facility is scheduled to expire on December 31, 2026. At all times during which it is a party to the facility, each participant is obligated to pledge to Citibank Europe securities with a value that equals or exceeds the aggregate face amount of its then outstanding letters of credit. In the case of an event of default under the facility with respect to a participant, Citibank Europe may exercise certain remedies, including terminating its commitment to such participant and taking certain actions with respect to the collateral pledged by such participant (including the sale thereof). In the facility letter, each participant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other undertakings.

At December 31, 2024, \$232.6 million aggregate face amount of letters of credit was outstanding and \$87.4 million remained unused and available to the participants under this facility.

Uncommitted, Unsecured Letter of Credit Facility with Citibank Europe

Renaissance Reinsurance, RenaissanceRe Specialty U.S., Renaissance Reinsurance U.S. and RREAG are parties to a Master Agreement for Issuance of Payment Instruments and a Facility Letter for Issuance of Payment Instruments with Citibank Europe dated March 22, 2019, as amended, which established an uncommitted, unsecured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of one or more of the applicants. The obligations of the applicants under this facility are guaranteed by RenaissanceRe.

Pursuant to the master agreement, each applicant makes representations and warranties that are customary for facilities of this type and agrees that it will comply with certain informational and other customary undertakings. The master agreement contains events of default customary for facilities of this type. In the case of an event of default under the facility,

Citibank Europe

Citibank Europe

may exercise certain remedies, including requiring that the relevant applicant pledge cash collateral in an amount equal to the maximum actual and contingent liability of the issuing bank under the letters of credit and similar instruments issued for such applicant under the facility, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof). In addition,

Citibank Europe

may require that the relevant applicant pledge cash collateral if certain minimum ratings are not satisfied.

At December 31, 2024, the aggregate face amount of the payment instruments issued and outstanding under this facility was \$293.0 million.

Unsecured Letter of Credit Facility with Credit Suisse

RREAG, Renaissance Reinsurance and RenaissanceRe were parties to a letter of credit facility agreement with Credit Suisse (Switzerland) Ltd. (“Credit Suisse”) dated December 16, 2021, as amended, and which provided for a \$200.0 million committed, unsecured letter of credit facility pursuant to which Credit Suisse (or any other fronting bank acting on behalf of Credit Suisse) may issue letters of credit or similar instruments in multiple currencies for the account of RREAG or Renaissance Reinsurance. The obligations of RREAG and Renaissance Reinsurance under the agreement were guaranteed by RenaissanceRe. The facility was allowed to expire in accordance with its terms on December 31, 2024.

At December 31, 2024, letters of credit issued by Credit Suisse under the agreement were outstanding in the face amount of \$19.1 million.

Uncommitted, Unsecured Standby Letter of Credit Facility with Nordea

Renaissance Reinsurance and RenaissanceRe are parties to a standby letter of credit agreement with Nordea Bank Abp, New York Branch (“Nordea”) dated October 3, 2024 which provides for an uncommitted, unsecured facility pursuant to which Nordea may issue standby letters of credit in multiple currencies for the accounts of RREAG and Renaissance Reinsurance. Pursuant to the agreement, RREAG and Renaissance Reinsurance may request letters of credit up to an aggregate amount of \$250.0 million. The obligations of RREAG and Renaissance Reinsurance under the agreement are guaranteed by RenaissanceRe.

At December 31, 2024, letters of credit issued by Nordea under the agreement were outstanding in the face amount of \$45.3 million.

Uncommitted Letter of Credit Facility with Société Générale

Renaissance Reinsurance is party to a letter of credit reimbursement agreement with Société Générale, New York Branch (“SocGen”), dated September 8, 2022, which provides for a \$250.0 million uncommitted letter of credit facility under which Renaissance Reinsurance may request either secured or unsecured letters of credit in multiple currencies for the account of Renaissance Reinsurance, subject to secured letters of credit comprising at least 40% of the maximum aggregate amount.

In the agreement, Renaissance Reinsurance makes representations, warranties and covenants that are customary for facilities of this type, and agrees to comply with certain informational and other customary undertakings. The agreement also contains certain financial covenants applicable to the Renaissance Reinsurance customary for facilities of this type.

The agreement contains events of default customary for facilities of this type. At any time on or after the occurrence of an event of default, SocGen may exercise remedies, including requiring that Renaissance Reinsurance pledge cash collateral in an amount equal to the maximum liability of the issuing bank under the unsecured letters of credit and similar instruments issued under the agreement, and taking certain actions with respect to the collateral pledged by such applicant (including the sale thereof).

At December 31, 2024, letters of credit issued by SocGen under the agreement were outstanding in the face amount of \$Nil.

Vermeer Letter of Credit Facility with Citibank Europe

Vermeer Reinsurance Ltd. (“Vermeer”) is party to an uncommitted, secured letter of credit facility pursuant to which Citibank Europe or one of its correspondents may issue standby letters of credit or similar instruments in multiple currencies for the account of the applicant. The obligations of Vermeer under this facility are not guaranteed by RenaissanceRe.

At December 31, 2024, the aggregate face amount of letters of credit outstanding under this facility was \$9.4 million.

Medici

RenaissanceRe Medici Fund Ltd. (“Medici”) and RenaissanceRe Fund Management Ltd. (“RFM”) are parties to a revolving credit facility, as amended, pursuant to which National Australia Bank Limited provides for a revolving commitment to Medici of \$75.0 million. The obligations of Medici and RFM under this facility are not guaranteed by RenaissanceRe.

[illegible]

[illegible]

RenaissanceRe controls all of Medici's issued voting shares, the financial statements of Medici are included in RenaissanceRe's consolidated financial statements. However, RenaissanceRe does not guarantee or provide credit support for Medici, and RenaissanceRe's financial exposure to Medici is limited to its investment in Medici's shares and counterparty credit risk arising from reinsurance transactions.

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581

[illegible]

[illegible]

[illegible]

noncontrolling interests, net of adjustments, of \$300.020. The portion of Medici's earnings owned by third parties is recorded in the consolidated statements of operations as net income (loss) attributable to redeemable noncontrolling interests. Any shareholder may redeem all or any portion of its shares as of the last day of any calendar month, upon at least 30 calendar days' prior irrevocable written notice to Medici. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2024, RenaissanceRe received cash inflows of \$163.6 million from subscriptions of shares in Medici by third-party investors and paid \$361.8 million as a result of redemptions of shares from and dividends to third-party investors. Refer to "Note 21. Subsequent Events" for additional information related to the Company's noncontrolling economic ownership in Medici subsequent to December 31, 2024. The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$531.4 million from subscriptions of shares in Medici by third-party investors, and paid \$102.2 million as a result of redemptions of shares from third-party investors. The Company expects its noncontrolling economic ownership in Medici to fluctuate over time. The activity in redeemable noncontrolling interest - Medici is detailed in the table below:

	2024	2023
Beginning balance	\$545.812	\$527.3
Redeemable Noncontrolling Interest - Medici	3,061,708	\$527.3
During 2024, investors subscribed for \$250.2 million, including \$50.6 million from the Company. In addition, investors redeemed \$382.0 million, of the participating, non-voting common shares of Medici, including \$0.3 million from the Company. Third party investors also received \$24.6 million in dividends. As a result of these transactions, the Company's noncontrolling economic ownership in Medici was 15.8% at December 31, 2024.	2,541,482	\$527.3
During 2023, investors subscribed for \$527.3 million, including \$45.2 million from the Company, and redeemed \$117.5 million, including \$10.0 million from the Company, of the participating, non-voting common shares of Medici. As a result of these net subscriptions, the Company's noncontrolling economic ownership in Medici was 11.7% at December 31, 2023.	\$545.812	\$527.3
The timing of cash flows associated with equity capital transactions can vary from one period to the next. During 2023, RenaissanceRe received \$531.4 million from subscriptions of shares in Medici by third-party investors, and paid \$102.2 million as a result of redemptions of shares from third-party investors.	\$545.812	\$527.3
The Company expects its noncontrolling economic ownership in Medici to fluctuate over time.	\$545.812	\$527.3

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

\$115.9 million (December 31, 2023 – \$88.3 million) is attributable to third-party investors.

During 2023, and following the release of collateral that was previously held by cedants associated with prior underwriting years' contracts, Upsilon RFO returned \$988.5 million of capital to investors of Upsilon RFO Diversified I, II and III, including \$125.5 million to the Company. In addition, Upsilon RFO issued \$39.8 million of non-voting preference shares to existing investors, including \$10.2 million to the Company, and \$1.4 million of non-voting preference shares to external investors of Upsilon RFO Diversified IV. At December 31, 2023, the Company's participation in the risks assumed by Upsilon RFO Diversified I, II and III was 14.3%.

RenaissanceRe Upsilon Diversified Fund ("Upsilon Diversified") is a segregated account of RenaissanceRe Upsilon Fund Ltd., ("Upsilon Fund"), an exempted company incorporated in Bermuda which is registered as a segregated accounts company and a Class A Professional Fund. Upsilon Diversified provides a fund structure through which investors can invest in reinsurance risk managed by the Company, which includes investments in Upsilon RFO and Medici. The Company concluded that Upsilon Diversified meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with Upsilon Diversified and concluded it is not the primary beneficiary of Upsilon Diversified, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to Upsilon Diversified, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of Upsilon Diversified. Upsilon Diversified meets the definition of an investment company in accordance with accounting guidance, and accordingly, is required to account for all of its investments, including its investments in Upsilon RFO and Medici, at fair value. The Company does not have, has not previously had, and does not expect to have, a material investment in Upsilon Diversified. In addition, the Company expects its absolute and relative ownership in Upsilon Diversified to remain minimal. Other than its current equity investment in Upsilon Diversified, the Company has not provided financial or other support to Upsilon Diversified that it was not contractually required to provide. The total assets of Upsilon Diversified principally reflect its investment in Upsilon RFO.

During 2024, and following the release of collateral from Upsilon RFO, Upsilon Diversified returned \$333.4 million of capital to investors, including \$0.5 million to the Company. In addition, third-party investors subscribed for \$16.9 million of non-voting preference shares. The fair value of the Company's indirect equity ownership in Upsilon Diversified is included in investments in other ventures and was \$0.5 million at December 31, 2024 (December 31, 2023 – \$0.8 million). At December 31, 2024, the total assets and total liabilities of Upsilon Diversified were \$440.6 million and \$140.9 million, respectively (December 31, 2023 – \$600.8 million and \$108.0 million, respectively). Upsilon Diversified's investment in Upsilon RFO was valued at \$304.0 million at December 31, 2024 (December 31, 2023 – \$503.1 million).

NOC1 is a segregated account of Upsilon Fund formed in 2023, that provides a fund structure through which investors can invest in a portfolio of insurance-linked securities, principally catastrophe bonds. The Company concluded that NOC1 meets the definition of a VIE as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns. The Company evaluated its relationship with NOC1 and concluded it is not the primary beneficiary of NOC1, as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to NOC1, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of NOC1. The Company does not have, and does not expect to have, a material investment in NOC1 and expects its absolute and relative ownership in NOC1 to remain minimal. Other than its current equity investment in NOC1, the Company has not provided financial or other support to NOC1 that it was not contractually required to provide.

During 2024, NOC1 issued \$20.0 million of non-voting preference shares to existing investors, including \$0.2 million to the Company. During the year ended December 31, 2024, NOC1 redeemed \$48.8 million of non-voting preference shares to existing investors, including \$0.5 million to the Company. The fair value of the Company's indirect equity ownership in NOC1 is included in investments in other ventures and was \$1.7 million at December 31, 2024 (December 31, 2023 – \$1.7 million). At December 31, 2024, the total assets and total liabilities of NOC1 were \$173.4 million and \$2.2 million, respectively (December 31, 2023 – \$196.5 million and \$22.8 million, respectively).

During 2023, NOC1 issued \$161.5 million of non-voting preference shares to existing investors, including \$1.6 million to the Company. Vermeer provides capacity focused on risk remote layers in the U.S. property catastrophe market. Refer to "Note 10. Noncontrolling Interests" for additional information regarding Vermeer.

At December 31, 2024, the Company's consolidated balance sheet included total assets and total liabilities of Vermeer of \$1.9 billion and \$93.0 million, respectively (2023 – \$1.7 billion and \$102.7 million, respectively). In addition, the Company's consolidated balance sheet included redeemable noncontrolling interests associated with Vermeer of \$1.8 billion at December 31, 2024 (2023 – \$1.6 billion).

Fontana provides reinsurance capacity focused on business written within the Company's Casualty and Specialty segment. Refer to "Note 10. Noncontrolling Interests" for additional information regarding Fontana.

At December 31, 2024, the Company's consolidated balance sheet included total assets and total liabilities of Fontana of \$2.2 billion and \$1.6 billion, respectively (2023 – \$1.5 billion and \$968.5 million, respectively). In addition, the Company's consolidated balance sheet included redeemable noncontrolling interests associated with Fontana of \$469.4 million at December 31, 2024 (2023 – \$353.8 million).

Mona Lisa Re Ltd., a Bermuda domiciled special purpose insurer ("SPI"), provides reinsurance capacity to subsidiaries of RenaissanceRe through reinsurance agreements which are collateralized and funded by Mona Lisa Re through the issuance of one or more series of principal-at-risk variable rate notes to third-party investors.

Upon issuance of a series of notes by Mona Lisa Re, all of the proceeds from the issuance are deposited into collateral accounts, separated by series, to fund any potential obligation under the reinsurance agreements entered into with Renaissance Reinsurance and/or DaVinci Reinsurance underlying such series of notes. The outstanding principal amount of each series of notes generally will be returned to holders of such notes upon the expiration of the risk period underlying such notes, unless an event occurs which causes a loss under the applicable series of notes, in which case the amount returned will be reduced by such noteholder's pro rata share of such loss, as specified in the applicable governing documents of such notes. In addition, holders of such notes are generally entitled to interest payments, payable quarterly, as determined by the applicable governing documents of each series of notes.

The Company concluded that Mona Lisa Re meets the definition of a VIE as it does not have sufficient equity capital to finance its activities. The Company evaluated its relationship with Mona Lisa Re and concluded it is not the primary beneficiary of Mona Lisa Re as it does not have the power over the activities that most significantly impact the economic performance of Mona Lisa Re, in accordance with the accounting guidance. As a result, the financial position and results of operations of Mona Lisa Re are not consolidated by the Company.

The only transactions related to Mona Lisa Re that are recorded in the Company's consolidated financial statements are the ceded reinsurance agreements entered into by Renaissance Reinsurance and DaVinci Reinsurance which are accounted for as prospective reinsurance under FASB ASC Topic 944.

Financial Services Insurance, and the fair value of the principal-at-risk variable rate notes owned by the Company. Other than its investment in the principal-at-risk variable rate notes of Mona Lisa Re, the Company has not provided financial or other support to Mona Lisa Re that it was not contractually required to provide.

Renaissance Reinsurance and DaVinci Reinsurance have together entered into ceded reinsurance contracts with Mona Lisa Re with ceded premiums written of

[illegible]

and OmegaCat Reinsurance Ltd. ("OmegaCat Re"), which give investors access to a range of property catastrophe risks. Prior to the Validus Acquisition, substantially all of the AlphaCat Funds had received full redemption requests from their investors and capital was being released accordingly, subject to certain constraints. The Company expects to run off the business over a period of time.

The Company concluded that the AlphaCat Funds, AlphaCat Re and OmegaCat Re meet the definition of VIEs as the voting rights are not proportional with the obligations to absorb losses and rights to receive residual returns.

The Company evaluated its relationship with the AlphaCat Funds, AlphaCat Re and OmegaCat Re and concluded it is not the primary beneficiary as it does not have the obligation to absorb expected losses and the right to receive expected benefits that could be significant to the AlphaCat Funds, AlphaCat Re and OmegaCat Re, in accordance with the accounting guidance. As a result, the Company does not consolidate the financial position or results of operations of the AlphaCat Funds, AlphaCat Re and OmegaCat Re. The Company has not provided financial or other support to the AlphaCat Funds, AlphaCat Re and OmegaCat Re that it was not contractually required to provide. The total assets of the AlphaCat Funds, AlphaCat Re and OmegaCat Re principally reflect their investments in OmegaCat Re and AlphaCat Re.

The fair value of the Company's direct equity ownership in the AlphaCat Funds and AlphaCat Re is included in other investments and was \$3.6 million at December 31, 2024 (2023 - \$4.4 million). At December 31, 2024, the total assets and total liabilities of the AlphaCat Funds, AlphaCat Re and OmegaCat Re were \$3.0 billion and \$1.3 billion, respectively (2023 - \$5.0 billion and \$2.4 billion, respectively).

Fund Investments

The Company's fund investments represent variable interests in limited partnerships entities with unaffiliated fund managers in the normal course of business. Refer to "Note 6. Fair Value Measurements" for additional information.

4 397600000	598000000	0.127	1900000000	1900000000	2400000000	2400000000	60500000	74200000	282200000	500000000	0	115900000	883000000	988500000	125500000	39800000	10200000	81400000	0.143	333400000	500000	16900000	500000	800000	440600000	140900000	600800000	108000000	0	304000000	0	503100000	844100000	1200000	30000000	0	100000	20000000	0	200000	48800000	500000	17000000	17000000	173400000	2200000	196500000	22800000	161500000	1600000	1900000000	93000000	0	1700000000	102700000	1800000000	1600000000	2200000000	1600000000	1500000000	968500000	469400000	353800000	45200000	11700000	32800000	8200000	39600000	9900000	39500000	10300000	32800000	8200000	39400000	9800000	35000000	15000000	8500000	100000000	25000000	936100000	936100000	436900000	436900000	7000000	0	2200000	42700000	0	42700000	6500000	416800000	416800000	417100000	417100000	0	800000	3600000	4400000	3000000000	0	1300000000	5000000000	0	2400000000	SHAREHOLDERS' EQUITY

The aggregate authorized capital of RenaissanceRe is 325 million shares consisting of 225 million common shares and 100 million preference shares. The following table is a summary of changes in common shares issued and outstanding:

	2024	2023
Beginning balance	52,694	43,718
Issuance of shares	8,568	44,445
Repurchase of shares	(2,711)	(2,711)
End of period	58,551	85,452

Issuance of shares

Repurchase of shares

Issuance of performance share and restricted

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

background-color:#ffffff;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceefff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceefff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt">Denominator for diluted income (loss) per RenaissanceRe common share – adjusted weighted average common shares and assumed conversions (2)</div></td><td colspan="2" style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:right;vertical-align:bottom">51,339 </td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47,607 </td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,040 </td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ceefff;border-right:1pt solid #000000;padding:0 1pt"></td><tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – basic </div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">35.31 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">52.40 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">52.40 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">25.50 </td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000000;padding:0 1pt"></td><tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Net income (loss) available (attributable) to RenaissanceRe common shareholders per common share – diluted </td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.21 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">52.27 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">52.27 </td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td style="background-color:#ceefff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">25.50 </td><td style="background-color:#ceefff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><tr><tr><td colspan="3" style="background-color:#ceefff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">(1) Represents earnings and dividends attributable to holders of unvested shares issued pursuant to the Company's stock compensation plans.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt">(2) In periods for which the Company has net loss allocated to RenaissanceRe common shareholders, the denominator used in calculating net loss attributable to RenaissanceRe common shareholders per common share – basic is also used in calculating net loss attributable to RenaissanceRe common shareholders per common share – diluted. For the year ended December 31, 2022, per common share equivalents of non-vested shares of 90 thousand could potentially be dilutive in future periods if the Company reports net income allocated to RenaissanceRe common shareholders.</div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt">During 2024, the Company recorded \$115.1 million (2023 – \$96.8 million, 2022 – \$82.0 million) of gross premiums written assumed from the Tower Hill Companies and its subsidiaries and affiliates. Gross premiums earned totaled \$119.0 million (2023 – \$83.3 million, 2022 – \$80.0 million) and expenses incurred were \$14.2 million (2023 – \$12.7 million, 2022 – \$15.8 million) for 2024. The Company had a net related outstanding receivable balance of \$31.9 million as of December 31, 2024 (2023 – receivable of \$37.0 million). During 2024, the Company assumed net claims and claim expenses of \$94.5 million (2023 – recovered net claims and claim expenses of \$9.8 million, 2022 – assumed net claims and claim expenses of \$68.6 million) and, as of December 31, 2024, had a net reserve for claims and claim expenses of \$95.2 million (2023 – \$50.2 million).</div><div style="margin-top:6pt">In addition, the Company received distributions of \$34.4 million from the Tower Hill Companies during 2024 (2023 – \$22.6 million, 2022 – \$10.5 million).</div><div style="margin-top:6pt">Top Layer</div><div style="margin-top:6pt">During 2024, the Company received distributions from Top Layer of \$16.8 million (2023 – \$7.8 million, 2022 – \$8.7 million), and recorded a management fee of \$3.0 million (2023 – \$3.4 million, 2022 – \$2.4 million). The management fee reimburses the Company for services it provides to Top Layer.</div><div style="margin-top:6pt">Broker Concentration</div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400

Company's joint ventures and managed funds, starting in 2025 as a result of the enactment of the Bermuda Corporate Income Tax Act 2023 ("CIT") on December 27, 2023. Furthermore, the Company generally expects that the profits generated in Bermuda on or after January 1, 2025 by the Company's joint ventures and managed funds, except to the extent those profits are attributable to redeemable noncontrolling interests, will also be taxed at 15% as a result of the enactment or expected enactment of provisions similar to the global anti-base erosion model rules ("GloBE Rules") by many of the jurisdictions in which the Company operates. As a result, the Company expects its income taxes to increase beginning in 2025.

RenaissanceRe Finance and its subsidiaries are subject to income taxes imposed by U.S. federal and state authorities and file a consolidated U.S. federal income tax return. Should the U.S. subsidiaries pay a dividend to RenaissanceRe, withholding taxes would apply to the extent of current year or accumulated earnings and profits at an expected tax rate of 5.0%. The Company has not accrued withholding taxes on the unremitted earnings of RenaissanceRe Finance to date as there is no intention to remit such earnings. The cumulative amount that would be subject to withholding tax, if distributed, is not practicable to compute. The Company also has operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, Canada and Australia which are subject to income taxes imposed by the respective jurisdictions in which they operate. Withholding taxes would not be expected to apply to dividends paid to RenaissanceRe from its operations in Ireland, the U.K., Singapore, Switzerland, Luxembourg, and Australia.

The following is a summary of the Company's income (loss) before taxes allocated between domestic and foreign operations:

	2024	2023
Domestic	11.498%	11.498%
Foreign	5.57%	5.57%
U.S.	1.0%	1.0%
Ireland	1.0%	1.0%
Singapore	1.0%	1.0%
Switzerland	1.0%	1.0%
Luxembourg	1.0%	1.0%
Canada	1.0%	1.0%
Australia	1.0%	1.0%

Year ended December 31, 2023

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

1980

1979

1978

1977

1976

1975

1974

1973

1972

1971

1970

1969

1968

1967

1966

1965

1964

1963

1962

1961

1960

1959

1958

1957

1956

1955

1954

1953

1952

1951

1950

1949

1948

1947

1946

1945

1944

1943

1942

1941

1940

1939

1938

1937

1936

1935

1934

1933

1932

1931

1930

1929

1928

1927

1926

1925

1924

1923

1922

1921

1920

1919

1918

1917

1916

1915

1914

1913

1912

1911

1910

1909

1908

1907

1906

1905

1904

1903

1902

1901

1900

1899

1898

1897

1896

1895

1894

1893

1892

1891

1890

1889

1888

1887

1886

1885

1884

1883

1882

1881

1880

1879

1878

1877

1876

1875

1874

1873

1872

1871

1870

1869

1868

1867

1866

1865

1864

1863

1862

1861

1860

1859

1858

1857

1856

1855

1854

1853

1852

1851

1850

1849

1848

1847

1846

1845

1844

1843

1842

1841

1840

1839

1838

1837

1836

1835

1834

1833

1832

1831

1830

1829

1828

1827

1826

1825

1824

1823

1822

1821

1820

1819

1818

1817

1816

1815

1814

1813

1812

1811

1810

1809

1808

1807

1806

1805

1804

1803

1802

1801

1800

1799

1798

1797

1796

1795

1794

1793

1792

1791

1790

1789

1788

1787

1786

1785

1784

1783

1782

1781

1780

1779

1778

1777

1776

1775

1774

1773

1772

1771

1770

1769

1768

1767

1766

1765

1764

1763

1762

1761

1760

1759

1758

1757

1756

1755

1754

1753

1752

1751

1750

1749

1748

1747

1746

1745

1744

1743

1742

1741

1740

1739

1738

1737

1736

1735

1734

1733

1732

1731

1730

1729

1728

1727

1726

1725

1724

1723

1722

1721

1720

1719

1718

1717

1716

1715

1714

1713

1712

1711

1710

1709

1708

1707

1706

1705

1704

1703

1702

1701

1700

1699

1698

1697

1696

1695

1694

1693

1692

1691

1690

1689

1688

1687

1686

1685

1684

1683

1682

1681

1680

1679

1678

1677

1676

1675

1674

1673

1672

1671

1670

1669

1668

1667

1666

1665

1664

1663

1662

1661

1660

1659

1658

1657

1656

1655

1654

1653

1652

1651

1650

1649

<

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

height:120%">The Company's net deferred tax asset primarily relates to net operating loss carryforwards and capital loss carryforwards, unrealized losses in the U.S. investment portfolio, and GAAP versus tax basis accounting differences relating to unearned premiums, reserves for claims and claim expenses, deferred finance charges, deferred underwriting results, accrued expenses, investments, value of in-force business, intangible assets, VOBA, deferred acquisition expenses and amortization and depreciation. The Company's valuation allowance assessment is based on all available information including projections of future GAAP taxable income from each tax-paying component in each tax jurisdiction. During 2024, the Company recorded a net decrease to the valuation allowance of \$66.2 million (2023 - increase of \$19.6 million, 2022 - increase of \$62.1 million).
A valuation allowance has been provided against certain deferred tax assets in the U.S., Canada, Ireland, the U.K., Luxembourg and Switzerland. These deferred tax assets relate primarily to net operating loss carryforwards, deferred finance charges, capital loss carryforwards and unrealized losses in the U.S. investment portfolio. In the U.S. and Switzerland, the Company has net operating loss carryforwards of \$97.3 million and \$350.0 million respectively. Under applicable law, the U.S. and Swiss net operating loss carryforwards will begin to expire in 2037 and 2025 respectively. The Company has net operating loss carryforwards of \$141.2 million in the U.K., \$8.3 million in Ireland, and \$155.7 million in Luxembourg. Under applicable law, the U.K., Ireland and Luxembourg net operating losses can be carried forward for an indefinite period. The Company has capital loss carryforwards of \$131.6 million in the U.S. that begin to expire in 2027. The Company has unrealized losses in the U.S. investment portfolio of \$60.6 million. These unrealized investment losses do not expire. However, if realized, these losses may only offset realized capital gains and would expire, if unused, at the end of the fifth taxable year following their realization.
The Company made net payments for U.S. federal and state, Canada, Ireland, U.K., Singapore, Switzerland and Australia income taxes of \$99.5 million for the year ended 2024 (2023 - net payments of \$26.8 million, 2022 - net payments of \$3.1 million).
The Company had no unrecognized tax benefits at December 31, 2024 and December 31, 2023. Interest and penalties related to unrecognized tax benefits would be recognized in income tax expense. At December 31, 2024 and December 31, 2023, there were no interest or penalties accrued on unrecognized tax benefits.
The following filed income tax returns are open for examination with the applicable tax authorities: tax years 2018 through 2023 with the U.S.; 2020 through 2023 with Ireland; 2022 through 2023 with the U.K.; 2020 through 2023 with Singapore; 2021 through 2023 with Switzerland; 2020 through 2023 with Australia; 2020 through 2023 with Canada; and 2019 through 2023 with Luxembourg. The Company does not expect the resolution of these open years to have a significant impact on its consolidated statements of operations and financial condition.
0.050
The following is a summary of the Company's income (loss) before taxes allocated between domestic and foreign operations:

	2024	2023	2022
Domestic	\$222.3	\$222.3	\$222.3
Foreign	\$2,622.066	\$2,622.066	\$2,622.066
Total	\$2,844.366	\$2,844.366	\$2,844.366

Bermuda
Singapore
Ireland
Luxembourg
United Kingdom
Switzerland
Australia
Canada

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Net claims and claim expenses

Net claims and claim expenses
Acquisition expenses
Underwriting income (loss)
Net foreign exchange gains (losses)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Income tax benefit (expense)

Net (income) loss attributable to redeemable noncontrolling interests

Dividends on preference shares

Net income (loss) available (attributable) to RenaissanceRe common shareholders

Net claims and claim expenses incurred – current accident year

Net claims and claim expenses incurred – prior accident years

Net claims and claim expenses incurred – total

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Section 1.0

The Company is authorized to issue restricted stock awards, restricted stock units, performance share awards, stock options and

other share-based awards to its employees and directors pursuant to various stock incentive compensation plans.

On May 16, 2022, the Company's shareholders approved the Company's First Amended and Restated 2016 Long-Term Incentive Plan, which amended and restated the plan initially approved by the shareholders in May 2016 (as amended from time to time, the "2016 Long-Term Incentive Plan"). The Company is authorized to issue up to 3,060,092 common shares pursuant to the 2016 Long-Term Incentive Plan. The 2016 Long-Term Incentive Plan permits the grant of restricted stock awards, restricted stock units, performance share awards (including cash-based performance awards), stock options and other share-based awards to employees, officers, non-employee directors and consultants or advisors of the Company and its affiliates.

In November 2016, the Company instituted a cash settled restricted stock unit ("CSRSU") plan, the 2016 Restricted Stock Unit Plan, which allows for the issuance of equity awards in the form of CSRSUs. There are currently no outstanding awards under this plan.

Restricted Stock Awards

Restricted stock awards granted to employees under the 2016 Long-Term Incentive Plan generally vest ratably over a four-year period. Restricted stock awards granted to non-employee directors generally vest ratably over a three-year period.

Performance Share Awards

Performance share awards granted to certain of the Company's executive officers pursuant to the 2016 Long-Term Incentive Plan are subject to vesting conditions based on both continued service and the attainment of pre-established performance goals. If performance goals are achieved, the performance share awards will vest up to a maximum of 200% of target. Performance share awards generally cliff vest at the end of a three-year vesting period based on the attainment of performance goals over the three-year performance period.

Performance Share Awards Granted in March 2019

Performance share awards granted in March 2019 had a performance condition, which was the percentage change in the Company's tangible book value per common share plus change in accumulated dividends, or, in the event of a change in control, a market condition, which was the Company's total shareholder return relative to its peer group.

Performance Share Awards Granted Beginning in March 2020

Beginning with awards granted in March 2020, performance share awards have performance conditions, which are the average percentage change in the Company's book value per common share plus change in accumulated dividends over three years and the three-year average underwriting expense ratio rank compared to peers, or, in the event of a change in control, a market condition, which is the Company's total shareholder return relative to its peer group. The performance conditions are calculated in accordance with the terms of the applicable award agreement.

Valuation Assumptions

For performance share awards granted in March 2019, the performance metric related to the percentage change in tangible book value per share plus change in accumulated dividends which is classified as a performance condition under FASB ASC Topic 718.

Performance Share Awards Granted in March 2019

For performance share awards granted in March 2019, the performance metric related to the percentage change in tangible book value per share plus change in accumulated dividends which is classified as a performance condition under FASB ASC Topic 718.

Compensation - Stock

As a result, the fair value of the performance share awards was determined based on the fair market value of RenaissanceRe's common shares on the grant date. The estimated fair value of performance share awards was amortized as an expense over the requisite service period.

Performance Share Awards Granted Beginning in March 2020

For performance share awards granted beginning in March 2020, the performance metrics relate to (i) the percentage change in book value per share plus change in accumulated dividends and (ii) average underwriting expense ratio rank compared to peers, both of which are classified as performance conditions under FASB ASC Topic 718.

Compensation - Stock

As a result, the fair value of the performance share awards is determined based on the fair market value of RenaissanceRe's common shares on the grant date. The estimated fair value of performance share awards is amortized as an expense over the requisite service period.

Restricted Stock Awards

The fair value of restricted stock awards is determined based on the fair market value of RenaissanceRe's common shares on the grant date. The estimated fair value of restricted stock awards is amortized as an expense over the requisite service period. The Company has elected to recognize forfeitures as they occurred rather than estimating service-based forfeitures over the requisite service period.

Summary of Stock Compensation

Activity	Performance Share Awards	Restricted Stock Awards	Weighted Average Grant Date Fair Value
Number of Shares	11,498	71,340	163.98

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

insurers and collateralized insurers are fully funded to meet their (re)insurance obligations. Renaissance Re Europe AG, Bermuda Branch, a Class 3B general business insurer, has modified requirements, which are addressed under Switzerland, below.

Class 4, Class 3B and Class 3A insurers are prohibited from declaring or paying any dividends if in breach of the required minimum solvency margin or minimum liquidity ratio, or if the declaration or payment of such dividend would cause the insurer to fail to meet the required minimum solvency margin or minimum liquidity ratio. Further, certain categories of insurers are prohibited to declare or pay dividends over certain thresholds without the BMA's approval. These restrictions on declaring or paying dividends and distributions under the Insurance Act are in addition to the solvency requirements under the Bermuda Companies Act 1981.

Switzerland

RREAG is a reinsurance company licensed and supervised by the Swiss Financial Market Supervisory Authority FINMA ("FINMA"). The minimum capital requirement for a Swiss reinsurance company under the Insurance Supervisory Act for reinsurance license class C1 is CHF 10 million. RREAG must further maintain adequate solvency and provide for sufficient free and unencumbered capital in relation to its activities in accordance with the Swiss Solvency Test ("SST"). The solvency requirement is met if the available risk-bearing capital exceeds the required target capital. It is then assessed whether the identified available capital can meet the SST requirements and is sufficient to cover the company's obligations in less favorable scenarios. RREAG maintains branch operations in Australia, Bermuda, the U.K. and the U.S., each in accordance with applicable local regulations, which may include statutory capital requirements.

RREAG may only distribute dividends out of its retained earnings or distributable reserves based on the audited annual accounts of the company. Any distribution of dividends remains subject to the approval of FINMA (as a change of the regulatory business plan) if they have a bearing on the solvency of the reinsurer and/or the interests of the insured. The solvency and capital requirements must still be met following any distribution.

U.K.

The underwriting capacity of a member of Lloyd's must be supported by providing a deposit, referred to as "Funds at Lloyd's" or "FAL," in the form of cash, securities or letters of credit in an amount determined under the capital adequacy regime of the U.K. Prudential Regulatory Authority ("PRA"). The amount of such deposit is calculated for each member through the completion of a quarterly capital adequacy exercise. Under these requirements, Lloyd's must demonstrate that each member has sufficient assets to meet its underwriting liabilities plus a required solvency margin. The amount of FAL for Syndicate 1458 is determined by Lloyd's and is based on Syndicate 1458's solvency and capital requirement as calculated through its internal model.

Dividends from a Lloyd's managing agent and a Lloyd's corporate member can be declared and paid provided the relevant company has sufficient profits available for distribution.

U.S.

Renaissance Reinsurance U.S. is required to meet certain minimum statutory capital and surplus requirements under Maryland law. Renaissance Reinsurance U.S. is also subject to risk-based capital ("RBC") requirements under Maryland law, and must file an annual report of its RBC levels. If the report shows Renaissance Reinsurance U.S.'s statutory capital and surplus or total adjusted capital is below certain levels, Renaissance Reinsurance U.S. may be required to take certain corrective action or the Maryland Insurance Administration ("MIA") may be permitted or required to take certain regulatory action.

Maryland law places limitations on the amounts of dividends or distributions payable by Renaissance Reinsurance U.S. At December 31, 2024, Renaissance Reinsurance U.S. had an ordinary dividend capacity of \$125.5 million which can be paid in 2025. Payment of ordinary dividends by Renaissance Reinsurance U.S. requires notice to the MIA. Declaration of an extraordinary dividend, which must be paid out of earned surplus, generally requires thirty days' prior notice to and approval or non-disapproval of the MIA. An extraordinary dividend includes any dividend whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the lesser of (1) ten percent of the insurer's surplus as regards policyholders as of December 31 of the preceding year or (2) the insurer's net investment income, excluding realized capital gains (as determined under statutory accounting principles), for the twelve month period ending December 31 of the preceding year and pro rata distributions of any class of the insurer's own securities, plus any amounts of net investment income (subject to the foregoing exclusions), in the three calendar years prior to the preceding year which have not been distributed.

Multi-Beneficiary Reinsurance Trusts

Each of Renaissance Reinsurance, DaVinci Reinsurance, and RREAG was approved as a Trusteed Reinsurer and established a multi-beneficiary reinsurance trust ("MBRT") to collateralize its (re)insurance liabilities. The MBRTs are subject to rules and regulations including but not limited to certain minimum capital funding requirements, investment guidelines, capital distribution restrictions and regulatory reporting requirements.

	Renaissance Reinsurance	DaVinci Reinsurance	RREAG
Assets Held Under Trust	\$1,000,000,000	\$1,000,000,000	\$1,000,000,000
Background Color	Black	Black	Black
Border	1pt solid black	1pt solid black	1pt solid black
Padding	2px	2px	2px
Text Alignment	Left	Left	Left
Vertical Alignment	Bottom	Bottom	Bottom
Font Color	Black	Black	Black
Font Family	Arial	Arial	Arial
Font Size	8pt	8pt	8pt
Font Weight	Normal	Normal	Normal
Line Height	100%	100%	100%
Position	Relative	Relative	Relative
Top	3.15pt	3.15pt	3.15pt
Vertical Align	Baseline	Baseline	Baseline
Left	0	0	0
Right	0	0	0
Bottom	0	0	0

Assets Held Under Trust

Minimum Amount Required

Background Color

Border

Padding

Text Alignment

Vertical Alignment

Font Color

Font Family

Font Size

Font Weight

Line Height

Position

Relative

Top

3.15pt

Vertical Align

Baseline

Left

0

Right

0

Bottom

0

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]


```
<table><tr><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Commodity options		
Commodity futures		
Other liabilities		
Foreign currency forward contracts		
Derivative instruments designated as hedges		
Derivative instruments not designated as hedges		
Total derivative instruments		
Total		

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

II

(7:7+7+7+7)*P\$VM)YID4;7*5T M<T>#IM/6T2G%-PIN30I0SN/IN<..M>+&^M^+P2-O-?^WGB6MU&+QJ9(VRMG M;Z&S'9>SUI\$J3'
!L:C:L0+I+EI(H'YUH:8+76_PY@%I2 M%4M>DXLRIN)Q@M9^<\$E\$W<V3L@M^ UQ2N<^US.W@/TFQ8:KX';M!IBT M?
>V\$9HG\$IO<=>4#@9\$ 3HU4JO/4TUIV@62S"V853UB=R>E&^L(O)S"4/-&B0#%I^PSTIP8C9>I N3 MK7% H"RH\$!BXE#DY:IK3P.)IW:=T:VC4NP=^VZH
MYW#BPP)H3M^<3Z3(5+>M5&4<4^1<..4DF(0S:~>H>SB_5 8N&QE2&YK^+IVJ
M:~%8YV\$X%+>76^E H.%HY3QQQAALV(3Q,I>KCH^=:(0A14D^<G67I)K!~MBS54OJUY% E(JH1-F,+ +0NX!"@-%?("IA14G9LMBZ~.13F6?
1#R>3:PWARQ\$ M! MJT^KKE=3.#.F#M'DISIBU+PE:I+<L%Y%IVP23J/HHMB>I^CN@^T(WM^M*8%T4F^IG6YF6W^~.#04@M3;/L.QDHL,KV+
(!^T>NAMI ZX<I6\$?EY^FJO M1&+PEW^(-%<IG+RLJ\$T200EZH2IVJ^<%"PB1.6I9HT&G)G6)IEI0ISFU"U^W
MS;LNX.V~..2.RU2RH+!\$!@L1L00E7P.5\$)DDEFT9KD~N?>GIVY^VHDBOP_UAWSLGDW^Z^8_~J0&JELU\$>K^FB~J%U\$&22I^H3
MA5)16G(V^<@=0~1UB1IBJ#I~2L_!(G;^JHP4>6:RISHRC MWWW7B7.4>TA6=1/ZJSS1+OH(2FNA2)35;D""NED61D*LIB.\$G\$G^&G!+PA
MIG+6^+90Y&Z="2Y2E")^<+@6\$EB2=Y0+09^&D^<M4JXQ.M^>.\$3ZBN MJKR~9>I=KBA6VY^SR>"9S;4)>(% 3C4(85(L+ G??(AP5QE_#%
IUBM@=IME MD067W56NIZ31LC2I^"6A+(<(4:10/E(8M4A7HJW:QD=YB:HJ3+V^1YVVV^P
M4 IW>:~)MSUZ1^JOKSY1 NW5NQM#9W\$X 3N.SA:S9_~Z3>Q9 M4U1.%<N5&CIV^SIBJ46_8LAR#HBAK7G7I5EL@D1@T216W0A62B4IE
M.UXR^6U1I-85G0I+M.E9N?33SXLAFI\$5\$%^<^WJH>HJ.#.\$X#G^T9CRGYJ6/7^25KK_~U~F6B;+ORJ#70=XWNC17>0XR>~N7OK.3IC H3WGZ=1AI
MBUX8 K^EG7VFCYPM~J%<G>5M2I47JIR3OK(HOY>Z.OJDMNOO.V~.I=1@* M&KJN0=IHB;IS0!@B]^C(DH/QQ3^VIM~I\$10I#P3I]=/G<.<9V?
3.IORK M\$3I2I7VB550YU^8IJLXZG>4BY#5K&F)(UJ^M7^ITOS29+BG;J07B^H MUKG@QET7293>6>7^8POR_>~(HGFED42I.UIMN 9.4%9
B9:@!F1@OQ.VS-H0?&\$8\$9 MU JD^DHG/N:9_-\$R)K2S<#^RM?@^LH5#BZ#B/XIU3.~KEG440D5^IG8TX&JB8)&QM.Y+UIP+ MZ^)?F
~8^FC^J&R30(I> 3KFIZ;~N5>=GY6I1^67HDL>3:J4B.\$?I2V88 M16);~DZTKN28#IPG=H#UT^PHO)Z6F>QL>WS622=4P)0\$^O@H^<@&=FIBZ+
MD&RC+<S@BV&R^DVP_~L@ZG^X2(5=B56?I<&RC&A@I2@62^A.#D-GB4^M4G CAU^NW>VUAY^6E5WOP>7I~)*=3#;C5I0:@Z-P^IU-
L7%3+^X5UIP?PEJ^C^> MW227IDITIX^=ON? DPDIDS<0?3.UFEX&ID^L+!B M>KP+>ON>.%QE+<~I8Y9QTX\$Z3KN ZZ^
I8@J:P~1^1P^EIK10+&O9.GQOB.H^UIX(^HAGK@0\$QLGSYXHOJH@I49LH@F9IVT MRJT#*P<=3NFS^H0W^T^I6E3^4PLZAI(3IY95;=?
%#@F122ILK2(6)QWV^M^IEY^85;@=3#1G0S_GQISX3>2..JY^<^OIN^&^RFO^<V2^<3A69UNX@61H.M.U<^<6 2^E+V66:E\$SE=CQ;?^~.9R?#.?Q
MOMQXIM729^JPQ^<^((GG(PL^IN@%\$?>5G8U!><4L.IA>5>?)298X&JS^~;^MK^T@=I=D)3(TUCXB^>^*E.G^<60Z.3I^?P
>%ZQIF2Q:1.OGPM,F>IYIS=I^M~..028U.BS\$KS+2NIE SJ3K^>R&M42K+J^*?K&SWE^WRI)%)OJETBY@B\$U.MTDL#^HD^";&X;R)1C9BX\$H^/3.P)^
+Q9:91\$2I2^CJHP^3EY^8I9LDFB MX(!>A)>E+<C2U=^I^C96DN8>JA)6BKJ#3\$V3NFK^K5M5>6 X%N/T^\$I\$<
M^DXO@&HJ\$<IJOJ2<8W^TTF^94I>U?%>~)CZHXFFKXJ99<^9T G>~<@&3^<IB8
MQIVZH<IN:&..M^<L=W^KOM_N^TB4(I^OA7UD^A&Y29Z3(I@1E^K=J0HS4)(@)3F4^G^G^W.JG.M704
TWXXD>^RVI^>~JL^<B2^C)Z4^JL0Z>5ESFHS^JSVIE@~L..W00IP2 M6^C&C^&5DPC^QR.H=7Q5:74.3#~!IF+JZWKF4RM=F6^SBPT<4B8X8<\$B.W
MPB7POBDD3M.JI<I&Z^<8AJNKK2&E^H.W.O7:~IUV+FE^BOJ7N512>~6VY~MVH(QE3IRI(PJ>LUVU IJ7(+VENA5BBW9=&..P.ITNE3=3?
V^RM^<DN9;LH.MX%F%NEIG^MXGV2Y^"~..HAA<~IB^W216L6@A%Z8F&^HJ@=H^MEXU5WI@6KJ9Q(^GX>4K^W92\$>6S M5P\$?3I>R_~
M>~!#)MK+62;7^AAM9+4%I<7M8?P^4ADM05?#~+6.CD.^OZ%<U^N^..HIF M)Q&G^894.@2FZZWB^0^E(^SYRC74G;G!@S5NI#..LE.2@~"
%IV#150RU^C M_XI9B@%\$%\$<@08 H^"7^TCG2+<L^#P5>+>I5U\$^WUD M3C~20^W4CAX(GC@&^&G5Q+>9^9^!^I4IF^>WQF&MQ\$(01A.DITL=^+
MT6L7EMJ\$O.4R^EZ:5D12^MT\$&4BWI> MP6FM&B\$C;8Q%IUCS+CIW2W.P.&BD^<UD_K^<LJ#>)>U)*K_H745\$U4Q#""A^M1IM8^<CM3+2?
YE.DZ7\$CE5;+)^S.U.E@0A28I^M0I=A^&S^E8YVW2%~.1IW^>WBIQ=B&S^S^3R6QV.W3R DN> MTN+QD^PEF@_DCI:B6LVA^R^<I&V M8%=?
~7G%~^LIX^<^%SD&CP:37.^?%IMK6(20GK^LEHUI%\$X1Z@>B3UN M>O GEN3%MYIX2F\$U)IVF8U6.E^I^PV.)>G(W(U^MW8EHCQ
I^D4Q#N=3#Z M3Q_~S^#BJ35YPG^ZG^W^#EUDYI^WM^FV63^MOI_~<+&8Z\$>Y2P^I.D<.(HWC@^IFB;F^A.YITXX M=LIJK@/^NA2E^"16&
DNU+9;#^YIYH\$UYZ^D%3@S=M)OWI=HLZ+JK>6 M=6^*%&=>EJXXE^1WRP^2^M<..1\$+<^TGA\$V5_~O!0FC<~.M40A^RMK 4-GM=3^Y^15R?
M6H9I77I;J.^#?2IG0?KT5^I^J905IP>@I5Z30I^BZ8F#0^U03.;2_1_M1A=9AJ>9I^K+8>H^E^WU1^D+JG~1^3PZ62&H945^"C^I?
>~%5%>@AY#WU^EHKY73CI>~8Q%RBL~D7Q^0T20+CO7I%\$EFW 82GUG8 MDH5K^P=003^2=F.EI.L^?I>6M@H;I2I~6.%+Y4
MDR6+VJ\$~0I@~I84LB604K8<~B3^P4^4 M<~2S15U@+Y+A4G;@BE#T8LK MQH15.8#2^<DMHE^C2UZXIJ.D^<RK
7H79KYC>I3.;3RW.UK3^13KEXPZ M0E1D^CRN^CIKW4^264FMZH^7N^?X?92U40<>7\$OPF9I^LW^M^I#UM MP27#@9R-
8A)MFM^VMN^AW7^4^90^<2B64B1W4V^~BH3I5Q(ZX=BI^V^<9# ME^S=3;D^I1NS6<~)PY^#2I(DI9LEH^N1Z7GHF25==^0^349^F^AY/I
MPN^/Z1<<~.M!>OSZ155D^F)=0@~IMO;V6X N9VTOQS^DJ+>[NP+4TY?/8 M<~RDK\$3+I.>E^JPC.RI\$E15^>^Y KOC9RTD^4\$H^A)8IP%EPM^TJP^IQJ
M05X7W8^I&^&^I#<Z>7\$^IUIJG\$C^M&@<^>^U_X^"AIZXK66^PV6N2MIQ?<M^OIT^"ITOI^IMZUN:UCRI^!\$S?NISQ=I?2\$5
=9EKLU^<NZDGOZB^<UDBO^M13A^HBB^H^JUD42%\$42Q^Y UQ;X^MHB12Q5^>7^955E;FR<8U157>L^TU;
M&DPC^T75U!~!8VRR=F7BHOJFLE(HIAT?I%I^<^E/AL@I#~8A5^BZT=I^WJ=5.M!\$+!HQU=#PK@L7(K5^!D6CL!\$=I29I@>^I4)H8WJZ^P3MD.WY:X
FRY\$4I MA+IWLN3@I^<QIN02MLKXIR M_I2/HIHTFUE^P9.C.RFL8F^W.Z?>FAV.T0@ M3L^<7XUDT=5AV^WWIR^AMODY>+I MY
>2X!<IGL^"IAZIH=Z>~<PM0_ MMJ^I6@Y4+DQ\$13(5I=I^G^#DMZ>OSS&S^KV2IKQ>2VUBT.3LK6@~MM96@.^*MQ8L^E^R\$EX7%(N&8PH-
#IUM9IS+IO(7^&J^#O^*~>@#1BAY5 M&YF)2(I7CKYS+E!0B2^I5I.2DA2ZP^ MS8G7.4%1Y%0I>~.#.1^14C+IY9_1
6(Y#&KE1BDD3@<^<I^E^B/GUE^KI^>M+IG7^IGRLL^OT42L0L1@<ZI^SR912\$IAMUL2)<5 8I2\$G3W^&OCNJT^
MKB=N#I^S^TLDWYR=7546I^<Z>OYUZ^S^UJ513(IG80H5^3-G\$%^E^"IEE M+I.051VW+6=P/P9/QD8E(^R+I3U#B^7 R6V>E13B?
%&TR&^TA^ZJ2RR\$=M\$&85^0)YD0I\$IT^PS(SCGW)^J^Q+M90W^<O@<0\$N2XK^YSI\$~VL^"~?2EH7^E^G>DO_~S!\$J^IJOIO^C^TTGR3^LG M#.B!\$@~S
=I^FAQ%EDQZ&=UMC:I>^I^ASP9^VAGRHV5YVW^&^Z88W^VMJ^MT<7BIRL+KXN^I.U?^F7>6I<8;#DIH47^OK@>9U&3>?>^*W&Z@VA%YVW4&
(^VO.08 N^TW4~.OZ&VXQ=>+>2~RAI^K\$ M6#PYHW)^*@S=20_~E1^0I^ZC6K^IWOB#=>V^&HS3#D3^<H^QQW\$~.OO&VZ@Q-
NLMZ&4U+0562Y^KML<2JY^IGD M^N^G61SLX2>QQW\$;M3^L^FOYFU^WN_~.22I.M54QB6N^A5IG^<I\$H4#<~%M^YX7^K^I^QF-6@IG;N^X^XQ-
FR:CK>\$1=L6I^"=5NMH09 V^KX^I3I^<I^H;0BCIRAJ^:AQ#< QIUC^Y\$K^C.^2%>8M<@S^X2P/Q^Y^Z2LCF&A^MK?J#2^J^I^W^KE5H4I^P(+<ES-M<+
(02F^KHR\$K^I^W^#KRWT<~9H0I^4? MJOV^S^FAXX+IWM^4I2+~.GO.R5I3H^<2^AIC^N@CY.(8^L^N^K+H>@~M99\$9I^8I^I^H^W^5W^~OKO.YD?
+4B^&C=33X^<6..R8ED16@?2 M6LOH^YIGYB^C^I3W^6EVL 7^HEJ51S<5HD^I^A^9XN^X^E^G^I^AAZH^L^B=22
X)ELI.LS6Z0+M^<ZB6X5>~>^~WL&A^IA=^F.B;^<+Z_~\$I04.AWH35I.(2A)H=F.4B#WTE>~&T^WU;C2_U^*27ER)^.4@E5^&M;H+J6*
MRE@HCDLME7>~%9L;H.YU%G8&7QCDX^NQ05^8H^IYKG^C^L^<^Y\$NIG^<L^MXN^W9GQ?G^I.OY620SK@0W;HHJLO^V9R=9R%9ZC>E:~@~M7?&br/>A^2.PO#I^FOPZT M4F%F6AN^I2AES^WN^#EZ8ZRI6^KYDRIR^W^I1+I^G<~>OW<~^ICXZ3%BQW MNU8S90UG3(^JW5+9
V\$(@~(87HJJY6@40S5VQ.UHIC^I^<YUWHZG#;I^J^M^<^P^AHU#_~^D@U>615P^D+%)D<~I>C5HY_22QAY>U+^#PIZ<~?&F68
MFCIDY25I1F6&H^<~>2I7^<I^>I^J^S^>P^URHW27N M3I^<N\$%9CM%16^<N^ZL^ZM^09Q>92Q8^2YSF^I^<@^A^O1^W3U^P^Q1L^<@~
MO62IM2MPSGR<3I^>ZIG8;@JBYAVOSQX^DH:~C^Y#I^>F98O(5^Y^YXZYVM^M.D97DMZ\$5S6IA+2^<S\$PV45K2=6#N^IPOQ^<@>A^I^V.M@2@U;BN2
G4^A0J#JIR82DFV%>@D:~NN^@S.K0@&9)C-\$%2R%>ER#I^WJ#3%9.8Q(U6NL7!^V^I^4.LQ> MCP9SIH^=^%>07%>P\$X8%&T\$>O^P^J^GC0Z.MIG1-
M2)MIS^L^%S^A9^&D#@<@J.M^H\$<Q(XI^B\$D6WZ>QPOCA2^CH.UOK^4H^<76IV6+>~<6X^L^C^YSDPO^I^U^~M813@<@AUI=MA3N^NK2NH7I
SG&3HYV(W.0R>I+0.W:Z 4V13I~8@Z~9F.MJB=^H)~(M^PA^T)ZE42WRJBI<^Z;@<S^PD0SB+SNQXXJ9YGA^QOH^YH8U^6 MHH-
>U>32RJVRIL^ISGVI^H^<SD#^FY^0HKI^&EX4IT5D#^I^7Y-30&^).6 M6 Y:HF F<1+P^ZJZR.QI3I^32I^/2IOE^IKZ2N^<@%VOI^NX4BT\$H M2-
PG6AI2G.16;C^8T^+0ZIGUH^Y9>X2Y^R~1^KI4GJL^V8 X6FHH^OX>2S M= 505Q9JN^I8+9(N^I^R^4(QEA^<9TCCZ(IT+Z).MK9.5-Y^YWF<I31B;R^6
M^<@#D^4ZRMF.ZC#G-FW8&~2>YB^OP3I^<G^<V1\$^H*H>^I4RA)5N^9MZI^!OI ME^AK8Q>X V+Z\$^050_<I>~I^I>(<=TSN@FM7^S/2+3Y^F2.
IS2QCAC4^EQPM^MB04068^LHJ6;<I2^2I2@<I^I9I=IPU^F>Z(RN&L^RUV^<S\$<1%>Z+M9+MLQIMG^98"
QYC+O&G61QOW^IQS^V6^YJ7^FB>O&5MG:IELR.2WV^H.R@<S^M.MD;I^XY&38&WY^I^JHR8_9YKPTIBOI(^H^AOFNK;EB32^IXD0^~VBGZ9VJ+7
M.P@U^NUC^KAG7I^<~RT0A9?F^N^B;Y^Y.F8;I^<V@<I9Y^J_OSSIT^<Z5%K\$S%KD&^7YI^P2 E2I.NX#YXV
ME/U^IG.BFKQYQQ1^I4I=5I^N^CI45Q<3L4 T2ZR2I2R^HA5WP+&F.3X8^I^ZJ M.BEEY^A^Q876IH=^%=(S6I&I^RIP30<=OR(Z#6I^Y^GBIE^QRZ3UH;
QIV.MRKO:CNXP^<5^HOB@6S0CX3#NDK@WQC\$~UNI%)I2<~>=\$Q>9J^0A=9WAH=R.MDRT96=IRIC:3IO^<(5)\$7X6<(#ADE^NORZC
^INDI^PXI93^I3E;G@CAS&^MGRIR05U^=BN^RY&H^I0UVE79^>I^8I0G=3\$@<MK16(K)^#9I=H9_X^T4&I6R6 M8DZAG6I@#.#(32^D4"
^YTIQ>G<~@0I^D^SSMI0P_IRM8&J5H15FB2)@IH.MH3.0^&E\$4 2&C^<FE^J56O7KEC.O^L3M^<C^Q^&8@7^6EDT6^%#898Q^ZDPRMI^KIG/I0+>^%ID
MLVJISS^FHCZ^I^A&IN^0(W%?+O~6:08KB(SI^8LU8X<~.YIE&63X)\$E9T^L MG1JQ&>J^VX&KQVJ^H.ZB.QT^L.U+K&J;H+4^1B/B<8N\$57K MI
KCZ2K2>5908Q026C0N^N22I^U1^&2XC+PID^3.M.D>+Y^N&E.T9(E.WGJ9
MWPCR5ZAMC^3_6EUHT3AHRKM33HYCE^D+M=I^7FJ7^RAZHY2=ST^6I12 MGJ9QHYT^JZ 4SH<5DI8I^WUOIN>U^PY<^\$JX^GO M:8&05
1.48U#\$.7.<^"VILDV!<N%_CW-W^I>UC^FD66*^R5D^~B)^>Q0^B^MQLZ^S9\$F^<B=H^DG<=\$\$FXI6Q^R4I\$0L^<="EHROI><~"YT^Q3@4^KDHCT
MNF&T4\$6%O(BJ2P;=&E4U3I^=ZET)^IG.M.2Q.I#^<EDIGQO8ILM^O.5(M^#FA=3TK6LSU^DG3.FAZP^MU@B^N1JD=2.W(Q:B^<T@N^I#0^V^>V^O^"
(7^>O&VWL^KOP<@I#B3I^)(JOT^MTVTLN)&I^<S\$THZ9^3==<K<IN^WA^"(+SU^JZIVATZ5N_R431^&RK^HBE@ MOPBL9IY&^ID^9
49UE.ST6_7CJL^I=I190I=4^Z2:735^9\$JXD 474I MJ@UJ.HW4F^LZ&^W2GB^20X^47H+CU.QI#1(I2M^<G^GHR^(VH&QWA.N
M@HX<#1A>#9H2#JBB6 QV(P)XXZ2230AJG^&9N2^U1%I^/ NIB2Y^I^<8Q7I0S&^9&X M^#6SD=Z^0.9QCM^J;U3
N;AIS@<I>+I03^VJ20@=AUU)GWI^TQ^<I1K^T:H34A=5@8I2^I<8~M^IT2H&Z^<ICPD?G16.NRY\$65
M>OY(+XILTEA^>@7>20>J^HUIQSP.15/PV^OYV1%5I(M=M4>=361UW^%6#C.3_~.1~9+~88^C2I=9X^I^Y^<PI^I7EF^<CI\$96^/MXOQK0A8D?
W>S(3=JU^%G.P^EH)##^?I^!^H)D^#5\$O>M)@<^DH-6%~I^H M5K(^VGIH^<^NF^<#V^I^J7=B.9A^K\$^UWTMA^I8QWT@<@551^I^89+<~PH
MYGE^Y37D130_X3I^<VQ5V3Z\$XPQ25<=IDN8ZZ^<UBDR^QL\$+3^H^5X^I4H^ML7B^UMI^<6EC^I^N^<LZ^<AC^<Q^G^ISSI^D^DXDIEC.6E>^VMK M
4M^<X+3.8&Q^UDM70A@T^I^GWB^..02=ZI>~>2^A=W.V5^HZA&K^E6L^<3^F^M^C^I^B^>~>OA_~O^H6&YAM\$S^3C^I2G^ZFAERC^Q^JZID^ES&F^27BCV&
C<ML 2WYV^<P1KSI8M9ZNO^UW6^>6T=^SH+EI5\$0^("SPK^*BXS^UCIAK>86^IX^MZ2+Y^EYFGI>P6>5I5A^UPT@6B\$MIBX
2S6E9D(6I7C#&9C^4I5@H%>3Y3^T^G&HWA>? MQFID.D.I1 M^OQ5_~A0<~<G^<2X^K^1M^I^V^HQCQWG^ZI^I^V^U^H^Q^O/N6#~..2CIA6F9Z M^S"
@N3I25692(KX2<~<M^#B6I2^ZD/>G&^8W>Z3^<W2V\$S^I^Y\$81F.M^"Q9FBO5B^XBD^N@<~MDZ.IH^SH^9\$==IY6K^MWG1I/6+<G^&VY^*RV 7R!
M2S4QSID8C.9D=.LKP90^V>~>L^I^<@7W.1R.903QZ6W4M^>OZI96%" CR%" MH=@I\$Y.IF\$%^#OZPS609^P8N^Y^I^H5^TCL^%QM/9?^>TIV3
=^<I0>@SEYLB.MTUB.%C\$COM2F2DK230VD#>~3T&Z699^WKS+>=>F9>TY^<GJAB^S^I3M^ZK8N? MOB 9X5I>G)IE?
LOG^TG.U5I^7YMFEI(BI^<ZF^4I)SM^<^Y.H^* 8C^<UFR>M^<6GD2+<C^*3SKH.PI=BD0F<5<YSYU.WK8_~APWIF?GQLCK(QR?7_K=A^#X
M^I^ZQ>KGU>?&9\$UYI^M9UWJ^AK@<@<@/I^..W.YHH^<B.T.F%3I&A^AM6H.I94P7IC MHK#>M^D^IC.FQH^KZ)=WLS^9G^QMYI^U^<EK@<^+XZ
SHE^T^ZIN^<G1=QM^P.MW<3^TP&KQ3&IUM:AS.8>X^I.OP2U>#I^/J9P\$Y_3_~IWQOD<~<YV3C^5 MFI^S^&DOS>^YAF85^<5NEK2&~.
>ZAR/I.XWAI^RQON^76@~M7<0Q5^Y(U^&X(QI=Q^QVITW4^>A=>#N1^D^F7I^<@HU^@F+>@<P<^VH^<S^I\$R M^Z<0N7LLNHHB1/6<~8?
212IQU^YH^I00^I3^#B.KV@SDT65<0N^PYAGK(HXB M^!=>Q^%L=^AXN0^MM6^<L53^<K^T49HU\$) 3GEVHVJ^BZ;#9JID<2^TCH0V^M87D)?

^8=2.MP/7L2KNM4[NW(.H4ZFUS\$~)L]HPJX EJC#JHW6IH<QJBJ"%MA:L MB1&42)HF62S #S%/4^+!+6P!O=Y=7& MJ/S;:1HK6A!_0-A0Z1&T!Q_8
LP2V/21DMS;E!H/912Y MGVN,J+U<#BSYF86B=524\$5!7!_16KJD!>2==<\$6<J!D2O&YT(.!A4WN>J!M Y>+?
[RGA^N\$^!M<2&5PL"S.O9ZPIJRU2%5/+&4D=&5T_L^U3(3*Q9>J",LE>./^GH,S*(^&GEGRJF3+ M=F#J!@4<^22Y;F;AA6MY!_!Z!|<^6+!-/E0!-7\$)
+YA(!Q7_1&\$^C6D^MHC%#6%&S&:Y2QBPP7%/T@:;F+9^RMWV)NDB,&YHA!)DRC5_!0&LJ^=0!F3 M#R#W_!<^&#>;E7&KSM=P>M^7(!>
I6_70(N^K^X4>T!&Q_29QG=S(!+>+!J MGM;C8U%Q(41*#>2K,AF.8OY0_/G^C5^W>^Z%*X!_"JR.?@SF/H!N^&IQ>S MO_
IQ_0F0BGV MUANS+WC_3H4!_53>.*MB.Z05!<@U>!)A_8+KU>=0F+>+!MGCPhV_..5#4^+JP5(!F>+..735JBHHC">_
KAB%+XYXK#WGLK610MG;0GWWM;@M^~_1G30^>9JZD6==J>HUL;H\$^0XB*IE>7)AD)<0B^).RUGWT;J7ULCFX M9^9H0%B^K<_
^8Z&X^K.C0!^3.T=LNH!^R\$;^!J0C2N^T^T%9C1^;(!98 MA(4QDG>D_~_30^!+<+>9QIV\$;_7^J9O><@3&V(J!&V)M6!M;B^HZ)YT
M(!13.W~;..F3MDRM\$;.#N^YVM!>+>..I9!8C;DIY!<4^>..PTSOA(S!M^M^3TWM2!SR@AIRY=NP9.I2!>9E(W;OXIG!H<^&KRG^M+
MA4RZ7\$^0^<YULX#L)J+>?S=BM">=R@W!X_0XKWNYID=H(2E\$!N^!OOTNAGC M0Y+Y%FI(U5;W!1M_>7^VM L(BCO\$!0^"U\$E!U_R!_IDA0?
3^M;PD^+C<*TO M+!5TH!0HW>@>WTM9=1U9!RBO!H^1^8.E7K)<2>@5P!^I(NBCK !Q\$^3WO2 MUU;JUUN^RR\$>?_GJW^ZK!R!FKS!H2!>T^/
J3908;3BUA=^..6#5>G0HDF0 M3^!161=XB" NOG=7Y^!V!C;T!A!J2H^!L^@O>U^X;"^!M+8Q@_4L6X#1+MA#4?0^9SLX56!P4#?
G!0!BEV<1Q%JMXMS8Y8:9QN;..S4M%~..\$M!3B&_J MC5\$53BCZ79T+Y%N.W6G8J^RX?W.A(3^>7!>H4<;?T&5H%aMU!F)E M=Q
H58_D6QJF6D+TDY+M!&H07&A9P4!>H^0R>..5ACW!FYU05^WSQ\$F M>=>H^*%&J!C>>P5E.C&SB(O B>3;N_8^W!OQP8C=&T3!O:
<..AX\$;&JF2!<G\$ M\$;..QD\$)FGJ.H60?BL^CIA4==>GQ25R!0XY1EL!O>U\$&6^M2^44L\$5L!&B M2\$57D64)M5>Y%#E%9E^K/3CIBUO
!6CLB>VYK)>_K;?0)EQ^U0TN1%2LT MEQIWG!)7VS@!)DHG5>OY_9O10^A6^!JHZ*<^!EVETE!VJ@J^GU_0%OB>TL39> M>@&E%K=
!VG6GJ!&T)G!SA!T!22U!U^"KCQ46%>+!SR&(!L3Z^P6^"EKYF!P8GY2 M.40Z^MR!UOP\$<0P^R^T@<^AMH!^U6Q890?3^9H\$^XAUTFFEXE!O!_W
R9U M !U!M>4^ W<_>Y^N2PX0!A2^4^!Q8@Q@JN^G^A^"XB"E%F!C!O13U_W2P5!V M\$;D2VPIN!%_?0P1Z=>3VAVDUG^A4^N%+VEV3!Z!
6KE&_4@#(X^MI9R+1O MY RV+D!^S^+!J03UG#V\$SNE/18H830!P**>5Q! KQFPX(MEWA9>NJ4Z/S!J M_E&\$!B+2/X_OBG/M!1DLG962N1
+TFIZL"QVO^RTMVH!QO_UV1\$!&J!U!MM+!1QV_!KO!B P9UXQVY5!9Z<_<9R!Q!^UX2TS;9P8CZH@(&5F&@G7K_GPTN M 6^"~R6M.EV
_H_EGL.C=.%0FN_VJROS%K!A\$^HJ>^>X^D M^<89V M^<2!H M^<Q?G7?V@_EW!RH!H!QIREXIPPH%03%9Q?P!^TAI+T^8G2!U= M!+SOBO
G>76\$5^4P>Q! W0U!H3 !U!V04!^PP6!<F_ YSCSTXZ!^Z/@Q2 M(4V B0>P!U M^<#J!B;6\$>T^P.88>@>^&Z^O#_#^3TE_GBG!AOQBS"U%J^*E94%D
MLIRIR2!EZV3^FW_H2ASZ_MRC"KGSF)FFLO@>F4_JU_1_YHKDS_4@&@).C=VN.Q!X^>""^?D_&Y^N!)E!M!+S%&V78^XMOUE/!9KX>UDQ;N=UGT?
!6ZV//H!E;^C(&1E;R=0P^7D@0M M_UHN.8K2K7<=^&J0!^!U3!0Z MB_+<^\$;_NOT8!+U!)_!>X^;?KM!^98K
M(943%750R3D@<CA0!4\$SDP_TL4^>GLNPEYMI\$B^RW!MQ5!J2!O!C0L_Z0E5 ME5!^L!V0K!JVL^C^!U!XRRBP;FWK+A^_AW!PGS^~_5U!U%~^T?
C6M7W8!W^~(MGGT^>_..Q^4^*@M2A+NM8_YW^8HHE8^7FE\$^F%>T M@>_QDXG=NPX!H!X2N_1M^"SE0\$.QWB2_X\$!L!CO!D(U!T@JK33!
M!\$9C>^"YXW"/GHKK^<..3S!O2X^!7)TEB%7\$A^HBAUR87!K!2BEE+25TK2_33X^F!QR=69.6*>UFLP_&_SE7!^4!^ M^PIZ>2;L+!O/CX!+?
Y!JVCMB8!P5HMJ&^<^<^O!<@>^!^2^NV\$<^U^HOV M^<R^RMN_..H!7\$BZ^%FK^T^Y4K!+ #H/J!X^U9!ZBL=QCSF_EHJ(N39.P M?(!*^_0_U4G
(!K&@!6)AL^KE8VGD#^!<CT<3!2!^Y_TN/P@U#2WS?#^!H5)P=J^R^L5D^X#^=VAB@KW^X_%! MMVA&0M?^!L8U(2^E+P7
<1@Y!P^#T7Z8EFTK0\$%FJ2@!<#N5B+K!\$O^<^!MX!R^9&H!&^\$=&_G_~+7M6&@FXO&U0\$^7X08!0B54DC\$^!%KWW+V^X!HVT?C\$X)5S
W2>53KN2_!X#7B+LSTG/MZKB=^P!6^FHUY"OYU^<SLZOVHX9\$&N^X^!_6.H_R_0\$CO4RF!D(ER6G;0B5 QM\$4^Q%WTP_ZP(TLZB\$8P
M+^S6+PAR=\$\$+^@IGP?E0.">F+!V5//NV^*G!^*9DS;6UJS+7.SM(6)=8N MM^E(6G!<=VN_IV/TL\$8^!V1=#^Y6^).KCO\$84RUW)P)*M^..N\$07_45P=;
M=7=TYGJV+CL!6P2@H_Q@P^CX^#X>_>Q1GHZ_8NFVMF!C\$S>6+X+!<=J M\$8V0^ET249_QGQM\$60_64E!6^5K74_1P!3!S_P27M^&S
W6^~N!L_N_SZ M^*YK!07W?JW??O!>J!SUH!G5^!O!>H4!&@<^DN! MM^X!6WPGHXS!W9V^O_QCP^Q?G0!X<=+<+9R_N!33^WT M?
L>_PU&YNA_Z6N\$!G!O#^F/ISZC)M\$(!4NW!B!@<OPRBAPVABAB\$N+MK<=^<F^9=UJZ!F7&SODWM_Z.2^DV@'&^0Q.<@F^5L<5/C>^<DKG/AQ3G
M.6MPBC_A758E^Y)JH"?=+H! MX%5L_03BF(!+1XQ\$>_T!R^*B9Q/P!^!_86QD!)!8 M^*X=5^E_S(ZRX4SD!^XRQOB_>/P?XZ
!M87N^!<E8^+!>T=8L^H&G.TM7?^540?A?O@!L M M^<5A5PR=8^..#G RK^A!^!D^W<_
&AX!X<3!@A!K5AZ_26!5Z_E!W<=<#&U\$Z_!H!N!T^!\$A<10G!&JUO M(2!>7!<L_0WB8H!OY^<!(H3WH<^!LLRY!YK)H82TP502H0C_OD/!^9UW_Q+^A
M%<^!<=&6B!UC!<QK/3WG8!5_2FGH64\$!3M/8.25;99N";.C6G(\$S^"K_12 MR!U3RA!"_U120!_W:3W0GHD_U!"H29!L2T^4!U2!7GE76SM\$RR!H08N^
M!<JB=H+6ZK!N<00!0N!<@<KE MTGD>ZUACK?7\$<@<B_3_K/6K)CFW=BV87HZD6Y+XW<0SK^+<XWNZKT8@!H7 M?
+L!<YX\$BVZ;..G67!GL_J2_Y!HUN^ M@!C+MACYH_XRAH4_70(AS!<6%PLDE?Z!UR!<6D^0!<H5<^&Z2^O!V4!F^T MG7M?
(!%J_!<FG4S?(69!<7HZ_V=%H!M!2!_!Q!TOT4FP_MVE4=VQ3_"Z_!FE;#D!H!)WC_A3;\$W_7+!L!\$M>)>_UJSI^<F>(!38^4E0<^
MGPZL!U(\$&TK\$UK)5^!YRA!L3B;UT^D#K0\$!IM&^!MJKC!U_ZRC^5EWHW";
M^<@!RDFC!H050!D2Y!<KOH=&Z!H)U5!<TST8!2P!+!JAKP!NGC^&J^V^ MTKRX@W%=<X08\$BL!K!<L>F%<90\$H90A78\$0!
S!_V8;I!^*~70FV/RYM8_T> MYZD7R^Y!UWPK*\$E4R\$#A!)7^4=23P@<01DN^N5SS^9U!ZDMD)Z_!2T?>4
MHE_Q_!P7^WR7B52T!<YF0P40A&Q^M M&^<2!3^<@<B^XP+!+E%J!C=<S_ZR^!M!>2NW7K8K^R_2R!_8%IOJ@<_!A!N^A!<LFF^S(TIV7>QJ_V9G!H^4J
M^<G!K3AM!<#_#B!U!K!HE)B^Y!GCGXOS!\$)Z%!C^4!<^ND^ND^Q^MCL^!<G^MYXN&(\$0\$A9!6JA_U&EM^9\$J8T!+WSP=^F!#4RIKR5!H7N!Z!>7!KG
J_M<(<K78TK0V=<7^B-G M^"73D!S(2?#_~^<4!H@Q>%C2^N^T<_<@>IVM%!'#_CWB_QU=O&U=FS+LU4^ MMU?
GKW^<Q^*8!<W\$9;XP^W!5;HLE(FW6_W!<GHF+!1!U^ZQZ+6T\$!<^!D M79;20!&R!>P2>C4N\$G^<^X;Q_<OW_SV
MKS!O!X!ELF6Y!O)HG+D^0^7(H!H08 MLXSL!QEM4V5VX^UAF&SM;I(ZR^!<0>@<Z^NOL">_<G^38!^W7D;O^FP^@<F5J M^0#D_+E9#8FZ!0)
!6!D!H!9">(2GF+^40C^E^A2K<@>)(D140Q^&BM;3!D!V MR^F;B0\$QOF!U!<^>9!7P^_*XEA!<6\$8N^Q!QM+FD!H!Z;50XHA2%UHV
MY!D!H_ SPZ7=A>QAIWM2K2_<^FH^?2^K^<@>_L_K!C^!\$Y@Y5K5CA7:9 MNE9H;8J^HO^H^ZQ:EGP_C5L2!%@!<60!QMD.K^<GR_G!+*U_2UB!
!FK64X^M!<HMDA_R^!56M7T_0_85^0V46=TB!>^!S MB^R!U!<OMZ_Z_KKAV!JF^!T M^<1>R!L6N^H!MWFA00A;ZN!V!U_KDH!
!K(AF!HBPX!_S8\$)F6C^#<K9N_M!<T!U!XK39\$VUXFK^!HK@<Q!<447A80;M^5_LBGCR(!<!PX<=<=>QW7R!R^C@<WGN!52BL> M93B!7QU=
!\$>B98R^YT3H!49%+VZ\$+B5^<K_WCKF80R0_~^V)ZRR!QZ8PPVX MYOAWZNU90%<L3/&DB>10B^FB@<+E\$>^@<P!UOC">^!<B M^<39;2
B>FQ!VY6MC&L!A^07!62!U_V=IG5^D_0\$5;EYFQDU5_MJ^F;_#O!BPRNRM>M4W=D(^HA&K_0WHTU<6M^!%G8CFKTO!K!<1^TN+M/B
M!<J3H6BG>+!>+Z!<^K_!<60H@NB@<PUVU_Z BB\$!AFBCF!<!O+<^<S=<+JN M_VVAY<L%5G=RCB_ZXN&10!HOEN@Q_SOCKX+3!22&^2!
<VM:~@!@H!<9VRA! M^=JW!<^V\$N^A30^ M<7UU7HR^"MHZ9">(^VBKP!<FX!M?A MMF4<^!<=3CY6\$2\$%<@<"531^2")#MMQFV!\$<UERE?
2>@<+RZ+!WN!9KF2AX^V MZ^<E!B79@!)!E(K!8!Q!B!J^<3^>J!H^"6U\$5%00T6A<5_8ZG!V^!W6!E!M^"5^U!T)^!%2^PB;K!<D.EB2^KZ/NM.0%J
<F_V_E2&@<S2%F9_5F&6763^MLKXFF!V\$!A(!<4AR!^KYNGE^~!WD!7_N.D@<C!\$LV!<7W3!E9_15E!H^<M\$5532!ACH!^R9U2QK!AN0!P^YXN!W
WU-S>IOZDKS;8!K@5_PH9+5W!QZ2HUS2&)B^EZ;Z!+O^W)W5U_W!TUS^#33E=(3(5(*WY.9(VH(3))\$RISCLGFM_3^J!<P@<OY M9KST.\$?
H=YT^<CGG!H_PBJ@<^!W!7!W3_03^4Z^UDD!<1=9^AP!<P.N@<Q!M^<MX8<^!<L_2X&_..HH_0BV(RT+!<C_SZ_2>@3@!2K0EGA!E0!T.PBAC!5!
M&^<IR7406_UVP9@<D!<W^TA_WH=&JY!RSB_+Q!<L^!Z!H!<NE+<^<U!<3Y<^<NL_MZ^ML^Z!<J2^!<V!<9_!62>_Y?3%T@<X!)B!<2^Z!2!
M>9AF4!+!<E>=>L^G=M^D M!S^"RA^<B!MN^?2!T>7>@<J^F=7)2/7!2!U!\$5(62C0@<PHME8Q&^!Q_#^Y
M2!<#5CYG@<T!OY\$<+!FE\$G_H_Z^<^!Q2K!<^!<648WX^USVBC-Q+)<T M5\$<CEKY+GL^DHWPNCGH!<^F52+!3 MB^<5_L=X.3WD!
<9/R5\$5ZE+R!O!\$*\$J^<A(14\$^!T2A_NLPA=IL8_>7^ M9^V5RM!VF80!1WOD^OD\$H!X!<H+!<Z!<G_YW3+SA_K-K_2!<+R!<U+Y9RVU2^M_YR=?
WD5^<MBMEQYS_EW!<G_N\$F20!Y.R^"0\$;T%G^<P+<8HY^!XUGD0^<^<M^<L^4JNE4+!X090%ZLKNY7GYQ^+ MZ@<T9U2R^?
GH8+5#U5!9H;KD>S4OP M^!2GB_F27+ZHS^!<G&G\$;U\$^FRM<5!2=L!N>_XUHS8W7K^<A^R!H^"MU^<MRN5=2G!<B5@L!<^C^G
F/G^9EVCV\$=<BKIV_KD7U4\$<D+3QCP=E@O;GX&AD M_1Z^<^TX!<^<UH1^<KL!<W\$%P4%_!<U_VP;CF>8^!F!<3FOOQN30C2.B>4#\$\$\$ MS+!<HE#U_Y
M!<M8N30UUG(N!<89!Q!B!<F5_97DYDFZE!U!PYHG<^!Y!<DTS MQ!<K=^Y!<L^<8A35%V!<D!B\$P!6!^A@<6MXXK^N^70 M6G^OROI=H
^!<@<N6!U#^"AV!2^42!<=^<S%<U\$!F^Z3DU!<G^T9^&^<K!^*H!<M!<JAH!<FL@<^<^<H@<V>^<9A^+H9^!<X^B042%>GCFX@<TYWR_72=L!<L^!<L5+
M!<NUNX!H+R3_0P.T.NV4_F!<V\$=<@3;R(RB!>+343&+<E\$S\$Y!<H!<W!<^!<2 M^6P+W<=C_OH_RUL^FO93B!<P^9!<HM.156%N!<J8!ZMN!<X^<^!<1UB^Y
Z!<M!<3G^%B=3G_V0#K_N4Y_3N2!^<F!<D!<V^YR!<+Z!<0!<6K&K\$0!<2\$<^!<5E6\$V M>4!<8_63+8=#1N.D8^A!<2%<KW^Q>=<=<M^2!32K!<A!<6!%<6!%<WR>?
GBZOF^_FR^60 M!<RS06WMG^2;IBE4@!)Y!R.K&6+B/C(6A_KA&=<1/SE!MQVD MA94;3R^QJ!<^EP=I0^H_OJ45N!<4V4 GE0!TB<=<Z;8LC(>?<#F
MFS_PVZ^<Jf2^<U\$995!<1%=<1%4!<+!<H0=<@<8E!<L^<M!<R!<O;3G@B!<K^<K!<@0!<^E#<E#B3U_B<!<5!<F^!<Q!<R^K
M!<N!<Y!<RHN!<2!<H@<=<MAZ065!<1W(U!<RERR^ZS_2>YOR\$!<T^!<^<U\$5>HW+V MHQ^<^>Q>1^"VU!<5D H!E0Q^!<1>1XLF\$HJ?
<_X8F0V!<H^#24BUZCLA0#<_&&X_M+>W_U!<XFCO_ZA!<^FE#<+6^B!<Y(ZOU/>^*D_C!<20QW&BNK!<W!<R!<Y!<X!<F6^<^!<K8
U53!7E!M!<^<LUGA^<NDZ0!<B!<D!<G>4>+!<6!<+!<Q MDP\$!<H!<RE^<D_!<K<=<L^<J+VE!<S!<M!<749_!<Y^<^<08K6!<B!<X>^<F!<K>+BZ^<Y
^*T2!<G!<FX^#0#X^"1237D_CK@YX\$W6V_Y.NZ^<+!<R_K M2!<T!<F59^!<ZNO!<A>5XEOBY4YX!<6T\$XV&5&5_P03_<^!<X^M^DZ_!<7FW4K4!<M.8
V25\$^!<H!<S^#<_UV! M!<^<K.RWK%<S;J>E_!<62%<L_H/K!<C^<T!<60!<G!<P>^<IWC^*G!<D<9HP4!<Q=8CB0#_M&@<F.A\$3+!<XV5!<^>?<B!<^YXFWU7T8!<#<+?
>^!<2BM53BK_RHD_YR!<ZDP\$ M!<^<2_T5R_L3+QAR+R64\$<QM^%+!<10_D5N^>Y5!<EK26T!<V^!<HSDX63>^<D!<H
MVP!<77!<+2E!<K3;9!<59\$1T&@<+0!<5!<L!<SHKG66\$<CWND_C.Q@<9Q>?<+<+3!<H!<M8!<8D9YU!<+<T7ZKU2G>YW@<+WMB;T!<G4>N^<A!<19!<TV00KNO^
4G^<@!<85M M\$6!<L^7UG8W^E2;54&_06<^<D!<20!<FSLKWFY^>_<J!<527.67G0!<^<M^<2^<X_W!<MM9^<WD^<E66A^<DKP!<W!<D.E2!<UPY^<J!<NTE?
1Q!<S3P+K7!<Q@<^7G%<MP\$!<L>P7!<M=<^<U6_W!<6!<W!<C4?<T_C!<JU^D_!<V^<H>^>_<ZGSJ!<^<O_24V>2;62^2^3#(<6U3!<S!
MP8\$6Q0!<1>8YR2&G949XZCS+VUE!<G_9_~_0YQZP!<5+<GZ!<X2_934!<0!<39?1_2R2^\$Y8?0!<@<J!<9<36+!<+4^<6GM+H^* M1>%Q:<#^<N\$!
L!<H!<F07>J!<O_X0^D^<G_4DS_4&^!<61=<K!<Y0P\$X2P8785 M\$G^T\$<2!<W8+XQ3E!<T7M\$<^<M^<V^<^<=<1%<S_2N_PA^+!<+Q!<TADD1
D!<P!<M^<0R5_<P_@<^A9.44!<YHG^>X^ M^<^<5!<N!<Q!<22/Q!<^<^<J+7^<QF!<ZD60R5M0/ KP(7!<3RQ+P!<94!<LG6^<^<2Z07_R5
M&!<S=<L_W!<O!<H!<3!<T^V^<#30545!<Z>^<TR2NZ!<ED2<N!<B O(CN!<N9Y0Q5B&WH MG;YAH!<H!<U_Y!<H!<63A0\$<H!<QYH4^O_Z0VSD85BW0Z<^<3N2F%P?
M!<W%<#_MR@<@<^<G!<Y^<^<213^06>@<^*W!<P^<BE8^6958!<0!<P1^<H!<O^<+B_<CN\$^ M7@<AO\$<13Y!<13\$A!<SOE\$<S!<1^<JN!<W029^<^<A=<V8?
R2!<F!<K>K<G<N^*U^<7UIR!<H!<U!<M!<^<X\$>)>T38(DQ>NLSZWKU39A>0E8FC^5(1?G/EQK28!<R^K%<9M1^28T<M^!<28P_0=(!<^\$)<D>#9*
9!)UQ2<^4628^T^*2^<2+CW^G2^<+!<H!<P28\$H=<J!<C M^<Y88M!<6H7Y=>+<^<L!<ZK^<F!<H!<PA^<@<X^<H!<H80N!<ESGZ(\$
MS9&@<K!<P!<V!<H!<R!<G!<O!<T9TB!<GSV!<H!<G+6P!<^>STIG=<N7^2E!<H\$^ YC!<Z_VZ1 MM80C3J6!<4_P0MM\$>OZWM M^<P^<BU>U8V!<^9^<2W_ST!<5ZH M?
GCS!<H!<O!<QZ_?<=V!<IOWWS!<+<D=<^<Y^<4U+!<?<^<Y^<Y^<J%_F9Y!<O!<N^<MYS!<G!<K^<Y4_GY><+<+<17%Z!<N!<ZMU!<O!<FOOBV?<D!<K^<JK_0%<1W!<W!<Y!<B3
M!<Q!<U!<V!<N+6^<^!<5!<G.TG!<G!<H5_M!<O_0_4_<2GFQ!<+<R^<P!<M!<^<6!<JM2^<JX M_ZE5767@<GDLA8M_137!<GVX+<CNU!<8?<E8!<FGO3^<=GG!<H!<X6L2\$B2Z2!<H!<^"Y
M!<O<G_ZD!<C=<D!<P!<18G_K!<1><8U!<M!<U!<O^<_H8X!<1^<V!<H!<EOC_N(8AX^!<^<CV4 MJDX!<A!<X!<B!<9!<FX!<G!<MFC!<M61
(<CD7!<R>^<+<H!<HG2^>QFVX;J<^!<W?7^<H!<F!<SYMRO!<H!<ZP!<^<M!<O!<A^<EXP_2!<3B?<O60!<H!<9Z7^<P!<M!<RQ?Z!<O!<J2800G!<H!<T?<RQV!<XV!<AO M6Z%
M4>+!<@>6\$9\$Z4D_X^BDQ_2!<0!<L^<QF9B!<=52G; M>WS4R+X=I^Q^!<0_2ET!<T^P=3K;VH3!<S^<_<W+VH_OL?<#N4!<_2#3!<2U
M!<RQ7>0+DQ!<^H!<B!<D!<Z98U0^<=HTK2_L>=<R@<^<V!<EQP!<9!<6!<UNC.A?<^%M_<O7;22!<R!<47^<^<U!<@7;ZT!<9Z_D^<#<SRRH_8!<I0^<9!<JSC38!<S!<L8!<7T
M!<JDK^<S;R!<129!<H!<D06G@<^*5.LX^<W!<M72U>W7^<W!<O3!<K!<Q!<F>O!<X^<W!<H!<P!<V!<D^<5(CWE>2>T!<X_<=19Y\$R!<2R^<^<RMD<^<M^<J!<K3A=

[illegible]

[illegible]

U>OKFI,ST_82+3W^_NUU+V+9K@.S^\$B%M1(2)H(4"8 MP"/UQZ,J9IC5TK(CV,C,JX^O^J^FN9RM=WW7I+WI1/OTY4,G:EOBTB(1)M ML+H8D8LKR>4RX7V0P(D)@.l^_l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f5=NXOLP1<^&HW+NIXNRIP^TIRZ^_I^W4&0V^J2<^MP0#Z^>+1^ED5=^VY49DKEO^>#7FUJ^?G=^2RU>^M9O#2#J^*+^1\$F@_MM^0)N1 (OEl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

++W(1@ZGRU.P7.E(3MG2/3%N;MJZ021*VPX4*M0N=5V\&H.#P6%;#H@B%&B2*MDI.ZU."**"DR"SYUQJ4M4L<9&001VV+720QJ16:3G?23
\$WP.2+1WY283HU@#J4Y@66C1@08Z0:YMYQVUJ6P@>6830:GP:IL-39D%%M(7R(%%)%%=>(XH:L.H3@ZP&LH16)-F.M.F-1A-
R-G>4IKLVBH31@%\$%HH&Q@1-11YV.FAT(O)=8\$BPM"1.G-41K%ML%=>80(7*9-R1TN(H2I>N-)&8JE.HT@P@TRLPKB#F\$Q@-BT&\$R4+AH!>19U<
M;JL%T\$=F6G45<(<JFZH^4PHLT2G^JHT4@6(^\$1"W83Z4FWF*KHJ/>+Y9.MDPBUW@=3VVMX*M1&C&XEJA'5M7*31
MG'4E1"PJE"GU"U"<9/68(TB\5-.M2K.L8ZP=1%0!F2VYUKAR5YCDQNGJ5:08*BC.HS.B:D'@'2J>1>2%0!&1+ME1)1U:YZW1+R\$5MAUPI<881:YIN?>
>8T&W@/K*=>0BEE.E1XGBXB'526<@L.M=>Y\$X\$-PCMAPMA'1J/8.F.ITJ@'BM\$0M5>@H214L<-@>30MD27(ZY.J3.M6U81.6)M\$V\$8*TO>Z^3P?>
52:~X&G\$D@1'1'P.~@>(9:\$)K.'/D)A+159.MIZ1<3FL(W@5QC%UKG:9-1DY.CR6\$S/W^C\$SVG^FA!\$2=>\$.#JRE'11'MH1#6*2U.W0!HVQL=12R
K#L5)-#>:SZ2-J.3L1Q2OPC6Y4WEND:ME@BS<@>8W@-7.M1<L1UFLGIGT@'YZV58C:6X/D1231'=-5K)U:AZ&OD
M:14JZ&2V%P^T^>1LTO:URT^EY.CP:A16<1^FBL8&66379@K#EGIP:=(=Q.MPRX7WK^QIG^L:~@1+JFI^#:=5Q-U%Q^X^H>~.TT0=40A!1-3
CKBZCJCKM<:0'5GW8P7C\$H.OD04C@:7J.WF621>TA^WUJ.R4^HKZ4WT:~\$M72@=>7Q:YHV6^>1-9V/L3.Y2^RL'Q3'H7^RF5-
3NYM'8C>~NWU8KR#J.M+J@'G1^Z.20FF+HB'UP'D=2@W5O6P.6B1^PK'10'>(S30TF6="QUKK6GF.M7\$FBC&O>Z.M2_O>S:(EIR?NVAA:BIMX:~
~IOS+<R.A7^>XRD8C0K'450.M4'>9IA1^4+EHJ^TBYHG.O.C+I>~>+00N<#=\$A>)>SNOPXG15:1.MMN.W'4^FR'DF.F-
C&640HS3&NKIP1R4:2THH24VY96;&40FE&9X0MH(A#F\$1G/C50^0!F.MY&KRK.P9\$(Q\$<8'>C\$C^0!1U)4EDPE
M1ZRJEJXS+&INZ94~.1Q1^/9FIDUFI3Z6MN0/0>KG~~~~.05:&40&:2TIA1M4B8TTA+SSDVE5>5.Y5BEH1#L.P/33H&6XZPD.613Q>0!>.@&91-4#~*F
ME-J+CSFV@1>4ZHSF533~J7H1.OP^R'306FEH2>=M&(&99E1.MY90UO%\$9TPMQV8-'D7B9G.Q5GR!P19I@4.0'F8EWG7^ZS+ULH84ZMYB
M>3^8TB66Q10'P.M'G&XUBS.QOW7H^4R1Y1^H\$H>BT&<2)=WHLXWP^@RZ*1.M2TF@X2Y4JGLCH10DXL9N:3.)A1'9>Y\$GS3H^B-U^KG-
FYAN50'=-.M.6EHJ.%)7HNXN<3)7Z'DH^21.MHBR2FAIVW0+OD+#+.(1N8I9<6<S^&I+ICNZTO^X8J3R8\$-%QA-'M6HE_W>R^3637Y?
1IKVQ0Q8U.E/(<X(3W49CJ4ES2EGEK>.#121#EN-'ZFB.MPC8BJWQFKC.&21)\$=12XIFB50@.03KH1FE1^2.9E'LG.795M9-)>WF@NJ.MLKOZGG-
'89096'G<9%0!1ET98<(&'9)52>'9W<5\$5WR~HL^ZPNM1L2S.MHPB#2=>2SR'7Y(1TTPSWH1)MMX(G1C8:23;
(MIGYNHH.N.P1@9D.5C3JH1U80C1"MO'10\$2AT""IZZP^HS.WN.M6-BN#*6%BKIB&=U3^)/Z.A^?P\$N;A)"VONKASG.6#FZ@I^T^5C>1#(&1)
M2EH&6PCE&O@7.0^P^7^=-6ZE@7%M^E2N^1.WL/P2T4'~#1^OD=1^=JLE^Y^M.C^1L+1Q.K^WPCD(=L59DG)!NL^QYVCZ85A^X.MH#AN^*KB9>1:
(/U7^U90TK@K'5>~%P/SBI^N1\$=<#P)7RA^M+1E3C00@1.M1:J2T31.5+1.Y>26FIC61TQ:100%>XFLR8C3L.PN1(8'G^51V^Y9:~1
M=UPS^F6J40BR^NGJWH544LL^161ATRY.N4M7^5VM4WQW/4&7Y5-'H'/S5XJ.K9-B'56)QD!<1<~%U^MO/(OC\$KL/W7%W1~.6N
MKM.@14M4CA&^8VC1Q.GFSDZ.XX8X8VCJ3X+US@N7H%YMI=^1^Y22VZ27D.MYX+1)/SG&H.2Y2BOM^J#~.S7C(1%1882BJ5;
(3CEPV08TY50V5'E:E28.M1)(FF(I\$EOH145+1H7KM.#>~XT&7^9N&IGU1.OX1GP?Q#N?/@V^7C-08AN@19T.RJLP^A#9:~QL1?>
#0Kp5=1+&BN^VP1^NOT^*K1.MC21^1^MO/HU1U1U.17)>#1/0371>3>~<3J+^W1O(X^*AEYK1>9WZ01S18KIV>BCNE.M&R^C&C@0T*41+~\$OPT@B@)
7C@C.ZUO9M&D(I\$A40A\$5^X86.'##~#G%&8U.MA#P.3<~K_1^TX^X<4)DMA^Y.23#C<@I=IBYORK\$UTIA^F(I&0H+O.MX)+TL07?
5E&BPX4A_PS=KS<~1424BU9T^CR<*YBF^X'J'JC5'0NDY.U4GC6.M1MN^V6+S4QV'.QIGZ453^UWN^H=5?1)'%P.E.C.Y>~%P0KB&8>(@6Q
MAGS010PQ\$B&5\$1^VH3_Y^1E0K365\$56WK20&2W.VYPUY2CBZ1M.8QI%*~#M1YU&M^DQO\$-8%(7(A^D:DDK40>Y=J^T.H81V(3R8HWNV1^S1
NQ4_Y/D@73(SFC<#8VEP613J^2NP851.MR1<~N.Z1^O2^_Y6=&L^Z^&A^CK2)<G>=>00H^W^12>NKE7(PY<~\$=BDDPK1.M^H1+
<~P@81&3+MRJH3Z6\$XSQ=>1^%&C5ZX.M2\$N<5%XE16M3_3<~N#&TIT251@'JSXMYNWO1^~.TP<~<~W/XN^J^BO1_3LWO?>
>WV7IN7G(YA1^%ND);FW=5~/T.M(GT23V.EQNF=FIDV1&S^4)M:3.H1T^DPR1^1G<(<D~.B\$OI>IKPMJ.M4F^#(1L.85A161~1^@H&@C.R)~
<~.WR117K1.Y17+P-V=FV^*VY^>M.F.MO@SNN504+24UMX^\$H.H1JA.E&DJ6WRAA^IA6^Z4^EFBV^*8J^ZSAFUOZX.MJA8ZN-
M.B~M.MK09+1N2R<3Z1^BU10.A1\$1C+Z.3^P^HUBVY^V(VY1.2L.MXC05GS2.H^*0_~+XL.5E>~TY^Y(5&D/ZMH(W1^1~.40Q8NB^&M9:~1
>5^>F\$1L5.B2N1H.S<2~>~.0KJ#84H4L1PT^%PKN\$R^>C)(1\$FL&E/AGIK^*N<2>R.MJF.G>N>H>~.1OIN^=E3<~I\$Z\$T^GPK+1^HMNN(7P8=
<1.T@KCJ0^>~W0.MME!XAU.DK1(FW+1.1NZJX8R^TI~1.N^>3X2J^V9H11H^A(W14G2D^1.M1.\$(M^HHRN:1F-PQV
FW6BB@RK1^7SL=~=R^&X@&0<~<9G&C\$<~\$-1HE99.M(O\$E8WD4&3C81^1U.U1~%>^/O<15B02.D#&S^24PPP<~&7^WEA-0CQ2
M44=+QM8B@OHU+1^C^NHORM-5.OH1&J/D5+SHZD.M1QAR<2>S^THOZY5^>F35^O1XQV\$M.7=025=FHZ9>/G.^114A.3&D^
M@A^"ZS<0C@.DV^")K6IV)IB.P83Z40'=31??Z^1^I3Y.N19.YRJ\$)@'B/M.M1^G^*8^18B4)=1\$Q)F+U.25KTIQ=1J^2X1L(2!>5=TH&Z.IBRXIE3F6
M.F@DUNB9IV#0DEPW80^NX4YK\$9R^900>=1^+S.YZGQID<"<+H.F(OBIN.M^M^+B8<~2C
KNV7H1M.V)U4B.C@P1^+SV;)OK47YK^R^M1<~>599T^...&HID.MZ)HDH+D1LJUKYX^TKM84Q555IUD:N.FLIGX^127CR^2T2.FT^#)U^*IUW=EH-6?>
551=Y#H6P^ZF&92QRLV.M<~919D^92+D08X3.P1C\$(5K^*#X2<~>=T/CJZJ^>#OC.6UJ5.H\$~1)MY\$00(A
A10/A\$K%8TQJ>78B^W+&VH4(V^~#MF2HH^RKQ>M=R^PY&V)~1X.3.M1.D+NG2DW1@1F)1L.C1^7R7>399JISO=3.6Q1H1H:T+UOM1H)=1\$(V2MG<
M9)S.^IRTZG1)94&X^~HBK>T@LG=D>0^M^LDM0MVEK/8A/E^FVZ/FU8+M^2>2A12O

!)Y2&3P8TK1T5IL'E:U1!^70 M30:WLBHQ6B(^(^DN9PMU)\S\MIS)\I6TLUCBY":XHHDL311C'U.=8W5*U MZ@?>
S'T#H.HK#E2E05(0^:#BE4TBWUJ/P5\$5CHZ4U75,XY1VP Y'J/MFFHA ZN@QO7NAG=6G=\$6SVT@2,Y'RHG:TZ3'N*9BK'UICA0\$0I2*)BH'XS
M7E:F"FG ZJ^?BQ6:~PKUF.M1K3@>Q=,39Z;>8CCD(-,^C%UV^PP WG_X+M;_)Q'BV')#E0R&^_ Z&DV@-6&Q'0X_G=I/3+3UN>;C&N+=VF7.C?
&_Y M SE&.<#1.%!EKP@03_)@Q\$! TUFM:~^CC#Y5/S^SBA/=O588Y."S6?# MTY9."?@_SH#W2+9 M7A2D?
#B4C5~F.F02I03USX:CR;@73083#.60\$S-05\$4I<.@F\$BFSI"4RK3Y MY2B.D/2+IGT=1 ("GPT6I+7P2^OJT+I3WILASL IU:IS WY#T.T).3<96/
M@_9G>_J^*TW)Y372K^7.G17Z4AWAB=0DP\$IUWIL(ZE2ECB: MK8G#6.UZJ MMG@=E_P6 *O1PHCXB7P2P'EJ46@B@#0 MZ\$18PDSMYLX:
(YR@NW@KP:=6&OASE1@EY)(<177HC">RXH.XTWT>:B->9 MDI"YU)F%Q>0!@5.%!YT7:U7LZX/5CM-CYIO^/3 S2*)JYJUN\$ #T?
MF0I<LW@_.GF2(5V^4RM4#EJOV"=@7_RGG9Q.<RG/7A0+NVW TZ7I0 MJN2_7/BF@;14FEV)Y27"OS\$+0F4QCY5<8*FG6H?
BM>TXI73MFOFYQIU+06 MFI<2_79H2U+3I^1=7N M42IM\$4JZM +B_5M +BYQINYL6LP&I9E7+WJLG26*TKW'6I'H+@V&EZZ M'Q4EWAM:
0\$4GE U@3\$=M7LJ^YX^I4\$:(A7A2C7=0T@BCWYX:BM0B:BG:\$)Q95+H8#(K M' A&83^R JYP"7 BNSVYL=YJ\$F*RD5< MG?_ BWYI!-%?
15JOQJ8IU9>\$P<A&X! 8Z1R#P@VLP5X<@DHC.6B8T."XJ M<68I_2Y/Y2^7JAO/F;^+U9%6VY)WAFZOGIAS/IC.A.9U8Q:7V>
MZ4ZS(FJNA:HU\$2Q>V+ME:H23Z2TLI0<96GBN\$9S "JRTRD MM7ME*JOPQN!DJMY@4VYIP -(8_?P+00<@)Q(T-9*1ERT.G Q'O>=A* V
MQ^CS-SX?B@!M*SNW.695K6J&9*F*BGAC0BFQPI=1TU..0Z(=JL&M8C5;+B MC=?HID+2MIM+J:8B(^(F/RI^!-!\$.)A41QYQI@=8.\$Z"B9X(K8-U
N>X M'WJNC KW:B;#L5?<=7L I9>C/K#42<[N.=Q-9N)H>7DG/YK#J^/THO"~ M:JMPZPF:6I3Y#AHTF9=ALF:
ZH #K1+!<@C\$#2:ZIO@UE@<HCQ&#*TR1H M#Q/DLA#<^YD6G2#P.M'7=3WHZ#HJR@P&T@Q_0_HS3?US7.Z9K/=?R6=Z?ZW:
IKB_I+9L K#VPSPWP?P+&* S@_P>P M9X\$UQAX!)SP:3P#<+!^!@%1S_7S\D:Q(SU4Q6TGS7Q4M(C M2DG+*FKJ&L K\$:
I76"SETF>TWT>TW+W4QM:WL LR=W M2Z7MK Q^QNI M9X.PEX+^IR(CHE BXU+3KJ52S[B1E74L THW<@HQ\HJBLJHYX*2VJ:EE
MM:WJ+4=G;I^_H'MTE#E&H)Q^3GJZ(7Y=2I=H"N+BTW!_@)C/SY_MBIAN^Q KEN>=IE?"N^EGI@=5.6108M'Q-B:U^VLZ\$;M*ZO%JH3DE3?
R*6PI M0A4<_Z77DIAZ)S6^I+SWIYSH6IE JV=ZIFN A@%I3@YXICB%_13_8MZ. M4P5^EI E9 E9?H8 EE+TA&4+
QG&I@1TB72.UJ.UOLEHS(85%_RE37I7_8 M^E*E28Y^C9^>N.V.##6R@I9(I+L2>\$Y3%0I3%-2JV^SZY7.K.#N.-MO #.1.N09.3;0%+"HA) F
^6X&C:P5^F^&M^D%#XIAZNYU5L95G17FBE^I6 M8<3H8)GFX X=D7)AVP%U
MA^NF(1I@IRON\$D:ZJNZQL8Y+37F5OD:60Q^P7^8&L.7<53I2I@I^I> MOCUIX '7+8\DNIGD^D^73Q/?!SUC V6JQ.Q MY^VJ-7FJV_K2:
=,HTG+9&I55%#8LGF#0T7!#EF4BSO7?BUYSD_IAX;+5 M^0X.Z2L:GEQNN^KF "%PI02I^0+<2ODCUL8.H;& BD7WC#%:FQ'/?^I_M>8D_#=#A
_DBSWSK.NBS;"#A.#)NH\$<@X L_6B^XU:CVJ"66XJG MZ#%3B0)LX^TIG0:(K7I@.KMN\JH8_80.K8 E1W&S19K2_7I9E=)BUIC5_
M>OMC\$PH79Z(4WA>2AD>6#C^<3W2%16623IS80\$ I^>Y+>4HJ24LX=#C.MLJHB+IBUD;&U=IV0B+0.8IYW2Y3S24+(I2%#L:
9/IM:RXE"NOI+I(=<48@A.MCYQQKS39_I=&+^0#33.ZI0I^UHI^88E%>(19Q_N7KY"9.YHID.(7J8R>+M^>J(U:H\VR9)8SHHMF_Q_A9H3AU\$
WQQ9.ADA42IVIKQ)B-BQM=0IRF0+ M7Z!+=9X?L^_CK%Z&19IFJJA5\$S! ZMC\$IV9L=S;_U@AGJ6=^*I^E6H!+_MXK>I
&#VVO7P0>I3\$ #1!=^UL7D0I^64%W2I2_#I.YU2532TR-CL MN(WGE55=I*L/K^F WJ_9&!
<113)+R15%DXCTP12D^&NW8#;T9HJ8P,>?)Q#NV0!_8I^H%L:WZ\$XKYA^R:0_*IVPV@H8CMXFBF(Y&=P M:RS@QER)IM@W:R:CMF98@%4.K^1P)
(#3)*UY9>+13QI8Z<68KS#<_I3.A.M!>0^IY6I!>ON>3/TH@_WOV\$F8WK#_L>S9;_B>CRZH+Q6XAFDBANFP^10UX5
MM#Q^NYIWP1%#.#I@8K/Q1<9.1.5LP(QG+YPI0Q^<_098_14QI:QA^D M<9)8V?^I Y J9JH:V\$S;U&E-7%
<IHVQR7_L2HS(35G#I07359V4RW2G(CMU=@3/7?U5B*15Y>7.6NIF.%G&J?A<03FHV9(Z.PD^C87^NX7/A/DO@PW12 MSE/+FA7ISIRG.#3V)(-OLF=
MDPKPD9.P&0JQXLT6SY0I2B@)IB+FY?29^A17Q(C^FQ^Y+ M8P)U:E73 (8K78@&A/U-R#GU! CPJ@)3(C)8G2&_I2ZD&5/R@+<3G(=-Z M/DOAL^
#0\$S:OKT'Q.PIYJ"INKUUI".I4XKB&^=DA16Q.Z^YIF_I^Q^V+U M.M-55U39N13&7A^C@8I_2AE9G3.@:IZM4YF/+Y7X M_KV15I^4E?D!>:W
MRB^KJ^SIDM(BT>?>TM3&#J=Z2CN9D_M\$IV@T@)3MG>S^H8P=URFF\$KMI(CI\$G6=H.16>46?>:ZO>J55E/F\$3_I M/TKP=%C.I2SOE\$(N>MDZ?
0+4>#IQ+I2GVR6B1ZGWA2 M85C6AT&O3N5SWBCUSIF72+J1<_Q8?NXU!L@H@H_2DK0%&XZVJ90)+#AM^_MOI-G&EY^L T#1.0H+^I^B-
4HHHWE/C(G.DZ6?ZIU+(5V4@.R.P.%;1 M.A:\$K#XSU(C^<#U3I>+&2_0I6^C-TL#KJW.DQ%U#^QI^_M8ZL\$ H:B)PB1=YOTIRWF<IG*R;
MZ:N(QVA+I4S=BA1YBQ5;U\$S:PSE2&^TPGWBF^FD2/4^C^VRZDUYI MR8W/O.@X.S8BOH.8THRE5U;IB-PW5IGHA%>)N"?
YUNIM^WDV@:N+AI(I^Y/IW)S>H<+L#<36% MG^E^:AS;K5+=CJ5)2I^_D^*Q KDXNMX^==.0X\$ _2*#1AN90.D/+5UT>M MC=:R@9I4?
THEGN+E>I+K=5FX.MZ(H'B'R:QM^IGPRL644IUB124^6*10RQ^ MU^<767%_I^_D/ KY?UIN:OO/TC^<KM7M.#\$;SB9.LSTN.W:F^C@JH1<^I#N
H&CZQSKC I^D+A6IT6QKJ^IYF&KJ MB^HJH;D(ICA9)GYU9B1A_I E.I2 MDI70I^F IJZ:I THO.TI_2AHW M.
I4HHQA&S@/4_@/U+I+>+>Z(IQACUIS4/ZT6^-(83HJLNU5LNY8T1 M^7/G+EGJHA#BEW@2I_W/.#NK%JH#
I/C^Q^+T^O^#>474BGRNFHO=:Y34U@#C M^?="I^_F.0K4I2I^_3ZP)8F8ADU3I^_23MB7_#sL7I7P!\$^6ZFA(M<=<0 M&)+3Q&J
H(U_)+S6+E)T)P^I1@&7T_&CIS:KMCOTBQ^_<^DK15^F_ M2L1I^_0Y5=,^&I^C/L W2G#V1 (A6:20#HO.4&Y\$45IP.V^#49M=*M,7ZA0<49P0
4'EJ\$4WP9/2_#4M6#&I=U)AE2+WV+^#3&_B^_GDNAU2)Y&(V4->BR(7H&H(243?D^_-=I2S:P8B/+ M4V^&#WLT.DZ-8A-
+S^Q&^V8/WYU(I=I=Q4V)QP.^JZ#(=I#47GQY=IYC+I72 M8-Y@2)9E4I5.CSVQ^DU>?ZJNT^4(\$&QW3YLT<+91IYZI27<0_B2!%|
MWB.FW7 VY3(BKTZ.R:AMH)1TP^Y4GQ^<34\$-UP1^QXF74MN%05I6P.M&HJH78E)35HF(F&H2I2PON^_W^Z@W:Y?O(8TH+
IAHK^LE^U4G%/%F^K_ M6-S+U8(1A-(^>AAF@VL\$IN^2YLPH&U^_GNAFK\$^RI^YQC&_)Q(C^&I MW3JH9G;).6B-1_2
IKEO^PX\$GZ7^6^L0^J%CF22^N2B6:9SXWU:U9S9 MU56^AKB2S=+I S18D& M5_7IS+W1!_@U=OW^AQ6R53_IPO(6E!HJ83^2_K<I4-57AG(72-
SC= F^ MDC.#&NjX^C:T893+>^**V&A;^(TV-ID=:AA@I9I;@3_4_UIE=N^SYD)8 M41C)DYWGH^KQI961\$96R<252;1+5^C)QU=#9;
#MLJMQ^4%WFG:P6QB> MIE@K^Y_7H=I.MWO28L6LW1\$U=^UWV7723F&SRI@ VMA>I3C_K4AH7 MIF\$+>#UP?>
7:10HK7B25EZS71H1*PI&#IU@F71%NI^%F&S.3&ADG^Y51L(C M&IG>:>X0L7"N:JN#27H5_W19%6O&X^&^I@_%QK2JIS_%!#B^W30^VIE
M:++6IK^V1-W!=-U1C W@X8^ACG^?@3-T3<IG^H+I2 I7\$ 09X;_1X^?_ MKVN^3K9_Z&Y BMLZ^&KSI^VCYIG&@:F)WVHBY1E=5((\$@6K1#2J2
LLQI@GN\$<+Q6BS4X1+U8Z14T(C^<Y99MM.<I=>GEI?2_G I^<Q^_N.@_ M OMH."824+24I<)<^>
<^XJ^I+L%2%2YMF^A^WYVRHSQ:DD(@17_KI#WWK MU7K?>UGB@S8I96:&^QHJV7C3(7%&_TO&_928@-7ETT5N!&_N6_S^<ZQ M1A9?
5&*X/K0U=TSN@OGIA0(20VBMO_1#0KZ^FS9(I^PLA>ZMTFT7ZF-N^8 MTF+YLP19WJIG^M(C7JISKJPCTAL.TZ>6%49\$W1X4ZJSK4BXPIBGS
M2Z2:HJIB^4HJ M0QLX L_Z^A.5P\$+V&M1&Y&8Z@&7YS-TF52)H8P) MA3\$JPK^9YWV5.5M L F3)4HY010A@T^PD+Q^+=+U E K
MJC(Y^EJ#2#OR_ AC^2+2\$BQFGBDW^8N_8C5\$ZU:L M4_@J(3&#>_#31/0GJ?>=2#_WIC24548G;KB=8LFT07^92;IN=OL=YCU:
M2Z2:L579=I_Q^*#_9@7K7F+CJD= (GW3ZC OYZ<647\$Y:HB&A^DGMWFH_6KM#T@CB^E&A/BU:&8>#&=JB^9HJVU30 F4ID84E&F?
M=64A)A>K<4ASZ7^6+^I@QBFSI<2EUK^Z9W#H(C^Y)AL00)Q7EGEJH1M4QDYZC12W%Q2&9CMY62=&C6CQF.MT=Q\$+1SI^I^I
MAB7/I2C2_?RUIY^R IBRA6#@^BVN@I9)E#IOP10_U\$WW7J#WHO.R.#K65T M\$8PZNFPDIDIG;#7N^8Y.(LA>*K/JA!_Z&#X&I<+A?>
^IY5MDL^V\$FBH(M8_I>R#^B^\$X<I2EG,+I REAI59#;0B1542UH_L-EIYIMRO.IHC0I+@I MFW93W/ &F8#1A%Q^CI# LRF=^JM Q)
3^2S_<9DRM^&MUZR\$KMAJXK5MN M^0>#>#I/A754KQOX L_XX3#PJB>Y^4^TU07I7#7Z.9(8Y#=#G6^&8BH%_MYV7<9"S>QE+^2_Q>I
I^R&R(HH>H^T5:43_Z M6EKRI_@=7/O8!M:U.B6JYQ4BYH7^QFA8MV6X_E7N6CHIC^Y^>_8V:7
MEN+4\$T^PU:RIH@I)AQW/H:YS=*5AQ&I@3K9K6C/RM0H6H#7I5C M6I0Q7EV^&#JH15&M9:WF#_72PFIU4H=4S\$KWZCD?PICU6<42I#_D<:>
IPLI M:GB07E+@)U^L^AA_S1L^W^_0C%_Jf3.OP05#ZVCIMJ+3FSKGK RKI5L M:W(WH6KY%&H4?
TDOK(=8@+^18^6E.SWA2.YI30+X+1_3>8D(NA>J\$N^MH@:G H1 5PD>_#SV65YT^7E1?>3ERKH181C&9H0B_DUE%SGMT:RC_GNVF
MLI#IE(-6390%K^+WIG4.K^VY2+^&^E@8=DYWJ&=0.(TV\$#K/OBH%XM^X&=7 M_O95WYIA+25^<=O\$ATW&S_WK\$!?
&8ZX5C2_H1SNE:L&K31VW^+R95^ASTD^ M12+MX/R@E_VK9>B1.6^CGHJW_<6%#J#B^257O5E(1DOA^P7=SE49 M:M.T.4(P
GJKQ@<@WXI#<K#5I8_8J^IIP35CI7_\$W8IHOF3&9L\$H=K9K_4GYCRDIG4^IPVFM>G9^NUIGGAWW\$B7
M14AL T8I3KJWIA3^M3^H7O2I^M2GLN^_MY<@5IW46^TGY^REYMXYC^7RN MIQ+J2ZYTL^OSDIU#Y8T+&&A_RGV0PE.BKFKIOY\$>=CPY)
I5YNGZ60I^YX! M4>IU054 UC-5 PTJES^FDU8^5B\$JPIV I^3>_?"2\$D8LM;_#AXI50K> MV^AAIPH=E^SRDQ^&IX M^_Y^F#@6@:
MT=Y^B6\$@=JTI.R:2<^YS1HJ4I2QZV6295W\$YU8NG+JCP\$7>@R#_9U9D0 M@:(^>O6QEX\$3>UCZ.2I^PL\$A.MAXL@&7U(NKV0^V^I
(6NFE9/^FH+5EX(&@D/9IC/HXPSSXN2^T9J@KEIB M#&JX;E!"@53#^I5_&_\$(I-0^+H90+B#(XZ>L<_O\$AY&@^J4%GDC#G#
MU(LAJCGCCVQSP6M7+^2A.6-34CK53_L.#)7^4QI^_W^B?>@<F^B^<U&4Y2U^C+I0D&XC.AFE81^BRD H_FL\$10H2E.T? MT^U=3R^2.OR#?
I5I Q^#^I>P=F9HJZGG6W+^J6.8I&S^2FEV7_8OYUJ^0^5KI F:CC5Y9%&RI&M<=<3%Q^2<^XG=L&S MC@K&EP9K65#=#P;)(H8SG3-?
X400HJ0XH#\$(BA+7RHYX4ZHY#VJUIZ_ M^*IJM#4200^%5!07S+7N@46\$QC TN9QI%0_Q:14^@CV5IC+CFGQHK_XI
M.MC\$HSWOLHU^<BO7V:E_X^<GJ37Z_#U8F^>OIR_MIKB72^>MKS_7P_IXGV#^BZL#41HJ5^R)H4Z1YX+^V<_W<I M>C8CN35U3T^0MSS00W^#M
MZ2&XN:RZ3P^U+54IYV6@JH^I_LX4I&4 M2Y-M@WJ;@>=KW^UEO..I@3-D)WKS^I4GJHGKTIQVE^9\$9DMMBOV MZZ\$37
UL04T^XF:SELN\$V3./>K_3YM7K.3IL489^5Q4+^VK02=-8R+WT MC05H@IF#<#C^IMP3E57S_<M45TIT-CY:PR7VW.ISIT.Y:W106K8G+NQ7WH
(0G_5I9ABO&0^4I20K\$4 MQQF(EEA:SV M=IJ=^702708:"WJ)&_0_ LXCMIY(C^Q^HEI#@<5#ZH@F.# M^J8W+9C^_8C.%1-6@#2AIW%D5\$8#>
(+L=O7HHW;KKKNQD)H8Z)H2L>ME MU7ZA.\$L04W22+@7.TQ8F7H I=IK@9LH&E:9U74W)(05#)=^BU7K>2_I2D70
ME#SUI9.W0I^HAZQAUB_7R2W^_2S^_DLN.6<I C_>W=ZQPLM2R^H.3FUI/MBL^<GE7=4>L2.Y/G>+WF_54>IU5U708UX0EX^XBJ8?
+HBY^N^X@8+7D@%2Q^IGI^EY<^SRQ+ELTN6%>^J\$W8K3H^T2=3:2V1 MGU%5\$*Q2\$T N0J5=B1B%#^ZB)?
NFIW14ZUIH7(O>#9H.PAJN2@>NEX MKN^MHQ>_FP.AM_4VJ8^CXR2F1@QEZ.\$1-BE4>2\$(8RK:VIUJ.G9>I7G M4056W*10JLZX^YQ>BVAQ:
N!>=\$1^R@<80I3#<#<U.V9):\$W6A!&S8YV MZ LCQ FSYSQGE4I)Y4A_SII^+ONN3=3KVLBGX>YVN MNV>3^B@H5EMG MU1(G:BUNQI)+IR
(^+IRKQ:2_C5@(\$B):0F&PN25M10_GL2)_18H0H^MZ);A5K24ALHZL^?GEO40(CV+T^D M1?
Z^O^P3^+^I^R^T^K+R3ZPQBF^68PPHXJ9G14+47Y34FENI@9F M^7H^K_OKXI4V!L_O6I6H4X10PD^T^_#ZB54ILIG^!B5(CX&M6I^M^R^5.P?
4OPW5.BK?>VH#0=7>_J^NU1^G9P7\$>ATH\$>N.NI2Z^@H7I0TKFIP3OUB&#_D)S^# M^I_8INXO1XKK&3S_=-KKZ^7SA^!
I:UFD(C6D)R3^<WX1P^_QF9E.HO4BK) MVFT^+^F=G.S(;E+7&_>C7R:=>I9^#_8LS=B45WIM5E^_W^CJDD?^M@)Q(C)>YBL@-
_QA^&KU!^SPD)M:4R!Y6Y^EYEEI.CJN9D@6.YC:5\$C(TP12)543=L M^IFG_9&6XJ6(I>)_667Y>RNIJWU02I+96I25L=G=&I@^3FI^09<(^5
MB2+#+8ZNDDES)^HV+74G(C32) LWAP(C^U8S=GGI:7Y^YY^ AISPIQM1T M3@_IU0>329IAA_U@AAO&5Y>T+IKJXHEWDNI@>2GMN+>?>?
+*_WG M4^IYO4T^T#:(&TST)Z:2K^I^B/ BL E^F&2T1<^&Q^_X)662^K=\$ M.K&@C2XTHR4P^J9@I@1^\$KSC4^MY6I^9_X6IS
MZD0%GRTIU_4KA^TKZC^QK0B=5LAIA+X0)0RJ&GVH^L9QJRE M-B:A4YCT2JYNMVD7UUS^<TY5T(^XRTXVDQKN.6>XHJWJ26%6HG4^UIPHU
MT6=8%8^N\$X5A:7%GHR^Q?K_OUL9XJN^75A.A=W^_M^5_45V(Y@U^_SL<X&=)QI^2KLZ^KK@&66&6^<HDB7^EUTU>BKU>M
M7VIDI=9<4_LYHQHY^SN JH+FU48CPK(I=I^I^I&E5&V^WEV^<WO M^T^I^#ZGTC+^_NJC=DU:(S=>^_6.QBO^_YH9?XZK)IK7^E:RR5@&+3\$
IWS^N&LWV:Q57QW=F6.<I_MV<^>9VN94X^AT<=I0Z_D6JIS3_2H\$ R=E^2@IG2NEPT(^JHW5)GZKUCDDW^F+M+5R\$SRWD9!?
RX^N1.YP4R/HJ#N.&8 M^RI=03JUI5K^R^SYW\$3J^U6IT+^PBF M-A-G\$^I C^X^9F3_0N\$R^Y>3K&^38I2D8Z6X^(R,I^I^YSXX)%CVFS.UWGI
MZCHIR9R.AH(HB>_H006VYDI^D1_IG7_HP_K1N7:M2#0E1WTWB^_W^IV.8 M^L<5_&_I375I^L\$4E2K&7MLK6QBLD%M@&I.(P\$?

[illegible]

M03G)A!,'>3||=4\$>P74BP"/D23^N\$ M=BBFA,G+H0]::7*J5CI7% JTLF"A M-OI85S1#JIVI?L7-XKG*IR<:,@.4LX;O>.< #KKJ3TQ[]6-^24Y?4I#X^N
MNE[HD WEJH4I3@_&36O@_50E/^K^I-\$_:"D9MAA1S@R:%IF&GD73E8M.%8V;+YT;_J#6MCN6Y M%:.64%%H?LM;Y.LJCN6"WL
T#8U4DM#UJH1A6!70(C>AQF JD';j*;*JH_XG M&DT01RM#5_?RA"V=?4.O&#"H_JIV&BX3Z_M_"7RIXCW1+/Y^+YV=EXO_MJO>J68+!
Q!&%_@@IR+!"523>^RI1QY6>3JfM6JB.M2WT>37M@|<@DW=)UT+ M.26\$L::3H^&?)?2(7>@)U9I/%8&K&QB4TD((=;IG?LG>K;Y6C)>
(N&1PD@ZX\$2\$/K%WXIDJ\$Z MSZR\$M/T!K0I0H=98-AW20P^\$Z=HIZ,TWGIQ>OE95O%(RN()9.835YD9.) M#U_VGJ?6Q+
(=2B\$SVI4<#Z0\$5@5**RE0ZIESNMQ0U;BR9)5JT'=)2W1&KRG MJHJB?FCZ!E,X<'Q;? M'8;^9<.BO>?9?KA(O.ASS6OZA"DT^6C/K L\$Y8 Y8)H.D U_?
J)?LPAEHW_MLYAHU9J@YR&YIEFDAI^A%IE#.W!P^>Q\$^_M8&%1XI#"!FI4-L(OUT::;\$232FIK\3&PQMXOKH2R)P*N"-N9.Y\$>G0R<!
MOTX("ZCG7!6&Z,P?N@.2KPW18A; MPIC8DV--Y;CN*0I6S",2.?9O;HY7;36Z(!"!X) 5@HP0MHJE8IE@LJK.O
M9TU\$.46A2;GTRR0%E&Y2)M;^R\$J/\$9UW/0DI-NQE4!L?SDM =;1H)^?ZQG MP!Q2BFH2HEUH+PY!2P?""2G&WW&L#
!A2@+K9S!Z%HZC'\$T=27X!9OJEYD MOA6DI#BKZCS+LS!DO?L%S>'<4Y?LHUTYHQSGBC/TUINO(4RVPBZ M"
IH&N/R0ZAIG49=W*FJHV3ZP%BI7LWKCRE@/YIG%(9K;K>=0 MYI2Q15BGOEQX;-